words,sentence_id,labels
Electrocardiographic,0,O
changes,0,O
and,0,O
cardiac,0,B-Disease
arrhythmias,0,I-Disease
in,0,O
patients,0,O
receiving,0,O
psychotropic,0,O
drugs,0,O
.,0,O
Eight,1,O
patients,1,O
had,1,O
cardiac,1,O
manifestations,1,O
that,1,O
were,1,O
life-threatening,1,O
in,1,O
five,1,O
while,1,O
taking,1,O
psychotropic,1,O
drugs,1,O
",",1,O
either,1,O
phenothiazines,1,B-Chemical
or,1,O
tricyclic,1,O
antidepressants,1,O
.,1,O
Although,2,O
most,2,O
patients,2,O
were,2,O
receiving,2,O
several,2,O
drugs,2,O
",",2,O
Mellaril,2,B-Chemical
(,2,O
thioridazine,2,B-Chemical
),2,O
appeared,2,O
to,2,O
be,2,O
responsible,2,O
for,2,O
five,2,O
cases,2,O
of,2,O
ventricular,2,B-Disease
tachycardia,2,I-Disease
",",2,O
one,2,O
of,2,O
which,2,O
was,2,O
fatal,2,O
in,2,O
a,2,O
35,2,O
year,2,O
old,2,O
woman,2,O
.,2,O
Supraventricular,3,B-Disease
tachycardia,3,I-Disease
developed,3,O
in,3,O
one,3,O
patient,3,O
receiving,3,O
Thorazine,3,B-Chemical
(,3,O
chlorpromazine,3,B-Chemical
),3,O
.,3,O
Aventyl,4,B-Chemical
(,4,O
nortriptyline,4,B-Chemical
),4,O
and,4,O
Elavil,4,B-Chemical
(,4,O
amitriptyline,4,B-Chemical
),4,O
each,4,O
produced,4,O
left,4,B-Disease
bundle,4,I-Disease
branch,4,I-Disease
block,4,I-Disease
in,4,O
a,4,O
73,4,O
year,4,O
old,4,O
woman,4,O
.,4,O
Electrocardiographic,5,O
T,5,O
and,5,O
U,5,O
wave,5,O
abnormalities,5,O
were,5,O
present,5,O
in,5,O
most,5,O
patients,5,O
.,5,O
The,6,O
ventricular,6,B-Disease
arrhythmias,6,I-Disease
responded,6,O
to,6,O
intravenous,6,O
administration,6,O
of,6,O
lidocaine,6,B-Chemical
and,6,O
to,6,O
direct,6,O
current,6,O
electric,6,O
shock,6,O
;,6,O
ventricular,6,O
pacing,6,O
was,6,O
required,6,O
in,6,O
some,6,O
instances,6,O
and,6,O
intravenous,6,O
administration,6,O
of,6,O
propranolol,6,B-Chemical
combined,6,O
with,6,O
ventricular,6,O
pacing,6,O
in,6,O
one,6,O
.,6,O
The,7,O
tachyarrhythmias,7,B-Disease
generally,7,O
subsided,7,O
within,7,O
48,7,O
hours,7,O
after,7,O
administration,7,O
of,7,O
the,7,O
drugs,7,O
was,7,O
stopped,7,O
.,7,O
Five,8,O
of,8,O
the,8,O
eight,8,O
patients,8,O
were,8,O
50,8,O
years,8,O
of,8,O
age,8,O
or,8,O
younger,8,O
;,8,O
only,8,O
one,8,O
clearly,8,O
had,8,O
antecedent,8,O
heart,8,B-Disease
disease,8,I-Disease
.,8,O
Major,9,O
cardiac,9,B-Disease
arrhythmias,9,I-Disease
are,9,O
a,9,O
potential,9,O
hazard,9,O
in,9,O
patients,9,O
without,9,O
heart,9,B-Disease
disease,9,I-Disease
who,9,O
are,9,O
receiving,9,O
customary,9,O
therapeutic,9,O
doses,9,O
of,9,O
psychotropic,9,O
drugs,9,O
.,9,O
A,10,O
prospective,10,O
clinical,10,O
trial,10,O
is,10,O
suggested,10,O
to,10,O
quantify,10,O
the,10,O
risk,10,O
of,10,O
cardiac,10,B-Disease
complications,10,I-Disease
to,10,O
patients,10,O
receiving,10,O
phenothiazines,10,B-Chemical
or,10,O
tricyclic,10,O
antidepressant,10,O
drugs,10,O
.,10,O
Initial,11,O
potassium,11,B-Chemical
loss,11,O
and,11,O
hypokalaemia,11,B-Disease
during,11,O
chlorthalidone,11,B-Chemical
administration,11,O
in,11,O
patients,11,O
with,11,O
essential,11,O
hypertension,11,B-Disease
:,11,O
the,11,O
influence,11,O
of,11,O
dietary,11,O
sodium,11,B-Chemical
restriction,11,O
.,11,O
To,12,O
investigate,12,O
the,12,O
initial,12,O
potassium,12,B-Chemical
loss,12,O
and,12,O
development,12,O
of,12,O
hypokalaemia,12,B-Disease
during,12,O
the,12,O
administration,12,O
of,12,O
an,12,O
oral,12,O
diuretic,12,O
",",12,O
metabolic,12,O
balance,12,O
studies,12,O
were,12,O
performed,12,O
in,12,O
ten,12,O
patients,12,O
with,12,O
essential,12,O
hypertension,12,B-Disease
who,12,O
had,12,O
shown,12,O
hypokalaemia,12,B-Disease
under,12,O
prior,12,O
oral,12,O
diuretic,12,O
treatment,12,O
.,12,O
Chlorthalidone,13,B-Chemical
(,13,O
50,13,O
mg,13,O
daily,13,O
),13,O
was,13,O
given,13,O
for,13,O
14,13,O
days,13,O
.,13,O
Six,14,O
patients,14,O
received,14,O
a,14,O
normal-sodium,14,O
diet,14,O
and,14,O
four,14,O
a,14,O
low-sodium,14,O
(,14,O
17,14,O
mmol/day,14,O
),14,O
diet,14,O
.,14,O
All,15,O
patients,15,O
had,15,O
a,15,O
normal,15,O
initial,15,O
total,15,O
body,15,O
potassium,15,B-Chemical
(,15,O
40K,15,O
),15,O
.,15,O
The,16,O
electrolyte,16,O
balances,16,O
",",16,O
weight,16,O
",",16,O
bromide,16,O
space,16,O
",",16,O
plasma,16,O
renin,16,O
activity,16,O
",",16,O
and,16,O
aldosterone,16,B-Chemical
secretion,16,O
rate,16,O
were,16,O
measured,16,O
.,16,O
In,17,O
both,17,O
groups,17,O
a,17,O
potassium,17,B-Chemical
deficit,17,O
developed,17,O
",",17,O
with,17,O
proportionally,17,O
larger,17,O
losses,17,O
from,17,O
the,17,O
extracellular,17,O
than,17,O
from,17,O
the,17,O
intracellular,17,O
compartment,17,O
.,17,O
In,18,O
the,18,O
normal-sodium,18,O
group,18,O
the,18,O
highest,18,O
mean,18,O
potassium,18,B-Chemical
deficit,18,O
was,18,O
176,18,O
mmol,18,O
on,18,O
day,18,O
9,18,O
",",18,O
after,18,O
which,18,O
some,18,O
potassium,18,B-Chemical
was,18,O
regained,18,O
;,18,O
in,18,O
the,18,O
low-sodium,18,O
group,18,O
the,18,O
highest,18,O
deficit,18,O
was,18,O
276,18,O
mmol,18,O
on,18,O
day,18,O
13,18,O
.,18,O
The,19,O
normal-sodium,19,O
group,19,O
showed,19,O
an,19,O
immediate,19,O
but,19,O
temporary,19,O
rise,19,O
of,19,O
the,19,O
renin,19,O
and,19,O
aldosterone,19,B-Chemical
levels,19,O
;,19,O
in,19,O
the,19,O
low-sodium,19,O
group,19,O
renin,19,O
and,19,O
aldosterone,19,B-Chemical
increased,19,O
more,19,O
slowly,19,O
but,19,O
remained,19,O
elevated,19,O
.,19,O
It,20,O
is,20,O
concluded,20,O
that,20,O
dietary,20,O
sodium,20,B-Chemical
restriction,20,O
increases,20,O
diuretic-induced,20,O
potassium,20,B-Chemical
loss,20,O
",",20,O
presumably,20,O
by,20,O
an,20,O
increased,20,O
activity,20,O
of,20,O
the,20,O
renin-angiotensin-aldosterone,20,O
system,20,O
",",20,O
while,20,O
sodium,20,B-Chemical
delivery,20,O
to,20,O
the,20,O
distal,20,O
renal,20,O
tubules,20,O
remains,20,O
sufficiently,20,O
high,20,O
to,20,O
allow,20,O
increased,20,O
potassium,20,B-Chemical
secretion,20,O
.,20,O
Ethopropazine,21,B-Chemical
and,21,O
benztropine,21,B-Chemical
in,21,O
neuroleptic-induced,21,O
parkinsonism,21,B-Disease
.,21,O
In,22,O
a,22,O
12-week,22,O
controlled,22,O
study,22,O
ethopropazine,22,B-Chemical
was,22,O
compared,22,O
to,22,O
benztropine,22,B-Chemical
in,22,O
the,22,O
treatment,22,O
of,22,O
parkinsonism,22,B-Disease
induced,22,O
by,22,O
fluphenazine,22,B-Chemical
enanthate,22,I-Chemical
in,22,O
60,22,O
schizophrenic,22,B-Disease
outpatients,22,O
.,22,O
Ethopropazine,23,B-Chemical
and,23,O
benztropine,23,B-Chemical
were,23,O
found,23,O
to,23,O
be,23,O
equally,23,O
effective,23,O
in,23,O
controlling,23,O
parkinsonian,23,B-Disease
symptoms,23,I-Disease
and,23,O
were,23,O
as,23,O
efficacious,23,O
as,23,O
procyclidine,23,B-Chemical
",",23,O
their,23,O
previous,23,O
antiparkinsonian,23,O
drug,23,O
.,23,O
However,24,O
",",24,O
benztropine,24,B-Chemical
treated,24,O
patients,24,O
had,24,O
a,24,O
significant,24,O
increase,24,O
in,24,O
tardive,24,B-Disease
dyskinesia,24,I-Disease
compared,24,O
to,24,O
their,24,O
condition,24,O
during,24,O
procyclindine,24,B-Chemical
treatment,24,O
",",24,O
and,24,O
significantly,24,O
more,24,O
anxiety,24,B-Disease
and,24,O
depression,24,B-Disease
than,24,O
ethopropazine,24,B-Chemical
treated,24,O
patients,24,O
.,24,O
This,25,O
suggests,25,O
that,25,O
benztropine,25,B-Chemical
is,25,O
not,25,O
the,25,O
anticholinergic,25,O
drug,25,O
of,25,O
choice,25,O
in,25,O
the,25,O
treatment,25,O
of,25,O
neuroleptic-induced,25,O
parkinsonian,25,B-Disease
symptoms,25,I-Disease
",",25,O
because,25,O
of,25,O
its,25,O
more,25,O
toxic,25,O
central,25,O
and,25,O
peripheral,25,O
atropinic,25,O
effect,25,O
.,25,O
Quinidine,26,B-Chemical
hepatitis,26,B-Disease
.,26,O
Long-term,27,O
administration,27,O
of,27,O
quinidine,27,B-Chemical
was,27,O
associated,27,O
with,27,O
persistent,27,O
elevation,27,O
of,27,O
serum,27,O
concentrations,27,O
of,27,O
SGOT,27,O
",",27,O
lactic,27,B-Chemical
acid,27,I-Chemical
dehydrogenase,27,O
",",27,O
and,27,O
alkaline,27,O
phosphatase,27,O
.,27,O
Liver,28,O
biopsy,28,O
showed,28,O
active,28,O
hepatitis,28,B-Disease
.,28,O
Discontinuance,29,O
of,29,O
quinidine,29,B-Chemical
therapy,29,O
led,29,O
to,29,O
normalization,29,O
of,29,O
liver,29,O
function,29,O
tests,29,O
.,29,O
A,30,O
challenge,30,O
dose,30,O
of,30,O
quinidine,30,B-Chemical
caused,30,O
clinical,30,O
symptoms,30,O
and,30,O
abrupt,30,O
elevation,30,O
of,30,O
SGOT,30,O
",",30,O
alkaline,30,O
phosphatase,30,O
",",30,O
and,30,O
lactic,30,B-Chemical
acid,30,I-Chemical
dehydrogenase,30,O
values,30,O
.,30,O
We,31,O
concluded,31,O
that,31,O
this,31,O
patient,31,O
had,31,O
quinidine,31,B-Chemical
hepatotoxicity,31,B-Disease
and,31,O
believe,31,O
that,31,O
this,31,O
is,31,O
the,31,O
first,31,O
case,31,O
reported,31,O
with,31,O
liver,31,O
biopsy,31,O
documentation,31,O
.,31,O
This,32,O
report,32,O
also,32,O
suggests,32,O
that,32,O
",",32,O
even,32,O
after,32,O
long-term,32,O
administration,32,O
",",32,O
the,32,O
hepatic,32,B-Disease
toxicity,32,I-Disease
is,32,O
reversible,32,O
.,32,O
Changes,33,O
in,33,O
peroxisomes,33,O
in,33,O
preneoplastic,33,O
liver,33,O
and,33,O
hepatoma,33,B-Disease
of,33,O
mice,33,O
induced,33,O
by,33,O
alpha-benzene,33,B-Chemical
hexachloride,33,I-Chemical
.,33,O
Peroxisomes,34,O
in,34,O
hepatomas,34,B-Disease
and,34,O
hyperplastic,34,O
preneoplastic,34,O
liver,34,B-Disease
lesions,34,I-Disease
induced,34,O
in,34,O
mice,34,O
by,34,O
500,34,O
ppm,34,O
alpha-benzene,34,B-Chemical
hexachloride,34,I-Chemical
were,34,O
examined,34,O
histochemically,34,O
and,34,O
electron,34,O
microscopically,34,O
.,34,O
Although,35,O
most,35,O
of,35,O
the,35,O
hepatomas,35,B-Disease
were,35,O
well-differentiated,35,O
tumors,35,B-Disease
and,35,O
contained,35,O
a,35,O
considerable,35,O
number,35,O
of,35,O
peroxisomes,35,O
",",35,O
the,35,O
tumor,35,B-Disease
cells,35,O
did,35,O
not,35,O
respond,35,O
to,35,O
ethyl-alpha-p-chlorophenoxyisobutyrate,35,B-Chemical
with,35,O
proliferation,35,O
of,35,O
peroxisomes,35,O
.,35,O
At,36,O
the,36,O
16th,36,O
week,36,O
of,36,O
carcinogen,36,O
feeding,36,O
",",36,O
hyperplastic,36,O
nodules,36,O
appeared,36,O
and,36,O
advanced,36,O
to,36,O
further,36,O
stages,36,O
.,36,O
A,37,O
majority,37,O
of,37,O
the,37,O
nodules,37,O
showed,37,O
a,37,O
considerable,37,O
number,37,O
of,37,O
peroxisomes,37,O
and,37,O
the,37,O
inductive,37,O
proliferation,37,O
of,37,O
peroxisomes,37,O
.,37,O
Within,38,O
the,38,O
nodules,38,O
",",38,O
foci,38,O
of,38,O
proliferation,38,O
of,38,O
the,38,O
cells,38,O
that,38,O
showed,38,O
no,38,O
inducibility,38,O
of,38,O
proliferation,38,O
of,38,O
peroxisomes,38,O
appeared,38,O
.,38,O
These,39,O
cells,39,O
proliferated,39,O
further,39,O
",",39,O
replacing,39,O
the,39,O
most,39,O
part,39,O
of,39,O
the,39,O
nodules,39,O
",",39,O
and,39,O
with,39,O
this,39,O
process,39,O
hepatomas,39,B-Disease
appeared,39,O
to,39,O
have,39,O
been,39,O
formed,39,O
.,39,O
No,40,O
abnormal,40,O
matrical,40,O
inclusions,40,O
of,40,O
peroxisomes,40,O
were,40,O
formed,40,O
in,40,O
the,40,O
cells,40,O
of,40,O
hyperplastic,40,O
nodules,40,O
by,40,O
ethyl-alpha-p-chlorophenoxyisobutyrate,40,B-Chemical
unlike,40,O
in,40,O
the,40,O
case,40,O
of,40,O
rats,40,O
.,40,O
Progestational,41,O
agents,41,O
and,41,O
blood,41,B-Disease
coagulation,41,I-Disease
.,41,O
VII,42,O
.,42,O
Thromboembolic,43,B-Disease
and,43,O
other,43,O
complications,43,O
of,43,O
oral,43,B-Chemical
contraceptive,43,I-Chemical
therapy,43,O
in,43,O
relationship,43,O
to,43,O
pretreatment,43,O
levels,43,O
of,43,O
blood,43,B-Disease
coagulation,43,I-Disease
factors,43,O
:,43,O
summary,43,O
report,43,O
of,43,O
a,43,O
ten-year,43,O
study,43,O
.,43,O
During,44,O
a,44,O
ten-year,44,O
period,44,O
",",44,O
348,44,O
women,44,O
were,44,O
studied,44,O
for,44,O
a,44,O
total,44,O
of,44,O
"5,877",44,O
patient,44,O
months,44,O
in,44,O
four,44,O
separate,44,O
studies,44,O
relating,44,O
oral,44,B-Chemical
contraceptives,44,I-Chemical
to,44,O
changes,44,O
in,44,O
hematologic,44,O
parameters,44,O
.,44,O
Significant,45,O
increases,45,O
in,45,O
certain,45,O
factors,45,O
of,45,O
the,45,O
blood,45,B-Disease
coagulation,45,I-Disease
and,45,O
fibrinolysin,45,O
systems,45,O
(,45,O
factors,45,O
I,45,O
",",45,O
II,45,O
",",45,O
VII,45,O
",",45,O
VIII,45,O
",",45,O
IX,45,O
",",45,O
and,45,O
X,45,O
and,45,O
plasminogen,45,O
),45,O
were,45,O
observed,45,O
in,45,O
the,45,O
treated,45,O
groups,45,O
.,45,O
Severe,46,O
complications,46,O
developed,46,O
in,46,O
four,46,O
patients,46,O
.,46,O
All,47,O
four,47,O
had,47,O
an,47,O
abnormal,47,O
blood,47,B-Disease
coagulation,47,I-Disease
profile,47,O
",",47,O
suggesting,47,O
``,47,O
hypercoagulability,47,B-Disease
'',47,O
before,47,O
initiation,47,O
of,47,O
therapy,47,O
.,47,O
Some,48,O
of,48,O
these,48,O
findings,48,O
represented,48,O
the,48,O
most,48,O
extreme,48,O
abnormalities,48,O
seen,48,O
in,48,O
the,48,O
entire,48,O
group,48,O
of,48,O
patients,48,O
;,48,O
some,48,O
increased,48,O
further,48,O
during,48,O
therapy,48,O
.,48,O
One,49,O
of,49,O
these,49,O
patients,49,O
developed,49,O
a,49,O
myocardial,49,B-Disease
infarction,49,I-Disease
before,49,O
receiving,49,O
any,49,O
medication,49,O
",",49,O
shortly,49,O
after,49,O
the,49,O
base-line,49,O
values,49,O
were,49,O
obtained,49,O
.,49,O
One,50,O
patient,50,O
developed,50,O
retinopathy,50,B-Disease
19,50,O
months,50,O
after,50,O
she,50,O
began,50,O
therapy,50,O
",",50,O
and,50,O
another,50,O
developed,50,O
thrombophlebitis,50,B-Disease
after,50,O
27,50,O
months,50,O
of,50,O
therapy,50,O
.,50,O
The,51,O
fourth,51,O
patient,51,O
developed,51,O
thrombophlebitis,51,B-Disease
14,51,O
days,51,O
after,51,O
initiation,51,O
of,51,O
contraceptive,51,O
therapy,51,O
.,51,O
All,52,O
four,52,O
patients,52,O
were,52,O
of,52,O
the,52,O
A,52,O
or,52,O
AB,52,O
blood,52,O
group,52,O
.,52,O
Previous,53,O
studies,53,O
suggested,53,O
the,53,O
possiblility,53,O
of,53,O
increased,53,O
propensity,53,O
for,53,O
thromboembolic,53,B-Disease
episodes,53,I-Disease
in,53,O
patients,53,O
possessing,53,O
the,53,O
A,53,O
antigen,53,O
.,53,O
It,54,O
appears,54,O
from,54,O
these,54,O
data,54,O
that,54,O
hematologic,54,O
work-ups,54,O
may,54,O
be,54,O
useful,54,O
in,54,O
women,54,O
who,54,O
are,54,O
about,54,O
to,54,O
start,54,O
long-term,54,O
oral,54,B-Chemical
contraceptive,54,I-Chemical
therapy,54,O
.,54,O
Etiologic,55,O
factors,55,O
in,55,O
the,55,O
pathogenesis,55,O
of,55,O
liver,55,B-Disease
tumors,55,I-Disease
associated,55,O
with,55,O
oral,55,B-Chemical
contraceptives,55,I-Chemical
.,55,O
Within,56,O
the,56,O
last,56,O
several,56,O
years,56,O
",",56,O
previously,56,O
rare,56,O
liver,56,B-Disease
tumors,56,I-Disease
have,56,O
been,56,O
seen,56,O
in,56,O
young,56,O
women,56,O
using,56,O
oral,56,B-Chemical
contraceptive,56,I-Chemical
steroids,56,B-Chemical
.,56,O
The,57,O
Registry,57,O
for,57,O
Liver,57,B-Disease
Tumors,57,I-Disease
Associated,57,O
with,57,O
Oral,57,B-Chemical
Contraceptives,57,I-Chemical
at,57,O
the,57,O
University,57,O
of,57,O
California,57,O
",",57,O
Irvine,57,O
",",57,O
has,57,O
clearly,57,O
identified,57,O
27,57,O
cases,57,O
.,57,O
The,58,O
recent,58,O
literature,58,O
contains,58,O
44,58,O
case,58,O
reports,58,O
.,58,O
Common,59,O
to,59,O
these,59,O
71,59,O
cases,59,O
has,59,O
been,59,O
a,59,O
histopathologic,59,O
diagnosis,59,O
of,59,O
focal,59,B-Disease
nodular,59,I-Disease
hyperplasia,59,I-Disease
",",59,O
adenoma,59,B-Disease
",",59,O
hamartoma,59,B-Disease
",",59,O
and,59,O
hepatoma,59,B-Disease
.,59,O
Significant,60,O
statistical,60,O
etiologic,60,O
factors,60,O
include,60,O
prolonged,60,O
uninterrupted,60,O
usage,60,O
of,60,O
oral,60,B-Chemical
contraceptive,60,I-Chemical
steroids,60,B-Chemical
.,60,O
Eight,61,O
deaths,61,O
and,61,O
liver,61,O
rupture,61,B-Disease
in,61,O
18,61,O
patients,61,O
attest,61,O
to,61,O
the,61,O
seriousness,61,O
of,61,O
this,61,O
new,61,O
potentially,61,O
lethal,61,O
adverse,61,O
phenomenon,61,O
.,61,O
Amelioration,62,O
of,62,O
bendrofluazide-induced,62,B-Chemical
hypokalemia,62,B-Disease
by,62,O
timolol,62,B-Chemical
.,62,O
The,63,O
beta,63,O
adrenergic,63,O
blocking,63,O
drug,63,O
",",63,O
timolol,63,B-Chemical
",",63,O
tended,63,O
to,63,O
correct,63,O
the,63,O
hypokalemia,63,B-Disease
of,63,O
short-term,63,O
bendrofluazide,63,B-Chemical
treatment,63,O
in,63,O
6,63,O
healthy,63,O
male,63,O
subjects,63,O
and,63,O
although,63,O
the,63,O
effect,63,O
was,63,O
small,63,O
it,63,O
was,63,O
significant,63,O
.,63,O
Timolol,64,B-Chemical
also,64,O
reduced,64,O
the,64,O
rise,64,O
in,64,O
plasma,64,O
aldosterone,64,B-Chemical
and,64,O
urine,64,O
potassium,64,B-Chemical
excretion,64,O
following,64,O
bendrofluazide,64,B-Chemical
and,64,O
increased,64,O
the,64,O
urine,64,O
sodium/potassium,64,B-Chemical
ratio,64,O
.,64,O
There,65,O
was,65,O
no,65,O
evidence,65,O
of,65,O
a,65,O
shift,65,O
of,65,O
potassium,65,B-Chemical
from,65,O
the,65,O
intracellular,65,O
to,65,O
the,65,O
extracellular,65,O
space,65,O
.,65,O
Type,66,B-Disease
B,66,I-Disease
hepatitis,66,I-Disease
after,66,O
needle-stick,66,O
exposure,66,O
:,66,O
prevention,66,O
with,66,O
hepatitis,66,B-Disease
B,66,I-Disease
immune,66,O
globulin,66,O
.,66,O
Final,67,O
report,67,O
of,67,O
the,67,O
Veterans,67,O
Administration,67,O
Cooperative,67,O
Study,67,O
.,67,O
Hepatitis,68,B-Disease
B,68,I-Disease
immune,68,O
globulin,68,O
(,68,O
HBIG,68,O
),68,O
and,68,O
immune,68,O
serum,68,O
globulin,68,O
(,68,O
ISG,68,O
),68,O
were,68,O
examined,68,O
in,68,O
a,68,O
randomized,68,O
",",68,O
double-blind,68,O
trial,68,O
to,68,O
assess,68,O
their,68,O
relative,68,O
efficacies,68,O
in,68,O
preventing,68,O
type,68,B-Disease
B,68,I-Disease
hepatitis,68,I-Disease
after,68,O
needle-stick,68,O
exposure,68,O
to,68,O
hepatitis,68,B-Chemical
B,68,I-Chemical
surface,68,I-Chemical
antigen,68,I-Chemical
(,68,O
HBsAG,68,B-Chemical
),68,O
-positive,68,O
donors,68,O
.,68,O
Clinical,69,O
hepatitis,69,B-Disease
developed,69,O
in,69,O
1.4,69,O
%,69,O
of,69,O
HBIG,69,O
and,69,O
in,69,O
5.9,69,O
%,69,O
of,69,O
ISG,69,O
recipients,69,O
(,69,O
P,69,O
=,69,O
0.016,69,O
),69,O
",",69,O
and,69,O
seroconversion,69,O
(,69,O
anti-HBs,69,O
),69,O
occurred,69,O
in,69,O
5.6,69,O
%,69,O
and,69,O
20.7,69,O
%,69,O
of,69,O
them,69,O
respectively,69,O
(,69,O
P,69,O
less,69,O
than,69,O
0.001,69,O
),69,O
.,69,O
Mild,70,O
and,70,O
transient,70,O
side-effects,70,O
were,70,O
noted,70,O
in,70,O
3.0,70,O
%,70,O
of,70,O
ISG,70,O
and,70,O
in,70,O
3.2,70,O
%,70,O
of,70,O
HBIG,70,O
recipients,70,O
.,70,O
Available,71,O
donor,71,O
sera,71,O
were,71,O
examined,71,O
for,71,O
DNA,71,O
polymerase,71,O
(,71,O
DNAP,71,O
),71,O
and,71,O
e,71,O
antigen,71,O
and,71,O
antibody,71,O
(,71,O
HBeAg,71,B-Chemical
;,71,O
anti-HBE,71,O
),71,O
.,71,O
Both,72,O
DNAP,72,O
and,72,O
HBeAg,72,B-Chemical
showed,72,O
a,72,O
highly,72,O
statistically,72,O
significant,72,O
correlation,72,O
with,72,O
the,72,O
infectivity,72,O
of,72,O
HBsAg-positive,72,B-Chemical
donors,72,O
.,72,O
Hepatitis,73,B-Disease
B,73,I-Disease
immune,73,O
globulin,73,O
remained,73,O
significantly,73,O
superior,73,O
to,73,O
ISG,73,O
in,73,O
preventing,73,O
type,73,B-Disease
B,73,I-Disease
hepatitis,73,I-Disease
even,73,O
when,73,O
the,73,O
analysis,73,O
was,73,O
confined,73,O
to,73,O
these,73,O
two,73,O
high-risk,73,O
subgroups,73,O
.,73,O
The,74,O
efficacy,74,O
of,74,O
ISG,74,O
in,74,O
preventing,74,O
type,74,B-Disease
B,74,I-Disease
hepatitis,74,I-Disease
can,74,O
not,74,O
be,74,O
ascertained,74,O
because,74,O
a,74,O
true,74,O
placebo,74,O
group,74,O
was,74,O
not,74,O
included,74,O
.,74,O
Bilateral,75,B-Disease
optic,75,I-Disease
neuropathy,75,I-Disease
due,75,O
to,75,O
combined,75,O
ethambutol,75,B-Chemical
and,75,O
isoniazid,75,B-Chemical
treatment,75,O
.,75,O
The,76,O
case,76,O
of,76,O
a,76,O
40-year-old,76,O
patient,76,O
who,76,O
underwent,76,O
an,76,O
unsuccessful,76,O
cadaver,76,O
kidney,76,O
transplantation,76,O
and,76,O
was,76,O
treated,76,O
with,76,O
ethambutol,76,B-Chemical
and,76,O
isoniazid,76,B-Chemical
is,76,O
reported,76,O
.,76,O
A,77,O
bilateral,77,B-Disease
retrobulbar,77,I-Disease
neuropathy,77,I-Disease
with,77,O
an,77,O
unusual,77,O
central,77,O
bitemporal,77,O
hemianopic,77,O
scotoma,77,B-Disease
was,77,O
found,77,O
.,77,O
Ethambutol,78,B-Chemical
was,78,O
stopped,78,O
and,78,O
only,78,O
small,78,O
improvement,78,O
of,78,O
the,78,O
visual,78,O
acuity,78,O
followed,78,O
.,78,O
Isoniazid,79,B-Chemical
was,79,O
discontinued,79,O
later,79,O
",",79,O
followed,79,O
by,79,O
a,79,O
dramatic,79,O
improvement,79,O
in,79,O
the,79,O
visual,79,O
acuity,79,O
.,79,O
The,80,O
hazards,80,O
of,80,O
optic,80,O
nerve,80,O
toxicity,80,B-Disease
due,80,O
to,80,O
ethambutol,80,B-Chemical
are,80,O
known,80,O
.,80,O
We,81,O
emphasize,81,O
the,81,O
potential,81,O
danger,81,O
in,81,O
the,81,O
use,81,O
of,81,O
ethambutol,81,B-Chemical
and,81,O
isoniazid,81,B-Chemical
.,81,O
Transient,82,O
hemiparesis,82,B-Disease
:,82,O
a,82,O
rare,82,O
manifestation,82,O
of,82,O
diphenylhydantoin,82,B-Chemical
toxicity,82,B-Disease
.,82,O
Report,83,O
of,83,O
two,83,O
cases,83,O
.,83,O
Among,84,O
the,84,O
common,84,O
side,84,O
effects,84,O
of,84,O
diphenylhydantoin,84,B-Chemical
(,84,O
DPH,84,B-Chemical
),84,O
overdose,84,B-Disease
",",84,O
the,84,O
most,84,O
frequently,84,O
encountered,84,O
neurological,84,O
signs,84,O
are,84,O
those,84,O
of,84,O
cerebellar,84,B-Disease
dysfunction,84,I-Disease
.,84,O
Very,85,O
rarely,85,O
",",85,O
the,85,O
toxic,85,O
neurological,85,O
manifestations,85,O
of,85,O
this,85,O
drug,85,O
are,85,O
of,85,O
cerebral,85,O
origin,85,O
.,85,O
Two,86,O
patients,86,O
are,86,O
presented,86,O
who,86,O
suffered,86,O
progressive,86,O
hemiparesis,86,B-Disease
due,86,O
to,86,O
DPH,86,B-Chemical
overdose,86,B-Disease
.,86,O
Both,87,O
had,87,O
brain,87,O
surgery,87,O
before,87,O
DPH,87,B-Chemical
treatment,87,O
.,87,O
It,88,O
is,88,O
assumed,88,O
that,88,O
patients,88,O
with,88,O
some,88,O
cerebral,88,B-Disease
damage,88,I-Disease
are,88,O
liable,88,O
to,88,O
manifest,88,O
DPH,88,B-Chemical
toxicity,88,B-Disease
as,88,O
focal,88,O
neurological,88,O
signs,88,O
.,88,O
Tiapride,89,B-Chemical
in,89,O
levodopa-induced,89,B-Chemical
involuntary,89,B-Disease
movements,89,I-Disease
.,89,O
Tiapride,90,B-Chemical
",",90,O
a,90,O
substituted,90,O
benzamide,90,B-Chemical
derivative,90,O
closely,90,O
related,90,O
to,90,O
metoclopramide,90,B-Chemical
",",90,O
reduced,90,O
levodopa-induced,90,B-Chemical
peak,90,O
dose,90,O
involuntary,90,B-Disease
movements,90,I-Disease
in,90,O
16,90,O
patients,90,O
with,90,O
idiopathic,90,B-Disease
Parkinson,90,I-Disease
's,90,I-Disease
disease,90,I-Disease
.,90,O
However,91,O
",",91,O
an,91,O
unacceptable,91,O
increase,91,O
in,91,O
disability,91,O
from,91,O
Parkinsonism,91,B-Disease
with,91,O
aggravation,91,O
of,91,O
end-of-dose,91,O
akinesia,91,B-Disease
led,91,O
to,91,O
its,91,O
cessation,91,O
in,91,O
14,91,O
patients,91,O
.,91,O
Tiapride,92,B-Chemical
had,92,O
no,92,O
effect,92,O
on,92,O
levodopa-induced,92,B-Chemical
early,92,O
morning,92,O
of,92,O
``,92,O
off-period,92,O
'',92,O
segmental,92,O
dystonia,92,B-Disease
.,92,O
These,93,O
results,93,O
fail,93,O
to,93,O
support,93,O
the,93,O
notion,93,O
that,93,O
levodopa-induced,93,B-Chemical
dyskinesias,93,B-Disease
are,93,O
caused,93,O
by,93,O
overstimulation,93,O
of,93,O
a,93,O
separate,93,O
group,93,O
of,93,O
dopamine,93,B-Chemical
receptors,93,O
.,93,O
Arterial,94,O
thromboembolism,94,B-Disease
in,94,O
patients,94,O
receiving,94,O
systemic,94,O
heparin,94,B-Chemical
therapy,94,O
:,94,O
a,94,O
complication,94,O
associated,94,O
with,94,O
heparin-induced,94,B-Chemical
thrombocytopenia,94,B-Disease
.,94,O
Arterial,95,O
thromboembolism,95,B-Disease
is,95,O
a,95,O
recognized,95,O
complication,95,O
of,95,O
systemic,95,O
heparin,95,B-Chemical
therapy,95,O
.,95,O
Characteristic,96,O
of,96,O
the,96,O
entity,96,O
is,96,O
arterial,96,B-Disease
occlusion,96,I-Disease
by,96,O
platelet-fibrin,96,O
thrombi,96,B-Disease
with,96,O
distal,96,O
ischemia,96,B-Disease
occurring,96,O
four,96,O
to,96,O
twenty,96,O
days,96,O
after,96,O
the,96,O
initiation,96,O
of,96,O
heparin,96,B-Chemical
therapy,96,O
",",96,O
preceded,96,O
by,96,O
profound,96,O
thrombocytopenia,96,B-Disease
with,96,O
platelet,96,O
counts,96,O
in,96,O
the,96,O
range,96,O
of,96,O
"30,000",96,O
to,96,O
"40,000",96,O
per,96,O
cubic,96,O
millimeter,96,O
.,96,O
The,97,O
clinically,97,O
apparent,97,O
occlusion,97,O
may,97,O
be,97,O
preceded,97,O
by,97,O
gastrointestinal,97,O
and,97,O
musculoskeletal,97,O
symptoms,97,O
that,97,O
appear,97,O
to,97,O
be,97,O
ischemic,97,B-Disease
in,97,O
origin,97,O
",",97,O
and,97,O
might,97,O
serve,97,O
to,97,O
warn,97,O
the,97,O
clinician,97,O
of,97,O
these,97,O
complications,97,O
.,97,O
Previous,98,O
reports,98,O
of,98,O
these,98,O
phenomena,98,O
as,98,O
well,98,O
as,98,O
recent,98,O
studies,98,O
of,98,O
the,98,O
effect,98,O
of,98,O
heparin,98,B-Chemical
are,98,O
reviewed,98,O
.,98,O
The,99,O
common,99,O
factor,99,O
relating,99,O
thromboembolism,99,B-Disease
and,99,O
thrombocytopenia,99,B-Disease
is,99,O
heparin-induced,99,B-Chemical
platelet,99,B-Disease
aggregation,99,I-Disease
.,99,O
Appropriate,100,O
treatment,100,O
consists,100,O
of,100,O
discontinuation,100,O
of,100,O
heparin,100,B-Chemical
",",100,O
and,100,O
anticoagulation,100,O
with,100,O
sodium,100,B-Chemical
warfarin,100,I-Chemical
if,100,O
necessary,100,O
.,100,O
Vascular,101,O
procedures,101,O
are,101,O
performed,101,O
as,101,O
indicated,101,O
.,101,O
Obsolete,102,O
but,102,O
dangerous,102,O
antacid,102,O
preparations,102,O
.,102,O
One,103,O
case,103,O
of,103,O
acute,103,O
hypercalcaemia,103,B-Disease
and,103,O
two,103,O
of,103,O
recurrent,103,O
nephrolithiasis,103,B-Disease
are,103,O
reported,103,O
in,103,O
patients,103,O
who,103,O
had,103,O
regularly,103,O
consumed,103,O
large,103,O
amounts,103,O
of,103,O
calcium,103,B-Chemical
carbon-ate-sodium,103,O
bicarbonate,103,I-Chemical
powders,103,O
for,103,O
more,103,O
than,103,O
20,103,O
years,103,O
.,103,O
The,104,O
powders,104,O
had,104,O
been,104,O
obtained,104,O
from,104,O
pharmacists,104,O
unknown,104,O
to,104,O
the,104,O
patients,104,O
',104,O
medical,104,O
practitioners,104,O
.,104,O
It,105,O
is,105,O
suggested,105,O
that,105,O
these,105,O
preparations,105,O
were,105,O
responsible,105,O
for,105,O
the,105,O
patient,105,O
's,105,O
problems,105,O
",",105,O
and,105,O
that,105,O
such,105,O
powders,105,O
should,105,O
no,105,O
longer,105,O
be,105,O
freely,105,O
obtainable,105,O
.,105,O
Ventricular,106,B-Disease
fibrillation,106,I-Disease
from,106,O
diatrizoate,106,B-Chemical
with,106,O
and,106,O
without,106,O
chelating,106,O
agents,106,O
.,106,O
The,107,O
toxicity,107,B-Disease
of,107,O
Renografin,107,B-Chemical
76,107,I-Chemical
%,107,I-Chemical
was,107,O
compared,107,O
with,107,O
that,107,O
of,107,O
Hypaque,107,B-Chemical
76,107,I-Chemical
%,107,I-Chemical
by,107,O
selective,107,O
injection,107,O
of,107,O
each,107,O
into,107,O
the,107,O
right,107,O
coronary,107,O
artery,107,O
of,107,O
dogs,107,O
.,107,O
Renografin,108,B-Chemical
contains,108,O
the,108,O
chelating,108,O
agents,108,O
sodium,108,B-Chemical
citrate,108,I-Chemical
and,108,O
disodium,108,B-Chemical
edetate,108,I-Chemical
",",108,O
while,108,O
Hypaque,108,B-Chemical
contains,108,O
calcium,108,B-Chemical
disodium,108,I-Chemical
edetate,108,I-Chemical
and,108,O
no,108,O
sodium,108,B-Chemical
citrate,108,I-Chemical
.,108,O
Ventricular,109,B-Disease
fibrillation,109,I-Disease
occurred,109,O
significantly,109,O
more,109,O
often,109,O
with,109,O
Renografin,109,B-Chemical
",",109,O
suggesting,109,O
that,109,O
chelating,109,O
agents,109,O
contribute,109,O
to,109,O
toxicity,109,B-Disease
in,109,O
coronary,109,O
angiography,109,O
.,109,O
Reversal,110,O
of,110,O
ammonia,110,B-Chemical
coma,110,B-Disease
in,110,O
rats,110,O
by,110,O
L-dopa,110,B-Chemical
:,110,O
a,110,O
peripheral,110,O
effect,110,O
.,110,O
Ammonia,111,B-Chemical
coma,111,B-Disease
was,111,O
produced,111,O
in,111,O
rats,111,O
within,111,O
10,111,O
to,111,O
15,111,O
minutes,111,O
of,111,O
an,111,O
intraperitonealinjection,111,O
of,111,O
1.7,111,O
mmol,111,O
NH4CL,111,B-Chemical
.,111,O
This,112,O
coma,112,B-Disease
was,112,O
prevented,112,O
with,112,O
1.68,112,O
mmol,112,O
L-dopa,112,B-Chemical
given,112,O
by,112,O
gastric,112,O
intubation,112,O
15,112,O
minutes,112,O
before,112,O
the,112,O
ammonium,112,B-Chemical
salt,112,I-Chemical
injection,112,O
.,112,O
The,113,O
effect,113,O
of,113,O
L-dopa,113,B-Chemical
was,113,O
correlated,113,O
with,113,O
a,113,O
decrease,113,O
in,113,O
blood,113,O
and,113,O
brain,113,O
ammonia,113,B-Chemical
",",113,O
an,113,O
increase,113,O
in,113,O
brain,113,O
dopamine,113,B-Chemical
",",113,O
and,113,O
an,113,O
increase,113,O
in,113,O
renal,113,O
excretion,113,O
of,113,O
ammonia,113,B-Chemical
and,113,O
urea,113,B-Chemical
.,113,O
Intraventricular,114,O
infusion,114,O
of,114,O
dopamine,114,B-Chemical
sufficient,114,O
to,114,O
raise,114,O
the,114,O
brain,114,O
dopamine,114,B-Chemical
to,114,O
the,114,O
same,114,O
extent,114,O
did,114,O
not,114,O
prevent,114,O
the,114,O
ammonia,114,B-Chemical
coma,114,B-Disease
nor,114,O
affect,114,O
the,114,O
blood,114,O
and,114,O
brain,114,O
ammonia,114,B-Chemical
concentrations,114,O
.,114,O
Bilateral,115,O
nephrectomy,115,O
eliminated,115,O
the,115,O
beneficial,115,O
effect,115,O
of,115,O
L-dopa,115,B-Chemical
on,115,O
blood,115,O
and,115,O
brain,115,O
ammonia,115,B-Chemical
and,115,O
the,115,O
ammonia,115,B-Chemical
coma,115,B-Disease
was,115,O
not,115,O
prevented,115,O
.,115,O
Thus,116,O
",",116,O
the,116,O
reduction,116,O
in,116,O
blood,116,O
and,116,O
brain,116,O
ammonia,116,B-Chemical
and,116,O
the,116,O
prevention,116,O
of,116,O
ammonia,116,B-Chemical
coma,116,B-Disease
after,116,O
L-dopa,116,B-Chemical
",",116,O
can,116,O
be,116,O
accounted,116,O
for,116,O
by,116,O
the,116,O
peripheral,116,O
effect,116,O
of,116,O
dopamine,116,B-Chemical
on,116,O
renal,116,O
function,116,O
rather,116,O
than,116,O
its,116,O
central,116,O
action,116,O
.,116,O
These,117,O
results,117,O
provide,117,O
a,117,O
reasonable,117,O
explanation,117,O
for,117,O
the,117,O
beneficial,117,O
effects,117,O
observed,117,O
in,117,O
some,117,O
encephalopathic,117,B-Disease
patients,117,O
receiving,117,O
L-dopa,117,B-Chemical
.,117,O
Effects,118,O
of,118,O
ouabain,118,B-Chemical
on,118,O
myocardial,118,O
oxygen,118,B-Chemical
supply,118,O
and,118,O
demand,118,O
in,118,O
patients,118,O
with,118,O
chronic,118,O
coronary,118,B-Disease
artery,118,I-Disease
disease,118,I-Disease
.,118,O
A,119,O
hemodynamic,119,O
",",119,O
volumetric,119,O
",",119,O
and,119,O
metabolic,119,O
study,119,O
in,119,O
patients,119,O
without,119,O
heart,119,B-Disease
failure,119,I-Disease
.,119,O
The,120,O
effects,120,O
of,120,O
digitalis,120,B-Chemical
glycosides,120,I-Chemical
on,120,O
myocardial,120,O
oxygen,120,B-Chemical
supply,120,O
and,120,O
demand,120,O
are,120,O
of,120,O
particular,120,O
interest,120,O
in,120,O
the,120,O
presence,120,O
of,120,O
obstructive,120,O
coronary,120,B-Disease
artery,120,I-Disease
disease,120,I-Disease
",",120,O
but,120,O
have,120,O
not,120,O
been,120,O
measured,120,O
previously,120,O
in,120,O
man,120,O
.,120,O
We,121,O
assessed,121,O
the,121,O
effects,121,O
of,121,O
ouabain,121,B-Chemical
(,121,O
0.015,121,O
mg/kg,121,O
body,121,O
weight,121,O
),121,O
on,121,O
hemodynamic,121,O
",",121,O
volumetric,121,O
",",121,O
and,121,O
metabolic,121,O
parameters,121,O
in,121,O
11,121,O
patients,121,O
with,121,O
severe,121,O
chronic,121,O
coronary,121,B-Disease
artery,121,I-Disease
disease,121,I-Disease
without,121,O
clinical,121,O
congestive,121,B-Disease
heart,121,I-Disease
failure,121,I-Disease
.,121,O
Because,122,O
the,122,O
protocol,122,O
was,122,O
long,122,O
and,122,O
involved,122,O
interventions,122,O
which,122,O
might,122,O
affect,122,O
the,122,O
determinations,122,O
",",122,O
we,122,O
also,122,O
studied,122,O
in,122,O
nine,122,O
patients,122,O
using,122,O
an,122,O
identical,122,O
protocol,122,O
except,122,O
that,122,O
ouabain,122,B-Chemical
administration,122,O
was,122,O
omitted,122,O
.,122,O
Left,123,O
ventricular,123,O
end-diastolic,123,O
pressure,123,O
and,123,O
left,123,O
ventricular,123,O
end-diastolic,123,O
volume,123,O
fell,123,O
in,123,O
each,123,O
patient,123,O
given,123,O
ouabain,123,B-Chemical
",",123,O
even,123,O
though,123,O
they,123,O
were,123,O
initially,123,O
elevated,123,O
in,123,O
only,123,O
two,123,O
patients,123,O
.,123,O
Left,124,O
ventricular,124,O
end-diastolic,124,O
pressure,124,O
fell,124,O
from,124,O
11.5+/-1.4,124,O
(,124,O
mean+/-SE,124,O
),124,O
to,124,O
5.6+/-0.9,124,O
mm,124,O
Hg,124,O
(,124,O
P,124,O
less,124,O
than,124,O
0.001,124,O
),124,O
and,124,O
left,124,O
ventricular,124,O
end-diastolic,124,O
volume,124,O
fell,124,O
from,124,O
100+/-17,124,O
to,124,O
82+/-12,124,O
ml/m2,124,O
(,124,O
P,124,O
less,124,O
than,124,O
0.01,124,O
),124,O
1,124,O
h,124,O
after,124,O
ouabain,124,B-Chemical
infusion,124,O
was,124,O
completed,124,O
.,124,O
The,125,O
maximum,125,O
velocity,125,O
of,125,O
contractile,125,O
element,125,O
shortening,125,O
increased,125,O
from,125,O
1.68+/-0.11,125,O
ml/s,125,O
to,125,O
2.18+/-0.21,125,O
muscle-lengths/s,125,O
(,125,O
P,125,O
less,125,O
than,125,O
0.05,125,O
),125,O
and,125,O
is,125,O
consistent,125,O
with,125,O
an,125,O
increase,125,O
in,125,O
contractility,125,O
.,125,O
No,126,O
significant,126,O
change,126,O
in,126,O
these,126,O
parameters,126,O
occurred,126,O
in,126,O
the,126,O
control,126,O
patients,126,O
.,126,O
No,127,O
significant,127,O
change,127,O
in,127,O
myocardial,127,O
oxygen,127,B-Chemical
consumption,127,O
occurred,127,O
after,127,O
ouabain,127,B-Chemical
administration,127,O
but,127,O
this,127,O
may,127,O
be,127,O
related,127,O
to,127,O
a,127,O
greater,127,O
decrease,127,O
in,127,O
mean,127,O
arterial,127,O
pressure,127,O
in,127,O
the,127,O
ouabain,127,B-Chemical
patients,127,O
than,127,O
in,127,O
the,127,O
control,127,O
patients,127,O
.,127,O
We,128,O
conclude,128,O
that,128,O
in,128,O
patients,128,O
with,128,O
chronic,128,O
coronary,128,B-Disease
artery,128,I-Disease
disease,128,I-Disease
who,128,O
are,128,O
not,128,O
in,128,O
clinical,128,O
congestive,128,B-Disease
heart,128,I-Disease
failure,128,I-Disease
left,128,B-Disease
ventricular,128,I-Disease
end-diastolic,128,I-Disease
volume,128,I-Disease
falls,128,I-Disease
after,128,O
ouabain,128,B-Chemical
administration,128,O
even,128,O
when,128,O
it,128,O
is,128,O
initially,128,O
normal,128,O
.,128,O
Though,129,O
this,129,O
fall,129,O
would,129,O
be,129,O
associated,129,O
with,129,O
a,129,O
decrease,129,O
in,129,O
wall,129,O
tension,129,O
",",129,O
and,129,O
",",129,O
therefore,129,O
",",129,O
of,129,O
myocardial,129,O
oxygen,129,B-Chemical
consumption,129,O
",",129,O
it,129,O
may,129,O
not,129,O
be,129,O
of,129,O
sufficient,129,O
magnitude,129,O
to,129,O
prevent,129,O
a,129,O
net,129,O
increase,129,O
in,129,O
myocardial,129,O
oxygen,129,B-Chemical
consumption,129,O
.,129,O
Nevertheless,130,O
",",130,O
compensatory,130,O
mechanisms,130,O
prevent,130,O
a,130,O
deterioration,130,O
of,130,O
resting,130,O
myocardial,130,O
metabolism,130,O
.,130,O
Water,131,B-Disease
intoxication,131,I-Disease
associated,131,O
with,131,O
oxytocin,131,B-Chemical
administration,131,O
during,131,O
saline-induced,131,O
abortion,131,B-Disease
.,131,O
Four,132,O
cases,132,O
of,132,O
water,132,B-Disease
intoxication,132,I-Disease
in,132,O
connection,132,O
with,132,O
oxytocin,132,B-Chemical
administration,132,O
during,132,O
saline-induced,132,O
abortions,132,B-Disease
are,132,O
described,132,O
.,132,O
The,133,O
mechanism,133,O
of,133,O
water,133,B-Disease
intoxication,133,I-Disease
is,133,O
discussed,133,O
in,133,O
regard,133,O
to,133,O
these,133,O
cases,133,O
.,133,O
Oxytocin,134,B-Chemical
administration,134,O
during,134,O
midtrimester-induced,134,O
abortions,134,B-Disease
is,134,O
advocated,134,O
only,134,O
if,134,O
it,134,O
can,134,O
be,134,O
carried,134,O
out,134,O
under,134,O
careful,134,O
observations,134,O
of,134,O
an,134,O
alert,134,O
nursing,134,O
staff,134,O
",",134,O
aware,134,O
of,134,O
the,134,O
symptoms,134,O
of,134,O
water,134,B-Disease
intoxication,134,I-Disease
and,134,O
instructed,134,O
to,134,O
watch,134,O
the,134,O
diuresis,134,O
and,134,O
report,134,O
such,134,O
early,134,O
signs,134,O
of,134,O
the,134,O
syndrome,134,O
as,134,O
asthenia,134,B-Disease
",",134,O
muscular,134,O
irritability,134,B-Disease
",",134,O
or,134,O
headaches,134,B-Disease
.,134,O
The,135,O
oxytocin,135,B-Chemical
should,135,O
be,135,O
given,135,O
only,135,O
in,135,O
Ringers,135,O
lactate,135,B-Chemical
or,135,O
",",135,O
alternately,135,O
",",135,O
in,135,O
Ringers,135,O
lactate,135,B-Chemical
and,135,O
a,135,O
5,135,O
per,135,O
cent,135,O
dextrose,135,B-Chemical
and,135,O
water,135,O
solutions,135,O
.,135,O
The,136,O
urinary,136,O
output,136,O
should,136,O
be,136,O
monitored,136,O
and,136,O
the,136,O
oxytocin,136,B-Chemical
administration,136,O
discontinued,136,O
and,136,O
the,136,O
serum,136,O
electrolytes,136,O
checked,136,O
if,136,O
the,136,O
urinary,136,O
output,136,O
decreases,136,O
.,136,O
The,137,O
oxytocin,137,B-Chemical
should,137,O
not,137,O
be,137,O
administered,137,O
in,137,O
excess,137,O
of,137,O
36,137,O
hours,137,O
.,137,O
If,138,O
the,138,O
patient,138,O
has,138,O
not,138,O
aborted,138,O
by,138,O
then,138,O
the,138,O
oxytocin,138,B-Chemical
should,138,O
be,138,O
discontinued,138,O
for,138,O
10,138,O
to,138,O
12,138,O
hours,138,O
in,138,O
order,138,O
to,138,O
perform,138,O
electrolyte,138,O
determinations,138,O
and,138,O
correct,138,O
any,138,O
electrolyte,138,O
imbalance,138,O
.,138,O
Light,139,O
chain,139,O
proteinuria,139,B-Disease
and,139,O
cellular,139,O
mediated,139,O
immunity,139,O
in,139,O
rifampin,139,B-Chemical
treated,139,O
patients,139,O
with,139,O
tuberculosis,139,B-Disease
.,139,O
Light,140,O
chain,140,O
proteinuria,140,B-Disease
was,140,O
found,140,O
in,140,O
9,140,O
of,140,O
17,140,O
tuberculosis,140,B-Disease
patients,140,O
treated,140,O
with,140,O
rifampin,140,B-Chemical
.,140,O
Concomitant,141,O
assay,141,O
of,141,O
cellular,141,O
mediated,141,O
immunity,141,O
in,141,O
these,141,O
patients,141,O
using,141,O
skin,141,O
test,141,O
antigen,141,O
and,141,O
a,141,O
lymphokine,141,O
in,141,O
vitro,141,O
test,141,O
provided,141,O
results,141,O
that,141,O
were,141,O
different,141,O
.,141,O
Response,142,O
to,142,O
Varidase,142,O
skin,142,O
test,142,O
antigen,142,O
was,142,O
negative,142,O
for,142,O
all,142,O
eight,142,O
tuberculosis,142,B-Disease
patients,142,O
tested,142,O
",",142,O
but,142,O
there,142,O
occurred,142,O
a,142,O
hyper-responsiveness,142,O
of,142,O
the,142,O
lymphocytes,142,O
of,142,O
these,142,O
eight,142,O
patients,142,O
to,142,O
phytomitogen,142,O
(,142,O
PHA-P,142,O
),142,O
.,142,O
as,143,O
well,143,O
as,143,O
of,143,O
those,143,O
of,143,O
seven,143,O
other,143,O
tuberculous,143,B-Disease
patients,143,O
.,143,O
This,144,O
last,144,O
finding,144,O
may,144,O
be,144,O
related,144,O
to,144,O
time,144,O
of,144,O
testing,144,O
and/or,144,O
endogenous,144,O
serum,144,O
binding,144,O
of,144,O
rifampin,144,B-Chemical
which,144,O
could,144,O
have,144,O
inhibited,144,O
mitogen,144,O
activity,144,O
for,144,O
the,144,O
lymphocyte,144,O
.,144,O
Hepatic,145,O
adenomas,145,B-Disease
and,145,O
focal,145,B-Disease
nodular,145,I-Disease
hyperplasia,145,I-Disease
of,145,O
the,145,O
liver,145,O
in,145,O
young,145,O
women,145,O
on,145,O
oral,145,B-Chemical
contraceptives,145,I-Chemical
:,145,O
case,145,O
reports,145,O
.,145,O
Two,146,O
cases,146,O
of,146,O
hepatic,146,O
adenoma,146,B-Disease
and,146,O
one,146,O
of,146,O
focal,146,B-Disease
nodular,146,I-Disease
hyperplasia,146,I-Disease
presumably,146,O
associated,146,O
with,146,O
the,146,O
use,146,O
of,146,O
oral,146,B-Chemical
contraceptives,146,I-Chemical
",",146,O
are,146,O
reported,146,O
.,146,O
Special,147,O
reference,147,O
is,147,O
made,147,O
to,147,O
their,147,O
clinical,147,O
presentation,147,O
",",147,O
which,147,O
may,147,O
be,147,O
totally,147,O
asymptomatic,147,O
.,147,O
Liver-function,148,O
tests,148,O
are,148,O
of,148,O
little,148,O
diagnostic,148,O
value,148,O
",",148,O
but,148,O
valuable,148,O
information,148,O
may,148,O
be,148,O
obtained,148,O
from,148,O
both,148,O
liver,148,O
scanning,148,O
and,148,O
hepatic,148,O
angiography,148,O
.,148,O
Histologic,149,O
differences,149,O
and,149,O
clinical,149,O
similarities,149,O
between,149,O
hepatic,149,O
adenoma,149,B-Disease
and,149,O
focal,149,B-Disease
nodular,149,I-Disease
hyperplasia,149,I-Disease
of,149,O
the,149,O
liver,149,O
are,149,O
discussed,149,O
.,149,O
The,150,O
use,150,O
of,150,O
serum,150,O
cholinesterase,150,O
in,150,O
succinylcholine,150,B-Chemical
apnoea,150,B-Disease
.,150,O
Fifteen,151,O
patients,151,O
demonstrating,151,O
unexpected,151,O
prolonged,151,O
apnoea,151,B-Disease
lasting,151,O
several,151,O
hours,151,O
after,151,O
succinylcholine,151,B-Chemical
have,151,O
been,151,O
treated,151,O
by,151,O
a,151,O
new,151,O
preparation,151,O
of,151,O
human,151,O
serum,151,O
cholinesterase,151,O
.,151,O
Adequate,152,O
spontaneous,152,O
respiration,152,O
was,152,O
re-established,152,O
in,152,O
an,152,O
average,152,O
period,152,O
of,152,O
ten,152,O
minutes,152,O
after,152,O
the,152,O
injection,152,O
.,152,O
In,153,O
12,153,O
patients,153,O
biochemical,153,O
genetic,153,O
examinations,153,O
confirmed,153,O
the,153,O
presence,153,O
of,153,O
an,153,O
atypical,153,O
serum,153,O
cholinesterase,153,O
.,153,O
In,154,O
three,154,O
patients,154,O
none,154,O
of,154,O
the,154,O
usual,154,O
variants,154,O
were,154,O
found,154,O
.,154,O
It,155,O
is,155,O
therefore,155,O
supposed,155,O
that,155,O
other,155,O
unknown,155,O
variants,155,O
of,155,O
serum,155,O
cholinesterase,155,O
exist,155,O
which,155,O
can,155,O
not,155,O
hydrolyze,155,O
succinylcholine,155,B-Chemical
.,155,O
The,156,O
use,156,O
of,156,O
serum,156,O
cholinesterase,156,O
in,156,O
succinylcholine,156,B-Chemical
apnoea,156,B-Disease
provided,156,O
considerable,156,O
relief,156,O
to,156,O
both,156,O
patient,156,O
and,156,O
anaesthetist,156,O
.,156,O
Increased,157,O
sulfation,157,O
and,157,O
decreased,157,O
7alpha-hydroxylation,157,O
of,157,O
deoxycholic,157,B-Chemical
acid,157,I-Chemical
in,157,O
ethinyl,157,B-Chemical
estradiol-induced,157,O
cholestasis,157,B-Disease
in,157,O
rats,157,O
.,157,O
Deoxycholic,158,B-Chemical
acid,158,I-Chemical
conjugation,158,O
",",158,O
transport,158,O
capacity,158,O
",",158,O
and,158,O
metabolism,158,O
were,158,O
compared,158,O
in,158,O
control,158,O
and,158,O
ethinyl,158,B-Chemical
estradiol-treated,158,O
rats,158,O
.,158,O
Control,159,O
rats,159,O
were,159,O
found,159,O
to,159,O
have,159,O
a,159,O
lower,159,O
capacity,159,O
to,159,O
transport,159,O
deoxycholic,159,B-Chemical
acid,159,I-Chemical
than,159,O
taurodeoxycholic,159,B-Chemical
acid,159,I-Chemical
",",159,O
and,159,O
both,159,O
were,159,O
decreased,159,O
by,159,O
ethinyl,159,B-Chemical
estradiol,159,I-Chemical
treatment,159,O
.,159,O
During,160,O
[,160,O
24-14C,160,O
],160,O
sodium,160,B-Chemical
deoxycholate,160,I-Chemical
infusion,160,O
",",160,O
[,160,O
14C,160,O
],160,O
biliary,160,O
bile,160,B-Chemical
acid,160,I-Chemical
secretion,160,O
increased,160,O
",",160,O
but,160,O
bile,160,O
flow,160,O
did,160,O
not,160,O
change,160,O
significantly,160,O
in,160,O
either,160,O
control,160,O
or,160,O
ethinyl,160,B-Chemical
estradiol-treated,160,O
rats,160,O
.,160,O
Ethinyl,161,B-Chemical
estradiol-treated,161,O
animals,161,O
excreted,161,O
significantly,161,O
less,161,O
14C,161,O
as,161,O
taurocholic,161,B-Chemical
acid,161,I-Chemical
than,161,O
did,161,O
control,161,O
animals,161,O
",",161,O
consistent,161,O
with,161,O
an,161,O
impairment,161,O
of,161,O
7alpha-hydroxylation,161,O
of,161,O
taurodeoxycholic,161,B-Chemical
acid,161,I-Chemical
.,161,O
Ethinyl,162,B-Chemical
estradiol,162,I-Chemical
treatment,162,O
did,162,O
not,162,O
impair,162,O
conjugation,162,O
of,162,O
deoxycholic,162,B-Chemical
acid,162,I-Chemical
",",162,O
but,162,O
did,162,O
result,162,O
in,162,O
an,162,O
increase,162,O
in,162,O
sulfation,162,O
of,162,O
taurodeoxycholic,162,B-Chemical
acid,162,I-Chemical
from,162,O
1.5,162,O
%,162,O
in,162,O
controls,162,O
to,162,O
nearly,162,O
4.0,162,O
%,162,O
(,162,O
P,162,O
less,162,O
than,162,O
0.01,162,O
),162,O
.,162,O
These,163,O
results,163,O
are,163,O
consistent,163,O
with,163,O
the,163,O
hypothesis,163,O
that,163,O
the,163,O
rat,163,O
has,163,O
a,163,O
poorer,163,O
tolerance,163,O
for,163,O
deoxycholic,163,B-Chemical
acid,163,I-Chemical
than,163,O
do,163,O
certain,163,O
other,163,O
species,163,O
.,163,O
Furthermore,164,O
",",164,O
the,164,O
rat,164,O
converts,164,O
deoxycholic,164,B-Chemical
acid,164,I-Chemical
",",164,O
a,164,O
poor,164,O
choleretic,164,O
",",164,O
to,164,O
taurocholic,164,B-Chemical
acid,164,I-Chemical
",",164,O
a,164,O
good,164,O
choleretic,164,O
.,164,O
When,165,O
this,165,O
conversion,165,O
is,165,O
impaired,165,O
with,165,O
ethinyl,165,B-Chemical
estradiol,165,I-Chemical
treatment,165,O
",",165,O
sulfation,165,O
may,165,O
be,165,O
an,165,O
important,165,O
alternate,165,O
pathway,165,O
for,165,O
excretion,165,O
of,165,O
this,165,O
potentially,165,O
harmful,165,O
bile,165,B-Chemical
acid,165,I-Chemical
.,165,O
Biphasic,166,O
response,166,O
of,166,O
the,166,O
SA,166,O
node,166,O
of,166,O
the,166,O
dog,166,O
heart,166,O
in,166,O
vivo,166,O
to,166,O
selective,166,O
administration,166,O
of,166,O
ketamine,166,B-Chemical
.,166,O
Effect,167,O
of,167,O
ketamine,167,B-Chemical
on,167,O
the,167,O
SA,167,O
node,167,O
of,167,O
the,167,O
dog,167,O
heart,167,O
was,167,O
studied,167,O
in,167,O
vivo,167,O
using,167,O
a,167,O
selective,167,O
perfusion,167,O
technique,167,O
of,167,O
the,167,O
SA,167,O
node,167,O
artery,167,O
.,167,O
Injections,168,O
of,168,O
ketamine,168,B-Chemical
in,168,O
doses,168,O
from,168,O
100,168,O
microgram,168,O
to,168,O
3,168,O
mg,168,O
into,168,O
the,168,O
artery,168,O
produced,168,O
a,168,O
depression,168,B-Disease
of,168,O
the,168,O
SA,168,O
nodal,168,O
activity,168,O
by,168,O
a,168,O
direct,168,O
action,168,O
.,168,O
This,169,O
depression,169,B-Disease
was,169,O
followed,169,O
by,169,O
the,169,O
sudden,169,O
appearance,169,O
of,169,O
a,169,O
stimulatory,169,O
phase,169,O
.,169,O
Bilateral,170,O
vagotomy,170,O
and,170,O
sympathectomy,170,O
or,170,O
prior,170,O
administration,170,O
of,170,O
a,170,O
ganglion,170,O
blocker,170,O
failed,170,O
to,170,O
inhibit,170,O
the,170,O
occurrence,170,O
of,170,O
the,170,O
ketamine-induced,170,B-Chemical
tachycardia,170,B-Disease
",",170,O
while,170,O
it,170,O
was,170,O
completely,170,O
abolished,170,O
in,170,O
the,170,O
reserpinized,170,O
dogs,170,O
or,170,O
by,170,O
a,170,O
prior,170,O
injection,170,O
of,170,O
a,170,O
beta-blocking,170,O
agent,170,O
into,170,O
the,170,O
SA,170,O
node,170,O
artery,170,O
.,170,O
This,171,O
may,171,O
indicate,171,O
that,171,O
an,171,O
activation,171,O
of,171,O
the,171,O
peripheral,171,O
adrenergic,171,O
mechanism,171,O
plays,171,O
an,171,O
important,171,O
role,171,O
in,171,O
the,171,O
induction,171,O
of,171,O
the,171,O
excitatory,171,O
effect,171,O
of,171,O
ketamine,171,B-Chemical
injected,171,O
in,171,O
the,171,O
SA,171,O
node,171,O
artery,171,O
.,171,O
Immunopathology,172,O
of,172,O
penicillamine-induced,172,B-Chemical
glomerular,172,B-Disease
disease,172,I-Disease
.,172,O
Four,173,O
patients,173,O
with,173,O
rheumatoid,173,B-Disease
arthritis,173,I-Disease
developed,173,O
heavy,173,O
proteinuria,173,B-Disease
after,173,O
five,173,O
to,173,O
12,173,O
months,173,O
of,173,O
treatment,173,O
with,173,O
D-penicillamine,173,B-Chemical
.,173,O
Light,174,O
microscopy,174,O
of,174,O
renal,174,O
biopsy,174,O
samples,174,O
showed,174,O
minimal,174,O
glomerular,174,O
capillary,174,O
wall,174,O
thickening,174,O
and,174,O
mesangial,174,O
matrix,174,O
increase,174,O
",",174,O
or,174,O
no,174,O
departure,174,O
from,174,O
normal,174,O
.,174,O
Electron,175,O
microscopy,175,O
",",175,O
however,175,O
",",175,O
revealed,175,O
subepithelial,175,O
electron-dense,175,O
deposits,175,O
",",175,O
fusion,175,O
of,175,O
epithelial,175,O
cell,175,O
foot,175,O
processes,175,O
",",175,O
and,175,O
evidence,175,O
of,175,O
mesangial,175,O
cell,175,O
hyperactivity,175,O
.,175,O
Immunofluorescence,176,O
microscopy,176,O
demonstrated,176,O
granular,176,O
capillary,176,O
wall,176,O
deposits,176,O
of,176,O
IgG,176,O
and,176,O
C3,176,O
.,176,O
The,177,O
findings,177,O
were,177,O
similar,177,O
to,177,O
those,177,O
in,177,O
early,177,O
membranous,177,B-Disease
glomerulonephritis,177,I-Disease
",",177,O
differences,177,O
being,177,O
observed,177,O
however,177,O
in,177,O
the,177,O
results,177,O
of,177,O
staining,177,O
for,177,O
the,177,O
early-acting,177,O
complement,177,O
components,177,O
C1q,177,O
and,177,O
C4,177,O
.,177,O
It,178,O
is,178,O
tentatively,178,O
concluded,178,O
that,178,O
complement,178,O
was,178,O
activated,178,O
by,178,O
the,178,O
classical,178,O
pathway,178,O
.,178,O
Acute,179,B-Disease
renal,179,I-Disease
failure,179,I-Disease
subsequent,179,O
to,179,O
the,179,O
administration,179,O
of,179,O
rifampicin,179,B-Chemical
.,179,O
A,180,O
follow-up,180,O
study,180,O
of,180,O
cases,180,O
reported,180,O
earlier,180,O
.,180,O
A,181,O
clinical,181,O
presentation,181,O
is,181,O
made,181,O
of,181,O
a,181,O
2-3,181,O
year,181,O
follow-up,181,O
of,181,O
six,181,O
cases,181,O
of,181,O
acute,181,B-Disease
renal,181,I-Disease
failure,181,I-Disease
that,181,O
have,181,O
been,181,O
reported,181,O
earlier,181,O
.,181,O
The,182,O
patients,182,O
had,182,O
developed,182,O
transient,182,O
renal,182,B-Disease
failure,182,I-Disease
after,182,O
the,182,O
intermittent,182,O
administration,182,O
of,182,O
rifampicin,182,B-Chemical
.,182,O
The,183,O
stage,183,O
of,183,O
olig-anuria,183,O
lasted,183,O
for,183,O
1-3,183,O
weeks,183,O
",",183,O
and,183,O
five,183,O
of,183,O
the,183,O
patients,183,O
were,183,O
treated,183,O
by,183,O
hemodialysis,183,O
.,183,O
Two,184,O
of,184,O
the,184,O
patients,184,O
died,184,O
due,184,O
to,184,O
unrelated,184,O
causes,184,O
during,184,O
the,184,O
follow-up,184,O
period,184,O
.,184,O
The,185,O
four,185,O
patients,185,O
re-examined,185,O
were,185,O
clinically,185,O
cured,185,O
.,185,O
Pathologic,186,O
findings,186,O
by,186,O
light,186,O
microscopy,186,O
and,186,O
immunofluorescence,186,O
at,186,O
biopsy,186,O
were,186,O
scarce,186,O
.,186,O
Nothing,187,O
abnormal,187,O
was,187,O
seen,187,O
by,187,O
electron,187,O
microscopy,187,O
in,187,O
two,187,O
of,187,O
the,187,O
cases,187,O
studied,187,O
.,187,O
Renal,188,O
function,188,O
was,188,O
normal,188,O
.,188,O
In,189,O
three,189,O
cases,189,O
the,189,O
excretion,189,O
at,189,O
131I-hippuran,189,O
renography,189,O
was,189,O
slightly,189,O
slowed,189,O
.,189,O
Although,190,O
in,190,O
the,190,O
acute,190,O
stage,190,O
the,190,O
renal,190,B-Disease
lesions,190,I-Disease
histologically,190,O
appeared,190,O
toxic,190,O
",",190,O
evidence,190,O
suggestive,190,O
of,190,O
an,190,O
immunological,190,O
mechanism,190,O
can,190,O
not,190,O
be,190,O
excluded,190,O
.,190,O
Ocular,191,O
manifestations,191,O
of,191,O
juvenile,191,B-Disease
rheumatoid,191,I-Disease
arthritis,191,I-Disease
.,191,O
We,192,O
followed,192,O
210,192,O
cases,192,O
of,192,O
juvenile,192,B-Disease
rheumatoid,192,I-Disease
arthritis,192,I-Disease
closely,192,O
for,192,O
eleven,192,O
years,192,O
.,192,O
Thirty-six,193,O
of,193,O
the,193,O
210,193,O
patients,193,O
(,193,O
17.2,193,O
%,193,O
),193,O
developed,193,O
iridocyclitis,193,B-Disease
.,193,O
Iridocyclitis,194,B-Disease
was,194,O
seen,194,O
most,194,O
frequently,194,O
in,194,O
young,194,O
female,194,O
patients,194,O
(,194,O
0,194,O
to,194,O
4,194,O
years,194,O
),194,O
with,194,O
the,194,O
monoarticular,194,O
or,194,O
pauciatricular,194,O
form,194,O
of,194,O
the,194,O
arthritis,194,B-Disease
.,194,O
However,195,O
",",195,O
30,195,O
%,195,O
of,195,O
the,195,O
patients,195,O
developed,195,O
uveitis,195,B-Disease
after,195,O
16,195,O
years,195,O
of,195,O
age,195,O
.,195,O
Although,196,O
61,196,O
%,196,O
of,196,O
patients,196,O
had,196,O
a,196,O
noncontributory,196,O
ocular,196,O
history,196,O
on,196,O
entry,196,O
",",196,O
42,196,O
%,196,O
had,196,O
active,196,O
uveitis,196,B-Disease
on,196,O
entry,196,O
.,196,O
Our,197,O
approach,197,O
was,197,O
effective,197,O
in,197,O
detecting,197,O
uveitis,197,B-Disease
in,197,O
new,197,O
cases,197,O
and,197,O
exacerbations,197,O
of,197,O
uveitis,197,B-Disease
in,197,O
established,197,O
cases,197,O
.,197,O
Forty-four,198,O
percent,198,O
of,198,O
patients,198,O
with,198,O
uveitis,198,B-Disease
had,198,O
one,198,O
or,198,O
more,198,O
identifiable,198,O
signs,198,O
or,198,O
symptoms,198,O
",",198,O
such,198,O
as,198,O
red,198,O
eye,198,O
",",198,O
ocular,198,B-Disease
pain,198,I-Disease
",",198,O
decreased,198,B-Disease
visual,198,I-Disease
acuity,198,I-Disease
",",198,O
or,198,O
photophobia,198,B-Disease
",",198,O
in,198,O
order,198,O
of,198,O
decreasing,198,O
frequency,198,O
.,198,O
Even,199,O
after,199,O
early,199,O
detection,199,O
and,199,O
prompt,199,O
treatment,199,O
",",199,O
41,199,O
%,199,O
of,199,O
cases,199,O
of,199,O
uveitis,199,B-Disease
did,199,O
not,199,O
respond,199,O
to,199,O
more,199,O
than,199,O
six,199,O
months,199,O
of,199,O
intensive,199,O
topical,199,O
treatment,199,O
with,199,O
corticosteroids,199,B-Chemical
and,199,O
mydriatics,199,O
.,199,O
Despite,200,O
this,200,O
",",200,O
there,200,O
was,200,O
a,200,O
dramatic,200,O
decrease,200,O
in,200,O
the,200,O
50,200,O
%,200,O
incidence,200,O
of,200,O
blinding,200,O
complications,200,O
of,200,O
uveitis,200,B-Disease
cited,200,O
in,200,O
earlier,200,O
studies,200,O
.,200,O
Cataract,201,B-Disease
and,201,O
band,201,B-Disease
keratopathy,201,I-Disease
occurred,201,O
in,201,O
only,201,O
22,201,O
and,201,O
13,201,O
%,201,O
of,201,O
our,201,O
group,201,O
",",201,O
respectively,201,O
.,201,O
We,202,O
used,202,O
chloroquine,202,B-Chemical
or,202,O
hydroxychloroquine,202,B-Chemical
in,202,O
173,202,O
of,202,O
210,202,O
cases,202,O
and,202,O
found,202,O
only,202,O
one,202,O
case,202,O
of,202,O
chorioretinopathy,202,B-Disease
attributable,202,O
to,202,O
these,202,O
drugs,202,O
.,202,O
Systemically,203,O
administered,203,O
corticosteroids,203,B-Chemical
were,203,O
used,203,O
in,203,O
75,203,O
of,203,O
210,203,O
cases,203,O
;,203,O
a,203,O
significant,203,O
number,203,O
of,203,O
posterior,203,O
subcapsular,203,O
cataracts,203,B-Disease
was,203,O
found,203,O
.,203,O
Typical,204,O
keratoconjunctivitis,204,B-Disease
sicca,204,O
developed,204,O
in,204,O
three,204,O
of,204,O
the,204,O
uveitis,204,B-Disease
cases,204,O
.,204,O
This,205,O
association,205,O
with,205,O
uveitis,205,B-Disease
and,205,O
JRA,205,O
was,205,O
not,205,O
noted,205,O
previously,205,O
.,205,O
Surgical,206,O
treatment,206,O
of,206,O
cataracts,206,B-Disease
",",206,O
band,206,B-Disease
keratopathy,206,I-Disease
",",206,O
and,206,O
glaucoma,206,B-Disease
achieved,206,O
uniformly,206,O
discouraging,206,O
results,206,O
.,206,O
The,207,O
renal,207,O
pathology,207,O
in,207,O
a,207,O
case,207,O
of,207,O
lithium-induced,207,B-Chemical
diabetes,207,B-Disease
insipidus,207,I-Disease
.,207,O
A,208,O
case,208,O
of,208,O
lithium-induced,208,B-Chemical
diabetes,208,B-Disease
insipidus,208,I-Disease
is,208,O
reported,208,O
.,208,O
At,209,O
necropsy,209,O
microscopy,209,O
shoed,209,O
unique,209,O
and,209,O
extensive,209,O
damage,209,O
to,209,O
cells,209,O
lining,209,O
the,209,O
distal,209,O
nephron,209,O
.,209,O
It,210,O
is,210,O
suggested,210,O
that,210,O
these,210,O
changes,210,O
represent,210,O
a,210,O
specific,210,O
toxic,210,O
effect,210,O
of,210,O
lithium,210,B-Chemical
",",210,O
reported,210,O
here,210,O
for,210,O
the,210,O
first,210,O
time,210,O
in,210,O
man,210,O
.,210,O
Pyeloureteral,211,O
filling,211,O
defects,211,O
associated,211,O
with,211,O
systemic,211,O
anticoagulation,211,O
:,211,O
a,211,O
case,211,O
report,211,O
.,211,O
The,212,O
etiology,212,O
of,212,O
pyeloureteritis,212,B-Disease
cystica,212,I-Disease
has,212,O
long,212,O
been,212,O
attributed,212,O
to,212,O
chronic,212,O
infection,212,B-Disease
and,212,O
inflammation,212,B-Disease
.,212,O
A,213,O
case,213,O
is,213,O
presented,213,O
that,213,O
is,213,O
unique,213,O
in,213,O
that,213,O
the,213,O
acute,213,O
onset,213,O
and,213,O
the,213,O
rapid,213,O
resolution,213,O
of,213,O
pyeloureteral,213,O
filling,213,O
defects,213,O
in,213,O
this,213,O
patient,213,O
were,213,O
documented,213,O
by,213,O
radiography,213,O
.,213,O
There,214,O
is,214,O
no,214,O
evidence,214,O
of,214,O
antecedent,214,O
or,214,O
concurrent,214,O
infection,214,B-Disease
in,214,O
this,214,O
patient,214,O
.,214,O
The,215,O
disease,215,O
occurred,215,O
subsequent,215,O
to,215,O
the,215,O
initiation,215,O
of,215,O
heparin,215,B-Chemical
therapy,215,O
for,215,O
suspected,215,O
pelvic,215,O
thrombophlebitis,215,B-Disease
and,215,O
cleared,215,O
rapidly,215,O
subsequent,215,O
to,215,O
its,215,O
discontinuation,215,O
.,215,O
The,216,O
rate,216,O
of,216,O
resolution,216,O
of,216,O
the,216,O
radiographic,216,O
findings,216,O
may,216,O
be,216,O
helpful,216,O
in,216,O
distinguishing,216,O
between,216,O
true,216,O
pyeloureteritis,216,B-Disease
cystica,216,I-Disease
and,216,O
submucosal,216,B-Disease
hemorrhage,216,I-Disease
.,216,O
Reversal,217,O
of,217,O
central,217,O
benzodiazepine,217,B-Chemical
effects,217,O
by,217,O
flumazenil,217,B-Chemical
after,217,O
intravenous,217,O
conscious,217,O
sedation,217,O
with,217,O
diazepam,217,B-Chemical
and,217,O
opioids,217,O
:,217,O
report,217,O
of,217,O
a,217,O
double-blind,217,O
multicenter,217,O
study,217,O
.,217,O
The,218,O
Flumazenil,218,B-Chemical
in,218,O
Intravenous,218,O
Conscious,218,O
Sedation,218,O
with,218,O
Diazepam,218,B-Chemical
Multicenter,218,O
Study,218,O
Group,218,O
II,218,O
.,218,O
The,219,O
efficacy,219,O
and,219,O
safety,219,O
of,219,O
a,219,O
new,219,O
benzodiazepine,219,B-Chemical
antagonist,219,O
",",219,O
flumazenil,219,B-Chemical
",",219,O
were,219,O
assessed,219,O
in,219,O
a,219,O
double-blind,219,O
multicenter,219,O
study,219,O
.,219,O
Flumazenil,220,B-Chemical
(,220,O
mean,220,O
dose,220,O
",",220,O
0.76,220,O
mg,220,O
),220,O
or,220,O
placebo,220,O
(,220,O
mean,220,O
dose,220,O
",",220,O
8.9,220,O
ml,220,O
),220,O
was,220,O
administered,220,O
intravenously,220,O
to,220,O
130,220,O
and,220,O
67,220,O
patients,220,O
",",220,O
respectively,220,O
",",220,O
who,220,O
had,220,O
been,220,O
given,220,O
diazepam,220,B-Chemical
in,220,O
conjunction,220,O
with,220,O
an,220,O
opioid,220,O
(,220,O
fentanyl,220,B-Chemical
",",220,O
meperidine,220,B-Chemical
",",220,O
or,220,O
morphine,220,B-Chemical
),220,O
for,220,O
the,220,O
induction,220,O
and,220,O
maintenance,220,O
of,220,O
intravenous,220,O
conscious,220,O
sedation,220,O
for,220,O
diagnostic,220,O
or,220,O
therapeutic,220,O
surgical,220,O
procedures,220,O
.,220,O
The,221,O
group,221,O
assessable,221,O
for,221,O
efficacy,221,O
comprised,221,O
122,221,O
patients,221,O
treated,221,O
with,221,O
flumazenil,221,B-Chemical
and,221,O
64,221,O
patients,221,O
given,221,O
placebo,221,O
.,221,O
After,222,O
5,222,O
minutes,222,O
",",222,O
80/115,222,O
(,222,O
70,222,O
%,222,O
),222,O
flumazenil-treated,222,B-Chemical
patients,222,O
",",222,O
compared,222,O
with,222,O
21/63,222,O
(,222,O
33,222,O
%,222,O
),222,O
placebo-treated,222,O
patients,222,O
",",222,O
were,222,O
completely,222,O
awake,222,O
and,222,O
alert,222,O
",",222,O
as,222,O
indicated,222,O
by,222,O
a,222,O
score,222,O
of,222,O
5,222,O
on,222,O
the,222,O
Observer,222,O
's,222,O
Assessment,222,O
of,222,O
Alertness/Sedation,222,O
Scale,222,O
.,222,O
Ninety-five,223,O
percent,223,O
of,223,O
patients,223,O
in,223,O
each,223,O
group,223,O
who,223,O
attained,223,O
a,223,O
score,223,O
of,223,O
5,223,O
at,223,O
the,223,O
5-minute,223,O
assessment,223,O
showed,223,O
no,223,O
loss,223,O
of,223,O
alertness,223,O
throughout,223,O
the,223,O
180-minute,223,O
assessment,223,O
period,223,O
.,223,O
Flumazenil-treated,224,B-Chemical
patients,224,O
also,224,O
performed,224,O
significantly,224,O
better,224,O
on,224,O
the,224,O
Finger-to-Nose,224,O
Test,224,O
and,224,O
the,224,O
recall,224,O
of,224,O
pictures,224,O
shown,224,O
at,224,O
the,224,O
5-minute,224,O
assessment,224,O
.,224,O
Flumazenil,225,B-Chemical
was,225,O
well,225,O
tolerated,225,O
",",225,O
with,225,O
no,225,O
serious,225,O
adverse,225,O
effects,225,O
reported,225,O
.,225,O
Thirty-nine,226,O
(,226,O
30,226,O
%,226,O
),226,O
of,226,O
flumazenil-treated,226,B-Chemical
patients,226,O
",",226,O
compared,226,O
with,226,O
17,226,O
(,226,O
25,226,O
%,226,O
),226,O
of,226,O
placebo-treated,226,O
patients,226,O
had,226,O
one,226,O
or,226,O
more,226,O
drug-related,226,O
adverse,226,O
experiences,226,O
.,226,O
The,227,O
most,227,O
common,227,O
adverse,227,O
effects,227,O
were,227,O
nausea,227,B-Disease
and,227,O
vomiting,227,B-Disease
in,227,O
the,227,O
flumazenil,227,B-Chemical
group,227,O
and,227,O
nausea,227,B-Disease
and,227,O
injection-site,227,O
pain,227,B-Disease
in,227,O
the,227,O
placebo,227,O
group,227,O
.,227,O
Flumazenil,228,B-Chemical
was,228,O
found,228,O
to,228,O
promptly,228,O
reverse,228,O
sedation,228,O
induced,228,O
by,228,O
diazepam,228,B-Chemical
in,228,O
the,228,O
presence,228,O
of,228,O
opioids,228,O
.,228,O
Potential,229,O
deleterious,229,O
effect,229,O
of,229,O
furosemide,229,B-Chemical
in,229,O
radiocontrast,229,O
nephropathy,229,B-Disease
.,229,O
The,230,O
purpose,230,O
of,230,O
the,230,O
study,230,O
was,230,O
to,230,O
determine,230,O
the,230,O
efficacy,230,O
of,230,O
furosemide,230,B-Chemical
in,230,O
addition,230,O
to,230,O
intravenous,230,O
fluids,230,O
in,230,O
the,230,O
prevention,230,O
of,230,O
radiocontrast,230,O
nephropathy,230,B-Disease
.,230,O
18,231,O
patients,231,O
",",231,O
referred,231,O
to,231,O
a,231,O
radiocontrast,231,O
study,231,O
",",231,O
considered,231,O
at,231,O
risk,231,O
because,231,O
of,231,O
preexisting,231,O
renal,231,B-Disease
insufficiency,231,I-Disease
",",231,O
were,231,O
enrolled,231,O
in,231,O
a,231,O
prospective,231,O
",",231,O
randomized,231,O
",",231,O
controlled,231,O
trial,231,O
",",231,O
performed,231,O
at,231,O
the,231,O
secondary,231,O
care,231,O
center,231,O
of,231,O
a,231,O
"1,100-bed",231,O
private,231,O
university,231,O
hospital,231,O
.,231,O
In,232,O
addition,232,O
to,232,O
fluids,232,O
",",232,O
the,232,O
treatment,232,O
group,232,O
received,232,O
furosemide,232,B-Chemical
(,232,O
mean,232,O
dose,232,O
110,232,O
mg,232,O
),232,O
intravenously,232,O
30,232,O
min,232,O
prior,232,O
to,232,O
the,232,O
injection,232,O
of,232,O
contrast,232,O
material,232,O
.,232,O
The,233,O
control,233,O
group,233,O
received,233,O
fluids,233,O
(,233,O
mean,233,O
3,233,O
liters,233,O
),233,O
.,233,O
Radiological,234,O
studies,234,O
were,234,O
mostly,234,O
angiographies,234,O
performed,234,O
with,234,O
both,234,O
ionic,234,O
and,234,O
non-ionic,234,O
contrast,234,O
material,234,O
",",234,O
at,234,O
an,234,O
average,234,O
dose,234,O
of,234,O
245,234,O
ml,234,O
.,234,O
Renal,235,B-Disease
function,235,I-Disease
significantly,235,I-Disease
deteriorated,235,I-Disease
in,235,O
the,235,O
group,235,O
pretreated,235,O
with,235,O
furosemide,235,B-Chemical
(,235,O
p,235,O
<,235,O
0.005,235,O
by,235,O
ANOVA,235,O
),235,O
",",235,O
with,235,O
a,235,O
rise,235,O
in,235,O
serum,235,O
creatinine,235,B-Chemical
from,235,O
145,235,O
+/-,235,O
13,235,O
to,235,O
182,235,O
+/-,235,O
16,235,O
mumol/l,235,O
at,235,O
24,235,O
h,235,O
",",235,O
while,235,O
no,235,O
change,235,O
occurred,235,O
in,235,O
the,235,O
control,235,O
group,235,O
(,235,O
from,235,O
141,235,O
+/-,235,O
6,235,O
to,235,O
142,235,O
+/-,235,O
7,235,O
mumol/l,235,O
),235,O
.,235,O
Renal,236,B-Disease
failure,236,I-Disease
was,236,O
associated,236,O
with,236,O
weight,236,B-Disease
loss,236,I-Disease
in,236,O
the,236,O
furosemide-treated,236,B-Chemical
group,236,O
.,236,O
Furosemide,237,B-Chemical
may,237,O
be,237,O
deleterious,237,O
in,237,O
the,237,O
prevention,237,O
of,237,O
radiocontrast,237,O
nephropathy,237,B-Disease
.,237,O
Orthostatic,238,B-Disease
hypotension,238,I-Disease
occurs,238,O
following,238,O
alpha,238,O
2-adrenoceptor,238,O
blockade,238,O
in,238,O
chronic,238,O
prazosin-pretreated,238,B-Chemical
conscious,238,O
spontaneously,238,O
hypertensive,238,B-Disease
rats,238,O
.,238,O
1,239,O
.,239,O
Studies,240,O
were,240,O
performed,240,O
to,240,O
evaluate,240,O
whether,240,O
chronic,240,O
prazosin,240,B-Chemical
treatment,240,O
alters,240,O
the,240,O
alpha,240,O
2-adrenoceptor,240,O
function,240,O
for,240,O
orthostatic,240,O
control,240,O
of,240,O
arterial,240,O
blood,240,O
pressure,240,O
in,240,O
conscious,240,O
spontaneously,240,O
hypertensive,240,B-Disease
rats,240,O
(,240,O
SHR,240,O
),240,O
.,240,O
2,241,O
.,241,O
Conscious,242,O
SHR,242,O
(,242,O
male,242,O
300-350,242,O
g,242,O
),242,O
were,242,O
subjected,242,O
to,242,O
90,242,O
degrees,242,O
head-up,242,O
tilts,242,O
for,242,O
60,242,O
s,242,O
following,242,O
acute,242,O
administration,242,O
of,242,O
prazosin,242,B-Chemical
(,242,O
0.1,242,O
mg,242,O
kg-1,242,O
i.p,242,O
.,242,O
),242,O
or,243,O
rauwolscine,243,B-Chemical
(,243,O
3,243,O
mg,243,O
kg-1,243,O
i.v,243,O
.,243,O
),243,O
.,243,O
Orthostatic,244,B-Disease
hypotension,244,I-Disease
was,244,O
determined,244,O
by,244,O
the,244,O
average,244,O
decrease,244,O
(,244,O
%,244,O
),244,O
in,244,O
mean,244,O
arterial,244,O
pressure,244,O
(,244,O
MAP,244,O
femoral,244,O
),244,O
over,244,O
the,244,O
60-s,244,O
tilt,244,O
period,244,O
.,244,O
The,245,O
basal,245,O
MAP,245,O
of,245,O
conscious,245,O
SHR,245,O
was,245,O
reduced,245,O
to,245,O
a,245,O
similar,245,O
extent,245,O
by,245,O
prazosin,245,B-Chemical
(,245,O
-23,245,O
%,245,O
(,245,O
-,245,O
),245,O
-26,245,O
%,245,O
MAP,245,O
),245,O
and,245,O
rauwolscine,245,B-Chemical
(,245,O
-16,245,O
%,245,O
(,245,O
-,245,O
),245,O
-33,245,O
%,245,O
MAP,245,O
),245,O
.,245,O
However,246,O
",",246,O
the,246,O
head-up,246,O
tilt,246,O
induced,246,O
orthostatic,246,B-Disease
hypotension,246,I-Disease
in,246,O
the,246,O
SHR,246,O
treated,246,O
with,246,O
prazosin,246,B-Chemical
(,246,O
-16,246,O
%,246,O
MAP,246,O
",",246,O
n,246,O
=,246,O
6,246,O
),246,O
",",246,O
but,246,O
not,246,O
in,246,O
the,246,O
SHR,246,O
treated,246,O
with,246,O
rauwolscine,246,B-Chemical
(,246,O
less,246,O
than,246,O
+2,246,O
%,246,O
MAP,246,O
",",246,O
n,246,O
=,246,O
6,246,O
),246,O
.,246,O
3,247,O
.,247,O
Conscious,248,O
SHR,248,O
were,248,O
treated,248,O
for,248,O
4,248,O
days,248,O
with,248,O
prazosin,248,B-Chemical
at,248,O
2,248,O
mg,248,O
kg-1,248,O
day-1,248,O
i.p,248,O
.,248,O
for,249,O
chronic,249,O
alpha,249,O
1-adrenoceptor,249,O
blockade,249,O
.,249,O
MAP,250,O
in,250,O
conscious,250,O
SHR,250,O
after,250,O
chronic,250,O
prazosin,250,B-Chemical
treatment,250,O
was,250,O
14,250,O
%,250,O
lower,250,O
than,250,O
in,250,O
the,250,O
untreated,250,O
SHR,250,O
(,250,O
n,250,O
=,250,O
8,250,O
),250,O
.,250,O
Head-up,251,O
tilts,251,O
in,251,O
these,251,O
rats,251,O
did,251,O
not,251,O
produce,251,O
orthostatic,251,B-Disease
hypotension,251,I-Disease
when,251,O
performed,251,O
either,251,O
prior,251,O
to,251,O
or,251,O
after,251,O
acute,251,O
dosing,251,O
of,251,O
prazosin,251,B-Chemical
(,251,O
0.1,251,O
mg,251,O
kg-1,251,O
i.p,251,O
.,251,O
),251,O
.,251,O
Conversely,252,O
",",252,O
administration,252,O
of,252,O
rauwolscine,252,B-Chemical
(,252,O
3,252,O
mg,252,O
kg-1,252,O
i.v,252,O
.,252,O
),252,O
in,253,O
chronic,253,O
prazosin,253,B-Chemical
treated,253,O
SHR,253,O
decreased,253,O
the,253,O
basal,253,O
MAP,253,O
by,253,O
12-31,253,O
%,253,O
(,253,O
n,253,O
=,253,O
4,253,O
),253,O
",",253,O
and,253,O
subsequent,253,O
tilts,253,O
induced,253,O
further,253,O
drops,253,O
of,253,O
MAP,253,O
by,253,O
19-23,253,O
%,253,O
in,253,O
these,253,O
rats,253,O
.,253,O
4,254,O
.,254,O
The,255,O
pressor,255,O
responses,255,O
and,255,O
bradycardia,255,B-Disease
to,255,O
the,255,O
alpha,255,O
1-agonist,255,O
cirazoline,255,B-Chemical
(,255,O
0.6,255,O
and,255,O
2,255,O
micrograms,255,O
kg-1,255,O
i.v,255,O
.,255,O
),256,O
",",256,O
the,256,O
alpha,256,O
2-agonist,256,O
Abbott-53693,256,O
(,256,O
1,256,O
and,256,O
3,256,O
micrograms,256,O
kg-1,256,O
i.v,256,O
.,256,O
),257,O
",",257,O
and,257,O
noradrenaline,257,O
(,257,O
0.1,257,O
and,257,O
1.0,257,O
micrograms,257,O
kg-1,257,O
i.v,257,O
.,257,O
),257,O
were,258,O
determined,258,O
in,258,O
conscious,258,O
SHR,258,O
with,258,O
and,258,O
without,258,O
chronic,258,O
prazosin,258,O
pretreatment,258,O
.,258,O
Both,259,O
the,259,O
pressor,259,O
and,259,O
bradycardia,259,O
effects,259,O
of,259,O
cirazoline,259,O
were,259,O
abolished,259,O
in,259,O
chronic,259,O
prazosin,259,O
treated,259,O
SHR,259,O
(,259,O
n,259,O
=,259,O
4,259,O
),259,O
as,259,O
compared,259,O
to,259,O
the,259,O
untreated,259,O
SHR,259,O
(,259,O
n,259,O
=,259,O
4,259,O
),259,O
.,259,O
On,260,O
the,260,O
other,260,O
hand,260,O
",",260,O
the,260,O
pressor,260,O
effects,260,O
of,260,O
Abbott-53693,260,O
were,260,O
similar,260,O
in,260,O
both,260,O
groups,260,O
of,260,O
SHR,260,O
",",260,O
but,260,O
the,260,O
accompanying,260,O
bradycardia,260,O
was,260,O
greater,260,O
in,260,O
SHR,260,O
with,260,O
chronic,260,O
prazosin,260,O
treatment,260,O
than,260,O
without,260,O
such,260,O
treatment,260,O
.,260,O
Furthermore,261,O
",",261,O
the,261,O
bradycardia,261,O
that,261,O
accompanied,261,O
the,261,O
noradrenaline-induced,261,O
pressor,261,O
effect,261,O
in,261,O
SHR,261,O
was,261,O
similar,261,O
with,261,O
and,261,O
without,261,O
chronic,261,O
prazosin,261,O
treatment,261,O
despite,261,O
a,261,O
47-71,261,O
%,261,O
reduction,261,O
of,261,O
the,261,O
pressor,261,O
effect,261,O
in,261,O
chronic,261,O
alpha,261,O
1-receptor,261,O
blocked,261,O
SHR,261,O
.,261,O
(,262,O
ABSTRACT,262,O
TRUNCATED,262,O
AT,262,O
400,262,O
WORDS,262,O
),262,O
Hemolytic-uremic,263,B-Disease
syndrome,263,I-Disease
associated,263,O
with,263,O
ingestion,263,O
of,263,O
quinine,263,B-Chemical
.,263,O
Hemolytic-uremic,264,B-Disease
syndrome,264,I-Disease
following,264,O
quinine,264,B-Chemical
ingestion,264,O
is,264,O
a,264,O
newly,264,O
described,264,O
phenomenon,264,O
",",264,O
with,264,O
just,264,O
two,264,O
previous,264,O
descriptions,264,O
of,264,O
4,264,O
cases,264,O
in,264,O
the,264,O
literature,264,O
.,264,O
We,265,O
describe,265,O
a,265,O
5th,265,O
case,265,O
.,265,O
The,266,O
reaction,266,O
may,266,O
be,266,O
mediated,266,O
by,266,O
the,266,O
presence,266,O
of,266,O
antibodies,266,O
reactive,266,O
against,266,O
platelets,266,O
in,266,O
the,266,O
presence,266,O
of,266,O
quinine,266,B-Chemical
.,266,O
Treatment,267,O
has,267,O
included,267,O
use,267,O
of,267,O
plasma,267,O
exchange,267,O
",",267,O
prednisone,267,B-Chemical
",",267,O
aspirin,267,B-Chemical
",",267,O
and,267,O
dipyridamole,267,B-Chemical
.,267,O
The,268,O
patients,268,O
have,268,O
all,268,O
regained,268,O
some,268,O
degree,268,O
of,268,O
renal,268,O
function,268,O
.,268,O
However,269,O
",",269,O
it,269,O
is,269,O
unclear,269,O
whether,269,O
pharmacological,269,O
treatment,269,O
or,269,O
spontaneous,269,O
resolution,269,O
is,269,O
responsible,269,O
for,269,O
the,269,O
improvement,269,O
.,269,O
Quinine-associated,270,B-Chemical
hemolytic-uremic,270,B-Disease
syndrome,270,I-Disease
probably,270,O
occurs,270,O
more,270,O
often,270,O
than,270,O
is,270,O
recognized,270,O
.,270,O
It,271,O
is,271,O
important,271,O
to,271,O
recognize,271,O
this,271,O
reaction,271,O
when,271,O
it,271,O
occurs,271,O
and,271,O
to,271,O
avoid,271,O
further,271,O
quinine,271,B-Chemical
exposure,271,O
",",271,O
since,271,O
the,271,O
reaction,271,O
seems,271,O
to,271,O
be,271,O
recurrent,271,O
.,271,O
Amnestic,272,B-Disease
syndrome,272,I-Disease
associated,272,O
with,272,O
propranolol,272,B-Chemical
toxicity,272,B-Disease
:,272,O
a,272,O
case,272,O
report,272,O
.,272,O
An,273,O
elderly,273,O
woman,273,O
developed,273,O
an,273,O
Alzheimer-like,273,B-Disease
subacute,273,O
dementia,273,B-Disease
as,273,O
a,273,O
result,273,O
of,273,O
propranolol,273,B-Chemical
toxicity,273,B-Disease
.,273,O
Analysis,274,O
of,274,O
the,274,O
manifestations,274,O
showed,274,O
that,274,O
severe,274,O
impairment,274,O
of,274,O
memory,274,O
accounted,274,O
for,274,O
virtually,274,O
all,274,O
of,274,O
the,274,O
abnormalities,274,O
.,274,O
There,275,O
is,275,O
evidence,275,O
that,275,O
cerebral,275,O
reactions,275,O
to,275,O
drug,275,O
toxicity,275,B-Disease
can,275,O
exhibit,275,O
patterns,275,O
that,275,O
suggest,275,O
highly,275,O
selective,275,O
involvement,275,O
of,275,O
functional,275,O
subdivisions,275,O
of,275,O
the,275,O
brain,275,O
.,275,O
Cefotetan-induced,276,B-Chemical
immune,276,O
hemolytic,276,B-Disease
anemia,276,I-Disease
.,276,O
Immune,277,O
hemolytic,277,B-Disease
anemia,277,I-Disease
due,277,O
to,277,O
a,277,O
drug-adsorption,277,O
mechanism,277,O
has,277,O
been,277,O
described,277,O
primarily,277,O
in,277,O
patients,277,O
receiving,277,O
penicillins,277,B-Chemical
and,277,O
first-generation,277,O
cephalosporins,277,B-Chemical
.,277,O
We,278,O
describe,278,O
a,278,O
patient,278,O
who,278,O
developed,278,O
anemia,278,B-Disease
while,278,O
receiving,278,O
intravenous,278,O
cefotetan,278,B-Chemical
.,278,O
Cefotetan-dependent,279,B-Chemical
antibodies,279,O
were,279,O
detected,279,O
in,279,O
the,279,O
patient,279,O
's,279,O
serum,279,O
and,279,O
in,279,O
an,279,O
eluate,279,O
prepared,279,O
from,279,O
his,279,O
red,279,O
blood,279,O
cells,279,O
.,279,O
The,280,O
eluate,280,O
also,280,O
reacted,280,O
weakly,280,O
with,280,O
red,280,O
blood,280,O
cells,280,O
in,280,O
the,280,O
absence,280,O
of,280,O
cefotetan,280,B-Chemical
",",280,O
suggesting,280,O
the,280,O
concomitant,280,O
formation,280,O
of,280,O
warm-reactive,280,O
autoantibodies,280,O
.,280,O
These,281,O
observations,281,O
",",281,O
in,281,O
conjunction,281,O
with,281,O
clinical,281,O
and,281,O
laboratory,281,O
evidence,281,O
of,281,O
extravascular,281,O
hemolysis,281,B-Disease
",",281,O
are,281,O
consistent,281,O
with,281,O
drug-induced,281,O
hemolytic,281,B-Disease
anemia,281,I-Disease
",",281,O
possibly,281,O
involving,281,O
both,281,O
drug-adsorption,281,O
and,281,O
autoantibody,281,O
formation,281,O
mechanisms,281,O
.,281,O
This,282,O
case,282,O
emphasizes,282,O
the,282,O
need,282,O
for,282,O
increased,282,O
awareness,282,O
of,282,O
hemolytic,282,O
reactions,282,O
to,282,O
all,282,O
cephalosporins,282,B-Chemical
.,282,O
Hypersensitivity,283,B-Disease
immune,283,O
reaction,283,O
as,283,O
a,283,O
mechanism,283,O
for,283,O
dilevalol-associated,283,B-Chemical
hepatitis,283,B-Disease
.,283,O
OBJECTIVE,284,O
:,284,O
To,284,O
assess,284,O
lymphocyte,284,O
reactivity,284,O
to,284,O
dilevalol,284,B-Chemical
and,284,O
to,284,O
serum,284,O
containing,284,O
putative,284,O
ex,284,O
vivo,284,O
dilevalol,284,B-Chemical
antigens,284,O
or,284,O
metabolites,284,O
in,284,O
a,284,O
case,284,O
of,284,O
dilevalol-induced,284,B-Chemical
liver,284,B-Disease
injury,284,I-Disease
.,284,O
PATIENT,285,O
:,285,O
A,285,O
58-year-old,285,O
woman,285,O
with,285,O
a,285,O
clinical,285,O
diagnosis,285,O
of,285,O
dilevalol-induced,285,B-Chemical
liver,285,B-Disease
injury,285,I-Disease
.,285,O
METHODS,286,O
:,286,O
Peripheral,286,O
blood,286,O
mononuclear,286,O
cells,286,O
collected,286,O
from,286,O
the,286,O
patient,286,O
were,286,O
cultured,286,O
in,286,O
the,286,O
presence,286,O
of,286,O
a,286,O
solution,286,O
of,286,O
dilevalol,286,B-Chemical
and,286,O
also,286,O
with,286,O
sera,286,O
collected,286,O
from,286,O
a,286,O
volunteer,286,O
before,286,O
and,286,O
after,286,O
dilevalol,286,B-Chemical
intake,286,O
.,286,O
A,287,O
similar,287,O
protocol,287,O
was,287,O
performed,287,O
with,287,O
lymphocytes,287,O
from,287,O
a,287,O
healthy,287,O
subject,287,O
.,287,O
RESULTS,288,O
:,288,O
No,288,O
lymphocyte,288,O
proliferation,288,O
was,288,O
observed,288,O
either,288,O
in,288,O
the,288,O
patient,288,O
or,288,O
in,288,O
the,288,O
healthy,288,O
volunteer,288,O
in,288,O
the,288,O
presence,288,O
of,288,O
dilevalol,288,B-Chemical
solutions,288,O
.,288,O
A,289,O
significant,289,O
proliferative,289,O
response,289,O
to,289,O
serum,289,O
collected,289,O
after,289,O
dilevalol,289,B-Chemical
intake,289,O
was,289,O
observed,289,O
in,289,O
the,289,O
case,289,O
of,289,O
the,289,O
patient,289,O
compared,289,O
with,289,O
the,289,O
proliferative,289,O
response,289,O
to,289,O
the,289,O
serum,289,O
collected,289,O
before,289,O
the,289,O
drug,289,O
intake,289,O
.,289,O
No,290,O
reactivity,290,O
was,290,O
found,290,O
when,290,O
lymphocytes,290,O
from,290,O
the,290,O
healthy,290,O
subject,290,O
were,290,O
tested,290,O
under,290,O
similar,290,O
conditions,290,O
.,290,O
CONCLUSIONS,291,O
:,291,O
The,291,O
methodology,291,O
used,291,O
allowed,291,O
the,291,O
detection,291,O
of,291,O
lymphocyte,291,O
sensitization,291,O
to,291,O
sera,291,O
containing,291,O
ex,291,O
vivo-prepared,291,O
dilevalol,291,B-Chemical
antigens,291,O
",",291,O
suggesting,291,O
the,291,O
involvement,291,O
of,291,O
an,291,O
immunologic,291,O
mechanism,291,O
in,291,O
dilevalol-induced,291,B-Chemical
liver,291,B-Disease
injury,291,I-Disease
.,291,O
Yohimbine,292,B-Chemical
treatment,292,O
of,292,O
sexual,292,B-Disease
side,292,I-Disease
effects,292,I-Disease
induced,292,O
by,292,O
serotonin,292,B-Chemical
reuptake,292,O
blockers,292,O
.,292,O
BACKGROUND,293,O
:,293,O
Preclinical,293,O
and,293,O
clinical,293,O
studies,293,O
suggest,293,O
that,293,O
yohimbine,293,B-Chemical
facilitates,293,O
sexual,293,O
behavior,293,O
and,293,O
may,293,O
be,293,O
helpful,293,O
in,293,O
the,293,O
treatment,293,O
of,293,O
male,293,B-Disease
impotence,293,I-Disease
.,293,O
A,294,O
single,294,O
case,294,O
report,294,O
suggests,294,O
that,294,O
yohimbine,294,B-Chemical
may,294,O
be,294,O
used,294,O
to,294,O
treat,294,O
the,294,O
sexual,294,B-Disease
side,294,I-Disease
effects,294,I-Disease
of,294,O
clomipramine,294,B-Chemical
.,294,O
This,295,O
study,295,O
evaluated,295,O
yohimbine,295,B-Chemical
as,295,O
a,295,O
treatment,295,O
for,295,O
the,295,O
sexual,295,B-Disease
side,295,I-Disease
effects,295,I-Disease
caused,295,O
by,295,O
serotonin,295,B-Chemical
reuptake,295,O
blockers,295,O
.,295,O
METHOD,296,O
:,296,O
Six,296,O
patients,296,O
with,296,O
either,296,O
obsessive,296,B-Disease
compulsive,296,I-Disease
disorder,296,I-Disease
",",296,O
trichotillomania,296,B-Disease
",",296,O
anxiety,296,B-Disease
",",296,O
or,296,O
affective,296,B-Disease
disorders,296,I-Disease
who,296,O
suffered,296,O
sexual,296,B-Disease
side,296,I-Disease
effects,296,I-Disease
after,296,O
treatment,296,O
with,296,O
serotonin,296,B-Chemical
reuptake,296,O
blockers,296,O
were,296,O
given,296,O
yohimbine,296,B-Chemical
on,296,O
a,296,O
p.r.n,296,O
.,296,O
basis,297,O
in,297,O
an,297,O
open,297,O
clinical,297,O
trial,297,O
.,297,O
Various,298,O
doses,298,O
of,298,O
yohimbine,298,B-Chemical
were,298,O
used,298,O
to,298,O
determine,298,O
the,298,O
ideal,298,O
dose,298,O
for,298,O
each,298,O
patient,298,O
.,298,O
RESULTS,299,O
:,299,O
Five,299,O
of,299,O
the,299,O
six,299,O
patients,299,O
experienced,299,O
improved,299,O
sexual,299,O
functioning,299,O
after,299,O
taking,299,O
yohimbine,299,B-Chemical
.,299,O
One,300,O
patient,300,O
who,300,O
failed,300,O
to,300,O
comply,300,O
with,300,O
yohimbine,300,B-Chemical
treatment,300,O
had,300,O
no,300,O
therapeutic,300,O
effects,300,O
.,300,O
Side,301,O
effects,301,O
of,301,O
yohimbine,301,B-Chemical
included,301,O
excessive,301,O
sweating,301,O
",",301,O
increased,301,O
anxiety,301,B-Disease
",",301,O
and,301,O
a,301,O
wound-up,301,O
feeling,301,O
in,301,O
some,301,O
patients,301,O
.,301,O
CONCLUSION,302,O
:,302,O
The,302,O
results,302,O
of,302,O
this,302,O
study,302,O
indicate,302,O
that,302,O
yohimbine,302,B-Chemical
may,302,O
be,302,O
an,302,O
effective,302,O
treatment,302,O
for,302,O
the,302,O
sexual,302,B-Disease
side,302,I-Disease
effects,302,I-Disease
caused,302,O
by,302,O
serotonin,302,B-Chemical
reuptake,302,O
blockers,302,O
.,302,O
Future,303,O
controlled,303,O
studies,303,O
are,303,O
needed,303,O
to,303,O
further,303,O
investigate,303,O
the,303,O
effectiveness,303,O
and,303,O
safety,303,O
of,303,O
yohimbine,303,B-Chemical
for,303,O
this,303,O
indication,303,O
.,303,O
Hemorrhagic,304,O
cystitis,304,O
complicating,304,O
bone,304,O
marrow,304,O
transplantation,304,O
.,304,O
Hemorrhagic,305,O
cystitis,305,O
is,305,O
a,305,O
potentially,305,O
serious,305,O
complication,305,O
of,305,O
high-dose,305,O
cyclophosphamide,305,B-Chemical
therapy,305,O
administered,305,O
before,305,O
bone,305,O
marrow,305,O
transplantation,305,O
.,305,O
As,306,O
standard,306,O
practice,306,O
at,306,O
our,306,O
institution,306,O
",",306,O
patients,306,O
who,306,O
are,306,O
scheduled,306,O
to,306,O
receive,306,O
a,306,O
bone,306,O
marrow,306,O
transplant,306,O
are,306,O
treated,306,O
prophylactically,306,O
with,306,O
forced,306,O
hydration,306,O
and,306,O
bladder,306,O
irrigation,306,O
.,306,O
In,307,O
an,307,O
attempt,307,O
to,307,O
obviate,307,O
the,307,O
inconvenience,307,O
of,307,O
bladder,307,O
irrigation,307,O
",",307,O
we,307,O
conducted,307,O
a,307,O
feasibility,307,O
trial,307,O
of,307,O
uroprophylaxis,307,O
with,307,O
mesna,307,B-Chemical
",",307,O
which,307,O
neutralizes,307,O
the,307,O
hepatic,307,O
metabolite,307,O
of,307,O
cyclophosphamide,307,B-Chemical
that,307,O
causes,307,O
hemorrhagic,307,O
cystitis,307,O
.,307,O
Of,308,O
97,308,O
patients,308,O
who,308,O
received,308,O
standard,308,O
prophylaxis,308,O
",",308,O
4,308,O
had,308,O
symptomatic,308,O
hemorrhagic,308,O
cystitis,308,O
.,308,O
In,309,O
contrast,309,O
",",309,O
two,309,O
of,309,O
four,309,O
consecutive,309,O
patients,309,O
who,309,O
received,309,O
mesna,309,B-Chemical
uroprophylaxis,309,O
before,309,O
allogeneic,309,O
bone,309,O
marrow,309,O
transplantation,309,O
had,309,O
severe,309,O
hemorrhagic,309,O
cystitis,309,O
for,309,O
at,309,O
least,309,O
2,309,O
weeks,309,O
.,309,O
Because,310,O
of,310,O
this,310,O
suboptimal,310,O
result,310,O
",",310,O
we,310,O
resumed,310,O
the,310,O
use,310,O
of,310,O
bladder,310,O
irrigation,310,O
and,310,O
forced,310,O
hydration,310,O
to,310,O
minimize,310,O
the,310,O
risk,310,O
of,310,O
hemorrhagic,310,O
cystitis,310,O
.,310,O
Relation,311,O
of,311,O
perfusion,311,O
defects,311,O
observed,311,O
with,311,O
myocardial,311,O
contrast,311,O
echocardiography,311,O
to,311,O
the,311,O
severity,311,O
of,311,O
coronary,311,B-Disease
stenosis,311,I-Disease
:,311,O
correlation,311,O
with,311,O
thallium-201,311,B-Chemical
single-photon,311,O
emission,311,O
tomography,311,O
.,311,O
It,312,O
has,312,O
been,312,O
previously,312,O
shown,312,O
that,312,O
myocardial,312,O
contrast,312,O
echocardiography,312,O
is,312,O
a,312,O
valuable,312,O
technique,312,O
for,312,O
delineating,312,O
regions,312,O
of,312,O
myocardial,312,O
underperfusion,312,O
secondary,312,O
to,312,O
coronary,312,B-Disease
occlusion,312,I-Disease
and,312,O
to,312,O
critical,312,O
coronary,312,B-Disease
stenoses,312,I-Disease
in,312,O
the,312,O
presence,312,O
of,312,O
hyperemic,312,B-Disease
stimulation,312,O
.,312,O
The,313,O
aim,313,O
of,313,O
this,313,O
study,313,O
was,313,O
to,313,O
determine,313,O
whether,313,O
myocardial,313,O
contrast,313,O
echocardiography,313,O
performed,313,O
with,313,O
a,313,O
stable,313,O
solution,313,O
of,313,O
sonicated,313,O
albumin,313,O
could,313,O
detect,313,O
regions,313,O
of,313,O
myocardial,313,O
underperfusion,313,O
resulting,313,O
from,313,O
various,313,O
degrees,313,O
of,313,O
coronary,313,B-Disease
stenosis,313,I-Disease
.,313,O
The,314,O
perfusion,314,O
defect,314,O
produced,314,O
in,314,O
16,314,O
open,314,O
chest,314,O
dogs,314,O
was,314,O
compared,314,O
with,314,O
the,314,O
anatomic,314,O
area,314,O
at,314,O
risk,314,O
measured,314,O
by,314,O
the,314,O
postmortem,314,O
dual-perfusion,314,O
technique,314,O
and,314,O
with,314,O
thallium-201,314,B-Chemical
single-photon,314,O
emission,314,O
tomography,314,O
(,314,O
SPECT,314,O
),314,O
.,314,O
During,315,O
a,315,O
transient,315,O
(,315,O
20-s,315,O
),315,O
coronary,315,B-Disease
occlusion,315,I-Disease
",",315,O
a,315,O
perfusion,315,O
defect,315,O
was,315,O
observed,315,O
with,315,O
contrast,315,O
echocardiography,315,O
in,315,O
14,315,O
of,315,O
the,315,O
15,315,O
dogs,315,O
in,315,O
which,315,O
the,315,O
occlusion,315,O
was,315,O
produced,315,O
.,315,O
The,316,O
perfusion,316,O
defect,316,O
correlated,316,O
significantly,316,O
with,316,O
the,316,O
anatomic,316,O
area,316,O
at,316,O
risk,316,O
(,316,O
r,316,O
=,316,O
0.74,316,O
;,316,O
p,316,O
less,316,O
than,316,O
0.002,316,O
),316,O
.,316,O
During,317,O
dipyridamole-induced,317,B-Chemical
hyperemia,317,B-Disease
",",317,O
12,317,O
of,317,O
the,317,O
16,317,O
dogs,317,O
with,317,O
a,317,O
partial,317,O
coronary,317,B-Disease
stenosis,317,I-Disease
had,317,O
a,317,O
visible,317,O
area,317,O
of,317,O
hypoperfusion,317,O
by,317,O
contrast,317,O
echocardiography,317,O
.,317,O
The,318,O
four,318,O
dogs,318,O
without,318,O
a,318,O
perfusion,318,O
defect,318,O
had,318,O
a,318,O
stenosis,318,O
that,318,O
resulted,318,O
in,318,O
a,318,O
mild,318,O
(,318,O
0,318,O
%,318,O
to,318,O
50,318,O
%,318,O
),318,O
reduction,318,O
in,318,O
dipyridamole-induced,318,B-Chemical
hyperemia,318,B-Disease
.,318,O
The,319,O
size,319,O
of,319,O
the,319,O
perfusion,319,O
defect,319,O
during,319,O
stenosis,319,O
correlated,319,O
significantly,319,O
with,319,O
the,319,O
anatomic,319,O
area,319,O
at,319,O
risk,319,O
(,319,O
r,319,O
=,319,O
0.61,319,O
;,319,O
p,319,O
=,319,O
0.02,319,O
),319,O
.,319,O
Thallium-201,320,B-Chemical
SPECT,320,O
demonstrated,320,O
a,320,O
perfusion,320,O
defect,320,O
in,320,O
all,320,O
14,320,O
dogs,320,O
analyzed,320,O
during,320,O
dipyridamole-induced,320,B-Chemical
hyperemia,320,B-Disease
;,320,O
the,320,O
size,320,O
of,320,O
the,320,O
perfusion,320,O
defect,320,O
correlated,320,O
with,320,O
the,320,O
anatomic,320,O
area,320,O
at,320,O
risk,320,O
(,320,O
r,320,O
=,320,O
0.58,320,O
;,320,O
p,320,O
less,320,O
than,320,O
0.03,320,O
),320,O
and,320,O
with,320,O
the,320,O
perfusion,320,O
defect,320,O
by,320,O
contrast,320,O
echocardiography,320,O
(,320,O
r,320,O
=,320,O
0.58,320,O
;,320,O
p,320,O
less,320,O
than,320,O
0.03,320,O
),320,O
.,320,O
Thus,321,O
",",321,O
myocardial,321,O
contrast,321,O
echocardiography,321,O
can,321,O
be,321,O
used,321,O
to,321,O
visualize,321,O
and,321,O
quantitate,321,O
the,321,O
amount,321,O
of,321,O
jeopardized,321,O
myocardium,321,O
during,321,O
moderate,321,O
to,321,O
severe,321,O
degrees,321,O
of,321,O
coronary,321,B-Disease
stenosis,321,I-Disease
.,321,O
The,322,O
results,322,O
obtained,322,O
show,322,O
a,322,O
correlation,322,O
with,322,O
the,322,O
anatomic,322,O
area,322,O
at,322,O
risk,322,O
similar,322,O
to,322,O
that,322,O
obtained,322,O
with,322,O
thallium-201,322,B-Chemical
SPECT,322,O
.,322,O
Amiodarone,323,B-Chemical
pulmonary,323,B-Disease
toxicity,323,I-Disease
.,323,O
Amiodarone,324,B-Chemical
is,324,O
an,324,O
effective,324,O
antiarrhythmic,324,O
agent,324,O
whose,324,O
utility,324,O
is,324,O
limited,324,O
by,324,O
many,324,O
side-effects,324,O
",",324,O
the,324,O
most,324,O
problematic,324,O
being,324,O
pneumonitis,324,B-Disease
.,324,O
The,325,O
pulmonary,325,B-Disease
toxicity,325,I-Disease
of,325,O
amiodarone,325,B-Chemical
is,325,O
thought,325,O
to,325,O
result,325,O
from,325,O
direct,325,O
injury,325,O
related,325,O
to,325,O
the,325,O
intracellular,325,O
accumulation,325,O
of,325,O
phospholipid,325,O
and,325,O
T,325,O
cell-mediated,325,O
hypersensitivity,325,O
pneumonitis,325,O
.,325,O
The,326,O
clinical,326,O
and,326,O
radiographic,326,O
features,326,O
of,326,O
amiodarone-induced,326,B-Chemical
pulmonary,326,B-Disease
toxicity,326,I-Disease
are,326,O
characteristic,326,O
but,326,O
nonspecific,326,O
.,326,O
The,327,O
diagnosis,327,O
depends,327,O
on,327,O
exclusion,327,O
of,327,O
other,327,O
entities,327,O
",",327,O
such,327,O
as,327,O
heart,327,B-Disease
failure,327,I-Disease
",",327,O
infection,327,B-Disease
",",327,O
and,327,O
malignancy,327,B-Disease
.,327,O
While,328,O
withdrawal,328,O
of,328,O
amiodarone,328,B-Chemical
leads,328,O
to,328,O
clinical,328,O
improvement,328,O
in,328,O
majority,328,O
of,328,O
cases,328,O
",",328,O
this,328,O
is,328,O
not,328,O
always,328,O
possible,328,O
or,328,O
advisable,328,O
.,328,O
Dose,329,O
reduction,329,O
or,329,O
concomitant,329,O
steroid,329,B-Chemical
therapy,329,O
may,329,O
have,329,O
a,329,O
role,329,O
in,329,O
selected,329,O
patients,329,O
.,329,O
Cocaine-induced,330,B-Chemical
brainstem,330,O
seizures,330,B-Disease
and,330,O
behavior,330,O
.,330,O
A,331,O
variety,331,O
of,331,O
abnormal,331,O
sensory/motor,331,O
behaviors,331,O
associated,331,O
with,331,O
electrical,331,O
discharges,331,O
recorded,331,O
from,331,O
the,331,O
bilateral,331,O
brainstem,331,O
were,331,O
induced,331,O
in,331,O
adult,331,O
WKY,331,O
rats,331,O
by,331,O
mechanical,331,O
(,331,O
electrode,331,O
implants,331,O
),331,O
and,331,O
DC,331,O
electrical,331,O
current,331,O
stimulations,331,O
and,331,O
by,331,O
acute,331,O
and,331,O
chronic,331,O
administration,331,O
of,331,O
cocaine,331,B-Chemical
.,331,O
The,332,O
electrode,332,O
implant,332,O
implicated,332,O
one,332,O
side,332,O
or,332,O
the,332,O
other,332,O
of,332,O
the,332,O
reticular,332,O
system,332,O
of,332,O
the,332,O
brainstem,332,O
but,332,O
subjects,332,O
were,332,O
not,332,O
incapacitated,332,O
by,332,O
the,332,O
stimulations,332,O
.,332,O
Cocaine,333,B-Chemical
(,333,O
40,333,O
mg/kg,333,O
),333,O
was,333,O
injected,333,O
subcutaneously,333,O
for,333,O
an,333,O
acute,333,O
experiment,333,O
and,333,O
subsequent,333,O
20,333,O
mg/kg,333,O
doses,333,O
twice,333,O
daily,333,O
for,333,O
3,333,O
days,333,O
in,333,O
a,333,O
chronic,333,O
study,333,O
.,333,O
Cocaine,334,B-Chemical
generated,334,O
more,334,O
abnormal,334,O
behaviors,334,O
in,334,O
the,334,O
brainstem,334,O
perturbation,334,O
group,334,O
",",334,O
especially,334,O
the,334,O
electrically,334,O
perturbated,334,O
subjects,334,O
.,334,O
The,335,O
abnormal,335,O
behaviors,335,O
were,335,O
yawning,335,O
",",335,O
retrocollis,335,O
",",335,O
hyperactivity,335,B-Disease
",",335,O
hypersensitivity,335,B-Disease
",",335,O
``,335,O
beating,335,O
drum,335,O
'',335,O
behavior,335,O
",",335,O
squealing,335,O
",",335,O
head,335,O
bobbing,335,O
",",335,O
circling,335,O
",",335,O
sniffing,335,O
",",335,O
abnormal,335,O
posturing,335,O
",",335,O
and,335,O
facial,335,O
twitching,335,O
.,335,O
Shifts,336,O
in,336,O
the,336,O
power,336,O
frequency,336,O
spectra,336,O
of,336,O
the,336,O
discharge,336,O
patterns,336,O
were,336,O
noted,336,O
between,336,O
quiet,336,O
and,336,O
pacing,336,O
behavioral,336,O
states,336,O
.,336,O
Hypersensitivity,337,B-Disease
to,337,O
various,337,O
auditory,337,O
",",337,O
tactile,337,O
",",337,O
and,337,O
visual,337,O
stimulation,337,O
was,337,O
present,337,O
and,337,O
shifts,337,O
in,337,O
the,337,O
brainstem,337,O
ambient,337,O
power,337,O
spectral,337,O
frequency,337,O
occurred,337,O
in,337,O
response,337,O
to,337,O
tactile,337,O
stimulation,337,O
.,337,O
These,338,O
findings,338,O
suggest,338,O
that,338,O
the,338,O
brainstem,338,O
generates,338,O
and,338,O
propagates,338,O
pathological,338,O
discharges,338,O
that,338,O
can,338,O
be,338,O
elicited,338,O
by,338,O
mechanical,338,O
and,338,O
DC,338,O
electrical,338,O
perturbation,338,O
.,338,O
Cocaine,339,B-Chemical
was,339,O
found,339,O
to,339,O
activate,339,O
the,339,O
discharge,339,O
system,339,O
and,339,O
thus,339,O
induce,339,O
abnormal,339,O
behaviors,339,O
that,339,O
are,339,O
generated,339,O
at,339,O
the,339,O
discharge,339,O
site,339,O
and,339,O
at,339,O
distant,339,O
sites,339,O
to,339,O
which,339,O
the,339,O
discharge,339,O
propagates,339,O
.,339,O
Cognitive,340,O
functions,340,O
may,340,O
also,340,O
be,340,O
involved,340,O
since,340,O
dopaminergic,340,O
and,340,O
serotonergic,340,O
cellular,340,O
elements,340,O
at,340,O
the,340,O
brainstem,340,O
level,340,O
are,340,O
also,340,O
implicated,340,O
.,340,O
Chloroquine,341,B-Chemical
related,341,O
complete,341,O
heart,341,B-Disease
block,341,I-Disease
with,341,O
blindness,341,B-Disease
:,341,O
case,341,O
report,341,O
.,341,O
A,342,O
27-year,342,O
old,342,O
African,342,O
woman,342,O
with,342,O
history,342,O
of,342,O
regular,342,O
chloroquine,342,B-Chemical
ingestion,342,O
presented,342,O
with,342,O
progressive,342,O
deterioration,342,B-Disease
of,342,I-Disease
vision,342,I-Disease
",",342,O
easy,342,O
fatiguability,342,B-Disease
",",342,O
dyspnoea,342,B-Disease
",",342,O
dizziness,342,B-Disease
progressing,342,O
to,342,O
syncopal,342,B-Disease
attacks,342,I-Disease
.,342,O
Ophthalmological,343,O
assessment,343,O
revealed,343,O
features,343,O
of,343,O
chloroquine,343,B-Chemical
retinopathy,343,B-Disease
",",343,O
cardiac,343,O
assessment,343,O
revealed,343,O
features,343,O
of,343,O
heart,343,B-Disease
failure,343,I-Disease
and,343,O
a,343,O
complete,343,O
heart,343,B-Disease
block,343,I-Disease
with,343,O
right,343,B-Disease
bundle,343,I-Disease
branch,343,I-Disease
block,343,I-Disease
pattern,343,O
.,343,O
The,344,O
heart,344,B-Disease
block,344,I-Disease
was,344,O
treated,344,O
by,344,O
pacemaker,344,O
insertion,344,O
and,344,O
the,344,O
heart,344,B-Disease
failure,344,I-Disease
resolved,344,O
spontaneously,344,O
following,344,O
chloroquine,344,B-Chemical
discontinuation,344,O
.,344,O
She,345,O
however,345,O
remains,345,O
blind,345,B-Disease
.,345,O
Effects,346,O
of,346,O
suprofen,346,B-Chemical
on,346,O
the,346,O
isolated,346,O
perfused,346,O
rat,346,O
kidney,346,O
.,346,O
Although,347,O
suprofen,347,B-Chemical
has,347,O
been,347,O
associated,347,O
with,347,O
the,347,O
development,347,O
of,347,O
acute,347,B-Disease
renal,347,I-Disease
failure,347,I-Disease
in,347,O
greater,347,O
than,347,O
100,347,O
subjects,347,O
",",347,O
the,347,O
mechanism,347,O
of,347,O
damage,347,O
remains,347,O
unclear,347,O
.,347,O
The,348,O
direct,348,O
nephrotoxic,348,B-Disease
effects,348,O
of,348,O
a,348,O
single,348,O
dose,348,O
of,348,O
15,348,O
mg,348,O
of,348,O
suprofen,348,B-Chemical
were,348,O
compared,348,O
in,348,O
the,348,O
recirculating,348,O
isolated,348,O
rat,348,O
kidney,348,O
perfused,348,O
with,348,O
cell-free,348,O
buffer,348,O
with,348,O
or,348,O
without,348,O
the,348,O
addition,348,O
of,348,O
5,348,O
mg/dL,348,O
of,348,O
uric,348,B-Chemical
acid,348,I-Chemical
.,348,O
There,349,O
were,349,O
no,349,O
significant,349,O
differences,349,O
in,349,O
renal,349,O
sodium,349,B-Chemical
excretion,349,O
",",349,O
oxygen,349,B-Chemical
consumption,349,O
",",349,O
or,349,O
urinary,349,O
flow,349,O
rates,349,O
in,349,O
kidneys,349,O
perfused,349,O
with,349,O
suprofen,349,B-Chemical
compared,349,O
with,349,O
the,349,O
drug-free,349,O
control,349,O
groups,349,O
.,349,O
In,350,O
contrast,350,O
",",350,O
a,350,O
significant,350,O
decline,350,O
in,350,O
glomerular,350,O
filtration,350,O
rate,350,O
was,350,O
found,350,O
after,350,O
the,350,O
introduction,350,O
of,350,O
suprofen,350,B-Chemical
to,350,O
the,350,O
kidney,350,O
perfused,350,O
with,350,O
uric,350,B-Chemical
acid,350,I-Chemical
;,350,O
no,350,O
changes,350,O
were,350,O
found,350,O
with,350,O
suprofen,350,B-Chemical
in,350,O
the,350,O
absence,350,O
of,350,O
uric,350,B-Chemical
acid,350,I-Chemical
.,350,O
A,351,O
significant,351,O
decrease,351,O
in,351,O
the,351,O
baseline,351,O
excretion,351,O
rate,351,O
of,351,O
uric,351,B-Chemical
acid,351,I-Chemical
was,351,O
found,351,O
in,351,O
rats,351,O
given,351,O
suprofen,351,B-Chemical
",",351,O
compared,351,O
with,351,O
drug-free,351,O
controls,351,O
.,351,O
However,352,O
",",352,O
the,352,O
fractional,352,O
excretion,352,O
of,352,O
uric,352,B-Chemical
acid,352,I-Chemical
was,352,O
unchanged,352,O
between,352,O
the,352,O
groups,352,O
over,352,O
the,352,O
experimental,352,O
period,352,O
.,352,O
In,353,O
summary,353,O
",",353,O
suprofen,353,B-Chemical
causes,353,O
acute,353,B-Disease
declines,353,I-Disease
in,353,I-Disease
renal,353,I-Disease
function,353,I-Disease
",",353,O
most,353,O
likely,353,O
by,353,O
directly,353,O
altering,353,O
the,353,O
intrarenal,353,O
distribution,353,O
of,353,O
uric,353,B-Chemical
acid,353,I-Chemical
.,353,O
Blockade,354,O
of,354,O
both,354,O
D-1,354,O
and,354,O
D-2,354,O
dopamine,354,B-Chemical
receptors,354,O
may,354,O
induce,354,O
catalepsy,354,B-Disease
in,354,O
mice,354,O
.,354,O
1,355,O
.,355,O
The,356,O
catalepsy,356,B-Disease
induced,356,O
by,356,O
dopamine,356,B-Chemical
antagonists,356,O
has,356,O
been,356,O
tested,356,O
and,356,O
the,356,O
possible,356,O
dopamine,356,B-Chemical
subtypes,356,O
involved,356,O
in,356,O
catalepsy,356,B-Disease
was,356,O
determined,356,O
.,356,O
2,357,O
.,357,O
Dopamine,358,B-Chemical
antagonist,358,O
fluphenazine,358,B-Chemical
",",358,O
D-1,358,O
antagonist,358,O
SCH,358,B-Chemical
23390,358,I-Chemical
or,358,O
D-2,358,O
antagonist,358,O
sulpiride,358,B-Chemical
induced,358,O
catalepsy,358,B-Disease
.,358,O
The,359,O
effect,359,O
of,359,O
fluphenazine,359,B-Chemical
and,359,O
sulpiride,359,B-Chemical
was,359,O
dose-dependent,359,O
.,359,O
Combination,360,O
of,360,O
SCH,360,B-Chemical
23390,360,I-Chemical
with,360,O
sulpiride,360,B-Chemical
did,360,O
not,360,O
induce,360,O
catalepsy,360,B-Disease
potentiation,360,O
.,360,O
3,361,O
.,361,O
D-1,362,O
agonist,362,O
SKF,362,B-Chemical
38393,362,I-Chemical
or,362,O
D-2,362,O
agonist,362,O
quinpirole,362,B-Chemical
decreased,362,O
the,362,O
catalepsy,362,B-Disease
induced,362,O
by,362,O
fluphenazine,362,B-Chemical
",",362,O
SCH,362,B-Chemical
23390,362,I-Chemical
or,362,O
sulpiride,362,B-Chemical
.,362,O
4,363,O
.,363,O
Combination,364,O
of,364,O
SKF,364,B-Chemical
38393,364,I-Chemical
with,364,O
quinpirole,364,B-Chemical
did,364,O
not,364,O
cause,364,O
potentiated,364,O
inhibitory,364,O
effect,364,O
on,364,O
catalepsy,364,B-Disease
induced,364,O
by,364,O
dopamine,364,B-Chemical
antagonists,364,O
.,364,O
5,365,O
.,365,O
The,366,O
data,366,O
may,366,O
indicate,366,O
that,366,O
although,366,O
D-2,366,O
receptor,366,O
blockade,366,O
is,366,O
involved,366,O
in,366,O
catalepsy,366,B-Disease
",",366,O
the,366,O
D-1,366,O
receptor,366,O
may,366,O
plan,366,O
a,366,O
role,366,O
.,366,O
Antiarrhythmic,367,O
effects,367,O
of,367,O
optical,367,O
isomers,367,O
of,367,O
cibenzoline,367,B-Chemical
on,367,O
canine,367,O
ventricular,367,B-Disease
arrhythmias,367,I-Disease
.,367,O
Antiarrhythmic,368,O
effects,368,O
of,368,O
(,368,O
+,368,O
),368,O
-cibenzoline,368,O
and,368,O
(,368,O
-,368,O
),368,O
-cibenzoline,368,O
were,368,O
examined,368,O
using,368,O
two,368,O
canine,368,O
ventricular,368,B-Disease
arrhythmia,368,I-Disease
models,368,O
.,368,O
Digitalis,369,B-Chemical
arrhythmia,369,B-Disease
",",369,O
which,369,O
is,369,O
suppressed,369,O
by,369,O
Na,369,B-Chemical
channel,369,O
blockers,369,O
",",369,O
was,369,O
induced,369,O
by,369,O
intermittent,369,O
intravenous,369,O
(,369,O
i.v,369,O
.,369,O
),369,O
injection,370,O
of,370,O
ouabain,370,B-Chemical
in,370,O
pentobarbital-anesthetized,370,B-Chemical
dogs,370,O
.,370,O
Adrenaline,371,B-Disease
arrhythmia,371,I-Disease
",",371,O
which,371,O
is,371,O
suppressed,371,O
by,371,O
Ca,371,B-Chemical
channel,371,O
blockers,371,O
",",371,O
was,371,O
induced,371,O
by,371,O
adrenaline,371,B-Chemical
infusion,371,O
in,371,O
halothane-anesthetized,371,B-Chemical
dogs,371,O
.,371,O
Ten,372,O
and,372,O
5,372,O
mg/kg,372,O
i.v,372,O
.,372,O
(,373,O
+,373,O
),373,O
-cibenzoline,373,O
suppressed,373,O
digitalis-,373,B-Chemical
and,373,O
adrenaline-induced,373,B-Chemical
arrhythmias,373,B-Disease
",",373,O
respectively,373,O
.,373,O
The,374,O
minimum,374,O
effective,374,O
plasma,374,O
concentrations,374,O
of,374,O
(,374,O
+,374,O
),374,O
-cibenzoline,374,O
for,374,O
digitalis-,374,B-Chemical
and,374,O
adrenaline-induced,374,B-Chemical
arrhythmias,374,B-Disease
were,374,O
1.4,374,O
+/-,374,O
0.4,374,O
and,374,O
2.0,374,O
+/-,374,O
0.6,374,O
micrograms/ml,374,O
",",374,O
respectively,374,O
(,374,O
mean,374,O
+/-,374,O
SD,374,O
",",374,O
n,374,O
=,374,O
6,374,O
),374,O
.,374,O
A,375,O
lower,375,O
dose,375,O
of,375,O
1,375,O
mg/kg,375,O
i.v,375,O
.,375,O
of,376,O
(,376,O
-,376,O
),376,O
-cibenzoline,376,O
suppressed,376,O
the,376,O
digitalis-induced,376,B-Chemical
arrhythmia,376,B-Disease
",",376,O
whereas,376,O
5,376,O
mg/kg,376,O
i.v,376,O
.,376,O
was,377,O
needed,377,O
to,377,O
suppress,377,O
adrenaline-induced,377,B-Chemical
arrhythmias,377,B-Disease
.,377,O
The,378,O
minimum,378,O
effective,378,O
plasma,378,O
concentrations,378,O
of,378,O
(,378,O
-,378,O
),378,O
-cibenzoline,378,O
for,378,O
digitalis-,378,B-Chemical
and,378,O
adrenaline-induced,378,B-Chemical
arrhythmia,378,B-Disease
were,378,O
0.06,378,O
+/-,378,O
0.04,378,O
and,378,O
0.7,378,O
+/-,378,O
0.1,378,O
micrograms/ml,378,O
",",378,O
respectively,378,O
(,378,O
mean,378,O
+/-,378,O
SD,378,O
",",378,O
n,378,O
=,378,O
6,378,O
),378,O
.,378,O
The,379,O
stronger,379,O
antiarrhythmic,379,O
effect,379,O
of,379,O
(,379,O
-,379,O
),379,O
-cibenzoline,379,O
indicates,379,O
that,379,O
(,379,O
-,379,O
),379,O
-isomer,379,O
may,379,O
have,379,O
an,379,O
effect,379,O
nearly,379,O
5-20,379,O
times,379,O
stronger,379,O
in,379,O
suppressing,379,O
Na,379,B-Chemical
channels,379,O
",",379,O
but,379,O
effects,379,O
of,379,O
both,379,O
drugs,379,O
on,379,O
Ca,379,B-Chemical
channels,379,O
may,379,O
be,379,O
almost,379,O
equipotent,379,O
.,379,O
Delayed,380,O
institution,380,O
of,380,O
hypertension,380,B-Disease
during,380,O
focal,380,O
cerebral,380,B-Disease
ischemia,380,I-Disease
:,380,O
effect,380,O
on,380,O
brain,380,B-Disease
edema,380,I-Disease
.,380,O
The,381,O
effect,381,O
of,381,O
induced,381,O
hypertension,381,B-Disease
instituted,381,O
after,381,O
a,381,O
2-h,381,O
delay,381,O
following,381,O
middle,381,B-Disease
cerebral,381,I-Disease
artery,381,I-Disease
occlusion,381,I-Disease
(,381,O
MCAO,381,B-Disease
),381,O
on,381,O
brain,381,B-Disease
edema,381,I-Disease
formation,381,O
and,381,O
histochemical,381,O
injury,381,O
was,381,O
studied,381,O
.,381,O
Under,382,O
isoflurane,382,B-Chemical
anesthesia,382,O
",",382,O
the,382,O
MCA,382,O
of,382,O
14,382,O
spontaneously,382,O
hypertensive,382,B-Disease
rats,382,O
was,382,O
occluded,382,O
.,382,O
In,383,O
the,383,O
control,383,O
group,383,O
(,383,O
n,383,O
=,383,O
7,383,O
),383,O
",",383,O
the,383,O
mean,383,O
arterial,383,O
pressure,383,O
(,383,O
MAP,383,O
),383,O
was,383,O
not,383,O
manipulated,383,O
.,383,O
In,384,O
the,384,O
hypertensive,384,B-Disease
group,384,O
(,384,O
n,384,O
=,384,O
7,384,O
),384,O
",",384,O
the,384,O
MAP,384,O
was,384,O
elevated,384,O
by,384,O
25-30,384,O
mm,384,O
Hg,384,O
beginning,384,O
2,384,O
h,384,O
after,384,O
MCAO,384,B-Disease
.,384,O
Four,385,O
hours,385,O
after,385,O
MCAO,385,B-Disease
",",385,O
the,385,O
rats,385,O
were,385,O
killed,385,O
and,385,O
the,385,O
brains,385,O
harvested,385,O
.,385,O
The,386,O
brains,386,O
were,386,O
sectioned,386,O
along,386,O
coronal,386,O
planes,386,O
spanning,386,O
the,386,O
distribution,386,O
of,386,O
ischemia,386,B-Disease
produced,386,O
by,386,O
MCAO,386,B-Disease
.,386,O
Specific,387,O
gravity,387,O
(,387,O
SG,387,O
),387,O
was,387,O
determined,387,O
in,387,O
the,387,O
subcortex,387,O
and,387,O
in,387,O
two,387,O
sites,387,O
in,387,O
the,387,O
cortex,387,O
(,387,O
core,387,O
and,387,O
periphery,387,O
of,387,O
the,387,O
ischemic,387,B-Disease
territory,387,O
),387,O
.,387,O
The,388,O
extent,388,O
of,388,O
neuronal,388,B-Disease
injury,388,I-Disease
was,388,O
determined,388,O
by,388,O
"2,3,5-triphenyltetrazolium",388,B-Chemical
staining,388,O
.,388,O
In,389,O
the,389,O
ischemic,389,B-Disease
core,389,O
",",389,O
there,389,O
was,389,O
no,389,O
difference,389,O
in,389,O
SG,389,O
in,389,O
the,389,O
subcortex,389,O
and,389,O
cortex,389,O
in,389,O
the,389,O
two,389,O
groups,389,O
.,389,O
In,390,O
the,390,O
periphery,390,O
of,390,O
the,390,O
ischemic,390,B-Disease
territory,390,O
",",390,O
SG,390,O
in,390,O
the,390,O
cortex,390,O
was,390,O
greater,390,O
(,390,O
less,390,O
edema,390,B-Disease
accumulation,390,O
),390,O
in,390,O
the,390,O
hypertensive,390,B-Disease
group,390,O
(,390,O
1.041,390,O
+/-,390,O
0.001,390,O
vs,390,O
1.039,390,O
+/-,390,O
0.001,390,O
",",390,O
P,390,O
less,390,O
than,390,O
0.05,390,O
),390,O
.,390,O
The,391,O
area,391,O
of,391,O
histochemical,391,O
injury,391,O
(,391,O
as,391,O
a,391,O
percent,391,O
of,391,O
the,391,O
cross-sectional,391,O
area,391,O
of,391,O
the,391,O
hemisphere,391,O
),391,O
was,391,O
less,391,O
in,391,O
the,391,O
hypertensive,391,B-Disease
group,391,O
(,391,O
33,391,O
+/-,391,O
3,391,O
%,391,O
vs,391,O
21,391,O
+/-,391,O
2,391,O
%,391,O
",",391,O
P,391,O
less,391,O
than,391,O
0.05,391,O
),391,O
.,391,O
The,392,O
data,392,O
indicate,392,O
that,392,O
phenylephrine-induced,392,B-Chemical
hypertension,392,B-Disease
instituted,392,O
2,392,O
h,392,O
after,392,O
MCAO,392,B-Disease
does,392,O
not,392,O
aggravate,392,O
edema,392,B-Disease
in,392,O
the,392,O
ischemic,392,B-Disease
core,392,O
",",392,O
that,392,O
it,392,O
improves,392,O
edema,392,B-Disease
in,392,O
the,392,O
periphery,392,O
of,392,O
the,392,O
ischemic,392,B-Disease
territory,392,O
",",392,O
and,392,O
that,392,O
it,392,O
reduces,392,O
the,392,O
area,392,O
of,392,O
histochemical,392,O
neuronal,392,B-Disease
dysfunction,392,I-Disease
.,392,O
Carbamazepine-induced,393,B-Chemical
cardiac,393,B-Disease
dysfunction,393,I-Disease
.,393,O
Characterization,394,O
of,394,O
two,394,O
distinct,394,O
clinical,394,O
syndromes,394,O
.,394,O
A,395,O
patient,395,O
with,395,O
sinus,395,O
bradycardia,395,B-Disease
and,395,O
atrioventricular,395,B-Disease
block,395,I-Disease
",",395,O
induced,395,O
by,395,O
carbamazepine,395,B-Chemical
",",395,O
prompted,395,O
an,395,O
extensive,395,O
literature,395,O
review,395,O
of,395,O
all,395,O
previously,395,O
reported,395,O
cases,395,O
.,395,O
From,396,O
the,396,O
analysis,396,O
of,396,O
these,396,O
cases,396,O
",",396,O
two,396,O
distinct,396,O
forms,396,O
of,396,O
carbamazepine-associated,396,B-Chemical
cardiac,396,B-Disease
dysfunction,396,I-Disease
emerged,396,O
.,396,O
One,397,O
patient,397,O
group,397,O
developed,397,O
sinus,397,B-Disease
tachycardias,397,I-Disease
in,397,O
the,397,O
setting,397,O
of,397,O
a,397,O
massive,397,O
carbamazepine,397,B-Chemical
overdose,397,B-Disease
.,397,O
The,398,O
second,398,O
group,398,O
consisted,398,O
almost,398,O
exclusively,398,O
of,398,O
elderly,398,O
women,398,O
who,398,O
developed,398,O
potentially,398,O
life-threatening,398,O
bradyarrhythmias,398,B-Disease
or,398,O
atrioventricular,398,B-Disease
conduction,398,I-Disease
delay,398,I-Disease
",",398,O
associated,398,O
with,398,O
either,398,O
therapeutic,398,O
or,398,O
modestly,398,O
elevated,398,O
carbamazepine,398,B-Chemical
serum,398,O
levels,398,O
.,398,O
Because,399,O
carbamazepine,399,B-Chemical
is,399,O
widely,399,O
used,399,O
in,399,O
the,399,O
treatment,399,O
of,399,O
many,399,O
neurologic,399,O
and,399,O
psychiatric,399,B-Disease
conditions,399,O
",",399,O
the,399,O
recognition,399,O
of,399,O
the,399,O
latter,399,O
syndrome,399,O
has,399,O
important,399,O
implications,399,O
for,399,O
the,399,O
use,399,O
of,399,O
this,399,O
drug,399,O
in,399,O
elderly,399,O
patients,399,O
.,399,O
Detection,400,O
of,400,O
abnormal,400,O
cardiac,400,O
adrenergic,400,O
neuron,400,O
activity,400,O
in,400,O
adriamycin-induced,400,B-Chemical
cardiomyopathy,400,B-Disease
with,400,O
iodine-125-metaiodobenzylguanidine,400,B-Chemical
.,400,O
Radiolabeled,401,B-Chemical
metaiodobenzylguanidine,401,I-Chemical
(,401,O
MIBG,401,B-Chemical
),401,O
",",401,O
an,401,O
analog,401,O
of,401,O
norepinephrine,401,B-Chemical
(,401,O
NE,401,B-Chemical
),401,O
",",401,O
serves,401,O
as,401,O
an,401,O
index,401,O
of,401,O
adrenergic,401,O
neuron,401,O
integrity,401,O
and,401,O
function,401,O
.,401,O
Using,402,O
a,402,O
rat,402,O
model,402,O
of,402,O
adriamycin-induced,402,B-Chemical
cardiomyopathy,402,B-Disease
",",402,O
we,402,O
tested,402,O
the,402,O
hypothesis,402,O
that,402,O
abnormal,402,O
cardiac,402,O
adrenergic,402,O
neuron,402,O
activity,402,O
may,402,O
appear,402,O
and,402,O
be,402,O
exacerbated,402,O
dose-dependently,402,O
in,402,O
adriamycin,402,B-Chemical
cardiomyopathy,402,B-Disease
.,402,O
The,403,O
degree,403,O
of,403,O
vacuolar,403,B-Disease
degeneration,403,I-Disease
of,403,I-Disease
myocardial,403,I-Disease
cells,403,I-Disease
was,403,O
analyzed,403,O
in,403,O
relation,403,O
to,403,O
the,403,O
duration,403,O
of,403,O
adriamycin,403,B-Chemical
treatment,403,O
(,403,O
2,403,O
mg/kg,403,O
",",403,O
once,403,O
a,403,O
week,403,O
),403,O
.,403,O
There,404,O
were,404,O
no,404,O
abnormalities,404,O
or,404,O
only,404,O
isolated,404,O
degeneration,404,O
in,404,O
the,404,O
1-,404,O
or,404,O
2-wk,404,O
treatment,404,O
groups,404,O
",",404,O
isolated,404,O
or,404,O
scattered,404,O
degeneration,404,O
in,404,O
half,404,O
of,404,O
the,404,O
3-wk,404,O
group,404,O
",",404,O
frequent,404,O
scattered,404,O
degeneration,404,O
in,404,O
the,404,O
4-wk,404,O
group,404,O
",",404,O
scattered,404,O
or,404,O
focal,404,O
degeneration,404,O
in,404,O
the,404,O
5-wk,404,O
group,404,O
",",404,O
and,404,O
extensive,404,O
degeneration,404,O
in,404,O
the,404,O
8-wk,404,O
group,404,O
.,404,O
Myocardial,405,O
accumulation,405,O
of,405,O
[,405,O
125I,405,O
],405,O
MIBG,405,B-Chemical
4,405,O
hr,405,O
after,405,O
intravenous,405,O
injection,405,O
did,405,O
not,405,O
differ,405,O
between,405,O
the,405,O
controls,405,O
and,405,O
the,405,O
groups,405,O
treated,405,O
3,405,O
wk,405,O
or,405,O
less,405,O
.,405,O
However,406,O
",",406,O
the,406,O
4-wk,406,O
group,406,O
had,406,O
a,406,O
slightly,406,O
lower,406,O
accumulation,406,O
in,406,O
the,406,O
right,406,O
ventricular,406,O
wall,406,O
(,406,O
82,406,O
%,406,O
of,406,O
the,406,O
control,406,O
),406,O
and,406,O
significantly,406,O
lower,406,O
accumulation,406,O
in,406,O
the,406,O
left,406,O
ventricular,406,O
wall,406,O
(,406,O
about,406,O
66,406,O
%,406,O
of,406,O
the,406,O
control,406,O
:,406,O
p,406,O
less,406,O
than,406,O
0.05,406,O
),406,O
.,406,O
In,407,O
the,407,O
5-wk,407,O
group,407,O
",",407,O
MIBG,407,B-Chemical
accumulation,407,O
in,407,O
the,407,O
right,407,O
and,407,O
left,407,O
ventricular,407,O
wall,407,O
was,407,O
35,407,O
%,407,O
and,407,O
27,407,O
%,407,O
of,407,O
that,407,O
in,407,O
controls,407,O
",",407,O
respectively,407,O
(,407,O
p,407,O
less,407,O
than,407,O
0.001,407,O
),407,O
.,407,O
In,408,O
the,408,O
8-wk,408,O
group,408,O
",",408,O
MIBG,408,B-Chemical
accumulation,408,O
in,408,O
the,408,O
right,408,O
and,408,O
left,408,O
ventricular,408,O
wall,408,O
was,408,O
18,408,O
%,408,O
and,408,O
14,408,O
%,408,O
of,408,O
that,408,O
in,408,O
controls,408,O
",",408,O
respectively,408,O
(,408,O
p,408,O
less,408,O
than,408,O
0.001,408,O
),408,O
.,408,O
Thus,409,O
",",409,O
MIBG,409,B-Chemical
accumulation,409,O
in,409,O
the,409,O
myocardium,409,O
decreased,409,O
in,409,O
an,409,O
adriamycin,409,B-Chemical
dose-dependent,409,O
manner,409,O
.,409,O
The,410,O
appearance,410,O
of,410,O
impaired,410,O
cardiac,410,O
adrenergic,410,O
neuron,410,O
activity,410,O
in,410,O
the,410,O
presence,410,O
of,410,O
slight,410,O
myocardial,410,B-Disease
impairment,410,I-Disease
(,410,O
scattered,410,O
or,410,O
focal,410,O
vacuolar,410,B-Disease
degeneration,410,I-Disease
),410,O
indicates,410,O
that,410,O
MIBG,410,B-Chemical
scintigraphy,410,O
may,410,O
be,410,O
a,410,O
useful,410,O
method,410,O
for,410,O
detection,410,O
of,410,O
adriamycin-induced,410,B-Chemical
cardiomyopathy,410,B-Disease
.,410,O
Debrisoquine,411,B-Chemical
phenotype,411,O
and,411,O
the,411,O
pharmacokinetics,411,O
and,411,O
beta-2,411,O
receptor,411,O
pharmacodynamics,411,O
of,411,O
metoprolol,411,B-Chemical
and,411,O
its,411,O
enantiomers,411,O
.,411,O
The,412,O
metabolism,412,O
of,412,O
the,412,O
cardioselective,412,O
beta-blocker,412,O
metoprolol,412,B-Chemical
is,412,O
under,412,O
genetic,412,O
control,412,O
of,412,O
the,412,O
debrisoquine/sparteine,412,B-Chemical
type,412,O
.,412,O
The,413,O
two,413,O
metabolic,413,O
phenotypes,413,O
",",413,O
extensive,413,O
(,413,O
EM,413,O
),413,O
and,413,O
poor,413,O
metabolizers,413,O
(,413,O
PM,413,O
),413,O
",",413,O
show,413,O
different,413,O
stereoselective,413,O
metabolism,413,O
",",413,O
resulting,413,O
in,413,O
apparently,413,O
higher,413,O
beta-1,413,O
adrenoceptor,413,O
antagonistic,413,O
potency,413,O
of,413,O
racemic,413,O
metoprolol,413,B-Chemical
in,413,O
EMs,413,O
.,413,O
We,414,O
investigated,414,O
if,414,O
the,414,O
latter,414,O
also,414,O
applies,414,O
to,414,O
the,414,O
beta-2,414,O
adrenoceptor,414,O
antagonism,414,O
by,414,O
metoprolol,414,B-Chemical
.,414,O
The,415,O
drug,415,O
effect,415,O
studied,415,O
was,415,O
the,415,O
antagonism,415,O
by,415,O
metoprolol,415,B-Chemical
of,415,O
terbutaline-induced,415,B-Chemical
hypokalemia,415,B-Disease
.,415,O
By,416,O
using,416,O
pharmacokinetic,416,O
pharmacodynamic,416,O
modeling,416,O
the,416,O
pharmacodynamics,416,O
of,416,O
racemic,416,O
metoprolol,416,B-Chemical
and,416,O
the,416,O
active,416,O
S-isomer,416,O
",",416,O
were,416,O
quantitated,416,O
in,416,O
EMs,416,O
and,416,O
PMs,416,O
in,416,O
terms,416,O
of,416,O
IC50,416,O
values,416,O
",",416,O
representing,416,O
metoprolol,416,B-Chemical
plasma,416,O
concentrations,416,O
resulting,416,O
in,416,O
half-maximum,416,O
receptor,416,O
occupancy,416,O
.,416,O
Six,417,O
EMs,417,O
received,417,O
0.5,417,O
mg,417,O
of,417,O
terbutaline,417,B-Chemical
s.c.,417,O
on,417,O
two,417,O
different,417,O
occasions,417,O
:,417,O
1,417,O
),417,O
1,417,O
hr,417,O
after,417,O
administration,417,O
of,417,O
a,417,O
placebo,417,O
and,417,O
2,417,O
),417,O
1,417,O
hr,417,O
after,417,O
150,417,O
mg,417,O
of,417,O
metoprolol,417,B-Chemical
p.o,417,O
.,417,O
Five,418,O
PMs,418,O
were,418,O
studied,418,O
according,418,O
to,418,O
the,418,O
same,418,O
protocol,418,O
",",418,O
except,418,O
for,418,O
a,418,O
higher,418,O
terbutaline,418,B-Chemical
dose,418,O
(,418,O
0.75,418,O
mg,418,O
),418,O
on,418,O
day,418,O
2,418,O
.,418,O
Blood,419,O
samples,419,O
for,419,O
the,419,O
analysis,419,O
of,419,O
plasma,419,O
potassium,419,B-Chemical
",",419,O
terbutaline,419,B-Chemical
",",419,O
metoprolol,419,B-Chemical
(,419,O
racemic,419,O
",",419,O
R-,419,O
and,419,O
S-isomer,419,O
),419,O
",",419,O
and,419,O
alpha-hydroxymetoprolol,419,B-Chemical
concentrations,419,O
were,419,O
taken,419,O
at,419,O
regular,419,O
time,419,O
intervals,419,O
",",419,O
during,419,O
8,419,O
hr,419,O
after,419,O
metoprolol,419,B-Chemical
.,419,O
In,420,O
PMs,420,O
",",420,O
metoprolol,420,B-Chemical
increased,420,O
the,420,O
terbutaline,420,B-Chemical
area,420,O
under,420,O
the,420,O
plasma,420,O
concentration,420,O
vs.,420,O
time,420,O
curve,420,O
(,420,O
+67,420,O
%,420,O
),420,O
.,420,O
Higher,421,O
metoprolol/alpha-hydroxymetoprolol,421,B-Chemical
ratios,421,O
in,421,O
PMs,421,O
were,421,O
predictive,421,O
for,421,O
higher,421,O
R-/S-isomer,421,O
ratios,421,O
of,421,O
unchanged,421,O
drug,421,O
.,421,O
There,422,O
was,422,O
a,422,O
difference,422,O
in,422,O
metoprolol,422,B-Chemical
potency,422,O
with,422,O
higher,422,O
racemic,422,O
metoprolol,422,B-Chemical
IC50,422,O
values,422,O
in,422,O
PMs,422,O
(,422,O
72,422,O
+/-,422,O
7,422,O
ng.ml-1,422,O
),422,O
than,422,O
EMs,422,O
(,422,O
42,422,O
+/-,422,O
8,422,O
ng.ml-1,422,O
",",422,O
P,422,O
less,422,O
than,422,O
.001,422,O
),422,O
.,422,O
(,423,O
ABSTRACT,423,O
TRUNCATED,423,O
AT,423,O
250,423,O
WORDS,423,O
),423,O
Ifosfamide,424,B-Chemical
continuous,424,O
infusion,424,O
without,424,O
mesna,424,B-Chemical
.,424,O
A,425,O
phase,425,O
I,425,O
trial,425,O
of,425,O
a,425,O
14-day,425,O
cycle,425,O
.,425,O
Twenty,426,O
patients,426,O
received,426,O
27,426,O
courses,426,O
of,426,O
ifosfamide,426,B-Chemical
administered,426,O
as,426,O
a,426,O
24-hour,426,O
continuous,426,O
infusion,426,O
for,426,O
14,426,O
days,426,O
without,426,O
Mesna,426,B-Chemical
.,426,O
The,427,O
goal,427,O
of,427,O
the,427,O
study,427,O
was,427,O
to,427,O
deliver,427,O
a,427,O
dose,427,O
rate,427,O
and,427,O
total,427,O
cumulative,427,O
dose,427,O
of,427,O
ifosfamide,427,B-Chemical
that,427,O
would,427,O
be,427,O
comparable,427,O
to,427,O
standard,427,O
bolus,427,O
or,427,O
short-term,427,O
infusions,427,O
administered,427,O
with,427,O
Mesna,427,B-Chemical
.,427,O
Dose,428,O
escalations,428,O
proceeded,428,O
from,428,O
200,428,O
to,428,O
300,428,O
",",428,O
400,428,O
",",428,O
450,428,O
",",428,O
500,428,O
",",428,O
and,428,O
550,428,O
mg/m2/d,428,O
.,428,O
Four,429,O
patients,429,O
developed,429,O
transient,429,O
microscopic,429,O
hematuria,429,B-Disease
at,429,O
400,429,O
",",429,O
450,429,O
",",429,O
and,429,O
500,429,O
mg/m2/d,429,O
.,429,O
There,430,O
were,430,O
no,430,O
instances,430,O
of,430,O
macroscopic,430,O
hematuria,430,B-Disease
.,430,O
At,431,O
550,431,O
mg/m2/d,431,O
",",431,O
three,431,O
patients,431,O
experienced,431,O
nonurologic,431,O
toxicity,431,B-Disease
;,431,O
confusion,431,B-Disease
(,431,O
1,431,O
),431,O
",",431,O
nausea,431,B-Disease
(,431,O
1,431,O
),431,O
",",431,O
and,431,O
Grade,431,O
2,431,O
leukopenia,431,B-Disease
(,431,O
1,431,O
),431,O
.,431,O
The,432,O
recommended,432,O
dose,432,O
of,432,O
500,432,O
mg/m2/d,432,O
delivers,432,O
a,432,O
total,432,O
dose,432,O
of,432,O
7,432,O
g/m2,432,O
per,432,O
cycle,432,O
",",432,O
which,432,O
is,432,O
comparable,432,O
to,432,O
that,432,O
delivered,432,O
in,432,O
clinical,432,O
practice,432,O
for,432,O
bolus,432,O
or,432,O
short-term,432,O
infusion,432,O
.,432,O
Because,433,O
few,433,O
patients,433,O
received,433,O
multiple,433,O
courses,433,O
over,433,O
time,433,O
",",433,O
the,433,O
cumulative,433,O
effects,433,O
are,433,O
indeterminate,433,O
in,433,O
the,433,O
present,433,O
trial,433,O
.,433,O
The,434,O
frequency,434,O
and,434,O
predictability,434,O
of,434,O
hematuria,434,B-Disease
are,434,O
not,434,O
precise,434,O
",",434,O
and,434,O
at,434,O
least,434,O
daily,434,O
monitoring,434,O
by,434,O
urine,434,O
Hematest,434,O
is,434,O
essential,434,O
",",434,O
adding,434,O
Mesna,434,B-Chemical
to,434,O
the,434,O
infusate,434,O
in,434,O
patients,434,O
with,434,O
persistent,434,O
hematuria,434,B-Disease
.,434,O
The,435,O
protracted,435,O
infusion,435,O
schedule,435,O
for,435,O
ifosfamide,435,B-Chemical
permits,435,O
convenient,435,O
outpatient,435,O
administration,435,O
without,435,O
Mesna,435,B-Chemical
and,435,O
reduces,435,O
the,435,O
drug,435,O
cost,435,O
of,435,O
clinical,435,O
usage,435,O
of,435,O
this,435,O
agent,435,O
by,435,O
up,435,O
to,435,O
890,435,O
per,435,O
cycle,435,O
.,435,O
Clinical,436,O
activity,436,O
was,436,O
demonstrated,436,O
in,436,O
a,436,O
single,436,O
patient,436,O
",",436,O
but,436,O
a,436,O
comparative,436,O
trial,436,O
of,436,O
standard,436,O
bolus,436,O
schedules,436,O
with,436,O
the,436,O
protracted,436,O
infusion,436,O
schedule,436,O
will,436,O
be,436,O
necessary,436,O
to,436,O
determine,436,O
if,436,O
the,436,O
clinical,436,O
effectiveness,436,O
of,436,O
the,436,O
drug,436,O
is,436,O
maintained,436,O
.,436,O
Naloxone,437,B-Chemical
reversal,437,O
of,437,O
hypotension,437,B-Disease
due,437,O
to,437,O
captopril,437,B-Chemical
overdose,437,B-Disease
.,437,O
The,438,O
hemodynamic,438,O
effects,438,O
of,438,O
captopril,438,B-Chemical
and,438,O
other,438,O
angiotensin-converting,438,B-Chemical
enzyme,438,I-Chemical
inhibitors,438,I-Chemical
may,438,O
be,438,O
mediated,438,O
by,438,O
the,438,O
endogenous,438,O
opioid,438,O
system,438,O
.,438,O
The,439,O
opioid,439,O
antagonist,439,O
naloxone,439,B-Chemical
has,439,O
been,439,O
shown,439,O
to,439,O
block,439,O
or,439,O
reverse,439,O
the,439,O
hypotensive,439,B-Disease
actions,439,O
of,439,O
captopril,439,B-Chemical
.,439,O
We,440,O
report,440,O
a,440,O
case,440,O
of,440,O
an,440,O
intentional,440,O
captopril,440,B-Chemical
overdose,440,B-Disease
",",440,O
manifested,440,O
by,440,O
marked,440,O
hypotension,440,B-Disease
",",440,O
that,440,O
resolved,440,O
promptly,440,O
with,440,O
the,440,O
administration,440,O
of,440,O
naloxone,440,B-Chemical
.,440,O
To,441,O
our,441,O
knowledge,441,O
",",441,O
this,441,O
is,441,O
the,441,O
first,441,O
reported,441,O
case,441,O
of,441,O
captopril-induced,441,B-Chemical
hypotension,441,B-Disease
treated,441,O
with,441,O
naloxone,441,B-Chemical
.,441,O
Our,442,O
experience,442,O
demonstrates,442,O
a,442,O
possible,442,O
role,442,O
of,442,O
naloxone,442,B-Chemical
in,442,O
the,442,O
reversal,442,O
of,442,O
hypotension,442,B-Disease
resulting,442,O
from,442,O
captopril,442,B-Chemical
.,442,O
Preservation,443,O
of,443,O
renal,443,O
blood,443,O
flow,443,O
during,443,O
hypotension,443,B-Disease
induced,443,O
with,443,O
fenoldopam,443,B-Chemical
in,443,O
dogs,443,O
.,443,O
The,444,O
introduction,444,O
of,444,O
drugs,444,O
that,444,O
could,444,O
induce,444,O
hypotension,444,B-Disease
with,444,O
different,444,O
pharmacological,444,O
actions,444,O
would,444,O
be,444,O
advantageous,444,O
because,444,O
side,444,O
effects,444,O
unique,444,O
to,444,O
a,444,O
specific,444,O
drug,444,O
could,444,O
be,444,O
minimized,444,O
by,444,O
selecting,444,O
appropriate,444,O
therapy,444,O
.,444,O
Specific,445,O
dopamine-1,445,B-Chemical
",",445,O
(,445,O
DA1,445,B-Chemical
),445,O
and,445,O
dopamine-2,445,B-Chemical
(,445,O
DA2,445,B-Chemical
),445,O
receptor,445,O
agonists,445,O
are,445,O
now,445,O
under,445,O
clinical,445,O
investigation,445,O
.,445,O
Fenoldopam,446,B-Chemical
mesylate,446,I-Chemical
is,446,O
a,446,O
specific,446,O
DA1,446,O
receptor,446,O
agonist,446,O
that,446,O
lowers,446,O
blood,446,O
pressure,446,O
by,446,O
vasodilatation,446,O
.,446,O
The,447,O
hypothesis,447,O
that,447,O
fenoldopam,447,B-Chemical
could,447,O
be,447,O
used,447,O
to,447,O
induce,447,O
hypotension,447,B-Disease
and,447,O
preserve,447,O
blood,447,O
flow,447,O
to,447,O
the,447,O
kidney,447,O
was,447,O
tested,447,O
.,447,O
Systemic,448,O
aortic,448,O
blood,448,O
pressure,448,O
and,448,O
renal,448,O
blood,448,O
flow,448,O
were,448,O
measured,448,O
continuously,448,O
with,448,O
a,448,O
carotid,448,O
arterial,448,O
catheter,448,O
and,448,O
an,448,O
electromagnetic,448,O
flow,448,O
probe,448,O
respectively,448,O
",",448,O
in,448,O
order,448,O
to,448,O
compare,448,O
the,448,O
cardiovascular,448,O
and,448,O
renal,448,O
vascular,448,O
effects,448,O
of,448,O
fenoldopam,448,B-Chemical
and,448,O
sodium,448,B-Chemical
nitroprusside,448,B-Chemical
in,448,O
ten,448,O
dogs,448,O
under,448,O
halothane,448,B-Chemical
general,448,O
anaesthesia,448,O
.,448,O
Mean,449,O
arterial,449,O
pressure,449,O
was,449,O
decreased,449,O
30,449,O
+/-,449,O
8,449,O
per,449,O
cent,449,O
from,449,O
control,449,O
with,449,O
infusion,449,O
of,449,O
fenoldopam,449,B-Chemical
(,449,O
3.4,449,O
+/-,449,O
2.0,449,O
micrograms.kg-1.min-1,449,O
),449,O
and,449,O
34,449,O
+/-,449,O
4,449,O
per,449,O
cent,449,O
with,449,O
infusion,449,O
of,449,O
sodium,449,B-Chemical
nitroprusside,449,B-Chemical
(,449,O
5.9,449,O
micrograms.kg-1.min-1,449,O
),449,O
(,449,O
NS,449,O
),449,O
.,449,O
Renal,450,O
blood,450,O
flow,450,O
(,450,O
RBF,450,O
),450,O
increased,450,O
during,450,O
fenoldopam-induced,450,B-Chemical
hypotension,450,B-Disease
11,450,O
+/-,450,O
7,450,O
per,450,O
cent,450,O
and,450,O
decreased,450,O
21,450,O
+/-,450,O
8,450,O
per,450,O
cent,450,O
during,450,O
sodium,450,B-Chemical
nitroprusside-induced,450,B-Chemical
hypotension,450,B-Disease
(,450,O
P,450,O
less,450,O
than,450,O
0.01,450,O
),450,O
.,450,O
Sodium,451,O
nitroprusside,451,B-Chemical
is,451,O
a,451,O
non-selective,451,O
arteriolar,451,O
and,451,O
venous,451,O
vasodilator,451,O
that,451,O
can,451,O
produce,451,O
redistribution,451,O
of,451,O
blood,451,O
flow,451,O
away,451,O
from,451,O
the,451,O
kidney,451,O
during,451,O
induced,451,O
hypotension,451,B-Disease
.,451,O
Fenoldopam,452,O
is,452,O
a,452,O
selective,452,O
dopamine-1,452,B-Chemical
(,452,O
DA1,452,O
),452,O
receptor,452,O
agonist,452,O
that,452,O
causes,452,O
vasodilatation,452,O
to,452,O
the,452,O
kidney,452,O
and,452,O
other,452,O
organs,452,O
with,452,O
DA1,452,O
receptors,452,O
and,452,O
preserves,452,O
blood,452,O
flow,452,O
to,452,O
the,452,O
kidney,452,O
during,452,O
induced,452,O
hypotension,452,B-Disease
.,452,O
Sensitivity,453,O
of,453,O
erythroid,453,O
progenitor,453,O
colonies,453,O
to,453,O
erythropoietin,453,O
in,453,O
azidothymidine,453,B-Chemical
treated,453,O
immunodeficient,453,B-Disease
mice,453,O
.,453,O
The,454,O
anaemia,454,B-Disease
induced,454,O
by,454,O
3'-azido-3'dideoxythymidine,454,B-Chemical
(,454,O
AZT,454,B-Chemical
),454,O
is,454,O
poorly,454,O
understood,454,O
.,454,O
We,455,O
have,455,O
used,455,O
a,455,O
murine,455,O
model,455,O
of,455,O
AIDS,455,B-Disease
",",455,O
infection,455,B-Disease
of,455,O
female,455,O
C57BL/6,455,O
mice,455,O
with,455,O
LP-BM5,455,O
murine,455,O
leukaemia,455,B-Disease
(,455,O
MuLV,455,O
),455,O
virus,455,O
",",455,O
to,455,O
determine,455,O
if,455,O
AZT-induced,455,B-Chemical
anaemia,455,B-Disease
is,455,O
due,455,O
",",455,O
in,455,O
part,455,O
",",455,O
to,455,O
decreased,455,O
responsiveness,455,O
of,455,O
erythropoietic,455,O
precursors,455,O
(,455,O
BFU-e,455,O
),455,O
to,455,O
erythropoietin,455,O
(,455,O
EPO,455,O
),455,O
.,455,O
Mice,456,O
in,456,O
the,456,O
early,456,O
stage,456,O
of,456,O
LP-BM5,456,O
MuLV,456,O
disease,456,O
were,456,O
given,456,O
AZT,456,B-Chemical
in,456,O
their,456,O
drinking,456,O
water,456,O
at,456,O
1.0,456,O
and,456,O
2.5,456,O
mg/ml,456,O
.,456,O
AZT,457,B-Chemical
produced,457,O
anaemia,457,B-Disease
in,457,O
both,457,O
groups,457,O
",",457,O
in,457,O
a,457,O
dose-dependent,457,O
fashion,457,O
.,457,O
Despite,458,O
the,458,O
anaemia,458,B-Disease
",",458,O
the,458,O
number,458,O
of,458,O
splenic,458,O
and,458,O
bone,458,O
marrow,458,O
BFU-e,458,O
in,458,O
AZT,458,B-Chemical
treated,458,O
mice,458,O
increased,458,O
up,458,O
to,458,O
five-fold,458,O
over,458,O
levels,458,O
observed,458,O
in,458,O
infected,458,O
untreated,458,O
animals,458,O
after,458,O
15,458,O
d,458,O
of,458,O
treatment,458,O
.,458,O
Colony,459,O
formation,459,O
by,459,O
splenic,459,O
and,459,O
bone,459,O
marrow,459,O
BFUe,459,O
was,459,O
stimulated,459,O
at,459,O
lower,459,O
concentrations,459,O
of,459,O
EPO,459,O
in,459,O
mice,459,O
receiving,459,O
AZT,459,B-Chemical
for,459,O
15,459,O
d,459,O
than,459,O
for,459,O
infected,459,O
",",459,O
untreated,459,O
mice,459,O
.,459,O
By,460,O
day,460,O
30,460,O
",",460,O
sensitivity,460,O
of,460,O
both,460,O
splenic,460,O
and,460,O
bone,460,O
marrow,460,O
BFU-e,460,O
of,460,O
treated,460,O
animals,460,O
returned,460,O
to,460,O
that,460,O
observed,460,O
from,460,O
cells,460,O
of,460,O
infected,460,O
untreated,460,O
animals,460,O
.,460,O
The,461,O
mean,461,O
plasma,461,O
levels,461,O
of,461,O
EPO,461,O
observed,461,O
in,461,O
AZT,461,B-Chemical
treated,461,O
mice,461,O
were,461,O
appropriate,461,O
for,461,O
the,461,O
degree,461,O
of,461,O
anaemia,461,B-Disease
observed,461,O
when,461,O
compared,461,O
with,461,O
phenylhydrazine,461,B-Chemical
(,461,O
PHZ,461,B-Chemical
),461,O
treated,461,O
mice,461,O
.,461,O
The,462,O
numbers,462,O
of,462,O
BFU-e,462,O
and,462,O
the,462,O
percentage,462,O
of,462,O
bone,462,O
marrow,462,O
erythroblasts,462,O
observed,462,O
were,462,O
comparable,462,O
in,462,O
AZT,462,B-Chemical
and,462,O
PHZ,462,B-Chemical
treated,462,O
mice,462,O
with,462,O
similar,462,O
degrees,462,O
of,462,O
anaemia,462,B-Disease
.,462,O
However,463,O
",",463,O
reticulocytosis,463,B-Disease
was,463,O
inappropriate,463,O
for,463,O
the,463,O
degree,463,O
of,463,O
anaemia,463,B-Disease
observed,463,O
in,463,O
AZT,463,B-Chemical
treated,463,O
infected,463,O
mice,463,O
.,463,O
AZT-induced,464,B-Chemical
peripheral,464,O
anaemia,464,B-Disease
in,464,O
the,464,O
face,464,O
of,464,O
increased,464,O
numbers,464,O
of,464,O
BFU-e,464,O
and,464,O
increased,464,O
levels,464,O
of,464,O
plasma,464,O
EPO,464,O
suggest,464,O
a,464,O
lesion,464,O
in,464,O
terminal,464,O
differentiation,464,O
.,464,O
Renal,465,O
function,465,O
and,465,O
hemodynamics,465,O
during,465,O
prolonged,465,O
isoflurane-induced,465,B-Chemical
hypotension,465,B-Disease
in,465,O
humans,465,O
.,465,O
The,466,O
effect,466,O
of,466,O
isoflurane-induced,466,B-Chemical
hypotension,466,B-Disease
on,466,O
glomerular,466,O
function,466,O
and,466,O
renal,466,O
blood,466,O
flow,466,O
was,466,O
investigated,466,O
in,466,O
20,466,O
human,466,O
subjects,466,O
.,466,O
Glomerular,467,O
filtration,467,O
rate,467,O
(,467,O
GFR,467,O
),467,O
and,467,O
effective,467,O
renal,467,O
plasma,467,O
flow,467,O
(,467,O
ERPF,467,O
),467,O
were,467,O
measured,467,O
by,467,O
inulin,467,O
and,467,O
para-aminohippurate,467,B-Chemical
(,467,O
PAH,467,B-Chemical
),467,O
clearance,467,O
",",467,O
respectively,467,O
.,467,O
Anesthesia,468,O
was,468,O
maintained,468,O
with,468,O
fentanyl,468,B-Chemical
",",468,O
nitrous,468,B-Chemical
oxide,468,I-Chemical
",",468,O
oxygen,468,B-Chemical
",",468,O
and,468,O
isoflurane,468,B-Chemical
.,468,O
Hypotension,469,B-Disease
was,469,O
induced,469,O
for,469,O
236.9,469,O
+/-,469,O
15.1,469,O
min,469,O
by,469,O
increasing,469,O
the,469,O
isoflurane,469,B-Chemical
inspired,469,O
concentration,469,O
to,469,O
maintain,469,O
a,469,O
mean,469,O
arterial,469,O
pressure,469,O
of,469,O
59.8,469,O
+/-,469,O
0.4,469,O
mmHg,469,O
.,469,O
GFR,470,O
and,470,O
ERPF,470,O
decreased,470,O
with,470,O
the,470,O
induction,470,O
of,470,O
anesthesia,470,O
but,470,O
not,470,O
significantly,470,O
more,470,O
during,470,O
hypotension,470,B-Disease
.,470,O
Postoperatively,471,O
",",471,O
ERPF,471,O
returned,471,O
to,471,O
preoperative,471,O
values,471,O
",",471,O
whereas,471,O
GFR,471,O
was,471,O
higher,471,O
than,471,O
preoperative,471,O
values,471,O
.,471,O
Renal,472,O
vascular,472,O
resistance,472,O
increased,472,O
during,472,O
anesthesia,472,O
but,472,O
decreased,472,O
when,472,O
hypotension,472,B-Disease
was,472,O
induced,472,O
",",472,O
allowing,472,O
the,472,O
maintenance,472,O
of,472,O
renal,472,O
blood,472,O
flow,472,O
.,472,O
We,473,O
conclude,473,O
that,473,O
renal,473,O
compensatory,473,O
mechanisms,473,O
are,473,O
preserved,473,O
during,473,O
isoflurane-induced,473,B-Chemical
hypotension,473,B-Disease
and,473,O
that,473,O
renal,473,O
function,473,O
and,473,O
hemodynamics,473,O
quickly,473,O
return,473,O
to,473,O
normal,473,O
when,473,O
normotension,473,O
is,473,O
resumed,473,O
.,473,O
Reversible,474,O
cholestasis,474,B-Disease
with,474,O
bile,474,B-Disease
duct,474,I-Disease
injury,474,I-Disease
following,474,O
azathioprine,474,B-Chemical
therapy,474,O
.,474,O
A,475,O
case,475,O
report,475,O
.,475,O
A,476,O
67-year-old,476,O
patient,476,O
",",476,O
with,476,O
primary,476,O
polymyositis,476,B-Disease
and,476,O
without,476,O
previous,476,O
evidence,476,O
of,476,O
liver,476,B-Disease
disease,476,I-Disease
",",476,O
developed,476,O
clinical,476,O
and,476,O
biochemical,476,O
features,476,O
of,476,O
severe,476,O
cholestasis,476,B-Disease
3,476,O
months,476,O
after,476,O
initiation,476,O
of,476,O
azathioprine,476,B-Chemical
therapy,476,O
.,476,O
Liver,477,O
biopsy,477,O
showed,477,O
cholestasis,477,B-Disease
with,477,O
both,477,O
cytological,477,O
and,477,O
architectural,477,O
alterations,477,O
of,477,O
interlobular,477,O
bile,477,O
ducts,477,O
.,477,O
Azathioprine,478,B-Chemical
withdrawal,478,O
resulted,478,O
after,478,O
7,478,O
weeks,478,O
in,478,O
the,478,O
resolution,478,O
of,478,O
clinical,478,O
and,478,O
biochemical,478,O
abnormalities,478,O
.,478,O
It,479,O
is,479,O
believed,479,O
that,479,O
this,479,O
is,479,O
the,479,O
first,479,O
reported,479,O
case,479,O
of,479,O
reversible,479,O
azathioprine-induced,479,B-Chemical
cholestasis,479,B-Disease
associated,479,O
with,479,O
histological,479,O
evidence,479,O
of,479,O
bile,479,B-Disease
duct,479,I-Disease
injury,479,I-Disease
.,479,O
The,480,O
ability,480,O
of,480,O
insulin,480,O
treatment,480,O
to,480,O
reverse,480,O
or,480,O
prevent,480,O
the,480,O
changes,480,O
in,480,O
urinary,480,O
bladder,480,O
function,480,O
caused,480,O
by,480,O
streptozotocin-induced,480,B-Chemical
diabetes,480,B-Disease
mellitus,480,I-Disease
.,480,O
1,481,O
.,481,O
The,482,O
effects,482,O
of,482,O
insulin,482,O
treatment,482,O
on,482,O
in,482,O
vivo,482,O
and,482,O
in,482,O
vitro,482,O
urinary,482,O
bladder,482,O
function,482,O
in,482,O
streptozotocin-diabetic,482,B-Chemical
rats,482,O
were,482,O
investigated,482,O
.,482,O
2,483,O
.,483,O
Diabetes,484,B-Disease
of,484,O
2,484,O
months,484,O
duration,484,O
resulted,484,O
in,484,O
decreases,484,O
in,484,O
body,484,O
weight,484,O
and,484,O
increases,484,O
in,484,O
fluid,484,O
consumption,484,O
",",484,O
urine,484,O
volume,484,O
",",484,O
frequency,484,O
of,484,O
micturition,484,O
",",484,O
and,484,O
average,484,O
volume,484,O
per,484,O
micturition,484,O
;,484,O
effects,484,O
which,484,O
were,484,O
prevented,484,O
by,484,O
insulin,484,O
treatment,484,O
.,484,O
3,485,O
.,485,O
Insulin,486,O
treatment,486,O
also,486,O
prevented,486,O
the,486,O
increases,486,O
in,486,O
contractile,486,O
responses,486,O
of,486,O
bladder,486,O
body,486,O
strips,486,O
from,486,O
diabetic,486,B-Disease
rats,486,O
to,486,O
nerve,486,O
stimulation,486,O
",",486,O
ATP,486,B-Chemical
",",486,O
and,486,O
bethanechol,486,B-Chemical
.,486,O
4,487,O
.,487,O
Diabetes,488,B-Disease
of,488,O
4,488,O
months,488,O
duration,488,O
also,488,O
resulted,488,O
in,488,O
decreases,488,O
in,488,O
body,488,O
weight,488,O
",",488,O
and,488,O
increases,488,O
in,488,O
fluid,488,O
consumption,488,O
",",488,O
urine,488,O
volume,488,O
",",488,O
frequency,488,O
of,488,O
micturition,488,O
",",488,O
and,488,O
average,488,O
volume,488,O
per,488,O
micturition,488,O
",",488,O
effects,488,O
which,488,O
were,488,O
reversed,488,O
by,488,O
insulin,488,O
treatment,488,O
for,488,O
the,488,O
final,488,O
2,488,O
months,488,O
of,488,O
the,488,O
study,488,O
.,488,O
5,489,O
.,489,O
Insulin,490,O
treatment,490,O
reversed,490,O
the,490,O
increases,490,O
in,490,O
contractile,490,O
responses,490,O
of,490,O
bladder,490,O
body,490,O
strips,490,O
from,490,O
diabetic,490,B-Disease
rats,490,O
to,490,O
nerve,490,O
stimulation,490,O
",",490,O
ATP,490,B-Chemical
",",490,O
and,490,O
bethanechol,490,B-Chemical
.,490,O
6,491,O
.,491,O
The,492,O
data,492,O
indicate,492,O
that,492,O
the,492,O
effects,492,O
of,492,O
streptozotocin-induced,492,B-Chemical
diabetes,492,B-Disease
on,492,O
urinary,492,O
bladder,492,O
function,492,O
are,492,O
both,492,O
prevented,492,O
and,492,O
reversed,492,O
by,492,O
insulin,492,O
treatment,492,O
.,492,O
Central,493,O
vein,493,B-Disease
thrombosis,493,I-Disease
and,493,O
topical,493,O
dipivalyl,493,B-Chemical
epinephrine,493,I-Chemical
.,493,O
A,494,O
report,494,O
is,494,O
given,494,O
on,494,O
an,494,O
83-year-old,494,O
female,494,O
who,494,O
acquired,494,O
central,494,O
vein,494,B-Disease
thrombosis,494,I-Disease
in,494,O
her,494,O
seeing,494,O
eye,494,O
one,494,O
day,494,O
after,494,O
having,494,O
started,494,O
topical,494,O
medication,494,O
with,494,O
dipivalyl,494,B-Chemical
epinephrine,494,I-Chemical
for,494,O
advanced,494,O
glaucoma,494,B-Disease
discovered,494,O
in,494,O
the,494,O
other,494,O
eye,494,O
.,494,O
From,495,O
present,495,O
knowledge,495,O
about,495,O
the,495,O
effects,495,O
of,495,O
adrenergic,495,O
eye,495,O
drops,495,O
on,495,O
ocular,495,O
blood,495,O
circulation,495,O
",",495,O
it,495,O
is,495,O
difficult,495,O
to,495,O
suggest,495,O
an,495,O
association,495,O
between,495,O
the,495,O
two,495,O
events,495,O
",",495,O
which,495,O
may,495,O
be,495,O
coincidental,495,O
only,495,O
.,495,O
Benzylacyclouridine,496,B-Chemical
reverses,496,O
azidothymidine-induced,496,B-Chemical
marrow,496,B-Disease
suppression,496,I-Disease
without,496,O
impairment,496,O
of,496,O
anti-human,496,O
immunodeficiency,496,B-Disease
virus,496,O
activity,496,O
.,496,O
Increased,497,O
extracellular,497,O
concentrations,497,O
of,497,O
uridine,497,B-Chemical
(,497,O
Urd,497,B-Chemical
),497,O
have,497,O
been,497,O
reported,497,O
to,497,O
reduce,497,O
",",497,O
in,497,O
vitro,497,O
",",497,O
azidothymidine,497,B-Chemical
(,497,O
AZT,497,B-Chemical
),497,O
-induced,497,O
inhibition,497,O
of,497,O
human,497,O
granulocyte-macrophage,497,O
progenitor,497,O
cells,497,O
without,497,O
impairment,497,O
of,497,O
its,497,O
antihuman,497,O
immunodeficiency,497,B-Disease
virus,497,O
(,497,O
HIV,497,O
),497,O
activity,497,O
.,497,O
Because,498,O
of,498,O
the,498,O
clinical,498,O
toxicities,498,B-Disease
associated,498,O
with,498,O
chronic,498,O
Urd,498,B-Chemical
administration,498,O
",",498,O
the,498,O
ability,498,O
of,498,O
benzylacyclouridine,498,B-Chemical
(,498,O
BAU,498,B-Chemical
),498,O
to,498,O
effect,498,O
",",498,O
in,498,O
vivo,498,O
",",498,O
AZT-induced,498,B-Chemical
anemia,498,B-Disease
and,498,O
leukopenia,498,B-Disease
was,498,O
assessed,498,O
.,498,O
This,499,O
agent,499,O
inhibits,499,O
Urd,499,B-Chemical
catabolism,499,O
and,499,O
",",499,O
in,499,O
vivo,499,O
",",499,O
increases,499,O
the,499,O
plasma,499,O
concentration,499,O
of,499,O
Urd,499,B-Chemical
in,499,O
a,499,O
dose-dependent,499,O
manner,499,O
",",499,O
without,499,O
Urd-related,499,B-Chemical
toxicity,499,B-Disease
.,499,O
In,500,O
mice,500,O
rendered,500,O
anemic,500,B-Disease
and,500,O
leukopenic,500,B-Disease
by,500,O
the,500,O
administration,500,O
of,500,O
AZT,500,B-Chemical
for,500,O
28,500,O
days,500,O
in,500,O
drinking,500,O
water,500,O
(,500,O
1.5,500,O
mg/mL,500,O
),500,O
",",500,O
the,500,O
continued,500,O
administration,500,O
of,500,O
AZT,500,B-Chemical
plus,500,O
daily,500,O
BAU,500,B-Chemical
(,500,O
300,500,O
mg/kg,500,O
",",500,O
orally,500,O
),500,O
partially,500,O
reversed,500,O
AZT-induced,500,B-Chemical
anemia,500,B-Disease
and,500,O
leukopenia,500,B-Disease
(,500,O
P,500,O
less,500,O
than,500,O
.05,500,O
),500,O
",",500,O
increased,500,O
peripheral,500,O
reticulocytes,500,O
(,500,O
to,500,O
4.9,500,O
%,500,O
",",500,O
P,500,O
less,500,O
than,500,O
.01,500,O
),500,O
",",500,O
increased,500,O
cellularity,500,O
in,500,O
the,500,O
marrow,500,O
",",500,O
and,500,O
improved,500,O
megaloblastosis,500,B-Disease
.,500,O
When,501,O
coadministered,501,O
with,501,O
AZT,501,B-Chemical
from,501,O
the,501,O
onset,501,O
of,501,O
drug,501,O
administration,501,O
",",501,O
BAU,501,B-Chemical
reduced,501,O
AZT-induced,501,B-Chemical
marrow,501,B-Disease
toxicity,501,I-Disease
.,501,O
In,502,O
vitro,502,O
",",502,O
at,502,O
a,502,O
concentration,502,O
of,502,O
100,502,O
mumol/L,502,O
",",502,O
BAU,502,B-Chemical
possesses,502,O
minimal,502,O
anti-HIV,502,O
activity,502,O
and,502,O
has,502,O
no,502,O
effect,502,O
on,502,O
the,502,O
ability,502,O
of,502,O
AZT,502,B-Chemical
to,502,O
reverse,502,O
the,502,O
HIV-induced,502,O
cytopathic,502,O
effect,502,O
in,502,O
MT4,502,O
cells,502,O
.,502,O
The,503,O
clinical,503,O
and,503,O
biochemical,503,O
implications,503,O
of,503,O
these,503,O
findings,503,O
are,503,O
discussed,503,O
.,503,O
Lethal,504,O
anuria,504,B-Disease
complicating,504,O
high,504,O
dose,504,O
ifosfamide,504,B-Chemical
chemotherapy,504,O
in,504,O
a,504,O
breast,504,B-Disease
cancer,504,I-Disease
patient,504,O
with,504,O
an,504,O
impaired,504,B-Disease
renal,504,I-Disease
function,504,I-Disease
.,504,O
A,505,O
sixty-year-old,505,O
woman,505,O
with,505,O
advanced,505,O
breast,505,B-Disease
cancer,505,I-Disease
",",505,O
previously,505,O
treated,505,O
with,505,O
cisplatin,505,B-Chemical
",",505,O
developed,505,O
an,505,O
irreversible,505,O
lethal,505,O
renal,505,B-Disease
failure,505,I-Disease
with,505,O
anuria,505,B-Disease
",",505,O
the,505,O
day,505,O
after,505,O
5,505,O
g/m2,505,O
bolus,505,O
ifosfamide,505,B-Chemical
.,505,O
Postrenal,506,B-Disease
failure,506,I-Disease
was,506,O
excluded,506,O
by,506,O
echography,506,O
.,506,O
A,507,O
prerenal,507,O
component,507,O
could,507,O
have,507,O
contributed,507,O
to,507,O
renal,507,B-Disease
failure,507,I-Disease
because,507,O
of,507,O
a,507,O
transient,507,O
hypotension,507,B-Disease
",",507,O
due,507,O
to,507,O
an,507,O
increasing,507,O
ascitis,507,O
",",507,O
occurring,507,O
just,507,O
before,507,O
anuria,507,B-Disease
.,507,O
However,508,O
",",508,O
correction,508,O
of,508,O
the,508,O
hemodynamic,508,O
parameters,508,O
did,508,O
not,508,O
improve,508,O
renal,508,O
function,508,O
.,508,O
Ifosfamide,509,B-Chemical
is,509,O
a,509,O
known,509,O
nephrotoxic,509,B-Disease
drug,509,O
with,509,O
demonstrated,509,O
tubulopathies,509,B-Disease
.,509,O
We,510,O
strongly,510,O
suspect,510,O
that,510,O
this,510,O
lethal,510,O
anuria,510,B-Disease
was,510,O
mainly,510,O
due,510,O
to,510,O
ifosfamide,510,B-Chemical
",",510,O
occurring,510,O
in,510,O
a,510,O
patient,510,O
having,510,O
received,510,O
previous,510,O
cisplatin,510,B-Chemical
chemotherapy,510,O
and,510,O
with,510,O
poor,510,O
kidney,510,O
perfusion,510,O
due,510,O
to,510,O
transient,510,O
hypotension,510,B-Disease
.,510,O
We,511,O
recommend,511,O
careful,511,O
use,511,O
of,511,O
ifosfamide,511,B-Chemical
in,511,O
patients,511,O
pretreated,511,O
with,511,O
nephrotoxic,511,B-Disease
chemotherapy,511,O
and,511,O
inadequate,511,O
renal,511,O
perfusion,511,O
.,511,O
Nociceptive,512,O
effects,512,O
induced,512,O
by,512,O
intrathecal,512,O
administration,512,O
of,512,O
prostaglandin,512,O
D2,512,O
",",512,O
E2,512,O
",",512,O
or,512,O
F2,512,O
alpha,512,O
to,512,O
conscious,512,O
mice,512,O
.,512,O
The,513,O
effects,513,O
of,513,O
intrathecal,513,O
administration,513,O
of,513,O
prostaglandins,513,B-Chemical
on,513,O
pain,513,B-Disease
responses,513,O
in,513,O
conscious,513,O
mice,513,O
were,513,O
evaluated,513,O
by,513,O
using,513,O
hot,513,O
plate,513,O
and,513,O
acetic,513,B-Chemical
acid,513,I-Chemical
writhing,513,O
tests,513,O
.,513,O
Prostaglandin,514,B-Chemical
D2,514,I-Chemical
(,514,O
0.5-3,514,O
ng/mouse,514,O
),514,O
had,514,O
a,514,O
hyperalgesic,514,B-Disease
action,514,O
on,514,O
the,514,O
response,514,O
to,514,O
a,514,O
hot,514,O
plate,514,O
during,514,O
a,514,O
3-60,514,O
min,514,O
period,514,O
after,514,O
injection,514,O
.,514,O
Prostaglandin,515,B-Chemical
E2,515,I-Chemical
showed,515,O
a,515,O
hyperalgesic,515,B-Disease
effect,515,O
at,515,O
doses,515,O
of,515,O
1,515,O
pg,515,B-Chemical
to,515,O
10,515,O
ng/mouse,515,O
",",515,O
but,515,O
the,515,O
effect,515,O
lasted,515,O
shorter,515,O
(,515,O
3-30,515,O
min,515,O
),515,O
than,515,O
that,515,O
of,515,O
prostaglandin,515,B-Chemical
D2,515,I-Chemical
.,515,O
Similar,516,O
results,516,O
were,516,O
obtained,516,O
by,516,O
acetic,516,B-Chemical
acid,516,I-Chemical
writhing,516,O
tests,516,O
.,516,O
The,517,O
hyperalgesic,517,B-Disease
effect,517,O
of,517,O
prostaglandin,517,B-Chemical
D2,517,I-Chemical
was,517,O
blocked,517,O
by,517,O
simultaneous,517,O
injection,517,O
of,517,O
a,517,O
substance,517,O
P,517,O
antagonist,517,O
(,517,O
greater,517,O
than,517,O
or,517,O
equal,517,O
to,517,O
100,517,O
ng,517,O
),517,O
but,517,O
not,517,O
by,517,O
AH6809,517,B-Chemical
",",517,O
a,517,O
prostanoid,517,O
EP1-receptor,517,O
antagonist,517,O
.,517,O
Conversely,518,O
",",518,O
prostaglandin,518,B-Chemical
E2-induced,518,O
hyperalgesia,518,B-Disease
was,518,O
blocked,518,O
by,518,O
AH6809,518,B-Chemical
(,518,O
greater,518,O
than,518,O
or,518,O
equal,518,O
to,518,O
500,518,O
ng,518,O
),518,O
but,518,O
not,518,O
by,518,O
the,518,O
substance,518,O
P,518,O
antagonist,518,O
.,518,O
Prostaglandin,519,B-Chemical
F2,519,I-Chemical
alpha,519,I-Chemical
had,519,O
little,519,O
effect,519,O
on,519,O
pain,519,B-Disease
responses,519,O
.,519,O
These,520,O
results,520,O
demonstrate,520,O
that,520,O
both,520,O
prostaglandin,520,B-Chemical
D2,520,I-Chemical
and,520,O
prostaglandin,520,B-Chemical
E2,520,I-Chemical
exert,520,O
hyperalgesia,520,B-Disease
in,520,O
the,520,O
spinal,520,O
cord,520,O
",",520,O
but,520,O
in,520,O
different,520,O
ways,520,O
.,520,O
D-penicillamine,521,B-Chemical
in,521,O
the,521,O
treatment,521,O
of,521,O
localized,521,B-Disease
scleroderma,521,I-Disease
.,521,O
Localized,522,B-Disease
scleroderma,522,I-Disease
has,522,O
no,522,O
recognized,522,O
internal,522,O
organ,522,O
involvement,522,O
but,522,O
may,522,O
be,522,O
disfiguring,522,O
and,522,O
disabling,522,O
when,522,O
the,522,O
cutaneous,522,O
lesions,522,O
are,522,O
extensive,522,O
or,522,O
affect,522,O
children,522,O
.,522,O
There,523,O
is,523,O
no,523,O
accepted,523,O
or,523,O
proven,523,O
treatment,523,O
for,523,O
localized,523,B-Disease
scleroderma,523,I-Disease
.,523,O
Case,524,O
reports,524,O
of,524,O
11,524,O
patients,524,O
with,524,O
severe,524,O
",",524,O
extensive,524,O
localized,524,B-Disease
scleroderma,524,I-Disease
who,524,O
were,524,O
treated,524,O
with,524,O
D-penicillamine,524,B-Chemical
are,524,O
summarized,524,O
in,524,O
this,524,O
article,524,O
.,524,O
This,525,O
drug,525,O
was,525,O
judged,525,O
to,525,O
have,525,O
a,525,O
favorable,525,O
effect,525,O
on,525,O
the,525,O
disease,525,O
course,525,O
in,525,O
7,525,O
(,525,O
64,525,O
%,525,O
),525,O
of,525,O
11,525,O
patients,525,O
.,525,O
Improvement,526,O
began,526,O
within,526,O
3,526,O
to,526,O
6,526,O
months,526,O
and,526,O
consisted,526,O
of,526,O
cessation,526,O
of,526,O
active,526,O
cutaneous,526,O
lesions,526,O
in,526,O
all,526,O
7,526,O
patients,526,O
",",526,O
skin,526,O
softening,526,O
in,526,O
5,526,O
",",526,O
and,526,O
more,526,O
normal,526,O
growth,526,O
of,526,O
the,526,O
affected,526,O
limb,526,O
in,526,O
2,526,O
of,526,O
3,526,O
children,526,O
.,526,O
Joint,527,O
stiffness,527,O
and,527,O
contractures,527,B-Disease
also,527,O
improved,527,O
.,527,O
The,528,O
dose,528,O
of,528,O
D-penicillamine,528,B-Chemical
associated,528,O
with,528,O
a,528,O
favorable,528,O
response,528,O
was,528,O
as,528,O
low,528,O
as,528,O
2,528,O
to,528,O
5,528,O
mg/kg,528,O
per,528,O
day,528,O
given,528,O
over,528,O
a,528,O
period,528,O
ranging,528,O
from,528,O
15,528,O
to,528,O
53,528,O
months,528,O
.,528,O
D-Penicillamine,529,B-Chemical
caused,529,O
nephrotic,529,B-Disease
syndrome,529,I-Disease
in,529,O
1,529,O
patient,529,O
and,529,O
milder,529,O
reversible,529,O
proteinuria,529,B-Disease
in,529,O
3,529,O
other,529,O
patients,529,O
;,529,O
none,529,O
developed,529,O
renal,529,B-Disease
insufficiency,529,I-Disease
.,529,O
These,530,O
data,530,O
suggest,530,O
that,530,O
D-penicillamine,530,B-Chemical
may,530,O
be,530,O
effective,530,O
in,530,O
severe,530,O
cases,530,O
of,530,O
localized,530,B-Disease
scleroderma,530,I-Disease
.,530,O
Cerebral,531,B-Disease
sinus,531,I-Disease
thrombosis,531,I-Disease
as,531,O
a,531,O
potential,531,O
hazard,531,O
of,531,O
antifibrinolytic,531,O
treatment,531,O
in,531,O
menorrhagia,531,B-Disease
.,531,O
We,532,O
describe,532,O
a,532,O
42-year-old,532,O
woman,532,O
who,532,O
developed,532,O
superior,532,O
sagittal,532,O
and,532,O
left,532,O
transverse,532,O
sinus,532,O
thrombosis,532,O
associated,532,O
with,532,O
prolonged,532,O
epsilon-aminocaproic,532,B-Chemical
acid,532,I-Chemical
therapy,532,O
for,532,O
menorrhagia,532,B-Disease
.,532,O
This,533,O
antifibrinolytic,533,O
agent,533,O
has,533,O
been,533,O
used,533,O
in,533,O
women,533,O
with,533,O
menorrhagia,533,B-Disease
to,533,O
promote,533,O
clotting,533,O
and,533,O
reduce,533,O
blood,533,B-Disease
loss,533,I-Disease
.,533,O
Although,534,O
increased,534,O
risk,534,O
of,534,O
thromboembolic,534,B-Disease
disease,534,I-Disease
has,534,O
been,534,O
reported,534,O
during,534,O
treatment,534,O
with,534,O
epsilon-aminocaproic,534,B-Chemical
acid,534,I-Chemical
",",534,O
cerebral,534,B-Disease
sinus,534,I-Disease
thrombosis,534,I-Disease
has,534,O
not,534,O
been,534,O
previously,534,O
described,534,O
.,534,O
Careful,535,O
use,535,O
of,535,O
epsilon-aminocaproic,535,B-Chemical
acid,535,I-Chemical
therapy,535,O
is,535,O
recommended,535,O
.,535,O
Seizure,536,B-Disease
activity,536,O
with,536,O
imipenem,536,B-Chemical
therapy,536,O
:,536,O
incidence,536,O
and,536,O
risk,536,O
factors,536,O
.,536,O
Two,537,O
elderly,537,O
patients,537,O
with,537,O
a,537,O
history,537,O
of,537,O
either,537,O
cerebral,537,B-Disease
vascular,537,I-Disease
accident,537,I-Disease
(,537,O
CVA,537,B-Disease
),537,O
or,537,O
head,537,B-Disease
trauma,537,I-Disease
and,537,O
no,537,O
evidence,537,O
of,537,O
renal,537,B-Disease
disease,537,I-Disease
developed,537,O
seizures,537,B-Disease
while,537,O
receiving,537,O
maximum,537,O
doses,537,O
of,537,O
imipenem/cilastatin,537,B-Chemical
.,537,O
Neither,538,O
patient,538,O
had,538,O
reported,538,O
previous,538,O
seizures,538,B-Disease
or,538,O
seizure-like,538,B-Disease
activity,538,O
nor,538,O
was,538,O
receiving,538,O
anticonvulsant,538,O
agents,538,O
.,538,O
All,539,O
seizures,539,B-Disease
were,539,O
controlled,539,O
with,539,O
therapeutic,539,O
doses,539,O
of,539,O
phenytoin,539,B-Chemical
.,539,O
Both,540,O
patients,540,O
had,540,O
received,540,O
maximum,540,O
doses,540,O
of,540,O
other,540,O
beta-lactam,540,B-Chemical
antibiotics,540,O
without,540,O
evidence,540,O
of,540,O
seizure,540,B-Disease
activity,540,O
.,540,O
Midline,541,O
B3,541,O
serotonin,541,B-Chemical
nerves,541,O
in,541,O
rat,541,O
medulla,541,O
are,541,O
involved,541,O
in,541,O
hypotensive,541,B-Disease
effect,541,O
of,541,O
methyldopa,541,B-Chemical
.,541,O
Previous,542,O
experiments,542,O
in,542,O
this,542,O
laboratory,542,O
have,542,O
shown,542,O
that,542,O
microinjection,542,O
of,542,O
methyldopa,542,B-Chemical
onto,542,O
the,542,O
ventrolateral,542,O
cells,542,O
of,542,O
the,542,O
B3,542,O
serotonin,542,B-Chemical
neurons,542,O
in,542,O
the,542,O
medulla,542,O
elicits,542,O
a,542,O
hypotensive,542,B-Disease
response,542,O
mediated,542,O
by,542,O
a,542,O
projection,542,O
descending,542,O
into,542,O
the,542,O
spinal,542,O
cord,542,O
.,542,O
The,543,O
present,543,O
experiments,543,O
were,543,O
designed,543,O
to,543,O
investigate,543,O
the,543,O
role,543,O
of,543,O
the,543,O
midline,543,O
cells,543,O
of,543,O
the,543,O
B3,543,O
serotonin,543,B-Chemical
neurons,543,O
in,543,O
the,543,O
medulla,543,O
",",543,O
coinciding,543,O
with,543,O
the,543,O
raphe,543,O
magnus,543,O
.,543,O
In,544,O
spontaneously,544,O
hypertensive,544,B-Disease
",",544,O
stroke-prone,544,B-Disease
rats,544,O
",",544,O
microinjection,544,O
of,544,O
methyldopa,544,B-Chemical
into,544,O
the,544,O
area,544,O
of,544,O
the,544,O
midline,544,O
B3,544,O
serotonin,544,B-Chemical
cell,544,O
group,544,O
in,544,O
the,544,O
ventral,544,O
medulla,544,O
caused,544,O
a,544,O
potent,544,O
hypotension,544,B-Disease
of,544,O
30-40,544,O
mm,544,O
Hg,544,O
",",544,O
which,544,O
was,544,O
maximal,544,O
2-3,544,O
h,544,O
after,544,O
administration,544,O
and,544,O
was,544,O
abolished,544,O
by,544,O
the,544,O
serotonin,544,B-Chemical
neurotoxin,544,O
"5,7-dihydroxytryptamine",544,B-Chemical
(,544,O
"5,7-DHT",544,B-Chemical
),544,O
injected,544,O
intracerebroventricularly,544,O
.,544,O
However,545,O
",",545,O
intraspinal,545,O
injection,545,O
of,545,O
"5,7-DHT",545,B-Chemical
to,545,O
produce,545,O
a,545,O
more,545,O
selective,545,O
lesion,545,O
of,545,O
only,545,O
descending,545,O
serotonin,545,B-Chemical
projections,545,O
in,545,O
the,545,O
spinal,545,O
cord,545,O
did,545,O
not,545,O
affect,545,O
this,545,O
hypotension,545,B-Disease
.,545,O
Further,546,O
",",546,O
"5,7-DHT",546,B-Chemical
lesion,546,O
of,546,O
serotonin,546,B-Chemical
nerves,546,O
travelling,546,O
in,546,O
the,546,O
median,546,O
forebrain,546,O
bundle,546,O
",",546,O
one,546,O
of,546,O
the,546,O
main,546,O
ascending,546,O
pathways,546,O
from,546,O
the,546,O
B3,546,O
serotonin,546,B-Chemical
cells,546,O
",",546,O
did,546,O
not,546,O
affect,546,O
the,546,O
fall,546,O
in,546,O
blood,546,O
pressure,546,O
associated,546,O
with,546,O
a,546,O
midline,546,O
B3,546,O
serotonin,546,B-Chemical
methyldopa,546,B-Chemical
injection,546,O
.,546,O
It,547,O
is,547,O
concluded,547,O
therefore,547,O
that,547,O
",",547,O
unlike,547,O
the,547,O
ventrolateral,547,O
B3,547,O
cells,547,O
which,547,O
mediate,547,O
a,547,O
methyldopa-induced,547,B-Chemical
hypotension,547,B-Disease
via,547,O
descending,547,O
projections,547,O
",",547,O
the,547,O
midline,547,O
serotonin,547,B-Chemical
B3,547,O
cells,547,O
in,547,O
the,547,O
medulla,547,O
contribute,547,O
to,547,O
the,547,O
hypotensive,547,B-Disease
action,547,O
of,547,O
methyldopa,547,B-Chemical
",",547,O
either,547,O
by,547,O
way,547,O
of,547,O
an,547,O
ascending,547,O
projection,547,O
which,547,O
does,547,O
not,547,O
pass,547,O
through,547,O
the,547,O
median,547,O
forebrain,547,O
bundle,547,O
",",547,O
or,547,O
through,547,O
a,547,O
projection,547,O
restricted,547,O
to,547,O
the,547,O
caudal,547,O
brainstem,547,O
.,547,O
Antiarrhythmic,548,O
plasma,548,O
concentrations,548,O
of,548,O
cibenzoline,548,B-Chemical
on,548,O
canine,548,O
ventricular,548,B-Disease
arrhythmias,548,I-Disease
.,548,O
Using,549,O
two-stage,549,O
coronary,549,O
ligation-,549,O
",",549,O
digitalis-,549,B-Chemical
",",549,O
and,549,O
adrenaline-induced,549,B-Chemical
canine,549,O
ventricular,549,B-Disease
arrhythmias,549,I-Disease
",",549,O
antiarrhythmic,549,O
effects,549,O
of,549,O
cibenzoline,549,B-Chemical
were,549,O
examined,549,O
and,549,O
the,549,O
minimum,549,O
effective,549,O
plasma,549,O
concentration,549,O
for,549,O
each,549,O
arrhythmia,549,B-Disease
model,549,O
was,549,O
determined,549,O
.,549,O
Cibenzoline,550,B-Chemical
suppressed,550,O
all,550,O
the,550,O
arrhythmias,550,B-Disease
",",550,O
and,550,O
the,550,O
minimum,550,O
effective,550,O
plasma,550,O
concentrations,550,O
for,550,O
arrhythmias,550,B-Disease
induced,550,O
by,550,O
24-h,550,O
coronary,550,O
ligation,550,O
",",550,O
48-h,550,O
coronary,550,O
ligation,550,O
",",550,O
digitalis,550,B-Chemical
",",550,O
and,550,O
adrenaline,550,B-Chemical
were,550,O
1.9,550,O
+/-,550,O
0.9,550,O
(,550,O
by,550,O
8,550,O
mg/kg,550,O
i.v,550,O
.,550,O
),551,O
",",551,O
1.6,551,O
+/-,551,O
0.5,551,O
(,551,O
by,551,O
8,551,O
mg/kg,551,O
i.v,551,O
.,551,O
),552,O
",",552,O
0.6,552,O
+/-,552,O
0.2,552,O
(,552,O
by,552,O
2,552,O
mg/kg,552,O
i.v,552,O
.,552,O
),553,O
",",553,O
and,553,O
3.5,553,O
+/-,553,O
1.3,553,O
(,553,O
by,553,O
5,553,O
mg/kg,553,O
i.v,553,O
.,553,O
),553,O
micrograms/ml,554,O
",",554,O
respectively,554,O
(,554,O
mean,554,O
+/-,554,O
SDM,554,O
",",554,O
n,554,O
=,554,O
6-7,554,O
),554,O
.,554,O
The,555,O
concentration,555,O
for,555,O
adrenaline-induced,555,O
arrhythmia,555,O
was,555,O
significantly,555,O
higher,555,O
than,555,O
those,555,O
for,555,O
the,555,O
other,555,O
types,555,O
of,555,B-Disease
arrhythmias,555,O
.,555,O
This,556,O
pharmacological,556,O
profile,556,O
is,556,O
similar,556,O
to,556,O
those,556,O
of,556,B-Chemical
mexiletine,556,O
and,556,O
tocainide,556,O
",",556,O
and,556,O
all,556,O
three,556,O
drugs,556,O
have,556,O
central,556,O
nervous,556,O
system,556,O
(,556,O
CNS,556,O
),556,O
stimulant,556,O
action,556,O
.,556,O
Because,557,O
cibenzoline,557,O
had,557,O
only,557,O
weak,557,O
hypotensive,557,O
and,557,O
sinus,557,O
node,557,O
depressive,557,O
effects,557,O
and,557,O
was,557,O
found,557,O
to,557,O
be,557,O
orally,557,O
active,557,O
when,557,O
given,557,O
to,557,O
coronary,557,O
ligation,557,O
arrhythmia,557,O
dogs,557,O
",",557,O
its,557,O
clinical,557,O
usefulness,557,O
is,557,O
expected,557,O
.,557,O
Continuous,558,O
ambulatory,558,O
ECG,558,O
monitoring,558,O
during,558,O
fluorouracil,558,B-Chemical
therapy,558,O
:,558,O
a,558,O
prospective,558,O
study,558,O
.,558,O
Although,559,O
there,559,O
have,559,O
been,559,O
anecdotal,559,O
reports,559,O
of,559,O
cardiac,559,B-Disease
toxicity,559,I-Disease
associated,559,O
with,559,O
fluorouracil,559,B-Chemical
(,559,O
5-FU,559,B-Chemical
),559,O
therapy,559,O
",",559,O
this,559,O
phenomenon,559,O
has,559,O
not,559,O
been,559,O
studied,559,O
in,559,O
a,559,O
systematic,559,O
fashion,559,O
.,559,O
We,560,O
prospectively,560,O
performed,560,O
continuous,560,O
ambulatory,560,O
ECG,560,O
monitoring,560,O
on,560,O
25,560,O
patients,560,O
undergoing,560,O
5-FU,560,B-Chemical
infusion,560,O
for,560,O
treatment,560,O
of,560,O
solid,560,O
tumors,560,B-Disease
in,560,O
order,560,O
to,560,O
assess,560,O
the,560,O
incidence,560,O
of,560,O
ischemic,560,B-Disease
ST,560,O
changes,560,O
.,560,O
Patients,561,O
were,561,O
monitored,561,O
for,561,O
23,561,O
+/-,561,O
4,561,O
hours,561,O
before,561,O
5-FU,561,B-Chemical
infusion,561,O
",",561,O
and,561,O
98,561,O
+/-,561,O
9,561,O
hours,561,O
during,561,O
5-FU,561,B-Chemical
infusion,561,O
.,561,O
Anginal,562,B-Disease
episodes,562,O
were,562,O
rare,562,O
:,562,O
only,562,O
one,562,O
patient,562,O
had,562,O
angina,562,B-Disease
(,562,O
during,562,O
5-FU,562,B-Chemical
infusion,562,O
),562,O
.,562,O
However,563,O
",",563,O
asymptomatic,563,O
ST,563,O
changes,563,O
(,563,O
greater,563,O
than,563,O
or,563,O
equal,563,O
to,563,O
1,563,O
mm,563,O
ST,563,O
deviation,563,O
),563,O
were,563,O
common,563,O
:,563,O
six,563,O
of,563,O
25,563,O
patients,563,O
(,563,O
24,563,O
%,563,O
),563,O
had,563,O
ST,563,O
changes,563,O
before,563,O
5-FU,563,B-Chemical
infusion,563,O
v,563,O
17,563,O
(,563,O
68,563,O
%,563,O
),563,O
during,563,O
5-FU,563,B-Chemical
infusion,563,O
(,563,O
P,563,O
less,563,O
than,563,O
.002,563,O
),563,O
.,563,O
The,564,O
incidence,564,O
of,564,O
ischemic,564,B-Disease
episodes,564,O
per,564,O
patient,564,O
per,564,O
hour,564,O
was,564,O
0.05,564,O
+/-,564,O
0.02,564,O
prior,564,O
to,564,O
5-FU,564,B-Chemical
infusion,564,O
v,564,O
0.13,564,O
+/-,564,O
0.03,564,O
during,564,O
5-FU,564,B-Chemical
infusion,564,O
(,564,O
P,564,O
less,564,O
than,564,O
.001,564,O
),564,O
;,564,O
the,564,O
duration,564,O
of,564,O
ECG,564,O
changes,564,O
was,564,O
0.6,564,O
+/-,564,O
0.3,564,O
minutes,564,O
per,564,O
patient,564,O
per,564,O
hour,564,O
before,564,O
5-FU,564,B-Chemical
v,564,O
1.9,564,O
+/-,564,O
0.5,564,O
minutes,564,O
per,564,O
patient,564,O
per,564,O
hour,564,O
during,564,O
5-FU,564,B-Chemical
(,564,O
P,564,O
less,564,O
than,564,O
.01,564,O
),564,O
.,564,O
ECG,565,O
changes,565,O
were,565,O
more,565,O
common,565,O
among,565,O
patients,565,O
with,565,O
known,565,O
coronary,565,B-Disease
artery,565,I-Disease
disease,565,I-Disease
.,565,O
There,566,O
were,566,O
two,566,O
cases,566,O
of,566,O
sudden,566,B-Disease
death,566,I-Disease
",",566,O
both,566,O
of,566,O
which,566,O
occurred,566,O
at,566,O
the,566,O
end,566,O
of,566,O
the,566,O
chemotherapy,566,O
course,566,O
.,566,O
We,567,O
conclude,567,O
that,567,O
5-FU,567,B-Chemical
infusion,567,O
is,567,O
associated,567,O
with,567,O
a,567,O
significant,567,O
increase,567,O
in,567,O
silent,567,O
ST,567,O
segment,567,O
deviation,567,O
suggestive,567,O
of,567,O
ischemia,567,B-Disease
",",567,O
particularly,567,O
among,567,O
patients,567,O
with,567,O
coronary,567,B-Disease
artery,567,I-Disease
disease,567,I-Disease
.,567,O
The,568,O
mechanism,568,O
and,568,O
clinical,568,O
significance,568,O
of,568,O
these,568,O
ECG,568,O
changes,568,O
remain,568,O
to,568,O
be,568,O
determined,568,O
.,568,O
Nature,569,O
",",569,O
time,569,O
course,569,O
and,569,O
dose,569,O
dependence,569,O
of,569,O
zidovudine-related,569,B-Chemical
side,569,O
effects,569,O
:,569,O
results,569,O
from,569,O
the,569,O
Multicenter,569,O
Canadian,569,O
Azidothymidine,569,B-Chemical
Trial,569,O
.,569,O
To,570,O
characterize,570,O
the,570,O
nature,570,O
",",570,O
time,570,O
course,570,O
and,570,O
dose,570,O
dependency,570,O
of,570,O
zidovudine-related,570,B-Chemical
side,570,O
effects,570,O
",",570,O
we,570,O
undertook,570,O
a,570,O
multicenter,570,O
",",570,O
prospective,570,O
",",570,O
dose-range,570,O
finding,570,O
study,570,O
.,570,O
Our,571,O
study,571,O
group,571,O
consisted,571,O
of,571,O
74,571,O
HIV-positive,571,O
homosexual,571,O
men,571,O
belonging,571,O
to,571,O
groups,571,O
II,571,O
B,571,O
",",571,O
III,571,O
and,571,O
IV,571,O
C2,571,O
from,571,O
the,571,O
Centers,571,O
for,571,O
Disease,571,O
Control,571,O
(,571,O
CDC,571,O
),571,O
classification,571,O
of,571,O
HIV,571,B-Disease
disease,571,I-Disease
.,571,O
Following,572,O
a,572,O
3-week,572,O
observation,572,O
period,572,O
",",572,O
volunteers,572,O
were,572,O
treated,572,O
with,572,O
zidovudine,572,B-Chemical
600,572,O
mg/day,572,O
for,572,O
18,572,O
weeks,572,O
",",572,O
900,572,O
mg/day,572,O
for,572,O
9,572,O
weeks,572,O
and,572,O
1200,572,O
mg/day,572,O
for,572,O
9,572,O
weeks,572,O
",",572,O
followed,572,O
by,572,O
a,572,O
washout,572,O
period,572,O
of,572,O
6,572,O
weeks,572,O
after,572,O
which,572,O
they,572,O
were,572,O
re-started,572,O
on,572,O
1200,572,O
mg/day,572,O
or,572,O
the,572,O
highest,572,O
tolerated,572,O
dose,572,O
at,572,O
8-hourly,572,O
intervals,572,O
.,572,O
Subjects,573,O
were,573,O
randomly,573,O
assigned,573,O
to,573,O
4-hourly,573,O
or,573,O
8-hourly,573,O
regimens,573,O
within,573,O
CDC,573,O
groups,573,O
while,573,O
taking,573,O
600,573,O
and,573,O
1200,573,O
mg/day,573,O
.,573,O
Clinical,574,O
and,574,O
laboratory,574,O
evaluations,574,O
were,574,O
performed,574,O
at,574,O
3-week,574,O
intervals,574,O
.,574,O
Symptomatic,575,O
adverse,575,O
effects,575,O
were,575,O
present,575,O
in,575,O
96,575,O
%,575,O
of,575,O
subjects,575,O
",",575,O
most,575,O
commonly,575,O
nausea,575,B-Disease
(,575,O
64,575,O
%,575,O
),575,O
",",575,O
fatigue,575,B-Disease
(,575,O
55,575,O
%,575,O
),575,O
and,575,O
headache,575,B-Disease
(,575,O
49,575,O
%,575,O
),575,O
.,575,O
These,576,O
were,576,O
generally,576,O
self-limited,576,O
",",576,O
reappearing,576,O
briefly,576,O
at,576,O
each,576,O
dose,576,O
increment,576,O
.,576,O
A,577,O
decrease,577,O
in,577,O
hemoglobin,577,O
occurred,577,O
shortly,577,O
after,577,O
initiation,577,O
of,577,O
therapy,577,O
.,577,O
This,578,O
was,578,O
not,578,O
dose,578,O
dependent,578,O
and,578,O
reversed,578,O
rapidly,578,O
upon,578,O
discontinuation,578,O
of,578,O
treatment,578,O
.,578,O
A,579,O
red,579,O
blood,579,O
cell,579,O
count,579,O
decrease,579,O
",",579,O
a,579,O
mean,579,O
cell,579,O
volume,579,O
increase,579,O
and,579,O
a,579,O
granulocyte,579,O
count,579,O
decrease,579,O
developed,579,O
early,579,O
in,579,O
a,579,O
dose-independent,579,O
fashion,579,O
",",579,O
reverting,579,O
at,579,O
least,579,O
partially,579,O
during,579,O
the,579,O
washout,579,O
phase,579,O
.,579,O
The,580,O
decrease,580,O
in,580,O
reticulocyte,580,O
count,580,O
was,580,O
dose,580,O
related,580,O
between,580,O
600,580,O
and,580,O
900,580,O
mg/day,580,O
with,580,O
no,580,O
further,580,O
change,580,O
when,580,O
the,580,O
dose,580,O
was,580,O
escalated,580,O
to,580,O
1200,580,O
mg/day,580,O
.,580,O
Bone,581,O
marrow,581,O
changes,581,O
occurred,581,O
rapidly,581,O
as,581,O
demonstrated,581,O
by,581,O
megaloblastosis,581,B-Disease
in,581,O
95,581,O
%,581,O
of,581,O
65,581,O
specimens,581,O
at,581,O
week,581,O
18,581,O
.,581,O
(,582,O
ABSTRACT,582,O
TRUNCATED,582,O
AT,582,O
250,582,O
WORDS,582,O
),582,O
National,583,O
project,583,O
on,583,O
the,583,O
prevention,583,O
of,583,O
mother-to-infant,583,O
infection,583,B-Disease
by,583,I-Disease
hepatitis,583,I-Disease
B,583,I-Disease
virus,583,I-Disease
in,583,O
Japan,583,O
.,583,O
In,584,O
Japan,584,O
",",584,O
a,584,O
nationwide,584,O
prevention,584,O
program,584,O
against,584,O
mother-to-infant,584,O
infection,584,B-Disease
by,584,I-Disease
hepatitis,584,I-Disease
B,584,I-Disease
virus,584,I-Disease
(,584,O
HBV,584,O
),584,O
started,584,O
in,584,O
1985,584,O
.,584,O
This,585,O
program,585,O
consists,585,O
of,585,O
double,585,O
screenings,585,O
of,585,O
pregnant,585,O
women,585,O
and,585,O
prophylactic,585,O
treatment,585,O
to,585,O
the,585,O
infants,585,O
born,585,O
to,585,O
both,585,O
hepatitis,585,B-Chemical
B,585,I-Chemical
surface,585,I-Chemical
antigen,585,I-Chemical
(,585,O
HBsAg,585,B-Chemical
),585,O
and,585,O
hepatitis,585,B-Chemical
B,585,I-Chemical
e,585,I-Chemical
antigen,585,I-Chemical
(,585,O
HBeAg,585,B-Chemical
),585,O
positive,585,O
mothers,585,O
.,585,O
These,586,O
infants,586,O
are,586,O
treated,586,O
with,586,O
two,586,O
injections,586,O
of,586,O
hepatitis,586,B-Disease
B,586,I-Disease
immune,586,O
globulin,586,O
(,586,O
HBIG,586,O
),586,O
and,586,O
at,586,O
least,586,O
three,586,O
injections,586,O
of,586,O
plasma,586,O
derived,586,O
hepatitis,586,B-Chemical
B,586,I-Chemical
vaccine,586,I-Chemical
.,586,O
We,587,O
sent,587,O
questionnaires,587,O
about,587,O
the,587,O
numbers,587,O
of,587,O
each,587,O
procedure,587,O
or,587,O
examination,587,O
during,587,O
nine,587,O
months,587,O
of,587,O
investigation,587,O
period,587,O
to,587,O
each,587,O
local,587,O
government,587,O
in,587,O
1986,587,O
and,587,O
1987,587,O
.,587,O
93.4,588,O
%,588,O
pregnant,588,O
women,588,O
had,588,O
the,588,O
chance,588,O
to,588,O
be,588,O
examined,588,O
for,588,O
HBsAg,588,B-Chemical
",",588,O
and,588,O
the,588,O
positive,588,O
rate,588,O
was,588,O
1.4,588,O
to,588,O
1.5,588,O
%,588,O
.,588,O
The,589,O
HBeAg,589,B-Chemical
positive,589,O
rate,589,O
in,589,O
HBsAg,589,B-Chemical
positive,589,O
was,589,O
23,589,O
to,589,O
26,589,O
%,589,O
.,589,O
The,590,O
HBsAg,590,B-Chemical
positive,590,O
rate,590,O
in,590,O
neonates,590,O
and,590,O
in,590,O
infants,590,O
before,590,O
two,590,O
months,590,O
were,590,O
3,590,O
%,590,O
and,590,O
2,590,O
%,590,O
respectively,590,O
.,590,O
Some,591,O
problems,591,O
may,591,O
arise,591,O
",",591,O
because,591,O
27,591,O
to,591,O
30,591,O
%,591,O
of,591,O
infants,591,O
need,591,O
the,591,O
fourth,591,O
vaccination,591,O
in,591,O
some,591,O
restricted,591,O
areas,591,O
.,591,O
Involvement,592,O
of,592,O
the,592,O
mu-opiate,592,O
receptor,592,O
in,592,O
peripheral,592,O
analgesia,592,B-Disease
.,592,O
The,593,O
intradermal,593,O
injection,593,O
of,593,O
mu,593,O
(,593,O
morphine,593,B-Chemical
",",593,O
Tyr-D-Ala-Gly-NMe-Phe-Gly-ol,593,B-Chemical
and,593,O
morphiceptin,593,B-Chemical
),593,O
",",593,O
kappa,593,O
(,593,O
"trans-3,4-dichloro-N-methyl-N",593,B-Chemical
[,593,I-Chemical
2-,593,I-Chemical
(,593,I-Chemical
1-pyrrolidinyl,593,I-Chemical
),593,I-Chemical
cyclohexyl,593,I-Chemical
],593,I-Chemical
benzeneactemide,593,I-Chemical
),593,O
and,593,O
delta,593,O
(,593,O
[,593,B-Chemical
D-Pen2.5,593,I-Chemical
],593,I-Chemical
-enkephalin,593,I-Chemical
and,593,O
[,593,B-Chemical
D-Ser2,593,I-Chemical
],593,I-Chemical
-,593,I-Chemical
[,593,I-Chemical
Leu,593,I-Chemical
],593,I-Chemical
enkephalin-Thr,593,I-Chemical
),593,O
selective,593,O
opioid-agonists,593,O
",",593,O
by,593,O
themselves,593,O
",",593,O
did,593,O
not,593,O
significantly,593,O
affect,593,O
the,593,O
mechanical,593,O
nociceptive,593,O
threshold,593,O
in,593,O
the,593,O
hindpaw,593,O
of,593,O
the,593,O
rat,593,O
.,593,O
Intradermal,594,O
injection,594,O
of,594,O
mu,594,O
",",594,O
but,594,O
not,594,O
delta,594,O
or,594,O
kappa,594,O
opioid-agonists,594,O
",",594,O
however,594,O
",",594,O
produced,594,O
dose-dependent,594,O
inhibition,594,O
of,594,O
prostaglandin,594,B-Chemical
E2-induced,594,O
hyperalgesia,594,B-Disease
.,594,O
The,595,O
analgesic,595,O
effect,595,O
of,595,O
the,595,O
mu-agonist,595,O
morphine,595,B-Chemical
was,595,O
dose-dependently,595,O
antagonized,595,O
by,595,O
naloxone,595,B-Chemical
and,595,O
prevented,595,O
by,595,O
co-injection,595,O
of,595,O
pertussis,595,O
toxin,595,O
.,595,O
Morphine,596,B-Chemical
did,596,O
not,596,O
",",596,O
however,596,O
",",596,O
alter,596,O
the,596,O
hyperalgesia,596,B-Disease
induced,596,O
by,596,O
8-bromo,596,B-Chemical
cyclic,596,I-Chemical
adenosine,596,I-Chemical
monophosphate,596,I-Chemical
.,596,O
We,597,O
conclude,597,O
that,597,O
the,597,O
analgesic,597,O
action,597,O
of,597,O
opioids,597,O
on,597,O
the,597,O
peripheral,597,O
terminals,597,O
of,597,O
primary,597,O
afferents,597,O
is,597,O
via,597,O
a,597,O
binding,597,O
site,597,O
with,597,O
characteristics,597,O
of,597,O
the,597,O
mu-opioid,597,O
receptor,597,O
and,597,O
that,597,O
this,597,O
action,597,O
is,597,O
mediated,597,O
by,597,O
inhibition,597,O
of,597,O
the,597,O
cyclic,597,B-Chemical
adenosine,597,I-Chemical
monophosphate,597,I-Chemical
second,597,O
messenger,597,O
system,597,O
.,597,O
Involvement,598,O
of,598,O
locus,598,O
coeruleus,598,O
and,598,O
noradrenergic,598,O
neurotransmission,598,O
in,598,O
fentanyl-induced,598,B-Chemical
muscular,598,B-Disease
rigidity,598,I-Disease
in,598,O
the,598,O
rat,598,O
.,598,O
Whereas,599,O
muscular,599,B-Disease
rigidity,599,I-Disease
is,599,O
a,599,O
well-known,599,O
side,599,O
effect,599,O
that,599,O
is,599,O
associated,599,O
with,599,O
high-dose,599,O
fentanyl,599,B-Chemical
anesthesia,599,O
",",599,O
a,599,O
paucity,599,O
of,599,O
information,599,O
exists,599,O
with,599,O
regard,599,O
to,599,O
its,599,O
underlying,599,O
mechanism,599,O
(,599,O
s,599,O
),599,O
.,599,O
We,600,O
investigated,600,O
in,600,O
this,600,O
study,600,O
the,600,O
possible,600,O
engagement,600,O
of,600,O
locus,600,O
coeruleus,600,O
of,600,O
the,600,O
pons,600,O
in,600,O
this,600,O
phenomenon,600,O
",",600,O
using,600,O
male,600,O
Sprague-Dawley,600,O
rats,600,O
anesthetized,600,O
with,600,O
ketamine,600,B-Chemical
.,600,O
Under,601,O
proper,601,O
control,601,O
of,601,O
respiration,601,O
",",601,O
body,601,O
temperature,601,O
and,601,O
end-tidal,601,O
CO2,601,B-Chemical
",",601,O
intravenous,601,O
administration,601,O
of,601,O
fentanyl,601,B-Chemical
(,601,O
50,601,O
or,601,O
100,601,O
micrograms/kg,601,O
),601,O
consistently,601,O
promoted,601,O
an,601,O
increase,601,O
in,601,O
electromyographic,601,O
activity,601,O
recorded,601,O
from,601,O
the,601,O
gastrocnemius,601,O
and,601,O
abdominal,601,O
rectus,601,O
muscles,601,O
.,601,O
Such,602,O
an,602,O
induced,602,O
muscular,602,B-Disease
rigidity,602,I-Disease
by,602,O
the,602,O
narcotic,602,O
agent,602,O
was,602,O
significantly,602,O
antagonized,602,O
or,602,O
even,602,O
reduced,602,O
by,602,O
prior,602,O
electrolytic,602,O
lesions,602,O
of,602,O
the,602,O
locus,602,O
coeruleus,602,O
or,602,O
pretreatment,602,O
with,602,O
the,602,O
alpha-adrenoceptor,602,O
blocker,602,O
",",602,O
prazosin,602,B-Chemical
.,602,O
Microinjection,603,O
of,603,O
fentanyl,603,B-Chemical
(,603,O
2.5,603,O
micrograms/50,603,O
nl,603,O
),603,O
directly,603,O
into,603,O
this,603,O
pontine,603,O
nucleus,603,O
",",603,O
on,603,O
the,603,O
other,603,O
hand,603,O
",",603,O
elicited,603,O
discernible,603,O
electromyographic,603,O
excitation,603,O
.,603,O
It,604,O
is,604,O
speculated,604,O
that,604,O
the,604,O
induction,604,O
of,604,O
muscular,604,B-Disease
rigidity,604,I-Disease
by,604,O
fentanyl,604,B-Chemical
may,604,O
involve,604,O
the,604,O
coerulospinal,604,O
noradrenergic,604,O
fibers,604,O
to,604,O
the,604,O
spinal,604,O
motoneurons,604,O
.,604,O
Dexmedetomidine,605,B-Chemical
",",605,O
acting,605,O
through,605,O
central,605,O
alpha-2,605,O
adrenoceptors,605,O
",",605,O
prevents,605,O
opiate-induced,605,O
muscle,605,B-Disease
rigidity,605,I-Disease
in,605,O
the,605,O
rat,605,O
.,605,O
The,606,O
highly-selective,606,O
alpha-2,606,O
adrenergic,606,O
agonist,606,O
dexmedetomidine,606,B-Chemical
(,606,O
D-MED,606,B-Chemical
),606,O
is,606,O
capable,606,O
of,606,O
inducing,606,O
muscle,606,B-Disease
flaccidity,606,I-Disease
and,606,O
anesthesia,606,O
in,606,O
rats,606,O
and,606,O
dogs,606,O
.,606,O
Intense,607,O
generalized,607,O
muscle,607,B-Disease
rigidity,607,I-Disease
is,607,O
an,607,O
undesirable,607,O
side,607,O
effect,607,O
of,607,O
potent,607,O
opiate,607,O
agonists,607,O
.,607,O
Although,608,O
the,608,O
neurochemistry,608,O
of,608,O
opiate-induced,608,O
rigidity,608,B-Disease
has,608,O
yet,608,O
to,608,O
be,608,O
fully,608,O
elucidated,608,O
",",608,O
recent,608,O
work,608,O
suggests,608,O
a,608,O
role,608,O
for,608,O
a,608,O
central,608,O
adrenergic,608,O
mechanism,608,O
.,608,O
In,609,O
the,609,O
present,609,O
study,609,O
",",609,O
the,609,O
authors,609,O
determined,609,O
if,609,O
treatment,609,O
with,609,O
D-MED,609,B-Chemical
prevents,609,O
the,609,O
muscle,609,B-Disease
rigidity,609,I-Disease
caused,609,O
by,609,O
high-dose,609,O
alfentanil,609,B-Chemical
anesthesia,609,O
in,609,O
the,609,O
rat,609,O
.,609,O
Animals,610,O
(,610,O
n,610,O
=,610,O
42,610,O
),610,O
were,610,O
treated,610,O
intraperitoneally,610,O
with,610,O
one,610,O
of,610,O
the,610,O
following,610,O
six,610,O
regimens,610,O
:,610,O
1,610,O
),610,O
L-MED,610,O
(,610,O
the,610,O
inactive,610,O
L-isomer,610,O
of,610,O
medetomidine,610,B-Chemical
),610,O
",",610,O
30,610,O
micrograms/kg,610,O
;,610,O
2,610,O
),610,O
D-MED,610,B-Chemical
",",610,O
10,610,O
micrograms/kg,610,O
;,610,O
3,610,O
),610,O
D-MED,610,B-Chemical
",",610,O
30,610,O
micrograms/kg,610,O
;,610,O
4,610,O
),610,O
D-MED,610,B-Chemical
[,610,O
30,610,O
micrograms/kg,610,O
],610,O
and,610,O
the,610,O
central-acting,610,O
alpha-2,610,O
antagonist,610,O
",",610,O
idazoxan,610,B-Chemical
[,610,O
10,610,O
mg/kg,610,O
],610,O
;,610,O
5,610,O
),610,O
D-MED,610,B-Chemical
[,610,O
30,610,O
micrograms/kg,610,O
],610,O
and,610,O
the,610,O
peripheral-acting,610,O
alpha-2,610,O
antagonist,610,O
DG-5128,610,B-Chemical
[,610,O
10,610,O
mg/kg,610,O
],610,O
",",610,O
or,610,O
;,610,O
6,610,O
),610,O
saline,610,O
.,610,O
Baseline,611,O
electromyographic,611,O
activity,611,O
was,611,O
recorded,611,O
from,611,O
the,611,O
gastrocnemius,611,O
muscle,611,O
before,611,O
and,611,O
after,611,O
drug,611,O
treatment,611,O
.,611,O
Each,612,O
rat,612,O
was,612,O
then,612,O
injected,612,O
with,612,O
alfentanil,612,B-Chemical
(,612,O
ALF,612,B-Chemical
",",612,O
0.5,612,O
mg/kg,612,O
sc,612,O
),612,O
.,612,O
ALF,613,B-Chemical
injection,613,O
resulted,613,O
in,613,O
a,613,O
marked,613,O
increase,613,O
in,613,O
hindlimb,613,O
EMG,613,O
activity,613,O
in,613,O
the,613,O
L-MED,613,O
treatment,613,O
group,613,O
which,613,O
was,613,O
indistinguishable,613,O
from,613,O
that,613,O
seen,613,O
in,613,O
animals,613,O
treated,613,O
with,613,O
saline,613,O
.,613,O
In,614,O
contrast,614,O
",",614,O
D-MED,614,B-Chemical
prevented,614,O
alfentanil-induced,614,B-Chemical
muscle,614,B-Disease
rigidity,614,I-Disease
in,614,O
a,614,O
dose-dependent,614,O
fashion,614,O
.,614,O
The,615,O
small,615,O
EMG,615,O
values,615,O
obtained,615,O
in,615,O
the,615,O
high-dose,615,O
D-MED,615,B-Chemical
group,615,O
were,615,O
comparable,615,O
with,615,O
those,615,O
recorded,615,O
in,615,O
earlier,615,O
studies,615,O
from,615,O
control,615,O
animals,615,O
not,615,O
given,615,O
any,615,O
opiate,615,O
.,615,O
The,616,O
high-dose,616,O
D-MED,616,B-Chemical
animals,616,O
were,616,O
flaccid,616,O
",",616,O
akinetic,616,B-Disease
",",616,O
and,616,O
lacked,616,O
a,616,O
startle,616,B-Disease
response,616,O
during,616,O
the,616,O
entire,616,O
experimental,616,O
period,616,O
.,616,O
(,617,O
ABSTRACT,617,O
TRUNCATED,617,O
AT,617,O
250,617,O
WORDS,617,O
),617,O
Some,618,O
central,618,O
effects,618,O
of,618,O
repeated,618,O
treatment,618,O
with,618,O
fluvoxamine,618,B-Chemical
.,618,O
We,619,O
investigated,619,O
the,619,O
effect,619,O
of,619,O
repeated,619,O
treatment,619,O
with,619,O
fluvoxamine,619,B-Chemical
",",619,O
a,619,O
selective,619,O
serotonin,619,B-Chemical
uptake,619,O
inhibitor,619,O
",",619,O
on,619,O
behavioral,619,O
effects,619,O
of,619,O
dopaminomimetics,619,O
and,619,O
methoxamine,619,B-Chemical
and,619,O
on,619,O
the,619,O
animal,619,O
behavior,619,O
in,619,O
the,619,O
``,619,O
behavioral,619,O
despair,619,O
'',619,O
test,619,O
.,619,O
A,620,O
repeated,620,O
treatment,620,O
with,620,O
fluvoxamine,620,B-Chemical
(,620,O
twice,620,O
daily,620,O
for,620,O
14,620,O
days,620,O
),620,O
potentiated,620,O
in,620,O
mice,620,O
and,620,O
in,620,O
rats,620,O
(,620,O
weaker,620,O
),620,O
the,620,O
amphetamine-induced,620,B-Chemical
hyperactivity,620,B-Disease
.,620,O
The,621,O
hyperactivity,621,B-Disease
induced,621,O
by,621,O
nomifensine,621,B-Chemical
in,621,O
mice,621,O
remained,621,O
unaffected,621,O
by,621,O
fluvoxamine,621,B-Chemical
.,621,O
The,622,O
stimulation,622,O
of,622,O
locomotor,622,O
activity,622,O
by,622,O
intracerebroventricularly,622,O
administered,622,O
methoxamine,622,B-Chemical
was,622,O
not,622,O
affected,622,O
by,622,O
repeated,622,O
treatment,622,O
with,622,O
fluvoxamine,622,B-Chemical
.,622,O
Given,623,O
three,623,O
times,623,O
fluvoxamine,623,B-Chemical
had,623,O
no,623,O
effect,623,O
on,623,O
the,623,O
immobilization,623,O
time,623,O
in,623,O
the,623,O
``,623,O
behavioral,623,O
despair,623,O
'',623,O
test,623,O
in,623,O
rats,623,O
.,623,O
The,624,O
results,624,O
indicate,624,O
that,624,O
fluvoxamine,624,B-Chemical
given,624,O
repeatedly,624,O
acts,624,O
differently,624,O
than,624,O
citalopram,624,B-Chemical
",",624,O
another,624,O
selective,624,O
serotonin,624,B-Chemical
uptake,624,O
inhibitor,624,O
",",624,O
and,624,O
differs,624,O
also,624,O
from,624,O
other,624,O
antidepressant,624,O
drugs,624,O
.,624,O
Protective,625,O
effect,625,O
of,625,O
a,625,O
specific,625,O
platelet-activating,625,O
factor,625,O
antagonist,625,O
",",625,O
BN,625,B-Chemical
52021,625,I-Chemical
",",625,O
on,625,O
bupivacaine-induced,625,B-Chemical
cardiovascular,625,B-Disease
impairments,625,I-Disease
in,625,O
rats,625,O
.,625,O
Administration,626,O
of,626,O
the,626,O
local,626,O
anaesthetic,626,O
bupivacaine,626,B-Chemical
(,626,O
1.5,626,O
or,626,O
2,626,O
mg/kg,626,O
",",626,O
i.v,626,O
.,626,O
),626,O
to,627,O
rats,627,O
elicited,627,O
a,627,O
marked,627,O
decrease,627,O
of,627,O
mean,627,O
arterial,627,O
blood,627,O
pressure,627,O
(,627,O
MBP,627,O
),627,O
and,627,O
heart,627,O
rate,627,O
(,627,O
HR,627,O
),627,O
leading,627,O
to,627,O
death,627,O
(,627,O
in,627,O
67,627,O
%,627,O
or,627,O
90,627,O
%,627,O
of,627,O
animals,627,O
respectively,627,O
),627,O
.,627,O
Intravenous,628,O
injection,628,O
of,628,O
the,628,O
specific,628,O
platelet-activating,628,O
factor,628,O
(,628,O
PAF,628,O
),628,O
antagonist,628,O
BN,628,B-Chemical
52021,628,I-Chemical
(,628,O
10,628,O
mg/kg,628,O
),628,O
",",628,O
30,628,O
min,628,O
before,628,O
bupivacaine,628,B-Chemical
administration,628,O
(,628,O
2,628,O
mg/kg,628,O
i.v,628,O
.,628,O
),628,O
suppressed,629,O
both,629,O
the,629,O
decrease,629,O
of,629,O
MBP,629,O
and,629,O
HR,629,O
.,629,O
In,630,O
contrast,630,O
",",630,O
doses,630,O
of,630,O
1,630,O
mg/kg,630,O
BN,630,B-Chemical
52021,630,I-Chemical
given,630,O
30,630,O
min,630,O
before,630,O
or,630,O
10,630,O
mg/kg,630,O
administered,630,O
5,630,O
min,630,O
before,630,O
i.v,630,O
.,630,O
injection,631,O
of,631,O
bupivacaine,631,B-Chemical
were,631,O
ineffective,631,O
.,631,O
When,632,O
BN,632,B-Chemical
52021,632,I-Chemical
(,632,O
20,632,O
mg/kg,632,O
i.v,632,O
.,632,O
),632,O
was,633,O
injected,633,O
immediately,633,O
after,633,O
bupivacaine,633,B-Chemical
(,633,O
2,633,O
mg/kg,633,O
),633,O
",",633,O
a,633,O
partial,633,O
reversion,633,O
of,633,O
the,633,O
decrease,633,O
of,633,O
MBP,633,O
and,633,O
HR,633,O
was,633,O
observed,633,O
",",633,O
whereas,633,O
the,633,O
dose,633,O
of,633,O
10,633,O
mg/kg,633,O
was,633,O
ineffective,633,O
.,633,O
A,634,O
partial,634,O
recovery,634,O
of,634,O
bupivacaine-induced,634,B-Chemical
ECG,634,O
alterations,634,O
was,634,O
observed,634,O
after,634,O
pretreatment,634,O
of,634,O
the,634,O
rats,634,O
with,634,O
BN,634,B-Chemical
52021,634,I-Chemical
.,634,O
Since,635,O
the,635,O
administration,635,O
of,635,O
BN,635,B-Chemical
52021,635,I-Chemical
",",635,O
at,635,O
all,635,O
doses,635,O
studied,635,O
",",635,O
did,635,O
not,635,O
alter,635,O
MBP,635,O
and,635,O
HR,635,O
at,635,O
the,635,O
doses,635,O
used,635,O
",",635,O
the,635,O
bulk,635,O
of,635,O
these,635,O
results,635,O
clearly,635,O
demonstrate,635,O
a,635,O
protective,635,O
action,635,O
of,635,O
BN,635,B-Chemical
52021,635,I-Chemical
",",635,O
a,635,O
specific,635,O
antagonist,635,O
of,635,O
PAF,635,O
",",635,O
against,635,O
bupivacaine-induced,635,B-Chemical
cardiovascular,635,B-Disease
toxicity,635,I-Disease
.,635,O
Thus,636,O
",",636,O
consistent,636,O
with,636,O
its,636,O
direct,636,O
effect,636,O
on,636,O
heart,636,O
",",636,O
PAF,636,O
appears,636,O
to,636,O
be,636,O
implicated,636,O
in,636,O
bupivacaine-induced,636,B-Chemical
cardiovascular,636,B-Disease
alterations,636,I-Disease
.,636,O
The,637,O
epidemiology,637,O
of,637,O
the,637,O
acute,637,O
flank,637,B-Disease
pain,637,I-Disease
syndrome,637,O
from,637,O
suprofen,637,B-Chemical
.,637,O
Suprofen,638,B-Chemical
",",638,O
a,638,O
new,638,O
nonsteroidal,638,O
anti-inflammatory,638,O
drug,638,O
",",638,O
was,638,O
marketed,638,O
in,638,O
early,638,O
1986,638,O
as,638,O
an,638,O
analgesic,638,O
agent,638,O
.,638,O
Until,639,O
physicians,639,O
began,639,O
reporting,639,O
an,639,O
unusual,639,O
acute,639,O
flank,639,B-Disease
pain,639,I-Disease
syndrome,639,O
to,639,O
the,639,O
spontaneous,639,O
reporting,639,O
system,639,O
",",639,O
"700,000",639,O
persons,639,O
used,639,O
the,639,O
drug,639,O
in,639,O
the,639,O
United,639,O
States,639,O
.,639,O
Through,640,O
August,640,O
1986,640,O
",",640,O
a,640,O
total,640,O
of,640,O
163,640,O
cases,640,O
of,640,O
this,640,O
syndrome,640,O
were,640,O
reported,640,O
.,640,O
To,641,O
elucidate,641,O
the,641,O
epidemiology,641,O
of,641,O
the,641,O
syndrome,641,O
",",641,O
a,641,O
case-control,641,O
study,641,O
was,641,O
performed,641,O
",",641,O
comparing,641,O
62,641,O
of,641,O
the,641,O
case,641,O
patients,641,O
who,641,O
had,641,O
been,641,O
reported,641,O
to,641,O
the,641,O
spontaneous,641,O
reporting,641,O
system,641,O
to,641,O
185,641,O
suprofen-exposed,641,B-Chemical
control,641,O
subjects,641,O
who,641,O
did,641,O
not,641,O
have,641,O
the,641,O
syndrome,641,O
.,641,O
Case,642,O
patients,642,O
were,642,O
more,642,O
likely,642,O
to,642,O
be,642,O
men,642,O
(,642,O
odds,642,O
ratio,642,O
",",642,O
3.8,642,O
;,642,O
95,642,O
%,642,O
confidence,642,O
interval,642,O
",",642,O
1.2-12.1,642,O
),642,O
",",642,O
suffer,642,O
from,642,O
hay,642,B-Disease
fever,642,I-Disease
and,642,O
asthma,642,B-Disease
(,642,O
odds,642,O
ratio,642,O
",",642,O
3.4,642,O
;,642,O
95,642,O
%,642,O
confidence,642,O
interval,642,O
",",642,O
1.0-11.9,642,O
),642,O
;,642,O
to,642,O
participate,642,O
in,642,O
regular,642,O
exercise,642,O
(,642,O
odds,642,O
ratio,642,O
",",642,O
5.9,642,O
;,642,O
95,642,O
%,642,O
confidence,642,O
interval,642,O
",",642,O
1.1-30.7,642,O
),642,O
",",642,O
especially,642,O
in,642,O
the,642,O
use,642,O
of,642,O
Nautilus,642,O
equipment,642,O
(,642,O
p,642,O
=,642,O
0.02,642,O
),642,O
;,642,O
and,642,O
to,642,O
use,642,O
alcohol,642,B-Chemical
(,642,O
odds,642,O
ratio,642,O
",",642,O
4.4,642,O
;,642,O
95,642,O
%,642,O
confidence,642,O
interval,642,O
",",642,O
1.1-17.5,642,O
),642,O
.,642,O
Possible,643,O
risk,643,O
factors,643,O
included,643,O
young,643,O
age,643,O
",",643,O
concurrent,643,O
use,643,O
of,643,O
other,643,O
analgesic,643,O
agents,643,O
(,643,O
especially,643,O
ibuprofen,643,B-Chemical
),643,O
",",643,O
preexisting,643,O
renal,643,B-Disease
disease,643,I-Disease
",",643,O
a,643,O
history,643,O
of,643,O
kidney,643,B-Disease
stones,643,I-Disease
",",643,O
a,643,O
history,643,O
of,643,O
gout,643,B-Disease
",",643,O
a,643,O
recent,643,O
increase,643,O
in,643,O
activity,643,O
",",643,O
a,643,O
recent,643,O
increase,643,O
in,643,O
sun,643,O
exposure,643,O
",",643,O
and,643,O
residence,643,O
in,643,O
the,643,O
Sunbelt,643,O
.,643,O
These,644,O
were,644,O
findings,644,O
that,644,O
were,644,O
suggestive,644,O
but,644,O
did,644,O
not,644,O
reach,644,O
conventional,644,O
statistical,644,O
significance,644,O
.,644,O
These,645,O
findings,645,O
are,645,O
consistent,645,O
with,645,O
the,645,O
postulated,645,O
mechanism,645,O
for,645,O
this,645,O
unusual,645,O
syndrome,645,O
:,645,O
acute,645,O
diffuse,645,O
crystallization,645,O
of,645,O
uric,645,B-Chemical
acid,645,I-Chemical
in,645,O
renal,645,O
tubules,645,O
.,645,O
Phlorizin-induced,646,B-Chemical
glycosuria,646,B-Disease
does,646,O
not,646,O
prevent,646,O
gentamicin,646,B-Chemical
nephrotoxicity,646,B-Disease
in,646,O
rats,646,O
.,646,O
Because,647,O
rats,647,O
with,647,O
streptozotocin-induced,647,B-Chemical
diabetes,647,B-Disease
mellitus,647,I-Disease
(,647,O
DM,647,B-Disease
),647,O
have,647,O
a,647,O
high,647,O
solute,647,O
diuresis,647,O
(,647,O
glycosuria,647,B-Disease
of,647,O
10,647,O
to,647,O
12,647,O
g/day,647,O
),647,O
",",647,O
we,647,O
have,647,O
suggested,647,O
that,647,O
this,647,O
may,647,O
in,647,O
part,647,O
be,647,O
responsible,647,O
for,647,O
their,647,O
resistance,647,O
to,647,O
gentamicin-induced,647,B-Chemical
acute,647,B-Disease
renal,647,I-Disease
failure,647,I-Disease
(,647,O
ARF,647,B-Disease
),647,O
.,647,O
The,648,O
protection,648,O
from,648,O
gentamicin,648,B-Chemical
nephrotoxicity,648,B-Disease
was,648,O
studied,648,O
in,648,O
non-diabetic,648,O
rats,648,O
with,648,O
chronic,648,O
solute,648,O
diuresis,648,O
induced,648,O
by,648,O
blockage,648,O
of,648,O
tubular,648,O
glucose,648,B-Chemical
reabsorption,648,O
with,648,O
phlorizin,648,B-Chemical
(,648,O
P,648,B-Chemical
),648,O
.,648,O
DM,649,B-Disease
rats,649,O
with,649,O
mild,649,O
glycosuria,649,B-Disease
(,649,O
similar,649,O
in,649,O
degree,649,O
to,649,O
that,649,O
of,649,O
the,649,O
P,649,B-Chemical
treated,649,O
animals,649,O
),649,O
were,649,O
also,649,O
studied,649,O
.,649,O
Unanesthetized,650,O
adult,650,O
female,650,O
",",650,O
Sprague-Dawley,650,O
rats,650,O
were,650,O
divided,650,O
in,650,O
four,650,O
groups,650,O
and,650,O
studied,650,O
for,650,O
15,650,O
days,650,O
.,650,O
Group,651,O
1,651,O
(,651,O
P,651,B-Chemical
alone,651,O
),651,O
received,651,O
P,651,B-Chemical
",",651,O
360,651,O
mg/day,651,O
",",651,O
for,651,O
15,651,O
days,651,O
;,651,O
Group,651,O
II,651,O
(,651,O
P,651,B-Chemical
+,651,O
gentamicin,651,B-Chemical
),651,O
;,651,O
Group,651,O
III,651,O
(,651,O
gentamicin,651,B-Chemical
alone,651,O
),651,O
and,651,O
Group,651,O
IV,651,O
(,651,O
mild,651,O
DM,651,B-Disease
+,651,O
gentamicin,651,B-Chemical
),651,O
.,651,O
Nephrotoxic,652,B-Disease
doses,652,O
(,652,O
40,652,O
mg/kg,652,O
body,652,O
wt/day,652,O
),652,O
of,652,O
gentamicin,652,B-Chemical
were,652,O
injected,652,O
during,652,O
the,652,O
last,652,O
nine,652,O
days,652,O
of,652,O
study,652,O
to,652,O
the,652,O
animals,652,O
of,652,O
groups,652,O
II,652,O
to,652,O
IV,652,O
.,652,O
In,653,O
Group,653,O
I,653,O
",",653,O
P,653,B-Chemical
induced,653,O
a,653,O
moderate,653,O
and,653,O
stable,653,O
glycosuria,653,B-Disease
(,653,O
3.9,653,O
+/-,653,O
0.1,653,O
g/day,653,O
",",653,O
SE,653,O
),653,O
",",653,O
and,653,O
no,653,O
functional,653,O
or,653,O
morphologic,653,O
evidence,653,O
of,653,O
renal,653,B-Disease
dysfunction,653,I-Disease
(,653,O
baseline,653,O
CCr,653,O
2.1,653,O
+/-,653,O
0.1,653,O
ml/min,653,O
",",653,O
undetectable,653,O
lysozymuria,653,O
),653,O
or,653,O
damage,653,O
(,653,O
tubular,653,B-Disease
necrosis,653,I-Disease
score,653,O
[,653,O
maximum,653,O
4,653,O
],653,O
",",653,O
zero,653,O
),653,O
.,653,O
In,654,O
Group,654,O
II,654,O
",",654,O
P,654,B-Chemical
did,654,O
not,654,O
prevent,654,O
gentamicin-ARF,654,B-Chemical
(,654,O
maximal,654,O
decrease,654,O
in,654,O
CCr,654,O
at,654,O
day,654,O
9.89,654,O
%,654,O
",",654,O
P,654,B-Chemical
less,654,O
than,654,O
0.001,654,O
;,654,O
peak,654,O
lysozymuria,654,O
",",654,O
1863,654,O
+/-,654,O
321,654,O
micrograms/day,654,O
;,654,O
and,654,O
tubular,654,B-Disease
necrosis,654,I-Disease
score,654,O
",",654,O
3.9,654,O
+/-,654,O
0.1,654,O
),654,O
.,654,O
These,655,O
values,655,O
were,655,O
not,655,O
different,655,O
from,655,O
those,655,O
of,655,O
Group,655,O
III,655,O
:,655,O
maximal,655,O
decrease,655,O
in,655,O
CCr,655,O
73,655,O
%,655,O
(,655,O
P,655,B-Chemical
less,655,O
than,655,O
0.001,655,O
),655,O
;,655,O
lysozymuria,655,O
",",655,O
2147,655,O
+/-,655,O
701,655,O
micrograms/day,655,O
;,655,O
tubular,655,B-Disease
necrosis,655,I-Disease
score,655,O
",",655,O
3.8,655,O
+/-,655,O
0.1,655,O
.,655,O
(,656,O
ABSTRACT,656,O
TRUNCATED,656,O
AT,656,O
250,656,O
WORDS,656,O
),656,O
Catalepsy,657,B-Disease
induced,657,O
by,657,O
combinations,657,O
of,657,O
ketamine,657,B-Chemical
and,657,O
morphine,657,B-Chemical
:,657,O
potentiation,657,O
",",657,O
antagonism,657,O
",",657,O
tolerance,657,O
and,657,O
cross-tolerance,657,O
in,657,O
the,657,O
rat,657,O
.,657,O
Previous,658,O
studies,658,O
demonstrated,658,O
that,658,O
both,658,O
ketamine,658,B-Chemical
and,658,O
morphine,658,B-Chemical
induced,658,O
analgesia,658,B-Disease
and,658,O
catalepsy,658,B-Disease
in,658,O
the,658,O
rat,658,O
.,658,O
Pre-treatment,659,O
with,659,O
ketamine,659,B-Chemical
produced,659,O
cross-tolerance,659,O
to,659,O
morphine,659,B-Chemical
",",659,O
whereas,659,O
pretreatment,659,O
with,659,O
morphine,659,B-Chemical
did,659,O
not,659,O
induce,659,O
cross-tolerance,659,O
to,659,O
ketamine,659,B-Chemical
but,659,O
rather,659,O
augmented,659,O
the,659,O
cataleptic,659,B-Disease
response,659,O
;,659,O
this,659,O
augmentation,659,O
was,659,O
attributed,659,O
to,659,O
residual,659,O
morphine,659,B-Chemical
in,659,O
the,659,O
brain,659,O
.,659,O
The,660,O
present,660,O
studies,660,O
explored,660,O
the,660,O
duration,660,O
of,660,O
the,660,O
loss,660,O
of,660,O
righting,660,O
reflex,660,O
induced,660,O
by,660,O
sub-effective,660,O
doses,660,O
of,660,O
ketamine,660,B-Chemical
and,660,O
morphine,660,B-Chemical
",",660,O
administered,660,O
simultaneously,660,O
.,660,O
There,661,O
was,661,O
mutual,661,O
potentiation,661,O
between,661,O
sub-effective,661,O
doses,661,O
of,661,O
ketamine,661,B-Chemical
and,661,O
morphine,661,B-Chemical
",",661,O
but,661,O
sub-effective,661,O
doses,661,O
of,661,O
ketamine,661,B-Chemical
partly,661,O
antagonized,661,O
fully-effective,661,O
doses,661,O
of,661,O
morphine,661,B-Chemical
.,661,O
Latency,662,O
to,662,O
the,662,O
loss,662,O
of,662,O
righting,662,O
reflex,662,O
",",662,O
rigidity,662,B-Disease
and,662,O
behavior,662,O
on,662,O
recovery,662,O
",",662,O
reflected,662,O
the,662,O
relative,662,O
predominance,662,O
of,662,O
ketamine,662,B-Chemical
or,662,O
morphine,662,B-Chemical
in,662,O
each,662,O
combination,662,O
.,662,O
Naloxone,663,B-Chemical
inhibited,663,O
the,663,O
induced,663,O
cataleptic,663,B-Disease
effects,663,O
.,663,O
The,664,O
degree,664,O
and,664,O
time,664,O
course,664,O
of,664,O
development,664,O
of,664,O
tolerance,664,O
to,664,O
daily,664,O
administration,664,O
of,664,O
sub-effective,664,O
dose,664,O
combinations,664,O
of,664,O
ketamine,664,B-Chemical
and,664,O
morphine,664,B-Chemical
were,664,O
similar,664,O
.,664,O
Rats,665,O
",",665,O
tolerant,665,O
to,665,O
ketamine-dominant,665,B-Chemical
combinations,665,O
",",665,O
were,665,O
cross-tolerant,665,O
to,665,O
both,665,O
drugs,665,O
",",665,O
while,665,O
those,665,O
tolerant,665,O
to,665,O
morphine-dominant,665,B-Chemical
combinations,665,O
were,665,O
cross-tolerant,665,O
to,665,O
morphine,665,B-Chemical
but,665,O
showed,665,O
either,665,O
no,665,O
cross-tolerance,665,O
or,665,O
an,665,O
augmented,665,O
response,665,O
to,665,O
ketamine,665,B-Chemical
.,665,O
While,666,O
the,666,O
mutual,666,O
potentiation,666,O
",",666,O
antagonism,666,O
and,666,O
tolerance,666,O
suggest,666,O
common,666,O
mechanisms,666,O
for,666,O
the,666,O
induced,666,O
catalepsy,666,B-Disease
",",666,O
differences,666,O
in,666,O
latency,666,O
",",666,O
rigidity,666,B-Disease
and,666,O
behavior,666,O
",",666,O
asymmetry,666,O
of,666,O
cross-tolerance,666,O
and,666,O
a,666,O
widely-different,666,O
ID50,666,O
for,666,O
naloxone,666,B-Chemical
would,666,O
argue,666,O
against,666,O
an,666,O
action,666,O
at,666,O
a,666,O
single,666,O
opioid,666,O
site,666,O
.,666,O
Hydrocortisone-induced,667,B-Chemical
hypertension,667,B-Disease
in,667,O
humans,667,O
:,667,O
pressor,667,O
responsiveness,667,O
and,667,O
sympathetic,667,O
function,667,O
.,667,O
Oral,668,O
hydrocortisone,668,B-Chemical
increases,668,O
blood,668,O
pressure,668,O
and,668,O
enhances,668,O
pressor,668,O
responsiveness,668,O
in,668,O
normal,668,O
human,668,O
subjects,668,O
.,668,O
We,669,O
studied,669,O
the,669,O
effects,669,O
of,669,O
1,669,O
week,669,O
of,669,O
oral,669,O
hydrocortisone,669,B-Chemical
(,669,O
200,669,O
mg/day,669,O
),669,O
on,669,O
blood,669,O
pressure,669,O
",",669,O
cardiac,669,O
output,669,O
",",669,O
total,669,O
peripheral,669,O
resistance,669,O
",",669,O
forearm,669,O
vascular,669,O
resistance,669,O
",",669,O
and,669,O
norepinephrine,669,B-Chemical
spillover,669,O
to,669,O
plasma,669,O
in,669,O
eight,669,O
healthy,669,O
male,669,O
volunteers,669,O
.,669,O
Although,670,O
diastolic,670,O
blood,670,O
pressure,670,O
remained,670,O
unchanged,670,O
",",670,O
systolic,670,O
blood,670,O
pressure,670,O
increased,670,O
from,670,O
119,670,O
to,670,O
135,670,O
mm,670,O
Hg,670,O
(,670,O
SED,670,O
+/-,670,O
3.4,670,O
",",670,O
p,670,O
less,670,O
than,670,O
0.01,670,O
),670,O
",",670,O
associated,670,O
with,670,O
an,670,O
increased,670,B-Disease
cardiac,670,I-Disease
output,670,I-Disease
(,670,O
5.85-7.73,670,O
l/min,670,O
",",670,O
SED,670,O
+/-,670,O
0.46,670,O
",",670,O
p,670,O
less,670,O
than,670,O
0.01,670,O
),670,O
.,670,O
Total,671,O
peripheral,671,O
vascular,671,O
resistance,671,O
fell,671,O
from,671,O
15.1,671,O
to,671,O
12.2,671,O
mm,671,O
Hg/l/min,671,O
(,671,O
SED,671,O
+/-,671,O
1.03,671,O
",",671,O
p,671,O
less,671,O
than,671,O
0.05,671,O
),671,O
.,671,O
Resting,672,O
forearm,672,O
vascular,672,O
resistance,672,O
remained,672,O
unchanged,672,O
",",672,O
but,672,O
the,672,O
reflex,672,O
response,672,O
to,672,O
the,672,O
cold,672,O
pressor,672,O
test,672,O
was,672,O
accentuated,672,O
",",672,O
the,672,O
rise,672,O
in,672,O
resistance,672,O
increasing,672,O
from,672,O
10.5,672,O
mm,672,O
Hg/ml/100,672,O
ml/min,672,O
(,672,O
R,672,O
units,672,O
),672,O
before,672,O
treatment,672,O
to,672,O
32.6,672,O
R,672,O
units,672,O
after,672,O
treatment,672,O
(,672,O
SED,672,O
+/-,672,O
6.4,672,O
",",672,O
p,672,O
less,672,O
than,672,O
0.025,672,O
),672,O
.,672,O
The,673,O
rise,673,O
in,673,O
forearm,673,O
vascular,673,O
resistance,673,O
accompanying,673,O
intra-arterial,673,O
norepinephrine,673,B-Chemical
(,673,O
25,673,O
",",673,O
50,673,O
",",673,O
and,673,O
100,673,O
ng/min,673,O
),673,O
was,673,O
also,673,O
significantly,673,O
greater,673,O
after,673,O
hydrocortisone,673,B-Chemical
",",673,O
increasing,673,O
from,673,O
an,673,O
average,673,O
of,673,O
14.9,673,O
+/-,673,O
2.4,673,O
R,673,O
units,673,O
before,673,O
treatment,673,O
to,673,O
35.1,673,O
+/-,673,O
5.5,673,O
R,673,O
units,673,O
after,673,O
hydrocortisone,673,B-Chemical
(,673,O
SED,673,O
+/-,673,O
6.0,673,O
",",673,O
p,673,O
less,673,O
than,673,O
0.05,673,O
),673,O
.,673,O
A,674,O
shift,674,O
to,674,O
the,674,O
left,674,O
in,674,O
the,674,O
dose-response,674,O
relation,674,O
and,674,O
fall,674,O
in,674,O
threshold,674,O
suggested,674,O
increased,674,O
sensitivity,674,O
to,674,O
norepinephrine,674,B-Chemical
after,674,O
treatment,674,O
.,674,O
Measurement,675,O
of,675,O
resting,675,O
norepinephrine,675,B-Chemical
spillover,675,O
rate,675,O
to,675,O
plasma,675,O
and,675,O
norepinephrine,675,B-Chemical
uptake,675,O
indicated,675,O
that,675,O
overall,675,O
resting,675,O
sympathetic,675,O
nervous,675,O
system,675,O
activity,675,O
was,675,O
not,675,O
increased,675,O
.,675,O
The,676,O
rise,676,B-Disease
in,676,I-Disease
resting,676,I-Disease
blood,676,I-Disease
pressure,676,I-Disease
with,676,O
hydrocortisone,676,B-Chemical
is,676,O
associated,676,O
with,676,O
an,676,O
increased,676,B-Disease
cardiac,676,I-Disease
output,676,I-Disease
(,676,O
presumably,676,O
due,676,O
to,676,O
increased,676,O
blood,676,O
volume,676,O
),676,O
.,676,O
(,677,O
ABSTRACT,677,O
TRUNCATED,677,O
AT,677,O
250,677,O
WORDS,677,O
),677,O
Neuromuscular,678,B-Disease
blockade,678,I-Disease
with,678,O
magnesium,678,B-Chemical
sulfate,678,I-Chemical
and,678,O
nifedipine,678,B-Chemical
.,678,O
A,679,O
patient,679,O
who,679,O
received,679,O
tocolysis,679,O
with,679,O
nifedipine,679,B-Chemical
developed,679,O
neuromuscular,679,B-Disease
blockade,679,I-Disease
after,679,O
500,679,O
mg,679,O
of,679,O
magnesium,679,B-Chemical
sulfate,679,I-Chemical
was,679,O
administered,679,O
.,679,O
This,680,O
reaction,680,O
demonstrates,680,O
that,680,O
nifedipine,680,B-Chemical
can,680,O
seriously,680,O
potentiate,680,O
the,680,O
toxicity,680,B-Disease
of,680,O
magnesium,680,B-Chemical
.,680,O
Caution,681,O
should,681,O
be,681,O
exercised,681,O
when,681,O
these,681,O
two,681,O
tocolytics,681,O
are,681,O
combined,681,O
.,681,O
Chronic,682,O
carbamazepine,682,B-Chemical
inhibits,682,O
the,682,O
development,682,O
of,682,O
local,682,O
anesthetic,682,O
seizures,682,B-Disease
kindled,682,O
by,682,O
cocaine,682,B-Chemical
and,682,O
lidocaine,682,B-Chemical
.,682,O
The,683,O
effects,683,O
of,683,O
carbamazepine,683,B-Chemical
(,683,O
CBZ,683,B-Chemical
),683,O
treatment,683,O
on,683,O
local,683,O
anesthetic-kindled,683,O
seizures,683,B-Disease
and,683,O
lethality,683,O
were,683,O
evaluated,683,O
in,683,O
different,683,O
stages,683,O
of,683,O
the,683,O
kindling,683,O
process,683,O
and,683,O
under,683,O
different,683,O
methods,683,O
of,683,O
CBZ,683,B-Chemical
administration,683,O
.,683,O
Chronic,684,O
oral,684,O
CBZ,684,B-Chemical
inhibited,684,O
the,684,O
development,684,O
of,684,O
both,684,O
lidocaine-,684,B-Chemical
and,684,O
cocaine-induced,684,B-Chemical
seizures,684,B-Disease
",",684,O
but,684,O
had,684,O
little,684,O
effect,684,O
on,684,O
the,684,O
fully,684,O
developed,684,O
local,684,O
anesthetic,684,O
seizures,684,B-Disease
.,684,O
Chronic,685,O
CBZ,685,B-Chemical
also,685,O
decreased,685,O
the,685,O
incidence,685,O
of,685,O
seizure-related,685,B-Disease
mortality,685,O
in,685,O
the,685,O
cocaine-injected,685,B-Chemical
rats,685,O
.,685,O
Acute,686,O
CBZ,686,B-Chemical
over,686,O
a,686,O
range,686,O
of,686,O
doses,686,O
(,686,O
15-50,686,O
mg/kg,686,O
),686,O
had,686,O
no,686,O
effect,686,O
on,686,O
completed,686,O
lidocaine-kindled,686,B-Chemical
or,686,O
acute,686,O
cocaine-induced,686,B-Chemical
seizures,686,B-Disease
.,686,O
Repeated,687,O
i.p,687,O
.,687,O
injection,688,O
of,688,O
CBZ,688,B-Chemical
(,688,O
15,688,O
mg/kg,688,O
),688,O
also,688,O
was,688,O
without,688,O
effect,688,O
on,688,O
the,688,O
development,688,O
of,688,O
lidocaine-,688,B-Chemical
or,688,O
cocaine-kindled,688,B-Chemical
seizures,688,B-Disease
.,688,O
The,689,O
differential,689,O
effects,689,O
of,689,O
CBZ,689,B-Chemical
depending,689,O
upon,689,O
stage,689,O
of,689,O
seizure,689,B-Disease
development,689,O
suggest,689,O
that,689,O
distinct,689,O
mechanisms,689,O
underlie,689,O
the,689,O
development,689,O
versus,689,O
maintenance,689,O
of,689,O
local,689,O
anesthetic-kindled,689,O
seizures,689,B-Disease
.,689,O
The,690,O
effectiveness,690,O
of,690,O
chronic,690,O
but,690,O
not,690,O
repeated,690,O
",",690,O
intermittent,690,O
injections,690,O
of,690,O
CBZ,690,B-Chemical
suggests,690,O
that,690,O
different,690,O
biochemical,690,O
consequences,690,O
result,690,O
from,690,O
the,690,O
different,690,O
treatment,690,O
regimens,690,O
.,690,O
The,691,O
possible,691,O
utility,691,O
of,691,O
chronic,691,O
CBZ,691,B-Chemical
in,691,O
preventing,691,O
the,691,O
development,691,O
of,691,O
toxic,691,O
side,691,O
effects,691,O
in,691,O
human,691,O
cocaine,691,B-Chemical
users,691,O
is,691,O
suggested,691,O
by,691,O
these,691,O
data,691,O
",",691,O
but,691,O
remains,691,O
to,691,O
be,691,O
directly,691,O
evaluated,691,O
.,691,O
Magnetic,692,O
resonance,692,O
imaging,692,O
of,692,O
cerebral,692,O
venous,692,B-Disease
thrombosis,692,I-Disease
secondary,692,O
to,692,O
``,692,O
low-dose,692,O
'',692,O
birth,692,O
control,692,O
pills,692,O
.,692,O
The,693,O
clinical,693,O
and,693,O
radiographic,693,O
features,693,O
of,693,O
cerebral,693,O
deep,693,B-Disease
venous,693,I-Disease
thrombosis,693,I-Disease
in,693,O
a,693,O
21-year-old,693,O
white,693,O
woman,693,O
are,693,O
presented,693,O
.,693,O
This,694,O
nulliparous,694,O
patient,694,O
presented,694,O
with,694,O
relatively,694,O
mild,694,O
clinical,694,O
symptoms,694,O
and,694,O
progressing,694,O
mental,694,O
status,694,O
changes,694,O
.,694,O
The,695,O
only,695,O
known,695,O
risk,695,O
factor,695,O
was,695,O
``,695,O
low-dose,695,O
'',695,O
oral,695,B-Chemical
contraceptive,695,I-Chemical
pills,695,O
.,695,O
The,696,O
magnetic,696,O
resonance,696,O
image,696,O
(,696,O
MRI,696,O
),696,O
showed,696,O
increased,696,O
signal,696,O
intensity,696,O
from,696,O
the,696,O
internal,696,O
cerebral,696,O
veins,696,O
",",696,O
vein,696,O
of,696,O
Galen,696,O
",",696,O
and,696,O
straight,696,O
sinus,696,O
.,696,O
The,697,O
diagnosis,697,O
was,697,O
confirmed,697,O
by,697,O
arterial,697,O
angiography,697,O
.,697,O
Beta-2-adrenoceptor-mediated,698,O
hypokalemia,698,B-Disease
and,698,O
its,698,O
abolishment,698,O
by,698,O
oxprenolol,698,B-Chemical
.,698,O
The,699,O
time,699,O
course,699,O
and,699,O
concentration-effect,699,O
relationship,699,O
of,699,O
terbutaline-induced,699,B-Chemical
hypokalemia,699,B-Disease
was,699,O
studied,699,O
",",699,O
using,699,O
computer-aided,699,O
pharmacokinetic-dynamic,699,O
modeling,699,O
.,699,O
Subsequently,700,O
we,700,O
investigated,700,O
the,700,O
efficacy,700,O
of,700,O
oxprenolol,700,B-Chemical
in,700,O
antagonizing,700,O
such,700,O
hypokalemia,700,B-Disease
",",700,O
together,700,O
with,700,O
the,700,O
pharmacokinetic,700,O
interaction,700,O
between,700,O
both,700,O
drugs,700,O
.,700,O
Six,701,O
healthy,701,O
subjects,701,O
were,701,O
given,701,O
a,701,O
0.5,701,O
mg,701,O
subcutaneous,701,O
dose,701,O
of,701,O
terbutaline,701,B-Chemical
on,701,O
two,701,O
occasions,701,O
:,701,O
1,701,O
hour,701,O
after,701,O
oral,701,O
administration,701,O
of,701,O
a,701,O
placebo,701,O
and,701,O
1,701,O
hour,701,O
after,701,O
80,701,O
mg,701,O
oxprenolol,701,B-Chemical
orally,701,O
.,701,O
In,702,O
the,702,O
7-hour,702,O
period,702,O
after,702,O
terbutaline,702,B-Chemical
administration,702,O
",",702,O
plasma,702,O
samples,702,O
were,702,O
taken,702,O
for,702,O
determination,702,O
of,702,O
plasma,702,O
potassium,702,B-Chemical
levels,702,O
and,702,O
drug,702,O
concentrations,702,O
.,702,O
The,703,O
sigmoid,703,O
Emax,703,O
model,703,O
offered,703,O
a,703,O
good,703,O
description,703,O
of,703,O
the,703,O
relation,703,O
between,703,O
terbutaline,703,B-Chemical
concentrations,703,O
and,703,O
potassium,703,B-Chemical
effects,703,O
.,703,O
Oxprenolol,704,B-Chemical
caused,704,O
decreases,704,O
of,704,O
65,704,O
%,704,O
and,704,O
56,704,O
%,704,O
of,704,O
terbutaline,704,B-Chemical
volume,704,O
of,704,O
distribution,704,O
and,704,O
clearance,704,O
",",704,O
respectively,704,O
",",704,O
and,704,O
an,704,O
increase,704,O
of,704,O
130,704,O
%,704,O
of,704,O
its,704,O
AUC,704,O
.,704,O
In,705,O
spite,705,O
of,705,O
higher,705,O
terbutaline,705,B-Chemical
concentrations,705,O
after,705,O
oxprenolol,705,B-Chemical
pretreatment,705,O
",",705,O
the,705,O
hypokalemia,705,B-Disease
was,705,O
almost,705,O
completely,705,O
antagonized,705,O
by,705,O
the,705,O
beta,705,O
2-blocking,705,O
action,705,O
.,705,O
A,706,O
dystonia-like,706,B-Disease
syndrome,706,O
after,706,O
neuropeptide,706,O
(,706,O
MSH/ACTH,706,B-Chemical
),706,O
stimulation,706,O
of,706,O
the,706,O
rat,706,O
locus,706,O
ceruleus,706,O
.,706,O
The,707,O
movement,707,B-Disease
disorder,707,I-Disease
investigated,707,O
in,707,O
these,707,O
studies,707,O
has,707,O
some,707,O
features,707,O
in,707,O
common,707,O
with,707,O
human,707,O
idiopathic,707,O
dystonia,707,B-Disease
",",707,O
and,707,O
information,707,O
obtained,707,O
in,707,O
these,707,O
studies,707,O
may,707,O
be,707,O
of,707,O
potential,707,O
clinical,707,O
benefit,707,O
.,707,O
The,708,O
present,708,O
experimental,708,O
results,708,O
indicated,708,O
that,708,O
peptidergic,708,O
stimulation,708,O
of,708,O
the,708,O
LC,708,O
resulted,708,O
in,708,O
a,708,O
NE-mediated,708,O
inhibition,708,O
of,708,O
cerebellar,708,O
Purkinje,708,O
cells,708,O
located,708,O
at,708,O
terminals,708,O
of,708,O
the,708,O
ceruleo-cerebellar,708,O
pathway,708,O
.,708,O
However,709,O
",",709,O
it,709,O
is,709,O
not,709,O
certain,709,O
as,709,O
to,709,O
the,709,O
following,709,O
:,709,O
(,709,O
a,709,O
),709,O
what,709,O
receptors,709,O
were,709,O
stimulated,709,O
by,709,O
the,709,O
ACTH,709,B-Chemical
N-terminal,709,O
fragments,709,O
at,709,O
the,709,O
LC,709,O
that,709,O
resulted,709,O
in,709,O
this,709,O
disorder,709,O
;,709,O
(,709,O
b,709,O
),709,O
whether,709,O
NE,709,O
",",709,O
released,709,O
onto,709,O
Purkinje,709,O
cell,709,O
synapses,709,O
located,709,O
at,709,O
terminals,709,O
of,709,O
the,709,O
ceruleo-cerebellar,709,O
pathway,709,O
",",709,O
did,709,O
indeed,709,O
cause,709,O
the,709,O
long-term,709,O
depression,709,B-Disease
at,709,O
Purkinje,709,O
cell,709,O
synapses,709,O
(,709,O
previously,709,O
described,709,O
by,709,O
others,709,O
),709,O
that,709,O
resulted,709,O
in,709,O
the,709,O
long,709,O
duration,709,O
of,709,O
the,709,O
movement,709,B-Disease
disorder,709,I-Disease
;,709,O
(,709,O
c,709,O
),709,O
whether,709,O
the,709,O
inhibition,709,O
of,709,O
inhibitory,709,O
Purkinje,709,O
cells,709,O
resulted,709,O
in,709,O
disinhibition,709,O
or,709,O
increased,709,O
excitability,709,O
of,709,O
the,709,O
unilateral,709,O
cerebellar,709,O
fastigial,709,O
or,709,O
interpositus,709,O
nuclei,709,O
",",709,O
the,709,O
output,709,O
targets,709,O
of,709,O
the,709,O
Purkinje,709,O
cell,709,O
axons,709,O
",",709,O
that,709,O
may,709,O
have,709,O
been,709,O
an,709,O
important,709,O
contributing,709,O
factor,709,O
to,709,O
this,709,O
disorder,709,O
.,709,O
These,710,O
questions,710,O
are,710,O
currently,710,O
being,710,O
investigated,710,O
.,710,O
Enhanced,711,O
stimulus-induced,711,O
neurotransmitter,711,O
overflow,711,O
in,711,O
epinephrine-induced,711,B-Chemical
hypertensive,711,B-Disease
rats,711,O
is,711,O
not,711,O
mediated,711,O
by,711,O
prejunctional,711,O
beta-adrenoceptor,711,O
activation,711,O
.,711,O
The,712,O
present,712,O
study,712,O
examines,712,O
the,712,O
effect,712,O
of,712,O
6-day,712,O
epinephrine,712,B-Chemical
treatment,712,O
(,712,O
100,712,O
micrograms/kg,712,O
per,712,O
h,712,O
",",712,O
s.c.,712,O
),712,O
on,712,O
stimulus-induced,712,O
(,712,O
1,712,O
Hz,712,O
),712,O
endogenous,712,O
neurotransmitter,712,O
overflow,712,O
from,712,O
the,712,O
isolated,712,O
perfused,712,O
kidney,712,O
of,712,O
vehicle-,712,O
and,712,O
epinephrine-treated,712,B-Chemical
rats,712,O
.,712,O
Renal,713,O
catecholamine,713,B-Chemical
stores,713,O
and,713,O
stimulus-induced,713,O
overflow,713,O
in,713,O
the,713,O
vehicle-treated,713,O
group,713,O
consisted,713,O
of,713,O
norepinephrine,713,B-Chemical
only,713,O
.,713,O
However,714,O
",",714,O
epinephrine,714,B-Chemical
treatment,714,O
resulted,714,O
in,714,O
the,714,O
incorporation,714,O
of,714,O
epinephrine,714,B-Chemical
into,714,O
renal,714,O
catecholamine,714,B-Chemical
stores,714,O
such,714,O
that,714,O
approximately,714,O
40,714,O
%,714,O
of,714,O
the,714,O
catecholamine,714,B-Chemical
present,714,O
was,714,O
epinephrine,714,B-Chemical
while,714,O
the,714,O
norepinephrine,714,B-Chemical
content,714,O
was,714,O
reduced,714,O
by,714,O
a,714,O
similar,714,O
degree,714,O
.,714,O
Total,715,O
tissue,715,O
catecholamine,715,B-Chemical
content,715,O
of,715,O
the,715,O
kidney,715,O
on,715,O
a,715,O
molar,715,O
basis,715,O
was,715,O
unchanged,715,O
.,715,O
Stimulus-induced,716,O
fractional,716,O
overflow,716,O
of,716,O
neurotransmitter,716,O
from,716,O
the,716,O
epinephrine-treated,716,B-Chemical
kidneys,716,O
was,716,O
approximately,716,O
twice,716,O
normal,716,O
and,716,O
consisted,716,O
of,716,O
both,716,O
norepinephrine,716,B-Chemical
and,716,O
epinephrine,716,B-Chemical
in,716,O
proportions,716,O
similar,716,O
to,716,O
those,716,O
found,716,O
in,716,O
the,716,O
kidney,716,O
.,716,O
This,717,O
difference,717,O
in,717,O
fractional,717,O
overflow,717,O
between,717,O
groups,717,O
was,717,O
not,717,O
affected,717,O
by,717,O
neuronal,717,O
and,717,O
extraneuronal,717,O
uptake,717,O
blockade,717,O
.,717,O
Propranolol,718,B-Chemical
had,718,O
no,718,O
effect,718,O
on,718,O
stimulus-induced,718,O
overflow,718,O
in,718,O
either,718,O
group,718,O
.,718,O
Phentolamine,719,B-Chemical
increased,719,O
stimulus-induced,719,O
overflow,719,O
in,719,O
both,719,O
groups,719,O
although,719,O
the,719,O
increment,719,O
in,719,O
overflow,719,O
was,719,O
greater,719,O
in,719,O
the,719,O
epinephrine-treated,719,B-Chemical
group,719,O
.,719,O
In,720,O
conclusion,720,O
",",720,O
chronic,720,O
epinephrine,720,B-Chemical
treatment,720,O
results,720,O
in,720,O
enhanced,720,O
fractional,720,O
neurotransmitter,720,O
overflow,720,O
.,720,O
However,721,O
",",721,O
neither,721,O
alterations,721,O
in,721,O
prejunctional,721,O
beta-adrenoceptor,721,O
influences,721,O
nor,721,O
alterations,721,O
in,721,O
neuronal,721,O
and,721,O
extraneuronal,721,O
uptake,721,O
mechanisms,721,O
appear,721,O
to,721,O
be,721,O
responsible,721,O
for,721,O
this,721,O
alteration,721,O
.,721,O
Furthermore,722,O
",",722,O
data,722,O
obtained,722,O
with,722,O
phentolamine,722,B-Chemical
alone,722,O
do,722,O
not,722,O
suggest,722,O
alpha-adrenoceptor,722,O
desensitization,722,O
as,722,O
the,722,O
cause,722,O
of,722,O
the,722,O
enhanced,722,O
neurotransmitter,722,O
overflow,722,O
after,722,O
epinephrine,722,B-Chemical
treatment,722,O
.,722,O
GABA,723,B-Chemical
involvement,723,O
in,723,O
naloxone,723,B-Chemical
induced,723,O
reversal,723,O
of,723,O
respiratory,723,B-Disease
paralysis,723,I-Disease
produced,723,O
by,723,O
thiopental,723,B-Chemical
.,723,O
No,724,O
agent,724,O
is,724,O
yet,724,O
available,724,O
to,724,O
reverse,724,O
respiratory,724,B-Disease
paralysis,724,I-Disease
produced,724,O
by,724,O
CNS,724,O
depressants,724,O
",",724,O
such,724,O
as,724,O
general,724,O
anesthetics,724,O
.,724,O
In,725,O
this,725,O
study,725,O
naloxone,725,B-Chemical
reversed,725,O
respiratory,725,B-Disease
paralysis,725,I-Disease
induced,725,O
by,725,O
thiopental,725,B-Chemical
in,725,O
rats,725,O
.,725,O
25,726,O
mg/kg,726,O
",",726,O
i.v,726,O
.,726,O
thiopental,727,B-Chemical
produced,727,O
anesthesia,727,O
without,727,O
altering,727,O
respiratory,727,O
rate,727,O
",",727,O
increased,727,O
GABA,727,B-Chemical
",",727,O
decreased,727,O
glutamate,727,B-Chemical
",",727,O
and,727,O
had,727,O
no,727,O
effect,727,O
on,727,O
aspartate,727,B-Chemical
or,727,O
glycine,727,B-Chemical
levels,727,O
compared,727,O
to,727,O
controls,727,O
in,727,O
rat,727,O
cortex,727,O
and,727,O
brain,727,O
stem,727,O
.,727,O
Pretreatment,728,O
of,728,O
rats,728,O
with,728,O
thiosemicarbazide,728,B-Chemical
for,728,O
30,728,O
minutes,728,O
abolished,728,O
the,728,O
anesthetic,728,O
action,728,O
as,728,O
well,728,O
as,728,O
the,728,O
respiratory,728,O
depressant,728,O
action,728,O
of,728,O
thiopental,728,B-Chemical
.,728,O
50,729,O
mg/kg,729,O
",",729,O
i.v,729,O
.,729,O
thiopental,730,B-Chemical
produced,730,O
respiratory,730,B-Disease
arrest,730,I-Disease
with,730,O
further,730,O
increase,730,O
in,730,O
GABA,730,B-Chemical
and,730,O
decrease,730,O
in,730,O
glutamate,730,B-Chemical
again,730,O
in,730,O
cortex,730,O
and,730,O
brain,730,O
stem,730,O
without,730,O
affecting,730,O
any,730,O
of,730,O
the,730,O
amino,730,B-Chemical
acids,730,I-Chemical
studied,730,O
in,730,O
four,730,O
regions,730,O
of,730,O
rat,730,O
brain,730,O
.,730,O
Naloxone,731,B-Chemical
(,731,O
2.5,731,O
mg/kg,731,O
",",731,O
i.v,731,O
.,731,O
),731,O
reversed,732,O
respiratory,732,B-Disease
paralysis,732,I-Disease
",",732,O
glutamate,732,B-Chemical
and,732,O
GABA,732,B-Chemical
levels,732,O
to,732,O
control,732,O
values,732,O
in,732,O
brain,732,O
stem,732,O
and,732,O
cortex,732,O
with,732,O
no,732,O
changes,732,O
in,732,O
caudate,732,O
or,732,O
cerebellum,732,O
.,732,O
These,733,O
data,733,O
suggest,733,O
naloxone,733,B-Chemical
reverses,733,O
respiratory,733,B-Disease
paralysis,733,I-Disease
produced,733,O
by,733,O
thiopental,733,B-Chemical
and,733,O
involves,733,O
GABA,733,B-Chemical
in,733,O
its,733,O
action,733,O
.,733,O
Diazepam,734,B-Chemical
facilitates,734,O
reflex,734,O
bradycardia,734,B-Disease
in,734,O
conscious,734,O
rats,734,O
.,734,O
The,735,O
effects,735,O
of,735,O
diazepam,735,B-Chemical
on,735,O
cardiovascular,735,O
function,735,O
were,735,O
assessed,735,O
in,735,O
conscious,735,O
rats,735,O
.,735,O
Intravenous,736,O
administration,736,O
of,736,O
diazepam,736,B-Chemical
(,736,O
1-30,736,O
mg,736,O
kg-1,736,O
),736,O
produced,736,O
a,736,O
dose-dependent,736,O
decrease,736,O
in,736,O
both,736,O
the,736,O
mean,736,O
arterial,736,O
pressure,736,O
and,736,O
the,736,O
heart,736,O
rate,736,O
.,736,O
Also,737,O
",",737,O
reflex,737,O
bradycardia,737,B-Disease
was,737,O
produced,737,O
in,737,O
rats,737,O
by,737,O
intravenous,737,O
infusion,737,O
of,737,O
adrenaline,737,B-Chemical
(,737,O
1.25-2.5,737,O
micrograms,737,O
kg-1,737,O
),737,O
.,737,O
Intravenous,738,O
pretreatment,738,O
of,738,O
the,738,O
rats,738,O
with,738,O
diazepam,738,B-Chemical
",",738,O
although,738,O
causing,738,O
no,738,O
change,738,O
in,738,O
the,738,O
adrenaline-induced,738,B-Chemical
pressor,738,O
effect,738,O
",",738,O
did,738,O
enhance,738,O
the,738,O
adrenaline-induced,738,B-Chemical
reflex,738,O
bradycardia,738,B-Disease
.,738,O
However,739,O
",",739,O
the,739,O
diazepam,739,B-Chemical
enhancement,739,O
of,739,O
adrenaline-induced,739,B-Chemical
reflex,739,O
bradycardia,739,B-Disease
was,739,O
antagonized,739,O
by,739,O
pretreatment,739,O
of,739,O
rats,739,O
with,739,O
an,739,O
intravenous,739,O
dose,739,O
of,739,O
picrotoxin,739,B-Chemical
(,739,O
an,739,O
agent,739,O
blocks,739,O
chloride,739,B-Chemical
channels,739,O
by,739,O
binding,739,O
to,739,O
sites,739,O
associated,739,O
with,739,O
the,739,O
benzodiazepine-GABA-chloride,739,B-Chemical
channel,739,O
macromolecular,739,O
complex,739,O
),739,O
.,739,O
The,740,O
data,740,O
indicate,740,O
that,740,O
diazepam,740,B-Chemical
acts,740,O
through,740,O
the,740,O
benzodiazepine-GABA-chloride,740,B-Chemical
channel,740,O
macromolecular,740,O
complex,740,O
within,740,O
the,740,O
central,740,O
nervous,740,O
system,740,O
to,740,O
facilitate,740,O
reflex,740,O
bradycardia,740,B-Disease
mediated,740,O
through,740,O
baroreceptor,740,O
reflexes,740,O
in,740,O
response,740,O
to,740,O
an,740,O
acute,740,O
increase,740,O
in,740,O
arterial,740,O
pressure,740,O
.,740,O
Reversal,741,O
of,741,O
neuroleptic-induced,741,O
catalepsy,741,B-Disease
by,741,O
novel,741,O
aryl-piperazine,741,B-Chemical
anxiolytic,741,O
drugs,741,O
.,741,O
The,742,O
novel,742,O
anxiolytic,742,O
drug,742,O
",",742,O
buspirone,742,B-Chemical
",",742,O
reverses,742,O
catalepsy,742,B-Disease
induced,742,O
by,742,O
haloperidol,742,B-Chemical
.,742,O
A,743,O
series,743,O
of,743,O
aryl-piperazine,743,B-Chemical
analogues,743,O
of,743,O
buspirone,743,B-Chemical
and,743,O
other,743,O
5-hydroxytryptaminergic,743,B-Chemical
agonists,743,I-Chemical
were,743,O
tested,743,O
for,743,O
their,743,O
ability,743,O
to,743,O
reverse,743,O
haloperidol,743,B-Chemical
induced,743,O
catalepsy,743,B-Disease
.,743,O
Those,744,O
drugs,744,O
with,744,O
strong,744,O
affinity,744,O
for,744,O
5-hydroxytryptamine1a,744,B-Chemical
receptors,744,O
were,744,O
able,744,O
to,744,O
reverse,744,O
catalepsy,744,B-Disease
.,744,O
Drugs,745,O
with,745,O
affinity,745,O
for,745,O
other,745,O
5-HT,745,B-Chemical
receptors,745,O
or,745,O
weak,745,O
affinity,745,O
were,745,O
ineffective,745,O
.,745,O
However,746,O
",",746,O
inhibition,746,O
of,746,O
postsynaptic,746,O
5-HT,746,B-Chemical
receptors,746,O
neither,746,O
inhibited,746,O
nor,746,O
potentiated,746,O
reversal,746,O
of,746,O
catalepsy,746,B-Disease
and,746,O
leaves,746,O
open,746,O
the,746,O
question,746,O
as,746,O
to,746,O
the,746,O
site,746,O
or,746,O
mechanism,746,O
for,746,O
this,746,O
effect,746,O
.,746,O
Glycopyrronium,747,B-Chemical
requirements,747,O
for,747,O
antagonism,747,O
of,747,O
the,747,O
muscarinic,747,O
side,747,O
effects,747,O
of,747,O
edrophonium,747,B-Chemical
.,747,O
We,748,O
have,748,O
compared,748,O
",",748,O
in,748,O
60,748,O
adult,748,O
patients,748,O
",",748,O
the,748,O
cardiovascular,748,O
effects,748,O
of,748,O
glycopyrronium,748,B-Chemical
5,748,O
micrograms,748,O
kg-1,748,O
and,748,O
10,748,O
micrograms,748,O
kg-1,748,O
given,748,O
either,748,O
simultaneously,748,O
or,748,O
1,748,O
min,748,O
before,748,O
edrophonium,748,B-Chemical
1,748,O
mg,748,O
kg-1,748,O
.,748,O
Significant,749,O
differences,749,O
between,749,O
the,749,O
four,749,O
groups,749,O
were,749,O
detected,749,O
(,749,O
P,749,O
less,749,O
than,749,O
0.001,749,O
),749,O
.,749,O
Both,750,O
groups,750,O
receiving,750,O
10,750,O
micrograms,750,O
kg-1,750,O
showed,750,O
increases,750,O
in,750,O
heart,750,O
rate,750,O
of,750,O
up,750,O
to,750,O
30,750,O
beat,750,O
min-1,750,O
(,750,O
95,750,O
%,750,O
confidence,750,O
limits,750,O
28-32,750,O
beat,750,O
min-1,750,O
),750,O
.,750,O
Use,751,O
of,751,O
glycopyrronium,751,B-Chemical
5,751,O
micrograms,751,O
kg-1,751,O
provided,751,O
greater,751,O
cardiovascular,751,O
stability,751,O
and,751,O
",",751,O
given,751,O
1,751,O
min,751,O
before,751,O
the,751,O
edrophonium,751,B-Chemical
",",751,O
was,751,O
sufficient,751,O
to,751,O
minimize,751,O
early,751,O
",",751,O
edrophonium-induced,751,B-Chemical
bradycardias,751,B-Disease
.,751,O
This,752,O
low,752,O
dose,752,O
of,752,O
glycopyrronium,752,B-Chemical
provided,752,O
good,752,O
control,752,O
of,752,O
oropharyngeal,752,O
secretions,752,O
.,752,O
Selective,753,O
injection,753,O
of,753,O
iopentol,753,B-Chemical
",",753,O
iohexol,753,B-Chemical
and,753,O
metrizoate,753,B-Chemical
into,753,O
the,753,O
left,753,O
coronary,753,O
artery,753,O
of,753,O
the,753,O
dog,753,O
.,753,O
Induction,754,O
of,754,O
ventricular,754,B-Disease
fibrillation,754,I-Disease
and,754,O
decrease,754,O
of,754,O
aortic,754,O
pressure,754,O
.,754,O
In,755,O
twenty,755,O
beagle,755,O
dogs,755,O
selective,755,O
injections,755,O
were,755,O
made,755,O
into,755,O
the,755,O
left,755,O
coronary,755,O
artery,755,O
with,755,O
iopentol,755,B-Chemical
",",755,O
iohexol,755,B-Chemical
and,755,O
metrizoate,755,B-Chemical
in,755,O
doses,755,O
of,755,O
4,755,O
ml,755,O
",",755,O
8,755,O
ml,755,O
and,755,O
16,755,O
ml,755,O
.,755,O
Thirty-six,756,O
iopentol,756,B-Chemical
injections,756,O
",",756,O
35,756,O
iohexol,756,B-Chemical
injections,756,O
and,756,O
37,756,O
metrizoate,756,B-Chemical
injections,756,O
were,756,O
made,756,O
.,756,O
Frequencies,757,O
of,757,O
ventricular,757,B-Disease
fibrillation,757,I-Disease
were,757,O
significantly,757,O
lower,757,O
(,757,O
p,757,O
less,757,O
than,757,O
0.05,757,O
),757,O
after,757,O
iopentol,757,B-Chemical
(,757,O
0,757,O
%,757,O
),757,O
and,757,O
iohexol,757,B-Chemical
(,757,O
3,757,O
%,757,O
),757,O
than,757,O
after,757,O
metrizoate,757,B-Chemical
(,757,O
22,757,O
%,757,O
),757,O
.,757,O
Iopentol,758,B-Chemical
and,758,O
iohexol,758,B-Chemical
also,758,O
produced,758,O
significantly,758,O
less,758,O
decrease,758,O
in,758,O
aortic,758,O
blood,758,O
pressure,758,O
than,758,O
metrizoate,758,B-Chemical
at,758,O
the,758,O
different,758,O
doses,758,O
.,758,O
Thyroid,759,O
function,759,O
and,759,O
urine-concentrating,759,O
ability,759,O
during,759,O
lithium,759,B-Chemical
treatment,759,O
.,759,O
It,760,O
has,760,O
been,760,O
suggested,760,O
that,760,O
adenylate,760,O
cyclase,760,O
inhibition,760,O
may,760,O
be,760,O
important,760,O
in,760,O
the,760,O
development,760,O
of,760,O
both,760,O
nephrogenic,760,B-Disease
diabetes,760,I-Disease
insipidus,760,I-Disease
and,760,O
hypothyroidism,760,B-Disease
during,760,O
lithium,760,B-Chemical
treatment,760,O
.,760,O
We,761,O
measured,761,O
serum,761,O
thyroxine,761,B-Chemical
and,761,O
urine-concentrating,761,O
ability,761,O
(,761,O
Umax,761,O
),761,O
in,761,O
response,761,O
to,761,O
desmopressin,761,O
(,761,O
DDAVP,761,O
),761,O
in,761,O
85,761,O
patients,761,O
receiving,761,O
lithium,761,B-Chemical
.,761,O
Hypothyroidism,762,B-Disease
developed,762,O
in,762,O
eight,762,O
patients,762,O
while,762,O
they,762,O
were,762,O
taking,762,O
lithium,762,B-Chemical
.,762,O
Impaired,763,O
Umax,763,O
was,763,O
found,763,O
in,763,O
both,763,O
euthyroid,763,O
and,763,O
hypothyroid,763,B-Disease
patients,763,O
while,763,O
some,763,O
hypothyroid,763,B-Disease
patients,763,O
concentrated,763,O
their,763,O
urine,763,O
well,763,O
.,763,O
It,764,O
is,764,O
concluded,764,O
that,764,O
the,764,O
dominant,764,O
mechanisms,764,O
by,764,O
which,764,O
lithium,764,B-Chemical
exerts,764,O
these,764,O
two,764,O
effects,764,O
are,764,O
different,764,O
.,764,O
Remodelling,765,O
of,765,O
nerve,765,O
structure,765,O
in,765,O
experimental,765,O
isoniazid,765,B-Chemical
neuropathy,765,B-Disease
in,765,O
the,765,O
rat,765,O
.,765,O
The,766,O
neuropathy,766,B-Disease
caused,766,O
by,766,O
a,766,O
single,766,O
dose,766,O
of,766,O
isoniazid,766,B-Chemical
in,766,O
rats,766,O
was,766,O
studied,766,O
with,766,O
a,766,O
computer-assisted,766,O
morphometric,766,O
method,766,O
.,766,O
Scatter,767,O
diagrams,767,O
of,767,O
the,767,O
g,767,O
ratio,767,O
(,767,O
quotient,767,O
fibre,767,O
diameter/axon,767,O
diameter,767,O
),767,O
define,767,O
regenerating,767,O
fibres,767,O
as,767,O
a,767,O
distinct,767,O
population,767,O
",",767,O
distinguishable,767,O
from,767,O
the,767,O
surviving,767,O
fibres,767,O
by,767,O
reduced,767,O
sheath,767,O
thickness,767,O
and,767,O
reduced,767,O
axon,767,O
calibre,767,O
.,767,O
There,768,O
was,768,O
also,768,O
evidence,768,O
of,768,O
a,768,O
subtle,768,O
direct,768,O
toxic,768,O
effect,768,O
on,768,O
the,768,O
entire,768,O
fibre,768,O
population,768,O
",",768,O
causing,768,O
axon,768,O
shrinkage,768,O
masked,768,O
by,768,O
readjustment,768,O
of,768,O
the,768,O
myelin,768,O
sheath,768,O
.,768,O
Multicenter,769,O
",",769,O
double-blind,769,O
",",769,O
multiple-dose,769,O
",",769,O
parallel-groups,769,O
efficacy,769,O
and,769,O
safety,769,O
trial,769,O
of,769,O
azelastine,769,B-Chemical
",",769,O
chlorpheniramine,769,B-Chemical
",",769,O
and,769,O
placebo,769,O
in,769,O
the,769,O
treatment,769,O
of,769,O
spring,769,B-Disease
allergic,769,I-Disease
rhinitis,769,I-Disease
.,769,O
Azelastine,770,B-Chemical
",",770,O
a,770,O
novel,770,O
antiallergic,770,O
medication,770,O
",",770,O
was,770,O
compared,770,O
with,770,O
chlorpheniramine,770,B-Chemical
maleate,770,I-Chemical
and,770,O
placebo,770,O
for,770,O
efficacy,770,O
and,770,O
safety,770,O
in,770,O
the,770,O
treatment,770,O
of,770,O
spring,770,B-Disease
allergic,770,I-Disease
rhinitis,770,I-Disease
in,770,O
a,770,O
multicenter,770,O
",",770,O
double-blind,770,O
",",770,O
multiple-dose,770,O
",",770,O
parallel-groups,770,O
study,770,O
.,770,O
One,771,O
hundred,771,O
fifty-five,771,O
subjects,771,O
participated,771,O
.,771,O
Subjects,772,O
ranged,772,O
in,772,O
age,772,O
from,772,O
18,772,O
to,772,O
60,772,O
years,772,O
of,772,O
age,772,O
and,772,O
had,772,O
at,772,O
least,772,O
a,772,O
2-year,772,O
history,772,O
of,772,O
spring,772,B-Disease
allergic,772,I-Disease
rhinitis,772,I-Disease
",",772,O
confirmed,772,O
by,772,O
positive,772,O
skin,772,O
test,772,O
to,772,O
spring,772,O
aeroallergens,772,O
.,772,O
Medications,773,O
were,773,O
given,773,O
four,773,O
times,773,O
daily,773,O
;,773,O
the,773,O
azelastine,773,B-Chemical
groups,773,O
received,773,O
0.5,773,O
",",773,O
1.0,773,O
",",773,O
or,773,O
2.0,773,O
mg,773,O
in,773,O
the,773,O
morning,773,O
and,773,O
evening,773,O
with,773,O
placebo,773,O
in,773,O
the,773,O
early,773,O
and,773,O
late,773,O
afternoon,773,O
;,773,O
the,773,O
chlorpheniramine,773,B-Chemical
group,773,O
received,773,O
4.0,773,O
mg,773,O
four,773,O
times,773,O
daily,773,O
.,773,O
Daily,774,O
subject,774,O
symptom,774,O
cards,774,O
were,774,O
completed,774,O
during,774,O
a,774,O
screening,774,O
period,774,O
to,774,O
assess,774,O
pretreatment,774,O
symptoms,774,O
and,774,O
during,774,O
a,774,O
4-week,774,O
treatment,774,O
period,774,O
while,774,O
subjects,774,O
received,774,O
study,774,O
medications,774,O
.,774,O
Individual,775,O
symptoms,775,O
",",775,O
total,775,O
symptoms,775,O
",",775,O
and,775,O
major,775,O
symptoms,775,O
were,775,O
compared,775,O
to,775,O
determine,775,O
efficacy,775,O
of,775,O
medication,775,O
.,775,O
Elicited,776,O
",",776,O
volunteered,776,O
",",776,O
and,776,O
observed,776,O
adverse,776,O
experiences,776,O
were,776,O
recorded,776,O
for,776,O
each,776,O
subject,776,O
and,776,O
compared,776,O
among,776,O
groups,776,O
.,776,O
Vital,777,O
signs,777,O
",",777,O
body,777,O
weights,777,O
",",777,O
serum,777,O
chemistry,777,O
values,777,O
",",777,O
complete,777,O
blood,777,O
cell,777,O
counts,777,O
",",777,O
urine,777,O
studies,777,O
",",777,O
and,777,O
electrocardiograms,777,O
were,777,O
obtained,777,O
for,777,O
each,777,O
subject,777,O
and,777,O
compared,777,O
among,777,O
groups,777,O
.,777,O
Symptoms,778,O
relief,778,O
in,778,O
the,778,O
group,778,O
receiving,778,O
the,778,O
highest,778,O
concentration,778,O
of,778,O
azelastine,778,B-Chemical
(,778,O
2.0,778,O
mg,778,O
twice,778,O
daily,778,O
),778,O
was,778,O
statistically,778,O
greater,778,O
than,778,O
in,778,O
the,778,O
placebo,778,O
group,778,O
during,778,O
all,778,O
weeks,778,O
of,778,O
the,778,O
study,778,O
.,778,O
Lower,779,O
doses,779,O
of,779,O
azelastine,779,B-Chemical
were,779,O
statistically,779,O
more,779,O
effective,779,O
than,779,O
placebo,779,O
only,779,O
during,779,O
portions,779,O
of,779,O
the,779,O
first,779,O
3,779,O
weeks,779,O
of,779,O
the,779,O
study,779,O
.,779,O
In,780,O
contrast,780,O
",",780,O
although,780,O
the,780,O
chlorpheniramine,780,B-Chemical
group,780,O
did,780,O
have,780,O
fewer,780,O
symptoms,780,O
than,780,O
the,780,O
placebo,780,O
group,780,O
during,780,O
the,780,O
study,780,O
",",780,O
the,780,O
difference,780,O
never,780,O
reached,780,O
statistical,780,O
significance,780,O
during,780,O
any,780,O
week,780,O
of,780,O
the,780,O
study,780,O
.,780,O
There,781,O
were,781,O
no,781,O
serious,781,O
side,781,O
effects,781,O
in,781,O
any,781,O
of,781,O
the,781,O
treatment,781,O
groups,781,O
.,781,O
Drowsiness,782,B-Disease
and,782,O
altered,782,B-Disease
taste,782,I-Disease
perception,782,I-Disease
were,782,O
increased,782,O
significantly,782,O
over,782,O
placebo,782,O
only,782,O
in,782,O
the,782,O
high-dose,782,O
azelastine,782,B-Chemical
group,782,O
.,782,O
Azelastine,783,B-Chemical
appears,783,O
to,783,O
be,783,O
a,783,O
safe,783,O
",",783,O
efficacious,783,O
medication,783,O
for,783,O
seasonal,783,B-Disease
allergic,783,I-Disease
rhinitis,783,I-Disease
.,783,O
Toxicity,784,B-Disease
due,784,O
to,784,O
remission,784,O
inducing,784,O
drugs,784,O
in,784,O
rheumatoid,784,B-Disease
arthritis,784,I-Disease
.,784,O
Association,785,O
with,785,O
HLA-B35,785,O
and,785,O
Cw4,785,O
antigens,785,O
.,785,O
Twenty-five,786,O
patients,786,O
with,786,O
rheumatoid,786,B-Disease
arthritis,786,I-Disease
(,786,O
RA,786,B-Disease
),786,O
who,786,O
developed,786,O
toxicity,786,B-Disease
while,786,O
taking,786,O
remission,786,O
inducing,786,O
drugs,786,O
and,786,O
30,786,O
without,786,O
toxicity,786,B-Disease
were,786,O
studied,786,O
for,786,O
possible,786,O
associations,786,O
with,786,O
class,786,O
I,786,O
and,786,O
II,786,O
HLA,786,O
antigens,786,O
.,786,O
A,787,O
strong,787,O
association,787,O
has,787,O
been,787,O
found,787,O
between,787,O
nephritis,787,B-Disease
and,787,O
dermatitis,787,B-Disease
due,787,O
to,787,O
Tiopronin,787,B-Chemical
(,787,O
a,787,O
D-Penicillamine,787,B-Chemical
like,787,O
compound,787,O
),787,O
and,787,O
class,787,O
I,787,O
antigens,787,O
B35-Cw4,787,O
",",787,O
and,787,O
between,787,O
dermatitis,787,B-Disease
due,787,O
to,787,O
gold,787,B-Chemical
thiosulphate,787,B-Chemical
and,787,O
B35,787,O
.,787,O
Compared,788,O
to,788,O
healthy,788,O
controls,788,O
a,788,O
lower,788,O
DR5,788,O
frequency,788,O
was,788,O
observed,788,O
in,788,O
patients,788,O
with,788,O
RA,788,B-Disease
except,788,O
for,788,O
the,788,O
Tiopronin,788,B-Chemical
related,788,O
nephritis,788,B-Disease
group,788,O
.,788,O
Transient,789,O
contralateral,789,B-Disease
rotation,789,I-Disease
following,789,O
unilateral,789,O
substantia,789,B-Disease
nigra,789,I-Disease
lesion,789,I-Disease
reflects,789,O
susceptibility,789,O
of,789,O
the,789,O
nigrostriatal,789,O
system,789,O
to,789,O
exhaustion,789,O
by,789,O
amphetamine,789,B-Chemical
.,789,O
Following,790,O
unilateral,790,O
6-OHDA,790,B-Chemical
induced,790,O
SN,790,B-Disease
lesion,790,I-Disease
",",790,O
a,790,O
transient,790,O
period,790,O
of,790,O
contralateral,790,B-Disease
rotation,790,I-Disease
has,790,O
been,790,O
reported,790,O
to,790,O
precede,790,O
the,790,O
predominant,790,O
ipsilateral,790,B-Disease
circling,790,I-Disease
.,790,O
In,791,O
order,791,O
to,791,O
clarify,791,O
the,791,O
nature,791,O
of,791,O
this,791,O
initial,791,O
contralateral,791,B-Disease
rotation,791,I-Disease
we,791,O
examined,791,O
the,791,O
effect,791,O
of,791,O
the,791,O
duration,791,O
of,791,O
recovery,791,O
period,791,O
after,791,O
the,791,O
lesion,791,O
",",791,O
on,791,O
amphetamine-induced,791,B-Chemical
rotational,791,B-Disease
behavior,791,I-Disease
.,791,O
Three,792,O
days,792,O
post,792,O
lesion,792,O
",",792,O
most,792,O
rats,792,O
circled,792,O
predominantly,792,O
contralaterally,792,O
to,792,O
the,792,O
lesion,792,O
.,792,O
Such,793,O
contralateral,793,B-Disease
rotation,793,I-Disease
may,793,O
result,793,O
from,793,O
either,793,O
degeneration-induced,793,O
breakdown,793,O
of,793,O
the,793,O
DA,793,O
pool,793,O
",",793,O
or,793,O
lesion-induced,793,O
increase,793,O
of,793,O
DA,793,O
turnover,793,O
in,793,O
the,793,O
spared,793,O
neurons,793,O
.,793,O
A,794,O
substantial,794,O
degree,794,O
of,794,O
contralateral,794,O
preference,794,O
was,794,O
still,794,O
evident,794,O
when,794,O
amphetamine,794,B-Chemical
was,794,O
administered,794,O
for,794,O
the,794,O
first,794,O
time,794,O
24,794,O
days,794,O
after,794,O
lesioning,794,O
",",794,O
indicating,794,O
involvement,794,O
of,794,O
spared,794,O
cells,794,O
in,794,O
the,794,O
contralateral,794,B-Disease
rotation,794,I-Disease
.,794,O
However,795,O
",",795,O
regardless,795,O
of,795,O
the,795,O
duration,795,O
of,795,O
recovery,795,O
(,795,O
and,795,O
irrespective,795,O
of,795,O
either,795,O
lesion,795,O
volume,795,O
",",795,O
amphetamine,795,B-Chemical
dose,795,O
",",795,O
or,795,O
post-lesion,795,O
motor,795,O
exercise,795,O
),795,O
",",795,O
amphetamine-induced,795,B-Chemical
rotation,795,B-Disease
tended,795,O
to,795,O
become,795,O
gradually,795,O
more,795,O
ipsilateral,795,O
as,795,O
the,795,O
observation,795,O
session,795,O
progressed,795,O
",",795,O
and,795,O
all,795,O
rats,795,O
circled,795,O
ipsilaterally,795,O
to,795,O
the,795,O
lesion,795,O
in,795,O
response,795,O
to,795,O
further,795,O
amphetamine,795,B-Chemical
injections,795,O
.,795,O
These,796,O
findings,796,O
suggest,796,O
that,796,O
amphetamine,796,B-Chemical
has,796,O
an,796,O
irreversible,796,O
effect,796,O
on,796,O
the,796,O
post-lesion,796,O
DA,796,O
pool,796,O
contributing,796,O
to,796,O
contralateral,796,B-Disease
rotation,796,I-Disease
.,796,O
Mitomycin,797,B-Chemical
C,797,I-Chemical
associated,797,O
hemolytic,797,B-Disease
uremic,797,I-Disease
syndrome,797,I-Disease
.,797,O
Mitomycin,798,B-Chemical
C,798,I-Chemical
associated,798,O
Hemolytic,798,B-Disease
Uremic,798,I-Disease
Syndrome,798,I-Disease
(,798,O
HUS,798,B-Disease
),798,O
is,798,O
a,798,O
potentially,798,O
fatal,798,O
but,798,O
uncommon,798,O
condition,798,O
that,798,O
is,798,O
not,798,O
yet,798,O
widely,798,O
recognised,798,O
.,798,O
It,799,O
consists,799,O
of,799,O
microangiopathic,799,O
hemolytic,799,B-Disease
anemia,799,I-Disease
",",799,O
thrombocytopenia,799,B-Disease
and,799,O
progressive,799,O
renal,799,B-Disease
failure,799,I-Disease
associated,799,O
with,799,O
mitomycin,799,B-Chemical
C,799,I-Chemical
treatment,799,O
and,799,O
affects,799,O
about,799,O
10,799,O
%,799,O
of,799,O
patients,799,O
treated,799,O
with,799,O
this,799,O
agent,799,O
.,799,O
The,800,O
renal,800,B-Disease
failure,800,I-Disease
usually,800,O
develops,800,O
about,800,O
8-10,800,O
mth,800,O
after,800,O
start,800,O
of,800,O
mitomycin,800,B-Chemical
C,800,I-Chemical
treatment,800,O
and,800,O
the,800,O
mortality,800,O
is,800,O
approximately,800,O
60,800,O
%,800,O
from,800,O
renal,800,B-Disease
failure,800,I-Disease
or,800,O
pulmonary,800,B-Disease
edema,800,I-Disease
.,800,O
Renal,801,B-Disease
lesions,801,I-Disease
are,801,O
similar,801,O
to,801,O
those,801,O
seen,801,O
in,801,O
idiopathic,801,O
HUS,801,B-Disease
and,801,O
include,801,O
arteriolar,801,O
fibrin,801,O
thrombi,801,B-Disease
",",801,O
expanded,801,O
subendothelial,801,O
zones,801,O
in,801,O
glomerular,801,O
capillary,801,O
walls,801,O
",",801,O
ischemic,801,B-Disease
wrinkling,801,O
of,801,O
glomerular,801,O
basement,801,O
membranes,801,O
and,801,O
mesangiolysis,801,O
.,801,O
The,802,O
mechanism,802,O
of,802,O
action,802,O
is,802,O
postulated,802,O
as,802,O
mitomycin,802,B-Chemical
C-induced,802,O
endothelial,802,O
cell,802,O
damage,802,O
.,802,O
We,803,O
describe,803,O
the,803,O
clinical,803,O
course,803,O
and,803,O
pathological,803,O
findings,803,O
in,803,O
a,803,O
65,803,O
yr-old,803,O
man,803,O
with,803,O
gastric,803,B-Disease
adenocarcinoma,803,I-Disease
who,803,O
developed,803,O
renal,803,B-Disease
failure,803,I-Disease
and,803,O
thrombocytopenia,803,B-Disease
while,803,O
on,803,O
treatment,803,O
with,803,O
mitomycin,803,B-Chemical
C,803,I-Chemical
and,803,O
died,803,O
in,803,O
pulmonary,803,B-Disease
edema,803,I-Disease
.,803,O
Ketanserin,804,B-Chemical
pretreatment,804,O
reverses,804,O
alfentanil-induced,804,B-Chemical
muscle,804,B-Disease
rigidity,804,I-Disease
.,804,O
Systemic,805,O
pretreatment,805,O
with,805,O
ketanserin,805,B-Chemical
",",805,O
a,805,O
relatively,805,O
specific,805,O
type-2,805,O
serotonin,805,B-Chemical
receptor,805,O
antagonist,805,O
",",805,O
significantly,805,O
attenuated,805,O
the,805,O
muscle,805,B-Disease
rigidity,805,I-Disease
produced,805,O
in,805,O
rats,805,O
by,805,O
the,805,O
potent,805,O
short-acting,805,O
opiate,805,O
agonist,805,O
alfentanil,805,B-Chemical
.,805,O
Following,806,O
placement,806,O
of,806,O
subcutaneous,806,O
electrodes,806,O
in,806,O
each,806,O
animal,806,O
's,806,O
left,806,O
gastrocnemius,806,O
muscle,806,O
",",806,O
rigidity,806,B-Disease
was,806,O
assessed,806,O
by,806,O
analyzing,806,O
root-mean-square,806,O
electromyographic,806,O
activity,806,O
.,806,O
Intraperitoneal,807,O
ketanserin,807,B-Chemical
administration,807,O
at,807,O
doses,807,O
of,807,O
0.63,807,O
and,807,O
2.5,807,O
mg/kg,807,O
prevented,807,O
the,807,O
alfentanil-induced,807,B-Chemical
increase,807,O
in,807,O
electromyographic,807,O
activity,807,O
compared,807,O
with,807,O
animals,807,O
pretreated,807,O
with,807,O
saline,807,O
.,807,O
Chlordiazepoxide,808,B-Chemical
at,808,O
doses,808,O
up,808,O
to,808,O
10,808,O
mg/kg,808,O
failed,808,O
to,808,O
significantly,808,O
influence,808,O
the,808,O
rigidity,808,B-Disease
produced,808,O
by,808,O
alfentanil,808,B-Chemical
.,808,O
Despite,809,O
the,809,O
absence,809,O
of,809,O
rigidity,809,B-Disease
",",809,O
animals,809,O
that,809,O
received,809,O
ketanserin,809,B-Chemical
(,809,O
greater,809,O
than,809,O
0.31,809,O
mg/kg,809,O
i.p,809,O
.,809,O
),809,O
followed,810,O
by,810,O
alfentanil,810,B-Chemical
were,810,O
motionless,810,O
",",810,O
flaccid,810,O
",",810,O
and,810,O
less,810,O
responsive,810,O
to,810,O
external,810,O
stimuli,810,O
than,810,O
were,810,O
animals,810,O
receiving,810,O
alfentanil,810,B-Chemical
alone,810,O
.,810,O
Rats,811,O
that,811,O
received,811,O
ketanserin,811,B-Chemical
and,811,O
alfentanil,811,B-Chemical
exhibited,811,O
less,811,O
rearing,811,O
and,811,O
exploratory,811,O
behavior,811,O
at,811,O
the,811,O
end,811,O
of,811,O
the,811,O
60-min,811,O
recording,811,O
period,811,O
than,811,O
did,811,O
animals,811,O
that,811,O
received,811,O
ketanserin,811,B-Chemical
alone,811,O
.,811,O
These,812,O
results,812,O
",",812,O
in,812,O
combination,812,O
with,812,O
previous,812,O
work,812,O
",",812,O
suggest,812,O
that,812,O
muscle,812,B-Disease
rigidity,812,I-Disease
",",812,O
a,812,O
clinically,812,O
relevant,812,O
side-effect,812,O
of,812,O
parenteral,812,O
narcotic,812,O
administration,812,O
",",812,O
may,812,O
be,812,O
partly,812,O
mediated,812,O
via,812,O
serotonergic,812,O
pathways,812,O
.,812,O
Pretreatment,813,O
with,813,O
type-2,813,O
serotonin,813,B-Chemical
antagonists,813,O
may,813,O
be,813,O
clinically,813,O
useful,813,O
in,813,O
attenuating,813,O
opiate-induced,813,O
rigidity,813,B-Disease
",",813,O
although,813,O
further,813,O
studies,813,O
will,813,O
be,813,O
necessary,813,O
to,813,O
assess,813,O
the,813,O
interaction,813,O
of,813,O
possibly,813,O
enhanced,813,O
CNS,813,O
",",813,O
cardiovascular,813,O
",",813,O
and,813,O
respiratory,813,O
depression,813,O
.,813,O
Antagonism,814,O
of,814,O
diazepam-induced,814,B-Chemical
sedative,814,O
effects,814,O
by,814,O
Ro15-1788,814,B-Chemical
in,814,O
patients,814,O
after,814,O
surgery,814,O
under,814,O
lumbar,814,O
epidural,814,O
block,814,O
.,814,O
A,815,O
double-blind,815,O
placebo-controlled,815,O
investigation,815,O
of,815,O
efficacy,815,O
and,815,O
safety,815,O
.,815,O
The,816,O
aim,816,O
of,816,O
this,816,O
study,816,O
was,816,O
to,816,O
assess,816,O
the,816,O
efficacy,816,O
of,816,O
Ro15-1788,816,B-Chemical
and,816,O
a,816,O
placebo,816,O
in,816,O
reversing,816,O
diazepam-induced,816,B-Chemical
effects,816,O
after,816,O
surgery,816,O
under,816,O
epidural,816,O
block,816,O
",",816,O
and,816,O
to,816,O
evaluate,816,O
the,816,O
local,816,O
tolerance,816,O
and,816,O
general,816,O
safety,816,O
of,816,O
Ro15-1788,816,B-Chemical
.,816,O
Fifty-seven,817,O
patients,817,O
were,817,O
sedated,817,O
with,817,O
diazepam,817,B-Chemical
for,817,O
surgery,817,O
under,817,O
epidural,817,O
anaesthesia,817,O
.,817,O
Antagonism,818,O
of,818,O
diazepam-induced,818,B-Chemical
effects,818,O
by,818,O
Ro15-1788,818,B-Chemical
was,818,O
investigated,818,O
postoperatively,818,O
in,818,O
a,818,O
double-blind,818,O
placebo-controlled,818,O
trial,818,O
.,818,O
The,819,O
patient,819,O
's,819,O
subjective,819,O
assessment,819,O
of,819,O
mood,819,O
rating,819,O
",",819,O
an,819,O
objective,819,O
test,819,O
of,819,O
performance,819,O
",",819,O
a,819,O
test,819,O
for,819,O
amnesia,819,B-Disease
",",819,O
and,819,O
vital,819,O
signs,819,O
were,819,O
recorded,819,O
for,819,O
up,819,O
to,819,O
300,819,O
min,819,O
after,819,O
administration,819,O
of,819,O
the,819,O
trial,819,O
drug,819,O
.,819,O
No,820,O
significant,820,O
differences,820,O
between,820,O
the,820,O
two,820,O
groups,820,O
were,820,O
observed,820,O
for,820,O
mood,820,O
rating,820,O
",",820,O
amnesia,820,B-Disease
",",820,O
or,820,O
vital,820,O
signs,820,O
.,820,O
The,821,O
Ro15-1788,821,B-Chemical
group,821,O
showed,821,O
a,821,O
significant,821,O
improvement,821,O
in,821,O
the,821,O
performance,821,O
test,821,O
up,821,O
to,821,O
120,821,O
min,821,O
after,821,O
administration,821,O
of,821,O
the,821,O
drug,821,O
.,821,O
There,822,O
was,822,O
no,822,O
evidence,822,O
of,822,O
reaction,822,O
at,822,O
the,822,O
injection,822,O
site,822,O
.,822,O
Chorea,823,B-Disease
associated,823,O
with,823,O
oral,823,B-Chemical
contraception,823,I-Chemical
.,823,O
Three,824,O
patients,824,O
developed,824,O
chorea,824,B-Disease
while,824,O
receiving,824,O
oral,824,B-Chemical
contraceptives,824,I-Chemical
.,824,O
Two,825,O
were,825,O
young,825,O
patients,825,O
whose,825,O
chorea,825,B-Disease
developed,825,O
long,825,O
after,825,O
treatment,825,O
had,825,O
been,825,O
started,825,O
and,825,O
disappeared,825,O
soon,825,O
after,825,O
it,825,O
had,825,O
been,825,O
discontinued,825,O
.,825,O
The,826,O
third,826,O
patient,826,O
had,826,O
acute,826,O
amphetamine-induced,826,B-Chemical
chorea,826,B-Disease
after,826,O
prolonged,826,O
oral,826,B-Chemical
contraception,826,I-Chemical
.,826,O
Prolonged,827,O
administration,827,O
of,827,O
female,827,O
sex,827,O
hormones,827,O
is,827,O
a,827,O
possible,827,O
cause,827,O
of,827,O
chorea,827,B-Disease
in,827,O
women,827,O
who,827,O
have,827,O
not,827,O
previously,827,O
had,827,O
chorea,827,B-Disease
or,827,O
rheumatic,827,B-Disease
fever,827,I-Disease
.,827,O
Co-carcinogenic,828,O
effect,828,O
of,828,O
retinyl,828,B-Chemical
acetate,828,I-Chemical
on,828,O
forestomach,828,B-Disease
carcinogenesis,828,I-Disease
of,828,O
male,828,O
F344,828,O
rats,828,O
induced,828,O
with,828,O
butylated,828,B-Chemical
hydroxyanisole,828,I-Chemical
.,828,O
The,829,O
potential,829,O
modifying,829,O
effect,829,O
of,829,O
retinyl,829,B-Chemical
acetate,829,I-Chemical
(,829,O
RA,829,B-Chemical
),829,O
on,829,O
butylated,829,B-Chemical
hydroxyanisole,829,I-Chemical
(,829,O
BHA,829,B-Chemical
),829,O
-induced,829,O
rat,829,O
forestomach,829,B-Disease
tumorigenesis,829,I-Disease
was,829,O
examined,829,O
.,829,O
Male,830,O
F344,830,O
rats,830,O
",",830,O
5,830,O
weeks,830,O
of,830,O
age,830,O
",",830,O
were,830,O
maintained,830,O
on,830,O
diet,830,O
containing,830,O
1,830,O
%,830,O
or,830,O
2,830,O
%,830,O
BHA,830,B-Chemical
by,830,O
weight,830,O
and,830,O
simultaneously,830,O
on,830,O
drinking,830,O
water,830,O
supplemented,830,O
with,830,O
RA,830,B-Chemical
at,830,O
various,830,O
concentrations,830,O
(,830,O
w/v,830,O
),830,O
for,830,O
52,830,O
weeks,830,O
.,830,O
In,831,O
groups,831,O
given,831,O
2,831,O
%,831,O
BHA,831,B-Chemical
",",831,O
although,831,O
marked,831,O
hyperplastic,831,O
changes,831,O
of,831,O
the,831,O
forestomach,831,O
epithelium,831,O
were,831,O
observed,831,O
in,831,O
all,831,O
animals,831,O
",",831,O
co-administration,831,O
of,831,O
0.25,831,O
%,831,O
RA,831,B-Chemical
significantly,831,O
(,831,O
P,831,O
less,831,O
than,831,O
0.05,831,O
),831,O
increased,831,O
the,831,O
incidence,831,O
of,831,O
forestomach,831,B-Disease
tumors,831,I-Disease
(,831,O
squamous,831,B-Disease
cell,831,I-Disease
papilloma,831,I-Disease
and,831,O
carcinoma,831,B-Disease
),831,O
to,831,O
60,831,O
%,831,O
(,831,O
9/15,831,O
",",831,O
2,831,O
rats,831,O
with,831,O
carcinoma,831,B-Disease
),831,O
from,831,O
15,831,O
%,831,O
(,831,O
3/20,831,O
",",831,O
one,831,O
rat,831,O
with,831,O
carcinoma,831,B-Disease
),831,O
in,831,O
the,831,O
group,831,O
given,831,O
RA-free,831,B-Chemical
water,831,O
.,831,O
In,832,O
rats,832,O
given,832,O
1,832,O
%,832,O
BHA,832,B-Chemical
",",832,O
RA,832,B-Chemical
co-administered,832,O
at,832,O
a,832,O
dose,832,O
of,832,O
0.05,832,O
",",832,O
0.1,832,O
",",832,O
0.2,832,O
or,832,O
0.25,832,O
%,832,O
showed,832,O
a,832,O
dose-dependent,832,O
enhancing,832,O
effect,832,O
on,832,O
the,832,O
development,832,O
of,832,O
the,832,O
BHA-induced,832,B-Chemical
epithelial,832,B-Disease
hyperplasia,832,I-Disease
.,832,O
Tumors,833,B-Disease
",",833,O
all,833,O
papillomas,833,B-Disease
",",833,O
were,833,O
induced,833,O
in,833,O
3,833,O
rats,833,O
(,833,O
17,833,O
%,833,O
),833,O
with,833,O
0.25,833,O
%,833,O
RA,833,B-Chemical
and,833,O
in,833,O
one,833,O
rat,833,O
(,833,O
10,833,O
%,833,O
),833,O
with,833,O
0.05,833,O
%,833,O
RA,833,B-Chemical
co-administration,833,O
.,833,O
RA,834,B-Chemical
alone,834,O
did,834,O
not,834,O
induce,834,O
hyperplastic,834,O
changes,834,O
in,834,O
the,834,O
forestomach,834,O
.,834,O
These,835,O
findings,835,O
indicate,835,O
that,835,O
RA,835,B-Chemical
acted,835,O
as,835,O
a,835,O
co-carcinogen,835,O
in,835,O
the,835,O
BHA,835,B-Chemical
forestomach,835,B-Disease
carcinogenesis,835,I-Disease
of,835,O
the,835,O
rat,835,O
.,835,O
A,836,O
prospective,836,O
study,836,O
on,836,O
the,836,O
dose,836,O
dependency,836,O
of,836,O
cardiotoxicity,836,B-Disease
induced,836,O
by,836,O
mitomycin,836,B-Chemical
C.,836,O
Since,836,O
1975,836,O
mitomycin,836,B-Chemical
C,836,I-Chemical
(,836,O
MMC,836,B-Chemical
),836,O
has,836,O
been,836,O
suggested,836,O
to,836,O
be,836,O
cardiotoxic,836,B-Disease
",",836,O
especially,836,O
when,836,O
combined,836,O
with,836,O
or,836,O
given,836,O
following,836,O
doxorubicin,836,B-Chemical
.,836,O
Data,837,O
on,837,O
dose,837,O
dependency,837,O
or,837,O
incidence,837,O
concerning,837,O
this,837,O
side,837,O
effect,837,O
were,837,O
not,837,O
known,837,O
.,837,O
We,838,O
have,838,O
initiated,838,O
a,838,O
prospective,838,O
study,838,O
to,838,O
obtain,838,O
some,838,O
more,838,O
data,838,O
on,838,O
these,838,O
subjects,838,O
.,838,O
Forty-four,839,O
MMC-treated,839,B-Chemical
patients,839,O
were,839,O
studied,839,O
",",839,O
37,839,O
of,839,O
them,839,O
could,839,O
be,839,O
evaluated,839,O
.,839,O
All,840,O
patients,840,O
were,840,O
studied,840,O
by,840,O
repeated,840,O
physical,840,O
examinations,840,O
",",840,O
chest,840,O
X-rays,840,O
",",840,O
electro-,840,O
and,840,O
echocardiography,840,O
and,840,O
radionuclide,840,O
left,840,O
ventricular,840,O
ejection,840,O
fraction,840,O
(,840,O
EF,840,O
),840,O
determinations,840,O
.,840,O
The,841,O
results,841,O
were,841,O
evaluated,841,O
per,841,O
cumulative,841,O
dose,841,O
level,841,O
.,841,O
One,842,O
of,842,O
the,842,O
patients,842,O
developed,842,O
cardiac,842,B-Disease
failure,842,I-Disease
after,842,O
30,842,O
mg,842,O
m-2,842,O
MMC,842,B-Chemical
and,842,O
only,842,O
150,842,O
mg,842,O
m-2,842,O
doxorubicin,842,B-Chemical
.,842,O
The,843,O
cardiac,843,B-Disease
failure,843,I-Disease
was,843,O
predicted,843,O
by,843,O
a,843,O
drop,843,O
in,843,O
EF,843,O
determined,843,O
during,843,O
a,843,O
cold,843,O
pressor,843,O
test,843,O
.,843,O
None,844,O
of,844,O
the,844,O
other,844,O
patients,844,O
developed,844,O
clinical,844,O
cardiotoxicity,844,B-Disease
",",844,O
nor,844,O
did,844,O
the,844,O
studied,844,O
parameters,844,O
change,844,O
.,844,O
The,845,O
literature,845,O
on,845,O
this,845,O
subject,845,O
was,845,O
also,845,O
reviewed,845,O
.,845,O
Based,846,O
on,846,O
the,846,O
combined,846,O
data,846,O
from,846,O
the,846,O
present,846,O
study,846,O
and,846,O
the,846,O
literature,846,O
",",846,O
we,846,O
suggest,846,O
that,846,O
MMC-related,846,B-Chemical
cardiotoxicity,846,B-Disease
is,846,O
dose,846,O
dependent,846,O
",",846,O
occurring,846,O
at,846,O
cumulative,846,O
dose,846,O
levels,846,O
of,846,O
30,846,O
mg,846,O
m-2,846,O
or,846,O
more,846,O
",",846,O
mainly,846,O
in,846,O
patients,846,O
also,846,O
(,846,O
previously,846,O
or,846,O
simultaneously,846,O
),846,O
treated,846,O
with,846,O
doxorubicin,846,B-Chemical
.,846,O
The,847,O
incidence,847,O
is,847,O
likely,847,O
to,847,O
be,847,O
less,847,O
than,847,O
10,847,O
%,847,O
even,847,O
for,847,O
this,847,O
risk,847,O
group,847,O
.,847,O
Reversible,848,O
cerebral,848,B-Disease
lesions,848,I-Disease
associated,848,O
with,848,O
tiazofurin,848,B-Chemical
usage,848,O
:,848,O
MR,848,O
demonstration,848,O
.,848,O
Tiazofurin,849,B-Chemical
is,849,O
an,849,O
experimental,849,O
chemotherapeutic,849,O
agent,849,O
currently,849,O
undergoing,849,O
clinical,849,O
evaluation,849,O
.,849,O
We,850,O
report,850,O
our,850,O
results,850,O
with,850,O
magnetic,850,O
resonance,850,O
(,850,O
MR,850,O
),850,O
in,850,O
demonstrating,850,O
reversible,850,O
cerebral,850,B-Disease
abnormalities,850,I-Disease
concurrent,850,O
with,850,O
the,850,O
use,850,O
of,850,O
this,850,O
drug,850,O
.,850,O
The,851,O
abnormalities,851,O
on,851,O
MR,851,O
were,851,O
correlated,851,O
with,851,O
findings,851,O
on,851,O
CT,851,O
as,851,O
well,851,O
as,851,O
with,851,O
cerebral,851,O
angiography,851,O
.,851,O
The,852,O
utility,852,O
of,852,O
MR,852,O
in,852,O
the,852,O
evaluation,852,O
of,852,O
patients,852,O
receiving,852,O
this,852,O
new,852,O
agent,852,O
is,852,O
illustrated,852,O
.,852,O
Receptor,853,O
mechanisms,853,O
of,853,O
nicotine-induced,853,B-Chemical
locomotor,853,B-Disease
hyperactivity,853,I-Disease
in,853,O
chronic,853,O
nicotine-treated,853,B-Chemical
rats,853,O
.,853,O
Rats,854,O
were,854,O
pretreated,854,O
with,854,O
saline,854,O
or,854,O
nicotine,854,B-Chemical
(,854,O
1.5,854,O
mg/kg,854,O
per,854,O
day,854,O
),854,O
by,854,O
subcutaneously,854,O
implanting,854,O
each,854,O
animal,854,O
with,854,O
an,854,O
Alzet,854,O
osmotic,854,O
mini-pump,854,O
which,854,O
continuously,854,O
released,854,O
saline,854,O
or,854,O
nicotine,854,B-Chemical
for,854,O
1,854,O
",",854,O
5,854,O
and,854,O
14,854,O
days,854,O
.,854,O
At,855,O
the,855,O
end,855,O
of,855,O
each,855,O
pretreatment,855,O
period,855,O
",",855,O
animals,855,O
were,855,O
used,855,O
for,855,O
(,855,O
i,855,O
),855,O
determining,855,O
their,855,O
locomotor,855,O
response,855,O
to,855,O
acutely,855,O
injected,855,O
nicotine,855,B-Chemical
(,855,O
0.2,855,O
mg/kg,855,O
",",855,O
s.c.,855,O
),855,O
and,855,O
(,855,O
ii,855,O
),855,O
measuring,855,O
the,855,O
density,855,O
of,855,O
L-,855,O
[,855,O
3H,855,O
],855,O
nicotine,855,B-Chemical
and,855,O
[,855,O
3H,855,O
],855,O
spiperone,855,B-Chemical
binding,855,O
sites,855,O
in,855,O
the,855,O
striatum,855,O
.,855,O
We,856,O
observed,856,O
no,856,O
changes,856,O
in,856,O
nicotine-induced,856,B-Chemical
locomotor,856,O
response,856,O
",",856,O
striatal,856,O
L-,856,O
[,856,O
3H,856,O
],856,O
nicotine,856,B-Chemical
and,856,O
[,856,O
3H,856,O
],856,O
spiperone,856,B-Chemical
binding,856,O
in,856,O
the,856,O
animals,856,O
pretreated,856,O
with,856,O
nicotine,856,B-Chemical
for,856,O
1,856,O
day,856,O
.,856,O
In,857,O
rats,857,O
which,857,O
were,857,O
pretreated,857,O
with,857,O
nicotine,857,B-Chemical
for,857,O
5,857,O
days,857,O
",",857,O
there,857,O
was,857,O
a,857,O
significant,857,O
increase,857,O
in,857,O
the,857,O
nicotine-stimulated,857,B-Chemical
locomotor,857,O
response,857,O
which,857,O
was,857,O
associated,857,O
with,857,O
an,857,O
increase,857,O
in,857,O
the,857,O
number,857,O
of,857,O
L-,857,O
[,857,O
3H,857,O
],857,O
nicotine,857,B-Chemical
binding,857,O
sites,857,O
and,857,O
also,857,O
with,857,O
an,857,O
elevated,857,O
dopamine,857,B-Chemical
(,857,O
DA,857,B-Chemical
),857,O
level,857,O
in,857,O
the,857,O
striatum,857,O
.,857,O
The,858,O
number,858,O
of,858,O
striatal,858,O
[,858,O
3H,858,O
],858,O
spiperone,858,B-Chemical
binding,858,O
sites,858,O
was,858,O
not,858,O
affected,858,O
.,858,O
In,859,O
animals,859,O
pretreated,859,O
with,859,O
nicotine,859,B-Chemical
for,859,O
14,859,O
days,859,O
",",859,O
the,859,O
nicotine-induced,859,B-Chemical
locomotor,859,O
response,859,O
remained,859,O
to,859,O
be,859,O
potentiated,859,O
.,859,O
However,860,O
",",860,O
this,860,O
response,860,O
was,860,O
correlated,860,O
with,860,O
an,860,O
elevated,860,O
number,860,O
of,860,O
striatal,860,O
[,860,O
3H,860,O
],860,O
spiperone,860,B-Chemical
binding,860,O
sites,860,O
",",860,O
whereas,860,O
the,860,O
number,860,O
of,860,O
striatal,860,O
L-,860,O
[,860,O
3H,860,O
],860,O
nicotine,860,B-Chemical
binding,860,O
sites,860,O
and,860,O
the,860,O
striatal,860,O
DA,860,B-Chemical
level,860,O
were,860,O
normal,860,O
.,860,O
These,861,O
results,861,O
suggest,861,O
that,861,O
chronic,861,O
nicotine-treated,861,B-Chemical
rats,861,O
develop,861,O
locomotor,861,B-Disease
hyperactivity,861,I-Disease
in,861,O
response,861,O
to,861,O
nicotine,861,B-Chemical
initially,861,O
due,861,O
to,861,O
increases,861,O
of,861,O
both,861,O
the,861,O
density,861,O
of,861,O
nicotinic,861,O
receptors,861,O
and,861,O
DA,861,B-Chemical
concentration,861,O
",",861,O
followed,861,O
by,861,O
inducing,861,O
DA,861,B-Chemical
receptor,861,O
supersensitivity,861,O
in,861,O
the,861,O
striatum,861,O
.,861,O
St.,862,B-Disease
Anthony,862,I-Disease
's,862,I-Disease
fire,862,I-Disease
",",862,O
then,862,O
and,862,O
now,862,O
:,862,O
a,862,O
case,862,O
report,862,O
and,862,O
historical,862,O
review,862,O
.,862,O
A,863,O
rare,863,O
case,863,O
of,863,O
morbid,863,O
vasospasm,863,B-Disease
",",863,O
together,863,O
with,863,O
striking,863,O
angiographic,863,O
findings,863,O
",",863,O
is,863,O
described,863,O
secondary,863,O
to,863,O
the,863,O
ingestion,863,O
of,863,O
methysergide,863,B-Chemical
by,863,O
a,863,O
48-year-old,863,O
woman,863,O
.,863,O
A,864,O
brief,864,O
review,864,O
of,864,O
the,864,O
literature,864,O
on,864,O
similar,864,O
cases,864,O
is,864,O
presented,864,O
.,864,O
A,865,O
discussion,865,O
of,865,O
the,865,O
history,865,O
of,865,O
ergot,865,B-Chemical
includes,865,O
its,865,O
original,865,O
discovery,865,O
",",865,O
the,865,O
epidemics,865,O
of,865,O
gangrene,865,B-Disease
that,865,O
it,865,O
has,865,O
caused,865,O
through,865,O
the,865,O
ages,865,O
and,865,O
its,865,O
past,865,O
and,865,O
present,865,O
role,865,O
in,865,O
the,865,O
management,865,O
of,865,O
migraine,865,B-Disease
headache,865,I-Disease
.,865,O
Despite,866,O
the,866,O
advent,866,O
of,866,O
calcium,866,B-Chemical
channel,866,O
blockers,866,O
and,866,O
beta-adrenergic,866,O
antagonists,866,O
",",866,O
ergot,866,B-Chemical
preparations,866,O
continue,866,O
to,866,O
play,866,O
a,866,O
major,866,O
role,866,O
in,866,O
migraine,866,B-Disease
therapy,866,O
",",866,O
so,866,O
that,866,O
the,866,O
danger,866,O
of,866,O
St.,866,B-Disease
Anthony,866,I-Disease
's,866,I-Disease
fire,866,I-Disease
persists,866,O
.,866,O
Cardiac,867,O
transplantation,867,O
:,867,O
improved,867,O
quality,867,O
of,867,O
survival,867,O
with,867,O
a,867,O
modified,867,O
immunosuppressive,867,O
protocol,867,O
.,867,O
The,868,O
effects,868,O
on,868,O
renal,868,O
function,868,O
on,868,O
two,868,O
different,868,O
immunosuppressive,868,O
protocols,868,O
were,868,O
evaluated,868,O
retrospectively,868,O
in,868,O
two,868,O
subsequent,868,O
groups,868,O
of,868,O
heart,868,O
transplant,868,O
recipients,868,O
.,868,O
In,869,O
group,869,O
I,869,O
",",869,O
cyclosporine,869,B-Chemical
was,869,O
given,869,O
before,869,O
the,869,O
procedure,869,O
at,869,O
a,869,O
loading,869,O
dose,869,O
of,869,O
17.5,869,O
mg/kg,869,O
and,869,O
then,869,O
continued,869,O
after,869,O
the,869,O
procedure,869,O
to,869,O
keep,869,O
a,869,O
whole,869,O
blood,869,O
level,869,O
about,869,O
1000,869,O
ng/ml,869,O
.,869,O
In,870,O
group,870,O
II,870,O
",",870,O
cyclosporine,870,B-Chemical
was,870,O
started,870,O
only,870,O
after,870,O
the,870,O
procedure,870,O
at,870,O
a,870,O
lower,870,O
dosage,870,O
and,870,O
was,870,O
complemented,870,O
by,870,O
azathioprine,870,B-Chemical
",",870,O
which,870,O
was,870,O
used,870,O
for,870,O
the,870,O
first,870,O
postoperative,870,O
week,870,O
.,870,O
Group,871,O
II,871,O
showed,871,O
a,871,O
better,871,O
perioperative,871,O
renal,871,O
function,871,O
as,871,O
determined,871,O
by,871,O
serum,871,O
blood,871,O
urea,871,B-Chemical
nitrogen,871,I-Chemical
and,871,O
serum,871,O
creatinine,871,B-Chemical
levels,871,O
.,871,O
Group,872,O
II,872,O
also,872,O
showed,872,O
a,872,O
significant,872,O
decrease,872,O
of,872,O
chronic,872,O
nephrotoxicity,872,B-Disease
secondary,872,O
to,872,O
long-term,872,O
therapy,872,O
with,872,O
cyclosporine,872,B-Chemical
.,872,O
Despite,873,O
this,873,O
improvement,873,O
in,873,O
late,873,O
renal,873,O
function,873,O
",",873,O
group,873,O
II,873,O
still,873,O
shows,873,O
a,873,O
slow,873,O
rise,873,O
in,873,O
serum,873,O
creatinine,873,B-Chemical
.,873,O
We,874,O
think,874,O
that,874,O
even,874,O
these,874,O
lower,874,O
dosages,874,O
of,874,O
cyclosporine,874,B-Chemical
can,874,O
cause,874,O
chronic,874,O
nephrotoxicity,874,B-Disease
and,874,O
that,874,O
further,874,O
modification,874,O
of,874,O
the,874,O
immunosuppressive,874,O
regimen,874,O
is,874,O
required,874,O
to,874,O
completely,874,O
abolish,874,O
this,874,O
toxic,874,O
side,874,O
effect,874,O
.,874,O
Quinidine,875,B-Chemical
phenylethylbarbiturate-induced,875,O
fulminant,875,O
hepatitis,875,B-Disease
in,875,O
a,875,O
pregnant,875,O
woman,875,O
.,875,O
A,876,O
case,876,O
report,876,O
.,876,O
We,877,O
report,877,O
the,877,O
case,877,O
of,877,O
a,877,O
19-year-old,877,O
Laotian,877,O
patient,877,O
affected,877,O
by,877,O
fulminant,877,O
hepatitis,877,B-Disease
during,877,O
the,877,O
third,877,O
trimester,877,O
of,877,O
her,877,O
pregnancy,877,O
after,877,O
a,877,O
1-month,877,O
administration,877,O
of,877,O
quinidine,877,B-Chemical
phenylethylbarbiturate,877,I-Chemical
.,877,O
After,878,O
delivery,878,O
",",878,O
the,878,O
patient,878,O
underwent,878,O
orthotopic,878,O
liver,878,O
transplantation,878,O
.,878,O
The,879,O
patient,879,O
was,879,O
in,879,O
good,879,O
condition,879,O
16,879,O
months,879,O
after,879,O
liver,879,O
transplantation,879,O
.,879,O
Quinidine,880,B-Chemical
itself,880,O
or,880,O
phenylethylbarbiturate,880,B-Chemical
may,880,O
be,880,O
responsible,880,O
for,880,O
fulminant,880,O
hepatitis,880,B-Disease
in,880,O
this,880,O
patient,880,O
.,880,O
Mechanisms,881,O
of,881,O
myocardial,881,B-Disease
ischemia,881,I-Disease
induced,881,O
by,881,O
epinephrine,881,B-Chemical
:,881,O
comparison,881,O
with,881,O
exercise-induced,881,O
ischemia,881,B-Disease
.,881,O
The,882,O
role,882,O
of,882,O
epinephrine,882,B-Chemical
in,882,O
eliciting,882,O
myocardial,882,B-Disease
ischemia,882,I-Disease
was,882,O
examined,882,O
in,882,O
patients,882,O
with,882,O
coronary,882,B-Disease
artery,882,I-Disease
disease,882,I-Disease
.,882,O
Objective,883,O
signs,883,O
of,883,O
ischemia,883,B-Disease
and,883,O
factors,883,O
increasing,883,O
myocardial,883,O
oxygen,883,B-Chemical
consumption,883,O
were,883,O
compared,883,O
during,883,O
epinephrine,883,B-Chemical
infusion,883,O
and,883,O
supine,883,O
bicycle,883,O
exercise,883,O
.,883,O
Both,884,O
epinephrine,884,B-Chemical
and,884,O
exercise,884,O
produced,884,O
myocardial,884,B-Disease
ischemia,884,I-Disease
as,884,O
evidenced,884,O
by,884,O
ST,884,O
segment,884,O
depression,884,B-Disease
and,884,O
angina,884,B-Disease
.,884,O
However,885,O
",",885,O
the,885,O
mechanisms,885,O
of,885,O
myocardial,885,B-Disease
ischemia,885,I-Disease
induced,885,O
by,885,O
epinephrine,885,B-Chemical
were,885,O
significantly,885,O
different,885,O
from,885,O
those,885,O
of,885,O
exercise,885,O
.,885,O
Exercise-induced,886,O
myocardial,886,B-Disease
ischemia,886,I-Disease
was,886,O
marked,886,O
predominantly,886,O
by,886,O
increased,886,O
heart,886,O
rate,886,O
and,886,O
rate-pressure,886,O
product,886,O
with,886,O
a,886,O
minor,886,O
contribution,886,O
of,886,O
end-diastolic,886,O
volume,886,O
",",886,O
while,886,O
epinephrine-induced,886,B-Chemical
ischemia,886,B-Disease
was,886,O
characterized,886,O
by,886,O
a,886,O
marked,886,O
increase,886,O
in,886,O
contractility,886,O
and,886,O
a,886,O
less,886,O
pronounced,886,O
increase,886,O
in,886,O
heart,886,O
rate,886,O
and,886,O
rate-pressure,886,O
product,886,O
.,886,O
These,887,O
findings,887,O
indicate,887,O
that,887,O
ischemia,887,B-Disease
produced,887,O
by,887,O
epinephrine,887,B-Chemical
",",887,O
as,887,O
may,887,O
occur,887,O
during,887,O
states,887,O
of,887,O
emotional,887,O
distress,887,O
",",887,O
has,887,O
a,887,O
mechanism,887,O
distinct,887,O
from,887,O
that,887,O
due,887,O
to,887,O
physical,887,O
exertion,887,O
.,887,O
Recent,888,O
preclinical,888,O
and,888,O
clinical,888,O
studies,888,O
with,888,O
the,888,O
thymidylate,888,O
synthase,888,O
inhibitor,888,O
"N10-propargyl-5,8-dideazafolic",888,B-Chemical
acid,888,I-Chemical
(,888,O
CB,888,B-Chemical
3717,888,I-Chemical
),888,O
.,888,O
CB,889,B-Chemical
3717,889,I-Chemical
",",889,O
"N10-propargyl-5,8-dideazafolic",889,B-Chemical
acid,889,I-Chemical
",",889,O
is,889,O
a,889,O
tight-binding,889,O
inhibitor,889,O
of,889,O
thymidylate,889,O
synthase,889,O
(,889,O
TS,889,O
),889,O
whose,889,O
cytotoxicity,889,B-Disease
is,889,O
mediated,889,O
solely,889,O
through,889,O
the,889,O
inhibition,889,O
of,889,O
this,889,O
enzyme,889,O
.,889,O
Recent,890,O
preclinical,890,O
studies,890,O
have,890,O
focused,890,O
on,890,O
the,890,O
intracellular,890,O
formation,890,O
of,890,O
CB,890,B-Chemical
3717,890,I-Chemical
polyglutamates,890,O
.,890,O
Following,891,O
a,891,O
12-hour,891,O
exposure,891,O
of,891,O
L1210,891,O
cells,891,O
to,891,O
50,891,O
microM,891,O
[,891,O
3H,891,O
],891,O
CB,891,B-Chemical
3717,891,I-Chemical
",",891,O
30,891,O
%,891,O
of,891,O
the,891,O
extractable,891,O
radioactivity,891,O
could,891,O
be,891,O
accounted,891,O
for,891,O
as,891,O
CB,891,B-Chemical
3717,891,I-Chemical
tetra-,891,O
and,891,O
pentaglutamate,891,O
",",891,O
as,891,O
determined,891,O
by,891,O
high-pressure,891,O
liquid,891,O
chromatography,891,O
(,891,O
HPLC,891,O
),891,O
analyses,891,O
.,891,O
As,892,O
inhibitors,892,O
of,892,O
isolated,892,O
L1210,892,O
TS,892,O
",",892,O
CB,892,O
3717,892,O
di-,892,O
",",892,O
tri-,892,O
",",892,O
tetra-,892,O
and,892,O
pentaglutamate,892,O
are,892,O
26-,892,O
",",892,O
87-,892,O
",",892,O
119-,892,O
and,892,O
114-fold,892,O
more,892,O
potent,892,O
than,892,O
CB,892,B-Chemical
3717,892,I-Chemical
",",892,O
respectively,892,O
",",892,O
and,892,O
their,892,O
formation,892,O
may,892,O
",",892,O
therefore,892,O
",",892,O
be,892,O
an,892,O
important,892,O
determinant,892,O
of,892,O
CB,892,B-Chemical
3717,892,I-Chemical
cytotoxicity,892,B-Disease
.,892,O
In,893,O
early,893,O
clinical,893,O
studies,893,O
with,893,O
CB,893,B-Chemical
3717,893,I-Chemical
",",893,O
activity,893,O
has,893,O
been,893,O
seen,893,O
in,893,O
breast,893,B-Disease
cancer,893,I-Disease
",",893,O
ovarian,893,B-Disease
cancer,893,I-Disease
",",893,O
hepatoma,893,B-Disease
",",893,O
and,893,O
mesothelioma,893,B-Disease
.,893,O
Toxicities,894,B-Disease
included,894,O
hepatotoxicity,894,B-Disease
",",894,O
malaise,894,B-Disease
",",894,O
and,894,O
dose-limiting,894,O
nephrotoxicity,894,B-Disease
.,894,O
This,895,O
latter,895,O
effect,895,O
is,895,O
thought,895,O
to,895,O
be,895,O
due,895,O
to,895,O
drug,895,O
precipitation,895,O
within,895,O
the,895,O
renal,895,O
tubule,895,O
as,895,O
a,895,O
result,895,O
of,895,O
the,895,O
poor,895,O
solubility,895,O
of,895,O
CB,895,B-Chemical
3717,895,I-Chemical
under,895,O
acidic,895,O
conditions,895,O
.,895,O
In,896,O
an,896,O
attempt,896,O
to,896,O
overcome,896,O
this,896,O
problem,896,O
",",896,O
a,896,O
clinical,896,O
trial,896,O
of,896,O
CB,896,B-Chemical
3717,896,I-Chemical
administered,896,O
with,896,O
alkaline,896,O
diuresis,896,O
is,896,O
under,896,O
way,896,O
.,896,O
Preliminary,897,O
results,897,O
at,897,O
400,897,O
and,897,O
500,897,O
mg/m2,897,O
suggest,897,O
that,897,O
a,897,O
reduction,897,O
in,897,O
nephrotoxicity,897,B-Disease
may,897,O
have,897,O
been,897,O
achieved,897,O
with,897,O
only,897,O
1,897,O
instance,897,O
of,897,O
renal,897,B-Disease
toxicity,897,I-Disease
in,897,O
10,897,O
patients,897,O
.,897,O
Hepatotoxicity,898,B-Disease
and,898,O
malaise,898,B-Disease
are,898,O
again,898,O
the,898,O
most,898,O
frequent,898,O
side,898,O
effects,898,O
.,898,O
Evidence,899,O
of,899,O
antitumor,899,O
activity,899,O
has,899,O
been,899,O
seen,899,O
in,899,O
3,899,O
patients,899,O
.,899,O
Pharmacokinetic,900,O
investigations,900,O
have,900,O
shown,900,O
that,900,O
alkaline,900,O
diuresis,900,O
does,900,O
not,900,O
alter,900,O
CB,900,B-Chemical
3717,900,I-Chemical
plasma,900,O
levels,900,O
or,900,O
urinary,900,O
excretion,900,O
and,900,O
that,900,O
satisfactory,900,O
urinary,900,O
alkalinization,900,O
can,900,O
be,900,O
readily,900,O
achieved,900,O
.,900,O
Production,901,O
of,901,O
autochthonous,901,O
prostate,901,B-Disease
cancer,901,I-Disease
in,901,O
Lobund-Wistar,901,O
rats,901,O
by,901,O
treatments,901,O
with,901,O
N-nitroso-N-methylurea,901,B-Chemical
and,901,O
testosterone,901,B-Chemical
.,901,O
More,902,O
than,902,O
50,902,O
%,902,O
of,902,O
Lobund-Wistar,902,O
(,902,O
L-W,902,O
),902,O
strain,902,O
rats,902,O
developed,902,O
large,902,O
",",902,O
palpable,902,O
prostate,902,B-Disease
adenocarcinomas,902,I-Disease
(,902,O
PAs,902,B-Disease
),902,O
following,902,O
treatments,902,O
with,902,O
N-nitroso-N-methylurea,902,B-Chemical
(,902,O
CAS,902,O
:,902,O
684-93-5,902,O
),902,O
and,902,O
testosterone,902,B-Chemical
propionate,902,I-Chemical
[,902,O
(,902,O
TP,902,B-Chemical
),902,O
CAS,902,O
:,902,O
57-85-2,902,O
],902,O
",",902,O
and,902,O
most,902,O
of,902,O
the,902,O
tumor-bearing,902,B-Disease
rats,902,O
manifested,902,O
metastatic,902,O
lesions,902,O
.,902,O
The,903,O
incubation,903,O
periods,903,O
averaged,903,O
10.6,903,O
months,903,O
.,903,O
Within,904,O
the,904,O
same,904,O
timeframe,904,O
",",904,O
no,904,O
L-W,904,O
rat,904,O
developed,904,O
a,904,O
similar,904,O
palpable,904,O
PA,904,B-Disease
when,904,O
treated,904,O
only,904,O
with,904,O
TP,904,B-Chemical
.,904,O
In,905,O
L-W,905,O
rats,905,O
",",905,O
TP,905,B-Chemical
acted,905,O
as,905,O
a,905,O
tumor,905,B-Disease
enhancement,905,O
agent,905,O
",",905,O
with,905,O
primary,905,O
emphasis,905,O
on,905,O
the,905,O
development,905,O
of,905,O
prostate,905,B-Disease
cancer,905,I-Disease
.,905,O
Relative,906,O
efficacy,906,O
and,906,O
toxicity,906,B-Disease
of,906,O
netilmicin,906,B-Chemical
and,906,O
tobramycin,906,B-Chemical
in,906,O
oncology,906,O
patients,906,O
.,906,O
We,907,O
prospectively,907,O
compared,907,O
the,907,O
efficacy,907,O
and,907,O
safety,907,O
of,907,O
netilmicin,907,B-Chemical
sulfate,907,I-Chemical
or,907,O
tobramycin,907,B-Chemical
sulfate,907,I-Chemical
in,907,O
conjunction,907,O
with,907,O
piperacillin,907,B-Chemical
sodium,907,I-Chemical
in,907,O
118,907,O
immunocompromised,907,O
patients,907,O
with,907,O
presumed,907,O
severe,907,O
infections,907,B-Disease
.,907,O
The,908,O
two,908,O
treatment,908,O
regimens,908,O
were,908,O
equally,908,O
efficacious,908,O
.,908,O
Nephrotoxicity,909,B-Disease
occurred,909,O
in,909,O
a,909,O
similar,909,O
proportion,909,O
in,909,O
patients,909,O
treated,909,O
with,909,O
netilmicin,909,B-Chemical
and,909,O
tobramycin,909,B-Chemical
(,909,O
17,909,O
%,909,O
vs,909,O
11,909,O
%,909,O
),909,O
.,909,O
Ototoxicity,910,B-Disease
occurred,910,O
in,910,O
four,910,O
(,910,O
9.5,910,O
%,910,O
),910,O
of,910,O
42,910,O
netilmicin,910,B-Chemical
and,910,O
piperacillin,910,B-Chemical
and,910,O
in,910,O
12,910,O
(,910,O
22,910,O
%,910,O
),910,O
of,910,O
54,910,O
tobramycin,910,B-Chemical
and,910,O
piperacillin-treated,910,B-Chemical
patients,910,O
.,910,O
Of,911,O
those,911,O
evaluated,911,O
with,911,O
posttherapy,911,O
audiograms,911,O
",",911,O
three,911,O
of,911,O
four,911,O
netilmicin,911,B-Chemical
and,911,O
piperacillin-treated,911,B-Chemical
patients,911,O
had,911,O
auditory,911,O
thresholds,911,O
return,911,O
to,911,O
baseline,911,O
compared,911,O
with,911,O
one,911,O
of,911,O
nine,911,O
tobramycin,911,B-Chemical
and,911,O
piperacillin-treated,911,B-Chemical
patients,911,O
.,911,O
The,912,O
number,912,O
of,912,O
greater,912,O
than,912,O
or,912,O
equal,912,O
to,912,O
15-dB,912,O
increases,912,O
in,912,O
auditory,912,O
threshold,912,O
as,912,O
a,912,O
proportion,912,O
of,912,O
total,912,O
greater,912,O
than,912,O
or,912,O
equal,912,O
to,912,O
15-dB,912,O
changes,912,O
(,912,O
increases,912,O
and,912,O
decreases,912,O
),912,O
was,912,O
significantly,912,O
lower,912,O
in,912,O
netilmicin,912,B-Chemical
and,912,O
piperacillin-,912,B-Chemical
vs,912,O
tobramycin,912,B-Chemical
and,912,O
piperacillin-treated,912,B-Chemical
patients,912,O
(,912,O
18,912,O
of,912,O
78,912,O
vs,912,O
67,912,O
of,912,O
115,912,O
),912,O
.,912,O
We,913,O
conclude,913,O
that,913,O
aminoglycoside-associated,913,B-Chemical
ototoxicity,913,B-Disease
was,913,O
less,913,O
severe,913,O
and,913,O
more,913,O
often,913,O
reversible,913,O
with,913,O
netilmicin,913,B-Chemical
than,913,O
with,913,O
tobramycin,913,B-Chemical
.,913,O
Urinary,914,O
enzymes,914,O
and,914,O
protein,914,O
patterns,914,O
as,914,O
indicators,914,O
of,914,O
injury,914,B-Disease
to,914,I-Disease
different,914,I-Disease
regions,914,I-Disease
of,914,I-Disease
the,914,I-Disease
kidney,914,I-Disease
.,914,O
Acute,915,B-Disease
experimental,915,I-Disease
models,915,I-Disease
of,915,I-Disease
renal,915,I-Disease
damage,915,I-Disease
to,915,O
the,915,O
proximal,915,O
tubular,915,O
",",915,O
glomerular,915,O
",",915,O
and,915,O
papillary,915,O
regions,915,O
of,915,O
the,915,O
rat,915,O
were,915,O
produced,915,O
by,915,O
administration,915,O
of,915,O
hexachloro-1:3-butadiene,915,B-Chemical
(,915,O
HCBD,915,B-Chemical
),915,O
",",915,O
puromycin,915,B-Chemical
aminonucleoside,915,I-Chemical
(,915,O
PAN,915,B-Chemical
),915,O
",",915,O
and,915,O
2-bromoethylamine,915,B-Chemical
(,915,O
BEA,915,B-Chemical
),915,O
",",915,O
respectively,915,O
.,915,O
Several,916,O
routine,916,O
indicators,916,O
of,916,O
nephrotoxicity,916,B-Disease
",",916,O
the,916,O
enzymes,916,O
alkaline,916,O
phosphatase,916,O
and,916,O
N-acetyl-beta-glucosaminidase,916,O
",",916,O
and,916,O
the,916,O
molecular,916,O
weight,916,O
of,916,O
protein,916,B-Disease
excretion,916,I-Disease
were,916,O
determined,916,O
on,916,O
urine,916,O
samples,916,O
.,916,O
Tubular,917,O
damage,917,O
produced,917,O
by,917,O
HCBD,917,B-Chemical
or,917,O
BEA,917,B-Chemical
was,917,O
discriminated,917,O
both,917,O
quantitatively,917,O
and,917,O
qualitatively,917,O
from,917,O
glomerular,917,B-Disease
damage,917,I-Disease
produced,917,O
by,917,O
PAN,917,B-Chemical
.,917,O
The,918,O
latter,918,O
was,918,O
characterized,918,O
by,918,O
a,918,O
pronounced,918,O
increase,918,O
in,918,O
protein,918,B-Disease
excretion,918,I-Disease
",",918,O
especially,918,O
proteins,918,O
with,918,O
molecular,918,O
weight,918,O
greater,918,O
than,918,O
"40,000",918,O
Da,918,O
.,918,O
In,919,O
contrast,919,O
",",919,O
protein,919,B-Disease
excretion,919,I-Disease
in,919,O
tubular,919,O
damage,919,O
was,919,O
raised,919,O
only,919,O
slightly,919,O
and,919,O
characterized,919,O
by,919,O
excretion,919,B-Disease
of,919,I-Disease
proteins,919,I-Disease
of,919,O
a,919,O
wide,919,O
range,919,O
of,919,O
molecular,919,O
weights,919,O
.,919,O
Proximal,920,O
tubular,920,O
damage,920,O
caused,920,O
by,920,O
HCBD,920,B-Chemical
and,920,O
papillary,920,O
damage,920,O
caused,920,O
by,920,O
BEA,920,B-Chemical
were,920,O
distinguished,920,O
both,920,O
by,920,O
conventional,920,O
urinalysis,920,O
(,920,O
volume,920,O
and,920,O
specific,920,O
gravity,920,O
),920,O
and,920,O
by,920,O
measurement,920,O
of,920,O
the,920,O
two,920,O
urinary,920,O
enzymes,920,O
.,920,O
Alkaline,921,O
phosphatase,921,O
and,921,O
glucose,921,B-Chemical
were,921,O
markedly,921,O
and,921,O
transiently,921,O
elevated,921,O
in,921,O
proximal,921,O
tubular,921,O
damage,921,O
and,921,O
N-acetyl-beta-glucosaminidase,921,O
showed,921,O
a,921,O
sustained,921,O
elevation,921,O
in,921,O
papillary,921,O
damage,921,O
.,921,O
It,922,O
is,922,O
concluded,922,O
that,922,O
both,922,O
selective,922,O
urinary,922,O
enzymes,922,O
and,922,O
the,922,O
molecular,922,O
weight,922,O
pattern,922,O
of,922,O
urinary,922,O
proteins,922,O
can,922,O
be,922,O
used,922,O
to,922,O
provide,922,O
diagnostic,922,O
information,922,O
about,922,O
the,922,O
possible,922,O
site,922,O
of,922,O
renal,922,B-Disease
damage,922,I-Disease
.,922,O
A,923,O
catch,923,O
in,923,O
the,923,O
Reye,923,B-Disease
.,923,O
Twenty-six,924,O
cases,924,O
of,924,O
Reye,924,B-Disease
syndrome,924,I-Disease
from,924,O
The,924,O
Children,924,O
's,924,O
Hospital,924,O
",",924,O
Camperdown,924,O
",",924,O
Australia,924,O
",",924,O
occurring,924,O
between,924,O
1973,924,O
and,924,O
1982,924,O
were,924,O
reviewed,924,O
.,924,O
Of,925,O
these,925,O
",",925,O
20,925,O
cases,925,O
met,925,O
the,925,O
US,925,O
Public,925,O
Health,925,O
Service,925,O
Centers,925,O
for,925,O
Disease,925,O
Control,925,O
criteria,925,O
for,925,O
the,925,O
diagnosis,925,O
of,925,O
Reye,925,B-Disease
syndrome,925,I-Disease
.,925,O
Aspirin,926,B-Chemical
or,926,O
salicylate,926,B-Chemical
ingestion,926,O
had,926,O
occurred,926,O
in,926,O
only,926,O
one,926,O
of,926,O
the,926,O
20,926,O
cases,926,O
(,926,O
5,926,O
%,926,O
),926,O
",",926,O
and,926,O
paracetamol,926,B-Chemical
(,926,O
acetaminophen,926,B-Chemical
),926,O
had,926,O
been,926,O
administered,926,O
in,926,O
only,926,O
six,926,O
of,926,O
the,926,O
cases,926,O
(,926,O
30,926,O
%,926,O
),926,O
.,926,O
Pathologic,927,O
confirmation,927,O
of,927,O
the,927,O
diagnosis,927,O
of,927,O
Reye,927,B-Disease
syndrome,927,I-Disease
was,927,O
accomplished,927,O
in,927,O
90,927,O
%,927,O
of,927,O
the,927,O
cases,927,O
.,927,O
The,928,O
incidence,928,O
of,928,O
Reye,928,B-Disease
syndrome,928,I-Disease
in,928,O
New,928,O
South,928,O
Wales,928,O
",",928,O
Australia,928,O
",",928,O
is,928,O
estimated,928,O
from,928,O
this,928,O
study,928,O
to,928,O
be,928,O
approximately,928,O
nine,928,O
cases,928,O
per,928,O
1,928,O
million,928,O
children,928,O
compared,928,O
with,928,O
recent,928,O
US,928,O
data,928,O
of,928,O
ten,928,O
to,928,O
20,928,O
cases,928,O
per,928,O
1,928,O
million,928,O
children,928,O
and,928,O
three,928,O
to,928,O
seven,928,O
cases,928,O
per,928,O
1,928,O
million,928,O
children,928,O
in,928,O
Great,928,O
Britain,928,O
.,928,O
The,929,O
mortality,929,O
for,929,O
these,929,O
Reye,929,B-Disease
syndrome,929,I-Disease
cases,929,O
in,929,O
Australia,929,O
was,929,O
45,929,O
%,929,O
as,929,O
compared,929,O
with,929,O
a,929,O
32,929,O
%,929,O
case-fatality,929,O
rate,929,O
in,929,O
the,929,O
United,929,O
States,929,O
.,929,O
In,930,O
Australia,930,O
",",930,O
the,930,O
pediatric,930,O
usage,930,O
of,930,O
aspirin,930,B-Chemical
has,930,O
been,930,O
extremely,930,O
low,930,O
for,930,O
the,930,O
past,930,O
25,930,O
years,930,O
(,930,O
less,930,O
than,930,O
1,930,O
%,930,O
of,930,O
total,930,O
dosage,930,O
units,930,O
sold,930,O
),930,O
",",930,O
with,930,O
paracetamol,930,B-Chemical
(,930,O
acetaminophen,930,B-Chemical
),930,O
dominating,930,O
the,930,O
pediatric,930,O
analgesic,930,O
and,930,O
antipyretic,930,O
market,930,O
.,930,O
Reye,931,B-Disease
syndrome,931,I-Disease
may,931,O
be,931,O
disappearing,931,O
from,931,O
Australia,931,O
despite,931,O
a,931,O
total,931,O
lack,931,O
of,931,O
association,931,O
with,931,O
salicylates,931,B-Chemical
or,931,O
aspirin,931,B-Chemical
ingestion,931,O
",",931,O
since,931,O
there,931,O
were,931,O
no,931,O
cases,931,O
found,931,O
at,931,O
The,931,O
Children,931,O
's,931,O
Hospital,931,O
in,931,O
1983,931,O
",",931,O
1984,931,O
",",931,O
or,931,O
1985,931,O
.,931,O
Postpartum,932,O
psychosis,932,B-Disease
induced,932,O
by,932,O
bromocriptine,932,B-Chemical
.,932,O
Two,933,O
multigravida,933,O
patients,933,O
with,933,O
no,933,O
prior,933,O
psychiatric,933,B-Disease
history,933,O
were,933,O
seen,933,O
with,933,O
postpartum,933,O
psychosis,933,B-Disease
",",933,O
having,933,O
received,933,O
bromocriptine,933,B-Chemical
for,933,O
inhibition,933,B-Disease
of,933,I-Disease
lactation,933,I-Disease
.,933,O
Bromocriptine,934,B-Chemical
given,934,O
in,934,O
high,934,O
doses,934,O
has,934,O
been,934,O
associated,934,O
with,934,O
psychosis,934,B-Disease
in,934,O
patients,934,O
receiving,934,O
the,934,O
drug,934,O
for,934,O
Parkinson,934,B-Disease
's,934,I-Disease
disease,934,I-Disease
.,934,O
These,935,O
cases,935,O
demonstrate,935,O
that,935,O
bromocriptine,935,B-Chemical
may,935,O
cause,935,O
psychosis,935,B-Disease
even,935,O
when,935,O
given,935,O
in,935,O
low,935,O
doses,935,O
.,935,O
Hyperglycemic,936,O
acidotic,936,O
coma,936,O
and,936,O
death,936,O
in,936,O
Kearns-Sayre,936,B-Disease
syndrome,936,I-Disease
.,936,O
This,937,O
paper,937,O
presents,937,O
the,937,O
clinical,937,O
and,937,O
metabolic,937,O
findings,937,O
in,937,O
two,937,O
young,937,O
boys,937,O
with,937,O
long-standing,937,O
Kearns-Sayre,937,B-Disease
syndrome,937,I-Disease
.,937,O
Following,938,O
short,938,O
exposure,938,O
to,938,O
oral,938,O
prednisone,938,B-Chemical
",",938,O
both,938,O
boys,938,O
developed,938,O
lethargy,938,B-Disease
",",938,O
increasing,938,O
somnolence,938,B-Disease
",",938,O
polydipsia,938,B-Disease
",",938,O
polyphagia,938,B-Disease
",",938,O
and,938,O
polyuria,938,B-Disease
.,938,O
Both,939,O
presented,939,O
in,939,O
the,939,O
emergency,939,O
room,939,O
with,939,O
profound,939,O
coma,939,B-Disease
",",939,O
hypotension,939,B-Disease
",",939,O
severe,939,O
hyperglycemia,939,B-Disease
",",939,O
and,939,O
acidosis,939,B-Disease
.,939,O
Nonketotic,940,O
lactic,940,B-Disease
acidosis,940,I-Disease
was,940,O
present,940,O
in,940,O
one,940,O
and,940,O
ketosis,940,B-Disease
without,940,O
a,940,O
known,940,O
serum,940,O
lactate,940,B-Chemical
level,940,O
was,940,O
present,940,O
in,940,O
the,940,O
other,940,O
.,940,O
Respiratory,941,B-Disease
failure,941,I-Disease
rapidly,941,O
ensued,941,O
and,941,O
both,941,O
patients,941,O
expired,941,O
in,941,O
spite,941,O
of,941,O
efforts,941,O
at,941,O
resuscitation,941,O
.,941,O
We,942,O
believe,942,O
these,942,O
two,942,O
cases,942,O
represent,942,O
a,942,O
newly,942,O
described,942,O
and,942,O
catastrophic,942,O
metabolic-endocrine,942,B-Disease
failure,942,I-Disease
in,942,O
the,942,O
Kearns-Sayre,942,B-Disease
syndrome,942,I-Disease
.,942,O
Experimental,943,O
cyclosporine,943,B-Chemical
nephrotoxicity,943,B-Disease
:,943,O
risk,943,O
of,943,O
concomitant,943,O
chemotherapy,943,O
.,943,O
The,944,O
role,944,O
of,944,O
cyclosporine,944,B-Chemical
(,944,O
CSA,944,B-Chemical
),944,O
alone,944,O
or,944,O
in,944,O
combination,944,O
with,944,O
various,944,O
chemotherapeutics,944,O
in,944,O
the,944,O
development,944,O
of,944,O
renal,944,B-Disease
toxicity,944,I-Disease
was,944,O
evaluated,944,O
in,944,O
rats,944,O
.,944,O
Administration,945,O
of,945,O
20,945,O
mg/kg/day,945,O
CSA,945,B-Chemical
for,945,O
4,945,O
weeks,945,O
caused,945,O
renal,945,O
functional,945,O
and,945,O
structural,945,O
changes,945,O
similar,945,O
to,945,O
those,945,O
reported,945,O
in,945,O
man,945,O
.,945,O
The,946,O
combined,946,O
administration,946,O
of,946,O
CSA,946,B-Chemical
and,946,O
various,946,O
chemotherapeutic,946,O
drugs,946,O
with,946,O
a,946,O
nephrotoxic,946,B-Disease
potential,946,O
",",946,O
such,946,O
as,946,O
gentamicin,946,B-Chemical
(,946,O
at,946,O
therapeutic,946,O
doses,946,O
),946,O
",",946,O
amphothericin,946,B-Chemical
B,946,I-Chemical
and,946,O
ketoconazole,946,B-Chemical
",",946,O
which,946,O
are,946,O
frequently,946,O
used,946,O
in,946,O
immunosuppressed,946,O
patients,946,O
",",946,O
did,946,O
not,946,O
aggravate,946,O
the,946,O
CSA,946,B-Chemical
induced,946,O
toxicity,946,B-Disease
in,946,O
the,946,O
rat,946,O
model,946,O
.,946,O
Gentamicin,947,B-Chemical
at,947,O
toxic,947,O
doses,947,O
",",947,O
however,947,O
",",947,O
increased,947,O
CSA,947,B-Chemical
nephrotoxicity,947,B-Disease
.,947,O
Thus,948,O
",",948,O
the,948,O
nephrotoxicity,948,B-Disease
induced,948,O
by,948,O
CSA,948,B-Chemical
has,948,O
a,948,O
different,948,O
pathogenetic,948,O
mechanism,948,O
.,948,O
Diuretics,949,O
",",949,O
potassium,949,B-Chemical
and,949,O
arrhythmias,949,B-Disease
in,949,O
hypertensive,949,B-Disease
coronary,949,B-Disease
disease,949,I-Disease
.,949,O
It,950,O
has,950,O
been,950,O
proposed,950,O
that,950,O
modest,950,O
changes,950,O
in,950,O
plasma,950,O
potassium,950,B-Chemical
can,950,O
alter,950,O
the,950,O
tendency,950,O
towards,950,O
cardiac,950,B-Disease
arrhythmias,950,I-Disease
.,950,O
If,951,O
this,951,O
were,951,O
so,951,O
",",951,O
patients,951,O
with,951,O
coronary,951,B-Disease
artery,951,I-Disease
disease,951,I-Disease
might,951,O
be,951,O
especially,951,O
susceptible,951,O
.,951,O
Thus,952,O
",",952,O
myocardial,952,O
electrical,952,O
excitability,952,O
was,952,O
measured,952,O
in,952,O
patients,952,O
with,952,O
mild,952,O
essential,952,O
hypertension,952,B-Disease
and,952,O
known,952,O
coronary,952,B-Disease
artery,952,I-Disease
disease,952,I-Disease
after,952,O
8,952,O
weeks,952,O
of,952,O
treatment,952,O
with,952,O
a,952,O
potassium-conserving,952,B-Chemical
diuretic,952,O
(,952,O
amiloride,952,B-Chemical
),952,O
and,952,O
a,952,O
similar,952,O
period,952,O
on,952,O
a,952,O
potassium-losing,952,B-Chemical
diuretic,952,O
(,952,O
chlorthalidone,952,B-Chemical
),952,O
in,952,O
a,952,O
randomised,952,O
study,952,O
.,952,O
Plasma,953,O
potassium,953,B-Chemical
concentrations,953,O
were,953,O
on,953,O
average,953,O
1,953,O
mmol/L,953,O
lower,953,O
during,953,O
the,953,O
chlorthalidone,953,B-Chemical
phase,953,O
compared,953,O
to,953,O
amiloride,953,B-Chemical
therapy,953,O
.,953,O
Blood,954,O
pressure,954,O
and,954,O
volume,954,O
states,954,O
as,954,O
assessed,954,O
by,954,O
bodyweight,954,O
",",954,O
plasma,954,O
renin,954,O
and,954,O
noradrenaline,954,B-Chemical
(,954,O
norepinephrine,954,B-Chemical
),954,O
concentrations,954,O
were,954,O
similar,954,O
on,954,O
the,954,O
2,954,O
regimens,954,O
.,954,O
Compared,955,O
to,955,O
amiloride,955,B-Chemical
treatment,955,O
",",955,O
the,955,O
chlorthalidone,955,B-Chemical
phase,955,O
was,955,O
associated,955,O
with,955,O
an,955,O
increased,955,O
frequency,955,O
of,955,O
ventricular,955,B-Disease
ectopic,955,I-Disease
beats,955,I-Disease
(,955,O
24-hour,955,O
Holter,955,O
monitoring,955,O
),955,O
and,955,O
a,955,O
higher,955,O
Lown,955,O
grading,955,O
",",955,O
increased,955,O
upslope,955,O
and,955,O
duration,955,O
of,955,O
the,955,O
monophasic,955,O
action,955,O
potential,955,O
",",955,O
prolonged,955,O
ventricular,955,O
effective,955,O
refractory,955,O
period,955,O
",",955,O
and,955,O
increased,955,O
electrical,955,O
instability,955,O
during,955,O
programmed,955,O
ventricular,955,O
stimulation,955,O
.,955,O
The,956,O
above,956,O
results,956,O
indicate,956,O
that,956,O
because,956,O
potassium-losing,956,B-Chemical
diuretic,956,O
therapy,956,O
can,956,O
increase,956,O
myocardial,956,O
electrical,956,O
excitability,956,O
in,956,O
patients,956,O
with,956,O
ischaemic,956,B-Disease
heart,956,I-Disease
disease,956,I-Disease
",",956,O
even,956,O
minor,956,O
falls,956,O
in,956,O
plasma,956,O
potassium,956,B-Chemical
concentrations,956,O
are,956,O
probably,956,O
best,956,O
avoided,956,O
in,956,O
such,956,O
patients,956,O
.,956,O
Transketolase,957,O
abnormality,957,O
in,957,O
tolazamide-induced,957,B-Chemical
Wernicke,957,B-Disease
's,957,I-Disease
encephalopathy,957,I-Disease
.,957,O
We,958,O
studied,958,O
a,958,O
thiamine-dependent,958,B-Chemical
enzyme,958,O
",",958,O
transketolase,958,O
",",958,O
from,958,O
fibroblasts,958,O
of,958,O
a,958,O
diabetic,958,B-Disease
patient,958,O
who,958,O
developed,958,O
Wernicke,958,B-Disease
's,958,I-Disease
encephalopathy,958,I-Disease
when,958,O
treated,958,O
with,958,O
tolazamide,958,B-Chemical
",",958,O
in,958,O
order,958,O
to,958,O
delineate,958,O
if,958,O
this,958,O
patient,958,O
also,958,O
had,958,O
transketolase,958,O
abnormality,958,O
[,958,O
high,958,O
Km,958,O
for,958,O
thiamine,958,B-Chemical
pyrophosphate,958,I-Chemical
(,958,O
TPP,958,B-Chemical
),958,O
],958,O
",",958,O
as,958,O
previously,958,O
reported,958,O
in,958,O
postalcoholic,958,O
Wernicke-Korsakoff,958,B-Disease
syndrome,958,I-Disease
.,958,O
In,959,O
addition,959,O
to,959,O
this,959,O
patient,959,O
",",959,O
we,959,O
also,959,O
studied,959,O
this,959,O
enzyme,959,O
from,959,O
three,959,O
diabetic,959,B-Disease
kindreds,959,O
without,959,O
any,959,O
history,959,O
of,959,O
Wernicke,959,B-Disease
's,959,I-Disease
encephalopathy,959,I-Disease
and,959,O
from,959,O
four,959,O
normal,959,O
controls,959,O
.,959,O
We,960,O
found,960,O
that,960,O
the,960,O
above-mentioned,960,O
patient,960,O
and,960,O
one,960,O
of,960,O
the,960,O
diabetic,960,B-Disease
kindreds,960,O
with,960,O
no,960,O
history,960,O
of,960,O
Wernicke,960,B-Disease
's,960,I-Disease
encephalopathy,960,I-Disease
had,960,O
abnormal,960,O
transketolase,960,O
as,960,O
determined,960,O
by,960,O
its,960,O
Km,960,O
for,960,O
TPP,960,B-Chemical
.,960,O
These,961,O
data,961,O
suggest,961,O
a,961,O
similarity,961,O
between,961,O
postalcoholic,961,O
Wernicke-Korsakoff,961,B-Disease
syndrome,961,I-Disease
and,961,O
the,961,O
patient,961,O
with,961,O
tolazamide-induced,961,B-Chemical
Wernicke,961,B-Disease
's,961,I-Disease
encephalopathy,961,I-Disease
from,961,O
the,961,O
standpoint,961,O
of,961,O
transketolase,961,O
abnormality,961,O
.,961,O
Bradycardia,962,B-Disease
due,962,O
to,962,O
trihexyphenidyl,962,B-Chemical
hydrochloride,962,I-Chemical
.,962,O
A,963,O
chronic,963,O
schizophrenic,963,B-Disease
patient,963,O
was,963,O
treated,963,O
with,963,O
an,963,O
anticholinergic,963,O
drug,963,O
",",963,O
trihexyphenidyl,963,B-Chemical
hydrochloride,963,I-Chemical
.,963,O
The,964,O
patient,964,O
developed,964,O
",",964,O
paradoxically,964,O
",",964,O
sinus,964,O
bradycardia,964,B-Disease
.,964,O
The,965,O
reaction,965,O
was,965,O
specific,965,O
to,965,O
trihexyphenidyl,965,B-Chemical
and,965,O
not,965,O
to,965,O
other,965,O
anticholinergic,965,O
drugs,965,O
.,965,O
This,966,O
antidyskinetic,966,O
drug,966,O
is,966,O
widely,966,O
used,966,O
in,966,O
clinical,966,O
psychiatric,966,B-Disease
practice,966,O
and,966,O
physicians,966,O
should,966,O
be,966,O
aware,966,O
of,966,O
this,966,O
side,966,O
effect,966,O
.,966,O
Post-operative,967,O
rigidity,967,B-Disease
after,967,O
fentanyl,967,B-Chemical
administration,967,O
.,967,O
A,968,O
case,968,O
of,968,O
thoraco-abdominal,968,O
rigidity,968,B-Disease
leading,968,O
to,968,O
respiratory,968,B-Disease
failure,968,I-Disease
is,968,O
described,968,O
in,968,O
the,968,O
post-operative,968,O
period,968,O
in,968,O
an,968,O
elderly,968,O
patient,968,O
who,968,O
received,968,O
a,968,O
moderate,968,O
dose,968,O
of,968,O
fentanyl,968,B-Chemical
.,968,O
This,969,O
was,969,O
successfully,969,O
reversed,969,O
by,969,O
naloxone,969,B-Chemical
.,969,O
The,970,O
mechanisms,970,O
possibly,970,O
implicated,970,O
in,970,O
this,970,O
accident,970,O
are,970,O
discussed,970,O
.,970,O
Anti-carcinogenic,971,O
action,971,O
of,971,O
phenobarbital,971,B-Chemical
given,971,O
simultaneously,971,O
with,971,O
diethylnitrosamine,971,B-Chemical
in,971,O
the,971,O
rat,971,O
.,971,O
The,972,O
present,972,O
work,972,O
has,972,O
been,972,O
planned,972,O
in,972,O
order,972,O
to,972,O
elucidate,972,O
the,972,O
effect,972,O
of,972,O
phenobarbital,972,B-Chemical
(,972,O
PB,972,B-Chemical
:,972,O
15,972,O
mg,972,O
per,972,O
rat,972,O
of,972,O
ingested,972,O
dose,972,O
),972,O
on,972,O
carcinogenesis,972,B-Disease
when,972,O
it,972,O
is,972,O
administered,972,O
simultaneously,972,O
with,972,O
diethylnitrosamine,972,B-Chemical
(,972,O
DEN,972,B-Chemical
:,972,O
10,972,O
mg/kg/day,972,O
),972,O
.,972,O
Wistar,973,O
rats,973,O
(,973,O
180,973,O
g,973,O
),973,O
were,973,O
treated,973,O
by,973,O
DEN,973,B-Chemical
alone,973,O
or,973,O
by,973,O
DEN,973,B-Chemical
+,973,O
PB,973,B-Chemical
during,973,O
2,973,O
",",973,O
4,973,O
and,973,O
6,973,O
weeks,973,O
according,973,O
to,973,O
our,973,O
schedule,973,O
for,973,O
hepatocarcinogenesis,973,B-Disease
.,973,O
After,974,O
the,974,O
end,974,O
of,974,O
the,974,O
treatment,974,O
",",974,O
the,974,O
number,974,O
and,974,O
the,974,O
size,974,O
of,974,O
induced,974,O
PAS,974,O
positive,974,O
preneoplastic,974,B-Disease
foci,974,I-Disease
was,974,O
significantly,974,O
reduced,974,O
when,974,O
PB,974,B-Chemical
was,974,O
given,974,O
simultaneously,974,O
with,974,O
DEN,974,B-Chemical
for,974,O
4,974,O
and,974,O
6,974,O
weeks,974,O
.,974,O
The,975,O
mitotic,975,O
inhibition,975,O
and,975,O
the,975,O
production,975,O
of,975,O
micronuclei,975,O
normally,975,O
observed,975,O
after,975,O
partial,975,O
hepatectomy,975,O
in,975,O
DEN,975,B-Chemical
treated,975,O
rats,975,O
were,975,O
also,975,O
significantly,975,O
decreased,975,O
in,975,O
DEN,975,B-Chemical
+,975,O
PB,975,B-Chemical
treated,975,O
rats,975,O
.,975,O
When,976,O
the,976,O
treatment,976,O
last,976,O
only,976,O
2,976,O
weeks,976,O
",",976,O
the,976,O
presence,976,O
of,976,O
PB,976,B-Chemical
did,976,O
not,976,O
change,976,O
significantly,976,O
the,976,O
last,976,O
parameters,976,O
.,976,O
In,977,O
DEN,977,B-Chemical
+,977,O
PB,977,B-Chemical
treated,977,O
rats,977,O
",",977,O
the,977,O
survival,977,O
was,977,O
prolonged,977,O
and,977,O
the,977,O
tumor,977,B-Disease
incidence,977,O
decreased,977,O
as,977,O
compared,977,O
with,977,O
the,977,O
results,977,O
obtained,977,O
by,977,O
DEN,977,B-Chemical
alone,977,O
.,977,O
It,978,O
is,978,O
concluded,978,O
that,978,O
PB,978,B-Chemical
",",978,O
which,978,O
promotes,978,O
carcinogenesis,978,B-Disease
when,978,O
administered,978,O
after,978,O
the,978,O
DEN,978,B-Chemical
treatment,978,O
",",978,O
reduces,978,O
the,978,O
carcinogen,978,O
effect,978,O
when,978,O
given,978,O
simultaneously,978,O
with,978,O
DEN,978,B-Chemical
.,978,O
This,979,O
'anti-carcinogen,979,O
',979,O
effect,979,O
acts,979,O
on,979,O
the,979,O
initiation,979,O
as,979,O
well,979,O
as,979,O
on,979,O
the,979,O
promotion,979,O
of,979,O
the,979,O
precancerous,979,B-Disease
lesions,979,I-Disease
.,979,O
Biochemical,980,O
investigations,980,O
are,980,O
in,980,O
progress,980,O
to,980,O
obtain,980,O
more,980,O
information,980,O
about,980,O
this,980,O
'paradoxical,980,O
',980,O
PB,980,B-Chemical
effect,980,O
.,980,O
A,981,O
prospective,981,O
study,981,O
of,981,O
adverse,981,O
reactions,981,O
associated,981,O
with,981,O
vancomycin,981,B-Chemical
therapy,981,O
.,981,O
A,982,O
prospective,982,O
evaluation,982,O
of,982,O
the,982,O
efficacy,982,O
and,982,O
safety,982,O
of,982,O
vancomycin,982,B-Chemical
was,982,O
conducted,982,O
in,982,O
54,982,O
consecutive,982,O
patients,982,O
over,982,O
a,982,O
16-month,982,O
period,982,O
.,982,O
Vancomycin,983,B-Chemical
was,983,O
curative,983,O
in,983,O
95,983,O
%,983,O
of,983,O
43,983,O
patients,983,O
with,983,O
proven,983,O
infection,983,B-Disease
.,983,O
Drugs,984,O
were,984,O
ceased,984,O
in,984,O
six,984,O
patients,984,O
because,984,O
of,984,O
adverse,984,O
reactions,984,O
;,984,O
in,984,O
three,984,O
of,984,O
these,984,O
vancomycin,984,B-Chemical
was,984,O
considered,984,O
the,984,O
likely,984,O
cause,984,O
.,984,O
Reactions,985,O
included,985,O
thrombophlebitis,985,B-Disease
(,985,O
20,985,O
of,985,O
54,985,O
patients,985,O
),985,O
",",985,O
rash,985,B-Disease
(,985,O
4,985,O
of,985,O
54,985,O
),985,O
",",985,O
nephrotoxicity,985,B-Disease
(,985,O
4,985,O
of,985,O
50,985,O
),985,O
",",985,O
proteinuria,985,B-Disease
(,985,O
1,985,O
of,985,O
50,985,O
),985,O
and,985,O
ototoxicity,985,B-Disease
(,985,O
1,985,O
of,985,O
11,985,O
patients,985,O
tested,985,O
by,985,O
audiometry,985,O
),985,O
.,985,O
Thrombophlebitis,986,B-Disease
occurred,986,O
only,986,O
with,986,O
infusion,986,O
through,986,O
peripheral,986,O
cannulae,986,O
;,986,O
nephrotoxicity,986,B-Disease
and,986,O
ototoxicity,986,B-Disease
were,986,O
confined,986,O
to,986,O
patients,986,O
receiving,986,O
an,986,O
aminoglycoside,986,B-Chemical
plus,986,O
vancomycin,986,B-Chemical
.,986,O
We,987,O
conclude,987,O
that,987,O
vancomycin,987,B-Chemical
",",987,O
administered,987,O
appropriately,987,O
",",987,O
constitutes,987,O
safe,987,O
",",987,O
effective,987,O
therapy,987,O
for,987,O
infections,987,B-Disease
caused,987,O
by,987,O
susceptible,987,O
bacteria,987,O
.,987,O
Factors,988,O
associated,988,O
with,988,O
nephrotoxicity,988,B-Disease
and,988,O
clinical,988,O
outcome,988,O
in,988,O
patients,988,O
receiving,988,O
amikacin,988,B-Chemical
.,988,O
Data,989,O
from,989,O
60,989,O
patients,989,O
treated,989,O
with,989,O
amikacin,989,B-Chemical
were,989,O
analyzed,989,O
for,989,O
factors,989,O
associated,989,O
with,989,O
nephrotoxicity,989,B-Disease
.,989,O
In,990,O
42,990,O
of,990,O
these,990,O
patients,990,O
",",990,O
data,990,O
were,990,O
examined,990,O
for,990,O
factors,990,O
associated,990,O
with,990,O
clinical,990,O
outcome,990,O
.,990,O
Variables,991,O
evaluated,991,O
included,991,O
patient,991,O
weight,991,O
",",991,O
age,991,O
",",991,O
sex,991,O
",",991,O
serum,991,O
creatinine,991,B-Chemical
level,991,O
",",991,O
creatinine,991,B-Chemical
clearance,991,O
",",991,O
duration,991,O
of,991,O
therapy,991,O
",",991,O
total,991,O
dose,991,O
",",991,O
mean,991,O
daily,991,O
dose,991,O
",",991,O
organism,991,O
minimum,991,O
inhibitory,991,O
concentration,991,O
(,991,O
MIC,991,O
),991,O
",",991,O
mean,991,O
peak,991,O
levels,991,O
",",991,O
mean,991,O
trough,991,O
levels,991,O
",",991,O
mean,991,O
area,991,O
under,991,O
the,991,O
serum,991,O
concentration-time,991,O
curve,991,O
(,991,O
AUC,991,O
),991,O
",",991,O
total,991,O
AUC,991,O
",",991,O
mean,991,O
AUC,991,O
greater,991,O
than,991,O
MIC,991,O
",",991,O
total,991,O
AUC,991,O
greater,991,O
than,991,O
MIC,991,O
",",991,O
mean,991,O
Schumacher,991,O
's,991,O
intensity,991,O
factor,991,O
(,991,O
IF,991,O
),991,O
",",991,O
total,991,O
IF,991,O
",",991,O
In,991,O
(,991,O
mean,991,O
maximum,991,O
concentration,991,O
[,991,O
Cmax,991,O
],991,O
/MIC,991,O
),991,O
.,991,O
Model-dependent,992,O
pharmacokinetic,992,O
parameters,992,O
were,992,O
calculated,992,O
by,992,O
computer,992,O
based,992,O
on,992,O
a,992,O
one-compartment,992,O
model,992,O
.,992,O
When,993,O
the,993,O
parameters,993,O
were,993,O
examined,993,O
individually,993,O
",",993,O
duration,993,O
of,993,O
therapy,993,O
and,993,O
total,993,O
AUC,993,O
correlated,993,O
significantly,993,O
(,993,O
P,993,O
less,993,O
than,993,O
.05,993,O
),993,O
with,993,O
nephrotoxicity,993,B-Disease
.,993,O
In,994,O
contrast,994,O
",",994,O
a,994,O
stepwise,994,O
discriminant,994,O
function,994,O
analysis,994,O
identified,994,O
only,994,O
duration,994,O
of,994,O
therapy,994,O
(,994,O
P,994,O
less,994,O
than,994,O
.001,994,O
),994,O
as,994,O
an,994,O
important,994,O
factor,994,O
.,994,O
Based,995,O
on,995,O
this,995,O
model,995,O
and,995,O
on,995,O
Bayes,995,O
',995,O
theorem,995,O
",",995,O
the,995,O
predictive,995,O
accuracy,995,O
of,995,O
identifying,995,O
``,995,O
nephrotoxic,995,B-Disease
'',995,O
patients,995,O
increased,995,O
from,995,O
0.17,995,O
to,995,O
0.39,995,O
.,995,O
When,996,O
examined,996,O
individually,996,O
",",996,O
mean,996,O
IF,996,O
",",996,O
MIC,996,O
",",996,O
total,996,O
dose,996,O
",",996,O
mean,996,O
daily,996,O
dose,996,O
",",996,O
and,996,O
ln,996,O
(,996,O
mean,996,O
Cmax/MIC,996,O
),996,O
correlated,996,O
significantly,996,O
(,996,O
P,996,O
less,996,O
than,996,O
.05,996,O
),996,O
with,996,O
cure,996,O
.,996,O
In,997,O
contrast,997,O
",",997,O
a,997,O
simultaneous,997,O
multivariable,997,O
analysis,997,O
identified,997,O
IF,997,O
",",997,O
MIC,997,O
",",997,O
and,997,O
total,997,O
dose,997,O
according,997,O
to,997,O
one,997,O
model,997,O
and,997,O
ln,997,O
(,997,O
mean,997,O
Cmax/MIC,997,O
),997,O
according,997,O
to,997,O
a,997,O
second,997,O
statistical,997,O
model,997,O
of,997,O
parameters,997,O
selected,997,O
to,997,O
have,997,O
the,997,O
greatest,997,O
prospective,997,O
value,997,O
.,997,O
Based,998,O
on,998,O
Bayes,998,O
',998,O
theorem,998,O
and,998,O
the,998,O
first,998,O
model,998,O
",",998,O
the,998,O
predictive,998,O
accuracy,998,O
of,998,O
identifying,998,O
patients,998,O
not,998,O
cured,998,O
increased,998,O
from,998,O
0.19,998,O
to,998,O
0.83,998,O
.,998,O
For,999,O
the,999,O
second,999,O
model,999,O
",",999,O
the,999,O
predictive,999,O
accuracy,999,O
increased,999,O
from,999,O
0.19,999,O
to,999,O
0.50,999,O
.,999,O
(,1000,O
ABSTRACT,1000,O
TRUNCATED,1000,O
AT,1000,O
250,1000,O
WORDS,1000,O
),1000,O
Cardiac,1001,B-Disease
toxicity,1001,I-Disease
of,1001,O
5-fluorouracil,1001,B-Chemical
.,1001,O
Report,1002,O
of,1002,O
a,1002,O
case,1002,O
of,1002,O
spontaneous,1002,O
angina,1002,B-Disease
.,1002,O
We,1003,O
report,1003,O
a,1003,O
case,1003,O
of,1003,O
a,1003,O
patient,1003,O
with,1003,O
colon,1003,B-Disease
carcinoma,1003,I-Disease
and,1003,O
liver,1003,O
metastasis,1003,B-Disease
who,1003,O
presented,1003,O
chest,1003,B-Disease
pain,1003,I-Disease
after,1003,O
5-fluorouracil,1003,B-Chemical
(,1003,O
5-FU,1003,B-Chemical
),1003,O
administration,1003,O
.,1003,O
Clinical,1004,O
electrocardiographic,1004,O
evolution,1004,O
was,1004,O
similar,1004,O
to,1004,O
that,1004,O
observed,1004,O
in,1004,O
Prinzmetal,1004,B-Disease
's,1004,I-Disease
angina,1004,I-Disease
",",1004,O
and,1004,O
chest,1004,B-Disease
pain,1004,I-Disease
promptly,1004,O
resolved,1004,O
with,1004,O
nifedipine,1004,B-Chemical
.,1004,O
These,1005,O
data,1005,O
suggest,1005,O
that,1005,O
coronary,1005,B-Disease
spasm,1005,I-Disease
may,1005,O
be,1005,O
the,1005,O
cause,1005,O
of,1005,O
cardiotoxicity,1005,B-Disease
due,1005,O
to,1005,O
5-FU,1005,B-Chemical
",",1005,O
and,1005,O
that,1005,O
calcium,1005,B-Chemical
antagonists,1005,O
may,1005,O
probably,1005,O
be,1005,O
used,1005,O
in,1005,O
the,1005,O
prevention,1005,O
or,1005,O
treatment,1005,O
of,1005,O
5-FU,1005,B-Chemical
cardiotoxicity,1005,B-Disease
.,1005,O
Dose-related,1006,O
beneficial,1006,O
and,1006,O
adverse,1006,O
effects,1006,O
of,1006,O
dietary,1006,O
corticosterone,1006,B-Chemical
on,1006,O
organophosphorus-induced,1006,B-Chemical
delayed,1006,O
neuropathy,1006,B-Disease
in,1006,O
chickens,1006,O
.,1006,O
Tri-ortho-tolyl,1007,B-Chemical
phosphate,1007,I-Chemical
(,1007,O
TOTP,1007,B-Chemical
),1007,O
",",1007,O
360,1007,O
mg/kg,1007,O
",",1007,O
po,1007,O
",",1007,O
and,1007,O
"0,0'-diisopropyl",1007,B-Chemical
phosphorofluoridate,1007,I-Chemical
(,1007,O
DFP,1007,B-Chemical
),1007,O
",",1007,O
1,1007,O
mg/kg,1007,O
sc,1007,O
",",1007,O
were,1007,O
administered,1007,O
to,1007,O
adult,1007,O
White,1007,O
Leghorn,1007,O
chickens,1007,O
24,1007,O
hr,1007,O
after,1007,O
they,1007,O
were,1007,O
placed,1007,O
on,1007,O
diets,1007,O
containing,1007,O
0,1007,O
to,1007,O
300,1007,O
ppm,1007,O
corticosterone,1007,B-Chemical
.,1007,O
Supplemented,1008,O
diets,1008,O
were,1008,O
continued,1008,O
until,1008,O
clinical,1008,O
signs,1008,O
and,1008,O
lesions,1008,O
of,1008,O
delayed,1008,O
neuropathy,1008,B-Disease
appeared,1008,O
.,1008,O
Although,1009,O
low,1009,O
concentrations,1009,O
(,1009,O
less,1009,O
than,1009,O
or,1009,O
equal,1009,O
to,1009,O
50,1009,O
ppm,1009,O
),1009,O
of,1009,O
corticosterone,1009,B-Chemical
had,1009,O
beneficial,1009,O
effects,1009,O
on,1009,O
TOTP-induced,1009,B-Chemical
neuropathy,1009,B-Disease
",",1009,O
greater,1009,O
than,1009,O
or,1009,O
equal,1009,O
to,1009,O
200,1009,O
ppm,1009,O
exacerbated,1009,O
clinical,1009,O
signs,1009,O
in,1009,O
chickens,1009,O
given,1009,O
either,1009,O
TOTP,1009,B-Chemical
or,1009,O
DFP,1009,B-Chemical
.,1009,O
Neurotoxic,1010,B-Disease
esterase,1010,O
activities,1010,O
24,1010,O
hr,1010,O
after,1010,O
TOTP,1010,B-Chemical
or,1010,O
DFP,1010,B-Chemical
were,1010,O
less,1010,O
than,1010,O
20,1010,O
%,1010,O
of,1010,O
values,1010,O
measured,1010,O
in,1010,O
chickens,1010,O
not,1010,O
given,1010,O
organophosphorous,1010,B-Chemical
compounds,1010,O
.,1010,O
Chickens,1011,O
given,1011,O
200,1011,O
ppm,1011,O
corticosterone,1011,B-Chemical
without,1011,O
TOTP,1011,B-Chemical
or,1011,O
DFP,1011,B-Chemical
had,1011,O
significantly,1011,O
elevated,1011,O
activity,1011,O
of,1011,O
plasma,1011,O
cholinesterase,1011,O
and,1011,O
significantly,1011,O
inhibited,1011,O
activity,1011,O
of,1011,O
liver,1011,O
carboxylesterase,1011,O
.,1011,O
Degenerating,1012,B-Disease
myelinated,1012,I-Disease
fibers,1012,I-Disease
were,1012,O
also,1012,O
evident,1012,O
in,1012,O
distal,1012,O
levels,1012,O
of,1012,O
the,1012,O
peripheral,1012,O
nerves,1012,O
of,1012,O
chickens,1012,O
given,1012,O
TOTP,1012,B-Chemical
or,1012,O
DFP,1012,B-Chemical
.,1012,O
Hepatotoxicity,1013,B-Disease
of,1013,O
amiodarone,1013,B-Chemical
.,1013,O
Amiodarone,1014,B-Chemical
has,1014,O
proved,1014,O
very,1014,O
effective,1014,O
in,1014,O
the,1014,O
treatment,1014,O
of,1014,O
otherwise,1014,O
resistant,1014,O
cardiac,1014,O
tachyarrhythmias,1014,B-Disease
.,1014,O
The,1015,O
use,1015,O
of,1015,O
amiodarone,1015,B-Chemical
has,1015,O
",",1015,O
however,1015,O
",",1015,O
been,1015,O
limited,1015,O
due,1015,O
to,1015,O
its,1015,O
serious,1015,O
side-effects,1015,O
.,1015,O
A,1016,O
patient,1016,O
with,1016,O
cholestatic,1016,O
hepatitis,1016,O
due,1016,O
to,1016,O
amiodarone,1016,B-Chemical
treatment,1016,O
is,1016,O
presented,1016,O
below,1016,O
and,1016,O
a,1016,O
review,1016,O
of,1016,O
the,1016,O
hepatotoxicity,1016,B-Disease
of,1016,O
amiodarone,1016,B-Chemical
is,1016,O
given,1016,O
.,1016,O
It,1017,O
is,1017,O
concluded,1017,O
that,1017,O
solid,1017,O
evidence,1017,O
exists,1017,O
of,1017,O
hepatic,1017,B-Disease
injury,1017,I-Disease
due,1017,O
to,1017,O
amiodarone,1017,B-Chemical
treatment,1017,O
",",1017,O
including,1017,O
steatosis,1017,B-Disease
",",1017,O
alterations,1017,O
resembling,1017,O
alcoholic,1017,B-Disease
hepatitis,1017,I-Disease
",",1017,O
cholestatic,1017,O
hepatitis,1017,O
and,1017,O
micronodular,1017,O
cirrhosis,1017,B-Disease
of,1017,I-Disease
the,1017,I-Disease
liver,1017,I-Disease
.,1017,O
Patients,1018,O
receiving,1018,O
amiodarone,1018,B-Chemical
should,1018,O
be,1018,O
regularly,1018,O
screened,1018,O
with,1018,O
respect,1018,O
to,1018,O
hepatic,1018,O
enzyme,1018,O
levels,1018,O
.,1018,O
Therapy,1019,O
should,1019,O
be,1019,O
discontinued,1019,O
on,1019,O
the,1019,O
suspicion,1019,O
of,1019,O
cholestatic,1019,B-Disease
injury,1019,I-Disease
or,1019,O
hepatomegaly,1019,B-Disease
.,1019,O
Promotional,1020,O
effects,1020,O
of,1020,O
testosterone,1020,B-Chemical
and,1020,O
dietary,1020,O
fat,1020,O
on,1020,O
prostate,1020,O
carcinogenesis,1020,B-Disease
in,1020,O
genetically,1020,O
susceptible,1020,O
rats,1020,O
.,1020,O
Germfree,1021,O
(,1021,O
GF,1021,O
),1021,O
Lobund,1021,O
strain,1021,O
Wistar,1021,O
(,1021,O
LW,1021,O
),1021,O
rats,1021,O
",",1021,O
fed,1021,O
vegetable,1021,O
diet,1021,O
L-485,1021,O
",",1021,O
have,1021,O
developed,1021,O
prostate,1021,B-Disease
adenocarcinomas,1021,I-Disease
spontaneously,1021,O
(,1021,O
10,1021,O
%,1021,O
incidence,1021,O
),1021,O
at,1021,O
average,1021,O
age,1021,O
34,1021,O
months,1021,O
.,1021,O
Conventional,1022,O
LW,1022,O
rats,1022,O
",",1022,O
implanted,1022,O
with,1022,O
testosterone,1022,B-Chemical
at,1022,O
age,1022,O
4,1022,O
months,1022,O
",",1022,O
developed,1022,O
a,1022,O
higher,1022,O
incidence,1022,O
of,1022,O
prostate,1022,B-Disease
cancer,1022,I-Disease
after,1022,O
an,1022,O
average,1022,O
interval,1022,O
of,1022,O
14,1022,O
months,1022,O
:,1022,O
24,1022,O
%,1022,O
had,1022,O
developed,1022,O
gross,1022,O
tumors,1022,B-Disease
",",1022,O
and,1022,O
40,1022,O
%,1022,O
when,1022,O
it,1022,O
included,1022,O
microscopic,1022,O
tumors,1022,B-Disease
.,1022,O
Preliminary,1023,O
results,1023,O
indicate,1023,O
that,1023,O
testosterone-treated,1023,B-Chemical
LW,1023,O
rats,1023,O
that,1023,O
were,1023,O
fed,1023,O
the,1023,O
same,1023,O
diet,1023,O
",",1023,O
which,1023,O
was,1023,O
supplemented,1023,O
with,1023,O
corn,1023,O
oil,1023,O
up,1023,O
to,1023,O
20,1023,O
%,1023,O
fat,1023,O
",",1023,O
developed,1023,O
prostate,1023,B-Disease
cancer,1023,I-Disease
after,1023,O
intervals,1023,O
of,1023,O
6-12,1023,O
months,1023,O
.,1023,O
Aged,1024,O
GF,1024,O
Sprague-Dawley,1024,O
(,1024,O
SD,1024,O
),1024,O
rats,1024,O
have,1024,O
not,1024,O
developed,1024,O
prostate,1024,B-Disease
cancer,1024,I-Disease
spontaneously,1024,O
.,1024,O
Conventional,1025,O
SD,1025,O
rats,1025,O
fed,1025,O
diet,1025,O
L-485,1025,O
and,1025,O
treated,1025,O
with,1025,O
testosterone,1025,B-Chemical
developed,1025,O
only,1025,O
prostatitis,1025,B-Disease
.,1025,O
Experimental,1026,O
designs,1026,O
should,1026,O
consider,1026,O
genetic,1026,O
susceptibility,1026,O
as,1026,O
a,1026,O
basic,1026,O
prerequisite,1026,O
for,1026,O
studies,1026,O
on,1026,O
experimental,1026,O
prostate,1026,B-Disease
cancer,1026,I-Disease
.,1026,O
Time,1027,O
course,1027,O
alterations,1027,O
of,1027,O
QTC,1027,O
interval,1027,O
due,1027,O
to,1027,O
hypaque,1027,B-Chemical
76,1027,I-Chemical
.,1027,O
Sequential,1028,O
measurement,1028,O
of,1028,O
QT,1028,O
interval,1028,O
during,1028,O
left,1028,O
ventricular,1028,O
angiography,1028,O
was,1028,O
made,1028,O
30,1028,O
seconds,1028,O
and,1028,O
one,1028,O
",",1028,O
three,1028,O
",",1028,O
five,1028,O
and,1028,O
ten,1028,O
minutes,1028,O
after,1028,O
injection,1028,O
of,1028,O
hypaque,1028,B-Chemical
76,1028,I-Chemical
.,1028,O
The,1029,O
subjects,1029,O
were,1029,O
ten,1029,O
patients,1029,O
found,1029,O
to,1029,O
have,1029,O
normal,1029,O
left,1029,O
ventricles,1029,O
and,1029,O
coronary,1029,O
arteries,1029,O
.,1029,O
Significant,1030,O
QTC,1030,B-Disease
prolongation,1030,I-Disease
occurred,1030,O
in,1030,O
30,1030,O
seconds,1030,O
to,1030,O
one,1030,O
minute,1030,O
in,1030,O
association,1030,O
with,1030,O
marked,1030,O
hypotension,1030,B-Disease
and,1030,O
elevation,1030,O
of,1030,O
cardiac,1030,O
output,1030,O
.,1030,O
Rat,1031,O
extraocular,1031,O
muscle,1031,O
regeneration,1031,O
.,1031,O
Repair,1032,O
of,1032,O
local,1032,O
anesthetic-induced,1032,O
damage,1032,O
.,1032,O
Local,1033,O
anesthetics,1033,O
that,1033,O
are,1033,O
commonly,1033,O
used,1033,O
in,1033,O
ophthalmic,1033,O
surgery,1033,O
(,1033,O
0.75,1033,O
%,1033,O
bupivacaine,1033,B-Chemical
hydrochloride,1033,I-Chemical
",",1033,O
2.0,1033,O
%,1033,O
mepivacaine,1033,B-Chemical
hydrochloride,1033,I-Chemical
",",1033,O
and,1033,O
2.0,1033,O
%,1033,O
lidocaine,1033,B-Chemical
hydrochloride,1033,I-Chemical
plus,1033,O
"1:100,000",1033,O
epinephrine,1033,B-Chemical
),1033,O
were,1033,O
injected,1033,O
into,1033,O
the,1033,O
retrobulbar,1033,O
area,1033,O
of,1033,O
rat,1033,O
eyes,1033,O
.,1033,O
Controls,1034,O
were,1034,O
injected,1034,O
with,1034,O
physiological,1034,O
saline,1034,O
.,1034,O
All,1035,O
three,1035,O
anesthetics,1035,O
produced,1035,O
massive,1035,O
degeneration,1035,O
of,1035,O
the,1035,O
extraocular,1035,O
muscles,1035,O
.,1035,O
Muscle,1036,B-Disease
degeneration,1036,I-Disease
is,1036,O
followed,1036,O
by,1036,O
regeneration,1036,O
of,1036,O
the,1036,O
damaged,1036,O
muscle,1036,O
fibers,1036,O
.,1036,O
In,1037,O
addition,1037,O
to,1037,O
muscle,1037,B-Disease
damage,1037,I-Disease
",",1037,O
severe,1037,O
damage,1037,O
was,1037,O
also,1037,O
seen,1037,O
in,1037,O
harderian,1037,O
glands,1037,O
",",1037,O
especially,1037,O
after,1037,O
exposure,1037,O
to,1037,O
mepivacaine,1037,B-Chemical
and,1037,O
lidocaine,1037,B-Chemical
plus,1037,O
epinephrine,1037,B-Chemical
.,1037,O
With,1038,O
these,1038,O
findings,1038,O
in,1038,O
rats,1038,O
",",1038,O
it,1038,O
is,1038,O
hypothesized,1038,O
that,1038,O
the,1038,O
temporary,1038,O
diplopia,1038,B-Disease
sometimes,1038,O
seen,1038,O
in,1038,O
patients,1038,O
after,1038,O
ophthalmic,1038,O
surgery,1038,O
might,1038,O
be,1038,O
due,1038,O
to,1038,O
anesthetic-induced,1038,O
damage,1038,O
to,1038,O
the,1038,O
extraocular,1038,O
muscles,1038,O
.,1038,O
Gentamicin,1039,B-Chemical
nephropathy,1039,B-Disease
in,1039,O
a,1039,O
neonate,1039,O
.,1039,O
The,1040,O
clinical,1040,O
and,1040,O
autopsy,1040,O
findings,1040,O
in,1040,O
a,1040,O
premature,1040,O
baby,1040,O
who,1040,O
died,1040,O
of,1040,O
acute,1040,B-Disease
renal,1040,I-Disease
failure,1040,I-Disease
after,1040,O
therapy,1040,O
with,1040,O
gentamicin,1040,B-Chemical
(,1040,O
5,1040,O
mg/kg/day,1040,O
),1040,O
and,1040,O
penicillin,1040,B-Chemical
are,1040,O
presented,1040,O
.,1040,O
The,1041,O
serum,1041,O
gentamicin,1041,B-Chemical
concentration,1041,O
had,1041,O
reached,1041,O
toxic,1041,O
levels,1041,O
when,1041,O
anuria,1041,B-Disease
developed,1041,O
.,1041,O
Numerous,1042,O
periodic,1042,B-Chemical
acid,1042,I-Chemical
Schiff,1042,O
(,1042,O
PAS,1042,O
),1042,O
positive,1042,O
",",1042,O
diastase,1042,O
resistant,1042,O
cytoplasmic,1042,O
inclusion,1042,O
bodies,1042,O
which,1042,O
appeared,1042,O
as,1042,O
myelin,1042,O
figures,1042,O
in,1042,O
cytosegresomes,1042,O
under,1042,O
the,1042,O
electron,1042,O
microscope,1042,O
were,1042,O
identified,1042,O
in,1042,O
the,1042,O
proximal,1042,O
convoluted,1042,O
tubules,1042,O
.,1042,O
The,1043,O
pathological,1043,O
changes,1043,O
induced,1043,O
by,1043,O
gentamicin,1043,B-Chemical
in,1043,O
the,1043,O
human,1043,O
neonatal,1043,O
kidneys,1043,O
have,1043,O
not,1043,O
been,1043,O
previously,1043,O
reported,1043,O
.,1043,O
Induction,1044,O
by,1044,O
paracetamol,1044,B-Chemical
of,1044,O
bladder,1044,O
and,1044,O
liver,1044,O
tumours,1044,O
in,1044,O
the,1044,O
rat,1044,O
.,1044,O
Effects,1045,O
on,1045,O
hepatocyte,1045,O
fine,1045,O
structure,1045,O
.,1045,O
Groups,1046,O
of,1046,O
male,1046,O
and,1046,O
female,1046,O
inbred,1046,O
Leeds,1046,O
strain,1046,O
rats,1046,O
were,1046,O
fed,1046,O
diets,1046,O
containing,1046,O
either,1046,O
0.5,1046,O
%,1046,O
or,1046,O
1.0,1046,O
%,1046,O
paracetamol,1046,B-Chemical
by,1046,O
weight,1046,O
for,1046,O
up,1046,O
to,1046,O
18,1046,O
months,1046,O
.,1046,O
At,1047,O
the,1047,O
1.0,1047,O
%,1047,O
dosage,1047,O
level,1047,O
",",1047,O
20,1047,O
%,1047,O
of,1047,O
rats,1047,O
of,1047,O
both,1047,O
sexes,1047,O
developed,1047,O
neoplastic,1047,O
nodules,1047,O
of,1047,O
the,1047,O
liver,1047,O
",",1047,O
a,1047,O
statistically,1047,O
significant,1047,O
incidence,1047,O
.,1047,O
These,1048,O
rats,1048,O
also,1048,O
showed,1048,O
gross,1048,O
enlargement,1048,O
of,1048,O
their,1048,O
livers,1048,O
and,1048,O
an,1048,O
increase,1048,O
in,1048,O
foci,1048,O
of,1048,O
cellular,1048,O
alteration,1048,O
",",1048,O
the,1048,O
latter,1048,O
also,1048,O
being,1048,O
observed,1048,O
in,1048,O
the,1048,O
low,1048,O
dosage,1048,O
male,1048,O
rats,1048,O
.,1048,O
Papillomas,1049,B-Disease
of,1049,O
the,1049,O
transitional,1049,O
epithelium,1049,O
of,1049,O
the,1049,O
bladder,1049,O
developed,1049,O
in,1049,O
all,1049,O
paracetamol-treated,1049,B-Chemical
groups,1049,O
",",1049,O
and,1049,O
three,1049,O
rats,1049,O
bore,1049,O
bladder,1049,B-Disease
carcinomas,1049,I-Disease
.,1049,O
However,1050,O
",",1050,O
significant,1050,O
yields,1050,O
of,1050,O
bladder,1050,B-Disease
tumours,1050,I-Disease
were,1050,O
only,1050,O
obtained,1050,O
from,1050,O
low,1050,O
dosage,1050,O
females,1050,O
and,1050,O
high,1050,O
dosage,1050,O
males,1050,O
.,1050,O
Additionally,1051,O
",",1051,O
20,1051,O
to,1051,O
25,1051,O
%,1051,O
of,1051,O
paracetamol-treated,1051,B-Chemical
rats,1051,O
developed,1051,O
hyperplasia,1051,B-Disease
of,1051,O
the,1051,O
bladder,1051,O
epithelium,1051,O
",",1051,O
which,1051,O
was,1051,O
not,1051,O
coincident,1051,O
with,1051,O
the,1051,O
presence,1051,O
of,1051,O
bladder,1051,B-Disease
calculi,1051,I-Disease
.,1051,O
A,1052,O
low,1052,O
yield,1052,O
of,1052,O
tumours,1052,B-Disease
at,1052,O
various,1052,O
other,1052,O
sites,1052,O
also,1052,O
arose,1052,O
following,1052,O
paracetamol,1052,B-Chemical
feeding,1052,O
.,1052,O
An,1053,O
electron,1053,O
microscope,1053,O
study,1053,O
of,1053,O
the,1053,O
livers,1053,O
of,1053,O
paracetamol-treated,1053,B-Chemical
rats,1053,O
revealed,1053,O
ultrastructural,1053,O
changes,1053,O
in,1053,O
the,1053,O
hepatocytes,1053,O
that,1053,O
resemble,1053,O
those,1053,O
that,1053,O
result,1053,O
from,1053,O
exposure,1053,O
to,1053,O
a,1053,O
variety,1053,O
of,1053,O
known,1053,O
hepatocarcinogens,1053,B-Disease
.,1053,O
Pharmacology,1054,O
of,1054,O
GYKI-41,1054,B-Chemical
099,1054,I-Chemical
(,1054,O
chlorpropanol,1054,B-Chemical
",",1054,O
Tobanum,1054,B-Chemical
),1054,O
a,1054,O
new,1054,O
potent,1054,O
beta-adrenergic,1054,O
antagonist,1054,O
.,1054,O
The,1055,O
compound,1055,O
GYKI-41,1055,B-Chemical
099,1055,I-Chemical
",",1055,O
as,1055,O
a,1055,O
beta-adrenergic,1055,O
antagonist,1055,O
",",1055,O
is,1055,O
3-8,1055,O
times,1055,O
more,1055,O
potent,1055,O
than,1055,O
propranolol,1055,B-Chemical
in,1055,O
vitro,1055,O
and,1055,O
in,1055,O
vivo,1055,O
.,1055,O
Its,1056,O
antiarrhythmic,1056,O
effectiveness,1056,O
surpasses,1056,O
that,1056,O
of,1056,O
propranolol,1056,B-Chemical
and,1056,O
pindolol,1056,B-Chemical
inhibiting,1056,O
the,1056,O
ouabain,1056,B-Chemical
arrhythmia,1056,B-Disease
in,1056,O
dogs,1056,O
and,1056,O
cats,1056,O
.,1056,O
GYKI-41,1057,B-Chemical
900,1057,I-Chemical
has,1057,O
a,1057,O
negligible,1057,O
cardiodepressant,1057,O
activity,1057,O
;,1057,O
it,1057,O
is,1057,O
not,1057,O
cardioselective,1057,O
.,1057,O
The,1058,O
compound,1058,O
shows,1058,O
a,1058,O
rapid,1058,O
and,1058,O
long,1058,O
lasting,1058,O
effect,1058,O
.,1058,O
There,1059,O
was,1059,O
a,1059,O
prolonged,1059,O
elimination,1059,O
of,1059,O
the,1059,O
radioactivity,1059,O
after,1059,O
the,1059,O
injection,1059,O
of,1059,O
14C-41,1059,B-Chemical
099,1059,I-Chemical
to,1059,O
rats,1059,O
and,1059,O
dogs,1059,O
.,1059,O
The,1060,O
half,1060,O
life,1060,O
of,1060,O
the,1060,O
unlabeled,1060,O
substance,1060,O
in,1060,O
humans,1060,O
was,1060,O
more,1060,O
than,1060,O
10,1060,O
hours,1060,O
.,1060,O
Adverse,1061,O
reactions,1061,O
to,1061,O
bendrofluazide,1061,B-Chemical
and,1061,O
propranolol,1061,B-Chemical
for,1061,O
the,1061,O
treatment,1061,O
of,1061,O
mild,1061,O
hypertension,1061,B-Disease
.,1061,O
Report,1062,O
of,1062,O
Medical,1062,O
Research,1062,O
Council,1062,O
Working,1062,O
Party,1062,O
on,1062,O
Mild,1062,O
to,1062,O
Moderate,1062,O
Hypertension,1062,B-Disease
.,1062,O
Participants,1063,O
in,1063,O
the,1063,O
Medical,1063,O
Research,1063,O
Council,1063,O
treatment,1063,O
trial,1063,O
for,1063,O
mild,1063,O
hypertension,1063,B-Disease
are,1063,O
randomly,1063,O
allocated,1063,O
to,1063,O
one,1063,O
of,1063,O
four,1063,O
treatment,1063,O
groups,1063,O
:,1063,O
bendrofluazide,1063,B-Chemical
",",1063,O
propranolol,1063,B-Chemical
",",1063,O
or,1063,O
a,1063,O
placebo,1063,O
for,1063,O
either,1063,O
of,1063,O
these,1063,O
drugs,1063,O
.,1063,O
The,1064,O
trial,1064,O
is,1064,O
single-blind,1064,O
.,1064,O
23,1065,O
582,1065,O
patient-years,1065,O
of,1065,O
observation,1065,O
have,1065,O
been,1065,O
completed,1065,O
so,1065,O
far,1065,O
",",1065,O
10,1065,O
684,1065,O
on,1065,O
active,1065,O
drugs,1065,O
and,1065,O
12,1065,O
898,1065,O
on,1065,O
placebos,1065,O
.,1065,O
The,1066,O
results,1066,O
show,1066,O
an,1066,O
association,1066,O
between,1066,O
bendrofluazide,1066,B-Chemical
treatment,1066,O
and,1066,O
impotence,1066,B-Disease
",",1066,O
and,1066,O
impotence,1066,B-Disease
also,1066,O
occurred,1066,O
more,1066,O
frequently,1066,O
in,1066,O
patients,1066,O
taking,1066,O
propranolol,1066,B-Chemical
than,1066,O
in,1066,O
those,1066,O
taking,1066,O
placebos,1066,O
.,1066,O
Other,1067,O
adverse,1067,O
reactions,1067,O
significantly,1067,O
linked,1067,O
with,1067,O
active,1067,O
drugs,1067,O
include,1067,O
impaired,1067,B-Disease
glucose,1067,I-Disease
tolerance,1067,I-Disease
in,1067,O
men,1067,O
and,1067,O
women,1067,O
and,1067,O
gout,1067,B-Disease
in,1067,O
men,1067,O
",",1067,O
associated,1067,O
with,1067,O
bendrofluazide,1067,B-Chemical
treatment,1067,O
",",1067,O
and,1067,O
Raynaud,1067,B-Disease
's,1067,I-Disease
phenomenon,1067,I-Disease
and,1067,O
dyspnoea,1067,B-Disease
in,1067,O
men,1067,O
and,1067,O
women,1067,O
taking,1067,O
propranolol,1067,B-Chemical
.,1067,O
No,1068,O
corneal,1068,B-Disease
disease,1068,I-Disease
is,1068,O
known,1068,O
to,1068,O
have,1068,O
occurred,1068,O
in,1068,O
the,1068,O
propranolol,1068,B-Chemical
group,1068,O
.,1068,O
Mean,1069,O
serum,1069,O
potassium,1069,B-Chemical
level,1069,O
fell,1069,O
",",1069,O
and,1069,O
urea,1069,B-Chemical
and,1069,O
uric,1069,B-Chemical
acid,1069,I-Chemical
levels,1069,O
rose,1069,O
",",1069,O
in,1069,O
men,1069,O
and,1069,O
women,1069,O
taking,1069,O
bendrofluazide,1069,B-Chemical
.,1069,O
In,1070,O
the,1070,O
propranolol,1070,B-Chemical
group,1070,O
",",1070,O
serum,1070,O
potassium,1070,B-Chemical
and,1070,O
uric,1070,B-Chemical
acid,1070,I-Chemical
levels,1070,O
rose,1070,O
in,1070,O
both,1070,O
sexes,1070,O
",",1070,O
but,1070,O
the,1070,O
urea,1070,B-Chemical
level,1070,O
rose,1070,O
significantly,1070,O
in,1070,O
women,1070,O
only,1070,O
.,1070,O
Serotonergic,1071,O
drugs,1071,O
",",1071,O
benzodiazepines,1071,B-Chemical
and,1071,O
baclofen,1071,B-Chemical
block,1071,O
muscimol-induced,1071,B-Chemical
myoclonic,1071,B-Disease
jerks,1071,I-Disease
in,1071,O
a,1071,O
strain,1071,O
of,1071,O
mice,1071,O
.,1071,O
In,1072,O
male,1072,O
Swiss,1072,O
mice,1072,O
",",1072,O
muscimol,1072,B-Chemical
produced,1072,O
myoclonic,1072,B-Disease
jerks,1072,I-Disease
.,1072,O
A,1073,O
3,1073,O
mg/kg,1073,O
(,1073,O
i.p,1073,O
.,1073,O
),1073,O
dose,1074,O
induced,1074,O
this,1074,O
response,1074,O
in,1074,O
all,1074,O
of,1074,O
the,1074,O
mice,1074,O
tested,1074,O
and,1074,O
the,1074,O
peak,1074,O
response,1074,O
of,1074,O
73,1074,O
jerks,1074,O
per,1074,O
min,1074,O
was,1074,O
observed,1074,O
between,1074,O
27,1074,O
and,1074,O
45,1074,O
min,1074,O
.,1074,O
Increasing,1075,O
the,1075,O
brain,1075,O
serotonin,1075,B-Chemical
levels,1075,O
by,1075,O
the,1075,O
administration,1075,O
of,1075,O
5-hydroxytryptophan,1075,B-Chemical
(,1075,O
80-160,1075,O
mg/kg,1075,O
),1075,O
in,1075,O
combination,1075,O
with,1075,O
a,1075,O
peripheral,1075,O
decarboxylase,1075,O
inhibitor,1075,O
resulted,1075,O
in,1075,O
an,1075,O
inhibition,1075,O
of,1075,O
the,1075,O
muscimol,1075,B-Chemical
effect,1075,O
.,1075,O
However,1076,O
",",1076,O
in,1076,O
a,1076,O
similar,1076,O
experiment,1076,O
l-dopa,1076,B-Chemical
(,1076,O
80-160,1076,O
mg/kg,1076,O
),1076,O
was,1076,O
without,1076,O
effect,1076,O
.,1076,O
In,1077,O
doses,1077,O
of,1077,O
3-10,1077,O
mg/kg,1077,O
",",1077,O
the,1077,O
serotonin,1077,B-Chemical
receptor,1077,O
agonist,1077,O
MK-212,1077,B-Chemical
caused,1077,O
a,1077,O
dose-dependent,1077,O
blockade,1077,O
of,1077,O
the,1077,O
response,1077,O
of,1077,O
muscimol,1077,B-Chemical
.,1077,O
Of,1078,O
the,1078,O
benzodiazepines,1078,B-Chemical
",",1078,O
clonazepam,1078,B-Chemical
(,1078,O
0.1-0.3,1078,O
mg/kg,1078,O
),1078,O
was,1078,O
found,1078,O
to,1078,O
be,1078,O
several,1078,O
fold,1078,O
more,1078,O
potent,1078,O
than,1078,O
diazepam,1078,B-Chemical
(,1078,O
0.3-3,1078,O
mg/kg,1078,O
),1078,O
in,1078,O
blocking,1078,O
the,1078,O
myoclonic,1078,B-Disease
jerks,1078,I-Disease
.,1078,O
While,1079,O
(,1079,O
-,1079,O
),1079,O
-baclofen,1079,O
(,1079,O
1-3,1079,O
mg/kg,1079,O
),1079,O
proved,1079,O
to,1079,O
be,1079,O
an,1079,O
effective,1079,O
antagonist,1079,O
of,1079,O
muscimol,1079,B-Chemical
",",1079,O
its,1079,O
(,1079,O
+,1079,O
),1079,O
-isomer,1079,O
(,1079,O
5-20,1079,O
mg/kg,1079,O
),1079,O
lacked,1079,O
this,1079,O
property,1079,O
.,1079,O
Considering,1080,O
the,1080,O
fact,1080,O
that,1080,O
5-HTP,1080,B-Chemical
and,1080,O
the,1080,O
benzodiazepines,1080,B-Chemical
have,1080,O
been,1080,O
found,1080,O
to,1080,O
be,1080,O
beneficial,1080,O
in,1080,O
the,1080,O
management,1080,O
of,1080,O
clinical,1080,O
myoclonus,1080,B-Disease
",",1080,O
the,1080,O
muscimol-induced,1080,B-Chemical
myoclonus,1080,B-Disease
seems,1080,O
to,1080,O
be,1080,O
a,1080,O
satisfactory,1080,O
animal,1080,O
model,1080,O
that,1080,O
may,1080,O
prove,1080,O
useful,1080,O
for,1080,O
the,1080,O
development,1080,O
of,1080,O
new,1080,O
drug,1080,O
treatments,1080,O
for,1080,O
this,1080,O
condition,1080,O
.,1080,O
Our,1081,O
present,1081,O
study,1081,O
indicated,1081,O
the,1081,O
possible,1081,O
value,1081,O
of,1081,O
MK-212,1081,B-Chemical
and,1081,O
(,1081,O
-,1081,O
),1081,O
-baclofen,1081,O
in,1081,O
the,1081,O
management,1081,O
of,1081,O
clinical,1081,O
myoclonus,1081,B-Disease
.,1081,O
Adverse,1082,O
interaction,1082,O
between,1082,O
beta-adrenergic,1082,B-Chemical
blocking,1082,I-Chemical
drugs,1082,I-Chemical
and,1082,O
verapamil,1082,B-Chemical
--,1082,O
report,1082,O
of,1082,O
three,1082,O
cases,1082,O
.,1082,O
Three,1083,O
patients,1083,O
with,1083,O
ischaemic,1083,B-Disease
heart,1083,I-Disease
disease,1083,I-Disease
developed,1083,O
profound,1083,O
cardiac,1083,B-Disease
failure,1083,I-Disease
",",1083,O
hypotension,1083,B-Disease
and,1083,O
bradycardia,1083,B-Disease
during,1083,O
combined,1083,O
therapy,1083,O
with,1083,O
verapamil,1083,B-Chemical
and,1083,O
beta-adrenergic,1083,B-Chemical
blocking,1083,I-Chemical
drugs,1083,I-Chemical
.,1083,O
This,1084,O
clinical,1084,O
picture,1084,O
resolved,1084,O
completely,1084,O
with,1084,O
cessation,1084,O
of,1084,O
the,1084,O
combined,1084,O
therapy,1084,O
.,1084,O
Baseline,1085,O
left,1085,O
ventricular,1085,O
function,1085,O
",",1085,O
assessed,1085,O
by,1085,O
cardiac,1085,O
catheterisation,1085,O
or,1085,O
nuclear,1085,O
angiography,1085,O
",",1085,O
was,1085,O
normal,1085,O
in,1085,O
two,1085,O
patients,1085,O
and,1085,O
only,1085,O
mildly,1085,O
reduced,1085,O
in,1085,O
the,1085,O
other,1085,O
.,1085,O
Simultaneously,1086,O
administration,1086,O
of,1086,O
beta-adrenergic,1086,B-Chemical
blocking,1086,I-Chemical
drugs,1086,I-Chemical
and,1086,O
verapamil,1086,B-Chemical
may,1086,O
result,1086,O
in,1086,O
profound,1086,O
adverse,1086,O
interactions,1086,O
and,1086,O
should,1086,O
only,1086,O
be,1086,O
administered,1086,O
with,1086,O
great,1086,O
caution,1086,O
.,1086,O
Comparison,1087,O
of,1087,O
the,1087,O
effectiveness,1087,O
of,1087,O
ranitidine,1087,B-Chemical
and,1087,O
cimetidine,1087,B-Chemical
in,1087,O
inhibiting,1087,O
acid,1087,O
secretion,1087,O
in,1087,O
patients,1087,O
with,1087,O
gastric,1087,O
hypersecretory,1087,O
states,1087,O
.,1087,O
The,1088,O
H2-histamine,1088,O
receptor,1088,O
antagonists,1088,O
ranitidine,1088,B-Chemical
and,1088,O
cimetidine,1088,B-Chemical
were,1088,O
compared,1088,O
for,1088,O
their,1088,O
abilities,1088,O
to,1088,O
control,1088,O
gastric,1088,O
acid,1088,O
hypersecretion,1088,O
on,1088,O
a,1088,O
short-,1088,O
and,1088,O
long-term,1088,O
basis,1088,O
in,1088,O
22,1088,O
patients,1088,O
with,1088,O
gastric,1088,O
acid,1088,O
hypersecretory,1088,O
states,1088,O
.,1088,O
Nineteen,1089,O
patients,1089,O
had,1089,O
Zollinger-Ellison,1089,B-Disease
syndrome,1089,I-Disease
",",1089,O
one,1089,O
patient,1089,O
had,1089,O
systemic,1089,B-Disease
mastocytosis,1089,I-Disease
",",1089,O
and,1089,O
two,1089,O
patients,1089,O
had,1089,O
idiopathic,1089,O
hypersecretion,1089,O
.,1089,O
The,1090,O
rates,1090,O
of,1090,O
onset,1090,O
of,1090,O
the,1090,O
action,1090,O
of,1090,O
cimetidine,1090,B-Chemical
and,1090,O
ranitidine,1090,B-Chemical
were,1090,O
the,1090,O
same,1090,O
.,1090,O
The,1091,O
actions,1091,O
of,1091,O
both,1091,O
drugs,1091,O
were,1091,O
increased,1091,O
by,1091,O
anticholinergic,1091,O
agents,1091,O
",",1091,O
and,1091,O
there,1091,O
was,1091,O
a,1091,O
close,1091,O
correlation,1091,O
between,1091,O
the,1091,O
daily,1091,O
maintenance,1091,O
dose,1091,O
of,1091,O
each,1091,O
drug,1091,O
needed,1091,O
to,1091,O
control,1091,O
acid,1091,O
secretion,1091,O
.,1091,O
However,1092,O
",",1092,O
ranitidine,1092,B-Chemical
was,1092,O
threefold,1092,O
more,1092,O
potent,1092,O
than,1092,O
cimetidine,1092,B-Chemical
both,1092,O
in,1092,O
acute,1092,O
inhibition,1092,O
studies,1092,O
and,1092,O
in,1092,O
the,1092,O
median,1092,O
maintenance,1092,O
dose,1092,O
needed,1092,O
(,1092,O
1.2,1092,O
g,1092,O
per,1092,O
day,1092,O
for,1092,O
ranitidine,1092,B-Chemical
and,1092,O
3.6,1092,O
g,1092,O
per,1092,O
day,1092,O
for,1092,O
cimetidine,1092,B-Chemical
),1092,O
.,1092,O
Sixty,1093,O
percent,1093,O
of,1093,O
the,1093,O
males,1093,O
developed,1093,O
breast,1093,O
changes,1093,O
or,1093,O
impotence,1093,B-Disease
while,1093,O
taking,1093,O
cimetidine,1093,B-Chemical
and,1093,O
in,1093,O
all,1093,O
cases,1093,O
these,1093,O
changes,1093,O
disappeared,1093,O
when,1093,O
cimetidine,1093,B-Chemical
was,1093,O
replaced,1093,O
by,1093,O
ranitidine,1093,B-Chemical
.,1093,O
Treatment,1094,O
with,1094,O
high,1094,O
doses,1094,O
of,1094,O
cimetidine,1094,B-Chemical
(,1094,O
one,1094,O
to,1094,O
60,1094,O
months,1094,O
;,1094,O
median,1094,O
",",1094,O
11,1094,O
months,1094,O
),1094,O
or,1094,O
ranitidine,1094,B-Chemical
(,1094,O
two,1094,O
to,1094,O
31,1094,O
months,1094,O
;,1094,O
median,1094,O
",",1094,O
14,1094,O
months,1094,O
),1094,O
was,1094,O
not,1094,O
associated,1094,O
with,1094,O
hepatic,1094,O
or,1094,O
hematologic,1094,O
toxicity,1094,O
or,1094,O
alterations,1094,O
of,1094,O
serum,1094,O
gastrin,1094,O
concentrations,1094,O
",",1094,O
but,1094,O
ranitidine,1094,B-Chemical
therapy,1094,O
was,1094,O
associated,1094,O
with,1094,O
a,1094,O
significantly,1094,O
lower,1094,O
serum,1094,O
creatinine,1094,B-Chemical
level,1094,O
than,1094,O
seen,1094,O
with,1094,O
cimetidine,1094,B-Chemical
therapy,1094,O
.,1094,O
The,1095,O
results,1095,O
show,1095,O
that,1095,O
both,1095,O
drugs,1095,O
can,1095,O
adequately,1095,O
inhibit,1095,O
acid,1095,O
secretion,1095,O
in,1095,O
patients,1095,O
with,1095,O
gastric,1095,O
hypersecretory,1095,O
states,1095,O
.,1095,O
Both,1096,O
are,1096,O
safe,1096,O
at,1096,O
high,1096,O
doses,1096,O
",",1096,O
but,1096,O
ranitidine,1096,B-Chemical
is,1096,O
threefold,1096,O
more,1096,O
potent,1096,O
and,1096,O
does,1096,O
not,1096,O
cause,1096,O
the,1096,O
antiandrogen,1096,O
side,1096,O
effects,1096,O
frequently,1096,O
seen,1096,O
with,1096,O
high,1096,O
doses,1096,O
of,1096,O
cimetidine,1096,B-Chemical
.,1096,O
Epileptogenic,1097,O
properties,1097,O
of,1097,O
enflurane,1097,B-Chemical
and,1097,O
their,1097,O
clinical,1097,O
interpretation,1097,O
.,1097,O
Three,1098,O
cases,1098,O
of,1098,O
EEG,1098,O
changes,1098,O
induced,1098,O
by,1098,O
single,1098,O
exposure,1098,O
to,1098,O
enflurane,1098,B-Chemical
anesthesia,1098,O
are,1098,O
reported,1098,O
.,1098,O
In,1099,O
one,1099,O
patient,1099,O
",",1099,O
enflurane,1099,B-Chemical
administered,1099,O
during,1099,O
a,1099,O
donor,1099,O
nephrectomy,1099,O
resulted,1099,O
in,1099,O
unexpected,1099,O
partial,1099,O
motor,1099,O
seizures,1099,B-Disease
.,1099,O
Until,1100,O
the,1100,O
cause,1100,O
of,1100,O
the,1100,O
seizures,1100,B-Disease
was,1100,O
correctly,1100,O
identified,1100,O
",",1100,O
the,1100,O
patient,1100,O
was,1100,O
inappropriately,1100,O
treated,1100,O
with,1100,O
anticonvulsants,1100,O
.,1100,O
Two,1101,O
other,1101,O
patients,1101,O
suffered,1101,O
from,1101,O
partial,1101,O
",",1101,O
complex,1101,O
and,1101,O
generalized,1101,O
seizures,1101,B-Disease
uncontrolled,1101,O
by,1101,O
medication,1101,O
.,1101,O
Epileptic,1102,B-Disease
foci,1102,O
delineated,1102,O
and,1102,O
activated,1102,O
by,1102,O
enflurane,1102,B-Chemical
were,1102,O
surgically,1102,O
ablated,1102,O
and,1102,O
the,1102,O
patients,1102,O
are,1102,O
now,1102,O
seizure-free,1102,B-Disease
.,1102,O
Previous,1103,O
exposures,1103,O
to,1103,O
enflurane,1103,B-Chemical
have,1103,O
to,1103,O
be,1103,O
disclosed,1103,O
to,1103,O
avoid,1103,O
mistakes,1103,O
in,1103,O
clinical,1103,O
interpretation,1103,O
of,1103,O
the,1103,O
EEG,1103,O
.,1103,O
On,1104,O
the,1104,O
other,1104,O
hand,1104,O
",",1104,O
enflurane,1104,B-Chemical
may,1104,O
prove,1104,O
to,1104,O
be,1104,O
a,1104,O
safe,1104,O
fast,1104,O
acting,1104,O
activator,1104,O
of,1104,O
epileptic,1104,B-Disease
foci,1104,O
during,1104,O
corticography,1104,O
or,1104,O
depth,1104,O
electrode,1104,O
intraoperative,1104,O
recordings,1104,O
.,1104,O
Development,1105,O
of,1105,O
isoproterenol-induced,1105,B-Chemical
cardiac,1105,B-Disease
hypertrophy,1105,I-Disease
.,1105,O
The,1106,O
development,1106,O
of,1106,O
cardiac,1106,B-Disease
hypertrophy,1106,I-Disease
was,1106,O
studied,1106,O
in,1106,O
adult,1106,O
female,1106,O
Wistar,1106,O
rats,1106,O
following,1106,O
daily,1106,O
subcutaneous,1106,O
injections,1106,O
of,1106,O
isoproterenol,1106,B-Chemical
(,1106,O
ISO,1106,B-Chemical
),1106,O
(,1106,O
0.3,1106,O
mg/kg,1106,O
body,1106,O
weight,1106,O
),1106,O
.,1106,O
A,1107,O
time,1107,O
course,1107,O
was,1107,O
established,1107,O
for,1107,O
the,1107,O
change,1107,O
in,1107,O
tissue,1107,O
mass,1107,O
",",1107,O
RNA,1107,O
and,1107,O
DNA,1107,O
content,1107,O
",",1107,O
as,1107,O
well,1107,O
as,1107,O
hydroxyproline,1107,B-Chemical
content,1107,O
.,1107,O
Heart,1108,O
weight,1108,O
increased,1108,O
44,1108,O
%,1108,O
after,1108,O
8,1108,O
days,1108,O
of,1108,O
treatment,1108,O
with,1108,O
a,1108,O
half,1108,O
time,1108,O
of,1108,O
3.4,1108,O
days,1108,O
.,1108,O
Ventricular,1109,O
RNA,1109,O
content,1109,O
was,1109,O
elevated,1109,O
26,1109,O
%,1109,O
after,1109,O
24,1109,O
h,1109,O
of,1109,O
a,1109,O
single,1109,O
injection,1109,O
and,1109,O
reached,1109,O
a,1109,O
maximal,1109,O
level,1109,O
following,1109,O
8,1109,O
days,1109,O
of,1109,O
therapy,1109,O
.,1109,O
The,1110,O
half,1110,O
time,1110,O
for,1110,O
RNA,1110,O
accumulation,1110,O
was,1110,O
2.0,1110,O
days,1110,O
.,1110,O
The,1111,O
total,1111,O
content,1111,O
of,1111,O
hydroxyproline,1111,B-Chemical
remained,1111,O
stable,1111,O
during,1111,O
the,1111,O
first,1111,O
2,1111,O
days,1111,O
of,1111,O
treatment,1111,O
but,1111,O
increased,1111,O
46,1111,O
%,1111,O
after,1111,O
4,1111,O
days,1111,O
of,1111,O
therapy,1111,O
.,1111,O
Ventricular,1112,O
DNA,1112,O
content,1112,O
was,1112,O
unchanged,1112,O
during,1112,O
the,1112,O
early,1112,O
stage,1112,O
(,1112,O
1-4,1112,O
days,1112,O
),1112,O
of,1112,O
hypertrophic,1112,B-Disease
growth,1112,O
but,1112,O
increased,1112,O
to,1112,O
a,1112,O
new,1112,O
steady-state,1112,O
level,1112,O
19,1112,O
%,1112,O
above,1112,O
the,1112,O
controls,1112,O
after,1112,O
8,1112,O
days,1112,O
of,1112,O
treatment,1112,O
.,1112,O
Intraventricular,1113,O
pressures,1113,O
and,1113,O
coronary,1113,O
flow,1113,O
measures,1113,O
were,1113,O
similar,1113,O
for,1113,O
control,1113,O
and,1113,O
experimental,1113,O
animals,1113,O
following,1113,O
4,1113,O
days,1113,O
of,1113,O
developed,1113,O
hypertrophy,1113,B-Disease
.,1113,O
However,1114,O
",",1114,O
dP/dt,1114,O
in,1114,O
the,1114,O
ISO-treated,1114,B-Chemical
hearts,1114,O
was,1114,O
slightly,1114,O
but,1114,O
significantly,1114,O
(,1114,O
P,1114,O
less,1114,O
than,1114,O
0.05,1114,O
),1114,O
elevated,1114,O
.,1114,O
These,1115,O
data,1115,O
indicate,1115,O
that,1115,O
the,1115,O
adaptive,1115,O
response,1115,O
to,1115,O
ISO,1115,B-Chemical
shows,1115,O
an,1115,O
early,1115,O
hypertrophic,1115,B-Disease
phase,1115,O
(,1115,O
1-4,1115,O
days,1115,O
),1115,O
characterized,1115,O
by,1115,O
a,1115,O
substantial,1115,O
increase,1115,O
in,1115,O
RNA,1115,O
content,1115,O
and,1115,O
cardiac,1115,O
mass,1115,O
in,1115,O
the,1115,O
absence,1115,O
of,1115,O
changes,1115,O
in,1115,O
DNA,1115,O
.,1115,O
However,1116,O
",",1116,O
prolonged,1116,O
stimulation,1116,O
(,1116,O
8-12,1116,O
days,1116,O
),1116,O
appears,1116,O
to,1116,O
represent,1116,O
a,1116,O
complex,1116,O
integration,1116,O
of,1116,O
both,1116,O
cellular,1116,O
hypertrophy,1116,B-Disease
and,1116,O
hyperplasia,1116,B-Disease
within,1116,O
the,1116,O
heart,1116,O
.,1116,O
Multiple,1117,O
side,1117,O
effects,1117,O
of,1117,O
penicillamine,1117,B-Chemical
therapy,1117,O
in,1117,O
one,1117,O
patient,1117,O
with,1117,O
rheumatoid,1117,B-Disease
arthritis,1117,I-Disease
.,1117,O
Skin,1118,B-Disease
rashes,1118,I-Disease
",",1118,O
proteinuria,1118,B-Disease
",",1118,O
systemic,1118,B-Disease
lupus,1118,I-Disease
erythematosus,1118,I-Disease
",",1118,O
polymyositis,1118,B-Disease
and,1118,O
myasthenia,1118,B-Disease
gravis,1118,I-Disease
have,1118,O
all,1118,O
been,1118,O
recorded,1118,O
as,1118,O
complications,1118,O
of,1118,O
penicillamine,1118,B-Chemical
therapy,1118,O
in,1118,O
patients,1118,O
with,1118,O
rheumatoid,1118,B-Disease
arthritis,1118,I-Disease
.,1118,O
A,1119,O
patient,1119,O
who,1119,O
had,1119,O
developed,1119,O
all,1119,O
5,1119,O
is,1119,O
now,1119,O
described,1119,O
.,1119,O
The,1120,O
skin,1120,B-Disease
lesion,1120,I-Disease
resembled,1120,O
elastosis,1120,B-Disease
perforans,1120,I-Disease
serpiginosa,1120,I-Disease
",",1120,O
which,1120,O
has,1120,O
been,1120,O
reported,1120,O
as,1120,O
a,1120,O
rare,1120,O
side,1120,O
effect,1120,O
in,1120,O
patients,1120,O
with,1120,O
Wilson,1120,B-Disease
's,1120,I-Disease
disease,1120,I-Disease
but,1120,O
not,1120,O
in,1120,O
patients,1120,O
with,1120,O
rheumatoid,1120,B-Disease
arthritis,1120,I-Disease
treated,1120,O
with,1120,O
penicillamine,1120,B-Chemical
.,1120,O
Doxorubicin,1121,B-Chemical
cardiomyopathy,1121,B-Disease
in,1121,O
children,1121,O
with,1121,O
left-sided,1121,O
Wilms,1121,B-Disease
tumor,1121,I-Disease
.,1121,O
Two,1122,O
children,1122,O
with,1122,O
Wilms,1122,B-Disease
tumor,1122,I-Disease
of,1122,O
the,1122,O
left,1122,O
kidney,1122,O
experienced,1122,O
severe,1122,O
anthracycline,1122,B-Chemical
cardiomyopathy,1122,B-Disease
after,1122,O
irradiation,1122,O
to,1122,O
the,1122,O
tumor,1122,B-Disease
bed,1122,O
and,1122,O
conventional,1122,O
dosage,1122,O
of,1122,O
doxorubicin,1122,B-Chemical
.,1122,O
The,1123,O
cardiomyopathy,1123,B-Disease
is,1123,O
attributed,1123,O
1,1123,O
),1123,O
to,1123,O
the,1123,O
fact,1123,O
that,1123,O
radiation,1123,O
fields,1123,O
for,1123,O
left,1123,O
Wilms,1123,B-Disease
tumor,1123,I-Disease
include,1123,O
the,1123,O
lower,1123,O
portion,1123,O
of,1123,O
the,1123,O
heart,1123,O
and,1123,O
2,1123,O
),1123,O
to,1123,O
the,1123,O
interaction,1123,O
of,1123,O
doxorubicin,1123,B-Chemical
and,1123,O
irradiation,1123,O
on,1123,O
cardiac,1123,O
muscle,1123,O
.,1123,O
It,1124,O
is,1124,O
recommended,1124,O
that,1124,O
doxorubicin,1124,B-Chemical
dosage,1124,O
be,1124,O
sharply,1124,O
restricted,1124,O
in,1124,O
children,1124,O
with,1124,O
Wilms,1124,B-Disease
tumor,1124,I-Disease
of,1124,O
the,1124,O
left,1124,O
kidney,1124,O
who,1124,O
receive,1124,O
postoperative,1124,O
irradiation,1124,O
.,1124,O
Effects,1125,O
of,1125,O
calcitonin,1125,O
on,1125,O
rat,1125,O
extrapyramidal,1125,O
motor,1125,O
system,1125,O
:,1125,O
behavioral,1125,O
and,1125,O
biochemical,1125,O
data,1125,O
.,1125,O
The,1126,O
effects,1126,O
of,1126,O
i.v.c,1126,O
.,1126,O
injection,1127,O
of,1127,O
human,1127,O
and,1127,O
salmon,1127,O
calcitonin,1127,O
on,1127,O
biochemical,1127,O
and,1127,O
behavioral,1127,O
parameters,1127,O
related,1127,O
to,1127,O
the,1127,O
extrapyramidal,1127,O
motor,1127,O
system,1127,O
",",1127,O
were,1127,O
investigated,1127,O
in,1127,O
male,1127,O
rats,1127,O
.,1127,O
Calcitonin,1128,O
injection,1128,O
resulted,1128,O
in,1128,O
a,1128,O
potentiation,1128,O
of,1128,O
haloperidol-induced,1128,B-Chemical
catalepsy,1128,B-Disease
and,1128,O
a,1128,O
partial,1128,O
prevention,1128,O
of,1128,O
apomorphine-induced,1128,B-Chemical
hyperactivity,1128,B-Disease
.,1128,O
Moreover,1129,O
calcitonin,1129,O
induced,1129,O
a,1129,O
significant,1129,O
decrease,1129,O
in,1129,O
nigral,1129,O
GAD,1129,O
activity,1129,O
but,1129,O
no,1129,O
change,1129,O
in,1129,O
striatal,1129,O
DA,1129,B-Chemical
and,1129,O
DOPAC,1129,B-Chemical
concentration,1129,O
or,1129,O
GAD,1129,O
activity,1129,O
.,1129,O
The,1130,O
results,1130,O
are,1130,O
discussed,1130,O
in,1130,O
view,1130,O
of,1130,O
a,1130,O
primary,1130,O
action,1130,O
of,1130,O
calcitonin,1130,O
on,1130,O
the,1130,O
striatonigral,1130,O
GABAergic,1130,O
pathway,1130,O
mediating,1130,O
the,1130,O
DA-related,1130,B-Chemical
behavioral,1130,O
messages,1130,O
of,1130,O
striatal,1130,O
origin,1130,O
.,1130,O
Naloxazone,1131,B-Chemical
pretreatment,1131,O
modifies,1131,O
cardiorespiratory,1131,O
",",1131,O
temperature,1131,O
",",1131,O
and,1131,O
behavioral,1131,O
effects,1131,O
of,1131,O
morphine,1131,B-Chemical
.,1131,O
Behavioral,1132,O
and,1132,O
cardiorespiratory,1132,O
responses,1132,O
to,1132,O
a,1132,O
lethal,1132,O
dose,1132,O
of,1132,O
morphine,1132,B-Chemical
were,1132,O
evaluated,1132,O
in,1132,O
rats,1132,O
pretreated,1132,O
with,1132,O
saline,1132,O
or,1132,O
naloxazone,1132,B-Chemical
",",1132,O
an,1132,O
antagonist,1132,O
of,1132,O
high-affinity,1132,O
mu,1132,O
1,1132,O
opioid,1132,O
receptors,1132,O
.,1132,O
Pretreatment,1133,O
with,1133,O
naloxazone,1133,B-Chemical
significantly,1133,O
blocked,1133,O
morphine,1133,B-Chemical
analgesia,1133,B-Disease
",",1133,O
catalepsy,1133,B-Disease
and,1133,O
hypothermia,1133,B-Disease
at,1133,O
a,1133,O
dose,1133,O
which,1133,O
completely,1133,O
eliminated,1133,O
high-affinity,1133,O
binding,1133,O
in,1133,O
brain,1133,O
membranes,1133,O
.,1133,O
Moreover,1134,O
",",1134,O
naloxazone,1134,B-Chemical
significantly,1134,O
attenuated,1134,O
the,1134,O
morphine-induced,1134,B-Chemical
hypotension,1134,B-Disease
and,1134,O
respiratory,1134,B-Disease
depression,1134,I-Disease
",",1134,O
whereas,1134,O
morphine-induced,1134,B-Chemical
bradycardia,1134,B-Disease
was,1134,O
less,1134,O
affected,1134,O
.,1134,O
Results,1135,O
indicate,1135,O
that,1135,O
subpopulations,1135,O
of,1135,O
mu,1135,O
receptors,1135,O
may,1135,O
mediate,1135,O
selective,1135,O
behavioral,1135,O
and,1135,O
cardiorespiratory,1135,O
responses,1135,O
to,1135,O
morphine,1135,B-Chemical
.,1135,O
Modification,1136,O
of,1136,O
drug,1136,O
action,1136,O
by,1136,O
hyperammonemia,1136,B-Disease
.,1136,O
Pretreatment,1137,O
with,1137,O
ammonium,1137,B-Chemical
acetate,1137,I-Chemical
(,1137,O
NH4Ac,1137,B-Chemical
),1137,O
(,1137,O
6,1137,O
mmol/kg,1137,O
s.c.,1137,O
),1137,O
approximately,1137,O
doubled,1137,O
the,1137,O
time,1137,O
morphine-treated,1137,B-Chemical
mice,1137,O
remained,1137,O
on,1137,O
a,1137,O
hot,1137,O
surface,1137,O
and,1137,O
similarly,1137,O
increased,1137,O
muscular,1137,O
incoordination,1137,B-Disease
by,1137,O
diazepam,1137,B-Chemical
",",1137,O
but,1137,O
NH4Ac,1137,B-Chemical
treatment,1137,O
alone,1137,O
had,1137,O
no,1137,O
effect,1137,O
.,1137,O
Thus,1138,O
",",1138,O
hyperammonemia,1138,B-Disease
is,1138,O
capable,1138,O
of,1138,O
altering,1138,O
drug,1138,O
action,1138,O
and,1138,O
must,1138,O
be,1138,O
considered,1138,O
along,1138,O
with,1138,O
impaired,1138,O
drug,1138,O
metabolism,1138,O
in,1138,O
enhanced,1138,O
drug,1138,O
responses,1138,O
associated,1138,O
with,1138,O
liver,1138,B-Disease
disease,1138,I-Disease
.,1138,O
Experiments,1139,O
in,1139,O
vitro,1139,O
showed,1139,O
that,1139,O
acetylcholine-induced,1139,B-Chemical
catecholamine,1139,B-Chemical
release,1139,O
from,1139,O
bovine,1139,O
adrenal,1139,O
medulla,1139,O
is,1139,O
depressed,1139,O
as,1139,O
much,1139,O
as,1139,O
50,1139,O
%,1139,O
by,1139,O
0.3,1139,O
mM,1139,O
NH4Ac,1139,B-Chemical
and,1139,O
KCl-induced,1139,B-Chemical
contractions,1139,O
of,1139,O
guinea-pig,1139,O
ileum,1139,O
were,1139,O
inhibited,1139,O
20,1139,O
%,1139,O
by,1139,O
5,1139,O
mM,1139,O
NH4Ac,1139,B-Chemical
.,1139,O
Addition,1140,O
of,1140,O
excess,1140,O
calcium,1140,B-Chemical
reversed,1140,O
the,1140,O
depression,1140,B-Disease
in,1140,O
both,1140,O
tissues,1140,O
",",1140,O
but,1140,O
calcium-independent,1140,B-Chemical
catecholamine,1140,B-Chemical
release,1140,O
by,1140,O
acetaldehyde,1140,B-Chemical
was,1140,O
not,1140,O
blocked,1140,O
by,1140,O
NH4Ac,1140,B-Chemical
.,1140,O
These,1141,O
results,1141,O
suggested,1141,O
that,1141,O
ammonia,1141,B-Chemical
blocks,1141,O
calcium,1141,B-Chemical
channels,1141,O
.,1141,O
Parallels,1142,O
in,1142,O
the,1142,O
actions,1142,O
of,1142,O
NH4Ac,1142,B-Chemical
and,1142,O
the,1142,O
calcium,1142,B-Chemical
channel,1142,O
blocker,1142,O
verapamil,1142,B-Chemical
support,1142,O
this,1142,O
concept,1142,O
.,1142,O
Both,1143,O
verapamil,1143,B-Chemical
(,1143,O
10,1143,O
mg/kg,1143,O
i.p,1143,O
.,1143,O
),1143,O
and,1144,O
NH4Ac,1144,B-Chemical
pretreatment,1144,O
enhanced,1144,O
morphine,1144,B-Chemical
analgesia-,1144,B-Disease
and,1144,O
diazepam-induced,1144,B-Chemical
muscular,1144,O
incoordination,1144,B-Disease
and,1144,O
antagonized,1144,O
amphetamine-induced,1144,B-Chemical
motor,1144,O
activity,1144,O
",",1144,O
and,1144,O
neither,1144,O
verapamil,1144,B-Chemical
nor,1144,O
NH4Ac,1144,B-Chemical
affected,1144,O
the,1144,O
convulsant,1144,O
action,1144,O
of,1144,O
metrazol,1144,B-Chemical
.,1144,O
The,1145,O
data,1145,O
suggest,1145,O
that,1145,O
hyperammonemia,1145,B-Disease
exerts,1145,O
a,1145,O
calcium,1145,B-Chemical
channel,1145,O
blocking,1145,O
action,1145,O
which,1145,O
enhances,1145,O
the,1145,O
effects,1145,O
of,1145,O
central,1145,O
nervous,1145,O
system,1145,O
depressants,1145,O
and,1145,O
certain,1145,O
opioid,1145,O
analgesics,1145,O
.,1145,O
Levodopa-induced,1146,B-Chemical
dyskinesia,1146,B-Disease
and,1146,O
thalamotomy,1146,O
.,1146,O
Levodopa-induced,1147,B-Chemical
dyskinesia,1147,B-Disease
of,1147,O
the,1147,O
limbs,1147,O
in,1147,O
thirteen,1147,O
cases,1147,O
of,1147,O
Parkinsonism,1147,B-Disease
",",1147,O
which,1147,O
was,1147,O
choreic,1147,O
",",1147,O
ballistic,1147,O
or,1147,O
dystonic,1147,B-Disease
in,1147,O
type,1147,O
",",1147,O
was,1147,O
alleviated,1147,O
almost,1147,O
completely,1147,O
by,1147,O
stereotaxic,1147,O
surgery,1147,O
using,1147,O
a,1147,O
microelectrode,1147,O
technique,1147,O
for,1147,O
the,1147,O
ventralis,1147,O
oralis,1147,O
anterior,1147,O
and,1147,O
posterior,1147,O
nuclei,1147,O
of,1147,O
the,1147,O
thalamus,1147,O
",",1147,O
but,1147,O
much,1147,O
less,1147,O
by,1147,O
the,1147,O
ventralis,1147,O
intermedius,1147,O
nucleus,1147,O
.,1147,O
Control,1148,O
of,1148,O
levodopa-induced,1148,B-Chemical
dyskinesias,1148,B-Disease
by,1148,O
thalamic,1148,B-Disease
lesions,1148,I-Disease
in,1148,O
the,1148,O
course,1148,O
of,1148,O
routine,1148,O
treatment,1148,O
of,1148,O
Parkinsonism,1148,B-Disease
is,1148,O
discussed,1148,O
.,1148,O
Treatment,1149,O
of,1149,O
ifosfamide-induced,1149,B-Chemical
urothelial,1149,B-Disease
toxicity,1149,I-Disease
by,1149,O
oral,1149,O
administration,1149,O
of,1149,O
sodium,1149,B-Chemical
2-mercaptoethane,1149,I-Chemical
sulphonate,1149,I-Chemical
(,1149,O
MESNA,1149,B-Chemical
),1149,O
to,1149,O
patients,1149,O
with,1149,O
inoperable,1149,O
lung,1149,B-Disease
cancer,1149,I-Disease
.,1149,O
The,1150,O
protective,1150,O
effect,1150,O
of,1150,O
oral,1150,O
administration,1150,O
of,1150,O
the,1150,O
thiol,1150,B-Chemical
compound,1150,O
sodium,1150,B-Chemical
2-mercaptoethane,1150,I-Chemical
sulphonate,1150,I-Chemical
(,1150,O
MESNA,1150,B-Chemical
),1150,O
against,1150,O
urothelial,1150,B-Disease
toxicity,1150,I-Disease
induced,1150,O
by,1150,O
ifosfamide,1150,B-Chemical
(,1150,O
IF,1150,B-Chemical
),1150,O
was,1150,O
tested,1150,O
in,1150,O
a,1150,O
group,1150,O
of,1150,O
45,1150,O
patients,1150,O
with,1150,O
inoperable,1150,O
lung,1150,B-Disease
cancer,1150,I-Disease
under,1150,O
treatment,1150,O
with,1150,O
IF,1150,B-Chemical
(,1150,O
2250,1150,O
mg/m2,1150,O
on,1150,O
days,1150,O
2-5,1150,O
),1150,O
as,1150,O
part,1150,O
of,1150,O
a,1150,O
polychemotherapy,1150,O
regimen,1150,O
repeated,1150,O
in,1150,O
a,1150,O
4-week,1150,O
cycle,1150,O
.,1150,O
MESNA,1151,B-Chemical
was,1151,O
given,1151,O
orally,1151,O
on,1151,O
the,1151,O
days,1151,O
of,1151,O
treatment,1151,O
with,1151,O
IF,1151,B-Chemical
in,1151,O
3,1151,O
doses,1151,O
of,1151,O
840,1151,O
mg/m2,1151,O
",",1151,O
each,1151,O
administered,1151,O
at,1151,O
0,1151,O
hr,1151,O
(,1151,O
=,1151,O
injection,1151,O
of,1151,O
IF,1151,B-Chemical
),1151,O
",",1151,O
4,1151,O
hr,1151,O
and,1151,O
8,1151,O
hr,1151,O
p.i,1151,O
.,1151,O
Out,1152,O
of,1152,O
a,1152,O
total,1152,O
of,1152,O
88,1152,O
courses,1152,O
of,1152,O
this,1152,O
treatment,1152,O
we,1152,O
observed,1152,O
10,1152,O
episodes,1152,O
of,1152,O
asymptomatic,1152,O
microscopic,1152,O
haematuria,1152,B-Disease
and,1152,O
no,1152,O
episodes,1152,O
of,1152,O
gross,1152,O
haematuria,1152,B-Disease
.,1152,O
In,1153,O
this,1153,O
group,1153,O
of,1153,O
45,1153,O
patients,1153,O
under,1153,O
protection,1153,O
with,1153,O
MESNA,1153,B-Chemical
there,1153,O
were,1153,O
5,1153,O
complete,1153,O
remissions,1153,O
and,1153,O
9,1153,O
partial,1153,O
remissions,1153,O
(,1153,O
total,1153,O
31,1153,O
%,1153,O
),1153,O
.,1153,O
A,1154,O
further,1154,O
group,1154,O
of,1154,O
25,1154,O
patients,1154,O
under,1154,O
polychemotherapy,1154,O
with,1154,O
IF,1154,B-Chemical
were,1154,O
treated,1154,O
by,1154,O
conventional,1154,O
prophylactic,1154,O
measures,1154,O
(,1154,O
raised,1154,O
fluid,1154,O
intake,1154,O
and,1154,O
forced,1154,O
diuresis,1154,O
),1154,O
.,1154,O
In,1155,O
this,1155,O
group,1155,O
there,1155,O
were,1155,O
1,1155,O
complete,1155,O
and,1155,O
5,1155,O
partial,1155,O
remissions,1155,O
(,1155,O
total,1155,O
24,1155,O
%,1155,O
),1155,O
",",1155,O
but,1155,O
nearly,1155,O
all,1155,O
patients,1155,O
developed,1155,O
either,1155,O
gross,1155,O
haematuria,1155,B-Disease
and/or,1155,O
symptoms,1155,O
of,1155,O
bladder,1155,B-Disease
irritation,1155,I-Disease
(,1155,O
cystitis,1155,B-Disease
and,1155,O
pollakisuria,1155,B-Disease
),1155,O
.,1155,O
There,1156,O
were,1156,O
no,1156,O
appreciable,1156,O
differences,1156,O
between,1156,O
the,1156,O
MESNA,1156,B-Chemical
series,1156,O
and,1156,O
the,1156,O
conventional,1156,O
prophylaxis,1156,O
series,1156,O
with,1156,O
respect,1156,O
to,1156,O
either,1156,O
haematological,1156,O
or,1156,O
systemic,1156,O
toxicity,1156,B-Disease
of,1156,O
the,1156,O
cytostatic,1156,O
treatment,1156,O
.,1156,O
Our,1157,O
results,1157,O
support,1157,O
the,1157,O
view,1157,O
that,1157,O
MESNA,1157,B-Chemical
",",1157,O
given,1157,O
orally,1157,O
in,1157,O
conjunction,1157,O
with,1157,O
combined,1157,O
cytostatic,1157,O
regimens,1157,O
which,1157,O
include,1157,O
IF,1157,B-Chemical
",",1157,O
simplifies,1157,O
the,1157,O
treatment,1157,O
and,1157,O
provides,1157,O
optimum,1157,O
protection,1157,O
for,1157,O
the,1157,O
urinary,1157,O
epithelium,1157,O
.,1157,O
Protection,1158,O
with,1158,O
oral,1158,O
MESNA,1158,B-Chemical
is,1158,O
particularly,1158,O
suitable,1158,O
for,1158,O
outpatients,1158,O
.,1158,O
Myoclonic,1159,O
",",1159,O
atonic,1159,O
",",1159,O
and,1159,O
absence,1159,O
seizures,1159,O
following,1159,O
institution,1159,O
of,1159,O
carbamazepine,1159,B-Chemical
therapy,1159,O
in,1159,O
children,1159,O
.,1159,O
Five,1160,O
children,1160,O
",",1160,O
aged,1160,O
3,1160,O
to,1160,O
11,1160,O
years,1160,O
",",1160,O
treated,1160,O
with,1160,O
carbamazepine,1160,B-Chemical
for,1160,O
epilepsy,1160,B-Disease
",",1160,O
had,1160,O
an,1160,O
acute,1160,O
aberrant,1160,O
reaction,1160,O
characterized,1160,O
by,1160,O
the,1160,O
onset,1160,O
of,1160,O
myoclonic,1160,O
",",1160,O
atypical,1160,O
absence,1160,O
and/or,1160,O
atonic,1160,O
(,1160,O
minor,1160,O
motor,1160,O
),1160,O
seizures,1160,O
within,1160,O
a,1160,O
few,1160,O
days,1160,O
.,1160,O
When,1161,O
the,1161,O
carbamazepine,1161,B-Chemical
was,1161,O
discontinued,1161,O
",",1161,O
two,1161,O
of,1161,O
the,1161,O
children,1161,O
returned,1161,O
to,1161,O
their,1161,O
former,1161,O
state,1161,O
very,1161,O
quickly,1161,O
",",1161,O
two,1161,O
had,1161,O
the,1161,O
minor,1161,O
motor,1161,O
seizures,1161,B-Disease
resolve,1161,O
in,1161,O
3,1161,O
and,1161,O
6,1161,O
months,1161,O
",",1161,O
and,1161,O
one,1161,O
had,1161,O
the,1161,O
seizures,1161,B-Disease
persist,1161,O
.,1161,O
The,1162,O
child,1162,O
in,1162,O
whom,1162,O
the,1162,O
seizures,1162,B-Disease
persisted,1162,O
was,1162,O
later,1162,O
found,1162,O
to,1162,O
have,1162,O
ceroid,1162,B-Disease
lipofuscinosis,1162,I-Disease
.,1162,O
The,1163,O
other,1163,O
children,1163,O
are,1163,O
doing,1163,O
well,1163,O
on,1163,O
other,1163,O
anticonvulsants,1163,O
.,1163,O
Effect,1164,O
of,1164,O
prostaglandin,1164,B-Chemical
synthetase,1164,O
inhibitors,1164,O
on,1164,O
experimentally,1164,O
induced,1164,O
convulsions,1164,B-Disease
in,1164,O
rats,1164,O
.,1164,O
To,1165,O
investigate,1165,O
the,1165,O
relationship,1165,O
of,1165,O
prostaglandins,1165,B-Chemical
(,1165,O
PGs,1165,B-Chemical
),1165,O
to,1165,O
seizure,1165,B-Disease
induction,1165,O
",",1165,O
the,1165,O
effects,1165,O
of,1165,O
six,1165,O
PG,1165,O
synthetase,1165,O
inhibitors,1165,O
on,1165,O
convulsions,1165,B-Disease
induced,1165,O
by,1165,O
flurothyl,1165,B-Chemical
",",1165,O
picrotoxin,1165,B-Chemical
",",1165,O
pentetrazol,1165,B-Chemical
(,1165,O
PTZ,1165,B-Chemical
),1165,O
",",1165,O
electroshock,1165,O
or,1165,O
bicuculline,1165,B-Chemical
were,1165,O
evaluated,1165,O
.,1165,O
Ibuprofen,1166,B-Chemical
",",1166,O
sulindac,1166,B-Chemical
",",1166,O
mefenamic,1166,B-Chemical
acid,1166,I-Chemical
",",1166,O
and,1166,O
low,1166,O
dose,1166,O
meclofenamic,1166,B-Chemical
acid,1166,I-Chemical
increased,1166,O
the,1166,O
latency-to-onset,1166,O
in,1166,O
the,1166,O
flurothyl,1166,B-Chemical
and/or,1166,O
PTZ,1166,B-Chemical
models,1166,O
;,1166,O
the,1166,O
electroshock,1166,O
",",1166,O
picrotoxin,1166,B-Chemical
and,1166,O
bicuculline,1166,B-Chemical
models,1166,O
were,1166,O
not,1166,O
significantly,1166,O
affected,1166,O
by,1166,O
any,1166,O
of,1166,O
the,1166,O
pretreatment,1166,O
agents,1166,O
.,1166,O
These,1167,O
results,1167,O
suggest,1167,O
that,1167,O
PGs,1167,B-Chemical
are,1167,O
involved,1167,O
in,1167,O
the,1167,O
mechanism,1167,O
(,1167,O
s,1167,O
),1167,O
underlying,1167,O
fluorthyl-,1167,B-Chemical
and,1167,O
PTZ-induced,1167,B-Chemical
convulsions,1167,B-Disease
",",1167,O
but,1167,O
not,1167,O
picrotoxin-,1167,B-Chemical
",",1167,O
electroshock-,1167,O
",",1167,O
or,1167,O
bicuculline-induced,1167,B-Chemical
convulsions,1167,B-Disease
.,1167,O
Acute,1168,O
changes,1168,O
of,1168,O
blood,1168,O
ammonia,1168,B-Chemical
may,1168,O
predict,1168,O
short-term,1168,O
adverse,1168,O
effects,1168,O
of,1168,O
valproic,1168,B-Chemical
acid,1168,I-Chemical
.,1168,O
Valproic,1169,B-Chemical
acid,1169,I-Chemical
(,1169,O
VPA,1169,B-Chemical
),1169,O
was,1169,O
given,1169,O
to,1169,O
24,1169,O
epileptic,1169,B-Disease
patients,1169,O
who,1169,O
were,1169,O
already,1169,O
being,1169,O
treated,1169,O
with,1169,O
other,1169,O
antiepileptic,1169,O
drugs,1169,O
.,1169,O
A,1170,O
standardized,1170,O
loading,1170,O
dose,1170,O
of,1170,O
VPA,1170,B-Chemical
was,1170,O
administered,1170,O
",",1170,O
and,1170,O
venous,1170,O
blood,1170,O
was,1170,O
sampled,1170,O
at,1170,O
0,1170,O
",",1170,O
1,1170,O
",",1170,O
2,1170,O
",",1170,O
3,1170,O
",",1170,O
and,1170,O
4,1170,O
hours,1170,O
.,1170,O
Ammonia,1171,B-Chemical
(,1171,O
NH3,1171,B-Chemical
),1171,O
was,1171,O
higher,1171,O
in,1171,O
patients,1171,O
who,1171,O
",",1171,O
during,1171,O
continuous,1171,O
therapy,1171,O
",",1171,O
complained,1171,O
of,1171,O
drowsiness,1171,B-Disease
(,1171,O
7,1171,O
patients,1171,O
),1171,O
than,1171,O
in,1171,O
those,1171,O
who,1171,O
were,1171,O
symptom-free,1171,O
(,1171,O
17,1171,O
patients,1171,O
),1171,O
",",1171,O
although,1171,O
VPA,1171,B-Chemical
plasma,1171,O
levels,1171,O
were,1171,O
similar,1171,O
in,1171,O
both,1171,O
groups,1171,O
.,1171,O
By,1172,O
measuring,1172,O
VPA-induced,1172,B-Chemical
changes,1172,O
of,1172,O
blood,1172,O
NH3,1172,B-Chemical
content,1172,O
",",1172,O
it,1172,O
may,1172,O
be,1172,O
possible,1172,O
to,1172,O
identify,1172,O
patients,1172,O
at,1172,O
higher,1172,O
risk,1172,O
of,1172,O
obtundation,1172,O
when,1172,O
VPA,1172,B-Chemical
is,1172,O
given,1172,O
chronically,1172,O
.,1172,O
Effect,1173,O
of,1173,O
captopril,1173,B-Chemical
on,1173,O
pre-existing,1173,O
and,1173,O
aminonucleoside-induced,1173,B-Chemical
proteinuria,1173,B-Disease
in,1173,O
spontaneously,1173,O
hypertensive,1173,B-Disease
rats,1173,O
.,1173,O
Proteinuria,1174,B-Disease
is,1174,O
a,1174,O
side,1174,O
effect,1174,O
of,1174,O
captopril,1174,B-Chemical
treatment,1174,O
in,1174,O
hypertensive,1174,B-Disease
patients,1174,O
.,1174,O
The,1175,O
possibility,1175,O
of,1175,O
reproducing,1175,O
the,1175,O
same,1175,O
renal,1175,B-Disease
abnormality,1175,I-Disease
with,1175,O
captopril,1175,B-Chemical
was,1175,O
examined,1175,O
in,1175,O
SHR,1175,O
.,1175,O
Oral,1176,O
administration,1176,O
of,1176,O
captopril,1176,B-Chemical
at,1176,O
100,1176,O
mg/kg,1176,O
for,1176,O
14,1176,O
days,1176,O
failed,1176,O
to,1176,O
aggravate,1176,O
proteinuria,1176,B-Disease
pre-existing,1176,O
in,1176,O
SHR,1176,O
.,1176,O
Also,1177,O
",",1177,O
captopril,1177,B-Chemical
treatment,1177,O
failed,1177,O
to,1177,O
potentiate,1177,O
or,1177,O
facilitate,1177,O
development,1177,O
of,1177,O
massive,1177,O
proteinuria,1177,B-Disease
invoked,1177,O
by,1177,O
puromycin,1177,B-Chemical
aminonucleoside,1177,I-Chemical
in,1177,O
SHR,1177,O
.,1177,O
Captopril,1178,B-Chemical
had,1178,O
little,1178,O
or,1178,O
no,1178,O
demonstrable,1178,O
effects,1178,O
on,1178,O
serum,1178,O
electrolyte,1178,O
concentrations,1178,O
",",1178,O
excretion,1178,O
of,1178,O
urine,1178,O
",",1178,O
sodium,1178,B-Chemical
and,1178,O
potassium,1178,B-Chemical
",",1178,O
endogenous,1178,O
creatinine,1178,B-Chemical
clearance,1178,O
",",1178,O
body,1178,O
weight,1178,O
",",1178,O
and,1178,O
food,1178,O
and,1178,O
water,1178,O
consumption,1178,O
.,1178,O
However,1179,O
",",1179,O
ketone,1179,B-Chemical
bodies,1179,O
were,1179,O
consistently,1179,O
present,1179,O
in,1179,O
urine,1179,O
and,1179,O
several,1179,O
lethalities,1179,O
occurred,1179,O
during,1179,O
multiple,1179,O
dosing,1179,O
of,1179,O
captopril,1179,B-Chemical
in,1179,O
SHR,1179,O
.,1179,O
Complete,1180,O
heart,1180,B-Disease
block,1180,I-Disease
following,1180,O
a,1180,O
single,1180,O
dose,1180,O
of,1180,O
trazodone,1180,B-Chemical
.,1180,O
Forty,1181,O
minutes,1181,O
after,1181,O
receiving,1181,O
a,1181,O
single,1181,O
starting,1181,O
dose,1181,O
of,1181,O
trazodone,1181,B-Chemical
",",1181,O
a,1181,O
patient,1181,O
developed,1181,O
complete,1181,O
heart,1181,B-Disease
block,1181,I-Disease
.,1181,O
The,1182,O
case,1182,O
illustrates,1182,O
that,1182,O
",",1182,O
despite,1182,O
the,1182,O
results,1182,O
of,1182,O
earlier,1182,O
studies,1182,O
",",1182,O
trazodone,1182,B-Chemical
's,1182,O
effect,1182,O
on,1182,O
cardiac,1182,O
conduction,1182,O
may,1182,O
be,1182,O
severe,1182,O
in,1182,O
individuals,1182,O
at,1182,O
risk,1182,O
for,1182,O
conduction,1182,O
delay,1182,O
.,1182,O
Phenobarbital-induced,1183,B-Chemical
dyskinesia,1183,B-Disease
in,1183,O
a,1183,O
neurologically-impaired,1183,B-Disease
child,1183,O
.,1183,O
A,1184,O
2-year-old,1184,O
child,1184,O
with,1184,O
known,1184,O
neurologic,1184,B-Disease
impairment,1184,I-Disease
developed,1184,O
a,1184,O
dyskinesia,1184,B-Disease
soon,1184,O
after,1184,O
starting,1184,O
phenobarbital,1184,B-Chemical
therapy,1184,O
for,1184,O
seizures,1184,B-Disease
.,1184,O
Known,1185,O
causes,1185,O
of,1185,O
movement,1185,B-Disease
disorders,1185,I-Disease
were,1185,O
eliminated,1185,O
after,1185,O
evaluation,1185,O
.,1185,O
On,1186,O
repeat,1186,O
challenge,1186,O
with,1186,O
phenobarbital,1186,B-Chemical
",",1186,O
the,1186,O
dyskinesia,1186,B-Disease
recurred,1186,O
.,1186,O
Phenobarbital,1187,B-Chemical
should,1187,O
be,1187,O
added,1187,O
to,1187,O
the,1187,O
list,1187,O
of,1187,O
anticonvulsant,1187,O
drugs,1187,O
that,1187,O
can,1187,O
cause,1187,O
movement,1187,B-Disease
disorders,1187,I-Disease
.,1187,O
Effects,1188,O
of,1188,O
amine,1188,B-Chemical
pretreatment,1188,O
on,1188,O
ketamine,1188,B-Chemical
catatonia,1188,B-Disease
in,1188,O
pinealectomized,1188,O
or,1188,O
hypophysectomized,1188,O
animals,1188,O
.,1188,O
The,1189,O
present,1189,O
studies,1189,O
were,1189,O
designed,1189,O
to,1189,O
clarify,1189,O
the,1189,O
role,1189,O
of,1189,O
catecholamines,1189,B-Chemical
and,1189,O
pineal,1189,O
idolamines,1189,O
on,1189,O
ketamine-induced,1189,B-Chemical
catatonia,1189,B-Disease
in,1189,O
the,1189,O
intact,1189,O
",",1189,O
pinealectomized,1189,O
or,1189,O
hypophysectomized,1189,O
chick,1189,O
and,1189,O
rat,1189,O
.,1189,O
In,1190,O
the,1190,O
pinealectomized,1190,O
chick,1190,O
",",1190,O
pretreatment,1190,O
with,1190,O
dopamine,1190,B-Chemical
increased,1190,O
the,1190,O
duration,1190,O
of,1190,O
catatonia,1190,B-Disease
(,1190,O
DOC,1190,O
),1190,O
after,1190,O
ketamine,1190,B-Chemical
",",1190,O
but,1190,O
pretreatment,1190,O
with,1190,O
norepinephrine,1190,B-Chemical
did,1190,O
not,1190,O
.,1190,O
The,1191,O
pineal,1191,O
indolamines,1191,O
exhibited,1191,O
mixed,1191,O
actions,1191,O
.,1191,O
Serotonin,1192,B-Chemical
and,1192,O
N-acetyl,1192,B-Chemical
serotonin,1192,I-Chemical
which,1192,O
augmented,1192,O
ketamine,1192,B-Chemical
DOC,1192,O
",",1192,O
did,1192,O
not,1192,O
do,1192,O
so,1192,O
in,1192,O
the,1192,O
absence,1192,O
of,1192,O
the,1192,O
pineal,1192,O
gland,1192,O
",",1192,O
whereas,1192,O
melatonin,1192,B-Chemical
potentiated,1192,O
the,1192,O
ketamine,1192,B-Chemical
DOC,1192,O
in,1192,O
both,1192,O
the,1192,O
intact,1192,O
and,1192,O
pinealectomized,1192,O
chick,1192,O
.,1192,O
Ketamine,1193,B-Chemical
was,1193,O
more,1193,O
potent,1193,O
in,1193,O
the,1193,O
hypophysectomized,1193,O
chick,1193,O
and,1193,O
the,1193,O
circadian,1193,O
rhythm,1193,O
noted,1193,O
in,1193,O
the,1193,O
intact,1193,O
chick,1193,O
was,1193,O
absent,1193,O
;,1193,O
furthermore,1193,O
",",1193,O
melatonin,1193,B-Chemical
did,1193,O
not,1193,O
augment,1193,O
the,1193,O
ketamine,1193,B-Chemical
DOC,1193,O
whereas,1193,O
dopamine,1193,B-Chemical
continued,1193,O
to,1193,O
do,1193,O
so,1193,O
.,1193,O
This,1194,O
study,1194,O
did,1194,O
not,1194,O
demonstrate,1194,O
a,1194,O
species,1194,O
difference,1194,O
regarding,1194,O
the,1194,O
role,1194,O
of,1194,O
the,1194,O
amines,1194,B-Chemical
on,1194,O
the,1194,O
pineal,1194,O
in,1194,O
spite,1194,O
of,1194,O
the,1194,O
immature,1194,O
blood-brain,1194,O
barrier,1194,O
in,1194,O
the,1194,O
young,1194,O
chick,1194,O
and,1194,O
the,1194,O
intact,1194,O
barrier,1194,O
in,1194,O
the,1194,O
rat,1194,O
.,1194,O
In,1195,O
addition,1195,O
",",1195,O
these,1195,O
data,1195,O
indicate,1195,O
a,1195,O
direct,1195,O
role,1195,O
of,1195,O
the,1195,O
pituitary,1195,O
in,1195,O
the,1195,O
augmentation,1195,O
of,1195,O
ketamine,1195,B-Chemical
DOC,1195,O
induced,1195,O
by,1195,O
melatonin,1195,B-Chemical
.,1195,O
Furthermore,1196,O
",",1196,O
dopamine,1196,B-Chemical
appeared,1196,O
to,1196,O
act,1196,O
on,1196,O
systems,1196,O
more,1196,O
closely,1196,O
involved,1196,O
with,1196,O
the,1196,O
induction,1196,O
of,1196,O
ketamine,1196,B-Chemical
catatonia,1196,B-Disease
rather,1196,O
than,1196,O
directly,1196,O
on,1196,O
the,1196,O
pituitary,1196,O
.,1196,O
Heparin-induced,1197,B-Chemical
thrombocytopenia,1197,B-Disease
",",1197,O
thrombosis,1197,B-Disease
",",1197,O
and,1197,O
hemorrhage,1197,B-Disease
.,1197,O
Sixty-two,1198,O
patients,1198,O
with,1198,O
a,1198,O
heparin-induced,1198,B-Chemical
thrombocytopenia,1198,B-Disease
are,1198,O
reported,1198,O
.,1198,O
Clinical,1199,O
manifestations,1199,O
of,1199,O
this,1199,O
disorder,1199,O
include,1199,O
hemorrhage,1199,B-Disease
or,1199,O
",",1199,O
more,1199,O
frequently,1199,O
",",1199,O
thromboembolic,1199,B-Disease
events,1199,O
in,1199,O
patients,1199,O
receiving,1199,O
heparin,1199,B-Chemical
.,1199,O
Laboratory,1200,O
testing,1200,O
has,1200,O
revealed,1200,O
a,1200,B-Disease
falling,1200,I-Disease
platelet,1200,I-Disease
count,1200,I-Disease
",",1200,O
increased,1200,O
resistance,1200,O
to,1200,O
heparin,1200,B-Chemical
",",1200,O
and,1200,O
aggregation,1200,O
of,1200,O
platelets,1200,O
by,1200,O
the,1200,O
patient,1200,O
's,1200,O
plasma,1200,O
when,1200,O
heparin,1200,B-Chemical
is,1200,O
added,1200,O
.,1200,O
Immunologic,1201,O
testing,1201,O
has,1201,O
demonstrated,1201,O
the,1201,O
presence,1201,O
of,1201,O
a,1201,O
heparin-dependent,1201,B-Chemical
platelet,1201,O
membrane,1201,O
antibody,1201,O
.,1201,O
The,1202,O
20,1202,O
deaths,1202,O
",",1202,O
52,1202,O
hemorrhagic,1202,O
and,1202,O
thromboembolic,1202,O
complications,1202,O
",",1202,O
and,1202,O
21,1202,O
surgical,1202,O
procedures,1202,O
to,1202,O
manage,1202,O
the,1202,O
complications,1202,O
confirm,1202,O
the,1202,O
seriousness,1202,O
of,1202,O
the,1202,O
disorder,1202,O
.,1202,O
Specific,1203,O
risk,1203,O
factors,1203,O
have,1203,O
not,1203,O
been,1203,O
identified,1203,O
;,1203,O
therefore,1203,O
",",1203,O
all,1203,O
patients,1203,O
receiving,1203,O
heparin,1203,B-Chemical
should,1203,O
be,1203,O
monitored,1203,O
.,1203,O
If,1204,O
the,1204,O
platelet,1204,O
count,1204,O
falls,1204,O
to,1204,O
less,1204,O
than,1204,O
"100,000/mm3",1204,O
",",1204,O
while,1204,O
the,1204,O
patient,1204,O
is,1204,O
receiving,1204,O
heparin,1204,B-Chemical
",",1204,O
platelet,1204,B-Disease
aggregation,1204,I-Disease
testing,1204,O
",",1204,O
using,1204,O
the,1204,O
patient,1204,O
's,1204,O
plasma,1204,O
",",1204,O
is,1204,O
indicated,1204,O
.,1204,O
Management,1205,O
consists,1205,O
of,1205,O
cessation,1205,O
of,1205,O
heparin,1205,B-Chemical
",",1205,O
platelet,1205,O
anti-aggregating,1205,O
agents,1205,O
",",1205,O
and,1205,O
alternate,1205,O
forms,1205,O
of,1205,O
anticoagulation,1205,O
when,1205,O
indicated,1205,O
.,1205,O
Long-term,1206,O
efficacy,1206,O
and,1206,O
toxicity,1206,B-Disease
of,1206,O
high-dose,1206,O
amiodarone,1206,B-Chemical
therapy,1206,O
for,1206,O
ventricular,1206,B-Disease
tachycardia,1206,I-Disease
or,1206,O
ventricular,1206,B-Disease
fibrillation,1206,I-Disease
.,1206,O
Amiodarone,1207,B-Chemical
was,1207,O
administered,1207,O
to,1207,O
154,1207,O
patients,1207,O
who,1207,O
had,1207,O
sustained,1207,O
",",1207,O
symptomatic,1207,O
ventricular,1207,B-Disease
tachycardia,1207,I-Disease
(,1207,O
VT,1207,B-Disease
),1207,O
(,1207,O
n,1207,O
=,1207,O
118,1207,O
),1207,O
or,1207,O
a,1207,O
cardiac,1207,B-Disease
arrest,1207,I-Disease
(,1207,O
n,1207,O
=,1207,O
36,1207,O
),1207,O
and,1207,O
who,1207,O
were,1207,O
refractory,1207,O
to,1207,O
conventional,1207,O
antiarrhythmic,1207,O
drugs,1207,O
.,1207,O
The,1208,O
loading,1208,O
dose,1208,O
was,1208,O
800,1208,O
mg/day,1208,O
for,1208,O
6,1208,O
weeks,1208,O
and,1208,O
the,1208,O
maintenance,1208,O
dose,1208,O
was,1208,O
600,1208,O
mg/day,1208,O
.,1208,O
Sixty-nine,1209,O
percent,1209,O
of,1209,O
patients,1209,O
continued,1209,O
treatment,1209,O
with,1209,O
amiodarone,1209,B-Chemical
and,1209,O
had,1209,O
no,1209,O
recurrence,1209,O
of,1209,O
symptomatic,1209,O
VT,1209,B-Disease
or,1209,O
ventricular,1209,B-Disease
fibrillation,1209,I-Disease
(,1209,O
VF,1209,B-Disease
),1209,O
over,1209,O
a,1209,O
follow-up,1209,O
of,1209,O
6,1209,O
to,1209,O
52,1209,O
months,1209,O
(,1209,O
mean,1209,O
+/-,1209,O
standard,1209,O
deviation,1209,O
14.2,1209,O
+/-,1209,O
8.2,1209,O
),1209,O
.,1209,O
Six,1210,O
percent,1210,O
of,1210,O
the,1210,O
patients,1210,O
had,1210,O
a,1210,O
nonfatal,1210,O
recurrence,1210,O
of,1210,O
VT,1210,B-Disease
and,1210,O
were,1210,O
successfully,1210,O
managed,1210,O
by,1210,O
continuing,1210,O
amiodarone,1210,B-Chemical
at,1210,O
a,1210,O
higher,1210,O
dose,1210,O
or,1210,O
by,1210,O
the,1210,O
addition,1210,O
of,1210,O
a,1210,O
conventional,1210,O
antiarrhythmic,1210,O
drug,1210,O
.,1210,O
One,1211,O
or,1211,O
more,1211,O
adverse,1211,O
drug,1211,O
reactions,1211,O
occurred,1211,O
in,1211,O
51,1211,O
%,1211,O
of,1211,O
patients,1211,O
.,1211,O
Adverse,1212,O
effects,1212,O
forced,1212,O
a,1212,O
reduction,1212,O
in,1212,O
the,1212,O
dose,1212,O
of,1212,O
amiodarone,1212,B-Chemical
in,1212,O
41,1212,O
%,1212,O
and,1212,O
discontinuation,1212,O
of,1212,O
amiodarone,1212,B-Chemical
in,1212,O
10,1212,O
%,1212,O
of,1212,O
patients,1212,O
.,1212,O
The,1213,O
most,1213,O
common,1213,O
symptomatic,1213,O
adverse,1213,O
reactions,1213,O
were,1213,O
tremor,1213,B-Disease
or,1213,O
ataxia,1213,B-Disease
(,1213,O
35,1213,O
%,1213,O
),1213,O
",",1213,O
nausea,1213,B-Disease
and,1213,O
anorexia,1213,B-Disease
(,1213,O
8,1213,O
%,1213,O
),1213,O
",",1213,O
visual,1213,B-Disease
halos,1213,I-Disease
or,1213,I-Disease
blurring,1213,I-Disease
(,1213,O
6,1213,O
%,1213,O
),1213,O
",",1213,O
thyroid,1213,B-Disease
function,1213,I-Disease
abnormalities,1213,I-Disease
(,1213,O
6,1213,O
%,1213,O
),1213,O
and,1213,O
pulmonary,1213,B-Disease
interstitial,1213,I-Disease
infiltrates,1213,I-Disease
(,1213,O
5,1213,O
%,1213,O
),1213,O
.,1213,O
Although,1214,O
large-dose,1214,O
amiodarone,1214,B-Chemical
is,1214,O
highly,1214,O
effective,1214,O
in,1214,O
the,1214,O
long-term,1214,O
treatment,1214,O
of,1214,O
VT,1214,B-Disease
or,1214,O
VF,1214,B-Disease
refractory,1214,O
to,1214,O
conventional,1214,O
antiarrhythmic,1214,O
drugs,1214,O
",",1214,O
it,1214,O
causes,1214,O
significant,1214,O
toxicity,1214,B-Disease
in,1214,O
approximately,1214,O
50,1214,O
%,1214,O
of,1214,O
patients,1214,O
.,1214,O
However,1215,O
",",1215,O
when,1215,O
the,1215,O
dose,1215,O
is,1215,O
adjusted,1215,O
based,1215,O
on,1215,O
clinical,1215,O
response,1215,O
or,1215,O
the,1215,O
development,1215,O
of,1215,O
adverse,1215,O
effects,1215,O
",",1215,O
75,1215,O
%,1215,O
of,1215,O
patients,1215,O
with,1215,O
VT,1215,B-Disease
or,1215,O
VF,1215,B-Disease
can,1215,O
be,1215,O
successfully,1215,O
managed,1215,O
with,1215,O
amiodarone,1215,B-Chemical
.,1215,O
Why,1216,O
may,1216,O
epsilon-aminocaproic,1216,B-Chemical
acid,1216,I-Chemical
(,1216,O
EACA,1216,B-Chemical
),1216,O
induce,1216,O
myopathy,1216,B-Disease
in,1216,O
man,1216,O
?,1216,O
Report,1217,O
of,1217,O
a,1217,O
case,1217,O
and,1217,O
literature,1217,O
review,1217,O
.,1217,O
A,1218,O
case,1218,O
of,1218,O
necrotizing,1218,O
myopathy,1218,O
due,1218,O
to,1218,O
a,1218,O
short,1218,O
epsilon-aminocaproic,1218,B-Chemical
acid,1218,I-Chemical
(,1218,O
EACA,1218,B-Chemical
),1218,O
treatment,1218,O
in,1218,O
a,1218,O
72,1218,O
year-old,1218,O
patient,1218,O
with,1218,O
subarachnoid,1218,B-Disease
haemorrhage,1218,I-Disease
(,1218,O
SAH,1218,B-Disease
),1218,O
is,1218,O
described,1218,O
.,1218,O
Pathogenetic,1219,O
hypotheses,1219,O
are,1219,O
discussed,1219,O
.,1219,O
Cerebral,1220,B-Disease
hemorrhage,1220,I-Disease
associated,1220,O
with,1220,O
phenylpropanolamine,1220,B-Chemical
in,1220,O
combination,1220,O
with,1220,O
caffeine,1220,B-Chemical
.,1220,O
Phenylpropanolamine,1221,B-Chemical
(,1221,O
PPA,1221,B-Chemical
),1221,O
is,1221,O
a,1221,O
drug,1221,O
that,1221,O
has,1221,O
been,1221,O
associated,1221,O
with,1221,O
serious,1221,O
side,1221,O
effects,1221,O
including,1221,O
stroke,1221,B-Disease
.,1221,O
It,1222,O
is,1222,O
often,1222,O
combined,1222,O
with,1222,O
caffeine,1222,B-Chemical
in,1222,O
diet,1222,O
preparations,1222,O
and,1222,O
``,1222,O
look-alike,1222,O
'',1222,O
pills,1222,O
.,1222,O
In,1223,O
order,1223,O
to,1223,O
determine,1223,O
if,1223,O
PPA/caffeine,1223,B-Chemical
can,1223,O
lead,1223,O
to,1223,O
stroke,1223,B-Disease
in,1223,O
normotensive,1223,O
and/or,1223,O
hypertensive,1223,B-Disease
rats,1223,O
",",1223,O
we,1223,O
administered,1223,O
the,1223,O
combination,1223,O
in,1223,O
six,1223,O
times,1223,O
the,1223,O
allowed,1223,O
human,1223,O
dose,1223,O
calculated,1223,O
on,1223,O
a,1223,O
per,1223,O
weight,1223,O
basis,1223,O
for,1223,O
the,1223,O
rats,1223,O
two,1223,O
times,1223,O
per,1223,O
day,1223,O
for,1223,O
five,1223,O
days,1223,O
.,1223,O
Subarachnoid,1224,O
and,1224,O
cerebral,1224,O
hemorrhage,1224,O
was,1224,O
noted,1224,O
in,1224,O
18,1224,O
%,1224,O
of,1224,O
the,1224,O
hypertensive,1224,B-Disease
rats,1224,O
.,1224,O
A,1225,O
single,1225,O
PPA/caffeine,1225,B-Chemical
administration,1225,O
(,1225,O
same,1225,O
dose,1225,O
),1225,O
lead,1225,O
to,1225,O
acute,1225,O
hypertension,1225,B-Disease
in,1225,O
both,1225,O
the,1225,O
normotensive,1225,O
and,1225,O
hypertensive,1225,B-Disease
animals,1225,O
.,1225,O
These,1226,O
results,1226,O
suggest,1226,O
that,1226,O
PPA/caffeine,1226,B-Chemical
can,1226,O
lead,1226,O
to,1226,O
cerebral,1226,B-Disease
hemorrhage,1226,I-Disease
in,1226,O
previously,1226,O
hypertensive,1226,B-Disease
animals,1226,O
when,1226,O
administered,1226,O
in,1226,O
greater,1226,O
than,1226,O
the,1226,O
allowed,1226,O
dosage,1226,O
.,1226,O
An,1227,O
acute,1227,O
elevation,1227,O
in,1227,O
blood,1227,O
pressure,1227,O
may,1227,O
be,1227,O
a,1227,O
contributing,1227,O
factor,1227,O
.,1227,O
Renal,1228,B-Disease
papillary,1228,I-Disease
necrosis,1228,I-Disease
due,1228,O
to,1228,O
naproxen,1228,B-Chemical
.,1228,O
A,1229,O
31-year-old,1229,O
man,1229,O
with,1229,O
rheumatoid,1229,B-Disease
arthritis,1229,I-Disease
",",1229,O
who,1229,O
had,1229,O
previously,1229,O
been,1229,O
treated,1229,O
with,1229,O
sulindac,1229,B-Chemical
",",1229,O
fenoprofen,1229,B-Chemical
calcium,1229,I-Chemical
",",1229,O
high,1229,O
dose,1229,O
salicylates,1229,B-Chemical
and,1229,O
gold,1229,B-Chemical
salts,1229,O
",",1229,O
developed,1229,O
renal,1229,B-Disease
papillary,1229,I-Disease
necrosis,1229,I-Disease
(,1229,O
RPN,1229,B-Disease
),1229,O
4,1229,O
months,1229,O
after,1229,O
institution,1229,O
of,1229,O
naproxen,1229,B-Chemical
therapy,1229,O
.,1229,O
No,1230,O
other,1230,O
factor,1230,O
predisposing,1230,O
to,1230,O
RPN,1230,B-Disease
could,1230,O
be,1230,O
discovered,1230,O
.,1230,O
Sulindac,1231,B-Chemical
was,1231,O
substituted,1231,O
for,1231,O
naproxen,1231,B-Chemical
and,1231,O
no,1231,O
further,1231,O
adverse,1231,O
renal,1231,O
effects,1231,O
occurred,1231,O
over,1231,O
the,1231,O
next,1231,O
12,1231,O
months,1231,O
.,1231,O
We,1232,O
review,1232,O
previous,1232,O
reports,1232,O
linking,1232,O
RPN,1232,B-Disease
to,1232,O
antiinflammatory,1232,O
drug,1232,O
use,1232,O
and,1232,O
discuss,1232,O
possible,1232,O
advantages,1232,O
of,1232,O
sulindac,1232,B-Chemical
in,1232,O
patients,1232,O
who,1232,O
have,1232,O
experienced,1232,O
renal,1232,B-Disease
toxicity,1232,I-Disease
from,1232,O
other,1232,O
antiinflammatory,1232,O
agents,1232,O
.,1232,O
Nephrotoxic,1233,B-Disease
effects,1233,O
of,1233,O
aminoglycoside,1233,B-Chemical
treatment,1233,O
on,1233,O
renal,1233,O
protein,1233,O
reabsorption,1233,O
and,1233,O
accumulation,1233,O
.,1233,O
To,1234,O
quantify,1234,O
the,1234,O
effects,1234,O
of,1234,O
gentamicin,1234,B-Chemical
",",1234,O
kanamycin,1234,B-Chemical
and,1234,O
netilmicin,1234,B-Chemical
on,1234,O
renal,1234,O
protein,1234,O
reabsorption,1234,O
and,1234,O
accumulation,1234,O
",",1234,O
these,1234,O
drugs,1234,O
were,1234,O
administered,1234,O
to,1234,O
rats,1234,O
intraperitoneally,1234,O
(,1234,O
30,1234,O
mg/kg/day,1234,O
),1234,O
for,1234,O
7,1234,O
",",1234,O
14,1234,O
or,1234,O
21,1234,O
days,1234,O
.,1234,O
Scanning,1235,O
electron,1235,O
microscopy,1235,O
of,1235,O
the,1235,O
glomerular,1235,O
endothelia,1235,O
",",1235,O
urinary,1235,O
measurements,1235,O
of,1235,O
sodium,1235,B-Chemical
",",1235,O
potassium,1235,B-Chemical
",",1235,O
endogenous,1235,O
lysozyme,1235,O
",",1235,O
N-acetyl-beta-D-glucosaminidase,1235,O
(,1235,O
NAG,1235,O
),1235,O
as,1235,O
well,1235,O
as,1235,O
clearance,1235,O
and,1235,O
accumulation,1235,O
experiments,1235,O
after,1235,O
i.v,1235,O
.,1235,O
administration,1236,O
of,1236,O
egg-white,1236,O
lysozyme,1236,O
and,1236,O
measurements,1236,O
of,1236,O
inulin,1236,O
clearance,1236,O
(,1236,O
GFR,1236,O
),1236,O
were,1236,O
done,1236,O
in,1236,O
each,1236,O
treatment,1236,O
group,1236,O
.,1236,O
Gentamicin,1237,B-Chemical
administration,1237,O
decreased,1237,O
diameter,1237,O
",",1237,O
density,1237,O
and,1237,O
shape,1237,O
of,1237,O
endothelial,1237,O
fenestrae,1237,O
.,1237,O
Kanamycin,1238,B-Chemical
and,1238,O
netilmicin,1238,B-Chemical
appeared,1238,O
to,1238,O
have,1238,O
no,1238,O
effect,1238,O
at,1238,O
the,1238,O
dose,1238,O
used,1238,O
.,1238,O
All,1239,O
three,1239,O
aminoglycosides,1239,B-Chemical
decreased,1239,O
GFR,1239,O
and,1239,O
increased,1239,O
urinary,1239,O
excretion,1239,O
of,1239,O
sodium,1239,B-Chemical
and,1239,O
potassium,1239,B-Chemical
.,1239,O
While,1240,O
gentamicin,1240,B-Chemical
and,1240,O
kanamycin,1240,B-Chemical
decreased,1240,O
the,1240,O
percentage,1240,O
reabsorption,1240,O
and,1240,O
accumulation,1240,O
of,1240,O
lysozyme,1240,O
after,1240,O
i.v,1240,O
.,1240,O
administration,1241,O
of,1241,O
egg-white,1241,O
lysozyme,1241,O
netilmicin,1241,B-Chemical
had,1241,O
no,1241,O
effect,1241,O
.,1241,O
Daily,1242,O
excretion,1242,O
of,1242,O
total,1242,O
protein,1242,O
",",1242,O
endogenous,1242,O
lysozyme,1242,O
and,1242,O
NAG,1242,O
increased,1242,O
only,1242,O
after,1242,O
treatment,1242,O
with,1242,O
kanamycin,1242,B-Chemical
and,1242,O
gentamicin,1242,B-Chemical
.,1242,O
Thus,1243,O
",",1243,O
aminoglycosides,1243,B-Chemical
may,1243,O
act,1243,O
as,1243,O
nephrotoxicants,1243,O
at,1243,O
glomerular,1243,O
and/or,1243,O
tubular,1243,O
level,1243,O
inducing,1243,O
impairment,1243,B-Disease
of,1243,I-Disease
renal,1243,I-Disease
reabsorption,1243,I-Disease
and,1243,O
accumulation,1243,O
of,1243,O
proteins,1243,O
.,1243,O
Induction,1244,O
of,1244,O
the,1244,O
obstructive,1244,B-Disease
sleep,1244,I-Disease
apnea,1244,I-Disease
syndrome,1244,I-Disease
in,1244,O
a,1244,O
woman,1244,O
by,1244,O
exogenous,1244,O
androgen,1244,B-Chemical
administration,1244,O
.,1244,O
We,1245,O
documented,1245,O
airway,1245,O
occlusion,1245,O
during,1245,O
sleep,1245,O
and,1245,O
an,1245,O
abnormally,1245,O
high,1245,O
supraglottic,1245,O
resistance,1245,O
while,1245,O
awake,1245,O
in,1245,O
a,1245,O
54-yr-old,1245,O
woman,1245,O
who,1245,O
had,1245,O
developed,1245,O
physical,1245,O
changes,1245,O
and,1245,O
the,1245,O
syndrome,1245,B-Disease
of,1245,I-Disease
obstructive,1245,I-Disease
sleep,1245,I-Disease
apnea,1245,I-Disease
while,1245,O
being,1245,O
administered,1245,O
exogenous,1245,O
androgens,1245,B-Chemical
.,1245,O
When,1246,O
the,1246,O
androgens,1246,B-Chemical
were,1246,O
withdrawn,1246,O
",",1246,O
the,1246,O
patient,1246,O
's,1246,O
physical,1246,O
changes,1246,O
",",1246,O
symptoms,1246,O
",",1246,O
sleep,1246,O
study,1246,O
",",1246,O
and,1246,O
supraglottic,1246,O
resistance,1246,O
all,1246,O
returned,1246,O
to,1246,O
normal,1246,O
.,1246,O
A,1247,O
rechallenge,1247,O
with,1247,O
androgen,1247,B-Chemical
produced,1247,O
symptoms,1247,O
of,1247,O
obstructive,1247,B-Disease
sleep,1247,I-Disease
apnea,1247,I-Disease
that,1247,O
abated,1247,O
upon,1247,O
withdrawal,1247,O
of,1247,O
the,1247,O
hormone,1247,O
.,1247,O
Previous,1248,O
reports,1248,O
have,1248,O
favored,1248,O
a,1248,O
role,1248,O
of,1248,O
androgens,1248,B-Chemical
in,1248,O
the,1248,O
pathogenesis,1248,O
of,1248,O
sleep,1248,B-Disease
apnea,1248,I-Disease
.,1248,O
Our,1249,O
report,1249,O
provides,1249,O
direct,1249,O
evidence,1249,O
for,1249,O
this,1249,O
role,1249,O
.,1249,O
Structural,1250,O
and,1250,O
functional,1250,O
measurements,1250,O
indicate,1250,O
that,1250,O
androgens,1250,B-Chemical
exert,1250,O
a,1250,O
permissive,1250,O
or,1250,O
necessary,1250,O
action,1250,O
on,1250,O
the,1250,O
structural,1250,O
configuration,1250,O
of,1250,O
the,1250,O
oropharynx,1250,O
that,1250,O
predisposes,1250,O
to,1250,O
obstruction,1250,O
during,1250,O
sleep,1250,O
.,1250,O
Development,1251,O
of,1251,O
the,1251,O
obstructive,1251,B-Disease
sleep,1251,I-Disease
apnea,1251,I-Disease
syndrome,1251,I-Disease
must,1251,O
be,1251,O
considered,1251,O
a,1251,O
possible,1251,O
side,1251,O
effect,1251,O
of,1251,O
androgen,1251,B-Chemical
therapy,1251,O
.,1251,O
Cardiotoxic,1252,B-Disease
and,1252,O
possible,1252,O
leukemogenic,1252,O
effects,1252,O
of,1252,O
adriamycin,1252,B-Chemical
in,1252,O
nonhuman,1252,O
primates,1252,O
.,1252,O
10,1253,O
monkeys,1253,O
(,1253,O
macaques,1253,O
),1253,O
received,1253,O
adriamycin,1253,B-Chemical
by,1253,O
monthly,1253,O
intravenous,1253,O
injections,1253,O
at,1253,O
12,1253,O
mg/m2,1253,O
(,1253,O
1,1253,O
mg/kg,1253,O
),1253,O
.,1253,O
8,1254,O
of,1254,O
the,1254,O
10,1254,O
monkeys,1254,O
developed,1254,O
congestive,1254,B-Disease
heart,1254,I-Disease
failure,1254,I-Disease
at,1254,O
an,1254,O
average,1254,O
cumulative,1254,O
adriamycin,1254,B-Chemical
dose,1254,O
(,1254,O
310,1254,O
mg/m2,1254,O
),1254,O
well,1254,O
below,1254,O
that,1254,O
considered,1254,O
the,1254,O
safe,1254,O
upper,1254,O
limit,1254,O
(,1254,O
550,1254,O
mg/m2,1254,O
),1254,O
in,1254,O
man,1254,O
.,1254,O
Histologically,1255,O
",",1255,O
the,1255,O
myocardial,1255,B-Disease
lesions,1255,I-Disease
resembled,1255,O
those,1255,O
found,1255,O
in,1255,O
human,1255,O
anthracycline-induced,1255,B-Chemical
cardiomyopathy,1255,B-Disease
.,1255,O
1,1256,O
of,1256,O
the,1256,O
10,1256,O
monkeys,1256,O
developed,1256,O
acute,1256,B-Disease
myeloblastic,1256,I-Disease
leukemia,1256,I-Disease
after,1256,O
receiving,1256,O
324,1256,O
mg/m2,1256,O
of,1256,O
adriamycin,1256,B-Chemical
;,1256,O
the,1256,O
10th,1256,O
monkey,1256,O
is,1256,O
alive,1256,O
and,1256,O
well,1256,O
26,1256,O
months,1256,O
after,1256,O
the,1256,O
last,1256,O
dose,1256,O
of,1256,O
drug,1256,O
.,1256,O
Our,1257,O
results,1257,O
suggest,1257,O
that,1257,O
adriamycin,1257,B-Chemical
is,1257,O
a,1257,O
more,1257,O
potent,1257,O
cardiotoxin,1257,O
in,1257,O
monkeys,1257,O
than,1257,O
in,1257,O
man,1257,O
",",1257,O
and,1257,O
that,1257,O
leukemia,1257,B-Disease
may,1257,O
be,1257,O
a,1257,O
consequence,1257,O
of,1257,O
prolonged,1257,O
treatment,1257,O
with,1257,O
this,1257,O
drug,1257,O
.,1257,O
Tricuspid,1258,B-Disease
valve,1258,I-Disease
regurgitation,1258,I-Disease
and,1258,O
lithium,1258,B-Chemical
carbonate,1258,I-Chemical
toxicity,1258,B-Disease
in,1258,O
a,1258,O
newborn,1258,O
infant,1258,O
.,1258,O
A,1259,O
newborn,1259,O
with,1259,O
massive,1259,O
tricuspid,1259,B-Disease
regurgitation,1259,I-Disease
",",1259,O
atrial,1259,B-Disease
flutter,1259,I-Disease
",",1259,O
congestive,1259,B-Disease
heart,1259,I-Disease
failure,1259,I-Disease
",",1259,O
and,1259,O
a,1259,O
high,1259,O
serum,1259,O
lithium,1259,B-Chemical
level,1259,O
is,1259,O
described,1259,O
.,1259,O
This,1260,O
is,1260,O
the,1260,O
first,1260,O
patient,1260,O
to,1260,O
initially,1260,O
manifest,1260,O
tricuspid,1260,B-Disease
regurgitation,1260,I-Disease
and,1260,O
atrial,1260,B-Disease
flutter,1260,I-Disease
",",1260,O
and,1260,O
the,1260,O
11th,1260,O
described,1260,O
patient,1260,O
with,1260,O
cardiac,1260,B-Disease
disease,1260,I-Disease
among,1260,O
infants,1260,O
exposed,1260,O
to,1260,O
lithium,1260,B-Chemical
compounds,1260,O
in,1260,O
the,1260,O
first,1260,O
trimester,1260,O
of,1260,O
pregnancy,1260,O
.,1260,O
Sixty-three,1261,O
percent,1261,O
of,1261,O
these,1261,O
infants,1261,O
had,1261,O
tricuspid,1261,O
valve,1261,O
involvement,1261,O
.,1261,O
Lithium,1262,B-Chemical
carbonate,1262,I-Chemical
may,1262,O
be,1262,O
a,1262,O
factor,1262,O
in,1262,O
the,1262,O
increasing,1262,O
incidence,1262,O
of,1262,O
congenital,1262,B-Disease
heart,1262,I-Disease
disease,1262,I-Disease
when,1262,O
taken,1262,O
during,1262,O
early,1262,O
pregnancy,1262,O
.,1262,O
It,1263,O
also,1263,O
causes,1263,O
neurologic,1263,B-Disease
depression,1263,I-Disease
",",1263,O
cyanosis,1263,B-Disease
",",1263,O
and,1263,O
cardiac,1263,B-Disease
arrhythmia,1263,I-Disease
when,1263,O
consumed,1263,O
prior,1263,O
to,1263,O
delivery,1263,O
.,1263,O
Effects,1264,O
of,1264,O
the,1264,O
novel,1264,O
compound,1264,O
aniracetam,1264,B-Chemical
(,1264,O
Ro,1264,B-Chemical
13-5057,1264,I-Chemical
),1264,O
upon,1264,O
impaired,1264,O
learning,1264,O
and,1264,O
memory,1264,O
in,1264,O
rodents,1264,O
.,1264,O
The,1265,O
effect,1265,O
of,1265,O
aniracetam,1265,B-Chemical
(,1265,O
Ro,1265,B-Chemical
13-5057,1265,I-Chemical
",",1265,O
1-anisoyl-2-pyrrolidinone,1265,B-Chemical
),1265,O
was,1265,O
studied,1265,O
on,1265,O
various,1265,O
forms,1265,O
of,1265,O
experimentally,1265,O
impaired,1265,B-Disease
cognitive,1265,I-Disease
functions,1265,I-Disease
(,1265,O
learning,1265,O
and,1265,O
memory,1265,O
),1265,O
in,1265,O
rodents,1265,O
and,1265,O
produced,1265,O
the,1265,O
following,1265,O
effects,1265,O
:,1265,O
(,1265,O
1,1265,O
),1265,O
almost,1265,O
complete,1265,O
prevention,1265,O
of,1265,O
the,1265,O
incapacity,1265,O
to,1265,O
learn,1265,O
a,1265,O
discrete,1265,O
escape,1265,O
response,1265,O
in,1265,O
rats,1265,O
exposed,1265,O
to,1265,O
sublethal,1265,O
hypercapnia,1265,B-Disease
immediately,1265,O
before,1265,O
the,1265,O
acquisition,1265,O
session,1265,O
;,1265,O
(,1265,O
2,1265,O
),1265,O
partial,1265,O
(,1265,O
rats,1265,O
),1265,O
or,1265,O
complete,1265,O
(,1265,O
mice,1265,O
),1265,O
prevention,1265,O
of,1265,O
the,1265,O
scopolamine-induced,1265,B-Chemical
short-term,1265,O
amnesia,1265,B-Disease
for,1265,O
a,1265,O
passive,1265,O
avoidance,1265,O
task,1265,O
;,1265,O
(,1265,O
3,1265,O
),1265,O
complete,1265,O
protection,1265,O
against,1265,O
amnesia,1265,B-Disease
for,1265,O
a,1265,O
passive,1265,O
avoidance,1265,O
task,1265,O
in,1265,O
rats,1265,O
submitted,1265,O
to,1265,O
electroconvulsive,1265,O
shock,1265,O
immediately,1265,O
after,1265,O
avoidance,1265,O
acquisition,1265,O
;,1265,O
(,1265,O
4,1265,O
),1265,O
prevention,1265,O
of,1265,O
the,1265,O
long-term,1265,O
retention-,1265,O
or,1265,O
retrieval-deficit,1265,O
for,1265,O
a,1265,O
passive,1265,O
avoidance,1265,O
task,1265,O
induced,1265,O
in,1265,O
rats,1265,O
and,1265,O
mice,1265,O
by,1265,O
chloramphenicol,1265,B-Chemical
or,1265,O
cycloheximide,1265,B-Chemical
administered,1265,O
immediately,1265,O
after,1265,O
acquisition,1265,O
;,1265,O
(,1265,O
5,1265,O
),1265,O
reversal,1265,O
",",1265,O
when,1265,O
administered,1265,O
as,1265,O
late,1265,O
as,1265,O
1,1265,O
h,1265,O
before,1265,O
the,1265,O
retention,1265,O
test,1265,O
",",1265,O
of,1265,O
the,1265,O
deficit,1265,O
in,1265,O
retention,1265,O
or,1265,O
retrieval,1265,O
of,1265,O
a,1265,O
passive,1265,O
avoidance,1265,O
task,1265,O
induced,1265,O
by,1265,O
cycloheximide,1265,B-Chemical
injected,1265,O
2,1265,O
days,1265,O
previously,1265,O
;,1265,O
(,1265,O
6,1265,O
),1265,O
prevention,1265,O
of,1265,O
the,1265,O
deficit,1265,O
in,1265,O
the,1265,O
retrieval,1265,O
of,1265,O
an,1265,O
active,1265,O
avoidance,1265,O
task,1265,O
induced,1265,O
in,1265,O
mice,1265,O
by,1265,O
subconvulsant,1265,O
electroshock,1265,O
or,1265,O
hypercapnia,1265,B-Disease
applied,1265,O
immediately,1265,O
before,1265,O
retrieval,1265,O
testing,1265,O
(,1265,O
24,1265,O
h,1265,O
after,1265,O
acquisition,1265,O
),1265,O
.,1265,O
These,1266,O
improvements,1266,O
or,1266,O
normalizations,1266,O
of,1266,O
impaired,1266,B-Disease
cognitive,1266,I-Disease
functions,1266,I-Disease
were,1266,O
seen,1266,O
at,1266,O
oral,1266,O
aniracetam,1266,B-Chemical
doses,1266,O
of,1266,O
10-100,1266,O
mg/kg,1266,O
.,1266,O
Generally,1267,O
",",1267,O
the,1267,O
dose-response,1267,O
curves,1267,O
were,1267,O
bell-shaped,1267,O
.,1267,O
The,1268,O
mechanisms,1268,O
underlying,1268,O
the,1268,O
activity,1268,O
of,1268,O
aniracetam,1268,B-Chemical
and,1268,O
its,1268,O
'therapeutic,1268,O
window,1268,O
',1268,O
are,1268,O
unknown,1268,O
.,1268,O
Piracetam,1269,B-Chemical
",",1269,O
another,1269,O
pyrrolidinone,1269,B-Chemical
derivative,1269,O
was,1269,O
used,1269,O
for,1269,O
comparison,1269,O
.,1269,O
It,1270,O
was,1270,O
active,1270,O
only,1270,O
in,1270,O
six,1270,O
of,1270,O
nine,1270,O
tests,1270,O
and,1270,O
had,1270,O
about,1270,O
one-tenth,1270,O
the,1270,O
potency,1270,O
of,1270,O
aniracetam,1270,B-Chemical
.,1270,O
The,1271,O
results,1271,O
indicate,1271,O
that,1271,O
aniracetam,1271,B-Chemical
improves,1271,O
cognitive,1271,O
functions,1271,O
which,1271,O
are,1271,O
impaired,1271,O
by,1271,O
different,1271,O
procedure,1271,O
and,1271,O
in,1271,O
different,1271,O
phases,1271,O
of,1271,O
the,1271,O
learning,1271,O
and,1271,O
memory,1271,O
process,1271,O
.,1271,O
Effect,1272,O
of,1272,O
calcium,1272,B-Chemical
chloride,1272,I-Chemical
on,1272,O
gross,1272,O
behavioural,1272,O
changes,1272,O
produced,1272,O
by,1272,O
carbachol,1272,B-Chemical
and,1272,O
eserine,1272,B-Chemical
in,1272,O
cats,1272,O
.,1272,O
The,1273,O
effect,1273,O
of,1273,O
calcium,1273,B-Chemical
chloride,1273,I-Chemical
injected,1273,O
into,1273,O
the,1273,O
cerebral,1273,O
ventricles,1273,O
of,1273,O
group-housed,1273,O
unanaesthetized,1273,O
cats,1273,O
upon,1273,O
vocalization,1273,O
(,1273,O
rage,1273,O
",",1273,O
hissing,1273,O
and,1273,O
snarling,1273,O
),1273,O
",",1273,O
fighting,1273,O
(,1273,O
attack,1273,O
with,1273,O
paws,1273,O
and,1273,O
claws,1273,O
",",1273,O
defense,1273,O
with,1273,O
paws,1273,O
and,1273,O
claws,1273,O
and,1273,O
biting,1273,O
),1273,O
",",1273,O
mydriasis,1273,B-Disease
",",1273,O
tremor,1273,B-Disease
and,1273,O
clonic-tonic,1273,B-Disease
convulsions,1273,I-Disease
produced,1273,O
by,1273,O
carbachol,1273,B-Chemical
and,1273,O
eserine,1273,B-Chemical
injected,1273,O
similarly,1273,O
was,1273,O
investigated,1273,O
.,1273,O
Calcium,1274,B-Chemical
chloride,1274,I-Chemical
depressed,1274,O
or,1274,O
almost,1274,O
completely,1274,O
abolished,1274,O
the,1274,O
vocalization,1274,O
and,1274,O
fighting,1274,O
due,1274,O
to,1274,O
carbachol,1274,B-Chemical
and,1274,O
eserine,1274,B-Chemical
.,1274,O
On,1275,O
the,1275,O
other,1275,O
hand,1275,O
",",1275,O
mydriasis,1275,B-Disease
",",1275,O
tremor,1275,B-Disease
and,1275,O
clonic-tonic,1275,B-Disease
convulsions,1275,I-Disease
evoked,1275,O
by,1275,O
carbachol,1275,B-Chemical
and,1275,O
eserine,1275,B-Chemical
were,1275,O
not,1275,O
significantly,1275,O
changed,1275,O
by,1275,O
calcium,1275,B-Chemical
chloride,1275,I-Chemical
.,1275,O
It,1276,O
is,1276,O
apparent,1276,O
that,1276,O
calcium,1276,B-Chemical
chloride,1276,I-Chemical
can,1276,O
``,1276,O
dissociate,1276,O
'',1276,O
vocalization,1276,O
and,1276,O
fighting,1276,O
from,1276,O
autonomic,1276,O
and,1276,O
motor,1276,O
phenomena,1276,O
such,1276,O
as,1276,O
mydriasis,1276,B-Disease
",",1276,O
tremor,1276,B-Disease
and,1276,O
clonic-tonic,1276,B-Disease
convulsions,1276,I-Disease
caused,1276,O
by,1276,O
carbachol,1276,B-Chemical
and,1276,O
eserine,1276,B-Chemical
.,1276,O
Calcium,1277,B-Chemical
chloride,1277,I-Chemical
inhibited,1277,O
the,1277,O
vocalization,1277,O
and,1277,O
fighting,1277,O
produced,1277,O
by,1277,O
carbachol,1277,B-Chemical
and,1277,O
eserine,1277,B-Chemical
most,1277,O
probably,1277,O
by,1277,O
a,1277,O
nonspecific,1277,O
stabilizing,1277,O
action,1277,O
on,1277,O
central,1277,O
muscarinic,1277,O
cholinoceptive,1277,O
sites,1277,O
.,1277,O
These,1278,O
results,1278,O
further,1278,O
support,1278,O
the,1278,O
view,1278,O
that,1278,O
calcium,1278,B-Chemical
ions,1278,O
in,1278,O
excess,1278,O
have,1278,O
an,1278,O
atropine-like,1278,B-Chemical
action,1278,O
also,1278,O
in,1278,O
the,1278,O
central,1278,O
nervous,1278,O
system,1278,O
.,1278,O
Thiazide,1279,B-Chemical
diuretics,1279,O
",",1279,O
hypokalemia,1279,B-Disease
and,1279,O
cardiac,1279,B-Disease
arrhythmias,1279,I-Disease
.,1279,O
Thiazide,1280,B-Chemical
diuretics,1280,O
are,1280,O
widely,1280,O
accepted,1280,O
as,1280,O
the,1280,O
cornerstone,1280,O
of,1280,O
antihypertensive,1280,O
treatment,1280,O
programs,1280,O
.,1280,O
Hypokalemia,1281,B-Disease
is,1281,O
a,1281,O
commonly,1281,O
encountered,1281,O
metabolic,1281,O
consequence,1281,O
of,1281,O
chronic,1281,O
thiazide,1281,B-Chemical
therapy,1281,O
.,1281,O
We,1282,O
treated,1282,O
38,1282,O
patients,1282,O
(,1282,O
22,1282,O
low,1282,O
renin,1282,O
",",1282,O
16,1282,O
normal,1282,O
renin,1282,O
),1282,O
with,1282,O
moderate,1282,O
diastolic,1282,B-Disease
hypertension,1282,I-Disease
with,1282,O
hydrochlorothiazide,1282,B-Chemical
(,1282,O
HCTC,1282,B-Chemical
),1282,O
administered,1282,O
on,1282,O
a,1282,O
twice,1282,O
daily,1282,O
schedule,1282,O
.,1282,O
Initial,1283,O
dose,1283,O
was,1283,O
50,1283,O
mg,1283,O
and,1283,O
the,1283,O
dose,1283,O
was,1283,O
increased,1283,O
at,1283,O
monthly,1283,O
intervals,1283,O
to,1283,O
100,1283,O
mg,1283,O
",",1283,O
150,1283,O
mg,1283,O
and,1283,O
200,1283,O
mg,1283,O
daily,1283,O
until,1283,O
blood,1283,O
pressure,1283,O
normalized,1283,O
.,1283,O
The,1284,O
serum,1284,O
K,1284,B-Chemical
during,1284,O
the,1284,O
control,1284,O
period,1284,O
was,1284,O
4.5,1284,O
+/-,1284,O
0.2,1284,O
mEq/l,1284,O
an,1284,O
on,1284,O
50,1284,O
",",1284,O
100,1284,O
",",1284,O
150,1284,O
and,1284,O
200,1284,O
mg,1284,O
HCTZ,1284,B-Chemical
daily,1284,O
3.9,1284,O
+/-,1284,O
0.3,1284,O
",",1284,O
3.4,1284,O
+/-,1284,O
0.2,1284,O
",",1284,O
2.9,1284,O
+/-,1284,O
0.2,1284,O
",",1284,O
and,1284,O
2.4,1284,O
+/-,1284,O
0.3,1284,O
mEq/l,1284,O
",",1284,O
respectively,1284,O
.,1284,O
Corresponding,1285,O
figures,1285,O
for,1285,O
whole,1285,O
body,1285,O
K,1285,B-Chemical
were,1285,O
4107,1285,O
+/-,1285,O
208,1285,O
",",1285,O
3722,1285,O
+/-,1285,O
319,1285,O
",",1285,O
3628,1285,O
+/-,1285,O
257,1285,O
",",1285,O
3551,1285,O
+/-,1285,O
336,1285,O
",",1285,O
and,1285,O
3269,1285,O
+/-,1285,O
380,1285,O
mEq,1285,O
",",1285,O
respectively,1285,O
.,1285,O
In,1286,O
13,1286,O
patients,1286,O
we,1286,O
observed,1286,O
the,1286,O
effects,1286,O
of,1286,O
HCTZ,1286,B-Chemical
therapy,1286,O
(,1286,O
100,1286,O
mg,1286,O
daily,1286,O
),1286,O
on,1286,O
the,1286,O
occurrence,1286,O
of,1286,O
PVC,1286,O
's,1286,O
during,1286,O
rest,1286,O
as,1286,O
well,1286,O
as,1286,O
during,1286,O
static,1286,O
and,1286,O
dynamic,1286,O
exercise,1286,O
.,1286,O
During,1287,O
rest,1287,O
we,1287,O
observed,1287,O
0.6,1287,O
+/-,1287,O
0.08,1287,O
PVC,1287,O
beats/min,1287,O
+/-,1287,O
SEM,1287,O
and,1287,O
during,1287,O
static,1287,O
and,1287,O
dynamic,1287,O
exercise,1287,O
0.6,1287,O
+/-,1287,O
0.06,1287,O
and,1287,O
0.8,1287,O
+/-,1287,O
0.15,1287,O
",",1287,O
respectively,1287,O
.,1287,O
Corresponding,1288,O
figures,1288,O
during,1288,O
HCTZ,1288,B-Chemical
therapy,1288,O
100,1288,O
mg,1288,O
daily,1288,O
were,1288,O
1.4,1288,O
+/-,1288,O
0.1,1288,O
",",1288,O
3.6,1288,O
+/-,1288,O
0.7,1288,O
and,1288,O
5.7,1288,O
4/-,1288,O
0.8,1288,O
",",1288,O
respectively,1288,O
.,1288,O
The,1289,O
occurrence,1289,O
of,1289,O
PVC,1289,O
's,1289,O
correlated,1289,O
significantly,1289,O
with,1289,O
the,1289,O
fall,1289,O
in,1289,O
serum,1289,O
K+,1289,B-Chemical
observed,1289,O
r,1289,O
=,1289,O
0.72,1289,O
",",1289,O
p,1289,O
less,1289,O
than,1289,O
0.001,1289,O
.,1289,O
In,1290,O
conclusion,1290,O
we,1290,O
found,1290,O
that,1290,O
thiazide,1290,B-Chemical
diuretics,1290,O
cause,1290,O
hypokalemia,1290,B-Disease
and,1290,O
depletion,1290,O
of,1290,O
body,1290,O
potassium,1290,B-Chemical
.,1290,O
The,1291,O
more,1291,O
profound,1291,O
hypokalemia,1291,B-Disease
",",1291,O
the,1291,O
greater,1291,O
the,1291,O
propensity,1291,O
for,1291,O
the,1291,O
occurrence,1291,O
of,1291,O
PVC,1291,O
's,1291,O
.,1291,O
Circulating,1292,O
lysosomal,1292,O
enzymes,1292,O
and,1292,O
acute,1292,B-Disease
hepatic,1292,I-Disease
necrosis,1292,I-Disease
.,1292,O
The,1293,O
activities,1293,O
of,1293,O
the,1293,O
lysosomal,1293,O
enzymes,1293,O
acid,1293,O
and,1293,O
neutral,1293,O
protease,1293,O
",",1293,O
N-acetylglucosaminidase,1293,O
",",1293,O
and,1293,O
acid,1293,O
phosphatase,1293,O
were,1293,O
measured,1293,O
in,1293,O
the,1293,O
serum,1293,O
of,1293,O
patients,1293,O
with,1293,O
fulminant,1293,B-Disease
hepatic,1293,I-Disease
failure,1293,I-Disease
.,1293,O
Acid,1294,O
protease,1294,O
(,1294,O
cathepsin,1294,O
D,1294,O
),1294,O
activity,1294,O
was,1294,O
increased,1294,O
about,1294,O
tenfold,1294,O
in,1294,O
patients,1294,O
who,1294,O
died,1294,O
and,1294,O
nearly,1294,O
fourfold,1294,O
in,1294,O
those,1294,O
who,1294,O
survived,1294,O
fulminant,1294,B-Disease
hepatic,1294,I-Disease
failure,1294,I-Disease
after,1294,O
paracetamol,1294,B-Chemical
overdose,1294,B-Disease
",",1294,O
whereas,1294,O
activities,1294,O
were,1294,O
increased,1294,O
equally,1294,O
in,1294,O
patients,1294,O
with,1294,O
fulminant,1294,B-Disease
hepatic,1294,I-Disease
failure,1294,I-Disease
due,1294,O
to,1294,O
viral,1294,B-Disease
hepatitis,1294,I-Disease
whether,1294,O
or,1294,O
not,1294,O
they,1294,O
survived,1294,O
.,1294,O
A,1295,O
correlation,1295,O
was,1295,O
found,1295,O
between,1295,O
serum,1295,O
acid,1295,O
protease,1295,O
activity,1295,O
and,1295,O
prothrombin,1295,O
time,1295,O
",",1295,O
and,1295,O
the,1295,O
increase,1295,O
in,1295,O
cathepsin,1295,O
D,1295,O
activity,1295,O
was,1295,O
sustained,1295,O
over,1295,O
several,1295,O
days,1295,O
compared,1295,O
with,1295,O
aspartate,1295,B-Chemical
aminotransferase,1295,O
",",1295,O
which,1295,O
showed,1295,O
a,1295,O
sharp,1295,O
early,1295,O
peak,1295,O
and,1295,O
then,1295,O
a,1295,O
fall,1295,O
.,1295,O
Circulating,1296,O
lysosomal,1296,O
proteases,1296,O
can,1296,O
damage,1296,O
other,1296,O
organs,1296,O
",",1296,O
and,1296,O
measurement,1296,O
of,1296,O
their,1296,O
activity,1296,O
may,1296,O
therefore,1296,O
be,1296,O
of,1296,O
added,1296,O
value,1296,O
in,1296,O
assessing,1296,O
prognosis,1296,O
in,1296,O
this,1296,O
condition,1296,O
.,1296,O
Hepatic,1297,B-Disease
veno-occlusive,1297,I-Disease
disease,1297,I-Disease
caused,1297,O
by,1297,O
6-thioguanine,1297,B-Chemical
.,1297,O
Clinically,1298,O
reversible,1298,O
veno-occlusive,1298,B-Disease
disease,1298,I-Disease
of,1298,I-Disease
the,1298,I-Disease
liver,1298,I-Disease
developed,1298,O
in,1298,O
a,1298,O
23-year-old,1298,O
man,1298,O
with,1298,O
acute,1298,B-Disease
lymphocytic,1298,I-Disease
leukemia,1298,I-Disease
after,1298,O
10,1298,O
months,1298,O
of,1298,O
maintenance,1298,O
therapy,1298,O
with,1298,O
6-thioguanine,1298,B-Chemical
.,1298,O
Serial,1299,O
liver,1299,O
biopsies,1299,O
showed,1299,O
the,1299,O
development,1299,O
and,1299,O
resolution,1299,O
of,1299,O
intense,1299,O
sinusoidal,1299,O
engorgement,1299,O
.,1299,O
Although,1300,O
this,1300,O
disease,1300,O
was,1300,O
clinically,1300,O
reversible,1300,O
",",1300,O
some,1300,O
subintimal,1300,O
fibrosis,1300,B-Disease
about,1300,O
the,1300,O
terminal,1300,O
hepatic,1300,O
veins,1300,O
persisted,1300,O
.,1300,O
This,1301,O
case,1301,O
presented,1301,O
a,1301,O
unique,1301,O
opportunity,1301,O
to,1301,O
observe,1301,O
the,1301,O
histologic,1301,O
features,1301,O
of,1301,O
clinically,1301,O
reversible,1301,O
hepatic,1301,B-Disease
veno-occlusive,1301,I-Disease
disease,1301,I-Disease
over,1301,O
time,1301,O
",",1301,O
and,1301,O
may,1301,O
be,1301,O
the,1301,O
first,1301,O
case,1301,O
of,1301,O
veno-occlusive,1301,O
related,1301,O
solely,1301,O
to,1301,O
6-thioguanine,1301,B-Chemical
.,1301,O
Chlorpropamide-induced,1302,B-Chemical
optic,1302,B-Disease
neuropathy,1302,I-Disease
.,1302,O
A,1303,O
65-year-old,1303,O
woman,1303,O
with,1303,O
adult-onset,1303,B-Disease
diabetes,1303,I-Disease
treated,1303,O
with,1303,O
chlorpropamide,1303,B-Chemical
(,1303,O
Diabenese,1303,B-Chemical
),1303,O
had,1303,O
a,1303,O
toxic,1303,B-Disease
optic,1303,I-Disease
neuropathy,1303,I-Disease
that,1303,O
resolved,1303,O
with,1303,O
discontinuation,1303,O
of,1303,O
chlorpropamide,1303,B-Chemical
therapy,1303,O
.,1303,O
Visual,1304,B-Disease
loss,1304,I-Disease
occurs,1304,O
in,1304,O
diabetics,1304,B-Disease
for,1304,O
a,1304,O
variety,1304,O
of,1304,O
reasons,1304,O
",",1304,O
and,1304,O
accurate,1304,O
diagnosis,1304,O
is,1304,O
necessary,1304,O
to,1304,O
institute,1304,O
appropriate,1304,O
therapy,1304,O
.,1304,O
The,1305,O
possibility,1305,O
of,1305,O
a,1305,O
drug-induced,1305,O
optic,1305,B-Disease
neuropathy,1305,I-Disease
should,1305,O
be,1305,O
considered,1305,O
in,1305,O
the,1305,O
differential,1305,O
diagnosis,1305,O
of,1305,O
visual,1305,B-Disease
loss,1305,I-Disease
in,1305,O
diabetics,1305,B-Disease
.,1305,O
Plasma,1306,O
and,1306,O
urinary,1306,O
lipids,1306,O
and,1306,O
lipoproteins,1306,O
during,1306,O
the,1306,O
development,1306,O
of,1306,O
nephrotic,1306,B-Disease
syndrome,1306,I-Disease
induced,1306,O
in,1306,O
the,1306,O
rat,1306,O
by,1306,O
puromycin,1306,B-Chemical
aminonucleoside,1306,I-Chemical
.,1306,O
This,1307,O
study,1307,O
was,1307,O
undertaken,1307,O
to,1307,O
ascertain,1307,O
whether,1307,O
the,1307,O
alterations,1307,O
of,1307,O
plasma,1307,O
lipoproteins,1307,O
found,1307,O
in,1307,O
nephrotic,1307,B-Disease
syndrome,1307,I-Disease
induced,1307,O
by,1307,O
puromycin,1307,B-Chemical
aminonucleoside,1307,I-Chemical
were,1307,O
due,1307,O
to,1307,O
nephrotic,1307,B-Disease
syndrome,1307,I-Disease
per,1307,O
se,1307,O
",",1307,O
or,1307,O
",",1307,O
at,1307,O
least,1307,O
in,1307,O
part,1307,O
",",1307,O
to,1307,O
the,1307,O
aminonucleoside,1307,B-Chemical
.,1307,O
The,1308,O
purpose,1308,O
of,1308,O
the,1308,O
present,1308,O
study,1308,O
was,1308,O
to,1308,O
investigate,1308,O
the,1308,O
changes,1308,O
in,1308,O
plasma,1308,O
and,1308,O
urinary,1308,O
lipoproteins,1308,O
during,1308,O
the,1308,O
administration,1308,O
of,1308,O
puromycin,1308,B-Chemical
aminonucleoside,1308,I-Chemical
(,1308,O
20,1308,O
mg/kg,1308,O
for,1308,O
7,1308,O
days,1308,O
),1308,O
and,1308,O
the,1308,O
subsequent,1308,O
development,1308,O
of,1308,O
nephrotic,1308,B-Disease
syndrome,1308,I-Disease
.,1308,O
Since,1309,O
massive,1309,O
albuminuria,1309,B-Disease
occurred,1309,O
after,1309,O
6,1309,O
days,1309,O
of,1309,O
treatment,1309,O
",",1309,O
the,1309,O
time-course,1309,O
study,1309,O
was,1309,O
divided,1309,O
into,1309,O
two,1309,O
stages,1309,O
:,1309,O
pre-nephrotic,1309,O
stage,1309,O
(,1309,O
day,1309,O
1-5,1309,O
),1309,O
and,1309,O
nephrotic,1309,B-Disease
stage,1309,O
(,1309,O
day,1309,O
6-11,1309,O
),1309,O
.,1309,O
In,1310,O
pre-nephrotic,1310,O
stage,1310,O
the,1310,O
plasma,1310,O
level,1310,O
of,1310,O
fatty,1310,B-Chemical
acids,1310,I-Chemical
",",1310,O
triacylglycerol,1310,B-Chemical
and,1310,O
VLDL,1310,O
decreased,1310,O
while,1310,O
that,1310,O
of,1310,O
phospholipid,1310,O
",",1310,O
cholesteryl,1310,B-Chemical
esters,1310,I-Chemical
and,1310,O
HDL,1310,O
remained,1310,O
constant,1310,O
.,1310,O
Plasma,1311,O
apolipoprotein,1311,O
A-I,1311,O
tended,1311,O
to,1311,O
increase,1311,O
(,1311,O
40,1311,O
%,1311,O
increase,1311,O
at,1311,O
day,1311,O
5,1311,O
),1311,O
.,1311,O
At,1312,O
the,1312,O
beginning,1312,O
of,1312,O
nephrotic,1312,B-Disease
stage,1312,O
(,1312,O
day,1312,O
6,1312,O
),1312,O
the,1312,O
concentration,1312,O
of,1312,O
plasma,1312,O
albumin,1312,O
dropped,1312,O
to,1312,O
a,1312,O
very,1312,O
low,1312,O
level,1312,O
",",1312,O
while,1312,O
that,1312,O
of,1312,O
apolipoprotein,1312,O
A-I,1312,O
increased,1312,O
abruptly,1312,O
(,1312,O
4-fold,1312,O
increase,1312,O
),1312,O
and,1312,O
continued,1312,O
to,1312,O
rise,1312,O
",",1312,O
although,1312,O
less,1312,O
steeply,1312,O
",",1312,O
in,1312,O
the,1312,O
following,1312,O
days,1312,O
.,1312,O
The,1313,O
plasma,1313,O
concentration,1313,O
of,1313,O
HDL,1313,O
followed,1313,O
the,1313,O
same,1313,O
pattern,1313,O
.,1313,O
Plasma,1314,O
VLDL,1314,O
and,1314,O
LDL,1314,O
increased,1314,O
at,1314,O
a,1314,O
later,1314,O
stage,1314,O
(,1314,O
day,1314,O
9,1314,O
),1314,O
.,1314,O
Plasma,1315,O
apolipoprotein,1315,O
A-I,1315,O
was,1315,O
found,1315,O
not,1315,O
only,1315,O
in,1315,O
HDL,1315,O
(,1315,O
1.063-1.210,1315,O
g/ml,1315,O
),1315,O
but,1315,O
also,1315,O
in,1315,O
the,1315,O
LDL,1315,O
density,1315,O
class,1315,O
(,1315,O
1.025-1.050,1315,O
g/ml,1315,O
),1315,O
.,1315,O
In,1316,O
the,1316,O
pre-nephrotic,1316,O
stage,1316,O
lipoproteinuria,1316,O
was,1316,O
negligible,1316,O
",",1316,O
while,1316,O
in,1316,O
the,1316,O
early,1316,O
nephrotic,1316,B-Disease
stage,1316,O
the,1316,O
urinary,1316,O
loss,1316,O
of,1316,O
plasma,1316,O
lipoproteins,1316,O
consisted,1316,O
mainly,1316,O
of,1316,O
HDL,1316,O
.,1316,O
These,1317,O
observations,1317,O
indicate,1317,O
that,1317,O
puromycin,1317,B-Chemical
aminonucleoside,1317,I-Chemical
alters,1317,O
plasma,1317,O
lipoproteins,1317,O
by,1317,O
lowering,1317,O
VLDL,1317,O
and,1317,O
increasing,1317,O
HDL,1317,O
.,1317,O
It,1318,O
is,1318,O
likely,1318,O
that,1318,O
the,1318,O
early,1318,O
and,1318,O
striking,1318,O
increase,1318,O
of,1318,O
plasma,1318,O
HDL,1318,O
found,1318,O
in,1318,O
nephrotic,1318,B-Disease
rats,1318,O
is,1318,O
related,1318,O
to,1318,O
a,1318,O
direct,1318,O
effect,1318,O
of,1318,O
the,1318,O
drug,1318,O
on,1318,O
HDL,1318,O
metabolism,1318,O
.,1318,O
Fatal,1319,O
aplastic,1319,B-Disease
anemia,1319,I-Disease
following,1319,O
topical,1319,O
administration,1319,O
of,1319,O
ophthalmic,1319,O
chloramphenicol,1319,B-Chemical
.,1319,O
A,1320,O
73-year-old,1320,O
woman,1320,O
died,1320,O
of,1320,O
aplastic,1320,B-Disease
anemia,1320,I-Disease
less,1320,O
than,1320,O
two,1320,O
months,1320,O
after,1320,O
undergoing,1320,O
cataract,1320,B-Disease
extraction,1320,O
and,1320,O
beginning,1320,O
topical,1320,O
therapy,1320,O
with,1320,O
chloramphenicol,1320,B-Chemical
.,1320,O
The,1321,O
first,1321,O
signs,1321,O
of,1321,O
pancytopenia,1321,B-Disease
began,1321,O
within,1321,O
one,1321,O
month,1321,O
of,1321,O
the,1321,O
surgery,1321,O
.,1321,O
The,1322,O
pattern,1322,O
of,1322,O
the,1322,O
aplastic,1322,B-Disease
anemia,1322,I-Disease
was,1322,O
associated,1322,O
with,1322,O
an,1322,O
idiosyncratic,1322,O
response,1322,O
to,1322,O
chloramphenicol,1322,B-Chemical
.,1322,O
This,1323,O
was,1323,O
the,1323,O
second,1323,O
report,1323,O
of,1323,O
fatal,1323,O
aplastic,1323,B-Disease
anemia,1323,I-Disease
after,1323,O
topical,1323,O
treatment,1323,O
with,1323,O
chloramphenicol,1323,B-Chemical
for,1323,O
ocular,1323,O
conditions,1323,O
",",1323,O
although,1323,O
two,1323,O
cases,1323,O
of,1323,O
reversible,1323,O
bone,1323,B-Disease
marrow,1323,I-Disease
hypoplasia,1323,I-Disease
have,1323,O
also,1323,O
been,1323,O
reported,1323,O
.,1323,O
Any,1324,O
other,1324,O
suspected,1324,O
cases,1324,O
of,1324,O
ocular,1324,B-Disease
toxicity,1324,I-Disease
associated,1324,O
with,1324,O
topically,1324,O
applied,1324,O
chloramphenicol,1324,B-Chemical
should,1324,O
be,1324,O
reported,1324,O
to,1324,O
the,1324,O
National,1324,O
Registry,1324,O
of,1324,O
Drug-Induced,1324,O
Ocular,1324,O
Side,1324,O
Effects,1324,O
",",1324,O
Oregon,1324,O
Health,1324,O
Sciences,1324,O
University,1324,O
",",1324,O
Portland,1324,O
",",1324,O
OR,1324,O
97201,1324,O
.,1324,O
Midazolam,1325,B-Chemical
compared,1325,O
with,1325,O
thiopentone,1325,B-Chemical
as,1325,O
an,1325,O
induction,1325,O
agent,1325,O
.,1325,O
In,1326,O
patients,1326,O
premedicated,1326,O
with,1326,O
scopolamine,1326,B-Chemical
+,1326,O
morphine,1326,B-Chemical
(,1326,O
+5,1326,O
mg,1326,O
nitrazepam,1326,B-Chemical
the,1326,O
evening,1326,O
before,1326,O
surgery,1326,O
),1326,O
",",1326,O
the,1326,O
sleep-inducing,1326,O
effect,1326,O
of,1326,O
midazolam,1326,B-Chemical
0.15,1326,O
mg/kg,1326,O
i.v,1326,O
.,1326,O
was,1327,O
clearly,1327,O
slower,1327,O
in,1327,O
onset,1327,O
than,1327,O
that,1327,O
of,1327,O
thiopentone,1327,B-Chemical
4.67,1327,O
mg/kg,1327,O
i.v,1327,O
.,1327,O
Somewhat,1328,O
fewer,1328,O
cardiovascular,1328,O
and,1328,O
local,1328,O
sequelae,1328,O
were,1328,O
found,1328,O
in,1328,O
the,1328,O
midazolam,1328,B-Chemical
group,1328,O
",",1328,O
but,1328,O
",",1328,O
although,1328,O
apnoea,1328,B-Disease
occurred,1328,O
less,1328,O
often,1328,O
in,1328,O
the,1328,O
midazolam,1328,B-Chemical
group,1328,O
it,1328,O
lasted,1328,O
longer,1328,O
.,1328,O
On,1329,O
the,1329,O
whole,1329,O
",",1329,O
the,1329,O
differences,1329,O
between,1329,O
midazolam,1329,B-Chemical
and,1329,O
thiopentone,1329,B-Chemical
had,1329,O
no,1329,O
apparent,1329,O
clinical,1329,O
consequences,1329,O
.,1329,O
Midazolam,1330,B-Chemical
is,1330,O
a,1330,O
new,1330,O
alternative,1330,O
agent,1330,O
for,1330,O
induction,1330,O
in,1330,O
combination,1330,O
anaesthesia,1330,O
.,1330,O
Extrapyramidal,1331,O
side,1331,O
effects,1331,O
and,1331,O
oral,1331,O
haloperidol,1331,B-Chemical
:,1331,O
an,1331,O
analysis,1331,O
of,1331,O
explanatory,1331,O
patient,1331,O
and,1331,O
treatment,1331,O
characteristics,1331,O
.,1331,O
The,1332,O
incidence,1332,O
of,1332,O
extrapyramidal,1332,O
side,1332,O
effects,1332,O
(,1332,O
EPS,1332,O
),1332,O
was,1332,O
evaluated,1332,O
in,1332,O
98,1332,O
patients,1332,O
treated,1332,O
with,1332,O
haloperidol,1332,B-Chemical
.,1332,O
The,1333,O
incidence,1333,O
of,1333,O
parkinsonism,1333,B-Disease
was,1333,O
higher,1333,O
at,1333,O
higher,1333,O
doses,1333,O
of,1333,O
haloperidol,1333,B-Chemical
and,1333,O
in,1333,O
younger,1333,O
patients,1333,O
.,1333,O
Prophylactic,1334,O
antiparkinsonian,1334,O
medication,1334,O
was,1334,O
effective,1334,O
in,1334,O
younger,1334,O
but,1334,O
not,1334,O
in,1334,O
older,1334,O
patients,1334,O
.,1334,O
However,1335,O
",",1335,O
these,1335,O
medications,1335,O
were,1335,O
more,1335,O
effective,1335,O
in,1335,O
both,1335,O
young,1335,O
and,1335,O
old,1335,O
patients,1335,O
when,1335,O
given,1335,O
after,1335,O
parkinsonism,1335,B-Disease
developed,1335,O
.,1335,O
Akathisia,1336,B-Disease
was,1336,O
controlled,1336,O
by,1336,O
the,1336,O
benzodiazepine,1336,B-Chemical
lorazepam,1336,B-Chemical
in,1336,O
14,1336,O
out,1336,O
of,1336,O
16,1336,O
patients,1336,O
",",1336,O
while,1336,O
prophylactic,1336,O
antiparkinsonians,1336,O
were,1336,O
ineffective,1336,O
.,1336,O
The,1337,O
present,1337,O
study,1337,O
points,1337,O
to,1337,O
patient,1337,O
characteristics,1337,O
that,1337,O
may,1337,O
be,1337,O
of,1337,O
significance,1337,O
in,1337,O
the,1337,O
development,1337,O
of,1337,O
EPS,1337,O
due,1337,O
to,1337,O
haloperidol,1337,B-Chemical
.,1337,O
Deaths,1338,O
from,1338,O
local,1338,O
anesthetic-induced,1338,O
convulsions,1338,B-Disease
in,1338,O
mice,1338,O
.,1338,O
Median,1339,O
convulsant,1339,O
(,1339,O
CD50,1339,O
),1339,O
and,1339,O
median,1339,O
lethal,1339,O
(,1339,O
LD50,1339,O
),1339,O
doses,1339,O
of,1339,O
three,1339,O
representative,1339,O
local,1339,O
anesthetics,1339,O
were,1339,O
determined,1339,O
in,1339,O
adult,1339,O
mice,1339,O
to,1339,O
evaluate,1339,O
the,1339,O
threat,1339,O
to,1339,O
life,1339,O
of,1339,O
local,1339,O
anesthetic-induced,1339,O
convulsions,1339,B-Disease
.,1339,O
The,1340,O
CD50,1340,O
and,1340,O
LD50,1340,O
",",1340,O
respectively,1340,O
",",1340,O
were,1340,O
57.7,1340,O
and,1340,O
58.7,1340,O
mg/kg,1340,O
for,1340,O
bupivacaine,1340,B-Chemical
",",1340,O
111.0,1340,O
and,1340,O
133.1,1340,O
mg/kg,1340,O
for,1340,O
lidocaine,1340,B-Chemical
",",1340,O
and,1340,O
243.4,1340,O
and,1340,O
266.5,1340,O
mg/kg,1340,O
for,1340,O
chloroprocaine,1340,B-Chemical
.,1340,O
When,1341,O
given,1341,O
intraperitoneally,1341,O
",",1341,O
bupivacaine,1341,B-Chemical
thus,1341,O
was,1341,O
only,1341,O
about,1341,O
twice,1341,O
as,1341,O
toxic,1341,O
as,1341,O
lidocaine,1341,B-Chemical
and,1341,O
four,1341,O
times,1341,O
as,1341,O
toxic,1341,O
as,1341,O
chloroprocaine,1341,B-Chemical
.,1341,O
Convulsions,1342,B-Disease
always,1342,O
preceded,1342,O
death,1342,O
",",1342,O
except,1342,O
after,1342,O
precipitous,1342,O
cardiopulmonary,1342,B-Disease
arrest,1342,I-Disease
from,1342,O
extreme,1342,O
doses,1342,O
.,1342,O
A,1343,O
CD50,1343,O
dose,1343,O
of,1343,O
local,1343,O
anesthetic,1343,O
(,1343,O
causing,1343,O
convulsions,1343,B-Disease
in,1343,O
50,1343,O
%,1343,O
of,1343,O
mice,1343,O
),1343,O
was,1343,O
fatal,1343,O
in,1343,O
90,1343,O
%,1343,O
of,1343,O
bupivacaine-induced,1343,B-Chemical
seizures,1343,B-Disease
",",1343,O
in,1343,O
57,1343,O
%,1343,O
of,1343,O
the,1343,O
chloroprocaine,1343,B-Chemical
group,1343,O
",",1343,O
and,1343,O
in,1343,O
6,1343,O
%,1343,O
of,1343,O
the,1343,O
lidocaine,1343,B-Chemical
group,1343,O
.,1343,O
The,1344,O
narrow,1344,O
gap,1344,O
between,1344,O
convulsant,1344,O
and,1344,O
lethal,1344,O
doses,1344,O
of,1344,O
local,1344,O
anesthetics,1344,O
indicates,1344,O
that,1344,O
untreated,1344,O
convulsions,1344,B-Disease
present,1344,O
much,1344,O
more,1344,O
of,1344,O
a,1344,O
threat,1344,O
to,1344,O
life,1344,O
than,1344,O
heretofore,1344,O
appreciated,1344,O
.,1344,O
REM,1345,B-Disease
sleep,1345,I-Disease
deprivation,1345,I-Disease
changes,1345,O
behavioral,1345,O
response,1345,O
to,1345,O
catecholaminergic,1345,O
and,1345,O
serotonergic,1345,O
receptor,1345,O
activation,1345,O
in,1345,O
rats,1345,O
.,1345,O
The,1346,O
effects,1346,O
of,1346,O
REM,1346,B-Disease
sleep,1346,I-Disease
deprivation,1346,I-Disease
(,1346,O
REMD,1346,B-Disease
),1346,O
on,1346,O
apomorphine-induced,1346,B-Chemical
aggressiveness,1346,B-Disease
and,1346,O
quipazine-induced,1346,B-Chemical
head,1346,B-Disease
twitches,1346,I-Disease
in,1346,O
rats,1346,O
were,1346,O
determined,1346,O
.,1346,O
Forty-eight,1347,O
hr,1347,O
of,1347,O
REMD,1347,B-Disease
increased,1347,O
apomorphine-induced,1347,B-Chemical
aggressiveness,1347,B-Disease
",",1347,O
and,1347,O
reduced,1347,O
(,1347,O
immediately,1347,O
after,1347,O
completing,1347,O
of,1347,O
REMD,1347,B-Disease
),1347,O
or,1347,O
increased,1347,O
(,1347,O
96,1347,O
hr,1347,O
after,1347,O
completing,1347,O
of,1347,O
REMD,1347,B-Disease
),1347,O
quipazine-induced,1347,B-Chemical
head,1347,B-Disease
twitches,1347,I-Disease
.,1347,O
Results,1348,O
are,1348,O
discussed,1348,O
in,1348,O
terms,1348,O
of,1348,O
similarity,1348,O
to,1348,O
pharmacological,1348,O
effects,1348,O
of,1348,O
other,1348,O
antidepressive,1348,O
treatments,1348,O
.,1348,O
Fatal,1349,O
aplastic,1349,B-Disease
anemia,1349,I-Disease
due,1349,O
to,1349,O
indomethacin,1349,B-Chemical
--,1349,O
lymphocyte,1349,O
transformation,1349,O
tests,1349,O
in,1349,O
vitro,1349,O
.,1349,O
Although,1350,O
indomethacin,1350,B-Chemical
has,1350,O
been,1350,O
implicated,1350,O
as,1350,O
a,1350,O
possible,1350,O
cause,1350,O
of,1350,O
aplastic,1350,B-Disease
anemia,1350,I-Disease
on,1350,O
the,1350,O
basis,1350,O
of,1350,O
a,1350,O
few,1350,O
clinical,1350,O
observations,1350,O
",",1350,O
its,1350,O
role,1350,O
has,1350,O
not,1350,O
been,1350,O
definitely,1350,O
established,1350,O
.,1350,O
A,1351,O
case,1351,O
of,1351,O
fatal,1351,O
aplastic,1351,B-Disease
anemia,1351,I-Disease
is,1351,O
described,1351,O
in,1351,O
which,1351,O
no,1351,O
drugs,1351,O
other,1351,O
than,1351,O
allopurinol,1351,B-Chemical
and,1351,O
indomethacin,1351,B-Chemical
were,1351,O
given,1351,O
.,1351,O
Indomethacin,1352,B-Chemical
was,1352,O
first,1352,O
given,1352,O
four,1352,O
weeks,1352,O
prior,1352,O
to,1352,O
the,1352,O
onset,1352,O
of,1352,O
symptoms,1352,O
.,1352,O
A,1353,O
positive,1353,O
lymphocyte,1353,O
transformation,1353,O
test,1353,O
with,1353,O
indomethacin,1353,B-Chemical
in,1353,O
vitro,1353,O
further,1353,O
substantiates,1353,O
the,1353,O
potential,1353,O
role,1353,O
of,1353,O
this,1353,O
drug,1353,O
in,1353,O
causing,1353,O
aplastic,1353,B-Disease
anemia,1353,I-Disease
in,1353,O
a,1353,O
susceptible,1353,O
patient,1353,O
.,1353,O
Fortunately,1354,O
",",1354,O
this,1354,O
seems,1354,O
to,1354,O
be,1354,O
a,1354,O
very,1354,O
rare,1354,O
complication,1354,O
.,1354,O
Dose-effect,1355,O
and,1355,O
structure-function,1355,O
relationships,1355,O
in,1355,O
doxorubicin,1355,B-Chemical
cardiomyopathy,1355,B-Disease
.,1355,O
The,1356,O
cardiomyopathy,1356,B-Disease
(,1356,O
CM,1356,B-Disease
),1356,O
produced,1356,O
by,1356,O
the,1356,O
anticancer,1356,O
drug,1356,O
doxorubicin,1356,B-Chemical
(,1356,O
DXR,1356,B-Chemical
),1356,O
(,1356,O
Adriamycin,1356,B-Chemical
),1356,O
provides,1356,O
a,1356,O
unique,1356,O
opportunity,1356,O
to,1356,O
analyze,1356,O
dose-effect,1356,O
and,1356,O
structure-function,1356,O
relationships,1356,O
during,1356,O
development,1356,O
of,1356,O
myocardial,1356,B-Disease
disease,1356,I-Disease
.,1356,O
We,1357,O
measured,1357,O
the,1357,O
degree,1357,O
of,1357,O
morphologic,1357,O
damage,1357,O
by,1357,O
ultrastructural,1357,O
examination,1357,O
of,1357,O
endomyocardial,1357,O
biopsy,1357,O
and,1357,O
the,1357,O
degree,1357,O
of,1357,O
performance,1357,O
abnormally,1357,O
by,1357,O
right,1357,O
heart,1357,O
catheterization,1357,O
in,1357,O
patients,1357,O
receiving,1357,O
DXR,1357,B-Chemical
.,1357,O
Morphologic,1358,O
damage,1358,O
was,1358,O
variable,1358,O
but,1358,O
was,1358,O
proportional,1358,O
to,1358,O
the,1358,O
total,1358,O
cumulative,1358,O
DXR,1358,B-Chemical
dose,1358,O
between,1358,O
100,1358,O
and,1358,O
600,1358,O
mg/m2,1358,O
.,1358,O
Performance,1359,O
abnormalities,1359,O
correlated,1359,O
weakly,1359,O
with,1359,O
dose,1359,O
",",1359,O
exhibited,1359,O
a,1359,O
curvilinear,1359,O
relationship,1359,O
",",1359,O
and,1359,O
had,1359,O
a,1359,O
``,1359,O
threshold,1359,O
'',1359,O
for,1359,O
expression,1359,O
.,1359,O
Catheterization,1360,O
abnormalities,1360,O
correlated,1360,O
well,1360,O
with,1360,O
morphologic,1360,O
damage,1360,O
(,1360,O
r,1360,O
=,1360,O
0.57,1360,O
to,1360,O
0.78,1360,O
),1360,O
in,1360,O
a,1360,O
subgroup,1360,O
of,1360,O
patients,1360,O
in,1360,O
whom,1360,O
exercise,1360,O
hemodynamics,1360,O
were,1360,O
measured,1360,O
",",1360,O
and,1360,O
this,1360,O
relationship,1360,O
also,1360,O
exhibited,1360,O
a,1360,O
curvilinear,1360,O
",",1360,O
threshold,1360,O
configuration,1360,O
.,1360,O
In,1361,O
DXR-CM,1361,B-Chemical
myocardial,1361,B-Disease
damage,1361,I-Disease
is,1361,O
proportional,1361,O
to,1361,O
the,1361,O
degree,1361,O
of,1361,O
cytotoxic,1361,O
insult,1361,O
(,1361,O
DXR,1361,B-Chemical
dose,1361,O
),1361,O
while,1361,O
myocardial,1361,O
function,1361,O
is,1361,O
preserved,1361,O
until,1361,O
a,1361,O
critical,1361,O
dose,1361,O
or,1361,O
degree,1361,O
of,1361,O
damage,1361,O
is,1361,O
reached,1361,O
",",1361,O
after,1361,O
which,1361,O
myocardial,1361,O
performance,1361,O
deteriorates,1361,O
rapidly,1361,O
.,1361,O
Massive,1362,O
cerebral,1362,B-Disease
edema,1362,I-Disease
associated,1362,O
with,1362,O
fulminant,1362,O
hepatic,1362,B-Disease
failure,1362,I-Disease
in,1362,O
acetaminophen,1362,B-Chemical
overdose,1362,B-Disease
:,1362,O
possible,1362,O
role,1362,O
of,1362,O
cranial,1362,O
decompression,1362,O
.,1362,O
Cerebral,1363,B-Disease
edema,1363,I-Disease
may,1363,O
complicate,1363,O
the,1363,O
course,1363,O
of,1363,O
fulminant,1363,B-Disease
hepatic,1363,I-Disease
failure,1363,I-Disease
.,1363,O
Response,1364,O
to,1364,O
conventional,1364,O
therapy,1364,O
has,1364,O
been,1364,O
disappointing,1364,O
.,1364,O
We,1365,O
present,1365,O
a,1365,O
patient,1365,O
with,1365,O
fatal,1365,O
acetaminophen-induced,1365,B-Chemical
fulminant,1365,B-Disease
hepatic,1365,I-Disease
failure,1365,I-Disease
",",1365,O
with,1365,O
signs,1365,O
and,1365,O
symptoms,1365,O
of,1365,O
cerebral,1365,B-Disease
edema,1365,I-Disease
",",1365,O
unresponsive,1365,O
to,1365,O
conventional,1365,O
medical,1365,O
therapy,1365,O
.,1365,O
Cranial,1366,O
decompression,1366,O
was,1366,O
carried,1366,O
out,1366,O
.,1366,O
A,1367,O
justification,1367,O
of,1367,O
the,1367,O
need,1367,O
for,1367,O
further,1367,O
evaluation,1367,O
of,1367,O
cranial,1367,O
decompression,1367,O
in,1367,O
such,1367,O
patients,1367,O
is,1367,O
presented,1367,O
.,1367,O
Subjective,1368,O
assessment,1368,O
of,1368,O
sexual,1368,B-Disease
dysfunction,1368,I-Disease
of,1368,O
patients,1368,O
on,1368,O
long-term,1368,O
administration,1368,O
of,1368,O
digoxin,1368,B-Chemical
.,1368,O
Various,1369,O
data,1369,O
suggest,1369,O
that,1369,O
male,1369,O
patients,1369,O
who,1369,O
have,1369,O
received,1369,O
digoxin,1369,B-Chemical
on,1369,O
a,1369,O
longterm,1369,O
basis,1369,O
have,1369,O
increased,1369,O
levels,1369,O
of,1369,O
serum,1369,O
estrogen,1369,B-Chemical
and,1369,O
decreased,1369,O
levels,1369,O
of,1369,O
plasma,1369,O
testosterone,1369,B-Chemical
and,1369,O
luteinizing,1369,O
hormone,1369,O
(,1369,O
LH,1369,O
),1369,O
.,1369,O
This,1370,O
study,1370,O
was,1370,O
undertaken,1370,O
to,1370,O
investigate,1370,O
the,1370,O
links,1370,O
between,1370,O
the,1370,O
long-term,1370,O
administration,1370,O
of,1370,O
digoxin,1370,B-Chemical
therapy,1370,O
and,1370,O
sexual,1370,O
behavior,1370,O
",",1370,O
and,1370,O
the,1370,O
effect,1370,O
of,1370,O
digoxin,1370,B-Chemical
on,1370,O
plasma,1370,O
levels,1370,O
of,1370,O
estradiol,1370,B-Chemical
",",1370,O
testosterone,1370,B-Chemical
",",1370,O
and,1370,O
LH,1370,O
.,1370,O
The,1371,O
patients,1371,O
of,1371,O
the,1371,O
study,1371,O
and,1371,O
control,1371,O
group,1371,O
(,1371,O
without,1371,O
digoxin,1371,B-Chemical
),1371,O
were,1371,O
of,1371,O
similar,1371,O
cardiac,1371,O
functional,1371,O
capacity,1371,O
and,1371,O
age,1371,O
(,1371,O
25-40,1371,O
years,1371,O
),1371,O
and,1371,O
were,1371,O
randomly,1371,O
selected,1371,O
from,1371,O
the,1371,O
rheumatic,1371,B-Disease
heart,1371,I-Disease
disease,1371,I-Disease
patients,1371,O
.,1371,O
A,1372,O
subjective,1372,O
assessment,1372,O
of,1372,O
sexual,1372,O
behavior,1372,O
in,1372,O
the,1372,O
study,1372,O
and,1372,O
control,1372,O
groups,1372,O
was,1372,O
carried,1372,O
out,1372,O
",",1372,O
using,1372,O
parameters,1372,O
such,1372,O
as,1372,O
sexual,1372,O
desire,1372,O
",",1372,O
sexual,1372,O
excitement,1372,O
",",1372,O
and,1372,O
frequency,1372,O
of,1372,O
sexual,1372,O
relations,1372,O
.,1372,O
Personal,1373,O
interviews,1373,O
and,1373,O
a,1373,O
questionnaire,1373,O
were,1373,O
also,1373,O
used,1373,O
for,1373,O
the,1373,O
evaluation,1373,O
of,1373,O
sexual,1373,O
behavior,1373,O
.,1373,O
The,1374,O
findings,1374,O
support,1374,O
the,1374,O
reports,1374,O
concerning,1374,O
digoxin,1374,B-Chemical
effect,1374,O
on,1374,O
plasma,1374,O
estradiol,1374,B-Chemical
",",1374,O
testosterone,1374,B-Chemical
",",1374,O
and,1374,O
LH,1374,O
.,1374,O
The,1375,O
differences,1375,O
in,1375,O
the,1375,O
means,1375,O
were,1375,O
significant,1375,O
.,1375,O
Tests,1376,O
used,1376,O
to,1376,O
evaluate,1376,O
the,1376,O
changes,1376,O
in,1376,O
sexual,1376,O
behavior,1376,O
showed,1376,O
a,1376,O
significant,1376,O
decrease,1376,B-Disease
in,1376,I-Disease
sexual,1376,I-Disease
desire,1376,I-Disease
",",1376,O
sexual,1376,O
excitement,1376,O
phase,1376,O
(,1376,O
erection,1376,O
),1376,O
",",1376,O
and,1376,O
frequency,1376,O
of,1376,O
sexual,1376,O
relations,1376,O
in,1376,O
the,1376,O
study,1376,O
group,1376,O
.,1376,O
Endometrial,1377,B-Disease
carcinoma,1377,I-Disease
after,1377,O
Hodgkin,1377,B-Disease
disease,1377,I-Disease
in,1377,O
childhood,1377,O
.,1377,O
A,1378,O
34-year-old,1378,O
patient,1378,O
developed,1378,O
metastic,1378,O
endometrial,1378,B-Disease
carcinoma,1378,I-Disease
after,1378,O
Hodgkin,1378,B-Disease
disease,1378,I-Disease
in,1378,O
childhood,1378,O
.,1378,O
She,1379,O
had,1379,O
ovarian,1379,B-Disease
failure,1379,I-Disease
after,1379,O
abdominal,1379,O
irradiation,1379,O
and,1379,O
chemotherapy,1379,O
for,1379,O
Hodgkin,1379,B-Disease
disease,1379,I-Disease
",",1379,O
and,1379,O
received,1379,O
exogenous,1379,O
estrogens,1379,B-Chemical
",",1379,O
a,1379,O
treatment,1379,O
implicated,1379,O
in,1379,O
the,1379,O
development,1379,O
of,1379,O
endometrial,1379,B-Disease
cancer,1379,I-Disease
in,1379,O
menopausal,1379,O
women,1379,O
.,1379,O
Young,1380,O
women,1380,O
on,1380,O
replacement,1380,O
estrogens,1380,B-Chemical
for,1380,O
ovarian,1380,B-Disease
failure,1380,I-Disease
after,1380,O
cancer,1380,B-Disease
therapy,1380,O
may,1380,O
also,1380,O
have,1380,O
increased,1380,O
risk,1380,O
of,1380,O
endometrial,1380,B-Disease
carcinoma,1380,I-Disease
and,1380,O
should,1380,O
be,1380,O
examined,1380,O
periodically,1380,O
.,1380,O
Long-term,1381,O
lithium,1381,B-Chemical
treatment,1381,O
and,1381,O
the,1381,O
kidney,1381,O
.,1381,O
Interim,1382,O
report,1382,O
on,1382,O
fifty,1382,O
patients,1382,O
.,1382,O
This,1383,O
is,1383,O
a,1383,O
report,1383,O
on,1383,O
the,1383,O
first,1383,O
part,1383,O
of,1383,O
our,1383,O
study,1383,O
of,1383,O
the,1383,O
effects,1383,O
of,1383,O
long-term,1383,O
lithium,1383,B-Chemical
treatment,1383,O
on,1383,O
the,1383,O
kidney,1383,O
.,1383,O
Creatinine,1384,B-Chemical
clearance,1384,O
",",1384,O
maximum,1384,O
urinary,1384,O
osmolality,1384,O
and,1384,O
24,1384,O
hour,1384,O
urine,1384,O
volume,1384,O
have,1384,O
been,1384,O
tested,1384,O
in,1384,O
50,1384,O
affectively,1384,O
ill,1384,O
patients,1384,O
who,1384,O
have,1384,O
been,1384,O
on,1384,O
long-term,1384,O
lithium,1384,B-Chemical
for,1384,O
more,1384,O
than,1384,O
one,1384,O
year,1384,O
.,1384,O
These,1385,O
findings,1385,O
have,1385,O
been,1385,O
compared,1385,O
with,1385,O
norms,1385,O
and,1385,O
with,1385,O
values,1385,O
of,1385,O
the,1385,O
same,1385,O
tests,1385,O
from,1385,O
screening,1385,O
prior,1385,O
to,1385,O
lithium,1385,B-Chemical
",",1385,O
available,1385,O
for,1385,O
most,1385,O
of,1385,O
our,1385,O
patients,1385,O
.,1385,O
No,1386,O
evidence,1386,O
was,1386,O
found,1386,O
for,1386,O
any,1386,O
reduction,1386,O
of,1386,O
glomerular,1386,O
filtration,1386,O
during,1386,O
lithium,1386,B-Chemical
treatment,1386,O
.,1386,O
Low,1387,O
clearance,1387,O
values,1387,O
found,1387,O
in,1387,O
several,1387,O
patients,1387,O
could,1387,O
be,1387,O
accounted,1387,O
for,1387,O
by,1387,O
their,1387,O
age,1387,O
and,1387,O
their,1387,O
pre-lithium,1387,O
values,1387,O
.,1387,O
Urinary,1388,O
concentration,1388,O
defect,1388,O
appeared,1388,O
frequent,1388,O
but,1388,O
the,1388,O
extent,1388,O
of,1388,O
the,1388,O
impairment,1388,O
is,1388,O
difficult,1388,O
to,1388,O
assess,1388,O
because,1388,O
of,1388,O
the,1388,O
uncertainty,1388,O
about,1388,O
the,1388,O
norms,1388,O
applicable,1388,O
to,1388,O
this,1388,O
group,1388,O
of,1388,O
patients,1388,O
.,1388,O
The,1389,O
concentration,1389,O
defect,1389,O
appeared,1389,O
reversible,1389,O
",",1389,O
at,1389,O
least,1389,O
in,1389,O
part,1389,O
.,1389,O
Polyuria,1390,B-Disease
above,1390,O
3,1390,O
litres/24,1390,O
hours,1390,O
was,1390,O
found,1390,O
in,1390,O
10,1390,O
%,1390,O
of,1390,O
patients,1390,O
.,1390,O
An,1391,O
attempt,1391,O
is,1391,O
made,1391,O
to,1391,O
draw,1391,O
practical,1391,O
conclusions,1391,O
from,1391,O
the,1391,O
preliminary,1391,O
findings,1391,O
.,1391,O
Nephrotoxicity,1392,B-Disease
of,1392,O
cyclosporin,1392,B-Chemical
A,1392,I-Chemical
and,1392,O
FK506,1392,B-Chemical
:,1392,O
inhibition,1392,O
of,1392,O
calcineurin,1392,O
phosphatase,1392,O
.,1392,O
Cyclosporin,1393,B-Chemical
A,1393,I-Chemical
(,1393,O
CsA,1393,B-Chemical
;,1393,O
50,1393,O
mg/kg,1393,O
),1393,O
and,1393,O
Fujimycine,1393,B-Chemical
(,1393,O
FK506,1393,B-Chemical
;,1393,O
5,1393,O
mg/kg,1393,O
),1393,O
",",1393,O
but,1393,O
not,1393,O
the,1393,O
related,1393,O
macrolide,1393,B-Chemical
immunosuppressant,1393,O
rapamycin,1393,B-Chemical
(,1393,O
5,1393,O
mg/kg,1393,O
),1393,O
",",1393,O
caused,1393,O
a,1393,O
reduction,1393,O
of,1393,O
glomerular,1393,O
filtration,1393,O
rate,1393,O
",",1393,O
degenerative,1393,O
changes,1393,O
of,1393,O
proximal,1393,O
tubular,1393,O
epithelium,1393,O
",",1393,O
and,1393,O
hypertrophy,1393,B-Disease
of,1393,O
the,1393,O
juxtaglomerular,1393,O
apparatus,1393,O
in,1393,O
male,1393,O
Wistar,1393,O
rats,1393,O
when,1393,O
given,1393,O
for,1393,O
10,1393,O
days,1393,O
.,1393,O
The,1394,O
molecular,1394,O
mechanisms,1394,O
of,1394,O
CsA,1394,B-Chemical
and,1394,O
FK506,1394,B-Chemical
toxicity,1394,B-Disease
were,1394,O
investigated,1394,O
.,1394,O
Cyclophilin,1395,O
A,1395,O
and,1395,O
FK506-binding,1395,B-Chemical
protein,1395,O
",",1395,O
the,1395,O
main,1395,O
intracytoplasmic,1395,O
receptors,1395,O
for,1395,O
CsA,1395,B-Chemical
and,1395,O
FK506,1395,B-Chemical
",",1395,O
respectively,1395,O
",",1395,O
were,1395,O
each,1395,O
detected,1395,O
in,1395,O
renal,1395,O
tissue,1395,O
extract,1395,O
.,1395,O
In,1396,O
the,1396,O
kidney,1396,O
",",1396,O
high,1396,O
levels,1396,O
of,1396,O
immunoreactive,1396,O
and,1396,O
enzymatically,1396,O
active,1396,O
calcineurin,1396,O
were,1396,O
found,1396,O
which,1396,O
were,1396,O
inhibited,1396,O
by,1396,O
the,1396,O
immunosuppressants,1396,O
CsA,1396,B-Chemical
and,1396,O
FK506,1396,B-Chemical
",",1396,O
but,1396,O
not,1396,O
by,1396,O
rapamycin,1396,B-Chemical
.,1396,O
Finally,1397,O
",",1397,O
specific,1397,O
immunophilin-drug-calcineurin,1397,O
complexes,1397,O
formed,1397,O
only,1397,O
in,1397,O
the,1397,O
presence,1397,O
of,1397,O
CsA,1397,B-Chemical
and,1397,O
FK506,1397,B-Chemical
",",1397,O
but,1397,O
not,1397,O
rapamycin,1397,B-Chemical
.,1397,O
These,1398,O
results,1398,O
suggest,1398,O
that,1398,O
the,1398,O
nephrotoxic,1398,B-Disease
effects,1398,O
of,1398,O
CsA,1398,B-Chemical
and,1398,O
FK506,1398,B-Chemical
is,1398,O
likely,1398,O
mediated,1398,O
through,1398,O
binding,1398,O
to,1398,O
renal,1398,O
immunophilin,1398,O
and,1398,O
inhibiting,1398,O
calcineurin,1398,O
phosphatase,1398,O
.,1398,O
Acute,1399,B-Disease
renal,1399,I-Disease
failure,1399,I-Disease
in,1399,O
high,1399,O
dose,1399,O
carboplatin,1399,B-Chemical
chemotherapy,1399,O
.,1399,O
Carboplatin,1400,B-Chemical
has,1400,O
been,1400,O
reported,1400,O
to,1400,O
cause,1400,O
acute,1400,B-Disease
renal,1400,I-Disease
failure,1400,I-Disease
when,1400,O
administered,1400,O
in,1400,O
high,1400,O
doses,1400,O
to,1400,O
adult,1400,O
patients,1400,O
.,1400,O
We,1401,O
report,1401,O
a,1401,O
4,1401,O
1/2-year-old,1401,O
girl,1401,O
who,1401,O
was,1401,O
treated,1401,O
with,1401,O
high-dose,1401,O
carboplatin,1401,B-Chemical
for,1401,O
metastatic,1401,O
parameningeal,1401,O
embryonal,1401,B-Disease
rhabdomyosarcoma,1401,I-Disease
.,1401,O
Acute,1402,B-Disease
renal,1402,I-Disease
failure,1402,I-Disease
developed,1402,O
followed,1402,O
by,1402,O
a,1402,O
slow,1402,O
partial,1402,O
recovery,1402,O
of,1402,O
renal,1402,O
function,1402,O
.,1402,O
Possible,1403,O
contributing,1403,O
factors,1403,O
are,1403,O
discussed,1403,O
.,1403,O
Clinical,1404,O
evaluation,1404,O
on,1404,O
combined,1404,O
administration,1404,O
of,1404,O
oral,1404,O
prostacyclin,1404,B-Chemical
analogue,1404,O
beraprost,1404,B-Chemical
and,1404,O
phosphodiesterase,1404,O
inhibitor,1404,O
cilostazol,1404,B-Chemical
.,1404,O
Among,1405,O
various,1405,O
oral,1405,O
antiplatelets,1405,O
",",1405,O
a,1405,O
combination,1405,O
of,1405,O
a,1405,O
novel,1405,O
prostacyclin,1405,B-Chemical
analogue,1405,O
beraprost,1405,B-Chemical
(,1405,O
BPT,1405,B-Chemical
),1405,O
and,1405,O
a,1405,O
potent,1405,O
phosphodiesterase,1405,O
inhibitor,1405,O
cilostazol,1405,B-Chemical
(,1405,O
CLZ,1405,B-Chemical
),1405,O
may,1405,O
result,1405,O
in,1405,O
untoward,1405,O
clinical,1405,O
effects,1405,O
due,1405,O
to,1405,O
possible,1405,O
synergistic,1405,O
elevation,1405,O
of,1405,O
intracellular,1405,O
cAMP,1405,B-Chemical
(,1405,O
cyclic,1405,B-Chemical
adenosine,1405,I-Chemical
"3',5'-monophosphate",1405,I-Chemical
),1405,O
.,1405,O
Thereby,1406,O
",",1406,O
a,1406,O
clinical,1406,O
study,1406,O
of,1406,O
the,1406,O
combined,1406,O
administration,1406,O
of,1406,O
the,1406,O
two,1406,O
agents,1406,O
was,1406,O
attempted,1406,O
.,1406,O
Twelve,1407,O
healthy,1407,O
volunteers,1407,O
were,1407,O
assigned,1407,O
to,1407,O
take,1407,O
BPT/CLZ,1407,B-Chemical
in,1407,O
the,1407,O
following,1407,O
schedule,1407,O
;,1407,O
BPT,1407,B-Chemical
:,1407,O
40,1407,O
micrograms,1407,O
at,1407,O
day,1407,O
1,1407,O
and,1407,O
120,1407,O
micrograms,1407,O
t.i.d,1407,O
.,1407,O
from,1408,O
day,1408,O
7,1408,O
to,1408,O
14,1408,O
",",1408,O
CLZ,1408,B-Chemical
:,1408,O
200,1408,O
mg,1408,O
t.i.d,1408,O
.,1408,O
from,1409,O
day,1409,O
3,1409,O
to,1409,O
14,1409,O
.,1409,O
At,1410,O
various,1410,O
time,1410,O
intervals,1410,O
",",1410,O
physical,1410,O
examination,1410,O
and,1410,O
blood,1410,O
collection,1410,O
for,1410,O
ex,1410,O
vivo,1410,O
platelet,1410,B-Disease
aggregation,1410,I-Disease
and,1410,O
determination,1410,O
of,1410,O
intraplatelet,1410,O
cAMP,1410,B-Chemical
were,1410,O
performed,1410,O
.,1410,O
Throughout,1411,O
the,1411,O
observation,1411,O
period,1411,O
",",1411,O
no,1411,O
significant,1411,O
alteration,1411,O
in,1411,O
vital,1411,O
signs,1411,O
was,1411,O
observed,1411,O
.,1411,O
Seven,1412,O
out,1412,O
of,1412,O
12,1412,O
subjects,1412,O
experienced,1412,O
headache,1412,B-Disease
of,1412,O
a,1412,O
short,1412,O
duration,1412,O
accompanying,1412,O
facial,1412,B-Disease
flush,1412,I-Disease
in,1412,O
one,1412,O
and,1412,O
nausea,1412,B-Disease
in,1412,O
one,1412,O
",",1412,O
especially,1412,O
after,1412,O
ingestion,1412,O
of,1412,O
CLZ,1412,B-Chemical
.,1412,O
All,1413,O
of,1413,O
these,1413,O
symptoms,1413,O
",",1413,O
probably,1413,O
caused,1413,O
by,1413,O
the,1413,O
vasodilating,1413,O
effect,1413,O
of,1413,O
the,1413,O
two,1413,O
agents,1413,O
",",1413,O
were,1413,O
of,1413,O
mild,1413,O
degree,1413,O
and,1413,O
no,1413,O
special,1413,O
treatment,1413,O
was,1413,O
required,1413,O
.,1413,O
Intraplatelet,1414,O
cAMP,1414,B-Chemical
content,1414,O
was,1414,O
gradually,1414,O
but,1414,O
significantly,1414,O
increased,1414,O
to,1414,O
9.84,1414,O
+/-,1414,O
4.59,1414,O
pmol,1414,O
per,1414,O
10,1414,O
(,1414,O
9,1414,O
),1414,O
platelets,1414,O
at,1414,O
day,1414,O
14,1414,O
in,1414,O
comparison,1414,O
with,1414,O
the,1414,O
initial,1414,O
value,1414,O
(,1414,O
6.87,1414,O
+/-,1414,O
2.25,1414,O
pmol,1414,O
),1414,O
.,1414,O
The,1415,O
platelet,1415,O
aggregability,1415,O
was,1415,O
significantly,1415,O
suppressed,1415,O
at,1415,O
various,1415,O
time,1415,O
intervals,1415,O
but,1415,O
no,1415,O
additive,1415,O
or,1415,O
synergistic,1415,O
inhibitory,1415,O
effect,1415,O
by,1415,O
the,1415,O
combined,1415,O
administration,1415,O
was,1415,O
noted,1415,O
.,1415,O
In,1416,O
conclusion,1416,O
",",1416,O
the,1416,O
combined,1416,O
administration,1416,O
of,1416,O
BPT/CLZ,1416,B-Chemical
is,1416,O
safe,1416,O
at,1416,O
doses,1416,O
used,1416,O
in,1416,O
the,1416,O
study,1416,O
",",1416,O
though,1416,O
the,1416,O
beneficial,1416,O
clinical,1416,O
effect,1416,O
of,1416,O
the,1416,O
combined,1416,O
administration,1416,O
has,1416,O
yet,1416,O
to,1416,O
be,1416,O
elucidated,1416,O
.,1416,O
Pravastatin-associated,1417,B-Chemical
myopathy,1417,B-Disease
.,1417,O
Report,1418,O
of,1418,O
a,1418,O
case,1418,O
.,1418,O
A,1419,O
case,1419,O
of,1419,O
acute,1419,O
inflammatory,1419,B-Disease
myopathy,1419,I-Disease
associated,1419,O
with,1419,O
the,1419,O
use,1419,O
of,1419,O
pravastatin,1419,B-Chemical
",",1419,O
a,1419,O
new,1419,O
hydrophilic,1419,O
3-hydroxy-3,1419,O
methylglutaril,1419,O
coenzyme,1419,O
A,1419,O
reductase,1419,O
inhibitor,1419,O
",",1419,O
is,1419,O
reported,1419,O
.,1419,O
The,1420,O
patient,1420,O
",",1420,O
a,1420,O
69-year-old,1420,O
man,1420,O
was,1420,O
affected,1420,O
by,1420,O
non-insulin-dependent,1420,B-Disease
diabetes,1420,I-Disease
mellitus,1420,I-Disease
and,1420,O
hypertension,1420,B-Disease
.,1420,O
He,1421,O
assumed,1421,O
pravastatin,1421,B-Chemical
(,1421,O
20,1421,O
mg/day,1421,O
),1421,O
because,1421,O
of,1421,O
hypercholesterolemia,1421,B-Disease
.,1421,O
He,1422,O
was,1422,O
admitted,1422,O
with,1422,O
acute,1422,O
myopathy,1422,B-Disease
of,1422,O
the,1422,O
lower,1422,O
limbs,1422,O
which,1422,O
resolved,1422,O
in,1422,O
a,1422,O
few,1422,O
days,1422,O
after,1422,O
pravastatin,1422,B-Chemical
discontinuation,1422,O
.,1422,O
A,1423,O
previously,1423,O
unknown,1423,O
hypothyroidism,1423,B-Disease
",",1423,O
probably,1423,O
due,1423,O
to,1423,O
chronic,1423,O
autoimmune,1423,B-Disease
thyroiditis,1423,I-Disease
",",1423,O
was,1423,O
evidenced,1423,O
.,1423,O
Muscle,1424,O
biopsy,1424,O
(,1424,O
left,1424,O
gastrocnemius,1424,O
),1424,O
revealed,1424,O
a,1424,O
perimysial,1424,O
and,1424,O
endomysial,1424,O
inflammatory,1424,O
infiltrate,1424,O
with,1424,O
a,1424,O
prevalence,1424,O
of,1424,O
CD4+,1424,O
lymphocytes,1424,O
.,1424,O
While,1425,O
lovastatin,1425,B-Chemical
and,1425,O
simvastatin,1425,B-Chemical
have,1425,O
been,1425,O
associated,1425,O
with,1425,O
toxic,1425,O
myopathy,1425,B-Disease
",",1425,O
pravastatin-associated,1425,B-Chemical
myopathy,1425,B-Disease
could,1425,O
represent,1425,O
a,1425,O
distinct,1425,O
",",1425,O
inflammatory,1425,O
entity,1425,O
.,1425,O
Etoposide-related,1426,B-Chemical
myocardial,1426,B-Disease
infarction,1426,I-Disease
.,1426,O
The,1427,O
occurrence,1427,O
of,1427,O
a,1427,O
myocardial,1427,B-Disease
infarction,1427,I-Disease
is,1427,O
reported,1427,O
after,1427,O
chemotherapy,1427,O
containing,1427,O
etoposide,1427,B-Chemical
",",1427,O
in,1427,O
a,1427,O
man,1427,O
with,1427,O
no,1427,O
risk,1427,O
factors,1427,O
for,1427,O
coronary,1427,B-Disease
heart,1427,I-Disease
disease,1427,I-Disease
.,1427,O
Possible,1428,O
causal,1428,O
mechanisms,1428,O
are,1428,O
discussed,1428,O
.,1428,O
Halogenated,1429,O
anesthetics,1429,O
form,1429,O
liver,1429,O
adducts,1429,O
and,1429,O
antigens,1429,O
that,1429,O
cross-react,1429,O
with,1429,O
halothane-induced,1429,B-Chemical
antibodies,1429,O
.,1429,O
Two,1430,O
halogenated,1430,O
anesthetics,1430,O
",",1430,O
enflurane,1430,B-Chemical
and,1430,O
isoflurane,1430,B-Chemical
",",1430,O
have,1430,O
been,1430,O
associated,1430,O
with,1430,O
an,1430,O
allergic-type,1430,O
hepatic,1430,B-Disease
injury,1430,I-Disease
both,1430,O
alone,1430,O
and,1430,O
following,1430,O
previous,1430,O
exposure,1430,O
to,1430,O
halothane,1430,B-Chemical
.,1430,O
Halothane,1431,B-Chemical
hepatitis,1431,B-Disease
appears,1431,O
to,1431,O
involve,1431,O
an,1431,O
aberrant,1431,O
immune,1431,O
response,1431,O
.,1431,O
An,1432,O
antibody,1432,O
response,1432,O
to,1432,O
a,1432,O
protein-bound,1432,O
biotransformation,1432,O
product,1432,O
(,1432,O
trifluoroacetyl,1432,B-Chemical
adduct,1432,O
),1432,O
has,1432,O
been,1432,O
detected,1432,O
on,1432,O
halothane,1432,B-Chemical
hepatitis,1432,B-Disease
patients,1432,O
.,1432,O
This,1433,O
study,1433,O
was,1433,O
performed,1433,O
to,1433,O
determine,1433,O
cross-reactivity,1433,O
between,1433,O
enflurane,1433,B-Chemical
and,1433,O
isoflurane,1433,B-Chemical
with,1433,O
the,1433,O
hypersensitivity,1433,B-Disease
induced,1433,O
by,1433,O
halothane,1433,B-Chemical
.,1433,O
The,1434,O
subcellular,1434,O
and,1434,O
lobular,1434,O
production,1434,O
of,1434,O
hepatic,1434,O
neoantigens,1434,O
recognized,1434,O
by,1434,O
halothane-induced,1434,B-Chemical
antibodies,1434,O
following,1434,O
enflurane,1434,B-Chemical
and,1434,O
isoflurane,1434,B-Chemical
",",1434,O
and,1434,O
the,1434,O
biochemical,1434,O
nature,1434,O
of,1434,O
these,1434,O
neoantigens,1434,O
was,1434,O
investigated,1434,O
in,1434,O
two,1434,O
animal,1434,O
models,1434,O
.,1434,O
Enflurane,1435,B-Chemical
administration,1435,O
resulted,1435,O
in,1435,O
neoantigens,1435,O
detected,1435,O
in,1435,O
both,1435,O
the,1435,O
microsomal,1435,O
and,1435,O
cytosolic,1435,O
fraction,1435,O
of,1435,O
liver,1435,O
homogenates,1435,O
and,1435,O
in,1435,O
the,1435,O
centrilobular,1435,O
region,1435,O
of,1435,O
the,1435,O
liver,1435,O
.,1435,O
In,1436,O
the,1436,O
same,1436,O
liver,1436,O
",",1436,O
biochemical,1436,O
analysis,1436,O
detected,1436,O
fluorinated,1436,O
liver,1436,O
adducts,1436,O
that,1436,O
were,1436,O
up,1436,O
to,1436,O
20-fold,1436,O
greater,1436,O
in,1436,O
guinea,1436,O
pigs,1436,O
than,1436,O
in,1436,O
rats,1436,O
.,1436,O
This,1437,O
supports,1437,O
and,1437,O
extends,1437,O
previous,1437,O
evidence,1437,O
for,1437,O
a,1437,O
mechanism,1437,O
by,1437,O
which,1437,O
enflurane,1437,B-Chemical
and/or,1437,O
isoflurane,1437,B-Chemical
could,1437,O
produce,1437,O
a,1437,O
hypersensitivity,1437,B-Disease
condition,1437,O
similar,1437,O
to,1437,O
that,1437,O
of,1437,O
halothane,1437,B-Chemical
hepatitis,1437,B-Disease
either,1437,O
alone,1437,O
or,1437,O
subsequent,1437,O
to,1437,O
halothane,1437,B-Chemical
administration,1437,O
.,1437,O
The,1438,O
guinea,1438,O
pig,1438,O
would,1438,O
appear,1438,O
to,1438,O
be,1438,O
a,1438,O
useful,1438,O
model,1438,O
for,1438,O
further,1438,O
investigations,1438,O
of,1438,O
the,1438,O
immunological,1438,O
response,1438,O
to,1438,O
these,1438,O
antigens,1438,O
.,1438,O
Cholinergic,1439,O
toxicity,1439,B-Disease
resulting,1439,O
from,1439,O
ocular,1439,O
instillation,1439,O
of,1439,O
echothiophate,1439,B-Chemical
iodide,1439,I-Chemical
eye,1439,O
drops,1439,O
.,1439,O
A,1440,O
patient,1440,O
developed,1440,O
a,1440,O
severe,1440,O
cholinergic,1440,O
syndrome,1440,O
from,1440,O
the,1440,O
use,1440,O
of,1440,O
echothiophate,1440,B-Chemical
iodide,1440,I-Chemical
ophthalmic,1440,O
drops,1440,O
",",1440,O
presented,1440,O
with,1440,O
profound,1440,O
muscle,1440,B-Disease
weakness,1440,I-Disease
and,1440,O
was,1440,O
initially,1440,O
given,1440,O
the,1440,O
diagnosis,1440,O
of,1440,O
myasthenia,1440,B-Disease
gravis,1440,I-Disease
.,1440,O
Red,1441,O
blood,1441,O
cell,1441,O
and,1441,O
serum,1441,O
cholinesterase,1441,O
levels,1441,O
were,1441,O
severely,1441,O
depressed,1441,O
and,1441,O
symptoms,1441,O
resolved,1441,O
spontaneously,1441,O
following,1441,O
discontinuation,1441,O
of,1441,O
the,1441,O
eye,1441,O
drops,1441,O
.,1441,O
Seizure,1442,B-Disease
after,1442,O
flumazenil,1442,B-Chemical
administration,1442,O
in,1442,O
a,1442,O
pediatric,1442,O
patient,1442,O
.,1442,O
Flumazenil,1443,B-Chemical
is,1443,O
a,1443,O
benzodiazepine,1443,B-Chemical
receptor,1443,O
antagonist,1443,O
used,1443,O
to,1443,O
reverse,1443,O
sedation,1443,O
and,1443,O
respiratory,1443,B-Disease
depression,1443,I-Disease
induced,1443,O
by,1443,O
benzodiazepines,1443,B-Chemical
.,1443,O
Seizures,1444,B-Disease
and,1444,O
cardiac,1444,B-Disease
arrhythmias,1444,I-Disease
have,1444,O
complicated,1444,O
its,1444,O
use,1444,O
in,1444,O
adult,1444,O
patients,1444,O
.,1444,O
Overdose,1445,B-Disease
patients,1445,O
who,1445,O
have,1445,O
coingested,1445,O
tricyclic,1445,O
antidepressants,1445,O
have,1445,O
a,1445,O
higher,1445,O
risk,1445,O
of,1445,O
these,1445,O
complications,1445,O
.,1445,O
Little,1446,O
information,1446,O
exists,1446,O
concerning,1446,O
adverse,1446,O
effects,1446,O
of,1446,O
flumazenil,1446,B-Chemical
in,1446,O
children,1446,O
.,1446,O
We,1447,O
report,1447,O
the,1447,O
occurrence,1447,O
of,1447,O
a,1447,O
generalized,1447,O
tonic-clonic,1447,B-Disease
seizure,1447,I-Disease
in,1447,O
a,1447,O
pediatric,1447,O
patient,1447,O
following,1447,O
the,1447,O
administration,1447,O
of,1447,O
flumazenil,1447,B-Chemical
.,1447,O
Phase,1448,O
I,1448,O
trial,1448,O
of,1448,O
13-cis-retinoic,1448,B-Chemical
acid,1448,I-Chemical
in,1448,O
children,1448,O
with,1448,O
neuroblastoma,1448,B-Disease
following,1448,O
bone,1448,O
marrow,1448,O
transplantation,1448,O
.,1448,O
PURPOSE,1449,O
:,1449,O
Treatment,1449,O
of,1449,O
neuroblastoma,1449,B-Disease
cell,1449,O
lines,1449,O
with,1449,O
13-cis-retinoic,1449,B-Chemical
acid,1449,I-Chemical
(,1449,O
cis-RA,1449,B-Chemical
),1449,O
can,1449,O
cause,1449,O
sustained,1449,O
inhibition,1449,O
of,1449,O
proliferation,1449,O
.,1449,O
Since,1450,O
cis-RA,1450,B-Chemical
has,1450,O
demonstrated,1450,O
clinical,1450,O
responses,1450,O
in,1450,O
neuroblastoma,1450,B-Disease
patients,1450,O
",",1450,O
it,1450,O
may,1450,O
be,1450,O
effective,1450,O
in,1450,O
preventing,1450,O
relapse,1450,O
after,1450,O
cytotoxic,1450,O
therapy,1450,O
.,1450,O
This,1451,O
phase,1451,O
I,1451,O
trial,1451,O
was,1451,O
designed,1451,O
to,1451,O
determine,1451,O
the,1451,O
maximal-tolerated,1451,O
dosage,1451,O
(,1451,O
MTD,1451,O
),1451,O
",",1451,O
toxicities,1451,B-Disease
",",1451,O
and,1451,O
pharmacokinetics,1451,O
of,1451,O
cis-RA,1451,B-Chemical
administered,1451,O
on,1451,O
an,1451,O
intermittent,1451,O
schedule,1451,O
in,1451,O
children,1451,O
with,1451,O
neuroblastoma,1451,B-Disease
following,1451,O
bone,1451,O
marrow,1451,O
transplantation,1451,O
(,1451,O
BMT,1451,O
),1451,O
.,1451,O
PATIENTS,1452,O
AND,1452,O
METHODS,1452,O
:,1452,O
Fifty-one,1452,O
assessable,1452,O
patients,1452,O
",",1452,O
2,1452,O
to,1452,O
12,1452,O
years,1452,O
of,1452,O
age,1452,O
",",1452,O
were,1452,O
treated,1452,O
with,1452,O
oral,1452,O
cis-RA,1452,B-Chemical
administered,1452,O
in,1452,O
two,1452,O
equally,1452,O
divided,1452,O
doses,1452,O
daily,1452,O
for,1452,O
2,1452,O
weeks,1452,O
",",1452,O
followed,1452,O
by,1452,O
a,1452,O
2-week,1452,O
rest,1452,O
period,1452,O
",",1452,O
for,1452,O
up,1452,O
to,1452,O
12,1452,O
courses,1452,O
.,1452,O
The,1453,O
dose,1453,O
was,1453,O
escalated,1453,O
from,1453,O
100,1453,O
to,1453,O
200,1453,O
mg/m2/d,1453,O
until,1453,O
dose-limiting,1453,O
toxicity,1453,B-Disease
(,1453,O
DLT,1453,O
),1453,O
was,1453,O
observed,1453,O
.,1453,O
A,1454,O
single,1454,O
intrapatient,1454,O
dose,1454,O
escalation,1454,O
was,1454,O
permitted,1454,O
.,1454,O
RESULTS,1455,O
:,1455,O
The,1455,O
MTD,1455,O
of,1455,O
cis-RA,1455,B-Chemical
was,1455,O
160,1455,O
mg/m2/d,1455,O
.,1455,O
Dose-limiting,1456,O
toxicities,1456,B-Disease
in,1456,O
six,1456,O
of,1456,O
nine,1456,O
patients,1456,O
at,1456,O
200,1456,O
mg/m2/d,1456,O
included,1456,O
hypercalcemia,1456,B-Disease
(,1456,O
n,1456,O
=,1456,O
3,1456,O
),1456,O
",",1456,O
rash,1456,B-Disease
(,1456,O
n,1456,O
=,1456,O
2,1456,O
),1456,O
",",1456,O
and,1456,O
anemia/thrombocytopenia/emesis/rash,1456,B-Disease
(,1456,O
n,1456,O
=,1456,O
1,1456,O
),1456,O
.,1456,O
All,1457,O
toxicities,1457,B-Disease
resolved,1457,O
after,1457,O
cis-RA,1457,B-Chemical
was,1457,O
discontinued,1457,O
.,1457,O
Three,1458,O
complete,1458,O
responses,1458,O
were,1458,O
observed,1458,O
in,1458,O
marrow,1458,O
metastases,1458,B-Disease
.,1458,O
Serum,1459,O
levels,1459,O
of,1459,O
7.4,1459,O
+/-,1459,O
3.0,1459,O
mumol/L,1459,O
(,1459,O
peak,1459,O
),1459,O
and,1459,O
4.0,1459,O
+/-,1459,O
2.8,1459,O
mumol/L,1459,O
(,1459,O
trough,1459,O
),1459,O
at,1459,O
the,1459,O
MTD,1459,O
were,1459,O
maintained,1459,O
during,1459,O
14,1459,O
days,1459,O
of,1459,O
therapy,1459,O
.,1459,O
The,1460,O
DLT,1460,O
correlated,1460,O
with,1460,O
serum,1460,O
levels,1460,O
>,1460,O
or,1460,O
=,1460,O
10,1460,O
mumol/L,1460,O
.,1460,O
CONCLUSION,1461,O
:,1461,O
The,1461,O
MTD,1461,O
of,1461,O
cis-RA,1461,B-Chemical
given,1461,O
on,1461,O
this,1461,O
intermittent,1461,O
schedule,1461,O
was,1461,O
160,1461,O
mg/m2/d,1461,O
.,1461,O
Serum,1462,O
levels,1462,O
known,1462,O
to,1462,O
be,1462,O
effective,1462,O
against,1462,O
neuroblastoma,1462,B-Disease
in,1462,O
vitro,1462,O
were,1462,O
achieved,1462,O
at,1462,O
this,1462,O
dose,1462,O
.,1462,O
The,1463,O
DLT,1463,O
included,1463,O
hypercalcemia,1463,B-Disease
",",1463,O
and,1463,O
may,1463,O
be,1463,O
predicted,1463,O
by,1463,O
serum,1463,O
cis-RA,1463,B-Chemical
levels,1463,O
.,1463,O
Monitoring,1464,O
of,1464,O
serum,1464,O
calcium,1464,B-Chemical
and,1464,O
cis-RA,1464,B-Chemical
levels,1464,O
is,1464,O
indicated,1464,O
in,1464,O
future,1464,O
trials,1464,O
.,1464,O
Time,1465,O
dependence,1465,O
of,1465,O
plasma,1465,O
malondialdehyde,1465,B-Chemical
",",1465,O
oxypurines,1465,B-Chemical
",",1465,O
and,1465,O
nucleosides,1465,B-Chemical
during,1465,O
incomplete,1465,O
cerebral,1465,B-Disease
ischemia,1465,I-Disease
in,1465,O
the,1465,O
rat,1465,O
.,1465,O
Incomplete,1466,O
cerebral,1466,B-Disease
ischemia,1466,I-Disease
(,1466,O
30,1466,O
min,1466,O
),1466,O
was,1466,O
induced,1466,O
in,1466,O
the,1466,O
rat,1466,O
by,1466,O
bilaterally,1466,O
clamping,1466,O
the,1466,O
common,1466,O
carotid,1466,O
arteries,1466,O
.,1466,O
Peripheral,1467,O
venous,1467,O
blood,1467,O
samples,1467,O
were,1467,O
withdrawn,1467,O
from,1467,O
the,1467,O
femoral,1467,O
vein,1467,O
four,1467,O
times,1467,O
(,1467,O
once,1467,O
every,1467,O
5,1467,O
min,1467,O
),1467,O
before,1467,O
ischemia,1467,B-Disease
(,1467,O
0,1467,O
time,1467,O
),1467,O
and,1467,O
5,1467,O
",",1467,O
15,1467,O
",",1467,O
and,1467,O
30,1467,O
min,1467,O
after,1467,O
ischemia,1467,B-Disease
.,1467,O
Plasma,1468,O
extracts,1468,O
were,1468,O
analyzed,1468,O
by,1468,O
a,1468,O
highly,1468,O
sensitive,1468,O
high-performance,1468,O
liquid,1468,O
chromatographic,1468,O
method,1468,O
for,1468,O
the,1468,O
direct,1468,O
determination,1468,O
of,1468,O
malondialdehyde,1468,B-Chemical
",",1468,O
oxypurines,1468,B-Chemical
",",1468,O
and,1468,O
nucleosides,1468,B-Chemical
.,1468,O
During,1469,O
ischemia,1469,B-Disease
",",1469,O
a,1469,O
time-dependent,1469,O
increase,1469,O
of,1469,O
plasma,1469,O
oxypurines,1469,B-Chemical
and,1469,O
nucleosides,1469,B-Chemical
was,1469,O
observed,1469,O
.,1469,O
Plasma,1470,O
malondialdehyde,1470,B-Chemical
",",1470,O
which,1470,O
was,1470,O
present,1470,O
in,1470,O
minimal,1470,O
amount,1470,O
at,1470,O
zero,1470,O
time,1470,O
(,1470,O
0.058,1470,O
mumol/liter,1470,O
plasma,1470,O
;,1470,O
SD,1470,O
0.015,1470,O
),1470,O
",",1470,O
increased,1470,O
after,1470,O
5,1470,O
min,1470,O
of,1470,O
ischemia,1470,B-Disease
",",1470,O
resulting,1470,O
in,1470,O
a,1470,O
fivefold,1470,O
increase,1470,O
after,1470,O
30,1470,O
min,1470,O
of,1470,O
carotid,1470,O
occlusion,1470,O
(,1470,O
0.298,1470,O
mumol/liter,1470,O
plasma,1470,O
;,1470,O
SD,1470,O
0.078,1470,O
),1470,O
.,1470,O
Increased,1471,O
plasma,1471,O
malondialdehyde,1471,B-Chemical
was,1471,O
also,1471,O
recorded,1471,O
in,1471,O
two,1471,O
other,1471,O
groups,1471,O
of,1471,O
animals,1471,O
subjected,1471,O
to,1471,O
the,1471,O
same,1471,O
experimental,1471,O
model,1471,O
",",1471,O
one,1471,O
receiving,1471,O
20,1471,O
mg/kg,1471,O
b.w,1471,O
.,1471,O
of,1472,O
the,1472,O
cyclooxygenase,1472,O
inhibitor,1472,O
acetylsalicylate,1472,B-Chemical
intravenously,1472,O
immediately,1472,O
before,1472,O
ischemia,1472,B-Disease
",",1472,O
the,1472,O
other,1472,O
receiving,1472,O
650,1472,O
micrograms/kg,1472,O
b.w,1472,O
.,1472,O
of,1473,O
the,1473,O
hypotensive,1473,B-Disease
drug,1473,O
nitroprusside,1473,B-Chemical
at,1473,O
a,1473,O
flow,1473,O
rate,1473,O
of,1473,O
103,1473,O
microliters/min,1473,O
intravenously,1473,O
during,1473,O
ischemia,1473,B-Disease
",",1473,O
although,1473,O
in,1473,O
this,1473,O
latter,1473,O
group,1473,O
malondialdehyde,1473,B-Chemical
was,1473,O
significantly,1473,O
higher,1473,O
.,1473,O
The,1474,O
present,1474,O
data,1474,O
indicate,1474,O
that,1474,O
the,1474,O
determination,1474,O
of,1474,O
malondialdehyde,1474,B-Chemical
",",1474,O
oxypurines,1474,B-Chemical
",",1474,O
and,1474,O
nucleosides,1474,B-Chemical
in,1474,O
peripheral,1474,O
blood,1474,O
",",1474,O
may,1474,O
be,1474,O
used,1474,O
to,1474,O
monitor,1474,O
the,1474,O
metabolic,1474,O
alterations,1474,O
of,1474,O
tissues,1474,O
occurring,1474,O
during,1474,O
ischemic,1474,B-Disease
phenomena,1474,O
.,1474,O
(,1475,O
ABSTRACT,1475,O
TRUNCATED,1475,O
AT,1475,O
250,1475,O
WORDS,1475,O
),1475,O
Acute,1476,O
renal,1476,B-Disease
toxicity,1476,I-Disease
of,1476,O
doxorubicin,1476,B-Chemical
(,1476,O
adriamycin,1476,B-Chemical
),1476,O
-loaded,1476,O
cyanoacrylate,1476,B-Chemical
nanoparticles,1476,O
.,1476,O
Acute,1477,O
doxorubicin-loaded,1477,B-Chemical
nanoparticle,1477,O
(,1477,O
DXNP,1477,O
),1477,O
renal,1477,B-Disease
toxicity,1477,I-Disease
was,1477,O
explored,1477,O
in,1477,O
both,1477,O
normal,1477,O
rats,1477,O
and,1477,O
rats,1477,O
with,1477,O
experimental,1477,O
glomerulonephritis,1477,B-Disease
.,1477,O
In,1478,O
normal,1478,O
rats,1478,O
",",1478,O
2/6,1478,O
rats,1478,O
given,1478,O
free,1478,O
doxorubicin,1478,B-Chemical
(,1478,O
DX,1478,B-Chemical
),1478,O
(,1478,O
5,1478,O
mg/kg,1478,O
),1478,O
died,1478,O
within,1478,O
one,1478,O
week,1478,O
",",1478,O
whereas,1478,O
all,1478,O
control,1478,O
animals,1478,O
and,1478,O
all,1478,O
rats,1478,O
having,1478,O
received,1478,O
free,1478,O
NP,1478,O
or,1478,O
DXNP,1478,O
survived,1478,O
.,1478,O
A,1479,O
3,1479,O
times,1479,O
higher,1479,O
proteinuria,1479,B-Disease
appeared,1479,O
in,1479,O
animals,1479,O
treated,1479,O
with,1479,O
DXNP,1479,O
than,1479,O
in,1479,O
those,1479,O
treated,1479,O
with,1479,O
DX,1479,B-Chemical
.,1479,O
Free,1480,O
NP,1480,O
did,1480,O
not,1480,O
provoke,1480,O
any,1480,O
proteinuria,1480,B-Disease
.,1480,O
Two,1481,O
hr,1481,O
post-injection,1481,O
",",1481,O
DXNP,1481,O
was,1481,O
2.7,1481,O
times,1481,O
more,1481,O
concentrated,1481,O
in,1481,O
kidneys,1481,O
than,1481,O
free,1481,O
DX,1481,B-Chemical
(,1481,O
p,1481,O
<,1481,O
0.025,1481,O
),1481,O
.,1481,O
In,1482,O
rats,1482,O
with,1482,O
immune,1482,O
experimental,1482,O
glomerulonephritis,1482,B-Disease
",",1482,O
5/6,1482,O
rats,1482,O
given,1482,O
DX,1482,B-Chemical
died,1482,O
within,1482,O
7,1482,O
days,1482,O
",",1482,O
in,1482,O
contrast,1482,O
to,1482,O
animals,1482,O
treated,1482,O
by,1482,O
DXNP,1482,O
",",1482,O
NP,1482,O
",",1482,O
or,1482,O
untreated,1482,O
",",1482,O
which,1482,O
all,1482,O
survived,1482,O
.,1482,O
Proteinuria,1483,B-Disease
appeared,1483,O
in,1483,O
all,1483,O
series,1483,O
",",1483,O
but,1483,O
was,1483,O
2-5,1483,O
times,1483,O
more,1483,O
intense,1483,O
(,1483,O
p,1483,O
>,1483,O
0.001,1483,O
),1483,O
and,1483,O
prolonged,1483,O
after,1483,O
doxorubicin,1483,B-Chemical
treatment,1483,O
(,1483,O
400-700,1483,O
mg/day,1483,O
),1483,O
",",1483,O
without,1483,O
significant,1483,O
difference,1483,O
between,1483,O
DXNP,1483,O
and,1483,O
DX,1483,B-Chemical
.,1483,O
Rats,1484,O
treated,1484,O
by,1484,O
unloaded,1484,O
NP,1484,O
behaved,1484,O
as,1484,O
controls,1484,O
.,1484,O
These,1485,O
results,1485,O
demonstrate,1485,O
that,1485,O
",",1485,O
in,1485,O
these,1485,O
experimental,1485,O
conditions,1485,O
",",1485,O
DXNP,1485,O
killed,1485,O
less,1485,O
animals,1485,O
than,1485,O
free,1485,O
DX,1485,B-Chemical
",",1485,O
despite,1485,O
of,1485,O
an,1485,O
enhanced,1485,O
renal,1485,B-Disease
toxicity,1485,I-Disease
of,1485,O
the,1485,O
former,1485,O
.,1485,O
Both,1486,O
effects,1486,O
(,1486,O
better,1486,O
survival,1486,O
and,1486,O
nephrosis,1486,B-Disease
),1486,O
are,1486,O
most,1486,O
probably,1486,O
related,1486,O
to,1486,O
an,1486,O
enhanced,1486,O
capture,1486,O
of,1486,O
DXNP,1486,O
by,1486,O
cells,1486,O
of,1486,O
the,1486,O
mononuclear,1486,O
phagocyte,1486,O
system,1486,O
",",1486,O
including,1486,O
mesangial,1486,O
cells,1486,O
.,1486,O
Prostaglandin,1487,B-Chemical
E2-induced,1487,O
bladder,1487,B-Disease
hyperactivity,1487,I-Disease
in,1487,O
normal,1487,O
",",1487,O
conscious,1487,O
rats,1487,O
:,1487,O
involvement,1487,O
of,1487,O
tachykinins,1487,B-Chemical
?,1487,O
In,1488,O
normal,1488,O
conscious,1488,O
rats,1488,O
investigated,1488,O
by,1488,O
continuous,1488,O
cystometry,1488,O
",",1488,O
intravesically,1488,O
instilled,1488,O
prostaglandin,1488,B-Chemical
(,1488,I-Chemical
PG,1488,I-Chemical
),1488,I-Chemical
E2,1488,I-Chemical
facilitated,1488,O
micturition,1488,O
and,1488,O
increased,1488,O
basal,1488,O
intravesical,1488,O
pressure,1488,O
.,1488,O
The,1489,O
effect,1489,O
was,1489,O
attenuated,1489,O
by,1489,O
both,1489,O
the,1489,O
NK1,1489,O
receptor,1489,O
selective,1489,O
antagonist,1489,O
RP,1489,B-Chemical
"67,580",1489,I-Chemical
and,1489,O
the,1489,O
NK2,1489,O
receptor,1489,O
selective,1489,O
antagonist,1489,O
SR,1489,B-Chemical
"48,968",1489,I-Chemical
",",1489,O
given,1489,O
intra-arterially,1489,O
",",1489,O
suggesting,1489,O
that,1489,O
it,1489,O
was,1489,O
mediated,1489,O
by,1489,O
stimulation,1489,O
of,1489,O
both,1489,O
NK1,1489,O
and,1489,O
NK2,1489,O
receptors,1489,O
.,1489,O
Intra-arterially,1490,O
given,1490,O
PGE2,1490,B-Chemical
produced,1490,O
a,1490,O
distinct,1490,O
increase,1490,O
in,1490,O
bladder,1490,O
pressure,1490,O
before,1490,O
initiating,1490,O
a,1490,O
micturition,1490,O
reflex,1490,O
",",1490,O
indicating,1490,O
that,1490,O
the,1490,O
PG,1490,B-Chemical
had,1490,O
a,1490,O
direct,1490,O
contractant,1490,O
effect,1490,O
on,1490,O
the,1490,O
detrusor,1490,O
smooth,1490,O
muscle,1490,O
.,1490,O
The,1491,O
effect,1491,O
of,1491,O
intra-arterial,1491,O
PGE2,1491,B-Chemical
could,1491,O
not,1491,O
be,1491,O
blocked,1491,O
by,1491,O
intra-arterial,1491,O
RP,1491,B-Chemical
"67,580",1491,I-Chemical
or,1491,O
SR,1491,B-Chemical
"48,968",1491,I-Chemical
",",1491,O
which,1491,O
opens,1491,O
the,1491,O
possibility,1491,O
that,1491,O
the,1491,O
micturition,1491,O
reflex,1491,O
elicited,1491,O
by,1491,O
intra-arterial,1491,O
PGE2,1491,B-Chemical
was,1491,O
mediated,1491,O
by,1491,O
pathways,1491,O
other,1491,O
than,1491,O
the,1491,O
reflex,1491,O
initiated,1491,O
when,1491,O
the,1491,O
PG,1491,B-Chemical
was,1491,O
given,1491,O
intravesically,1491,O
.,1491,O
The,1492,O
present,1492,O
results,1492,O
thus,1492,O
suggest,1492,O
that,1492,O
intra-arterial,1492,O
PGE2,1492,B-Chemical
",",1492,O
given,1492,O
near,1492,O
the,1492,O
bladder,1492,O
",",1492,O
may,1492,O
initiate,1492,O
micturition,1492,O
in,1492,O
the,1492,O
normal,1492,O
rat,1492,O
chiefly,1492,O
by,1492,O
directly,1492,O
contracting,1492,O
the,1492,O
smooth,1492,O
muscle,1492,O
of,1492,O
the,1492,O
detrusor,1492,O
.,1492,O
However,1493,O
",",1493,O
when,1493,O
given,1493,O
intravesically,1493,O
",",1493,O
PGE2,1493,B-Chemical
may,1493,O
stimulate,1493,O
micturition,1493,O
by,1493,O
releasing,1493,O
tachykinins,1493,B-Chemical
from,1493,O
nerves,1493,O
in,1493,O
and/or,1493,O
immediately,1493,O
below,1493,O
the,1493,O
urothelium,1493,O
.,1493,O
These,1494,O
tachykinins,1494,B-Chemical
",",1494,O
in,1494,O
turn,1494,O
",",1494,O
initiate,1494,O
a,1494,O
micturition,1494,O
reflex,1494,O
by,1494,O
stimulating,1494,O
NK1,1494,O
and,1494,O
NK2,1494,O
receptors,1494,O
.,1494,O
Prostanoids,1495,B-Chemical
may,1495,O
",",1495,O
via,1495,O
release,1495,O
of,1495,O
tachykinins,1495,B-Chemical
",",1495,O
contribute,1495,O
to,1495,O
both,1495,O
urge,1495,O
and,1495,O
bladder,1495,B-Disease
hyperactivity,1495,I-Disease
seen,1495,O
in,1495,O
inflammatory,1495,O
conditions,1495,O
of,1495,O
the,1495,O
lower,1495,O
urinary,1495,O
tract,1495,O
.,1495,O
Refractory,1496,O
cardiogenic,1496,B-Disease
shock,1496,I-Disease
and,1496,O
complete,1496,O
heart,1496,B-Disease
block,1496,I-Disease
after,1496,O
verapamil,1496,B-Chemical
SR,1496,O
and,1496,O
metoprolol,1496,B-Chemical
treatment,1496,O
.,1496,O
A,1497,O
case,1497,O
report,1497,O
.,1497,O
A,1498,O
seventy-eight-year-old,1498,O
woman,1498,O
presented,1498,O
with,1498,O
complete,1498,O
heart,1498,B-Disease
block,1498,I-Disease
and,1498,O
refractory,1498,O
hypotension,1498,B-Disease
two,1498,O
days,1498,O
after,1498,O
a,1498,O
therapeutic,1498,O
dose,1498,O
of,1498,O
sustained-release,1498,O
verapamil,1498,B-Chemical
with,1498,O
concomitant,1498,O
use,1498,O
of,1498,O
metoprolol,1498,B-Chemical
.,1498,O
The,1499,O
patient,1499,O
continued,1499,O
to,1499,O
remain,1499,O
hypotensive,1499,B-Disease
with,1499,O
complete,1499,O
heart,1499,B-Disease
block,1499,I-Disease
",",1499,O
even,1499,O
with,1499,O
multiple,1499,O
uses,1499,O
of,1499,O
intravenous,1499,O
atropine,1499,B-Chemical
as,1499,O
well,1499,O
as,1499,O
high,1499,O
doses,1499,O
of,1499,O
pressor,1499,O
agents,1499,O
such,1499,O
as,1499,O
dopamine,1499,B-Chemical
and,1499,O
dobutamine,1499,B-Chemical
.,1499,O
However,1500,O
",",1500,O
shortly,1500,O
after,1500,O
the,1500,O
use,1500,O
of,1500,O
intravenous,1500,O
calcium,1500,B-Chemical
chloride,1500,I-Chemical
",",1500,O
the,1500,O
refractory,1500,O
hypotension,1500,B-Disease
and,1500,O
complete,1500,O
heart,1500,B-Disease
block,1500,I-Disease
resolved,1500,O
.,1500,O
Protective,1501,O
effect,1501,O
of,1501,O
misoprostol,1501,B-Chemical
on,1501,O
indomethacin,1501,B-Chemical
induced,1501,O
renal,1501,B-Disease
dysfunction,1501,I-Disease
in,1501,O
elderly,1501,O
patients,1501,O
.,1501,O
OBJECTIVE,1502,O
:,1502,O
To,1502,O
evaluate,1502,O
the,1502,O
possible,1502,O
protective,1502,O
effects,1502,O
of,1502,O
misoprostol,1502,B-Chemical
on,1502,O
renal,1502,O
function,1502,O
in,1502,O
hospitalized,1502,O
elderly,1502,O
patients,1502,O
treated,1502,O
with,1502,O
indomethacin,1502,B-Chemical
.,1502,O
METHODS,1503,O
:,1503,O
Forty-five,1503,O
hospitalized,1503,O
elderly,1503,O
patients,1503,O
(,1503,O
>,1503,O
65,1503,O
years,1503,O
old,1503,O
),1503,O
who,1503,O
required,1503,O
therapy,1503,O
with,1503,O
nonsteroidal,1503,O
antiinflammatory,1503,O
drugs,1503,O
(,1503,O
NSAID,1503,O
),1503,O
were,1503,O
randomly,1503,O
assigned,1503,O
to,1503,O
receive,1503,O
either,1503,O
indomethacin,1503,B-Chemical
",",1503,O
150,1503,O
mg/day,1503,O
(,1503,O
Group,1503,O
A,1503,O
),1503,O
",",1503,O
or,1503,O
indomethacin,1503,B-Chemical
150,1503,O
mg/day,1503,O
plus,1503,O
misoprostol,1503,B-Chemical
at,1503,O
0.6,1503,O
mg/day,1503,O
(,1503,O
Group,1503,O
B,1503,O
),1503,O
.,1503,O
Laboratory,1504,O
variables,1504,O
of,1504,O
renal,1504,O
function,1504,O
[,1504,O
serum,1504,O
creatinine,1504,B-Chemical
",",1504,O
blood,1504,B-Chemical
urea,1504,I-Chemical
nitrogen,1504,I-Chemical
(,1504,O
BUN,1504,B-Chemical
),1504,O
and,1504,O
electrolytes,1504,O
],1504,O
were,1504,O
evaluated,1504,O
before,1504,O
initiation,1504,O
of,1504,O
therapy,1504,O
and,1504,O
every,1504,O
2,1504,O
days,1504,O
",",1504,O
until,1504,O
termination,1504,O
of,1504,O
the,1504,O
study,1504,O
(,1504,O
a,1504,O
period,1504,O
of,1504,O
at,1504,O
least,1504,O
6,1504,O
days,1504,O
),1504,O
.,1504,O
Response,1505,O
to,1505,O
treatment,1505,O
was,1505,O
estimated,1505,O
by,1505,O
the,1505,O
visual,1505,O
analog,1505,O
scale,1505,O
for,1505,O
severity,1505,O
of,1505,O
pain,1505,B-Disease
.,1505,O
RESULTS,1506,O
:,1506,O
Forty-two,1506,O
patients,1506,O
completed,1506,O
the,1506,O
study,1506,O
",",1506,O
22,1506,O
in,1506,O
Group,1506,O
A,1506,O
and,1506,O
20,1506,O
in,1506,O
Group,1506,O
B.,1506,O
BUN,1506,B-Chemical
and,1506,O
creatinine,1506,B-Chemical
increased,1506,O
by,1506,O
>,1506,O
50,1506,O
%,1506,O
of,1506,O
baseline,1506,O
levels,1506,O
in,1506,O
54,1506,O
and,1506,O
45,1506,O
%,1506,O
of,1506,O
Group,1506,O
A,1506,O
patients,1506,O
",",1506,O
respectively,1506,O
",",1506,O
compared,1506,O
to,1506,O
only,1506,O
20,1506,O
and,1506,O
10,1506,O
%,1506,O
of,1506,O
Group,1506,O
B,1506,O
patients,1506,O
(,1506,O
p,1506,O
<,1506,O
0.05,1506,O
),1506,O
.,1506,O
Potassium,1507,B-Chemical
(,1507,O
K,1507,B-Chemical
),1507,O
increment,1507,O
of,1507,O
0.6,1507,O
mEq/l,1507,O
or,1507,O
more,1507,O
was,1507,O
observed,1507,O
in,1507,O
50,1507,O
%,1507,O
of,1507,O
Group,1507,O
A,1507,O
",",1507,O
but,1507,O
in,1507,O
only,1507,O
15,1507,O
%,1507,O
of,1507,O
Group,1507,O
B,1507,O
patients,1507,O
(,1507,O
p,1507,O
<,1507,O
0.05,1507,O
),1507,O
.,1507,O
The,1508,O
mean,1508,O
increments,1508,O
in,1508,O
BUN,1508,B-Chemical
",",1508,O
creatinine,1508,B-Chemical
",",1508,O
and,1508,O
K,1508,B-Chemical
were,1508,O
reduced,1508,O
by,1508,O
63,1508,O
",",1508,O
80,1508,O
",",1508,O
and,1508,O
42,1508,O
%,1508,O
",",1508,O
respectively,1508,O
",",1508,O
in,1508,O
Group,1508,O
B,1508,O
patients,1508,O
compared,1508,O
to,1508,O
Group,1508,O
A,1508,O
.,1508,O
Response,1509,O
to,1509,O
treatment,1509,O
did,1509,O
not,1509,O
differ,1509,O
significantly,1509,O
between,1509,O
the,1509,O
2,1509,O
groups,1509,O
.,1509,O
CONCLUSION,1510,O
:,1510,O
Hospitalized,1510,O
elderly,1510,O
patients,1510,O
are,1510,O
at,1510,O
risk,1510,O
for,1510,O
developing,1510,O
indomethacin,1510,B-Chemical
related,1510,O
renal,1510,B-Disease
dysfunction,1510,I-Disease
.,1510,O
Addition,1511,O
of,1511,O
misoprostol,1511,B-Chemical
can,1511,O
minimize,1511,O
this,1511,O
renal,1511,B-Disease
impairment,1511,I-Disease
without,1511,O
affecting,1511,O
pain,1511,B-Disease
control,1511,O
.,1511,O
Cognitive,1512,B-Disease
deterioration,1512,I-Disease
from,1512,O
long-term,1512,O
abuse,1512,O
of,1512,O
dextromethorphan,1512,B-Chemical
:,1512,O
a,1512,O
case,1512,O
report,1512,O
.,1512,O
Dextromethorphan,1513,B-Chemical
(,1513,O
DM,1513,B-Chemical
),1513,O
",",1513,O
the,1513,O
dextrorotatory,1513,O
isomer,1513,O
of,1513,O
3-hydroxy-N-methylmorphinan,1513,B-Chemical
",",1513,O
is,1513,O
the,1513,O
main,1513,O
ingredient,1513,O
in,1513,O
a,1513,O
number,1513,O
of,1513,O
widely,1513,O
available,1513,O
",",1513,O
over-the-counter,1513,O
antitussives,1513,O
.,1513,O
Initial,1514,O
studies,1514,O
(,1514,O
Bornstein,1514,O
1968,1514,O
),1514,O
showed,1514,O
that,1514,O
it,1514,O
possessed,1514,O
no,1514,O
respiratory,1514,O
suppressant,1514,O
effects,1514,O
and,1514,O
no,1514,O
addiction,1514,O
liability,1514,O
.,1514,O
Subsequently,1515,O
",",1515,O
however,1515,O
",",1515,O
several,1515,O
articles,1515,O
reporting,1515,O
abuse,1515,O
of,1515,O
this,1515,O
drug,1515,O
have,1515,O
appeared,1515,O
in,1515,O
the,1515,O
literature,1515,O
.,1515,O
The,1516,O
drug,1516,O
is,1516,O
known,1516,O
to,1516,O
cause,1516,O
a,1516,O
variety,1516,O
of,1516,O
acute,1516,O
toxic,1516,O
effects,1516,O
",",1516,O
ranging,1516,O
from,1516,O
nausea,1516,B-Disease
",",1516,O
restlessness,1516,B-Disease
",",1516,O
insomnia,1516,B-Disease
",",1516,O
ataxia,1516,B-Disease
",",1516,O
slurred,1516,O
speech,1516,O
and,1516,O
nystagmus,1516,B-Disease
to,1516,O
mood,1516,O
changes,1516,O
",",1516,O
perceptual,1516,O
alterations,1516,O
",",1516,O
inattention,1516,O
",",1516,O
disorientation,1516,O
and,1516,O
aggressive,1516,B-Disease
behavior,1516,I-Disease
(,1516,O
Rammer,1516,O
et,1516,O
al,1516,O
1988,1516,O
;,1516,O
Katona,1516,O
and,1516,O
Watson,1516,O
1986,1516,O
;,1516,O
Isbell,1516,O
and,1516,O
Fraser,1516,O
1953,1516,O
;,1516,O
Devlin,1516,O
et,1516,O
al,1516,O
1985,1516,O
;,1516,O
McCarthy,1516,O
1971,1516,O
;,1516,O
Dodds,1516,O
and,1516,O
Revai,1516,O
1967,1516,O
;,1516,O
Degkwitz,1516,O
1964,1516,O
;,1516,O
Hildebrand,1516,O
et,1516,O
al,1516,O
1989,1516,O
),1516,O
.,1516,O
There,1517,O
have,1517,O
also,1517,O
been,1517,O
two,1517,O
reported,1517,O
fatalities,1517,O
from,1517,O
DM,1517,B-Chemical
overdoses,1517,O
(,1517,O
Fleming,1517,O
1986,1517,O
),1517,O
.,1517,O
However,1518,O
",",1518,O
there,1518,O
are,1518,O
no,1518,O
reports,1518,O
describing,1518,O
the,1518,O
effects,1518,O
of,1518,O
chronic,1518,O
abuse,1518,O
.,1518,O
This,1519,O
report,1519,O
describes,1519,O
a,1519,O
case,1519,O
of,1519,O
cognitive,1519,B-Disease
deterioration,1519,I-Disease
resulting,1519,O
from,1519,O
prolonged,1519,O
use,1519,O
of,1519,O
DM,1519,B-Chemical
.,1519,O
Dexamethasone-induced,1520,B-Chemical
ocular,1520,B-Disease
hypertension,1520,I-Disease
in,1520,O
perfusion-cultured,1520,O
human,1520,O
eyes,1520,O
.,1520,O
PURPOSE,1521,O
:,1521,O
Glucocorticoid,1521,O
administration,1521,O
can,1521,O
lead,1521,O
to,1521,O
the,1521,O
development,1521,O
of,1521,O
ocular,1521,B-Disease
hypertension,1521,I-Disease
and,1521,O
corticosteroid,1521,B-Disease
glaucoma,1521,I-Disease
in,1521,O
a,1521,O
subset,1521,O
of,1521,O
the,1521,O
population,1521,O
through,1521,O
a,1521,O
decrease,1521,O
in,1521,O
the,1521,O
aqueous,1521,O
humor,1521,O
outflow,1521,O
facility,1521,O
.,1521,O
The,1522,O
purpose,1522,O
of,1522,O
this,1522,O
study,1522,O
was,1522,O
to,1522,O
determine,1522,O
whether,1522,O
glucocorticoid,1522,O
treatment,1522,O
can,1522,O
directly,1522,O
affect,1522,O
the,1522,O
outflow,1522,O
facility,1522,O
of,1522,O
isolated,1522,O
",",1522,O
perfusion-cultured,1522,O
human,1522,O
eyes,1522,O
.,1522,O
METHODS,1523,O
:,1523,O
The,1523,O
anterior,1523,O
segments,1523,O
of,1523,O
human,1523,O
donor,1523,O
eyes,1523,O
from,1523,O
regional,1523,O
eye,1523,O
banks,1523,O
were,1523,O
placed,1523,O
in,1523,O
a,1523,O
constant,1523,O
flow,1523,O
",",1523,O
variable,1523,O
pressure,1523,O
perfusion,1523,O
culture,1523,O
system,1523,O
.,1523,O
Paired,1524,O
eyes,1524,O
were,1524,O
perfused,1524,O
in,1524,O
serum-free,1524,O
media,1524,O
with,1524,O
or,1524,O
without,1524,O
10,1524,O
(,1524,O
-7,1524,O
),1524,O
M,1524,O
dexamethasone,1524,B-Chemical
for,1524,O
12,1524,O
days,1524,O
.,1524,O
Intraocular,1525,O
pressure,1525,O
was,1525,O
monitored,1525,O
daily,1525,O
.,1525,O
After,1526,O
incubation,1526,O
",",1526,O
the,1526,O
eyes,1526,O
were,1526,O
morphologically,1526,O
characterized,1526,O
by,1526,O
light,1526,O
microscopy,1526,O
",",1526,O
transmission,1526,O
and,1526,O
scanning,1526,O
electron,1526,O
microscopy,1526,O
",",1526,O
and,1526,O
scanning,1526,O
laser,1526,O
confocal,1526,O
microscopy,1526,O
.,1526,O
RESULTS,1527,O
:,1527,O
A,1527,O
significant,1527,O
increase,1527,O
in,1527,O
intraocular,1527,O
pressure,1527,O
developed,1527,O
in,1527,O
13,1527,O
of,1527,O
the,1527,O
44,1527,O
pairs,1527,O
of,1527,O
eyes,1527,O
perfused,1527,O
with,1527,O
dexamethasone,1527,B-Chemical
with,1527,O
an,1527,O
average,1527,O
pressure,1527,O
rise,1527,O
of,1527,O
17.5,1527,O
+/-,1527,O
3.8,1527,O
mm,1527,O
Hg,1527,O
after,1527,O
12,1527,O
days,1527,O
of,1527,O
dexamethasone,1527,B-Chemical
exposure,1527,O
.,1527,O
The,1528,O
contralateral,1528,O
control,1528,O
eyes,1528,O
",",1528,O
which,1528,O
did,1528,O
not,1528,O
receive,1528,O
dexamethasone,1528,B-Chemical
",",1528,O
maintained,1528,O
a,1528,O
stable,1528,O
intraocular,1528,O
pressure,1528,O
during,1528,O
the,1528,O
same,1528,O
period,1528,O
.,1528,O
The,1529,O
outflow,1529,O
pathway,1529,O
of,1529,O
the,1529,O
untreated,1529,O
eyes,1529,O
appeared,1529,O
morphologically,1529,O
normal,1529,O
.,1529,O
In,1530,O
contrast,1530,O
",",1530,O
the,1530,O
dexamethasone-treated,1530,B-Chemical
hypertensive,1530,B-Disease
eyes,1530,I-Disease
had,1530,O
thickened,1530,O
trabecular,1530,O
beams,1530,O
",",1530,O
decreased,1530,O
intertrabecular,1530,O
spaces,1530,O
",",1530,O
thickened,1530,O
juxtacanalicular,1530,O
tissue,1530,O
",",1530,O
activated,1530,O
trabecular,1530,O
meshwork,1530,O
cells,1530,O
",",1530,O
and,1530,O
increased,1530,O
amounts,1530,O
of,1530,O
amorphogranular,1530,O
extracellular,1530,O
material,1530,O
",",1530,O
especially,1530,O
in,1530,O
the,1530,O
juxtacanalicular,1530,O
tissue,1530,O
and,1530,O
beneath,1530,O
the,1530,O
endothelial,1530,O
lining,1530,O
of,1530,O
the,1530,O
canal,1530,O
of,1530,O
Schlemm,1530,O
.,1530,O
The,1531,O
dexamethasone-treated,1531,B-Chemical
nonresponder,1531,O
eyes,1531,O
appeared,1531,O
to,1531,O
be,1531,O
morphologically,1531,O
similar,1531,O
to,1531,O
the,1531,O
untreated,1531,O
eyes,1531,O
",",1531,O
although,1531,O
several,1531,O
subtle,1531,O
dexamethasone-induced,1531,B-Chemical
morphologic,1531,O
changes,1531,O
were,1531,O
evident,1531,O
.,1531,O
CONCLUSION,1532,O
:,1532,O
Dexamethasone,1532,B-Chemical
treatment,1532,O
of,1532,O
isolated,1532,O
",",1532,O
perfusion-cultured,1532,O
human,1532,O
eyes,1532,O
led,1532,O
to,1532,O
the,1532,O
generation,1532,O
of,1532,O
ocular,1532,B-Disease
hypertension,1532,I-Disease
in,1532,O
approximately,1532,O
30,1532,O
%,1532,O
of,1532,O
the,1532,O
dexamethasone-treated,1532,B-Chemical
eyes,1532,O
.,1532,O
Steroid,1533,B-Chemical
treatment,1533,O
resulted,1533,O
in,1533,O
morphologic,1533,O
changes,1533,O
in,1533,O
the,1533,O
trabecular,1533,O
meshwork,1533,O
similar,1533,O
to,1533,O
those,1533,O
reported,1533,O
for,1533,O
corticosteroid,1533,B-Disease
glaucoma,1533,I-Disease
and,1533,O
open,1533,B-Disease
angle,1533,I-Disease
glaucoma,1533,I-Disease
.,1533,O
This,1534,O
system,1534,O
may,1534,O
provide,1534,O
an,1534,O
acute,1534,O
model,1534,O
in,1534,O
which,1534,O
to,1534,O
study,1534,O
the,1534,O
pathogenic,1534,O
mechanisms,1534,O
involved,1534,O
in,1534,O
steroid,1534,B-Disease
glaucoma,1534,I-Disease
and,1534,O
primary,1534,B-Disease
open,1534,I-Disease
angle,1534,I-Disease
glaucoma,1534,I-Disease
.,1534,O
Auditory,1535,O
disturbance,1535,O
associated,1535,O
with,1535,O
interscalene,1535,O
brachial,1535,O
plexus,1535,O
block,1535,O
.,1535,O
We,1536,O
performed,1536,O
an,1536,O
audiometric,1536,O
study,1536,O
in,1536,O
20,1536,O
patients,1536,O
who,1536,O
underwent,1536,O
surgery,1536,O
of,1536,O
the,1536,O
shoulder,1536,O
region,1536,O
under,1536,O
an,1536,O
interscalene,1536,O
brachial,1536,O
plexus,1536,O
block,1536,O
(,1536,O
IBPB,1536,O
),1536,O
.,1536,O
Bupivacaine,1537,B-Chemical
0.75,1537,O
%,1537,O
with,1537,O
adrenaline,1537,B-Chemical
was,1537,O
given,1537,O
followed,1537,O
by,1537,O
a,1537,O
24-hr,1537,O
continuous,1537,O
infusion,1537,O
of,1537,O
0.25,1537,O
%,1537,O
bupivacaine,1537,B-Chemical
.,1537,O
Three,1538,O
audiometric,1538,O
threshold,1538,O
measurements,1538,O
(,1538,O
0.25-18,1538,O
kHz,1538,O
),1538,O
were,1538,O
made,1538,O
:,1538,O
the,1538,O
first,1538,O
before,1538,O
IBPB,1538,O
",",1538,O
the,1538,O
second,1538,O
2-6,1538,O
h,1538,O
after,1538,O
surgery,1538,O
and,1538,O
the,1538,O
third,1538,O
on,1538,O
the,1538,O
first,1538,O
day,1538,O
after,1538,O
operation,1538,O
.,1538,O
In,1539,O
four,1539,O
patients,1539,O
hearing,1539,B-Disease
impairment,1539,I-Disease
on,1539,O
the,1539,O
side,1539,O
of,1539,O
the,1539,O
block,1539,O
was,1539,O
demonstrated,1539,O
after,1539,O
operation,1539,O
",",1539,O
in,1539,O
three,1539,O
measurements,1539,O
on,1539,O
the,1539,O
day,1539,O
of,1539,O
surgery,1539,O
and,1539,O
in,1539,O
one,1539,O
on,1539,O
the,1539,O
following,1539,O
day,1539,O
.,1539,O
The,1540,O
frequencies,1540,O
at,1540,O
which,1540,O
the,1540,O
impairment,1540,O
occurred,1540,O
varied,1540,O
between,1540,O
patients,1540,O
;,1540,O
in,1540,O
one,1540,O
only,1540,O
low,1540,O
frequencies,1540,O
(,1540,O
0.25-0.5,1540,O
kHz,1540,O
),1540,O
were,1540,O
involved,1540,O
.,1540,O
The,1541,O
maximum,1541,O
change,1541,O
in,1541,O
threshold,1541,O
was,1541,O
35,1541,O
dB,1541,O
at,1541,O
6,1541,O
kHz,1541,O
measured,1541,O
at,1541,O
the,1541,O
end,1541,O
of,1541,O
the,1541,O
continuous,1541,O
infusion,1541,O
of,1541,O
bupivacaine,1541,B-Chemical
.,1541,O
This,1542,O
patient,1542,O
had,1542,O
hearing,1542,O
threshold,1542,O
changes,1542,O
(,1542,O
15-20,1542,O
dB,1542,O
),1542,O
at,1542,O
6-10,1542,O
kHz,1542,O
on,1542,O
the,1542,O
opposite,1542,O
side,1542,O
also,1542,O
.,1542,O
IBPB,1543,O
may,1543,O
cause,1543,O
transient,1543,O
auditory,1543,B-Disease
dysfunction,1543,I-Disease
in,1543,O
the,1543,O
ipsilateral,1543,O
ear,1543,O
",",1543,O
possibly,1543,O
via,1543,O
an,1543,O
effect,1543,O
on,1543,O
sympathetic,1543,O
innervation,1543,O
.,1543,O
The,1544,O
safety,1544,O
and,1544,O
efficacy,1544,O
of,1544,O
combination,1544,O
N-butyl-deoxynojirimycin,1544,B-Chemical
(,1544,O
SC-48334,1544,B-Chemical
),1544,O
and,1544,O
zidovudine,1544,B-Chemical
in,1544,O
patients,1544,O
with,1544,O
HIV-1,1544,B-Disease
infection,1544,I-Disease
and,1544,O
200-500,1544,O
CD4,1544,O
cells/mm3,1544,O
.,1544,O
We,1545,O
conducted,1545,O
a,1545,O
double-blind,1545,O
",",1545,O
randomized,1545,O
phase,1545,O
II,1545,O
study,1545,O
to,1545,O
evaluate,1545,O
the,1545,O
safety,1545,O
and,1545,O
activity,1545,O
of,1545,O
combination,1545,O
therapy,1545,O
with,1545,O
N-butyl-deoxynojirimycin,1545,B-Chemical
(,1545,O
SC-48334,1545,B-Chemical
),1545,O
(,1545,O
an,1545,O
alpha-glucosidase,1545,O
I,1545,O
inhibitor,1545,O
),1545,O
and,1545,O
zidovudine,1545,B-Chemical
versus,1545,O
zidovudine,1545,B-Chemical
alone,1545,O
.,1545,O
Patients,1546,O
with,1546,O
200,1546,O
to,1546,O
500,1546,O
CD4,1546,O
cells/mm3,1546,O
who,1546,O
tolerated,1546,O
<,1546,O
or,1546,O
=,1546,O
12,1546,O
weeks,1546,O
of,1546,O
prior,1546,O
zidovudine,1546,B-Chemical
therapy,1546,O
received,1546,O
SC-48334,1546,B-Chemical
(,1546,O
1000,1546,O
mg,1546,O
every,1546,O
8,1546,O
h,1546,O
),1546,O
and,1546,O
zidovudine,1546,B-Chemical
(,1546,O
100,1546,O
mg,1546,O
every,1546,O
8,1546,O
h,1546,O
),1546,O
or,1546,O
zidovudine,1546,B-Chemical
and,1546,O
placebo,1546,O
.,1546,O
Sixty,1547,O
patients,1547,O
received,1547,O
combination,1547,O
therapy,1547,O
and,1547,O
58,1547,O
",",1547,O
zidovudine,1547,B-Chemical
and,1547,O
placebo,1547,O
.,1547,O
Twenty-three,1548,O
patients,1548,O
(,1548,O
38,1548,O
%,1548,O
),1548,O
and,1548,O
15,1548,O
(,1548,O
26,1548,O
%,1548,O
),1548,O
",",1548,O
in,1548,O
the,1548,O
combination,1548,O
and,1548,O
zidovudine,1548,B-Chemical
groups,1548,O
",",1548,O
respectively,1548,O
",",1548,O
discontinued,1548,O
therapy,1548,O
(,1548,O
p,1548,O
=,1548,O
0.15,1548,O
),1548,O
.,1548,O
The,1549,O
mean,1549,O
SC-48334,1549,B-Chemical
steady-state,1549,O
trough,1549,O
level,1549,O
(,1549,O
4.04,1549,O
+/-,1549,O
0.99,1549,O
micrograms/ml,1549,O
),1549,O
was,1549,O
below,1549,O
the,1549,O
in,1549,O
vitro,1549,O
inhibitory,1549,O
concentration,1549,O
for,1549,O
human,1549,O
immunodeficiency,1549,B-Disease
virus,1549,O
(,1549,O
HIV,1549,O
),1549,O
.,1549,O
The,1550,O
mean,1550,O
increase,1550,O
in,1550,O
CD4,1550,O
cells,1550,O
at,1550,O
week,1550,O
4,1550,O
was,1550,O
73.8,1550,O
cells/mm3,1550,O
and,1550,O
52.4,1550,O
cells/mm3,1550,O
for,1550,O
the,1550,O
combination,1550,O
and,1550,O
zidovudine,1550,B-Chemical
groups,1550,O
",",1550,O
respectively,1550,O
(,1550,O
p,1550,O
>,1550,O
0.36,1550,O
),1550,O
.,1550,O
For,1551,O
patients,1551,O
with,1551,O
prior,1551,O
zidovudine,1551,B-Chemical
therapy,1551,O
",",1551,O
the,1551,O
mean,1551,O
change,1551,O
in,1551,O
CD4,1551,O
cells,1551,O
in,1551,O
the,1551,O
combination,1551,O
and,1551,O
zidovudine,1551,B-Chemical
groups,1551,O
was,1551,O
63.7,1551,O
cells/mm3,1551,O
and,1551,O
4.9,1551,O
cells/mm3,1551,O
at,1551,O
week,1551,O
8,1551,O
and,1551,O
6.8,1551,O
cells/mm3,1551,O
and,1551,O
-45.1,1551,O
cells/mm3,1551,O
at,1551,O
week,1551,O
16,1551,O
",",1551,O
respectively,1551,O
.,1551,O
The,1552,O
number,1552,O
of,1552,O
patients,1552,O
with,1552,O
suppression,1552,O
of,1552,O
HIV,1552,O
p24,1552,O
antigenemia,1552,O
in,1552,O
the,1552,O
combination,1552,O
and,1552,O
zidovudine,1552,B-Chemical
groups,1552,O
was,1552,O
six,1552,O
(,1552,O
40,1552,O
%,1552,O
),1552,O
and,1552,O
two,1552,O
(,1552,O
11,1552,O
%,1552,O
),1552,O
at,1552,O
week,1552,O
4,1552,O
(,1552,O
p,1552,O
=,1552,O
0.10,1552,O
),1552,O
and,1552,O
five,1552,O
(,1552,O
45,1552,O
%,1552,O
),1552,O
and,1552,O
two,1552,O
(,1552,O
14,1552,O
%,1552,O
),1552,O
at,1552,O
week,1552,O
24,1552,O
(,1552,O
p,1552,O
=,1552,O
0.08,1552,O
),1552,O
",",1552,O
respectively,1552,O
.,1552,O
Diarrhea,1553,B-Disease
",",1553,O
flatulence,1553,B-Disease
",",1553,O
abdominal,1553,B-Disease
pain,1553,I-Disease
",",1553,O
and,1553,O
weight,1553,B-Disease
loss,1553,I-Disease
were,1553,O
common,1553,O
for,1553,O
combination,1553,O
recipients,1553,O
.,1553,O
(,1554,O
ABSTRACT,1554,O
TRUNCATED,1554,O
AT,1554,O
250,1554,O
WORDS,1554,O
),1554,O
Prolonged,1555,O
paralysis,1555,B-Disease
due,1555,O
to,1555,O
nondepolarizing,1555,B-Chemical
neuromuscular,1555,I-Chemical
blocking,1555,I-Chemical
agents,1555,I-Chemical
and,1555,O
corticosteroids,1555,B-Chemical
.,1555,O
The,1556,O
long-term,1556,O
use,1556,O
of,1556,O
nondepolarizing,1556,B-Chemical
neuromuscular,1556,I-Chemical
blocking,1556,I-Chemical
agents,1556,I-Chemical
(,1556,O
ND-NMBA,1556,B-Chemical
),1556,O
has,1556,O
recently,1556,O
been,1556,O
implicated,1556,O
as,1556,O
a,1556,O
cause,1556,O
of,1556,O
prolonged,1556,O
muscle,1556,B-Disease
weakness,1556,I-Disease
",",1556,O
although,1556,O
the,1556,O
site,1556,O
of,1556,O
the,1556,O
lesion,1556,O
and,1556,O
the,1556,O
predisposing,1556,O
factors,1556,O
have,1556,O
been,1556,O
unclear,1556,O
.,1556,O
We,1557,O
report,1557,O
3,1557,O
patients,1557,O
(,1557,O
age,1557,O
37-52,1557,O
years,1557,O
),1557,O
with,1557,O
acute,1557,O
respiratory,1557,B-Disease
insufficiency,1557,I-Disease
who,1557,O
developed,1557,O
prolonged,1557,O
weakness,1557,B-Disease
following,1557,O
the,1557,O
discontinuation,1557,O
of,1557,O
ND-NMBAs,1557,B-Chemical
.,1557,O
Two,1558,O
patients,1558,O
also,1558,O
received,1558,O
intravenous,1558,O
corticosteroids,1558,B-Chemical
.,1558,O
Renal,1559,O
function,1559,O
was,1559,O
normal,1559,O
but,1559,O
hepatic,1559,O
function,1559,O
was,1559,O
impaired,1559,O
in,1559,O
all,1559,O
patients,1559,O
",",1559,O
and,1559,O
all,1559,O
had,1559,O
acidosis,1559,B-Disease
.,1559,O
Electrophysiologic,1560,O
studies,1560,O
revealed,1560,O
low,1560,O
amplitude,1560,O
compound,1560,O
motor,1560,O
action,1560,O
potentials,1560,O
",",1560,O
normal,1560,O
sensory,1560,O
studies,1560,O
",",1560,O
and,1560,O
fibrillations,1560,O
.,1560,O
Repetitive,1561,O
stimulation,1561,O
at,1561,O
2,1561,O
Hz,1561,O
showed,1561,O
a,1561,O
decremental,1561,O
response,1561,O
in,1561,O
2,1561,O
patients,1561,O
.,1561,O
The,1562,O
serum,1562,O
vecuronium,1562,B-Chemical
level,1562,O
measured,1562,O
in,1562,O
1,1562,O
patient,1562,O
14,1562,O
days,1562,O
after,1562,O
the,1562,O
drug,1562,O
had,1562,O
been,1562,O
discontinued,1562,O
was,1562,O
172,1562,O
ng/mL,1562,O
.,1562,O
A,1563,O
muscle,1563,O
biopsy,1563,O
in,1563,O
this,1563,O
patient,1563,O
showed,1563,O
loss,1563,B-Disease
of,1563,I-Disease
thick,1563,I-Disease
",",1563,I-Disease
myosin,1563,I-Disease
filaments,1563,I-Disease
.,1563,O
The,1564,O
weakness,1564,B-Disease
in,1564,O
these,1564,O
patients,1564,O
is,1564,O
due,1564,O
to,1564,O
pathology,1564,B-Disease
at,1564,I-Disease
both,1564,I-Disease
the,1564,I-Disease
neuromuscular,1564,I-Disease
junction,1564,I-Disease
(,1564,O
most,1564,O
likely,1564,O
due,1564,O
to,1564,O
ND-NMBA,1564,B-Chemical
),1564,O
and,1564,O
muscle,1564,O
(,1564,O
most,1564,O
likely,1564,O
due,1564,O
to,1564,O
corticosteroids,1564,B-Chemical
),1564,O
.,1564,O
Hepatic,1565,B-Disease
dysfunction,1565,I-Disease
and,1565,O
acidosis,1565,B-Disease
are,1565,O
contributing,1565,O
risk,1565,O
factors,1565,O
.,1565,O
Failure,1566,O
of,1566,O
ancrod,1566,O
in,1566,O
the,1566,O
treatment,1566,O
of,1566,O
heparin-induced,1566,B-Chemical
arterial,1566,O
thrombosis,1566,B-Disease
.,1566,O
The,1567,O
morbidity,1567,O
and,1567,O
mortality,1567,O
associated,1567,O
with,1567,O
heparin-induced,1567,B-Chemical
thrombosis,1567,B-Disease
remain,1567,O
high,1567,O
despite,1567,O
numerous,1567,O
empirical,1567,O
therapies,1567,O
.,1567,O
Ancrod,1568,O
has,1568,O
been,1568,O
used,1568,O
successfully,1568,O
for,1568,O
prophylaxis,1568,O
against,1568,O
development,1568,O
of,1568,O
thrombosis,1568,B-Disease
in,1568,O
patients,1568,O
with,1568,O
heparin,1568,B-Chemical
induced,1568,O
platelet,1568,B-Disease
aggregation,1568,I-Disease
who,1568,O
require,1568,O
brief,1568,O
reexposure,1568,O
to,1568,O
heparin,1568,B-Chemical
",",1568,O
but,1568,O
its,1568,O
success,1568,O
in,1568,O
patients,1568,O
who,1568,O
have,1568,O
developed,1568,O
the,1568,O
thrombosis,1568,B-Disease
syndrome,1568,O
is,1568,O
not,1568,O
well,1568,O
defined,1568,O
.,1568,O
The,1569,O
authors,1569,O
present,1569,O
a,1569,O
case,1569,O
of,1569,O
failure,1569,O
of,1569,O
ancrod,1569,O
treatment,1569,O
in,1569,O
a,1569,O
patient,1569,O
with,1569,O
heparin-induced,1569,B-Chemical
thrombosis,1569,B-Disease
.,1569,O
KF17837,1570,B-Chemical
:,1570,O
a,1570,O
novel,1570,O
selective,1570,O
adenosine,1570,B-Chemical
A2A,1570,O
receptor,1570,O
antagonist,1570,O
with,1570,O
anticataleptic,1570,O
activity,1570,O
.,1570,O
KF17837,1571,B-Chemical
is,1571,O
a,1571,O
novel,1571,O
selective,1571,O
adenosine,1571,B-Chemical
A2A,1571,O
receptor,1571,O
antagonist,1571,O
.,1571,O
Oral,1572,O
administration,1572,O
of,1572,O
KF17837,1572,B-Chemical
(,1572,O
2.5,1572,O
",",1572,O
10.0,1572,O
and,1572,O
30.0,1572,O
mg/kg,1572,O
),1572,O
significantly,1572,O
ameliorated,1572,O
the,1572,O
cataleptic,1572,B-Disease
responses,1572,O
induced,1572,O
by,1572,O
intracerebroventricular,1572,O
administration,1572,O
of,1572,O
an,1572,O
adenosine,1572,B-Chemical
A2A,1572,O
receptor,1572,O
agonist,1572,O
",",1572,O
CGS,1572,B-Chemical
21680,1572,I-Chemical
(,1572,O
10,1572,O
micrograms,1572,O
),1572,O
",",1572,O
in,1572,O
a,1572,O
dose-dependent,1572,O
manner,1572,O
.,1572,O
KF17837,1573,B-Chemical
also,1573,O
reduced,1573,O
the,1573,O
catalepsy,1573,B-Disease
induced,1573,O
by,1573,O
haloperidol,1573,B-Chemical
(,1573,O
1,1573,O
mg/kg,1573,O
i.p,1573,O
.,1573,O
),1573,O
and,1574,O
by,1574,O
reserpine,1574,B-Chemical
(,1574,O
5,1574,O
mg/kg,1574,O
i.p,1574,O
.,1574,O
),1574,O
.,1574,O
These,1575,O
anticataleptic,1575,O
effects,1575,O
were,1575,O
exhibited,1575,O
dose,1575,O
dependently,1575,O
at,1575,O
doses,1575,O
from,1575,O
0.625,1575,O
and,1575,O
2.5,1575,O
mg/kg,1575,O
p.o.,1575,O
",",1575,O
respectively,1575,O
.,1575,O
Moreover,1576,O
",",1576,O
KF17837,1576,B-Chemical
(,1576,O
0.625,1576,O
mg/kg,1576,O
p.o,1576,O
.,1576,O
),1576,O
potentiated,1577,O
the,1577,O
anticataleptic,1577,O
effects,1577,O
of,1577,O
a,1577,O
subthreshold,1577,O
dose,1577,O
of,1577,O
"L-3,4-dihydroxyphenylalanine",1577,B-Chemical
(,1577,O
L-DOPA,1577,B-Chemical
;,1577,O
25,1577,O
mg/kg,1577,O
i.p,1577,O
.,1577,O
),1577,O
plus,1578,O
benserazide,1578,B-Chemical
(,1578,O
6.25,1578,O
mg/kg,1578,O
i.p,1578,O
.,1578,O
),1578,O
.,1578,O
These,1579,O
results,1579,O
suggested,1579,O
that,1579,O
KF17837,1579,B-Chemical
is,1579,O
a,1579,O
centrally,1579,O
active,1579,O
adenosine,1579,B-Chemical
A2A,1579,O
receptor,1579,O
antagonist,1579,O
and,1579,O
that,1579,O
the,1579,O
dopaminergic,1579,O
function,1579,O
of,1579,O
the,1579,O
nigrostriatal,1579,O
pathway,1579,O
is,1579,O
potentiated,1579,O
by,1579,O
adenosine,1579,B-Chemical
A2A,1579,O
receptor,1579,O
antagonists,1579,O
.,1579,O
Furthermore,1580,O
",",1580,O
KF17837,1580,B-Chemical
may,1580,O
be,1580,O
a,1580,O
useful,1580,O
drug,1580,O
in,1580,O
the,1580,O
treatment,1580,O
of,1580,O
parkinsonism,1580,B-Disease
.,1580,O
Effect,1581,O
of,1581,O
nondopaminergic,1581,O
drugs,1581,O
on,1581,O
L-dopa-induced,1581,B-Chemical
dyskinesias,1581,B-Disease
in,1581,O
MPTP-treated,1581,B-Chemical
monkeys,1581,O
.,1581,O
A,1582,O
group,1582,O
of,1582,O
four,1582,O
monkeys,1582,O
was,1582,O
rendered,1582,O
parkinsonian,1582,B-Disease
with,1582,O
the,1582,O
toxin,1582,O
MPTP,1582,B-Chemical
.,1582,O
They,1583,O
were,1583,O
then,1583,O
treated,1583,O
chronically,1583,O
with,1583,O
L-DOPA/benserazide,1583,B-Chemical
50/12.5,1583,O
mg/kg,1583,O
given,1583,O
orally,1583,O
daily,1583,O
for,1583,O
2,1583,O
months,1583,O
.,1583,O
This,1584,O
dose,1584,O
produced,1584,O
a,1584,O
striking,1584,O
antiparkinsonian,1584,O
effect,1584,O
",",1584,O
but,1584,O
all,1584,O
animals,1584,O
manifested,1584,O
dyskinesia,1584,B-Disease
.,1584,O
A,1585,O
series,1585,O
of,1585,O
agents,1585,O
acting,1585,O
primarily,1585,O
on,1585,O
neurotransmitters,1585,O
other,1585,O
than,1585,O
dopamine,1585,B-Chemical
were,1585,O
then,1585,O
tested,1585,O
in,1585,O
combination,1585,O
with,1585,O
L-DOPA,1585,B-Chemical
to,1585,O
see,1585,O
if,1585,O
the,1585,O
dyskinetic,1585,B-Disease
movements,1585,O
would,1585,O
be,1585,O
modified,1585,O
.,1585,O
Several,1586,O
drugs,1586,O
",",1586,O
including,1586,O
clonidine,1586,B-Chemical
",",1586,O
physostigmine,1586,B-Chemical
",",1586,O
methysergide,1586,B-Chemical
",",1586,O
5-MDOT,1586,B-Chemical
",",1586,O
propranolol,1586,B-Chemical
",",1586,O
and,1586,O
MK-801,1586,B-Chemical
",",1586,O
markedly,1586,O
reduced,1586,O
the,1586,O
dyskinetic,1586,B-Disease
movements,1586,O
but,1586,O
at,1586,O
the,1586,O
cost,1586,O
of,1586,O
a,1586,O
return,1586,O
of,1586,O
parkinsonian,1586,B-Disease
symptomatology,1586,O
.,1586,O
However,1587,O
",",1587,O
yohimbine,1587,B-Chemical
and,1587,O
meperidine,1587,B-Chemical
reduced,1587,O
predominantly,1587,O
the,1587,O
dyskinetic,1587,B-Disease
movements,1587,O
.,1587,O
Baclofen,1588,B-Chemical
was,1588,O
also,1588,O
useful,1588,O
in,1588,O
one,1588,O
monkey,1588,O
against,1588,O
a,1588,O
more,1588,O
dystonic,1588,B-Disease
form,1588,O
of,1588,O
dyskinesia,1588,B-Disease
.,1588,O
Atropine,1589,B-Chemical
converted,1589,O
the,1589,O
dystonic,1589,B-Disease
movements,1589,O
into,1589,O
chorea,1589,B-Disease
.,1589,O
Hallucinations,1590,B-Disease
and,1590,O
ifosfamide-induced,1590,B-Chemical
neurotoxicity,1590,B-Disease
.,1590,O
BACKGROUND,1591,O
:,1591,O
Hallucinations,1591,B-Disease
as,1591,O
a,1591,O
symptom,1591,O
of,1591,O
central,1591,O
neurotoxicity,1591,B-Disease
are,1591,O
a,1591,O
known,1591,O
but,1591,O
poorly,1591,O
described,1591,O
side,1591,O
effect,1591,O
of,1591,O
ifosfamide,1591,B-Chemical
.,1591,O
Most,1592,O
cases,1592,O
of,1592,O
ifosfamide-induced,1592,B-Chemical
hallucinations,1592,B-Disease
have,1592,O
been,1592,O
reported,1592,O
with,1592,O
other,1592,O
mental,1592,O
status,1592,O
changes,1592,O
.,1592,O
METHODS,1593,O
:,1593,O
The,1593,O
authors,1593,O
interviewed,1593,O
six,1593,O
persons,1593,O
with,1593,O
ifosfamide-induced,1593,B-Chemical
hallucinations,1593,B-Disease
in,1593,O
the,1593,O
presence,1593,O
of,1593,O
a,1593,O
clear,1593,O
sensorium,1593,O
.,1593,O
All,1594,O
patients,1594,O
were,1594,O
receiving,1594,O
high-dose,1594,O
ifosfamide,1594,B-Chemical
as,1594,O
part,1594,O
of,1594,O
their,1594,O
bone,1594,O
marrow,1594,O
transplant,1594,O
procedure,1594,O
.,1594,O
RESULTS,1595,O
:,1595,O
Hallucinations,1595,B-Disease
occurred,1595,O
only,1595,O
when,1595,O
the,1595,O
patient,1595,O
's,1595,O
eyes,1595,O
were,1595,O
closed,1595,O
and,1595,O
",",1595,O
in,1595,O
all,1595,O
but,1595,O
one,1595,O
case,1595,O
",",1595,O
were,1595,O
reported,1595,O
as,1595,O
disturbing,1595,O
or,1595,O
frightening,1595,O
.,1595,O
Underreporting,1596,O
of,1596,O
these,1596,O
hallucinations,1596,B-Disease
by,1596,O
patients,1596,O
is,1596,O
likely,1596,O
.,1596,O
CONCLUSIONS,1597,O
:,1597,O
Hallucinations,1597,B-Disease
may,1597,O
be,1597,O
the,1597,O
sole,1597,O
or,1597,O
first,1597,O
manifestation,1597,O
of,1597,O
neurotoxicity,1597,B-Disease
.,1597,O
The,1598,O
incidence,1598,O
may,1598,O
be,1598,O
dose,1598,O
and,1598,O
infusion-time,1598,O
related,1598,O
.,1598,O
The,1599,O
clinician,1599,O
should,1599,O
be,1599,O
alerted,1599,O
for,1599,O
possible,1599,O
ifosfamide-induced,1599,B-Chemical
hallucinations,1599,B-Disease
",",1599,O
which,1599,O
may,1599,O
occur,1599,O
without,1599,O
other,1599,O
signs,1599,O
of,1599,O
neurotoxicity,1599,B-Disease
.,1599,O
``,1600,O
Eyes-closed,1600,O
'',1600,O
hallucinatory,1600,B-Disease
experiences,1600,O
appear,1600,O
to,1600,O
be,1600,O
an,1600,O
unusual,1600,O
feature,1600,O
of,1600,O
this,1600,O
presentation,1600,O
.,1600,O
Patients,1601,O
anxious,1601,O
about,1601,O
this,1601,O
experience,1601,O
respond,1601,O
well,1601,O
to,1601,O
support,1601,O
and,1601,O
education,1601,O
about,1601,O
this,1601,O
occurrence,1601,O
.,1601,O
Optimal,1602,O
pharmacologic,1602,O
management,1602,O
of,1602,O
disturbed,1602,O
patients,1602,O
is,1602,O
unclear,1602,O
.,1602,O
If,1603,O
agitation,1603,B-Disease
becomes,1603,O
marked,1603,O
",",1603,O
high-potency,1603,O
neuroleptics,1603,O
(,1603,O
i.e.,1603,O
",",1603,O
haloperidol,1603,B-Chemical
),1603,O
may,1603,O
be,1603,O
effective,1603,O
.,1603,O
Photodistributed,1604,O
nifedipine-induced,1604,B-Chemical
facial,1604,O
telangiectasia,1604,B-Disease
.,1604,O
Five,1605,O
months,1605,O
after,1605,O
starting,1605,O
nifedipine,1605,B-Chemical
(,1605,O
Adalat,1605,B-Chemical
),1605,O
",",1605,O
two,1605,O
patients,1605,O
developed,1605,O
photodistributed,1605,O
facial,1605,O
telangiectasia,1605,B-Disease
",",1605,O
which,1605,O
became,1605,O
more,1605,O
noticeable,1605,O
with,1605,O
time,1605,O
.,1605,O
Neither,1606,O
patient,1606,O
complained,1606,O
of,1606,O
photosensitivity,1606,O
or,1606,O
flushing,1606,B-Disease
.,1606,O
Both,1607,O
patients,1607,O
reported,1607,O
a,1607,O
significant,1607,O
cosmetic,1607,O
improvement,1607,O
after,1607,O
discontinuing,1607,O
the,1607,O
drug,1607,O
.,1607,O
One,1608,O
commenced,1608,O
the,1608,O
closely,1608,O
related,1608,O
drug,1608,O
amlodipine,1608,B-Chemical
3,1608,O
years,1608,O
later,1608,O
",",1608,O
with,1608,O
recurrence,1608,O
of,1608,O
telangiectasia,1608,B-Disease
.,1608,O
The,1609,O
photodistribution,1609,O
of,1609,O
the,1609,O
telangiectasia,1609,B-Disease
suggests,1609,O
a,1609,O
significant,1609,O
drug/light,1609,O
interaction,1609,O
.,1609,O
Penicillamine-induced,1610,B-Chemical
rapidly,1610,O
progressive,1610,O
glomerulonephritis,1610,B-Disease
in,1610,O
a,1610,O
patient,1610,O
with,1610,O
rheumatoid,1610,B-Disease
arthritis,1610,I-Disease
.,1610,O
A,1611,O
67-year-old,1611,O
woman,1611,O
with,1611,O
rheumatoid,1611,B-Disease
arthritis,1611,I-Disease
presented,1611,O
rapidly,1611,O
progressive,1611,O
glomerulonephritis,1611,B-Disease
(,1611,O
RPGN,1611,B-Disease
),1611,O
after,1611,O
5,1611,O
months,1611,O
of,1611,O
D-penicillamine,1611,B-Chemical
(,1611,O
250,1611,O
mg/day,1611,O
),1611,O
treatment,1611,O
.,1611,O
Light,1612,O
microscopy,1612,O
study,1612,O
showed,1612,O
severe,1612,O
glomerulonephritis,1612,B-Disease
with,1612,O
crescent,1612,O
formation,1612,O
in,1612,O
60,1612,O
%,1612,O
of,1612,O
the,1612,O
glomeruli,1612,O
and,1612,O
infiltration,1612,O
of,1612,O
inflammatory,1612,O
cells,1612,O
in,1612,O
the,1612,O
wall,1612,O
of,1612,O
an,1612,O
arteriole,1612,O
.,1612,O
Immunofluorescence,1613,O
revealed,1613,O
scanty,1613,O
granular,1613,O
IgG,1613,O
",",1613,O
IgA,1613,O
and,1613,O
C3,1613,O
deposits,1613,O
along,1613,O
the,1613,O
capillary,1613,O
walls,1613,O
and,1613,O
mesangium,1613,O
.,1613,O
The,1614,O
patient,1614,O
was,1614,O
treated,1614,O
with,1614,O
steroid,1614,B-Chemical
pulse,1614,O
",",1614,O
plasmapheresis,1614,O
",",1614,O
cyclophosphamide,1614,B-Chemical
and,1614,O
antiplatelet,1614,B-Chemical
agents,1614,I-Chemical
.,1614,O
A,1615,O
complete,1615,O
recovery,1615,O
of,1615,O
renal,1615,O
function,1615,O
was,1615,O
achieved,1615,O
in,1615,O
a,1615,O
few,1615,O
weeks,1615,O
.,1615,O
This,1616,O
new,1616,O
case,1616,O
of,1616,O
RPGN,1616,B-Disease
in,1616,O
the,1616,O
course,1616,O
of,1616,O
D-penicillamine,1616,B-Chemical
treatment,1616,O
emphasizes,1616,O
the,1616,O
need,1616,O
for,1616,O
frequent,1616,O
monitoring,1616,O
of,1616,O
renal,1616,O
function,1616,O
and,1616,O
evaluation,1616,O
of,1616,O
urinary,1616,O
sediment,1616,O
and,1616,O
proteinuria,1616,B-Disease
in,1616,O
these,1616,O
patients,1616,O
.,1616,O
The,1617,O
prompt,1617,O
discontinuation,1617,O
of,1617,O
D-penicillamine,1617,B-Chemical
and,1617,O
vigorous,1617,O
treatment,1617,O
measures,1617,O
could,1617,O
allow,1617,O
for,1617,O
a,1617,O
good,1617,O
prognosis,1617,O
as,1617,O
in,1617,O
this,1617,O
case,1617,O
.,1617,O
A,1618,O
case,1618,O
of,1618,O
polymyositis,1618,B-Disease
in,1618,O
a,1618,O
patient,1618,O
with,1618,O
primary,1618,B-Disease
biliary,1618,I-Disease
cirrhosis,1618,I-Disease
treated,1618,O
with,1618,O
D-penicillamine,1618,B-Chemical
.,1618,O
Although,1619,O
D-penicillamine,1619,B-Chemical
has,1619,O
been,1619,O
used,1619,O
for,1619,O
many,1619,O
rheumatologic,1619,B-Disease
diseases,1619,I-Disease
",",1619,O
toxicity,1619,B-Disease
limits,1619,O
its,1619,O
usefulness,1619,O
in,1619,O
many,1619,O
patients,1619,O
.,1619,O
Polymyositis/dermatomyositis,1620,B-Disease
can,1620,O
develop,1620,O
as,1620,O
one,1620,O
of,1620,O
the,1620,O
autoimmune,1620,O
complications,1620,O
of,1620,O
D-penicillamine,1620,B-Chemical
treatment,1620,O
",",1620,O
but,1620,O
its,1620,O
exact,1620,O
pathogenesis,1620,O
remains,1620,O
unclear,1620,O
.,1620,O
We,1621,O
report,1621,O
a,1621,O
patient,1621,O
with,1621,O
primary,1621,B-Disease
biliary,1621,I-Disease
cirrhosis,1621,I-Disease
",",1621,O
who,1621,O
developed,1621,O
polymyositis,1621,B-Disease
while,1621,O
receiving,1621,O
D-penicillamine,1621,B-Chemical
therapy,1621,O
.,1621,O
We,1622,O
described,1622,O
the,1622,O
special,1622,O
clinical,1622,O
course,1622,O
of,1622,O
the,1622,O
patient,1622,O
.,1622,O
Patients,1623,O
receiving,1623,O
D-penicillamine,1623,B-Chemical
therapy,1623,O
should,1623,O
be,1623,O
followed,1623,O
carefully,1623,O
for,1623,O
the,1623,O
development,1623,O
of,1623,O
autoimmune,1623,O
complications,1623,O
like,1623,O
polymyositis/dermatomyositis,1623,B-Disease
.,1623,O
Hyperalgesia,1624,B-Disease
and,1624,O
myoclonus,1624,B-Disease
in,1624,O
terminal,1624,O
cancer,1624,B-Disease
patients,1624,O
treated,1624,O
with,1624,O
continuous,1624,O
intravenous,1624,O
morphine,1624,B-Chemical
.,1624,O
Eight,1625,O
cancer,1625,B-Disease
patients,1625,O
in,1625,O
the,1625,O
terminal,1625,O
stages,1625,O
of,1625,O
the,1625,O
disease,1625,O
treated,1625,O
with,1625,O
high,1625,O
doses,1625,O
of,1625,O
intravenous,1625,O
morphine,1625,B-Chemical
developed,1625,O
hyperalgesia,1625,B-Disease
.,1625,O
All,1626,O
cases,1626,O
were,1626,O
retrospectively,1626,O
sampled,1626,O
from,1626,O
three,1626,O
different,1626,O
hospitals,1626,O
in,1626,O
Copenhagen,1626,O
.,1626,O
Five,1627,O
patients,1627,O
developed,1627,O
universal,1627,O
hyperalgesia,1627,B-Disease
and,1627,O
hyperesthesia,1627,B-Disease
which,1627,O
in,1627,O
2,1627,O
cases,1627,O
were,1627,O
accompanied,1627,O
by,1627,O
myoclonus,1627,B-Disease
.,1627,O
In,1628,O
3,1628,O
patients,1628,O
a,1628,O
pre-existing,1628,O
neuralgia,1628,B-Disease
increased,1628,O
to,1628,O
excruciating,1628,O
intensity,1628,O
and,1628,O
in,1628,O
2,1628,O
of,1628,O
these,1628,O
cases,1628,O
myoclonus,1628,B-Disease
occurred,1628,O
simultaneously,1628,O
.,1628,O
Although,1629,O
only,1629,O
few,1629,O
clinical,1629,O
descriptions,1629,O
of,1629,O
the,1629,O
relationship,1629,O
between,1629,O
hyperalgesia/myoclonus,1629,B-Disease
and,1629,O
high,1629,O
doses,1629,O
of,1629,O
morphine,1629,B-Chemical
are,1629,O
available,1629,O
",",1629,O
experimental,1629,O
support,1629,O
from,1629,O
animal,1629,O
studies,1629,O
indicates,1629,O
that,1629,O
morphine,1629,B-Chemical
",",1629,O
or,1629,O
its,1629,O
metabolites,1629,O
",",1629,O
plays,1629,O
a,1629,O
causative,1629,O
role,1629,O
for,1629,O
the,1629,O
observed,1629,O
behavioural,1629,O
syndrome,1629,O
.,1629,O
The,1630,O
possible,1630,O
mechanisms,1630,O
are,1630,O
discussed,1630,O
and,1630,O
treatment,1630,O
proposals,1630,O
given,1630,O
suggesting,1630,O
the,1630,O
use,1630,O
of,1630,O
more,1630,O
efficacious,1630,O
opioids,1630,O
with,1630,O
less,1630,O
excitatory,1630,O
potency,1630,O
in,1630,O
these,1630,O
situations,1630,O
.,1630,O
Liposomal,1631,O
daunorubicin,1631,B-Chemical
in,1631,O
advanced,1631,O
Kaposi,1631,B-Disease
's,1631,I-Disease
sarcoma,1631,I-Disease
:,1631,O
a,1631,O
phase,1631,O
II,1631,O
study,1631,O
.,1631,O
We,1632,O
report,1632,O
a,1632,O
non-randomized,1632,O
Phase,1632,O
II,1632,O
clinical,1632,O
trial,1632,O
to,1632,O
assess,1632,O
the,1632,O
efficacy,1632,O
and,1632,O
safety,1632,O
of,1632,O
liposomal,1632,O
daunorubicin,1632,B-Chemical
(,1632,O
DaunoXome,1632,O
),1632,O
in,1632,O
the,1632,O
treatment,1632,O
of,1632,O
AIDS,1632,B-Disease
related,1632,O
Kaposi,1632,B-Disease
's,1632,I-Disease
sarcoma,1632,I-Disease
.,1632,O
Eleven,1633,O
homosexual,1633,O
men,1633,O
with,1633,O
advanced,1633,O
Kaposi,1633,B-Disease
's,1633,I-Disease
sarcoma,1633,I-Disease
were,1633,O
entered,1633,O
in,1633,O
the,1633,O
trial,1633,O
.,1633,O
Changes,1634,O
in,1634,O
size,1634,O
",",1634,O
colour,1634,O
and,1634,O
associated,1634,O
oedema,1634,B-Disease
of,1634,O
selected,1634,O
'target,1634,O
',1634,O
lesions,1634,O
were,1634,O
measured,1634,O
.,1634,O
Clinical,1635,O
",",1635,O
biochemical,1635,O
and,1635,O
haematological,1635,O
toxicities,1635,B-Disease
were,1635,O
assessed,1635,O
.,1635,O
Ten,1636,O
subjects,1636,O
were,1636,O
evaluated,1636,O
.,1636,O
A,1637,O
partial,1637,O
response,1637,O
was,1637,O
achieved,1637,O
in,1637,O
four,1637,O
",",1637,O
of,1637,O
whom,1637,O
two,1637,O
subsequently,1637,O
relapsed,1637,O
.,1637,O
Stabilization,1638,O
of,1638,O
Kaposi,1638,B-Disease
's,1638,I-Disease
sarcoma,1638,I-Disease
occurred,1638,O
in,1638,O
the,1638,O
remaining,1638,O
six,1638,O
",",1638,O
maintained,1638,O
until,1638,O
the,1638,O
end,1638,O
of,1638,O
the,1638,O
trial,1638,O
period,1638,O
in,1638,O
four,1638,O
.,1638,O
The,1639,O
drug,1639,O
was,1639,O
generally,1639,O
well,1639,O
tolerated,1639,O
",",1639,O
with,1639,O
few,1639,O
mild,1639,O
symptoms,1639,O
of,1639,O
toxicity,1639,B-Disease
.,1639,O
The,1640,O
main,1640,O
problem,1640,O
encountered,1640,O
was,1640,O
haematological,1640,O
toxicity,1640,B-Disease
",",1640,O
with,1640,O
three,1640,O
subjects,1640,O
experiencing,1640,O
severe,1640,O
neutropenia,1640,B-Disease
(,1640,O
neutrophil,1640,O
count,1640,O
<,1640,O
0.5,1640,O
x,1640,O
10,1640,O
(,1640,O
9,1640,O
),1640,O
/l,1640,O
),1640,O
.,1640,O
There,1641,O
was,1641,O
no,1641,O
evidence,1641,O
of,1641,O
cardiotoxicity,1641,B-Disease
.,1641,O
In,1642,O
this,1642,O
small,1642,O
patient,1642,O
sample,1642,O
",",1642,O
liposomal,1642,O
daunorubicin,1642,B-Chemical
was,1642,O
an,1642,O
effective,1642,O
and,1642,O
well,1642,O
tolerated,1642,O
agent,1642,O
in,1642,O
the,1642,O
treatment,1642,O
of,1642,O
Kaposi,1642,B-Disease
's,1642,I-Disease
sarcoma,1642,I-Disease
.,1642,O
Long-term,1643,O
effects,1643,O
of,1643,O
vincristine,1643,B-Chemical
on,1643,O
the,1643,O
peripheral,1643,O
nervous,1643,O
system,1643,O
.,1643,O
Forty,1644,O
patients,1644,O
with,1644,O
Non-Hodgkin,1644,B-Disease
's,1644,I-Disease
Lymphoma,1644,I-Disease
treated,1644,O
with,1644,O
vincristine,1644,B-Chemical
between,1644,O
1984,1644,O
and,1644,O
1990,1644,O
(,1644,O
cumulative,1644,O
dose,1644,O
12,1644,O
mg,1644,O
in,1644,O
18-24,1644,O
weeks,1644,O
),1644,O
were,1644,O
investigated,1644,O
in,1644,O
order,1644,O
to,1644,O
evaluate,1644,O
the,1644,O
long,1644,O
term,1644,O
effects,1644,O
of,1644,O
vincristine,1644,B-Chemical
on,1644,O
the,1644,O
peripheral,1644,O
nervous,1644,O
system,1644,O
.,1644,O
The,1645,O
patients,1645,O
were,1645,O
interviewed,1645,O
with,1645,O
emphasis,1645,O
on,1645,O
neuropathic,1645,B-Disease
symptoms,1645,I-Disease
.,1645,O
Physical,1646,O
and,1646,O
quantitative,1646,O
sensory,1646,O
examination,1646,O
with,1646,O
determination,1646,O
of,1646,O
vibratory,1646,O
perception,1646,O
and,1646,O
thermal,1646,O
discrimination,1646,O
thresholds,1646,O
were,1646,O
performed,1646,O
",",1646,O
four,1646,O
to,1646,O
77,1646,O
months,1646,O
(,1646,O
median,1646,O
34,1646,O
months,1646,O
),1646,O
after,1646,O
vincristine,1646,B-Chemical
treatment,1646,O
.,1646,O
Twenty-seven,1647,O
patients,1647,O
reported,1647,O
neuropathic,1647,B-Disease
symptoms,1647,I-Disease
.,1647,O
In,1648,O
13,1648,O
of,1648,O
these,1648,O
27,1648,O
patients,1648,O
symptoms,1648,O
were,1648,O
still,1648,O
present,1648,O
at,1648,O
the,1648,O
time,1648,O
of,1648,O
examination,1648,O
.,1648,O
In,1649,O
these,1649,O
patients,1649,O
sensory,1649,O
signs,1649,O
and,1649,O
symptoms,1649,O
predominated,1649,O
.,1649,O
In,1650,O
the,1650,O
other,1650,O
14,1650,O
patients,1650,O
symptoms,1650,O
had,1650,O
been,1650,O
present,1650,O
in,1650,O
the,1650,O
past,1650,O
.,1650,O
Symptoms,1651,O
persisted,1651,O
maximally,1651,O
40,1651,O
months,1651,O
since,1651,O
cessation,1651,O
of,1651,O
therapy,1651,O
.,1651,O
There,1652,O
was,1652,O
no,1652,O
age,1652,O
difference,1652,O
between,1652,O
patients,1652,O
with,1652,O
and,1652,O
without,1652,O
complaints,1652,O
at,1652,O
the,1652,O
time,1652,O
of,1652,O
examination,1652,O
.,1652,O
Normal,1653,O
reflexes,1653,O
were,1653,O
found,1653,O
in,1653,O
two,1653,O
third,1653,O
of,1653,O
patients,1653,O
.,1653,O
Neuropathic,1654,O
complaints,1654,O
were,1654,O
not,1654,O
very,1654,O
troublesome,1654,O
on,1654,O
the,1654,O
long,1654,O
term,1654,O
.,1654,O
It,1655,O
is,1655,O
concluded,1655,O
that,1655,O
with,1655,O
the,1655,O
above,1655,O
mentioned,1655,O
vincristine,1655,B-Chemical
dose,1655,O
schedule,1655,O
signs,1655,O
and,1655,O
symptoms,1655,O
of,1655,O
vincristine,1655,B-Chemical
neuropathy,1655,B-Disease
are,1655,O
reversible,1655,O
for,1655,O
a,1655,O
great,1655,O
deal,1655,O
and,1655,O
prognosis,1655,O
is,1655,O
fairly,1655,O
good,1655,O
.,1655,O
Loss,1656,O
of,1656,O
glutamate,1656,B-Chemical
decarboxylase,1656,O
mRNA-containing,1656,O
neurons,1656,O
in,1656,O
the,1656,O
rat,1656,O
dentate,1656,O
gyrus,1656,O
following,1656,O
pilocarpine-induced,1656,B-Chemical
seizures,1656,B-Disease
.,1656,O
In,1657,O
situ,1657,O
hybridization,1657,O
methods,1657,O
were,1657,O
used,1657,O
to,1657,O
determine,1657,O
if,1657,O
glutamic,1657,B-Chemical
acid,1657,I-Chemical
decarboxylase,1657,O
(,1657,O
GAD,1657,O
),1657,O
mRNA-containing,1657,O
neurons,1657,O
within,1657,O
the,1657,O
hilus,1657,O
of,1657,O
the,1657,O
dentate,1657,O
gyrus,1657,O
are,1657,O
vulnerable,1657,O
to,1657,O
seizure-induced,1657,B-Disease
damage,1657,O
in,1657,O
a,1657,O
model,1657,O
of,1657,O
chronic,1657,O
seizures,1657,B-Disease
.,1657,O
Sprague-Dawley,1658,O
rats,1658,O
were,1658,O
injected,1658,O
intraperitoneally,1658,O
with,1658,O
pilocarpine,1658,B-Chemical
",",1658,O
and,1658,O
the,1658,O
hippocampal,1658,O
formation,1658,O
was,1658,O
studied,1658,O
histologically,1658,O
at,1658,O
1,1658,O
",",1658,O
2,1658,O
",",1658,O
4,1658,O
",",1658,O
and,1658,O
8,1658,O
week,1658,O
intervals,1658,O
after,1658,O
pilocarpine-induced,1658,B-Chemical
seizures,1658,B-Disease
.,1658,O
In,1659,O
situ,1659,O
hybridization,1659,O
histochemistry,1659,O
",",1659,O
using,1659,O
a,1659,O
digoxigenin-labeled,1659,B-Chemical
GAD,1659,O
cRNA,1659,O
probe,1659,O
",",1659,O
demonstrated,1659,O
a,1659,O
substantial,1659,O
decrease,1659,O
in,1659,O
the,1659,O
number,1659,O
of,1659,O
GAD,1659,O
mRNA-containing,1659,O
neurons,1659,O
in,1659,O
the,1659,O
hilus,1659,O
of,1659,O
the,1659,O
dentate,1659,O
gyrus,1659,O
in,1659,O
the,1659,O
pilocarpine-treated,1659,B-Chemical
rats,1659,O
as,1659,O
compared,1659,O
to,1659,O
controls,1659,O
at,1659,O
all,1659,O
time,1659,O
intervals,1659,O
.,1659,O
Additional,1660,O
neuronanatomical,1660,O
studies,1660,O
",",1660,O
including,1660,O
cresyl,1660,B-Chemical
violet,1660,I-Chemical
staining,1660,O
",",1660,O
neuronal,1660,B-Disease
degeneration,1660,I-Disease
methods,1660,O
",",1660,O
and,1660,O
histochemical,1660,O
localization,1660,O
of,1660,O
glial,1660,O
fibrillary,1660,O
acidic,1660,O
protein,1660,O
",",1660,O
suggested,1660,O
that,1660,O
the,1660,O
decrease,1660,O
in,1660,O
the,1660,O
number,1660,O
of,1660,O
GAD,1660,O
mRNA-containing,1660,O
neurons,1660,O
was,1660,O
related,1660,O
to,1660,O
neuronal,1660,B-Disease
loss,1660,I-Disease
rather,1660,O
than,1660,O
to,1660,O
a,1660,O
decrease,1660,O
in,1660,O
GAD,1660,O
mRNA,1660,O
levels,1660,O
.,1660,O
The,1661,O
loss,1661,O
of,1661,O
GAD,1661,O
mRNA-containing,1661,O
neurons,1661,O
in,1661,O
the,1661,O
hilus,1661,O
contrasted,1661,O
with,1661,O
the,1661,O
relative,1661,O
preservation,1661,O
of,1661,O
labeled,1661,O
putative,1661,O
basket,1661,O
cells,1661,O
along,1661,O
the,1661,O
inner,1661,O
margin,1661,O
of,1661,O
the,1661,O
granule,1661,O
cell,1661,O
layer,1661,O
.,1661,O
Quantitative,1662,O
analyses,1662,O
of,1662,O
labeled,1662,O
neurons,1662,O
in,1662,O
three,1662,O
regions,1662,O
of,1662,O
the,1662,O
dentate,1662,O
gyrus,1662,O
in,1662,O
the,1662,O
1,1662,O
and,1662,O
2,1662,O
week,1662,O
groups,1662,O
showed,1662,O
statistically,1662,O
significant,1662,O
decreases,1662,O
in,1662,O
the,1662,O
mean,1662,O
number,1662,O
of,1662,O
GAD,1662,O
mRNA-containing,1662,O
neurons,1662,O
in,1662,O
the,1662,O
hilus,1662,O
of,1662,O
both,1662,O
groups,1662,O
of,1662,O
experimental,1662,O
animals,1662,O
.,1662,O
No,1663,O
significant,1663,O
differences,1663,O
were,1663,O
found,1663,O
in,1663,O
the,1663,O
molecular,1663,O
layer,1663,O
or,1663,O
the,1663,O
granule,1663,O
cell,1663,O
layer,1663,O
",",1663,O
which,1663,O
included,1663,O
labeled,1663,O
neurons,1663,O
along,1663,O
the,1663,O
lower,1663,O
margin,1663,O
of,1663,O
the,1663,O
granule,1663,O
cell,1663,O
layer,1663,O
.,1663,O
The,1664,O
results,1664,O
indicate,1664,O
that,1664,O
",",1664,O
in,1664,O
this,1664,O
model,1664,O
",",1664,O
a,1664,O
subpopulation,1664,O
of,1664,O
GAD,1664,O
mRNA-containing,1664,O
neurons,1664,O
within,1664,O
the,1664,O
dentate,1664,O
gyrus,1664,O
is,1664,O
selectively,1664,O
vulnerable,1664,O
to,1664,O
seizure-induced,1664,B-Disease
damage,1664,O
.,1664,O
Such,1665,O
differential,1665,O
vulnerability,1665,O
appears,1665,O
to,1665,O
be,1665,O
another,1665,O
indication,1665,O
of,1665,O
the,1665,O
heterogeneity,1665,O
of,1665,O
GABA,1665,B-Chemical
neurons,1665,O
.,1665,O
Effects,1666,O
of,1666,O
deliberate,1666,O
hypotension,1666,B-Disease
induced,1666,O
by,1666,O
labetalol,1666,B-Chemical
with,1666,O
isoflurane,1666,B-Chemical
on,1666,O
neuropsychological,1666,O
function,1666,O
.,1666,O
The,1667,O
effect,1667,O
of,1667,O
deliberate,1667,O
hypotension,1667,B-Disease
on,1667,O
brain,1667,O
function,1667,O
measured,1667,O
by,1667,O
neuropsychological,1667,O
tests,1667,O
was,1667,O
studied,1667,O
in,1667,O
41,1667,O
adult,1667,O
patients,1667,O
.,1667,O
Twenty-four,1668,O
patients,1668,O
were,1668,O
anaesthetized,1668,O
for,1668,O
middle-ear,1668,O
surgery,1668,O
with,1668,O
deliberate,1668,O
hypotension,1668,B-Disease
induced,1668,O
by,1668,O
labetalol,1668,B-Chemical
with,1668,O
isoflurane,1668,B-Chemical
(,1668,O
hypotensive,1668,B-Disease
group,1668,O
),1668,O
.,1668,O
Seventeen,1669,O
patients,1669,O
without,1669,O
hypotension,1669,B-Disease
served,1669,O
as,1669,O
a,1669,O
control,1669,O
group,1669,O
.,1669,O
The,1670,O
mean,1670,O
arterial,1670,O
pressure,1670,O
was,1670,O
77,1670,O
+/-,1670,O
2,1670,O
mmHg,1670,O
(,1670,O
10.3,1670,O
+/-,1670,O
0.3,1670,O
kPa,1670,O
),1670,O
before,1670,O
hypotension,1670,B-Disease
and,1670,O
50,1670,O
+/-,1670,O
0,1670,O
mmHg,1670,O
(,1670,O
6.7,1670,O
+/-,1670,O
0.0,1670,O
kPa,1670,O
),1670,O
during,1670,O
hypotension,1670,B-Disease
in,1670,O
the,1670,O
hypotensive,1670,B-Disease
group,1670,O
",",1670,O
and,1670,O
86,1670,O
+/-,1670,O
2,1670,O
mmHg,1670,O
(,1670,O
11.5,1670,O
+/-,1670,O
0.3,1670,O
kPa,1670,O
),1670,O
during,1670,O
anaesthesia,1670,O
in,1670,O
the,1670,O
control,1670,O
group,1670,O
.,1670,O
The,1671,O
following,1671,O
psychological,1671,O
tests,1671,O
were,1671,O
performed,1671,O
:,1671,O
four,1671,O
subtests,1671,O
of,1671,O
the,1671,O
Wechsler,1671,O
Adult,1671,O
Intelligence,1671,O
Scale,1671,O
(,1671,O
similarities,1671,O
",",1671,O
digit,1671,O
span,1671,O
",",1671,O
vocabulary,1671,O
and,1671,O
digit,1671,O
symbol,1671,O
),1671,O
",",1671,O
Trail-Making,1671,O
tests,1671,O
A,1671,O
and,1671,O
B,1671,O
",",1671,O
Zung,1671,O
tests,1671,O
(,1671,O
self-rating,1671,O
anxiety,1671,B-Disease
scale,1671,O
and,1671,O
self-rating,1671,O
depression,1671,B-Disease
scale,1671,O
),1671,O
and,1671,O
two-part,1671,O
memory,1671,O
test,1671,O
battery,1671,O
with,1671,O
immediate,1671,O
and,1671,O
delayed,1671,O
recall,1671,O
.,1671,O
The,1672,O
tests,1672,O
were,1672,O
performed,1672,O
preoperatively,1672,O
and,1672,O
2,1672,O
days,1672,O
postoperatively,1672,O
.,1672,O
There,1673,O
were,1673,O
no,1673,O
statistically,1673,O
significant,1673,O
differences,1673,O
between,1673,O
the,1673,O
groups,1673,O
in,1673,O
any,1673,O
of,1673,O
the,1673,O
tests,1673,O
in,1673,O
the,1673,O
changes,1673,O
from,1673,O
preoperative,1673,O
value,1673,O
to,1673,O
postoperative,1673,O
value,1673,O
.,1673,O
The,1674,O
results,1674,O
indicate,1674,O
that,1674,O
hypotension,1674,B-Disease
induced,1674,O
by,1674,O
labetalol,1674,B-Chemical
with,1674,O
isoflurane,1674,B-Chemical
has,1674,O
no,1674,O
significant,1674,O
harmful,1674,O
effects,1674,O
on,1674,O
mental,1674,O
functions,1674,O
compared,1674,O
to,1674,O
normotensive,1674,O
anaesthesia,1674,O
.,1674,O
Apparent,1675,O
cure,1675,O
of,1675,O
rheumatoid,1675,B-Disease
arthritis,1675,I-Disease
by,1675,O
bone,1675,O
marrow,1675,O
transplantation,1675,O
.,1675,O
We,1676,O
describe,1676,O
the,1676,O
induction,1676,O
of,1676,O
sustained,1676,O
remissions,1676,O
and,1676,O
possible,1676,O
cure,1676,O
of,1676,O
severe,1676,O
erosive,1676,O
rheumatoid,1676,B-Disease
arthritis,1676,I-Disease
(,1676,O
RA,1676,B-Disease
),1676,O
by,1676,O
bone,1676,O
marrow,1676,O
transplantation,1676,O
(,1676,O
BMT,1676,O
),1676,O
in,1676,O
2,1676,O
patients,1676,O
.,1676,O
BMT,1677,O
was,1677,O
used,1677,O
to,1677,O
treat,1677,O
severe,1677,O
aplastic,1677,B-Disease
anemia,1677,I-Disease
which,1677,O
was,1677,O
caused,1677,O
by,1677,O
gold,1677,B-Chemical
in,1677,O
one,1677,O
case,1677,O
and,1677,O
D-penicillamine,1677,B-Chemical
in,1677,O
the,1677,O
other,1677,O
.,1677,O
In,1678,O
the,1678,O
8,1678,O
and,1678,O
6,1678,O
years,1678,O
since,1678,O
the,1678,O
transplants,1678,O
(,1678,O
representing,1678,O
8,1678,O
and,1678,O
4,1678,O
years,1678,O
since,1678,O
cessation,1678,O
of,1678,O
all,1678,O
immunosuppressive,1678,O
therapy,1678,O
",",1678,O
respectively,1678,O
),1678,O
",",1678,O
the,1678,O
RA,1678,B-Disease
in,1678,O
each,1678,O
case,1678,O
has,1678,O
been,1678,O
completely,1678,O
quiescent,1678,O
.,1678,O
Although,1679,O
short,1679,O
term,1679,O
remission,1679,O
of,1679,O
severe,1679,O
RA,1679,B-Disease
following,1679,O
BMT,1679,O
has,1679,O
been,1679,O
reported,1679,O
",",1679,O
these,1679,O
are,1679,O
the,1679,O
first,1679,O
cases,1679,O
for,1679,O
which,1679,O
prolonged,1679,O
followup,1679,O
has,1679,O
been,1679,O
available,1679,O
.,1679,O
This,1680,O
experience,1680,O
raises,1680,O
the,1680,O
question,1680,O
of,1680,O
the,1680,O
role,1680,O
of,1680,O
BMT,1680,O
itself,1680,O
as,1680,O
a,1680,O
therapeutic,1680,O
option,1680,O
for,1680,O
patients,1680,O
with,1680,O
uncontrolled,1680,O
destructive,1680,O
synovitis,1680,B-Disease
.,1680,O
Seizures,1681,B-Disease
induced,1681,O
by,1681,O
combined,1681,O
levomepromazine-fluvoxamine,1681,B-Chemical
treatment,1681,O
.,1681,O
We,1682,O
report,1682,O
a,1682,O
case,1682,O
of,1682,O
combined,1682,O
levomepromazine-fluvoxamine,1682,B-Chemical
treatment-induced,1682,O
seizures,1682,B-Disease
.,1682,O
It,1683,O
seems,1683,O
that,1683,O
combined,1683,O
treatment,1683,O
of,1683,O
fluvoxamine,1683,B-Chemical
with,1683,O
phenothiazines,1683,B-Chemical
may,1683,O
possess,1683,O
proconvulsive,1683,O
activity,1683,O
.,1683,O
Case,1684,O
report,1684,O
:,1684,O
pentamidine,1684,B-Chemical
and,1684,O
polymorphic,1684,O
ventricular,1684,B-Disease
tachycardia,1684,I-Disease
revisited,1684,O
.,1684,O
Pentamidine,1685,B-Chemical
isethionate,1685,I-Chemical
has,1685,O
been,1685,O
associated,1685,O
with,1685,O
ventricular,1685,B-Disease
tachyarrhythmias,1685,I-Disease
",",1685,O
including,1685,O
torsade,1685,B-Disease
de,1685,I-Disease
pointes,1685,I-Disease
.,1685,O
This,1686,O
article,1686,O
reports,1686,O
two,1686,O
cases,1686,O
of,1686,O
this,1686,O
complication,1686,O
and,1686,O
reviews,1686,O
all,1686,O
reported,1686,O
cases,1686,O
to,1686,O
date,1686,O
.,1686,O
Pentamidine-induced,1687,B-Chemical
torsade,1687,B-Disease
de,1687,I-Disease
pointes,1687,I-Disease
may,1687,O
be,1687,O
related,1687,O
to,1687,O
serum,1687,O
magnesium,1687,B-Chemical
levels,1687,O
and,1687,O
hypomagnesemia,1687,B-Disease
may,1687,O
synergistically,1687,O
induce,1687,O
torsade,1687,O
.,1687,O
Torsade,1688,B-Disease
de,1688,I-Disease
pointes,1688,I-Disease
occurred,1688,O
after,1688,O
an,1688,O
average,1688,O
of,1688,O
10,1688,O
days,1688,O
of,1688,O
treatment,1688,O
with,1688,O
pentamidine,1688,B-Chemical
.,1688,O
In,1689,O
these,1689,O
patients,1689,O
",",1689,O
no,1689,O
other,1689,O
acute,1689,O
side,1689,O
effects,1689,O
of,1689,O
pentamidine,1689,B-Chemical
were,1689,O
observed,1689,O
.,1689,O
Torsade,1690,B-Disease
de,1690,I-Disease
pointes,1690,I-Disease
can,1690,O
be,1690,O
treated,1690,O
when,1690,O
recognized,1690,O
early,1690,O
",",1690,O
possibly,1690,O
without,1690,O
discontinuation,1690,O
of,1690,O
pentamidine,1690,B-Chemical
.,1690,O
When,1691,O
QTc,1691,B-Disease
interval,1691,I-Disease
prolongation,1691,I-Disease
is,1691,O
observed,1691,O
",",1691,O
early,1691,O
magnesium,1691,B-Chemical
supplementation,1691,O
is,1691,O
advocated,1691,O
.,1691,O
Efficacy,1692,O
and,1692,O
tolerability,1692,O
of,1692,O
lovastatin,1692,B-Chemical
in,1692,O
3390,1692,O
women,1692,O
with,1692,O
moderate,1692,O
hypercholesterolemia,1692,B-Disease
.,1692,O
OBJECTIVE,1693,O
:,1693,O
To,1693,O
evaluate,1693,O
the,1693,O
efficacy,1693,O
and,1693,O
safety,1693,O
of,1693,O
lovastatin,1693,B-Chemical
in,1693,O
women,1693,O
with,1693,O
moderate,1693,O
hypercholesterolemia,1693,B-Disease
.,1693,O
DESIGN,1694,O
:,1694,O
The,1694,O
Expanded,1694,O
Clinical,1694,O
Evaluation,1694,O
of,1694,O
Lovastatin,1694,B-Chemical
(,1694,O
EXCEL,1694,O
),1694,O
Study,1694,O
",",1694,O
a,1694,O
multicenter,1694,O
",",1694,O
double-blind,1694,O
",",1694,O
diet-,1694,O
and,1694,O
placebo-controlled,1694,O
trial,1694,O
",",1694,O
in,1694,O
which,1694,O
participants,1694,O
were,1694,O
randomly,1694,O
assigned,1694,O
to,1694,O
receive,1694,O
placebo,1694,O
or,1694,O
lovastatin,1694,B-Chemical
at,1694,O
doses,1694,O
of,1694,O
20,1694,O
or,1694,O
40,1694,O
mg,1694,O
once,1694,O
daily,1694,O
",",1694,O
or,1694,O
20,1694,O
or,1694,O
40,1694,O
mg,1694,O
twice,1694,O
daily,1694,O
for,1694,O
48,1694,O
weeks,1694,O
.,1694,O
SETTING,1695,O
:,1695,O
Ambulatory,1695,O
patients,1695,O
recruited,1695,O
by,1695,O
362,1695,O
participating,1695,O
centers,1695,O
throughout,1695,O
the,1695,O
United,1695,O
States,1695,O
.,1695,O
PATIENTS,1696,O
:,1696,O
Women,1696,O
(,1696,O
n,1696,O
=,1696,O
3390,1696,O
),1696,O
from,1696,O
the,1696,O
total,1696,O
cohort,1696,O
of,1696,O
8245,1696,O
volunteers,1696,O
.,1696,O
MEASUREMENTS,1697,O
:,1697,O
Plasma,1697,O
total,1697,O
",",1697,O
low-density,1697,O
lipoprotein,1697,O
(,1697,O
LDL,1697,O
),1697,O
",",1697,O
and,1697,O
high-density,1697,O
lipoprotein,1697,O
(,1697,O
HDL,1697,O
),1697,O
cholesterol,1697,B-Chemical
",",1697,O
and,1697,O
triglycerides,1697,B-Chemical
;,1697,O
and,1697,O
laboratory,1697,O
and,1697,O
clinical,1697,O
evidence,1697,O
of,1697,O
adverse,1697,O
events,1697,O
monitored,1697,O
periodically,1697,O
throughout,1697,O
the,1697,O
study,1697,O
.,1697,O
RESULTS,1698,O
:,1698,O
Among,1698,O
women,1698,O
",",1698,O
lovastatin,1698,B-Chemical
(,1698,O
20,1698,O
to,1698,O
80,1698,O
mg/d,1698,O
),1698,O
produced,1698,O
sustained,1698,O
(,1698,O
12-,1698,O
to,1698,O
48-week,1698,O
),1698,O
",",1698,O
dose-related,1698,O
changes,1698,O
(,1698,O
P,1698,O
<,1698,O
0.001,1698,O
),1698,O
:,1698,O
decreases,1698,O
in,1698,O
LDL,1698,O
cholesterol,1698,B-Chemical
(,1698,O
24,1698,O
%,1698,O
to,1698,O
40,1698,O
%,1698,O
),1698,O
and,1698,O
triglycerides,1698,B-Chemical
(,1698,O
9,1698,O
%,1698,O
to,1698,O
18,1698,O
%,1698,O
),1698,O
",",1698,O
and,1698,O
increases,1698,O
in,1698,O
HDL,1698,O
cholesterol,1698,B-Chemical
(,1698,O
6.7,1698,O
%,1698,O
to,1698,O
8.6,1698,O
%,1698,O
),1698,O
.,1698,O
Depending,1699,O
on,1699,O
the,1699,O
dose,1699,O
",",1699,O
from,1699,O
82,1699,O
%,1699,O
to,1699,O
95,1699,O
%,1699,O
of,1699,O
lovastatin-treated,1699,B-Chemical
women,1699,O
achieved,1699,O
the,1699,O
National,1699,O
Cholesterol,1699,B-Chemical
Education,1699,O
Program,1699,O
goal,1699,O
of,1699,O
LDL,1699,O
cholesterol,1699,B-Chemical
levels,1699,O
less,1699,O
than,1699,O
4.14,1699,O
mmol/L,1699,O
(,1699,O
160,1699,O
mg/dL,1699,O
),1699,O
",",1699,O
and,1699,O
40,1699,O
%,1699,O
to,1699,O
87,1699,O
%,1699,O
achieved,1699,O
the,1699,O
goal,1699,O
of,1699,O
3.36,1699,O
mmol/L,1699,O
(,1699,O
130,1699,O
mg/dL,1699,O
),1699,O
.,1699,O
Successive,1700,O
transaminase,1700,O
elevations,1700,O
greater,1700,O
than,1700,O
three,1700,O
times,1700,O
the,1700,O
upper,1700,O
limit,1700,O
of,1700,O
normal,1700,O
occurred,1700,O
in,1700,O
0.1,1700,O
%,1700,O
of,1700,O
women,1700,O
and,1700,O
were,1700,O
dose,1700,O
dependent,1700,O
above,1700,O
the,1700,O
20-mg,1700,O
dose,1700,O
.,1700,O
Myopathy,1701,B-Disease
",",1701,O
defined,1701,O
as,1701,O
muscle,1701,O
symptoms,1701,O
with,1701,O
creatine,1701,B-Chemical
kinase,1701,O
elevations,1701,O
greater,1701,O
than,1701,O
10,1701,O
times,1701,O
the,1701,O
upper,1701,O
limit,1701,O
of,1701,O
normal,1701,O
",",1701,O
was,1701,O
rare,1701,O
and,1701,O
associated,1701,O
with,1701,O
the,1701,O
highest,1701,O
recommended,1701,O
daily,1701,O
dose,1701,O
of,1701,O
lovastatin,1701,B-Chemical
(,1701,O
80,1701,O
mg,1701,O
),1701,O
.,1701,O
Estrogen-replacement,1702,O
therapy,1702,O
appeared,1702,O
to,1702,O
have,1702,O
no,1702,O
effect,1702,O
on,1702,O
either,1702,O
the,1702,O
efficacy,1702,O
or,1702,O
safety,1702,O
profile,1702,O
of,1702,O
lovastatin,1702,B-Chemical
.,1702,O
CONCLUSION,1703,O
:,1703,O
Lovastatin,1703,B-Chemical
is,1703,O
highly,1703,O
effective,1703,O
and,1703,O
generally,1703,O
well,1703,O
tolerated,1703,O
as,1703,O
therapy,1703,O
for,1703,O
primary,1703,O
hypercholesterolemia,1703,B-Disease
in,1703,O
women,1703,O
.,1703,O
Tetany,1704,B-Disease
and,1704,O
rhabdomyolysis,1704,B-Disease
due,1704,O
to,1704,O
surreptitious,1704,O
furosemide,1704,B-Chemical
--,1704,O
importance,1704,O
of,1704,O
magnesium,1704,B-Chemical
supplementation,1704,O
.,1704,O
Diuretics,1705,O
may,1705,O
induce,1705,O
hypokalemia,1705,B-Disease
",",1705,O
hypocalcemia,1705,B-Disease
and,1705,O
hypomagnesemia,1705,B-Disease
.,1705,O
While,1706,O
severe,1706,O
hypokalemia,1706,B-Disease
may,1706,O
cause,1706,O
muscle,1706,B-Disease
weakness,1706,I-Disease
",",1706,O
severe,1706,O
hypomagnesemia,1706,B-Disease
is,1706,O
associated,1706,O
with,1706,O
muscle,1706,B-Disease
spasms,1706,I-Disease
and,1706,O
tetany,1706,B-Disease
which,1706,O
can,1706,O
not,1706,O
be,1706,O
corrected,1706,O
by,1706,O
potassium,1706,B-Chemical
and,1706,O
calcium,1706,B-Chemical
supplementation,1706,O
alone,1706,O
(,1706,O
"1,2",1706,O
),1706,O
.,1706,O
Surreptitious,1707,O
diuretic,1707,O
ingestion,1707,O
has,1707,O
been,1707,O
described,1707,O
",",1707,O
mainly,1707,O
in,1707,O
women,1707,O
who,1707,O
are,1707,O
concerned,1707,O
that,1707,O
they,1707,O
are,1707,O
obese,1707,B-Disease
or,1707,O
edematous,1707,B-Disease
.,1707,O
Symptomatic,1708,O
hypokalemia,1708,B-Disease
has,1708,O
been,1708,O
reported,1708,O
in,1708,O
such,1708,O
patients,1708,O
(,1708,O
3-7,1708,O
),1708,O
and,1708,O
in,1708,O
one,1708,O
case,1708,O
hypocalcemia,1708,B-Disease
was,1708,O
observed,1708,O
(,1708,O
8,1708,O
),1708,O
",",1708,O
but,1708,O
the,1708,O
effects,1708,O
of,1708,O
magnesium,1708,B-Chemical
depletion,1708,O
were,1708,O
not,1708,O
noted,1708,O
in,1708,O
these,1708,O
patients,1708,O
.,1708,O
Ciprofloxacin-induced,1709,B-Chemical
nephrotoxicity,1709,B-Disease
in,1709,O
patients,1709,O
with,1709,O
cancer,1709,B-Disease
.,1709,O
Nephrotoxicity,1710,B-Disease
associated,1710,O
with,1710,O
ciprofloxacin,1710,B-Chemical
is,1710,O
uncommon,1710,O
.,1710,O
Five,1711,O
patients,1711,O
with,1711,O
cancer,1711,B-Disease
who,1711,O
developed,1711,O
acute,1711,B-Disease
renal,1711,I-Disease
failure,1711,I-Disease
that,1711,O
followed,1711,O
treatment,1711,O
with,1711,O
ciprofloxacin,1711,B-Chemical
are,1711,O
described,1711,O
and,1711,O
an,1711,O
additional,1711,O
15,1711,O
cases,1711,O
reported,1711,O
in,1711,O
the,1711,O
literature,1711,O
are,1711,O
reviewed,1711,O
.,1711,O
Other,1712,O
than,1712,O
elevation,1712,O
of,1712,O
serum,1712,O
creatinine,1712,B-Chemical
levels,1712,O
",",1712,O
characteristic,1712,O
clinical,1712,O
manifestations,1712,O
and,1712,O
abnormal,1712,O
laboratory,1712,O
findings,1712,O
are,1712,O
not,1712,O
frequently,1712,O
present,1712,O
.,1712,O
Allergic,1713,O
interstitial,1713,B-Disease
nephritis,1713,I-Disease
is,1713,O
believed,1713,O
to,1713,O
be,1713,O
the,1713,O
underlying,1713,O
pathological-process,1713,O
.,1713,O
Definitive,1714,O
diagnosis,1714,O
requires,1714,O
performance,1714,O
of,1714,O
renal,1714,O
biopsy,1714,O
",",1714,O
although,1714,O
this,1714,O
is,1714,O
not,1714,O
always,1714,O
feasible,1714,O
.,1714,O
An,1715,O
improvement,1715,O
in,1715,O
renal,1715,O
function,1715,O
that,1715,O
followed,1715,O
the,1715,O
discontinuation,1715,O
of,1715,O
the,1715,O
offending,1715,O
antibiotic,1715,O
supports,1715,O
the,1715,O
presumptive,1715,O
diagnosis,1715,O
of,1715,O
ciprofloxacin-induced,1715,B-Chemical
acute,1715,B-Disease
renal,1715,I-Disease
failure,1715,I-Disease
.,1715,O
Venous,1716,B-Disease
complications,1716,I-Disease
of,1716,O
midazolam,1716,B-Chemical
versus,1716,O
diazepam,1716,B-Chemical
.,1716,O
Although,1717,O
some,1717,O
studies,1717,O
have,1717,O
suggested,1717,O
fewer,1717,O
venous,1717,B-Disease
complications,1717,I-Disease
are,1717,O
associated,1717,O
with,1717,O
midazolam,1717,B-Chemical
than,1717,O
with,1717,O
diazepam,1717,B-Chemical
for,1717,O
endoscopic,1717,O
procedures,1717,O
",",1717,O
this,1717,O
variable,1717,O
has,1717,O
not,1717,O
been,1717,O
well,1717,O
documented,1717,O
.,1717,O
We,1718,O
prospectively,1718,O
evaluated,1718,O
the,1718,O
incidence,1718,O
of,1718,O
venous,1718,B-Disease
complications,1718,I-Disease
after,1718,O
intravenous,1718,O
injection,1718,O
of,1718,O
diazepam,1718,B-Chemical
or,1718,O
midazolam,1718,B-Chemical
in,1718,O
122,1718,O
consecutive,1718,O
patients,1718,O
undergoing,1718,O
colonoscopy,1718,O
and,1718,O
esophagogastroduodenoscopy,1718,O
.,1718,O
Overall,1719,O
",",1719,O
venous,1719,B-Disease
complications,1719,I-Disease
were,1719,O
more,1719,O
frequent,1719,O
with,1719,O
diazepam,1719,B-Chemical
(,1719,O
22,1719,O
of,1719,O
62,1719,O
patients,1719,O
),1719,O
than,1719,O
with,1719,O
midazolam,1719,B-Chemical
(,1719,O
4,1719,O
of,1719,O
60,1719,O
patients,1719,O
),1719,O
(,1719,O
p,1719,O
<,1719,O
0.001,1719,O
),1719,O
.,1719,O
A,1720,O
palpable,1720,O
venous,1720,O
cord,1720,O
was,1720,O
present,1720,O
in,1720,O
23,1720,O
%,1720,O
(,1720,O
14,1720,O
of,1720,O
62,1720,O
),1720,O
of,1720,O
patients,1720,O
in,1720,O
the,1720,O
diazepam,1720,B-Chemical
group,1720,O
",",1720,O
compared,1720,O
with,1720,O
2,1720,O
%,1720,O
(,1720,O
1,1720,O
of,1720,O
60,1720,O
patients,1720,O
),1720,O
in,1720,O
the,1720,O
midazolam,1720,B-Chemical
group,1720,O
(,1720,O
p,1720,O
<,1720,O
0.002,1720,O
),1720,O
.,1720,O
Pain,1721,B-Disease
at,1721,O
the,1721,O
injection,1721,O
site,1721,O
occurred,1721,O
in,1721,O
35,1721,O
%,1721,O
(,1721,O
22,1721,O
of,1721,O
62,1721,O
),1721,O
of,1721,O
patients,1721,O
in,1721,O
the,1721,O
diazepam,1721,B-Chemical
group,1721,O
compared,1721,O
with,1721,O
7,1721,O
%,1721,O
(,1721,O
4,1721,O
of,1721,O
60,1721,O
patients,1721,O
),1721,O
in,1721,O
the,1721,O
midazolam,1721,B-Chemical
group,1721,O
(,1721,O
p,1721,O
<,1721,O
0.001,1721,O
),1721,O
.,1721,O
Swelling,1722,B-Disease
and,1722,O
warmth,1722,O
at,1722,O
the,1722,O
injection,1722,O
site,1722,O
were,1722,O
not,1722,O
significantly,1722,O
different,1722,O
between,1722,O
the,1722,O
two,1722,O
groups,1722,O
.,1722,O
Smoking,1723,O
",",1723,O
nonsteroidal,1723,O
anti-inflammatory,1723,O
drug,1723,O
use,1723,O
",",1723,O
intravenous,1723,O
catheter,1723,O
site,1723,O
",",1723,O
dwell,1723,O
time,1723,O
of,1723,O
the,1723,O
needle,1723,O
",",1723,O
alcohol,1723,B-Chemical
use,1723,O
",",1723,O
and,1723,O
pain,1723,B-Disease
during,1723,O
the,1723,O
injection,1723,O
had,1723,O
no,1723,O
effect,1723,O
on,1723,O
the,1723,O
incidence,1723,O
of,1723,O
venous,1723,B-Disease
complications,1723,I-Disease
.,1723,O
Clarithromycin-associated,1724,B-Chemical
visual,1724,B-Disease
hallucinations,1724,I-Disease
in,1724,O
a,1724,O
patient,1724,O
with,1724,O
chronic,1724,B-Disease
renal,1724,I-Disease
failure,1724,I-Disease
on,1724,O
continuous,1724,O
ambulatory,1724,O
peritoneal,1724,O
dialysis,1724,O
.,1724,O
Visual,1725,B-Disease
hallucinations,1725,I-Disease
are,1725,O
a,1725,O
rare,1725,O
event,1725,O
in,1725,O
chronic,1725,B-Disease
renal,1725,I-Disease
failure,1725,I-Disease
and,1725,O
not,1725,O
related,1725,O
to,1725,O
uremia,1725,B-Disease
per,1725,O
se,1725,O
.,1725,O
Unreported,1726,O
in,1726,O
the,1726,O
literature,1726,O
is,1726,O
visual,1726,B-Disease
hallucinations,1726,I-Disease
occurring,1726,O
in,1726,O
association,1726,O
with,1726,O
the,1726,O
new,1726,O
macrolide,1726,B-Chemical
antibiotic,1726,O
",",1726,O
clarithromycin,1726,B-Chemical
.,1726,O
We,1727,O
describe,1727,O
such,1727,O
a,1727,O
case,1727,O
in,1727,O
a,1727,O
patient,1727,O
with,1727,O
end-stage,1727,B-Disease
renal,1727,I-Disease
disease,1727,I-Disease
(,1727,O
ESRD,1727,B-Disease
),1727,O
maintained,1727,O
on,1727,O
continuous,1727,O
ambulatory,1727,O
peritoneal,1727,O
dialysis,1727,O
(,1727,O
CAPD,1727,O
),1727,O
.,1727,O
The,1728,O
combination,1728,O
of,1728,O
a,1728,O
relatively,1728,O
high,1728,O
dose,1728,O
of,1728,O
clarithromycin,1728,B-Chemical
in,1728,O
face,1728,O
of,1728,O
chronic,1728,B-Disease
renal,1728,I-Disease
failure,1728,I-Disease
in,1728,O
a,1728,O
functionally,1728,O
anephric,1728,O
patient,1728,O
",",1728,O
with,1728,O
underlying,1728,O
aluminum,1728,B-Chemical
intoxication,1728,O
",",1728,O
may,1728,O
have,1728,O
facilitated,1728,O
the,1728,O
appearance,1728,O
of,1728,O
this,1728,O
neurotoxic,1728,B-Disease
side,1728,O
effect,1728,O
.,1728,O
It,1729,O
is,1729,O
important,1729,O
to,1729,O
understand,1729,O
the,1729,O
pharmacokinetics,1729,O
of,1729,O
medications,1729,O
in,1729,O
face,1729,O
of,1729,O
chronic,1729,B-Disease
renal,1729,I-Disease
failure,1729,I-Disease
",",1729,O
the,1729,O
possibility,1729,O
of,1729,O
drug,1729,O
interactions,1729,O
",",1729,O
and,1729,O
how,1729,O
these,1729,O
factors,1729,O
should,1729,O
help,1729,O
guide,1729,O
medication,1729,O
therapy,1729,O
in,1729,O
the,1729,O
ESRD,1729,B-Disease
patient,1729,O
.,1729,O
Contribution,1730,O
of,1730,O
the,1730,O
sympathetic,1730,O
nervous,1730,O
system,1730,O
to,1730,O
salt-sensitivity,1730,O
in,1730,O
lifetime,1730,O
captopril-treated,1730,B-Chemical
spontaneously,1730,O
hypertensive,1730,B-Disease
rats,1730,O
.,1730,O
OBJECTIVE,1731,O
:,1731,O
To,1731,O
test,1731,O
the,1731,O
hypothesis,1731,O
that,1731,O
",",1731,O
in,1731,O
lifetime,1731,O
captopril-treated,1731,B-Chemical
spontaneously,1731,O
hypertensive,1731,B-Disease
rats,1731,O
(,1731,O
SHR,1731,O
),1731,O
",",1731,O
the,1731,O
sympathetic,1731,O
nervous,1731,O
system,1731,O
contributes,1731,O
importantly,1731,O
to,1731,O
the,1731,O
hypertensive,1731,B-Disease
effect,1731,O
of,1731,O
dietary,1731,B-Chemical
sodium,1731,I-Chemical
chloride,1731,I-Chemical
supplementation,1731,O
.,1731,O
METHODS,1732,O
:,1732,O
Male,1732,O
SHR,1732,O
(,1732,O
aged,1732,O
6,1732,O
weeks,1732,O
),1732,O
that,1732,O
had,1732,O
been,1732,O
treated,1732,O
from,1732,O
conception,1732,O
onward,1732,O
with,1732,O
either,1732,O
captopril,1732,B-Chemical
or,1732,O
vehicle,1732,O
remained,1732,O
on,1732,O
a,1732,O
basal,1732,O
sodium,1732,B-Chemical
chloride,1732,I-Chemical
diet,1732,O
or,1732,O
were,1732,O
fed,1732,O
a,1732,O
high,1732,O
sodium,1732,B-Chemical
chloride,1732,I-Chemical
diet,1732,O
.,1732,O
After,1733,O
2,1733,O
weeks,1733,O
",",1733,O
the,1733,O
rats,1733,O
were,1733,O
subjected,1733,O
to,1733,O
ganglionic,1733,O
blockade,1733,O
and,1733,O
2,1733,O
days,1733,O
later,1733,O
",",1733,O
an,1733,O
infusion,1733,O
of,1733,O
clonidine,1733,B-Chemical
.,1733,O
RESULTS,1734,O
:,1734,O
Lifetime,1734,O
captopril,1734,B-Chemical
treatment,1734,O
significantly,1734,O
lowered,1734,O
mean,1734,O
arterial,1734,O
pressure,1734,O
in,1734,O
both,1734,O
groups,1734,O
.,1734,O
Intravenous,1735,O
infusion,1735,O
of,1735,O
the,1735,O
ganglionic,1735,O
blocker,1735,O
hexamethonium,1735,B-Chemical
resulted,1735,O
in,1735,O
a,1735,O
rapid,1735,O
decline,1735,O
in,1735,O
MAP,1735,O
that,1735,O
eliminated,1735,O
the,1735,O
dietary,1735,B-Chemical
sodium,1735,I-Chemical
chloride-induced,1735,O
increase,1735,B-Disease
in,1735,I-Disease
MAP,1735,I-Disease
in,1735,O
both,1735,O
groups,1735,O
.,1735,O
Infusion,1736,O
of,1736,O
the,1736,O
central,1736,O
nervous,1736,O
system,1736,O
alpha2-adrenergic,1736,B-Chemical
receptor,1736,I-Chemical
agonist,1736,I-Chemical
clonidine,1736,B-Chemical
also,1736,O
resulted,1736,O
in,1736,O
a,1736,O
greater,1736,O
reduction,1736,O
in,1736,O
MAP,1736,O
in,1736,O
both,1736,O
groups,1736,O
of,1736,O
SHR,1736,O
that,1736,O
were,1736,O
fed,1736,O
the,1736,O
high,1736,O
(,1736,O
compared,1736,O
with,1736,O
the,1736,O
basal,1736,O
),1736,O
sodium,1736,B-Chemical
chloride,1736,I-Chemical
diet,1736,O
.,1736,O
CONCLUSIONS,1737,O
:,1737,O
In,1737,O
both,1737,O
lifetime,1737,O
captopril-treated,1737,B-Chemical
and,1737,O
control,1737,O
SHR,1737,O
",",1737,O
the,1737,O
sympathetic,1737,O
nervous,1737,O
system,1737,O
contributes,1737,O
to,1737,O
the,1737,O
pressor,1737,O
effects,1737,O
of,1737,O
a,1737,O
high,1737,O
sodium,1737,B-Chemical
chloride,1737,I-Chemical
diet,1737,O
.,1737,O
Angioedema,1738,B-Disease
associated,1738,O
with,1738,O
droperidol,1738,B-Chemical
administration,1738,O
.,1738,O
Angioedema,1739,B-Disease
",",1739,O
also,1739,O
known,1739,O
as,1739,O
angioneurotic,1739,B-Disease
edema,1739,I-Disease
or,1739,O
Quincke,1739,B-Disease
's,1739,I-Disease
disease,1739,I-Disease
",",1739,O
is,1739,O
a,1739,O
well-demarcated,1739,O
",",1739,O
localized,1739,O
edema,1739,B-Disease
involving,1739,O
the,1739,O
subcutaneous,1739,O
tissues,1739,O
that,1739,O
may,1739,O
cause,1739,O
upper-airway,1739,B-Disease
obstruction,1739,I-Disease
.,1739,O
We,1740,O
report,1740,O
the,1740,O
case,1740,O
of,1740,O
a,1740,O
previously,1740,O
healthy,1740,O
19-year-old,1740,O
man,1740,O
with,1740,O
no,1740,O
known,1740,O
drug,1740,B-Disease
allergies,1740,I-Disease
in,1740,O
whom,1740,O
angioedema,1740,B-Disease
with,1740,O
significant,1740,O
tongue,1740,O
swelling,1740,O
and,1740,O
protrusion,1740,O
developed,1740,O
within,1740,O
10,1740,O
minutes,1740,O
of,1740,O
the,1740,O
administration,1740,O
of,1740,O
a,1740,O
single,1740,O
IV,1740,O
dose,1740,O
of,1740,O
droperidol,1740,B-Chemical
.,1740,O
Late,1741,O
cardiotoxicity,1741,B-Disease
after,1741,O
treatment,1741,O
for,1741,O
a,1741,O
malignant,1741,O
bone,1741,B-Disease
tumor,1741,I-Disease
.,1741,O
Cardiac,1742,O
function,1742,O
was,1742,O
assessed,1742,O
in,1742,O
long-term,1742,O
survivors,1742,O
of,1742,O
malignant,1742,O
bone,1742,B-Disease
tumors,1742,I-Disease
who,1742,O
were,1742,O
treated,1742,O
according,1742,O
to,1742,O
Rosen,1742,B-Chemical
's,1742,I-Chemical
T5,1742,I-Chemical
or,1742,I-Chemical
T10,1742,I-Chemical
protocol,1742,I-Chemical
",",1742,O
both,1742,O
including,1742,O
doxorubicin,1742,B-Chemical
.,1742,O
Thirty-one,1743,O
patients,1743,O
",",1743,O
age,1743,O
10-45,1743,O
years,1743,O
(,1743,O
median,1743,O
age,1743,O
17.8,1743,O
years,1743,O
),1743,O
were,1743,O
evaluated,1743,O
2.3-14.1,1743,O
years,1743,O
(,1743,O
median,1743,O
8.9,1743,O
years,1743,O
),1743,O
following,1743,O
completion,1743,O
of,1743,O
treatment,1743,O
.,1743,O
Cumulative,1744,O
doses,1744,O
of,1744,O
doxorubicin,1744,B-Chemical
were,1744,O
225-550,1744,O
mg/m2,1744,O
(,1744,O
median,1744,O
dose,1744,O
360,1744,O
),1744,O
.,1744,O
The,1745,O
evaluation,1745,O
consisted,1745,O
of,1745,O
a,1745,O
history,1745,O
",",1745,O
physical,1745,O
examination,1745,O
",",1745,O
electrocardiogram,1745,O
(,1745,O
ECG,1745,O
),1745,O
",",1745,O
signal,1745,O
averaged,1745,O
ECG,1745,O
",",1745,O
24-hour,1745,O
ambulatory,1745,O
ECG,1745,O
",",1745,O
echocardiography,1745,O
and,1745,O
radionuclide,1745,O
angiography,1745,O
.,1745,O
Eighteen,1746,O
of,1746,O
31,1746,O
(,1746,O
58,1746,O
%,1746,O
),1746,O
patients,1746,O
showed,1746,O
cardiac,1746,B-Disease
toxicity,1746,I-Disease
",",1746,O
defined,1746,O
as,1746,O
having,1746,O
one,1746,O
or,1746,O
more,1746,O
of,1746,O
the,1746,O
following,1746,O
abnormalities,1746,O
:,1746,O
late,1746,O
potentials,1746,O
",",1746,O
complex,1746,O
ventricular,1746,B-Disease
arrhythmias,1746,I-Disease
",",1746,O
left,1746,O
ventricular,1746,B-Disease
dilation,1746,I-Disease
",",1746,O
decreased,1746,O
shortening,1746,O
fraction,1746,O
",",1746,O
or,1746,O
decreased,1746,O
ejection,1746,O
fraction,1746,O
.,1746,O
The,1747,O
incidence,1747,O
of,1747,O
cardiac,1747,B-Disease
abnormalities,1747,I-Disease
increased,1747,O
with,1747,O
length,1747,O
of,1747,O
follow-up,1747,O
(,1747,O
P,1747,O
<,1747,O
or,1747,O
=,1747,O
.05,1747,O
),1747,O
.,1747,O
No,1748,O
correlation,1748,O
could,1748,O
be,1748,O
demonstrated,1748,O
between,1748,O
cumulative,1748,O
dose,1748,O
of,1748,O
doxorubicin,1748,B-Chemical
and,1748,O
cardiac,1748,O
status,1748,O
",",1748,O
except,1748,O
for,1748,O
heart,1748,O
rate,1748,O
variability,1748,O
.,1748,O
When,1749,O
adjusted,1749,O
to,1749,O
body,1749,O
surface,1749,O
area,1749,O
",",1749,O
the,1749,O
left,1749,O
ventricular,1749,O
posterior,1749,O
wall,1749,O
thickness,1749,O
(,1749,O
LVPW,1749,O
index,1749,O
),1749,O
was,1749,O
decreased,1749,O
in,1749,O
all,1749,O
patients,1749,O
.,1749,O
The,1750,O
incidence,1750,O
of,1750,O
doxorubicin-induced,1750,B-Chemical
cardiotoxicity,1750,B-Disease
is,1750,O
high,1750,O
and,1750,O
increases,1750,O
with,1750,O
follow-up,1750,O
",",1750,O
irrespective,1750,O
of,1750,O
cumulative,1750,O
dose,1750,O
.,1750,O
Life-long,1751,O
cardiac,1751,O
follow-up,1751,O
in,1751,O
these,1751,O
patients,1751,O
is,1751,O
warranted,1751,O
.,1751,O
The,1752,O
results,1752,O
of,1752,O
our,1752,O
study,1752,O
suggest,1752,O
that,1752,O
heart,1752,O
rate,1752,O
variability,1752,O
and,1752,O
LVPW,1752,O
index,1752,O
could,1752,O
be,1752,O
sensitive,1752,O
indicators,1752,O
for,1752,O
cardiotoxicity,1752,B-Disease
.,1752,O
Acute,1753,O
blood,1753,O
pressure,1753,O
elevations,1753,O
with,1753,O
caffeine,1753,B-Chemical
in,1753,O
men,1753,O
with,1753,O
borderline,1753,O
systemic,1753,O
hypertension,1753,B-Disease
.,1753,O
Whether,1754,O
the,1754,O
vasoconstrictive,1754,O
actions,1754,O
of,1754,O
caffeine,1754,B-Chemical
are,1754,O
enhanced,1754,O
in,1754,O
hypertensive,1754,B-Disease
persons,1754,O
has,1754,O
not,1754,O
been,1754,O
demonstrated,1754,O
.,1754,O
Thus,1755,O
",",1755,O
caffeine,1755,B-Chemical
(,1755,O
3.3,1755,O
mg/kg,1755,O
),1755,O
versus,1755,O
placebo,1755,O
was,1755,O
tested,1755,O
in,1755,O
48,1755,O
healthy,1755,O
men,1755,O
(,1755,O
aged,1755,O
20,1755,O
to,1755,O
35,1755,O
years,1755,O
),1755,O
selected,1755,O
after,1755,O
screening,1755,O
on,1755,O
2,1755,O
separate,1755,O
occasions,1755,O
.,1755,O
Borderline,1756,O
hypertensive,1756,B-Disease
men,1756,O
(,1756,O
n,1756,O
=,1756,O
24,1756,O
),1756,O
were,1756,O
selected,1756,O
with,1756,O
screening,1756,O
systolic,1756,O
blood,1756,O
pressure,1756,O
(,1756,O
BP,1756,O
),1756,O
of,1756,O
140,1756,O
to,1756,O
160,1756,O
mm,1756,O
Hg,1756,O
and/or,1756,O
diastolic,1756,O
BP,1756,O
90,1756,O
to,1756,O
99,1756,O
mm,1756,O
Hg,1756,O
.,1756,O
Low-risk,1757,O
controls,1757,O
(,1757,O
n,1757,O
=,1757,O
24,1757,O
),1757,O
reported,1757,O
no,1757,O
parental,1757,O
history,1757,O
of,1757,O
hypertension,1757,B-Disease
and,1757,O
had,1757,O
screening,1757,O
BP,1757,O
<,1757,O
130/85,1757,O
mm,1757,O
Hg,1757,O
.,1757,O
Participants,1758,O
were,1758,O
then,1758,O
tested,1758,O
on,1758,O
2,1758,O
occasions,1758,O
after,1758,O
12-hour,1758,O
abstinence,1758,O
from,1758,O
caffeine,1758,B-Chemical
in,1758,O
each,1758,O
of,1758,O
2,1758,O
protocols,1758,O
;,1758,O
this,1758,O
required,1758,O
a,1758,O
total,1758,O
of,1758,O
4,1758,O
laboratory,1758,O
visits,1758,O
.,1758,O
Caffeine-induced,1759,B-Chemical
changes,1759,O
in,1759,O
diastolic,1759,O
BP,1759,O
were,1759,O
2,1759,O
to,1759,O
3,1759,O
times,1759,O
larger,1759,O
in,1759,O
borderline,1759,O
subjects,1759,O
than,1759,O
in,1759,O
controls,1759,O
(,1759,O
+8.4,1759,O
vs,1759,O
+3.8,1759,O
mm,1759,O
Hg,1759,O
",",1759,O
p,1759,O
<,1759,O
0.0001,1759,O
),1759,O
",",1759,O
and,1759,O
were,1759,O
attributable,1759,O
to,1759,O
larger,1759,O
changes,1759,O
in,1759,O
impedance-derived,1759,O
measures,1759,O
of,1759,O
systemic,1759,O
vascular,1759,O
resistance,1759,O
(,1759,O
+135,1759,O
vs,1759,O
+45,1759,O
dynes.s.cm-5,1759,O
",",1759,O
p,1759,O
<,1759,O
0.004,1759,O
),1759,O
.,1759,O
These,1760,O
findings,1760,O
were,1760,O
consistent,1760,O
and,1760,O
reached,1760,O
significance,1760,O
in,1760,O
both,1760,O
protocols,1760,O
.,1760,O
The,1761,O
percentage,1761,O
of,1761,O
borderline,1761,O
subjects,1761,O
in,1761,O
whom,1761,O
diastolic,1761,O
BP,1761,O
changes,1761,O
exceeded,1761,O
the,1761,O
median,1761,O
control,1761,O
response,1761,O
was,1761,O
96,1761,O
%,1761,O
.,1761,O
Consequently,1762,O
",",1762,O
whereas,1762,O
all,1762,O
participants,1762,O
exhibited,1762,O
normotensive,1762,O
levels,1762,O
during,1762,O
the,1762,O
resting,1762,O
predrug,1762,O
baseline,1762,O
",",1762,O
33,1762,O
%,1762,O
of,1762,O
borderline,1762,O
subjects,1762,O
achieved,1762,O
hypertensive,1762,B-Disease
BP,1762,O
levels,1762,O
after,1762,O
caffeine,1762,B-Chemical
ingestion,1762,O
.,1762,O
Thus,1763,O
",",1763,O
in,1763,O
borderline,1763,O
hypertensive,1763,B-Disease
men,1763,O
",",1763,O
exaggerated,1763,O
responses,1763,O
to,1763,O
caffeine,1763,B-Chemical
were,1763,O
:,1763,O
selective,1763,O
for,1763,O
diastolic,1763,O
BP,1763,O
",",1763,O
consistent,1763,O
with,1763,O
greater,1763,O
vasoconstriction,1763,O
",",1763,O
replicated,1763,O
in,1763,O
2,1763,O
protocols,1763,O
",",1763,O
and,1763,O
representative,1763,O
of,1763,O
nearly,1763,O
all,1763,O
borderline,1763,O
hypertensives,1763,B-Disease
.,1763,O
We,1764,O
suspect,1764,O
that,1764,O
the,1764,O
potential,1764,O
for,1764,O
caffeine,1764,B-Chemical
to,1764,O
stabilize,1764,O
high,1764,O
resistance,1764,O
states,1764,O
in,1764,O
susceptible,1764,O
persons,1764,O
suggests,1764,O
that,1764,O
its,1764,O
use,1764,O
may,1764,O
facilitate,1764,O
their,1764,O
disease,1764,O
progression,1764,O
",",1764,O
as,1764,O
well,1764,O
as,1764,O
hinder,1764,O
accurate,1764,O
diagnosis,1764,O
and,1764,O
treatment,1764,O
.,1764,O
Absence,1765,O
of,1765,O
effect,1765,O
of,1765,O
sertraline,1765,B-Chemical
on,1765,O
time-based,1765,O
sensitization,1765,O
of,1765,O
cognitive,1765,B-Disease
impairment,1765,I-Disease
with,1765,O
haloperidol,1765,B-Chemical
.,1765,O
This,1766,O
double-blind,1766,O
",",1766,O
randomized,1766,O
",",1766,O
placebo-controlled,1766,O
study,1766,O
evaluated,1766,O
the,1766,O
effects,1766,O
of,1766,O
haloperidol,1766,B-Chemical
alone,1766,O
and,1766,O
haloperidol,1766,B-Chemical
plus,1766,O
sertraline,1766,B-Chemical
on,1766,O
cognitive,1766,O
and,1766,O
psychomotor,1766,O
function,1766,O
in,1766,O
24,1766,O
healthy,1766,O
male,1766,O
subjects,1766,O
.,1766,O
METHOD,1767,O
:,1767,O
All,1767,O
subjects,1767,O
received,1767,O
placebo,1767,O
on,1767,O
Day,1767,O
1,1767,O
and,1767,O
haloperidol,1767,B-Chemical
2,1767,O
mg,1767,O
on,1767,O
Days,1767,O
2,1767,O
and,1767,O
25,1767,O
.,1767,O
From,1768,O
Days,1768,O
9,1768,O
to,1768,O
25,1768,O
",",1768,O
subjects,1768,O
were,1768,O
randomly,1768,O
assigned,1768,O
to,1768,O
either,1768,O
sertraline,1768,B-Chemical
(,1768,O
12,1768,O
subjects,1768,O
),1768,O
or,1768,O
placebo,1768,O
(,1768,O
12,1768,O
subjects,1768,O
),1768,O
;,1768,O
the,1768,O
sertraline,1768,B-Chemical
dose,1768,O
was,1768,O
titrated,1768,O
from,1768,O
50,1768,O
to,1768,O
200,1768,O
mg/day,1768,O
from,1768,O
Days,1768,O
9,1768,O
to,1768,O
16,1768,O
",",1768,O
and,1768,O
remained,1768,O
at,1768,O
200,1768,O
mg/day,1768,O
for,1768,O
the,1768,O
final,1768,O
10,1768,O
days,1768,O
of,1768,O
the,1768,O
drug,1768,O
administration,1768,O
period,1768,O
.,1768,O
Cognitive,1769,O
function,1769,O
testing,1769,O
was,1769,O
performed,1769,O
before,1769,O
dosing,1769,O
and,1769,O
over,1769,O
a,1769,O
24-hour,1769,O
period,1769,O
after,1769,O
dosing,1769,O
on,1769,O
Days,1769,O
1,1769,O
",",1769,O
2,1769,O
",",1769,O
and,1769,O
25,1769,O
.,1769,O
RESULTS,1770,O
:,1770,O
Impairment,1770,B-Disease
of,1770,I-Disease
cognitive,1770,I-Disease
function,1770,I-Disease
was,1770,O
observed,1770,O
6,1770,O
to,1770,O
8,1770,O
hours,1770,O
after,1770,O
administration,1770,O
of,1770,O
haloperidol,1770,B-Chemical
on,1770,O
Day,1770,O
2,1770,O
but,1770,O
was,1770,O
not,1770,O
evident,1770,O
23,1770,O
hours,1770,O
after,1770,O
dosing,1770,O
.,1770,O
When,1771,O
single-dose,1771,O
haloperidol,1771,B-Chemical
was,1771,O
given,1771,O
again,1771,O
25,1771,O
days,1771,O
later,1771,O
",",1771,O
greater,1771,O
impairment,1771,O
with,1771,O
earlier,1771,O
onset,1771,O
was,1771,O
noted,1771,O
in,1771,O
several,1771,O
tests,1771,O
in,1771,O
both,1771,O
treatment,1771,O
groups,1771,O
",",1771,O
suggesting,1771,O
enhancement,1771,O
of,1771,O
this,1771,O
effect,1771,O
.,1771,O
There,1772,O
was,1772,O
no,1772,O
indication,1772,O
that,1772,O
sertraline,1772,B-Chemical
exacerbated,1772,O
the,1772,O
impairment,1772,O
produced,1772,O
by,1772,O
haloperidol,1772,B-Chemical
since,1772,O
an,1772,O
equivalent,1772,O
effect,1772,O
also,1772,O
occurred,1772,O
in,1772,O
the,1772,O
placebo,1772,O
group,1772,O
.,1772,O
Three,1773,O
subjects,1773,O
(,1773,O
2,1773,O
on,1773,O
sertraline,1773,B-Chemical
and,1773,O
1,1773,O
on,1773,O
placebo,1773,O
),1773,O
withdrew,1773,O
from,1773,O
the,1773,O
study,1773,O
because,1773,O
of,1773,O
side,1773,O
effects,1773,O
.,1773,O
Ten,1774,O
subjects,1774,O
in,1774,O
each,1774,O
group,1774,O
reported,1774,O
side,1774,O
effects,1774,O
related,1774,O
to,1774,O
treatment,1774,O
.,1774,O
The,1775,O
side,1775,O
effect,1775,O
profiles,1775,O
of,1775,O
sertraline,1775,B-Chemical
and,1775,O
of,1775,O
placebo,1775,O
were,1775,O
similar,1775,O
.,1775,O
CONCLUSION,1776,O
:,1776,O
Haloperidol,1776,B-Chemical
produced,1776,O
a,1776,O
clear,1776,O
profile,1776,O
of,1776,O
cognitive,1776,B-Disease
impairment,1776,I-Disease
that,1776,O
was,1776,O
not,1776,O
worsened,1776,O
by,1776,O
concomitant,1776,O
sertraline,1776,B-Chemical
administration,1776,O
.,1776,O
Coexistence,1777,O
of,1777,O
cerebral,1777,O
venous,1777,O
sinus,1777,O
and,1777,O
internal,1777,O
carotid,1777,O
artery,1777,O
thrombosis,1777,O
associated,1777,O
with,1777,O
exogenous,1777,O
sex,1777,O
hormones,1777,O
.,1777,O
A,1778,O
case,1778,O
report,1778,O
.,1778,O
A,1779,O
forty-six,1779,O
year-old,1779,O
premenopausal,1779,O
woman,1779,O
developed,1779,O
headache,1779,B-Disease
",",1779,O
nausea,1779,B-Disease
and,1779,O
vomiting,1779,B-Disease
",",1779,O
left,1779,O
hemiparesis,1779,B-Disease
and,1779,O
seizure,1779,B-Disease
two,1779,O
days,1779,O
after,1779,O
parenteral,1779,O
use,1779,O
of,1779,O
progesterone,1779,B-Chemical
and,1779,O
estradiol,1779,B-Chemical
.,1779,O
Diabetes,1780,B-Disease
mellitus,1780,I-Disease
(,1780,O
DM,1780,B-Disease
),1780,O
was,1780,O
found,1780,O
during,1780,O
admission,1780,O
.,1780,O
Computed,1781,O
tomography,1781,O
showed,1781,O
a,1781,O
hemorrhagic,1781,O
infarct,1781,O
in,1781,O
the,1781,O
right,1781,O
frontal,1781,O
lobe,1781,O
and,1781,O
increased,1781,O
density,1781,O
in,1781,O
the,1781,O
superior,1781,O
sagittal,1781,O
sinus,1781,O
(,1781,O
SSS,1781,O
),1781,O
.,1781,O
Left,1782,O
carotid,1782,O
angiography,1782,O
found,1782,O
occlusion,1782,B-Disease
of,1782,I-Disease
the,1782,I-Disease
left,1782,I-Disease
internal,1782,I-Disease
carotid,1782,I-Disease
artery,1782,I-Disease
(,1782,O
ICA,1782,O
),1782,O
.,1782,O
Right,1783,O
carotid,1783,O
angiograms,1783,O
failed,1783,O
to,1783,O
show,1783,O
the,1783,O
SSS,1783,O
and,1783,O
inferior,1783,O
sagittal,1783,O
sinus,1783,O
",",1783,O
suggestive,1783,O
of,1783,O
venous,1783,B-Disease
sinus,1783,I-Disease
thrombosis,1783,I-Disease
.,1783,O
Coexistence,1784,O
of,1784,O
the,1784,O
cerebral,1784,O
artery,1784,O
and,1784,O
the,1784,O
venous,1784,O
sinus,1784,O
occlusion,1784,O
has,1784,O
been,1784,O
described,1784,O
infrequently,1784,O
.,1784,O
In,1785,O
this,1785,O
case,1785,O
",",1785,O
the,1785,O
authors,1785,O
postulate,1785,O
that,1785,O
the,1785,O
use,1785,O
of,1785,O
estradiol,1785,B-Chemical
and,1785,O
progesterone,1785,B-Chemical
and,1785,O
the,1785,O
underlying,1785,O
DM,1785,B-Disease
increased,1785,O
vascular,1785,O
thrombogenicity,1785,O
",",1785,O
which,1785,O
provided,1785,O
a,1785,O
common,1785,O
denominator,1785,O
for,1785,O
thrombosis,1785,O
of,1785,O
both,1785,O
the,1785,O
ICA,1785,O
and,1785,O
the,1785,O
venous,1785,O
sinus,1785,O
.,1785,O
Chemotherapy,1786,O
of,1786,O
advanced,1786,O
inoperable,1786,O
non-small,1786,B-Disease
cell,1786,I-Disease
lung,1786,I-Disease
cancer,1786,I-Disease
with,1786,O
paclitaxel,1786,B-Chemical
:,1786,O
a,1786,O
phase,1786,O
II,1786,O
trial,1786,O
.,1786,O
Paclitaxel,1787,B-Chemical
(,1787,O
Taxol,1787,B-Chemical
;,1787,O
Bristol-Myers,1787,O
Squibb,1787,O
Company,1787,O
",",1787,O
Princeton,1787,O
",",1787,O
NJ,1787,O
),1787,O
has,1787,O
demonstrated,1787,O
significant,1787,O
antineoplastic,1787,O
activity,1787,O
against,1787,O
different,1787,O
tumor,1787,B-Disease
types,1787,O
",",1787,O
notably,1787,O
ovarian,1787,O
and,1787,O
breast,1787,O
carcinoma,1787,O
.,1787,O
Two,1788,O
phase,1788,O
II,1788,O
trials,1788,O
of,1788,O
24-hour,1788,O
paclitaxel,1788,B-Chemical
infusions,1788,O
in,1788,O
chemotherapy-naive,1788,O
patients,1788,O
with,1788,O
stage,1788,O
IIIB,1788,O
or,1788,O
IV,1788,O
non-small,1788,B-Disease
cell,1788,I-Disease
lung,1788,I-Disease
cancer,1788,I-Disease
(,1788,O
NSCLC,1788,B-Disease
),1788,O
reported,1788,O
response,1788,O
rates,1788,O
of,1788,O
21,1788,O
%,1788,O
and,1788,O
24,1788,O
%,1788,O
.,1788,O
Leukopenia,1789,B-Disease
was,1789,O
dose,1789,O
limiting,1789,O
:,1789,O
as,1789,O
many,1789,O
as,1789,O
62.5,1789,O
%,1789,O
of,1789,O
patients,1789,O
experienced,1789,O
grade,1789,O
4,1789,O
leukopenia,1789,B-Disease
.,1789,O
We,1790,O
investigated,1790,O
the,1790,O
efficacy,1790,O
and,1790,O
toxicity,1790,B-Disease
of,1790,O
a,1790,O
3-hour,1790,O
paclitaxel,1790,B-Chemical
infusion,1790,O
in,1790,O
a,1790,O
phase,1790,O
II,1790,O
trial,1790,O
in,1790,O
patients,1790,O
with,1790,O
inoperable,1790,O
stage,1790,O
IIIB,1790,O
or,1790,O
IV,1790,O
NSCLC,1790,B-Disease
.,1790,O
The,1791,O
58,1791,O
patients,1791,O
treated,1791,O
(,1791,O
41,1791,O
men,1791,O
and,1791,O
17,1791,O
women,1791,O
),1791,O
had,1791,O
a,1791,O
median,1791,O
age,1791,O
of,1791,O
59,1791,O
years,1791,O
(,1791,O
age,1791,O
range,1791,O
",",1791,O
25,1791,O
to,1791,O
75,1791,O
),1791,O
and,1791,O
a,1791,O
performance,1791,O
status,1791,O
of,1791,O
0,1791,O
through,1791,O
2,1791,O
.,1791,O
Most,1792,O
patients,1792,O
(,1792,O
72.4,1792,O
%,1792,O
),1792,O
had,1792,O
stage,1792,O
IV,1792,O
NSCLC,1792,B-Disease
.,1792,O
Paclitaxel,1793,B-Chemical
225,1793,O
mg/m2,1793,O
was,1793,O
infused,1793,O
over,1793,O
3,1793,O
hours,1793,O
every,1793,O
3,1793,O
weeks,1793,O
with,1793,O
standard,1793,O
prophylactic,1793,O
premedication,1793,O
.,1793,O
Of,1794,O
50,1794,O
patients,1794,O
evaluable,1794,O
for,1794,O
response,1794,O
",",1794,O
12,1794,O
(,1794,O
24,1794,O
%,1794,O
),1794,O
had,1794,O
partial,1794,O
remission,1794,O
",",1794,O
26,1794,O
(,1794,O
52,1794,O
%,1794,O
),1794,O
had,1794,O
no,1794,O
change,1794,O
",",1794,O
and,1794,O
12,1794,O
had,1794,O
disease,1794,O
progression,1794,O
(,1794,O
24,1794,O
%,1794,O
),1794,O
.,1794,O
Hematologic,1795,O
toxicities,1795,B-Disease
were,1795,O
mild,1795,O
:,1795,O
only,1795,O
one,1795,O
patient,1795,O
(,1795,O
2,1795,O
%,1795,O
),1795,O
developed,1795,O
grade,1795,O
3,1795,O
or,1795,O
4,1795,O
neutropenia,1795,B-Disease
",",1795,O
while,1795,O
29,1795,O
%,1795,O
had,1795,O
grade,1795,O
1,1795,O
or,1795,O
2,1795,O
.,1795,O
Grade,1796,O
1,1796,O
or,1796,O
2,1796,O
polyneuropathy,1796,B-Disease
affected,1796,O
56,1796,O
%,1796,O
of,1796,O
patients,1796,O
while,1796,O
only,1796,O
one,1796,O
(,1796,O
2,1796,O
%,1796,O
),1796,O
experienced,1796,O
severe,1796,O
polyneuropathy,1796,B-Disease
.,1796,O
Similarly,1797,O
",",1797,O
grade,1797,O
1,1797,O
or,1797,O
2,1797,O
myalgia/arthralgia,1797,B-Disease
was,1797,O
observed,1797,O
in,1797,O
63.2,1797,O
%,1797,O
of,1797,O
patients,1797,O
",",1797,O
but,1797,O
only,1797,O
14.3,1797,O
%,1797,O
experienced,1797,O
grade,1797,O
3,1797,O
or,1797,O
4,1797,O
.,1797,O
Nausea,1798,B-Disease
and,1798,O
vomiting,1798,B-Disease
were,1798,O
infrequent,1798,O
",",1798,O
with,1798,O
14,1798,O
%,1798,O
of,1798,O
patients,1798,O
experiencing,1798,O
grade,1798,O
1,1798,O
or,1798,O
2,1798,O
and,1798,O
only,1798,O
2,1798,O
%,1798,O
experiencing,1798,O
grade,1798,O
3,1798,O
or,1798,O
4,1798,O
.,1798,O
Paclitaxel,1799,B-Chemical
is,1799,O
thus,1799,O
an,1799,O
active,1799,O
single,1799,O
agent,1799,O
in,1799,O
this,1799,O
patient,1799,O
population,1799,O
",",1799,O
with,1799,O
a,1799,O
3-hour,1799,O
infusion,1799,O
proving,1799,O
comparably,1799,O
effective,1799,O
to,1799,O
a,1799,O
24-hour,1799,O
infusion,1799,O
and,1799,O
superior,1799,O
in,1799,O
terms,1799,O
of,1799,O
the,1799,O
incidence,1799,O
of,1799,O
hematologic,1799,O
and,1799,O
nonhematologic,1799,O
toxicity,1799,B-Disease
.,1799,O
Further,1800,O
phase,1800,O
II,1800,O
studies,1800,O
with,1800,O
paclitaxel,1800,B-Chemical
combined,1800,O
with,1800,O
other,1800,O
drugs,1800,O
active,1800,O
against,1800,O
NSCLC,1800,B-Disease
are,1800,O
indicated,1800,O
",",1800,O
and,1800,O
phase,1800,O
III,1800,O
studies,1800,O
comparing,1800,O
paclitaxel,1800,B-Chemical
with,1800,O
standard,1800,O
chemotherapy,1800,O
remain,1800,O
to,1800,O
be,1800,O
completed,1800,O
.,1800,O
Paclitaxel,1801,B-Chemical
combined,1801,O
with,1801,O
carboplatin,1801,B-Chemical
in,1801,O
the,1801,O
first-line,1801,O
treatment,1801,O
of,1801,O
advanced,1801,O
ovarian,1801,B-Disease
cancer,1801,I-Disease
.,1801,O
In,1802,O
a,1802,O
phase,1802,O
I,1802,O
study,1802,O
to,1802,O
determine,1802,O
the,1802,O
maximum,1802,O
tolerated,1802,O
dose,1802,O
of,1802,O
paclitaxel,1802,B-Chemical
(,1802,O
Taxol,1802,B-Chemical
;,1802,O
Bristol-Myers,1802,O
Squibb,1802,O
Company,1802,O
",",1802,O
Princeton,1802,O
",",1802,O
NJ,1802,O
),1802,O
given,1802,O
as,1802,O
a,1802,O
3-hour,1802,O
infusion,1802,O
in,1802,O
combination,1802,O
with,1802,O
carboplatin,1802,B-Chemical
administered,1802,O
every,1802,O
21,1802,O
days,1802,O
to,1802,O
women,1802,O
with,1802,O
advanced,1802,O
ovarian,1802,B-Disease
cancer,1802,I-Disease
",",1802,O
paclitaxel,1802,B-Chemical
doses,1802,O
were,1802,O
escalated,1802,O
as,1802,O
follows,1802,O
:,1802,O
level,1802,O
1,1802,O
",",1802,O
135,1802,O
mg/m2,1802,O
;,1802,O
level,1802,O
2,1802,O
",",1802,O
160,1802,O
mg/m2,1802,O
;,1802,O
level,1802,O
3,1802,O
",",1802,O
185,1802,O
mg/m2,1802,O
;,1802,O
and,1802,O
level,1802,O
"4,210",1802,O
mg/m2,1802,O
.,1802,O
The,1803,O
fixed,1803,O
dose,1803,O
of,1803,O
carboplatin,1803,B-Chemical
at,1803,O
levels,1803,O
1,1803,O
through,1803,O
4,1803,O
was,1803,O
given,1803,O
to,1803,O
achieve,1803,O
an,1803,O
area,1803,O
under,1803,O
the,1803,O
concentration-time,1803,O
curve,1803,O
(,1803,O
AUC,1803,O
),1803,O
of,1803,O
5,1803,O
using,1803,O
the,1803,O
Calvert,1803,O
formula,1803,O
.,1803,O
In,1804,O
levels,1804,O
5,1804,O
and,1804,O
6,1804,O
the,1804,O
carboplatin,1804,B-Chemical
dose,1804,O
was,1804,O
targeted,1804,O
at,1804,O
AUCs,1804,O
of,1804,O
6,1804,O
and,1804,O
7.5,1804,O
",",1804,O
respectively,1804,O
",",1804,O
combined,1804,O
with,1804,O
a,1804,O
fixed,1804,O
paclitaxel,1804,B-Chemical
dose,1804,O
of,1804,O
185,1804,O
mg/m2,1804,O
.,1804,O
To,1805,O
date,1805,O
",",1805,O
30,1805,O
previously,1805,O
untreated,1805,O
patients,1805,O
",",1805,O
all,1805,O
with,1805,O
a,1805,O
good,1805,O
performance,1805,O
status,1805,O
(,1805,O
Eastern,1805,O
Cooperative,1805,O
Oncology,1805,O
Group,1805,O
0,1805,O
to,1805,O
2,1805,O
),1805,O
have,1805,O
been,1805,O
entered,1805,O
into,1805,O
this,1805,O
ongoing,1805,O
study,1805,O
.,1805,O
The,1806,O
dose-limiting,1806,O
toxicity,1806,B-Disease
of,1806,O
the,1806,O
combination,1806,O
was,1806,O
myelosuppression,1806,B-Disease
(,1806,O
leukopenia,1806,B-Disease
",",1806,O
granulocytopenia,1806,B-Disease
",",1806,O
and,1806,O
thrombocytopenia,1806,B-Disease
),1806,O
.,1806,O
Neurotoxicity,1807,B-Disease
was,1807,O
largely,1807,O
moderate,1807,O
.,1807,O
So,1808,O
far,1808,O
",",1808,O
14,1808,O
patients,1808,O
are,1808,O
evaluable,1808,O
for,1808,O
response,1808,O
;,1808,O
of,1808,O
these,1808,O
",",1808,O
eight,1808,O
(,1808,O
57,1808,O
%,1808,O
),1808,O
showed,1808,O
objective,1808,O
(,1808,O
complete,1808,O
or,1808,O
partial,1808,O
),1808,O
response,1808,O
and,1808,O
disease,1808,O
stabilized,1808,O
in,1808,O
six,1808,O
patients,1808,O
.,1808,O
No,1809,O
patient,1809,O
had,1809,O
disease,1809,O
progression,1809,O
.,1809,O
We,1810,O
conclude,1810,O
that,1810,O
the,1810,O
combination,1810,O
of,1810,O
paclitaxel,1810,B-Chemical
185,1810,O
mg/m2,1810,O
administered,1810,O
as,1810,O
a,1810,O
3-hour,1810,O
infusion,1810,O
followed,1810,O
immediately,1810,O
by,1810,O
a,1810,O
1-hour,1810,O
infusion,1810,O
of,1810,O
carboplatin,1810,B-Chemical
at,1810,O
an,1810,O
AUC,1810,O
of,1810,O
6,1810,O
can,1810,O
be,1810,O
administered,1810,O
safely,1810,O
in,1810,O
a,1810,O
21-day,1810,O
schedule,1810,O
in,1810,O
the,1810,O
outpatient,1810,O
setting,1810,O
.,1810,O
The,1811,O
recommended,1811,O
dose,1811,O
for,1811,O
phase,1811,O
III,1811,O
studies,1811,O
is,1811,O
paclitaxel,1811,B-Chemical
185,1811,O
mg/m2,1811,O
and,1811,O
carboplatin,1811,B-Chemical
AUC,1811,O
6,1811,O
.,1811,O
Effects,1812,O
of,1812,O
acute,1812,O
steroid,1812,B-Chemical
administration,1812,O
on,1812,O
ventilatory,1812,O
and,1812,O
peripheral,1812,O
muscles,1812,O
in,1812,O
rats,1812,O
.,1812,O
Occasional,1813,O
case,1813,O
reports,1813,O
have,1813,O
shown,1813,O
that,1813,O
acute,1813,O
myopathy,1813,B-Disease
may,1813,O
occur,1813,O
in,1813,O
patients,1813,O
treated,1813,O
with,1813,O
massive,1813,O
doses,1813,O
of,1813,O
corticosteroids,1813,B-Chemical
.,1813,O
The,1814,O
mechanism,1814,O
of,1814,O
this,1814,O
myopathy,1814,B-Disease
is,1814,O
poorly,1814,O
understood,1814,O
.,1814,O
Therefore,1815,O
",",1815,O
60,1815,O
male,1815,O
rats,1815,O
were,1815,O
randomly,1815,O
assigned,1815,O
to,1815,O
receive,1815,O
daily,1815,O
injection,1815,O
of,1815,O
saline,1815,O
(,1815,O
C,1815,O
),1815,O
",",1815,O
methylprednisolone,1815,B-Chemical
(,1815,O
M,1815,B-Chemical
),1815,O
",",1815,O
or,1815,O
triamcinolone,1815,B-Chemical
(,1815,O
T,1815,B-Chemical
),1815,O
80,1815,O
mg/kg/d,1815,O
for,1815,O
5,1815,O
d.,1815,O
Nutritional,1815,O
intake,1815,O
",",1815,O
measured,1815,O
daily,1815,O
in,1815,O
15,1815,O
animals,1815,O
",",1815,O
showed,1815,O
a,1815,O
significant,1815,O
reduction,1815,B-Disease
of,1815,I-Disease
food,1815,I-Disease
intake,1815,I-Disease
in,1815,O
the,1815,O
steroid-treated,1815,B-Chemical
groups,1815,O
(,1815,O
-50,1815,O
and,1815,O
-79,1815,O
%,1815,O
in,1815,O
M,1815,B-Chemical
and,1815,O
T,1815,B-Chemical
",",1815,O
respectively,1815,O
),1815,O
.,1815,O
This,1816,O
was,1816,O
associated,1816,O
with,1816,O
a,1816,O
similar,1816,O
loss,1816,B-Disease
in,1816,I-Disease
body,1816,I-Disease
weight,1816,I-Disease
.,1816,O
In,1817,O
the,1817,O
45,1817,O
remaining,1817,O
animals,1817,O
",",1817,O
diaphragm,1817,O
contractility,1817,O
and,1817,O
histopathologic,1817,O
features,1817,O
of,1817,O
several,1817,O
muscles,1817,O
were,1817,O
studied,1817,O
.,1817,O
Weights,1818,O
of,1818,O
respiratory,1818,O
and,1818,O
peripheral,1818,O
muscles,1818,O
were,1818,O
similarly,1818,O
decreased,1818,O
after,1818,O
steroid,1818,B-Chemical
treatment,1818,O
.,1818,O
Maximal,1819,O
twitches,1819,O
of,1819,O
the,1819,O
diaphragm,1819,O
were,1819,O
lower,1819,O
in,1819,O
the,1819,O
C,1819,O
group,1819,O
(,1819,O
653,1819,O
+/-,1819,O
174,1819,O
g/cm,1819,O
(,1819,O
2,1819,O
),1819,O
),1819,O
than,1819,O
in,1819,O
the,1819,O
M,1819,B-Chemical
group,1819,O
(,1819,O
837,1819,O
+/-,1819,O
171,1819,O
g/cm,1819,O
(,1819,O
2,1819,O
),1819,O
;,1819,O
p,1819,O
<,1819,O
0.05,1819,O
),1819,O
and,1819,O
the,1819,O
T,1819,B-Chemical
group,1819,O
(,1819,O
765,1819,O
+/-,1819,O
145,1819,O
g/cm,1819,O
(,1819,O
2,1819,O
),1819,O
",",1819,O
NS,1819,O
),1819,O
.,1819,O
Half-relaxation,1820,O
time,1820,O
was,1820,O
prolonged,1820,O
in,1820,O
both,1820,O
steroid,1820,B-Chemical
groups,1820,O
",",1820,O
and,1820,O
time,1820,O
to,1820,O
peak,1820,O
tension,1820,O
was,1820,O
longer,1820,O
with,1820,O
M,1820,B-Chemical
",",1820,O
whereas,1820,O
tetanic,1820,B-Disease
tensions,1820,O
were,1820,O
similar,1820,O
.,1820,O
Steroid,1821,B-Chemical
treatment,1821,O
also,1821,O
induced,1821,O
a,1821,O
leftward,1821,O
shift,1821,O
of,1821,O
the,1821,O
force-frequency,1821,O
curve,1821,O
at,1821,O
25,1821,O
and,1821,O
50,1821,O
Hz,1821,O
when,1821,O
compared,1821,O
with,1821,O
saline,1821,O
treatment,1821,O
(,1821,O
p,1821,O
<,1821,O
0.05,1821,O
),1821,O
.,1821,O
ATPase,1822,O
staining,1822,O
of,1822,O
the,1822,O
diaphragm,1822,O
",",1822,O
scalenus,1822,O
medius,1822,O
",",1822,O
and,1822,O
gastrocnemius,1822,O
showed,1822,O
type,1822,O
IIb,1822,O
fiber,1822,O
atrophy,1822,B-Disease
in,1822,O
the,1822,O
steroid,1822,B-Chemical
groups,1822,O
and,1822,O
also,1822,O
diaphragmatic,1822,O
type,1822,O
IIa,1822,O
atrophy,1822,B-Disease
with,1822,O
T,1822,B-Chemical
",",1822,O
whereas,1822,O
histologic,1822,O
examinations,1822,O
revealed,1822,O
a,1822,O
normal,1822,O
muscular,1822,O
pattern,1822,O
with,1822,O
absence,1822,O
of,1822,O
necrosis,1822,B-Disease
.,1822,O
Finally,1823,O
",",1823,O
a,1823,O
pair-fed,1823,O
(,1823,O
PF,1823,O
),1823,O
study,1823,O
",",1823,O
performed,1823,O
in,1823,O
18,1823,O
rats,1823,O
(,1823,O
C,1823,O
",",1823,O
T,1823,B-Chemical
",",1823,O
and,1823,O
PF,1823,O
),1823,O
",",1823,O
showed,1823,O
that,1823,O
muscle,1823,B-Disease
atrophy,1823,I-Disease
was,1823,O
considerably,1823,O
less,1823,O
pronounced,1823,O
in,1823,O
PF,1823,O
animals,1823,O
than,1823,O
in,1823,O
T-treated,1823,B-Chemical
animals,1823,O
.,1823,O
We,1824,O
conclude,1824,O
that,1824,O
(,1824,O
1,1824,O
),1824,O
short-term,1824,O
treatment,1824,O
with,1824,O
massive,1824,O
doses,1824,O
of,1824,O
steroids,1824,B-Chemical
induced,1824,O
severe,1824,O
respiratory,1824,O
and,1824,O
limb,1824,O
muscle,1824,O
wasting,1824,O
;,1824,O
(,1824,O
2,1824,O
),1824,O
both,1824,O
types,1824,O
of,1824,O
steroids,1824,B-Chemical
induced,1824,O
predominantly,1824,O
type,1824,O
IIb,1824,O
atrophy,1824,B-Disease
",",1824,O
resulting,1824,O
in,1824,O
the,1824,O
expected,1824,O
alterations,1824,O
in,1824,O
diaphragm,1824,O
contractile,1824,O
properties,1824,O
;,1824,O
(,1824,O
3,1824,O
),1824,O
neither,1824,O
steroid,1824,B-Chemical
caused,1824,O
muscle,1824,O
necrosis,1824,B-Disease
;,1824,O
(,1824,O
4,1824,O
),1824,O
type,1824,O
IIb,1824,O
atrophy,1824,B-Disease
was,1824,O
not,1824,O
caused,1824,O
by,1824,O
acute,1824,O
nutritional,1824,O
deprivation,1824,O
alone,1824,O
.,1824,O
Continuous,1825,O
subcutaneous,1825,O
administration,1825,O
of,1825,O
mesna,1825,B-Chemical
to,1825,O
prevent,1825,O
ifosfamide-induced,1825,B-Chemical
hemorrhagic,1825,O
cystitis,1825,O
.,1825,O
Hemorrhagic,1826,O
cystitis,1826,O
is,1826,O
a,1826,O
major,1826,O
potential,1826,O
toxicity,1826,B-Disease
of,1826,O
ifosfamide,1826,B-Chemical
that,1826,O
can,1826,O
be,1826,O
prevented,1826,O
by,1826,O
administering,1826,O
mesna,1826,B-Chemical
along,1826,O
with,1826,O
the,1826,O
cytotoxic,1826,O
agent,1826,O
.,1826,O
Mesna,1827,B-Chemical
is,1827,O
generally,1827,O
administered,1827,O
by,1827,O
the,1827,O
intravenous,1827,O
route,1827,O
",",1827,O
although,1827,O
experience,1827,O
with,1827,O
oral,1827,O
delivery,1827,O
of,1827,O
the,1827,O
drug,1827,O
has,1827,O
increased,1827,O
.,1827,O
The,1828,O
continuous,1828,O
subcutaneous,1828,O
administration,1828,O
of,1828,O
mesna,1828,B-Chemical
has,1828,O
the,1828,O
advantage,1828,O
of,1828,O
not,1828,O
requiring,1828,O
intravenous,1828,O
access,1828,O
.,1828,O
In,1829,O
addition,1829,O
",",1829,O
subcutaneous,1829,O
delivery,1829,O
of,1829,O
the,1829,O
neutralizing,1829,O
agent,1829,O
will,1829,O
not,1829,O
be,1829,O
associated,1829,O
with,1829,O
the,1829,O
risk,1829,O
of,1829,O
inadequate,1829,O
urinary,1829,O
mesna,1829,B-Chemical
concentrations,1829,O
",",1829,O
such,1829,O
as,1829,O
in,1829,O
a,1829,O
patient,1829,O
taking,1829,O
oral,1829,O
mesna,1829,B-Chemical
who,1829,O
experiences,1829,O
severe,1829,O
ifosfamide-induced,1829,B-Chemical
emesis,1829,B-Disease
and,1829,O
is,1829,O
unable,1829,O
to,1829,O
absorb,1829,O
the,1829,O
drug,1829,O
.,1829,O
Limited,1830,O
clinical,1830,O
experience,1830,O
with,1830,O
continuous,1830,O
subcutaneous,1830,O
mesna,1830,B-Chemical
administration,1830,O
suggests,1830,O
it,1830,O
is,1830,O
a,1830,O
safe,1830,O
",",1830,O
practical,1830,O
",",1830,O
and,1830,O
economic,1830,O
method,1830,O
of,1830,O
drug,1830,O
delivery,1830,O
that,1830,O
permits,1830,O
ifosfamide,1830,B-Chemical
to,1830,O
be,1830,O
administered,1830,O
successfully,1830,O
in,1830,O
the,1830,O
outpatient,1830,O
setting,1830,O
.,1830,O
Leg,1831,B-Disease
and,1831,I-Disease
back,1831,I-Disease
pain,1831,I-Disease
after,1831,O
spinal,1831,O
anaesthesia,1831,O
involving,1831,O
hyperbaric,1831,O
5,1831,O
%,1831,O
lignocaine,1831,B-Chemical
.,1831,O
Fifty-four,1832,O
patients,1832,O
",",1832,O
aged,1832,O
27-90,1832,O
years,1832,O
",",1832,O
who,1832,O
were,1832,O
given,1832,O
lignocaine,1832,B-Chemical
5,1832,O
%,1832,O
in,1832,O
6.8,1832,O
%,1832,O
glucose,1832,B-Chemical
solution,1832,O
for,1832,O
spinal,1832,O
anaesthesia,1832,O
were,1832,O
studied,1832,O
.,1832,O
Thirteen,1833,O
of,1833,O
these,1833,O
patients,1833,O
experienced,1833,O
pain,1833,B-Disease
in,1833,I-Disease
the,1833,I-Disease
legs,1833,I-Disease
and/or,1833,I-Disease
back,1833,I-Disease
after,1833,O
recovery,1833,O
from,1833,O
anaesthesia,1833,O
.,1833,O
The,1834,O
patients,1834,O
affected,1834,O
were,1834,O
younger,1834,O
(,1834,O
p,1834,O
<,1834,O
0.05,1834,O
),1834,O
and,1834,O
the,1834,O
site,1834,O
of,1834,O
the,1834,O
dural,1834,O
puncture,1834,O
was,1834,O
higher,1834,O
(,1834,O
p,1834,O
<,1834,O
0.01,1834,O
),1834,O
than,1834,O
those,1834,O
individuals,1834,O
without,1834,O
pain,1834,B-Disease
.,1834,O
Five,1835,O
of,1835,O
the,1835,O
13,1835,O
patients,1835,O
(,1835,O
38,1835,O
%,1835,O
),1835,O
with,1835,O
pain,1835,B-Disease
and,1835,O
seven,1835,O
of,1835,O
the,1835,O
41,1835,O
patients,1835,O
(,1835,O
17,1835,O
%,1835,O
),1835,O
without,1835,O
pain,1835,B-Disease
admitted,1835,O
to,1835,O
a,1835,O
high,1835,O
alcohol,1835,B-Chemical
intake,1835,O
",",1835,O
which,1835,O
might,1835,O
be,1835,O
a,1835,O
contributing,1835,O
factor,1835,O
.,1835,O
Leg,1836,B-Disease
and/or,1836,I-Disease
back,1836,I-Disease
pain,1836,I-Disease
is,1836,O
associated,1836,O
with,1836,O
the,1836,O
intrathecal,1836,O
use,1836,O
of,1836,O
hyperbaric,1836,O
5,1836,O
%,1836,O
lignocaine,1836,B-Chemical
.,1836,O
Influence,1837,O
of,1837,O
diet,1837,O
free,1837,O
of,1837,O
NAD-precursors,1837,B-Chemical
on,1837,O
acetaminophen,1837,B-Chemical
hepatotoxicity,1837,B-Disease
in,1837,O
mice,1837,O
.,1837,O
Recently,1838,O
",",1838,O
we,1838,O
demonstrated,1838,O
the,1838,O
hepatoprotective,1838,O
effects,1838,O
of,1838,O
nicotinic,1838,B-Chemical
acid,1838,I-Chemical
amide,1838,I-Chemical
",",1838,O
a,1838,O
selective,1838,O
inhibitor,1838,O
of,1838,O
poly,1838,B-Chemical
(,1838,I-Chemical
ADP-ribose,1838,I-Chemical
),1838,I-Chemical
polymerase,1838,O
(,1838,O
PARP,1838,O
;,1838,O
EC,1838,O
2.4.2.30,1838,O
),1838,O
on,1838,O
mice,1838,O
suffering,1838,O
from,1838,O
acetaminophen,1838,B-Chemical
(,1838,O
AAP,1838,B-Chemical
),1838,O
-hepatitis,1838,O
",",1838,O
suggesting,1838,O
that,1838,O
the,1838,O
AAP-induced,1838,B-Chemical
liver,1838,B-Disease
injury,1838,I-Disease
involves,1838,O
a,1838,O
step,1838,O
which,1838,O
depends,1838,O
on,1838,O
adenoribosylation,1838,O
.,1838,O
The,1839,O
present,1839,O
study,1839,O
investigates,1839,O
the,1839,O
effects,1839,O
of,1839,O
a,1839,O
diet,1839,O
free,1839,O
of,1839,O
precursors,1839,O
of,1839,O
NAD,1839,B-Chemical
",",1839,O
the,1839,O
substrate,1839,O
on,1839,O
which,1839,O
PARP,1839,O
acts,1839,O
",",1839,O
in,1839,O
female,1839,O
NMRI,1839,O
mice,1839,O
with,1839,O
AAP,1839,B-Chemical
hepatitis,1839,B-Disease
and,1839,O
evaluates,1839,O
the,1839,O
influence,1839,O
of,1839,O
simultaneous,1839,O
ethanol,1839,B-Chemical
consumption,1839,O
in,1839,O
these,1839,O
animals,1839,O
.,1839,O
Liver,1840,B-Disease
injuries,1840,I-Disease
were,1840,O
quantified,1840,O
as,1840,O
serum,1840,O
activities,1840,O
of,1840,O
glutamate-oxaloacetate,1840,B-Chemical
transaminase,1840,O
(,1840,O
GOT,1840,O
),1840,O
and,1840,O
glutamate-pyruvate,1840,B-Chemical
transaminase,1840,O
(,1840,O
GPT,1840,O
),1840,O
.,1840,O
While,1841,O
AAP,1841,B-Chemical
caused,1841,O
a,1841,O
117-fold,1841,O
elevation,1841,O
of,1841,O
serum,1841,O
transaminase,1841,O
activities,1841,O
in,1841,O
mice,1841,O
kept,1841,O
on,1841,O
a,1841,O
standard,1841,O
laboratory,1841,O
diet,1841,O
",",1841,O
which,1841,O
was,1841,O
significantly,1841,O
exacerbated,1841,O
by,1841,O
ethanol,1841,B-Chemical
and,1841,O
inhibited,1841,O
by,1841,O
nicotinic,1841,B-Chemical
acid,1841,I-Chemical
amide,1841,I-Chemical
(,1841,O
NAA,1841,B-Chemical
),1841,O
",",1841,O
adverse,1841,O
effects,1841,O
were,1841,O
noted,1841,O
in,1841,O
animals,1841,O
fed,1841,O
a,1841,O
diet,1841,O
free,1841,O
of,1841,O
precursors,1841,O
of,1841,O
NAD,1841,B-Chemical
.,1841,O
In,1842,O
these,1842,O
animals,1842,O
",",1842,O
only,1842,O
minor,1842,O
increases,1842,O
of,1842,O
serum,1842,O
transaminase,1842,O
activities,1842,O
were,1842,O
measured,1842,O
in,1842,O
the,1842,O
presence,1842,O
of,1842,O
AAP,1842,B-Chemical
",",1842,O
and,1842,O
unlike,1842,O
the,1842,O
exacerbation,1842,O
caused,1842,O
by,1842,O
ethanol,1842,B-Chemical
in,1842,O
mice,1842,O
on,1842,O
a,1842,O
standard,1842,O
diet,1842,O
",",1842,O
the,1842,O
liver,1842,B-Disease
damage,1842,I-Disease
was,1842,O
inhibited,1842,O
by,1842,O
50,1842,O
%,1842,O
by,1842,O
ethanol,1842,B-Chemical
.,1842,O
A,1843,O
further,1843,O
64,1843,O
%,1843,O
reduction,1843,O
of,1843,O
hepatitis,1843,B-Disease
was,1843,O
observed,1843,O
",",1843,O
when,1843,O
NAA,1843,B-Chemical
was,1843,O
given,1843,O
to,1843,O
ethanol/AAP-mice,1843,B-Chemical
.,1843,O
Our,1844,O
results,1844,O
provide,1844,O
evidence,1844,O
that,1844,O
the,1844,O
AAP-induced,1844,B-Chemical
hepatitis,1844,B-Disease
and,1844,O
its,1844,O
exacerbation,1844,O
by,1844,O
ethanol,1844,B-Chemical
can,1844,O
either,1844,O
be,1844,O
reduced,1844,O
by,1844,O
end-product,1844,O
inhibition,1844,O
of,1844,O
PARP,1844,O
by,1844,O
NAA,1844,B-Chemical
or,1844,O
by,1844,O
dietary,1844,O
depletion,1844,O
of,1844,O
the,1844,O
enzyme,1844,O
's,1844,O
substrate,1844,O
NAD,1844,B-Chemical
.,1844,O
We,1845,O
see,1845,O
the,1845,O
main,1845,O
application,1845,O
of,1845,O
NAA,1845,B-Chemical
as,1845,O
for,1845,O
the,1845,O
combinational,1845,O
use,1845,O
in,1845,O
pharmaceutical,1845,O
preparations,1845,O
of,1845,O
acetaminophen,1845,B-Chemical
in,1845,O
order,1845,O
to,1845,O
avoid,1845,O
hepatic,1845,B-Disease
damage,1845,I-Disease
in,1845,O
patients,1845,O
treated,1845,O
with,1845,O
this,1845,O
widely,1845,O
used,1845,O
analgesic,1845,O
.,1845,O
Nightmares,1846,O
and,1846,O
hallucinations,1846,B-Disease
after,1846,O
long-term,1846,O
intake,1846,O
of,1846,O
tramadol,1846,B-Chemical
combined,1846,O
with,1846,O
antidepressants,1846,O
.,1846,O
Tramadol,1847,B-Chemical
is,1847,O
a,1847,O
weak,1847,O
opioid,1847,O
with,1847,O
effects,1847,O
on,1847,O
adrenergic,1847,O
and,1847,O
serotonergic,1847,O
neurotransmission,1847,O
that,1847,O
is,1847,O
used,1847,O
to,1847,O
treat,1847,O
cancer,1847,B-Disease
pain,1847,B-Disease
and,1847,O
chronic,1847,O
non,1847,O
malignant,1847,O
pain,1847,B-Disease
.,1847,O
This,1848,O
drug,1848,O
was,1848,O
initiated,1848,O
in,1848,O
association,1848,O
with,1848,O
paroxetine,1848,B-Chemical
and,1848,O
dosulepine,1848,B-Chemical
hydrochloride,1848,I-Chemical
in,1848,O
a,1848,O
tetraparetic,1848,B-Disease
patient,1848,O
with,1848,O
chronic,1848,B-Disease
pain,1848,I-Disease
.,1848,O
Fifty-six,1849,O
days,1849,O
after,1849,O
initiation,1849,O
of,1849,O
the,1849,O
treatment,1849,O
the,1849,O
patient,1849,O
presented,1849,O
hallucinations,1849,B-Disease
that,1849,O
only,1849,O
stopped,1849,O
after,1849,O
the,1849,O
withdrawal,1849,O
of,1849,O
psycho-active,1849,O
drugs,1849,O
and,1849,O
tramadol,1849,B-Chemical
.,1849,O
The,1850,O
case,1850,O
report,1850,O
questions,1850,O
the,1850,O
long,1850,O
term,1850,O
use,1850,O
of,1850,O
pain,1850,B-Disease
killers,1850,O
combined,1850,O
with,1850,O
psycho-active,1850,O
drugs,1850,O
in,1850,O
chronic,1850,O
non,1850,O
malignant,1850,O
pain,1850,B-Disease
",",1850,O
especially,1850,O
if,1850,O
pain,1850,B-Disease
is,1850,O
under,1850,O
control,1850,O
.,1850,O
Effect,1851,O
of,1851,O
calcium,1851,B-Chemical
chloride,1851,I-Chemical
and,1851,O
4-aminopyridine,1851,B-Chemical
therapy,1851,O
on,1851,O
desipramine,1851,B-Chemical
toxicity,1851,B-Disease
in,1851,O
rats,1851,O
.,1851,O
BACKGROUND,1852,O
:,1852,O
Hypotension,1852,B-Disease
is,1852,O
a,1852,O
major,1852,O
contributor,1852,O
to,1852,O
mortality,1852,O
in,1852,O
tricyclic,1852,O
antidepressant,1852,O
overdose,1852,B-Disease
.,1852,O
Recent,1853,O
data,1853,O
suggest,1853,O
that,1853,O
tricyclic,1853,O
antidepressants,1853,O
inhibit,1853,O
calcium,1853,B-Chemical
influx,1853,O
in,1853,O
some,1853,O
tissues,1853,O
.,1853,O
This,1854,O
study,1854,O
addressed,1854,O
the,1854,O
potential,1854,O
role,1854,O
of,1854,O
calcium,1854,B-Chemical
channel,1854,O
blockade,1854,O
in,1854,O
tricyclic,1854,O
antidepressant-induced,1854,O
hypotension,1854,B-Disease
.,1854,O
METHODS,1855,O
:,1855,O
Two,1855,O
interventions,1855,O
were,1855,O
studied,1855,O
that,1855,O
have,1855,O
been,1855,O
shown,1855,O
previously,1855,O
to,1855,O
improve,1855,O
blood,1855,O
pressure,1855,O
with,1855,O
calcium,1855,B-Chemical
channel,1855,O
blocker,1855,O
overdose,1855,B-Disease
.,1855,O
CaCl2,1856,B-Chemical
and,1856,O
4-aminopyridine,1856,B-Chemical
.,1856,O
Anesthetized,1857,O
rats,1857,O
received,1857,O
the,1857,O
tricyclic,1857,O
antidepressant,1857,O
desipramine,1857,B-Chemical
IP,1857,O
to,1857,O
produce,1857,O
hypotension,1857,B-Disease
",",1857,O
QRS,1857,O
prolongation,1857,O
",",1857,O
and,1857,O
bradycardia,1857,B-Disease
.,1857,O
Fifteen,1858,O
min,1858,O
later,1858,O
",",1858,O
animals,1858,O
received,1858,O
CaCl2,1858,B-Chemical
",",1858,O
NaHCO3,1858,B-Chemical
",",1858,O
or,1858,O
saline,1858,O
.,1858,O
In,1859,O
a,1859,O
second,1859,O
experiment,1859,O
",",1859,O
rats,1859,O
received,1859,O
tricyclic,1859,O
antidepressant,1859,O
desipramine,1859,B-Chemical
IP,1859,O
followed,1859,O
in,1859,O
15,1859,O
min,1859,O
by,1859,O
4-aminopyridine,1859,B-Chemical
or,1859,O
saline,1859,O
.,1859,O
RESULTS,1860,O
:,1860,O
NaHCO3,1860,B-Chemical
briefly,1860,O
(,1860,O
5,1860,O
min,1860,O
),1860,O
reversed,1860,O
hypotension,1860,B-Disease
and,1860,O
QRS,1860,O
prolongation,1860,O
.,1860,O
CaCl2,1861,B-Chemical
and,1861,O
4-aminopyridine,1861,B-Chemical
failed,1861,O
to,1861,O
improve,1861,O
blood,1861,O
pressure,1861,O
.,1861,O
The,1862,O
incidence,1862,O
of,1862,O
ventricular,1862,B-Disease
arrhythmias,1862,I-Disease
(,1862,O
p,1862,O
=,1862,O
0.004,1862,O
),1862,O
and,1862,O
seizures,1862,B-Disease
(,1862,O
p,1862,O
=,1862,O
0.03,1862,O
),1862,O
in,1862,O
the,1862,O
CaCl2,1862,B-Chemical
group,1862,O
was,1862,O
higher,1862,O
than,1862,O
the,1862,O
other,1862,O
groups,1862,O
.,1862,O
CONCLUSION,1863,O
:,1863,O
The,1863,O
administration,1863,O
of,1863,O
CaCl2,1863,B-Chemical
or,1863,O
4-aminopyridine,1863,B-Chemical
did,1863,O
not,1863,O
reverse,1863,O
tricyclic,1863,O
antidepressant-induced,1863,O
hypotension,1863,B-Disease
in,1863,O
rats,1863,O
.,1863,O
CaCl2,1864,B-Chemical
therapy,1864,O
may,1864,O
possibly,1864,O
worsen,1864,O
both,1864,O
cardiovascular,1864,O
and,1864,O
central,1864,O
nervous,1864,O
system,1864,O
toxicity,1864,O
.,1864,O
These,1865,O
findings,1865,O
do,1865,O
not,1865,O
support,1865,O
a,1865,O
role,1865,O
for,1865,O
calcium,1865,B-Chemical
channel,1865,O
inhibition,1865,O
in,1865,O
the,1865,O
pathogenesis,1865,O
of,1865,O
tricyclic,1865,O
antidepressant-induced,1865,O
hypotension,1865,B-Disease
.,1865,O
Valsartan,1866,B-Chemical
",",1866,O
a,1866,O
new,1866,O
angiotensin,1866,B-Chemical
II,1866,I-Chemical
antagonist,1866,O
for,1866,O
the,1866,O
treatment,1866,O
of,1866,O
essential,1866,O
hypertension,1866,B-Disease
:,1866,O
a,1866,O
comparative,1866,O
study,1866,O
of,1866,O
the,1866,O
efficacy,1866,O
and,1866,O
safety,1866,O
against,1866,O
amlodipine,1866,B-Chemical
.,1866,O
OBJECTIVE,1867,O
:,1867,O
To,1867,O
compare,1867,O
the,1867,O
antihypertensive,1867,O
efficacy,1867,O
of,1867,O
a,1867,O
new,1867,O
angiotensin,1867,B-Chemical
II,1867,I-Chemical
antagonist,1867,O
",",1867,O
valsartan,1867,B-Chemical
",",1867,O
with,1867,O
a,1867,O
reference,1867,O
therapy,1867,O
",",1867,O
amlodipine,1867,B-Chemical
.,1867,O
METHODS,1868,O
:,1868,O
One,1868,O
hundred,1868,O
sixty-eight,1868,O
adult,1868,O
outpatients,1868,O
with,1868,O
mild,1868,O
to,1868,O
moderate,1868,O
hypertension,1868,B-Disease
were,1868,O
randomly,1868,O
allocated,1868,O
in,1868,O
double-blind,1868,O
fashion,1868,O
and,1868,O
equal,1868,O
number,1868,O
to,1868,O
receive,1868,O
80,1868,O
mg,1868,O
valsartan,1868,B-Chemical
or,1868,O
5,1868,O
mg,1868,O
amlodipine,1868,B-Chemical
for,1868,O
12,1868,O
weeks,1868,O
.,1868,O
After,1869,O
8,1869,O
weeks,1869,O
of,1869,O
therapy,1869,O
",",1869,O
in,1869,O
patients,1869,O
whose,1869,O
blood,1869,O
pressure,1869,O
remained,1869,O
uncontrolled,1869,O
",",1869,O
5,1869,O
mg,1869,O
amlodipine,1869,B-Chemical
was,1869,O
added,1869,O
to,1869,O
the,1869,O
initial,1869,O
therapy,1869,O
.,1869,O
Patients,1870,O
were,1870,O
assessed,1870,O
at,1870,O
4,1870,O
",",1870,O
8,1870,O
",",1870,O
and,1870,O
12,1870,O
weeks,1870,O
.,1870,O
The,1871,O
primary,1871,O
efficacy,1871,O
variable,1871,O
was,1871,O
change,1871,O
from,1871,O
baseline,1871,O
in,1871,O
mean,1871,O
sitting,1871,O
diastolic,1871,O
blood,1871,O
pressure,1871,O
at,1871,O
8,1871,O
weeks,1871,O
.,1871,O
Secondary,1872,O
variables,1872,O
included,1872,O
change,1872,O
in,1872,O
sitting,1872,O
systolic,1872,O
blood,1872,O
pressure,1872,O
and,1872,O
responder,1872,O
rates,1872,O
.,1872,O
RESULTS,1873,O
:,1873,O
Both,1873,O
valsartan,1873,B-Chemical
and,1873,O
amlodipine,1873,B-Chemical
were,1873,O
effective,1873,O
at,1873,O
lowering,1873,O
blood,1873,O
pressure,1873,O
at,1873,O
4,1873,O
",",1873,O
8,1873,O
",",1873,O
and,1873,O
12,1873,O
weeks,1873,O
.,1873,O
Similar,1874,O
decreases,1874,O
were,1874,O
observed,1874,O
in,1874,O
both,1874,O
groups,1874,O
",",1874,O
with,1874,O
no,1874,O
statistically,1874,O
significant,1874,O
differences,1874,O
between,1874,O
the,1874,O
groups,1874,O
for,1874,O
any,1874,O
variable,1874,O
analyzed,1874,O
.,1874,O
For,1875,O
the,1875,O
primary,1875,O
variable,1875,O
the,1875,O
difference,1875,O
was,1875,O
0.5,1875,O
mm,1875,O
Hg,1875,O
in,1875,O
favor,1875,O
of,1875,O
valsartan,1875,B-Chemical
(,1875,O
p,1875,O
=,1875,O
0.68,1875,O
;,1875,O
95,1875,O
%,1875,O
confidence,1875,O
interval,1875,O
",",1875,O
-2.7,1875,O
to,1875,O
1.7,1875,O
),1875,O
.,1875,O
Responder,1876,O
rates,1876,O
at,1876,O
8,1876,O
weeks,1876,O
were,1876,O
66.7,1876,O
%,1876,O
for,1876,O
valsartan,1876,B-Chemical
and,1876,O
60.2,1876,O
%,1876,O
for,1876,O
amlodipine,1876,B-Chemical
(,1876,O
p,1876,O
=,1876,O
0.39,1876,O
),1876,O
.,1876,O
Both,1877,O
treatments,1877,O
were,1877,O
well,1877,O
tolerated,1877,O
.,1877,O
The,1878,O
incidence,1878,O
of,1878,O
drug-related,1878,O
dependent,1878,O
edema,1878,B-Disease
was,1878,O
somewhat,1878,O
higher,1878,O
in,1878,O
the,1878,O
amlodipine,1878,B-Chemical
group,1878,O
",",1878,O
particularly,1878,O
at,1878,O
a,1878,O
dose,1878,O
of,1878,O
10,1878,O
mg,1878,O
per,1878,O
day,1878,O
(,1878,O
2.4,1878,O
%,1878,O
for,1878,O
80,1878,O
mg,1878,O
valsartan,1878,B-Chemical
;,1878,O
3.6,1878,O
%,1878,O
for,1878,O
5,1878,O
mg,1878,O
amlodipine,1878,B-Chemical
;,1878,O
0,1878,O
%,1878,O
for,1878,O
valsartan,1878,B-Chemical
plus,1878,O
5,1878,O
mg,1878,O
amlodipine,1878,B-Chemical
;,1878,O
14.3,1878,O
%,1878,O
for,1878,O
10,1878,O
mg,1878,O
amlodipine,1878,B-Chemical
),1878,O
.,1878,O
CONCLUSIONS,1879,O
:,1879,O
The,1879,O
data,1879,O
show,1879,O
that,1879,O
valsartan,1879,B-Chemical
is,1879,O
at,1879,O
least,1879,O
as,1879,O
effective,1879,O
as,1879,O
amlodipine,1879,B-Chemical
in,1879,O
the,1879,O
treatment,1879,O
of,1879,O
mild,1879,O
to,1879,O
moderate,1879,O
hypertension,1879,B-Disease
.,1879,O
The,1880,O
results,1880,O
also,1880,O
show,1880,O
valsartan,1880,B-Chemical
to,1880,O
be,1880,O
well,1880,O
tolerated,1880,O
and,1880,O
suggest,1880,O
that,1880,O
it,1880,O
is,1880,O
not,1880,O
associated,1880,O
with,1880,O
side,1880,O
effects,1880,O
characteristic,1880,O
of,1880,O
this,1880,O
comparator,1880,O
class,1880,O
",",1880,O
dihydropyridine,1880,B-Chemical
calcium,1880,B-Chemical
antagonists,1880,O
.,1880,O
A,1881,O
measure,1881,O
of,1881,O
pupillary,1881,B-Disease
oscillation,1881,I-Disease
as,1881,O
a,1881,O
marker,1881,O
of,1881,O
cocaine-induced,1881,B-Chemical
paranoia,1881,B-Disease
.,1881,O
Cocaine-induced,1882,B-Chemical
paranoia,1882,B-Disease
(,1882,O
CIP,1882,B-Disease
),1882,O
remains,1882,O
an,1882,O
important,1882,O
drug-induced,1882,O
model,1882,O
of,1882,O
idiopathic,1882,O
paranoia,1882,B-Disease
for,1882,O
which,1882,O
no,1882,O
psychophysiologic,1882,O
marker,1882,O
has,1882,O
yet,1882,O
emerged,1882,O
.,1882,O
Measures,1883,O
of,1883,O
pupillary,1883,B-Disease
oscillation,1883,I-Disease
were,1883,O
able,1883,O
to,1883,O
significantly,1883,O
distinguish,1883,O
a,1883,O
group,1883,O
of,1883,O
abstinent,1883,O
crack,1883,B-Chemical
cocaine,1883,I-Chemical
abusers,1883,O
endorsing,1883,O
past,1883,O
CIP,1883,B-Disease
(,1883,O
n,1883,O
=,1883,O
32,1883,O
),1883,O
from,1883,O
another,1883,O
group,1883,O
of,1883,O
crack,1883,B-Chemical
addicts,1883,O
who,1883,O
denied,1883,O
past,1883,O
CIP,1883,B-Disease
(,1883,O
n,1883,O
=,1883,O
29,1883,O
),1883,O
.,1883,O
Serotonin,1884,B-Disease
syndrome,1884,I-Disease
from,1884,O
venlafaxine-tranylcypromine,1884,B-Chemical
interaction,1884,O
.,1884,O
Excessive,1885,O
stimulation,1885,O
of,1885,O
serotonin,1885,B-Chemical
5HT1A,1885,O
receptors,1885,O
causes,1885,O
a,1885,O
syndrome,1885,O
of,1885,O
serotonin,1885,B-Chemical
excess,1885,O
that,1885,O
consists,1885,O
of,1885,O
shivering,1885,O
",",1885,O
muscle,1885,B-Disease
rigidity,1885,I-Disease
",",1885,O
salivation,1885,B-Disease
",",1885,O
confusion,1885,B-Disease
",",1885,O
agitation,1885,B-Disease
and,1885,O
hyperthermia,1885,B-Disease
.,1885,O
The,1886,O
most,1886,O
common,1886,O
cause,1886,O
of,1886,O
this,1886,O
syndrome,1886,O
is,1886,O
an,1886,O
interaction,1886,O
between,1886,O
a,1886,O
monoamine,1886,O
oxidase,1886,O
inhibitor,1886,O
(,1886,O
MAOI,1886,O
),1886,O
and,1886,O
a,1886,O
specific,1886,O
serotonin,1886,B-Chemical
reuptake,1886,O
inhibitor,1886,O
.,1886,O
Venlafaxine,1887,B-Chemical
is,1887,O
a,1887,O
new,1887,O
antidepressant,1887,O
agent,1887,O
that,1887,O
inhibits,1887,O
the,1887,O
reuptake,1887,O
of,1887,O
serotonin,1887,B-Chemical
and,1887,O
norepinephrine,1887,B-Chemical
.,1887,O
We,1888,O
report,1888,O
a,1888,O
venlafaxine-MAOI,1888,B-Chemical
interaction,1888,O
that,1888,O
resulted,1888,O
in,1888,O
the,1888,O
serotonin,1888,B-Disease
syndrome,1888,I-Disease
in,1888,O
a,1888,O
23-y-old,1888,O
male,1888,O
who,1888,O
was,1888,O
taking,1888,O
tranylcypromine,1888,B-Chemical
for,1888,O
depression,1888,B-Disease
.,1888,O
He,1889,O
had,1889,O
been,1889,O
well,1889,O
until,1889,O
the,1889,O
morning,1889,O
of,1889,O
presentation,1889,O
when,1889,O
he,1889,O
took,1889,O
1/2,1889,O
tab,1889,O
of,1889,O
venlafaxine,1889,B-Chemical
.,1889,O
Within,1890,O
2,1890,O
h,1890,O
he,1890,O
became,1890,O
confused,1890,O
with,1890,O
jerking,1890,O
movements,1890,O
of,1890,O
his,1890,O
extremities,1890,O
",",1890,O
tremors,1890,B-Disease
and,1890,O
rigidity,1890,B-Disease
.,1890,O
He,1891,O
was,1891,O
brought,1891,O
directly,1891,O
to,1891,O
a,1891,O
hospital,1891,O
where,1891,O
he,1891,O
was,1891,O
found,1891,O
to,1891,O
be,1891,O
agitated,1891,O
and,1891,O
confused,1891,O
with,1891,O
shivering,1891,O
",",1891,O
myoclonic,1891,B-Disease
jerks,1891,I-Disease
",",1891,O
rigidity,1891,B-Disease
",",1891,O
salivation,1891,B-Disease
and,1891,O
diaphoresis,1891,O
.,1891,O
His,1892,O
pupils,1892,O
were,1892,O
7,1892,O
mm,1892,O
and,1892,O
sluggishly,1892,O
reactive,1892,O
to,1892,O
light,1892,O
.,1892,O
Vital,1893,O
signs,1893,O
were,1893,O
:,1893,O
blood,1893,O
pressure,1893,O
120/67,1893,O
mm,1893,O
Hg,1893,O
",",1893,O
heart,1893,O
rate,1893,O
127/min,1893,O
",",1893,O
respiratory,1893,O
rate,1893,O
28/min,1893,O
",",1893,O
and,1893,O
temperature,1893,O
97,1893,O
F.,1893,O
After,1893,O
180,1893,O
mg,1893,O
of,1893,O
diazepam,1893,B-Chemical
i.v,1893,O
.,1893,O
he,1894,O
remained,1894,O
tremulous,1894,O
with,1894,O
muscle,1894,B-Disease
rigidity,1894,I-Disease
and,1894,O
clenched,1894,O
jaws,1894,O
.,1894,O
He,1895,O
was,1895,O
intubated,1895,O
for,1895,O
airway,1895,O
protection,1895,O
and,1895,O
because,1895,O
of,1895,O
hypoventilation,1895,B-Disease
",",1895,O
and,1895,O
was,1895,O
paralyzed,1895,B-Disease
to,1895,O
control,1895,O
muscle,1895,B-Disease
rigidity,1895,I-Disease
.,1895,O
His,1896,O
subsequent,1896,O
course,1896,O
was,1896,O
remarkable,1896,O
for,1896,O
non-immune,1896,O
thrombocytopenia,1896,B-Disease
which,1896,O
resolved,1896,O
.,1896,O
The,1897,O
patient,1897,O
's,1897,O
maximal,1897,O
temperature,1897,O
was,1897,O
101.2,1897,O
F,1897,O
and,1897,O
his,1897,O
CPK,1897,O
remained,1897,O
<,1897,O
500,1897,O
units/L,1897,O
with,1897,O
no,1897,O
other,1897,O
evidence,1897,O
of,1897,O
rhabdomyolysis,1897,B-Disease
.,1897,O
His,1898,O
mental,1898,O
status,1898,O
normalized,1898,O
and,1898,O
he,1898,O
was,1898,O
transferred,1898,O
to,1898,O
a,1898,O
psychiatry,1898,O
ward,1898,O
.,1898,O
This,1899,O
patient,1899,O
survived,1899,O
without,1899,O
sequelae,1899,O
due,1899,O
to,1899,O
the,1899,O
aggressive,1899,O
sedation,1899,O
and,1899,O
neuromuscular,1899,O
paralysis,1899,B-Disease
.,1899,O
Cyclophosphamide,1900,B-Chemical
associated,1900,O
bladder,1900,B-Disease
cancer,1900,I-Disease
--,1900,O
a,1900,O
highly,1900,O
aggressive,1900,O
disease,1900,O
:,1900,O
analysis,1900,O
of,1900,O
12,1900,O
cases,1900,O
.,1900,O
PURPOSE,1901,O
:,1901,O
We,1901,O
gained,1901,O
knowledge,1901,O
of,1901,O
the,1901,O
etiology,1901,O
",",1901,O
treatment,1901,O
and,1901,O
prevention,1901,O
of,1901,O
cyclophosphamide,1901,B-Chemical
associated,1901,O
urothelial,1901,B-Disease
cancer,1901,I-Disease
.,1901,O
MATERIALS,1902,O
AND,1902,O
METHODS,1902,O
:,1902,O
The,1902,O
medical,1902,O
records,1902,O
of,1902,O
6,1902,O
men,1902,O
and,1902,O
6,1902,O
women,1902,O
(,1902,O
mean,1902,O
age,1902,O
55,1902,O
years,1902,O
),1902,O
with,1902,O
cyclophosphamide,1902,B-Chemical
associated,1902,O
bladder,1902,B-Disease
cancer,1902,I-Disease
were,1902,O
reviewed,1902,O
.,1902,O
RESULTS,1903,O
:,1903,O
All,1903,O
tumors,1903,B-Disease
were,1903,O
grade,1903,O
3,1903,O
or,1903,O
4,1903,O
transitional,1903,O
cell,1903,O
carcinoma,1903,B-Disease
.,1903,O
Of,1904,O
the,1904,O
5,1904,O
patients,1904,O
initially,1904,O
treated,1904,O
with,1904,O
endoscopic,1904,O
resection,1904,O
alone,1904,O
only,1904,O
1,1904,O
is,1904,O
alive,1904,O
without,1904,O
disease,1904,O
.,1904,O
Of,1905,O
the,1905,O
6,1905,O
patients,1905,O
who,1905,O
underwent,1905,O
early,1905,O
cystectomy,1905,O
4,1905,O
were,1905,O
alive,1905,O
at,1905,O
24,1905,O
to,1905,O
111,1905,O
months,1905,O
.,1905,O
The,1906,O
remaining,1906,O
patient,1906,O
with,1906,O
extensive,1906,O
cancer,1906,B-Disease
underwent,1906,O
partial,1906,O
cystectomy,1906,O
for,1906,O
palliation,1906,O
and,1906,O
died,1906,O
3,1906,O
months,1906,O
later,1906,O
.,1906,O
CONCLUSIONS,1907,O
:,1907,O
Cyclophosphamide,1907,B-Chemical
associated,1907,O
bladder,1907,B-Disease
tumor,1907,I-Disease
is,1907,O
an,1907,O
aggressive,1907,O
disease,1907,O
.,1907,O
However,1908,O
",",1908,O
long-term,1908,O
survival,1908,O
is,1908,O
possible,1908,O
when,1908,O
radical,1908,O
cystectomy,1908,O
is,1908,O
performed,1908,O
for,1908,O
bladder,1908,B-Disease
tumors,1908,I-Disease
with,1908,O
any,1908,O
sign,1908,O
of,1908,O
invasion,1908,O
and,1908,O
for,1908,O
recurrent,1908,O
high,1908,O
grade,1908,O
disease,1908,O
",",1908,O
even,1908,O
when,1908,O
noninvasive,1908,O
.,1908,O
A,1909,O
phase,1909,O
I,1909,O
clinical,1909,O
study,1909,O
of,1909,O
the,1909,O
antipurine,1909,B-Chemical
antifolate,1909,O
lometrexol,1909,B-Chemical
(,1909,O
DDATHF,1909,B-Chemical
),1909,O
given,1909,O
with,1909,O
oral,1909,O
folic,1909,B-Chemical
acid,1909,I-Chemical
.,1909,O
Lometrexol,1910,B-Chemical
is,1910,O
an,1910,O
antifolate,1910,O
which,1910,O
inhibits,1910,O
glycinamide,1910,B-Chemical
ribonucleotide,1910,I-Chemical
formyltransferase,1910,O
(,1910,O
GARFT,1910,O
),1910,O
",",1910,O
an,1910,O
enzyme,1910,O
essential,1910,O
for,1910,O
de,1910,O
novo,1910,O
purine,1910,B-Chemical
synthesis,1910,O
.,1910,O
Extensive,1911,O
experimental,1911,O
and,1911,O
limited,1911,O
clinical,1911,O
data,1911,O
have,1911,O
shown,1911,O
that,1911,O
lometrexol,1911,B-Chemical
has,1911,O
activity,1911,O
against,1911,O
tumours,1911,B-Disease
which,1911,O
are,1911,O
refractory,1911,O
to,1911,O
other,1911,O
drugs,1911,O
",",1911,O
notably,1911,O
methotrexate,1911,B-Chemical
.,1911,O
However,1912,O
",",1912,O
the,1912,O
initial,1912,O
clinical,1912,O
development,1912,O
of,1912,O
lometrexol,1912,B-Chemical
was,1912,O
curtailed,1912,O
because,1912,O
of,1912,O
severe,1912,O
and,1912,O
cumulative,1912,O
antiproliferative,1912,O
toxicities,1912,B-Disease
.,1912,O
Preclinical,1913,O
murine,1913,O
studies,1913,O
demonstrated,1913,O
that,1913,O
the,1913,O
toxicity,1913,B-Disease
of,1913,O
lometrexol,1913,B-Chemical
can,1913,O
be,1913,O
prevented,1913,O
by,1913,O
low,1913,O
dose,1913,O
folic,1913,B-Chemical
acid,1913,I-Chemical
administration,1913,O
",",1913,O
i.e,1913,O
.,1913,O
for,1914,O
7,1914,O
days,1914,O
prior,1914,O
to,1914,O
and,1914,O
7,1914,O
days,1914,O
following,1914,O
a,1914,O
single,1914,O
bolus,1914,O
dose,1914,O
.,1914,O
This,1915,O
observation,1915,O
prompted,1915,O
a,1915,O
Phase,1915,O
I,1915,O
clinical,1915,O
study,1915,O
of,1915,O
lometrexol,1915,B-Chemical
given,1915,O
with,1915,O
folic,1915,B-Chemical
acid,1915,I-Chemical
supplementation,1915,O
which,1915,O
has,1915,O
confirmed,1915,O
that,1915,O
the,1915,O
toxicity,1915,B-Disease
of,1915,O
lometrexol,1915,B-Chemical
can,1915,O
be,1915,O
markedly,1915,O
reduced,1915,O
by,1915,O
folic,1915,B-Chemical
acid,1915,I-Chemical
supplementation,1915,O
.,1915,O
Thrombocytopenia,1916,B-Disease
and,1916,O
mucositis,1916,B-Disease
were,1916,O
the,1916,O
major,1916,O
toxicities,1916,B-Disease
.,1916,O
There,1917,O
was,1917,O
no,1917,O
clear,1917,O
relationship,1917,O
between,1917,O
clinical,1917,O
toxicity,1917,B-Disease
and,1917,O
the,1917,O
extent,1917,O
of,1917,O
plasma,1917,O
folate,1917,B-Chemical
elevation,1917,O
.,1917,O
Associated,1918,O
studies,1918,O
demonstrated,1918,O
that,1918,O
lometrexol,1918,B-Chemical
plasma,1918,O
pharmacokinetics,1918,O
were,1918,O
not,1918,O
altered,1918,O
by,1918,O
folic,1918,B-Chemical
acid,1918,I-Chemical
administration,1918,O
indicating,1918,O
that,1918,O
supplementation,1918,O
is,1918,O
unlikely,1918,O
to,1918,O
reduce,1918,O
toxicity,1918,B-Disease
by,1918,O
enhancing,1918,O
lometrexol,1918,B-Chemical
plasma,1918,O
clearance,1918,O
.,1918,O
The,1919,O
work,1919,O
described,1919,O
in,1919,O
this,1919,O
report,1919,O
has,1919,O
identified,1919,O
for,1919,O
the,1919,O
first,1919,O
time,1919,O
a,1919,O
clinically,1919,O
acceptable,1919,O
schedule,1919,O
for,1919,O
the,1919,O
administration,1919,O
of,1919,O
a,1919,O
GARFT,1919,O
inhibitor,1919,O
.,1919,O
This,1920,O
information,1920,O
will,1920,O
facilitate,1920,O
the,1920,O
future,1920,O
evaluation,1920,O
of,1920,O
this,1920,O
class,1920,O
of,1920,O
compounds,1920,O
in,1920,O
cancer,1920,B-Disease
therapy,1920,O
.,1920,O
Fatal,1921,O
excited,1921,O
delirium,1921,B-Disease
following,1921,O
cocaine,1921,B-Chemical
use,1921,O
:,1921,O
epidemiologic,1921,O
findings,1921,O
provide,1921,O
new,1921,O
evidence,1921,O
for,1921,O
mechanisms,1921,O
of,1921,O
cocaine,1921,B-Chemical
toxicity,1921,B-Disease
.,1921,O
We,1922,O
describe,1922,O
an,1922,O
outbreak,1922,O
of,1922,O
deaths,1922,O
from,1922,O
cocaine-induced,1922,B-Chemical
excited,1922,O
delirium,1922,B-Disease
(,1922,O
EDDs,1922,B-Disease
),1922,O
in,1922,O
Dade,1922,O
County,1922,O
",",1922,O
Florida,1922,O
between,1922,O
1979,1922,O
and,1922,O
1990,1922,O
.,1922,O
From,1923,O
a,1923,O
registry,1923,O
of,1923,O
all,1923,O
cocaine-related,1923,B-Chemical
deaths,1923,O
in,1923,O
Dade,1923,O
County,1923,O
",",1923,O
Florida,1923,O
",",1923,O
from,1923,O
1969-1990,1923,O
",",1923,O
58,1923,O
EDDs,1923,B-Disease
were,1923,O
compared,1923,O
with,1923,O
125,1923,O
victims,1923,O
of,1923,O
accidental,1923,O
cocaine,1923,B-Chemical
overdose,1923,B-Disease
without,1923,O
excited,1923,O
delirium,1923,B-Disease
.,1923,O
Compared,1924,O
with,1924,O
controls,1924,O
",",1924,O
EDDs,1924,B-Disease
were,1924,O
more,1924,O
frequently,1924,O
black,1924,O
",",1924,O
male,1924,O
",",1924,O
and,1924,O
younger,1924,O
.,1924,O
They,1925,O
were,1925,O
less,1925,O
likely,1925,O
to,1925,O
have,1925,O
a,1925,O
low,1925,O
body,1925,O
mass,1925,O
index,1925,O
",",1925,O
and,1925,O
more,1925,O
likely,1925,O
to,1925,O
have,1925,O
died,1925,O
in,1925,O
police,1925,O
custody,1925,O
",",1925,O
to,1925,O
have,1925,O
received,1925,O
medical,1925,O
treatment,1925,O
immediately,1925,O
before,1925,O
death,1925,O
",",1925,O
to,1925,O
have,1925,O
survived,1925,O
for,1925,O
a,1925,O
longer,1925,O
period,1925,O
",",1925,O
to,1925,O
have,1925,O
developed,1925,O
hyperthermia,1925,B-Disease
",",1925,O
and,1925,O
to,1925,O
have,1925,O
died,1925,O
in,1925,O
summer,1925,O
months,1925,O
.,1925,O
EDDs,1926,B-Disease
had,1926,O
concentrations,1926,O
of,1926,O
cocaine,1926,B-Chemical
and,1926,O
benzoylecgonine,1926,B-Chemical
in,1926,O
autopsy,1926,O
blood,1926,O
that,1926,O
were,1926,O
similar,1926,O
to,1926,O
those,1926,O
for,1926,O
controls,1926,O
.,1926,O
The,1927,O
epidemiologic,1927,O
findings,1927,O
are,1927,O
most,1927,O
consistent,1927,O
with,1927,O
the,1927,O
hypothesis,1927,O
that,1927,O
chronic,1927,O
cocaine,1927,B-Chemical
use,1927,O
disrupts,1927,O
dopaminergic,1927,O
function,1927,O
and,1927,O
",",1927,O
when,1927,O
coupled,1927,O
with,1927,O
recent,1927,O
cocaine,1927,B-Chemical
use,1927,O
",",1927,O
may,1927,O
precipitate,1927,O
agitation,1927,B-Disease
",",1927,O
delirium,1927,B-Disease
",",1927,O
aberrant,1927,O
thermoregulation,1927,O
",",1927,O
rhabdomyolysis,1927,B-Disease
",",1927,O
and,1927,O
sudden,1927,B-Disease
death,1927,I-Disease
.,1927,O
Pemoline,1928,B-Chemical
induced,1928,O
acute,1928,O
choreoathetosis,1928,B-Disease
:,1928,O
case,1928,O
report,1928,O
and,1928,O
review,1928,O
of,1928,O
the,1928,O
literature,1928,O
.,1928,O
BACKGROUND,1929,O
:,1929,O
Pemoline,1929,B-Chemical
is,1929,O
an,1929,O
oxazolidine,1929,B-Chemical
derivative,1929,O
that,1929,O
is,1929,O
structurally,1929,O
different,1929,O
from,1929,O
amphetamines,1929,B-Chemical
and,1929,O
used,1929,O
in,1929,O
the,1929,O
treatment,1929,O
of,1929,O
attention,1929,B-Disease
deficit,1929,I-Disease
disorder,1929,I-Disease
.,1929,O
Pemoline,1930,B-Chemical
has,1930,O
not,1930,O
been,1930,O
commonly,1930,O
associated,1930,O
in,1930,O
the,1930,O
literature,1930,O
as,1930,O
a,1930,O
cause,1930,O
of,1930,O
acute,1930,O
movement,1930,B-Disease
disorders,1930,I-Disease
.,1930,O
The,1931,O
following,1931,O
case,1931,O
describes,1931,O
two,1931,O
children,1931,O
acutely,1931,O
poisoned,1931,O
with,1931,O
pemoline,1931,B-Chemical
who,1931,O
experienced,1931,O
profound,1931,O
choreoathetosis,1931,B-Disease
.,1931,O
CASE,1932,O
REPORT,1932,O
:,1932,O
Two,1932,O
",",1932,O
3-year-old,1932,O
male,1932,O
",",1932,O
identical,1932,O
twin,1932,O
siblings,1932,O
presented,1932,O
to,1932,O
the,1932,O
emergency,1932,O
department,1932,O
after,1932,O
found,1932,O
playing,1932,O
with,1932,O
a,1932,O
an,1932,O
empty,1932,O
bottle,1932,O
of,1932,O
pemoline,1932,B-Chemical
originally,1932,O
containing,1932,O
59,1932,O
tablets,1932,O
.,1932,O
The,1933,O
children,1933,O
had,1933,O
a,1933,O
medical,1933,O
history,1933,O
significant,1933,O
for,1933,O
attention,1933,B-Disease
deficit,1933,I-Disease
disorder,1933,I-Disease
previously,1933,O
treated,1933,O
with,1933,O
methylphenidate,1933,B-Chemical
without,1933,O
success,1933,O
.,1933,O
This,1934,O
was,1934,O
their,1934,O
first,1934,O
day,1934,O
of,1934,O
pemoline,1934,B-Chemical
therapy,1934,O
.,1934,O
The,1935,O
choreoathetoid,1935,B-Disease
movements,1935,O
began,1935,O
45,1935,O
min,1935,O
to,1935,O
1,1935,O
h,1935,O
after,1935,O
ingestion,1935,O
.,1935,O
The,1936,O
children,1936,O
gave,1936,O
no,1936,O
history,1936,O
of,1936,O
prior,1936,O
movement,1936,B-Disease
disorders,1936,I-Disease
and,1936,O
there,1936,O
was,1936,O
no,1936,O
family,1936,O
history,1936,O
of,1936,O
movement,1936,B-Disease
disorders,1936,I-Disease
.,1936,O
The,1937,O
children,1937,O
received,1937,O
gastrointestinal,1937,O
decontamination,1937,O
and,1937,O
high,1937,O
doses,1937,O
of,1937,O
intravenous,1937,O
benzodiazepines,1937,B-Chemical
in,1937,O
an,1937,O
attempt,1937,O
to,1937,O
control,1937,O
the,1937,O
choreoathetoid,1937,B-Disease
movements,1937,O
.,1937,O
Despite,1938,O
treatment,1938,O
",",1938,O
the,1938,O
children,1938,O
continued,1938,O
to,1938,O
have,1938,O
choreoathetosis,1938,B-Disease
for,1938,O
approximately,1938,O
24,1938,O
hours,1938,O
.,1938,O
Forty-eight,1939,O
hours,1939,O
after,1939,O
admission,1939,O
",",1939,O
the,1939,O
children,1939,O
appeared,1939,O
to,1939,O
be,1939,O
at,1939,O
their,1939,O
baseline,1939,O
and,1939,O
were,1939,O
discharged,1939,O
home,1939,O
.,1939,O
CONCLUSION,1940,O
:,1940,O
Pemoline,1940,B-Chemical
associated,1940,O
movement,1940,B-Disease
disorder,1940,I-Disease
has,1940,O
been,1940,O
rarely,1940,O
reported,1940,O
in,1940,O
the,1940,O
acute,1940,O
toxicology,1940,O
literature,1940,O
.,1940,O
The,1941,O
possibility,1941,O
of,1941,O
choreoathetoid,1941,B-Disease
movements,1941,O
should,1941,O
be,1941,O
considered,1941,O
in,1941,O
patients,1941,O
presenting,1941,O
after,1941,O
pemoline,1941,B-Chemical
overdose,1941,B-Disease
.,1941,O
Effect,1942,O
of,1942,O
myopic,1942,O
excimer,1942,O
laser,1942,O
photorefractive,1942,O
keratectomy,1942,O
on,1942,O
the,1942,O
electrophysiologic,1942,O
function,1942,O
of,1942,O
the,1942,O
retina,1942,O
and,1942,O
optic,1942,O
nerve,1942,O
.,1942,O
PURPOSE,1943,O
:,1943,O
To,1943,O
assess,1943,O
by,1943,O
electrophysiologic,1943,O
testing,1943,O
the,1943,O
effect,1943,O
of,1943,O
photorefractive,1943,O
keratectomy,1943,O
(,1943,O
PRK,1943,O
),1943,O
on,1943,O
the,1943,O
retina,1943,O
and,1943,O
optic,1943,O
nerve,1943,O
.,1943,O
SETTING,1944,O
:,1944,O
Eye,1944,O
Clinic,1944,O
",",1944,O
S.,1944,O
Salvatore,1944,O
Hospital,1944,O
",",1944,O
L'Aquila,1944,O
University,1944,O
",",1944,O
Italy,1944,O
.,1944,O
METHODS,1945,O
:,1945,O
Standard,1945,O
pattern,1945,O
electroretinograms,1945,O
(,1945,O
P-ERGs,1945,O
),1945,O
and,1945,O
standard,1945,O
pattern,1945,O
visual,1945,O
evoked,1945,O
potentials,1945,O
(,1945,O
P-VEPs,1945,O
),1945,O
were,1945,O
done,1945,O
in,1945,O
25,1945,O
eyes,1945,O
of,1945,O
25,1945,O
patients,1945,O
who,1945,O
had,1945,O
myopic,1945,O
PRK,1945,O
for,1945,O
an,1945,O
attempted,1945,O
correction,1945,O
between,1945,O
5.00,1945,O
and,1945,O
15.00,1945,O
diopters,1945,O
(,1945,O
D,1945,O
),1945,O
(,1945,O
mean,1945,O
8.00,1945,O
D,1945,O
),1945,O
.,1945,O
Testing,1946,O
was,1946,O
done,1946,O
preoperatively,1946,O
and,1946,O
3,1946,O
",",1946,O
6,1946,O
",",1946,O
12,1946,O
",",1946,O
and,1946,O
18,1946,O
months,1946,O
postoperatively,1946,O
.,1946,O
The,1947,O
contralateral,1947,O
eyes,1947,O
served,1947,O
as,1947,O
controls,1947,O
.,1947,O
During,1948,O
the,1948,O
follow-up,1948,O
",",1948,O
3,1948,O
patients,1948,O
(,1948,O
12,1948,O
%,1948,O
),1948,O
developed,1948,O
steroid-induced,1948,B-Chemical
elevated,1948,B-Disease
intraocular,1948,I-Disease
pressure,1948,I-Disease
(,1948,O
IOP,1948,O
),1948,O
that,1948,O
resolved,1948,O
after,1948,O
corticosteroid,1948,B-Chemical
therapy,1948,O
was,1948,O
discontinued,1948,O
.,1948,O
RESULTS,1949,O
:,1949,O
No,1949,O
statistically,1949,O
significant,1949,O
differences,1949,O
were,1949,O
seen,1949,O
between,1949,O
treated,1949,O
and,1949,O
control,1949,O
eyes,1949,O
nor,1949,O
between,1949,O
treated,1949,O
eyes,1949,O
preoperatively,1949,O
and,1949,O
postoperatively,1949,O
.,1949,O
CONCLUSION,1950,O
:,1950,O
Myopic,1950,O
excimer,1950,O
laser,1950,O
PRK,1950,O
did,1950,O
not,1950,O
seem,1950,O
to,1950,O
affect,1950,O
the,1950,O
posterior,1950,O
segment,1950,O
.,1950,O
The,1951,O
transient,1951,O
steroid-induced,1951,B-Chemical
IOP,1951,B-Disease
rise,1951,I-Disease
did,1951,O
not,1951,O
seem,1951,O
to,1951,O
cause,1951,O
functional,1951,O
impairment,1951,O
.,1951,O
Neutrophil,1952,O
superoxide,1952,B-Chemical
and,1952,O
hydrogen,1952,B-Chemical
peroxide,1952,I-Chemical
production,1952,O
in,1952,O
patients,1952,O
with,1952,O
acute,1952,B-Disease
liver,1952,I-Disease
failure,1952,I-Disease
.,1952,O
Defects,1953,O
in,1953,O
superoxide,1953,B-Chemical
and,1953,O
hydrogen,1953,B-Chemical
peroxide,1953,I-Chemical
production,1953,O
may,1953,O
be,1953,O
implicated,1953,O
in,1953,O
the,1953,O
high,1953,O
incidence,1953,O
of,1953,O
bacterial,1953,B-Disease
infections,1953,I-Disease
in,1953,O
patients,1953,O
with,1953,O
acute,1953,B-Disease
liver,1953,I-Disease
failure,1953,I-Disease
(,1953,O
ALF,1953,B-Disease
),1953,O
.,1953,O
In,1954,O
the,1954,O
present,1954,O
study,1954,O
",",1954,O
oxygen,1954,B-Chemical
radical,1954,O
production,1954,O
in,1954,O
patients,1954,O
with,1954,O
ALF,1954,B-Disease
due,1954,O
to,1954,O
paracetamol,1954,B-Chemical
overdose,1954,B-Disease
was,1954,O
compared,1954,O
with,1954,O
that,1954,O
of,1954,O
healthy,1954,O
volunteers,1954,O
.,1954,O
Neutrophils,1955,O
from,1955,O
14,1955,O
ALF,1955,B-Disease
patients,1955,O
were,1955,O
stimulated,1955,O
via,1955,O
the,1955,O
complement,1955,O
receptors,1955,O
using,1955,O
zymosan,1955,O
opsonized,1955,O
with,1955,O
ALF,1955,B-Disease
or,1955,O
control,1955,O
serum,1955,O
.,1955,O
Superoxide,1956,B-Chemical
and,1956,O
hydrogen,1956,B-Chemical
peroxide,1956,I-Chemical
production,1956,O
by,1956,O
ALF,1956,B-Disease
neutrophils,1956,O
stimulated,1956,O
with,1956,O
zymosan,1956,O
opsonized,1956,O
with,1956,O
ALF,1956,B-Disease
serum,1956,O
was,1956,O
significantly,1956,O
reduced,1956,O
compared,1956,O
with,1956,O
the,1956,O
control,1956,O
subjects,1956,O
(,1956,O
P,1956,O
<,1956,O
0.01,1956,O
),1956,O
.,1956,O
This,1957,O
defect,1957,O
persisted,1957,O
when,1957,O
zymosan,1957,O
opsonized,1957,O
by,1957,O
control,1957,O
serum,1957,O
was,1957,O
used,1957,O
(,1957,O
P,1957,O
<,1957,O
0.05,1957,O
),1957,O
.,1957,O
Superoxide,1958,B-Chemical
and,1958,O
hydrogen,1958,B-Chemical
peroxide,1958,I-Chemical
production,1958,O
in,1958,O
neutrophils,1958,O
stimulated,1958,O
with,1958,O
formyl-methionyl-leucyl-phenylalanine,1958,B-Chemical
(,1958,O
fMLP,1958,B-Chemical
),1958,O
from,1958,O
a,1958,O
further,1958,O
18,1958,O
ALF,1958,B-Disease
patients,1958,O
was,1958,O
unaffected,1958,O
compared,1958,O
with,1958,O
control,1958,O
neutrophils,1958,O
.,1958,O
Serum,1959,O
C3,1959,O
complement,1959,O
levels,1959,O
were,1959,O
significantly,1959,O
reduced,1959,O
in,1959,O
ALF,1959,B-Disease
patients,1959,O
compared,1959,O
with,1959,O
control,1959,O
subjects,1959,O
(,1959,O
P,1959,O
<,1959,O
0.0005,1959,O
),1959,O
.,1959,O
These,1960,O
results,1960,O
demonstrate,1960,O
a,1960,O
neutrophil,1960,O
defect,1960,O
in,1960,O
ALF,1960,B-Disease
due,1960,O
to,1960,O
paracetamol,1960,B-Chemical
overdose,1960,B-Disease
",",1960,O
that,1960,O
is,1960,O
complement,1960,O
dependent,1960,O
but,1960,O
independent,1960,O
of,1960,O
serum,1960,O
complement,1960,O
",",1960,O
possibly,1960,O
connected,1960,O
to,1960,O
the,1960,O
complement,1960,O
receptor,1960,O
.,1960,O
Cholesteryl,1961,B-Chemical
hemisuccinate,1961,I-Chemical
treatment,1961,O
protects,1961,O
rodents,1961,O
from,1961,O
the,1961,O
toxic,1961,O
effects,1961,O
of,1961,O
acetaminophen,1961,B-Chemical
",",1961,O
adriamycin,1961,B-Chemical
",",1961,O
carbon,1961,B-Chemical
tetrachloride,1961,I-Chemical
",",1961,O
chloroform,1961,B-Chemical
and,1961,O
galactosamine,1961,B-Chemical
.,1961,O
In,1962,O
addition,1962,O
to,1962,O
its,1962,O
use,1962,O
as,1962,O
a,1962,O
stabilizer/rigidifier,1962,O
of,1962,O
membranes,1962,O
",",1962,O
cholesteryl,1962,B-Chemical
hemisuccinate,1962,I-Chemical
",",1962,O
tris,1962,B-Chemical
salt,1962,I-Chemical
(,1962,O
CS,1962,B-Chemical
),1962,O
administration,1962,O
has,1962,O
also,1962,O
been,1962,O
shown,1962,O
to,1962,O
protect,1962,O
rats,1962,O
from,1962,O
the,1962,O
hepatotoxic,1962,B-Disease
effects,1962,O
of,1962,O
carbon,1962,B-Chemical
tetrachloride,1962,I-Chemical
(,1962,O
CCl4,1962,B-Chemical
),1962,O
.,1962,O
To,1963,O
further,1963,O
our,1963,O
understanding,1963,O
of,1963,O
the,1963,O
mechanism,1963,O
of,1963,O
CS,1963,B-Chemical
cytoprotection,1963,O
",",1963,O
we,1963,O
examined,1963,O
in,1963,O
rats,1963,O
and,1963,O
mice,1963,O
the,1963,O
protective,1963,O
abilities,1963,O
of,1963,O
CS,1963,B-Chemical
and,1963,O
the,1963,O
non-hydrolyzable,1963,O
ether,1963,O
form,1963,O
of,1963,O
CS,1963,B-Chemical
",",1963,O
gamma-cholesteryloxybutyric,1963,B-Chemical
acid,1963,I-Chemical
",",1963,O
tris,1963,B-Chemical
salt,1963,I-Chemical
(,1963,O
CSE,1963,B-Chemical
),1963,O
against,1963,O
acetaminophen-,1963,B-Chemical
",",1963,O
adriamycin-,1963,B-Chemical
",",1963,O
carbon,1963,B-Chemical
tetrachloride-,1963,O
",",1963,O
chloroform-,1963,B-Chemical
and,1963,O
galactosamine-induced,1963,B-Chemical
toxicity,1963,B-Disease
.,1963,O
The,1964,O
results,1964,O
of,1964,O
these,1964,O
studies,1964,O
demonstrated,1964,O
that,1964,O
CS-mediated,1964,B-Chemical
protection,1964,O
is,1964,O
not,1964,O
selective,1964,O
for,1964,O
a,1964,O
particular,1964,O
species,1964,O
",",1964,O
organ,1964,O
system,1964,O
or,1964,O
toxic,1964,O
chemical,1964,O
.,1964,O
A,1965,O
24-h,1965,O
pretreatment,1965,O
of,1965,O
both,1965,O
rats,1965,O
and,1965,O
mice,1965,O
with,1965,O
a,1965,O
single,1965,O
dose,1965,O
of,1965,O
CS,1965,B-Chemical
(,1965,O
100mg/kg,1965,O
",",1965,O
i.p,1965,O
.,1965,O
),1966,O
",",1966,O
resulted,1966,O
in,1966,O
significant,1966,O
protection,1966,O
against,1966,O
the,1966,O
hepatotoxic,1966,O
effects,1966,O
of,1966,O
CCl4,1966,O
",",1966,O
CHCl3,1966,O
",",1966,O
acetaminophen,1966,O
and,1966,O
galactosamine,1966,O
and,1966,O
against,1966,O
the,1966,O
lethal,1966,O
(,1966,O
and,1966,O
presumably,1966,O
cardiotoxic,1966,O
),1966,O
effect,1966,O
of,1966,O
adriamycin,1966,O
administration,1966,O
.,1966,O
Maximal,1967,O
CS-mediated,1967,O
protection,1967,O
was,1967,O
observed,1967,O
in,1967,O
experimental,1967,O
animals,1967,O
pretreated,1967,O
24,1967,O
h,1967,O
prior,1967,O
to,1967,O
the,1967,O
toxic,1967,O
insult,1967,O
.,1967,O
These,1968,O
data,1968,O
suggest,1968,O
that,1968,O
CS,1968,O
intervenes,1968,O
in,1968,O
a,1968,O
critical,1968,O
cellular,1968,O
event,1968,O
that,1968,O
is,1968,O
an,1968,O
important,1968,O
common,1968,O
pathway,1968,O
to,1968,O
toxic,1968,O
cell,1968,O
death,1968,O
.,1968,O
The,1969,O
mechanism,1969,O
of,1969,O
CS,1969,O
protection,1969,O
does,1969,O
not,1969,O
appear,1969,O
to,1969,O
be,1969,O
dependent,1969,O
on,1969,O
the,1969,O
inhibition,1969,O
of,1969,O
chemical,1969,O
bioactivation,1969,O
to,1969,O
a,1969,O
toxic,1969,O
reactive,1969,O
intermediate,1969,O
(,1969,O
in,1969,O
light,1969,O
of,1969,O
the,1969,O
protection,1969,O
observed,1969,O
against,1969,O
galactosamine,1969,O
hepatotoxicity,1969,O
),1969,O
.,1969,O
However,1970,O
",",1970,O
based,1970,O
on,1970,O
the,1970,O
data,1970,O
presented,1970,O
",",1970,O
we,1970,O
can,1970,O
not,1970,O
exclude,1970,O
the,1970,O
possibility,1970,O
that,1970,O
CS,1970,O
administration,1970,O
inhibits,1970,O
chemical,1970,O
bioactivation,1970,O
.,1970,O
Our,1971,O
findings,1971,O
do,1971,O
suggest,1971,O
that,1971,O
CS-mediated,1971,O
protection,1971,O
is,1971,O
dependent,1971,O
on,1971,O
the,1971,O
action,1971,O
of,1971,O
the,1971,O
intact,1971,O
anionic,1971,O
CS,1971,O
molecule,1971,O
(,1971,O
non-hydrolyzable,1971,O
CSE,1971,O
was,1971,O
as,1971,O
protective,1971,O
as,1971,O
CS,1971,O
),1971,O
",",1971,O
whose,1971,O
mechanism,1971,O
has,1971,O
yet,1971,O
to,1971,O
be,1971,O
defined,1971,O
.,1971,O
A,1972,O
murine,1972,O
model,1972,O
of,1972,O
adenomyosis,1972,B-Disease
:,1972,O
the,1972,O
effects,1972,O
of,1972,O
hyperprolactinemia,1972,B-Disease
induced,1972,O
by,1972,O
fluoxetine,1972,B-Chemical
hydrochloride,1972,I-Chemical
",",1972,O
a,1972,O
selective,1972,O
serotonin,1972,B-Chemical
reuptake,1972,O
inhibitor,1972,O
",",1972,O
on,1972,O
adenomyosis,1972,B-Disease
induction,1972,O
in,1972,O
Wistar,1972,O
albino,1972,O
rats,1972,O
.,1972,O
OBJECTIVE,1973,O
:,1973,O
The,1973,O
aim,1973,O
of,1973,O
this,1973,O
study,1973,O
was,1973,O
to,1973,O
investigate,1973,O
whether,1973,O
fluoxetine,1973,B-Chemical
given,1973,O
to,1973,O
castrated,1973,O
and,1973,O
noncastrated,1973,O
rats,1973,O
caused,1973,O
hyperprolactinemia,1973,B-Disease
and,1973,O
its,1973,O
effects,1973,O
with,1973,O
respect,1973,O
to,1973,O
adenomyosis,1973,B-Disease
.,1973,O
DESIGN,1974,O
:,1974,O
Fluoxetine,1974,B-Chemical
",",1974,O
a,1974,O
serotonin,1974,B-Chemical
reuptake,1974,O
inhibitor,1974,O
",",1974,O
was,1974,O
given,1974,O
to,1974,O
Wistar,1974,O
Albino,1974,O
rats,1974,O
for,1974,O
98,1974,O
days,1974,O
to,1974,O
produce,1974,O
hyperprolactinemia,1974,B-Disease
.,1974,O
The,1975,O
drug,1975,O
was,1975,O
given,1975,O
to,1975,O
two,1975,O
groups,1975,O
consisting,1975,O
of,1975,O
castrated,1975,O
and,1975,O
noncastrated,1975,O
rats,1975,O
and,1975,O
compared,1975,O
to,1975,O
two,1975,O
groups,1975,O
of,1975,O
castrated,1975,O
and,1975,O
noncastrated,1975,O
controls,1975,O
.,1975,O
Prolactin,1976,O
levels,1976,O
were,1976,O
measured,1976,O
and,1976,O
the,1976,O
uteri,1976,O
of,1976,O
the,1976,O
rats,1976,O
were,1976,O
removed,1976,O
for,1976,O
histopathological,1976,O
analysis,1976,O
at,1976,O
the,1976,O
end,1976,O
of,1976,O
98,1976,O
days,1976,O
.,1976,O
SETTING,1977,O
:,1977,O
Marmara,1977,O
University,1977,O
School,1977,O
of,1977,O
Medicine,1977,O
",",1977,O
Department,1977,O
of,1977,O
Histology,1977,O
and,1977,O
Embryology,1977,O
",",1977,O
Zeynep,1977,O
Kamil,1977,O
Women,1977,O
and,1977,O
Children,1977,O
's,1977,O
Hospital,1977,O
.,1977,O
MAIN,1978,O
OUTCOME,1978,O
MEASURES,1978,O
:,1978,O
Serum,1978,O
prolactin,1978,O
levels,1978,O
",",1978,O
uterine,1978,O
histopathology,1978,O
.,1978,O
RESULTS,1979,O
:,1979,O
The,1979,O
prolactin,1979,O
levels,1979,O
of,1979,O
castrated,1979,O
and,1979,O
noncastrated,1979,O
groups,1979,O
treated,1979,O
with,1979,O
fluoxetine,1979,B-Chemical
were,1979,O
statistically,1979,O
significantly,1979,O
higher,1979,O
when,1979,O
compared,1979,O
to,1979,O
their,1979,O
respective,1979,O
control,1979,O
groups,1979,O
.,1979,O
Histological,1980,O
studies,1980,O
revealed,1980,O
11,1980,O
cases,1980,O
of,1980,O
adenomyosis,1980,B-Disease
",",1980,O
all,1980,O
within,1980,O
the,1980,O
noncastrated,1980,O
group,1980,O
receiving,1980,O
fluoxetine,1980,B-Chemical
.,1980,O
CONCLUSION,1981,O
:,1981,O
It,1981,O
was,1981,O
suggested,1981,O
that,1981,O
high,1981,O
serum,1981,O
prolactin,1981,O
levels,1981,O
cause,1981,O
degeneration,1981,O
of,1981,O
myometrial,1981,O
cells,1981,O
in,1981,O
the,1981,O
presence,1981,O
of,1981,O
ovarian,1981,O
steroids,1981,B-Chemical
that,1981,O
results,1981,O
in,1981,O
a,1981,O
myometrial,1981,O
invasion,1981,O
by,1981,O
endometrial,1981,O
stroma,1981,O
.,1981,O
This,1982,O
invasion,1982,O
eventually,1982,O
progresses,1982,O
to,1982,O
adenomyosis,1982,B-Disease
.,1982,O
Postinfarction,1983,O
ventricular,1983,B-Disease
septal,1983,I-Disease
defect,1983,I-Disease
associated,1983,O
with,1983,O
long-term,1983,O
steroid,1983,B-Chemical
therapy,1983,O
.,1983,O
Two,1984,O
cases,1984,O
of,1984,O
postinfarction,1984,O
ventricular,1984,B-Disease
septal,1984,I-Disease
rupture,1984,I-Disease
in,1984,O
patients,1984,O
on,1984,O
long-term,1984,O
steroid,1984,B-Chemical
therapy,1984,O
are,1984,O
presented,1984,O
and,1984,O
the,1984,O
favourable,1984,O
outcome,1984,O
in,1984,O
both,1984,O
cases,1984,O
described,1984,O
.,1984,O
A,1985,O
possible,1985,O
association,1985,O
between,1985,O
steroid,1985,B-Chemical
therapy,1985,O
and,1985,O
subsequent,1985,O
postinfarction,1985,O
septal,1985,B-Disease
rupture,1985,I-Disease
is,1985,O
discussed,1985,O
.,1985,O
Neuroactive,1986,O
steroids,1986,B-Chemical
protect,1986,O
against,1986,O
pilocarpine-,1986,B-Chemical
and,1986,O
kainic,1986,B-Chemical
acid-induced,1986,O
limbic,1986,O
seizures,1986,B-Disease
and,1986,O
status,1986,B-Disease
epilepticus,1986,I-Disease
in,1986,O
mice,1986,O
.,1986,O
Several,1987,O
structurally,1987,O
related,1987,O
metabolites,1987,O
of,1987,O
progesterone,1987,B-Chemical
(,1987,O
3,1987,B-Chemical
alpha-hydroxy,1987,I-Chemical
pregnane-20-ones,1987,I-Chemical
),1987,O
and,1987,O
deoxycorticosterone,1987,B-Chemical
(,1987,O
3,1987,B-Chemical
alpha-hydroxy,1987,I-Chemical
pregnane-21-diol-20-ones,1987,I-Chemical
),1987,O
and,1987,O
their,1987,O
3,1987,O
beta-epimers,1987,O
were,1987,O
evaluated,1987,O
for,1987,O
protective,1987,O
activity,1987,O
against,1987,O
pilocarpine-,1987,B-Chemical
",",1987,O
kainic,1987,B-Chemical
acid-,1987,O
and,1987,O
N-methyl-D-aspartate,1987,B-Chemical
(,1987,O
NMDA,1987,B-Chemical
),1987,O
-induced,1987,O
seizures,1987,B-Disease
in,1987,O
mice,1987,O
.,1987,O
Steroids,1988,B-Chemical
with,1988,O
the,1988,O
3-hydroxy,1988,O
group,1988,O
in,1988,O
the,1988,O
alpha-position,1988,O
and,1988,O
5-H,1988,O
in,1988,O
the,1988,O
alpha-,1988,O
or,1988,O
beta-configurations,1988,O
were,1988,O
highly,1988,O
effective,1988,O
in,1988,O
protecting,1988,O
against,1988,O
pilocarpine,1988,B-Chemical
(,1988,O
416,1988,O
mg/kg,1988,O
",",1988,O
s.c.,1988,O
),1988,O
-induced,1988,O
limbic,1988,O
motor,1988,O
seizures,1988,B-Disease
and,1988,O
status,1988,B-Disease
epilepticus,1988,I-Disease
(,1988,O
ED50,1988,O
values,1988,O
",",1988,O
7.0-18.7,1988,O
mg/kg,1988,O
",",1988,O
i.p,1988,O
.,1988,O
),1988,O
.,1988,O
The,1989,O
corresponding,1989,O
epimers,1989,O
with,1989,O
the,1989,O
3-hydroxy,1989,O
group,1989,O
in,1989,O
the,1989,O
beta-position,1989,O
were,1989,O
also,1989,O
effective,1989,O
but,1989,O
less,1989,O
potent,1989,O
(,1989,O
ED50,1989,O
values,1989,O
",",1989,O
33.8-63.5,1989,O
",",1989,O
i.p,1989,O
.,1989,O
),1989,O
.,1989,O
Although,1990,O
the,1990,O
neuroactive,1990,O
steroids,1990,B-Chemical
were,1990,O
considerably,1990,O
less,1990,O
potent,1990,O
than,1990,O
the,1990,O
benzodiazepine,1990,B-Chemical
clonazepam,1990,B-Chemical
in,1990,O
protecting,1990,O
against,1990,O
pilocarpine,1990,B-Chemical
seizures,1990,B-Disease
",",1990,O
steroids,1990,B-Chemical
with,1990,O
the,1990,O
5,1990,O
"alpha,3",1990,O
alpha-configuration,1990,O
had,1990,O
comparable,1990,O
or,1990,O
higher,1990,O
protective,1990,O
index,1990,O
values,1990,O
(,1990,O
TD50,1990,O
for,1990,O
motor,1990,O
impairment,1990,O
divided,1990,O
by,1990,O
ED50,1990,O
for,1990,O
seizure,1990,B-Disease
protection,1990,O
),1990,O
than,1990,O
clonazepam,1990,B-Chemical
",",1990,O
indicating,1990,O
that,1990,O
some,1990,O
neuroactive,1990,O
steroids,1990,B-Chemical
may,1990,O
have,1990,O
lower,1990,O
relative,1990,O
toxicity,1990,B-Disease
.,1990,O
Steroids,1991,B-Chemical
with,1991,O
the,1991,O
5,1991,O
"alpha,3",1991,O
alpha-,1991,O
or,1991,O
5,1991,O
"beta,3",1991,O
alpha-configurations,1991,O
also,1991,O
produced,1991,O
a,1991,O
dose-dependent,1991,O
delay,1991,O
in,1991,O
the,1991,O
onset,1991,O
of,1991,O
limbic,1991,O
seizures,1991,B-Disease
induced,1991,O
by,1991,O
kainic,1991,B-Chemical
acid,1991,I-Chemical
(,1991,O
32,1991,O
mg/kg,1991,O
",",1991,O
s.c.,1991,O
),1991,O
",",1991,O
but,1991,O
did,1991,O
not,1991,O
completely,1991,O
protect,1991,O
against,1991,O
the,1991,O
seizures,1991,B-Disease
.,1991,O
However,1992,O
",",1992,O
when,1992,O
a,1992,O
second,1992,O
dose,1992,O
of,1992,O
the,1992,O
steroid,1992,B-Chemical
was,1992,O
administered,1992,O
1,1992,O
hr,1992,O
after,1992,O
the,1992,O
first,1992,O
dose,1992,O
",",1992,O
complete,1992,O
protection,1992,O
from,1992,O
the,1992,O
kainic,1992,B-Chemical
acid-induced,1992,O
limbic,1992,O
seizures,1992,B-Disease
and,1992,O
status,1992,B-Disease
epilepticus,1992,I-Disease
was,1992,O
obtained,1992,O
.,1992,O
The,1993,O
steroids,1993,B-Chemical
also,1993,O
caused,1993,O
a,1993,O
dose-dependent,1993,O
delay,1993,O
in,1993,O
NMDA,1993,B-Chemical
(,1993,O
257,1993,O
mg/kg,1993,O
",",1993,O
s.c.,1993,O
),1993,O
-induced,1993,O
lethality,1993,O
",",1993,O
but,1993,O
did,1993,O
not,1993,O
completely,1993,O
protect,1993,O
against,1993,O
NMDA,1993,B-Chemical
seizures,1993,B-Disease
or,1993,O
lethality,1993,O
.,1993,O
We,1994,O
conclude,1994,O
that,1994,O
neuroactive,1994,O
steroids,1994,B-Chemical
are,1994,O
highly,1994,O
effective,1994,O
in,1994,O
protecting,1994,O
against,1994,O
pilocarpine-,1994,B-Chemical
and,1994,O
kainic,1994,B-Chemical
acid-induced,1994,O
seizures,1994,B-Disease
and,1994,O
status,1994,B-Disease
epilepticus,1994,I-Disease
in,1994,O
mice,1994,O
",",1994,O
and,1994,O
may,1994,O
be,1994,O
of,1994,O
utility,1994,O
in,1994,O
the,1994,O
treatment,1994,O
of,1994,O
some,1994,O
forms,1994,O
of,1994,O
status,1994,B-Disease
epilepticus,1994,I-Disease
in,1994,O
humans,1994,O
.,1994,O
Hepatic,1995,O
and,1995,O
extrahepatic,1995,O
angiotensinogen,1995,O
gene,1995,O
expression,1995,O
in,1995,O
rats,1995,O
with,1995,O
acute,1995,O
nephrotic,1995,B-Disease
syndrome,1995,I-Disease
.,1995,O
Plasma,1996,O
concentration,1996,O
and,1996,O
urine,1996,O
excretion,1996,O
of,1996,O
the,1996,O
renin-angiotensin,1996,O
system,1996,O
proteins,1996,O
are,1996,O
altered,1996,O
in,1996,O
rats,1996,O
with,1996,O
nephrotic,1996,B-Disease
syndrome,1996,I-Disease
(,1996,O
NS,1996,B-Disease
),1996,O
.,1996,O
In,1997,O
this,1997,O
work,1997,O
the,1997,O
messenger,1997,O
ribonucleic,1997,O
acid,1997,O
(,1997,O
mRNA,1997,O
),1997,O
levels,1997,O
of,1997,O
angiotensinogen,1997,O
(,1997,O
Ao,1997,O
),1997,O
were,1997,O
analyzed,1997,O
with,1997,O
the,1997,O
slot-blot,1997,O
hybridization,1997,O
technique,1997,O
in,1997,O
liver,1997,O
and,1997,O
other,1997,O
extrahepatic,1997,O
tissues,1997,O
:,1997,O
kidney,1997,O
",",1997,O
heart,1997,O
",",1997,O
brain,1997,O
",",1997,O
and,1997,O
adrenal,1997,O
gland,1997,O
from,1997,O
control,1997,O
",",1997,O
nephrotic,1997,B-Disease
",",1997,O
and,1997,O
pair-fed,1997,O
(,1997,O
PF,1997,O
),1997,O
rats,1997,O
.,1997,O
NS,1998,B-Disease
was,1998,O
induced,1998,O
by,1998,O
a,1998,O
single,1998,O
injection,1998,O
of,1998,O
puromycin,1998,B-Chemical
amino-nucleoside,1998,I-Chemical
(,1998,O
PAN,1998,B-Chemical
),1998,O
.,1998,O
Although,1999,O
a,1999,O
great,1999,O
urinary,1999,O
excretion,1999,O
and,1999,O
half-normal,1999,O
plasma,1999,O
levels,1999,O
of,1999,O
Ao,1999,O
were,1999,O
observed,1999,O
on,1999,O
day,1999,O
6,1999,O
after,1999,O
PAN,1999,B-Chemical
injection,1999,O
",",1999,O
when,1999,O
NS,1999,B-Disease
was,1999,O
clearly,1999,O
established,1999,O
",",1999,O
hepatic,1999,O
Ao,1999,O
mRNA,1999,O
levels,1999,O
did,1999,O
not,1999,O
change,1999,O
.,1999,O
Furthermore,2000,O
",",2000,O
the,2000,O
Ao,2000,O
mRNA,2000,O
levels,2000,O
did,2000,O
not,2000,O
change,2000,O
in,2000,O
any,2000,O
of,2000,O
the,2000,O
extrahepatic,2000,O
tissues,2000,O
studied,2000,O
on,2000,O
day,2000,O
6,2000,O
",",2000,O
nor,2000,O
did,2000,O
its,2000,O
hepatic,2000,O
levels,2000,O
at,2000,O
days,2000,O
1,2000,O
",",2000,O
3,2000,O
",",2000,O
5,2000,O
",",2000,O
or,2000,O
7,2000,O
after,2000,O
PAN,2000,B-Chemical
injection,2000,O
.,2000,O
These,2001,O
data,2001,O
suggest,2001,O
that,2001,O
the,2001,O
hepatic,2001,O
and,2001,O
extrahepatic,2001,O
Ao,2001,O
mRNA,2001,O
levels,2001,O
are,2001,O
unaltered,2001,O
during,2001,O
the,2001,O
development,2001,O
of,2001,O
the,2001,O
acute,2001,O
NS,2001,B-Disease
induced,2001,O
by,2001,O
PAN,2001,B-Chemical
.,2001,O
Neuroleptic,2002,B-Disease
malignant,2002,I-Disease
syndrome,2002,I-Disease
with,2002,O
risperidone,2002,B-Chemical
.,2002,O
Neuroleptic,2003,B-Disease
malignant,2003,I-Disease
syndrome,2003,I-Disease
is,2003,O
thought,2003,O
to,2003,O
be,2003,O
a,2003,O
result,2003,O
of,2003,O
dopamine,2003,B-Chemical
D2,2003,O
receptor,2003,O
blockade,2003,O
in,2003,O
the,2003,O
striatum,2003,O
of,2003,O
the,2003,O
basal,2003,O
ganglia,2003,O
.,2003,O
Risperidone,2004,B-Chemical
",",2004,O
a,2004,O
benzisoxazole,2004,B-Chemical
derivative,2004,O
antipsychotic,2004,O
",",2004,O
has,2004,O
high,2004,O
serotonin,2004,B-Chemical
5-HT2,2004,O
receptor,2004,O
blockade,2004,O
and,2004,O
dose-related,2004,O
D2,2004,O
receptor,2004,O
blockade,2004,O
.,2004,O
The,2005,O
high,2005,O
ratio,2005,O
is,2005,O
believed,2005,O
to,2005,O
impart,2005,O
the,2005,O
low,2005,O
frequency,2005,O
of,2005,O
extrapyramidal,2005,B-Disease
symptoms,2005,I-Disease
with,2005,O
risperidone,2005,B-Chemical
at,2005,O
low,2005,O
dosages,2005,O
.,2005,O
With,2006,O
this,2006,O
low,2006,O
frequency,2006,O
of,2006,O
extrapyramidal,2006,B-Disease
symptoms,2006,I-Disease
",",2006,O
it,2006,O
was,2006,O
thought,2006,O
the,2006,O
frequency,2006,O
of,2006,O
neuroleptic,2006,B-Disease
malignant,2006,I-Disease
syndrome,2006,I-Disease
might,2006,O
also,2006,O
be,2006,O
lowered,2006,O
.,2006,O
A,2007,O
73-year-old,2007,O
woman,2007,O
developed,2007,O
neuroleptic,2007,B-Disease
malignant,2007,I-Disease
syndrome,2007,I-Disease
after,2007,O
monotherapy,2007,O
with,2007,O
risperidone,2007,B-Chemical
.,2007,O
The,2008,O
syndrome,2008,O
reversed,2008,O
after,2008,O
discontinuing,2008,O
risperidone,2008,B-Chemical
and,2008,O
starting,2008,O
treatment,2008,O
with,2008,O
dantrolene,2008,B-Chemical
and,2008,O
bromocriptine,2008,B-Chemical
.,2008,O
It,2009,O
appears,2009,O
that,2009,O
the,2009,O
protection,2009,O
from,2009,O
extrapyramidal,2009,O
side,2009,O
effects,2009,O
observed,2009,O
with,2009,O
risperidone,2009,B-Chemical
does,2009,O
not,2009,O
ensure,2009,O
protection,2009,O
from,2009,O
neuroleptic,2009,B-Disease
malignant,2009,I-Disease
syndrome,2009,I-Disease
.,2009,O
The,2010,O
attenuating,2010,O
effect,2010,O
of,2010,O
carteolol,2010,B-Chemical
hydrochloride,2010,I-Chemical
",",2010,O
a,2010,O
beta-adrenoceptor,2010,O
antagonist,2010,O
",",2010,O
on,2010,O
neuroleptic-induced,2010,O
catalepsy,2010,B-Disease
in,2010,O
rats,2010,O
.,2010,O
It,2011,O
is,2011,O
known,2011,O
that,2011,O
beta-adrenoceptor,2011,O
antagonists,2011,O
are,2011,O
effective,2011,O
in,2011,O
the,2011,O
treatment,2011,O
of,2011,O
akathisia,2011,B-Disease
",",2011,O
one,2011,O
of,2011,O
the,2011,O
extrapyramidal,2011,O
side,2011,O
effects,2011,O
that,2011,O
occur,2011,O
during,2011,O
neuroleptic,2011,O
treatment,2011,O
.,2011,O
Neuroleptic-induced,2012,O
catalepsy,2012,B-Disease
",",2012,O
a,2012,O
model,2012,O
of,2012,O
neuroleptic-induced,2012,O
extrapyramidal,2012,O
side,2012,O
effects,2012,O
",",2012,O
was,2012,O
considered,2012,O
suitable,2012,O
as,2012,O
a,2012,O
model,2012,O
for,2012,O
predicting,2012,O
neuroleptic-induced,2012,O
akathisia,2012,B-Disease
in,2012,O
humans,2012,O
",",2012,O
although,2012,O
neuroleptic-induced,2012,O
catalepsy,2012,B-Disease
was,2012,O
not,2012,O
considered,2012,O
a,2012,O
specific,2012,O
test,2012,O
for,2012,O
neuroleptic-induced,2012,O
akathisia,2012,B-Disease
.,2012,O
Therefore,2013,O
",",2013,O
the,2013,O
effects,2013,O
of,2013,O
carteolol,2013,B-Chemical
",",2013,O
a,2013,O
beta-adrenoceptor,2013,O
antagonist,2013,O
",",2013,O
on,2013,O
haloperidol-induced,2013,B-Chemical
catalepsy,2013,B-Disease
in,2013,O
rats,2013,O
were,2013,O
behaviorally,2013,O
studied,2013,O
and,2013,O
compared,2013,O
with,2013,O
those,2013,O
of,2013,O
propranolol,2013,B-Chemical
and,2013,O
biperiden,2013,B-Chemical
",",2013,O
a,2013,O
muscarinic,2013,O
receptor,2013,O
antagonist,2013,O
.,2013,O
Carteolol,2014,B-Chemical
",",2014,O
as,2014,O
well,2014,O
as,2014,O
propranolol,2014,B-Chemical
and,2014,O
biperiden,2014,B-Chemical
",",2014,O
inhibited,2014,O
the,2014,O
haloperidol-induced,2014,B-Chemical
catalepsy,2014,B-Disease
.,2014,O
The,2015,O
inhibitory,2015,O
effect,2015,O
of,2015,O
carteolol,2015,B-Chemical
was,2015,O
almost,2015,O
comparable,2015,O
to,2015,O
that,2015,O
of,2015,O
propranolol,2015,B-Chemical
",",2015,O
but,2015,O
was,2015,O
weaker,2015,O
than,2015,O
that,2015,O
of,2015,O
biperiden,2015,B-Chemical
.,2015,O
Carteolol,2016,B-Chemical
did,2016,O
not,2016,O
evoke,2016,O
postsynaptic,2016,O
dopamine,2016,B-Chemical
receptor-stimulating,2016,O
behavioral,2016,O
signs,2016,O
such,2016,O
as,2016,O
stereotypy,2016,O
and,2016,O
hyperlocomotion,2016,B-Disease
in,2016,O
rats,2016,O
.,2016,O
Carteolol,2017,B-Chemical
did,2017,O
not,2017,O
antagonize,2017,O
the,2017,O
inhibitory,2017,O
effects,2017,O
of,2017,O
haloperidol,2017,B-Chemical
on,2017,O
apomorphine-induced,2017,B-Chemical
stereotypy,2017,O
and,2017,O
locomotor,2017,O
activity,2017,O
in,2017,O
rats,2017,O
.,2017,O
In,2018,O
addition,2018,O
",",2018,O
carteolol,2018,B-Chemical
did,2018,O
not,2018,O
evoke,2018,O
5-HT1A,2018,O
receptor-stimulating,2018,O
behavioral,2018,O
signs,2018,O
such,2018,O
as,2018,O
flat,2018,O
body,2018,O
posture,2018,O
and,2018,O
forepaw,2018,O
treading,2018,O
and,2018,O
did,2018,O
not,2018,O
inhibit,2018,O
5-hydroxytryptophan-induced,2018,B-Chemical
head,2018,O
twitch,2018,O
in,2018,O
rats,2018,O
.,2018,O
Finally,2019,O
",",2019,O
carteolol,2019,B-Chemical
did,2019,O
not,2019,O
inhibit,2019,O
physostigmine-induced,2019,B-Chemical
lethality,2019,O
in,2019,O
rats,2019,O
.,2019,O
These,2020,O
results,2020,O
strongly,2020,O
suggest,2020,O
that,2020,O
carteolol,2020,B-Chemical
improves,2020,O
haloperidol-induced,2020,B-Chemical
catalepsy,2020,B-Disease
via,2020,O
its,2020,O
beta-adrenoceptor,2020,O
antagonistic,2020,O
activity,2020,O
and,2020,O
is,2020,O
expected,2020,O
to,2020,O
be,2020,O
effective,2020,O
in,2020,O
the,2020,O
treatment,2020,O
of,2020,O
akathisia,2020,B-Disease
without,2020,O
attenuating,2020,O
neuroleptic-induced,2020,O
antipsychotic,2020,O
effects,2020,O
due,2020,O
to,2020,O
its,2020,O
postsynaptic,2020,O
dopamine,2020,B-Chemical
receptor,2020,O
antagonistic,2020,O
activity,2020,O
.,2020,O
Granulosa,2021,B-Disease
cell,2021,I-Disease
tumor,2021,I-Disease
of,2021,I-Disease
the,2021,I-Disease
ovary,2021,I-Disease
associated,2021,O
with,2021,O
antecedent,2021,O
tamoxifen,2021,B-Chemical
use,2021,O
.,2021,O
BACKGROUND,2022,O
:,2022,O
Increased,2022,O
attention,2022,O
has,2022,O
been,2022,O
focused,2022,O
recently,2022,O
on,2022,O
the,2022,O
estrogenic,2022,O
effects,2022,O
of,2022,O
tamoxifen,2022,B-Chemical
.,2022,O
Review,2023,O
of,2023,O
the,2023,O
literature,2023,O
reveals,2023,O
an,2023,O
association,2023,O
between,2023,O
tamoxifen,2023,B-Chemical
use,2023,O
and,2023,O
gynecologic,2023,O
tumors,2023,B-Disease
.,2023,O
CASE,2024,O
:,2024,O
A,2024,O
52-year-old,2024,O
postmenopausal,2024,O
woman,2024,O
was,2024,O
treated,2024,O
with,2024,O
tamoxifen,2024,B-Chemical
for,2024,O
stage,2024,O
II,2024,O
estrogen,2024,B-Chemical
receptor-positive,2024,O
breast,2024,B-Disease
carcinoma,2024,I-Disease
.,2024,O
Her,2025,O
aspartate,2025,B-Chemical
transaminase,2025,O
and,2025,O
alanine,2025,B-Chemical
transaminase,2025,O
levels,2025,O
increase,2025,O
markedly,2025,O
after,2025,O
6,2025,O
months,2025,O
of,2025,O
tamoxifen,2025,B-Chemical
use,2025,O
.,2025,O
After,2026,O
an,2026,O
additional,2026,O
17,2026,O
months,2026,O
of,2026,O
elevated,2026,O
serum,2026,O
transaminases,2026,O
",",2026,O
the,2026,O
patient,2026,O
was,2026,O
found,2026,O
to,2026,O
have,2026,O
a,2026,O
stage,2026,O
Ic,2026,O
granulosa,2026,B-Disease
cell,2026,I-Disease
tumor,2026,I-Disease
of,2026,I-Disease
the,2026,I-Disease
ovary,2026,I-Disease
.,2026,O
CONCLUSION,2027,O
:,2027,O
Patients,2027,O
with,2027,O
tamoxifen-induced,2027,B-Chemical
liver,2027,B-Disease
dysfunction,2027,I-Disease
may,2027,O
be,2027,O
at,2027,O
increased,2027,O
risk,2027,O
for,2027,O
granulosa,2027,B-Disease
cell,2027,I-Disease
tumors,2027,I-Disease
because,2027,O
of,2027,O
alterations,2027,O
in,2027,O
tamoxifen,2027,B-Chemical
metabolism,2027,O
.,2027,O
Lifetime,2028,O
treatment,2028,O
of,2028,O
mice,2028,O
with,2028,O
azidothymidine,2028,B-Chemical
(,2028,O
AZT,2028,B-Chemical
),2028,O
produces,2028,O
myelodysplasia,2028,B-Disease
.,2028,O
AZT,2029,B-Chemical
has,2029,O
induced,2029,O
a,2029,O
macrocytic,2029,B-Disease
anemia,2029,I-Disease
in,2029,O
AIDS,2029,B-Disease
patients,2029,O
on,2029,O
long,2029,O
term,2029,O
AZT,2029,B-Chemical
therapy,2029,O
.,2029,O
It,2030,O
is,2030,O
generally,2030,O
assumed,2030,O
that,2030,O
DNA,2030,O
elongation,2030,O
is,2030,O
stopped,2030,O
by,2030,O
the,2030,O
insertion,2030,O
of,2030,O
AZT,2030,B-Chemical
into,2030,O
the,2030,O
chain,2030,O
in,2030,O
place,2030,O
of,2030,O
thymidine,2030,B-Chemical
thus,2030,O
preventing,2030,O
the,2030,O
phosphate,2030,B-Chemical
hydroxyl,2030,O
linkages,2030,O
and,2030,O
therefore,2030,O
suppresses,2030,O
hemopoietic,2030,O
progenitor,2030,O
cell,2030,O
proliferation,2030,O
in,2030,O
an,2030,O
early,2030,O
stage,2030,O
of,2030,O
differentiation,2030,O
.,2030,O
CBA/Ca,2031,O
male,2031,O
mice,2031,O
started,2031,O
on,2031,O
AZT,2031,B-Chemical
0.75,2031,O
mg/ml,2031,O
H2O,2031,O
at,2031,O
84,2031,O
days,2031,O
of,2031,O
age,2031,O
and,2031,O
kept,2031,O
on,2031,O
it,2031,O
for,2031,O
687,2031,O
days,2031,O
when,2031,O
dosage,2031,O
reduced,2031,O
to,2031,O
0.5,2031,O
mg/ml,2031,O
H2O,2031,O
for,2031,O
a,2031,O
group,2031,O
",",2031,O
another,2031,O
group,2031,O
removed,2031,O
from,2031,O
AZT,2031,B-Chemical
to,2031,O
see,2031,O
recovery,2031,O
",",2031,O
and,2031,O
third,2031,O
group,2031,O
remained,2031,O
on,2031,O
0.75,2031,O
mg.,2031,O
At,2031,O
687,2031,O
days,2031,O
mice,2031,O
that,2031,O
had,2031,O
been,2031,O
on,2031,O
0.75,2031,O
mg,2031,O
had,2031,O
average,2031,O
platelet,2031,O
counts,2031,O
of,2031,O
2.5,2031,O
x,2031,O
10,2031,O
(,2031,O
6,2031,O
),2031,O
.,2031,O
Histological,2032,O
examination,2032,O
on,2032,O
9,2032,O
of,2032,O
10,2032,O
mice,2032,O
with,2032,O
such,2032,O
thrombocytopenia,2032,B-Disease
showed,2032,O
changes,2032,O
compatible,2032,O
with,2032,O
myelodysplastic,2032,B-Disease
syndrome,2032,I-Disease
(,2032,O
MDS,2032,B-Disease
),2032,O
.,2032,O
A,2033,O
variety,2033,O
of,2033,O
histological,2033,O
patterns,2033,O
was,2033,O
observed,2033,O
.,2033,O
There,2034,O
were,2034,O
two,2034,O
cases,2034,O
of,2034,O
hypocellular,2034,O
myelodysplasia,2034,B-Disease
",",2034,O
two,2034,O
cases,2034,O
of,2034,O
hypersegmented,2034,O
myelodysplastic,2034,B-Disease
granulocytosis,2034,O
",",2034,O
two,2034,O
cases,2034,O
of,2034,O
hypercellular,2034,O
marrow,2034,O
with,2034,O
abnormal,2034,O
megakaryocytes,2034,O
with,2034,O
bizarre,2034,O
nuclei,2034,O
",",2034,O
one,2034,O
case,2034,O
of,2034,O
megakaryocytic,2034,O
myelosis,2034,O
associated,2034,O
with,2034,O
a,2034,O
hyperplastic,2034,B-Disease
marrow,2034,I-Disease
",",2034,O
dysmyelopoiesis,2034,B-Disease
and,2034,O
a,2034,O
hypocellular,2034,B-Disease
marrow,2034,I-Disease
and,2034,O
two,2034,O
cases,2034,O
of,2034,O
myelodysplasia,2034,B-Disease
with,2034,O
dyserythropoiesis,2034,B-Disease
",",2034,O
hemosiderosis,2034,B-Disease
and,2034,O
a,2034,O
hypocellular,2034,B-Disease
marrow,2034,I-Disease
.,2034,O
Above,2035,O
mentioned,2035,O
AZT,2035,B-Chemical
incorporation,2035,O
may,2035,O
have,2035,O
induced,2035,O
an,2035,O
ineffective,2035,O
hemopoiesis,2035,O
in,2035,O
the,2035,O
primitive,2035,O
hemopoietic,2035,O
progenitor,2035,O
cells,2035,O
",",2035,O
which,2035,O
is,2035,O
known,2035,O
to,2035,O
be,2035,O
seen,2035,O
commonly,2035,O
in,2035,O
the,2035,O
myelodysplastic,2035,B-Disease
syndrome,2035,I-Disease
.,2035,O
Over,2036,O
expression,2036,O
of,2036,O
vascular,2036,O
endothelial,2036,O
growth,2036,O
factor,2036,O
and,2036,O
its,2036,O
receptor,2036,O
during,2036,O
the,2036,O
development,2036,O
of,2036,O
estrogen-induced,2036,B-Chemical
rat,2036,O
pituitary,2036,B-Disease
tumors,2036,I-Disease
may,2036,O
mediate,2036,O
estrogen-initiated,2036,B-Chemical
tumor,2036,B-Disease
angiogenesis,2036,O
.,2036,O
Estrogens,2037,B-Chemical
",",2037,O
which,2037,O
have,2037,O
been,2037,O
associated,2037,O
with,2037,O
several,2037,O
types,2037,O
of,2037,O
human,2037,O
and,2037,O
animal,2037,O
cancers,2037,B-Disease
",",2037,O
can,2037,O
induce,2037,O
tumor,2037,B-Disease
angiogenesis,2037,O
in,2037,O
the,2037,O
pituitary,2037,O
of,2037,O
Fischer,2037,O
344,2037,O
rats,2037,O
.,2037,O
The,2038,O
mechanistic,2038,O
details,2038,O
of,2038,O
tumor,2038,B-Disease
angiogenesis,2038,O
induction,2038,O
",",2038,O
during,2038,O
estrogen,2038,B-Chemical
carcinogenesis,2038,B-Disease
",",2038,O
are,2038,O
still,2038,O
unknown,2038,O
.,2038,O
To,2039,O
elucidate,2039,O
the,2039,O
role,2039,O
of,2039,O
estrogen,2039,B-Chemical
in,2039,O
the,2039,O
regulation,2039,O
of,2039,O
tumor,2039,B-Disease
angiogenesis,2039,O
in,2039,O
the,2039,O
pituitary,2039,O
of,2039,O
female,2039,O
rats,2039,O
",",2039,O
the,2039,O
density,2039,O
of,2039,O
blood,2039,O
vessels,2039,O
was,2039,O
analysed,2039,O
using,2039,O
factor,2039,O
VIII,2039,O
related,2039,O
antigen,2039,O
(,2039,O
FVIIIRAg,2039,O
),2039,O
immunohistochemistry,2039,O
and,2039,O
the,2039,O
expression,2039,O
of,2039,O
vascular,2039,O
endothelial,2039,O
growth,2039,O
factor/vascular,2039,O
permeability,2039,O
factor,2039,O
(,2039,O
VEGF/VPF,2039,O
),2039,O
was,2039,O
examined,2039,O
by,2039,O
Western,2039,O
blot,2039,O
and,2039,O
immunohistochemical,2039,O
analysis,2039,O
.,2039,O
The,2040,O
expression,2040,O
of,2040,O
VEGF,2040,O
receptor,2040,O
(,2040,O
VEGFR-2/Flk-1/KDR,2040,O
),2040,O
was,2040,O
also,2040,O
examined,2040,O
by,2040,O
immunohistochemistry,2040,O
.,2040,O
The,2041,O
results,2041,O
demonstrated,2041,O
that,2041,O
17beta-estradiol,2041,B-Chemical
(,2041,O
E2,2041,B-Chemical
),2041,O
induces,2041,O
neovascularization,2041,O
",",2041,O
as,2041,O
well,2041,O
as,2041,O
the,2041,O
growth,2041,O
and,2041,O
enlargement,2041,O
of,2041,O
blood,2041,O
vessels,2041,O
after,2041,O
7,2041,O
days,2041,O
of,2041,O
exposure,2041,O
.,2041,O
The,2042,O
high,2042,O
tumor,2042,B-Disease
angiogenic,2042,O
potential,2042,O
was,2042,O
associated,2042,O
with,2042,O
an,2042,O
elevated,2042,O
VEGF/VPF,2042,O
protein,2042,O
expression,2042,O
in,2042,O
the,2042,O
E2,2042,B-Chemical
exposed,2042,O
pituitary,2042,O
of,2042,O
ovariectomized,2042,O
(,2042,O
OVEX,2042,O
),2042,O
rats,2042,O
.,2042,O
VEGF/VPF,2043,O
and,2043,O
FVIIIRAg,2043,O
immunohistochemistry,2043,O
and,2043,O
endothelial,2043,O
specific,2043,O
lectin,2043,O
(,2043,O
UEA1,2043,O
),2043,O
binding,2043,O
studies,2043,O
",",2043,O
indicate,2043,O
that,2043,O
the,2043,O
elevation,2043,O
of,2043,O
VEGF,2043,O
protein,2043,O
expression,2043,O
initially,2043,O
occurred,2043,O
in,2043,O
both,2043,O
blood,2043,O
vessels,2043,O
and,2043,O
non-endothelial,2043,O
cells,2043,O
.,2043,O
After,2044,O
15,2044,O
days,2044,O
of,2044,O
E2,2044,B-Chemical
exposure,2044,O
",",2044,O
VEGF/VPF,2044,O
protein,2044,O
expression,2044,O
",",2044,O
in,2044,O
the,2044,O
non-endothelial,2044,O
cell,2044,O
population,2044,O
",",2044,O
sharply,2044,O
declined,2044,O
and,2044,O
was,2044,O
restricted,2044,O
to,2044,O
the,2044,O
blood,2044,O
vessels,2044,O
.,2044,O
The,2045,O
function,2045,O
of,2045,O
non-endothelial-derived,2045,O
VEGF,2045,O
is,2045,O
not,2045,O
clear,2045,O
.,2045,O
Furthermore,2046,O
",",2046,O
immunohistochemical,2046,O
studies,2046,O
demonstrated,2046,O
that,2046,O
VEGFR-2,2046,O
(,2046,O
flk-1/KDR,2046,O
),2046,O
",",2046,O
expression,2046,O
was,2046,O
elevated,2046,O
significantly,2046,O
in,2046,O
the,2046,O
endothelial,2046,O
cells,2046,O
of,2046,O
microblood,2046,O
vessels,2046,O
after,2046,O
7,2046,O
days,2046,O
of,2046,O
E2,2046,B-Chemical
exposure,2046,O
.,2046,O
These,2047,O
findings,2047,O
suggest,2047,O
that,2047,O
over,2047,O
expression,2047,O
of,2047,O
VEGF,2047,O
and,2047,O
its,2047,O
receptor,2047,O
(,2047,O
VEGFR-2,2047,O
),2047,O
may,2047,O
play,2047,O
an,2047,O
important,2047,O
role,2047,O
in,2047,O
the,2047,O
initial,2047,O
step,2047,O
of,2047,O
the,2047,O
regulation,2047,O
of,2047,O
estrogen,2047,B-Chemical
induced,2047,O
tumor,2047,B-Disease
angiogenesis,2047,O
in,2047,O
the,2047,O
rat,2047,O
pituitary,2047,O
.,2047,O
Persistent,2048,O
nephrogenic,2048,B-Disease
diabetes,2048,I-Disease
insipidus,2048,I-Disease
following,2048,O
lithium,2048,B-Chemical
therapy,2048,O
.,2048,O
We,2049,O
report,2049,O
the,2049,O
case,2049,O
of,2049,O
a,2049,O
patient,2049,O
who,2049,O
developed,2049,O
severe,2049,O
hypernatraemic,2049,O
dehydration,2049,B-Disease
following,2049,O
a,2049,O
head,2049,B-Disease
injury,2049,I-Disease
.,2049,O
Ten,2050,O
years,2050,O
previously,2050,O
he,2050,O
had,2050,O
been,2050,O
diagnosed,2050,O
to,2050,O
have,2050,O
lithium-induced,2050,B-Chemical
nephrogenic,2050,B-Disease
diabetes,2050,I-Disease
insipidus,2050,I-Disease
",",2050,O
and,2050,O
lithium,2050,B-Chemical
therapy,2050,O
had,2050,O
been,2050,O
discontinued,2050,O
.,2050,O
He,2051,O
remained,2051,O
thirsty,2051,O
and,2051,O
polyuric,2051,B-Disease
despite,2051,O
cessation,2051,O
of,2051,O
lithium,2051,B-Chemical
and,2051,O
investigations,2051,O
on,2051,O
admission,2051,O
showed,2051,O
him,2051,O
to,2051,O
have,2051,O
normal,2051,O
osmoregulated,2051,O
thirst,2051,O
and,2051,O
vasopressin,2051,B-Chemical
secretion,2051,O
",",2051,O
with,2051,O
clear,2051,O
evidence,2051,O
of,2051,O
nephrogenic,2051,B-Disease
diabetes,2051,I-Disease
insipidus,2051,I-Disease
.,2051,O
Lithium,2052,B-Chemical
induced,2052,O
nephrogenic,2052,B-Disease
diabetes,2052,I-Disease
insipidus,2052,I-Disease
is,2052,O
considered,2052,O
to,2052,O
be,2052,O
reversible,2052,O
on,2052,O
cessation,2052,O
of,2052,O
therapy,2052,O
but,2052,O
polyuria,2052,B-Disease
persisted,2052,O
in,2052,O
this,2052,O
patient,2052,O
for,2052,O
ten,2052,O
years,2052,O
after,2052,O
lithium,2052,B-Chemical
was,2052,O
stopped,2052,O
.,2052,O
We,2053,O
discuss,2053,O
the,2053,O
possible,2053,O
renal,2053,O
mechanisms,2053,O
and,2053,O
the,2053,O
implications,2053,O
for,2053,O
management,2053,O
of,2053,O
patients,2053,O
with,2053,O
lithium-induced,2053,B-Chemical
nephrogenic,2053,B-Disease
diabetes,2053,I-Disease
insipidus,2053,I-Disease
.,2053,O
Effects,2054,O
of,2054,O
NIK-247,2054,B-Chemical
on,2054,O
cholinesterase,2054,O
and,2054,O
scopolamine-induced,2054,B-Chemical
amnesia,2054,B-Disease
.,2054,O
The,2055,O
effects,2055,O
of,2055,O
NIK-247,2055,B-Chemical
on,2055,O
cholinesterase,2055,O
",",2055,O
scopolamine-induced,2055,B-Chemical
amnesia,2055,B-Disease
and,2055,O
spontaneous,2055,O
movement,2055,O
were,2055,O
examined,2055,O
and,2055,O
compared,2055,O
with,2055,O
those,2055,O
of,2055,O
the,2055,O
well-known,2055,O
cholinesterase,2055,O
inhibitors,2055,O
tacrine,2055,B-Chemical
and,2055,O
E-2020,2055,B-Chemical
.,2055,O
NIK-247,2056,B-Chemical
",",2056,O
tacrine,2056,B-Chemical
and,2056,O
E-2020,2056,B-Chemical
all,2056,O
strongly,2056,O
inhibited,2056,O
acetylcholinesterase,2056,O
(,2056,O
AChE,2056,O
),2056,O
in,2056,O
human,2056,O
red,2056,O
blood,2056,O
cells,2056,O
(,2056,O
IC50s,2056,O
=,2056,O
1.0,2056,O
x,2056,O
10,2056,O
(,2056,O
-6,2056,O
),2056,O
",",2056,O
2.9,2056,O
x,2056,O
10,2056,O
(,2056,O
-7,2056,O
),2056,O
and,2056,O
3.7,2056,O
x,2056,O
10,2056,O
(,2056,O
-8,2056,O
),2056,O
M,2056,O
",",2056,O
respectively,2056,O
),2056,O
.,2056,O
In,2057,O
addition,2057,O
",",2057,O
NIK-247,2057,B-Chemical
and,2057,O
tacrine,2057,B-Chemical
",",2057,O
but,2057,O
not,2057,O
E-2020,2057,B-Chemical
",",2057,O
strongly,2057,O
inhibited,2057,O
butyrylcholinestrase,2057,O
(,2057,O
BuChE,2057,O
),2057,O
in,2057,O
human,2057,O
serum,2057,O
.,2057,O
All,2058,O
three,2058,O
drugs,2058,O
produced,2058,O
mixed,2058,O
inhibition,2058,O
of,2058,O
AChE,2058,O
activity,2058,O
.,2058,O
Moreover,2059,O
",",2059,O
the,2059,O
inhibitory,2059,O
effect,2059,O
of,2059,O
NIK-247,2059,B-Chemical
on,2059,O
AChE,2059,O
was,2059,O
reversible,2059,O
.,2059,O
All,2060,O
compounds,2060,O
at,2060,O
0.1-1,2060,O
mg/kg,2060,O
p.o,2060,O
.,2060,O
significantly,2061,O
improved,2061,O
the,2061,O
amnesia,2061,B-Disease
induced,2061,O
by,2061,O
scopolamine,2061,B-Chemical
(,2061,O
0.5,2061,O
mg/kg,2061,O
s.c.,2061,O
),2061,O
in,2061,O
rats,2061,O
performing,2061,O
a,2061,O
passive,2061,O
avoidance,2061,O
task,2061,O
.,2061,O
The,2062,O
three,2062,O
compounds,2062,O
at,2062,O
1,2062,O
and,2062,O
3,2062,O
mg/kg,2062,O
p.o,2062,O
.,2062,O
did,2063,O
not,2063,O
significantly,2063,O
decrease,2063,O
spontaneous,2063,O
movement,2063,O
by,2063,O
rats,2063,O
.,2063,O
These,2064,O
findings,2064,O
suggest,2064,O
that,2064,O
NIK-247,2064,B-Chemical
at,2064,O
a,2064,O
low,2064,O
dose,2064,O
(,2064,O
0.1-1,2064,O
mg/kg,2064,O
p.o,2064,O
.,2064,O
),2064,O
improves,2065,O
scopolamine-induced,2065,B-Chemical
amnesia,2065,B-Disease
but,2065,O
does,2065,O
not,2065,O
affect,2065,O
spontaneous,2065,O
movement,2065,O
.,2065,O
The,2066,O
findings,2066,O
suggest,2066,O
that,2066,O
NIK-247,2066,B-Chemical
may,2066,O
be,2066,O
a,2066,O
useful,2066,O
drug,2066,O
for,2066,O
the,2066,O
treatment,2066,O
of,2066,O
Alzheimer,2066,B-Disease
's,2066,I-Disease
disease,2066,I-Disease
.,2066,O
Potential,2067,O
therapeutic,2067,O
use,2067,O
of,2067,O
the,2067,O
selective,2067,O
dopamine,2067,B-Chemical
D1,2067,O
receptor,2067,O
agonist,2067,O
",",2067,O
A-86929,2067,B-Chemical
:,2067,O
an,2067,O
acute,2067,O
study,2067,O
in,2067,O
parkinsonian,2067,B-Disease
levodopa-primed,2067,B-Chemical
monkeys,2067,O
.,2067,O
The,2068,O
clinical,2068,O
utility,2068,O
of,2068,O
dopamine,2068,B-Chemical
(,2068,O
DA,2068,B-Chemical
),2068,O
D1,2068,O
receptor,2068,O
agonists,2068,O
in,2068,O
the,2068,O
treatment,2068,O
of,2068,O
Parkinson,2068,B-Disease
's,2068,I-Disease
disease,2068,I-Disease
(,2068,O
PD,2068,B-Disease
),2068,O
is,2068,O
still,2068,O
unclear,2068,O
.,2068,O
The,2069,O
therapeutic,2069,O
use,2069,O
of,2069,O
selective,2069,O
DA,2069,B-Chemical
D1,2069,O
receptor,2069,O
agonists,2069,O
such,2069,O
as,2069,O
SKF-82958,2069,B-Chemical
(,2069,O
"6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze",2069,B-Chemical
pine,2069,I-Chemical
hydrobromide,2069,I-Chemical
),2069,O
and,2069,O
A-77636,2069,B-Chemical
(,2069,O
[,2069,B-Chemical
1R,2069,I-Chemical
",",2069,I-Chemical
3S,2069,I-Chemical
],2069,I-Chemical
3-,2069,I-Chemical
[,2069,I-Chemical
1'-admantyl,2069,I-Chemical
],2069,I-Chemical
"-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo",2069,I-Chemical
pyran,2069,I-Chemical
hydrochloride,2069,I-Chemical
),2069,O
seems,2069,O
limited,2069,O
because,2069,O
of,2069,O
their,2069,O
duration,2069,O
of,2069,O
action,2069,O
",",2069,O
which,2069,O
is,2069,O
too,2069,O
short,2069,O
for,2069,O
SKF-82958,2069,B-Chemical
(,2069,O
<,2069,O
1,2069,O
hr,2069,O
),2069,O
and,2069,O
too,2069,O
long,2069,O
for,2069,O
A-77636,2069,B-Chemical
(,2069,O
>,2069,O
20,2069,O
hr,2069,O
",",2069,O
leading,2069,O
to,2069,O
behavioral,2069,O
tolerance,2069,O
),2069,O
.,2069,O
We,2070,O
therefore,2070,O
conducted,2070,O
the,2070,O
present,2070,O
acute,2070,O
dose-response,2070,O
study,2070,O
in,2070,O
four,2070,O
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",2070,B-Chemical
(,2070,O
MPTP,2070,B-Chemical
),2070,O
-exposed,2070,O
cynomolgus,2070,O
monkeys,2070,O
primed,2070,O
to,2070,O
exhibit,2070,O
levodopa-induced,2070,B-Chemical
dyskinesias,2070,B-Disease
to,2070,O
evaluate,2070,O
the,2070,O
locomotor,2070,O
and,2070,O
dyskinetic,2070,B-Disease
effects,2070,O
on,2070,O
challenge,2070,O
with,2070,O
four,2070,O
doses,2070,O
(,2070,O
from,2070,O
0.03,2070,O
to,2070,O
1.0,2070,O
mg/kg,2070,O
),2070,O
of,2070,O
A-86929,2070,B-Chemical
(,2070,O
[,2070,B-Chemical
-,2070,I-Chemical
],2070,I-Chemical
-,2070,I-Chemical
[,2070,I-Chemical
"5aR,11bS",2070,I-Chemical
],2070,I-Chemical
"-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+",2070,I-Chemical
++azacyclopent-1-,2070,I-Chemical
ena,2070,I-Chemical
[,2070,I-Chemical
c,2070,I-Chemical
],2070,I-Chemical
phenathrene-9-10-diol,2070,I-Chemical
),2070,O
",",2070,O
a,2070,O
selective,2070,O
and,2070,O
full,2070,O
DA,2070,B-Chemical
D1-like,2070,O
receptor,2070,O
agonist,2070,O
with,2070,O
an,2070,O
intermediate,2070,O
duration,2070,O
of,2070,O
action,2070,O
.,2070,O
Levodopa,2071,B-Chemical
and,2071,O
the,2071,O
DA,2071,B-Chemical
D2-like,2071,O
receptor,2071,O
agonist,2071,O
",",2071,O
LY-171555,2071,B-Chemical
(,2071,O
[,2071,B-Chemical
4aR-trans,2071,I-Chemical
],2071,I-Chemical
"-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo",2071,I-Chemical
lo-3-4-quinoline,2071,I-Chemical
hydrochloride,2071,I-Chemical
),2071,O
were,2071,O
also,2071,O
used,2071,O
for,2071,O
comparison,2071,O
.,2071,O
Acute,2072,O
administration,2072,O
of,2072,O
A-86929,2072,B-Chemical
was,2072,O
as,2072,O
efficacious,2072,O
in,2072,O
alleviating,2072,O
MPTP-induced,2072,B-Chemical
parkinsonism,2072,B-Disease
as,2072,O
levodopa,2072,B-Chemical
and,2072,O
LY-171555,2072,B-Chemical
",",2072,O
but,2072,O
was,2072,O
less,2072,O
likely,2072,O
to,2072,O
reproduce,2072,O
the,2072,O
levodopa-induced,2072,B-Chemical
dyskinesias,2072,B-Disease
in,2072,O
these,2072,O
animals,2072,O
than,2072,O
with,2072,O
either,2072,O
LY-171555,2072,B-Chemical
or,2072,O
subsequent,2072,O
challenge,2072,O
of,2072,O
levodopa,2072,B-Chemical
.,2072,O
Selective,2073,O
stimulation,2073,O
of,2073,O
the,2073,O
DA,2073,B-Chemical
D1,2073,O
receptor,2073,O
may,2073,O
provide,2073,O
better,2073,O
integration,2073,O
of,2073,O
neural,2073,O
inputs,2073,O
transmitted,2073,O
to,2073,O
the,2073,O
internal,2073,O
segment,2073,O
of,2073,O
the,2073,O
globus,2073,O
pallidus,2073,O
(,2073,O
referred,2073,O
to,2073,O
as,2073,O
the,2073,O
basal,2073,O
ganglia,2073,O
output,2073,O
),2073,O
compared,2073,O
with,2073,O
levodopa,2073,B-Chemical
and,2073,O
selective,2073,O
DA,2073,B-Chemical
D2,2073,O
receptor,2073,O
agonist,2073,O
.,2073,O
Potent,2074,O
DA,2074,B-Chemical
D1,2074,O
receptor,2074,O
agents,2074,O
with,2074,O
an,2074,O
intermediate,2074,O
duration,2074,O
of,2074,O
efficacy,2074,O
such,2074,O
as,2074,O
A-86929,2074,B-Chemical
(,2074,O
approximately,2074,O
4,2074,O
hr,2074,O
at,2074,O
higher,2074,O
doses,2074,O
tested,2074,O
),2074,O
are,2074,O
potential,2074,O
therapeutic,2074,O
tools,2074,O
in,2074,O
PD,2074,B-Disease
and,2074,O
merit,2074,O
further,2074,O
attention,2074,O
.,2074,O
Neuropeptide-Y,2075,O
immunoreactivity,2075,O
in,2075,O
the,2075,O
pilocarpine,2075,B-Chemical
model,2075,O
of,2075,O
temporal,2075,B-Disease
lobe,2075,I-Disease
epilepsy,2075,I-Disease
.,2075,O
Neuropeptide-Y,2076,O
(,2076,O
NPY,2076,O
),2076,O
is,2076,O
expressed,2076,O
by,2076,O
granule,2076,O
cells,2076,O
and,2076,O
mossy,2076,O
fibres,2076,O
of,2076,O
the,2076,O
hippocampal,2076,O
dentate,2076,O
gyrus,2076,O
during,2076,O
experimental,2076,O
temporal,2076,B-Disease
lobe,2076,I-Disease
epilepsy,2076,I-Disease
(,2076,O
TLE,2076,B-Disease
),2076,O
.,2076,O
This,2077,O
expression,2077,O
may,2077,O
represent,2077,O
an,2077,O
endogenous,2077,O
damping,2077,O
mechanism,2077,O
since,2077,O
NPY,2077,O
has,2077,O
been,2077,O
shown,2077,O
to,2077,O
block,2077,O
seizure-like,2077,B-Disease
events,2077,O
following,2077,O
high-frequency,2077,O
stimulation,2077,O
in,2077,O
hippocampal,2077,O
slices,2077,O
.,2077,O
The,2078,O
pilocarpine,2078,B-Chemical
(,2078,O
PILO,2078,B-Chemical
),2078,O
model,2078,O
of,2078,O
epilepsy,2078,B-Disease
is,2078,O
characterized,2078,O
by,2078,O
an,2078,O
acute,2078,O
period,2078,O
of,2078,O
status,2078,B-Disease
epilepticus,2078,I-Disease
followed,2078,O
by,2078,O
spontaneous,2078,O
recurrent,2078,O
seizures,2078,B-Disease
and,2078,O
related,2078,O
brain,2078,B-Disease
damage,2078,I-Disease
.,2078,O
We,2079,O
report,2079,O
peroxidase-antiperoxidase,2079,O
immunostaining,2079,O
for,2079,O
NPY,2079,O
in,2079,O
several,2079,O
brain,2079,O
regions,2079,O
in,2079,O
this,2079,O
model,2079,O
.,2079,O
PILO-injected,2080,B-Chemical
animals,2080,O
exhibited,2080,O
NPY,2080,O
immunoreactivity,2080,O
in,2080,O
the,2080,O
region,2080,O
of,2080,O
the,2080,O
mossy,2080,O
fibre,2080,O
terminals,2080,O
",",2080,O
in,2080,O
the,2080,O
dentate,2080,O
gyrus,2080,O
inner,2080,O
molecular,2080,O
layer,2080,O
and,2080,O
",",2080,O
in,2080,O
a,2080,O
few,2080,O
cases,2080,O
",",2080,O
within,2080,O
presumed,2080,O
granule,2080,O
cells,2080,O
.,2080,O
NPY,2081,O
immunoreactivity,2081,O
was,2081,O
also,2081,O
dramatically,2081,O
changed,2081,O
in,2081,O
the,2081,O
entorhinal,2081,O
cortex,2081,O
",",2081,O
amygdala,2081,O
and,2081,O
sensorimotor,2081,O
areas,2081,O
.,2081,O
In,2082,O
addition,2082,O
",",2082,O
PILO,2082,B-Chemical
injected,2082,O
animals,2082,O
exhibited,2082,O
a,2082,O
reduction,2082,O
in,2082,O
the,2082,O
number,2082,O
of,2082,O
NPY-immunoreactive,2082,O
interneurons,2082,O
compared,2082,O
with,2082,O
controls,2082,O
.,2082,O
The,2083,O
results,2083,O
demonstrate,2083,O
that,2083,O
changes,2083,O
in,2083,O
NPY,2083,O
expression,2083,O
",",2083,O
including,2083,O
expression,2083,O
in,2083,O
the,2083,O
granule,2083,O
cells,2083,O
and,2083,O
mossy,2083,O
fibres,2083,O
and,2083,O
the,2083,O
loss,2083,O
of,2083,O
vulnerable,2083,O
NPY,2083,O
neurons,2083,O
",",2083,O
are,2083,O
present,2083,O
in,2083,O
the,2083,O
PILO,2083,B-Chemical
model,2083,O
of,2083,O
TLE,2083,B-Disease
.,2083,O
However,2084,O
",",2084,O
the,2084,O
significance,2084,O
of,2084,O
this,2084,O
changed,2084,O
synthesis,2084,O
of,2084,O
NPY,2084,O
remains,2084,O
to,2084,O
be,2084,O
determined,2084,O
.,2084,O
Posteroventral,2085,O
medial,2085,O
pallidotomy,2085,O
in,2085,O
advanced,2085,O
Parkinson,2085,B-Disease
's,2085,I-Disease
disease,2085,I-Disease
.,2085,O
BACKGROUND,2086,O
:,2086,O
Posteroventral,2086,O
medial,2086,O
pallidotomy,2086,O
sometimes,2086,O
produces,2086,O
striking,2086,O
improvement,2086,O
in,2086,O
patients,2086,O
with,2086,O
advanced,2086,O
Parkinson,2086,B-Disease
's,2086,I-Disease
disease,2086,I-Disease
",",2086,O
but,2086,O
the,2086,O
studies,2086,O
to,2086,O
date,2086,O
have,2086,O
involved,2086,O
small,2086,O
numbers,2086,O
of,2086,O
patients,2086,O
and,2086,O
short-term,2086,O
follow-up,2086,O
.,2086,O
METHODS,2087,O
:,2087,O
Forty,2087,O
patients,2087,O
with,2087,O
Parkinson,2087,B-Disease
's,2087,I-Disease
disease,2087,I-Disease
underwent,2087,O
serial,2087,O
",",2087,O
detailed,2087,O
assessments,2087,O
both,2087,O
after,2087,O
drug,2087,O
withdrawal,2087,O
(,2087,O
``,2087,O
off,2087,O
'',2087,O
period,2087,O
),2087,O
and,2087,O
while,2087,O
taking,2087,O
their,2087,O
optimal,2087,O
medical,2087,O
regimens,2087,O
(,2087,O
``,2087,O
on,2087,I-Disease
'',2087,O
period,2087,O
),2087,O
.,2087,O
All,2088,O
patients,2088,O
were,2088,O
examined,2088,O
preoperatively,2088,O
and,2088,O
39,2088,O
were,2088,O
examined,2088,O
at,2088,O
six,2088,O
months,2088,O
;,2088,O
27,2088,O
of,2088,O
the,2088,O
patients,2088,O
were,2088,O
also,2088,O
examined,2088,O
at,2088,O
one,2088,O
year,2088,O
",",2088,O
and,2088,O
11,2088,O
at,2088,O
two,2088,O
years,2088,O
.,2088,O
RESULTS,2089,O
:,2089,O
The,2089,O
percent,2089,O
improvements,2089,O
at,2089,O
six,2089,O
months,2089,O
were,2089,O
as,2089,O
follows,2089,O
:,2089,O
off-period,2089,O
score,2089,O
for,2089,O
overall,2089,O
motor,2089,O
function,2089,O
",",2089,O
28,2089,O
percent,2089,O
(,2089,O
95,2089,O
percent,2089,O
confidence,2089,O
interval,2089,O
",",2089,O
19,2089,O
to,2089,O
38,2089,O
percent,2089,O
),2089,O
",",2089,O
with,2089,O
most,2089,O
of,2089,O
the,2089,O
improvement,2089,O
in,2089,O
the,2089,O
contralateral,2089,O
limbs,2089,O
;,2089,O
off-period,2089,O
score,2089,O
for,2089,O
activities,2089,O
of,2089,O
daily,2089,O
living,2089,O
",",2089,O
29,2089,O
percent,2089,O
(,2089,O
95,2089,O
percent,2089,O
confidence,2089,O
interval,2089,O
",",2089,O
19,2089,O
to,2089,O
39,2089,O
percent,2089,O
),2089,O
;,2089,O
on-period,2089,O
score,2089,O
for,2089,O
contralateral,2089,O
dyskinesias,2089,B-Disease
",",2089,O
82,2089,O
percent,2089,O
(,2089,O
95,2089,O
percent,2089,O
confidence,2089,O
interval,2089,O
",",2089,O
72,2089,O
to,2089,O
91,2089,O
percent,2089,O
),2089,O
;,2089,O
and,2089,O
on-period,2089,O
score,2089,O
for,2089,O
ipsilateral,2089,O
dyskinesias,2089,B-Disease
",",2089,O
44,2089,O
percent,2089,O
(,2089,O
95,2089,O
percent,2089,O
confidence,2089,O
interval,2089,O
",",2089,O
29,2089,O
to,2089,O
59,2089,O
percent,2089,O
),2089,O
.,2089,O
The,2090,O
improvements,2090,O
in,2090,O
dyskinesias,2090,B-Disease
and,2090,O
the,2090,O
total,2090,O
scores,2090,O
for,2090,O
off-period,2090,O
parkinsonism,2090,B-Disease
",",2090,O
contralateral,2090,O
bradykinesia,2090,B-Disease
",",2090,O
and,2090,O
rigidity,2090,B-Disease
were,2090,O
sustained,2090,O
in,2090,O
the,2090,O
11,2090,O
patients,2090,O
examined,2090,O
at,2090,O
two,2090,O
years,2090,O
.,2090,O
The,2091,O
improvement,2091,O
in,2091,O
ipsilateral,2091,O
dyskinesias,2091,B-Disease
was,2091,O
lost,2091,O
after,2091,O
one,2091,O
year,2091,O
",",2091,O
and,2091,O
the,2091,O
improvements,2091,O
in,2091,O
postural,2091,O
stability,2091,O
and,2091,O
gait,2091,O
lasted,2091,O
only,2091,O
three,2091,O
to,2091,O
six,2091,O
months,2091,O
.,2091,O
Approximately,2092,O
half,2092,O
the,2092,O
patients,2092,O
who,2092,O
had,2092,O
been,2092,O
dependent,2092,O
on,2092,O
assistance,2092,O
in,2092,O
activities,2092,O
of,2092,O
daily,2092,O
living,2092,O
in,2092,O
the,2092,O
off,2092,O
period,2092,O
before,2092,O
surgery,2092,O
became,2092,O
independent,2092,O
after,2092,O
surgery,2092,O
.,2092,O
The,2093,O
complications,2093,O
of,2093,O
surgery,2093,O
were,2093,O
generally,2093,O
well,2093,O
tolerated,2093,O
",",2093,O
and,2093,O
there,2093,O
were,2093,O
no,2093,O
significant,2093,O
changes,2093,O
in,2093,O
the,2093,O
use,2093,O
of,2093,O
medication,2093,O
.,2093,O
CONCLUSIONS,2094,O
:,2094,O
In,2094,O
late-stage,2094,O
Parkinson,2094,B-Disease
's,2094,I-Disease
disease,2094,I-Disease
",",2094,O
pallidotomy,2094,O
significantly,2094,O
reduces,2094,O
levodopa-induced,2094,B-Chemical
dyskinesias,2094,B-Disease
and,2094,O
off-period,2094,O
disability,2094,O
.,2094,O
Much,2095,O
of,2095,O
the,2095,O
benefit,2095,O
is,2095,O
sustained,2095,O
at,2095,O
two,2095,O
years,2095,O
",",2095,O
although,2095,O
some,2095,O
improvements,2095,O
",",2095,O
such,2095,O
as,2095,O
those,2095,O
on,2095,O
the,2095,O
ipsilateral,2095,O
side,2095,O
and,2095,O
in,2095,O
axial,2095,O
symptoms,2095,O
",",2095,O
wane,2095,O
within,2095,O
the,2095,O
first,2095,O
year,2095,O
.,2095,O
The,2096,O
on-period,2096,O
symptoms,2096,O
that,2096,O
are,2096,O
resistant,2096,O
to,2096,O
dopaminergic,2096,O
therapy,2096,O
do,2096,O
not,2096,O
respond,2096,O
to,2096,O
pallidotomy,2096,O
.,2096,O
Clarithromycin-induced,2097,B-Chemical
ventricular,2097,B-Disease
tachycardia,2097,I-Disease
.,2097,O
Clarithromycin,2098,B-Chemical
is,2098,O
a,2098,O
relatively,2098,O
new,2098,O
macrolide,2098,B-Chemical
antibiotic,2098,O
that,2098,O
offers,2098,O
twice-daily,2098,O
dosing,2098,O
.,2098,O
It,2099,O
differs,2099,O
from,2099,O
erythromycin,2099,B-Chemical
only,2099,O
in,2099,O
the,2099,O
methylation,2099,O
of,2099,O
the,2099,O
hydroxyl,2099,O
group,2099,O
at,2099,O
position,2099,O
6,2099,O
.,2099,O
Although,2100,O
the,2100,O
side-effect,2100,O
profile,2100,O
of,2100,O
erythromycin,2100,B-Chemical
is,2100,O
established,2100,O
",",2100,O
including,2100,O
gastroenteritis,2100,B-Disease
and,2100,O
interactions,2100,O
with,2100,O
other,2100,O
drugs,2100,O
subject,2100,O
to,2100,O
hepatic,2100,O
mixed-function,2100,O
oxidase,2100,O
metabolism,2100,O
",",2100,O
experience,2100,O
with,2100,O
the,2100,O
newer,2100,O
macrolides,2100,B-Chemical
is,2100,O
still,2100,O
being,2100,O
recorded,2100,O
.,2100,O
Cardiotoxicity,2101,B-Disease
has,2101,O
been,2101,O
demonstrated,2101,O
after,2101,O
both,2101,O
intravenous,2101,O
and,2101,O
oral,2101,O
administration,2101,O
of,2101,O
erythromycin,2101,B-Chemical
but,2101,O
has,2101,O
never,2101,O
been,2101,O
reported,2101,O
with,2101,O
the,2101,O
newer,2101,O
macrolides,2101,B-Chemical
.,2101,O
We,2102,O
report,2102,O
a,2102,O
case,2102,O
of,2102,O
ventricular,2102,B-Disease
dysrhythmias,2102,I-Disease
that,2102,O
occurred,2102,O
after,2102,O
six,2102,O
therapeutic,2102,O
doses,2102,O
of,2102,O
clarithromycin,2102,B-Chemical
.,2102,O
The,2103,O
dysrhythmias,2103,B-Disease
resolved,2103,O
after,2103,O
discontinuation,2103,O
of,2103,O
the,2103,O
drug,2103,O
.,2103,O
Effect,2104,O
of,2104,O
glyceryl,2104,B-Chemical
trinitrate,2104,I-Chemical
on,2104,O
the,2104,O
sphincter,2104,O
of,2104,O
Oddi,2104,O
spasm,2104,O
evoked,2104,O
by,2104,O
prostigmine-morphine,2104,B-Chemical
administration,2104,O
.,2104,O
OBJECTIVE,2105,O
:,2105,O
In,2105,O
this,2105,O
study,2105,O
the,2105,O
effect,2105,O
of,2105,O
glyceryl,2105,B-Chemical
trinitrate,2105,I-Chemical
on,2105,O
the,2105,O
prostigmine-morphine-induced,2105,B-Chemical
sphincter,2105,O
of,2105,O
Oddi,2105,O
spasm,2105,O
was,2105,O
evaluated,2105,O
in,2105,O
nine,2105,O
female,2105,O
patients,2105,O
with,2105,O
sphincter,2105,B-Disease
of,2105,I-Disease
Oddi,2105,I-Disease
dyskinesia,2105,I-Disease
.,2105,O
METHOD,2106,O
:,2106,O
Sphincter,2106,O
of,2106,O
Oddi,2106,O
spasm,2106,O
was,2106,O
induced,2106,O
by,2106,O
prostigmine-morphine,2106,B-Chemical
administration,2106,O
(,2106,O
0.5,2106,O
mg,2106,O
prostigmine,2106,B-Chemical
intramuscularly,2106,O
and,2106,O
10,2106,O
mg,2106,O
morphine,2106,B-Chemical
subcutaneously,2106,O
),2106,O
and,2106,O
visualized,2106,O
by,2106,O
quantitative,2106,O
hepatobiliary,2106,O
scintigraphy,2106,O
.,2106,O
The,2107,O
entire,2107,O
procedure,2107,O
was,2107,O
repeated,2107,O
during,2107,O
glyceryl,2107,B-Chemical
trinitrate,2107,I-Chemical
infusion,2107,O
(,2107,O
Nitrolingual,2107,B-Chemical
1,2107,O
microg/kg/min,2107,O
for,2107,O
120,2107,O
min,2107,O
),2107,O
.,2107,O
RESULTS,2108,O
:,2108,O
Prostigmine-morphine,2108,B-Chemical
provocation,2108,O
caused,2108,O
significant,2108,O
increases,2108,O
in,2108,O
the,2108,O
time,2108,O
to,2108,O
peak,2108,O
activity,2108,O
(,2108,O
Tmax,2108,O
),2108,O
over,2108,O
the,2108,O
hepatic,2108,O
hilum,2108,O
(,2108,O
HH,2108,O
:,2108,O
34.33,2108,O
+/-,2108,O
5.05,2108,O
vs.,2108,O
22.77,2108,O
+/-,2108,O
3.26,2108,O
),2108,O
and,2108,O
the,2108,O
common,2108,O
bile,2108,O
duct,2108,O
(,2108,O
CBD,2108,O
:,2108,O
60.44,2108,O
+/-,2108,O
5.99,2108,O
vs.,2108,O
40.0,2108,O
+/-,2108,O
2.88,2108,O
),2108,O
and,2108,O
in,2108,O
the,2108,O
half-time,2108,O
of,2108,O
excretion,2108,O
(,2108,O
T1/2,2108,O
),2108,O
over,2108,O
the,2108,O
liver,2108,O
parenchyma,2108,O
(,2108,O
LP,2108,O
:,2108,O
120.04,2108,O
+/-,2108,O
16.01,2108,O
vs.,2108,O
27.37,2108,O
+/-,2108,O
2.19,2108,O
),2108,O
",",2108,O
HH,2108,O
(,2108,O
117.61,2108,O
+/-,2108,O
14.71,2108,O
vs.,2108,O
31.85,2108,O
+/-,2108,O
3.99,2108,O
),2108,O
and,2108,O
CBD,2108,O
(,2108,O
158.11,2108,O
+/-,2108,O
9.18,2108,O
vs.,2108,O
40.1,2108,O
+/-,2108,O
6.24,2108,O
),2108,O
",",2108,O
indicating,2108,O
a,2108,O
complete,2108,O
spasm,2108,B-Disease
at,2108,O
the,2108,O
level,2108,O
of,2108,O
the,2108,O
sphincter,2108,O
of,2108,O
Oddi,2108,O
.,2108,O
Glyceryl,2109,B-Chemical
trinitrate,2109,I-Chemical
infusion,2109,O
completely,2109,O
normalized,2109,O
the,2109,O
prostigmine-morphine-induced,2109,B-Chemical
alterations,2109,O
in,2109,O
these,2109,O
quantitative,2109,O
parameters,2109,O
(,2109,O
TmaX,2109,O
over,2109,O
the,2109,O
LP,2109,O
:,2109,O
11.33,2109,O
+/-,2109,O
1.13,2109,O
;,2109,O
over,2109,O
the,2109,O
HH,2109,O
:,2109,O
18.88,2109,O
+/-,2109,O
1.48,2109,O
;,2109,O
and,2109,O
over,2109,O
the,2109,O
CBD,2109,O
:,2109,O
36.22,2109,O
+/-,2109,O
1.92,2109,O
;,2109,O
and,2109,O
T1/2,2109,O
over,2109,O
the,2109,O
LP,2109,O
:,2109,O
28.21,2109,O
+/-,2109,O
1.83,2109,O
;,2109,O
over,2109,O
the,2109,O
HH,2109,O
:,2109,O
33.42,2109,O
+/-,2109,O
3.10,2109,O
;,2109,O
and,2109,O
over,2109,O
the,2109,O
CBD,2109,O
:,2109,O
41.66,2109,O
+/-,2109,O
6.33,2109,O
),2109,O
",",2109,O
suggesting,2109,O
an,2109,O
effective,2109,O
sphincter-relaxing,2109,O
effect,2109,O
of,2109,O
glyceryl,2109,B-Chemical
trinitrate,2109,I-Chemical
.,2109,O
CONCLUSION,2110,O
:,2110,O
These,2110,O
results,2110,O
provide,2110,O
the,2110,O
first,2110,O
evidence,2110,O
of,2110,O
the,2110,O
effectiveness,2110,O
of,2110,O
glyceryl,2110,B-Chemical
trinitrate,2110,I-Chemical
on,2110,O
the,2110,O
morphine-induced,2110,B-Chemical
sphincter,2110,O
of,2110,O
Oddi,2110,O
spasm,2110,O
in,2110,O
humans,2110,O
.,2110,O
Since,2111,O
glyceryl,2111,B-Chemical
trinitrate,2111,I-Chemical
is,2111,O
able,2111,O
to,2111,O
overcome,2111,O
even,2111,O
the,2111,O
drastic,2111,O
effect,2111,O
of,2111,O
morphine,2111,B-Chemical
",",2111,O
it,2111,O
might,2111,O
be,2111,O
of,2111,O
relevance,2111,O
in,2111,O
the,2111,O
treatment,2111,O
of,2111,O
sphincter,2111,B-Disease
of,2111,I-Disease
Oddi,2111,I-Disease
dyskinesia,2111,I-Disease
.,2111,O
Experimental,2112,O
cranial,2112,O
pain,2112,B-Disease
elicited,2112,O
by,2112,O
capsaicin,2112,B-Chemical
:,2112,O
a,2112,O
PET,2112,O
study,2112,O
.,2112,O
Using,2113,O
a,2113,O
positron,2113,O
emission,2113,O
tomography,2113,O
(,2113,O
PET,2113,O
),2113,O
study,2113,O
it,2113,O
was,2113,O
shown,2113,O
recently,2113,O
that,2113,O
in,2113,O
migraine,2113,B-Disease
without,2113,O
aura,2113,O
certain,2113,O
areas,2113,O
in,2113,O
the,2113,O
brain,2113,O
stem,2113,O
were,2113,O
activated,2113,O
during,2113,O
the,2113,O
headache,2113,B-Disease
state,2113,O
",",2113,O
but,2113,O
not,2113,O
in,2113,O
the,2113,O
headache,2113,B-Disease
free,2113,O
interval,2113,O
.,2113,O
It,2114,O
was,2114,O
suggested,2114,O
that,2114,O
this,2114,O
brain,2114,O
stem,2114,O
activation,2114,O
is,2114,O
inherent,2114,O
to,2114,O
the,2114,O
migraine,2114,B-Disease
attack,2114,O
itself,2114,O
and,2114,O
represents,2114,O
the,2114,O
so,2114,O
called,2114,O
'migraine,2114,O
generator,2114,O
',2114,O
.,2114,O
To,2115,O
test,2115,O
this,2115,O
hypothesis,2115,O
we,2115,O
performed,2115,O
an,2115,O
experimental,2115,O
pain,2115,B-Disease
study,2115,O
in,2115,O
seven,2115,O
healthy,2115,O
volunteers,2115,O
",",2115,O
using,2115,O
the,2115,O
same,2115,O
positioning,2115,O
in,2115,O
the,2115,O
PET,2115,O
scanner,2115,O
as,2115,O
in,2115,O
the,2115,O
migraine,2115,B-Disease
patients,2115,O
.,2115,O
A,2116,O
small,2116,O
amount,2116,O
of,2116,O
capsaicin,2116,B-Chemical
was,2116,O
administered,2116,O
subcutaneously,2116,O
in,2116,O
the,2116,O
right,2116,O
forehead,2116,O
to,2116,O
evoke,2116,O
a,2116,O
burning,2116,O
painful,2116,B-Disease
sensation,2116,O
in,2116,O
the,2116,O
first,2116,O
division,2116,O
of,2116,O
the,2116,O
trigeminal,2116,O
nerve,2116,O
.,2116,O
Increases,2117,O
of,2117,O
regional,2117,O
cerebral,2117,O
blood,2117,O
flow,2117,O
(,2117,O
rCBF,2117,O
),2117,O
were,2117,O
found,2117,O
bilaterally,2117,O
in,2117,O
the,2117,O
insula,2117,O
",",2117,O
in,2117,O
the,2117,O
anterior,2117,O
cingulate,2117,O
cortex,2117,O
",",2117,O
the,2117,O
cavernous,2117,O
sinus,2117,O
and,2117,O
the,2117,O
cerebellum,2117,O
.,2117,O
Using,2118,O
the,2118,O
same,2118,O
stereotactic,2118,O
space,2118,O
limits,2118,O
as,2118,O
in,2118,O
the,2118,O
above,2118,O
mentioned,2118,O
migraine,2118,B-Disease
study,2118,O
no,2118,O
brain,2118,O
stem,2118,O
activation,2118,O
was,2118,O
found,2118,O
in,2118,O
the,2118,O
acute,2118,O
pain,2118,B-Disease
state,2118,O
compared,2118,O
to,2118,O
the,2118,O
pain,2118,B-Disease
free,2118,O
state,2118,O
.,2118,O
The,2119,O
increase,2119,O
of,2119,O
activation,2119,O
in,2119,O
the,2119,O
region,2119,O
of,2119,O
the,2119,O
cavernous,2119,O
sinus,2119,O
however,2119,O
",",2119,O
suggests,2119,O
that,2119,O
this,2119,O
structure,2119,O
is,2119,O
more,2119,O
likely,2119,O
to,2119,O
be,2119,O
involved,2119,O
in,2119,O
trigeminal,2119,O
transmitted,2119,O
pain,2119,B-Disease
as,2119,O
such,2119,O
",",2119,O
rather,2119,O
than,2119,O
in,2119,O
a,2119,O
specific,2119,O
type,2119,O
of,2119,O
headache,2119,B-Disease
as,2119,O
was,2119,O
suggested,2119,O
for,2119,O
cluster,2119,B-Disease
headache,2119,I-Disease
.,2119,O
Value,2120,O
of,2120,O
methylprednisolone,2120,B-Chemical
in,2120,O
prevention,2120,O
of,2120,O
the,2120,O
arthralgia-myalgia,2120,B-Disease
syndrome,2120,O
associated,2120,O
with,2120,O
the,2120,O
total,2120,O
dose,2120,O
infusion,2120,O
of,2120,O
iron,2120,B-Chemical
dextran,2120,I-Chemical
:,2120,O
a,2120,O
double,2120,O
blind,2120,O
randomized,2120,O
trial,2120,O
.,2120,O
The,2121,O
safety,2121,O
and,2121,O
efficacy,2121,O
of,2121,O
total,2121,O
dose,2121,O
infusion,2121,O
(,2121,O
TDI,2121,O
),2121,O
of,2121,O
iron,2121,B-Chemical
dextran,2121,I-Chemical
has,2121,O
been,2121,O
well,2121,O
documented,2121,O
.,2121,O
In,2122,O
40,2122,O
%,2122,O
of,2122,O
treated,2122,O
patients,2122,O
",",2122,O
an,2122,O
arthralgia-myalgia,2122,B-Disease
syndrome,2122,O
develops,2122,O
.,2122,O
The,2123,O
purpose,2123,O
of,2123,O
this,2123,O
randomized,2123,O
",",2123,O
double-blind,2123,O
",",2123,O
prospective,2123,O
study,2123,O
was,2123,O
to,2123,O
investigate,2123,O
whether,2123,O
intravenous,2123,O
(,2123,O
i.v,2123,O
.,2123,O
),2123,O
administration,2124,O
of,2124,O
methylprednisolone,2124,B-Chemical
(,2124,O
MP,2124,B-Chemical
),2124,O
prevents,2124,O
this,2124,O
complication,2124,O
.,2124,O
Sixty-five,2125,O
patients,2125,O
",",2125,O
34,2125,O
women,2125,O
and,2125,O
31,2125,O
men,2125,O
",",2125,O
ages,2125,O
36,2125,O
to,2125,O
80,2125,O
years,2125,O
",",2125,O
received,2125,O
either,2125,O
normal,2125,O
saline,2125,O
before,2125,O
and,2125,O
after,2125,O
TDI,2125,O
(,2125,O
group,2125,O
1,2125,O
),2125,O
",",2125,O
125,2125,O
mg,2125,O
i.v,2125,O
.,2125,O
MP,2126,B-Chemical
before,2126,O
and,2126,O
saline,2126,O
after,2126,O
TDI,2126,O
(,2126,O
group,2126,O
2,2126,O
),2126,O
",",2126,O
or,2126,O
125,2126,O
mg,2126,O
i.v,2126,O
.,2126,O
MP,2127,B-Chemical
before,2127,O
and,2127,O
after,2127,O
TDI,2127,O
(,2127,O
group,2127,O
3,2127,O
),2127,O
.,2127,O
Patients,2128,O
were,2128,O
observed,2128,O
for,2128,O
72,2128,O
hours,2128,O
and,2128,O
reactions,2128,O
were,2128,O
recorded,2128,O
and,2128,O
graded,2128,O
according,2128,O
to,2128,O
severity,2128,O
.,2128,O
Fifty-eight,2129,O
percent,2129,O
of,2129,O
group,2129,O
1,2129,O
patients,2129,O
",",2129,O
33,2129,O
%,2129,O
of,2129,O
group,2129,O
2,2129,O
",",2129,O
and,2129,O
26,2129,O
%,2129,O
of,2129,O
group,2129,O
3,2129,O
had,2129,O
reactions,2129,O
to,2129,O
TDI,2129,O
.,2129,O
The,2130,O
severity,2130,O
of,2130,O
reactions,2130,O
(,2130,O
minimal,2130,O
",",2130,O
mild,2130,O
",",2130,O
and,2130,O
moderate,2130,O
",",2130,O
respectively,2130,O
),2130,O
was,2130,O
as,2130,O
follows,2130,O
:,2130,O
group,2130,O
1,2130,O
--,2130,O
6,2130,O
",",2130,O
6,2130,O
",",2130,O
and,2130,O
2,2130,O
;,2130,O
group,2130,O
2,2130,O
--,2130,O
1,2130,O
",",2130,O
5,2130,O
",",2130,O
and,2130,O
0,2130,O
;,2130,O
group,2130,O
3,2130,O
--,2130,O
5,2130,O
",",2130,O
1,2130,O
",",2130,O
and,2130,O
0,2130,O
.,2130,O
Data,2131,O
were,2131,O
analyzed,2131,O
by,2131,O
the,2131,O
two-sided,2131,O
Fisher,2131,O
's,2131,O
exact,2131,O
test,2131,O
using,2131,O
95,2131,O
%,2131,O
confidence,2131,O
intervals,2131,O
with,2131,O
the,2131,O
approximation,2131,O
of,2131,O
Woolf,2131,O
.,2131,O
These,2132,O
data,2132,O
demonstrate,2132,O
that,2132,O
administration,2132,O
of,2132,O
MP,2132,B-Chemical
before,2132,O
and,2132,O
after,2132,O
TDI,2132,O
reduces,2132,O
the,2132,O
frequency,2132,O
and,2132,O
severity,2132,O
of,2132,O
the,2132,O
arthralgia-myalgia,2132,B-Disease
syndrome,2132,O
.,2132,O
We,2133,O
conclude,2133,O
that,2133,O
125,2133,O
mg,2133,O
i.v,2133,O
.,2133,O
MP,2134,B-Chemical
should,2134,O
be,2134,O
given,2134,O
routinely,2134,O
before,2134,O
and,2134,O
after,2134,O
TDI,2134,O
of,2134,O
iron,2134,B-Chemical
dextran,2134,I-Chemical
.,2134,O
Prolongation,2135,B-Disease
of,2135,I-Disease
the,2135,I-Disease
QT,2135,I-Disease
interval,2135,I-Disease
related,2135,O
to,2135,O
cisapride-diltiazem,2135,B-Chemical
interaction,2135,O
.,2135,O
Cisapride,2136,B-Chemical
",",2136,O
a,2136,O
cytochrome,2136,O
P450,2136,O
3A4,2136,O
(,2136,O
CYP3A4,2136,O
),2136,O
substrate,2136,O
",",2136,O
is,2136,O
widely,2136,O
prescribed,2136,O
for,2136,O
the,2136,O
treatment,2136,O
of,2136,O
gastrointestinal,2136,B-Disease
motility,2136,I-Disease
disorders,2136,I-Disease
.,2136,O
Prolongation,2137,B-Disease
of,2137,I-Disease
QT,2137,I-Disease
interval,2137,I-Disease
",",2137,O
torsades,2137,B-Disease
de,2137,I-Disease
pointes,2137,I-Disease
",",2137,O
and,2137,O
sudden,2137,B-Disease
cardiac,2137,I-Disease
death,2137,I-Disease
have,2137,O
been,2137,O
reported,2137,O
after,2137,O
concomitant,2137,O
administration,2137,O
with,2137,O
erythromycin,2137,B-Chemical
or,2137,O
azole,2137,B-Chemical
antifungal,2137,O
agents,2137,O
",",2137,O
but,2137,O
not,2137,O
with,2137,O
other,2137,O
CYP3A4,2137,O
inhibitors,2137,O
.,2137,O
A,2138,O
possible,2138,O
drug,2138,O
interaction,2138,O
occurred,2138,O
in,2138,O
a,2138,O
45-year-old,2138,O
woman,2138,O
who,2138,O
was,2138,O
taking,2138,O
cisapride,2138,B-Chemical
for,2138,O
gastroesophageal,2138,B-Disease
reflux,2138,I-Disease
disorder,2138,I-Disease
and,2138,O
diltiazem,2138,B-Chemical
",",2138,O
an,2138,O
agent,2138,O
that,2138,O
has,2138,O
inhibitory,2138,O
effect,2138,O
on,2138,O
CYP3A4,2138,O
",",2138,O
for,2138,O
hypertension,2138,B-Disease
.,2138,O
The,2139,O
patient,2139,O
was,2139,O
in,2139,O
near,2139,O
syncope,2139,B-Disease
and,2139,O
had,2139,O
QT-interval,2139,B-Disease
prolongation,2139,I-Disease
.,2139,O
After,2140,O
discontinuing,2140,O
cisapride,2140,B-Chemical
",",2140,O
the,2140,O
QT,2140,O
interval,2140,O
returned,2140,O
to,2140,O
normal,2140,O
and,2140,O
symptoms,2140,O
did,2140,O
not,2140,O
recur,2140,O
.,2140,O
We,2141,O
suggest,2141,O
that,2141,O
caution,2141,O
be,2141,O
taken,2141,O
when,2141,O
cisapride,2141,B-Chemical
is,2141,O
prescribed,2141,O
with,2141,O
any,2141,O
potent,2141,O
inhibitor,2141,O
of,2141,O
CYP3A4,2141,O
",",2141,O
including,2141,O
diltiazem,2141,B-Chemical
.,2141,O
Cortical,2142,O
motor,2142,O
overactivation,2142,O
in,2142,O
parkinsonian,2142,B-Disease
patients,2142,O
with,2142,O
L-dopa-induced,2142,B-Chemical
peak-dose,2142,O
dyskinesia,2142,B-Disease
.,2142,O
We,2143,O
have,2143,O
studied,2143,O
the,2143,O
regional,2143,O
cerebral,2143,O
blood,2143,O
flow,2143,O
(,2143,O
rCBF,2143,O
),2143,O
changes,2143,O
induced,2143,O
by,2143,O
the,2143,O
execution,2143,O
of,2143,O
a,2143,O
finger-to-thumb,2143,O
opposition,2143,O
motor,2143,O
task,2143,O
in,2143,O
the,2143,O
supplementary,2143,O
and,2143,O
primary,2143,O
motor,2143,O
cortex,2143,O
of,2143,O
two,2143,O
groups,2143,O
of,2143,O
parkinsonian,2143,B-Disease
patients,2143,O
on,2143,O
L-dopa,2143,B-Chemical
medication,2143,O
",",2143,O
the,2143,O
first,2143,O
one,2143,O
without,2143,O
L-dopa,2143,B-Chemical
induced,2143,O
dyskinesia,2143,B-Disease
(,2143,O
n,2143,O
=,2143,O
23,2143,O
),2143,O
and,2143,O
the,2143,O
other,2143,O
with,2143,O
moderate,2143,O
peak-dose,2143,O
dyskinesia,2143,B-Disease
(,2143,O
n,2143,O
=,2143,O
15,2143,O
),2143,O
",",2143,O
and,2143,O
of,2143,O
a,2143,O
group,2143,O
of,2143,O
14,2143,O
normal,2143,O
subjects,2143,O
.,2143,O
Single,2144,O
photon,2144,O
emission,2144,O
tomography,2144,O
with,2144,O
i.v,2144,O
.,2144,O
133Xe,2145,O
was,2145,O
used,2145,O
to,2145,O
measure,2145,O
the,2145,O
rCBF,2145,O
changes,2145,O
.,2145,O
The,2146,O
dyskinetic,2146,B-Disease
parkinsonian,2146,B-Disease
patients,2146,O
exhibited,2146,O
a,2146,O
pattern,2146,O
of,2146,O
response,2146,O
which,2146,O
was,2146,O
markedly,2146,O
different,2146,O
from,2146,O
those,2146,O
of,2146,O
the,2146,O
normal,2146,O
subjects,2146,O
and,2146,O
non-dyskinetic,2146,O
parkinsonian,2146,B-Disease
patients,2146,O
",",2146,O
with,2146,O
a,2146,O
significant,2146,O
overactivation,2146,O
in,2146,O
the,2146,O
supplementary,2146,O
motor,2146,O
area,2146,O
and,2146,O
the,2146,O
ipsi-,2146,O
and,2146,O
contralateral,2146,O
primary,2146,O
motor,2146,O
areas,2146,O
.,2146,O
These,2147,O
results,2147,O
are,2147,O
compatible,2147,O
with,2147,O
the,2147,O
hypothesis,2147,O
that,2147,O
an,2147,O
hyperkinetic,2147,B-Disease
abnormal,2147,B-Disease
involuntary,2147,I-Disease
movement,2147,I-Disease
",",2147,O
like,2147,O
L-dopa-induced,2147,B-Chemical
peak,2147,O
dose,2147,O
dyskinesia,2147,B-Disease
",",2147,O
is,2147,O
due,2147,O
to,2147,O
a,2147,O
disinhibition,2147,O
of,2147,O
the,2147,O
primary,2147,O
and,2147,O
associated,2147,O
motor,2147,O
cortex,2147,O
secondary,2147,O
to,2147,O
an,2147,O
excessive,2147,O
outflow,2147,O
of,2147,O
the,2147,O
pallidothalamocortical,2147,O
motor,2147,O
loop,2147,O
.,2147,O
Open-label,2148,O
assessment,2148,O
of,2148,O
levofloxacin,2148,B-Chemical
for,2148,O
the,2148,O
treatment,2148,O
of,2148,O
acute,2148,O
bacterial,2148,O
sinusitis,2148,B-Disease
in,2148,O
adults,2148,O
.,2148,O
PURPOSE,2149,O
:,2149,O
To,2149,O
evaluate,2149,O
the,2149,O
efficacy,2149,O
and,2149,O
safety,2149,O
of,2149,O
levofloxacin,2149,B-Chemical
(,2149,O
500,2149,O
mg,2149,O
orally,2149,O
once,2149,O
daily,2149,O
for,2149,O
10,2149,O
to,2149,O
14,2149,O
days,2149,O
),2149,O
in,2149,O
treating,2149,O
adult,2149,O
outpatients,2149,O
with,2149,O
acute,2149,O
bacterial,2149,O
sinusitis,2149,B-Disease
.,2149,O
PATIENTS,2150,O
AND,2150,O
METHODS,2150,O
:,2150,O
A,2150,O
total,2150,O
of,2150,O
329,2150,O
patients,2150,O
enrolled,2150,O
in,2150,O
the,2150,O
study,2150,O
at,2150,O
24,2150,O
centers,2150,O
.,2150,O
All,2151,O
patients,2151,O
had,2151,O
a,2151,O
pre-therapy,2151,O
Gram,2151,O
's,2151,O
stain,2151,O
and,2151,O
culture,2151,O
of,2151,O
sinus,2151,O
exudate,2151,O
obtained,2151,O
by,2151,O
antral,2151,O
puncture,2151,O
or,2151,O
nasal,2151,O
endoscopy,2151,O
.,2151,O
Clinical,2152,O
response,2152,O
was,2152,O
assessed,2152,O
on,2152,O
the,2152,O
basis,2152,O
of,2152,O
signs,2152,O
and,2152,O
symptoms,2152,O
and,2152,O
sinus,2152,O
radiograph,2152,O
or,2152,O
computed,2152,O
tomography,2152,O
results,2152,O
.,2152,O
Microbiologic,2153,O
cure,2153,O
rates,2153,O
were,2153,O
determined,2153,O
on,2153,O
the,2153,O
basis,2153,O
of,2153,O
presumed,2153,O
plus,2153,O
documented,2153,O
eradication,2153,O
of,2153,O
the,2153,O
pre-therapy,2153,O
pathogen,2153,O
(,2153,O
s,2153,O
),2153,O
.,2153,O
RESULTS,2154,O
:,2154,O
The,2154,O
most,2154,O
common,2154,O
pathogens,2154,O
were,2154,O
Haemophilus,2154,O
influenzae,2154,O
",",2154,O
Streptococcus,2154,O
pneumoniae,2154,O
",",2154,O
Staphylococcus,2154,O
aureus,2154,O
",",2154,O
and,2154,O
Moraxella,2154,O
catarrhalis,2154,O
.,2154,O
Of,2155,O
300,2155,O
clinically,2155,O
evaluable,2155,O
patients,2155,O
",",2155,O
175,2155,O
(,2155,O
58,2155,O
%,2155,O
),2155,O
were,2155,O
cured,2155,O
and,2155,O
90,2155,O
(,2155,O
30,2155,O
%,2155,O
),2155,O
were,2155,O
improved,2155,O
at,2155,O
the,2155,O
post-therapy,2155,O
evaluation,2155,O
",",2155,O
resulting,2155,O
in,2155,O
a,2155,O
clinical,2155,O
success,2155,O
rate,2155,O
of,2155,O
88,2155,O
%,2155,O
.,2155,O
Thirty-five,2156,O
patients,2156,O
(,2156,O
12,2156,O
%,2156,O
),2156,O
clinically,2156,O
failed,2156,O
treatment,2156,O
.,2156,O
The,2157,O
microbiologic,2157,O
eradication,2157,O
rate,2157,O
(,2157,O
presumed,2157,O
plus,2157,O
documented,2157,O
),2157,O
among,2157,O
138,2157,O
microbiologically,2157,O
evaluable,2157,O
patients,2157,O
was,2157,O
92,2157,O
%,2157,O
.,2157,O
Microbiologic,2158,O
eradication,2158,O
rates,2158,O
(,2158,O
presumed,2158,O
plus,2158,O
documented,2158,O
),2158,O
of,2158,O
the,2158,O
most,2158,O
common,2158,O
pathogens,2158,O
ranged,2158,O
from,2158,O
93,2158,O
%,2158,O
(,2158,O
M.,2158,O
catarrhalis,2158,O
),2158,O
to,2158,O
100,2158,O
%,2158,O
(,2158,O
S.,2158,O
pneumoniae,2158,O
),2158,O
at,2158,O
the,2158,O
post-therapy,2158,O
visit,2158,O
.,2158,O
All,2159,O
but,2159,O
one,2159,O
of,2159,O
the,2159,O
265,2159,O
patients,2159,O
who,2159,O
were,2159,O
cured,2159,O
or,2159,O
improved,2159,O
at,2159,O
post-therapy,2159,O
returned,2159,O
for,2159,O
a,2159,O
long-term,2159,O
follow-up,2159,O
visit,2159,O
;,2159,O
243,2159,O
(,2159,O
92,2159,O
%,2159,O
),2159,O
remained,2159,O
well,2159,O
4,2159,O
to,2159,O
6,2159,O
weeks,2159,O
after,2159,O
therapy,2159,O
;,2159,O
and,2159,O
21,2159,O
(,2159,O
8,2159,O
%,2159,O
),2159,O
had,2159,O
a,2159,O
relapse,2159,O
of,2159,O
symptoms,2159,O
.,2159,O
Adverse,2160,O
events,2160,O
considered,2160,O
to,2160,O
be,2160,O
related,2160,O
to,2160,O
levofloxacin,2160,B-Chemical
administration,2160,O
were,2160,O
reported,2160,O
by,2160,O
29,2160,O
patients,2160,O
(,2160,O
9,2160,O
%,2160,O
),2160,O
.,2160,O
The,2161,O
most,2161,O
common,2161,O
drug-related,2161,O
adverse,2161,O
events,2161,O
were,2161,O
diarrhea,2161,B-Disease
",",2161,O
flatulence,2161,B-Disease
",",2161,O
and,2161,O
nausea,2161,B-Disease
;,2161,O
most,2161,O
adverse,2161,O
events,2161,O
were,2161,O
mild,2161,O
to,2161,O
moderate,2161,O
in,2161,O
severity,2161,O
.,2161,O
CONCLUSION,2162,O
:,2162,O
The,2162,O
results,2162,O
of,2162,O
this,2162,O
study,2162,O
indicate,2162,O
that,2162,O
levofloxacin,2162,B-Chemical
500,2162,O
mg,2162,O
once,2162,O
daily,2162,O
is,2162,O
an,2162,O
effective,2162,O
and,2162,O
safe,2162,O
treatment,2162,O
for,2162,O
acute,2162,O
bacterial,2162,O
sinusitis,2162,B-Disease
.,2162,O
Iatrogenic,2163,O
risks,2163,O
of,2163,O
endometrial,2163,B-Disease
carcinoma,2163,I-Disease
after,2163,O
treatment,2163,O
for,2163,O
breast,2163,B-Disease
cancer,2163,I-Disease
in,2163,O
a,2163,O
large,2163,O
French,2163,O
case-control,2163,O
study,2163,O
.,2163,O
F,2164,O
d,2164,O
ration,2164,O
Nationale,2164,O
des,2164,O
Centres,2164,O
de,2164,O
Lutte,2164,O
Contre,2164,O
le,2164,O
Cancer,2164,O
(,2164,O
FNCLCC,2164,O
),2164,O
.,2164,O
Since,2165,O
tamoxifen,2165,B-Chemical
is,2165,O
widely,2165,O
used,2165,O
in,2165,O
breast,2165,B-Disease
cancer,2165,I-Disease
treatment,2165,O
and,2165,O
has,2165,O
been,2165,O
proposed,2165,O
for,2165,O
the,2165,O
prevention,2165,O
of,2165,O
breast,2165,B-Disease
cancer,2165,I-Disease
",",2165,O
its,2165,O
endometrial,2165,O
iatrogenic,2165,O
effects,2165,O
must,2165,O
be,2165,O
carefully,2165,O
examined,2165,O
.,2165,O
We,2166,O
have,2166,O
investigated,2166,O
the,2166,O
association,2166,O
between,2166,O
endometrial,2166,B-Disease
cancer,2166,I-Disease
and,2166,O
tamoxifen,2166,B-Chemical
use,2166,O
or,2166,O
other,2166,O
treatments,2166,O
in,2166,O
women,2166,O
treated,2166,O
for,2166,O
breast,2166,B-Disease
cancer,2166,I-Disease
in,2166,O
a,2166,O
case-control,2166,O
study,2166,O
.,2166,O
Cases,2167,O
of,2167,O
endometrial,2167,B-Disease
cancer,2167,I-Disease
diagnosed,2167,O
after,2167,O
breast,2167,B-Disease
cancer,2167,I-Disease
(,2167,O
n,2167,O
=,2167,O
135,2167,O
),2167,O
and,2167,O
467,2167,O
controls,2167,O
matched,2167,O
for,2167,O
age,2167,O
",",2167,O
year,2167,O
of,2167,O
diagnosis,2167,O
of,2167,O
breast,2167,B-Disease
cancer,2167,I-Disease
and,2167,O
hospital,2167,O
and,2167,O
survival,2167,O
time,2167,O
with,2167,O
an,2167,O
intact,2167,O
uterus,2167,O
were,2167,O
included,2167,O
.,2167,O
Women,2168,O
who,2168,O
had,2168,O
received,2168,O
tamoxifen,2168,B-Chemical
were,2168,O
significantly,2168,O
more,2168,O
likely,2168,O
to,2168,O
have,2168,O
endometrial,2168,B-Disease
cancer,2168,I-Disease
diagnosed,2168,O
than,2168,O
those,2168,O
who,2168,O
had,2168,O
not,2168,O
(,2168,O
crude,2168,O
relative,2168,O
risk,2168,O
=,2168,O
4.9,2168,O
",",2168,O
p,2168,O
=,2168,O
0.0001,2168,O
),2168,O
.,2168,O
Univariate,2169,O
and,2169,O
adjusted,2169,O
analyses,2169,O
showed,2169,O
that,2169,O
the,2169,O
risk,2169,O
increased,2169,O
with,2169,O
the,2169,O
length,2169,O
of,2169,O
treatment,2169,O
(,2169,O
p,2169,O
=,2169,O
0.0001,2169,O
),2169,O
or,2169,O
the,2169,O
cumulative,2169,O
dose,2169,O
of,2169,O
tamoxifen,2169,B-Chemical
received,2169,O
(,2169,O
p,2169,O
=,2169,O
0.0001,2169,O
),2169,O
",",2169,O
irrespective,2169,O
of,2169,O
the,2169,O
daily,2169,O
dose,2169,O
.,2169,O
Women,2170,O
who,2170,O
had,2170,O
undergone,2170,O
pelvic,2170,O
radiotherapy,2170,O
also,2170,O
had,2170,O
a,2170,O
higher,2170,O
risk,2170,O
(,2170,O
crude,2170,O
relative,2170,O
risk,2170,O
=,2170,O
7.8,2170,O
",",2170,O
p,2170,O
=,2170,O
0.0001,2170,O
),2170,O
.,2170,O
After,2171,O
adjusting,2171,O
for,2171,O
confounding,2171,O
factors,2171,O
",",2171,O
the,2171,O
risk,2171,O
was,2171,O
higher,2171,O
for,2171,O
tamoxifen,2171,B-Chemical
users,2171,O
(,2171,O
p,2171,O
=,2171,O
0.0012,2171,O
),2171,O
",",2171,O
treatment,2171,O
for,2171,O
more,2171,O
than,2171,O
3,2171,O
years,2171,O
(,2171,O
all,2171,O
p,2171,O
<,2171,O
0.03,2171,O
),2171,O
and,2171,O
pelvic,2171,O
radiotherapy,2171,O
(,2171,O
p,2171,O
=,2171,O
0.012,2171,O
),2171,O
.,2171,O
Women,2172,O
who,2172,O
had,2172,O
endometrial,2172,B-Disease
cancer,2172,I-Disease
and,2172,O
had,2172,O
received,2172,O
tamoxifen,2172,B-Chemical
had,2172,O
more,2172,O
advanced,2172,B-Disease
disease,2172,I-Disease
and,2172,O
poorer,2172,O
prognosis,2172,O
than,2172,O
those,2172,O
with,2172,O
endometrial,2172,B-Disease
cancer,2172,I-Disease
who,2172,O
had,2172,O
not,2172,O
received,2172,O
this,2172,O
treatment,2172,O
.,2172,O
Our,2173,O
results,2173,O
suggest,2173,O
a,2173,O
causal,2173,O
role,2173,O
of,2173,O
tamoxifen,2173,B-Chemical
in,2173,O
endometrial,2173,B-Disease
cancer,2173,I-Disease
",",2173,O
particularly,2173,O
when,2173,O
used,2173,O
as,2173,O
currently,2173,O
proposed,2173,O
for,2173,O
breast,2173,B-Disease
cancer,2173,I-Disease
prevention,2173,O
.,2173,O
Pelvic,2174,O
radiotherapy,2174,O
may,2174,O
be,2174,O
an,2174,O
additional,2174,O
iatrogenic,2174,O
factor,2174,O
for,2174,O
women,2174,O
with,2174,O
breast,2174,B-Disease
cancer,2174,I-Disease
.,2174,O
Endometrial,2175,B-Disease
cancers,2175,I-Disease
diagnosed,2175,O
in,2175,O
women,2175,O
treated,2175,O
with,2175,O
tamoxifen,2175,B-Chemical
have,2175,O
poorer,2175,O
prognosis,2175,O
.,2175,O
Women,2176,O
who,2176,O
receive,2176,O
tamoxifen,2176,B-Chemical
for,2176,O
breast,2176,B-Disease
cancer,2176,I-Disease
should,2176,O
be,2176,O
offered,2176,O
gynaecological,2176,O
surveillance,2176,O
during,2176,O
and,2176,O
after,2176,O
treatment,2176,O
.,2176,O
A,2177,O
long-term,2177,O
evaluation,2177,O
of,2177,O
the,2177,O
risk-benefit,2177,O
ratio,2177,O
of,2177,O
tamoxifen,2177,B-Chemical
as,2177,O
a,2177,O
preventive,2177,O
treatment,2177,O
for,2177,O
breast,2177,B-Disease
cancer,2177,I-Disease
is,2177,O
clearly,2177,O
warranted,2177,O
.,2177,O
Contribution,2178,O
of,2178,O
the,2178,O
glycine,2178,B-Chemical
site,2178,O
of,2178,O
NMDA,2178,B-Chemical
receptors,2178,O
in,2178,O
rostral,2178,O
and,2178,O
intermediate-caudal,2178,O
parts,2178,O
of,2178,O
the,2178,O
striatum,2178,O
to,2178,O
the,2178,O
regulation,2178,O
of,2178,O
muscle,2178,O
tone,2178,O
in,2178,O
rats,2178,O
.,2178,O
The,2179,O
aim,2179,O
of,2179,O
the,2179,O
present,2179,O
study,2179,O
was,2179,O
to,2179,O
assess,2179,O
the,2179,O
contribution,2179,O
of,2179,O
the,2179,O
glycine,2179,B-Chemical
site,2179,O
of,2179,O
NMDA,2179,B-Chemical
receptors,2179,O
in,2179,O
the,2179,O
striatum,2179,O
to,2179,O
the,2179,O
regulation,2179,O
of,2179,O
muscle,2179,O
tone,2179,O
.,2179,O
Muscle,2180,O
tone,2180,O
was,2180,O
examined,2180,O
using,2180,O
a,2180,O
combined,2180,O
mechanoand,2180,O
electromyographic,2180,O
method,2180,O
",",2180,O
which,2180,O
measured,2180,O
simultaneously,2180,O
the,2180,O
muscle,2180,O
resistance,2180,O
(,2180,O
MMG,2180,O
),2180,O
of,2180,O
the,2180,O
rat,2180,O
's,2180,O
hind,2180,O
foot,2180,O
to,2180,O
passive,2180,O
extension,2180,O
and,2180,O
flexion,2180,O
in,2180,O
the,2180,O
ankle,2180,O
joint,2180,O
and,2180,O
the,2180,O
electromyographic,2180,O
activity,2180,O
(,2180,O
EMG,2180,O
),2180,O
of,2180,O
the,2180,O
antagonistic,2180,O
muscles,2180,O
of,2180,O
that,2180,O
joint,2180,O
:,2180,O
gastrocnemius,2180,O
and,2180,O
tibialis,2180,O
anterior,2180,O
.,2180,O
Muscle,2181,B-Disease
rigidity,2181,I-Disease
was,2181,O
induced,2181,O
by,2181,O
haloperidol,2181,B-Chemical
(,2181,O
2.5,2181,O
mg/kg,2181,O
i.p,2181,O
.,2181,O
),2181,O
.,2181,O
"5,7-dichlorokynurenic",2182,B-Chemical
acid,2182,I-Chemical
(,2182,O
"5,7-DCKA",2182,B-Chemical
),2182,O
",",2182,O
a,2182,O
selective,2182,O
glycine,2182,B-Chemical
site,2182,O
antagonist,2182,O
",",2182,O
injected,2182,O
in,2182,O
doses,2182,O
of,2182,O
2.5,2182,O
and,2182,O
4.5,2182,O
microg/0.5,2182,O
microl,2182,O
bilaterally,2182,O
",",2182,O
into,2182,O
the,2182,O
rostral,2182,O
region,2182,O
of,2182,O
the,2182,O
striatum,2182,O
",",2182,O
decreased,2182,O
both,2182,O
the,2182,O
haloperidol-induced,2182,B-Chemical
muscle,2182,B-Disease
rigidity,2182,I-Disease
(,2182,O
MMG,2182,O
),2182,O
and,2182,O
the,2182,O
enhanced,2182,O
electromyographic,2182,O
activity,2182,O
(,2182,O
EMG,2182,O
),2182,O
.,2182,O
"5,7-DCKA",2183,B-Chemical
injected,2183,O
bilaterally,2183,O
in,2183,O
a,2183,O
dose,2183,O
of,2183,O
4.5,2183,O
microg/0.5,2183,O
microl,2183,O
into,2183,O
the,2183,O
intermediate-caudal,2183,O
region,2183,O
of,2183,O
the,2183,O
striatum,2183,O
of,2183,O
rats,2183,O
not,2183,O
pretreated,2183,O
with,2183,O
haloperidol,2183,B-Chemical
had,2183,O
no,2183,O
effect,2183,O
on,2183,O
the,2183,O
muscle,2183,O
tone,2183,O
.,2183,O
The,2184,O
present,2184,O
results,2184,O
suggest,2184,O
that,2184,O
blockade,2184,O
of,2184,O
the,2184,O
glycine,2184,B-Chemical
site,2184,O
of,2184,O
NMDA,2184,B-Chemical
receptors,2184,O
in,2184,O
the,2184,O
rostral,2184,O
part,2184,O
of,2184,O
the,2184,O
striatum,2184,O
may,2184,O
be,2184,O
mainly,2184,O
responsible,2184,O
for,2184,O
the,2184,O
antiparkinsonian,2184,O
action,2184,O
of,2184,O
this,2184,O
drug,2184,O
.,2184,O
Carboplatin,2185,B-Chemical
toxic,2185,O
effects,2185,O
on,2185,O
the,2185,O
peripheral,2185,O
nervous,2185,O
system,2185,O
of,2185,O
the,2185,O
rat,2185,O
.,2185,O
BACKGROUND,2186,O
:,2186,O
The,2186,O
most,2186,O
striking,2186,O
of,2186,O
carboplatin,2186,B-Chemical
's,2186,O
advantages,2186,O
(,2186,O
CBDCA,2186,B-Chemical
),2186,O
over,2186,O
cisplatin,2186,B-Chemical
(,2186,O
CDDP,2186,B-Chemical
),2186,O
is,2186,O
its,2186,O
markedly,2186,O
reduced,2186,O
rate,2186,O
of,2186,O
neurotoxic,2186,B-Disease
effects,2186,O
.,2186,O
However,2187,O
",",2187,O
the,2187,O
use,2187,O
of,2187,O
CBDCA,2187,B-Chemical
higher-intensity,2187,O
schedules,2187,O
and,2187,O
the,2187,O
association,2187,O
with,2187,O
other,2187,O
neurotoxic,2187,B-Disease
drugs,2187,O
in,2187,O
polychemotherapy,2187,O
may,2187,O
cause,2187,O
some,2187,O
concern,2187,O
about,2187,O
its,2187,O
safety,2187,O
with,2187,O
respect,2187,O
to,2187,O
peripheral,2187,B-Disease
nervous,2187,I-Disease
system,2187,I-Disease
damage,2187,I-Disease
.,2187,O
MATERIALS,2188,O
AND,2188,O
METHODS,2188,O
:,2188,O
Two,2188,O
different,2188,O
schedules,2188,O
of,2188,O
CBDCA,2188,B-Chemical
administration,2188,O
(,2188,O
10,2188,O
mg/kg,2188,O
and,2188,O
15,2188,O
mg/kg,2188,O
i.p,2188,O
.,2188,O
twice,2189,O
a,2189,O
week,2189,O
for,2189,O
nine,2189,O
times,2189,O
),2189,O
were,2189,O
evaluated,2189,O
in,2189,O
Wistar,2189,O
rats,2189,O
.,2189,O
Neurotoxicity,2190,B-Disease
was,2190,O
assessed,2190,O
for,2190,O
behavioral,2190,O
(,2190,O
tail-flick,2190,O
test,2190,O
),2190,O
",",2190,O
neurophysiological,2190,O
(,2190,O
nerve,2190,O
conduction,2190,O
velocity,2190,O
in,2190,O
the,2190,O
tail,2190,O
nerve,2190,O
),2190,O
",",2190,O
morphological,2190,O
",",2190,O
morphometrical,2190,O
and,2190,O
analytical,2190,O
effects,2190,O
.,2190,O
RESULTS,2191,O
:,2191,O
CBDCA,2191,B-Chemical
administration,2191,O
induced,2191,O
dose-dependent,2191,O
peripheral,2191,B-Disease
neurotoxicity,2191,I-Disease
.,2191,O
Pain,2192,B-Disease
perception,2192,O
and,2192,O
nerve,2192,O
conduction,2192,O
velocity,2192,O
in,2192,O
the,2192,O
tail,2192,O
were,2192,O
significantly,2192,O
impaired,2192,O
",",2192,O
particularly,2192,O
after,2192,O
the,2192,O
high-dose,2192,O
treatment,2192,O
.,2192,O
The,2193,O
dorsal,2193,O
root,2193,O
ganglia,2193,O
sensory,2193,O
neurons,2193,O
and,2193,O
",",2193,O
to,2193,O
a,2193,O
lesser,2193,O
extent,2193,O
",",2193,O
satellite,2193,O
cells,2193,O
showed,2193,O
the,2193,O
same,2193,O
changes,2193,O
as,2193,O
those,2193,O
induced,2193,O
by,2193,O
CDDP,2193,B-Chemical
",",2193,O
mainly,2193,O
affecting,2193,O
the,2193,O
nucleus,2193,O
and,2193,O
nucleolus,2193,O
of,2193,O
ganglionic,2193,O
sensory,2193,O
neurons,2193,O
.,2193,O
Moreover,2194,O
",",2194,O
significant,2194,O
amounts,2194,O
of,2194,O
platinum,2194,B-Chemical
were,2194,O
detected,2194,O
in,2194,O
the,2194,O
dorsal,2194,O
root,2194,O
ganglia,2194,O
and,2194,O
kidney,2194,O
after,2194,O
CBDCA,2194,B-Chemical
treatment,2194,O
.,2194,O
CONCLUSIONS,2195,O
:,2195,O
CBDCA,2195,B-Chemical
is,2195,O
neurotoxic,2195,B-Disease
in,2195,O
our,2195,O
model,2195,O
",",2195,O
and,2195,O
the,2195,O
type,2195,O
of,2195,O
pathological,2195,O
changes,2195,O
it,2195,O
induces,2195,O
are,2195,O
so,2195,O
closely,2195,O
similar,2195,O
to,2195,O
those,2195,O
caused,2195,O
by,2195,O
CDDP,2195,B-Chemical
that,2195,O
it,2195,O
is,2195,O
probable,2195,O
that,2195,O
neurotoxicity,2195,B-Disease
is,2195,O
induced,2195,O
in,2195,O
the,2195,O
two,2195,O
drugs,2195,O
by,2195,O
the,2195,O
same,2195,O
mechanism,2195,O
.,2195,O
This,2196,O
model,2196,O
can,2196,O
be,2196,O
used,2196,O
alone,2196,O
or,2196,O
in,2196,O
combination,2196,O
with,2196,O
other,2196,O
drugs,2196,O
to,2196,O
explore,2196,O
the,2196,O
effect,2196,O
of,2196,O
CBDCA,2196,B-Chemical
on,2196,O
the,2196,O
peripheral,2196,O
nervous,2196,O
system,2196,O
.,2196,O
Effects,2197,O
of,2197,O
cisapride,2197,B-Chemical
on,2197,O
symptoms,2197,O
and,2197,O
postcibal,2197,O
small-bowel,2197,O
motor,2197,O
function,2197,O
in,2197,O
patients,2197,O
with,2197,O
irritable,2197,B-Disease
bowel,2197,I-Disease
syndrome,2197,I-Disease
.,2197,O
BACKGROUND,2198,O
:,2198,O
Irritable,2198,B-Disease
bowel,2198,I-Disease
syndrome,2198,I-Disease
is,2198,O
a,2198,O
common,2198,O
cause,2198,O
of,2198,O
abdominal,2198,B-Disease
pain,2198,I-Disease
and,2198,O
discomfort,2198,O
and,2198,O
may,2198,O
be,2198,O
related,2198,O
to,2198,O
disordered,2198,B-Disease
gastrointestinal,2198,I-Disease
motility,2198,I-Disease
.,2198,O
Our,2199,O
aim,2199,O
was,2199,O
to,2199,O
assess,2199,O
the,2199,O
effects,2199,O
of,2199,O
long-term,2199,O
treatment,2199,O
with,2199,O
a,2199,O
prokinetic,2199,O
agent,2199,O
",",2199,O
cisapride,2199,B-Chemical
",",2199,O
on,2199,O
postprandial,2199,O
jejunal,2199,O
motility,2199,O
and,2199,O
symptoms,2199,O
in,2199,O
the,2199,O
irritable,2199,B-Disease
bowel,2199,I-Disease
syndrome,2199,I-Disease
(,2199,O
IBS,2199,B-Disease
),2199,O
.,2199,O
METHODS,2200,O
:,2200,O
Thirty-eight,2200,O
patients,2200,O
with,2200,O
IBS,2200,B-Disease
(,2200,O
constipation-predominant,2200,B-Disease
",",2200,O
n,2200,O
=,2200,O
17,2200,O
;,2200,O
diarrhoea-predominant,2200,B-Disease
",",2200,O
n,2200,O
=,2200,O
21,2200,O
),2200,O
underwent,2200,O
24-h,2200,O
ambulatory,2200,O
jejunal,2200,O
manometry,2200,O
before,2200,O
and,2200,O
after,2200,O
12,2200,O
week,2200,O
's,2200,O
treatment,2200,O
[,2200,O
cisapride,2200,B-Chemical
",",2200,O
5,2200,O
mg,2200,O
three,2200,O
times,2200,O
daily,2200,O
(,2200,O
n,2200,O
=,2200,O
19,2200,O
),2200,O
or,2200,O
placebo,2200,O
(,2200,O
n,2200,O
=,2200,O
19,2200,O
),2200,O
],2200,O
.,2200,O
RESULTS,2201,O
:,2201,O
In,2201,O
diarrhoea-predominant,2201,B-Disease
patients,2201,O
significant,2201,O
differences,2201,O
in,2201,O
contraction,2201,O
characteristics,2201,O
were,2201,O
observed,2201,O
between,2201,O
the,2201,O
cisapride,2201,B-Chemical
and,2201,O
placebo,2201,O
groups,2201,O
.,2201,O
In,2202,O
cisapride-treated,2202,B-Chemical
diarrhoea-predominant,2202,B-Disease
patients,2202,O
the,2202,O
mean,2202,O
contraction,2202,O
amplitude,2202,O
was,2202,O
higher,2202,O
(,2202,O
29.3,2202,O
+/-,2202,O
3.2,2202,O
versus,2202,O
24.9,2202,O
+/-,2202,O
2.6,2202,O
mm,2202,O
Hg,2202,O
",",2202,O
cisapride,2202,B-Chemical
versus,2202,O
placebo,2202,O
(,2202,O
P,2202,O
<,2202,O
0.001,2202,O
),2202,O
;,2202,O
pretreatment,2202,O
",",2202,O
25.7,2202,O
+/-,2202,O
6.0,2202,O
mm,2202,O
Hg,2202,O
),2202,O
",",2202,O
the,2202,O
mean,2202,O
contraction,2202,O
duration,2202,O
longer,2202,O
(,2202,O
3.4,2202,O
+/-,2202,O
0.2,2202,O
versus,2202,O
3.0,2202,O
+/-,2202,O
0.2,2202,O
sec,2202,O
",",2202,O
cisapride,2202,B-Chemical
versus,2202,O
placebo,2202,O
(,2202,O
P,2202,O
<,2202,O
0.001,2202,O
),2202,O
;,2202,O
pretreatment,2202,O
",",2202,O
3.1,2202,O
+/-,2202,O
0.5,2202,O
sec,2202,O
),2202,O
",",2202,O
and,2202,O
the,2202,O
mean,2202,O
contraction,2202,O
frequency,2202,O
lower,2202,O
(,2202,O
2.0,2202,O
+/-,2202,O
0.2,2202,O
versus,2202,O
2.5,2202,O
+/-,2202,O
0.4,2202,O
cont./min,2202,O
",",2202,O
cisapride,2202,B-Chemical
versus,2202,O
placebo,2202,O
(,2202,O
P,2202,O
<,2202,O
0.001,2202,O
),2202,O
;,2202,O
pretreatment,2202,O
",",2202,O
2.5,2202,O
+/-,2202,O
1.1,2202,O
cont./min,2202,O
],2202,O
than,2202,O
patients,2202,O
treated,2202,O
with,2202,O
placebo,2202,O
.,2202,O
No,2203,O
significant,2203,O
differences,2203,O
in,2203,O
jejunal,2203,O
motility,2203,O
were,2203,O
found,2203,O
in,2203,O
the,2203,O
constipation-predominant,2203,B-Disease
IBS,2203,B-Disease
group,2203,O
.,2203,O
Symptoms,2204,O
were,2204,O
assessed,2204,O
by,2204,O
using,2204,O
a,2204,O
visual,2204,O
analogue,2204,O
scale,2204,O
before,2204,O
and,2204,O
after,2204,O
treatment,2204,O
.,2204,O
Symptom,2205,O
scores,2205,O
relating,2205,O
to,2205,O
the,2205,O
severity,2205,O
of,2205,O
constipation,2205,B-Disease
were,2205,O
lower,2205,O
in,2205,O
cisapride-treated,2205,B-Chemical
constipation-predominant,2205,B-Disease
IBS,2205,B-Disease
patients,2205,O
[,2205,O
score,2205,O
",",2205,O
54,2205,O
+/-,2205,O
5,2205,O
versus,2205,O
67,2205,O
+/-,2205,O
14,2205,O
mm,2205,O
",",2205,O
cisapride,2205,B-Chemical
versus,2205,O
placebo,2205,O
(,2205,O
P,2205,O
<,2205,O
0.05,2205,O
),2205,O
;,2205,O
pretreatment,2205,O
",",2205,O
62,2205,O
+/-,2205,O
19,2205,O
mm,2205,O
],2205,O
.,2205,O
Diarrhoea-predominant,2206,B-Disease
IBS,2206,B-Disease
patients,2206,O
had,2206,O
a,2206,O
higher,2206,O
pain,2206,B-Disease
score,2206,O
after,2206,O
cisapride,2206,B-Chemical
therapy,2206,O
[,2206,O
score,2206,O
",",2206,O
55,2206,O
+/-,2206,O
15,2206,O
versus,2206,O
34,2206,O
+/-,2206,O
12,2206,O
mm,2206,O
",",2206,O
cisapride,2206,B-Chemical
versus,2206,O
placebo,2206,O
(,2206,O
P,2206,O
<,2206,O
0.05,2206,O
),2206,O
;,2206,O
pretreatment,2206,O
",",2206,O
67,2206,O
+/-,2206,O
19,2206,O
mm,2206,O
],2206,O
.,2206,O
CONCLUSION,2207,O
:,2207,O
Cisapride,2207,B-Chemical
affects,2207,O
jejunal,2207,O
contraction,2207,O
characteristics,2207,O
and,2207,O
some,2207,O
symptoms,2207,O
in,2207,O
IBS,2207,B-Disease
.,2207,O
Prevention,2208,O
of,2208,O
breast,2208,B-Disease
cancer,2208,I-Disease
with,2208,O
tamoxifen,2208,B-Chemical
:,2208,O
preliminary,2208,O
findings,2208,O
from,2208,O
the,2208,O
Italian,2208,O
randomised,2208,O
trial,2208,O
among,2208,O
hysterectomised,2208,O
women,2208,O
.,2208,O
Italian,2209,O
Tamoxifen,2209,B-Chemical
Prevention,2209,O
Study,2209,O
.,2209,O
BACKGROUND,2210,O
:,2210,O
Tamoxifen,2210,B-Chemical
is,2210,O
a,2210,O
candidate,2210,O
chemopreventive,2210,O
agent,2210,O
in,2210,O
breast,2210,B-Disease
cancer,2210,I-Disease
",",2210,O
although,2210,O
the,2210,O
drug,2210,O
may,2210,O
be,2210,O
associated,2210,O
with,2210,O
the,2210,O
development,2210,O
of,2210,O
endometrial,2210,B-Disease
cancer,2210,I-Disease
.,2210,O
Therefore,2211,O
we,2211,O
did,2211,O
a,2211,O
trial,2211,O
in,2211,O
hysterectomised,2211,O
women,2211,O
of,2211,O
tamoxifen,2211,B-Chemical
as,2211,O
a,2211,O
chemopreventive,2211,O
.,2211,O
METHODS,2212,O
:,2212,O
In,2212,O
October,2212,O
",",2212,O
1992,2212,O
",",2212,O
we,2212,O
started,2212,O
a,2212,O
double-blind,2212,O
placebo-controlled,2212,O
",",2212,O
randomised,2212,O
trial,2212,O
of,2212,O
tamoxifen,2212,B-Chemical
in,2212,O
women,2212,O
(,2212,O
mainly,2212,O
in,2212,O
Italy,2212,O
),2212,O
who,2212,O
did,2212,O
not,2212,O
have,2212,O
breast,2212,B-Disease
cancer,2212,I-Disease
and,2212,O
who,2212,O
had,2212,O
had,2212,O
a,2212,O
hysterectomy,2212,O
.,2212,O
Women,2213,O
were,2213,O
randomised,2213,O
to,2213,O
receive,2213,O
tamoxifen,2213,B-Chemical
20,2213,O
mg,2213,O
per,2213,O
day,2213,O
or,2213,O
placebo,2213,O
",",2213,O
both,2213,O
orally,2213,O
for,2213,O
5,2213,O
years,2213,O
.,2213,O
The,2214,O
original,2214,O
plan,2214,O
was,2214,O
to,2214,O
follow,2214,O
the,2214,O
intervention,2214,O
phase,2214,O
by,2214,O
5,2214,O
years,2214,O
',2214,O
follow-up,2214,O
.,2214,O
In,2215,O
June,2215,O
",",2215,O
1997,2215,O
",",2215,O
the,2215,O
trialists,2215,O
and,2215,O
the,2215,O
data-monitoring,2215,O
committee,2215,O
decided,2215,O
to,2215,O
end,2215,O
recruitment,2215,O
primarily,2215,O
because,2215,O
of,2215,O
the,2215,O
number,2215,O
of,2215,O
women,2215,O
dropping,2215,O
out,2215,O
of,2215,O
the,2215,O
study,2215,O
.,2215,O
Recruitment,2216,O
ended,2216,O
on,2216,O
July,2216,O
11,2216,O
",",2216,O
1997,2216,O
",",2216,O
and,2216,O
the,2216,O
study,2216,O
will,2216,O
continue,2216,O
as,2216,O
planned,2216,O
.,2216,O
The,2217,O
primary,2217,O
endpoints,2217,O
are,2217,O
the,2217,O
occurrence,2217,O
of,2217,O
and,2217,O
deaths,2217,O
from,2217,O
breast,2217,B-Disease
cancer,2217,I-Disease
.,2217,O
This,2218,O
preliminary,2218,O
interim,2218,O
analysis,2218,O
is,2218,O
based,2218,O
on,2218,O
intention-to-treat,2218,O
.,2218,O
FINDINGS,2219,O
:,2219,O
5408,2219,O
women,2219,O
were,2219,O
randomised,2219,O
;,2219,O
participating,2219,O
women,2219,O
have,2219,O
a,2219,O
median,2219,O
follow-up,2219,O
of,2219,O
46,2219,O
months,2219,O
for,2219,O
major,2219,O
endpoints,2219,O
.,2219,O
41,2220,O
cases,2220,O
of,2220,O
breast,2220,B-Disease
cancer,2220,I-Disease
occurred,2220,O
so,2220,O
far,2220,O
;,2220,O
there,2220,O
have,2220,O
been,2220,O
no,2220,O
deaths,2220,O
from,2220,O
breast,2220,B-Disease
cancer,2220,I-Disease
.,2220,O
There,2221,O
is,2221,O
no,2221,O
difference,2221,O
in,2221,O
breast-cancer,2221,B-Disease
frequency,2221,O
between,2221,O
the,2221,O
placebo,2221,O
(,2221,O
22,2221,O
cases,2221,O
),2221,O
and,2221,O
tamoxifen,2221,B-Chemical
(,2221,O
19,2221,O
),2221,O
arms,2221,O
.,2221,O
There,2222,O
is,2222,O
a,2222,O
statistically,2222,O
significant,2222,O
reduction,2222,O
of,2222,O
breast,2222,B-Disease
cancer,2222,I-Disease
among,2222,O
women,2222,O
receiving,2222,O
tamoxifen,2222,B-Chemical
who,2222,O
also,2222,O
used,2222,O
hormone-replacement,2222,O
therapy,2222,O
during,2222,O
the,2222,O
trial,2222,O
:,2222,O
among,2222,O
390,2222,O
women,2222,O
on,2222,O
such,2222,O
therapy,2222,O
and,2222,O
allocated,2222,O
to,2222,O
placebo,2222,O
",",2222,O
we,2222,O
found,2222,O
eight,2222,O
cases,2222,O
of,2222,O
breast,2222,B-Disease
cancer,2222,I-Disease
compared,2222,O
with,2222,O
one,2222,O
case,2222,O
among,2222,O
362,2222,O
women,2222,O
allocated,2222,O
to,2222,O
tamoxifen,2222,B-Chemical
.,2222,O
Compared,2223,O
with,2223,O
the,2223,O
placebo,2223,O
group,2223,O
",",2223,O
there,2223,O
was,2223,O
a,2223,O
significantly,2223,O
increased,2223,O
risk,2223,O
of,2223,O
vascular,2223,B-Disease
events,2223,I-Disease
and,2223,O
hypertriglyceridaemia,2223,B-Disease
among,2223,O
women,2223,O
on,2223,O
tamoxifen,2223,B-Chemical
.,2223,O
INTERPRETATION,2224,O
:,2224,O
Although,2224,O
this,2224,O
preliminary,2224,O
analysis,2224,O
has,2224,O
low,2224,O
power,2224,O
",",2224,O
in,2224,O
this,2224,O
cohort,2224,O
of,2224,O
women,2224,O
at,2224,O
low-to-normal,2224,O
risk,2224,O
of,2224,O
breast,2224,B-Disease
cancer,2224,I-Disease
",",2224,O
the,2224,O
postulated,2224,O
protective,2224,O
effects,2224,O
of,2224,O
tamoxifen,2224,B-Chemical
are,2224,O
not,2224,O
yet,2224,O
apparent,2224,O
.,2224,O
Women,2225,O
using,2225,O
hormone-replacement,2225,O
therapy,2225,O
appear,2225,O
to,2225,O
have,2225,O
benefited,2225,O
from,2225,O
use,2225,O
of,2225,O
tamoxifen,2225,B-Chemical
.,2225,O
There,2226,O
were,2226,O
no,2226,O
deaths,2226,O
from,2226,O
breast,2226,B-Disease
cancer,2226,I-Disease
recorded,2226,O
in,2226,O
women,2226,O
in,2226,O
the,2226,O
study,2226,O
.,2226,O
It,2227,O
is,2227,O
essential,2227,O
to,2227,O
continue,2227,O
follow-up,2227,O
to,2227,O
quantify,2227,O
the,2227,O
long-term,2227,O
risks,2227,O
and,2227,O
benefits,2227,O
of,2227,O
tamoxifen,2227,B-Chemical
therapy,2227,O
.,2227,O
Epileptogenic,2228,O
activity,2228,O
of,2228,O
folic,2228,B-Chemical
acid,2228,I-Chemical
after,2228,O
drug,2228,O
induces,2228,O
SLE,2228,B-Disease
(,2228,O
folic,2228,B-Chemical
acid,2228,I-Chemical
and,2228,O
epilepsy,2228,B-Disease
),2228,O
OBJECTIVE,2228,O
:,2228,O
To,2228,O
study,2228,O
the,2228,O
effect,2228,O
of,2228,O
folic,2228,B-Chemical
acid-containing,2228,O
multivitamin,2228,O
supplementation,2228,O
in,2228,O
epileptic,2228,B-Disease
women,2228,O
before,2228,O
and,2228,O
during,2228,O
pregnancy,2228,O
in,2228,O
order,2228,O
to,2228,O
determine,2228,O
the,2228,O
rate,2228,O
of,2228,O
structural,2228,O
birth,2228,B-Disease
defects,2228,I-Disease
and,2228,O
epilepsy-related,2228,B-Disease
side,2228,O
effects,2228,O
.,2228,O
STUDY,2229,O
DESIGN,2229,O
:,2229,O
First,2229,O
a,2229,O
randomised,2229,O
trial,2229,O
",",2229,O
later,2229,O
periconception,2229,O
care,2229,O
including,2229,O
in,2229,O
total,2229,O
12225,2229,O
females,2229,O
.,2229,O
RESULTS,2230,O
:,2230,O
Of,2230,O
60,2230,O
epileptic,2230,B-Disease
women,2230,O
with,2230,O
periconceptional,2230,O
folic,2230,B-Chemical
acid,2230,I-Chemical
(,2230,O
0.8,2230,O
mg,2230,O
),2230,O
-containing,2230,O
multivitamin,2230,O
supplementation,2230,O
",",2230,O
no,2230,O
one,2230,O
developed,2230,O
epilepsy-related,2230,B-Disease
side,2230,O
effects,2230,O
during,2230,O
the,2230,O
periconception,2230,O
period,2230,O
.,2230,O
One,2231,O
epileptic,2231,B-Disease
woman,2231,O
delivered,2231,O
a,2231,O
newborn,2231,O
with,2231,O
cleft,2231,O
lip,2231,O
and,2231,O
palate,2231,O
.,2231,O
Another,2232,O
patient,2232,O
exhibited,2232,O
with,2232,O
a,2232,O
cluster,2232,O
of,2232,O
seizures,2232,B-Disease
after,2232,O
the,2232,O
periconception,2232,O
period,2232,O
using,2232,O
another,2232,O
multivitamin,2232,O
.,2232,O
This,2233,O
22-year-old,2233,O
epileptic,2233,B-Disease
woman,2233,O
was,2233,O
treated,2233,O
continuously,2233,O
by,2233,O
carbamazepine,2233,B-Chemical
and,2233,O
a,2233,O
folic,2233,B-Chemical
acid,2233,I-Chemical
(,2233,O
1,2233,O
mg,2233,O
),2233,O
-containing,2233,O
multivitamin,2233,O
from,2233,O
the,2233,O
20th,2233,O
week,2233,O
of,2233,O
gestation,2233,O
.,2233,O
She,2234,O
developed,2234,O
status,2234,B-Disease
epilepticus,2234,I-Disease
and,2234,O
later,2234,O
symptoms,2234,O
of,2234,O
systemic,2234,B-Disease
lupus,2234,I-Disease
erythematodes,2234,I-Disease
.,2234,O
Her,2235,O
pregnancy,2235,O
ended,2235,O
with,2235,O
stillbirth,2235,B-Disease
.,2235,O
CONCLUSIONS,2236,O
:,2236,O
The,2236,O
epileptic,2236,B-Disease
pregnant,2236,O
patient,2236,O
's,2236,O
autoimmune,2236,B-Disease
disease,2236,I-Disease
(,2236,O
probably,2236,O
drug-induced,2236,O
lupus,2236,B-Disease
),2236,O
could,2236,O
damage,2236,O
the,2236,O
blood-brain,2236,O
barrier,2236,O
",",2236,O
therefore,2236,O
the,2236,O
therapeutic,2236,O
dose,2236,O
(,2236,O
>,2236,O
or,2236,O
=1,2236,O
mg,2236,O
),2236,O
of,2236,O
folic,2236,B-Chemical
acid,2236,I-Chemical
triggered,2236,O
a,2236,O
cluster,2236,O
of,2236,O
seizures,2236,B-Disease
.,2236,O
Physiological,2237,O
dose,2237,O
(,2237,O
<,2237,O
1,2237,O
mg,2237,O
),2237,O
of,2237,O
folic,2237,B-Chemical
acid,2237,I-Chemical
both,2237,O
in,2237,O
healthy,2237,O
and,2237,O
60,2237,O
epileptic,2237,B-Disease
women,2237,O
",",2237,O
all,2237,O
without,2237,O
any,2237,O
autoimmune,2237,B-Disease
disease,2237,I-Disease
",",2237,O
did,2237,O
not,2237,O
increase,2237,O
the,2237,O
risk,2237,O
for,2237,O
epileptic,2237,B-Disease
seizures,2237,I-Disease
.,2237,O
Stroke,2238,B-Disease
and,2238,O
cocaine,2238,B-Chemical
or,2238,O
amphetamine,2238,B-Chemical
use,2238,O
.,2238,O
The,2239,O
association,2239,O
of,2239,O
cocaine,2239,B-Chemical
and,2239,O
amphetamine,2239,B-Chemical
use,2239,O
with,2239,O
hemorrhagic,2239,O
and,2239,O
ischemic,2239,B-Disease
stroke,2239,B-Disease
is,2239,O
based,2239,O
almost,2239,O
solely,2239,O
on,2239,O
data,2239,O
from,2239,O
case,2239,O
series,2239,O
.,2239,O
The,2240,O
limited,2240,O
number,2240,O
of,2240,O
epidemiologic,2240,O
studies,2240,O
of,2240,O
stroke,2240,B-Disease
and,2240,O
use,2240,O
of,2240,O
cocaine,2240,B-Chemical
and/or,2240,O
amphetamine,2240,B-Chemical
have,2240,O
been,2240,O
done,2240,O
in,2240,O
settings,2240,O
that,2240,O
serve,2240,O
mostly,2240,O
the,2240,O
poor,2240,O
and/or,2240,O
minorities,2240,O
.,2240,O
This,2241,O
case-control,2241,O
study,2241,O
was,2241,O
conducted,2241,O
in,2241,O
the,2241,O
defined,2241,O
population,2241,O
comprising,2241,O
members,2241,O
of,2241,O
Kaiser,2241,O
Permanente,2241,O
of,2241,O
Northern,2241,O
and,2241,O
Southern,2241,O
California,2241,O
.,2241,O
We,2242,O
attempted,2242,O
to,2242,O
identify,2242,O
all,2242,O
incident,2242,O
strokes,2242,B-Disease
in,2242,O
women,2242,O
ages,2242,O
15-44,2242,O
years,2242,O
during,2242,O
a,2242,O
3-year,2242,O
period,2242,O
using,2242,O
hospital,2242,O
admission,2242,O
and,2242,O
discharge,2242,O
records,2242,O
",",2242,O
emergency,2242,O
department,2242,O
logs,2242,O
",",2242,O
and,2242,O
payment,2242,O
requests,2242,O
for,2242,O
out-of-plan,2242,O
hospitalizations,2242,O
.,2242,O
We,2243,O
selected,2243,O
controls,2243,O
",",2243,O
matched,2243,O
on,2243,O
age,2243,O
and,2243,O
facility,2243,O
of,2243,O
usual,2243,O
care,2243,O
",",2243,O
at,2243,O
random,2243,O
from,2243,O
healthy,2243,O
members,2243,O
of,2243,O
the,2243,O
health,2243,O
plan,2243,O
.,2243,O
We,2244,O
obtained,2244,O
information,2244,O
in,2244,O
face-to-face,2244,O
interviews,2244,O
.,2244,O
There,2245,O
were,2245,O
347,2245,O
confirmed,2245,O
stroke,2245,B-Disease
cases,2245,O
and,2245,O
"1,021",2245,O
controls,2245,O
.,2245,O
The,2246,O
univariate,2246,O
matched,2246,O
odds,2246,O
ratio,2246,O
for,2246,O
stroke,2246,B-Disease
in,2246,O
women,2246,O
who,2246,O
admitted,2246,O
to,2246,O
using,2246,O
cocaine,2246,B-Chemical
and/or,2246,O
amphetamine,2246,B-Chemical
was,2246,O
8.5,2246,O
(,2246,O
95,2246,O
%,2246,O
confidence,2246,O
interval,2246,O
=,2246,O
3.6-20.0,2246,O
),2246,O
.,2246,O
After,2247,O
further,2247,O
adjustment,2247,O
for,2247,O
potential,2247,O
confounders,2247,O
",",2247,O
the,2247,O
odds,2247,O
ratio,2247,O
in,2247,O
women,2247,O
who,2247,O
reported,2247,O
using,2247,O
cocaine,2247,B-Chemical
and/or,2247,O
amphetamine,2247,B-Chemical
was,2247,O
7.0,2247,O
(,2247,O
95,2247,O
%,2247,O
confidence,2247,O
interval,2247,O
=,2247,O
2.8-17.9,2247,O
),2247,O
.,2247,O
The,2248,O
use,2248,O
of,2248,O
cocaine,2248,B-Chemical
and/or,2248,O
amphetamine,2248,B-Chemical
is,2248,O
a,2248,O
strong,2248,O
risk,2248,O
factor,2248,O
for,2248,O
stroke,2248,B-Disease
in,2248,O
this,2248,O
socioeconomically,2248,O
heterogeneous,2248,O
",",2248,O
insured,2248,O
urban,2248,O
population,2248,O
.,2248,O
Chronic,2249,O
effects,2249,O
of,2249,O
a,2249,O
novel,2249,O
synthetic,2249,O
anthracycline,2249,B-Chemical
derivative,2249,O
(,2249,O
SM-5887,2249,B-Chemical
),2249,O
on,2249,O
normal,2249,O
heart,2249,O
and,2249,O
doxorubicin-induced,2249,B-Chemical
cardiomyopathy,2249,B-Disease
in,2249,O
beagle,2249,O
dogs,2249,O
.,2249,O
This,2250,O
study,2250,O
was,2250,O
designed,2250,O
to,2250,O
investigate,2250,O
the,2250,O
chronic,2250,O
cardiotoxic,2250,B-Disease
potential,2250,O
of,2250,O
SM-5887,2250,B-Chemical
and,2250,O
a,2250,O
possible,2250,O
deteriorating,2250,O
effect,2250,O
of,2250,O
SM-5887,2250,B-Chemical
on,2250,O
low-grade,2250,O
cardiotoxicity,2250,B-Disease
pre-induced,2250,O
by,2250,O
doxorubicin,2250,B-Chemical
in,2250,O
beagle,2250,O
dogs,2250,O
.,2250,O
In,2251,O
the,2251,O
chronic,2251,O
treatment,2251,O
",",2251,O
beagle,2251,O
dogs,2251,O
of,2251,O
each,2251,O
sex,2251,O
were,2251,O
given,2251,O
intravenously,2251,O
once,2251,O
every,2251,O
3,2251,O
weeks,2251,O
",",2251,O
either,2251,O
a,2251,O
sublethal,2251,O
dose,2251,O
of,2251,O
doxorubicin,2251,B-Chemical
(,2251,O
1.5,2251,O
mg/kg,2251,O
),2251,O
or,2251,O
SM-5887,2251,B-Chemical
(,2251,O
2.5,2251,O
mg/kg,2251,O
),2251,O
.,2251,O
The,2252,O
experiment,2252,O
was,2252,O
terminated,2252,O
3,2252,O
weeks,2252,O
after,2252,O
the,2252,O
ninth,2252,O
dosing,2252,O
.,2252,O
Animals,2253,O
which,2253,O
received,2253,O
over,2253,O
six,2253,O
courses,2253,O
of,2253,O
doxorubicin,2253,B-Chemical
demonstrated,2253,O
the,2253,O
electrocardiogram,2253,O
(,2253,O
ECG,2253,O
),2253,O
changes,2253,O
",",2253,O
decrease,2253,O
of,2253,O
blood,2253,O
pressure,2253,O
and,2253,O
high-grade,2253,O
histopathological,2253,O
cardiomyopathy,2253,B-Disease
",",2253,O
while,2253,O
animals,2253,O
which,2253,O
were,2253,O
terminally,2253,O
sacrificed,2253,O
after,2253,O
the,2253,O
SM-5887,2253,B-Chemical
administration,2253,O
did,2253,O
not,2253,O
show,2253,O
any,2253,O
changes,2253,O
in,2253,O
ECG,2253,O
",",2253,O
blood,2253,O
pressure,2253,O
and,2253,O
histopathological,2253,O
examinations,2253,O
.,2253,O
To,2254,O
examine,2254,O
a,2254,O
possibly,2254,O
deteriorating,2254,O
cardiotoxic,2254,B-Disease
effect,2254,O
of,2254,O
SM-5887,2254,B-Chemical
",",2254,O
low-grade,2254,O
cardiomyopathy,2254,B-Disease
was,2254,O
induced,2254,O
in,2254,O
dogs,2254,O
by,2254,O
four,2254,O
courses,2254,O
of,2254,O
doxorubicin,2254,B-Chemical
(,2254,O
1.5,2254,O
mg/kg,2254,O
),2254,O
.,2254,O
Nine,2255,O
weeks,2255,O
after,2255,O
pre-treatment,2255,O
",",2255,O
dogs,2255,O
were,2255,O
given,2255,O
four,2255,O
courses,2255,O
of,2255,O
either,2255,O
doxorubicin,2255,B-Chemical
(,2255,O
1.5,2255,O
mg/kg,2255,O
),2255,O
or,2255,O
SM-5887,2255,B-Chemical
(,2255,O
2.5,2255,O
mg/kg,2255,O
),2255,O
once,2255,O
every,2255,O
3,2255,O
weeks,2255,O
.,2255,O
The,2256,O
low-grade,2256,O
cardiotoxic,2256,B-Disease
changes,2256,O
were,2256,O
enhanced,2256,O
by,2256,O
the,2256,O
additional,2256,O
doxorubicin,2256,B-Chemical
treatment,2256,O
.,2256,O
On,2257,O
the,2257,O
contrary,2257,O
",",2257,O
the,2257,O
SM-5887,2257,B-Chemical
treatment,2257,O
did,2257,O
not,2257,O
progress,2257,O
the,2257,O
grade,2257,O
of,2257,O
cardiomyopathy,2257,B-Disease
.,2257,O
In,2258,O
conclusion,2258,O
",",2258,O
SM-5887,2258,B-Chemical
does,2258,O
not,2258,O
have,2258,O
any,2258,O
potential,2258,O
of,2258,O
chronic,2258,O
cardiotoxicity,2258,B-Disease
and,2258,O
deteriorating,2258,O
effect,2258,O
on,2258,O
doxorubicin-induced,2258,B-Chemical
cardiotoxicity,2258,B-Disease
in,2258,O
dogs,2258,O
.,2258,O
Risk,2259,O
for,2259,O
valvular,2259,B-Disease
heart,2259,I-Disease
disease,2259,I-Disease
among,2259,O
users,2259,O
of,2259,O
fenfluramine,2259,B-Chemical
and,2259,O
dexfenfluramine,2259,B-Chemical
who,2259,O
underwent,2259,O
echocardiography,2259,O
before,2259,O
use,2259,O
of,2259,O
medication,2259,O
.,2259,O
BACKGROUND,2260,O
:,2260,O
Because,2260,O
uncontrolled,2260,O
echocardiographic,2260,O
surveys,2260,O
suggested,2260,O
that,2260,O
up,2260,O
to,2260,O
30,2260,O
%,2260,O
to,2260,O
38,2260,O
%,2260,O
of,2260,O
users,2260,O
of,2260,O
fenfluramine,2260,B-Chemical
and,2260,O
dexfenfluramine,2260,B-Chemical
had,2260,O
valvular,2260,B-Disease
disease,2260,I-Disease
",",2260,O
these,2260,O
drugs,2260,O
were,2260,O
withdrawn,2260,O
from,2260,O
the,2260,O
market,2260,O
.,2260,O
OBJECTIVE,2261,O
:,2261,O
To,2261,O
determine,2261,O
the,2261,O
risk,2261,O
for,2261,O
new,2261,O
or,2261,O
worsening,2261,O
valvular,2261,B-Disease
abnormalities,2261,I-Disease
among,2261,O
users,2261,O
of,2261,O
fenfluramine,2261,B-Chemical
or,2261,O
dexfenfluramine,2261,B-Chemical
who,2261,O
underwent,2261,O
echocardiography,2261,O
before,2261,O
they,2261,O
began,2261,O
to,2261,O
take,2261,O
these,2261,O
medications,2261,O
.,2261,O
DESIGN,2262,O
:,2262,O
Cohort,2262,O
study,2262,O
.,2262,O
SETTING,2263,O
:,2263,O
Academic,2263,O
primary,2263,O
care,2263,O
practices,2263,O
.,2263,O
PATIENTS,2264,O
:,2264,O
46,2264,O
patients,2264,O
who,2264,O
used,2264,O
fenfluramine,2264,B-Chemical
or,2264,O
dexfenfluramine,2264,B-Chemical
for,2264,O
14,2264,O
days,2264,O
or,2264,O
more,2264,O
and,2264,O
had,2264,O
echocardiograms,2264,O
obtained,2264,O
before,2264,O
therapy,2264,O
.,2264,O
MEASUREMENTS,2265,O
:,2265,O
Follow-up,2265,O
echocardiography,2265,O
.,2265,O
The,2266,O
primary,2266,O
outcome,2266,O
was,2266,O
new,2266,O
or,2266,O
worsening,2266,O
valvulopathy,2266,B-Disease
",",2266,O
defined,2266,O
as,2266,O
progression,2266,O
of,2266,O
either,2266,O
aortic,2266,O
or,2266,O
mitral,2266,O
regurgitation,2266,O
by,2266,O
at,2266,O
least,2266,O
one,2266,O
degree,2266,O
of,2266,O
severity,2266,O
and,2266,O
disease,2266,O
that,2266,O
met,2266,O
U.S.,2266,O
Food,2266,O
and,2266,O
Drug,2266,O
Administration,2266,O
criteria,2266,O
(,2266,O
at,2266,O
least,2266,O
mild,2266,O
aortic,2266,B-Disease
regurgitation,2266,I-Disease
or,2266,O
moderate,2266,O
mitral,2266,B-Disease
regurgitation,2266,I-Disease
),2266,O
.,2266,O
RESULTS,2267,O
:,2267,O
Two,2267,O
patients,2267,O
(,2267,O
4.3,2267,O
%,2267,O
[,2267,O
95,2267,O
%,2267,O
CI,2267,O
",",2267,O
0.6,2267,O
%,2267,O
to,2267,O
14.8,2267,O
%,2267,O
],2267,O
),2267,O
receiving,2267,O
fenfluramine-phentermine,2267,B-Chemical
developed,2267,O
valvular,2267,B-Disease
heart,2267,I-Disease
disease,2267,I-Disease
.,2267,O
One,2268,O
had,2268,O
baseline,2268,O
bicuspid,2268,B-Disease
aortic,2268,I-Disease
valve,2268,I-Disease
and,2268,O
mild,2268,O
aortic,2268,B-Disease
regurgitation,2268,I-Disease
that,2268,O
progressed,2268,O
to,2268,O
moderate,2268,O
regurgitation,2268,O
.,2268,O
The,2269,O
second,2269,O
patient,2269,O
developed,2269,O
new,2269,O
moderate,2269,O
aortic,2269,B-Disease
insufficiency,2269,I-Disease
.,2269,O
CONCLUSION,2270,O
:,2270,O
Users,2270,O
of,2270,O
diet,2270,O
medications,2270,O
are,2270,O
at,2270,O
risk,2270,O
for,2270,O
valvular,2270,B-Disease
heart,2270,I-Disease
disease,2270,I-Disease
.,2270,O
However,2271,O
",",2271,O
the,2271,O
incidence,2271,O
may,2271,O
be,2271,O
lower,2271,O
than,2271,O
that,2271,O
reported,2271,O
previously,2271,O
.,2271,O
Therapeutic,2272,O
drug,2272,O
monitoring,2272,O
of,2272,O
tobramycin,2272,B-Chemical
:,2272,O
once-daily,2272,O
versus,2272,O
twice-daily,2272,O
dosage,2272,O
schedules,2272,O
.,2272,O
OBJECTIVE,2273,O
:,2273,O
To,2273,O
evaluate,2273,O
the,2273,O
effect,2273,O
of,2273,O
dosage,2273,O
regimen,2273,O
(,2273,O
once-daily,2273,O
vs.,2273,O
twice-daily,2273,O
),2273,O
of,2273,O
tobramicyn,2273,B-Chemical
on,2273,O
steady-state,2273,O
serum,2273,O
concentrations,2273,O
and,2273,O
toxicity,2273,B-Disease
.,2273,O
MATERIALS,2274,O
AND,2274,O
METHODS,2274,O
:,2274,O
Patients,2274,O
undergoing,2274,O
treatment,2274,O
with,2274,O
i.v,2274,O
.,2274,O
tobramycin,2275,B-Chemical
(,2275,O
4,2275,O
mg/kg/day,2275,O
),2275,O
were,2275,O
randomised,2275,O
to,2275,O
two,2275,O
groups,2275,O
.,2275,O
Group,2276,O
OD,2276,O
(,2276,O
n,2276,O
=,2276,O
22,2276,O
),2276,O
received,2276,O
a,2276,O
once-daily,2276,O
dose,2276,O
of,2276,O
tobramycin,2276,B-Chemical
and,2276,O
group,2276,O
TD,2276,O
(,2276,O
n,2276,O
=,2276,O
21,2276,O
),2276,O
received,2276,O
the,2276,O
same,2276,O
dose,2276,O
divided,2276,O
into,2276,O
two,2276,O
doses,2276,O
daily,2276,O
.,2276,O
Tobramycin,2277,B-Chemical
serum,2277,O
concentrations,2277,O
(,2277,O
peak,2277,O
and,2277,O
trough,2277,O
),2277,O
were,2277,O
measured,2277,O
by,2277,O
enzyme,2277,O
multiplied,2277,O
immunoassay,2277,O
.,2277,O
The,2278,O
renal,2278,O
and,2278,O
auditory,2278,O
functions,2278,O
of,2278,O
the,2278,O
patients,2278,O
were,2278,O
monitored,2278,O
before,2278,O
",",2278,O
during,2278,O
and,2278,O
immediately,2278,O
after,2278,O
treatment,2278,O
.,2278,O
RESULTS,2279,O
:,2279,O
The,2279,O
two,2279,O
groups,2279,O
were,2279,O
comparable,2279,O
with,2279,O
respect,2279,O
to,2279,O
sex,2279,O
",",2279,O
age,2279,O
",",2279,O
body,2279,O
weight,2279,O
and,2279,O
renal,2279,O
function,2279,O
.,2279,O
No,2280,O
statistically,2280,O
significant,2280,O
differences,2280,O
were,2280,O
found,2280,O
in,2280,O
mean,2280,O
daily,2280,O
dose,2280,O
",",2280,O
duration,2280,O
of,2280,O
treatment,2280,O
",",2280,O
or,2280,O
cumulative,2280,O
dose,2280,O
.,2280,O
Trough,2281,O
concentrations,2281,O
were,2281,O
<,2281,O
2,2281,O
g/ml,2281,O
in,2281,O
the,2281,O
two,2281,O
groups,2281,O
(,2281,O
100,2281,O
%,2281,O
),2281,O
.,2281,O
Peak,2282,O
concentrations,2282,O
were,2282,O
>,2282,O
6,2282,O
microg/ml,2282,O
in,2282,O
100,2282,O
%,2282,O
of,2282,O
the,2282,O
OD,2282,O
group,2282,O
and,2282,O
in,2282,O
67,2282,O
%,2282,O
of,2282,O
the,2282,O
TD,2282,O
group,2282,O
(,2282,O
P,2282,O
<,2282,O
0.01,2282,O
),2282,O
.,2282,O
Mean,2283,O
peak,2283,O
concentrations,2283,O
were,2283,O
markedly,2283,O
different,2283,O
:,2283,O
11.00+/-2.89,2283,O
microg/ml,2283,O
in,2283,O
OD,2283,O
vs.,2283,O
6.53+/-1.45,2283,O
microg/ml,2283,O
in,2283,O
TD,2283,O
(,2283,O
P,2283,O
<,2283,O
0.01,2283,O
),2283,O
.,2283,O
The,2284,O
pharmacokinetics,2284,O
parameters,2284,O
were,2284,O
:,2284,O
Ke,2284,O
",",2284,O
(,2284,O
0.15+/-0.03/h,2284,O
in,2284,O
OD,2284,O
vs.,2284,O
0.24+/-0.06/h,2284,O
in,2284,O
TD,2284,O
),2284,O
",",2284,O
t1/2,2284,O
",",2284,O
(,2284,O
4.95+/-1.41,2284,O
h,2284,O
in,2284,O
OD,2284,O
vs.,2284,O
3.07+/-0.71,2284,O
h,2284,O
in,2284,O
TD,2284,O
),2284,O
",",2284,O
Vd,2284,O
(,2284,O
0.35+/-0.11,2284,O
l/kg,2284,O
in,2284,O
OD,2284,O
vs.,2284,O
0.33+/-0.09,2284,O
l/kg,2284,O
in,2284,O
TD,2284,O
),2284,O
",",2284,O
Cl,2284,O
(,2284,O
0.86+/-0.29,2284,O
ml/min/kg,2284,O
in,2284,O
OD,2284,O
vs.,2284,O
1.28+/-0.33,2284,O
ml/min/kg,2284,O
in,2284,O
TD,2284,O
),2284,O
.,2284,O
Increased,2285,O
serum,2285,O
creatinine,2285,B-Chemical
was,2285,O
observed,2285,O
in,2285,O
73,2285,O
%,2285,O
of,2285,O
patients,2285,O
in,2285,O
OD,2285,O
versus,2285,O
57,2285,O
%,2285,O
of,2285,O
patients,2285,O
in,2285,O
TD,2285,O
",",2285,O
without,2285,O
evidence,2285,O
of,2285,O
nephrotoxicity,2285,B-Disease
.,2285,O
In,2286,O
TD,2286,O
group,2286,O
",",2286,O
three,2286,O
patients,2286,O
developed,2286,O
decreased,2286,B-Disease
auditory,2286,I-Disease
function,2286,I-Disease
",",2286,O
of,2286,O
which,2286,O
one,2286,O
presented,2286,O
with,2286,O
an,2286,O
auditory,2286,B-Disease
loss,2286,I-Disease
of,2286,O
-30,2286,O
dB,2286,O
",",2286,O
whereas,2286,O
in,2286,O
the,2286,O
OD,2286,O
group,2286,O
only,2286,O
one,2286,O
patient,2286,O
presented,2286,O
decreased,2286,B-Disease
auditory,2286,I-Disease
function,2286,I-Disease
.,2286,O
CONCLUSION,2287,O
:,2287,O
This,2287,O
small,2287,O
study,2287,O
suggests,2287,O
that,2287,O
a,2287,O
once-daily,2287,O
dosing,2287,O
regimen,2287,O
of,2287,O
tobramycin,2287,B-Chemical
is,2287,O
at,2287,O
least,2287,O
as,2287,O
effective,2287,O
as,2287,O
and,2287,O
is,2287,O
no,2287,O
more,2287,O
and,2287,O
possibly,2287,O
less,2287,O
toxic,2287,O
than,2287,O
the,2287,O
twice-daily,2287,O
regimen,2287,O
.,2287,O
Using,2288,O
a,2288,O
single-dose,2288,O
therapy,2288,O
",",2288,O
peak,2288,O
concentration,2288,O
determination,2288,O
is,2288,O
not,2288,O
necessary,2288,O
",",2288,O
only,2288,O
trough,2288,O
samples,2288,O
should,2288,O
be,2288,O
monitored,2288,O
to,2288,O
ensure,2288,O
levels,2288,O
below,2288,O
2,2288,O
microg/ml,2288,O
.,2288,O
Enhanced,2289,O
bradycardia,2289,B-Disease
induced,2289,O
by,2289,O
beta-adrenoceptor,2289,O
antagonists,2289,O
in,2289,O
rats,2289,O
pretreated,2289,O
with,2289,O
isoniazid,2289,B-Chemical
.,2289,O
High,2290,O
doses,2290,O
of,2290,O
isoniazid,2290,B-Chemical
increase,2290,O
hypotension,2290,B-Disease
induced,2290,O
by,2290,O
vasodilators,2290,O
and,2290,O
change,2290,O
the,2290,O
accompanying,2290,O
reflex,2290,O
tachycardia,2290,B-Disease
to,2290,O
bradycardia,2290,B-Disease
",",2290,O
an,2290,O
interaction,2290,O
attributed,2290,O
to,2290,O
decreased,2290,O
synthesis,2290,O
of,2290,O
brain,2290,O
gamma-aminobutyric,2290,B-Chemical
acid,2290,I-Chemical
(,2290,O
GABA,2290,B-Chemical
),2290,O
.,2290,O
In,2291,O
the,2291,O
present,2291,O
study,2291,O
",",2291,O
the,2291,O
possible,2291,O
enhancement,2291,O
by,2291,O
isoniazid,2291,B-Chemical
of,2291,O
bradycardia,2291,B-Disease
induced,2291,O
by,2291,O
beta-adrenoceptor,2291,O
antagonists,2291,O
was,2291,O
determined,2291,O
in,2291,O
rats,2291,O
anaesthetised,2291,O
with,2291,O
chloralose-urethane,2291,B-Chemical
.,2291,O
Isoniazid,2292,B-Chemical
significantly,2292,O
increased,2292,O
bradycardia,2292,B-Disease
after,2292,O
propranolol,2292,B-Chemical
",",2292,O
pindolol,2292,B-Chemical
",",2292,O
labetalol,2292,B-Chemical
and,2292,O
atenolol,2292,B-Chemical
",",2292,O
as,2292,O
well,2292,O
as,2292,O
after,2292,O
clonidine,2292,B-Chemical
",",2292,O
but,2292,O
not,2292,O
after,2292,O
hexamethonium,2292,B-Chemical
or,2292,O
carbachol,2292,B-Chemical
.,2292,O
Enhancement,2293,O
was,2293,O
not,2293,O
observed,2293,O
in,2293,O
rats,2293,O
pretreated,2293,O
with,2293,O
methylatropine,2293,B-Chemical
or,2293,O
previously,2293,O
vagotomised,2293,O
.,2293,O
These,2294,O
results,2294,O
are,2294,O
compatible,2294,O
with,2294,O
interference,2294,O
by,2294,O
isoniazid,2294,B-Chemical
with,2294,O
GABAergic,2294,O
inhibition,2294,O
of,2294,O
cardiac,2294,O
parasympathetic,2294,O
tone,2294,O
.,2294,O
Such,2295,O
interference,2295,O
could,2295,O
be,2295,O
exerted,2295,O
centrally,2295,O
",",2295,O
possibly,2295,O
at,2295,O
the,2295,O
nucleus,2295,O
ambiguus,2295,O
",",2295,O
or,2295,O
peripherally,2295,O
at,2295,O
the,2295,O
sinus,2295,O
node,2295,O
.,2295,O
Structural,2296,B-Disease
and,2296,I-Disease
functional,2296,I-Disease
impairment,2296,I-Disease
of,2296,I-Disease
mitochondria,2296,I-Disease
in,2296,O
adriamycin-induced,2296,B-Chemical
cardiomyopathy,2296,B-Disease
in,2296,O
mice,2296,O
:,2296,O
suppression,2296,O
of,2296,O
cytochrome,2296,O
c,2296,O
oxidase,2296,O
II,2296,O
gene,2296,O
expression,2296,O
.,2296,O
The,2297,O
use,2297,O
of,2297,O
adriamycin,2297,B-Chemical
(,2297,O
ADR,2297,B-Chemical
),2297,O
in,2297,O
cancer,2297,B-Disease
chemotherapy,2297,O
has,2297,O
been,2297,O
limited,2297,O
due,2297,O
to,2297,O
its,2297,O
cumulative,2297,O
cardiovascular,2297,B-Disease
toxicity,2297,I-Disease
.,2297,O
Earlier,2298,O
observations,2298,O
that,2298,O
ADR,2298,B-Chemical
interacts,2298,O
with,2298,O
mitochondrial,2298,O
cytochrome,2298,O
c,2298,O
oxidase,2298,O
(,2298,O
COX,2298,O
),2298,O
and,2298,O
suppresses,2298,O
its,2298,O
enzyme,2298,O
activity,2298,O
led,2298,O
us,2298,O
to,2298,O
investigate,2298,O
ADR,2298,B-Chemical
's,2298,O
action,2298,O
on,2298,O
the,2298,O
cardiovascular,2298,O
functions,2298,O
and,2298,O
heart,2298,O
mitochondrial,2298,O
morphology,2298,O
in,2298,O
Balb-c,2298,O
mice,2298,O
i.p,2298,O
.,2298,O
treated,2299,O
with,2299,O
ADR,2299,B-Chemical
for,2299,O
several,2299,O
weeks,2299,O
.,2299,O
At,2300,O
various,2300,O
times,2300,O
during,2300,O
treatment,2300,O
",",2300,O
the,2300,O
animals,2300,O
were,2300,O
assessed,2300,O
for,2300,O
cardiovascular,2300,O
functions,2300,O
by,2300,O
electrocardiography,2300,O
and,2300,O
for,2300,O
heart,2300,O
tissue,2300,O
damage,2300,O
by,2300,O
electron,2300,O
microscopy,2300,O
.,2300,O
In,2301,O
parallel,2301,O
",",2301,O
total,2301,O
RNA,2301,O
was,2301,O
extracted,2301,O
from,2301,O
samples,2301,O
of,2301,O
dissected,2301,O
heart,2301,O
and,2301,O
analyzed,2301,O
by,2301,O
Northern,2301,O
blot,2301,O
hybridization,2301,O
to,2301,O
determine,2301,O
the,2301,O
steady-state,2301,O
level,2301,O
of,2301,O
three,2301,O
RNA,2301,O
transcripts,2301,O
encoded,2301,O
by,2301,O
the,2301,O
COXII,2301,O
",",2301,O
COXIII,2301,O
",",2301,O
and,2301,O
COXIV,2301,O
genes,2301,O
.,2301,O
Similarly,2302,O
",",2302,O
samples,2302,O
obtained,2302,O
from,2302,O
the,2302,O
liver,2302,O
of,2302,O
the,2302,O
same,2302,O
animals,2302,O
were,2302,O
analyzed,2302,O
for,2302,O
comparative,2302,O
studies,2302,O
.,2302,O
Our,2303,O
results,2303,O
indicated,2303,O
that,2303,O
1,2303,O
),2303,O
treatment,2303,O
of,2303,O
mice,2303,O
with,2303,O
ADR,2303,B-Chemical
caused,2303,O
cardiovascular,2303,B-Disease
arrhythmias,2303,I-Disease
characterized,2303,O
by,2303,O
bradycardia,2303,B-Disease
",",2303,O
extension,2303,O
of,2303,O
ventricular,2303,O
depolarization,2303,O
time,2303,O
(,2303,O
tQRS,2303,O
),2303,O
",",2303,O
and,2303,O
failure,2303,O
of,2303,O
QRS,2303,O
at,2303,O
high,2303,O
concentrations,2303,O
(,2303,O
10-14,2303,O
mg/kg,2303,O
body,2303,O
weight,2303,O
cumulative,2303,O
dose,2303,O
),2303,O
;,2303,O
2,2303,O
),2303,O
the,2303,O
heart,2303,O
mitochondria,2303,O
underwent,2303,O
swelling,2303,B-Disease
",",2303,O
fusion,2303,O
",",2303,O
dissolution,2303,O
",",2303,O
and/or,2303,O
disruption,2303,O
of,2303,O
mitochondrial,2303,O
cristae,2303,O
after,2303,O
several,2303,O
weeks,2303,O
of,2303,O
treatment,2303,O
.,2303,O
Such,2304,O
abnormalities,2304,O
were,2304,O
not,2304,O
observed,2304,O
in,2304,O
the,2304,O
mitochondria,2304,O
of,2304,O
liver,2304,O
tissue,2304,O
;,2304,O
and,2304,O
3,2304,O
),2304,O
among,2304,O
the,2304,O
three,2304,O
genes,2304,O
of,2304,O
COX,2304,O
enzyme,2304,O
examined,2304,O
",",2304,O
only,2304,O
COXII,2304,O
gene,2304,O
expression,2304,O
was,2304,O
suppressed,2304,O
by,2304,O
ADR,2304,B-Chemical
treatment,2304,O
",",2304,O
mainly,2304,O
after,2304,O
8,2304,O
weeks,2304,O
in,2304,O
both,2304,O
heart,2304,O
and,2304,O
liver,2304,O
.,2304,O
Knowing,2305,O
that,2305,O
heart,2305,O
mitochondria,2305,O
represent,2305,O
almost,2305,O
40,2305,O
%,2305,O
of,2305,O
heart,2305,O
muscle,2305,O
by,2305,O
weight,2305,O
",",2305,O
we,2305,O
conclude,2305,O
that,2305,O
the,2305,O
deteriorating,2305,O
effects,2305,O
of,2305,O
ADR,2305,B-Chemical
on,2305,O
cardiovascular,2305,O
function,2305,O
involve,2305,O
mitochondrial,2305,B-Disease
structural,2305,I-Disease
and,2305,I-Disease
functional,2305,I-Disease
impairment,2305,I-Disease
.,2305,O
22-oxacalcitriol,2306,B-Chemical
suppresses,2306,O
secondary,2306,B-Disease
hyperparathyroidism,2306,I-Disease
without,2306,O
inducing,2306,O
low,2306,B-Disease
bone,2306,I-Disease
turnover,2306,I-Disease
in,2306,O
dogs,2306,O
with,2306,O
renal,2306,B-Disease
failure,2306,I-Disease
.,2306,O
BACKGROUND,2307,O
:,2307,O
Calcitriol,2307,B-Chemical
therapy,2307,O
suppresses,2307,O
serum,2307,O
levels,2307,O
of,2307,O
parathyroid,2307,O
hormone,2307,O
(,2307,O
PTH,2307,O
),2307,O
in,2307,O
patients,2307,O
with,2307,O
renal,2307,B-Disease
failure,2307,I-Disease
but,2307,O
has,2307,O
several,2307,O
drawbacks,2307,O
",",2307,O
including,2307,O
hypercalcemia,2307,B-Disease
and/or,2307,O
marked,2307,O
suppression,2307,B-Disease
of,2307,I-Disease
bone,2307,I-Disease
turnover,2307,I-Disease
",",2307,O
which,2307,O
may,2307,O
lead,2307,O
to,2307,O
adynamic,2307,B-Disease
bone,2307,I-Disease
disease,2307,I-Disease
.,2307,O
A,2308,O
new,2308,O
vitamin,2308,B-Chemical
D,2308,I-Chemical
analogue,2308,O
",",2308,O
22-oxacalcitriol,2308,B-Chemical
(,2308,O
OCT,2308,B-Chemical
),2308,O
",",2308,O
has,2308,O
been,2308,O
shown,2308,O
to,2308,O
have,2308,O
promising,2308,O
characteristics,2308,O
.,2308,O
This,2309,O
study,2309,O
was,2309,O
undertaken,2309,O
to,2309,O
determine,2309,O
the,2309,O
effects,2309,O
of,2309,O
OCT,2309,B-Chemical
on,2309,O
serum,2309,O
PTH,2309,O
levels,2309,O
and,2309,O
bone,2309,O
turnover,2309,O
in,2309,O
states,2309,O
of,2309,O
normal,2309,O
or,2309,O
impaired,2309,B-Disease
renal,2309,I-Disease
function,2309,I-Disease
.,2309,O
METHODS,2310,O
:,2310,O
Sixty,2310,O
dogs,2310,O
were,2310,O
either,2310,O
nephrectomized,2310,O
(,2310,O
Nx,2310,O
",",2310,O
N,2310,O
=,2310,O
38,2310,O
),2310,O
or,2310,O
sham-operated,2310,O
(,2310,O
Sham,2310,O
",",2310,O
N,2310,O
=,2310,O
22,2310,O
),2310,O
.,2310,O
The,2311,O
animals,2311,O
received,2311,O
supplemental,2311,O
phosphate,2311,B-Chemical
to,2311,O
enhance,2311,O
PTH,2311,O
secretion,2311,O
.,2311,O
Fourteen,2312,O
weeks,2312,O
after,2312,O
the,2312,O
start,2312,O
of,2312,O
phosphate,2312,B-Chemical
supplementation,2312,O
",",2312,O
half,2312,O
of,2312,O
the,2312,O
Nx,2312,O
and,2312,O
Sham,2312,O
dogs,2312,O
received,2312,O
doses,2312,O
of,2312,O
OCT,2312,B-Chemical
(,2312,O
three,2312,O
times,2312,O
per,2312,O
week,2312,O
),2312,O
;,2312,O
the,2312,O
other,2312,O
half,2312,O
were,2312,O
given,2312,O
vehicle,2312,O
for,2312,O
60,2312,O
weeks,2312,O
.,2312,O
Thereafter,2313,O
",",2313,O
the,2313,O
treatment,2313,O
modalities,2313,O
for,2313,O
a,2313,O
subset,2313,O
of,2313,O
animals,2313,O
were,2313,O
crossed,2313,O
over,2313,O
for,2313,O
an,2313,O
additional,2313,O
eight,2313,O
months,2313,O
.,2313,O
Biochemical,2314,O
and,2314,O
hormonal,2314,O
indices,2314,O
of,2314,O
calcium,2314,B-Chemical
and,2314,O
bone,2314,O
metabolism,2314,O
were,2314,O
measured,2314,O
throughout,2314,O
the,2314,O
study,2314,O
",",2314,O
and,2314,O
bone,2314,O
biopsies,2314,O
were,2314,O
done,2314,O
at,2314,O
baseline,2314,O
",",2314,O
60,2314,O
weeks,2314,O
after,2314,O
OCT,2314,B-Chemical
or,2314,O
vehicle,2314,O
treatment,2314,O
",",2314,O
and,2314,O
at,2314,O
the,2314,O
end,2314,O
of,2314,O
the,2314,O
crossover,2314,O
period,2314,O
.,2314,O
RESULTS,2315,O
:,2315,O
In,2315,O
Nx,2315,O
dogs,2315,O
",",2315,O
OCT,2315,B-Chemical
significantly,2315,O
decreased,2315,O
serum,2315,O
PTH,2315,O
levels,2315,O
soon,2315,O
after,2315,O
the,2315,O
induction,2315,O
of,2315,O
renal,2315,B-Disease
insufficiency,2315,I-Disease
.,2315,O
In,2316,O
long-standing,2316,O
secondary,2316,B-Disease
hyperparathyroidism,2316,I-Disease
",",2316,O
OCT,2316,B-Chemical
(,2316,O
0.03,2316,O
microg/kg,2316,O
),2316,O
stabilized,2316,O
serum,2316,O
PTH,2316,O
levels,2316,O
during,2316,O
the,2316,O
first,2316,O
months,2316,O
.,2316,O
Serum,2317,O
PTH,2317,O
levels,2317,O
rose,2317,O
thereafter,2317,O
",",2317,O
but,2317,O
the,2317,O
rise,2317,O
was,2317,O
less,2317,O
pronounced,2317,O
compared,2317,O
with,2317,O
baseline,2317,O
than,2317,O
the,2317,O
rise,2317,O
seen,2317,O
in,2317,O
Nx,2317,O
control,2317,O
.,2317,O
These,2318,O
effects,2318,O
were,2318,O
accompanied,2318,O
by,2318,O
episodes,2318,O
of,2318,O
hypercalcemia,2318,B-Disease
and,2318,O
hyperphosphatemia,2318,B-Disease
.,2318,O
In,2319,O
animals,2319,O
with,2319,O
normal,2319,O
renal,2319,O
function,2319,O
",",2319,O
OCT,2319,B-Chemical
induced,2319,O
a,2319,O
transient,2319,O
decrease,2319,O
in,2319,O
serum,2319,O
PTH,2319,O
levels,2319,O
at,2319,O
a,2319,O
dose,2319,O
of,2319,O
0.1,2319,O
microg/kg,2319,O
",",2319,O
which,2319,O
was,2319,O
not,2319,O
sustained,2319,O
with,2319,O
lowering,2319,O
of,2319,O
the,2319,O
doses,2319,O
.,2319,O
In,2320,O
Nx,2320,O
dogs,2320,O
",",2320,O
OCT,2320,B-Chemical
reversed,2320,O
abnormal,2320,O
bone,2320,O
formation,2320,O
",",2320,O
such,2320,O
as,2320,O
woven,2320,B-Disease
osteoid,2320,I-Disease
and,2320,O
fibrosis,2320,B-Disease
",",2320,O
but,2320,O
did,2320,O
not,2320,O
significantly,2320,O
alter,2320,O
the,2320,O
level,2320,O
of,2320,O
bone,2320,O
turnover,2320,O
.,2320,O
In,2321,O
addition,2321,O
",",2321,O
OCT,2321,B-Chemical
improved,2321,O
mineralization,2321,O
lag,2321,O
time,2321,O
",",2321,O
(,2321,O
that,2321,O
is,2321,O
",",2321,O
the,2321,O
rate,2321,O
at,2321,O
which,2321,O
osteoid,2321,O
mineralizes,2321,O
),2321,O
in,2321,O
both,2321,O
Nx,2321,O
and,2321,O
Sham,2321,O
dogs,2321,O
.,2321,O
CONCLUSIONS,2322,O
:,2322,O
These,2322,O
results,2322,O
indicate,2322,O
that,2322,O
even,2322,O
though,2322,O
OCT,2322,B-Chemical
does,2322,O
not,2322,O
completely,2322,O
prevent,2322,O
the,2322,O
occurrence,2322,O
of,2322,O
hypercalcemia,2322,B-Disease
in,2322,O
experimental,2322,O
dogs,2322,O
with,2322,O
renal,2322,B-Disease
insufficiency,2322,I-Disease
",",2322,O
it,2322,O
may,2322,O
be,2322,O
of,2322,O
use,2322,O
in,2322,O
the,2322,O
management,2322,O
of,2322,O
secondary,2322,B-Disease
hyperparathyroidism,2322,I-Disease
because,2322,O
it,2322,O
does,2322,O
not,2322,O
induce,2322,O
low,2322,B-Disease
bone,2322,I-Disease
turnover,2322,I-Disease
and,2322,O
",",2322,O
therefore,2322,O
",",2322,O
does,2322,O
not,2322,O
increase,2322,O
the,2322,O
risk,2322,O
of,2322,O
adynamic,2322,B-Disease
bone,2322,I-Disease
disease,2322,I-Disease
.,2322,O
Hypotension,2323,B-Disease
",",2323,O
bradycardia,2323,B-Disease
",",2323,O
and,2323,O
asystole,2323,B-Disease
after,2323,O
high-dose,2323,O
intravenous,2323,O
methylprednisolone,2323,B-Chemical
in,2323,O
a,2323,O
monitored,2323,O
patient,2323,O
.,2323,O
We,2324,O
report,2324,O
a,2324,O
case,2324,O
of,2324,O
hypotension,2324,B-Disease
",",2324,O
bradycardia,2324,B-Disease
",",2324,O
and,2324,O
asystole,2324,B-Disease
after,2324,O
intravenous,2324,O
administration,2324,O
of,2324,O
high-dose,2324,O
methylprednisolone,2324,B-Chemical
in,2324,O
a,2324,O
73-year-old,2324,O
patient,2324,O
who,2324,O
underwent,2324,O
electrocardiographic,2324,O
(,2324,O
ECG,2324,O
),2324,O
monitoring,2324,O
throughout,2324,O
the,2324,O
episode,2324,O
.,2324,O
There,2325,O
was,2325,O
a,2325,O
history,2325,O
of,2325,O
ischemic,2325,B-Disease
cardiac,2325,B-Disease
disease,2325,I-Disease
9,2325,O
years,2325,O
earlier,2325,O
.,2325,O
The,2326,O
patient,2326,O
was,2326,O
admitted,2326,O
with,2326,O
a,2326,O
pulmonary-renal,2326,B-Disease
syndrome,2326,I-Disease
with,2326,O
hemoptysis,2326,B-Disease
",",2326,O
rapidly,2326,O
progressive,2326,O
renal,2326,B-Disease
failure,2326,I-Disease
",",2326,O
and,2326,O
hypoxemia,2326,B-Disease
that,2326,O
required,2326,O
mechanical,2326,O
ventilation,2326,O
in,2326,O
the,2326,O
intensive,2326,O
care,2326,O
unit,2326,O
.,2326,O
After,2327,O
receiving,2327,O
advanced,2327,O
cardiopulmonary,2327,O
resuscitation,2327,O
",",2327,O
the,2327,O
patient,2327,O
recovered,2327,O
cardiac,2327,O
rhythm,2327,O
.,2327,O
The,2328,O
ECG,2328,O
showed,2328,O
a,2328,O
junctional,2328,O
rhythm,2328,O
without,2328,O
ventricular,2328,B-Disease
arrhythmia,2328,I-Disease
.,2328,O
This,2329,O
study,2329,O
reviews,2329,O
the,2329,O
current,2329,O
proposed,2329,O
mechanisms,2329,O
of,2329,O
sudden,2329,B-Disease
death,2329,I-Disease
after,2329,O
a,2329,O
high,2329,O
dose,2329,O
of,2329,O
intravenous,2329,O
methylprednisolone,2329,B-Chemical
(,2329,O
IVMP,2329,B-Chemical
),2329,O
.,2329,O
These,2330,O
mechanisms,2330,O
are,2330,O
not,2330,O
well,2330,O
understood,2330,O
because,2330,O
",",2330,O
in,2330,O
most,2330,O
cases,2330,O
",",2330,O
the,2330,O
patients,2330,O
were,2330,O
not,2330,O
monitored,2330,O
at,2330,O
the,2330,O
moment,2330,O
of,2330,O
the,2330,O
event,2330,O
.,2330,O
Rapid,2331,O
infusion,2331,O
and,2331,O
underlying,2331,O
cardiac,2331,B-Disease
disease,2331,I-Disease
were,2331,O
important,2331,O
risk,2331,O
factors,2331,O
in,2331,O
the,2331,O
case,2331,O
reported,2331,O
here,2331,O
",",2331,O
and,2331,O
the,2331,O
authors,2331,O
discount,2331,O
ventricular,2331,B-Disease
arrhythmia,2331,I-Disease
as,2331,O
the,2331,O
main,2331,O
mechanism,2331,O
.,2331,O
Worsening,2332,O
of,2332,O
levodopa-induced,2332,B-Chemical
dyskinesias,2332,B-Disease
by,2332,O
motor,2332,O
and,2332,O
mental,2332,O
tasks,2332,O
.,2332,O
Ten,2333,O
patients,2333,O
who,2333,O
had,2333,O
Parkinson,2333,B-Disease
's,2333,I-Disease
disease,2333,I-Disease
with,2333,O
disabling,2333,O
dyskinesia,2333,B-Disease
were,2333,O
included,2333,O
in,2333,O
this,2333,O
study,2333,O
to,2333,O
evaluate,2333,O
the,2333,O
role,2333,O
of,2333,O
mental,2333,O
(,2333,O
mental,2333,O
calculation,2333,O
),2333,O
and,2333,O
motor,2333,O
(,2333,O
flexion/extension,2333,O
of,2333,O
right,2333,O
fingers,2333,O
",",2333,O
flexion/extension,2333,O
of,2333,O
left,2333,O
fingers,2333,O
",",2333,O
flexion/extension,2333,O
of,2333,O
the,2333,O
neck,2333,O
",",2333,O
speaking,2333,O
aloud,2333,O
),2333,O
tasks,2333,O
on,2333,O
the,2333,O
worsening,2333,O
of,2333,O
peak-dose,2333,O
dyskinesia,2333,B-Disease
following,2333,O
administration,2333,O
of,2333,O
an,2333,O
effective,2333,O
single,2333,O
dose,2333,O
of,2333,O
apomorphine,2333,B-Chemical
.,2333,O
Compared,2334,O
with,2334,O
the,2334,O
score,2334,O
at,2334,O
rest,2334,O
(,2334,O
1.3+/-0.3,2334,O
),2334,O
",",2334,O
a,2334,O
significant,2334,O
aggravation,2334,O
of,2334,O
the,2334,O
dyskinesia,2334,B-Disease
score,2334,O
was,2334,O
observed,2334,O
during,2334,O
speaking,2334,O
aloud,2334,O
(,2334,O
5.2+/-1.1,2334,O
",",2334,O
p,2334,O
<,2334,O
0.05,2334,O
),2334,O
",",2334,O
movements,2334,O
of,2334,O
right,2334,O
(,2334,O
4.5+/-1.0,2334,O
",",2334,O
p,2334,O
<,2334,O
0.05,2334,O
),2334,O
and,2334,O
left,2334,O
(,2334,O
3.7+/-0.8,2334,O
",",2334,O
p,2334,O
<,2334,O
0.05,2334,O
),2334,O
fingers,2334,O
",",2334,O
movements,2334,O
of,2334,O
the,2334,O
neck,2334,O
(,2334,O
5.1+/-1.0,2334,O
",",2334,O
p,2334,O
<,2334,O
0.05,2334,O
),2334,O
",",2334,O
and,2334,O
mental,2334,O
calculation,2334,O
(,2334,O
3.1+/-1.0,2334,O
",",2334,O
p,2334,O
<,2334,O
0.05,2334,O
),2334,O
.,2334,O
These,2335,O
results,2335,O
suggest,2335,O
that,2335,O
activation,2335,O
tasks,2335,O
such,2335,O
as,2335,O
``,2335,O
speaking,2335,O
aloud,2335,O
'',2335,O
could,2335,O
be,2335,O
used,2335,O
for,2335,O
objective,2335,O
assessment,2335,O
of,2335,O
dyskinesia,2335,B-Disease
severity,2335,O
.,2335,O
Urine,2336,O
N-acetyl-beta-D-glucosaminidase,2336,O
--,2336,O
a,2336,O
marker,2336,O
of,2336,O
tubular,2336,O
damage,2336,O
?,2336,O
BACKGROUND,2337,O
:,2337,O
Although,2337,O
an,2337,O
indicator,2337,O
of,2337,O
renal,2337,B-Disease
tubular,2337,I-Disease
dysfunction,2337,I-Disease
",",2337,O
an,2337,O
increased,2337,O
urinary,2337,O
N-acetyl-beta-D-glucosaminidase,2337,O
(,2337,O
NAG,2337,O
),2337,O
activity,2337,O
might,2337,O
reflect,2337,O
increased,2337,O
lysosomal,2337,O
activity,2337,O
in,2337,O
renal,2337,O
tubular,2337,O
cells,2337,O
.,2337,O
METHODS,2338,O
:,2338,O
Puromycin,2338,B-Chemical
aminonucleoside,2338,I-Chemical
(,2338,O
PAN,2338,B-Chemical
),2338,O
was,2338,O
administered,2338,O
to,2338,O
Sprague,2338,O
Dawley,2338,O
rats,2338,O
to,2338,O
induce,2338,O
proteinuria,2338,B-Disease
.,2338,O
Total,2339,O
protein,2339,O
",",2339,O
albumin,2339,O
",",2339,O
NAG,2339,O
activity,2339,O
and,2339,O
protein,2339,O
electrophoretic,2339,O
pattern,2339,O
were,2339,O
assessed,2339,O
in,2339,O
daily,2339,O
urine,2339,O
samples,2339,O
for,2339,O
33,2339,O
days,2339,O
.,2339,O
The,2340,O
morphological,2340,O
appearance,2340,O
of,2340,O
the,2340,O
kidneys,2340,O
was,2340,O
examined,2340,O
on,2340,O
days,2340,O
three,2340,O
",",2340,O
four,2340,O
",",2340,O
six,2340,O
",",2340,O
eight,2340,O
and,2340,O
thirty,2340,O
three,2340,O
and,2340,O
the,2340,O
NAG,2340,O
isoenzyme,2340,O
patterns,2340,O
on,2340,O
days,2340,O
zero,2340,O
",",2340,O
four,2340,O
",",2340,O
eight,2340,O
and,2340,O
thirty,2340,O
three,2340,O
.,2340,O
RESULTS,2341,O
:,2341,O
Following,2341,O
intravenous,2341,O
PAN,2341,B-Chemical
urine,2341,O
volume,2341,O
and,2341,O
urine,2341,O
NAG,2341,O
activity,2341,O
increased,2341,O
significantly,2341,O
by,2341,O
day,2341,O
two,2341,O
",",2341,O
but,2341,O
returned,2341,O
to,2341,O
normal,2341,O
by,2341,O
day,2341,O
four,2341,O
.,2341,O
After,2342,O
day,2342,O
four,2342,O
all,2342,O
treated,2342,O
animals,2342,O
exhibited,2342,O
a,2342,O
marked,2342,O
rise,2342,O
in,2342,O
urine,2342,O
albumin,2342,O
",",2342,O
total,2342,O
protein,2342,O
excretion,2342,O
and,2342,O
NAG,2342,O
activity,2342,O
.,2342,O
Electrophoresis,2343,O
showed,2343,O
a,2343,O
generalised,2343,O
increase,2343,O
in,2343,O
middle,2343,O
and,2343,O
high,2343,O
molecular,2343,O
weight,2343,O
urine,2343,O
proteins,2343,O
from,2343,O
day,2343,O
four,2343,O
onwards,2343,O
.,2343,O
Protein,2344,O
droplets,2344,O
first,2344,O
appeared,2344,O
prominent,2344,O
in,2344,O
tubular,2344,O
cells,2344,O
on,2344,O
day,2344,O
four,2344,O
.,2344,O
Peak,2345,O
urine,2345,O
NAG,2345,O
activity,2345,O
and,2345,O
a,2345,O
change,2345,O
in,2345,O
NAG,2345,O
isoenzyme,2345,O
pattern,2345,O
coincided,2345,O
with,2345,O
both,2345,O
the,2345,O
peak,2345,O
proteinuria,2345,B-Disease
and,2345,O
the,2345,O
reduction,2345,O
in,2345,O
intracellular,2345,O
protein,2345,O
and,2345,O
NAG,2345,O
droplets,2345,O
(,2345,O
day,2345,O
six,2345,O
onwards,2345,O
),2345,O
.,2345,O
CONCLUSIONS,2346,O
:,2346,O
This,2346,O
animal,2346,O
model,2346,O
demonstrates,2346,O
that,2346,O
an,2346,O
increase,2346,O
in,2346,O
lysosomal,2346,O
turnover,2346,O
and,2346,O
hence,2346,O
urine,2346,O
NAG,2346,O
activity,2346,O
",",2346,O
occurs,2346,O
when,2346,O
increased,2346,O
protein,2346,O
is,2346,O
presented,2346,O
to,2346,O
the,2346,O
tubular,2346,O
cells,2346,O
.,2346,O
Urine,2347,O
NAG,2347,O
activity,2347,O
is,2347,O
thus,2347,O
a,2347,O
measure,2347,O
of,2347,O
altered,2347,O
function,2347,O
in,2347,O
the,2347,O
renal,2347,O
tubules,2347,O
and,2347,O
not,2347,O
simply,2347,O
an,2347,O
indicator,2347,O
of,2347,O
damage,2347,O
.,2347,O
Cauda,2348,B-Disease
equina,2348,I-Disease
syndrome,2348,I-Disease
after,2348,O
spinal,2348,O
anaesthesia,2348,O
with,2348,O
hyperbaric,2348,O
5,2348,O
%,2348,O
lignocaine,2348,B-Chemical
:,2348,O
a,2348,O
review,2348,O
of,2348,O
six,2348,O
cases,2348,O
of,2348,O
cauda,2348,B-Disease
equina,2348,I-Disease
syndrome,2348,I-Disease
reported,2348,O
to,2348,O
the,2348,O
Swedish,2348,O
Pharmaceutical,2348,O
Insurance,2348,O
1993-1997,2348,O
.,2348,O
Six,2349,O
cases,2349,O
of,2349,O
cauda,2349,B-Disease
equina,2349,I-Disease
syndrome,2349,I-Disease
with,2349,O
varying,2349,O
severity,2349,O
were,2349,O
reported,2349,O
to,2349,O
the,2349,O
Swedish,2349,O
Pharmaceutical,2349,O
Insurance,2349,O
during,2349,O
the,2349,O
period,2349,O
1993-1997,2349,O
.,2349,O
All,2350,O
were,2350,O
associated,2350,O
with,2350,O
spinal,2350,O
anaesthesia,2350,O
using,2350,O
hyperbaric,2350,O
5,2350,O
%,2350,O
lignocaine,2350,B-Chemical
.,2350,O
Five,2351,O
cases,2351,O
had,2351,O
single-shot,2351,O
spinal,2351,O
anaesthesia,2351,O
and,2351,O
one,2351,O
had,2351,O
a,2351,O
repeat,2351,O
spinal,2351,O
anaesthetic,2351,O
due,2351,O
to,2351,O
inadequate,2351,O
block,2351,O
.,2351,O
The,2352,O
dose,2352,O
of,2352,O
hyperbaric,2352,O
5,2352,O
%,2352,O
lignocaine,2352,B-Chemical
administered,2352,O
ranged,2352,O
from,2352,O
60,2352,O
to,2352,O
120,2352,O
mg.,2352,O
Three,2352,O
of,2352,O
the,2352,O
cases,2352,O
were,2352,O
most,2352,O
likely,2352,O
caused,2352,O
by,2352,O
direct,2352,O
neurotoxicity,2352,B-Disease
of,2352,O
hyperbaric,2352,O
5,2352,O
%,2352,O
lignocaine,2352,B-Chemical
.,2352,O
In,2353,O
the,2353,O
other,2353,O
3,2353,O
cases,2353,O
",",2353,O
direct,2353,O
neurotoxicity,2353,B-Disease
was,2353,O
also,2353,O
probable,2353,O
",",2353,O
but,2353,O
unfortunately,2353,O
radiological,2353,O
investigations,2353,O
were,2353,O
not,2353,O
done,2353,O
to,2353,O
definitely,2353,O
exclude,2353,O
a,2353,O
compressive,2353,O
aetiology,2353,O
.,2353,O
All,2354,O
cases,2354,O
sustained,2354,O
permanent,2354,O
neurological,2354,B-Disease
deficits,2354,I-Disease
.,2354,O
We,2355,O
recommend,2355,O
that,2355,O
hyperbaric,2355,O
lignocaine,2355,B-Chemical
should,2355,O
be,2355,O
administered,2355,O
in,2355,O
concentrations,2355,O
not,2355,O
greater,2355,O
than,2355,O
2,2355,O
%,2355,O
and,2355,O
at,2355,O
a,2355,O
total,2355,O
dose,2355,O
preferably,2355,O
not,2355,O
exceeding,2355,O
60,2355,O
mg,2355,O
.,2355,O
Systemic,2356,O
toxicity,2356,B-Disease
following,2356,O
administration,2356,O
of,2356,O
sirolimus,2356,B-Chemical
(,2356,O
formerly,2356,O
rapamycin,2356,B-Chemical
),2356,O
for,2356,O
psoriasis,2356,B-Disease
:,2356,O
association,2356,O
of,2356,O
capillary,2356,B-Disease
leak,2356,I-Disease
syndrome,2356,I-Disease
with,2356,O
apoptosis,2356,O
of,2356,O
lesional,2356,O
lymphocytes,2356,O
.,2356,O
BACKGROUND,2357,O
:,2357,O
Sirolimus,2357,B-Chemical
(,2357,O
formerly,2357,O
rapamycin,2357,B-Chemical
),2357,O
is,2357,O
an,2357,O
immunosuppressive,2357,O
agent,2357,O
that,2357,O
interferes,2357,O
with,2357,O
T-cell,2357,O
activation,2357,O
.,2357,O
After,2358,O
2,2358,O
individuals,2358,O
with,2358,O
psoriasis,2358,B-Disease
developed,2358,O
a,2358,O
capillary,2358,B-Disease
leak,2358,I-Disease
syndrome,2358,I-Disease
following,2358,O
treatment,2358,O
with,2358,O
oral,2358,O
sirolimus,2358,B-Chemical
lesional,2358,O
skin,2358,O
cells,2358,O
and,2358,O
activated,2358,O
peripheral,2358,O
blood,2358,O
cells,2358,O
were,2358,O
analyzed,2358,O
for,2358,O
induction,2358,O
of,2358,O
apoptosis,2358,O
.,2358,O
OBSERVATIONS,2359,O
:,2359,O
A,2359,O
keratome,2359,O
skin,2359,O
specimen,2359,O
from,2359,O
1,2359,O
patient,2359,O
with,2359,O
sirolimus-induced,2359,B-Chemical
capillary,2359,B-Disease
leak,2359,I-Disease
syndrome,2359,I-Disease
had,2359,O
a,2359,O
2.3-fold,2359,O
increase,2359,O
in,2359,O
percentage,2359,O
of,2359,O
apoptotic,2359,O
cells,2359,O
(,2359,O
to,2359,O
48,2359,O
%,2359,O
),2359,O
compared,2359,O
with,2359,O
an,2359,O
unaffected,2359,O
sirolimus-treated,2359,B-Chemical
patient,2359,O
with,2359,O
psoriasis,2359,B-Disease
(,2359,O
21,2359,O
%,2359,O
),2359,O
.,2359,O
Activated,2360,O
peripheral,2360,O
blood,2360,O
T,2360,O
cells,2360,O
from,2360,O
patients,2360,O
with,2360,O
psoriasis,2360,B-Disease
tended,2360,O
to,2360,O
exhibit,2360,O
greater,2360,O
spontaneous,2360,O
or,2360,O
dexamethasone-induced,2360,B-Chemical
apoptosis,2360,O
than,2360,O
did,2360,O
normal,2360,O
T,2360,O
cells,2360,O
",",2360,O
particularly,2360,O
in,2360,O
the,2360,O
presence,2360,O
of,2360,O
sirolimus,2360,B-Chemical
.,2360,O
CONCLUSIONS,2361,O
:,2361,O
Severe,2361,O
adverse,2361,O
effects,2361,O
of,2361,O
sirolimus,2361,B-Chemical
include,2361,O
fever,2361,B-Disease
",",2361,O
anemia,2361,B-Disease
",",2361,O
and,2361,O
capillary,2361,B-Disease
leak,2361,I-Disease
syndrome,2361,I-Disease
.,2361,O
These,2362,O
symptoms,2362,O
may,2362,O
be,2362,O
the,2362,O
result,2362,O
of,2362,O
drug-induced,2362,O
apoptosis,2362,O
of,2362,O
lesional,2362,O
leukocytes,2362,O
",",2362,O
especially,2362,O
activated,2362,O
T,2362,O
lymphocytes,2362,O
",",2362,O
and,2362,O
possibly,2362,O
release,2362,O
of,2362,O
inflammatory,2362,O
mediators,2362,O
.,2362,O
Because,2363,O
patients,2363,O
with,2363,O
severe,2363,O
psoriasis,2363,B-Disease
may,2363,O
develop,2363,O
capillary,2363,B-Disease
leak,2363,I-Disease
from,2363,O
various,2363,O
systemic,2363,O
therapies,2363,O
",",2363,O
clinical,2363,O
monitoring,2363,O
is,2363,O
advisable,2363,O
for,2363,O
patients,2363,O
with,2363,O
inflammatory,2363,B-Disease
diseases,2363,I-Disease
who,2363,O
are,2363,O
treated,2363,O
with,2363,O
immune,2363,O
modulators,2363,O
.,2363,O
Effect,2364,O
of,2364,O
lithium,2364,B-Chemical
maintenance,2364,O
therapy,2364,O
on,2364,O
thyroid,2364,O
and,2364,O
parathyroid,2364,O
function,2364,O
.,2364,O
OBJECTIVES,2365,O
:,2365,O
To,2365,O
assess,2365,O
changes,2365,O
induced,2365,O
by,2365,O
lithium,2365,B-Chemical
maintenance,2365,O
therapy,2365,O
on,2365,O
the,2365,O
incidence,2365,O
of,2365,O
thyroid,2365,O
",",2365,O
parathyroid,2365,O
and,2365,O
ion,2365,O
alterations,2365,O
.,2365,O
These,2366,O
were,2366,O
evaluated,2366,O
with,2366,O
respect,2366,O
to,2366,O
the,2366,O
duration,2366,O
of,2366,O
lithium,2366,B-Chemical
therapy,2366,O
",",2366,O
age,2366,O
",",2366,O
sex,2366,O
",",2366,O
and,2366,O
family,2366,O
history,2366,O
(,2366,O
whether,2366,O
or,2366,O
not,2366,O
the,2366,O
patient,2366,O
had,2366,O
a,2366,O
first-degree,2366,O
relative,2366,O
with,2366,O
thyroid,2366,B-Disease
disease,2366,I-Disease
),2366,O
.,2366,O
DESIGN,2367,O
:,2367,O
Prospective,2367,O
study,2367,O
.,2367,O
SETTING,2368,O
:,2368,O
Affective,2368,O
Disorders,2368,O
Clinic,2368,O
at,2368,O
St.,2368,O
Mary,2368,O
's,2368,O
Hospital,2368,O
",",2368,O
Montreal,2368,O
.,2368,O
PATIENTS,2369,O
:,2369,O
One,2369,O
hundred,2369,O
and,2369,O
one,2369,O
patients,2369,O
(,2369,O
28,2369,O
men,2369,O
and,2369,O
73,2369,O
women,2369,O
),2369,O
with,2369,O
bipolar,2369,B-Disease
disorder,2369,I-Disease
receiving,2369,O
lithium,2369,B-Chemical
maintenance,2369,O
therapy,2369,O
ranging,2369,O
from,2369,O
1,2369,O
year,2369,O
's,2369,O
to,2369,O
32,2369,O
years,2369,O
',2369,O
duration,2369,O
.,2369,O
The,2370,O
control,2370,O
group,2370,O
consisted,2370,O
of,2370,O
82,2370,O
patients,2370,O
with,2370,O
no,2370,O
psychiatric,2370,B-Disease
or,2370,O
endocrinological,2370,O
diagnoses,2370,O
from,2370,O
the,2370,O
hospital,2370,O
's,2370,O
out-patient,2370,O
clinics,2370,O
.,2370,O
OUTCOME,2371,O
MEASURES,2371,O
:,2371,O
Laboratory,2371,O
analyses,2371,O
of,2371,O
calcium,2371,B-Chemical
",",2371,O
magnesium,2371,B-Chemical
and,2371,O
thyroid-stimulating,2371,O
hormone,2371,O
levels,2371,O
performed,2371,O
before,2371,O
beginning,2371,O
lithium,2371,B-Chemical
therapy,2371,O
and,2371,O
at,2371,O
biannual,2371,O
follow-up,2371,O
.,2371,O
RESULTS,2372,O
:,2372,O
Hypothyroidism,2372,B-Disease
developed,2372,O
in,2372,O
40,2372,O
patients,2372,O
",",2372,O
excluding,2372,O
8,2372,O
patients,2372,O
who,2372,O
were,2372,O
hypothyroid,2372,B-Disease
at,2372,O
baseline,2372,O
.,2372,O
All,2373,O
patients,2373,O
having,2373,O
first-degree,2373,O
relatives,2373,O
affected,2373,O
by,2373,O
thyroid,2373,B-Disease
illness,2373,I-Disease
had,2373,O
accelerated,2373,O
onset,2373,O
of,2373,O
hypothyroidism,2373,B-Disease
(,2373,O
3.7,2373,O
years,2373,O
after,2373,O
onset,2373,O
of,2373,O
lithium,2373,B-Chemical
therapy,2373,O
),2373,O
compared,2373,O
with,2373,O
patients,2373,O
without,2373,O
a,2373,O
family,2373,O
history,2373,O
(,2373,O
8.6,2373,O
years,2373,O
after,2373,O
onset,2373,O
of,2373,O
lithium,2373,B-Chemical
therapy,2373,O
),2373,O
.,2373,O
Women,2374,O
over,2374,O
60,2374,O
years,2374,O
of,2374,O
age,2374,O
were,2374,O
more,2374,O
often,2374,O
affected,2374,O
by,2374,O
hypothyroidism,2374,B-Disease
than,2374,O
women,2374,O
under,2374,O
60,2374,O
years,2374,O
of,2374,O
age,2374,O
(,2374,O
34.6,2374,O
%,2374,O
versus,2374,O
31.9,2374,O
%,2374,O
),2374,O
.,2374,O
Magnesium,2375,B-Chemical
levels,2375,O
in,2375,O
patients,2375,O
on,2375,O
lithium,2375,B-Chemical
treatment,2375,O
were,2375,O
unchanged,2375,O
from,2375,O
baseline,2375,O
levels,2375,O
.,2375,O
After,2376,O
lithium,2376,B-Chemical
treatment,2376,O
",",2376,O
calcium,2376,B-Chemical
levels,2376,O
were,2376,O
higher,2376,O
than,2376,O
either,2376,O
baseline,2376,O
levels,2376,O
or,2376,O
control,2376,O
levels,2376,O
.,2376,O
Thus,2377,O
",",2377,O
lithium,2377,B-Chemical
treatment,2377,O
counteracted,2377,O
the,2377,O
decrease,2377,O
in,2377,O
plasma,2377,O
calcium,2377,B-Chemical
levels,2377,O
associated,2377,O
with,2377,O
aging,2377,O
.,2377,O
CONCLUSIONS,2378,O
:,2378,O
Familial,2378,O
thyroid,2378,B-Disease
illness,2378,I-Disease
is,2378,O
a,2378,O
risk,2378,O
factor,2378,O
for,2378,O
hypothyroidism,2378,B-Disease
and,2378,O
hypercalcemia,2378,B-Disease
during,2378,O
lithium,2378,B-Chemical
therapy,2378,O
.,2378,O
Severe,2379,O
immune,2379,O
hemolytic,2379,B-Disease
anemia,2379,I-Disease
associated,2379,O
with,2379,O
prophylactic,2379,O
use,2379,O
of,2379,O
cefotetan,2379,B-Chemical
in,2379,O
obstetric,2379,O
and,2379,O
gynecologic,2379,O
procedures,2379,O
.,2379,O
Second-,2380,O
and,2380,O
third-generation,2380,O
cephalosporins,2380,B-Chemical
",",2380,O
especially,2380,O
cefotetan,2380,B-Chemical
",",2380,O
are,2380,O
increasingly,2380,O
associated,2380,O
with,2380,O
severe,2380,O
",",2380,O
sometimes,2380,O
fatal,2380,O
immune,2380,O
hemolytic,2380,B-Disease
anemia,2380,I-Disease
.,2380,O
We,2381,O
noticed,2381,O
that,2381,O
10,2381,O
of,2381,O
our,2381,O
35,2381,O
cases,2381,O
of,2381,O
cefotetan-induced,2381,B-Chemical
hemolytic,2381,B-Disease
anemias,2381,I-Disease
were,2381,O
in,2381,O
patients,2381,O
who,2381,O
had,2381,O
received,2381,O
cefotetan,2381,B-Chemical
prophylactically,2381,O
for,2381,O
obstetric,2381,O
and,2381,O
gynecologic,2381,O
procedures,2381,O
.,2381,O
Eight,2382,O
of,2382,O
these,2382,O
cases,2382,O
of,2382,O
severe,2382,O
immune,2382,O
hemolytic,2382,B-Disease
anemia,2382,I-Disease
are,2382,O
described,2382,O
.,2382,O
Effects,2383,O
of,2383,O
nonsteroidal,2383,O
anti-inflammatory,2383,O
drugs,2383,O
on,2383,O
hemostasis,2383,O
in,2383,O
patients,2383,O
with,2383,O
aneurysmal,2383,B-Disease
subarachnoid,2383,I-Disease
hemorrhage,2383,I-Disease
.,2383,O
Platelet,2384,O
function,2384,O
is,2384,O
impaired,2384,O
by,2384,O
nonsteroidal,2384,O
anti-inflammatory,2384,O
drugs,2384,O
(,2384,O
NSAIDs,2384,O
),2384,O
with,2384,O
prominent,2384,O
anti-inflammatory,2384,O
properties,2384,O
.,2384,O
Their,2385,O
safety,2385,O
in,2385,O
patients,2385,O
undergoing,2385,O
intracranial,2385,O
surgery,2385,O
is,2385,O
under,2385,O
debate,2385,O
.,2385,O
Patients,2386,O
with,2386,O
aneurysmal,2386,B-Disease
subarachnoid,2386,I-Disease
hemorrhage,2386,I-Disease
(,2386,O
SAH,2386,B-Disease
),2386,O
were,2386,O
randomized,2386,O
to,2386,O
receive,2386,O
either,2386,O
ketoprofen,2386,B-Chemical
",",2386,O
100,2386,O
mg,2386,O
",",2386,O
three,2386,O
times,2386,O
a,2386,O
day,2386,O
(,2386,O
ketoprofen,2386,B-Chemical
group,2386,O
",",2386,O
n,2386,O
=,2386,O
9,2386,O
),2386,O
or,2386,O
a,2386,O
weak,2386,O
NSAID,2386,O
",",2386,O
acetaminophen,2386,B-Chemical
",",2386,O
1,2386,O
g,2386,O
",",2386,O
three,2386,O
times,2386,O
a,2386,O
day,2386,O
(,2386,O
acetaminophen,2386,B-Chemical
group,2386,O
",",2386,O
n,2386,O
=,2386,O
9,2386,O
),2386,O
starting,2386,O
immediately,2386,O
after,2386,O
the,2386,O
diagnosis,2386,O
of,2386,O
aneurysmal,2386,B-Disease
SAH,2386,B-Disease
.,2386,O
Treatment,2387,O
was,2387,O
continued,2387,O
for,2387,O
3,2387,O
days,2387,O
postoperatively,2387,O
.,2387,O
Test,2388,O
blood,2388,O
samples,2388,O
were,2388,O
taken,2388,O
before,2388,O
treatment,2388,O
and,2388,O
surgery,2388,O
as,2388,O
well,2388,O
as,2388,O
on,2388,O
the,2388,O
first,2388,O
",",2388,O
third,2388,O
",",2388,O
and,2388,O
fifth,2388,O
postoperative,2388,O
mornings,2388,O
.,2388,O
Maximal,2389,O
platelet,2389,B-Disease
aggregation,2389,I-Disease
induced,2389,O
by,2389,O
6,2389,O
microM,2389,O
of,2389,O
adenosine,2389,B-Chemical
diphosphate,2389,I-Chemical
decreased,2389,O
after,2389,O
administration,2389,O
of,2389,O
ketoprofen,2389,B-Chemical
.,2389,O
Aggregation,2390,O
was,2390,O
lower,2390,O
(,2390,O
P,2390,O
<,2390,O
.05,2390,O
),2390,O
in,2390,O
the,2390,O
ketoprofen,2390,B-Chemical
group,2390,O
than,2390,O
in,2390,O
the,2390,O
acetaminophen,2390,B-Chemical
group,2390,O
just,2390,O
before,2390,O
surgery,2390,O
and,2390,O
on,2390,O
the,2390,O
third,2390,O
postoperative,2390,O
day,2390,O
.,2390,O
In,2391,O
contrast,2391,O
",",2391,O
maximal,2391,O
platelet,2391,B-Disease
aggregation,2391,I-Disease
increased,2391,O
in,2391,O
the,2391,O
acetaminophen,2391,B-Chemical
group,2391,O
on,2391,O
the,2391,O
third,2391,O
postoperative,2391,O
day,2391,O
as,2391,O
compared,2391,O
with,2391,O
the,2391,O
pretreatment,2391,O
platelet,2391,B-Disease
aggregation,2391,I-Disease
results,2391,O
(,2391,O
P,2391,O
<,2391,O
.05,2391,O
),2391,O
.,2391,O
One,2392,O
patient,2392,O
in,2392,O
the,2392,O
ketoprofen,2392,B-Chemical
group,2392,O
developed,2392,O
a,2392,O
postoperative,2392,O
intracranial,2392,O
hematoma,2392,B-Disease
.,2392,O
Coagulation,2393,O
(,2393,O
prothrombin,2393,O
time,2393,O
[,2393,O
PT,2393,O
],2393,O
",",2393,O
activated,2393,O
partial,2393,O
thromboplastin,2393,O
time,2393,O
[,2393,O
APPT,2393,O
],2393,O
",",2393,O
fibrinogen,2393,O
concentration,2393,O
",",2393,O
and,2393,O
antithrombin,2393,O
III,2393,O
[,2393,O
AT,2393,O
III,2393,O
],2393,O
),2393,O
was,2393,O
comparable,2393,O
between,2393,O
the,2393,O
two,2393,O
groups,2393,O
.,2393,O
Ketoprofen,2394,B-Chemical
but,2394,O
not,2394,O
acetaminophen,2394,B-Chemical
impaired,2394,O
platelet,2394,O
function,2394,O
in,2394,O
patients,2394,O
with,2394,O
SAH,2394,B-Disease
.,2394,O
If,2395,O
ketoprofen,2395,B-Chemical
is,2395,O
used,2395,O
before,2395,O
surgery,2395,O
on,2395,O
cerebral,2395,O
artery,2395,B-Disease
aneurysms,2395,I-Disease
",",2395,O
it,2395,O
may,2395,O
pose,2395,O
an,2395,O
additional,2395,O
risk,2395,O
factor,2395,O
for,2395,O
hemorrhage,2395,B-Disease
.,2395,O
Nitric,2396,B-Chemical
oxide,2396,I-Chemical
synthase,2396,O
expression,2396,O
in,2396,O
the,2396,O
course,2396,O
of,2396,O
lead-induced,2396,B-Chemical
hypertension,2396,B-Disease
.,2396,O
We,2397,O
recently,2397,O
showed,2397,O
elevated,2397,O
reactive,2397,O
oxygen,2397,B-Chemical
species,2397,O
(,2397,O
ROS,2397,O
),2397,O
",",2397,O
reduced,2397,O
urinary,2397,O
excretion,2397,O
of,2397,O
NO,2397,B-Chemical
metabolites,2397,O
(,2397,O
NOx,2397,O
),2397,O
",",2397,O
and,2397,O
increased,2397,O
NO,2397,B-Chemical
sequestration,2397,O
as,2397,O
nitrotyrosine,2397,B-Chemical
in,2397,O
various,2397,O
tissues,2397,O
in,2397,O
rats,2397,O
with,2397,O
lead-induced,2397,B-Chemical
hypertension,2397,B-Disease
.,2397,O
This,2398,O
study,2398,O
was,2398,O
designed,2398,O
to,2398,O
discern,2398,O
whether,2398,O
the,2398,O
reduction,2398,O
in,2398,O
urinary,2398,O
NOx,2398,O
in,2398,O
lead-induced,2398,B-Chemical
hypertension,2398,B-Disease
is,2398,O
",",2398,O
in,2398,O
part,2398,O
",",2398,O
due,2398,O
to,2398,O
depressed,2398,O
NO,2398,B-Chemical
synthase,2398,O
(,2398,O
NOS,2398,O
),2398,O
expression,2398,O
.,2398,O
Male,2399,O
Sprague-Dawley,2399,O
rats,2399,O
were,2399,O
randomly,2399,O
assigned,2399,O
to,2399,O
a,2399,O
lead-treated,2399,B-Chemical
group,2399,O
(,2399,O
given,2399,O
lead,2399,B-Chemical
acetate,2399,I-Chemical
",",2399,O
100,2399,O
ppm,2399,O
",",2399,O
in,2399,O
drinking,2399,O
water,2399,O
and,2399,O
regular,2399,O
rat,2399,O
chow,2399,O
),2399,O
",",2399,O
a,2399,O
group,2399,O
given,2399,O
lead,2399,B-Chemical
and,2399,O
vitamin,2399,B-Chemical
E-fortified,2399,O
chow,2399,O
",",2399,O
or,2399,O
a,2399,O
normal,2399,O
control,2399,O
group,2399,O
given,2399,O
either,2399,O
regular,2399,O
food,2399,O
and,2399,O
water,2399,O
or,2399,O
vitamin,2399,B-Chemical
E-fortified,2399,O
food,2399,O
for,2399,O
12,2399,O
weeks,2399,O
.,2399,O
Tail,2400,O
blood,2400,O
pressure,2400,O
",",2400,O
urinary,2400,O
NOx,2400,O
excretion,2400,O
",",2400,O
plasma,2400,O
malondialdehyde,2400,B-Chemical
(,2400,O
MDA,2400,B-Chemical
),2400,O
",",2400,O
and,2400,O
endothelial,2400,O
and,2400,O
inducible,2400,O
NOS,2400,O
(,2400,O
eNOS,2400,O
and,2400,O
iNOS,2400,O
),2400,O
isotypes,2400,O
in,2400,O
the,2400,O
aorta,2400,O
and,2400,O
kidney,2400,O
were,2400,O
measured,2400,O
.,2400,O
The,2401,O
lead-treated,2401,B-Chemical
group,2401,O
exhibited,2401,O
a,2401,O
rise,2401,O
in,2401,O
blood,2401,O
pressure,2401,O
and,2401,O
plasma,2401,O
MDA,2401,B-Chemical
concentration,2401,O
",",2401,O
a,2401,O
fall,2401,O
in,2401,O
urinary,2401,O
NOx,2401,O
excretion,2401,O
",",2401,O
and,2401,O
a,2401,O
paradoxical,2401,O
rise,2401,O
in,2401,O
vascular,2401,O
and,2401,O
renal,2401,O
tissue,2401,O
eNOS,2401,O
and,2401,O
iNOS,2401,O
expression,2401,O
.,2401,O
Vitamin,2402,B-Chemical
E,2402,I-Chemical
supplementation,2402,O
ameliorated,2402,O
hypertension,2402,B-Disease
",",2402,O
lowered,2402,O
plasma,2402,O
MDA,2402,B-Chemical
concentration,2402,O
",",2402,O
and,2402,O
raised,2402,O
urinary,2402,O
NOx,2402,O
excretion,2402,O
while,2402,O
significantly,2402,O
lowering,2402,O
vascular,2402,O
",",2402,O
but,2402,O
not,2402,O
renal,2402,O
",",2402,O
tissue,2402,O
eNOS,2402,O
and,2402,O
iNOS,2402,O
expression,2402,O
.,2402,O
Vitamin,2403,B-Chemical
E,2403,I-Chemical
supplementation,2403,O
had,2403,O
no,2403,O
effect,2403,O
on,2403,O
either,2403,O
blood,2403,O
pressure,2403,O
",",2403,O
plasma,2403,O
MDA,2403,B-Chemical
",",2403,O
or,2403,O
NOS,2403,O
expression,2403,O
in,2403,O
the,2403,O
control,2403,O
group,2403,O
.,2403,O
The,2404,O
study,2404,O
also,2404,O
revealed,2404,O
significant,2404,O
inhibition,2404,O
of,2404,O
NOS,2404,O
enzymatic,2404,O
activity,2404,O
by,2404,O
lead,2404,B-Chemical
in,2404,O
cell-free,2404,O
preparations,2404,O
.,2404,O
In,2405,O
conclusion,2405,O
",",2405,O
lead-induced,2405,B-Chemical
hypertension,2405,B-Disease
in,2405,O
this,2405,O
model,2405,O
was,2405,O
associated,2405,O
with,2405,O
a,2405,O
compensatory,2405,O
upregulation,2405,O
of,2405,O
renal,2405,O
and,2405,O
vascular,2405,O
eNOS,2405,O
and,2405,O
iNOS,2405,O
expression,2405,O
.,2405,O
This,2406,O
is,2406,O
",",2406,O
in,2406,O
part,2406,O
",",2406,O
due,2406,O
to,2406,O
ROS-mediated,2406,O
NO,2406,B-Chemical
inactivation,2406,O
",",2406,O
lead-associated,2406,B-Chemical
inhibition,2406,O
of,2406,O
NOS,2406,O
activity,2406,O
",",2406,O
and,2406,O
perhaps,2406,O
stimulatory,2406,O
actions,2406,O
of,2406,O
increased,2406,O
shear,2406,O
stress,2406,O
associated,2406,O
with,2406,O
hypertension,2406,B-Disease
.,2406,O
Glyceryl,2407,B-Chemical
trinitrate,2407,I-Chemical
induces,2407,O
attacks,2407,O
of,2407,O
migraine,2407,B-Disease
without,2407,I-Disease
aura,2407,I-Disease
in,2407,O
sufferers,2407,O
of,2407,O
migraine,2407,B-Disease
with,2407,I-Disease
aura,2407,I-Disease
.,2407,O
Migraine,2408,B-Disease
with,2408,I-Disease
aura,2408,I-Disease
and,2408,O
migraine,2408,B-Disease
without,2408,I-Disease
aura,2408,I-Disease
have,2408,O
the,2408,O
same,2408,O
pain,2408,B-Disease
phase,2408,O
",",2408,O
thus,2408,O
indicating,2408,O
that,2408,O
migraine,2408,B-Disease
with,2408,I-Disease
aura,2408,I-Disease
and,2408,O
migraine,2408,B-Disease
without,2408,I-Disease
aura,2408,I-Disease
share,2408,O
a,2408,O
common,2408,O
pathway,2408,O
of,2408,O
nociception,2408,O
.,2408,O
In,2409,O
recent,2409,O
years,2409,O
",",2409,O
increasing,2409,O
evidence,2409,O
has,2409,O
suggested,2409,O
that,2409,O
the,2409,O
messenger,2409,O
molecule,2409,O
nitric,2409,B-Chemical
oxide,2409,I-Chemical
(,2409,O
NO,2409,B-Chemical
),2409,O
is,2409,O
involved,2409,O
in,2409,O
pain,2409,B-Disease
mechanisms,2409,O
of,2409,O
migraine,2409,B-Disease
without,2409,I-Disease
aura,2409,I-Disease
.,2409,O
In,2410,O
order,2410,O
to,2410,O
clarify,2410,O
whether,2410,O
the,2410,O
same,2410,O
is,2410,O
true,2410,O
for,2410,O
migraine,2410,B-Disease
with,2410,I-Disease
aura,2410,I-Disease
",",2410,O
in,2410,O
the,2410,O
present,2410,O
study,2410,O
we,2410,O
examined,2410,O
the,2410,O
headache,2410,B-Disease
response,2410,O
to,2410,O
intravenous,2410,O
infusion,2410,O
of,2410,O
glyceryl,2410,B-Chemical
trinitrate,2410,I-Chemical
(,2410,O
GTN,2410,B-Chemical
),2410,O
(,2410,O
0.5,2410,O
microg/kg/min,2410,O
for,2410,O
20,2410,O
min,2410,O
),2410,O
in,2410,O
12,2410,O
sufferers,2410,O
of,2410,O
migraine,2410,B-Disease
with,2410,I-Disease
aura,2410,I-Disease
.,2410,O
The,2411,O
specific,2411,O
aim,2411,O
was,2411,O
to,2411,O
elucidate,2411,O
whether,2411,O
an,2411,O
aura,2411,O
and/or,2411,O
an,2411,O
attack,2411,O
of,2411,O
migraine,2411,B-Disease
without,2411,I-Disease
aura,2411,I-Disease
could,2411,O
be,2411,O
induced,2411,O
.,2411,O
Fourteen,2412,O
healthy,2412,O
subjects,2412,O
served,2412,O
as,2412,O
controls,2412,O
.,2412,O
Aura,2413,O
symptoms,2413,O
were,2413,O
not,2413,O
elicited,2413,O
in,2413,O
any,2413,O
subject,2413,O
.,2413,O
Headache,2414,B-Disease
was,2414,O
more,2414,O
severe,2414,O
in,2414,O
migraineurs,2414,B-Disease
than,2414,O
in,2414,O
the,2414,O
controls,2414,O
during,2414,O
and,2414,O
immediately,2414,O
after,2414,O
GTN,2414,B-Chemical
infusion,2414,O
(,2414,O
p=0.037,2414,O
),2414,O
as,2414,O
well,2414,O
as,2414,O
during,2414,O
the,2414,O
following,2414,O
11,2414,O
h,2414,O
(,2414,O
p,2414,O
=,2414,O
0.008,2414,O
),2414,O
.,2414,O
In,2415,O
the,2415,O
controls,2415,O
",",2415,O
the,2415,O
GTN-induced,2415,B-Chemical
headache,2415,B-Disease
gradually,2415,O
disappeared,2415,O
",",2415,O
whereas,2415,O
in,2415,O
migraineurs,2415,B-Disease
peak,2415,O
headache,2415,B-Disease
intensity,2415,O
occurred,2415,O
at,2415,O
a,2415,O
mean,2415,O
time,2415,O
of,2415,O
240,2415,O
min,2415,O
post-infusion,2415,O
.,2415,O
At,2416,O
this,2416,O
time,2416,O
the,2416,O
induced,2416,O
headache,2416,B-Disease
in,2416,O
6,2416,O
of,2416,O
12,2416,O
migraineurs,2416,B-Disease
fulfilled,2416,O
the,2416,O
diagnostic,2416,O
criteria,2416,O
for,2416,O
migraine,2416,B-Disease
without,2416,I-Disease
aura,2416,I-Disease
of,2416,O
the,2416,O
International,2416,O
Headache,2416,B-Disease
Society,2416,O
.,2416,O
The,2417,O
results,2417,O
therefore,2417,O
suggest,2417,O
that,2417,O
NO,2417,B-Chemical
is,2417,O
involved,2417,O
in,2417,O
the,2417,O
pain,2417,B-Disease
mechanisms,2417,O
of,2417,O
migraine,2417,B-Disease
with,2417,I-Disease
aura,2417,I-Disease
.,2417,O
Since,2418,O
cortical,2418,O
spreading,2418,O
depression,2418,B-Disease
has,2418,O
been,2418,O
shown,2418,O
to,2418,O
liberate,2418,O
NO,2418,B-Chemical
in,2418,O
animals,2418,O
",",2418,O
this,2418,O
finding,2418,O
may,2418,O
help,2418,O
our,2418,O
understanding,2418,O
of,2418,O
the,2418,O
coupling,2418,O
between,2418,O
cortical,2418,O
spreading,2418,O
depression,2418,B-Disease
and,2418,O
headache,2418,B-Disease
in,2418,O
migraine,2418,B-Disease
with,2418,I-Disease
aura,2418,I-Disease
.,2418,O
Rapid,2419,O
reversal,2419,O
of,2419,O
life-threatening,2419,O
diltiazem-induced,2419,B-Chemical
tetany,2419,B-Disease
with,2419,O
calcium,2419,B-Chemical
chloride,2419,I-Chemical
.,2419,O
We,2420,O
describe,2420,O
a,2420,O
patient,2420,O
who,2420,O
developed,2420,O
tetany,2420,B-Disease
with,2420,O
sudden,2420,O
respiratory,2420,B-Disease
arrest,2420,I-Disease
after,2420,O
the,2420,O
infusion,2420,O
of,2420,O
intravenous,2420,O
diltiazem,2420,B-Chemical
.,2420,O
The,2421,O
administration,2421,O
of,2421,O
calcium,2421,B-Chemical
chloride,2421,I-Chemical
rapidly,2421,O
resolved,2421,O
the,2421,O
patient,2421,O
's,2421,O
tetany,2421,B-Disease
with,2421,O
prompt,2421,O
recovery,2421,O
of,2421,O
respiratory,2421,O
function,2421,O
",",2421,O
averting,2421,O
the,2421,O
need,2421,O
for,2421,O
more,2421,O
aggressive,2421,O
airway,2421,O
management,2421,O
and,2421,O
ventilatory,2421,O
support,2421,O
.,2421,O
The,2422,O
emergency,2422,O
physician,2422,O
should,2422,O
be,2422,O
aware,2422,O
that,2422,O
life-threatening,2422,O
tetany,2422,B-Disease
may,2422,O
accompany,2422,O
the,2422,O
administration,2422,O
of,2422,O
intravenous,2422,O
diltiazem,2422,B-Chemical
and,2422,O
that,2422,O
calcium,2422,B-Chemical
chloride,2422,I-Chemical
may,2422,O
be,2422,O
a,2422,O
rapid,2422,O
and,2422,O
effective,2422,O
remedy,2422,O
.,2422,O
Predictors,2423,O
of,2423,O
decreased,2423,B-Disease
renal,2423,I-Disease
function,2423,I-Disease
in,2423,O
patients,2423,O
with,2423,O
heart,2423,B-Disease
failure,2423,I-Disease
during,2423,O
angiotensin-converting,2423,B-Chemical
enzyme,2423,O
inhibitor,2423,O
therapy,2423,O
:,2423,O
results,2423,O
from,2423,O
the,2423,O
studies,2423,O
of,2423,O
left,2423,B-Disease
ventricular,2423,I-Disease
dysfunction,2423,I-Disease
(,2423,O
SOLVD,2423,O
),2423,O
BACKGROUND,2423,O
:,2423,O
Although,2423,O
angiotensin-converting,2423,B-Chemical
enzyme,2423,O
inhibitor,2423,O
therapy,2423,O
reduces,2423,O
mortality,2423,O
rates,2423,O
in,2423,O
patients,2423,O
with,2423,O
congestive,2423,B-Disease
heart,2423,I-Disease
failure,2423,I-Disease
(,2423,O
CHF,2423,B-Disease
),2423,O
",",2423,O
it,2423,O
may,2423,O
also,2423,O
cause,2423,O
decreased,2423,B-Disease
renal,2423,I-Disease
function,2423,I-Disease
.,2423,O
Little,2424,O
information,2424,O
is,2424,O
available,2424,O
to,2424,O
predict,2424,O
which,2424,O
patients,2424,O
are,2424,O
at,2424,O
highest,2424,O
risk,2424,O
for,2424,O
this,2424,O
complication,2424,O
.,2424,O
OBJECTIVE,2425,O
:,2425,O
To,2425,O
quantify,2425,O
specific,2425,O
clinical,2425,O
predictors,2425,O
of,2425,O
reduction,2425,B-Disease
in,2425,I-Disease
renal,2425,I-Disease
function,2425,I-Disease
in,2425,O
patients,2425,O
with,2425,O
CHF,2425,B-Disease
who,2425,O
are,2425,O
prescribed,2425,O
angiotensin-converting,2425,B-Chemical
enzyme,2425,O
inhibitor,2425,O
therapy,2425,O
.,2425,O
METHOD,2426,O
:,2426,O
We,2426,O
analyzed,2426,O
data,2426,O
from,2426,O
the,2426,O
Studies,2426,O
of,2426,O
Left,2426,B-Disease
Ventricular,2426,I-Disease
Dysfunction,2426,I-Disease
(,2426,O
SOLVD,2426,O
),2426,O
",",2426,O
a,2426,O
randomized,2426,O
",",2426,O
double-blind,2426,O
",",2426,O
placebo-controlled,2426,O
trial,2426,O
of,2426,O
enalapril,2426,B-Chemical
for,2426,O
the,2426,O
treatment,2426,O
of,2426,O
CHF,2426,B-Disease
.,2426,O
There,2427,O
were,2427,O
3379,2427,O
patients,2427,O
randomly,2427,O
assigned,2427,O
to,2427,O
enalapril,2427,B-Chemical
with,2427,O
a,2427,O
median,2427,O
follow-up,2427,O
of,2427,O
974,2427,O
days,2427,O
and,2427,O
3379,2427,O
patients,2427,O
randomly,2427,O
assigned,2427,O
to,2427,O
placebo,2427,O
with,2427,O
a,2427,O
mean,2427,O
follow-up,2427,O
of,2427,O
967,2427,O
days,2427,O
.,2427,O
Decreased,2428,B-Disease
renal,2428,I-Disease
function,2428,I-Disease
was,2428,O
defined,2428,O
as,2428,O
a,2428,O
rise,2428,O
in,2428,O
serum,2428,O
creatinine,2428,B-Chemical
>,2428,O
/=0.5,2428,O
mg/dL,2428,O
(,2428,O
44,2428,O
micromol/L,2428,O
),2428,O
from,2428,O
baseline,2428,O
.,2428,O
We,2429,O
used,2429,O
time-to-event,2429,O
analysis,2429,O
to,2429,O
identify,2429,O
potential,2429,O
predictors,2429,O
of,2429,O
decrease,2429,O
in,2429,O
renal,2429,O
function,2429,O
including,2429,O
age,2429,O
",",2429,O
baseline,2429,O
ejection,2429,O
fraction,2429,O
",",2429,O
baseline,2429,O
creatinine,2429,B-Chemical
",",2429,O
low,2429,O
systolic,2429,O
blood,2429,O
pressure,2429,O
(,2429,O
<,2429,O
100,2429,O
mm,2429,O
Hg,2429,O
),2429,O
",",2429,O
history,2429,O
of,2429,O
hypertension,2429,B-Disease
",",2429,O
diabetes,2429,B-Disease
",",2429,O
and,2429,O
use,2429,O
of,2429,O
antiplatelet,2429,O
",",2429,O
diuretic,2429,B-Chemical
",",2429,O
and,2429,O
beta-blocker,2429,O
therapy,2429,O
.,2429,O
RESULTS,2430,O
:,2430,O
Patients,2430,O
randomly,2430,O
assigned,2430,O
to,2430,O
enalapril,2430,B-Chemical
had,2430,O
a,2430,O
33,2430,O
%,2430,O
greater,2430,O
likelihood,2430,O
of,2430,O
decreased,2430,B-Disease
renal,2430,I-Disease
function,2430,I-Disease
than,2430,O
controls,2430,O
(,2430,O
P,2430,O
=.003,2430,O
),2430,O
.,2430,O
By,2431,O
multivariate,2431,O
analysis,2431,O
",",2431,O
in,2431,O
both,2431,O
the,2431,O
placebo,2431,O
and,2431,O
enalapril,2431,B-Chemical
groups,2431,O
older,2431,O
age,2431,O
",",2431,O
diuretic,2431,B-Chemical
therapy,2431,O
",",2431,O
and,2431,O
diabetes,2431,B-Disease
were,2431,O
associated,2431,O
with,2431,O
decreased,2431,B-Disease
renal,2431,I-Disease
function,2431,I-Disease
",",2431,O
whereas,2431,O
beta-blocker,2431,O
therapy,2431,O
and,2431,O
higher,2431,O
ejection,2431,O
fraction,2431,O
were,2431,O
renoprotective,2431,O
.,2431,O
Older,2432,O
age,2432,O
was,2432,O
associated,2432,O
with,2432,O
a,2432,O
greater,2432,O
risk,2432,O
of,2432,O
developing,2432,O
decreased,2432,B-Disease
renal,2432,I-Disease
function,2432,I-Disease
in,2432,O
both,2432,O
groups,2432,O
",",2432,O
but,2432,O
significantly,2432,O
more,2432,O
so,2432,O
in,2432,O
the,2432,O
enalapril,2432,B-Chemical
group,2432,O
(,2432,O
enalapril,2432,B-Chemical
:,2432,O
risk,2432,O
ratio,2432,O
[,2432,O
RR,2432,O
],2432,O
1.42,2432,O
per,2432,O
10,2432,O
years,2432,O
",",2432,O
95,2432,O
%,2432,O
confidence,2432,O
interval,2432,O
[,2432,O
CI,2432,O
],2432,O
1.32-1.52,2432,O
with,2432,O
enalapril,2432,B-Chemical
;,2432,O
placebo,2432,O
:,2432,O
RR,2432,O
1.18,2432,O
",",2432,O
95,2432,O
%,2432,O
CI,2432,O
1.12-1.25,2432,O
),2432,O
.,2432,O
Diuretic,2433,B-Chemical
therapy,2433,O
was,2433,O
likewise,2433,O
associated,2433,O
with,2433,O
a,2433,O
greater,2433,O
risk,2433,O
of,2433,O
decreased,2433,B-Disease
renal,2433,I-Disease
function,2433,I-Disease
in,2433,O
the,2433,O
enalapril,2433,B-Chemical
group,2433,O
(,2433,O
RR,2433,O
1.89,2433,O
",",2433,O
95,2433,O
%,2433,O
CI,2433,O
1.70-2.08,2433,O
),2433,O
than,2433,O
in,2433,O
the,2433,O
placebo,2433,O
group,2433,O
(,2433,O
RR,2433,O
1.35,2433,O
",",2433,O
95,2433,O
%,2433,O
CI,2433,O
1.09-1.66,2433,O
),2433,O
.,2433,O
Conversely,2434,O
",",2434,O
enalapril,2434,B-Chemical
had,2434,O
a,2434,O
relative,2434,O
renoprotective,2434,O
effect,2434,O
(,2434,O
RR,2434,O
1.33,2434,O
",",2434,O
95,2434,O
%,2434,O
CI,2434,O
1.13-1.53,2434,O
),2434,O
compared,2434,O
with,2434,O
placebo,2434,O
(,2434,O
RR,2434,O
1.96,2434,O
",",2434,O
95,2434,O
%,2434,O
CI,2434,O
1.57-2.44,2434,O
),2434,O
in,2434,O
patients,2434,O
with,2434,O
diabetes,2434,B-Disease
.,2434,O
A,2435,O
lower,2435,O
risk,2435,O
of,2435,O
renal,2435,B-Disease
impairment,2435,I-Disease
was,2435,O
seen,2435,O
in,2435,O
both,2435,O
groups,2435,O
with,2435,O
beta-blocker,2435,O
therapy,2435,O
(,2435,O
RR,2435,O
0.70,2435,O
",",2435,O
95,2435,O
%,2435,O
CI,2435,O
0.57-0.85,2435,O
),2435,O
and,2435,O
higher,2435,O
baseline,2435,O
ejection,2435,O
fraction,2435,O
(,2435,O
RR,2435,O
0.93,2435,O
per,2435,O
5,2435,O
%,2435,O
increment,2435,O
",",2435,O
95,2435,O
%,2435,O
CI,2435,O
0.91-0,2435,O
.,2435,O
96,2436,O
),2436,O
.,2436,O
CONCLUSIONS,2437,O
:,2437,O
Enalapril,2437,B-Chemical
use,2437,O
caused,2437,O
a,2437,O
33,2437,O
%,2437,O
increase,2437,O
in,2437,O
the,2437,O
risk,2437,O
of,2437,O
decreased,2437,B-Disease
renal,2437,I-Disease
function,2437,I-Disease
in,2437,O
patients,2437,O
with,2437,O
CHF,2437,B-Disease
.,2437,O
Diuretic,2438,B-Chemical
use,2438,O
and,2438,O
advanced,2438,O
age,2438,O
increased,2438,O
this,2438,O
risk,2438,O
.,2438,O
Diabetes,2439,B-Disease
was,2439,O
associated,2439,O
with,2439,O
an,2439,O
increased,2439,O
risk,2439,O
of,2439,O
renal,2439,B-Disease
impairment,2439,I-Disease
in,2439,O
all,2439,O
patients,2439,O
with,2439,O
CHF,2439,B-Disease
",",2439,O
but,2439,O
this,2439,O
risk,2439,O
was,2439,O
reduced,2439,O
in,2439,O
the,2439,O
enalapril,2439,B-Chemical
group,2439,O
compared,2439,O
with,2439,O
the,2439,O
placebo,2439,O
group,2439,O
.,2439,O
beta-Blocker,2440,O
therapy,2440,O
and,2440,O
higher,2440,O
ejection,2440,O
fraction,2440,O
were,2440,O
renoprotective,2440,O
in,2440,O
all,2440,O
patients,2440,O
regardless,2440,O
of,2440,O
therapy,2440,O
.,2440,O
Hypomania-like,2441,B-Disease
syndrome,2441,O
induced,2441,O
by,2441,O
olanzapine,2441,B-Chemical
.,2441,O
We,2442,O
report,2442,O
a,2442,O
female,2442,O
patient,2442,O
with,2442,O
a,2442,O
diagnosis,2442,O
of,2442,O
a,2442,O
not,2442,O
otherwise,2442,O
specified,2442,O
psychotic,2442,B-Disease
disorder,2442,I-Disease
(,2442,O
DSM-IV,2442,O
),2442,O
who,2442,O
developed,2442,O
hypomania,2442,B-Disease
shortly,2442,O
after,2442,O
the,2442,O
introduction,2442,O
of,2442,O
olanzapine,2442,B-Chemical
treatment,2442,O
.,2442,O
Acetazolamide-induced,2443,B-Chemical
Gerstmann,2443,B-Disease
syndrome,2443,I-Disease
.,2443,O
Acute,2444,O
confusion,2444,B-Disease
induced,2444,O
by,2444,O
acetazolamide,2444,B-Chemical
is,2444,O
a,2444,O
well,2444,O
known,2444,O
adverse,2444,O
drug,2444,O
reaction,2444,O
in,2444,O
patients,2444,O
with,2444,O
renal,2444,B-Disease
impairment,2444,I-Disease
.,2444,O
We,2445,O
report,2445,O
a,2445,O
case,2445,O
of,2445,O
acetazolamide-induced,2445,B-Chemical
Gerstmann,2445,B-Disease
syndrome,2445,I-Disease
in,2445,O
a,2445,O
patient,2445,O
with,2445,O
normal,2445,O
renal,2445,O
function,2445,O
",",2445,O
to,2445,O
highlight,2445,O
predisposing,2445,O
factors,2445,O
that,2445,O
are,2445,O
frequently,2445,O
overlooked,2445,O
.,2445,O
Vasopressin,2446,B-Chemical
in,2446,O
the,2446,O
treatment,2446,O
of,2446,O
milrinone-induced,2446,B-Chemical
hypotension,2446,B-Disease
in,2446,O
severe,2446,O
heart,2446,B-Disease
failure,2446,I-Disease
.,2446,O
The,2447,O
use,2447,O
of,2447,O
phosphodiesterase,2447,O
inhibitors,2447,O
such,2447,O
as,2447,O
milrinone,2447,B-Chemical
in,2447,O
the,2447,O
treatment,2447,O
of,2447,O
severe,2447,O
heart,2447,B-Disease
failure,2447,I-Disease
is,2447,O
frequently,2447,O
restricted,2447,O
because,2447,O
they,2447,O
cause,2447,O
vasodilation,2447,O
and,2447,O
hypotension,2447,B-Disease
.,2447,O
In,2448,O
patients,2448,O
with,2448,O
decompensated,2448,O
heart,2448,B-Disease
failure,2448,I-Disease
with,2448,O
hypotension,2448,B-Disease
after,2448,O
treatment,2448,O
with,2448,O
milrinone,2448,B-Chemical
",",2448,O
low,2448,O
doses,2448,O
of,2448,O
vasopressin,2448,B-Chemical
restored,2448,O
blood,2448,O
pressure,2448,O
without,2448,O
inhibiting,2448,O
the,2448,O
inotropic,2448,O
effect,2448,O
of,2448,O
milrinone,2448,B-Chemical
.,2448,O
Treatment,2449,O
of,2449,O
tacrolimus-related,2449,B-Chemical
adverse,2449,O
effects,2449,O
by,2449,O
conversion,2449,O
to,2449,O
cyclosporine,2449,B-Chemical
in,2449,O
liver,2449,O
transplant,2449,O
recipients,2449,O
.,2449,O
When,2450,O
tacrolimus,2450,B-Chemical
side,2450,O
effects,2450,O
persist,2450,O
despite,2450,O
dose,2450,O
reduction,2450,O
",",2450,O
conversion,2450,O
to,2450,O
cyclosporine-based,2450,B-Chemical
immunosuppression,2450,O
(,2450,O
CyA,2450,O
),2450,O
is,2450,O
necessary,2450,O
.,2450,O
We,2451,O
characterized,2451,O
tacrolimus,2451,B-Chemical
side,2451,O
effects,2451,O
that,2451,O
warranted,2451,O
discontinuation,2451,O
of,2451,O
the,2451,O
drug,2451,O
",",2451,O
and,2451,O
outcomes,2451,O
after,2451,O
conversion,2451,O
.,2451,O
Of,2452,O
388,2452,O
liver,2452,O
recipients,2452,O
who,2452,O
received,2452,O
tacrolimus,2452,B-Chemical
as,2452,O
primary,2452,O
immunosuppression,2452,O
",",2452,O
70,2452,O
required,2452,O
conversion,2452,O
to,2452,O
CyA,2452,O
.,2452,O
We,2453,O
recorded,2453,O
indication,2453,O
for,2453,O
conversion,2453,O
",",2453,O
whether,2453,O
conversion,2453,O
was,2453,O
early,2453,O
or,2453,O
late,2453,O
after,2453,O
transplantation,2453,O
",",2453,O
tacrolimus,2453,B-Chemical
dose,2453,O
and,2453,O
trough,2453,O
blood,2453,O
level,2453,O
at,2453,O
conversion,2453,O
",",2453,O
and,2453,O
incidence,2453,O
of,2453,O
rejection,2453,O
after,2453,O
conversion,2453,O
.,2453,O
Conversion,2454,O
was,2454,O
early,2454,O
in,2454,O
29,2454,O
patients,2454,O
(,2454,O
41.4,2454,O
%,2454,O
),2454,O
and,2454,O
late,2454,O
in,2454,O
41,2454,O
(,2454,O
58.6,2454,O
%,2454,O
),2454,O
.,2454,O
Indications,2455,O
for,2455,O
early,2455,O
conversion,2455,O
were,2455,O
neurotoxicity,2455,B-Disease
(,2455,O
20,2455,O
),2455,O
",",2455,O
(,2455,B-Disease
insulin-dependent,2455,I-Disease
),2455,I-Disease
diabetes,2455,I-Disease
mellitus,2455,I-Disease
(,2455,O
IDDM,2455,B-Disease
),2455,O
(,2455,O
5,2455,O
),2455,O
",",2455,O
nephrotoxicity,2455,B-Disease
(,2455,O
3,2455,O
),2455,O
",",2455,O
gastrointestinal,2455,B-Disease
(,2455,I-Disease
GI,2455,I-Disease
),2455,I-Disease
toxicity,2455,I-Disease
(,2455,O
6,2455,O
),2455,O
",",2455,O
and,2455,O
cardiomyopathy,2455,B-Disease
(,2455,O
1,2455,O
),2455,O
",",2455,O
and,2455,O
for,2455,O
late,2455,O
conversion,2455,O
were,2455,O
neurotoxicity,2455,B-Disease
(,2455,O
15,2455,O
),2455,O
",",2455,O
IDDM,2455,B-Disease
(,2455,O
12,2455,O
),2455,O
",",2455,O
nephrotoxicity,2455,B-Disease
(,2455,O
3,2455,O
),2455,O
",",2455,O
GI,2455,B-Disease
toxicity,2455,I-Disease
(,2455,O
5,2455,O
),2455,O
",",2455,O
hepatotoxicity,2455,B-Disease
(,2455,O
6,2455,O
),2455,O
",",2455,O
post-transplant,2455,B-Disease
lmphoproliferate,2455,I-Disease
disease,2455,I-Disease
(,2455,O
PTLD,2455,B-Disease
),2455,O
(,2455,O
2,2455,O
),2455,O
",",2455,O
cardiomyopathy,2455,B-Disease
(,2455,O
1,2455,O
),2455,O
",",2455,O
hemolytic,2455,B-Disease
anemia,2455,I-Disease
(,2455,O
1,2455,O
),2455,O
",",2455,O
and,2455,O
pruritus,2455,B-Disease
(,2455,O
1,2455,O
),2455,O
.,2455,O
All,2456,O
early-conversion,2456,O
patients,2456,O
showed,2456,O
improvement/resolution,2456,O
of,2456,O
symptoms,2456,O
.,2456,O
Among,2457,O
late-conversion,2457,O
patients,2457,O
",",2457,O
37,2457,O
(,2457,O
90.2,2457,O
%,2457,O
),2457,O
had,2457,O
improvement/resolution,2457,O
;,2457,O
in,2457,O
4,2457,O
(,2457,O
9.8,2457,O
%,2457,O
),2457,O
",",2457,O
adverse,2457,O
effects,2457,O
persisted,2457,O
.,2457,O
The,2458,O
overall,2458,O
rejection,2458,O
rate,2458,O
was,2458,O
30,2458,O
%,2458,O
.,2458,O
Sixty-two,2459,O
patients,2459,O
(,2459,O
88.6,2459,O
%,2459,O
),2459,O
are,2459,O
alive,2459,O
with,2459,O
functioning,2459,O
grafts,2459,O
686,2459,O
+/-,2459,O
362,2459,O
days,2459,O
(,2459,O
range,2459,O
",",2459,O
154-1433,2459,O
days,2459,O
),2459,O
after,2459,O
conversion,2459,O
.,2459,O
When,2460,O
tacrolimus,2460,B-Chemical
side,2460,O
effects,2460,O
are,2460,O
unresponsive,2460,O
to,2460,O
dose,2460,O
reduction,2460,O
",",2460,O
conversion,2460,O
to,2460,O
CyA,2460,O
can,2460,O
be,2460,O
accomplished,2460,O
safely,2460,O
",",2460,O
with,2460,O
no,2460,O
increased,2460,O
risk,2460,O
of,2460,O
rejection,2460,O
and,2460,O
excellent,2460,O
long-term,2460,O
outcome,2460,O
.,2460,O
Cyclophosphamide-induced,2461,B-Chemical
cystitis,2461,B-Disease
in,2461,O
freely-moving,2461,O
conscious,2461,O
rats,2461,O
:,2461,O
behavioral,2461,O
approach,2461,O
to,2461,O
a,2461,O
new,2461,O
model,2461,O
of,2461,O
visceral,2461,B-Disease
pain,2461,I-Disease
.,2461,O
PURPOSE,2462,O
:,2462,O
To,2462,O
develop,2462,O
a,2462,O
model,2462,O
of,2462,O
visceral,2462,B-Disease
pain,2462,I-Disease
in,2462,O
rats,2462,O
using,2462,O
a,2462,O
behavioral,2462,O
approach,2462,O
.,2462,O
Cyclophosphamide,2463,B-Chemical
(,2463,O
CP,2463,B-Chemical
),2463,O
",",2463,O
an,2463,O
antitumoral,2463,O
agent,2463,O
known,2463,O
to,2463,O
produce,2463,O
toxic,2463,O
effects,2463,O
on,2463,O
the,2463,O
bladder,2463,O
wall,2463,O
through,2463,O
its,2463,O
main,2463,O
toxic,2463,O
metabolite,2463,O
acrolein,2463,B-Chemical
",",2463,O
was,2463,O
used,2463,O
to,2463,O
induce,2463,O
cystitis,2463,B-Disease
.,2463,O
MATERIALS,2464,O
AND,2464,O
METHODS,2464,O
:,2464,O
CP,2464,B-Chemical
was,2464,O
administered,2464,O
at,2464,O
doses,2464,O
of,2464,O
50,2464,O
",",2464,O
100,2464,O
and,2464,O
200,2464,O
mg./kg,2464,O
.,2464,O
i.p,2465,O
.,2465,O
to,2466,O
male,2466,O
rats,2466,O
",",2466,O
and,2466,O
their,2466,O
behavior,2466,O
observed,2466,O
and,2466,O
scored,2466,O
.,2466,O
The,2467,O
effects,2467,O
of,2467,O
morphine,2467,B-Chemical
(,2467,O
0.5,2467,O
to,2467,O
4,2467,O
mg./kg,2467,O
.,2467,O
i.v,2468,O
.,2468,O
),2468,O
on,2469,O
CP-induced,2469,B-Chemical
behavioral,2469,O
modifications,2469,O
were,2469,O
tested,2469,O
administered,2469,O
alone,2469,O
and,2469,O
after,2469,O
naloxone,2469,B-Chemical
(,2469,O
1,2469,O
mg./kg,2469,O
.,2469,O
s.c.,2470,O
),2470,O
.,2470,O
In,2471,O
addition,2471,O
",",2471,O
90,2471,O
minutes,2471,O
after,2471,O
CP,2471,B-Chemical
injection,2471,O
",",2471,O
that,2471,O
is,2471,O
",",2471,O
at,2471,O
the,2471,O
time,2471,O
of,2471,O
administration,2471,O
of,2471,O
morphine,2471,B-Chemical
",",2471,O
the,2471,O
bladder,2471,O
was,2471,O
removed,2471,O
in,2471,O
some,2471,O
rats,2471,O
for,2471,O
histological,2471,O
examination,2471,O
.,2471,O
Finally,2472,O
",",2472,O
to,2472,O
show,2472,O
that,2472,O
the,2472,O
bladder,2472,O
is,2472,O
essential,2472,O
for,2472,O
the,2472,O
CP-induced,2472,B-Chemical
behavioral,2472,O
modifications,2472,O
",",2472,O
female,2472,O
rats,2472,O
also,2472,O
received,2472,O
CP,2472,B-Chemical
at,2472,O
doses,2472,O
of,2472,O
200,2472,O
mg./kg,2472,O
.,2472,O
i.p,2473,O
.,2473,O
and,2474,O
of,2474,O
20,2474,O
mg.,2474,O
by,2474,O
the,2474,O
intravesical,2474,O
route,2474,O
",",2474,O
and,2474,O
acrolein,2474,B-Chemical
at,2474,O
doses,2474,O
of,2474,O
0.5,2474,O
mg.,2474,O
by,2474,O
the,2474,O
intravesical,2474,O
route,2474,O
and,2474,O
of,2474,O
5,2474,O
mg./kg,2474,O
.,2474,O
i.v,2475,O
.,2475,O
RESULTS,2476,O
:,2476,O
CP,2476,B-Chemical
dose-relatedly,2476,O
induced,2476,O
marked,2476,O
behavioral,2476,O
modifications,2476,O
in,2476,O
male,2476,O
rats,2476,O
:,2476,O
breathing,2476,O
rate,2476,O
decrease,2476,O
",",2476,O
closing,2476,O
of,2476,O
the,2476,O
eyes,2476,O
and,2476,O
occurrence,2476,O
of,2476,O
specific,2476,O
postures,2476,O
.,2476,O
Morphine,2477,B-Chemical
dose-dependently,2477,O
reversed,2477,O
these,2477,O
behavioral,2477,B-Disease
disorders,2477,I-Disease
.,2477,O
A,2478,O
dose,2478,O
of,2478,O
0.5,2478,O
mg./kg,2478,O
.,2478,O
produced,2479,O
a,2479,O
reduction,2479,O
of,2479,O
almost,2479,O
50,2479,O
%,2479,O
of,2479,O
the,2479,O
behavioral,2479,O
score,2479,O
induced,2479,O
by,2479,O
CP,2479,B-Chemical
200,2479,O
mg./kg,2479,O
.,2479,O
This,2480,O
effect,2480,O
was,2480,O
completely,2480,O
prevented,2480,O
by,2480,O
pretreatment,2480,O
with,2480,O
naloxone,2480,B-Chemical
.,2480,O
At,2481,O
the,2481,O
time,2481,O
of,2481,O
administration,2481,O
of,2481,O
morphine,2481,B-Chemical
",",2481,O
histological,2481,O
modifications,2481,O
of,2481,O
the,2481,O
bladder,2481,O
wall,2481,O
",",2481,O
such,2481,O
as,2481,O
chorionic,2481,O
and,2481,O
muscle,2481,O
layer,2481,O
edema,2481,B-Disease
",",2481,O
were,2481,O
observed,2481,O
.,2481,O
In,2482,O
female,2482,O
rats,2482,O
",",2482,O
CP,2482,B-Chemical
200,2482,O
mg./kg,2482,O
.,2482,O
i.p,2483,O
.,2483,O
produced,2484,O
the,2484,O
same,2484,O
marked,2484,O
behavioral,2484,O
modifications,2484,O
as,2484,O
those,2484,O
observed,2484,O
in,2484,O
male,2484,O
rats,2484,O
.,2484,O
Administered,2485,O
at,2485,O
the,2485,O
dose,2485,O
of,2485,O
20,2485,O
mg.,2485,O
intravesically,2485,O
",",2485,O
CP,2485,B-Chemical
did,2485,O
not,2485,O
produce,2485,O
any,2485,O
behavioral,2485,O
effects,2485,O
",",2485,O
whereas,2485,O
acrolein,2485,B-Chemical
at,2485,O
0.5,2485,O
mg.,2485,O
intravesically,2485,O
induced,2485,O
behavioral,2485,O
modifications,2485,O
identical,2485,O
to,2485,O
those,2485,O
under,2485,O
CP,2485,B-Chemical
200,2485,O
mg./kg,2485,O
.,2485,O
i.p.,2486,O
",",2486,O
with,2486,O
the,2486,O
same,2486,O
maximal,2486,O
levels,2486,O
.,2486,O
Conversely,2487,O
",",2487,O
acrolein,2487,B-Chemical
5,2487,O
mg./kg,2487,O
.,2487,O
i.v,2488,O
.,2488,O
did,2489,O
not,2489,O
produce,2489,O
any,2489,O
behavioral,2489,O
effects,2489,O
at,2489,O
all,2489,O
.,2489,O
CONCLUSIONS,2490,O
:,2490,O
Overall,2490,O
",",2490,O
these,2490,O
results,2490,O
indicate,2490,O
that,2490,O
this,2490,O
experimental,2490,O
model,2490,O
of,2490,O
CP-induced,2490,B-Chemical
cystitis,2490,B-Disease
may,2490,O
be,2490,O
an,2490,O
interesting,2490,O
new,2490,O
behavioral,2490,O
model,2490,O
of,2490,O
inflammatory,2490,O
visceral,2490,B-Disease
pain,2490,I-Disease
",",2490,O
allowing,2490,O
a,2490,O
better,2490,O
understanding,2490,O
of,2490,O
these,2490,O
painful,2490,B-Disease
syndromes,2490,I-Disease
and,2490,O
thus,2490,O
a,2490,O
better,2490,O
therapeutic,2490,O
approach,2490,O
to,2490,O
them,2490,O
.,2490,O
Prednisolone-induced,2491,B-Chemical
muscle,2491,B-Disease
dysfunction,2491,I-Disease
is,2491,O
caused,2491,O
more,2491,O
by,2491,O
atrophy,2491,B-Disease
than,2491,O
by,2491,O
altered,2491,O
acetylcholine,2491,B-Chemical
receptor,2491,O
expression,2491,O
.,2491,O
Large,2492,O
doses,2492,O
of,2492,O
glucocorticoids,2492,O
can,2492,O
alter,2492,O
muscle,2492,O
physiology,2492,O
and,2492,O
susceptibility,2492,O
to,2492,O
neuromuscular,2492,O
blocking,2492,O
drugs,2492,O
by,2492,O
mechanisms,2492,O
not,2492,O
clearly,2492,O
understood,2492,O
.,2492,O
We,2493,O
investigated,2493,O
the,2493,O
effects,2493,O
of,2493,O
moderate,2493,O
and,2493,O
large,2493,O
doses,2493,O
of,2493,O
prednisolone,2493,B-Chemical
on,2493,O
muscle,2493,O
function,2493,O
and,2493,O
pharmacology,2493,O
",",2493,O
and,2493,O
their,2493,O
relationship,2493,O
to,2493,O
changes,2493,O
in,2493,O
muscle,2493,O
size,2493,O
and,2493,O
acetylcholine,2493,B-Chemical
receptor,2493,O
(,2493,O
AChR,2493,O
),2493,O
expression,2493,O
.,2493,O
With,2494,O
institutional,2494,O
approval,2494,O
",",2494,O
35,2494,O
Sprague-Dawley,2494,O
rats,2494,O
were,2494,O
randomly,2494,O
allocated,2494,O
to,2494,O
receive,2494,O
daily,2494,O
subcutaneous,2494,O
doses,2494,O
of,2494,O
10,2494,O
mg/kg,2494,O
prednisolone,2494,B-Chemical
(,2494,O
P10,2494,O
group,2494,O
),2494,O
",",2494,O
100,2494,O
mg/kg,2494,O
prednisolone,2494,B-Chemical
(,2494,O
P100,2494,O
group,2494,O
),2494,O
",",2494,O
or,2494,O
an,2494,O
equal,2494,O
volume,2494,O
of,2494,O
saline,2494,O
(,2494,O
S,2494,O
group,2494,O
),2494,O
for,2494,O
7,2494,O
days,2494,O
.,2494,O
A,2495,O
fourth,2495,O
group,2495,O
of,2495,O
rats,2495,O
was,2495,O
pair,2495,O
fed,2495,O
(,2495,O
food,2495,O
restricted,2495,O
),2495,O
with,2495,O
the,2495,O
P100,2495,O
rats,2495,O
for,2495,O
7,2495,O
days,2495,O
(,2495,O
FR,2495,O
group,2495,O
),2495,O
.,2495,O
On,2496,O
Day,2496,O
8,2496,O
",",2496,O
the,2496,O
nerve-evoked,2496,O
peak,2496,O
twitch,2496,O
tensions,2496,O
",",2496,O
tetanic,2496,B-Disease
tensions,2496,O
",",2496,O
and,2496,O
fatigability,2496,O
",",2496,O
and,2496,O
the,2496,O
dose-response,2496,O
curves,2496,O
of,2496,O
d-tubocurarine,2496,B-Chemical
in,2496,O
the,2496,O
tibialis,2496,O
cranialis,2496,O
muscle,2496,O
were,2496,O
measured,2496,O
in,2496,O
vivo,2496,O
and,2496,O
related,2496,O
to,2496,O
muscle,2496,O
mass,2496,O
or,2496,O
expression,2496,O
of,2496,O
AChRs,2496,O
.,2496,O
Rate,2497,O
of,2497,O
body,2497,O
weight,2497,O
gain,2497,O
was,2497,O
depressed,2497,O
in,2497,O
the,2497,O
P100,2497,O
",",2497,O
FR,2497,O
",",2497,O
and,2497,O
P10,2497,O
groups,2497,O
compared,2497,O
with,2497,O
the,2497,O
S,2497,O
group,2497,O
.,2497,O
Tibialis,2498,O
muscle,2498,O
mass,2498,O
was,2498,O
smaller,2498,O
in,2498,O
the,2498,O
P100,2498,O
group,2498,O
than,2498,O
in,2498,O
the,2498,O
P10,2498,O
or,2498,O
S,2498,O
groups,2498,O
.,2498,O
The,2499,O
evoked,2499,O
peak,2499,O
twitch,2499,O
and,2499,O
tetanic,2499,B-Disease
tensions,2499,O
were,2499,O
less,2499,O
in,2499,O
the,2499,O
P100,2499,O
group,2499,O
than,2499,O
in,2499,O
the,2499,O
P10,2499,O
or,2499,O
S,2499,O
groups,2499,O
",",2499,O
however,2499,O
",",2499,O
tension,2499,O
per,2499,O
milligram,2499,O
of,2499,O
muscle,2499,O
mass,2499,O
was,2499,O
greater,2499,O
in,2499,O
the,2499,O
P100,2499,O
group,2499,O
than,2499,O
in,2499,O
the,2499,O
S,2499,O
group,2499,O
.,2499,O
The,2500,O
50,2500,O
%,2500,O
effective,2500,O
dose,2500,O
of,2500,O
d-tubocurarine,2500,B-Chemical
(,2500,O
microg/kg,2500,O
),2500,O
in,2500,O
the,2500,O
tibialis,2500,O
muscle,2500,O
was,2500,O
smaller,2500,O
in,2500,O
the,2500,O
P10,2500,O
(,2500,O
33.6,2500,O
+/-,2500,O
5.4,2500,O
),2500,O
than,2500,O
in,2500,O
the,2500,O
S,2500,O
(,2500,O
61.9,2500,O
+/-,2500,O
5.0,2500,O
),2500,O
or,2500,O
the,2500,O
P100,2500,O
(,2500,O
71.3,2500,O
+/-,2500,O
9.6,2500,O
),2500,O
groups,2500,O
.,2500,O
AChR,2501,O
expression,2501,O
was,2501,O
less,2501,O
in,2501,O
the,2501,O
P10,2501,O
group,2501,O
than,2501,O
in,2501,O
the,2501,O
S,2501,O
group,2501,O
.,2501,O
The,2502,O
evoked,2502,O
tensions,2502,O
correlated,2502,O
with,2502,O
muscle,2502,O
mass,2502,O
(,2502,O
r,2502,O
(,2502,O
2,2502,O
),2502,O
=,2502,O
0.32,2502,O
",",2502,O
P,2502,O
<,2502,O
0.001,2502,O
),2502,O
",",2502,O
however,2502,O
",",2502,O
not,2502,O
with,2502,O
expression,2502,O
of,2502,O
AChR,2502,O
.,2502,O
The,2503,O
50,2503,O
%,2503,O
effective,2503,O
dose,2503,O
of,2503,O
d-tubocurarine,2503,B-Chemical
did,2503,O
not,2503,O
correlate,2503,O
with,2503,O
muscle,2503,O
mass,2503,O
or,2503,O
AChR,2503,O
expression,2503,O
.,2503,O
Our,2504,O
results,2504,O
suggest,2504,O
that,2504,O
the,2504,O
neuromuscular,2504,B-Disease
dysfunction,2504,I-Disease
after,2504,O
prednisolone,2504,B-Chemical
is,2504,O
dose-dependent,2504,O
",",2504,O
and,2504,O
derives,2504,O
primarily,2504,O
from,2504,O
muscle,2504,B-Disease
atrophy,2504,I-Disease
and,2504,O
derives,2504,O
less,2504,O
so,2504,O
from,2504,O
changes,2504,O
in,2504,O
AChR,2504,O
expression,2504,O
.,2504,O
IMPLICATIONS,2505,O
:,2505,O
The,2505,O
mechanisms,2505,O
by,2505,O
which,2505,O
chronic,2505,O
glucocorticoid,2505,O
therapy,2505,O
alters,2505,O
neuromuscular,2505,O
physiology,2505,O
and,2505,O
pharmacology,2505,O
are,2505,O
unclear,2505,O
.,2505,O
We,2506,O
suggest,2506,O
that,2506,O
the,2506,O
observed,2506,O
effects,2506,O
are,2506,O
dose-dependent,2506,O
and,2506,O
derive,2506,O
primarily,2506,O
from,2506,O
muscle,2506,B-Disease
atrophy,2506,I-Disease
and,2506,O
derive,2506,O
less,2506,O
from,2506,O
changes,2506,O
in,2506,O
acetylcholine,2506,B-Chemical
receptor,2506,O
expression,2506,O
.,2506,O
Apomorphine,2507,B-Chemical
:,2507,O
an,2507,O
underutilized,2507,O
therapy,2507,O
for,2507,O
Parkinson,2507,B-Disease
's,2507,I-Disease
disease,2507,I-Disease
.,2507,O
Apomorphine,2508,B-Chemical
was,2508,O
the,2508,O
first,2508,O
dopaminergic,2508,O
drug,2508,O
ever,2508,O
used,2508,O
to,2508,O
treat,2508,O
symptoms,2508,O
of,2508,O
Parkinson,2508,B-Disease
's,2508,I-Disease
disease,2508,I-Disease
.,2508,O
While,2509,O
powerful,2509,O
antiparkinsonian,2509,O
effects,2509,O
had,2509,O
been,2509,O
observed,2509,O
as,2509,O
early,2509,O
as,2509,O
1951,2509,O
",",2509,O
the,2509,O
potential,2509,O
of,2509,O
treating,2509,O
fluctuating,2509,O
Parkinson,2509,B-Disease
's,2509,I-Disease
disease,2509,I-Disease
by,2509,O
subcutaneous,2509,O
administration,2509,O
of,2509,O
apomorphine,2509,B-Chemical
has,2509,O
only,2509,O
recently,2509,O
become,2509,O
the,2509,O
subject,2509,O
of,2509,O
systematic,2509,O
study,2509,O
.,2509,O
A,2510,O
number,2510,O
of,2510,O
small,2510,O
scale,2510,O
clinical,2510,O
trials,2510,O
have,2510,O
unequivocally,2510,O
shown,2510,O
that,2510,O
intermittent,2510,O
subcutaneous,2510,O
apomorphine,2510,B-Chemical
injections,2510,O
produce,2510,O
antiparkinsonian,2510,O
benefit,2510,O
close,2510,O
if,2510,O
not,2510,O
identical,2510,O
to,2510,O
that,2510,O
seen,2510,O
with,2510,O
levodopa,2510,B-Chemical
and,2510,O
that,2510,O
apomorphine,2510,B-Chemical
rescue,2510,O
injections,2510,O
can,2510,O
reliably,2510,O
revert,2510,O
off-periods,2510,O
even,2510,O
in,2510,O
patients,2510,O
with,2510,O
complex,2510,O
on-off,2510,O
motor,2510,O
swings,2510,O
.,2510,O
Continuous,2511,O
subcutaneous,2511,O
apomorphine,2511,B-Chemical
infusions,2511,O
can,2511,O
reduce,2511,O
daily,2511,O
off-time,2511,O
by,2511,O
more,2511,O
than,2511,O
50,2511,O
%,2511,O
in,2511,O
this,2511,O
group,2511,O
of,2511,O
patients,2511,O
",",2511,O
which,2511,O
appears,2511,O
to,2511,O
be,2511,O
a,2511,O
stronger,2511,O
effect,2511,O
than,2511,O
that,2511,O
generally,2511,O
seen,2511,O
with,2511,O
add-on,2511,O
therapy,2511,O
with,2511,O
oral,2511,O
dopamine,2511,B-Chemical
agonists,2511,O
or,2511,O
COMT,2511,O
inhibitors,2511,O
.,2511,O
Extended,2512,O
follow-up,2512,O
studies,2512,O
of,2512,O
up,2512,O
to,2512,O
8,2512,O
years,2512,O
have,2512,O
demonstrated,2512,O
long-term,2512,O
persistence,2512,O
of,2512,O
apomorphine,2512,B-Chemical
efficacy,2512,O
.,2512,O
In,2513,O
addition,2513,O
",",2513,O
there,2513,O
is,2513,O
convincing,2513,O
clinical,2513,O
evidence,2513,O
that,2513,O
monotherapy,2513,O
with,2513,O
continuous,2513,O
subcutaneous,2513,O
apomorphine,2513,B-Chemical
infusions,2513,O
is,2513,O
associated,2513,O
with,2513,O
marked,2513,O
reductions,2513,O
of,2513,O
preexisting,2513,O
levodopa-induced,2513,B-Chemical
dyskinesias,2513,B-Disease
.,2513,O
The,2514,O
main,2514,O
side,2514,O
effects,2514,O
of,2514,O
subcutaneous,2514,O
apomorphine,2514,B-Chemical
treatment,2514,O
are,2514,O
related,2514,O
to,2514,O
cutaneous,2514,O
tolerability,2514,O
problems,2514,O
",",2514,O
whereas,2514,O
sedation,2514,O
and,2514,O
psychiatric,2514,B-Disease
complications,2514,O
play,2514,O
a,2514,O
lesser,2514,O
role,2514,O
.,2514,O
Given,2515,O
the,2515,O
marked,2515,O
degree,2515,O
of,2515,O
efficacy,2515,O
of,2515,O
subcutaneous,2515,O
apomorphine,2515,B-Chemical
treatment,2515,O
in,2515,O
fluctuating,2515,O
Parkinson,2515,B-Disease
's,2515,I-Disease
disease,2515,I-Disease
",",2515,O
this,2515,O
approach,2515,O
seems,2515,O
to,2515,O
deserve,2515,O
more,2515,O
widespread,2515,O
clinical,2515,O
use,2515,O
.,2515,O
Probing,2516,O
peripheral,2516,O
and,2516,O
central,2516,O
cholinergic,2516,O
system,2516,O
responses,2516,O
.,2516,O
OBJECTIVE,2517,O
:,2517,O
The,2517,O
pharmacological,2517,O
response,2517,O
to,2517,O
drugs,2517,O
that,2517,O
act,2517,O
on,2517,O
the,2517,O
cholinergic,2517,O
system,2517,O
of,2517,O
the,2517,O
iris,2517,O
has,2517,O
been,2517,O
used,2517,O
to,2517,O
predict,2517,O
deficits,2517,O
in,2517,O
central,2517,O
cholinergic,2517,O
functioning,2517,O
due,2517,O
to,2517,O
diseases,2517,O
such,2517,O
as,2517,O
Alzheimer,2517,B-Disease
's,2517,I-Disease
disease,2517,I-Disease
",",2517,O
yet,2517,O
correlations,2517,O
between,2517,O
central,2517,O
and,2517,O
peripheral,2517,O
responses,2517,O
have,2517,O
not,2517,O
been,2517,O
properly,2517,O
studied,2517,O
.,2517,O
This,2518,O
study,2518,O
assessed,2518,O
the,2518,O
effect,2518,O
of,2518,O
normal,2518,O
aging,2518,O
on,2518,O
(,2518,O
1,2518,O
),2518,O
the,2518,O
tropicamide-induced,2518,B-Chemical
increase,2518,O
in,2518,O
pupil,2518,O
diameter,2518,O
",",2518,O
and,2518,O
(,2518,O
2,2518,O
),2518,O
the,2518,O
reversal,2518,O
of,2518,O
this,2518,O
effect,2518,O
with,2518,O
pilocarpine,2518,B-Chemical
.,2518,O
Scopolamine,2519,B-Chemical
was,2519,O
used,2519,O
as,2519,O
a,2519,O
positive,2519,O
control,2519,O
to,2519,O
detect,2519,O
age-dependent,2519,O
changes,2519,O
in,2519,O
central,2519,O
cholinergic,2519,O
functioning,2519,O
in,2519,O
the,2519,O
elderly,2519,O
.,2519,O
DESIGN,2520,O
:,2520,O
Randomized,2520,O
double-blind,2520,O
controlled,2520,O
trial,2520,O
.,2520,O
PARTICIPANTS,2521,O
:,2521,O
Ten,2521,O
healthy,2521,O
elderly,2521,O
(,2521,O
mean,2521,O
age,2521,O
70,2521,O
),2521,O
and,2521,O
9,2521,O
young,2521,O
(,2521,O
mean,2521,O
age,2521,O
33,2521,O
),2521,O
volunteers,2521,O
.,2521,O
INTERVENTIONS,2522,O
:,2522,O
Pupil,2522,O
diameter,2522,O
was,2522,O
monitored,2522,O
using,2522,O
a,2522,O
computerized,2522,O
infrared,2522,O
pupillometer,2522,O
over,2522,O
4,2522,O
hours,2522,O
.,2522,O
The,2523,O
study,2523,O
involved,2523,O
4,2523,O
sessions,2523,O
.,2523,O
In,2524,O
1,2524,O
session,2524,O
",",2524,O
tropicamide,2524,B-Chemical
(,2524,O
20,2524,O
microL,2524,O
",",2524,O
0.01,2524,O
%,2524,O
),2524,O
was,2524,O
administered,2524,O
to,2524,O
one,2524,O
eye,2524,O
and,2524,O
placebo,2524,O
to,2524,O
the,2524,O
other,2524,O
.,2524,O
In,2525,O
another,2525,O
session,2525,O
",",2525,O
tropicamide,2525,B-Chemical
(,2525,O
20,2525,O
microL,2525,O
",",2525,O
0.01,2525,O
%,2525,O
),2525,O
was,2525,O
administered,2525,O
to,2525,O
both,2525,O
eyes,2525,O
",",2525,O
followed,2525,O
23,2525,O
minutes,2525,O
later,2525,O
by,2525,O
the,2525,O
application,2525,O
of,2525,O
pilocarpine,2525,B-Chemical
(,2525,O
20,2525,O
microL,2525,O
",",2525,O
0.1,2525,O
%,2525,O
),2525,O
to,2525,O
one,2525,O
eye,2525,O
and,2525,O
placebo,2525,O
to,2525,O
the,2525,O
other,2525,O
.,2525,O
All,2526,O
eye,2526,O
drops,2526,O
were,2526,O
given,2526,O
in,2526,O
a,2526,O
randomized,2526,O
order,2526,O
.,2526,O
In,2527,O
2,2527,O
separate,2527,O
sessions,2527,O
",",2527,O
a,2527,O
single,2527,O
dose,2527,O
of,2527,O
scopolamine,2527,B-Chemical
(,2527,O
0.5,2527,O
mg,2527,O
",",2527,O
intravenously,2527,O
),2527,O
or,2527,O
placebo,2527,O
was,2527,O
administered,2527,O
",",2527,O
and,2527,O
the,2527,O
effects,2527,O
on,2527,O
word,2527,O
recall,2527,O
were,2527,O
measured,2527,O
using,2527,O
the,2527,O
Buschke,2527,O
Selective,2527,O
Reminding,2527,O
Test,2527,O
over,2527,O
2,2527,O
hours,2527,O
.,2527,O
OUTCOME,2528,O
MEASURES,2528,O
:,2528,O
Pupil,2528,O
size,2528,O
at,2528,O
time,2528,O
points,2528,O
after,2528,O
administration,2528,O
of,2528,O
tropicamide,2528,B-Chemical
and,2528,O
pilocarpine,2528,B-Chemical
;,2528,O
scopolamine-induced,2528,B-Chemical
impairment,2528,B-Disease
in,2528,I-Disease
word,2528,I-Disease
recall,2528,I-Disease
.,2528,O
RESULTS,2529,O
:,2529,O
There,2529,O
was,2529,O
no,2529,O
significant,2529,O
difference,2529,O
between,2529,O
elderly,2529,O
and,2529,O
young,2529,O
volunteers,2529,O
in,2529,O
pupillary,2529,O
response,2529,O
to,2529,O
tropicamide,2529,B-Chemical
at,2529,O
any,2529,O
time,2529,O
point,2529,O
(,2529,O
p,2529,O
>,2529,O
0.05,2529,O
),2529,O
.,2529,O
The,2530,O
elderly,2530,O
group,2530,O
had,2530,O
a,2530,O
significantly,2530,O
greater,2530,O
pilocarpine-induced,2530,B-Chemical
net,2530,O
decrease,2530,O
in,2530,O
pupil,2530,O
size,2530,O
85,2530,O
",",2530,O
125,2530,O
",",2530,O
165,2530,O
and,2530,O
215,2530,O
minutes,2530,O
after,2530,O
administration,2530,O
",",2530,O
compared,2530,O
with,2530,O
the,2530,O
young,2530,O
group,2530,O
(,2530,O
p,2530,O
<,2530,O
0.05,2530,O
),2530,O
.,2530,O
Compared,2531,O
with,2531,O
the,2531,O
young,2531,O
group,2531,O
",",2531,O
the,2531,O
elderly,2531,O
group,2531,O
had,2531,O
greater,2531,O
scopolamine-induced,2531,B-Chemical
impairment,2531,B-Disease
in,2531,I-Disease
word,2531,I-Disease
recall,2531,I-Disease
60,2531,O
",",2531,O
90,2531,O
and,2531,O
120,2531,O
minutes,2531,O
after,2531,O
administration,2531,O
(,2531,O
p,2531,O
<,2531,O
0.05,2531,O
),2531,O
.,2531,O
CONCLUSION,2532,O
:,2532,O
There,2532,O
is,2532,O
an,2532,O
age-related,2532,O
pupillary,2532,O
response,2532,O
to,2532,O
pilocarpine,2532,B-Chemical
that,2532,O
is,2532,O
not,2532,O
found,2532,O
with,2532,O
tropicamide,2532,B-Chemical
.,2532,O
Thus,2533,O
",",2533,O
pilocarpine,2533,B-Chemical
may,2533,O
be,2533,O
useful,2533,O
to,2533,O
assess,2533,O
variations,2533,O
in,2533,O
central,2533,O
cholinergic,2533,O
function,2533,O
in,2533,O
elderly,2533,O
patients,2533,O
.,2533,O
Pain,2534,B-Disease
responses,2534,O
in,2534,O
methadone-maintained,2534,B-Chemical
opioid,2534,O
abusers,2534,O
.,2534,O
Providing,2535,O
pain,2535,B-Disease
management,2535,O
for,2535,O
known,2535,O
opioid,2535,O
abusers,2535,O
is,2535,O
a,2535,O
challenging,2535,O
clinical,2535,O
task,2535,O
",",2535,O
in,2535,O
part,2535,O
because,2535,O
little,2535,O
is,2535,O
known,2535,O
about,2535,O
their,2535,O
pain,2535,B-Disease
experience,2535,O
and,2535,O
analgesic,2535,O
requirements,2535,O
.,2535,O
This,2536,O
study,2536,O
was,2536,O
designed,2536,O
to,2536,O
describe,2536,O
pain,2536,B-Disease
tolerance,2536,O
and,2536,O
analgesic,2536,O
response,2536,O
in,2536,O
a,2536,O
sample,2536,O
of,2536,O
opioid,2536,B-Disease
addicts,2536,I-Disease
stabilized,2536,O
in,2536,O
methadone-maintenance,2536,B-Chemical
(,2536,O
MM,2536,O
),2536,O
treatment,2536,O
(,2536,O
n,2536,O
=,2536,O
60,2536,O
),2536,O
in,2536,O
comparison,2536,O
to,2536,O
matched,2536,O
nondependent,2536,O
control,2536,O
subjects,2536,O
(,2536,O
n,2536,O
=,2536,O
60,2536,O
),2536,O
.,2536,O
By,2537,O
using,2537,O
a,2537,O
placebo-controlled,2537,O
",",2537,O
two-way,2537,O
factorial,2537,O
design,2537,O
",",2537,O
tolerance,2537,O
to,2537,O
cold-pressor,2537,O
(,2537,O
CP,2537,O
),2537,O
pain,2537,B-Disease
was,2537,O
examined,2537,O
",",2537,O
both,2537,O
before,2537,O
and,2537,O
after,2537,O
oral,2537,O
administration,2537,O
of,2537,O
therapeutic,2537,O
doses,2537,O
of,2537,O
common,2537,O
opioid,2537,O
(,2537,O
hydromorphone,2537,B-Chemical
2,2537,O
mg,2537,O
),2537,O
and,2537,O
nonsteroidal,2537,O
anti-inflammatory,2537,O
(,2537,O
ketorolac,2537,B-Chemical
10,2537,O
mg,2537,O
),2537,O
analgesic,2537,O
agents,2537,O
.,2537,O
Results,2538,O
showed,2538,O
that,2538,O
MM,2538,O
individuals,2538,O
were,2538,O
significantly,2538,O
less,2538,O
tolerant,2538,O
of,2538,O
CP,2538,O
pain,2538,B-Disease
than,2538,O
control,2538,O
subjects,2538,O
",",2538,O
replicating,2538,O
previous,2538,O
work,2538,O
.,2538,O
Analgesic,2539,O
effects,2539,O
were,2539,O
significant,2539,O
neither,2539,O
for,2539,O
medication,2539,O
nor,2539,O
group,2539,O
.,2539,O
These,2540,O
data,2540,O
indicate,2540,O
that,2540,O
MM,2540,O
opioid,2540,O
abusers,2540,O
represent,2540,O
a,2540,O
pain-intolerant,2540,B-Disease
subset,2540,O
of,2540,O
clinical,2540,O
patients,2540,O
.,2540,O
Their,2541,O
complaints,2541,O
of,2541,O
pain,2541,B-Disease
should,2541,O
be,2541,O
evaluated,2541,O
seriously,2541,O
and,2541,O
managed,2541,O
aggressively,2541,O
.,2541,O
High-dose,2542,O
methylprednisolone,2542,B-Chemical
may,2542,O
do,2542,O
more,2542,O
harm,2542,O
for,2542,O
spinal,2542,B-Disease
cord,2542,I-Disease
injury,2542,I-Disease
.,2542,O
Because,2543,O
of,2543,O
the,2543,O
National,2543,O
Acute,2543,O
Spinal,2543,B-Disease
Cord,2543,I-Disease
Injury,2543,I-Disease
Studies,2543,O
(,2543,O
NASCIS,2543,O
),2543,O
",",2543,O
high-dose,2543,O
methylprednisolone,2543,B-Chemical
became,2543,O
the,2543,O
standard,2543,O
of,2543,O
care,2543,O
for,2543,O
the,2543,O
acute,2543,O
spinal,2543,B-Disease
cord,2543,I-Disease
injury,2543,I-Disease
.,2543,O
In,2544,O
the,2544,O
NASCIS,2544,O
",",2544,O
there,2544,O
was,2544,O
no,2544,O
mention,2544,O
regarding,2544,O
the,2544,O
possibility,2544,O
of,2544,O
acute,2544,O
corticosteroid,2544,B-Chemical
myopathy,2544,B-Disease
that,2544,O
high-dose,2544,O
methylprednisolone,2544,B-Chemical
may,2544,O
cause,2544,O
.,2544,O
The,2545,O
dosage,2545,O
of,2545,O
methylprednisolone,2545,B-Chemical
recommended,2545,O
by,2545,O
the,2545,O
NASCIS,2545,O
3,2545,O
is,2545,O
the,2545,O
highest,2545,O
dose,2545,O
of,2545,O
steroids,2545,B-Chemical
ever,2545,O
being,2545,O
used,2545,O
during,2545,O
a,2545,O
2-day,2545,O
period,2545,O
for,2545,O
any,2545,O
clinical,2545,O
condition,2545,O
.,2545,O
We,2546,O
hypothesize,2546,O
that,2546,O
it,2546,O
may,2546,O
cause,2546,O
some,2546,O
damage,2546,B-Disease
to,2546,I-Disease
the,2546,I-Disease
muscle,2546,I-Disease
of,2546,O
spinal,2546,B-Disease
cord,2546,I-Disease
injury,2546,I-Disease
patients,2546,O
.,2546,O
Further,2547,O
",",2547,O
steroid,2547,B-Chemical
myopathy,2547,B-Disease
recovers,2547,O
naturally,2547,O
and,2547,O
the,2547,O
neurological,2547,O
improvement,2547,O
shown,2547,O
in,2547,O
the,2547,O
NASCIS,2547,O
may,2547,O
be,2547,O
just,2547,O
a,2547,O
recording,2547,O
of,2547,O
this,2547,O
natural,2547,O
motor,2547,O
recovery,2547,O
from,2547,O
the,2547,O
steroid,2547,B-Chemical
myopathy,2547,B-Disease
",",2547,O
instead,2547,O
of,2547,O
any,2547,O
protection,2547,O
that,2547,O
methylprednisolone,2547,B-Chemical
offers,2547,O
to,2547,O
the,2547,O
spinal,2547,B-Disease
cord,2547,I-Disease
injury,2547,I-Disease
.,2547,O
To,2548,O
our,2548,O
knowledge,2548,O
",",2548,O
this,2548,O
is,2548,O
the,2548,O
first,2548,O
discussion,2548,O
considering,2548,O
the,2548,O
possibility,2548,O
that,2548,O
the,2548,O
methylprednisolone,2548,B-Chemical
recommended,2548,O
by,2548,O
NASCIS,2548,O
may,2548,O
cause,2548,O
acute,2548,O
corticosteroid,2548,B-Chemical
myopathy,2548,B-Disease
.,2548,O
Conversion,2549,O
to,2549,O
rapamycin,2549,B-Chemical
immunosuppression,2549,O
in,2549,O
renal,2549,O
transplant,2549,O
recipients,2549,O
:,2549,O
report,2549,O
of,2549,O
an,2549,O
initial,2549,O
experience,2549,O
.,2549,O
BACKGROUND,2550,O
:,2550,O
The,2550,O
aim,2550,O
of,2550,O
this,2550,O
study,2550,O
is,2550,O
to,2550,O
evaluate,2550,O
the,2550,O
effects,2550,O
of,2550,O
RAPA,2550,B-Chemical
conversion,2550,O
in,2550,O
patients,2550,O
undergoing,2550,O
cyclosporine,2550,B-Chemical
(,2550,O
CsA,2550,B-Chemical
),2550,O
or,2550,O
tacrolimus,2550,B-Chemical
(,2550,O
Tac,2550,B-Chemical
),2550,O
toxicity,2550,B-Disease
.,2550,O
METHODS,2551,O
:,2551,O
Twenty,2551,O
renal,2551,O
transplant,2551,O
recipients,2551,O
were,2551,O
switched,2551,O
to,2551,O
fixed,2551,O
dose,2551,O
rapamycin,2551,B-Chemical
(,2551,O
RAPA,2551,B-Chemical
),2551,O
(,2551,O
5,2551,O
mg/day,2551,O
),2551,O
0,2551,O
to,2551,O
204,2551,O
months,2551,O
posttransplant,2551,O
.,2551,O
Drug,2552,O
monitoring,2552,O
was,2552,O
not,2552,O
initially,2552,O
used,2552,O
to,2552,O
adjust,2552,O
doses,2552,O
.,2552,O
The,2553,O
indications,2553,O
for,2553,O
switch,2553,O
were,2553,O
chronic,2553,O
CsA,2553,B-Chemical
or,2553,O
Tac,2553,B-Chemical
nephrotoxicity,2553,B-Disease
(,2553,O
12,2553,O
),2553,O
",",2553,O
acute,2553,O
CsA,2553,B-Chemical
or,2553,O
Tac,2553,B-Chemical
toxicity,2553,B-Disease
(,2553,O
3,2553,O
),2553,O
",",2553,O
severe,2553,O
facial,2553,B-Disease
dysmorphism,2553,I-Disease
(,2553,O
2,2553,O
),2553,O
",",2553,O
posttransplant,2553,B-Disease
lymphoproliferative,2553,I-Disease
disorder,2553,I-Disease
(,2553,O
PTLD,2553,B-Disease
),2553,O
in,2553,O
remission,2553,O
(,2553,O
2,2553,O
),2553,O
",",2553,O
and,2553,O
hepatotoxicity,2553,B-Disease
in,2553,O
1,2553,O
.,2553,O
Follow-up,2554,O
is,2554,O
7,2554,O
to,2554,O
24,2554,O
months,2554,O
.,2554,O
RESULTS,2555,O
:,2555,O
In,2555,O
the,2555,O
12,2555,O
patients,2555,O
switched,2555,O
because,2555,O
of,2555,O
chronic,2555,O
nephrotoxicity,2555,B-Disease
there,2555,O
was,2555,O
a,2555,O
significant,2555,O
decrease,2555,O
in,2555,O
serum,2555,O
creatinine,2555,B-Chemical
[,2555,O
233+/-34,2555,O
to,2555,O
210+/-56,2555,O
micromol/liter,2555,O
(,2555,O
P,2555,O
<,2555,O
0.05,2555,O
),2555,O
at,2555,O
6,2555,O
months,2555,O
],2555,O
.,2555,O
Facial,2556,B-Disease
dysmorphism,2556,I-Disease
improved,2556,O
in,2556,O
two,2556,O
patients,2556,O
.,2556,O
No,2557,O
relapse,2557,O
of,2557,O
PTLD,2557,B-Disease
was,2557,O
observed,2557,O
.,2557,O
Five,2558,O
patients,2558,O
developed,2558,O
pneumonia,2558,B-Disease
(,2558,O
two,2558,O
Pneumocystis,2558,B-Disease
carinii,2558,I-Disease
pneumonia,2558,I-Disease
",",2558,O
one,2558,O
infectious,2558,B-Disease
mononucleosis,2558,I-Disease
with,2558,O
polyclonal,2558,O
PTLD,2558,B-Disease
lung,2558,O
infiltrate,2558,O
),2558,O
and,2558,O
two,2558,O
had,2558,O
bronchiolitis,2558,B-Disease
obliterans,2558,I-Disease
.,2558,O
There,2559,O
were,2559,O
no,2559,O
deaths,2559,O
.,2559,O
RAPA,2560,B-Chemical
was,2560,O
discontinued,2560,O
in,2560,O
four,2560,O
patients,2560,O
",",2560,O
because,2560,O
of,2560,O
pneumonia,2560,B-Disease
in,2560,O
two,2560,O
",",2560,O
PTLD,2560,B-Disease
in,2560,O
one,2560,O
",",2560,O
and,2560,O
oral,2560,O
aphtous,2560,B-Disease
ulcers,2560,I-Disease
in,2560,O
one,2560,O
.,2560,O
RAPA,2561,B-Chemical
levels,2561,O
were,2561,O
high,2561,O
(,2561,O
>,2561,O
15,2561,O
ng/ml,2561,O
),2561,O
in,2561,O
7,2561,O
of,2561,O
13,2561,O
(,2561,O
54,2561,O
%,2561,O
),2561,O
patients,2561,O
.,2561,O
CONCLUSIONS,2562,O
:,2562,O
RAPA,2562,B-Chemical
conversion,2562,O
provides,2562,O
adequate,2562,O
immunosuppression,2562,O
to,2562,O
enable,2562,O
CsA,2562,B-Chemical
withdrawal,2562,O
.,2562,O
However,2563,O
",",2563,O
when,2563,O
converting,2563,O
patients,2563,O
to,2563,O
RAPA,2563,B-Chemical
drug,2563,O
levels,2563,O
should,2563,O
be,2563,O
monitored,2563,O
to,2563,O
avoid,2563,O
over-immunosuppression,2563,O
and,2563,O
adequate,2563,O
antiviral,2563,O
and,2563,O
Pneumocystis,2563,B-Disease
carinii,2563,I-Disease
pneumonia,2563,I-Disease
prophylaxis,2563,O
should,2563,O
be,2563,O
given,2563,O
.,2563,O
Electro-oculography,2564,O
",",2564,O
electroretinography,2564,O
",",2564,O
visual,2564,O
evoked,2564,O
potentials,2564,O
",",2564,O
and,2564,O
multifocal,2564,O
electroretinography,2564,O
in,2564,O
patients,2564,O
with,2564,O
vigabatrin-attributed,2564,B-Chemical
visual,2564,B-Disease
field,2564,I-Disease
constriction,2564,I-Disease
.,2564,O
PURPOSE,2565,O
:,2565,O
Symptomatic,2565,O
visual,2565,B-Disease
field,2565,I-Disease
constriction,2565,I-Disease
thought,2565,O
to,2565,O
be,2565,O
associated,2565,O
with,2565,O
vigabatrin,2565,B-Chemical
has,2565,O
been,2565,O
reported,2565,O
.,2565,O
The,2566,O
current,2566,O
study,2566,O
investigated,2566,O
the,2566,O
visual,2566,O
fields,2566,O
and,2566,O
visual,2566,O
electrophysiology,2566,O
of,2566,O
eight,2566,O
patients,2566,O
with,2566,O
known,2566,O
vigabatrin-attributed,2566,B-Chemical
visual,2566,B-Disease
field,2566,I-Disease
loss,2566,I-Disease
",",2566,O
three,2566,O
of,2566,O
whom,2566,O
were,2566,O
reported,2566,O
previously,2566,O
.,2566,O
Six,2567,O
of,2567,O
the,2567,O
patients,2567,O
were,2567,O
no,2567,O
longer,2567,O
receiving,2567,O
vigabatrin,2567,B-Chemical
.,2567,O
METHODS,2568,O
:,2568,O
The,2568,O
central,2568,O
and,2568,O
peripheral,2568,O
fields,2568,O
were,2568,O
examined,2568,O
with,2568,O
the,2568,O
Humphrey,2568,O
Visual,2568,O
Field,2568,O
Analyzer,2568,O
.,2568,O
Full,2569,O
visual,2569,O
electrophysiology,2569,O
",",2569,O
including,2569,O
flash,2569,O
electroretinography,2569,O
(,2569,O
ERG,2569,O
),2569,O
",",2569,O
pattern,2569,O
electroretinography,2569,O
",",2569,O
multifocal,2569,O
ERG,2569,O
using,2569,O
the,2569,O
VERIS,2569,O
system,2569,O
",",2569,O
electro-oculography,2569,O
",",2569,O
and,2569,O
flash,2569,O
and,2569,O
pattern,2569,O
visual,2569,O
evoked,2569,O
potentials,2569,O
",",2569,O
was,2569,O
undertaken,2569,O
.,2569,O
RESULTS,2570,O
:,2570,O
Seven,2570,O
patients,2570,O
showed,2570,O
marked,2570,O
visual,2570,B-Disease
field,2570,I-Disease
constriction,2570,I-Disease
with,2570,O
some,2570,O
sparing,2570,O
of,2570,O
the,2570,O
temporal,2570,O
visual,2570,O
field,2570,O
.,2570,O
The,2571,O
eighth,2571,O
exhibited,2571,O
concentric,2571,O
constriction,2571,O
.,2571,O
Most,2572,O
electrophysiological,2572,O
responses,2572,O
were,2572,O
usually,2572,O
just,2572,O
within,2572,O
normal,2572,O
limits,2572,O
;,2572,O
two,2572,O
patients,2572,O
had,2572,O
subnormal,2572,O
Arden,2572,O
electro-oculography,2572,O
indices,2572,O
;,2572,O
and,2572,O
one,2572,O
patient,2572,O
showed,2572,O
an,2572,O
abnormally,2572,O
delayed,2572,O
photopic,2572,O
b,2572,O
wave,2572,O
.,2572,O
However,2573,O
",",2573,O
five,2573,O
patients,2573,O
showed,2573,O
delayed,2573,O
30-Hz,2573,O
flicker,2573,O
b,2573,O
waves,2573,O
",",2573,O
and,2573,O
seven,2573,O
patients,2573,O
showed,2573,O
delayed,2573,O
oscillatory,2573,O
potentials,2573,O
.,2573,O
Multifocal,2574,O
ERG,2574,O
showed,2574,O
abnormalities,2574,O
that,2574,O
sometimes,2574,O
correlated,2574,O
with,2574,O
the,2574,O
visual,2574,O
field,2574,O
appearance,2574,O
and,2574,O
confirmed,2574,O
that,2574,O
the,2574,O
deficit,2574,O
occurs,2574,O
at,2574,O
the,2574,O
retinal,2574,O
level,2574,O
.,2574,O
CONCLUSION,2575,O
:,2575,O
Marked,2575,O
visual,2575,B-Disease
field,2575,I-Disease
constriction,2575,I-Disease
appears,2575,O
to,2575,O
be,2575,O
associated,2575,O
with,2575,O
vigabatrin,2575,B-Chemical
therapy,2575,O
.,2575,O
The,2576,O
field,2576,O
defects,2576,O
and,2576,O
some,2576,O
electrophysiological,2576,O
abnormalities,2576,O
persist,2576,O
when,2576,O
vigabatrin,2576,B-Chemical
therapy,2576,O
is,2576,O
withdrawn,2576,O
.,2576,O
Myocardial,2577,B-Disease
ischemia,2577,I-Disease
due,2577,O
to,2577,O
coronary,2577,B-Disease
artery,2577,I-Disease
spasm,2577,I-Disease
during,2577,O
dobutamine,2577,B-Chemical
stress,2577,O
echocardiography,2577,O
.,2577,O
Dobutamine,2578,B-Chemical
stress,2578,O
echocardiography,2578,O
(,2578,O
DSE,2578,O
),2578,O
is,2578,O
a,2578,O
useful,2578,O
and,2578,O
safe,2578,O
provocation,2578,O
test,2578,O
for,2578,O
myocardial,2578,B-Disease
ischemia,2578,I-Disease
.,2578,O
Until,2579,O
now,2579,O
",",2579,O
the,2579,O
test,2579,O
has,2579,O
been,2579,O
focused,2579,O
only,2579,O
on,2579,O
the,2579,O
organic,2579,O
lesion,2579,O
in,2579,O
the,2579,O
coronary,2579,O
artery,2579,O
",",2579,O
and,2579,O
positive,2579,O
DSE,2579,O
has,2579,O
indicated,2579,O
the,2579,O
presence,2579,O
of,2579,O
significant,2579,O
fixed,2579,O
coronary,2579,B-Disease
artery,2579,I-Disease
stenosis,2579,I-Disease
.,2579,O
The,2580,O
aim,2580,O
of,2580,O
the,2580,O
present,2580,O
study,2580,O
is,2580,O
to,2580,O
examine,2580,O
whether,2580,O
myocardial,2580,B-Disease
ischemia,2580,I-Disease
due,2580,O
to,2580,O
coronary,2580,B-Disease
spasm,2580,I-Disease
is,2580,O
induced,2580,O
by,2580,O
dobutamine,2580,B-Chemical
.,2580,O
We,2581,O
performed,2581,O
DSE,2581,O
on,2581,O
51,2581,O
patients,2581,O
with,2581,O
coronary,2581,B-Disease
spastic,2581,I-Disease
angina,2581,I-Disease
but,2581,O
without,2581,O
significant,2581,O
fixed,2581,O
coronary,2581,B-Disease
artery,2581,I-Disease
stenosis,2581,I-Disease
.,2581,O
All,2582,O
patients,2582,O
had,2582,O
anginal,2582,B-Disease
attacks,2582,O
at,2582,O
rest,2582,O
with,2582,O
ST,2582,O
elevation,2582,O
on,2582,O
the,2582,O
electrocardiogram,2582,O
(,2582,O
variant,2582,B-Disease
angina,2582,I-Disease
),2582,O
.,2582,O
Coronary,2583,O
spasm,2583,O
was,2583,O
induced,2583,O
by,2583,O
intracoronary,2583,O
injection,2583,O
of,2583,O
acetylcholine,2583,B-Chemical
",",2583,O
and,2583,O
no,2583,O
fixed,2583,O
coronary,2583,B-Disease
artery,2583,I-Disease
stenosis,2583,I-Disease
was,2583,O
documented,2583,O
on,2583,O
angiograms,2583,O
in,2583,O
all,2583,O
patients,2583,O
.,2583,O
DSE,2584,O
was,2584,O
performed,2584,O
with,2584,O
intravenous,2584,O
dobutamine,2584,B-Chemical
infusion,2584,O
with,2584,O
an,2584,O
incremental,2584,O
doses,2584,O
of,2584,O
5,2584,O
",",2584,O
10,2584,O
",",2584,O
20,2584,O
",",2584,O
30,2584,O
",",2584,O
and,2584,O
40,2584,O
microg/kg/min,2584,O
every,2584,O
5,2584,O
minutes,2584,O
.,2584,O
Of,2585,O
the,2585,O
51,2585,O
patients,2585,O
",",2585,O
7,2585,O
patients,2585,O
showed,2585,O
asynergy,2585,O
with,2585,O
ST,2585,O
elevation,2585,O
.,2585,O
All,2586,O
7,2586,O
patients,2586,O
(,2586,O
13.7,2586,O
%,2586,O
),2586,O
had,2586,O
chest,2586,B-Disease
pain,2586,I-Disease
during,2586,O
asynergy,2586,O
",",2586,O
and,2586,O
both,2586,O
chest,2586,B-Disease
pain,2586,I-Disease
and,2586,O
electrocardiographic,2586,O
changes,2586,O
were,2586,O
preceded,2586,O
by,2586,O
asynergy,2586,O
.,2586,O
These,2587,O
findings,2587,O
indicate,2587,O
that,2587,O
dobutamine,2587,B-Chemical
can,2587,O
provoke,2587,O
coronary,2587,B-Disease
spasm,2587,I-Disease
in,2587,O
some,2587,O
patients,2587,O
with,2587,O
coronary,2587,B-Disease
spastic,2587,I-Disease
angina,2587,I-Disease
.,2587,O
When,2588,O
DSE,2588,O
is,2588,O
performed,2588,O
to,2588,O
evaluate,2588,O
coronary,2588,B-Disease
artery,2588,I-Disease
disease,2588,I-Disease
",",2588,O
not,2588,O
only,2588,O
fixed,2588,O
coronary,2588,B-Disease
stenosis,2588,I-Disease
",",2588,O
but,2588,O
also,2588,O
coronary,2588,B-Disease
spasm,2588,I-Disease
should,2588,O
be,2588,O
considered,2588,O
as,2588,O
a,2588,O
genesis,2588,O
of,2588,O
asynergy,2588,O
.,2588,O
Effect,2589,O
of,2589,O
intravenous,2589,O
metoprolol,2589,B-Chemical
or,2589,O
intravenous,2589,O
metoprolol,2589,B-Chemical
plus,2589,O
glucagon,2589,O
on,2589,O
dobutamine-induced,2589,B-Chemical
myocardial,2589,B-Disease
ischemia,2589,I-Disease
.,2589,O
STUDY,2590,O
OBJECTIVE,2590,O
:,2590,O
To,2590,O
determine,2590,O
the,2590,O
effect,2590,O
of,2590,O
metoprolol,2590,B-Chemical
on,2590,O
dobutamine,2590,B-Chemical
stress,2590,O
testing,2590,O
with,2590,O
technetium-99m,2590,B-Chemical
sestamibi,2590,I-Chemical
single-photon,2590,O
emission,2590,O
computed,2590,O
tomography,2590,O
imaging,2590,O
and,2590,O
ST-segment,2590,O
monitoring,2590,O
",",2590,O
and,2590,O
to,2590,O
assess,2590,O
the,2590,O
impact,2590,O
of,2590,O
intravenous,2590,O
glucagon,2590,O
on,2590,O
metoprolol,2590,B-Chemical
's,2590,O
effects,2590,O
.,2590,O
DESIGN,2591,O
:,2591,O
Randomized,2591,O
",",2591,O
double-blind,2591,O
",",2591,O
placebo-controlled,2591,O
trial,2591,O
.,2591,O
SETTING,2592,O
:,2592,O
Community,2592,O
hospital,2592,O
.,2592,O
PATIENTS,2593,O
:,2593,O
Twenty-two,2593,O
patients,2593,O
with,2593,O
known,2593,O
reversible,2593,O
perfusion,2593,O
defects,2593,O
.,2593,O
INTERVENTION,2594,O
:,2594,O
Patients,2594,O
underwent,2594,O
dobutamine,2594,B-Chemical
stress,2594,O
tests,2594,O
per,2594,O
standard,2594,O
protocol,2594,O
.,2594,O
Before,2595,O
dobutamine,2595,B-Chemical
was,2595,O
begun,2595,O
",",2595,O
no,2595,O
therapy,2595,O
was,2595,O
given,2595,O
during,2595,O
the,2595,O
first,2595,O
visit,2595,O
",",2595,O
and,2595,O
patients,2595,O
were,2595,O
randomized,2595,O
on,2595,O
subsequent,2595,O
visits,2595,O
to,2595,O
receive,2595,O
metoprolol,2595,B-Chemical
or,2595,O
metoprolol,2595,B-Chemical
plus,2595,O
glucagon,2595,O
1,2595,O
mg.,2595,O
Metoprolol,2595,B-Chemical
was,2595,O
dosed,2595,O
to,2595,O
achieve,2595,O
a,2595,O
resting,2595,O
predobutamine,2595,B-Chemical
heart,2595,O
rate,2595,O
below,2595,O
65,2595,O
beats/minute,2595,O
or,2595,O
a,2595,O
total,2595,O
intravenous,2595,O
dose,2595,O
of,2595,O
20,2595,O
mg.,2595,O
MEASUREMENTS,2595,O
AND,2595,O
MAIN,2595,O
RESULTS,2595,O
:,2595,O
Metoprolol,2595,B-Chemical
reduced,2595,O
maximum,2595,O
heart,2595,O
rate,2595,O
31,2595,O
%,2595,O
",",2595,O
summed,2595,O
stress,2595,O
scores,2595,O
29,2595,O
%,2595,O
",",2595,O
and,2595,O
summed,2595,O
difference,2595,O
scores,2595,O
43,2595,O
%,2595,O
versus,2595,O
control,2595,O
.,2595,O
Metoprolol,2596,B-Chemical
plus,2596,O
glucagon,2596,O
also,2596,O
reduced,2596,O
the,2596,O
maximum,2596,O
heart,2596,O
rate,2596,O
29,2596,O
%,2596,O
versus,2596,O
control,2596,O
.,2596,O
Summed,2597,O
stress,2597,O
and,2597,O
summed,2597,O
difference,2597,O
scores,2597,O
were,2597,O
not,2597,O
significantly,2597,O
reduced,2597,O
",",2597,O
although,2597,O
they,2597,O
were,2597,O
18,2597,O
%,2597,O
and,2597,O
30,2597,O
%,2597,O
lower,2597,O
",",2597,O
respectively,2597,O
",",2597,O
than,2597,O
control,2597,O
.,2597,O
No,2598,O
significant,2598,O
differences,2598,O
were,2598,O
found,2598,O
in,2598,O
any,2598,O
parameter,2598,O
between,2598,O
metoprolol,2598,B-Chemical
and,2598,O
metoprolol-glucagon,2598,B-Chemical
.,2598,O
CONCLUSION,2599,O
:,2599,O
During,2599,O
dobutamine,2599,B-Chemical
stress,2599,O
testing,2599,O
",",2599,O
metoprolol,2599,B-Chemical
attenuates,2599,O
or,2599,O
eliminates,2599,O
evidence,2599,O
of,2599,O
myocardial,2599,B-Disease
ischemia,2599,I-Disease
.,2599,O
Glucagon,2600,O
1,2600,O
mg,2600,O
",",2600,O
although,2600,O
somewhat,2600,O
effective,2600,O
",",2600,O
does,2600,O
not,2600,O
correct,2600,O
this,2600,O
effect,2600,O
to,2600,O
the,2600,O
extent,2600,O
that,2600,O
it,2600,O
can,2600,O
be,2600,O
administered,2600,O
clinically,2600,O
.,2600,O
Evidence,2601,O
of,2601,O
functional,2601,O
somatotopy,2601,O
in,2601,O
GPi,2601,O
from,2601,O
results,2601,O
of,2601,O
pallidotomy,2601,O
.,2601,O
The,2602,O
objective,2602,O
of,2602,O
this,2602,O
study,2602,O
was,2602,O
to,2602,O
explore,2602,O
the,2602,O
functional,2602,O
anatomy,2602,O
of,2602,O
the,2602,O
globus,2602,O
pallidus,2602,O
internus,2602,O
(,2602,O
GPi,2602,O
),2602,O
by,2602,O
studying,2602,O
the,2602,O
effects,2602,O
of,2602,O
unilateral,2602,O
pallidotomy,2602,O
on,2602,O
parkinsonian,2602,B-Disease
'off,2602,O
',2602,O
signs,2602,O
and,2602,O
levodopa-induced,2602,B-Chemical
dyskinesias,2602,B-Disease
(,2602,O
LID,2602,B-Disease
),2602,O
.,2602,O
We,2603,O
found,2603,O
significant,2603,O
positive,2603,O
correlations,2603,O
between,2603,O
the,2603,O
preoperative,2603,O
levodopa,2603,B-Chemical
responsiveness,2603,O
of,2603,O
motor,2603,O
signs,2603,O
and,2603,O
the,2603,O
levodopa,2603,B-Chemical
responsiveness,2603,O
of,2603,O
scores,2603,O
in,2603,O
timed,2603,O
tests,2603,O
(,2603,O
Core,2603,O
Assessment,2603,O
Program,2603,O
for,2603,O
Intracerebral,2603,O
Transplantations,2603,O
),2603,O
in,2603,O
the,2603,O
contralateral,2603,O
limbs,2603,O
and,2603,O
the,2603,O
improvement,2603,O
in,2603,O
these,2603,O
scores,2603,O
after,2603,O
surgery,2603,O
",",2603,O
whereas,2603,O
there,2603,O
was,2603,O
no,2603,O
correlation,2603,O
with,2603,O
the,2603,O
improvement,2603,O
in,2603,O
LID,2603,B-Disease
.,2603,O
We,2604,O
also,2604,O
found,2604,O
a,2604,O
highly,2604,O
significant,2604,O
correlation,2604,O
(,2604,O
P,2604,O
:,2604,O
<,2604,O
0.0001,2604,O
",",2604,O
r,2604,O
=,2604,O
0.8,2604,O
),2604,O
between,2604,O
the,2604,O
volume,2604,O
of,2604,O
the,2604,O
ventral,2604,O
lesion,2604,O
in,2604,O
the,2604,O
GPi,2604,O
and,2604,O
the,2604,O
improvement,2604,O
in,2604,O
LID,2604,B-Disease
in,2604,O
the,2604,O
contralateral,2604,O
limbs,2604,O
",",2604,O
whereas,2604,O
there,2604,O
was,2604,O
no,2604,O
correlation,2604,O
between,2604,O
the,2604,O
ventral,2604,O
volume,2604,O
and,2604,O
the,2604,O
improvement,2604,O
in,2604,O
parkinsonian,2604,B-Disease
'off,2604,O
',2604,O
signs,2604,O
.,2604,O
The,2605,O
volumes,2605,O
of,2605,O
the,2605,O
total,2605,O
lesion,2605,O
cylinder,2605,O
and,2605,O
the,2605,O
dorsal,2605,O
lesion,2605,O
did,2605,O
not,2605,O
correlate,2605,O
with,2605,O
the,2605,O
outcome,2605,O
of,2605,O
either,2605,O
dyskinesias,2605,B-Disease
or,2605,O
parkinsonian,2605,B-Disease
'off,2605,O
',2605,O
signs,2605,O
.,2605,O
The,2606,O
differential,2606,O
predictive,2606,O
value,2606,O
of,2606,O
levodopa,2606,B-Chemical
responsiveness,2606,O
for,2606,O
the,2606,O
outcome,2606,O
of,2606,O
parkinsonian,2606,B-Disease
'off,2606,O
',2606,O
signs,2606,O
and,2606,O
LID,2606,B-Disease
and,2606,O
the,2606,O
different,2606,O
correlations,2606,O
of,2606,O
ventral,2606,O
lesion,2606,O
volume,2606,O
with,2606,O
dyskinesias,2606,B-Disease
and,2606,O
parkinsonian,2606,B-Disease
'off,2606,O
',2606,O
signs,2606,O
indicate,2606,O
that,2606,O
different,2606,O
anatomical,2606,O
or,2606,O
pathophysiological,2606,O
substrates,2606,O
may,2606,O
be,2606,O
responsible,2606,O
for,2606,O
the,2606,O
generation,2606,O
of,2606,O
parkinsonian,2606,B-Disease
'off,2606,O
',2606,O
signs,2606,O
and,2606,O
dyskinesias,2606,B-Disease
.,2606,O
Whereas,2607,O
cells,2607,O
in,2607,O
a,2607,O
wider,2607,O
area,2607,O
of,2607,O
the,2607,O
GPi,2607,O
may,2607,O
be,2607,O
implicated,2607,O
in,2607,O
parkinsonism,2607,B-Disease
",",2607,O
the,2607,O
ventral,2607,O
GPi,2607,O
seems,2607,O
to,2607,O
be,2607,O
crucial,2607,O
for,2607,O
the,2607,O
manifestation,2607,O
of,2607,O
LID,2607,B-Disease
.,2607,O
We,2608,O
suggest,2608,O
that,2608,O
our,2608,O
observations,2608,O
are,2608,O
additional,2608,O
proof,2608,O
of,2608,O
the,2608,O
functional,2608,O
somatotopy,2608,O
of,2608,O
the,2608,O
systems,2608,O
within,2608,O
the,2608,O
GPi,2608,O
that,2608,O
mediate,2608,O
parkinsonism,2608,B-Disease
and,2608,O
dyskinesias,2608,B-Disease
",",2608,O
especially,2608,O
along,2608,O
the,2608,O
dorsoventral,2608,O
trajectory,2608,O
used,2608,O
in,2608,O
pallidotomy,2608,O
.,2608,O
The,2609,O
outcome,2609,O
of,2609,O
pallidotomy,2609,O
in,2609,O
which,2609,O
the,2609,O
lesion,2609,O
involves,2609,O
the,2609,O
ventral,2609,O
and,2609,O
dorsal,2609,O
GPi,2609,O
could,2609,O
be,2609,O
the,2609,O
net,2609,O
effect,2609,O
of,2609,O
alteration,2609,O
in,2609,O
the,2609,O
activity,2609,O
of,2609,O
pathways,2609,O
which,2609,O
mediate,2609,O
different,2609,O
symptoms,2609,O
",",2609,O
and,2609,O
hence,2609,O
could,2609,O
be,2609,O
variable,2609,O
.,2609,O
Screening,2610,O
for,2610,O
stimulant,2610,O
use,2610,O
in,2610,O
adult,2610,O
emergency,2610,O
department,2610,O
seizure,2610,B-Disease
patients,2610,O
.,2610,O
OBJECTIVE,2611,O
:,2611,O
The,2611,O
objective,2611,O
of,2611,O
this,2611,O
study,2611,O
was,2611,O
to,2611,O
determine,2611,O
the,2611,O
prevalence,2611,O
of,2611,O
positive,2611,O
plasma,2611,O
drug,2611,O
screening,2611,O
for,2611,O
cocaine,2611,B-Chemical
or,2611,O
amphetamine,2611,B-Chemical
in,2611,O
adult,2611,O
emergency,2611,O
department,2611,O
seizure,2611,B-Disease
patients,2611,O
.,2611,O
METHODS,2612,O
:,2612,O
This,2612,O
prospective,2612,O
study,2612,O
evaluated,2612,O
consecutive,2612,O
eligible,2612,O
seizure,2612,B-Disease
patients,2612,O
who,2612,O
had,2612,O
a,2612,O
plasma,2612,O
sample,2612,O
collected,2612,O
as,2612,O
part,2612,O
of,2612,O
their,2612,O
clinical,2612,O
evaluation,2612,O
.,2612,O
Plasma,2613,O
was,2613,O
tested,2613,O
for,2613,O
amphetamine,2613,B-Chemical
and,2613,O
the,2613,O
cocaine,2613,B-Chemical
metabolite,2613,O
benzoylecgonine,2613,B-Chemical
using,2613,O
enzyme-mediated,2613,O
immunoassay,2613,O
methodology,2613,O
.,2613,O
Plasma,2614,O
samples,2614,O
with,2614,O
benzoylecgonine,2614,B-Chemical
greater,2614,O
than,2614,O
150,2614,O
ng/mL,2614,O
or,2614,O
an,2614,O
amphetamine,2614,B-Chemical
greater,2614,O
than,2614,O
500,2614,O
ng/mL,2614,O
were,2614,O
defined,2614,O
as,2614,O
positive,2614,O
.,2614,O
Patient,2615,O
demographics,2615,O
",",2615,O
history,2615,O
of,2615,O
underlying,2615,O
drug,2615,O
or,2615,O
alcohol-related,2615,B-Chemical
seizure,2615,B-Disease
disorder,2615,O
",",2615,O
estimated,2615,O
time,2615,O
from,2615,O
seizure,2615,B-Disease
to,2615,O
sample,2615,O
collection,2615,O
",",2615,O
history,2615,O
or,2615,O
suspicion,2615,O
of,2615,O
cocaine,2615,O
or,2615,O
amphetamine,2615,O
abuse,2615,O
",",2615,O
results,2615,O
of,2615,O
clinical,2615,O
urine,2615,O
testing,2615,O
for,2615,O
drugs,2615,O
of,2615,O
abuse,2615,O
",",2615,O
and,2615,O
assay,2615,O
results,2615,O
were,2615,O
recorded,2615,O
without,2615,O
patient,2615,O
identifiers,2615,O
.,2615,O
RESULTS,2616,O
:,2616,O
Fourteen,2616,O
of,2616,O
248,2616,O
(,2616,O
5.6,2616,O
%,2616,O
",",2616,O
95,2616,O
%,2616,O
CI,2616,O
2.7,2616,O
%,2616,O
-8.5,2616,O
%,2616,O
),2616,O
plasma,2616,O
samples,2616,O
were,2616,O
positive,2616,O
by,2616,O
immunoassay,2616,O
testing,2616,O
for,2616,O
benzoylecgonine,2616,B-Chemical
and,2616,O
no,2616,O
samples,2616,O
(,2616,O
0,2616,O
%,2616,O
",",2616,O
95,2616,O
%,2616,O
CI,2616,O
0-1.2,2616,O
%,2616,O
),2616,O
were,2616,O
positive,2616,O
for,2616,O
amphetamine,2616,B-Chemical
.,2616,O
Positive,2617,O
test,2617,O
results,2617,O
were,2617,O
more,2617,O
common,2617,O
in,2617,O
patient,2617,O
visits,2617,O
where,2617,O
there,2617,O
was,2617,O
a,2617,O
history,2617,O
or,2617,O
suspicion,2617,O
of,2617,O
cocaine,2617,O
or,2617,O
amphetamine,2617,O
abuse,2617,O
(,2617,O
p,2617,O
<,2617,O
0.0005,2617,O
),2617,O
.,2617,O
CONCLUSIONS,2618,O
:,2618,O
During,2618,O
this,2618,O
study,2618,O
period,2618,O
",",2618,O
routine,2618,O
plasma,2618,O
screening,2618,O
for,2618,O
cocaine,2618,B-Chemical
and,2618,O
amphetamines,2618,B-Chemical
in,2618,O
adult,2618,O
seizure,2618,B-Disease
patients,2618,O
had,2618,O
a,2618,O
low,2618,O
yield,2618,O
.,2618,O
As,2619,O
a,2619,O
result,2619,O
",",2619,O
routine,2619,O
plasma,2619,O
screening,2619,O
would,2619,O
yield,2619,O
few,2619,O
cases,2619,O
of,2619,O
stimulant,2619,O
drug,2619,O
in,2619,O
which,2619,O
there,2619,O
was,2619,O
neither,2619,O
a,2619,O
history,2619,O
nor,2619,O
suspicion,2619,O
of,2619,O
drug,2619,B-Disease
abuse,2619,I-Disease
in,2619,O
this,2619,O
population,2619,O
.,2619,O
Contribution,2620,O
of,2620,O
sodium,2620,B-Chemical
valproate,2620,I-Chemical
to,2620,O
the,2620,O
syndrome,2620,B-Disease
of,2620,I-Disease
inappropriate,2620,I-Disease
secretion,2620,I-Disease
of,2620,I-Disease
antidiuretic,2620,I-Disease
hormone,2620,I-Disease
.,2620,O
We,2621,O
report,2621,O
the,2621,O
case,2621,O
of,2621,O
a,2621,O
62-year-old,2621,O
man,2621,O
who,2621,O
was,2621,O
administered,2621,O
sodium,2621,B-Chemical
valproate,2621,I-Chemical
(,2621,O
VPA,2621,B-Chemical
),2621,O
and,2621,O
who,2621,O
subsequently,2621,O
developed,2621,O
the,2621,O
syndrome,2621,B-Disease
of,2621,I-Disease
inappropriate,2621,I-Disease
secretion,2621,I-Disease
of,2621,I-Disease
antidiuretic,2621,I-Disease
hormone,2621,I-Disease
(,2621,O
SIADH,2621,B-Disease
),2621,O
.,2621,O
He,2622,O
had,2622,O
been,2622,O
taking,2622,O
VPA,2622,B-Chemical
for,2622,O
treatment,2622,O
of,2622,O
idiopathic,2622,O
generalized,2622,O
tonic-clonic,2622,B-Disease
convulsions,2622,I-Disease
since,2622,O
he,2622,O
was,2622,O
56,2622,O
years,2622,O
old,2622,O
.,2622,O
After,2623,O
substituting,2623,O
VPA,2623,B-Chemical
with,2623,O
zonisamide,2623,B-Chemical
",",2623,O
the,2623,O
serum,2623,O
sodium,2623,B-Chemical
level,2623,O
returned,2623,O
to,2623,O
normal,2623,O
.,2623,O
We,2624,O
consider,2624,O
this,2624,O
episode,2624,O
of,2624,O
SIADH,2624,B-Disease
to,2624,O
be,2624,O
the,2624,O
result,2624,O
of,2624,O
a,2624,O
combination,2624,O
of,2624,O
factors,2624,O
including,2624,O
a,2624,O
weakness,2624,B-Disease
of,2624,I-Disease
the,2624,I-Disease
central,2624,I-Disease
nervous,2624,I-Disease
system,2624,I-Disease
and,2624,O
the,2624,O
long-term,2624,O
administration,2624,O
of,2624,O
VPA,2624,B-Chemical
.,2624,O
Association,2625,O
of,2625,O
nitric,2625,B-Chemical
oxide,2625,I-Chemical
production,2625,O
and,2625,O
apoptosis,2625,O
in,2625,O
a,2625,O
model,2625,O
of,2625,O
experimental,2625,O
nephropathy,2625,B-Disease
.,2625,O
BACKGROUND,2626,O
:,2626,O
In,2626,O
recent,2626,O
studies,2626,O
increased,2626,O
amounts,2626,O
of,2626,O
nitric,2626,B-Chemical
oxide,2626,I-Chemical
(,2626,O
NO,2626,B-Chemical
),2626,O
and,2626,O
apoptosis,2626,O
have,2626,O
been,2626,O
implicated,2626,O
in,2626,O
various,2626,O
pathological,2626,O
conditions,2626,O
in,2626,O
the,2626,O
kidney,2626,O
.,2626,O
We,2627,O
have,2627,O
studied,2627,O
the,2627,O
role,2627,O
of,2627,O
NO,2627,B-Chemical
and,2627,O
its,2627,O
association,2627,O
with,2627,O
apoptosis,2627,O
in,2627,O
an,2627,O
experimental,2627,O
model,2627,O
of,2627,O
nephrotic,2627,B-Disease
syndrome,2627,I-Disease
induced,2627,O
by,2627,O
a,2627,O
single,2627,O
injection,2627,O
of,2627,O
adriamycin,2627,B-Chemical
(,2627,O
ADR,2627,B-Chemical
),2627,O
.,2627,O
METHODS,2628,O
:,2628,O
The,2628,O
alteration,2628,O
in,2628,O
the,2628,O
NO,2628,B-Chemical
pathway,2628,O
was,2628,O
assessed,2628,O
by,2628,O
measuring,2628,O
nitrite,2628,B-Chemical
levels,2628,O
in,2628,O
serum/urine,2628,O
and,2628,O
by,2628,O
evaluating,2628,O
the,2628,O
changes,2628,O
in,2628,O
vascular,2628,O
reactivity,2628,O
of,2628,O
the,2628,O
isolated,2628,O
perfused,2628,O
rat,2628,O
kidney,2628,O
(,2628,O
IPRK,2628,O
),2628,O
system,2628,O
.,2628,O
Rats,2629,O
were,2629,O
stratified,2629,O
into,2629,O
control,2629,O
groups,2629,O
and,2629,O
ADR-induced,2629,B-Chemical
nephropathy,2629,B-Disease
groups,2629,O
.,2629,O
These,2630,O
two,2630,O
groups,2630,O
were,2630,O
then,2630,O
divided,2630,O
into,2630,O
:,2630,O
group,2630,O
1,2630,O
",",2630,O
animals,2630,O
receiving,2630,O
saline,2630,O
;,2630,O
and,2630,O
group,2630,O
2,2630,O
",",2630,O
animals,2630,O
receiving,2630,O
aminoguanidine,2630,B-Chemical
(,2630,O
AG,2630,B-Chemical
),2630,O
which,2630,O
is,2630,O
a,2630,O
specific,2630,O
inhibitor,2630,O
of,2630,O
inducible-NO,2630,O
synthase,2630,O
.,2630,O
On,2631,O
day,2631,O
21,2631,O
",",2631,O
rats,2631,O
were,2631,O
sacrificed,2631,O
after,2631,O
obtaining,2631,O
material,2631,O
for,2631,O
biochemical,2631,O
analysis,2631,O
.,2631,O
RESULTS,2632,O
:,2632,O
Histopathological,2632,O
examination,2632,O
of,2632,O
the,2632,O
kidneys,2632,O
of,2632,O
rats,2632,O
treated,2632,O
with,2632,O
ADR,2632,B-Chemical
revealed,2632,O
focal,2632,O
areas,2632,O
of,2632,O
mesangial,2632,B-Disease
proliferation,2632,I-Disease
and,2632,O
mild,2632,O
tubulointerstitial,2632,B-Disease
inflammation,2632,I-Disease
.,2632,O
They,2633,O
also,2633,O
had,2633,O
significantly,2633,O
higher,2633,O
levels,2633,O
of,2633,O
proteinuria,2633,B-Disease
compared,2633,O
with,2633,O
control,2633,O
and,2633,O
treatment,2633,O
groups,2633,O
(,2633,O
P,2633,O
<,2633,O
0.05,2633,O
),2633,O
.,2633,O
Urine,2634,O
nitrite,2634,B-Chemical
levels,2634,O
were,2634,O
significantly,2634,O
increased,2634,O
in,2634,O
the,2634,O
ADR-nephropathy,2634,B-Chemical
group,2634,O
(,2634,O
P,2634,O
<,2634,O
0.05,2634,O
),2634,O
.,2634,O
In,2635,O
the,2635,O
IPRK,2635,O
phenylephrine,2635,B-Chemical
and,2635,O
acetylcholine,2635,B-Chemical
related,2635,O
responses,2635,O
were,2635,O
significantly,2635,O
impaired,2635,O
in,2635,O
the,2635,O
ADR-nephropathy,2635,B-Chemical
group,2635,O
.,2635,O
Apoptosis,2636,O
was,2636,O
not,2636,O
detected,2636,O
in,2636,O
controls,2636,O
.,2636,O
However,2637,O
",",2637,O
in,2637,O
the,2637,O
ADR-nephropathy,2637,B-Chemical
group,2637,O
",",2637,O
numerous,2637,O
apoptotic,2637,O
cells,2637,O
were,2637,O
identified,2637,O
in,2637,O
the,2637,O
tubulointerstitial,2637,O
areas,2637,O
.,2637,O
Double,2638,O
staining,2638,O
revealed,2638,O
numerous,2638,O
interstitial,2638,O
apoptotic,2638,O
cells,2638,O
to,2638,O
stain,2638,O
for,2638,O
ED1,2638,O
",",2638,O
a,2638,O
marker,2638,O
for,2638,O
monocytes/macrophages,2638,O
.,2638,O
Treatment,2639,O
with,2639,O
AG,2639,B-Chemical
prevented,2639,O
the,2639,O
impairment,2639,O
of,2639,O
renal,2639,O
vascular,2639,O
bed,2639,O
responses,2639,O
and,2639,O
reduced,2639,O
both,2639,O
urine,2639,O
nitrite,2639,B-Chemical
levels,2639,O
and,2639,O
apoptosis,2639,O
to,2639,O
control,2639,O
levels,2639,O
.,2639,O
CONCLUSION,2640,O
:,2640,O
We,2640,O
suggest,2640,O
that,2640,O
interactions,2640,O
between,2640,O
NO,2640,B-Chemical
and,2640,O
apoptosis,2640,O
are,2640,O
important,2640,O
in,2640,O
the,2640,O
pathogenesis,2640,O
of,2640,O
the,2640,O
ADR-induced,2640,B-Chemical
nephrosis,2640,B-Disease
.,2640,O
Dual,2641,O
effects,2641,O
of,2641,O
melatonin,2641,B-Chemical
on,2641,O
barbiturate-induced,2641,B-Chemical
narcosis,2641,B-Disease
in,2641,O
rats,2641,O
.,2641,O
Melatonin,2642,B-Chemical
affects,2642,O
the,2642,O
circadian,2642,O
sleep/wake,2642,O
cycle,2642,O
",",2642,O
but,2642,O
it,2642,O
is,2642,O
not,2642,O
clear,2642,O
whether,2642,O
it,2642,O
may,2642,O
influence,2642,O
drug-induced,2642,O
narcosis,2642,B-Disease
.,2642,O
Sodium,2643,B-Chemical
thiopenthal,2643,I-Chemical
was,2643,O
administered,2643,O
intraperitoneally,2643,O
into,2643,O
male,2643,O
rats,2643,O
pre-treated,2643,O
with,2643,O
melatonin,2643,B-Chemical
(,2643,O
0.05,2643,O
",",2643,O
0.5,2643,O
",",2643,O
5,2643,O
and,2643,O
50,2643,O
mg/kg,2643,O
),2643,O
.,2643,O
Melatonin,2644,B-Chemical
pre-treatment,2644,O
affected,2644,O
in,2644,O
a,2644,O
dual,2644,O
manner,2644,O
barbiturate,2644,B-Chemical
narcosis,2644,B-Disease
",",2644,O
however,2644,O
",",2644,O
no,2644,O
dose-effect,2644,O
correlation,2644,O
was,2644,O
found,2644,O
.,2644,O
In,2645,O
particular,2645,O
",",2645,O
low,2645,O
doses,2645,O
reduced,2645,O
the,2645,O
latency,2645,O
to,2645,O
and,2645,O
prolonged,2645,O
the,2645,O
duration,2645,O
of,2645,O
barbiturate,2645,B-Chemical
narcosis,2645,B-Disease
.,2645,O
In,2646,O
contrast,2646,O
",",2646,O
the,2646,O
highest,2646,O
dose,2646,O
of,2646,O
melatonin,2646,B-Chemical
(,2646,O
50,2646,O
mg/kg,2646,O
),2646,O
caused,2646,O
a,2646,O
paradoxical,2646,O
increase,2646,O
in,2646,O
the,2646,O
latency,2646,O
and,2646,O
produced,2646,O
a,2646,O
sustained,2646,O
reduction,2646,O
of,2646,O
the,2646,O
duration,2646,O
of,2646,O
narcosis,2646,B-Disease
",",2646,O
and,2646,O
a,2646,O
reduction,2646,O
in,2646,O
mortality,2646,O
rate,2646,O
.,2646,O
Melatonin,2647,B-Chemical
0.5,2647,O
and,2647,O
5,2647,O
mg/kg,2647,O
influenced,2647,O
the,2647,O
duration,2647,O
but,2647,O
not,2647,O
the,2647,O
latency,2647,O
of,2647,O
ketamine-,2647,B-Chemical
or,2647,O
diazepam-induced,2647,B-Chemical
narcosis,2647,B-Disease
.,2647,O
Thus,2648,O
",",2648,O
the,2648,O
dual,2648,O
action,2648,O
of,2648,O
melatonin,2648,B-Chemical
on,2648,O
pharmacological,2648,O
narcosis,2648,B-Disease
seems,2648,O
to,2648,O
be,2648,O
specific,2648,O
for,2648,O
the,2648,O
barbiturate,2648,B-Chemical
mechanism,2648,O
of,2648,O
action,2648,O
.,2648,O
Reduced,2649,O
cardiotoxicity,2649,B-Disease
and,2649,O
preserved,2649,O
antitumor,2649,O
efficacy,2649,O
of,2649,O
liposome-encapsulated,2649,O
doxorubicin,2649,B-Chemical
and,2649,O
cyclophosphamide,2649,B-Chemical
compared,2649,O
with,2649,O
conventional,2649,O
doxorubicin,2649,B-Chemical
and,2649,O
cyclophosphamide,2649,B-Chemical
in,2649,O
a,2649,O
randomized,2649,O
",",2649,O
multicenter,2649,O
trial,2649,O
of,2649,O
metastatic,2649,O
breast,2649,B-Disease
cancer,2649,I-Disease
.,2649,O
PURPOSE,2650,O
:,2650,O
To,2650,O
determine,2650,O
whether,2650,O
Myocet,2650,B-Chemical
(,2650,O
liposome-encapsulated,2650,O
doxorubicin,2650,B-Chemical
;,2650,O
The,2650,O
Liposome,2650,O
Company,2650,O
",",2650,O
Elan,2650,O
Corporation,2650,O
",",2650,O
Princeton,2650,O
",",2650,O
NJ,2650,O
),2650,O
in,2650,O
combination,2650,O
with,2650,O
cyclophosphamide,2650,B-Chemical
significantly,2650,O
reduces,2650,O
doxorubicin,2650,B-Chemical
cardiotoxicity,2650,B-Disease
while,2650,O
providing,2650,O
comparable,2650,O
antitumor,2650,O
efficacy,2650,O
in,2650,O
first-line,2650,O
treatment,2650,O
of,2650,O
metastatic,2650,O
breast,2650,B-Disease
cancer,2650,I-Disease
(,2650,O
MBC,2650,B-Disease
),2650,O
.,2650,O
PATIENTS,2651,O
AND,2651,O
METHODS,2651,O
:,2651,O
Two,2651,O
hundred,2651,O
ninety-seven,2651,O
patients,2651,O
with,2651,O
MBC,2651,B-Disease
and,2651,O
no,2651,O
prior,2651,O
chemotherapy,2651,O
for,2651,O
metastatic,2651,O
disease,2651,O
were,2651,O
randomized,2651,O
to,2651,O
receive,2651,O
either,2651,O
60,2651,O
mg/m,2651,O
(,2651,O
2,2651,O
),2651,O
of,2651,O
Myocet,2651,B-Chemical
(,2651,O
M,2651,O
),2651,O
or,2651,O
conventional,2651,O
doxorubicin,2651,B-Chemical
(,2651,O
A,2651,O
),2651,O
",",2651,O
in,2651,O
combination,2651,O
with,2651,O
600,2651,O
mg/m,2651,O
(,2651,O
2,2651,O
),2651,O
of,2651,O
cyclophosphamide,2651,B-Chemical
(,2651,O
C,2651,O
),2651,O
",",2651,O
every,2651,O
3,2651,O
weeks,2651,O
until,2651,O
disease,2651,O
progression,2651,O
or,2651,O
unacceptable,2651,O
toxicity,2651,B-Disease
.,2651,O
Cardiotoxicity,2652,B-Disease
was,2652,O
defined,2652,O
by,2652,O
reductions,2652,O
in,2652,O
left-ventricular,2652,O
ejection,2652,O
fraction,2652,O
",",2652,O
assessed,2652,O
by,2652,O
serial,2652,O
multigated,2652,O
radionuclide,2652,O
angiography,2652,O
scans,2652,O
",",2652,O
or,2652,O
congestive,2652,B-Disease
heart,2652,I-Disease
failure,2652,I-Disease
(,2652,O
CHF,2652,B-Disease
),2652,O
.,2652,O
Antitumor,2653,O
efficacy,2653,O
was,2653,O
assessed,2653,O
by,2653,O
objective,2653,O
tumor,2653,B-Disease
response,2653,O
rates,2653,O
(,2653,O
World,2653,O
Health,2653,O
Organization,2653,O
criteria,2653,O
),2653,O
",",2653,O
time,2653,O
to,2653,O
progression,2653,O
",",2653,O
and,2653,O
survival,2653,O
.,2653,O
RESULTS,2654,O
:,2654,O
Six,2654,O
percent,2654,O
of,2654,O
MC,2654,O
patients,2654,O
versus,2654,O
21,2654,O
%,2654,O
(,2654,O
including,2654,O
five,2654,O
cases,2654,O
of,2654,O
CHF,2654,B-Disease
),2654,O
of,2654,O
AC,2654,O
patients,2654,O
developed,2654,O
cardiotoxicity,2654,B-Disease
(,2654,O
P,2654,O
=.0002,2654,O
),2654,O
.,2654,O
Median,2655,O
cumulative,2655,O
doxorubicin,2655,B-Chemical
dose,2655,O
at,2655,O
onset,2655,O
was,2655,O
more,2655,O
than,2655,O
"2,220",2655,O
mg/m,2655,O
(,2655,O
2,2655,O
),2655,O
for,2655,O
MC,2655,O
versus,2655,O
480,2655,O
mg/m,2655,O
(,2655,O
2,2655,O
),2655,O
for,2655,O
AC,2655,O
(,2655,O
P,2655,O
=.0001,2655,O
",",2655,O
hazard,2655,O
ratio,2655,O
",",2655,O
5.04,2655,O
),2655,O
.,2655,O
MC,2656,O
patients,2656,O
also,2656,O
experienced,2656,O
less,2656,O
grade,2656,O
4,2656,O
neutropenia,2656,B-Disease
.,2656,O
Antitumor,2657,O
efficacy,2657,O
of,2657,O
MC,2657,O
versus,2657,O
AC,2657,O
was,2657,O
comparable,2657,O
:,2657,O
objective,2657,O
response,2657,O
rates,2657,O
",",2657,O
43,2657,O
%,2657,O
versus,2657,O
43,2657,O
%,2657,O
;,2657,O
median,2657,O
time,2657,O
to,2657,O
progression,2657,O
",",2657,O
5.1,2657,O
%,2657,O
versus,2657,O
5.5,2657,O
months,2657,O
;,2657,O
median,2657,O
time,2657,O
to,2657,O
treatment,2657,O
failure,2657,O
",",2657,O
4.6,2657,O
versus,2657,O
4.4,2657,O
months,2657,O
;,2657,O
and,2657,O
median,2657,O
survival,2657,O
",",2657,O
19,2657,O
versus,2657,O
16,2657,O
months,2657,O
.,2657,O
CONCLUSION,2658,O
:,2658,O
Myocet,2658,B-Chemical
improves,2658,O
the,2658,O
therapeutic,2658,O
index,2658,O
of,2658,O
doxorubicin,2658,B-Chemical
by,2658,O
significantly,2658,O
reducing,2658,O
cardiotoxicity,2658,B-Disease
and,2658,O
grade,2658,O
4,2658,O
neutropenia,2658,B-Disease
and,2658,O
provides,2658,O
comparable,2658,O
antitumor,2658,O
efficacy,2658,O
",",2658,O
when,2658,O
used,2658,O
in,2658,O
combination,2658,O
with,2658,O
cyclophosphamide,2658,B-Chemical
as,2658,O
first-line,2658,O
therapy,2658,O
for,2658,O
MBC,2658,B-Disease
.,2658,O
The,2659,O
role,2659,O
of,2659,O
nitrergic,2659,O
system,2659,O
in,2659,O
lidocaine-induced,2659,B-Chemical
convulsion,2659,B-Disease
in,2659,O
the,2659,O
mouse,2659,O
.,2659,O
The,2660,O
effects,2660,O
of,2660,O
N-nitro-L-arginine-methyl,2660,B-Chemical
ester,2660,I-Chemical
(,2660,O
L-NAME,2660,B-Chemical
),2660,O
a,2660,O
nitric,2660,B-Chemical
oxide,2660,I-Chemical
(,2660,O
NO,2660,B-Chemical
),2660,O
synthase,2660,O
inhibitor,2660,O
and,2660,O
L-arginine,2660,B-Chemical
",",2660,O
a,2660,O
NO,2660,B-Chemical
precursor,2660,O
",",2660,O
were,2660,O
investigated,2660,O
on,2660,O
lidocaine-induced,2660,B-Chemical
convulsions,2660,B-Disease
.,2660,O
In,2661,O
the,2661,O
first,2661,O
experiment,2661,O
",",2661,O
four,2661,O
groups,2661,O
of,2661,O
mice,2661,O
received,2661,O
physiological,2661,O
saline,2661,O
(,2661,O
0.9,2661,O
%,2661,O
),2661,O
",",2661,O
L-arginine,2661,B-Chemical
(,2661,O
300,2661,O
mg/kg,2661,O
",",2661,O
i.p,2661,O
.,2661,O
),2662,O
",",2662,O
L-NAME,2662,O
(,2662,O
100,2662,O
mg/kg,2662,O
",",2662,O
i.p,2662,O
.,2662,O
),2662,O
and,2663,O
diazepam,2663,O
(,2663,O
2,2663,O
mg/kg,2663,O
),2663,O
",",2663,O
respectively,2663,O
.,2663,O
Thirty,2664,O
minutes,2664,O
after,2664,O
these,2664,O
injections,2664,O
",",2664,O
all,2664,O
mice,2664,O
received,2664,O
lidocaine,2664,O
(,2664,O
50,2664,O
mg/kg,2664,O
",",2664,O
i.p,2664,O
.,2664,O
),2664,O
.,2664,O
In,2665,O
the,2665,O
second,2665,O
experiment,2665,O
",",2665,O
four,2665,O
groups,2665,O
of,2665,O
mice,2665,O
received,2665,O
similar,2665,O
treatment,2665,O
in,2665,O
the,2665,O
first,2665,O
experiment,2665,O
",",2665,O
and,2665,O
30,2665,O
min,2665,O
after,2665,O
these,2665,O
injections,2665,O
",",2665,O
all,2665,O
mice,2665,O
received,2665,O
a,2665,O
higher,2665,O
dose,2665,O
of,2665,O
lidocaine,2665,O
(,2665,O
80,2665,O
mg/kg,2665,O
),2665,O
.,2665,O
L-NAME,2666,O
(,2666,O
100,2666,O
mg/kg,2666,O
",",2666,O
i.p,2666,O
.,2666,O
),2666,O
and,2667,O
diazepam,2667,O
(,2667,O
2,2667,O
mg/kg,2667,O
),2667,O
significantly,2667,O
decreased,2667,O
the,2667,O
incidence,2667,O
of,2667,O
lidocaine,2667,O
(,2667,O
50,2667,O
mg/kg,2667,O
),2667,O
-induced,2667,O
convulsions,2667,O
.,2667,O
In,2668,O
contrast,2668,O
",",2668,O
the,2668,O
L-arginine,2668,O
treatment,2668,O
increased,2668,O
the,2668,O
incidence,2668,O
of,2668,O
lidocaine,2668,O
(,2668,O
80,2668,O
mg/kg,2668,O
",",2668,O
i.p,2668,O
.,2668,O
),2669,O
-induced,2669,O
convulsions,2669,O
significantly,2669,O
.,2669,O
These,2670,O
results,2670,O
may,2670,O
suggest,2670,O
that,2670,O
NO,2670,O
is,2670,O
a,2670,O
proconvulsant,2670,O
mediator,2670,O
in,2670,O
lidocaine-induced,2670,O
convulsions,2670,O
.,2670,O
Erythropoietin,2671,O
restores,2671,O
the,2671,O
anemia-induced,2671,B-Disease
reduction,2671,O
in,2671,O
cyclophosphamide,2671,B-Chemical
cytotoxicity,2671,B-Disease
in,2671,O
rat,2671,O
tumors,2671,B-Disease
.,2671,O
The,2672,O
aim,2672,O
of,2672,O
this,2672,O
study,2672,O
was,2672,O
to,2672,O
examine,2672,O
the,2672,O
impact,2672,O
of,2672,O
anemia,2672,B-Disease
prevention,2672,O
by,2672,O
recombinant,2672,O
human,2672,O
erythropoietin,2672,O
(,2672,O
rHuEPO,2672,O
),2672,O
treatment,2672,O
on,2672,O
the,2672,O
cytotoxicity,2672,B-Disease
of,2672,O
cyclophosphamide,2672,B-Chemical
in,2672,O
solid,2672,O
experimental,2672,O
tumors,2672,B-Disease
.,2672,O
Anemia,2673,B-Disease
was,2673,O
induced,2673,O
using,2673,O
a,2673,O
single,2673,O
dose,2673,O
of,2673,O
carboplatin,2673,B-Chemical
(,2673,O
50,2673,O
mg/kg,2673,O
i.v,2673,O
.,2673,O
),2673,O
resulting,2674,O
in,2674,O
a,2674,O
long-lasting,2674,O
reduction,2674,O
(,2674,O
30,2674,O
%,2674,O
),2674,O
of,2674,O
the,2674,O
hemoglobin,2674,O
concentration,2674,O
.,2674,O
In,2675,O
a,2675,O
second,2675,O
group,2675,O
",",2675,O
the,2675,O
development,2675,O
of,2675,O
anemia,2675,B-Disease
was,2675,O
prevented,2675,O
by,2675,O
rHuEPO,2675,O
(,2675,O
1000,2675,O
IU/kg,2675,O
),2675,O
administered,2675,O
s.c.,2675,O
three,2675,O
times/week,2675,O
starting,2675,O
7,2675,O
days,2675,O
before,2675,O
carboplatin,2675,B-Chemical
application,2675,O
.,2675,O
Four,2676,O
days,2676,O
after,2676,O
carboplatin,2676,B-Chemical
treatment,2676,O
",",2676,O
tumors,2676,B-Disease
(,2676,O
DS-sarcoma,2676,O
of,2676,O
the,2676,O
rat,2676,O
),2676,O
were,2676,O
implanted,2676,O
s.c.,2676,O
onto,2676,O
the,2676,O
hind,2676,O
food,2676,O
dorsum,2676,O
.,2676,O
Neither,2677,O
carboplatin,2677,B-Chemical
nor,2677,O
rHuEPO,2677,O
treatment,2677,O
influenced,2677,O
tumor,2677,B-Disease
growth,2677,O
rate,2677,O
per,2677,O
se,2677,O
.,2677,O
When,2678,O
tumors,2678,B-Disease
were,2678,O
treated,2678,O
with,2678,O
a,2678,O
single,2678,O
dose,2678,O
of,2678,O
cyclophosphamide,2678,B-Chemical
(,2678,O
60,2678,O
mg/kg,2678,O
i.p,2678,O
.,2678,O
),2678,O
5,2679,O
days,2679,O
after,2679,O
implantation,2679,O
",",2679,O
a,2679,O
growth,2679,O
delay,2679,O
with,2679,O
a,2679,O
subsequent,2679,O
regrowth,2679,O
of,2679,O
the,2679,O
tumors,2679,B-Disease
was,2679,O
observed,2679,O
.,2679,O
In,2680,O
the,2680,O
anemia,2680,B-Disease
group,2680,O
",",2680,O
the,2680,O
growth,2680,O
delay,2680,O
was,2680,O
significantly,2680,O
shorter,2680,O
compared,2680,O
with,2680,O
nonanemic,2680,O
controls,2680,O
(,2680,O
13.3,2680,O
days,2680,O
versus,2680,O
8.6,2680,O
days,2680,O
),2680,O
.,2680,O
In,2681,O
the,2681,O
group,2681,O
where,2681,O
anemia,2681,B-Disease
was,2681,O
prevented,2681,O
by,2681,O
rHuEPO,2681,O
treatment,2681,O
",",2681,O
growth,2681,O
delay,2681,O
was,2681,O
comparable,2681,O
with,2681,O
that,2681,O
of,2681,O
nonanemic,2681,O
controls,2681,O
(,2681,O
13.3,2681,O
days,2681,O
),2681,O
.,2681,O
These,2682,O
results,2682,O
suggest,2682,O
that,2682,O
chemotherapy-induced,2682,O
anemia,2682,B-Disease
reduces,2682,O
cytotoxicity,2682,B-Disease
of,2682,O
cyclophosphamide,2682,B-Chemical
in,2682,O
tumors,2682,B-Disease
",",2682,O
whereas,2682,O
correction,2682,O
of,2682,O
anemia,2682,B-Disease
by,2682,O
rHuEPO,2682,O
treatment,2682,O
(,2682,O
epoetin,2682,O
alpha,2682,O
),2682,O
increases,2682,O
the,2682,O
sensitivity,2682,O
",",2682,O
probably,2682,O
as,2682,O
a,2682,O
result,2682,O
of,2682,O
an,2682,O
improved,2682,O
oxygen,2682,B-Chemical
supply,2682,O
to,2682,O
tumor,2682,B-Disease
tissue,2682,O
.,2682,O
Fatal,2683,O
haemorrhagic,2683,O
myocarditis,2683,O
secondary,2683,O
to,2683,O
cyclophosphamide,2683,B-Chemical
therapy,2683,O
.,2683,O
Haemorrhagic,2684,O
myocarditis,2684,O
is,2684,O
a,2684,O
rare,2684,O
but,2684,O
important,2684,O
complication,2684,O
of,2684,O
cyclophosphamide,2684,B-Chemical
therapy,2684,O
.,2684,O
Echocardiographic,2685,O
identification,2685,O
of,2685,O
the,2685,O
disorder,2685,O
can,2685,O
be,2685,O
made,2685,O
.,2685,O
We,2686,O
believe,2686,O
that,2686,O
the,2686,O
ultrasound,2686,O
features,2686,O
of,2686,O
this,2686,O
disorder,2686,O
have,2686,O
not,2686,O
been,2686,O
previously,2686,O
reported,2686,O
.,2686,O
Effects,2687,O
of,2687,O
verapamil,2687,B-Chemical
on,2687,O
atrial,2687,B-Disease
fibrillation,2687,I-Disease
and,2687,O
its,2687,O
electrophysiological,2687,O
determinants,2687,O
in,2687,O
dogs,2687,O
.,2687,O
BACKGROUND,2688,O
:,2688,O
Atrial,2688,B-Disease
tachycardia-induced,2688,O
remodeling,2688,O
promotes,2688,O
the,2688,O
occurrence,2688,O
and,2688,O
maintenance,2688,O
of,2688,O
atrial,2688,B-Disease
fibrillation,2688,I-Disease
(,2688,O
AF,2688,B-Disease
),2688,O
and,2688,O
decreases,2688,O
L-type,2688,O
Ca,2688,B-Chemical
(,2688,O
2+,2688,O
),2688,O
current,2688,O
.,2688,O
There,2689,O
is,2689,O
also,2689,O
a,2689,O
clinical,2689,O
suggestion,2689,O
that,2689,O
acute,2689,O
L-type,2689,O
Ca,2689,B-Chemical
(,2689,O
2,2689,O
),2689,O
channel,2689,O
blockade,2689,O
can,2689,O
promote,2689,O
AF,2689,B-Disease
",",2689,O
consistent,2689,O
with,2689,O
an,2689,O
AF,2689,B-Disease
promoting,2689,O
effect,2689,O
of,2689,O
Ca,2689,B-Chemical
(,2689,O
2+,2689,O
),2689,O
channel,2689,O
inhibition,2689,O
.,2689,O
METHODS,2690,O
:,2690,O
To,2690,O
evaluate,2690,O
the,2690,O
potential,2690,O
mechanisms,2690,O
of,2690,O
AF,2690,B-Disease
promotion,2690,O
by,2690,O
Ca,2690,B-Chemical
(,2690,O
2+,2690,O
),2690,O
channel,2690,O
blockers,2690,O
",",2690,O
we,2690,O
administered,2690,O
verapamil,2690,B-Chemical
to,2690,O
morphine-chloralose,2690,B-Chemical
anesthetized,2690,O
dogs,2690,O
.,2690,O
Diltiazem,2691,B-Chemical
was,2691,O
used,2691,O
as,2691,O
a,2691,O
comparison,2691,O
drug,2691,O
and,2691,O
autonomic,2691,O
blockade,2691,O
with,2691,O
atropine,2691,B-Chemical
and,2691,O
nadolol,2691,B-Chemical
was,2691,O
applied,2691,O
in,2691,O
some,2691,O
experiments,2691,O
.,2691,O
Epicardial,2692,O
mapping,2692,O
with,2692,O
240,2692,O
epicardial,2692,O
electrodes,2692,O
was,2692,O
used,2692,O
to,2692,O
evaluate,2692,O
activation,2692,O
during,2692,O
AF,2692,B-Disease
.,2692,O
RESULTS,2693,O
:,2693,O
Verapamil,2693,B-Chemical
caused,2693,O
AF,2693,B-Disease
promotion,2693,O
in,2693,O
six,2693,O
dogs,2693,O
",",2693,O
increasing,2693,O
mean,2693,O
duration,2693,O
of,2693,O
AF,2693,B-Disease
induced,2693,O
by,2693,O
burst,2693,O
pacing,2693,O
",",2693,O
from,2693,O
8+/-4,2693,O
s,2693,O
(,2693,O
mean+/-S.E,2693,O
.,2693,O
),2693,O
to,2694,O
95+/-39,2694,O
s,2694,O
(,2694,O
P,2694,O
<,2694,O
0.01,2694,O
vs.,2694,O
control,2694,O
),2694,O
at,2694,O
a,2694,O
loading,2694,O
dose,2694,O
of,2694,O
0.1,2694,O
mg/kg,2694,O
and,2694,O
228+/-101,2694,O
s,2694,O
(,2694,O
P,2694,O
<,2694,O
0.0005,2694,O
vs.,2694,O
control,2694,O
),2694,O
at,2694,O
a,2694,O
dose,2694,O
of,2694,O
0.2,2694,O
mg/kg,2694,O
.,2694,O
Underlying,2695,O
electrophysiological,2695,O
mechanisms,2695,O
were,2695,O
studied,2695,O
in,2695,O
detail,2695,O
in,2695,O
five,2695,O
additional,2695,O
dogs,2695,O
under,2695,O
control,2695,O
conditions,2695,O
and,2695,O
in,2695,O
the,2695,O
presence,2695,O
of,2695,O
the,2695,O
higher,2695,O
dose,2695,O
of,2695,O
verapamil,2695,B-Chemical
.,2695,O
In,2696,O
these,2696,O
experiments,2696,O
",",2696,O
verapamil,2696,B-Chemical
shortened,2696,O
mean,2696,O
effective,2696,O
refractory,2696,O
period,2696,O
(,2696,O
ERP,2696,O
),2696,O
from,2696,O
122+/-5,2696,O
to,2696,O
114+/-4,2696,O
ms,2696,O
(,2696,O
P,2696,O
<,2696,O
0.02,2696,O
),2696,O
at,2696,O
a,2696,O
cycle,2696,O
length,2696,O
of,2696,O
300,2696,O
ms,2696,O
",",2696,O
decreased,2696,O
ERP,2696,O
heterogeneity,2696,O
(,2696,O
from,2696,O
15+/-1,2696,O
to,2696,O
10+/-1,2696,O
%,2696,O
",",2696,O
P,2696,O
<,2696,O
0.05,2696,O
),2696,O
",",2696,O
heterogeneously,2696,O
accelerated,2696,O
atrial,2696,O
conduction,2696,O
and,2696,O
decreased,2696,O
the,2696,O
cycle,2696,O
length,2696,O
of,2696,O
AF,2696,B-Disease
(,2696,O
94+/-4,2696,O
to,2696,O
84+/-3,2696,O
ms,2696,O
",",2696,O
P,2696,O
<,2696,O
0.005,2696,O
),2696,O
.,2696,O
Diltiazem,2697,B-Chemical
did,2697,O
not,2697,O
affect,2697,O
ERP,2697,O
",",2697,O
AF,2697,B-Disease
cycle,2697,O
length,2697,O
or,2697,O
AF,2697,B-Disease
duration,2697,O
",",2697,O
but,2697,O
produced,2697,O
conduction,2697,O
acceleration,2697,O
similar,2697,O
to,2697,O
that,2697,O
caused,2697,O
by,2697,O
verapamil,2697,B-Chemical
(,2697,O
n=5,2697,O
),2697,O
.,2697,O
In,2698,O
the,2698,O
presence,2698,O
of,2698,O
autonomic,2698,O
blockade,2698,O
",",2698,O
verapamil,2698,B-Chemical
failed,2698,O
to,2698,O
promote,2698,O
AF,2698,B-Disease
and,2698,O
increased,2698,O
",",2698,O
rather,2698,O
than,2698,O
decreasing,2698,O
",",2698,O
refractoriness,2698,O
.,2698,O
Neither,2699,O
verapamil,2699,B-Chemical
nor,2699,O
diltiazem,2699,B-Chemical
affected,2699,O
atrial,2699,O
conduction,2699,O
in,2699,O
the,2699,O
presence,2699,O
of,2699,O
autonomic,2699,O
blockade,2699,O
.,2699,O
Epicardial,2700,O
mapping,2700,O
suggested,2700,O
that,2700,O
verapamil,2700,B-Chemical
promoted,2700,O
AF,2700,B-Disease
by,2700,O
increasing,2700,O
the,2700,O
number,2700,O
of,2700,O
simultaneous,2700,O
wavefronts,2700,O
reflected,2700,O
by,2700,O
separate,2700,O
zones,2700,O
of,2700,O
reactivation,2700,O
in,2700,O
each,2700,O
cycle,2700,O
.,2700,O
CONCLUSIONS,2701,O
:,2701,O
Verapamil,2701,B-Chemical
promotes,2701,O
AF,2701,B-Disease
in,2701,O
normal,2701,O
dogs,2701,O
by,2701,O
promoting,2701,O
multiple,2701,O
circuit,2701,O
reentry,2701,O
",",2701,O
an,2701,O
effect,2701,O
dependent,2701,O
on,2701,O
intact,2701,O
autonomic,2701,O
tone,2701,O
and,2701,O
not,2701,O
shared,2701,O
by,2701,O
diltiazem,2701,B-Chemical
.,2701,O
Calcitonin,2702,O
gene-related,2702,O
peptide,2702,O
levels,2702,O
during,2702,O
nitric,2702,B-Chemical
oxide-induced,2702,O
headache,2702,B-Disease
in,2702,O
patients,2702,O
with,2702,O
chronic,2702,O
tension-type,2702,B-Disease
headache,2702,I-Disease
.,2702,O
It,2703,O
has,2703,O
been,2703,O
proposed,2703,O
that,2703,O
nitric,2703,B-Chemical
oxide,2703,I-Chemical
(,2703,O
NO,2703,B-Chemical
),2703,O
induced,2703,O
headache,2703,B-Disease
in,2703,O
primary,2703,B-Disease
headaches,2703,I-Disease
may,2703,O
be,2703,O
associated,2703,O
with,2703,O
release,2703,O
of,2703,O
calcitonin,2703,O
gene-related,2703,O
peptide,2703,O
(,2703,O
CGRP,2703,O
),2703,O
.,2703,O
In,2704,O
the,2704,O
present,2704,O
study,2704,O
we,2704,O
aimed,2704,O
to,2704,O
investigate,2704,O
plasma,2704,O
levels,2704,O
of,2704,O
CGRP,2704,O
during,2704,O
headache,2704,B-Disease
induced,2704,O
by,2704,O
the,2704,O
NO,2704,B-Chemical
donor,2704,O
glyceryl,2704,B-Chemical
trinitrate,2704,I-Chemical
(,2704,O
GTN,2704,B-Chemical
),2704,O
in,2704,O
16,2704,O
patients,2704,O
with,2704,O
chronic,2704,O
tension-type,2704,B-Disease
headache,2704,I-Disease
and,2704,O
16,2704,O
healthy,2704,O
controls,2704,O
.,2704,O
The,2705,O
subjects,2705,O
were,2705,O
randomly,2705,O
allocated,2705,O
to,2705,O
receive,2705,O
0.5,2705,O
microg/kg/min,2705,O
GTN,2705,B-Chemical
or,2705,O
placebo,2705,O
over,2705,O
20,2705,O
min,2705,O
on,2705,O
two,2705,O
headache-free,2705,B-Disease
days,2705,O
.,2705,O
Blood,2706,O
samples,2706,O
were,2706,O
collected,2706,O
at,2706,O
baseline,2706,O
",",2706,O
10,2706,O
",",2706,O
20,2706,O
and,2706,O
60,2706,O
min,2706,O
after,2706,O
start,2706,O
of,2706,O
infusion,2706,O
.,2706,O
Both,2707,O
patients,2707,O
and,2707,O
controls,2707,O
developed,2707,O
significantly,2707,O
stronger,2707,O
immediate,2707,O
headache,2707,B-Disease
on,2707,O
the,2707,O
GTN,2707,B-Chemical
day,2707,O
than,2707,O
on,2707,O
the,2707,O
placebo,2707,O
day,2707,O
and,2707,O
the,2707,O
headache,2707,B-Disease
was,2707,O
significantly,2707,O
more,2707,O
pronounced,2707,O
in,2707,O
patients,2707,O
than,2707,O
in,2707,O
controls,2707,O
.,2707,O
There,2708,O
was,2708,O
no,2708,O
difference,2708,O
between,2708,O
the,2708,O
area,2708,O
under,2708,O
the,2708,O
CGRP,2708,O
curve,2708,O
(,2708,O
AUCCGRP,2708,O
),2708,O
on,2708,O
GTN,2708,B-Chemical
vs.,2708,O
placebo,2708,O
day,2708,O
in,2708,O
either,2708,O
patients,2708,O
(,2708,O
P=0.65,2708,O
),2708,O
or,2708,O
controls,2708,O
(,2708,O
P=0.48,2708,O
),2708,O
.,2708,O
The,2709,O
AUCCGRP,2709,O
recorded,2709,O
on,2709,O
the,2709,O
GTN,2709,B-Chemical
day,2709,O
did,2709,O
not,2709,O
differ,2709,O
between,2709,O
patients,2709,O
and,2709,O
controls,2709,O
(,2709,O
P=0.36,2709,O
),2709,O
.,2709,O
Both,2710,O
in,2710,O
patients,2710,O
and,2710,O
controls,2710,O
",",2710,O
CGRP,2710,O
levels,2710,O
changed,2710,O
significantly,2710,O
over,2710,O
time,2710,O
",",2710,O
on,2710,O
both,2710,O
the,2710,O
GTN,2710,B-Chemical
and,2710,O
placebo,2710,O
days,2710,O
(,2710,O
P,2710,O
<,2710,O
0.05,2710,O
),2710,O
.,2710,O
The,2711,O
present,2711,O
study,2711,O
indicates,2711,O
that,2711,O
NO-induced,2711,B-Chemical
immediate,2711,O
headache,2711,B-Disease
is,2711,O
not,2711,O
associated,2711,O
with,2711,O
release,2711,O
of,2711,O
CGRP,2711,O
.,2711,O
Fluconazole-induced,2712,B-Chemical
torsade,2712,B-Disease
de,2712,I-Disease
pointes,2712,I-Disease
.,2712,O
OBJECTIVE,2713,O
:,2713,O
To,2713,O
present,2713,O
a,2713,O
case,2713,O
of,2713,O
fluconazole-associated,2713,B-Chemical
torsade,2713,B-Disease
de,2713,I-Disease
pointes,2713,I-Disease
(,2713,O
TDP,2713,B-Disease
),2713,O
and,2713,O
discuss,2713,O
fluconazole,2713,B-Chemical
's,2713,O
role,2713,O
in,2713,O
causing,2713,O
TDP,2713,B-Disease
.,2713,O
CASE,2714,O
SUMMARY,2714,O
:,2714,O
A,2714,O
68-year-old,2714,O
white,2714,O
woman,2714,O
with,2714,O
Candida,2714,O
glabrata,2714,O
isolated,2714,O
from,2714,O
a,2714,O
presacral,2714,O
abscess,2714,O
developed,2714,O
TDP,2714,B-Disease
eight,2714,O
days,2714,O
after,2714,O
commencing,2714,O
oral,2714,O
fluconazole,2714,B-Chemical
The,2714,O
patient,2714,O
had,2714,O
no,2714,O
other,2714,O
risk,2714,O
factors,2714,O
for,2714,O
TDP,2714,B-Disease
",",2714,O
including,2714,O
coronary,2714,B-Disease
artery,2714,I-Disease
disease,2714,I-Disease
",",2714,O
cardiomyopathy,2714,B-Disease
",",2714,O
congestive,2714,B-Disease
heart,2714,I-Disease
failure,2714,I-Disease
",",2714,O
and,2714,O
electrolyte,2714,O
abnormalities,2714,O
There,2714,O
was,2714,O
a,2714,O
temporal,2714,O
association,2714,O
between,2714,O
the,2714,O
initiation,2714,O
of,2714,O
fluconazole,2714,B-Chemical
and,2714,O
TDP,2714,B-Disease
.,2714,O
The,2715,O
TDP,2715,B-Disease
resolved,2715,O
when,2715,O
fluconazole,2715,B-Chemical
was,2715,O
discontinued,2715,O
;,2715,O
however,2715,O
",",2715,O
the,2715,O
patient,2715,O
continued,2715,O
to,2715,O
have,2715,O
premature,2715,B-Disease
ventricular,2715,I-Disease
contractions,2715,I-Disease
and,2715,O
nonsustained,2715,O
ventricular,2715,B-Disease
tachycardia,2715,I-Disease
(,2715,O
NSVT,2715,B-Disease
),2715,O
until,2715,O
six,2715,O
days,2715,O
after,2715,O
drug,2715,O
cessation,2715,O
DISCUSSION,2715,O
:,2715,O
Use,2715,O
of,2715,O
the,2715,O
Naranjo,2715,O
probability,2715,O
scale,2715,O
indicates,2715,O
a,2715,O
probable,2715,O
relationship,2715,O
between,2715,O
the,2715,O
use,2715,O
of,2715,O
fluconazole,2715,B-Chemical
and,2715,O
the,2715,O
development,2715,O
of,2715,O
TDP,2715,B-Disease
.,2715,O
The,2716,O
possible,2716,O
mechanism,2716,O
is,2716,O
depression,2716,B-Disease
of,2716,O
rapidly,2716,O
activating,2716,O
delayed,2716,O
rectifier,2716,O
potassium,2716,B-Chemical
currents,2716,O
.,2716,O
In,2717,O
our,2717,O
patient,2717,O
",",2717,O
there,2717,O
was,2717,O
no,2717,O
other,2717,O
etiology,2717,O
identified,2717,O
that,2717,O
could,2717,O
explain,2717,O
QT,2717,B-Disease
prolongation,2717,I-Disease
or,2717,O
TDP,2717,B-Disease
The,2717,O
complete,2717,O
disappearance,2717,O
of,2717,O
NSVT,2717,B-Disease
and,2717,O
premature,2717,B-Disease
ventricular,2717,I-Disease
contractions,2717,I-Disease
followed,2717,O
by,2717,O
normalization,2717,O
of,2717,O
QT,2717,O
interval,2717,O
after,2717,O
the,2717,O
drug,2717,O
was,2717,O
stopped,2717,O
strongly,2717,O
suggests,2717,O
fluconazole,2717,B-Chemical
as,2717,O
the,2717,O
etiology,2717,O
.,2717,O
CONCLUSIONS,2718,O
:,2718,O
Clinicians,2718,O
should,2718,O
be,2718,O
aware,2718,O
that,2718,O
fluconazole,2718,B-Chemical
",",2718,O
even,2718,O
at,2718,O
low,2718,O
doses,2718,O
",",2718,O
may,2718,O
cause,2718,O
prolongation,2718,B-Disease
of,2718,I-Disease
the,2718,I-Disease
QT,2718,I-Disease
interval,2718,I-Disease
",",2718,O
leading,2718,O
to,2718,O
TDP,2718,B-Disease
.,2718,O
Serial,2719,O
electrocardiographic,2719,O
monitoring,2719,O
may,2719,O
be,2719,O
considered,2719,O
when,2719,O
fluconazole,2719,B-Chemical
is,2719,O
administered,2719,O
in,2719,O
patients,2719,O
who,2719,O
are,2719,O
at,2719,O
risk,2719,O
for,2719,O
ventricular,2719,B-Disease
arrhythmias,2719,I-Disease
.,2719,O
Cutaneous,2720,B-Disease
leucocytoclastic,2720,I-Disease
vasculitis,2720,I-Disease
associated,2720,O
with,2720,O
oxacillin,2720,B-Chemical
.,2720,O
A,2721,O
67-year-old,2721,O
man,2721,O
who,2721,O
was,2721,O
treated,2721,O
with,2721,O
oxacillin,2721,B-Chemical
for,2721,O
one,2721,O
week,2721,O
because,2721,O
of,2721,O
Staphylococcus,2721,O
aureus,2721,O
bacteremia,2721,O
",",2721,O
developed,2721,O
renal,2721,B-Disease
failure,2721,I-Disease
and,2721,O
diffuse,2721,O
",",2721,O
symmetric,2721,O
",",2721,O
palpable,2721,O
purpuric,2721,B-Disease
lesions,2721,I-Disease
on,2721,O
his,2721,O
feet,2721,O
.,2721,O
Necrotic,2722,O
blisters,2722,O
were,2722,O
noted,2722,O
on,2722,O
his,2722,O
fingers,2722,O
.,2722,O
Skin,2723,O
biopsies,2723,O
showed,2723,O
findings,2723,O
diagnostic,2723,O
of,2723,O
leucocytoclastic,2723,B-Disease
vasculitis,2723,I-Disease
.,2723,O
Oxacillin,2724,B-Chemical
was,2724,O
discontinued,2724,O
and,2724,O
patient,2724,O
was,2724,O
treated,2724,O
with,2724,O
corticosteroids,2724,B-Chemical
.,2724,O
The,2725,O
rash,2725,B-Disease
disappeared,2725,O
after,2725,O
three,2725,O
weeks,2725,O
and,2725,O
renal,2725,O
function,2725,O
returned,2725,O
to,2725,O
normal,2725,O
.,2725,O
Leucocytoclastic,2726,B-Disease
vasculitis,2726,I-Disease
presents,2726,O
as,2726,O
palpable,2726,O
purpura,2726,B-Disease
of,2726,O
the,2726,O
lower,2726,O
extremities,2726,O
often,2726,O
accompanied,2726,O
by,2726,O
abdominal,2726,B-Disease
pain,2726,I-Disease
",",2726,O
arthralgia,2726,B-Disease
",",2726,O
and,2726,O
renal,2726,B-Disease
involvement,2726,I-Disease
.,2726,O
Etiologic,2727,O
factors,2727,O
or,2727,O
associated,2727,O
disorders,2727,O
include,2727,O
infections,2727,B-Disease
",",2727,O
medications,2727,O
",",2727,O
collagen,2727,B-Disease
vascular,2727,I-Disease
disease,2727,I-Disease
and,2727,O
neoplasia,2727,B-Disease
.,2727,O
However,2728,O
",",2728,O
in,2728,O
half,2728,O
of,2728,O
the,2728,O
cases,2728,O
no,2728,O
etiologic,2728,O
factor,2728,O
is,2728,O
identified,2728,O
.,2728,O
Usually,2729,O
it,2729,O
is,2729,O
a,2729,O
self-limited,2729,O
disorder,2729,O
",",2729,O
but,2729,O
corticosteroid,2729,B-Chemical
therapy,2729,O
may,2729,O
be,2729,O
needed,2729,O
in,2729,O
life-threatening,2729,O
cases,2729,O
since,2729,O
early,2729,O
treatment,2729,O
with,2729,O
corticosteroids,2729,B-Chemical
in,2729,O
severe,2729,O
cases,2729,O
can,2729,O
prevent,2729,O
complications,2729,O
.,2729,O
Oxacillin,2730,B-Chemical
should,2730,O
be,2730,O
included,2730,O
among,2730,O
the,2730,O
drugs,2730,O
that,2730,O
can,2730,O
cause,2730,O
leucocytoclastic,2730,B-Disease
vasculitis,2730,I-Disease
.,2730,O
Cholestatic,2731,B-Disease
jaundice,2731,I-Disease
associated,2731,O
with,2731,O
the,2731,O
use,2731,O
of,2731,O
metformin,2731,B-Chemical
.,2731,O
We,2732,O
report,2732,O
a,2732,O
patient,2732,O
who,2732,O
developed,2732,O
cholestatic,2732,B-Disease
jaundice,2732,I-Disease
shortly,2732,O
after,2732,O
initiation,2732,O
of,2732,O
treatment,2732,O
with,2732,O
metformin,2732,B-Chemical
hydrochloride,2732,I-Chemical
.,2732,O
Ultrasound,2733,O
of,2733,O
the,2733,O
liver,2733,O
and,2733,O
abdominal,2733,O
CT,2733,O
were,2733,O
normal,2733,O
.,2733,O
An,2734,O
ERCP,2734,O
showed,2734,O
normal,2734,O
biliary,2734,O
anatomy,2734,O
.,2734,O
A,2735,O
percutaneous,2735,O
liver,2735,O
biopsy,2735,O
was,2735,O
obtained,2735,O
showing,2735,O
marked,2735,O
cholestasis,2735,B-Disease
",",2735,O
with,2735,O
portal,2735,O
edema,2735,B-Disease
",",2735,O
ductular,2735,O
proliferation,2735,O
",",2735,O
and,2735,O
acute,2735,O
inflammation,2735,B-Disease
.,2735,O
Metformin,2736,B-Chemical
hydrochloride,2736,I-Chemical
was,2736,O
discontinued,2736,O
",",2736,O
and,2736,O
the,2736,O
patient,2736,O
's,2736,O
jaundice,2736,B-Disease
resolved,2736,O
slowly,2736,O
over,2736,O
a,2736,O
period,2736,O
of,2736,O
several,2736,O
months,2736,O
.,2736,O
Given,2737,O
the,2737,O
onset,2737,O
of,2737,O
his,2737,O
jaundice,2737,B-Disease
2,2737,O
wk,2737,O
after,2737,O
the,2737,O
initiation,2737,O
of,2737,O
metformin,2737,B-Chemical
",",2737,O
we,2737,O
believe,2737,O
that,2737,O
this,2737,O
case,2737,O
represents,2737,O
an,2737,O
example,2737,O
of,2737,O
metformin-associated,2737,B-Chemical
hepatotoxicity,2737,B-Disease
",",2737,O
the,2737,O
first,2737,O
such,2737,O
case,2737,O
reported,2737,O
.,2737,O
Systemic,2738,O
toxicity,2738,B-Disease
and,2738,O
resuscitation,2738,O
in,2738,O
bupivacaine-,2738,B-Chemical
",",2738,O
levobupivacaine-,2738,B-Chemical
",",2738,O
or,2738,O
ropivacaine-infused,2738,B-Chemical
rats,2738,O
.,2738,O
We,2739,O
compared,2739,O
the,2739,O
systemic,2739,O
toxicity,2739,B-Disease
of,2739,O
bupivacaine,2739,B-Chemical
",",2739,O
levobupivacaine,2739,B-Chemical
",",2739,O
and,2739,O
ropivacaine,2739,B-Chemical
in,2739,O
anesthetized,2739,O
rats,2739,O
.,2739,O
We,2740,O
also,2740,O
compared,2740,O
the,2740,O
ability,2740,O
to,2740,O
resuscitate,2740,O
rats,2740,O
after,2740,O
lethal,2740,O
doses,2740,O
of,2740,O
these,2740,O
local,2740,O
anesthetics,2740,O
.,2740,O
Bupivacaine,2741,B-Chemical
",",2741,O
levobupivacaine,2741,B-Chemical
",",2741,O
or,2741,O
ropivacaine,2741,B-Chemical
was,2741,O
infused,2741,O
at,2741,O
a,2741,O
rate,2741,O
of,2741,O
2,2741,O
mg.,2741,O
kg,2741,O
(,2741,O
-1,2741,O
),2741,O
.,2741,O
min,2742,O
(,2742,O
-1,2742,O
),2742,O
while,2742,O
electrocardiogram,2742,O
",",2742,O
electroencephalogram,2742,O
",",2742,O
and,2742,O
arterial,2742,O
pressure,2742,O
were,2742,O
continuously,2742,O
monitored,2742,O
.,2742,O
When,2743,O
asystole,2743,B-Disease
was,2743,O
recorded,2743,O
",",2743,O
drug,2743,O
infusion,2743,O
was,2743,O
stopped,2743,O
and,2743,O
a,2743,O
resuscitation,2743,O
sequence,2743,O
was,2743,O
begun,2743,O
.,2743,O
Epinephrine,2744,B-Chemical
0.01,2744,O
mg/kg,2744,O
was,2744,O
administered,2744,O
at,2744,O
1-min,2744,O
intervals,2744,O
while,2744,O
external,2744,O
cardiac,2744,O
compressions,2744,O
were,2744,O
applied,2744,O
.,2744,O
Resuscitation,2745,O
was,2745,O
considered,2745,O
successful,2745,O
when,2745,O
a,2745,O
systolic,2745,O
arterial,2745,O
pressure,2745,O
>,2745,O
or,2745,O
=100,2745,O
mm,2745,O
Hg,2745,O
was,2745,O
achieved,2745,O
within,2745,O
5,2745,O
min,2745,O
.,2745,O
The,2746,O
cumulative,2746,O
doses,2746,O
of,2746,O
levobupivacaine,2746,B-Chemical
and,2746,O
ropivacaine,2746,B-Chemical
that,2746,O
produced,2746,O
seizures,2746,B-Disease
were,2746,O
similar,2746,O
and,2746,O
were,2746,O
larger,2746,O
than,2746,O
those,2746,O
of,2746,O
bupivacaine,2746,B-Chemical
.,2746,O
The,2747,O
cumulative,2747,O
doses,2747,O
of,2747,O
levobupivacaine,2747,B-Chemical
that,2747,O
produced,2747,O
dysrhythmias,2747,B-Disease
and,2747,O
asystole,2747,B-Disease
were,2747,O
smaller,2747,O
than,2747,O
the,2747,O
corresponding,2747,O
doses,2747,O
of,2747,O
ropivacaine,2747,B-Chemical
",",2747,O
but,2747,O
they,2747,O
were,2747,O
larger,2747,O
than,2747,O
those,2747,O
of,2747,O
bupivacaine,2747,B-Chemical
.,2747,O
The,2748,O
number,2748,O
of,2748,O
successful,2748,O
resuscitations,2748,O
did,2748,O
not,2748,O
differ,2748,O
among,2748,O
groups,2748,O
.,2748,O
However,2749,O
",",2749,O
a,2749,O
smaller,2749,O
dose,2749,O
of,2749,O
epinephrine,2749,B-Chemical
was,2749,O
required,2749,O
in,2749,O
the,2749,O
Ropivacaine,2749,B-Chemical
group,2749,O
than,2749,O
in,2749,O
the,2749,O
other,2749,O
groups,2749,O
.,2749,O
We,2750,O
conclude,2750,O
that,2750,O
the,2750,O
systemic,2750,O
toxicity,2750,B-Disease
of,2750,O
levobupivacaine,2750,B-Chemical
is,2750,O
intermediate,2750,O
between,2750,O
that,2750,O
of,2750,O
ropivacaine,2750,B-Chemical
and,2750,O
bupivacaine,2750,B-Chemical
when,2750,O
administered,2750,O
at,2750,O
the,2750,O
same,2750,O
rate,2750,O
and,2750,O
that,2750,O
ropivacaine-induced,2750,B-Chemical
cardiac,2750,B-Disease
arrest,2750,I-Disease
appears,2750,O
to,2750,O
be,2750,O
more,2750,O
susceptible,2750,O
to,2750,O
treatment,2750,O
than,2750,O
that,2750,O
induced,2750,O
by,2750,O
bupivacaine,2750,B-Chemical
or,2750,O
levobupivacaine,2750,B-Chemical
.,2750,O
Amphotericin,2751,B-Chemical
B-induced,2751,O
seizures,2751,B-Disease
in,2751,O
a,2751,O
patient,2751,O
with,2751,O
AIDS,2751,B-Disease
.,2751,O
OBJECTIVE,2752,O
:,2752,O
To,2752,O
report,2752,O
a,2752,O
case,2752,O
of,2752,O
multiple,2752,O
episodes,2752,O
of,2752,O
seizure,2752,B-Disease
activity,2752,O
in,2752,O
an,2752,O
AIDS,2752,B-Disease
patent,2752,O
following,2752,O
amphotericin,2752,B-Chemical
B,2752,I-Chemical
infusion,2752,O
.,2752,O
CASE,2753,O
SUMMARY,2753,O
:,2753,O
A,2753,O
46-year-old,2753,O
African-American,2753,O
man,2753,O
experienced,2753,O
recurrent,2753,O
grand,2753,B-Disease
mal,2753,I-Disease
seizures,2753,I-Disease
during,2753,O
intravenous,2753,O
infusion,2753,O
of,2753,O
amphotericin,2753,B-Chemical
B,2753,I-Chemical
",",2753,O
then,2753,O
petit,2753,O
mal,2753,O
seizures,2753,B-Disease
as,2753,O
the,2753,O
infusion,2753,O
was,2753,O
stopped,2753,O
and,2753,O
the,2753,O
drug,2753,O
concentrations,2753,O
decreased,2753,O
with,2753,O
time,2753,O
.,2753,O
The,2754,O
patients,2754,O
concurrent,2754,O
medications,2754,O
included,2754,O
didanosine,2754,B-Chemical
",",2754,O
hydroxyzine,2754,B-Chemical
",",2754,O
promethazine,2754,B-Chemical
",",2754,O
hydrocortisone,2754,B-Chemical
",",2754,O
and,2754,O
prochlorperazine,2754,B-Chemical
.,2754,O
Despite,2755,O
administration,2755,O
of,2755,O
phenytoin,2755,B-Chemical
and,2755,O
lorazepam,2755,B-Chemical
",",2755,O
the,2755,O
seizures,2755,B-Disease
persisted,2755,O
and,2755,O
occurred,2755,O
only,2755,O
during,2755,O
amphotercin,2755,B-Chemical
B,2755,I-Chemical
administration,2755,O
.,2755,O
DISCUSSION,2756,O
:,2756,O
AIDS,2756,B-Disease
and,2756,O
cryptococcal,2756,B-Disease
meningitis,2756,I-Disease
",",2756,O
both,2756,O
of,2756,O
which,2756,O
the,2756,O
patient,2756,O
had,2756,O
",",2756,O
can,2756,O
potentially,2756,O
cause,2756,O
seizures,2756,B-Disease
.,2756,O
The,2757,O
patient,2757,O
had,2757,O
a,2757,O
history,2757,O
of,2757,O
alcohol,2757,B-Disease
abuse,2757,I-Disease
;,2757,O
alcohol,2757,B-Chemical
intake,2757,O
as,2757,O
well,2757,O
as,2757,O
withdrawal,2757,O
can,2757,O
also,2757,O
cause,2757,O
seizures,2757,B-Disease
.,2757,O
Didanosine,2758,B-Chemical
also,2758,O
has,2758,O
a,2758,O
potential,2758,O
for,2758,O
inducing,2758,O
seizures,2758,B-Disease
.,2758,O
However,2759,O
",",2759,O
these,2759,O
other,2759,O
potential,2759,O
causes,2759,O
of,2759,O
seizure,2759,B-Disease
were,2759,O
ruled,2759,O
out,2759,O
.,2759,O
The,2760,O
time,2760,O
course,2760,O
of,2760,O
events,2760,O
suggested,2760,O
that,2760,O
amphotericin,2760,B-Chemical
B,2760,I-Chemical
was,2760,O
the,2760,O
cause,2760,O
of,2760,O
the,2760,O
seizures,2760,B-Disease
in,2760,O
this,2760,O
AIDS,2760,B-Disease
patient,2760,O
.,2760,O
CONCLUSIONS,2761,O
:,2761,O
Amphotericin,2761,B-Chemical
B,2761,I-Chemical
seems,2761,O
to,2761,O
be,2761,O
the,2761,O
probable,2761,O
cause,2761,O
of,2761,O
the,2761,O
seizures,2761,B-Disease
.,2761,O
To,2762,O
date,2762,O
",",2762,O
only,2762,O
three,2762,O
cases,2762,O
of,2762,O
seizures,2762,B-Disease
associated,2762,O
with,2762,O
amphotericin,2762,B-Chemical
B,2762,I-Chemical
have,2762,O
been,2762,O
reported,2762,O
in,2762,O
the,2762,O
literature,2762,O
",",2762,O
but,2762,O
healthcare,2762,O
providers,2762,O
should,2762,O
be,2762,O
aware,2762,O
of,2762,O
the,2762,O
potential,2762,O
for,2762,O
this,2762,O
rare,2762,O
adverse,2762,O
effect,2762,O
.,2762,O
Sirolimus,2763,B-Chemical
and,2763,O
mycophenolate,2763,B-Chemical
mofetil,2763,I-Chemical
for,2763,O
calcineurin-free,2763,O
immunosuppression,2763,O
in,2763,O
renal,2763,O
transplant,2763,O
recipients,2763,O
.,2763,O
Calcineurin,2764,O
inhibitors,2764,O
",",2764,O
such,2764,O
as,2764,O
cyclosporine,2764,B-Chemical
and,2764,O
tacrolimus,2764,B-Chemical
",",2764,O
have,2764,O
been,2764,O
available,2764,O
for,2764,O
almost,2764,O
20,2764,O
years,2764,O
.,2764,O
Although,2765,O
these,2765,O
drugs,2765,O
are,2765,O
highly,2765,O
effective,2765,O
and,2765,O
represent,2765,O
the,2765,O
mainstay,2765,O
of,2765,O
transplant,2765,O
immunosuppression,2765,O
",",2765,O
they,2765,O
are,2765,O
associated,2765,O
with,2765,O
acute,2765,O
and,2765,O
chronic,2765,O
nephrotoxicity,2765,B-Disease
.,2765,O
Acute,2766,O
nephrotoxicity,2766,B-Disease
",",2766,O
which,2766,O
occurs,2766,O
in,2766,O
the,2766,O
early,2766,O
period,2766,O
after,2766,O
transplantation,2766,O
",",2766,O
leads,2766,O
to,2766,O
a,2766,O
higher,2766,O
rate,2766,O
of,2766,O
dialysis,2766,O
",",2766,O
and,2766,O
chronic,2766,O
nephrotoxicity,2766,B-Disease
may,2766,O
eventually,2766,O
result,2766,O
in,2766,O
graft,2766,O
loss,2766,O
.,2766,O
Acute,2767,O
and,2767,O
chronic,2767,O
nephrotoxicity,2767,B-Disease
is,2767,O
becoming,2767,O
more,2767,O
common,2767,O
as,2767,O
the,2767,O
use,2767,O
of,2767,O
marginal,2767,O
kidneys,2767,O
for,2767,O
transplantation,2767,O
increases,2767,O
.,2767,O
Two,2768,O
recently,2768,O
available,2768,O
immunosuppressive,2768,O
agents,2768,O
",",2768,O
mycophenolate,2768,B-Chemical
mofetil,2768,I-Chemical
and,2768,O
sirolimus,2768,B-Chemical
(,2768,O
rapamycin,2768,B-Chemical
),2768,O
",",2768,O
have,2768,O
no,2768,O
nephrotoxicity,2768,B-Disease
.,2768,O
The,2769,O
use,2769,O
of,2769,O
these,2769,O
drugs,2769,O
in,2769,O
combination,2769,O
with,2769,O
other,2769,O
agents,2769,O
has,2769,O
led,2769,O
to,2769,O
the,2769,O
development,2769,O
of,2769,O
new,2769,O
paradigms,2769,O
of,2769,O
immunosuppressive,2769,O
therapy,2769,O
.,2769,O
This,2770,O
paper,2770,O
reviews,2770,O
the,2770,O
results,2770,O
of,2770,O
clinical,2770,O
trials,2770,O
that,2770,O
have,2770,O
investigated,2770,O
these,2770,O
new,2770,O
approaches,2770,O
to,2770,O
immunosuppression,2770,O
in,2770,O
renal,2770,O
transplant,2770,O
recipients,2770,O
.,2770,O
Tolerability,2771,O
of,2771,O
nimesulide,2771,B-Chemical
and,2771,O
paracetamol,2771,B-Chemical
in,2771,O
patients,2771,O
with,2771,O
NSAID-induced,2771,B-Chemical
urticaria/angioedema,2771,B-Disease
.,2771,O
Previous,2772,O
studies,2772,O
evaluated,2772,O
the,2772,O
tolerance,2772,O
of,2772,O
nimesulide,2772,B-Chemical
and,2772,O
paracetamol,2772,B-Chemical
in,2772,O
subjects,2772,O
with,2772,O
cutaneous,2772,O
",",2772,O
respiratory,2772,O
and,2772,O
anaphylactoid,2772,O
reactions,2772,O
induced,2772,O
by,2772,O
nonsteroidal,2772,B-Chemical
anti-inflammatory,2772,I-Chemical
drugs,2772,I-Chemical
(,2772,O
NSAIDs,2772,B-Chemical
),2772,O
.,2772,O
In,2773,O
this,2773,O
study,2773,O
we,2773,O
investigated,2773,O
tolerability,2773,O
and,2773,O
reliability,2773,O
of,2773,O
nimesulide,2773,B-Chemical
and,2773,O
paracetamol,2773,B-Chemical
in,2773,O
a,2773,O
very,2773,O
large,2773,O
number,2773,O
of,2773,O
patients,2773,O
with,2773,O
an,2773,O
exclusive,2773,O
well-documented,2773,O
history,2773,O
of,2773,O
NSAID-induced,2773,B-Chemical
urticaria/angioedema,2773,B-Disease
.,2773,O
Furthermore,2774,O
",",2774,O
we,2774,O
evaluated,2774,O
whether,2774,O
some,2774,O
factors,2774,O
have,2774,O
the,2774,O
potential,2774,O
to,2774,O
increase,2774,O
the,2774,O
risk,2774,O
of,2774,O
reaction,2774,O
to,2774,O
paracetamol,2774,B-Chemical
and,2774,O
nimesulide,2774,B-Chemical
.,2774,O
A,2775,O
single-placebo-controlled,2775,O
oral,2775,O
challenge,2775,O
procedure,2775,O
with,2775,O
nimesulide,2775,B-Chemical
or,2775,O
paracetamol,2775,B-Chemical
was,2775,O
applied,2775,O
to,2775,O
829,2775,O
patients,2775,O
with,2775,O
a,2775,O
history,2775,O
of,2775,O
NSAID-induced,2775,B-Chemical
urticaria/angioedema,2775,B-Disease
.,2775,O
A,2776,O
total,2776,O
of,2776,O
75/829,2776,O
(,2776,O
9.4,2776,O
%,2776,O
),2776,O
patients,2776,O
experienced,2776,O
reactions,2776,O
to,2776,O
nimesulide,2776,B-Chemical
or,2776,O
paracetamol,2776,B-Chemical
.,2776,O
Of,2777,O
the,2777,O
715,2777,O
patients,2777,O
tested,2777,O
with,2777,O
nimesulide,2777,B-Chemical
62,2777,O
(,2777,O
8.6,2777,O
%,2777,O
),2777,O
showed,2777,O
a,2777,O
positive,2777,O
test,2777,O
",",2777,O
while,2777,O
of,2777,O
114,2777,O
subjects,2777,O
submitted,2777,O
to,2777,O
the,2777,O
challenge,2777,O
with,2777,O
paracetamol,2777,B-Chemical
",",2777,O
13,2777,O
(,2777,O
9.6,2777,O
%,2777,O
),2777,O
did,2777,O
not,2777,O
tolerate,2777,O
this,2777,O
drug,2777,O
.,2777,O
Furthermore,2778,O
",",2778,O
18.28,2778,O
%,2778,O
of,2778,O
patients,2778,O
with,2778,O
a,2778,O
history,2778,O
of,2778,O
chronic,2778,O
urticaria,2778,B-Disease
and,2778,O
11.8,2778,O
%,2778,O
of,2778,O
subjects,2778,O
with,2778,O
an,2778,O
history,2778,O
of,2778,O
NSAID-induced,2778,B-Chemical
urticaria/angioedema,2778,B-Disease
or,2778,O
angioedema,2778,B-Disease
alone,2778,O
(,2778,O
with,2778,O
or,2778,O
without,2778,O
chronic,2778,O
urticaria,2778,B-Disease
),2778,O
resulted,2778,O
to,2778,O
be,2778,O
intolerant,2778,O
to,2778,O
alternative,2778,O
drugs,2778,O
.,2778,O
Taken,2779,O
together,2779,O
",",2779,O
our,2779,O
results,2779,O
confirm,2779,O
the,2779,O
good,2779,O
tolerability,2779,O
of,2779,O
nimesulide,2779,B-Chemical
and,2779,O
paracetamol,2779,B-Chemical
in,2779,O
patients,2779,O
who,2779,O
experienced,2779,O
urticaria/angioedema,2779,B-Disease
caused,2779,O
by,2779,O
NSAIDs,2779,B-Chemical
.,2779,O
However,2780,O
",",2780,O
the,2780,O
risk,2780,O
of,2780,O
reaction,2780,O
to,2780,O
these,2780,O
alternative,2780,O
study,2780,O
drugs,2780,O
is,2780,O
statistically,2780,O
increased,2780,O
by,2780,O
a,2780,O
history,2780,O
of,2780,O
chronic,2780,O
urticaria,2780,B-Disease
and,2780,O
",",2780,O
above,2780,O
all,2780,O
",",2780,O
by,2780,O
a,2780,O
history,2780,O
of,2780,O
NSAID-induced,2780,B-Chemical
angioedema,2780,B-Disease
.,2780,O
Comparison,2781,O
of,2781,O
aqueous,2781,O
and,2781,O
gellan,2781,O
ophthalmic,2781,O
timolol,2781,B-Chemical
with,2781,O
placebo,2781,O
on,2781,O
the,2781,O
24-hour,2781,O
heart,2781,O
rate,2781,O
response,2781,O
in,2781,O
patients,2781,O
on,2781,O
treatment,2781,O
for,2781,O
glaucoma,2781,B-Disease
.,2781,O
PURPOSE,2782,O
:,2782,O
Topical,2782,O
beta-blocker,2782,O
treatment,2782,O
is,2782,O
routine,2782,O
therapy,2782,O
in,2782,O
the,2782,O
management,2782,O
of,2782,O
patients,2782,O
with,2782,O
glaucoma,2782,B-Disease
.,2782,O
Therapy,2783,O
results,2783,O
in,2783,O
systemic,2783,O
absorption,2783,O
",",2783,O
however,2783,O
",",2783,O
the,2783,O
degree,2783,O
of,2783,O
reduction,2783,O
of,2783,O
resting,2783,O
and,2783,O
peak,2783,O
heart,2783,O
rate,2783,O
has,2783,O
not,2783,O
been,2783,O
quantified,2783,O
.,2783,O
DESIGN,2784,O
:,2784,O
This,2784,O
trial,2784,O
evaluated,2784,O
the,2784,O
effect,2784,O
of,2784,O
placebo,2784,O
",",2784,O
0.5,2784,O
%,2784,O
aqueous,2784,O
timolol,2784,B-Chemical
(,2784,O
timolol,2784,B-Chemical
solution,2784,O
),2784,O
and,2784,O
a,2784,O
0.5,2784,O
%,2784,O
timolol,2784,B-Chemical
suspension,2784,O
that,2784,O
forms,2784,O
a,2784,O
gel,2784,O
on,2784,O
application,2784,O
to,2784,O
the,2784,O
conjunctiva,2784,O
(,2784,O
timolol,2784,B-Chemical
gellan,2784,O
),2784,O
on,2784,O
the,2784,O
24-hour,2784,O
heart,2784,O
rate,2784,O
in,2784,O
patients,2784,O
currently,2784,O
being,2784,O
treated,2784,O
for,2784,O
glaucoma,2784,B-Disease
to,2784,O
quantify,2784,O
the,2784,O
reduction,2784,O
in,2784,O
mean,2784,O
heart,2784,O
rate,2784,O
.,2784,O
METHODS,2785,O
:,2785,O
Forty-three,2785,O
Caucasian,2785,O
patients,2785,O
with,2785,O
primary,2785,O
open-angle,2785,B-Disease
glaucoma,2785,I-Disease
or,2785,O
ocular,2785,B-Disease
hypertension,2785,I-Disease
with,2785,O
a,2785,O
mean,2785,O
(,2785,O
+/-SD,2785,O
),2785,O
age,2785,O
of,2785,O
63,2785,O
(,2785,O
+/-8,2785,O
),2785,O
years,2785,O
were,2785,O
randomized,2785,O
and,2785,O
crossed,2785,O
over,2785,O
in,2785,O
a,2785,O
double-masked,2785,O
manner,2785,O
to,2785,O
14,2785,O
days,2785,O
of,2785,O
treatment,2785,O
with,2785,O
placebo,2785,O
(,2785,O
morning,2785,O
and,2785,O
evening,2785,O
in,2785,O
both,2785,O
eyes,2785,O
),2785,O
",",2785,O
timolol,2785,B-Chemical
solution,2785,O
(,2785,O
morning,2785,O
and,2785,O
evening,2785,O
in,2785,O
both,2785,O
eyes,2785,O
),2785,O
",",2785,O
or,2785,O
timolol,2785,B-Chemical
gellan,2785,O
(,2785,O
morning,2785,O
in,2785,O
both,2785,O
eyes,2785,O
with,2785,O
placebo,2785,O
in,2785,O
the,2785,O
evening,2785,O
),2785,O
.,2785,O
On,2786,O
the,2786,O
13th,2786,O
day,2786,O
of,2786,O
each,2786,O
period,2786,O
",",2786,O
heart,2786,O
rate,2786,O
was,2786,O
recorded,2786,O
continuously,2786,O
during,2786,O
a,2786,O
typical,2786,O
",",2786,O
ambulant,2786,O
24-hour,2786,O
period,2786,O
.,2786,O
RESULTS,2787,O
:,2787,O
Both,2787,O
timolol,2787,B-Chemical
solution,2787,O
and,2787,O
timolol,2787,B-Chemical
gellan,2787,O
reduced,2787,O
the,2787,O
mean,2787,O
24-hour,2787,O
heart,2787,O
rate,2787,O
compared,2787,O
with,2787,O
placebo,2787,O
(,2787,O
P,2787,O
<,2787,O
or,2787,O
=,2787,O
.001,2787,O
),2787,O
",",2787,O
and,2787,O
this,2787,O
reduction,2787,O
was,2787,O
most,2787,O
pronounced,2787,O
during,2787,O
the,2787,O
daytime,2787,O
(,2787,O
-7.5,2787,O
%,2787,O
change,2787,O
in,2787,O
mean,2787,O
heart,2787,O
rate,2787,O
",",2787,O
-5.7,2787,O
beats/min,2787,O
),2787,O
.,2787,O
Timolol,2788,B-Chemical
gellan,2788,O
showed,2788,O
a,2788,O
numerically,2788,O
but,2788,O
not,2788,O
significantly,2788,O
smaller,2788,O
reduction,2788,O
in,2788,O
24-hour,2788,O
heart,2788,O
rate,2788,O
",",2788,O
compared,2788,O
with,2788,O
timolol,2788,B-Chemical
solution,2788,O
.,2788,O
During,2789,O
the,2789,O
night,2789,O
",",2789,O
the,2789,O
mean,2789,O
12-hour,2789,O
heart,2789,O
rate,2789,O
on,2789,O
placebo,2789,O
and,2789,O
timolol,2789,B-Chemical
gellan,2789,O
were,2789,O
both,2789,O
significantly,2789,O
less,2789,O
than,2789,O
on,2789,O
timolol,2789,B-Chemical
solution,2789,O
;,2789,O
the,2789,O
difference,2789,O
between,2789,O
solution,2789,O
and,2789,O
gellan,2789,O
treatments,2789,O
was,2789,O
statistically,2789,O
significant,2789,O
(,2789,O
P,2789,O
=,2789,O
.01,2789,O
),2789,O
.,2789,O
CONCLUSIONS,2790,O
:,2790,O
Both,2790,O
timolol,2790,B-Chemical
solution,2790,O
and,2790,O
timolol,2790,B-Chemical
gellan,2790,O
decrease,2790,O
the,2790,O
mean,2790,O
24-hour,2790,O
heart,2790,O
rate,2790,O
compared,2790,O
with,2790,O
placebo,2790,O
.,2790,O
This,2791,O
response,2791,O
was,2791,O
most,2791,O
pronounced,2791,O
during,2791,O
the,2791,O
active,2791,O
daytime,2791,O
period,2791,O
.,2791,O
These,2792,O
data,2792,O
quantify,2792,O
the,2792,O
modest,2792,O
bradycardia,2792,B-Disease
associated,2792,O
with,2792,O
ophthalmic,2792,O
beta-blocker,2792,O
therapy,2792,O
in,2792,O
a,2792,O
typical,2792,O
patient,2792,O
population,2792,O
on,2792,O
therapy,2792,O
for,2792,O
glaucoma,2792,B-Disease
.,2792,O
Although,2793,O
exercise,2793,O
performance,2793,O
was,2793,O
not,2793,O
assessed,2793,O
in,2793,O
this,2793,O
trial,2793,O
",",2793,O
reductions,2793,O
of,2793,O
this,2793,O
magnitude,2793,O
should,2793,O
not,2793,O
have,2793,O
substantial,2793,O
clinical,2793,O
consequences,2793,O
.,2793,O
Management,2794,O
strategies,2794,O
for,2794,O
ribavirin-induced,2794,B-Chemical
hemolytic,2794,B-Disease
anemia,2794,I-Disease
in,2794,O
the,2794,O
treatment,2794,O
of,2794,O
hepatitis,2794,B-Disease
C,2794,I-Disease
:,2794,O
clinical,2794,O
and,2794,O
economic,2794,O
implications,2794,O
.,2794,O
OBJECTIVES,2795,O
:,2795,O
Recently,2795,O
published,2795,O
studies,2795,O
have,2795,O
demonstrated,2795,O
increased,2795,O
efficacy,2795,O
and,2795,O
cost-effectiveness,2795,O
of,2795,O
combination,2795,O
therapy,2795,O
with,2795,O
interferon,2795,O
and,2795,O
alpha-2b/ribavirin,2795,O
compared,2795,O
with,2795,O
interferon-alpha,2795,B-Chemical
monotherapy,2795,O
in,2795,O
the,2795,O
treatment,2795,O
of,2795,O
chronic,2795,B-Disease
hepatitis,2795,I-Disease
C,2795,I-Disease
(,2795,O
CHC,2795,B-Disease
),2795,O
.,2795,O
Combination,2796,O
therapy,2796,O
is,2796,O
associated,2796,O
with,2796,O
a,2796,O
clinically,2796,O
important,2796,O
adverse,2796,O
effect,2796,O
:,2796,O
ribavirin-induced,2796,B-Chemical
hemolytic,2796,B-Disease
anemia,2796,I-Disease
(,2796,O
RIHA,2796,B-Disease
),2796,O
.,2796,O
The,2797,O
objective,2797,O
of,2797,O
this,2797,O
study,2797,O
was,2797,O
to,2797,O
evaluate,2797,O
the,2797,O
direct,2797,O
health-care,2797,O
costs,2797,O
and,2797,O
management,2797,O
of,2797,O
RIHA,2797,B-Disease
during,2797,O
treatment,2797,O
of,2797,O
CHC,2797,B-Disease
in,2797,O
a,2797,O
clinical,2797,O
trial,2797,O
setting,2797,O
.,2797,O
METHODS,2798,O
:,2798,O
A,2798,O
systematic,2798,O
literature,2798,O
review,2798,O
was,2798,O
conducted,2798,O
to,2798,O
synthesize,2798,O
information,2798,O
on,2798,O
the,2798,O
incidence,2798,O
and,2798,O
management,2798,O
of,2798,O
RIHA,2798,B-Disease
.,2798,O
Decision-analytic,2799,O
techniques,2799,O
were,2799,O
used,2799,O
to,2799,O
estimate,2799,O
the,2799,O
cost,2799,O
of,2799,O
treating,2799,O
RIHA,2799,B-Disease
.,2799,O
Uncertainty,2800,O
was,2800,O
evaluated,2800,O
using,2800,O
sensitivity,2800,O
analyses,2800,O
.,2800,O
RESULTS,2801,O
:,2801,O
RIHA,2801,B-Disease
",",2801,O
defined,2801,O
as,2801,O
a,2801,O
reduction,2801,O
in,2801,O
hemoglobin,2801,O
to,2801,O
less,2801,O
than,2801,O
100,2801,O
g/L,2801,O
",",2801,O
occurs,2801,O
in,2801,O
approximately,2801,O
7,2801,O
%,2801,O
to,2801,O
9,2801,O
%,2801,O
of,2801,O
patients,2801,O
treated,2801,O
with,2801,O
combination,2801,O
therapy,2801,O
.,2801,O
The,2802,O
standard,2802,O
of,2802,O
care,2802,O
for,2802,O
management,2802,O
of,2802,O
RIHA,2802,B-Disease
is,2802,O
reduction,2802,O
or,2802,O
discontinuation,2802,O
of,2802,O
the,2802,O
ribavirin,2802,B-Chemical
dosage,2802,O
.,2802,O
We,2803,O
estimated,2803,O
the,2803,O
direct,2803,O
cost,2803,O
of,2803,O
treating,2803,O
clinically,2803,O
significant,2803,O
RIHA,2803,B-Disease
to,2803,O
be,2803,O
170,2803,O
per,2803,O
patient,2803,O
receiving,2803,O
combination,2803,O
therapy,2803,O
per,2803,O
48-week,2803,O
treatment,2803,O
course,2803,O
(,2803,O
range,2803,O
68-,2803,O
692,2803,O
),2803,O
.,2803,O
The,2804,O
results,2804,O
of,2804,O
the,2804,O
one-way,2804,O
sensitivity,2804,O
analyses,2804,O
ranged,2804,O
from,2804,O
57,2804,O
to,2804,O
317,2804,O
.,2804,O
In,2805,O
comparison,2805,O
",",2805,O
the,2805,O
cost,2805,O
of,2805,O
48,2805,O
weeks,2805,O
of,2805,O
combination,2805,O
therapy,2805,O
is,2805,O
"16,459",2805,O
.,2805,O
CONCLUSIONS,2806,O
:,2806,O
The,2806,O
direct,2806,O
cost,2806,O
of,2806,O
treating,2806,O
clinically,2806,O
significant,2806,O
RIHA,2806,B-Disease
is,2806,O
1,2806,O
%,2806,O
(,2806,O
170/,2806,O
"16,459",2806,O
),2806,O
of,2806,O
drug,2806,O
treatment,2806,O
costs,2806,O
.,2806,O
Questions,2807,O
remain,2807,O
about,2807,O
the,2807,O
optimal,2807,O
dose,2807,O
of,2807,O
ribavirin,2807,B-Chemical
and,2807,O
the,2807,O
incidence,2807,O
of,2807,O
RIHA,2807,B-Disease
in,2807,O
a,2807,O
real-world,2807,O
population,2807,O
.,2807,O
Despite,2808,O
these,2808,O
uncertainties,2808,O
",",2808,O
this,2808,O
initial,2808,O
evaluation,2808,O
of,2808,O
the,2808,O
direct,2808,O
cost,2808,O
of,2808,O
treating,2808,O
RIHA,2808,B-Disease
provides,2808,O
an,2808,O
estimate,2808,O
of,2808,O
the,2808,O
cost,2808,O
and,2808,O
management,2808,O
implications,2808,O
of,2808,O
this,2808,O
clinically,2808,O
important,2808,O
adverse,2808,O
effect,2808,O
.,2808,O
Preliminary,2809,O
efficacy,2809,O
assessment,2809,O
of,2809,O
intrathecal,2809,O
injection,2809,O
of,2809,O
an,2809,O
American,2809,O
formulation,2809,O
of,2809,O
adenosine,2809,B-Chemical
in,2809,O
humans,2809,O
.,2809,O
BACKGROUND,2810,O
:,2810,O
Preclinical,2810,O
studies,2810,O
of,2810,O
intrathecal,2810,O
adenosine,2810,B-Chemical
suggest,2810,O
it,2810,O
may,2810,O
be,2810,O
effective,2810,O
in,2810,O
the,2810,O
treatment,2810,O
of,2810,O
acute,2810,O
and,2810,O
chronic,2810,O
pain,2810,O
in,2810,O
humans,2810,O
",",2810,O
and,2810,O
preliminary,2810,O
studies,2810,O
in,2810,O
volunteers,2810,O
and,2810,O
patients,2810,O
with,2810,O
a,2810,O
Swedish,2810,O
formulation,2810,O
of,2810,O
adenosine,2810,B-Chemical
suggests,2810,O
it,2810,O
may,2810,O
be,2810,O
effective,2810,O
in,2810,O
hypersensitivity,2810,B-Disease
states,2810,O
but,2810,O
not,2810,O
with,2810,O
acute,2810,O
noxious,2810,O
stimulation,2810,O
.,2810,O
The,2811,O
purpose,2811,O
of,2811,O
this,2811,O
study,2811,O
was,2811,O
to,2811,O
screen,2811,O
for,2811,O
efficacy,2811,O
of,2811,O
a,2811,O
different,2811,O
formulation,2811,O
of,2811,O
adenosine,2811,B-Chemical
marketed,2811,O
in,2811,O
the,2811,O
US,2811,O
",",2811,O
using,2811,O
both,2811,O
acute,2811,O
noxious,2811,O
stimulation,2811,O
and,2811,O
capsaicin-evoked,2811,B-Chemical
mechanical,2811,O
hypersensitivity,2811,B-Disease
.,2811,O
METHODS,2812,O
:,2812,O
Following,2812,O
Food,2812,O
and,2812,O
Drug,2812,O
Administration,2812,O
and,2812,O
institutional,2812,O
review,2812,O
board,2812,O
approval,2812,O
and,2812,O
written,2812,O
informed,2812,O
consent,2812,O
",",2812,O
65,2812,O
volunteers,2812,O
were,2812,O
studied,2812,O
in,2812,O
two,2812,O
trials,2812,O
:,2812,O
an,2812,O
open-label,2812,O
",",2812,O
dose-escalating,2812,O
trial,2812,O
with,2812,O
intrathecal,2812,O
adenosine,2812,B-Chemical
doses,2812,O
of,2812,O
0.25-2.0,2812,O
mg,2812,O
and,2812,O
a,2812,O
double-blind,2812,O
",",2812,O
placebo-controlled,2812,O
trial,2812,O
of,2812,O
adenosine,2812,B-Chemical
",",2812,O
2,2812,O
mg.,2812,O
Cerebrospinal,2812,O
fluid,2812,O
was,2812,O
obtained,2812,O
for,2812,O
pharmacokinetic,2812,O
analysis,2812,O
",",2812,O
and,2812,O
pain,2812,B-Disease
ratings,2812,O
in,2812,O
response,2812,O
to,2812,O
acute,2812,O
heat,2812,O
stimuli,2812,O
and,2812,O
areas,2812,O
of,2812,O
mechanical,2812,B-Disease
hyperalgesia,2812,I-Disease
and,2812,O
allodynia,2812,B-Disease
after,2812,O
intradermal,2812,O
capsaicin,2812,B-Chemical
injection,2812,O
were,2812,O
determined,2812,O
.,2812,O
RESULTS,2813,O
:,2813,O
Adenosine,2813,B-Chemical
produced,2813,O
no,2813,O
effect,2813,O
on,2813,O
pain,2813,B-Disease
report,2813,O
to,2813,O
acute,2813,O
noxious,2813,O
thermal,2813,O
or,2813,O
chemical,2813,O
stimulation,2813,O
but,2813,O
reduced,2813,O
mechanical,2813,B-Disease
hyperalgesia,2813,I-Disease
and,2813,O
allodynia,2813,B-Disease
from,2813,O
intradermal,2813,O
capsaicin,2813,B-Chemical
injection,2813,O
for,2813,O
at,2813,O
least,2813,O
24,2813,O
h.,2813,O
In,2813,O
contrast,2813,O
",",2813,O
residence,2813,O
time,2813,O
of,2813,O
adenosine,2813,B-Chemical
in,2813,O
cerebrospinal,2813,O
fluid,2813,O
was,2813,O
short,2813,O
(,2813,O
<,2813,O
4,2813,O
h,2813,O
),2813,O
.,2813,O
CONCLUSIONS,2814,O
:,2814,O
These,2814,O
results,2814,O
show,2814,O
selective,2814,O
inhibition,2814,O
by,2814,O
intrathecal,2814,O
adenosine,2814,B-Chemical
of,2814,O
hypersensitivity,2814,B-Disease
",",2814,O
presumed,2814,O
to,2814,O
reflect,2814,O
central,2814,O
sensitization,2814,O
in,2814,O
humans,2814,O
after,2814,O
peripheral,2814,O
capsaicin,2814,B-Chemical
injection,2814,O
.,2814,O
The,2815,O
long-lasting,2815,O
effect,2815,O
is,2815,O
consistent,2815,O
with,2815,O
that,2815,O
observed,2815,O
in,2815,O
preliminary,2815,O
reports,2815,O
of,2815,O
patients,2815,O
with,2815,O
chronic,2815,O
neuropathic,2815,B-Disease
pain,2815,I-Disease
and,2815,O
is,2815,O
not,2815,O
due,2815,O
to,2815,O
prolonged,2815,O
residence,2815,O
of,2815,O
adenosine,2815,B-Chemical
in,2815,O
cerebrospinal,2815,O
fluid,2815,O
.,2815,O
Delayed-onset,2816,O
heparin-induced,2816,B-Chemical
thrombocytopenia,2816,B-Disease
.,2816,O
BACKGROUND,2817,O
:,2817,O
Heparin-induced,2817,B-Chemical
thrombocytopenia,2817,B-Disease
presents,2817,O
5,2817,O
to,2817,O
12,2817,O
days,2817,O
after,2817,O
heparin,2817,B-Chemical
exposure,2817,O
",",2817,O
with,2817,O
or,2817,O
without,2817,O
arterial,2817,O
or,2817,O
venous,2817,O
thromboemboli,2817,O
.,2817,O
Delayed,2818,O
recognition,2818,O
and,2818,O
treatment,2818,O
of,2818,O
heparin-induced,2818,B-Chemical
thrombocytopenia,2818,B-Disease
contribute,2818,O
to,2818,O
poor,2818,O
patient,2818,O
outcomes,2818,O
.,2818,O
OBJECTIVE,2819,O
:,2819,O
To,2819,O
describe,2819,O
and,2819,O
increase,2819,O
awareness,2819,O
of,2819,O
a,2819,O
clinical,2819,O
scenario,2819,O
in,2819,O
which,2819,O
the,2819,O
onset,2819,O
or,2819,O
manifestations,2819,O
of,2819,O
heparin-induced,2819,B-Chemical
thrombocytopenia,2819,B-Disease
are,2819,O
delayed,2819,O
.,2819,O
DESIGN,2820,O
:,2820,O
Retrospective,2820,O
case,2820,O
series,2820,O
.,2820,O
SETTING,2821,O
:,2821,O
Three,2821,O
large,2821,O
urban,2821,O
hospitals,2821,O
(,2821,O
with,2821,O
active,2821,O
cardiovascular,2821,O
surgery,2821,O
programs,2821,O
),2821,O
.,2821,O
PATIENTS,2822,O
:,2822,O
14,2822,O
patients,2822,O
seen,2822,O
over,2822,O
a,2822,O
3-year,2822,O
period,2822,O
in,2822,O
whom,2822,O
heparin-induced,2822,B-Chemical
thrombocytopenia,2822,B-Disease
became,2822,O
apparent,2822,O
on,2822,O
delayed,2822,O
presentation,2822,O
with,2822,O
thromboembolic,2822,B-Disease
complications,2822,O
.,2822,O
MEASUREMENTS,2823,O
:,2823,O
Platelet,2823,O
counts,2823,O
",",2823,O
onset,2823,O
of,2823,O
objectively,2823,O
determined,2823,O
thromboembolism,2823,B-Disease
",",2823,O
results,2823,O
of,2823,O
heparin-induced,2823,B-Chemical
platelet,2823,O
factor,2823,O
4,2823,O
antibody,2823,O
tests,2823,O
",",2823,O
and,2823,O
outcomes,2823,O
.,2823,O
RESULTS,2824,O
:,2824,O
Patients,2824,O
went,2824,O
home,2824,O
after,2824,O
hospitalizations,2824,O
that,2824,O
had,2824,O
included,2824,O
heparin,2824,B-Chemical
exposure,2824,O
--,2824,O
in,2824,O
most,2824,O
cases,2824,O
",",2824,O
with,2824,O
no,2824,O
thrombocytopenia,2824,B-Disease
recognized,2824,O
--,2824,O
only,2824,O
to,2824,O
return,2824,O
to,2824,O
the,2824,O
hospital,2824,O
(,2824,O
median,2824,O
",",2824,O
day,2824,O
14,2824,O
),2824,O
with,2824,O
thromboembolic,2824,B-Disease
complications,2824,O
.,2824,O
Thromboemboli,2825,B-Disease
were,2825,O
venous,2825,O
(,2825,O
12,2825,O
patients,2825,O
",",2825,O
7,2825,O
with,2825,O
pulmonary,2825,B-Disease
emboli,2825,I-Disease
),2825,O
or,2825,O
arterial,2825,O
(,2825,O
4,2825,O
patients,2825,O
),2825,O
or,2825,O
both,2825,O
.,2825,O
Platelet,2826,O
counts,2826,O
were,2826,O
mildly,2826,O
decreased,2826,O
in,2826,O
all,2826,O
but,2826,O
2,2826,O
patients,2826,O
on,2826,O
second,2826,O
presentation,2826,O
.,2826,O
On,2827,O
readmission,2827,O
",",2827,O
11,2827,O
patients,2827,O
received,2827,O
therapeutic,2827,O
heparin,2827,B-Chemical
",",2827,O
which,2827,O
worsened,2827,O
the,2827,O
patients,2827,O
',2827,O
clinical,2827,O
condition,2827,O
and,2827,O
",",2827,O
in,2827,O
all,2827,O
11,2827,O
cases,2827,O
",",2827,O
decreased,2827,O
the,2827,O
platelet,2827,O
count,2827,O
(,2827,O
mean,2827,O
at,2827,O
readmission,2827,O
",",2827,O
143,2827,O
x,2827,O
10,2827,O
(,2827,O
9,2827,O
),2827,O
cells/L,2827,O
;,2827,O
mean,2827,O
nadir,2827,O
after,2827,O
heparin,2827,B-Chemical
re-exposure,2827,O
",",2827,O
39,2827,O
x,2827,O
10,2827,O
(,2827,O
9,2827,O
),2827,O
cells/L,2827,O
),2827,O
.,2827,O
Results,2828,O
of,2828,O
serologic,2828,O
tests,2828,O
for,2828,O
heparin-induced,2828,B-Chemical
antibodies,2828,O
were,2828,O
positive,2828,O
in,2828,O
all,2828,O
patients,2828,O
.,2828,O
Subsequent,2829,O
treatments,2829,O
included,2829,O
alternative,2829,O
anticoagulants,2829,O
(,2829,O
11,2829,O
patients,2829,O
),2829,O
",",2829,O
thrombolytic,2829,O
drugs,2829,O
(,2829,O
3,2829,O
patients,2829,O
),2829,O
",",2829,O
inferior,2829,O
vena,2829,O
cava,2829,O
filters,2829,O
(,2829,O
3,2829,O
patients,2829,O
),2829,O
and,2829,O
",",2829,O
eventually,2829,O
",",2829,O
warfarin,2829,B-Chemical
(,2829,O
11,2829,O
patients,2829,O
),2829,O
.,2829,O
Three,2830,O
patients,2830,O
died,2830,O
.,2830,O
CONCLUSIONS,2831,O
:,2831,O
Delayed-onset,2831,O
heparin-induced,2831,B-Chemical
thrombocytopenia,2831,B-Disease
is,2831,O
increasingly,2831,O
being,2831,O
recognized,2831,O
.,2831,O
To,2832,O
avoid,2832,O
disastrous,2832,O
outcomes,2832,O
",",2832,O
physicians,2832,O
must,2832,O
consider,2832,O
heparin-induced,2832,B-Chemical
thrombocytopenia,2832,B-Disease
whenever,2832,O
a,2832,O
recently,2832,O
hospitalized,2832,O
patient,2832,O
returns,2832,O
with,2832,O
thromboembolism,2832,B-Disease
;,2832,O
therapy,2832,O
with,2832,O
alternative,2832,O
anticoagulants,2832,O
",",2832,O
not,2832,O
heparin,2832,B-Chemical
",",2832,O
should,2832,O
be,2832,O
initiated,2832,O
.,2832,O
Treatment,2833,O
of,2833,O
risperidone-induced,2833,B-Chemical
hyperprolactinemia,2833,B-Disease
with,2833,O
a,2833,O
dopamine,2833,B-Chemical
agonist,2833,O
in,2833,O
children,2833,O
.,2833,O
BACKGROUND,2834,O
:,2834,O
Risperidone,2834,B-Chemical
",",2834,O
a,2834,O
potent,2834,O
antagonist,2834,O
of,2834,O
both,2834,O
serotonergic,2834,O
(,2834,O
5HT2A,2834,O
),2834,O
and,2834,O
dopaminergic,2834,O
D2,2834,O
receptors,2834,O
is,2834,O
associated,2834,O
with,2834,O
hyperprolactinemia,2834,B-Disease
in,2834,O
adults,2834,O
and,2834,O
children,2834,O
.,2834,O
Chronically,2835,O
elevated,2835,O
prolactin,2835,O
levels,2835,O
in,2835,O
children,2835,O
with,2835,O
prolactinomas,2835,B-Disease
may,2835,O
be,2835,O
associated,2835,O
with,2835,O
arrested,2835,O
growth,2835,O
and,2835,O
development,2835,O
resulting,2835,O
in,2835,O
either,2835,O
delayed,2835,B-Disease
puberty,2835,I-Disease
or,2835,O
short,2835,O
stature,2835,O
.,2835,O
These,2836,O
possibilities,2836,O
stress,2836,O
the,2836,O
importance,2836,O
of,2836,O
developing,2836,O
a,2836,O
safe,2836,O
and,2836,O
effective,2836,O
approach,2836,O
to,2836,O
drug-induced,2836,O
hyperprolactinemia,2836,B-Disease
in,2836,O
youth,2836,O
.,2836,O
We,2837,O
report,2837,O
the,2837,O
successful,2837,O
treatment,2837,O
of,2837,O
risperidone-induced,2837,B-Chemical
hyperprolactinemia,2837,B-Disease
with,2837,O
cabergoline,2837,B-Chemical
in,2837,O
youth,2837,O
.,2837,O
METHODS,2838,O
:,2838,O
We,2838,O
undertook,2838,O
a,2838,O
retrospective,2838,O
case,2838,O
review,2838,O
of,2838,O
four,2838,O
children,2838,O
with,2838,O
risperidone-induced,2838,B-Chemical
hyperprolactinemia,2838,B-Disease
treated,2838,O
with,2838,O
cabergoline,2838,B-Chemical
.,2838,O
RESULTS,2839,O
:,2839,O
Four,2839,O
males,2839,O
(,2839,O
age,2839,O
6-11,2839,O
years,2839,O
),2839,O
with,2839,O
Diagnostic,2839,O
and,2839,O
Statistical,2839,O
Manual,2839,O
of,2839,O
Mental,2839,B-Disease
Disorders,2839,I-Disease
(,2839,O
fourth,2839,O
edition,2839,O
),2839,O
bipolar,2839,B-Disease
disorder,2839,I-Disease
or,2839,O
psychoses,2839,B-Disease
",",2839,O
with,2839,O
risperidone-induced,2839,B-Chemical
elevations,2839,O
in,2839,O
serum,2839,O
prolactin,2839,O
levels,2839,O
(,2839,O
57.5-129,2839,O
ng/mL,2839,O
",",2839,O
normal,2839,O
5-15,2839,O
ng/mL,2839,O
),2839,O
",",2839,O
were,2839,O
treated,2839,O
with,2839,O
cabergoline,2839,B-Chemical
(,2839,O
mean,2839,O
dose,2839,O
2.13,2839,O
+/-,2839,O
0.09,2839,O
mg/week,2839,O
),2839,O
.,2839,O
When,2840,O
serum,2840,O
prolactin,2840,O
levels,2840,O
normalized,2840,O
in,2840,O
all,2840,O
four,2840,O
subjects,2840,O
(,2840,O
mean,2840,O
11.2,2840,O
+/-,2840,O
10.9,2840,O
ng/mL,2840,O
),2840,O
",",2840,O
the,2840,O
cabergoline,2840,B-Chemical
dose,2840,O
was,2840,O
reduced,2840,O
to,2840,O
1,2840,O
mg/week,2840,O
in,2840,O
three,2840,O
of,2840,O
four,2840,O
subjects,2840,O
.,2840,O
The,2841,O
mean,2841,O
duration,2841,O
of,2841,O
therapy,2841,O
with,2841,O
cabergoline,2841,B-Chemical
was,2841,O
523.5,2841,O
+/-,2841,O
129.7,2841,O
days,2841,O
",",2841,O
and,2841,O
the,2841,O
mean,2841,O
duration,2841,O
of,2841,O
therapy,2841,O
with,2841,O
risperidone,2841,B-Chemical
was,2841,O
788.5,2841,O
+/-,2841,O
162.5,2841,O
days,2841,O
.,2841,O
Cabergoline,2842,B-Chemical
was,2842,O
well,2842,O
tolerated,2842,O
without,2842,O
adverse,2842,O
effects,2842,O
.,2842,O
CONCLUSIONS,2843,O
:,2843,O
Cabergoline,2843,B-Chemical
may,2843,O
be,2843,O
useful,2843,O
for,2843,O
the,2843,O
treatment,2843,O
of,2843,O
risperidone-induced,2843,B-Chemical
hyperprolactinemia,2843,B-Disease
in,2843,O
youth,2843,O
;,2843,O
however,2843,O
",",2843,O
further,2843,O
research,2843,O
is,2843,O
needed,2843,O
.,2843,O
Acute,2844,O
cholestatic,2844,O
hepatitis,2844,O
after,2844,O
exposure,2844,O
to,2844,O
isoflurane,2844,B-Chemical
.,2844,O
OBJECTIVE,2845,O
:,2845,O
To,2845,O
report,2845,O
a,2845,O
case,2845,O
of,2845,O
acute,2845,O
cholestatic,2845,O
hepatitis,2845,O
following,2845,O
exposure,2845,O
to,2845,O
the,2845,O
inhalational,2845,O
anesthetic,2845,O
isoflurane,2845,B-Chemical
.,2845,O
CASE,2846,O
SUMMARY,2846,O
:,2846,O
A,2846,O
70-year-old,2846,O
healthy,2846,O
woman,2846,O
from,2846,O
Iraq,2846,O
developed,2846,O
acute,2846,O
cholestatic,2846,O
hepatitis,2846,O
3,2846,O
weeks,2846,O
following,2846,O
repair,2846,O
of,2846,O
the,2846,O
right,2846,O
rotator,2846,O
cuff,2846,O
under,2846,O
general,2846,O
anesthesia,2846,O
.,2846,O
There,2847,O
was,2847,O
no,2847,O
evidence,2847,O
for,2847,O
viral,2847,O
",",2847,O
autoimmune,2847,O
",",2847,O
or,2847,O
metabolic,2847,O
causes,2847,O
of,2847,O
hepatitis,2847,B-Disease
.,2847,O
No,2848,O
other,2848,O
medications,2848,O
were,2848,O
involved,2848,O
except,2848,O
for,2848,O
dipyrone,2848,B-Chemical
for,2848,O
analgesia,2848,B-Disease
.,2848,O
The,2849,O
alanine,2849,B-Chemical
aminotransferase,2849,O
was,2849,O
elevated,2849,O
to,2849,O
a,2849,O
peak,2849,O
concentration,2849,O
of,2849,O
1533,2849,O
U/L,2849,O
and,2849,O
the,2849,O
serum,2849,O
bilirubin,2849,B-Chemical
reached,2849,O
a,2849,O
peak,2849,O
of,2849,O
17.0,2849,O
mg/dL,2849,O
.,2849,O
There,2850,O
was,2850,O
slow,2850,O
improvement,2850,O
over,2850,O
4,2850,O
months,2850,O
.,2850,O
Accidental,2851,O
reexposure,2851,O
by,2851,O
the,2851,O
patient,2851,O
to,2851,O
dipyrone,2851,B-Chemical
was,2851,O
uneventful,2851,O
.,2851,O
DISCUSSION,2852,O
:,2852,O
The,2852,O
clinical,2852,O
and,2852,O
histologic,2852,O
picture,2852,O
of,2852,O
this,2852,O
case,2852,O
resembles,2852,O
halothane,2852,B-Disease
hepatitis,2852,I-Disease
",",2852,O
which,2852,O
has,2852,O
a,2852,O
significant,2852,O
mortality,2852,O
rate,2852,O
.,2852,O
CONCLUSIONS,2853,O
:,2853,O
Isoflurane,2853,B-Chemical
",",2853,O
a,2853,O
common,2853,O
anesthetic,2853,O
agent,2853,O
",",2853,O
can,2853,O
cause,2853,O
severe,2853,O
cholestatic,2853,O
hepatitis,2853,O
.,2853,O
Torsade,2854,B-Disease
de,2854,I-Disease
pointes,2854,I-Disease
induced,2854,O
by,2854,O
metoclopramide,2854,B-Chemical
in,2854,O
an,2854,O
elderly,2854,O
woman,2854,O
with,2854,O
preexisting,2854,O
complete,2854,O
left,2854,B-Disease
bundle,2854,I-Disease
branch,2854,I-Disease
block,2854,I-Disease
.,2854,O
There,2855,O
is,2855,O
a,2855,O
growing,2855,O
list,2855,O
of,2855,O
drugs,2855,O
implicated,2855,O
in,2855,O
acquired,2855,O
long,2855,B-Disease
QT,2855,I-Disease
syndrome,2855,I-Disease
and,2855,O
torsade,2855,B-Disease
de,2855,I-Disease
pointes,2855,I-Disease
.,2855,O
However,2856,O
",",2856,O
the,2856,O
torsadogenic,2856,O
potential,2856,O
of,2856,O
metoclopramide,2856,B-Chemical
",",2856,O
a,2856,O
commonly,2856,O
used,2856,O
antiemetic,2856,O
and,2856,O
prokinetic,2856,O
drug,2856,O
",",2856,O
has,2856,O
not,2856,O
been,2856,O
reported,2856,O
in,2856,O
the,2856,O
literature,2856,O
",",2856,O
despite,2856,O
its,2856,O
chemical,2856,O
similarity,2856,O
to,2856,O
procainamide,2856,B-Chemical
.,2856,O
We,2857,O
report,2857,O
on,2857,O
a,2857,O
92-year-old,2857,O
woman,2857,O
with,2857,O
preexisting,2857,O
complete,2857,O
left,2857,B-Disease
bundle,2857,I-Disease
branch,2857,I-Disease
block,2857,I-Disease
who,2857,O
developed,2857,O
torsade,2857,B-Disease
de,2857,I-Disease
pointes,2857,I-Disease
after,2857,O
intravenous,2857,O
and,2857,O
oral,2857,O
administration,2857,O
of,2857,O
metoclopramide,2857,B-Chemical
.,2857,O
This,2858,O
patient,2858,O
also,2858,O
developed,2858,O
torsade,2858,B-Disease
de,2858,I-Disease
pointes,2858,I-Disease
when,2858,O
cisapride,2858,B-Chemical
and,2858,O
erythromycin,2858,B-Chemical
were,2858,O
given,2858,O
simultaneously,2858,O
.,2858,O
These,2859,O
two,2859,O
episodes,2859,O
were,2859,O
suppressed,2859,O
successfully,2859,O
after,2859,O
discontinuing,2859,O
the,2859,O
offending,2859,O
drugs,2859,O
and,2859,O
administering,2859,O
class,2859,O
IB,2859,O
drugs,2859,O
.,2859,O
This,2860,O
is,2860,O
the,2860,O
first,2860,O
documentation,2860,O
that,2860,O
metoclopramide,2860,B-Chemical
provokes,2860,O
torsade,2860,B-Disease
de,2860,I-Disease
pointes,2860,I-Disease
clinically,2860,O
.,2860,O
Metoclopramide,2861,B-Chemical
should,2861,O
be,2861,O
used,2861,O
cautiously,2861,O
in,2861,O
patients,2861,O
with,2861,O
a,2861,O
risk,2861,O
of,2861,O
torsade,2861,B-Disease
de,2861,I-Disease
pointes,2861,I-Disease
.,2861,O
Dopamine,2862,B-Chemical
D2,2862,O
receptor,2862,O
signaling,2862,O
controls,2862,O
neuronal,2862,O
cell,2862,O
death,2862,O
induced,2862,O
by,2862,O
muscarinic,2862,O
and,2862,O
glutamatergic,2862,O
drugs,2862,O
.,2862,O
Dopamine,2863,B-Chemical
(,2863,O
DA,2863,B-Chemical
),2863,O
",",2863,O
through,2863,O
D1/D2,2863,O
receptor-mediated,2863,O
signaling,2863,O
",",2863,O
plays,2863,O
a,2863,O
major,2863,O
role,2863,O
in,2863,O
the,2863,O
control,2863,O
of,2863,O
epileptic,2863,B-Disease
seizures,2863,I-Disease
arising,2863,O
in,2863,O
the,2863,O
limbic,2863,O
system,2863,O
.,2863,O
Excitotoxicity,2864,B-Disease
leading,2864,O
to,2864,O
neuronal,2864,O
cell,2864,O
death,2864,O
in,2864,O
the,2864,O
affected,2864,O
areas,2864,O
is,2864,O
a,2864,O
major,2864,O
consequence,2864,O
of,2864,O
seizures,2864,B-Disease
at,2864,O
the,2864,O
cellular,2864,O
level,2864,O
.,2864,O
In,2865,O
this,2865,O
respect,2865,O
",",2865,O
little,2865,O
is,2865,O
known,2865,O
about,2865,O
the,2865,O
role,2865,O
of,2865,O
DA,2865,B-Chemical
receptors,2865,O
in,2865,O
the,2865,O
occurrence,2865,O
of,2865,O
epilepsy-induced,2865,B-Disease
neuronal,2865,O
cell,2865,O
death,2865,O
.,2865,O
Here,2866,O
we,2866,O
analyze,2866,O
the,2866,O
occurrence,2866,O
of,2866,O
seizures,2866,B-Disease
and,2866,O
neurotoxicity,2866,B-Disease
in,2866,O
D2R,2866,O
-/-,2866,O
mice,2866,O
treated,2866,O
with,2866,O
the,2866,O
cholinergic,2866,O
agonist,2866,O
pilocarpine,2866,B-Chemical
.,2866,O
We,2867,O
compared,2867,O
these,2867,O
results,2867,O
with,2867,O
those,2867,O
previously,2867,O
obtained,2867,O
with,2867,O
kainic,2867,B-Chemical
acid,2867,I-Chemical
(,2867,O
KA,2867,B-Chemical
),2867,O
",",2867,O
a,2867,O
potent,2867,O
glutamate,2867,B-Chemical
agonist,2867,O
.,2867,O
Importantly,2868,O
",",2868,O
D2R,2868,O
-/-,2868,O
mice,2868,O
develop,2868,O
seizures,2868,B-Disease
at,2868,O
doses,2868,O
of,2868,O
both,2868,O
drugs,2868,O
that,2868,O
are,2868,O
not,2868,O
epileptogenic,2868,O
for,2868,O
WT,2868,O
littermates,2868,O
and,2868,O
show,2868,O
greater,2868,O
neurotoxicity,2868,B-Disease
.,2868,O
However,2869,O
",",2869,O
pilocarpine-induced,2869,B-Chemical
seizures,2869,B-Disease
result,2869,O
in,2869,O
a,2869,O
more,2869,O
widespread,2869,O
neuronal,2869,O
death,2869,O
in,2869,O
both,2869,O
WT,2869,O
and,2869,O
D2R,2869,O
-/-,2869,O
brains,2869,O
in,2869,O
comparison,2869,O
to,2869,O
KA,2869,B-Chemical
.,2869,O
Thus,2870,O
",",2870,O
the,2870,O
absence,2870,O
of,2870,O
D2R,2870,O
lowers,2870,O
the,2870,O
threshold,2870,O
for,2870,O
seizures,2870,B-Disease
induced,2870,O
by,2870,O
both,2870,O
glutamate,2870,B-Chemical
and,2870,O
acetylcholine,2870,B-Chemical
.,2870,O
Moreover,2871,O
",",2871,O
the,2871,O
dopaminergic,2871,O
control,2871,O
of,2871,O
epilepsy-induced,2871,B-Disease
neurodegeneration,2871,B-Disease
seems,2871,O
to,2871,O
be,2871,O
mediated,2871,O
by,2871,O
distinct,2871,O
interactions,2871,O
of,2871,O
D2R,2871,O
signaling,2871,O
with,2871,O
these,2871,O
two,2871,O
neurotransmitters,2871,O
.,2871,O
Steroid,2872,B-Chemical
structure,2872,O
and,2872,O
pharmacological,2872,O
properties,2872,O
determine,2872,O
the,2872,O
anti-amnesic,2872,O
effects,2872,O
of,2872,O
pregnenolone,2872,B-Chemical
sulphate,2872,I-Chemical
in,2872,O
the,2872,O
passive,2872,O
avoidance,2872,O
task,2872,O
in,2872,O
rats,2872,O
.,2872,O
Pregnenolone,2873,B-Chemical
sulphate,2873,I-Chemical
(,2873,O
PREGS,2873,B-Chemical
),2873,O
has,2873,O
generated,2873,O
interest,2873,O
as,2873,O
one,2873,O
of,2873,O
the,2873,O
most,2873,O
potent,2873,O
memory-enhancing,2873,O
neurosteroids,2873,O
to,2873,O
be,2873,O
examined,2873,O
in,2873,O
rodent,2873,O
learning,2873,O
studies,2873,O
",",2873,O
with,2873,O
particular,2873,O
importance,2873,O
in,2873,O
the,2873,O
ageing,2873,O
process,2873,O
.,2873,O
The,2874,O
mechanism,2874,O
by,2874,O
which,2874,O
this,2874,O
endogenous,2874,O
steroid,2874,B-Chemical
enhances,2874,O
memory,2874,O
formation,2874,O
is,2874,O
hypothesized,2874,O
to,2874,O
involve,2874,O
actions,2874,O
on,2874,O
glutamatergic,2874,O
and,2874,O
GABAergic,2874,O
systems,2874,O
.,2874,O
This,2875,O
hypothesis,2875,O
stems,2875,O
from,2875,O
findings,2875,O
that,2875,O
PREGS,2875,B-Chemical
is,2875,O
a,2875,O
potent,2875,O
positive,2875,O
modulator,2875,O
of,2875,O
N-methyl-d-aspartate,2875,B-Chemical
receptors,2875,O
(,2875,O
NMDARs,2875,O
),2875,O
and,2875,O
a,2875,O
negative,2875,O
modulator,2875,O
of,2875,O
gamma-aminobutyric,2875,B-Chemical
acid,2875,I-Chemical
(,2875,O
A,2875,O
),2875,O
receptors,2875,O
(,2875,O
GABA,2875,B-Chemical
(,2875,O
A,2875,O
),2875,O
Rs,2875,O
),2875,O
.,2875,O
Moreover,2876,O
",",2876,O
PREGS,2876,B-Chemical
is,2876,O
able,2876,O
to,2876,O
reverse,2876,O
the,2876,O
amnesic-like,2876,B-Disease
effects,2876,O
of,2876,O
NMDAR,2876,O
and,2876,O
GABA,2876,B-Chemical
(,2876,O
A,2876,O
),2876,O
R,2876,O
ligands,2876,O
.,2876,O
To,2877,O
investigate,2877,O
this,2877,O
hypothesis,2877,O
",",2877,O
the,2877,O
present,2877,O
study,2877,O
in,2877,O
rats,2877,O
examined,2877,O
the,2877,O
memory-altering,2877,O
abilities,2877,O
of,2877,O
structural,2877,O
analogs,2877,O
of,2877,O
PREGS,2877,B-Chemical
",",2877,O
which,2877,O
differ,2877,O
in,2877,O
their,2877,O
modulation,2877,O
of,2877,O
NMDAR,2877,O
and/or,2877,O
GABA,2877,B-Chemical
(,2877,O
A,2877,O
),2877,O
R,2877,O
function,2877,O
.,2877,O
The,2878,O
analogs,2878,O
tested,2878,O
were,2878,O
:,2878,O
11-ketopregnenolone,2878,B-Chemical
sulphate,2878,I-Chemical
(,2878,O
an,2878,O
agent,2878,O
that,2878,O
is,2878,O
inactive,2878,O
at,2878,O
GABA,2878,B-Chemical
(,2878,O
A,2878,O
),2878,O
Rs,2878,O
and,2878,O
NMDARs,2878,O
),2878,O
",",2878,O
epipregnanolone,2878,B-Chemical
(,2878,I-Chemical
[,2878,I-Chemical
3beta-hydroxy-5beta-pregnan-20-one,2878,I-Chemical
],2878,I-Chemical
sulphate,2878,I-Chemical
",",2878,O
an,2878,O
inhibitor,2878,O
of,2878,O
both,2878,O
GABA,2878,B-Chemical
(,2878,O
A,2878,O
),2878,O
Rs,2878,O
and,2878,O
NMDARs,2878,O
),2878,O
",",2878,O
and,2878,O
a,2878,O
newly,2878,O
synthesized,2878,O
(,2878,O
-,2878,O
),2878,O
PREGS,2878,B-Chemical
enantiomer,2878,O
(,2878,O
which,2878,O
is,2878,O
identical,2878,O
to,2878,O
PREGS,2878,B-Chemical
in,2878,O
effects,2878,O
on,2878,O
GABA,2878,B-Chemical
(,2878,O
A,2878,O
),2878,O
Rs,2878,O
and,2878,O
NMDARs,2878,O
),2878,O
.,2878,O
The,2879,O
memory-enhancing,2879,O
effects,2879,O
of,2879,O
PREGS,2879,B-Chemical
and,2879,O
its,2879,O
analogs,2879,O
were,2879,O
tested,2879,O
in,2879,O
the,2879,O
passive,2879,O
avoidance,2879,O
task,2879,O
using,2879,O
the,2879,O
model,2879,O
of,2879,O
scopolamine-induced,2879,B-Chemical
amnesia,2879,B-Disease
.,2879,O
Both,2880,O
PREGS,2880,B-Chemical
and,2880,O
its,2880,O
(,2880,O
-,2880,O
),2880,O
enantiomer,2880,O
blocked,2880,O
the,2880,O
effects,2880,O
of,2880,O
scopolamine,2880,B-Chemical
.,2880,O
The,2881,O
results,2881,O
show,2881,O
that,2881,O
",",2881,O
unlike,2881,O
PREGS,2881,B-Chemical
",",2881,O
11-ketopregnenolone,2881,B-Chemical
sulphate,2881,I-Chemical
and,2881,O
epipregnanolone,2881,B-Chemical
sulphate,2881,I-Chemical
failed,2881,O
to,2881,O
block,2881,O
the,2881,O
effect,2881,O
of,2881,O
scopolamine,2881,B-Chemical
",",2881,O
suggesting,2881,O
that,2881,O
altering,2881,O
the,2881,O
modulation,2881,O
of,2881,O
NMDA,2881,B-Chemical
receptors,2881,O
diminishes,2881,O
the,2881,O
memory-enhancing,2881,O
effects,2881,O
of,2881,O
PREGS,2881,B-Chemical
.,2881,O
Moreover,2882,O
",",2882,O
enantioselectivity,2882,O
was,2882,O
demonstrated,2882,O
by,2882,O
the,2882,O
ability,2882,O
of,2882,O
natural,2882,O
PREGS,2882,B-Chemical
to,2882,O
be,2882,O
an,2882,O
order,2882,O
of,2882,O
magnitude,2882,O
more,2882,O
effective,2882,O
than,2882,O
its,2882,O
synthetic,2882,O
enantiomer,2882,O
in,2882,O
reversing,2882,O
scopolamine-induced,2882,B-Chemical
amnesia,2882,B-Disease
.,2882,O
These,2883,O
results,2883,O
identify,2883,O
a,2883,O
novel,2883,O
neuropharmacological,2883,O
site,2883,O
for,2883,O
the,2883,O
modulation,2883,O
of,2883,O
memory,2883,O
processes,2883,O
by,2883,O
neuroactive,2883,O
steroids,2883,B-Chemical
.,2883,O
Activation,2884,O
of,2884,O
poly,2884,B-Chemical
(,2884,I-Chemical
ADP-ribose,2884,I-Chemical
),2884,I-Chemical
polymerase,2884,O
contributes,2884,O
to,2884,O
development,2884,O
of,2884,O
doxorubicin-induced,2884,B-Chemical
heart,2884,B-Disease
failure,2884,I-Disease
.,2884,O
Activation,2885,O
of,2885,O
the,2885,O
nuclear,2885,O
enzyme,2885,O
poly,2885,B-Chemical
(,2885,I-Chemical
ADP-ribose,2885,I-Chemical
),2885,I-Chemical
polymerase,2885,O
(,2885,O
PARP,2885,O
),2885,O
by,2885,O
oxidant-mediated,2885,O
DNA,2885,O
damage,2885,O
is,2885,O
an,2885,O
important,2885,O
pathway,2885,O
of,2885,O
cell,2885,O
dysfunction,2885,O
and,2885,O
tissue,2885,O
injury,2885,O
in,2885,O
conditions,2885,O
associated,2885,O
with,2885,O
oxidative,2885,O
stress,2885,O
.,2885,O
Increased,2886,O
oxidative,2886,O
stress,2886,O
is,2886,O
a,2886,O
major,2886,O
factor,2886,O
implicated,2886,O
in,2886,O
the,2886,O
cardiotoxicity,2886,B-Disease
of,2886,O
doxorubicin,2886,B-Chemical
(,2886,O
DOX,2886,B-Chemical
),2886,O
",",2886,O
a,2886,O
widely,2886,O
used,2886,O
antitumor,2886,O
anthracycline,2886,B-Chemical
antibiotic,2886,O
.,2886,O
Thus,2887,O
",",2887,O
we,2887,O
hypothesized,2887,O
that,2887,O
the,2887,O
activation,2887,O
of,2887,O
PARP,2887,O
may,2887,O
contribute,2887,O
to,2887,O
the,2887,O
DOX-induced,2887,B-Chemical
cardiotoxicity,2887,B-Disease
.,2887,O
Using,2888,O
a,2888,O
dual,2888,O
approach,2888,O
of,2888,O
PARP-1,2888,O
suppression,2888,O
",",2888,O
by,2888,O
genetic,2888,O
deletion,2888,O
or,2888,O
pharmacological,2888,O
inhibition,2888,O
with,2888,O
the,2888,O
phenanthridinone,2888,O
PARP,2888,O
inhibitor,2888,O
PJ34,2888,B-Chemical
",",2888,O
we,2888,O
now,2888,O
demonstrate,2888,O
the,2888,O
role,2888,O
of,2888,O
PARP,2888,O
in,2888,O
the,2888,O
development,2888,O
of,2888,O
cardiac,2888,B-Disease
dysfunction,2888,I-Disease
induced,2888,O
by,2888,O
DOX,2888,B-Chemical
.,2888,O
PARP-1+/+,2889,O
and,2889,O
PARP-1-/-,2889,O
mice,2889,O
received,2889,O
a,2889,O
single,2889,O
injection,2889,O
of,2889,O
DOX,2889,B-Chemical
(,2889,O
25,2889,O
mg/kg,2889,O
i.p,2889,O
),2889,O
.,2889,O
Five,2890,O
days,2890,O
after,2890,O
DOX,2890,B-Chemical
administration,2890,O
",",2890,O
left,2890,O
ventricular,2890,O
performance,2890,O
was,2890,O
significantly,2890,O
depressed,2890,O
in,2890,O
PARP-1+/+,2890,O
mice,2890,O
",",2890,O
but,2890,O
only,2890,O
to,2890,O
a,2890,O
smaller,2890,O
extent,2890,O
in,2890,O
PARP-1-/-,2890,O
ones,2890,O
.,2890,O
Similar,2891,O
experiments,2891,O
were,2891,O
conducted,2891,O
in,2891,O
BALB/c,2891,O
mice,2891,O
treated,2891,O
with,2891,O
PJ34,2891,B-Chemical
or,2891,O
vehicle,2891,O
.,2891,O
Treatment,2892,O
with,2892,O
a,2892,O
PJ34,2892,B-Chemical
significantly,2892,O
improved,2892,O
cardiac,2892,B-Disease
dysfunction,2892,I-Disease
and,2892,O
increased,2892,O
the,2892,O
survival,2892,O
of,2892,O
the,2892,O
animals,2892,O
.,2892,O
In,2893,O
addition,2893,O
PJ34,2893,B-Chemical
significantly,2893,O
reduced,2893,O
the,2893,O
DOX-induced,2893,B-Chemical
increase,2893,O
in,2893,O
the,2893,O
serum,2893,O
lactate,2893,B-Chemical
dehydrogenase,2893,O
and,2893,O
creatine,2893,B-Chemical
kinase,2893,O
activities,2893,O
but,2893,O
not,2893,O
metalloproteinase,2893,O
activation,2893,O
in,2893,O
the,2893,O
heart,2893,O
.,2893,O
Thus,2894,O
",",2894,O
PARP,2894,O
activation,2894,O
contributes,2894,O
to,2894,O
the,2894,O
cardiotoxicity,2894,B-Disease
of,2894,O
DOX,2894,B-Chemical
.,2894,O
PARP,2895,O
inhibitors,2895,O
may,2895,O
exert,2895,O
protective,2895,O
effects,2895,O
against,2895,O
the,2895,O
development,2895,O
of,2895,O
severe,2895,O
cardiac,2895,B-Disease
complications,2895,I-Disease
associated,2895,O
with,2895,O
the,2895,O
DOX,2895,B-Chemical
treatment,2895,O
.,2895,O
Spironolactone,2896,B-Chemical
:,2896,O
is,2896,O
it,2896,O
a,2896,O
novel,2896,O
drug,2896,O
for,2896,O
the,2896,O
prevention,2896,O
of,2896,O
amphotericin,2896,B-Chemical
B-related,2896,O
hypokalemia,2896,B-Disease
in,2896,O
cancer,2896,B-Disease
patients,2896,O
?,2896,O
OBJECTIVE,2897,O
:,2897,O
Nephrotoxicity,2897,B-Disease
is,2897,O
the,2897,O
major,2897,O
adverse,2897,O
effect,2897,O
of,2897,O
amphotericin,2897,B-Chemical
B,2897,I-Chemical
(,2897,O
AmB,2897,B-Chemical
),2897,O
",",2897,O
often,2897,O
limiting,2897,O
administration,2897,O
of,2897,O
full,2897,O
dosage,2897,O
.,2897,O
Selective,2898,O
distal,2898,O
tubular,2898,O
epithelial,2898,O
toxicity,2898,B-Disease
seems,2898,O
to,2898,O
be,2898,O
responsible,2898,O
for,2898,O
the,2898,O
profound,2898,O
potassium,2898,B-Chemical
wasting,2898,O
that,2898,O
is,2898,O
a,2898,O
major,2898,O
clinical,2898,O
side,2898,O
effect,2898,O
of,2898,O
treatment,2898,O
with,2898,O
AmB,2898,B-Chemical
.,2898,O
Potassium,2899,B-Chemical
depletion,2899,O
also,2899,O
potentiates,2899,O
the,2899,O
tubular,2899,O
toxicity,2899,B-Disease
of,2899,O
AmB,2899,B-Chemical
.,2899,O
This,2900,O
study,2900,O
was,2900,O
designed,2900,O
to,2900,O
assess,2900,O
the,2900,O
ability,2900,O
of,2900,O
spironolactone,2900,B-Chemical
to,2900,O
reduce,2900,O
potassium,2900,B-Chemical
requirements,2900,O
and,2900,O
to,2900,O
prevent,2900,O
hypokalemia,2900,B-Disease
in,2900,O
neutropenic,2900,B-Disease
patients,2900,O
on,2900,O
AmB,2900,B-Chemical
treatment,2900,O
.,2900,O
METHODS,2901,O
:,2901,O
In,2901,O
this,2901,O
study,2901,O
26,2901,O
patients,2901,O
with,2901,O
various,2901,O
hematological,2901,B-Disease
disorders,2901,I-Disease
were,2901,O
randomized,2901,O
to,2901,O
receive,2901,O
either,2901,O
intravenous,2901,O
AmB,2901,B-Chemical
alone,2901,O
or,2901,O
AmB,2901,B-Chemical
and,2901,O
oral,2901,O
spironolactone,2901,B-Chemical
100,2901,O
mg,2901,O
twice,2901,O
daily,2901,O
when,2901,O
developing,2901,O
a,2901,O
proven,2901,O
or,2901,O
suspected,2901,O
fungal,2901,B-Disease
infection,2901,I-Disease
.,2901,O
RESULTS,2902,O
:,2902,O
Patients,2902,O
receiving,2902,O
concomitant,2902,O
AmB,2902,B-Chemical
and,2902,O
spironolactone,2902,B-Chemical
had,2902,O
significantly,2902,O
higher,2902,O
plasma,2902,O
potassium,2902,B-Chemical
levels,2902,O
than,2902,O
those,2902,O
receiving,2902,O
AmB,2902,B-Chemical
alone,2902,O
(,2902,O
P,2902,O
=,2902,O
0.0027,2902,O
),2902,O
.,2902,O
Those,2903,O
patients,2903,O
receiving,2903,O
AmB,2903,B-Chemical
and,2903,O
spironolactone,2903,B-Chemical
required,2903,O
significantly,2903,O
less,2903,O
potassium,2903,B-Chemical
supplementation,2903,O
to,2903,O
maintain,2903,O
their,2903,O
plasma,2903,O
potassium,2903,B-Chemical
within,2903,O
the,2903,O
normal,2903,O
range,2903,O
(,2903,O
P,2903,O
=,2903,O
0.022,2903,O
),2903,O
.,2903,O
Moreover,2904,O
",",2904,O
urinary,2904,O
potassium,2904,B-Chemical
losses,2904,O
were,2904,O
significantly,2904,O
less,2904,O
in,2904,O
patients,2904,O
receiving,2904,O
AmB,2904,B-Chemical
and,2904,O
spironolactone,2904,B-Chemical
than,2904,O
those,2904,O
receiving,2904,O
AmB,2904,B-Chemical
alone,2904,O
(,2904,O
P,2904,O
=,2904,O
0.040,2904,O
),2904,O
.,2904,O
CONCLUSION,2905,O
:,2905,O
This,2905,O
study,2905,O
showed,2905,O
that,2905,O
spironolactone,2905,B-Chemical
can,2905,O
reduce,2905,O
potassium,2905,B-Chemical
requirements,2905,O
and,2905,O
prevent,2905,O
hypokalemia,2905,B-Disease
by,2905,O
reducing,2905,O
urinary,2905,O
potassium,2905,B-Chemical
loss,2905,O
in,2905,O
neutropenic,2905,B-Disease
patients,2905,O
on,2905,O
AmB,2905,B-Chemical
treatment,2905,O
.,2905,O
Erectile,2906,B-Disease
dysfunction,2906,I-Disease
occurs,2906,O
following,2906,O
substantia,2906,O
nigra,2906,O
lesions,2906,O
in,2906,O
the,2906,O
rat,2906,O
.,2906,O
Erectile,2907,O
function,2907,O
was,2907,O
assessed,2907,O
6,2907,O
weeks,2907,O
following,2907,O
uni-,2907,O
and,2907,O
bilateral,2907,O
injections,2907,O
of,2907,O
6-hydroxydopamine,2907,B-Chemical
in,2907,O
the,2907,O
substantia,2907,O
nigra,2907,O
nucleus,2907,O
of,2907,O
the,2907,O
brain,2907,O
.,2907,O
Behavioral,2908,O
apomorphine-induced,2908,B-Chemical
penile,2908,O
erections,2908,O
were,2908,O
reduced,2908,O
(,2908,O
5/8,2908,O
),2908,O
and,2908,O
increased,2908,O
(,2908,O
3/8,2908,O
),2908,O
in,2908,O
uni-,2908,O
and,2908,O
bilateral,2908,O
lesioned,2908,O
animals,2908,O
.,2908,O
Intracavernous,2909,O
pressures,2909,O
",",2909,O
following,2909,O
electrical,2909,O
stimulation,2909,O
of,2909,O
the,2909,O
cavernous,2909,O
nerve,2909,O
",",2909,O
decreased,2909,O
in,2909,O
lesioned,2909,O
animals,2909,O
.,2909,O
Lesions,2910,O
of,2910,O
the,2910,O
substantia,2910,O
nigra,2910,O
were,2910,O
confirmed,2910,O
by,2910,O
histology,2910,O
.,2910,O
Concentration,2911,O
of,2911,O
dopamine,2911,B-Chemical
and,2911,O
its,2911,O
metabolites,2911,O
were,2911,O
decreased,2911,O
in,2911,O
the,2911,O
striatum,2911,O
of,2911,O
substantia,2911,O
nigra,2911,O
lesioned,2911,O
rats,2911,O
.,2911,O
Lesions,2912,O
of,2912,O
the,2912,O
substantia,2912,O
nigra,2912,O
are,2912,O
therefore,2912,O
associated,2912,O
with,2912,O
erectile,2912,B-Disease
dysfunction,2912,I-Disease
in,2912,O
rats,2912,O
and,2912,O
may,2912,O
serve,2912,O
as,2912,O
a,2912,O
model,2912,O
to,2912,O
study,2912,O
erectile,2912,B-Disease
dysfunction,2912,I-Disease
in,2912,O
Parkinson,2912,B-Disease
's,2912,I-Disease
disease,2912,I-Disease
.,2912,O
Nicotine,2913,B-Chemical
potentiation,2913,O
of,2913,O
morphine-induced,2913,B-Chemical
catalepsy,2913,B-Disease
in,2913,O
mice,2913,O
.,2913,O
In,2914,O
the,2914,O
present,2914,O
study,2914,O
",",2914,O
effects,2914,O
of,2914,O
nicotine,2914,B-Chemical
on,2914,O
catalepsy,2914,B-Disease
induced,2914,O
by,2914,O
morphine,2914,B-Chemical
in,2914,O
mice,2914,O
have,2914,O
been,2914,O
investigated,2914,O
.,2914,O
Morphine,2915,B-Chemical
but,2915,O
not,2915,O
nicotine,2915,B-Chemical
induced,2915,O
a,2915,O
dose-dependent,2915,O
catalepsy,2915,B-Disease
.,2915,O
The,2916,O
response,2916,O
of,2916,O
morphine,2916,B-Chemical
was,2916,O
potentiated,2916,O
by,2916,O
nicotine,2916,B-Chemical
.,2916,O
Intraperitoneal,2917,O
administration,2917,O
of,2917,O
atropine,2917,B-Chemical
",",2917,O
naloxone,2917,B-Chemical
",",2917,O
mecamylamine,2917,B-Chemical
",",2917,O
and,2917,O
hexamethonium,2917,B-Chemical
to,2917,O
mice,2917,O
reduced,2917,O
catalepsy,2917,B-Disease
induced,2917,O
by,2917,O
a,2917,O
combination,2917,O
of,2917,O
morphine,2917,B-Chemical
with,2917,O
nicotine,2917,B-Chemical
.,2917,O
Intracerebroventricular,2918,O
injection,2918,O
of,2918,O
atropine,2918,B-Chemical
",",2918,O
hexamethonium,2918,B-Chemical
",",2918,O
and,2918,O
naloxone,2918,B-Chemical
also,2918,O
decreased,2918,O
catalepsy,2918,B-Disease
induced,2918,O
by,2918,O
morphine,2918,B-Chemical
plus,2918,O
nicotine,2918,B-Chemical
.,2918,O
Intraperitoneal,2919,O
administration,2919,O
of,2919,O
atropine,2919,B-Chemical
",",2919,O
but,2919,O
not,2919,O
intraperitoneal,2919,O
or,2919,O
intracerebroventricular,2919,O
injection,2919,O
of,2919,O
hexamethonium,2919,B-Chemical
",",2919,O
decreased,2919,O
the,2919,O
effect,2919,O
of,2919,O
a,2919,O
single,2919,O
dose,2919,O
of,2919,O
morphine,2919,B-Chemical
.,2919,O
It,2920,O
was,2920,O
concluded,2920,O
that,2920,O
morphine,2920,B-Chemical
catalepsy,2920,B-Disease
can,2920,O
be,2920,O
elicited,2920,O
by,2920,O
opioid,2920,O
and,2920,O
cholinergic,2920,O
receptors,2920,O
",",2920,O
and,2920,O
the,2920,O
potentiation,2920,O
of,2920,O
morphine,2920,B-Chemical
induced,2920,O
by,2920,O
nicotine,2920,B-Chemical
may,2920,O
also,2920,O
be,2920,O
mediated,2920,O
through,2920,O
cholinergic,2920,O
receptor,2920,O
mechanisms,2920,O
.,2920,O
Force,2921,O
overflow,2921,O
and,2921,O
levodopa-induced,2921,B-Chemical
dyskinesias,2921,B-Disease
in,2921,O
Parkinson,2921,B-Disease
's,2921,I-Disease
disease,2921,I-Disease
.,2921,O
We,2922,O
assessed,2922,O
force,2922,O
coordination,2922,O
of,2922,O
the,2922,O
hand,2922,O
in,2922,O
Parkinson,2922,B-Disease
's,2922,I-Disease
disease,2922,I-Disease
and,2922,O
its,2922,O
relationship,2922,O
to,2922,O
motor,2922,O
complications,2922,O
of,2922,O
levodopa,2922,B-Chemical
therapy,2922,O
",",2922,O
particularly,2922,O
to,2922,O
levodopa-induced,2922,B-Chemical
dyskinesias,2922,B-Disease
(,2922,O
LID,2922,B-Disease
),2922,O
.,2922,O
We,2923,O
studied,2923,O
two,2923,O
groups,2923,O
of,2923,O
Parkinson,2923,B-Disease
's,2923,I-Disease
disease,2923,I-Disease
patients,2923,O
with,2923,O
(,2923,O
Parkinson,2923,B-Disease
's,2923,I-Disease
disease,2923,I-Disease
+,2923,O
LID,2923,B-Disease
",",2923,O
n,2923,O
=,2923,O
23,2923,O
),2923,O
and,2923,O
without,2923,O
levodopa-induced,2923,B-Chemical
dyskinesias,2923,B-Disease
(,2923,O
Parkinson,2923,B-Disease
's,2923,I-Disease
disease,2923,I-Disease
-,2923,O
LID,2923,B-Disease
",",2923,O
n,2923,O
=,2923,O
10,2923,O
),2923,O
",",2923,O
and,2923,O
age-matched,2923,O
healthy,2923,O
controls,2923,O
.,2923,O
The,2924,O
motor,2924,O
score,2924,O
of,2924,O
the,2924,O
Unified,2924,O
Parkinson,2924,B-Disease
's,2924,I-Disease
Disease,2924,I-Disease
Rating,2924,O
Scale,2924,O
",",2924,O
a,2924,O
dyskinesia,2924,B-Disease
score,2924,O
and,2924,O
force,2924,O
in,2924,O
a,2924,O
grip-lift,2924,O
paradigm,2924,O
were,2924,O
assessed,2924,O
ON,2924,O
and,2924,O
OFF,2924,O
levodopa,2924,B-Chemical
.,2924,O
A,2925,O
pathological,2925,O
increase,2925,O
of,2925,O
forces,2925,O
was,2925,O
seen,2925,O
in,2925,O
ON-state,2925,O
in,2925,O
Parkinson,2925,B-Disease
's,2925,I-Disease
disease,2925,I-Disease
+,2925,O
LID,2925,B-Disease
only,2925,O
.,2925,O
In,2926,O
Parkinson,2926,B-Disease
's,2926,I-Disease
disease,2926,I-Disease
+,2926,O
LID,2926,B-Disease
",",2926,O
the,2926,O
force,2926,O
involved,2926,O
in,2926,O
pressing,2926,O
down,2926,O
the,2926,O
object,2926,O
before,2926,O
lifting,2926,O
was,2926,O
significantly,2926,O
increased,2926,O
by,2926,O
levodopa,2926,B-Chemical
(,2926,O
by,2926,O
61,2926,O
%,2926,O
",",2926,O
P,2926,O
<,2926,O
0.05,2926,O
),2926,O
.,2926,O
An,2927,O
overshooting,2927,O
of,2927,O
peak,2927,O
grip,2927,O
force,2927,O
by,2927,O
51,2927,O
%,2927,O
(,2927,O
P,2927,O
<,2927,O
0.05,2927,O
),2927,O
and,2927,O
of,2927,O
static,2927,O
grip,2927,O
force,2927,O
by,2927,O
45,2927,O
%,2927,O
(,2927,O
P,2927,O
<,2927,O
0.01,2927,O
),2927,O
was,2927,O
observed,2927,O
in,2927,O
the,2927,O
ON-,2927,O
compared,2927,O
with,2927,O
the,2927,O
OFF-drug,2927,O
condition,2927,O
.,2927,O
In,2928,O
contrast,2928,O
",",2928,O
no,2928,O
excessive,2928,O
force,2928,O
was,2928,O
found,2928,O
in,2928,O
Parkinson,2928,B-Disease
's,2928,I-Disease
disease,2928,I-Disease
-,2928,O
LID,2928,B-Disease
.,2928,O
Peak,2929,O
grip,2929,O
force,2929,O
in,2929,O
ON-state,2929,O
was,2929,O
140,2929,O
%,2929,O
(,2929,O
P,2929,O
<,2929,O
0.05,2929,O
),2929,O
higher,2929,O
in,2929,O
Parkinson,2929,B-Disease
's,2929,I-Disease
disease,2929,I-Disease
+,2929,O
LID,2929,B-Disease
than,2929,O
in,2929,O
Parkinson,2929,B-Disease
's,2929,I-Disease
disease,2929,I-Disease
-,2929,O
LID,2929,B-Disease
",",2929,O
while,2929,O
static,2929,O
grip,2929,O
force,2929,O
was,2929,O
increased,2929,O
by,2929,O
138,2929,O
%,2929,O
(,2929,O
P,2929,O
<,2929,O
0.01,2929,O
),2929,O
between,2929,O
groups,2929,O
.,2929,O
Severity,2930,O
of,2930,O
peak-dose,2930,O
dyskinesias,2930,B-Disease
was,2930,O
strongly,2930,O
correlated,2930,O
with,2930,O
grip,2930,O
force,2930,O
in,2930,O
ON-state,2930,O
(,2930,O
r,2930,O
=,2930,O
0.79,2930,O
with,2930,O
peak,2930,O
force,2930,O
",",2930,O
P,2930,O
<,2930,O
0.01,2930,O
),2930,O
.,2930,O
No,2931,O
correlation,2931,O
was,2931,O
observed,2931,O
between,2931,O
forces,2931,O
and,2931,O
the,2931,O
motor,2931,O
score,2931,O
as,2931,O
well,2931,O
as,2931,O
with,2931,O
the,2931,O
daily,2931,O
dose,2931,O
of,2931,O
dopaminergic,2931,O
medication,2931,O
.,2931,O
Force,2932,O
excess,2932,O
was,2932,O
only,2932,O
observed,2932,O
in,2932,O
patients,2932,O
with,2932,O
LID,2932,B-Disease
and,2932,O
motor,2932,O
fluctuations,2932,O
.,2932,O
A,2933,O
close,2933,O
relationship,2933,O
was,2933,O
seen,2933,O
between,2933,O
the,2933,O
overshooting,2933,O
of,2933,O
forces,2933,O
and,2933,O
dyskinesias,2933,B-Disease
in,2933,O
the,2933,O
ON-drug,2933,O
condition,2933,O
.,2933,O
We,2934,O
postulate,2934,O
that,2934,O
both,2934,O
LID,2934,B-Disease
and,2934,O
grip,2934,O
force,2934,O
excess,2934,O
share,2934,O
common,2934,O
pathophysiological,2934,O
mechanisms,2934,O
related,2934,O
to,2934,O
motor,2934,O
fluctuations,2934,O
.,2934,O
Behavioral,2935,O
effects,2935,O
of,2935,O
MK-801,2935,B-Chemical
on,2935,O
reserpine-treated,2935,B-Chemical
mice,2935,O
.,2935,O
The,2936,O
effects,2936,O
of,2936,O
dizocilpine,2936,B-Chemical
(,2936,O
MK-801,2936,B-Chemical
),2936,O
",",2936,O
a,2936,O
noncompetitive,2936,O
N-methyl-D-aspartate,2936,B-Chemical
(,2936,O
NMDA,2936,B-Chemical
),2936,O
receptor,2936,O
antagonist,2936,O
",",2936,O
were,2936,O
studied,2936,O
on,2936,O
dopamine-related,2936,B-Chemical
behaviors,2936,O
induced,2936,O
by,2936,O
reserpine,2936,B-Chemical
treatments,2936,O
.,2936,O
This,2937,O
study,2937,O
focuses,2937,O
on,2937,O
behavioral,2937,O
syndromes,2937,O
that,2937,O
may,2937,O
used,2937,O
as,2937,O
models,2937,O
for,2937,O
Parkinson,2937,B-Disease
's,2937,I-Disease
disease,2937,I-Disease
",",2937,O
or,2937,O
tardive,2937,B-Disease
dyskinesia,2937,I-Disease
",",2937,O
and,2937,O
its,2937,O
response,2937,O
after,2937,O
glutamatergic,2937,O
blockage,2937,O
.,2937,O
Reserpine,2938,B-Chemical
(,2938,O
1,2938,O
mg/kg,2938,O
),2938,O
",",2938,O
administered,2938,O
once,2938,O
every,2938,O
other,2938,O
day,2938,O
for,2938,O
4,2938,O
days,2938,O
",",2938,O
produced,2938,O
increases,2938,O
in,2938,O
orofacial,2938,B-Disease
dyskinesia,2938,I-Disease
",",2938,O
tongue,2938,O
protrusion,2938,O
and,2938,O
vacuous,2938,O
chewing,2938,O
in,2938,O
mice,2938,O
",",2938,O
which,2938,O
are,2938,O
signs,2938,O
indicative,2938,O
of,2938,O
tardive,2938,B-Disease
dyskinesia,2938,I-Disease
.,2938,O
Reserpine,2939,B-Chemical
also,2939,O
produced,2939,O
tremor,2939,B-Disease
and,2939,O
catalepsy,2939,B-Disease
",",2939,O
which,2939,O
are,2939,O
signs,2939,O
suggestive,2939,O
of,2939,O
Parkinson,2939,B-Disease
's,2939,I-Disease
disease,2939,I-Disease
.,2939,O
MK-801,2940,B-Chemical
(,2940,O
0.1,2940,O
mg/kg,2940,O
),2940,O
",",2940,O
administered,2940,O
30,2940,O
min,2940,O
before,2940,O
the,2940,O
observation,2940,O
test,2940,O
",",2940,O
prevented,2940,O
the,2940,O
vacuous,2940,O
chewing,2940,O
movements,2940,O
",",2940,O
tongue,2940,O
protrusions,2940,O
and,2940,O
catalepsy,2940,B-Disease
induced,2940,O
by,2940,O
reserpine,2940,B-Chemical
.,2940,O
However,2941,O
",",2941,O
MK-801,2941,B-Chemical
injection,2941,O
produced,2941,O
a,2941,O
significant,2941,O
increase,2941,O
of,2941,O
tremor,2941,B-Disease
in,2941,O
reserpine-treated,2941,B-Chemical
mice,2941,O
.,2941,O
Reserpine,2942,B-Chemical
(,2942,O
1,2942,O
mg/kg,2942,O
),2942,O
",",2942,O
administered,2942,O
90,2942,O
min,2942,O
before,2942,O
the,2942,O
test,2942,O
and,2942,O
followed,2942,O
by,2942,O
apomophine,2942,B-Chemical
injection,2942,O
(,2942,O
0.1,2942,O
mg/kg,2942,O
),2942,O
5,2942,O
min,2942,O
before,2942,O
the,2942,O
test,2942,O
",",2942,O
did,2942,O
not,2942,O
produce,2942,O
oral,2942,B-Disease
dyskinesia,2942,I-Disease
in,2942,O
mice,2942,O
.,2942,O
On,2943,O
the,2943,O
other,2943,O
hand,2943,O
",",2943,O
reserpine,2943,B-Chemical
induced,2943,O
increases,2943,O
in,2943,O
tremor,2943,B-Disease
and,2943,O
catalepsy,2943,B-Disease
compared,2943,O
to,2943,O
control,2943,O
mice,2943,O
.,2943,O
MK-801,2944,B-Chemical
(,2944,O
0.1,2944,O
mg/kg,2944,O
),2944,O
administration,2944,O
attenuated,2944,O
the,2944,O
catalepsy,2944,B-Disease
and,2944,O
tremor,2944,B-Disease
induced,2944,O
by,2944,O
reserpine,2944,B-Chemical
.,2944,O
Pretreatment,2945,O
with,2945,O
reserpine,2945,B-Chemical
(,2945,O
1,2945,O
mg/kg,2945,O
),2945,O
24,2945,O
h,2945,O
before,2945,O
the,2945,O
observation,2945,O
test,2945,O
produced,2945,O
increases,2945,O
in,2945,O
vacuous,2945,O
chewing,2945,O
movements,2945,O
and,2945,O
tongue,2945,O
protrusion,2945,O
",",2945,O
as,2945,O
well,2945,O
as,2945,O
increases,2945,O
in,2945,O
tremor,2945,B-Disease
and,2945,O
catalepsy,2945,B-Disease
",",2945,O
whereas,2945,O
MK-801,2945,B-Chemical
(,2945,O
0.1,2945,O
mg/kg,2945,O
),2945,O
injection,2945,O
90,2945,O
min,2945,O
before,2945,O
the,2945,O
test,2945,O
reversed,2945,O
the,2945,O
effects,2945,O
of,2945,O
reserpine,2945,B-Chemical
.,2945,O
These,2946,O
results,2946,O
show,2946,O
that,2946,O
reserpine,2946,B-Chemical
produces,2946,O
different,2946,O
and,2946,O
abnormal,2946,B-Disease
movements,2946,I-Disease
",",2946,O
which,2946,O
are,2946,O
related,2946,O
to,2946,O
dose,2946,O
and,2946,O
schedule,2946,O
employed,2946,O
and,2946,O
can,2946,O
be,2946,O
considered,2946,O
as,2946,O
parkinsonian-like,2946,B-Disease
and,2946,O
tardive,2946,B-Disease
dsykinesia,2946,I-Disease
signs,2946,O
.,2946,O
The,2947,O
glutamatergic,2947,O
blockage,2947,O
produced,2947,O
by,2947,O
NMDA,2947,B-Chemical
can,2947,O
restore,2947,O
these,2947,O
signs,2947,O
",",2947,O
such,2947,O
as,2947,O
vacuous,2947,O
chewing,2947,O
movements,2947,O
",",2947,O
tongue,2947,O
protrusions,2947,O
",",2947,O
catalepsy,2947,B-Disease
and,2947,O
tremor,2947,B-Disease
according,2947,O
to,2947,O
the,2947,O
employed,2947,O
model,2947,O
.,2947,O
Risperidone-associated,2948,B-Chemical
",",2948,O
benign,2948,O
transient,2948,O
visual,2948,B-Disease
disturbances,2948,I-Disease
in,2948,O
schizophrenic,2948,B-Disease
patients,2948,O
with,2948,O
a,2948,O
past,2948,O
history,2948,O
of,2948,O
LSD,2948,B-Chemical
abuse,2948,O
.,2948,O
Two,2949,O
schizophrenic,2949,B-Disease
patients,2949,O
",",2949,O
who,2949,O
had,2949,O
a,2949,O
prior,2949,O
history,2949,O
of,2949,O
LSD,2949,B-Chemical
abuse,2949,O
and,2949,O
who,2949,O
had,2949,O
previously,2949,O
developed,2949,O
EPS,2949,B-Disease
with,2949,O
classic,2949,O
antipsychotics,2949,O
",",2949,O
were,2949,O
successfully,2949,O
treated,2949,O
with,2949,O
risperidone,2949,B-Chemical
.,2949,O
They,2950,O
both,2950,O
reported,2950,O
short,2950,O
episodes,2950,O
of,2950,O
transient,2950,O
visual,2950,B-Disease
disturbances,2950,I-Disease
",",2950,O
which,2950,O
appeared,2950,O
immediately,2950,O
after,2950,O
starting,2950,O
treatment,2950,O
with,2950,O
risperidone,2950,B-Chemical
.,2950,O
This,2951,O
imagery,2951,O
resembled,2951,O
visual,2951,B-Disease
disturbances,2951,I-Disease
previously,2951,O
experienced,2951,O
as,2951,O
``,2951,O
flashbacks,2951,O
'',2951,O
related,2951,O
to,2951,O
prior,2951,O
LSD,2951,B-Chemical
consumption,2951,O
.,2951,O
Risperidone,2952,B-Chemical
administration,2952,O
was,2952,O
continued,2952,O
and,2952,O
the,2952,O
visual,2952,B-Disease
disturbances,2952,I-Disease
gradually,2952,O
wore,2952,O
off,2952,O
.,2952,O
During,2953,O
a,2953,O
six-month,2953,O
follow-up,2953,O
period,2953,O
",",2953,O
there,2953,O
was,2953,O
no,2953,O
recurrence,2953,O
of,2953,O
visual,2953,B-Disease
disturbances,2953,I-Disease
.,2953,O
This,2954,O
phenomenon,2954,O
may,2954,O
be,2954,O
interpreted,2954,O
as,2954,O
a,2954,O
benign,2954,O
",",2954,O
short-term,2954,O
and,2954,O
self-limiting,2954,O
side,2954,O
effect,2954,O
which,2954,O
does,2954,O
not,2954,O
contraindicate,2954,O
the,2954,O
use,2954,O
of,2954,O
risperidone,2954,B-Chemical
or,2954,O
interfere,2954,O
with,2954,O
treatment,2954,O
.,2954,O
Conclusions,2955,O
based,2955,O
on,2955,O
two,2955,O
case,2955,O
reports,2955,O
should,2955,O
be,2955,O
taken,2955,O
with,2955,O
appropriate,2955,O
caution,2955,O
.,2955,O
Topiramate-induced,2956,B-Chemical
nephrolithiasis,2956,B-Disease
.,2956,O
Topiramate,2957,B-Chemical
is,2957,O
a,2957,O
recently,2957,O
developed,2957,O
antiepileptic,2957,O
medication,2957,O
that,2957,O
is,2957,O
becoming,2957,O
more,2957,O
widely,2957,O
prescribed,2957,O
because,2957,O
of,2957,O
its,2957,O
efficacy,2957,O
in,2957,O
treating,2957,O
refractory,2957,B-Disease
seizures,2957,I-Disease
.,2957,O
Urologists,2958,O
should,2958,O
be,2958,O
aware,2958,O
that,2958,O
this,2958,O
medication,2958,O
can,2958,O
cause,2958,O
metabolic,2958,B-Disease
acidosis,2958,I-Disease
in,2958,O
patients,2958,O
secondary,2958,O
to,2958,O
inhibition,2958,O
of,2958,O
carbonic,2958,O
anhydrase,2958,O
.,2958,O
In,2959,O
addition,2959,O
",",2959,O
a,2959,O
distal,2959,O
tubular,2959,O
acidification,2959,O
defect,2959,O
may,2959,O
result,2959,O
",",2959,O
thus,2959,O
impairing,2959,O
the,2959,O
normal,2959,O
compensatory,2959,O
drop,2959,O
in,2959,O
urine,2959,O
pH,2959,O
.,2959,O
These,2960,O
factors,2960,O
can,2960,O
lead,2960,O
to,2960,O
the,2960,O
development,2960,O
of,2960,O
calcium,2960,B-Chemical
phosphate,2960,I-Chemical
nephrolithiasis,2960,B-Disease
.,2960,O
We,2961,O
report,2961,O
the,2961,O
first,2961,O
two,2961,O
cases,2961,O
of,2961,O
topiramate-induced,2961,B-Chemical
nephrolithiasis,2961,B-Disease
in,2961,O
the,2961,O
urologic,2961,O
literature,2961,O
.,2961,O
Ketamine,2962,B-Chemical
in,2962,O
war/tropical,2962,O
surgery,2962,O
(,2962,O
a,2962,O
final,2962,O
tribute,2962,O
to,2962,O
the,2962,O
racemic,2962,O
mixture,2962,O
),2962,O
.,2962,O
A,2963,O
technique,2963,O
of,2963,O
continuous,2963,O
intravenous,2963,O
anaesthesia,2963,O
with,2963,O
ketamine,2963,B-Chemical
was,2963,O
used,2963,O
successfully,2963,O
during,2963,O
the,2963,O
Somalia,2963,O
civil,2963,O
war,2963,O
in,2963,O
1994,2963,O
and,2963,O
in,2963,O
north,2963,O
Uganda,2963,O
in,2963,O
1999,2963,O
for,2963,O
64,2963,O
operations,2963,O
in,2963,O
62,2963,O
patients,2963,O
",",2963,O
aged,2963,O
from,2963,O
6,2963,O
weeks,2963,O
to,2963,O
70,2963,O
years,2963,O
",",2963,O
undergoing,2963,O
limb,2963,O
and,2963,O
abdominal,2963,O
surgery,2963,O
including,2963,O
caesarian,2963,O
sections,2963,O
and,2963,O
interventions,2963,O
in,2963,O
neonates,2963,O
.,2963,O
Operations,2964,O
lasting,2964,O
up,2964,O
to,2964,O
2h,2964,O
could,2964,O
be,2964,O
performed,2964,O
in,2964,O
the,2964,O
absence,2964,O
of,2964,O
sophisticated,2964,O
equipment,2964,O
such,2964,O
as,2964,O
pulse,2964,O
oximeters,2964,O
or,2964,O
ventilators,2964,O
in,2964,O
patients,2964,O
on,2964,O
spontaneous,2964,O
ventilation,2964,O
breathing,2964,O
air/oxygen,2964,O
only,2964,O
.,2964,O
After,2965,O
premedication,2965,O
with,2965,O
diazepam,2965,B-Chemical
",",2965,O
glycopyrrolate,2965,B-Chemical
and,2965,O
local,2965,O
anaesthesia,2965,O
",",2965,O
and,2965,O
induction,2965,O
with,2965,O
standard,2965,O
doses,2965,O
of,2965,O
ketamine,2965,B-Chemical
",",2965,O
a,2965,O
maintenance,2965,O
dose,2965,O
of,2965,O
10-20,2965,O
microg/kg/min,2965,O
of,2965,O
ketamine,2965,B-Chemical
proved,2965,O
safe,2965,O
and,2965,O
effective,2965,O
.,2965,O
Emphasis,2966,O
was,2966,O
placed,2966,O
on,2966,O
bedside,2966,O
clinical,2966,O
monitoring,2966,O
",",2966,O
relying,2966,O
heavily,2966,O
on,2966,O
the,2966,O
heart,2966,O
rate,2966,O
.,2966,O
Diazepam,2967,B-Chemical
",",2967,O
unless,2967,O
contraindicated,2967,O
or,2967,O
risky,2967,O
",",2967,O
remains,2967,O
the,2967,O
only,2967,O
necessary,2967,O
complementary,2967,O
drug,2967,O
to,2967,O
ketamine,2967,B-Chemical
as,2967,O
it,2967,O
buffers,2967,O
its,2967,O
cardiovascular,2967,O
response,2967,O
and,2967,O
decreases,2967,O
the,2967,O
duration,2967,O
and,2967,O
intensity,2967,O
of,2967,O
operative,2967,O
and,2967,O
postoperative,2967,O
hallucinations,2967,B-Disease
.,2967,O
Local,2968,O
anaesthetic,2968,O
blocks,2968,O
were,2968,O
useful,2968,O
in,2968,O
decreasing,2968,O
the,2968,O
requirement,2968,O
for,2968,O
postoperative,2968,O
analgesia,2968,B-Disease
.,2968,O
An,2969,O
antisialogue,2969,O
was,2969,O
usually,2969,O
unnecessary,2969,O
in,2969,O
operations,2969,O
lasting,2969,O
up,2969,O
to,2969,O
2,2969,O
h,2969,O
",",2969,O
glycopyrrolate,2969,B-Chemical
being,2969,O
the,2969,O
best,2969,O
choice,2969,O
for,2969,O
its,2969,O
lowest,2969,O
psychotropic,2969,O
and,2969,O
chronotropic,2969,O
effects,2969,O
",",2969,O
especially,2969,O
in,2969,O
a,2969,O
hot,2969,O
climate,2969,O
.,2969,O
Experience,2970,O
in,2970,O
war/tropical,2970,O
settings,2970,O
suggests,2970,O
this,2970,O
technique,2970,O
could,2970,O
be,2970,O
useful,2970,O
in,2970,O
civilian,2970,O
contexts,2970,O
such,2970,O
as,2970,O
outdoor,2970,O
life-saving,2970,O
emergency,2970,O
surgery,2970,O
or,2970,O
in,2970,O
mass,2970,O
casualties,2970,O
where,2970,O
",",2970,O
e.g,2970,O
.,2970,O
amputation,2971,O
and,2971,O
rapid,2971,O
extrication,2971,O
were,2971,O
required,2971,O
.,2971,O
Intravenous,2972,O
ribavirin,2972,B-Chemical
treatment,2972,O
for,2972,O
severe,2972,O
adenovirus,2972,B-Disease
disease,2972,I-Disease
in,2972,O
immunocompromised,2972,O
children,2972,O
.,2972,O
BACKGROUND,2973,O
:,2973,O
Adenovirus,2973,O
is,2973,O
an,2973,O
important,2973,O
cause,2973,O
of,2973,O
morbidity,2973,O
and,2973,O
mortality,2973,O
in,2973,O
the,2973,O
immunocompromised,2973,O
host,2973,O
.,2973,O
The,2974,O
incidence,2974,O
of,2974,O
severe,2974,O
adenovirus,2974,B-Disease
disease,2974,I-Disease
in,2974,O
pediatrics,2974,O
is,2974,O
increasing,2974,O
in,2974,O
association,2974,O
with,2974,O
growing,2974,O
numbers,2974,O
of,2974,O
immunocompromised,2974,O
children,2974,O
",",2974,O
where,2974,O
case,2974,O
fatality,2974,O
rates,2974,O
as,2974,O
high,2974,O
as,2974,O
50,2974,O
%,2974,O
to,2974,O
80,2974,O
%,2974,O
have,2974,O
been,2974,O
reported,2974,O
.,2974,O
There,2975,O
are,2975,O
no,2975,O
approved,2975,O
antiviral,2975,O
agents,2975,O
with,2975,O
proven,2975,O
efficacy,2975,O
for,2975,O
the,2975,O
treatment,2975,O
of,2975,O
severe,2975,O
adenovirus,2975,B-Disease
disease,2975,I-Disease
",",2975,O
nor,2975,O
are,2975,O
there,2975,O
any,2975,O
prospective,2975,O
randomized,2975,O
",",2975,O
controlled,2975,O
trials,2975,O
of,2975,O
potentially,2975,O
useful,2975,O
anti-adenovirus,2975,O
therapies,2975,O
.,2975,O
Apparent,2976,O
clinical,2976,O
success,2976,O
in,2976,O
the,2976,O
treatment,2976,O
of,2976,O
severe,2976,O
adenovirus,2976,B-Disease
disease,2976,I-Disease
is,2976,O
limited,2976,O
to,2976,O
a,2976,O
few,2976,O
case,2976,O
reports,2976,O
and,2976,O
small,2976,O
series,2976,O
.,2976,O
Experience,2977,O
is,2977,O
greatest,2977,O
with,2977,O
intravenous,2977,O
ribavirin,2977,B-Chemical
and,2977,O
cidofovir,2977,B-Chemical
.,2977,O
Ribavirin,2978,B-Chemical
",",2978,O
a,2978,O
guanosine,2978,B-Chemical
analogue,2978,O
",",2978,O
has,2978,O
broad,2978,O
antiviral,2978,O
activity,2978,O
against,2978,O
both,2978,O
RNA,2978,O
and,2978,O
DNA,2978,O
viruses,2978,O
",",2978,O
including,2978,O
documented,2978,O
activity,2978,O
against,2978,O
adenovirus,2978,O
in,2978,O
vitro,2978,O
.,2978,O
Ribavirin,2979,B-Chemical
is,2979,O
licensed,2979,O
in,2979,O
aerosol,2979,O
form,2979,O
for,2979,O
the,2979,O
treatment,2979,O
of,2979,O
respiratory,2979,B-Disease
syncytial,2979,I-Disease
virus,2979,I-Disease
infection,2979,I-Disease
",",2979,O
and,2979,O
orally,2979,O
in,2979,O
combination,2979,O
with,2979,O
interferon,2979,O
to,2979,O
treat,2979,O
hepatitis,2979,B-Disease
C.,2979,O
Intravenous,2979,O
ribavirin,2979,B-Chemical
is,2979,O
the,2979,O
treatment,2979,O
of,2979,O
choice,2979,O
for,2979,O
infection,2979,B-Disease
with,2979,I-Disease
hemorrhagic,2979,I-Disease
fever,2979,I-Disease
viruses,2979,I-Disease
.,2979,O
The,2980,O
most,2980,O
common,2980,O
adverse,2980,O
effect,2980,O
of,2980,O
intravenous,2980,O
ribavirin,2980,B-Chemical
is,2980,O
reversible,2980,O
mild,2980,O
anemia,2980,B-Disease
.,2980,O
The,2981,O
use,2981,O
of,2981,O
cidofovir,2981,B-Chemical
in,2981,O
severe,2981,O
adenovirus,2981,B-Disease
infection,2981,I-Disease
has,2981,O
been,2981,O
limited,2981,O
by,2981,O
adverse,2981,O
effects,2981,O
",",2981,O
the,2981,O
most,2981,O
significant,2981,O
of,2981,O
which,2981,O
is,2981,O
nephrotoxicity,2981,B-Disease
.,2981,O
OBJECTIVE,2982,O
:,2982,O
We,2982,O
report,2982,O
our,2982,O
experience,2982,O
with,2982,O
intravenous,2982,O
ribavirin,2982,B-Chemical
therapy,2982,O
for,2982,O
severe,2982,O
adenovirus,2982,B-Disease
disease,2982,I-Disease
in,2982,O
a,2982,O
series,2982,O
of,2982,O
immunocompromised,2982,O
children,2982,O
and,2982,O
review,2982,O
the,2982,O
literature,2982,O
.,2982,O
DESIGN/METHODS,2983,O
:,2983,O
We,2983,O
retrospectively,2983,O
reviewed,2983,O
the,2983,O
medical,2983,O
records,2983,O
of,2983,O
5,2983,O
children,2983,O
treated,2983,O
with,2983,O
intravenous,2983,O
ribavirin,2983,B-Chemical
for,2983,O
documented,2983,O
severe,2983,O
adenovirus,2983,B-Disease
disease,2983,I-Disease
.,2983,O
Two,2984,O
patients,2984,O
developed,2984,O
adenovirus,2984,O
hemorrhagic,2984,O
cystitis,2984,O
after,2984,O
cardiac,2984,O
and,2984,O
bone,2984,O
marrow,2984,O
transplants,2984,O
",",2984,O
respectively,2984,O
.,2984,O
The,2985,O
bone,2985,O
marrow,2985,O
transplant,2985,O
patient,2985,O
also,2985,O
received,2985,O
intravenous,2985,O
cidofovir,2985,B-Chemical
for,2985,O
progressive,2985,O
disseminated,2985,O
disease,2985,O
.,2985,O
An,2986,O
additional,2986,O
3,2986,O
children,2986,O
developed,2986,O
adenovirus,2986,O
pneumonia,2986,O
;,2986,O
2,2986,O
were,2986,O
neonates,2986,O
",",2986,O
1,2986,O
of,2986,O
whom,2986,O
had,2986,O
partial,2986,O
DiGeorge,2986,B-Disease
syndrome,2986,I-Disease
.,2986,O
The,2987,O
remaining,2987,O
infant,2987,O
had,2987,O
recently,2987,O
undergone,2987,O
a,2987,O
cardiac,2987,O
transplant,2987,O
.,2987,O
Intravenous,2988,O
ribavirin,2988,B-Chemical
was,2988,O
administered,2988,O
on,2988,O
a,2988,O
compassionate-use,2988,O
protocol,2988,O
.,2988,O
RESULTS,2989,O
:,2989,O
Complete,2989,O
clinical,2989,O
recovery,2989,O
followed,2989,O
later,2989,O
by,2989,O
viral,2989,O
clearance,2989,O
was,2989,O
observed,2989,O
in,2989,O
2,2989,O
children,2989,O
:,2989,O
the,2989,O
cardiac,2989,O
transplant,2989,O
recipient,2989,O
with,2989,O
adenovirus,2989,O
hemorrhagic,2989,O
cystitis,2989,O
and,2989,O
the,2989,O
immunocompetent,2989,O
neonate,2989,O
with,2989,O
adenovirus,2989,O
pneumonia,2989,O
.,2989,O
The,2990,O
remaining,2990,O
3,2990,O
children,2990,O
died,2990,O
of,2990,O
adenovirus,2990,B-Disease
disease,2990,I-Disease
.,2990,O
Intravenous,2991,O
ribavirin,2991,B-Chemical
therapy,2991,O
was,2991,O
well,2991,O
tolerated,2991,O
.,2991,O
Use,2992,O
of,2992,O
cidofovir,2992,B-Chemical
in,2992,O
1,2992,O
child,2992,O
was,2992,O
associated,2992,O
with,2992,O
progressive,2992,B-Disease
renal,2992,I-Disease
failure,2992,I-Disease
and,2992,O
neutropenia,2992,B-Disease
.,2992,O
DISCUSSION,2993,O
:,2993,O
Our,2993,O
series,2993,O
of,2993,O
patients,2993,O
is,2993,O
representative,2993,O
of,2993,O
the,2993,O
spectrum,2993,O
of,2993,O
immunocompromised,2993,O
children,2993,O
at,2993,O
greatest,2993,O
risk,2993,O
for,2993,O
severe,2993,O
adenovirus,2993,B-Disease
disease,2993,I-Disease
",",2993,O
namely,2993,O
solid-organ,2993,O
and,2993,O
bone,2993,O
marrow,2993,O
transplant,2993,O
recipients,2993,O
",",2993,O
neonates,2993,O
",",2993,O
and,2993,O
children,2993,O
with,2993,O
immunodeficiency,2993,B-Disease
.,2993,O
Although,2994,O
intravenous,2994,O
ribavirin,2994,B-Chemical
was,2994,O
not,2994,O
effective,2994,O
for,2994,O
all,2994,O
children,2994,O
with,2994,O
severe,2994,O
adenovirus,2994,B-Disease
disease,2994,I-Disease
in,2994,O
this,2994,O
series,2994,O
or,2994,O
in,2994,O
the,2994,O
literature,2994,O
",",2994,O
therapy,2994,O
is,2994,O
unlikely,2994,O
to,2994,O
be,2994,O
of,2994,O
benefit,2994,O
if,2994,O
begun,2994,O
late,2994,O
in,2994,O
the,2994,O
course,2994,O
of,2994,O
the,2994,O
infection,2994,B-Disease
.,2994,O
Early,2995,O
identification,2995,O
",",2995,O
eg,2995,O
by,2995,O
polymerase,2995,O
chain,2995,O
reaction,2995,O
of,2995,O
those,2995,O
patients,2995,O
at,2995,O
risk,2995,O
of,2995,O
disseminated,2995,O
adenovirus,2995,B-Disease
disease,2995,I-Disease
may,2995,O
permit,2995,O
earlier,2995,O
antiviral,2995,O
treatment,2995,O
and,2995,O
better,2995,O
evaluation,2995,O
of,2995,O
therapeutic,2995,O
response,2995,O
.,2995,O
CONCLUSIONS,2996,O
:,2996,O
Two,2996,O
of,2996,O
5,2996,O
children,2996,O
with,2996,O
severe,2996,O
adenovirus,2996,B-Disease
disease,2996,I-Disease
treated,2996,O
with,2996,O
intravenous,2996,O
ribavirin,2996,B-Chemical
recovered,2996,O
.,2996,O
The,2997,O
availability,2997,O
of,2997,O
newer,2997,O
rapid,2997,O
diagnostic,2997,O
techniques,2997,O
",",2997,O
such,2997,O
as,2997,O
polymerase,2997,O
chain,2997,O
reaction,2997,O
",",2997,O
may,2997,O
make,2997,O
earlier,2997,O
",",2997,O
more,2997,O
effective,2997,O
treatment,2997,O
of,2997,O
adenovirus,2997,B-Disease
infection,2997,I-Disease
possible,2997,O
.,2997,O
Given,2998,O
the,2998,O
seriousness,2998,O
and,2998,O
increasing,2998,O
prevalence,2998,O
of,2998,O
adenovirus,2998,B-Disease
disease,2998,I-Disease
in,2998,O
certain,2998,O
hosts,2998,O
",",2998,O
especially,2998,O
children,2998,O
",",2998,O
a,2998,O
large,2998,O
",",2998,O
multicenter,2998,O
clinical,2998,O
trial,2998,O
of,2998,O
potentially,2998,O
useful,2998,O
anti-adenoviral,2998,O
therapies,2998,O
",",2998,O
such,2998,O
as,2998,O
intravenous,2998,O
ribavirin,2998,B-Chemical
",",2998,O
is,2998,O
clearly,2998,O
required,2998,O
to,2998,O
demonstrate,2998,O
the,2998,O
most,2998,O
effective,2998,O
and,2998,O
least,2998,O
toxic,2998,O
therapy,2998,O
.,2998,O
Delayed,2999,O
asystolic,2999,B-Disease
cardiac,2999,B-Disease
arrest,2999,I-Disease
after,2999,O
diltiazem,2999,B-Chemical
overdose,2999,B-Disease
;,2999,O
resuscitation,2999,O
with,2999,O
high,2999,O
dose,2999,O
intravenous,2999,O
calcium,2999,B-Chemical
.,2999,O
A,3000,O
51,3000,O
year,3000,O
old,3000,O
man,3000,O
took,3000,O
a,3000,O
mixed,3000,O
overdose,3000,B-Disease
including,3000,O
1.8-3.6,3000,O
g,3000,O
of,3000,O
diltiazem,3000,B-Chemical
",",3000,O
paracetamol,3000,B-Chemical
",",3000,O
aspirin,3000,B-Chemical
",",3000,O
isosorbide,3000,B-Chemical
nitrate,3000,B-Chemical
",",3000,O
and,3000,O
alcohol,3000,B-Chemical
.,3000,O
He,3001,O
initially,3001,O
presented,3001,O
to,3001,O
hospital,3001,O
after,3001,O
six,3001,O
hours,3001,O
with,3001,O
mild,3001,O
hypotension,3001,B-Disease
and,3001,O
was,3001,O
treated,3001,O
with,3001,O
activated,3001,O
charcoal,3001,O
and,3001,O
intravenous,3001,O
fluids,3001,O
.,3001,O
Eighteen,3002,O
hours,3002,O
after,3002,O
the,3002,O
overdose,3002,B-Disease
he,3002,O
had,3002,O
two,3002,O
generalised,3002,O
tonic-clonic,3002,B-Disease
seizures,3002,I-Disease
.,3002,O
The,3003,O
patient,3003,O
remained,3003,O
unresponsive,3003,O
with,3003,O
junctional,3003,O
bradycardia,3003,B-Disease
",",3003,O
unrecordable,3003,O
blood,3003,O
pressure,3003,O
",",3003,O
and,3003,O
then,3003,O
became,3003,O
asystolic,3003,B-Disease
.,3003,O
He,3004,O
was,3004,O
resuscitated,3004,O
with,3004,O
high,3004,O
dose,3004,O
(,3004,O
13.5,3004,O
g,3004,O
),3004,O
intravenous,3004,O
calcium,3004,B-Chemical
and,3004,O
adrenaline,3004,B-Chemical
(,3004,O
epinephrine,3004,B-Chemical
),3004,O
.,3004,O
He,3005,O
required,3005,O
inotropic,3005,O
support,3005,O
and,3005,O
temporary,3005,O
pacing,3005,O
over,3005,O
the,3005,O
next,3005,O
48,3005,O
hours,3005,O
.,3005,O
This,3006,O
case,3006,O
suggests,3006,O
there,3006,O
is,3006,O
a,3006,O
role,3006,O
for,3006,O
aggressive,3006,O
high,3006,O
dose,3006,O
intravenous,3006,O
calcium,3006,B-Chemical
therapy,3006,O
in,3006,O
severe,3006,O
diltiazem,3006,B-Chemical
overdose,3006,B-Disease
",",3006,O
particularly,3006,O
with,3006,O
the,3006,O
onset,3006,O
of,3006,O
asystole,3006,B-Disease
.,3006,O
It,3007,O
should,3007,O
be,3007,O
considered,3007,O
early,3007,O
in,3007,O
cases,3007,O
of,3007,O
cardiac,3007,B-Disease
arrest,3007,I-Disease
after,3007,O
diltiazem,3007,B-Chemical
overdose,3007,B-Disease
.,3007,O
The,3008,O
case,3008,O
also,3008,O
highlights,3008,O
the,3008,O
problems,3008,O
with,3008,O
delayed,3008,O
toxicity,3008,B-Disease
when,3008,O
whole,3008,O
bowel,3008,O
irrigation,3008,O
is,3008,O
not,3008,O
administered,3008,O
.,3008,O
Low-molecular-weight,3009,B-Chemical
heparin,3009,I-Chemical
for,3009,O
the,3009,O
treatment,3009,O
of,3009,O
patients,3009,O
with,3009,O
mechanical,3009,O
heart,3009,O
valves,3009,O
.,3009,O
BACKGROUND,3010,O
:,3010,O
The,3010,O
interruption,3010,O
of,3010,O
oral,3010,O
anticoagulant,3010,O
(,3010,O
OAC,3010,O
),3010,O
administration,3010,O
is,3010,O
sometimes,3010,O
indicated,3010,O
in,3010,O
patients,3010,O
with,3010,O
mechanical,3010,O
heart,3010,O
valves,3010,O
",",3010,O
mainly,3010,O
before,3010,O
noncardiac,3010,O
surgery,3010,O
",",3010,O
non-surgical,3010,O
interventions,3010,O
",",3010,O
and,3010,O
pregnancy,3010,O
.,3010,O
Unfractionated,3011,B-Chemical
heparin,3011,I-Chemical
(,3011,O
UH,3011,B-Chemical
),3011,O
is,3011,O
currently,3011,O
the,3011,O
substitute,3011,O
for,3011,O
selected,3011,O
patients,3011,O
.,3011,O
Low-molecular-weight,3012,B-Chemical
heparin,3012,I-Chemical
(,3012,O
LMWH,3012,B-Chemical
),3012,O
offers,3012,O
theoretical,3012,O
advantages,3012,O
over,3012,O
UH,3012,B-Chemical
",",3012,O
but,3012,O
is,3012,O
not,3012,O
currently,3012,O
considered,3012,O
in,3012,O
clinical,3012,O
guidelines,3012,O
as,3012,O
an,3012,O
alternative,3012,O
to,3012,O
UH,3012,B-Chemical
in,3012,O
patients,3012,O
with,3012,O
prosthetic,3012,O
valves,3012,O
.,3012,O
HYPOTHESIS,3013,O
:,3013,O
The,3013,O
aim,3013,O
of,3013,O
the,3013,O
present,3013,O
study,3013,O
was,3013,O
to,3013,O
review,3013,O
the,3013,O
data,3013,O
accumulated,3013,O
so,3013,O
far,3013,O
on,3013,O
the,3013,O
use,3013,O
of,3013,O
LMWH,3013,B-Chemical
in,3013,O
this,3013,O
patient,3013,O
population,3013,O
and,3013,O
to,3013,O
discuss,3013,O
its,3013,O
applicability,3013,O
in,3013,O
common,3013,O
practice,3013,O
.,3013,O
METHODS,3014,O
:,3014,O
For,3014,O
this,3014,O
paper,3014,O
",",3014,O
the,3014,O
current,3014,O
medical,3014,O
literature,3014,O
on,3014,O
LMWH,3014,B-Chemical
in,3014,O
patients,3014,O
with,3014,O
mechanical,3014,O
heart,3014,O
valves,3014,O
was,3014,O
extensively,3014,O
reviewed,3014,O
.,3014,O
RESULTS,3015,O
:,3015,O
There,3015,O
were,3015,O
eight,3015,O
series,3015,O
and,3015,O
six,3015,O
case,3015,O
reports,3015,O
.,3015,O
None,3016,O
of,3016,O
the,3016,O
studies,3016,O
was,3016,O
randomized,3016,O
",",3016,O
and,3016,O
only,3016,O
one,3016,O
was,3016,O
prospective,3016,O
.,3016,O
Data,3017,O
to,3017,O
establish,3017,O
the,3017,O
thromboembolic,3017,B-Disease
risk,3017,O
were,3017,O
incomplete,3017,O
.,3017,O
After,3018,O
excluding,3018,O
case,3018,O
reports,3018,O
",",3018,O
the,3018,O
following,3018,O
groups,3018,O
were,3018,O
constructed,3018,O
:,3018,O
(,3018,O
a,3018,O
),3018,O
short-term,3018,O
administration,3018,O
",",3018,O
after,3018,O
valve,3018,O
insertion,3018,O
(,3018,O
n,3018,O
=,3018,O
212,3018,O
),3018,O
;,3018,O
(,3018,O
b,3018,O
),3018,O
short-term,3018,O
",",3018,O
perioperative,3018,O
(,3018,O
noncardiac,3018,O
),3018,O
/periprocedural,3018,O
(,3018,O
n,3018,O
=,3018,O
114,3018,O
),3018,O
;,3018,O
(,3018,O
c,3018,O
),3018,O
long-term,3018,O
",",3018,O
due,3018,O
to,3018,O
intolerance,3018,O
to,3018,O
OAC,3018,O
(,3018,O
n,3018,O
=,3018,O
16,3018,O
),3018,O
;,3018,O
(,3018,O
d,3018,O
),3018,O
long-term,3018,O
",",3018,O
in,3018,O
pregnancy,3018,O
(,3018,O
n,3018,O
=,3018,O
10,3018,O
),3018,O
.,3018,O
The,3019,O
incidence,3019,O
rate,3019,O
of,3019,O
thromboembolism,3019,B-Disease
was,3019,O
0.9,3019,O
%,3019,O
for,3019,O
all,3019,O
the,3019,O
studies,3019,O
and,3019,O
0.5,3019,O
",",3019,O
0,3019,O
",",3019,O
20,3019,O
",",3019,O
and,3019,O
0,3019,O
%,3019,O
in,3019,O
groups,3019,O
a,3019,O
",",3019,O
b,3019,O
",",3019,O
c,3019,O
",",3019,O
and,3019,O
d,3019,O
",",3019,O
respectively,3019,O
;,3019,O
for,3019,O
hemorrhage,3019,B-Disease
",",3019,O
the,3019,O
overall,3019,O
rate,3019,O
was,3019,O
3.4,3019,O
%,3019,O
(,3019,O
3.8,3019,O
",",3019,O
2.6,3019,O
",",3019,O
10,3019,O
",",3019,O
and,3019,O
0,3019,O
%,3019,O
for,3019,O
the,3019,O
respective,3019,O
groups,3019,O
),3019,O
.,3019,O
CONCLUSIONS,3020,O
:,3020,O
In,3020,O
patients,3020,O
with,3020,O
mechanical,3020,O
heart,3020,O
valves,3020,O
",",3020,O
short-term,3020,O
LMWH,3020,B-Chemical
therapy,3020,O
compares,3020,O
favorably,3020,O
with,3020,O
UH,3020,B-Chemical
.,3020,O
Data,3021,O
on,3021,O
mid-,3021,O
and,3021,O
long-term,3021,O
LMWH,3021,B-Chemical
administration,3021,O
in,3021,O
these,3021,O
patients,3021,O
are,3021,O
sparse,3021,O
.,3021,O
Further,3022,O
randomized,3022,O
studies,3022,O
are,3022,O
needed,3022,O
to,3022,O
confirm,3022,O
the,3022,O
safety,3022,O
and,3022,O
precise,3022,O
indications,3022,O
for,3022,O
the,3022,O
use,3022,O
of,3022,O
LMWH,3022,B-Chemical
in,3022,O
patients,3022,O
with,3022,O
mechanical,3022,O
heart,3022,O
valves,3022,O
.,3022,O
Cardiac,3023,B-Disease
arrest,3023,I-Disease
after,3023,O
intravenous,3023,O
metoclopramide,3023,B-Chemical
-,3023,O
a,3023,O
case,3023,O
of,3023,O
five,3023,O
repeated,3023,O
injections,3023,O
of,3023,O
metoclopramide,3023,B-Chemical
causing,3023,O
five,3023,O
episodes,3023,O
of,3023,O
cardiac,3023,B-Disease
arrest,3023,I-Disease
.,3023,O
We,3024,O
describe,3024,O
a,3024,O
patient,3024,O
where,3024,O
intravenous,3024,O
injection,3024,O
of,3024,O
metoclopramide,3024,B-Chemical
was,3024,O
immediately,3024,O
followed,3024,O
by,3024,O
asystole,3024,B-Disease
repeatedly,3024,O
.,3024,O
The,3025,O
patient,3025,O
received,3025,O
metoclopramide,3025,B-Chemical
10,3025,O
mg,3025,O
i.v,3025,O
.,3025,O
five,3026,O
times,3026,O
during,3026,O
48,3026,O
h.,3026,O
After,3026,O
interviewing,3026,O
the,3026,O
attending,3026,O
nurses,3026,O
and,3026,O
reviewing,3026,O
the,3026,O
written,3026,O
documentation,3026,O
",",3026,O
it,3026,O
is,3026,O
clear,3026,O
that,3026,O
every,3026,O
administration,3026,O
of,3026,O
metoclopramide,3026,B-Chemical
was,3026,O
immediately,3026,O
(,3026,O
within,3026,O
s,3026,O
),3026,O
followed,3026,O
by,3026,O
asystole,3026,B-Disease
.,3026,O
The,3027,O
asystole,3027,B-Disease
lasted,3027,O
15-30,3027,O
s,3027,O
on,3027,O
four,3027,O
occasions,3027,O
",",3027,O
on,3027,O
one,3027,O
occasion,3027,O
it,3027,O
lasted,3027,O
2,3027,O
min,3027,O
.,3027,O
The,3028,O
patient,3028,O
received,3028,O
atropine,3028,B-Chemical
0.5-1,3028,O
mg,3028,O
and,3028,O
chest,3028,O
compressions,3028,O
",",3028,O
before,3028,O
sinus,3028,O
rhythm,3028,O
again,3028,O
took,3028,O
over,3028,O
.,3028,O
We,3029,O
interpret,3029,O
this,3029,O
as,3029,O
episodes,3029,O
of,3029,O
cardiac,3029,B-Disease
arrest,3029,I-Disease
caused,3029,O
by,3029,O
metoclopramide,3029,B-Chemical
.,3029,O
The,3030,O
rapid,3030,O
injection,3030,O
via,3030,O
the,3030,O
central,3030,O
venous,3030,O
route,3030,O
and,3030,O
the,3030,O
concomitant,3030,O
tapering,3030,O
of,3030,O
dopamine,3030,B-Chemical
infusion,3030,O
might,3030,O
have,3030,O
contributed,3030,O
in,3030,O
precipitating,3030,O
the,3030,O
adverse,3030,O
drug,3030,O
reaction,3030,O
.,3030,O
Immunohistochemical,3031,O
study,3031,O
on,3031,O
inducible,3031,O
type,3031,O
of,3031,O
nitric,3031,B-Chemical
oxide,3031,I-Chemical
(,3031,O
iNOS,3031,O
),3031,O
",",3031,O
basic,3031,O
fibroblast,3031,O
growth,3031,O
factor,3031,O
(,3031,O
bFGF,3031,O
),3031,O
and,3031,O
tumor,3031,B-Disease
growth,3031,O
factor-beta1,3031,O
(,3031,O
TGF-beta1,3031,O
),3031,O
in,3031,O
arteritis,3031,B-Disease
induced,3031,O
in,3031,O
rats,3031,O
by,3031,O
fenoldopam,3031,B-Chemical
and,3031,O
theophylline,3031,B-Chemical
",",3031,O
vasodilators,3031,O
.,3031,O
Arteritis,3032,B-Disease
induced,3032,O
in,3032,O
rats,3032,O
by,3032,O
vasodilators,3032,O
",",3032,O
fenoldopam,3032,B-Chemical
and,3032,O
theophylline,3032,B-Chemical
",",3032,O
was,3032,O
examined,3032,O
immunohistochemically,3032,O
for,3032,O
expressions,3032,O
of,3032,O
inducible,3032,O
type,3032,O
of,3032,O
nitric,3032,B-Chemical
oxide,3032,I-Chemical
synthase,3032,O
(,3032,O
iNOS,3032,O
),3032,O
",",3032,O
basic,3032,O
fibroblast,3032,O
growth,3032,O
factor,3032,O
(,3032,O
bFGF,3032,O
),3032,O
and,3032,O
tumor,3032,B-Disease
growth,3032,O
factor-beta1,3032,O
(,3032,O
TGF-beta1,3032,O
),3032,O
.,3032,O
Rats,3033,O
were,3033,O
administered,3033,O
fenoldopam,3033,B-Chemical
for,3033,O
24,3033,O
hours,3033,O
by,3033,O
intravenous,3033,O
infusion,3033,O
with,3033,O
or,3033,O
without,3033,O
following,3033,O
repeated,3033,O
daily,3033,O
oral,3033,O
administrations,3033,O
of,3033,O
theophylline,3033,B-Chemical
.,3033,O
Irrespective,3034,O
of,3034,O
theophylline,3034,B-Chemical
administration,3034,O
",",3034,O
iNOS,3034,O
antigens,3034,O
were,3034,O
remarkably,3034,O
abundant,3034,O
in,3034,O
ED-1-positive,3034,O
cells,3034,O
on,3034,O
day,3034,O
5,3034,O
and,3034,O
8,3034,O
post-fenoldopam-infusion,3034,O
(,3034,O
DPI,3034,O
),3034,O
;,3034,O
bFGF,3034,O
antigens,3034,O
were,3034,O
remarkably,3034,O
abundant,3034,O
in,3034,O
ED-1-positive,3034,O
cells,3034,O
on,3034,O
1,3034,O
and,3034,O
3,3034,O
DPI,3034,O
;,3034,O
TGF-beta1,3034,O
antigens,3034,O
were,3034,O
observed,3034,O
in,3034,O
ED-1-positive,3034,O
cells,3034,O
on,3034,O
and,3034,O
after,3034,O
5,3034,O
DPI,3034,O
.,3034,O
These,3035,O
results,3035,O
suggest,3035,O
that,3035,O
the,3035,O
peak,3035,O
expression,3035,O
of,3035,O
iNOS,3035,O
antigen,3035,O
was,3035,O
followed,3035,O
by,3035,O
that,3035,O
of,3035,O
bFGF,3035,O
antigen,3035,O
",",3035,O
and,3035,O
bFGF,3035,O
may,3035,O
have,3035,O
a,3035,O
suppressive,3035,O
effect,3035,O
on,3035,O
iNOS,3035,O
expression,3035,O
in,3035,O
these,3035,O
rat,3035,O
arteritis,3035,B-Disease
models,3035,O
.,3035,O
On,3036,O
the,3036,O
other,3036,O
hand,3036,O
",",3036,O
TGF-beta1,3036,O
was,3036,O
not,3036,O
considered,3036,O
to,3036,O
have,3036,O
a,3036,O
suppressive,3036,O
effect,3036,O
on,3036,O
iNOS,3036,O
expression,3036,O
in,3036,O
these,3036,O
models,3036,O
.,3036,O
The,3037,O
striatum,3037,O
as,3037,O
a,3037,O
target,3037,O
for,3037,O
anti-rigor,3037,O
effects,3037,O
of,3037,O
an,3037,O
antagonist,3037,O
of,3037,O
mGluR1,3037,O
",",3037,O
but,3037,O
not,3037,O
an,3037,O
agonist,3037,O
of,3037,O
group,3037,O
II,3037,O
metabotropic,3037,O
glutamate,3037,B-Chemical
receptors,3037,O
.,3037,O
The,3038,O
aim,3038,O
of,3038,O
the,3038,O
present,3038,O
study,3038,O
was,3038,O
to,3038,O
find,3038,O
out,3038,O
whether,3038,O
the,3038,O
metabotropic,3038,O
receptor,3038,O
1,3038,O
(,3038,O
mGluR1,3038,O
),3038,O
and,3038,O
group,3038,O
II,3038,O
mGluRs,3038,O
",",3038,O
localized,3038,O
in,3038,O
the,3038,O
striatum,3038,O
",",3038,O
are,3038,O
involved,3038,O
in,3038,O
antiparkinsonian-like,3038,O
effects,3038,O
in,3038,O
rats,3038,O
.,3038,O
Haloperidol,3039,B-Chemical
(,3039,O
1,3039,O
mg/kg,3039,O
ip,3039,O
),3039,O
induced,3039,O
parkinsonian-like,3039,B-Disease
muscle,3039,B-Disease
rigidity,3039,I-Disease
",",3039,O
measured,3039,O
as,3039,O
an,3039,O
increased,3039,O
resistance,3039,O
of,3039,O
a,3039,O
rat,3039,O
's,3039,O
hind,3039,O
foot,3039,O
to,3039,O
passive,3039,O
flexion,3039,O
and,3039,O
extension,3039,O
at,3039,O
the,3039,O
ankle,3039,O
joint,3039,O
.,3039,O
(,3040,B-Chemical
RS,3040,I-Chemical
),3040,I-Chemical
"-1-aminoindan-1,5-dicarboxylic",3040,I-Chemical
acid,3040,I-Chemical
(,3040,O
AIDA,3040,B-Chemical
;,3040,O
0.5-15,3040,O
microg/0.5,3040,O
microl,3040,O
),3040,O
",",3040,O
a,3040,O
potent,3040,O
and,3040,O
selective,3040,O
mGluR1,3040,O
antagonist,3040,O
",",3040,O
or,3040,O
(,3040,B-Chemical
"2R,4R",3040,I-Chemical
),3040,I-Chemical
"-4-aminopyrrolidine-2,4-dicarboxylate",3040,I-Chemical
(,3040,O
"2R,4R-APDC",3040,B-Chemical
;,3040,O
7.5-15,3040,O
microg/0.5,3040,O
microl,3040,O
),3040,O
",",3040,O
a,3040,O
selective,3040,O
group,3040,O
II,3040,O
agonist,3040,O
",",3040,O
was,3040,O
injected,3040,O
bilaterally,3040,O
into,3040,O
the,3040,O
striatum,3040,O
of,3040,O
haloperidol-treated,3040,B-Chemical
animals,3040,O
.,3040,O
AIDA,3041,B-Chemical
in,3041,O
doses,3041,O
of,3041,O
7.5-15,3041,O
microg/0.5,3041,O
microl,3041,O
diminished,3041,O
the,3041,O
haloperidol-induced,3041,B-Chemical
muscle,3041,B-Disease
rigidity,3041,I-Disease
.,3041,O
In,3042,O
contrast,3042,O
",",3042,O
"2R,4R-APDC",3042,B-Chemical
injections,3042,O
were,3042,O
ineffective,3042,O
.,3042,O
The,3043,O
present,3043,O
results,3043,O
may,3043,O
suggest,3043,O
that,3043,O
the,3043,O
blockade,3043,O
of,3043,O
striatal,3043,O
mGluR1,3043,O
",",3043,O
but,3043,O
not,3043,O
the,3043,O
stimulation,3043,O
of,3043,O
group,3043,O
II,3043,O
mGluRs,3043,O
",",3043,O
may,3043,O
ameliorate,3043,O
parkinsonian,3043,B-Disease
muscle,3043,B-Disease
rigidity,3043,I-Disease
.,3043,O
A,3044,O
phase,3044,O
II,3044,O
study,3044,O
of,3044,O
thalidomide,3044,B-Chemical
in,3044,O
advanced,3044,O
metastatic,3044,O
renal,3044,B-Disease
cell,3044,I-Disease
carcinoma,3044,I-Disease
.,3044,O
OBJECTIVES,3045,O
:,3045,O
To,3045,O
evaluate,3045,O
the,3045,O
toxicity,3045,B-Disease
and,3045,O
activity,3045,O
of,3045,O
thalidomide,3045,B-Chemical
in,3045,O
patients,3045,O
with,3045,O
advanced,3045,O
metastatic,3045,O
renal,3045,B-Disease
cell,3045,I-Disease
cancer,3045,I-Disease
and,3045,O
to,3045,O
measure,3045,O
changes,3045,O
of,3045,O
one,3045,O
angiogenic,3045,O
factor,3045,O
",",3045,O
vascular,3045,O
endothelial,3045,O
growth,3045,O
factor,3045,O
(,3045,O
VEGF,3045,O
),3045,O
165,3045,O
",",3045,O
with,3045,O
therapy,3045,O
.,3045,O
PATIENTS,3046,O
AND,3046,O
METHODS,3046,O
:,3046,O
29,3046,O
patients,3046,O
were,3046,O
enrolled,3046,O
on,3046,O
a,3046,O
study,3046,O
of,3046,O
thalidomide,3046,B-Chemical
using,3046,O
an,3046,O
intra-patient,3046,O
dose,3046,O
escalation,3046,O
schedule,3046,O
.,3046,O
Patients,3047,O
began,3047,O
thalidomide,3047,B-Chemical
at,3047,O
400,3047,O
mg/d,3047,O
and,3047,O
escalated,3047,O
as,3047,O
tolerated,3047,O
to,3047,O
1200,3047,O
mg/d,3047,O
by,3047,O
day,3047,O
54,3047,O
.,3047,O
Fifty-nine,3048,O
per,3048,O
cent,3048,O
of,3048,O
patients,3048,O
had,3048,O
had,3048,O
previous,3048,O
therapy,3048,O
with,3048,O
IL-2,3048,O
and,3048,O
52,3048,O
%,3048,O
were,3048,O
performance,3048,O
status,3048,O
2,3048,O
or,3048,O
3,3048,O
.,3048,O
Systemic,3049,O
plasma,3049,O
VEGF165,3049,O
levels,3049,O
were,3049,O
measured,3049,O
by,3049,O
dual,3049,O
monoclonal,3049,O
ELISA,3049,O
in,3049,O
8,3049,O
patients,3049,O
.,3049,O
RESULTS,3050,O
:,3050,O
24,3050,O
patients,3050,O
were,3050,O
evaluable,3050,O
for,3050,O
response,3050,O
with,3050,O
one,3050,O
partial,3050,O
response,3050,O
of,3050,O
11,3050,O
months,3050,O
duration,3050,O
of,3050,O
a,3050,O
patient,3050,O
with,3050,O
hepatic,3050,O
and,3050,O
pulmonary,3050,O
metastases,3050,B-Disease
(,3050,O
4,3050,O
%,3050,O
),3050,O
",",3050,O
one,3050,O
minor,3050,O
response,3050,O
",",3050,O
and,3050,O
2,3050,O
patients,3050,O
stable,3050,O
for,3050,O
over,3050,O
6,3050,O
months,3050,O
.,3050,O
Somnolence,3051,B-Disease
and,3051,O
constipation,3051,B-Disease
were,3051,O
prominent,3051,O
toxicities,3051,B-Disease
and,3051,O
most,3051,O
patients,3051,O
could,3051,O
not,3051,O
tolerate,3051,O
the,3051,O
1200,3051,O
mg/day,3051,O
dose,3051,O
level,3051,O
.,3051,O
Systemic,3052,O
plasma,3052,O
VEGF165,3052,O
levels,3052,O
did,3052,O
not,3052,O
change,3052,O
with,3052,O
therapy,3052,O
.,3052,O
CONCLUSION,3053,O
:,3053,O
These,3053,O
results,3053,O
are,3053,O
consistent,3053,O
with,3053,O
a,3053,O
low,3053,O
level,3053,O
of,3053,O
activity,3053,O
of,3053,O
thalidomide,3053,B-Chemical
in,3053,O
renal,3053,B-Disease
cell,3053,I-Disease
carcinoma,3053,I-Disease
.,3053,O
Administration,3054,O
of,3054,O
doses,3054,O
over,3054,O
800,3054,O
mg/day,3054,O
was,3054,O
difficult,3054,O
to,3054,O
achieve,3054,O
in,3054,O
this,3054,O
patient,3054,O
population,3054,O
",",3054,O
however,3054,O
lower,3054,O
doses,3054,O
were,3054,O
practical,3054,O
.,3054,O
The,3055,O
dose-response,3055,O
relationship,3055,O
",",3055,O
if,3055,O
any,3055,O
",",3055,O
of,3055,O
thalidomide,3055,B-Chemical
for,3055,O
renal,3055,B-Disease
cell,3055,I-Disease
carcinoma,3055,I-Disease
is,3055,O
unclear,3055,O
.,3055,O
Can,3056,O
lidocaine,3056,B-Chemical
reduce,3056,O
succinylcholine,3056,B-Chemical
induced,3056,O
postoperative,3056,B-Disease
myalgia,3056,I-Disease
?,3056,O
This,3057,O
study,3057,O
was,3057,O
undertaken,3057,O
to,3057,O
determine,3057,O
the,3057,O
effect,3057,O
of,3057,O
lidocaine,3057,B-Chemical
pretreatment,3057,O
on,3057,O
reduction,3057,O
of,3057,O
succinylcholine-induced,3057,B-Chemical
myalgia,3057,B-Disease
in,3057,O
patients,3057,O
undergoing,3057,O
general,3057,O
anesthesia,3057,O
for,3057,O
gynecological,3057,O
surgery,3057,O
.,3057,O
One,3058,O
hundred,3058,O
and,3058,O
thirty-five,3058,O
patients,3058,O
were,3058,O
assigned,3058,O
to,3058,O
one,3058,O
of,3058,O
three,3058,O
groups,3058,O
in,3058,O
a,3058,O
prospective,3058,O
",",3058,O
double,3058,O
blind,3058,O
",",3058,O
randomized,3058,O
manner,3058,O
.,3058,O
Group,3059,O
PS,3059,O
",",3059,O
the,3059,O
control,3059,O
group,3059,O
",",3059,O
received,3059,O
normal,3059,O
saline,3059,O
and,3059,O
succinylcholine,3059,B-Chemical
1.5,3059,O
mg,3059,O
x,3059,O
kg,3059,O
(,3059,O
-1,3059,O
),3059,O
;,3059,O
Group,3059,O
LS,3059,O
",",3059,O
lidocaine,3059,B-Chemical
1.5,3059,O
mg,3059,O
x,3059,O
kg,3059,O
(,3059,O
-1,3059,O
),3059,O
and,3059,O
succinylcholine,3059,B-Chemical
1.5,3059,O
mg,3059,O
x,3059,O
kg,3059,O
(,3059,O
-1,3059,O
),3059,O
;,3059,O
Group,3059,O
PR,3059,O
",",3059,O
normal,3059,O
saline,3059,O
and,3059,O
rocuronium,3059,B-Chemical
0.6,3059,O
mg,3059,O
x,3059,O
kg,3059,O
(,3059,O
-1,3059,O
),3059,O
.,3059,O
Morphine,3060,B-Chemical
0.1,3060,O
mg,3060,O
x,3060,O
kg,3060,O
(,3060,O
-1,3060,O
),3060,O
iv,3060,O
was,3060,O
given,3060,O
for,3060,O
premedication,3060,O
and,3060,O
all,3060,O
patients,3060,O
were,3060,O
monitored,3060,O
with,3060,O
a,3060,O
noninvasive,3060,O
blood,3060,O
pressure,3060,O
monitor,3060,O
",",3060,O
ECG,3060,O
and,3060,O
pulse,3060,O
oximetry,3060,O
.,3060,O
Anesthesia,3061,O
was,3061,O
induced,3061,O
with,3061,O
5,3061,O
mg.kg,3061,O
(,3061,O
-1,3061,O
),3061,O
thiopental,3061,B-Chemical
iv,3061,O
.,3061,O
followed,3062,O
by,3062,O
succinylcholine,3062,B-Chemical
(,3062,O
Group,3062,O
PS,3062,O
",",3062,O
LS,3062,O
),3062,O
or,3062,O
rocuronium,3062,B-Chemical
(,3062,O
Group,3062,O
PR,3062,O
),3062,O
for,3062,O
tracheal,3062,O
intubation,3062,O
.,3062,O
Following,3063,O
administration,3063,O
of,3063,O
these,3063,O
agents,3063,O
",",3063,O
the,3063,O
presence,3063,O
",",3063,O
and,3063,O
degree,3063,O
of,3063,O
fasciculation,3063,B-Disease
were,3063,O
assessed,3063,O
visually,3063,O
on,3063,O
a,3063,O
four,3063,O
point,3063,O
scale,3063,O
by,3063,O
one,3063,O
investigator,3063,O
who,3063,O
was,3063,O
blinded,3063,O
to,3063,O
the,3063,O
drug,3063,O
administered,3063,O
.,3063,O
The,3064,O
blood,3064,O
pressure,3064,O
and,3064,O
heart,3064,O
rate,3064,O
of,3064,O
each,3064,O
patient,3064,O
were,3064,O
monitored,3064,O
on,3064,O
nine,3064,O
occasions,3064,O
.,3064,O
Twenty-four,3065,O
hours,3065,O
later,3065,O
",",3065,O
any,3065,O
myalgia,3065,B-Disease
experienced,3065,O
was,3065,O
assessed,3065,O
according,3065,O
to,3065,O
a,3065,O
structured,3065,O
questionaire,3065,O
and,3065,O
graded,3065,O
by,3065,O
a,3065,O
four,3065,O
point,3065,O
scale,3065,O
by,3065,O
one,3065,O
investigator,3065,O
blinded,3065,O
to,3065,O
the,3065,O
intraoperative,3065,O
management,3065,O
.,3065,O
The,3066,O
results,3066,O
indicate,3066,O
that,3066,O
muscle,3066,B-Disease
fasciculation,3066,I-Disease
was,3066,O
not,3066,O
found,3066,O
in,3066,O
Group,3066,O
PR,3066,O
while,3066,O
the,3066,O
patients,3066,O
in,3066,O
Group,3066,O
LS,3066,O
had,3066,O
a,3066,O
lower,3066,O
incidence,3066,O
of,3066,O
muscle,3066,B-Disease
fasciculation,3066,I-Disease
than,3066,O
those,3066,O
in,3066,O
Group,3066,O
PS,3066,O
(,3066,O
p,3066,O
<,3066,O
0.001,3066,O
),3066,O
.,3066,O
At,3067,O
24,3067,O
h,3067,O
",",3067,O
the,3067,O
incidence,3067,O
of,3067,O
myalgia,3067,B-Disease
was,3067,O
higher,3067,O
in,3067,O
Group,3067,O
PS,3067,O
than,3067,O
in,3067,O
Group,3067,O
LS,3067,O
and,3067,O
PR,3067,O
(,3067,O
p,3067,O
<,3067,O
0.05,3067,O
),3067,O
.,3067,O
A,3068,O
correlation,3068,O
was,3068,O
not,3068,O
found,3068,O
between,3068,O
the,3068,O
incidence,3068,O
of,3068,O
myalgia,3068,B-Disease
and,3068,O
the,3068,O
occurrence,3068,O
of,3068,O
muscle,3068,B-Disease
fasciculation,3068,I-Disease
.,3068,O
The,3069,O
changes,3069,O
in,3069,O
systolic,3069,O
and,3069,O
diastolic,3069,O
blood,3069,O
pressure,3069,O
and,3069,O
heart,3069,O
rate,3069,O
were,3069,O
not,3069,O
significant,3069,O
among,3069,O
the,3069,O
three,3069,O
groups,3069,O
.,3069,O
In,3070,O
conclusion,3070,O
",",3070,O
where,3070,O
succinylcholine,3070,B-Chemical
is,3070,O
used,3070,O
",",3070,O
lidocaine,3070,B-Chemical
is,3070,O
proven,3070,O
to,3070,O
be,3070,O
the,3070,O
useful,3070,O
pretreatment,3070,O
agent,3070,O
for,3070,O
the,3070,O
reduction,3070,O
of,3070,O
postoperative,3070,B-Disease
myalgia,3070,I-Disease
.,3070,O
Reduced,3071,O
sodium,3071,B-Chemical
channel,3071,O
density,3071,O
",",3071,O
altered,3071,O
voltage,3071,O
dependence,3071,O
of,3071,O
inactivation,3071,O
",",3071,O
and,3071,O
increased,3071,O
susceptibility,3071,O
to,3071,O
seizures,3071,B-Disease
in,3071,O
mice,3071,O
lacking,3071,O
sodium,3071,B-Chemical
channel,3071,O
beta,3071,O
2-subunits,3071,O
.,3071,O
Sodium,3072,B-Chemical
channel,3072,O
beta-subunits,3072,O
modulate,3072,O
channel,3072,O
gating,3072,O
",",3072,O
assembly,3072,O
",",3072,O
and,3072,O
cell,3072,O
surface,3072,O
expression,3072,O
in,3072,O
heterologous,3072,O
cell,3072,O
systems,3072,O
.,3072,O
We,3073,O
generated,3073,O
beta2,3073,O
(,3073,O
-/-,3073,O
),3073,O
mice,3073,O
to,3073,O
investigate,3073,O
the,3073,O
role,3073,O
of,3073,O
beta2,3073,O
in,3073,O
control,3073,O
of,3073,O
sodium,3073,B-Chemical
channel,3073,O
density,3073,O
",",3073,O
localization,3073,O
",",3073,O
and,3073,O
function,3073,O
in,3073,O
neurons,3073,O
in,3073,O
vivo,3073,O
.,3073,O
Measurements,3074,O
of,3074,O
[,3074,O
(,3074,O
3,3074,O
),3074,O
H,3074,O
],3074,O
saxitoxin,3074,B-Chemical
(,3074,O
STX,3074,B-Chemical
),3074,O
binding,3074,O
showed,3074,O
a,3074,O
significant,3074,O
reduction,3074,O
in,3074,O
the,3074,O
level,3074,O
of,3074,O
plasma,3074,O
membrane,3074,O
sodium,3074,B-Chemical
channels,3074,O
in,3074,O
beta2,3074,O
(,3074,O
-/-,3074,O
),3074,O
neurons,3074,O
.,3074,O
The,3075,O
loss,3075,O
of,3075,O
beta2,3075,O
resulted,3075,O
in,3075,O
negative,3075,O
shifts,3075,O
in,3075,O
the,3075,O
voltage,3075,O
dependence,3075,O
of,3075,O
inactivation,3075,O
as,3075,O
well,3075,O
as,3075,O
significant,3075,O
decreases,3075,O
in,3075,O
sodium,3075,B-Chemical
current,3075,O
density,3075,O
in,3075,O
acutely,3075,O
dissociated,3075,O
hippocampal,3075,O
neurons,3075,O
.,3075,O
The,3076,O
integral,3076,O
of,3076,O
the,3076,O
compound,3076,O
action,3076,O
potential,3076,O
in,3076,O
optic,3076,O
nerve,3076,O
was,3076,O
significantly,3076,O
reduced,3076,O
",",3076,O
and,3076,O
the,3076,O
threshold,3076,O
for,3076,O
action,3076,O
potential,3076,O
generation,3076,O
was,3076,O
increased,3076,O
",",3076,O
indicating,3076,O
a,3076,O
reduction,3076,O
in,3076,O
the,3076,O
level,3076,O
of,3076,O
functional,3076,O
plasma,3076,O
membrane,3076,O
sodium,3076,B-Chemical
channels,3076,O
.,3076,O
In,3077,O
contrast,3077,O
",",3077,O
the,3077,O
conduction,3077,O
velocity,3077,O
",",3077,O
the,3077,O
number,3077,O
and,3077,O
size,3077,O
of,3077,O
axons,3077,O
in,3077,O
the,3077,O
optic,3077,O
nerve,3077,O
",",3077,O
and,3077,O
the,3077,O
specific,3077,O
localization,3077,O
of,3077,O
Na,3077,B-Chemical
(,3077,O
v,3077,O
),3077,O
1.6,3077,O
channels,3077,O
in,3077,O
the,3077,O
nodes,3077,O
of,3077,O
Ranvier,3077,O
were,3077,O
unchanged,3077,O
.,3077,O
beta2,3078,O
(,3078,O
-/-,3078,O
),3078,O
mice,3078,O
displayed,3078,O
increased,3078,O
susceptibility,3078,O
to,3078,O
seizures,3078,B-Disease
",",3078,O
as,3078,O
indicated,3078,O
by,3078,O
reduced,3078,O
latency,3078,O
and,3078,O
threshold,3078,O
for,3078,O
pilocarpine-induced,3078,B-Chemical
seizures,3078,B-Disease
",",3078,O
but,3078,O
seemed,3078,O
normal,3078,O
in,3078,O
other,3078,O
neurological,3078,O
tests,3078,O
.,3078,O
Our,3079,O
observations,3079,O
show,3079,O
that,3079,O
beta2-subunits,3079,O
play,3079,O
an,3079,O
important,3079,O
role,3079,O
in,3079,O
the,3079,O
regulation,3079,O
of,3079,O
sodium,3079,B-Chemical
channel,3079,O
density,3079,O
and,3079,O
function,3079,O
in,3079,O
neurons,3079,O
in,3079,O
vivo,3079,O
and,3079,O
are,3079,O
required,3079,O
for,3079,O
normal,3079,O
action,3079,O
potential,3079,O
generation,3079,O
and,3079,O
control,3079,O
of,3079,O
excitability,3079,O
.,3079,O
Acute,3080,B-Disease
liver,3080,I-Disease
failure,3080,I-Disease
with,3080,O
concurrent,3080,O
bupropion,3080,B-Chemical
and,3080,O
carbimazole,3080,B-Chemical
therapy,3080,O
.,3080,O
OBJECTIVE,3081,O
:,3081,O
To,3081,O
report,3081,O
a,3081,O
case,3081,O
of,3081,O
fatal,3081,O
liver,3081,B-Disease
failure,3081,I-Disease
possibly,3081,O
associated,3081,O
with,3081,O
concurrent,3081,O
use,3081,O
of,3081,O
bupropion,3081,B-Chemical
and,3081,O
carbimazole,3081,B-Chemical
.,3081,O
CASE,3082,O
SUMMARY,3082,O
:,3082,O
A,3082,O
41-year-old,3082,O
Chinese,3082,O
man,3082,O
with,3082,O
a,3082,O
history,3082,O
of,3082,O
hyperthyroidism,3082,B-Disease
had,3082,O
been,3082,O
treated,3082,O
with,3082,O
carbimazole,3082,B-Chemical
and,3082,O
propranolol,3082,B-Chemical
for,3082,O
the,3082,O
past,3082,O
5,3082,O
years,3082,O
.,3082,O
He,3083,O
received,3083,O
a,3083,O
10-day,3083,O
course,3083,O
of,3083,O
bupropion,3083,B-Chemical
as,3083,O
an,3083,O
aid,3083,O
for,3083,O
smoking,3083,O
cessation,3083,O
10,3083,O
weeks,3083,O
prior,3083,O
to,3083,O
presentation,3083,O
.,3083,O
He,3084,O
developed,3084,O
acute,3084,B-Disease
liver,3084,I-Disease
failure,3084,I-Disease
with,3084,O
rapid,3084,O
deterioration,3084,O
of,3084,O
renal,3084,O
function,3084,O
.,3084,O
Liver,3085,O
biopsy,3085,O
showed,3085,O
evidence,3085,O
of,3085,O
nonspecific,3085,O
drug-induced,3085,B-Disease
acute,3085,I-Disease
liver,3085,I-Disease
injury,3085,I-Disease
.,3085,O
His,3086,O
condition,3086,O
was,3086,O
further,3086,O
complicated,3086,O
by,3086,O
sepsis,3086,B-Disease
and,3086,O
coagulopathy,3086,B-Disease
.,3086,O
Death,3087,O
resulted,3087,O
19,3087,O
days,3087,O
after,3087,O
the,3087,O
onset,3087,O
of,3087,O
symptoms,3087,O
.,3087,O
The,3088,O
likelihood,3088,O
that,3088,O
bupropion,3088,B-Chemical
induced,3088,O
hepatotoxicity,3088,B-Disease
in,3088,O
our,3088,O
patient,3088,O
was,3088,O
possible,3088,O
",",3088,O
based,3088,O
on,3088,O
the,3088,O
Naranjo,3088,O
probability,3088,O
scale,3088,O
.,3088,O
DISCUSSION,3089,O
:,3089,O
Although,3089,O
there,3089,O
is,3089,O
increasing,3089,O
evidence,3089,O
of,3089,O
hepatotoxicity,3089,B-Disease
induced,3089,O
by,3089,O
bupropion,3089,B-Chemical
",",3089,O
this,3089,O
is,3089,O
the,3089,O
first,3089,O
case,3089,O
of,3089,O
fatality,3089,O
that,3089,O
could,3089,O
have,3089,O
resulted,3089,O
from,3089,O
acute,3089,B-Disease
liver,3089,I-Disease
failure,3089,I-Disease
in,3089,O
a,3089,O
patient,3089,O
receiving,3089,O
bupropion,3089,B-Chemical
while,3089,O
on,3089,O
concomitant,3089,O
treatment,3089,O
with,3089,O
carbimazole,3089,B-Chemical
.,3089,O
CONCLUSIONS,3090,O
:,3090,O
Clinicians,3090,O
should,3090,O
be,3090,O
aware,3090,O
of,3090,O
the,3090,O
possibility,3090,O
of,3090,O
acute,3090,B-Disease
liver,3090,I-Disease
insult,3090,I-Disease
induced,3090,O
by,3090,O
bupropion,3090,B-Chemical
given,3090,O
concurrently,3090,O
with,3090,O
other,3090,O
hepatotoxic,3090,B-Disease
drugs,3090,O
.,3090,O
Nephrotoxic,3091,B-Disease
effects,3091,O
in,3091,O
high-risk,3091,O
patients,3091,O
undergoing,3091,O
angiography,3091,O
.,3091,O
BACKGROUND,3092,O
:,3092,O
The,3092,O
use,3092,O
of,3092,O
iodinated,3092,O
contrast,3092,O
medium,3092,O
can,3092,O
result,3092,O
in,3092,O
nephropathy,3092,B-Disease
.,3092,O
Whether,3093,O
iso-osmolar,3093,O
contrast,3093,O
medium,3093,O
is,3093,O
less,3093,O
nephrotoxic,3093,B-Disease
than,3093,O
low-osmolar,3093,O
contrast,3093,O
medium,3093,O
in,3093,O
high-risk,3093,O
patients,3093,O
is,3093,O
uncertain,3093,O
.,3093,O
METHODS,3094,O
:,3094,O
We,3094,O
conducted,3094,O
a,3094,O
randomized,3094,O
",",3094,O
double-blind,3094,O
",",3094,O
prospective,3094,O
",",3094,O
multicenter,3094,O
study,3094,O
comparing,3094,O
the,3094,O
nephrotoxic,3094,B-Disease
effects,3094,O
of,3094,O
an,3094,O
iso-osmolar,3094,O
",",3094,O
dimeric,3094,O
",",3094,O
nonionic,3094,O
contrast,3094,O
medium,3094,O
",",3094,O
iodixanol,3094,B-Chemical
",",3094,O
with,3094,O
those,3094,O
of,3094,O
a,3094,O
low-osmolar,3094,O
",",3094,O
nonionic,3094,O
",",3094,O
monomeric,3094,O
contrast,3094,O
medium,3094,O
",",3094,O
iohexol,3094,B-Chemical
.,3094,O
The,3095,O
study,3095,O
involved,3095,O
129,3095,O
patients,3095,O
with,3095,O
diabetes,3095,B-Disease
with,3095,O
serum,3095,O
creatinine,3095,B-Chemical
concentrations,3095,O
of,3095,O
1.5,3095,O
to,3095,O
3.5,3095,O
mg,3095,O
per,3095,O
deciliter,3095,O
who,3095,O
underwent,3095,O
coronary,3095,O
or,3095,O
aortofemoral,3095,O
angiography,3095,O
.,3095,O
The,3096,O
primary,3096,O
end,3096,O
point,3096,O
was,3096,O
the,3096,O
peak,3096,O
increase,3096,O
from,3096,O
base,3096,O
line,3096,O
in,3096,O
the,3096,O
creatinine,3096,B-Chemical
concentration,3096,O
during,3096,O
the,3096,O
three,3096,O
days,3096,O
after,3096,O
angiography,3096,O
.,3096,O
Other,3097,O
end,3097,O
points,3097,O
were,3097,O
an,3097,O
increase,3097,O
in,3097,O
the,3097,O
creatinine,3097,B-Chemical
concentration,3097,O
of,3097,O
0.5,3097,O
mg,3097,O
per,3097,O
deciliter,3097,O
or,3097,O
more,3097,O
",",3097,O
an,3097,O
increase,3097,O
of,3097,O
1.0,3097,O
mg,3097,O
per,3097,O
deciliter,3097,O
or,3097,O
more,3097,O
",",3097,O
and,3097,O
a,3097,O
change,3097,O
in,3097,O
the,3097,O
creatinine,3097,B-Chemical
concentration,3097,O
from,3097,O
day,3097,O
0,3097,O
to,3097,O
day,3097,O
7,3097,O
.,3097,O
RESULTS,3098,O
:,3098,O
The,3098,O
creatinine,3098,B-Chemical
concentration,3098,O
increased,3098,O
significantly,3098,O
less,3098,O
in,3098,O
patients,3098,O
who,3098,O
received,3098,O
iodixanol,3098,B-Chemical
.,3098,O
From,3099,O
day,3099,O
0,3099,O
to,3099,O
day,3099,O
3,3099,O
",",3099,O
the,3099,O
mean,3099,O
peak,3099,O
increase,3099,O
in,3099,O
creatinine,3099,B-Chemical
was,3099,O
0.13,3099,O
mg,3099,O
per,3099,O
deciliter,3099,O
in,3099,O
the,3099,O
iodixanol,3099,B-Chemical
group,3099,O
and,3099,O
0.55,3099,O
mg,3099,O
per,3099,O
deciliter,3099,O
in,3099,O
the,3099,O
iohexol,3099,B-Chemical
group,3099,O
(,3099,O
P=0.001,3099,O
;,3099,O
the,3099,O
increase,3099,O
with,3099,O
iodixanol,3099,B-Chemical
minus,3099,O
the,3099,O
increase,3099,O
with,3099,O
iohexol,3099,B-Chemical
",",3099,O
-0.42,3099,O
mg,3099,O
per,3099,O
deciliter,3099,O
[,3099,O
95,3099,O
percent,3099,O
confidence,3099,O
interval,3099,O
",",3099,O
-0.73,3099,O
to,3099,O
-0.22,3099,O
],3099,O
),3099,O
.,3099,O
Two,3100,O
of,3100,O
the,3100,O
64,3100,O
patients,3100,O
in,3100,O
the,3100,O
iodixanol,3100,B-Chemical
group,3100,O
(,3100,O
3,3100,O
percent,3100,O
),3100,O
had,3100,O
an,3100,O
increase,3100,O
in,3100,O
the,3100,O
creatinine,3100,B-Chemical
concentration,3100,O
of,3100,O
0.5,3100,O
mg,3100,O
per,3100,O
deciliter,3100,O
or,3100,O
more,3100,O
",",3100,O
as,3100,O
compared,3100,O
with,3100,O
17,3100,O
of,3100,O
the,3100,O
65,3100,O
patients,3100,O
in,3100,O
the,3100,O
iohexol,3100,B-Chemical
group,3100,O
(,3100,O
26,3100,O
percent,3100,O
),3100,O
(,3100,O
P=0.002,3100,O
;,3100,O
odds,3100,O
ratio,3100,O
for,3100,O
such,3100,O
an,3100,O
increase,3100,O
in,3100,O
the,3100,O
iodixanol,3100,B-Chemical
group,3100,O
",",3100,O
0.09,3100,O
[,3100,O
95,3100,O
percent,3100,O
confidence,3100,O
interval,3100,O
",",3100,O
0.02,3100,O
to,3100,O
0.41,3100,O
],3100,O
),3100,O
.,3100,O
No,3101,O
patient,3101,O
receiving,3101,O
iodixanol,3101,B-Chemical
had,3101,O
an,3101,O
increase,3101,O
of,3101,O
1.0,3101,O
mg,3101,O
per,3101,O
deciliter,3101,O
or,3101,O
more,3101,O
",",3101,O
but,3101,O
10,3101,O
patients,3101,O
in,3101,O
the,3101,O
iohexol,3101,B-Chemical
group,3101,O
(,3101,O
15,3101,O
percent,3101,O
),3101,O
did,3101,O
.,3101,O
The,3102,O
mean,3102,O
change,3102,O
in,3102,O
the,3102,O
creatinine,3102,B-Chemical
concentration,3102,O
from,3102,O
day,3102,O
0,3102,O
to,3102,O
day,3102,O
7,3102,O
was,3102,O
0.07,3102,O
mg,3102,O
per,3102,O
deciliter,3102,O
in,3102,O
the,3102,O
iodixanol,3102,B-Chemical
group,3102,O
and,3102,O
0.24,3102,O
mg,3102,O
per,3102,O
deciliter,3102,O
in,3102,O
the,3102,O
iohexol,3102,B-Chemical
group,3102,O
(,3102,O
P=0.003,3102,O
;,3102,O
value,3102,O
in,3102,O
the,3102,O
iodixanol,3102,B-Chemical
group,3102,O
minus,3102,O
the,3102,O
value,3102,O
in,3102,O
the,3102,O
iohexol,3102,B-Chemical
group,3102,O
",",3102,O
-0.17,3102,O
mg,3102,O
per,3102,O
deciliter,3102,O
[,3102,O
95,3102,O
percent,3102,O
confidence,3102,O
interval,3102,O
",",3102,O
-0.34,3102,O
to,3102,O
-0.07,3102,O
],3102,O
),3102,O
.,3102,O
CONCLUSIONS,3103,O
:,3103,O
Nephropathy,3103,B-Disease
induced,3103,O
by,3103,O
contrast,3103,O
medium,3103,O
may,3103,O
be,3103,O
less,3103,O
likely,3103,O
to,3103,O
develop,3103,O
in,3103,O
high-risk,3103,O
patients,3103,O
when,3103,O
iodixanol,3103,B-Chemical
is,3103,O
used,3103,O
rather,3103,O
than,3103,O
a,3103,O
low-osmolar,3103,O
",",3103,O
nonionic,3103,O
contrast,3103,O
medium,3103,O
.,3103,O
Protective,3104,O
effect,3104,O
of,3104,O
edaravone,3104,B-Chemical
against,3104,O
streptomycin-induced,3104,B-Chemical
vestibulotoxicity,3104,B-Disease
in,3104,O
the,3104,O
guinea,3104,O
pig,3104,O
.,3104,O
This,3105,O
study,3105,O
investigated,3105,O
alleviation,3105,O
of,3105,O
streptomycin-induced,3105,B-Chemical
vestibulotoxicity,3105,B-Disease
by,3105,O
edaravone,3105,B-Chemical
in,3105,O
guinea,3105,O
pigs,3105,O
.,3105,O
Edaravone,3106,B-Chemical
",",3106,O
a,3106,O
free,3106,O
radical,3106,O
scavenger,3106,O
",",3106,O
has,3106,O
potent,3106,O
free,3106,O
radical,3106,O
quenching,3106,O
action,3106,O
and,3106,O
is,3106,O
used,3106,O
in,3106,O
clinical,3106,O
practice,3106,O
to,3106,O
treat,3106,O
cerebral,3106,B-Disease
infarction,3106,I-Disease
.,3106,O
Streptomycin,3107,B-Chemical
was,3107,O
administered,3107,O
to,3107,O
the,3107,O
inner,3107,O
ear,3107,O
by,3107,O
osmotic,3107,O
pump,3107,O
for,3107,O
24,3107,O
h,3107,O
",",3107,O
and,3107,O
edaravone,3107,B-Chemical
(,3107,O
n=8,3107,O
),3107,O
or,3107,O
saline,3107,O
(,3107,O
n=6,3107,O
),3107,O
was,3107,O
intraperitoneally,3107,O
injected,3107,O
once,3107,O
a,3107,O
day,3107,O
for,3107,O
7,3107,O
days,3107,O
.,3107,O
We,3108,O
observed,3108,O
horizontal,3108,O
vestibulo-ocular,3108,O
reflex,3108,O
as,3108,O
a,3108,O
marker,3108,O
of,3108,O
postoperative,3108,O
vestibular,3108,O
function,3108,O
.,3108,O
Animals,3109,O
injected,3109,O
with,3109,O
saline,3109,O
showed,3109,O
statistically,3109,O
smaller,3109,O
gains,3109,O
than,3109,O
those,3109,O
injected,3109,O
with,3109,O
edaravone,3109,B-Chemical
.,3109,O
These,3110,O
results,3110,O
suggest,3110,O
that,3110,O
edaravone,3110,B-Chemical
suppresses,3110,O
streptomycin-induced,3110,B-Chemical
vestibulotoxicity,3110,B-Disease
.,3110,O
Levodopa-induced,3111,B-Chemical
oromandibular,3111,O
dystonia,3111,B-Disease
in,3111,O
progressive,3111,B-Disease
supranuclear,3111,I-Disease
palsy,3111,I-Disease
.,3111,O
Levodopa-induced,3112,B-Chemical
dyskinesias,3112,B-Disease
have,3112,O
been,3112,O
reported,3112,O
in,3112,O
Parkinson,3112,B-Disease
's,3112,I-Disease
disease,3112,I-Disease
and,3112,O
multiple,3112,B-Disease
system,3112,I-Disease
atrophy,3112,I-Disease
.,3112,O
Cranial,3113,O
dystonias,3113,B-Disease
are,3113,O
rare,3113,O
in,3113,O
patients,3113,O
with,3113,O
progressive,3113,B-Disease
supranuclear,3113,I-Disease
palsy,3113,I-Disease
(,3113,O
PSP,3113,B-Disease
),3113,O
.,3113,O
In,3114,O
this,3114,O
report,3114,O
we,3114,O
describe,3114,O
an,3114,O
unusual,3114,O
case,3114,O
of,3114,O
reversible,3114,O
levodopa-induced,3114,B-Chemical
Oromandibular,3114,B-Disease
dystonia,3114,I-Disease
(,3114,O
OMD,3114,B-Disease
),3114,O
in,3114,O
a,3114,O
PSP,3114,B-Disease
patient,3114,O
to,3114,O
highlight,3114,O
the,3114,O
importance,3114,O
of,3114,O
recognizing,3114,O
this,3114,O
drug,3114,O
related,3114,O
complication,3114,O
in,3114,O
the,3114,O
management,3114,O
of,3114,O
PSP,3114,B-Disease
",",3114,O
and,3114,O
discuss,3114,O
the,3114,O
possible,3114,O
underlying,3114,O
pathophysiology,3114,O
.,3114,O
Case,3115,O
report,3115,O
:,3115,O
Dexatrim,3115,B-Chemical
(,3115,O
Phenylpropanolamine,3115,B-Chemical
),3115,O
as,3115,O
a,3115,O
cause,3115,O
of,3115,O
myocardial,3115,B-Disease
infarction,3115,I-Disease
.,3115,O
Phenylpropanolamine,3116,B-Chemical
(,3116,O
PPA,3116,B-Chemical
),3116,O
is,3116,O
a,3116,O
sympathetic,3116,O
amine,3116,B-Chemical
used,3116,O
in,3116,O
over-the-counter,3116,O
cold,3116,O
remedies,3116,O
and,3116,O
weight-control,3116,O
preparations,3116,O
worldwide,3116,O
.,3116,O
Its,3117,O
use,3117,O
has,3117,O
been,3117,O
associated,3117,O
with,3117,O
hypertensive,3117,B-Disease
episodes,3117,O
and,3117,O
hemorrhagic,3117,O
strokes,3117,O
in,3117,O
younger,3117,O
women,3117,O
.,3117,O
Several,3118,O
reports,3118,O
have,3118,O
linked,3118,O
the,3118,O
abuse,3118,O
of,3118,O
PPA,3118,B-Chemical
with,3118,O
myocardial,3118,B-Disease
injury,3118,I-Disease
",",3118,O
especially,3118,O
when,3118,O
overdose,3118,B-Disease
is,3118,O
involved,3118,O
.,3118,O
We,3119,O
report,3119,O
here,3119,O
the,3119,O
first,3119,O
case,3119,O
of,3119,O
Dexatrim,3119,B-Chemical
(,3119,O
PPA,3119,B-Chemical
),3119,O
-induced,3119,O
myocardial,3119,B-Disease
injury,3119,I-Disease
in,3119,O
a,3119,O
young,3119,O
woman,3119,O
who,3119,O
was,3119,O
using,3119,O
it,3119,O
at,3119,O
recommended,3119,O
doses,3119,O
for,3119,O
weight,3119,O
control,3119,O
.,3119,O
In,3120,O
addition,3120,O
",",3120,O
we,3120,O
review,3120,O
the,3120,O
7,3120,O
other,3120,O
cases,3120,O
of,3120,O
PPA,3120,B-Chemical
related,3120,O
myocardial,3120,B-Disease
injury,3120,I-Disease
that,3120,O
have,3120,O
been,3120,O
reported,3120,O
so,3120,O
far,3120,O
.,3120,O
Physicians,3121,O
and,3121,O
patients,3121,O
should,3121,O
be,3121,O
alert,3121,O
to,3121,O
the,3121,O
potential,3121,O
cardiac,3121,O
risk,3121,O
associated,3121,O
with,3121,O
the,3121,O
use,3121,O
of,3121,O
PPA,3121,B-Chemical
",",3121,O
even,3121,O
at,3121,O
doses,3121,O
generally,3121,O
considered,3121,O
to,3121,O
be,3121,O
safe,3121,O
.,3121,O
Differential,3122,O
diagnosis,3122,O
of,3122,O
high,3122,O
serum,3122,O
creatine,3122,B-Chemical
kinase,3122,O
levels,3122,O
in,3122,O
systemic,3122,B-Disease
lupus,3122,I-Disease
erythematosus,3122,I-Disease
.,3122,O
We,3123,O
report,3123,O
the,3123,O
clinical,3123,O
and,3123,O
bioptic,3123,O
findings,3123,O
for,3123,O
a,3123,O
57-year-old,3123,O
woman,3123,O
with,3123,O
severe,3123,O
chloroquine-induced,3123,B-Chemical
myopathy,3123,B-Disease
.,3123,O
Since,3124,O
1989,3124,O
",",3124,O
she,3124,O
had,3124,O
been,3124,O
suffering,3124,O
from,3124,O
systemic,3124,B-Disease
lupus,3124,I-Disease
erythematosus,3124,I-Disease
(,3124,O
SLE,3124,B-Disease
),3124,O
with,3124,O
renal,3124,B-Disease
involvement,3124,I-Disease
and,3124,O
undergone,3124,O
periods,3124,O
of,3124,O
treatment,3124,O
with,3124,O
azathioprine,3124,B-Chemical
and,3124,O
cyclophosphamide,3124,B-Chemical
.,3124,O
Additional,3125,O
therapy,3125,O
with,3125,O
chloroquine,3125,B-Chemical
(,3125,O
CQ,3125,B-Chemical
),3125,O
was,3125,O
started,3125,O
because,3125,O
of,3125,O
arthralgia,3125,B-Disease
.,3125,O
At,3126,O
the,3126,O
same,3126,O
time,3126,O
",",3126,O
slightly,3126,O
increased,3126,O
creatine,3126,B-Chemical
kinase,3126,O
(,3126,O
CK,3126,O
),3126,O
levels,3126,O
were,3126,O
noted,3126,O
.,3126,O
Myositis,3127,B-Disease
was,3127,O
suspected,3127,O
",",3127,O
and,3127,O
the,3127,O
patient,3127,O
was,3127,O
treated,3127,O
with,3127,O
steroids,3127,B-Chemical
.,3127,O
The,3128,O
CK,3128,O
increase,3128,O
persisted,3128,O
",",3128,O
however,3128,O
",",3128,O
and,3128,O
she,3128,O
developed,3128,O
progressive,3128,O
muscular,3128,B-Disease
weakness,3128,I-Disease
and,3128,O
muscular,3128,B-Disease
atrophy,3128,I-Disease
.,3128,O
Routine,3129,O
controls,3129,O
revealed,3129,O
markedly,3129,O
elevated,3129,O
CK,3129,O
levels,3129,O
of,3129,O
"1,700",3129,O
U/l,3129,O
.,3129,O
The,3130,O
neurological,3130,O
and,3130,O
electrophysiological,3130,O
findings,3130,O
were,3130,O
not,3130,O
typical,3130,O
of,3130,O
myositis,3130,B-Disease
.,3130,O
Thus,3131,O
",",3131,O
muscle,3131,O
biopsy,3131,O
of,3131,O
the,3131,O
deltoid,3131,O
muscle,3131,O
was,3131,O
performed,3131,O
in,3131,O
order,3131,O
to,3131,O
exclude,3131,O
polymyositis,3131,B-Disease
or,3131,O
toxic,3131,O
myopathy,3131,B-Disease
.,3131,O
As,3132,O
it,3132,O
revealed,3132,O
chloroquine-induced,3132,B-Chemical
myopathy,3132,B-Disease
",",3132,O
medication,3132,O
was,3132,O
stopped,3132,O
.,3132,O
Discriminating,3133,O
between,3133,O
primary,3133,O
SLE-induced,3133,B-Disease
affection,3133,B-Disease
of,3133,I-Disease
the,3133,I-Disease
musculoskeletal,3133,I-Disease
system,3133,I-Disease
and,3133,O
drug-induced,3133,O
side,3133,O
effects,3133,O
is,3133,O
important,3133,O
for,3133,O
appropriate,3133,O
treatment,3133,O
of,3133,O
SLE,3133,B-Disease
patients,3133,O
.,3133,O
Seizure,3134,B-Disease
associated,3134,O
with,3134,O
sleep,3134,B-Disease
deprivation,3134,I-Disease
and,3134,O
sustained-release,3134,O
bupropion,3134,B-Chemical
.,3134,O
This,3135,O
case,3135,O
report,3135,O
describes,3135,O
a,3135,O
generalized,3135,O
seizure,3135,B-Disease
associated,3135,O
with,3135,O
sustained-release,3135,O
bupropion,3135,B-Chemical
use,3135,O
and,3135,O
sleep,3135,B-Disease
deprivation,3135,I-Disease
.,3135,O
The,3136,O
subject,3136,O
",",3136,O
a,3136,O
31-year-old,3136,O
female,3136,O
smoker,3136,O
",",3136,O
was,3136,O
participating,3136,O
in,3136,O
a,3136,O
clinical,3136,O
trial,3136,O
evaluating,3136,O
an,3136,O
investigational,3136,O
medication,3136,O
for,3136,O
smoking,3136,O
cessation,3136,O
that,3136,O
used,3136,O
sustained-release,3136,O
bupropion,3136,B-Chemical
as,3136,O
an,3136,O
active,3136,O
control,3136,O
.,3136,O
After,3137,O
5,3137,O
weeks,3137,O
of,3137,O
bupropion,3137,B-Chemical
use,3137,O
",",3137,O
the,3137,O
subject,3137,O
experienced,3137,O
a,3137,O
generalized,3137,O
tonic,3137,O
clonic,3137,O
seizure,3137,B-Disease
after,3137,O
staying,3137,O
up,3137,O
nearly,3137,O
all,3137,O
night,3137,O
packing,3137,O
and,3137,O
moving,3137,O
to,3137,O
a,3137,O
new,3137,O
residence,3137,O
.,3137,O
The,3138,O
patient,3138,O
had,3138,O
no,3138,O
other,3138,O
risk,3138,O
factors,3138,O
for,3138,O
seizures,3138,B-Disease
.,3138,O
We,3139,O
suggest,3139,O
that,3139,O
sleep,3139,B-Disease
deprivation,3139,I-Disease
may,3139,O
add,3139,O
to,3139,O
the,3139,O
risk,3139,O
of,3139,O
bupropion-associated,3139,B-Chemical
seizures,3139,B-Disease
.,3139,O
Postoperative,3140,B-Disease
myalgia,3140,I-Disease
after,3140,O
succinylcholine,3140,B-Chemical
:,3140,O
no,3140,O
evidence,3140,O
for,3140,O
an,3140,O
inflammatory,3140,O
origin,3140,O
.,3140,O
A,3141,O
common,3141,O
side,3141,O
effect,3141,O
associated,3141,O
with,3141,O
succinylcholine,3141,B-Chemical
is,3141,O
postoperative,3141,B-Disease
myalgia,3141,I-Disease
.,3141,O
The,3142,O
pathogenesis,3142,O
of,3142,O
this,3142,O
myalgia,3142,B-Disease
is,3142,O
still,3142,O
unclear,3142,O
;,3142,O
inflammation,3142,B-Disease
has,3142,O
been,3142,O
suggested,3142,O
but,3142,O
without,3142,O
convincing,3142,O
evidence,3142,O
.,3142,O
We,3143,O
designed,3143,O
the,3143,O
present,3143,O
study,3143,O
to,3143,O
investigate,3143,O
whether,3143,O
an,3143,O
inflammatory,3143,O
reaction,3143,O
contributes,3143,O
to,3143,O
this,3143,O
myalgia,3143,B-Disease
.,3143,O
The,3144,O
incidence,3144,O
and,3144,O
severity,3144,O
of,3144,O
succinylcholine-associated,3144,B-Chemical
myalgia,3144,B-Disease
was,3144,O
determined,3144,O
in,3144,O
64,3144,O
patients,3144,O
pretreated,3144,O
with,3144,O
saline,3144,O
or,3144,O
dexamethasone,3144,B-Chemical
before,3144,O
succinylcholine,3144,B-Chemical
(,3144,O
n,3144,O
=,3144,O
32,3144,O
for,3144,O
each,3144,O
),3144,O
.,3144,O
Incidence,3145,O
and,3145,O
severity,3145,O
of,3145,O
myalgia,3145,B-Disease
did,3145,O
not,3145,O
differ,3145,O
significantly,3145,O
between,3145,O
the,3145,O
two,3145,O
groups,3145,O
:,3145,O
15,3145,O
patients,3145,O
in,3145,O
the,3145,O
dexamethasone,3145,B-Chemical
group,3145,O
complained,3145,O
of,3145,O
myalgia,3145,B-Disease
compared,3145,O
with,3145,O
18,3145,O
patients,3145,O
in,3145,O
the,3145,O
saline,3145,O
group,3145,O
",",3145,O
and,3145,O
severe,3145,O
myalgia,3145,B-Disease
was,3145,O
reported,3145,O
by,3145,O
five,3145,O
patients,3145,O
and,3145,O
three,3145,O
patients,3145,O
",",3145,O
respectively,3145,O
(,3145,O
not,3145,O
significant,3145,O
),3145,O
.,3145,O
At,3146,O
48,3146,O
h,3146,O
after,3146,O
surgery,3146,O
",",3146,O
12,3146,O
patients,3146,O
in,3146,O
both,3146,O
groups,3146,O
still,3146,O
suffered,3146,O
from,3146,O
myalgia,3146,B-Disease
(,3146,O
not,3146,O
significant,3146,O
),3146,O
.,3146,O
In,3147,O
addition,3147,O
",",3147,O
interleukin-6,3147,O
(,3147,O
IL-6,3147,O
),3147,O
as,3147,O
an,3147,O
early,3147,O
marker,3147,O
of,3147,O
inflammation,3147,B-Disease
was,3147,O
assessed,3147,O
in,3147,O
a,3147,O
subgroup,3147,O
of,3147,O
10,3147,O
patients,3147,O
pretreated,3147,O
with,3147,O
saline,3147,O
.,3147,O
We,3148,O
found,3148,O
an,3148,O
increase,3148,O
of,3148,O
IL-6,3148,O
for,3148,O
only,3148,O
three,3148,O
patients,3148,O
",",3148,O
but,3148,O
only,3148,O
one,3148,O
patient,3148,O
reported,3148,O
myalgia,3148,B-Disease
;,3148,O
no,3148,O
relationship,3148,O
between,3148,O
myalgia,3148,B-Disease
and,3148,O
the,3148,O
increase,3148,O
of,3148,O
IL-6,3148,O
was,3148,O
found,3148,O
.,3148,O
In,3149,O
conclusion,3149,O
",",3149,O
there,3149,O
is,3149,O
no,3149,O
evidence,3149,O
for,3149,O
an,3149,O
inflammatory,3149,O
origin,3149,O
of,3149,O
succinylcholine-associated,3149,B-Chemical
myalgia,3149,B-Disease
.,3149,O
IMPLICATIONS,3150,O
:,3150,O
Administration,3150,O
of,3150,O
dexamethasone,3150,B-Chemical
before,3150,O
succinylcholine,3150,B-Chemical
was,3150,O
not,3150,O
effective,3150,O
in,3150,O
decreasing,3150,O
the,3150,O
incidence,3150,O
or,3150,O
the,3150,O
severity,3150,O
of,3150,O
succinylcholine-induced,3150,B-Chemical
postoperative,3150,B-Disease
myalgia,3150,I-Disease
.,3150,O
Furthermore,3151,O
",",3151,O
there,3151,O
was,3151,O
no,3151,O
significant,3151,O
relationship,3151,O
between,3151,O
postoperative,3151,B-Disease
myalgia,3151,I-Disease
and,3151,O
time,3151,O
course,3151,O
of,3151,O
interleukin-6,3151,O
concentrations,3151,O
",",3151,O
a,3151,O
marker,3151,O
of,3151,O
inflammation,3151,B-Disease
.,3151,O
Pretreatment,3152,O
with,3152,O
dexamethasone,3152,B-Chemical
is,3152,O
not,3152,O
justified,3152,O
to,3152,O
prevent,3152,O
postoperative,3152,B-Disease
myalgia,3152,I-Disease
after,3152,O
succinylcholine,3152,B-Chemical
.,3152,O
Effect,3153,O
of,3153,O
lindane,3153,B-Chemical
on,3153,O
hepatic,3153,O
and,3153,O
brain,3153,O
cytochrome,3153,O
P450s,3153,O
and,3153,O
influence,3153,O
of,3153,O
P450,3153,O
modulation,3153,O
in,3153,O
lindane,3153,B-Chemical
induced,3153,O
neurotoxicity,3153,B-Disease
.,3153,O
Oral,3154,O
administration,3154,O
of,3154,O
lindane,3154,B-Chemical
(,3154,O
2.5,3154,O
",",3154,O
5,3154,O
",",3154,O
10,3154,O
and,3154,O
15,3154,O
mg/kg,3154,O
",",3154,O
body,3154,O
weight,3154,O
),3154,O
for,3154,O
5,3154,O
days,3154,O
was,3154,O
found,3154,O
to,3154,O
produce,3154,O
a,3154,O
dose-dependent,3154,O
increase,3154,O
in,3154,O
the,3154,O
activity,3154,O
of,3154,O
P450,3154,O
dependent,3154,O
7-ethoxyresorufin-O-deethylase,3154,O
(,3154,O
EROD,3154,O
),3154,O
",",3154,O
7-pentoxyresorufin-O-dealkylase,3154,O
(,3154,O
PROD,3154,O
),3154,O
and,3154,O
N-nitrosodimethylamine,3154,B-Chemical
demethylase,3154,O
(,3154,O
NDMA-d,3154,B-Chemical
),3154,O
in,3154,O
rat,3154,O
brain,3154,O
and,3154,O
liver,3154,O
.,3154,O
A,3155,O
significant,3155,O
increase,3155,O
in,3155,O
the,3155,O
hepatic,3155,O
and,3155,O
brain,3155,O
P450,3155,O
monooxygenases,3155,O
was,3155,O
also,3155,O
observed,3155,O
when,3155,O
the,3155,O
duration,3155,O
of,3155,O
exposure,3155,O
of,3155,O
low,3155,O
dose,3155,O
(,3155,O
2.5,3155,O
mg/kg,3155,O
),3155,O
of,3155,O
lindane,3155,B-Chemical
was,3155,O
increased,3155,O
from,3155,O
5,3155,O
days,3155,O
to,3155,O
15,3155,O
or,3155,O
21,3155,O
days,3155,O
.,3155,O
As,3156,O
observed,3156,O
with,3156,O
different,3156,O
doses,3156,O
",",3156,O
the,3156,O
magnitude,3156,O
of,3156,O
induction,3156,O
in,3156,O
the,3156,O
activity,3156,O
of,3156,O
P450,3156,O
monooxygenases,3156,O
was,3156,O
several,3156,O
fold,3156,O
higher,3156,O
in,3156,O
liver,3156,O
microsomes,3156,O
when,3156,O
compared,3156,O
with,3156,O
the,3156,O
brain,3156,O
.,3156,O
Western,3157,O
blotting,3157,O
studies,3157,O
have,3157,O
indicated,3157,O
that,3157,O
the,3157,O
increase,3157,O
in,3157,O
the,3157,O
P450,3157,O
enzymes,3157,O
could,3157,O
be,3157,O
due,3157,O
to,3157,O
the,3157,O
increase,3157,O
in,3157,O
the,3157,O
expression,3157,O
of,3157,O
P450,3157,O
1A1/1A2,3157,O
",",3157,O
2B1/2B2,3157,O
and,3157,O
2E1,3157,O
isoenzymes,3157,O
.,3157,O
In,3158,O
vitro,3158,O
studies,3158,O
using,3158,O
organic,3158,O
inhibitors,3158,O
specific,3158,O
for,3158,O
individual,3158,O
P450,3158,O
isoenzymes,3158,O
and,3158,O
antibody,3158,O
inhibition,3158,O
experiments,3158,O
have,3158,O
further,3158,O
demonstrated,3158,O
that,3158,O
the,3158,O
increase,3158,O
in,3158,O
the,3158,O
activity,3158,O
of,3158,O
PROD,3158,O
",",3158,O
EROD,3158,O
and,3158,O
NDMA-d,3158,B-Chemical
are,3158,O
due,3158,O
to,3158,O
the,3158,O
increase,3158,O
in,3158,O
the,3158,O
levels,3158,O
of,3158,O
P450,3158,O
2B1/2B2,3158,O
",",3158,O
1A1/1A2,3158,O
and,3158,O
2E1,3158,O
isoenzymes,3158,O
",",3158,O
respectively,3158,O
.,3158,O
Induction,3159,O
studies,3159,O
have,3159,O
further,3159,O
shown,3159,O
that,3159,O
while,3159,O
pretreatment,3159,O
of,3159,O
3-methylcholanthrene,3159,B-Chemical
(,3159,O
MC,3159,B-Chemical
),3159,O
",",3159,O
an,3159,O
inducer,3159,O
of,3159,O
P4501A1/1A2,3159,O
",",3159,O
did,3159,O
not,3159,O
produce,3159,O
any,3159,O
significant,3159,O
effect,3159,O
in,3159,O
the,3159,O
incidence,3159,O
of,3159,O
lindane,3159,B-Chemical
induced,3159,O
convulsions,3159,B-Disease
",",3159,O
pretreatment,3159,O
with,3159,O
phenobarbital,3159,B-Chemical
(,3159,O
PB,3159,O
),3159,O
",",3159,O
an,3159,O
inducer,3159,O
of,3159,O
P450,3159,O
2B1/2B2,3159,O
or,3159,O
ethanol,3159,B-Chemical
",",3159,O
an,3159,O
inducer,3159,O
of,3159,O
P450,3159,O
2E1,3159,O
catalysed,3159,O
reactions,3159,O
",",3159,O
significantly,3159,O
increased,3159,O
the,3159,O
incidence,3159,O
of,3159,O
lindane,3159,B-Chemical
induced,3159,O
convulsions,3159,B-Disease
.,3159,O
Similarly,3160,O
",",3160,O
when,3160,O
the,3160,O
P450-mediated,3160,O
metabolism,3160,O
of,3160,O
lindane,3160,B-Chemical
was,3160,O
blocked,3160,O
by,3160,O
cobalt,3160,B-Chemical
chloride,3160,I-Chemical
incidence,3160,O
of,3160,O
convulsions,3160,B-Disease
was,3160,O
increased,3160,O
in,3160,O
animals,3160,O
treated,3160,O
with,3160,O
lindane,3160,B-Chemical
indicating,3160,O
that,3160,O
lindane,3160,B-Chemical
per,3160,O
se,3160,O
or,3160,O
its,3160,O
metabolites,3160,O
formed,3160,O
by,3160,O
PB,3160,O
or,3160,O
ethanol,3160,B-Chemical
inducible,3160,O
P450,3160,O
isoenzymes,3160,O
are,3160,O
involved,3160,O
in,3160,O
its,3160,O
neurobehavioral,3160,O
toxicity,3160,B-Disease
.,3160,O
Absolute,3161,O
and,3161,O
attributable,3161,O
risk,3161,O
of,3161,O
venous,3161,B-Disease
thromboembolism,3161,I-Disease
in,3161,O
women,3161,O
on,3161,O
combined,3161,O
cyproterone,3161,B-Chemical
acetate,3161,I-Chemical
and,3161,O
ethinylestradiol,3161,B-Chemical
.,3161,O
OBJECTIVE,3162,O
:,3162,O
To,3162,O
achieve,3162,O
absolute,3162,O
risk,3162,O
estimates,3162,O
of,3162,O
venous,3162,B-Disease
thromboembolism,3162,I-Disease
(,3162,O
VTE,3162,B-Disease
),3162,O
among,3162,O
women,3162,O
on,3162,O
cyproterone,3162,B-Chemical
acetate,3162,I-Chemical
plus,3162,O
ethinylestradiol,3162,B-Chemical
(,3162,O
CPA/EE,3162,B-Chemical
),3162,O
",",3162,O
and,3162,O
among,3162,O
women,3162,O
on,3162,O
combined,3162,B-Chemical
oral,3162,I-Chemical
contraceptives,3162,I-Chemical
(,3162,O
COCs,3162,B-Chemical
),3162,O
.,3162,O
METHODS,3163,O
:,3163,O
From,3163,O
the,3163,O
Danish,3163,O
National,3163,O
Register,3163,O
of,3163,O
Patients,3163,O
(,3163,O
NRP,3163,O
),3163,O
",",3163,O
1996,3163,O
to,3163,O
1998,3163,O
",",3163,O
the,3163,O
records,3163,O
of,3163,O
1.1,3163,O
million,3163,O
Danish,3163,O
women,3163,O
",",3163,O
ages,3163,O
15,3163,O
to,3163,O
44,3163,O
years,3163,O
",",3163,O
were,3163,O
searched,3163,O
for,3163,O
evidence,3163,O
of,3163,O
VTE,3163,B-Disease
.,3163,O
COC,3164,B-Chemical
use,3164,O
was,3164,O
ascertained,3164,O
through,3164,O
mailed,3164,O
questionnaires,3164,O
.,3164,O
Sales,3165,O
statistics,3165,O
of,3165,O
COCs,3165,B-Chemical
and,3165,O
CPA/EE,3165,B-Chemical
were,3165,O
provided,3165,O
through,3165,O
Danish,3165,O
Drug,3165,O
Statistics,3165,O
.,3165,O
RESULTS,3166,O
:,3166,O
During,3166,O
the,3166,O
time,3166,O
frame,3166,O
of,3166,O
the,3166,O
study,3166,O
",",3166,O
330,3166,O
women,3166,O
were,3166,O
found,3166,O
to,3166,O
have,3166,O
had,3166,O
VTE,3166,B-Disease
while,3166,O
on,3166,O
COCs,3166,B-Chemical
.,3166,O
Of,3167,O
these,3167,O
women,3167,O
",",3167,O
67,3167,O
were,3167,O
on,3167,O
levonorgestrel-containing,3167,B-Chemical
COCs,3167,B-Chemical
.,3167,O
Eleven,3168,O
were,3168,O
on,3168,O
CPA/EE,3168,B-Chemical
.,3168,O
The,3169,O
corresponding,3169,O
absolute,3169,O
risk,3169,O
of,3169,O
VTE,3169,B-Disease
was,3169,O
3.4,3169,O
(,3169,O
range,3169,O
",",3169,O
3.1-3.8,3169,O
),3169,O
per,3169,O
10,3169,O
000,3169,O
women,3169,O
years,3169,O
among,3169,O
the,3169,O
women,3169,O
on,3169,O
COCs,3169,B-Chemical
",",3169,O
4.2,3169,O
(,3169,O
range,3169,O
",",3169,O
3.2-5.2,3169,O
),3169,O
per,3169,O
10,3169,O
000,3169,O
women,3169,O
years,3169,O
among,3169,O
women,3169,O
on,3169,O
levonorgestrel-containing,3169,B-Chemical
COCs,3169,B-Chemical
",",3169,O
and,3169,O
3.1,3169,O
(,3169,O
range,3169,O
",",3169,O
1.3-4.9,3169,O
),3169,O
per,3169,O
10,3169,O
000,3169,O
women,3169,O
years,3169,O
among,3169,O
the,3169,O
women,3169,O
on,3169,O
CPA/EE,3169,B-Chemical
.,3169,O
CONCLUSION,3170,O
:,3170,O
Our,3170,O
results,3170,O
suggest,3170,O
the,3170,O
absolute,3170,O
risk,3170,O
of,3170,O
VTE,3170,B-Disease
among,3170,O
Danish,3170,O
women,3170,O
on,3170,O
COCs,3170,B-Chemical
is,3170,O
similar,3170,O
to,3170,O
that,3170,O
among,3170,O
women,3170,O
taking,3170,O
CPA/EE,3170,B-Chemical
.,3170,O
Comparison,3171,O
of,3171,O
developmental,3171,O
toxicology,3171,O
of,3171,O
aspirin,3171,B-Chemical
(,3171,O
acetylsalicylic,3171,B-Chemical
acid,3171,I-Chemical
),3171,O
in,3171,O
rats,3171,O
using,3171,O
selected,3171,O
dosing,3171,O
paradigms,3171,O
.,3171,O
BACKGROUND,3172,O
:,3172,O
Analysis,3172,O
of,3172,O
the,3172,O
literature,3172,O
for,3172,O
nonsteroidal,3172,O
anti-inflammatory,3172,O
drugs,3172,O
(,3172,O
NSAIDs,3172,O
),3172,O
suggests,3172,O
that,3172,O
a,3172,O
low,3172,O
incidence,3172,O
of,3172,O
developmental,3172,B-Disease
anomalies,3172,I-Disease
occurs,3172,O
in,3172,O
rats,3172,O
given,3172,O
NSAIDs,3172,O
on,3172,O
specific,3172,O
days,3172,O
during,3172,O
organogenesis,3172,O
.,3172,O
Aspirin,3173,B-Chemical
(,3173,O
acetylsalicylic,3173,B-Chemical
acid,3173,I-Chemical
[,3173,O
ASA,3173,B-Chemical
],3173,O
),3173,O
",",3173,O
an,3173,O
irreversible,3173,O
cyclooxygenase,3173,O
1,3173,O
and,3173,O
2,3173,O
inhibitor,3173,O
",",3173,O
induces,3173,O
developmental,3173,B-Disease
anomalies,3173,I-Disease
when,3173,O
administered,3173,O
to,3173,O
Wistar,3173,O
rats,3173,O
on,3173,O
gestational,3173,O
day,3173,O
(,3173,O
GD,3173,O
),3173,O
9,3173,O
",",3173,O
10,3173,O
",",3173,O
or,3173,O
11,3173,O
(,3173,O
Kimmel,3173,O
CA,3173,O
",",3173,O
Wilson,3173,O
JG,3173,O
",",3173,O
Schumacher,3173,O
HJ,3173,O
.,3173,O
Teratology,3174,O
4:15-24,3174,O
",",3174,O
1971,3174,O
),3174,O
.,3174,O
There,3175,O
are,3175,O
no,3175,O
published,3175,O
ASA,3175,B-Chemical
studies,3175,O
using,3175,O
the,3175,O
multiple,3175,O
dosing,3175,O
paradigm,3175,O
of,3175,O
GDs,3175,O
6,3175,O
to,3175,O
17,3175,O
.,3175,O
Objectives,3176,O
of,3176,O
the,3176,O
current,3176,O
study,3176,O
were,3176,O
to,3176,O
compare,3176,O
results,3176,O
between,3176,O
Sprague-Dawley,3176,O
(,3176,O
SD,3176,O
),3176,O
and,3176,O
Wistar,3176,O
strains,3176,O
when,3176,O
ASA,3176,B-Chemical
is,3176,O
administered,3176,O
on,3176,O
GD,3176,O
9,3176,O
",",3176,O
10,3176,O
",",3176,O
or,3176,O
11,3176,O
;,3176,O
to,3176,O
compare,3176,O
the,3176,O
malformation,3176,O
patterns,3176,O
following,3176,O
single,3176,O
and,3176,O
multiple,3176,O
dosings,3176,O
during,3176,O
organogenesis,3176,O
in,3176,O
SD,3176,O
rats,3176,O
;,3176,O
and,3176,O
to,3176,O
test,3176,O
the,3176,O
hypothesis,3176,O
that,3176,O
maternal,3176,O
gastrointestinal,3176,B-Disease
toxicity,3176,I-Disease
confounds,3176,O
the,3176,O
detection,3176,O
of,3176,O
low,3176,O
incidence,3176,O
malformations,3176,B-Disease
with,3176,O
ASA,3176,B-Chemical
when,3176,O
a,3176,O
multiple,3176,O
dosing,3176,O
paradigm,3176,O
is,3176,O
used,3176,O
.,3176,O
METHODS,3177,O
:,3177,O
ASA,3177,B-Chemical
was,3177,O
administered,3177,O
as,3177,O
a,3177,O
single,3177,O
dose,3177,O
on,3177,O
GD,3177,O
9,3177,O
(,3177,O
0,3177,O
",",3177,O
250,3177,O
",",3177,O
500,3177,O
",",3177,O
or,3177,O
625,3177,O
mg/kg,3177,O
),3177,O
",",3177,O
10,3177,O
(,3177,O
0,3177,O
",",3177,O
500,3177,O
",",3177,O
625,3177,O
",",3177,O
or,3177,O
750,3177,O
mg/kg,3177,O
),3177,O
",",3177,O
or,3177,O
11,3177,O
(,3177,O
0,3177,O
",",3177,O
500,3177,O
",",3177,O
750,3177,O
",",3177,O
or,3177,O
1000,3177,O
mg/kg,3177,O
),3177,O
and,3177,O
from,3177,O
GD,3177,O
6,3177,O
to,3177,O
GD,3177,O
17,3177,O
(,3177,O
0,3177,O
",",3177,O
50,3177,O
",",3177,O
125,3177,O
",",3177,O
or,3177,O
250,3177,O
mg/kg,3177,O
a,3177,O
day,3177,O
),3177,O
in,3177,O
the,3177,O
multiple,3177,O
dose,3177,O
study,3177,O
to,3177,O
SD,3177,O
rats,3177,O
.,3177,O
Animals,3178,O
were,3178,O
killed,3178,O
on,3178,O
GD,3178,O
21,3178,O
",",3178,O
and,3178,O
fetuses,3178,O
were,3178,O
examined,3178,O
viscerally,3178,O
.,3178,O
RESULTS,3179,O
:,3179,O
The,3179,O
literature,3179,O
evaluation,3179,O
suggested,3179,O
that,3179,O
NSAIDs,3179,O
induce,3179,O
ventricular,3179,B-Disease
septal,3179,I-Disease
defects,3179,I-Disease
(,3179,O
VSDs,3179,B-Disease
),3179,O
and,3179,O
midline,3179,B-Disease
defects,3179,I-Disease
(,3179,O
MDs,3179,B-Disease
),3179,O
in,3179,O
rats,3179,O
and,3179,O
diaphragmatic,3179,B-Disease
hernia,3179,I-Disease
(,3179,O
DH,3179,B-Disease
),3179,O
",",3179,O
MDs,3179,B-Disease
",",3179,O
and,3179,O
VSDs,3179,B-Disease
in,3179,O
rabbits,3179,O
(,3179,O
Cook,3179,O
JC,3179,O
et,3179,O
al.,3179,O
",",3179,O
2003,3179,O
),3179,O
;,3179,O
hence,3179,O
",",3179,O
the,3179,O
present,3179,O
study,3179,O
focused,3179,O
on,3179,O
these,3179,O
malformations,3179,B-Disease
",",3179,O
even,3179,O
though,3179,O
ASA,3179,B-Chemical
induces,3179,O
several,3179,O
other,3179,O
low-incidence,3179,O
malformations,3179,B-Disease
.,3179,O
In,3180,O
single,3180,O
dose,3180,O
studies,3180,O
",",3180,O
DH,3180,B-Disease
",",3180,O
MD,3180,B-Disease
",",3180,O
and,3180,O
VSD,3180,B-Disease
were,3180,O
induced,3180,O
on,3180,O
GDs,3180,O
9,3180,O
and,3180,O
10,3180,O
.,3180,O
VSD,3181,B-Disease
also,3181,O
was,3181,O
noted,3181,O
following,3181,O
treatment,3181,O
on,3181,O
GD,3181,O
11,3181,O
.,3181,O
In,3182,O
contrast,3182,O
",",3182,O
DH,3182,B-Disease
and,3182,O
MD,3182,B-Disease
were,3182,O
noted,3182,O
in,3182,O
the,3182,O
multiple,3182,O
dose,3182,O
study,3182,O
design,3182,O
only,3182,O
in,3182,O
the,3182,O
high-dose,3182,O
group,3182,O
",",3182,O
and,3182,O
VSD,3182,B-Disease
was,3182,O
noted,3182,O
across,3182,O
all,3182,O
dose,3182,O
groups,3182,O
.,3182,O
CONCLUSIONS,3183,O
:,3183,O
High,3183,O
concordance,3183,O
in,3183,O
major,3183,O
developmental,3183,B-Disease
anomalies,3183,I-Disease
between,3183,O
Wistar,3183,O
and,3183,O
SD,3183,O
rats,3183,O
were,3183,O
noted,3183,O
with,3183,O
the,3183,O
exception,3183,O
of,3183,O
VSD,3183,B-Disease
in,3183,O
the,3183,O
SD,3183,O
rats,3183,O
and,3183,O
hydrocephalus,3183,B-Disease
in,3183,O
the,3183,O
Wistar,3183,O
rats,3183,O
.,3183,O
Variations,3184,O
and,3184,O
malformations,3184,B-Disease
were,3184,O
similar,3184,O
when,3184,O
ASA,3184,B-Chemical
was,3184,O
administered,3184,O
as,3184,O
a,3184,O
single,3184,O
dose,3184,O
or,3184,O
during,3184,O
the,3184,O
period,3184,O
of,3184,O
organogenesis,3184,O
(,3184,O
GDs,3184,O
6,3184,O
to,3184,O
17,3184,O
),3184,O
.,3184,O
It,3185,O
was,3185,O
also,3185,O
evident,3185,O
that,3185,O
",",3185,O
by,3185,O
titrating,3185,O
the,3185,O
dose,3185,O
to,3185,O
achieve,3185,O
a,3185,O
maximum,3185,O
tolerated,3185,O
dose,3185,O
",",3185,O
malformations,3185,B-Disease
that,3185,O
normally,3185,O
occur,3185,O
at,3185,O
low,3185,O
incidence,3185,O
",",3185,O
as,3185,O
reported,3185,O
from,3185,O
previous,3185,O
single,3185,O
dose,3185,O
studies,3185,O
",",3185,O
could,3185,O
also,3185,O
be,3185,O
induced,3185,O
with,3185,O
ASA,3185,B-Chemical
given,3185,O
at,3185,O
multiple,3185,O
doses,3185,O
.,3185,O
Methylphenidate-induced,3186,B-Chemical
obsessive-compulsive,3186,B-Disease
symptoms,3186,I-Disease
in,3186,O
an,3186,O
elderly,3186,O
man,3186,O
.,3186,O
An,3187,O
82-year-old,3187,O
man,3187,O
with,3187,O
treatment-resistant,3187,B-Disease
depression,3187,I-Disease
and,3187,O
early,3187,O
Alzheimer,3187,B-Disease
's,3187,I-Disease
disease,3187,I-Disease
was,3187,O
started,3187,O
on,3187,O
methylphenidate,3187,B-Chemical
.,3187,O
Significant,3188,O
obsessive-compulsive,3188,B-Disease
behavior,3188,I-Disease
ensued,3188,O
but,3188,O
diminished,3188,O
over,3188,O
several,3188,O
weeks,3188,O
when,3188,O
methylphenidate,3188,B-Chemical
was,3188,O
replaced,3188,O
by,3188,O
fluvoxamine,3188,B-Chemical
.,3188,O
The,3189,O
patient,3189,O
had,3189,O
no,3189,O
prior,3189,O
psychiatric,3189,B-Disease
history,3189,O
",",3189,O
but,3189,O
he,3189,O
had,3189,O
a,3189,O
sister,3189,O
with,3189,O
obsessive-compulsive,3189,B-Disease
disorder,3189,I-Disease
.,3189,O
It,3190,O
appears,3190,O
that,3190,O
methylphenidate,3190,B-Chemical
precipitated,3190,O
the,3190,O
patient,3190,O
's,3190,O
pathological,3190,O
behavior,3190,O
.,3190,O
Ciprofloxacin-induced,3191,B-Chemical
acute,3191,O
interstitial,3191,B-Disease
nephritis,3191,I-Disease
and,3191,O
autoimmune,3191,B-Disease
hemolytic,3191,I-Disease
anemia,3191,I-Disease
.,3191,O
Ciprofloxacin,3192,B-Chemical
has,3192,O
been,3192,O
associated,3192,O
with,3192,O
several,3192,O
side,3192,O
effects,3192,O
including,3192,O
interstitial,3192,B-Disease
nephritis,3192,I-Disease
and,3192,O
hemolytic,3192,B-Disease
anemia,3192,I-Disease
.,3192,O
The,3193,O
combination,3193,O
of,3193,O
both,3193,O
side,3193,O
effects,3193,O
is,3193,O
extremely,3193,O
rare,3193,O
.,3193,O
In,3194,O
this,3194,O
report,3194,O
",",3194,O
we,3194,O
describe,3194,O
a,3194,O
case,3194,O
of,3194,O
ciprofloxacin-induced,3194,B-Chemical
interstitial,3194,B-Disease
nephritis,3194,I-Disease
and,3194,O
autoimmune,3194,B-Disease
hemolytic,3194,I-Disease
anemia,3194,I-Disease
.,3194,O
Hemolytic,3195,B-Disease
anemia,3195,I-Disease
improved,3195,O
after,3195,O
stopping,3195,O
the,3195,O
drug,3195,O
and,3195,O
initiation,3195,O
of,3195,O
steroid,3195,B-Chemical
therapy,3195,O
.,3195,O
Unfortunately,3196,O
",",3196,O
acute,3196,O
interstitial,3196,B-Disease
nephritis,3196,I-Disease
was,3196,O
irreversible,3196,O
and,3196,O
the,3196,O
patient,3196,O
developed,3196,O
end-stage,3196,B-Disease
renal,3196,I-Disease
disease,3196,I-Disease
.,3196,O
Use,3197,O
of,3197,O
dexamethasone,3197,B-Chemical
with,3197,O
mesna,3197,B-Chemical
for,3197,O
the,3197,O
prevention,3197,O
of,3197,O
ifosfamide-induced,3197,B-Chemical
hemorrhagic,3197,O
cystitis,3197,O
.,3197,O
AIM,3198,O
:,3198,O
Hemorrhagic,3198,O
cystitis,3198,O
(,3198,O
HC,3198,B-Disease
),3198,O
is,3198,O
a,3198,O
limiting,3198,O
side-effect,3198,O
of,3198,O
chemotherapy,3198,O
with,3198,O
ifosfamide,3198,B-Chemical
(,3198,O
IFS,3198,B-Chemical
),3198,O
.,3198,O
In,3199,O
the,3199,O
study,3199,O
presented,3199,O
here,3199,O
",",3199,O
we,3199,O
investigated,3199,O
the,3199,O
use,3199,O
of,3199,O
dexamethasone,3199,B-Chemical
in,3199,O
combination,3199,O
with,3199,O
mesna,3199,B-Chemical
for,3199,O
the,3199,O
prevention,3199,O
of,3199,O
IFS-induced,3199,B-Chemical
HC,3199,B-Disease
.,3199,O
METHODS,3200,O
:,3200,O
Male,3200,O
Wistar,3200,O
rats,3200,O
(,3200,O
150-200,3200,O
g,3200,O
;,3200,O
6,3200,O
rats,3200,O
per,3200,O
group,3200,O
),3200,O
were,3200,O
treated,3200,O
with,3200,O
saline,3200,O
or,3200,O
mesna,3200,B-Chemical
5,3200,O
min,3200,O
(,3200,O
i.p,3200,O
.,3200,O
),3200,O
before,3201,O
and,3201,O
2,3201,O
and,3201,O
6,3201,O
h,3201,O
after,3201,O
(,3201,O
v.o,3201,O
.,3201,O
),3201,O
administration,3202,O
of,3202,O
IFS,3202,B-Chemical
.,3202,O
One,3203,O
",",3203,O
two,3203,O
or,3203,O
three,3203,O
doses,3203,O
of,3203,O
mesna,3203,B-Chemical
were,3203,O
replaced,3203,O
with,3203,O
dexamethasone,3203,B-Chemical
alone,3203,O
or,3203,O
with,3203,O
dexamethasone,3203,B-Chemical
plus,3203,O
mesna,3203,B-Chemical
.,3203,O
Cystitis,3204,B-Disease
was,3204,O
evaluated,3204,O
24,3204,O
h,3204,O
after,3204,O
its,3204,O
induction,3204,O
by,3204,O
the,3204,O
changes,3204,O
in,3204,O
bladder,3204,O
wet,3204,O
weight,3204,O
and,3204,O
by,3204,O
macroscopic,3204,O
and,3204,O
microscopic,3204,O
analysis,3204,O
.,3204,O
RESULTS,3205,O
:,3205,O
The,3205,O
replacement,3205,O
of,3205,O
the,3205,O
last,3205,O
dose,3205,O
or,3205,O
the,3205,O
last,3205,O
two,3205,O
doses,3205,O
of,3205,O
mesna,3205,B-Chemical
with,3205,O
dexamethasone,3205,B-Chemical
reduced,3205,O
the,3205,O
increase,3205,O
in,3205,O
bladder,3205,O
wet,3205,O
weight,3205,O
induced,3205,O
by,3205,O
IFS,3205,B-Chemical
by,3205,O
84.79,3205,O
%,3205,O
and,3205,O
89.13,3205,O
%,3205,O
",",3205,O
respectively,3205,O
.,3205,O
In,3206,O
addition,3206,O
",",3206,O
it,3206,O
almost,3206,O
abolished,3206,O
the,3206,O
macroscopic,3206,O
and,3206,O
microscopic,3206,O
alterations,3206,O
induced,3206,O
by,3206,O
IFS,3206,B-Chemical
.,3206,O
Moreover,3207,O
",",3207,O
the,3207,O
addition,3207,O
of,3207,O
dexamethasone,3207,B-Chemical
to,3207,O
the,3207,O
last,3207,O
two,3207,O
doses,3207,O
of,3207,O
mesna,3207,B-Chemical
was,3207,O
more,3207,O
efficient,3207,O
than,3207,O
three,3207,O
doses,3207,O
of,3207,O
mesna,3207,B-Chemical
alone,3207,O
when,3207,O
evaluated,3207,O
microscopically,3207,O
.,3207,O
CONCLUSION,3208,O
:,3208,O
Dexamethasone,3208,B-Chemical
in,3208,O
combination,3208,O
with,3208,O
mesna,3208,B-Chemical
was,3208,O
efficient,3208,O
in,3208,O
blocking,3208,O
IFS-induced,3208,B-Chemical
HC,3208,B-Disease
.,3208,O
However,3209,O
",",3209,O
the,3209,O
replacement,3209,O
of,3209,O
last,3209,O
two,3209,O
doses,3209,O
of,3209,O
mesna,3209,B-Chemical
with,3209,O
saline,3209,O
or,3209,O
all,3209,O
of,3209,O
the,3209,O
mesna,3209,B-Chemical
doses,3209,O
with,3209,O
dexamethasone,3209,B-Chemical
did,3209,O
not,3209,O
prevent,3209,O
HC,3209,B-Disease
.,3209,O
All-,3210,B-Chemical
trans-retinoic,3210,I-Chemical
acid-induced,3210,O
erythema,3210,B-Disease
nodosum,3210,I-Disease
in,3210,O
patients,3210,O
with,3210,O
acute,3210,B-Disease
promyelocytic,3210,I-Disease
leukemia,3210,I-Disease
.,3210,O
Erythema,3211,B-Disease
nodosum,3211,I-Disease
associated,3211,O
with,3211,O
all-,3211,B-Chemical
trans-retinoic,3211,I-Chemical
acid,3211,I-Chemical
(,3211,O
ATRA,3211,B-Chemical
),3211,O
for,3211,O
acute,3211,B-Disease
promyelocytic,3211,I-Disease
leukemia,3211,I-Disease
(,3211,O
APL,3211,B-Disease
),3211,O
is,3211,O
very,3211,O
rare,3211,O
.,3211,O
We,3212,O
describe,3212,O
four,3212,O
patients,3212,O
with,3212,O
classic,3212,O
APL,3212,B-Disease
who,3212,O
developed,3212,O
erythema,3212,B-Disease
nodosum,3212,I-Disease
during,3212,O
ATRA,3212,B-Chemical
therapy,3212,O
.,3212,O
Fever,3213,B-Disease
and,3213,O
subsequent,3213,O
multiple,3213,O
painful,3213,B-Disease
erythematous,3213,B-Disease
nodules,3213,I-Disease
over,3213,O
extremities,3213,O
developed,3213,O
on,3213,O
D11,3213,O
",",3213,O
D16,3213,O
",",3213,O
D17,3213,O
",",3213,O
and,3213,O
D19,3213,O
",",3213,O
respectively,3213,O
",",3213,O
after,3213,O
ATRA,3213,B-Chemical
therapy,3213,O
.,3213,O
The,3214,O
skin,3214,O
biopsy,3214,O
taken,3214,O
from,3214,O
each,3214,O
patient,3214,O
was,3214,O
consistent,3214,O
with,3214,O
erythema,3214,B-Disease
nodosum,3214,I-Disease
.,3214,O
All,3215,O
patients,3215,O
received,3215,O
short,3215,O
course,3215,O
of,3215,O
steroids,3215,B-Chemical
.,3215,O
Fever,3216,B-Disease
subsided,3216,O
rapidly,3216,O
and,3216,O
the,3216,O
skin,3216,O
lesions,3216,O
regressed,3216,O
completely,3216,O
.,3216,O
All,3217,O
patients,3217,O
achieved,3217,O
complete,3217,O
remission,3217,O
without,3217,O
withdrawal,3217,O
of,3217,O
ATRA,3217,B-Chemical
.,3217,O
ATRA,3218,B-Chemical
seemed,3218,O
to,3218,O
be,3218,O
the,3218,O
most,3218,O
possible,3218,O
etiology,3218,O
of,3218,O
erythema,3218,B-Disease
nodosum,3218,I-Disease
in,3218,O
our,3218,O
patients,3218,O
.,3218,O
Short-term,3219,O
use,3219,O
of,3219,O
steroid,3219,B-Chemical
is,3219,O
very,3219,O
effective,3219,O
in,3219,O
ATRA-induced,3219,B-Chemical
erythema,3219,B-Disease
nodosum,3219,I-Disease
.,3219,O
Effect,3220,O
of,3220,O
some,3220,O
convulsants,3220,O
on,3220,O
the,3220,O
protective,3220,O
activity,3220,O
of,3220,O
loreclezole,3220,B-Chemical
and,3220,O
its,3220,O
combinations,3220,O
with,3220,O
valproate,3220,B-Chemical
or,3220,O
clonazepam,3220,B-Chemical
in,3220,O
amygdala-kindled,3220,O
rats,3220,O
.,3220,O
Loreclezole,3221,B-Chemical
(,3221,O
5,3221,O
mg/kg,3221,O
),3221,O
exerted,3221,O
a,3221,O
significant,3221,O
protective,3221,O
action,3221,O
in,3221,O
amygdala-kindled,3221,O
rats,3221,O
",",3221,O
reducing,3221,O
both,3221,O
seizure,3221,B-Disease
and,3221,O
afterdischarge,3221,O
durations,3221,O
.,3221,O
The,3222,O
combinations,3222,O
of,3222,O
loreclezole,3222,B-Chemical
(,3222,O
2.5,3222,O
mg/kg,3222,O
),3222,O
with,3222,O
valproate,3222,B-Chemical
",",3222,O
clonazepam,3222,B-Chemical
",",3222,O
or,3222,O
carbamazepine,3222,B-Chemical
(,3222,O
applied,3222,O
at,3222,O
their,3222,O
subprotective,3222,O
doses,3222,O
),3222,O
also,3222,O
exhibited,3222,O
antiseizure,3222,O
effect,3222,O
in,3222,O
this,3222,O
test,3222,O
.,3222,O
However,3223,O
",",3223,O
only,3223,O
two,3223,O
first,3223,O
combinations,3223,O
occurred,3223,O
to,3223,O
be,3223,O
of,3223,O
pharmacodynamic,3223,O
nature,3223,O
.,3223,O
Among,3224,O
several,3224,O
chemoconvulsants,3224,O
",",3224,O
bicuculline,3224,B-Chemical
",",3224,O
N-methyl-D-aspartic,3224,B-Chemical
acid,3224,I-Chemical
and,3224,O
BAY,3224,B-Chemical
k-8644,3224,I-Chemical
(,3224,O
the,3224,O
opener,3224,O
of,3224,O
L-type,3224,O
calcium,3224,B-Chemical
channels,3224,O
),3224,O
reversed,3224,O
the,3224,O
protective,3224,O
activity,3224,O
of,3224,O
loreclezole,3224,B-Chemical
alone,3224,O
and,3224,O
its,3224,O
combination,3224,O
with,3224,O
valproate,3224,B-Chemical
.,3224,O
On,3225,O
the,3225,O
other,3225,O
hand,3225,O
",",3225,O
bicuculline,3225,B-Chemical
",",3225,O
aminophylline,3225,B-Chemical
and,3225,O
BAY,3225,B-Chemical
k-8644,3225,I-Chemical
inhibited,3225,O
the,3225,O
anticonvulsive,3225,O
action,3225,O
of,3225,O
loreclezole,3225,B-Chemical
combined,3225,O
with,3225,O
clonazepam,3225,B-Chemical
.,3225,O
The,3226,O
results,3226,O
support,3226,O
the,3226,O
hypothesis,3226,O
that,3226,O
the,3226,O
protective,3226,O
activity,3226,O
of,3226,O
loreclezole,3226,B-Chemical
and,3226,O
its,3226,O
combinations,3226,O
with,3226,O
other,3226,O
antiepileptics,3226,O
may,3226,O
involve,3226,O
potentiation,3226,O
of,3226,O
GABAergic,3226,O
neurotransmission,3226,O
and,3226,O
blockade,3226,O
of,3226,O
L-type,3226,O
of,3226,O
calcium,3226,B-Chemical
channels,3226,O
.,3226,O
Mitochondrial,3227,O
DNA,3227,O
and,3227,O
its,3227,O
respiratory,3227,O
chain,3227,O
products,3227,O
are,3227,O
defective,3227,O
in,3227,O
doxorubicin,3227,B-Chemical
nephrosis,3227,B-Disease
.,3227,O
BACKGROUND,3228,O
:,3228,O
Doxorubicin,3228,B-Chemical
induces,3228,O
a,3228,O
self-perpetuating,3228,O
nephropathy,3228,B-Disease
characterized,3228,O
by,3228,O
early,3228,O
glomerular,3228,B-Disease
and,3228,I-Disease
late-onset,3228,I-Disease
tubular,3228,I-Disease
lesions,3228,I-Disease
in,3228,O
rats,3228,O
.,3228,O
We,3229,O
investigated,3229,O
the,3229,O
potential,3229,O
role,3229,O
of,3229,O
mitochondrial,3229,B-Disease
injury,3229,I-Disease
in,3229,O
the,3229,O
onset,3229,O
of,3229,O
these,3229,O
lesions,3229,O
.,3229,O
METHODS,3230,O
:,3230,O
Rats,3230,O
were,3230,O
treated,3230,O
with,3230,O
intravenous,3230,O
doxorubicin,3230,B-Chemical
(,3230,O
1,3230,O
mg,3230,O
kg,3230,O
(,3230,O
-1,3230,O
),3230,O
week,3230,O
(,3230,O
-1,3230,O
),3230,O
),3230,O
for,3230,O
7,3230,O
weeks,3230,O
and,3230,O
were,3230,O
sacrificed,3230,O
either,3230,O
1,3230,O
week,3230,O
(,3230,O
'short-term,3230,O
',3230,O
),3230,O
or,3230,O
30,3230,O
weeks,3230,O
(,3230,O
'long-term,3230,O
',3230,O
),3230,O
following,3230,O
the,3230,O
last,3230,O
dose,3230,O
.,3230,O
Additional,3231,O
rats,3231,O
received,3231,O
a,3231,O
single,3231,O
dose,3231,O
either,3231,O
6,3231,O
days,3231,O
or,3231,O
2,3231,O
h,3231,O
prior,3231,O
to,3231,O
euthanasia,3231,O
.,3231,O
All,3232,O
rats,3232,O
were,3232,O
killed,3232,O
at,3232,O
48,3232,O
weeks,3232,O
of,3232,O
age,3232,O
.,3232,O
Glomerular,3233,B-Disease
and,3233,I-Disease
tubular,3233,I-Disease
injury,3233,I-Disease
was,3233,O
monitored,3233,O
and,3233,O
correlated,3233,O
to,3233,O
the,3233,O
activity,3233,O
or,3233,O
expression,3233,O
of,3233,O
respiratory,3233,O
chain,3233,O
components,3233,O
.,3233,O
Finally,3234,O
",",3234,O
we,3234,O
quantified,3234,O
both,3234,O
nuclear,3234,O
and,3234,O
mitochondrial,3234,O
DNA,3234,O
(,3234,O
mtDNA,3234,O
),3234,O
as,3234,O
well,3234,O
as,3234,O
superoxide,3234,B-Chemical
production,3234,O
and,3234,O
the,3234,O
4834,3234,O
base,3234,O
pair,3234,O
'common,3234,O
',3234,O
mtDNA,3234,O
deletion,3234,O
.,3234,O
RESULTS,3235,O
:,3235,O
The,3235,O
'long-term,3235,O
',3235,O
group,3235,O
had,3235,O
significant,3235,O
glomerular,3235,B-Disease
and,3235,I-Disease
tubular,3235,I-Disease
lesions,3235,I-Disease
",",3235,O
depressed,3235,O
activities,3235,O
of,3235,O
mtDNA-encoded,3235,O
NADH,3235,O
dehydrogenase,3235,O
and,3235,O
cytochrome-c,3235,O
oxidase,3235,O
(,3235,O
COX,3235,O
),3235,O
and,3235,O
increased,3235,O
citrate,3235,B-Chemical
synthase,3235,O
activity,3235,O
.,3235,O
In,3236,O
addition,3236,O
",",3236,O
expression,3236,O
of,3236,O
the,3236,O
mtDNA-encoded,3236,O
COX,3236,O
subunit,3236,O
I,3236,O
was,3236,O
reduced,3236,O
and,3236,O
mtDNA,3236,O
levels,3236,O
were,3236,O
decreased,3236,O
.,3236,O
In,3237,O
'short-term,3237,O
',3237,O
rats,3237,O
",",3237,O
there,3237,O
were,3237,O
fewer,3237,O
tubular,3237,B-Disease
lesions,3237,I-Disease
",",3237,O
but,3237,O
similar,3237,O
numbers,3237,O
of,3237,O
glomerular,3237,B-Disease
lesions,3237,I-Disease
activity,3237,O
.,3237,O
Among,3238,O
all,3238,O
animals,3238,O
",",3238,O
glomerular,3238,B-Disease
and,3238,I-Disease
tubular,3238,I-Disease
injury,3238,I-Disease
were,3238,O
inversely,3238,O
correlated,3238,O
with,3238,O
mtDNA,3238,O
levels,3238,O
",",3238,O
mtDNA-encoded,3238,O
respiratory,3238,O
chain,3238,O
activities,3238,O
and,3238,O
with,3238,O
the,3238,O
expression,3238,O
of,3238,O
the,3238,O
mtDNA-encoded,3238,O
respiratory,3238,O
chain,3238,O
subunit,3238,O
COX-I,3238,O
.,3238,O
Injury,3239,O
was,3239,O
positively,3239,O
correlated,3239,O
with,3239,O
superoxide,3239,B-Chemical
production,3239,O
and,3239,O
the,3239,O
activities,3239,O
of,3239,O
nucleus-encoded,3239,O
mitochondrial,3239,O
or,3239,O
cytoplasmic,3239,O
enzymes,3239,O
.,3239,O
Kidneys,3240,O
from,3240,O
the,3240,O
'long-term,3240,O
',3240,O
group,3240,O
showed,3240,O
more,3240,O
mtDNA,3240,O
deletions,3240,O
than,3240,O
in,3240,O
'short-term,3240,O
',3240,O
animals,3240,O
and,3240,O
these,3240,O
were,3240,O
not,3240,O
observed,3240,O
in,3240,O
the,3240,O
other,3240,O
groups,3240,O
.,3240,O
CONCLUSIONS,3241,O
:,3241,O
These,3241,O
results,3241,O
suggest,3241,O
an,3241,O
important,3241,O
role,3241,O
for,3241,O
quantitative,3241,O
and,3241,O
qualitative,3241,O
mtDNA,3241,O
alterations,3241,O
through,3241,O
the,3241,O
reduction,3241,O
of,3241,O
mtDNA-encoded,3241,O
respiratory,3241,O
chain,3241,O
function,3241,O
and,3241,O
induction,3241,O
of,3241,O
superoxide,3241,B-Chemical
in,3241,O
doxorubicin-induced,3241,B-Chemical
renal,3241,B-Disease
lesions,3241,I-Disease
.,3241,O
A,3242,O
randomized,3242,O
",",3242,O
placebo-controlled,3242,O
",",3242,O
crossover,3242,O
study,3242,O
of,3242,O
ephedrine,3242,B-Chemical
for,3242,O
SSRI-induced,3242,O
female,3242,O
sexual,3242,B-Disease
dysfunction,3242,I-Disease
.,3242,O
The,3243,O
objective,3243,O
of,3243,O
this,3243,O
study,3243,O
was,3243,O
to,3243,O
determine,3243,O
whether,3243,O
ephedrine,3243,B-Chemical
",",3243,O
an,3243,O
alpha-,3243,O
and,3243,O
beta-adrenergic,3243,O
agonist,3243,O
previously,3243,O
shown,3243,O
to,3243,O
enhance,3243,O
genital,3243,O
blood,3243,O
flow,3243,O
in,3243,O
women,3243,O
",",3243,O
has,3243,O
beneficial,3243,O
effects,3243,O
in,3243,O
reversing,3243,O
antidepressant-induced,3243,O
sexual,3243,B-Disease
dysfunction,3243,I-Disease
.,3243,O
Nineteen,3244,O
sexually,3244,B-Disease
dysfunctional,3244,I-Disease
women,3244,O
receiving,3244,O
either,3244,O
fluoxetine,3244,B-Chemical
",",3244,O
sertraline,3244,B-Chemical
",",3244,O
or,3244,O
paroxetine,3244,B-Chemical
participated,3244,O
in,3244,O
an,3244,O
eight-week,3244,O
",",3244,O
double-blind,3244,O
",",3244,O
placebo-controlled,3244,O
",",3244,O
cross-over,3244,O
study,3244,O
of,3244,O
the,3244,O
effects,3244,O
of,3244,O
ephedrine,3244,B-Chemical
(,3244,O
50,3244,O
mg,3244,O
),3244,O
on,3244,O
self-report,3244,O
measures,3244,O
of,3244,O
sexual,3244,O
desire,3244,O
",",3244,O
arousal,3244,O
",",3244,O
orgasm,3244,O
",",3244,O
and,3244,O
sexual,3244,O
satisfaction,3244,O
.,3244,O
Although,3245,O
there,3245,O
were,3245,O
significant,3245,O
improvements,3245,O
relative,3245,O
to,3245,O
baseline,3245,O
in,3245,O
sexual,3245,O
desire,3245,O
and,3245,O
orgasm,3245,O
intensity/pleasure,3245,O
on,3245,O
50,3245,O
mg,3245,O
ephedrine,3245,B-Chemical
1-hr,3245,O
prior,3245,O
to,3245,O
sexual,3245,O
activity,3245,O
",",3245,O
significant,3245,O
improvements,3245,O
in,3245,O
these,3245,O
measures,3245,O
",",3245,O
as,3245,O
well,3245,O
as,3245,O
in,3245,O
sexual,3245,O
arousal,3245,O
and,3245,O
orgasmic,3245,O
ability,3245,O
also,3245,O
were,3245,O
noted,3245,O
with,3245,O
placebo,3245,O
.,3245,O
These,3246,O
findings,3246,O
highlight,3246,O
the,3246,O
importance,3246,O
of,3246,O
conducting,3246,O
placebo-controlled,3246,O
trials,3246,O
for,3246,O
this,3246,O
condition,3246,O
.,3246,O
Does,3247,O
hormone,3247,O
therapy,3247,O
for,3247,O
the,3247,O
treatment,3247,O
of,3247,O
breast,3247,B-Disease
cancer,3247,I-Disease
have,3247,O
a,3247,O
detrimental,3247,O
effect,3247,O
on,3247,O
memory,3247,O
and,3247,O
cognition,3247,O
?,3247,O
A,3248,O
pilot,3248,O
study,3248,O
.,3248,O
This,3249,O
pilot,3249,O
study,3249,O
examines,3249,O
whether,3249,O
hormone,3249,O
therapy,3249,O
for,3249,O
breast,3249,B-Disease
cancer,3249,I-Disease
affects,3249,O
cognition,3249,O
.,3249,O
Patients,3250,O
participating,3250,O
in,3250,O
a,3250,O
randomised,3250,O
trial,3250,O
of,3250,O
anastrozole,3250,B-Chemical
",",3250,O
tamoxifen,3250,B-Chemical
alone,3250,O
or,3250,O
combined,3250,O
(,3250,O
ATAC,3250,O
),3250,O
(,3250,O
n=94,3250,O
),3250,O
and,3250,O
a,3250,O
group,3250,O
of,3250,O
women,3250,O
without,3250,O
breast,3250,B-Disease
cancer,3250,I-Disease
(,3250,O
n=35,3250,O
),3250,O
completed,3250,O
a,3250,O
battery,3250,O
of,3250,O
neuropsychological,3250,O
measures,3250,O
.,3250,O
Compared,3251,O
with,3251,O
the,3251,O
control,3251,O
group,3251,O
",",3251,O
the,3251,O
patients,3251,O
were,3251,O
impaired,3251,O
on,3251,O
a,3251,O
processing,3251,O
speed,3251,O
task,3251,O
(,3251,O
p=0.032,3251,O
),3251,O
and,3251,O
on,3251,O
a,3251,O
measure,3251,O
of,3251,O
immediate,3251,O
verbal,3251,O
memory,3251,O
(,3251,O
p=0.026,3251,O
),3251,O
after,3251,O
controlling,3251,O
for,3251,O
the,3251,O
use,3251,O
of,3251,O
hormone,3251,O
replacement,3251,O
therapy,3251,O
in,3251,O
both,3251,O
groups,3251,O
.,3251,O
Patient,3252,O
group,3252,O
performance,3252,O
was,3252,O
not,3252,O
significantly,3252,O
related,3252,O
to,3252,O
length,3252,O
of,3252,O
treatment,3252,O
or,3252,O
measures,3252,O
of,3252,O
psychological,3252,O
morbidity,3252,O
.,3252,O
The,3253,O
results,3253,O
showed,3253,O
specific,3253,O
impairments,3253,O
in,3253,O
processing,3253,O
speed,3253,O
and,3253,O
verbal,3253,O
memory,3253,O
in,3253,O
women,3253,O
receiving,3253,O
hormonal,3253,O
therapy,3253,O
for,3253,O
the,3253,O
treatment,3253,O
of,3253,O
breast,3253,B-Disease
cancer,3253,I-Disease
.,3253,O
Verbal,3254,O
memory,3254,O
may,3254,O
be,3254,O
especially,3254,O
sensitive,3254,O
to,3254,O
changes,3254,O
in,3254,O
oestrogen,3254,B-Chemical
levels,3254,O
",",3254,O
a,3254,O
finding,3254,O
commonly,3254,O
reported,3254,O
in,3254,O
studies,3254,O
of,3254,O
hormone,3254,O
replacement,3254,O
therapy,3254,O
in,3254,O
healthy,3254,O
women,3254,O
.,3254,O
In,3255,O
view,3255,O
of,3255,O
the,3255,O
increased,3255,O
use,3255,O
of,3255,O
hormone,3255,O
therapies,3255,O
in,3255,O
an,3255,O
adjuvant,3255,O
and,3255,O
preventative,3255,O
setting,3255,O
their,3255,O
impact,3255,O
on,3255,O
cognitive,3255,O
functioning,3255,O
should,3255,O
be,3255,O
investigated,3255,O
more,3255,O
thoroughly,3255,O
.,3255,O
Expression,3256,O
of,3256,O
p300,3256,O
protects,3256,O
cardiac,3256,O
myocytes,3256,O
from,3256,O
apoptosis,3256,O
in,3256,O
vivo,3256,O
.,3256,O
Doxorubicin,3257,B-Chemical
is,3257,O
an,3257,O
anti-tumor,3257,O
agent,3257,O
that,3257,O
represses,3257,O
cardiac-specific,3257,O
gene,3257,O
expression,3257,O
and,3257,O
induces,3257,O
myocardial,3257,O
cell,3257,O
apoptosis,3257,O
.,3257,O
Doxorubicin,3258,B-Chemical
depletes,3258,O
cardiac,3258,O
p300,3258,O
",",3258,O
a,3258,O
transcriptional,3258,O
coactivator,3258,O
that,3258,O
is,3258,O
required,3258,O
for,3258,O
the,3258,O
maintenance,3258,O
of,3258,O
the,3258,O
differentiated,3258,O
phenotype,3258,O
of,3258,O
cardiac,3258,O
myocytes,3258,O
.,3258,O
However,3259,O
",",3259,O
the,3259,O
role,3259,O
of,3259,O
p300,3259,O
in,3259,O
protection,3259,O
against,3259,O
doxorubicin-induced,3259,B-Chemical
apoptosis,3259,O
is,3259,O
unknown,3259,O
.,3259,O
Transgenic,3260,O
mice,3260,O
overexpressing,3260,O
p300,3260,O
in,3260,O
the,3260,O
heart,3260,O
and,3260,O
wild-type,3260,O
mice,3260,O
were,3260,O
subjected,3260,O
to,3260,O
doxorubicin,3260,B-Chemical
treatment,3260,O
.,3260,O
Compared,3261,O
with,3261,O
wild-type,3261,O
mice,3261,O
",",3261,O
transgenic,3261,O
mice,3261,O
exhibited,3261,O
higher,3261,O
survival,3261,O
rate,3261,O
as,3261,O
well,3261,O
as,3261,O
more,3261,O
preserved,3261,O
left,3261,O
ventricular,3261,O
function,3261,O
and,3261,O
cardiac,3261,O
expression,3261,O
of,3261,O
alpha-sarcomeric,3261,O
actin,3261,O
.,3261,O
Doxorubicin,3262,B-Chemical
induced,3262,O
myocardial,3262,O
cell,3262,O
apoptosis,3262,O
in,3262,O
wild-type,3262,O
mice,3262,O
but,3262,O
not,3262,O
in,3262,O
transgenic,3262,O
mice,3262,O
.,3262,O
Expression,3263,O
of,3263,O
p300,3263,O
increased,3263,O
the,3263,O
cardiac,3263,O
level,3263,O
of,3263,O
bcl-2,3263,O
and,3263,O
mdm-2,3263,O
",",3263,O
but,3263,O
not,3263,O
that,3263,O
of,3263,O
p53,3263,O
or,3263,O
other,3263,O
members,3263,O
of,3263,O
the,3263,O
bcl-2,3263,O
family,3263,O
.,3263,O
These,3264,O
findings,3264,O
demonstrate,3264,O
that,3264,O
overexpression,3264,O
of,3264,O
p300,3264,O
protects,3264,O
cardiac,3264,O
myocytes,3264,O
from,3264,O
doxorubicin-induced,3264,B-Chemical
apoptosis,3264,O
and,3264,O
reduces,3264,O
the,3264,O
extent,3264,O
of,3264,O
acute,3264,O
heart,3264,B-Disease
failure,3264,I-Disease
in,3264,O
adult,3264,O
mice,3264,O
in,3264,O
vivo,3264,O
.,3264,O
Methimazole-induced,3265,B-Chemical
cholestatic,3265,B-Disease
jaundice,3265,I-Disease
.,3265,O
Methimazole,3266,B-Chemical
is,3266,O
a,3266,O
widely,3266,O
used,3266,O
and,3266,O
generally,3266,O
well-tolerated,3266,O
antithyroid,3266,O
agent,3266,O
.,3266,O
A,3267,O
43-year-old,3267,O
woman,3267,O
had,3267,O
severe,3267,O
jaundice,3267,B-Disease
and,3267,O
itching,3267,B-Disease
1,3267,O
month,3267,O
after,3267,O
receiving,3267,O
methimazole,3267,B-Chemical
(,3267,O
10,3267,O
mg,3267,O
tid,3267,O
),3267,O
and,3267,O
propranolol,3267,B-Chemical
(,3267,O
20,3267,O
mg,3267,O
tid,3267,O
),3267,O
for,3267,O
treatment,3267,O
of,3267,O
hyperthyroidism,3267,B-Disease
.,3267,O
The,3268,O
patient,3268,O
continued,3268,O
treatment,3268,O
for,3268,O
another,3268,O
4,3268,O
days,3268,O
after,3268,O
the,3268,O
appearance,3268,O
of,3268,O
jaundice,3268,B-Disease
until,3268,O
she,3268,O
finished,3268,O
both,3268,O
medications,3268,O
.,3268,O
When,3269,O
seen,3269,O
at,3269,O
the,3269,O
emergency,3269,O
department,3269,O
2,3269,O
weeks,3269,O
later,3269,O
",",3269,O
she,3269,O
still,3269,O
had,3269,O
severe,3269,O
icterus,3269,B-Disease
",",3269,O
pruritus,3269,B-Disease
",",3269,O
and,3269,O
hyperbilirubinemia,3269,B-Disease
",",3269,O
formed,3269,O
mainly,3269,O
of,3269,O
the,3269,O
conjugated,3269,O
fraction,3269,O
.,3269,O
Methimazole-induced,3270,B-Chemical
cholestasis,3270,B-Disease
was,3270,O
diagnosed,3270,O
",",3270,O
and,3270,O
propranolol,3270,B-Chemical
therapy,3270,O
was,3270,O
resumed,3270,O
.,3270,O
Over,3271,O
the,3271,O
following,3271,O
9,3271,O
days,3271,O
",",3271,O
the,3271,O
symptoms,3271,O
improved,3271,O
and,3271,O
plasma,3271,O
bilirubin,3271,B-Chemical
levels,3271,O
were,3271,O
normal,3271,O
after,3271,O
12,3271,O
weeks,3271,O
without,3271,O
methimazole,3271,B-Chemical
.,3271,O
In,3272,O
rare,3272,O
cases,3272,O
within,3272,O
the,3272,O
first,3272,O
few,3272,O
weeks,3272,O
of,3272,O
therapy,3272,O
",",3272,O
this,3272,O
drug,3272,O
can,3272,O
cause,3272,O
severe,3272,O
and,3272,O
reversible,3272,O
cholestatic,3272,B-Disease
jaundice,3272,I-Disease
.,3272,O
Physicians,3273,O
and,3273,O
patients,3273,O
should,3273,O
be,3273,O
aware,3273,O
of,3273,O
this,3273,O
adverse,3273,O
effect,3273,O
so,3273,O
that,3273,O
",",3273,O
upon,3273,O
occurrence,3273,O
",",3273,O
they,3273,O
can,3273,O
discontinue,3273,O
methimazole,3273,B-Chemical
therapy,3273,O
and,3273,O
avoid,3273,O
unnecessary,3273,O
invasive,3273,O
procedures,3273,O
.,3273,O
Atrial,3274,B-Disease
fibrillation,3274,I-Disease
following,3274,O
chemotherapy,3274,O
for,3274,O
stage,3274,O
IIIE,3274,O
diffuse,3274,O
large,3274,O
B-cell,3274,O
gastric,3274,B-Disease
lymphoma,3274,I-Disease
in,3274,O
a,3274,O
patient,3274,O
with,3274,O
myotonic,3274,B-Disease
dystrophy,3274,I-Disease
(,3274,O
Steinert,3274,B-Disease
's,3274,I-Disease
disease,3274,I-Disease
),3274,O
.,3274,O
The,3275,O
authors,3275,O
describe,3275,O
the,3275,O
unusual,3275,O
association,3275,O
between,3275,O
diffuse,3275,O
B-cell,3275,O
gastric,3275,B-Disease
lymphoma,3275,I-Disease
and,3275,O
myotonic,3275,B-Disease
dystrophy,3275,I-Disease
",",3275,O
the,3275,O
most,3275,O
common,3275,O
form,3275,O
of,3275,O
adult,3275,O
muscular,3275,B-Disease
dystrophy,3275,I-Disease
",",3275,O
and,3275,O
sudden,3275,O
atrial,3275,B-Disease
fibrillation,3275,I-Disease
following,3275,O
one,3275,O
cycle,3275,O
of,3275,O
doxorubicin-based,3275,B-Chemical
chemotherapy,3275,O
in,3275,O
the,3275,O
same,3275,O
patient,3275,O
.,3275,O
Atrial,3276,B-Disease
fibrillation,3276,I-Disease
or,3276,O
other,3276,O
cardiac,3276,B-Disease
arrhythmias,3276,I-Disease
are,3276,O
unusual,3276,O
complications,3276,O
in,3276,O
patients,3276,O
treated,3276,O
with,3276,O
chemotherapy,3276,O
.,3276,O
The,3277,O
cardiac,3277,B-Disease
toxicity,3277,I-Disease
intrinsically,3277,O
associated,3277,O
with,3277,O
the,3277,O
aggressive,3277,O
chemotherapy,3277,O
employed,3277,O
could,3277,O
function,3277,O
as,3277,O
a,3277,O
triggering,3277,O
factor,3277,O
for,3277,O
the,3277,O
arrhythmia,3277,B-Disease
in,3277,O
the,3277,O
predisposed,3277,O
myocardium,3277,O
of,3277,O
this,3277,O
patient,3277,O
.,3277,O
Increased,3278,O
expression,3278,O
and,3278,O
apical,3278,O
targeting,3278,O
of,3278,O
renal,3278,O
ENaC,3278,O
subunits,3278,O
in,3278,O
puromycin,3278,B-Chemical
aminonucleoside-induced,3278,O
nephrotic,3278,B-Disease
syndrome,3278,I-Disease
in,3278,O
rats,3278,O
.,3278,O
Nephrotic,3279,B-Disease
syndrome,3279,I-Disease
is,3279,O
often,3279,O
accompanied,3279,O
by,3279,O
sodium,3279,B-Chemical
retention,3279,O
and,3279,O
generalized,3279,O
edema,3279,B-Disease
.,3279,O
However,3280,O
",",3280,O
the,3280,O
molecular,3280,O
basis,3280,O
for,3280,O
the,3280,O
decreased,3280,O
renal,3280,O
sodium,3280,B-Chemical
excretion,3280,O
remains,3280,O
undefined,3280,O
.,3280,O
We,3281,O
hypothesized,3281,O
that,3281,O
epithelial,3281,O
Na,3281,B-Chemical
channel,3281,O
(,3281,O
ENaC,3281,O
),3281,O
subunit,3281,O
dysregulation,3281,O
may,3281,O
be,3281,O
responsible,3281,O
for,3281,O
the,3281,O
increased,3281,O
sodium,3281,B-Chemical
retention,3281,O
.,3281,O
An,3282,O
experimental,3282,O
group,3282,O
of,3282,O
rats,3282,O
was,3282,O
treated,3282,O
with,3282,O
puromycin,3282,B-Chemical
aminonucleoside,3282,I-Chemical
(,3282,O
PAN,3282,B-Chemical
;,3282,O
180,3282,O
mg/kg,3282,O
iv,3282,O
),3282,O
",",3282,O
whereas,3282,O
the,3282,O
control,3282,O
group,3282,O
received,3282,O
only,3282,O
vehicle,3282,O
.,3282,O
After,3283,O
7,3283,O
days,3283,O
",",3283,O
PAN,3283,B-Chemical
treatment,3283,O
induced,3283,O
significant,3283,O
proteinuria,3283,B-Disease
",",3283,O
hypoalbuminemia,3283,B-Disease
",",3283,O
decreased,3283,O
urinary,3283,O
sodium,3283,B-Chemical
excretion,3283,O
",",3283,O
and,3283,O
extensive,3283,O
ascites,3283,B-Disease
.,3283,O
The,3284,O
protein,3284,O
abundance,3284,O
of,3284,O
alpha-ENaC,3284,O
and,3284,O
beta-ENaC,3284,O
was,3284,O
increased,3284,O
in,3284,O
the,3284,O
inner,3284,O
stripe,3284,O
of,3284,O
the,3284,O
outer,3284,O
medulla,3284,O
(,3284,O
ISOM,3284,O
),3284,O
and,3284,O
in,3284,O
the,3284,O
inner,3284,O
medulla,3284,O
(,3284,O
IM,3284,O
),3284,O
but,3284,O
was,3284,O
not,3284,O
altered,3284,O
in,3284,O
the,3284,O
cortex,3284,O
.,3284,O
gamma-ENaC,3285,O
abundance,3285,O
was,3285,O
increased,3285,O
in,3285,O
the,3285,O
cortex,3285,O
",",3285,O
ISOM,3285,O
",",3285,O
and,3285,O
IM,3285,O
.,3285,O
Immunoperoxidase,3286,O
brightfield-,3286,O
and,3286,O
laser-scanning,3286,O
confocal,3286,O
fluorescence,3286,O
microscopy,3286,O
demonstrated,3286,O
increased,3286,O
targeting,3286,O
of,3286,O
alpha-ENaC,3286,O
",",3286,O
beta-ENaC,3286,O
",",3286,O
and,3286,O
gamma-ENaC,3286,O
subunits,3286,O
to,3286,O
the,3286,O
apical,3286,O
plasma,3286,O
membrane,3286,O
in,3286,O
the,3286,O
distal,3286,O
convoluted,3286,O
tubule,3286,O
(,3286,O
DCT2,3286,O
),3286,O
",",3286,O
connecting,3286,O
tubule,3286,O
",",3286,O
and,3286,O
cortical,3286,O
and,3286,O
medullary,3286,O
collecting,3286,O
duct,3286,O
segments,3286,O
.,3286,O
Immunoelectron,3287,O
microscopy,3287,O
further,3287,O
revealed,3287,O
an,3287,O
increased,3287,O
labeling,3287,O
of,3287,O
alpha-ENaC,3287,O
in,3287,O
the,3287,O
apical,3287,O
plasma,3287,O
membrane,3287,O
of,3287,O
cortical,3287,O
collecting,3287,O
duct,3287,O
principal,3287,O
cells,3287,O
of,3287,O
PAN-treated,3287,B-Chemical
rats,3287,O
",",3287,O
indicating,3287,O
enhanced,3287,O
apical,3287,O
targeting,3287,O
of,3287,O
alpha-ENaC,3287,O
subunits,3287,O
.,3287,O
In,3288,O
contrast,3288,O
",",3288,O
the,3288,O
protein,3288,O
abundances,3288,O
of,3288,O
Na,3288,B-Chemical
(,3288,O
+,3288,O
),3288,O
/H,3288,O
(,3288,O
+,3288,O
),3288,O
exchanger,3288,O
type,3288,O
3,3288,O
(,3288,O
NHE3,3288,O
),3288,O
",",3288,O
Na,3288,B-Chemical
(,3288,O
+,3288,O
),3288,O
-K,3288,O
(,3288,O
+,3288,O
),3288,O
-2Cl,3288,O
(,3288,O
-,3288,O
),3288,O
cotransporter,3288,O
(,3288,O
BSC-1,3288,O
),3288,O
",",3288,O
and,3288,O
thiazide-sensitive,3288,B-Chemical
Na,3288,B-Chemical
(,3288,O
+,3288,O
),3288,O
-Cl,3288,O
(,3288,O
-,3288,O
),3288,O
cotransporter,3288,O
(,3288,O
TSC,3288,O
),3288,O
were,3288,O
decreased,3288,O
.,3288,O
Moreover,3289,O
",",3289,O
the,3289,O
abundance,3289,O
of,3289,O
the,3289,O
alpha,3289,O
(,3289,O
1,3289,O
),3289,O
-subunit,3289,O
of,3289,O
the,3289,O
Na-K-ATPase,3289,B-Chemical
was,3289,O
decreased,3289,O
in,3289,O
the,3289,O
cortex,3289,O
and,3289,O
ISOM,3289,O
",",3289,O
but,3289,O
it,3289,O
remained,3289,O
unchanged,3289,O
in,3289,O
the,3289,O
IM,3289,O
.,3289,O
In,3290,O
conclusion,3290,O
",",3290,O
the,3290,O
increased,3290,O
or,3290,O
sustained,3290,O
expression,3290,O
of,3290,O
ENaC,3290,O
subunits,3290,O
combined,3290,O
with,3290,O
increased,3290,O
apical,3290,O
targeting,3290,O
in,3290,O
the,3290,O
DCT2,3290,O
",",3290,O
connecting,3290,O
tubule,3290,O
",",3290,O
and,3290,O
collecting,3290,O
duct,3290,O
are,3290,O
likely,3290,O
to,3290,O
play,3290,O
a,3290,O
role,3290,O
in,3290,O
the,3290,O
sodium,3290,B-Chemical
retention,3290,O
associated,3290,O
with,3290,O
PAN-induced,3290,B-Chemical
nephrotic,3290,B-Disease
syndrome,3290,I-Disease
.,3290,O
The,3291,O
decreased,3291,O
abundance,3291,O
of,3291,O
NHE3,3291,O
",",3291,O
BSC-1,3291,O
",",3291,O
TSC,3291,O
",",3291,O
and,3291,O
Na-K-ATPase,3291,B-Chemical
may,3291,O
play,3291,O
a,3291,O
compensatory,3291,O
role,3291,O
to,3291,O
promote,3291,O
sodium,3291,B-Chemical
excretion,3291,O
.,3291,O
Pallidal,3292,O
stimulation,3292,O
:,3292,O
an,3292,O
alternative,3292,O
to,3292,O
pallidotomy,3292,O
?,3292,O
A,3293,O
resurgence,3293,O
of,3293,O
interest,3293,O
in,3293,O
the,3293,O
surgical,3293,O
treatment,3293,O
of,3293,O
Parkinson,3293,B-Disease
's,3293,I-Disease
disease,3293,I-Disease
(,3293,O
PD,3293,B-Disease
),3293,O
came,3293,O
with,3293,O
the,3293,O
rediscovery,3293,O
of,3293,O
posteroventral,3293,O
pallidotomy,3293,O
by,3293,O
Laitinen,3293,O
in,3293,O
1985,3293,O
.,3293,O
Laitinen,3294,O
's,3294,O
procedure,3294,O
improved,3294,O
most,3294,O
symptoms,3294,O
in,3294,O
drug-resistant,3294,O
PD,3294,B-Disease
",",3294,O
which,3294,O
engendered,3294,O
wide,3294,O
interest,3294,O
in,3294,O
the,3294,O
neurosurgical,3294,O
community,3294,O
.,3294,O
Another,3295,O
lesioning,3295,O
procedure,3295,O
",",3295,O
ventrolateral,3295,O
thalamotomy,3295,O
",",3295,O
has,3295,O
become,3295,O
a,3295,O
powerful,3295,O
alternative,3295,O
to,3295,O
stimulate,3295,O
the,3295,O
nucleus,3295,O
ventralis,3295,O
intermedius,3295,O
",",3295,O
producing,3295,O
high,3295,O
long-term,3295,O
success,3295,O
rates,3295,O
and,3295,O
low,3295,O
morbidity,3295,O
rates,3295,O
.,3295,O
Pallidal,3296,O
stimulation,3296,O
has,3296,O
not,3296,O
met,3296,O
with,3296,O
the,3296,O
same,3296,O
success,3296,O
.,3296,O
According,3297,O
to,3297,O
the,3297,O
literature,3297,O
pallidotomy,3297,O
improves,3297,O
the,3297,O
``,3297,O
on,3297,O
'',3297,O
symptoms,3297,O
of,3297,O
PD,3297,B-Disease
",",3297,O
such,3297,O
as,3297,O
dyskinesias,3297,B-Disease
",",3297,O
as,3297,O
well,3297,O
as,3297,O
the,3297,O
``,3297,O
off,3297,O
'',3297,O
symptoms,3297,O
",",3297,O
such,3297,O
as,3297,O
rigidity,3297,B-Disease
",",3297,O
bradykinesia,3297,B-Disease
",",3297,O
and,3297,O
on-off,3297,O
fluctuations,3297,O
.,3297,O
Pallidal,3298,O
stimulation,3298,O
improves,3298,O
bradykinesia,3298,B-Disease
and,3298,O
rigidity,3298,B-Disease
to,3298,O
a,3298,O
minor,3298,O
extent,3298,O
;,3298,O
however,3298,O
",",3298,O
its,3298,O
strength,3298,O
seems,3298,O
to,3298,O
be,3298,O
in,3298,O
improving,3298,O
levodopa-induced,3298,B-Chemical
dyskinesias,3298,B-Disease
.,3298,O
Stimulation,3299,O
often,3299,O
produces,3299,O
an,3299,O
improvement,3299,O
in,3299,O
the,3299,O
hyper-,3299,B-Disease
or,3299,I-Disease
dyskinetic,3299,I-Disease
upper,3299,O
limbs,3299,O
",",3299,O
but,3299,O
increases,3299,O
the,3299,O
``,3299,O
freezing,3299,O
'',3299,O
phenomenon,3299,O
in,3299,O
the,3299,O
lower,3299,O
limbs,3299,O
at,3299,O
the,3299,O
same,3299,O
time,3299,O
.,3299,O
Considering,3300,O
the,3300,O
small,3300,O
increase,3300,O
in,3300,O
the,3300,O
patient,3300,O
's,3300,O
independence,3300,O
",",3300,O
the,3300,O
high,3300,O
costs,3300,O
of,3300,O
bilateral,3300,O
implants,3300,O
",",3300,O
and,3300,O
the,3300,O
difficulty,3300,O
most,3300,O
patients,3300,O
experience,3300,O
in,3300,O
handling,3300,O
the,3300,O
devices,3300,O
",",3300,O
the,3300,O
question,3300,O
arises,3300,O
as,3300,O
to,3300,O
whether,3300,O
bilateral,3300,O
pallidal,3300,O
stimulation,3300,O
is,3300,O
a,3300,O
real,3300,O
alternative,3300,O
to,3300,O
pallidotomy,3300,O
.,3300,O
Effects,3301,O
of,3301,O
the,3301,O
cyclooxygenase-2,3301,O
specific,3301,O
inhibitor,3301,O
valdecoxib,3301,B-Chemical
versus,3301,O
nonsteroidal,3301,O
antiinflammatory,3301,O
agents,3301,O
and,3301,O
placebo,3301,O
on,3301,O
cardiovascular,3301,O
thrombotic,3301,B-Disease
events,3301,O
in,3301,O
patients,3301,O
with,3301,O
arthritis,3301,B-Disease
.,3301,O
There,3302,O
have,3302,O
been,3302,O
concerns,3302,O
that,3302,O
the,3302,O
risk,3302,O
of,3302,O
cardiovascular,3302,O
thrombotic,3302,B-Disease
events,3302,O
may,3302,O
be,3302,O
higher,3302,O
with,3302,O
cyclooxygenase,3302,O
(,3302,O
COX,3302,O
),3302,O
-2-specific,3302,O
inhibitors,3302,O
than,3302,O
nonselective,3302,O
nonsteroidal,3302,O
antiinflammatory,3302,O
drugs,3302,O
(,3302,O
NSAIDs,3302,O
),3302,O
.,3302,O
We,3303,O
evaluated,3303,O
cardiovascular,3303,O
event,3303,O
data,3303,O
for,3303,O
valdecoxib,3303,B-Chemical
",",3303,O
a,3303,O
new,3303,O
COX-2-specific,3303,O
inhibitor,3303,O
in,3303,O
approximately,3303,O
8000,3303,O
patients,3303,O
with,3303,O
osteoarthritis,3303,B-Disease
and,3303,O
rheumatoid,3303,B-Disease
arthritis,3303,I-Disease
treated,3303,O
with,3303,O
this,3303,O
agent,3303,O
in,3303,O
randomized,3303,O
clinical,3303,O
trials,3303,O
.,3303,O
The,3304,O
incidence,3304,O
of,3304,O
cardiovascular,3304,O
thrombotic,3304,B-Disease
events,3304,O
(,3304,O
cardiac,3304,O
",",3304,O
cerebrovascular,3304,O
and,3304,O
peripheral,3304,O
vascular,3304,O
",",3304,O
or,3304,O
arterial,3304,O
thrombotic,3304,B-Disease
),3304,O
was,3304,O
determined,3304,O
by,3304,O
analyzing,3304,O
pooled,3304,O
valdecoxib,3304,B-Chemical
(,3304,O
10-80,3304,O
mg,3304,O
daily,3304,O
),3304,O
",",3304,O
nonselective,3304,O
NSAID,3304,O
(,3304,O
diclofenac,3304,B-Chemical
75,3304,O
mg,3304,O
bid,3304,O
",",3304,O
ibuprofen,3304,B-Chemical
800,3304,O
mg,3304,O
tid,3304,O
",",3304,O
or,3304,O
naproxen,3304,B-Chemical
500,3304,O
mg,3304,O
bid,3304,O
),3304,O
and,3304,O
placebo,3304,O
data,3304,O
from,3304,O
10,3304,O
randomized,3304,O
osteoarthritis,3304,B-Disease
and,3304,O
rheumatoid,3304,B-Disease
arthritis,3304,I-Disease
trials,3304,O
that,3304,O
were,3304,O
6-52,3304,O
weeks,3304,O
in,3304,O
duration,3304,O
.,3304,O
The,3305,O
incidence,3305,O
rates,3305,O
of,3305,O
events,3305,O
were,3305,O
determined,3305,O
in,3305,O
all,3305,O
patients,3305,O
(,3305,O
n,3305,O
=,3305,O
7934,3305,O
),3305,O
and,3305,O
in,3305,O
users,3305,O
of,3305,O
low-dose,3305,O
(,3305,O
<,3305,O
or,3305,O
=325,3305,O
mg,3305,O
daily,3305,O
),3305,O
aspirin,3305,B-Chemical
(,3305,O
n,3305,O
=,3305,O
1051,3305,O
),3305,O
and,3305,O
nonusers,3305,O
of,3305,O
aspirin,3305,B-Chemical
(,3305,O
n,3305,O
=,3305,O
6883,3305,O
),3305,O
.,3305,O
Crude,3306,O
and,3306,O
exposure-adjusted,3306,O
incidences,3306,O
of,3306,O
thrombotic,3306,B-Disease
events,3306,O
were,3306,O
similar,3306,O
for,3306,O
valdecoxib,3306,B-Chemical
",",3306,O
NSAIDs,3306,O
",",3306,O
and,3306,O
placebo,3306,O
.,3306,O
The,3307,O
risk,3307,O
of,3307,O
serious,3307,O
thrombotic,3307,B-Disease
events,3307,O
was,3307,O
also,3307,O
similar,3307,O
for,3307,O
each,3307,O
valdecoxib,3307,B-Chemical
dose,3307,O
.,3307,O
Thrombotic,3308,B-Disease
risk,3308,O
was,3308,O
consistently,3308,O
higher,3308,O
for,3308,O
users,3308,O
of,3308,O
aspirin,3308,B-Chemical
users,3308,O
than,3308,O
nonusers,3308,O
of,3308,O
aspirin,3308,B-Chemical
(,3308,O
placebo,3308,O
",",3308,O
1.4,3308,O
%,3308,O
vs.,3308,O
0,3308,O
%,3308,O
;,3308,O
valdecoxib,3308,B-Chemical
",",3308,O
1.7,3308,O
%,3308,O
vs.,3308,O
0.2,3308,O
%,3308,O
;,3308,O
NSAIDs,3308,O
",",3308,O
1.9,3308,O
%,3308,O
vs.,3308,O
0.5,3308,O
%,3308,O
),3308,O
.,3308,O
The,3309,O
rates,3309,O
of,3309,O
events,3309,O
in,3309,O
users,3309,O
of,3309,O
aspirin,3309,B-Chemical
were,3309,O
similar,3309,O
for,3309,O
all,3309,O
3,3309,O
treatment,3309,O
groups,3309,O
and,3309,O
across,3309,O
valdecoxib,3309,B-Chemical
doses,3309,O
.,3309,O
Short-,3310,O
and,3310,O
intermediate-term,3310,O
treatment,3310,O
with,3310,O
therapeutic,3310,O
(,3310,O
10,3310,O
or,3310,O
20,3310,O
mg,3310,O
daily,3310,O
),3310,O
and,3310,O
supratherapeutic,3310,O
(,3310,O
40,3310,O
or,3310,O
80,3310,O
mg,3310,O
daily,3310,O
),3310,O
valdecoxib,3310,B-Chemical
doses,3310,O
was,3310,O
not,3310,O
associated,3310,O
with,3310,O
an,3310,O
increased,3310,O
incidence,3310,O
of,3310,O
thrombotic,3310,B-Disease
events,3310,O
relative,3310,O
to,3310,O
nonselective,3310,O
NSAIDs,3310,O
or,3310,O
placebo,3310,O
in,3310,O
osteoarthritis,3310,B-Disease
and,3310,O
rheumatoid,3310,B-Disease
arthritis,3310,I-Disease
patients,3310,O
in,3310,O
controlled,3310,O
clinical,3310,O
trials,3310,O
.,3310,O
Hypersensitivity,3311,B-Disease
myocarditis,3311,B-Disease
complicating,3311,O
hypertrophic,3311,B-Disease
cardiomyopathy,3311,I-Disease
heart,3311,O
.,3311,O
The,3312,O
present,3312,O
report,3312,O
describes,3312,O
a,3312,O
case,3312,O
of,3312,O
eosinophilic,3312,O
myocarditis,3312,O
complicating,3312,O
hypertrophic,3312,B-Disease
cardiomyopathy,3312,I-Disease
.,3312,O
The,3313,O
47-year-old,3313,O
female,3313,O
patient,3313,O
",",3313,O
known,3313,O
to,3313,O
have,3313,O
hypertrophic,3313,B-Disease
cardiomyopathy,3313,I-Disease
",",3313,O
was,3313,O
admitted,3313,O
with,3313,O
biventricular,3313,B-Disease
failure,3313,I-Disease
and,3313,O
managed,3313,O
aggressively,3313,O
with,3313,O
dobutamine,3313,B-Chemical
infusion,3313,O
and,3313,O
other,3313,O
drugs,3313,O
while,3313,O
being,3313,O
assessed,3313,O
for,3313,O
heart,3313,O
transplantation,3313,O
.,3313,O
On,3314,O
transthoracic,3314,O
echocardiogram,3314,O
",",3314,O
she,3314,O
had,3314,O
moderate,3314,O
left,3314,B-Disease
ventricular,3314,I-Disease
dysfunction,3314,I-Disease
with,3314,O
regional,3314,O
variability,3314,O
and,3314,O
moderate,3314,O
mitral,3314,B-Disease
regurgitation,3314,I-Disease
.,3314,O
The,3315,O
recipient,3315,O
's,3315,O
heart,3315,O
showed,3315,O
the,3315,O
features,3315,O
of,3315,O
apical,3315,O
hypertrophic,3315,B-Disease
cardiomyopathy,3315,I-Disease
and,3315,O
myocarditis,3315,B-Disease
with,3315,O
abundant,3315,O
eosinophils,3315,O
.,3315,O
Myocarditis,3316,B-Disease
is,3316,O
rare,3316,O
and,3316,O
eosinophilic,3316,O
myocarditis,3316,O
is,3316,O
rarer,3316,O
.,3316,O
It,3317,O
is,3317,O
likely,3317,O
that,3317,O
the,3317,O
hypersensitivity,3317,B-Disease
(,3317,O
eosinophilic,3317,B-Disease
),3317,O
myocarditis,3317,B-Disease
was,3317,O
related,3317,O
to,3317,O
dobutamine,3317,B-Chemical
infusion,3317,O
therapy,3317,O
.,3317,O
Eosinophilic,3318,O
myocarditis,3318,O
has,3318,O
been,3318,O
reported,3318,O
with,3318,O
an,3318,O
incidence,3318,O
of,3318,O
2.4,3318,O
%,3318,O
to,3318,O
7.2,3318,O
%,3318,O
in,3318,O
explanted,3318,O
hearts,3318,O
and,3318,O
may,3318,O
be,3318,O
related,3318,O
to,3318,O
multidrug,3318,O
therapy,3318,O
.,3318,O
Time,3319,O
trends,3319,O
in,3319,O
warfarin-associated,3319,B-Chemical
hemorrhage,3319,B-Disease
.,3319,O
The,3320,O
annual,3320,O
incidence,3320,O
of,3320,O
warfarin-related,3320,B-Chemical
bleeding,3320,B-Disease
at,3320,O
Brigham,3320,O
and,3320,O
Women,3320,O
's,3320,O
Hospital,3320,O
increased,3320,O
from,3320,O
"0.97/1,000",3320,O
patient,3320,O
admissions,3320,O
in,3320,O
the,3320,O
first,3320,O
time,3320,O
period,3320,O
(,3320,O
January,3320,O
1995,3320,O
to,3320,O
October,3320,O
1998,3320,O
),3320,O
to,3320,O
"1.19/1,000",3320,O
patient,3320,O
admissions,3320,O
in,3320,O
the,3320,O
second,3320,O
time,3320,O
period,3320,O
(,3320,O
November,3320,O
1998,3320,O
to,3320,O
August,3320,O
2002,3320,O
),3320,O
of,3320,O
this,3320,O
study,3320,O
.,3320,O
The,3321,O
proportion,3321,O
of,3321,O
patients,3321,O
with,3321,O
major,3321,O
and,3321,O
intracranial,3321,B-Disease
bleeding,3321,I-Disease
increased,3321,O
from,3321,O
20.2,3321,O
%,3321,O
and,3321,O
1.9,3321,O
%,3321,O
",",3321,O
respectively,3321,O
",",3321,O
in,3321,O
the,3321,O
first,3321,O
time,3321,O
period,3321,O
",",3321,O
to,3321,O
33.3,3321,O
%,3321,O
and,3321,O
7.8,3321,O
%,3321,O
",",3321,O
respectively,3321,O
",",3321,O
in,3321,O
the,3321,O
second,3321,O
.,3321,O
Consensus,3322,O
statement,3322,O
concerning,3322,O
cardiotoxicity,3322,B-Disease
occurring,3322,O
during,3322,O
haematopoietic,3322,O
stem,3322,O
cell,3322,O
transplantation,3322,O
in,3322,O
the,3322,O
treatment,3322,O
of,3322,O
autoimmune,3322,B-Disease
diseases,3322,I-Disease
",",3322,O
with,3322,O
special,3322,O
reference,3322,O
to,3322,O
systemic,3322,B-Disease
sclerosis,3322,I-Disease
and,3322,O
multiple,3322,B-Disease
sclerosis,3322,I-Disease
.,3322,O
Autologous,3323,O
haematopoietic,3323,O
stem,3323,O
cell,3323,O
transplantation,3323,O
is,3323,O
now,3323,O
a,3323,O
feasible,3323,O
and,3323,O
effective,3323,O
treatment,3323,O
for,3323,O
selected,3323,O
patients,3323,O
with,3323,O
severe,3323,O
autoimmune,3323,B-Disease
diseases,3323,I-Disease
.,3323,O
Worldwide,3324,O
",",3324,O
over,3324,O
650,3324,O
patients,3324,O
have,3324,O
been,3324,O
transplanted,3324,O
in,3324,O
the,3324,O
context,3324,O
of,3324,O
phase,3324,O
I,3324,O
and,3324,O
II,3324,O
clinical,3324,O
trials,3324,O
.,3324,O
The,3325,O
results,3325,O
are,3325,O
encouraging,3325,O
enough,3325,O
to,3325,O
begin,3325,O
randomised,3325,O
phase,3325,O
III,3325,O
trials,3325,O
.,3325,O
However,3326,O
",",3326,O
as,3326,O
predicted,3326,O
",",3326,O
significant,3326,O
transplant-related,3326,O
morbidity,3326,O
and,3326,O
mortality,3326,O
have,3326,O
been,3326,O
observed,3326,O
.,3326,O
This,3327,O
is,3327,O
primarily,3327,O
due,3327,O
to,3327,O
complications,3327,O
related,3327,O
to,3327,O
either,3327,O
the,3327,O
stage,3327,O
of,3327,O
the,3327,O
disease,3327,O
at,3327,O
transplant,3327,O
or,3327,O
due,3327,O
to,3327,O
infections,3327,B-Disease
.,3327,O
The,3328,O
number,3328,O
of,3328,O
deaths,3328,O
related,3328,O
to,3328,O
cardiac,3328,B-Disease
toxicity,3328,I-Disease
is,3328,O
low,3328,O
.,3328,O
However,3329,O
",",3329,O
caution,3329,O
is,3329,O
required,3329,O
when,3329,O
cyclophosphamide,3329,B-Chemical
or,3329,O
anthracyclines,3329,B-Chemical
such,3329,O
as,3329,O
mitoxantrone,3329,B-Chemical
are,3329,O
used,3329,O
in,3329,O
patients,3329,O
with,3329,O
a,3329,O
possible,3329,O
underlying,3329,O
heart,3329,B-Disease
damage,3329,I-Disease
",",3329,O
for,3329,O
example,3329,O
",",3329,O
systemic,3329,B-Disease
sclerosis,3329,I-Disease
patients,3329,O
.,3329,O
In,3330,O
November,3330,O
2002,3330,O
",",3330,O
a,3330,O
meeting,3330,O
was,3330,O
held,3330,O
in,3330,O
Florence,3330,O
",",3330,O
bringing,3330,O
together,3330,O
a,3330,O
number,3330,O
of,3330,O
experts,3330,O
in,3330,O
various,3330,O
fields,3330,O
",",3330,O
including,3330,O
rheumatology,3330,O
",",3330,O
cardiology,3330,O
",",3330,O
neurology,3330,O
",",3330,O
pharmacology,3330,O
and,3330,O
transplantation,3330,O
medicine,3330,O
.,3330,O
The,3331,O
object,3331,O
of,3331,O
the,3331,O
meeting,3331,O
was,3331,O
to,3331,O
analyse,3331,O
existing,3331,O
data,3331,O
",",3331,O
both,3331,O
published,3331,O
or,3331,O
available,3331,O
",",3331,O
in,3331,O
the,3331,O
European,3331,O
Group,3331,O
for,3331,O
Blood,3331,O
and,3331,O
Marrow,3331,O
Transplantation,3331,O
autoimmune,3331,B-Disease
disease,3331,I-Disease
database,3331,O
",",3331,O
and,3331,O
to,3331,O
propose,3331,O
a,3331,O
safe,3331,O
approach,3331,O
to,3331,O
such,3331,O
patients,3331,O
.,3331,O
A,3332,O
full,3332,O
cardiological,3332,O
assessment,3332,O
before,3332,O
and,3332,O
during,3332,O
the,3332,O
transplant,3332,O
emerged,3332,O
as,3332,O
the,3332,O
major,3332,O
recommendation,3332,O
.,3332,O
Does,3333,O
supplemental,3333,O
vitamin,3333,B-Chemical
C,3333,I-Chemical
increase,3333,O
cardiovascular,3333,B-Disease
disease,3333,I-Disease
risk,3333,O
in,3333,O
women,3333,O
with,3333,O
diabetes,3333,B-Disease
?,3333,O
BACKGROUND,3334,O
:,3334,O
Vitamin,3334,B-Chemical
C,3334,I-Chemical
acts,3334,O
as,3334,O
a,3334,O
potent,3334,O
antioxidant,3334,O
;,3334,O
however,3334,O
",",3334,O
it,3334,O
can,3334,O
also,3334,O
be,3334,O
a,3334,O
prooxidant,3334,O
and,3334,O
glycate,3334,O
protein,3334,O
under,3334,O
certain,3334,O
circumstances,3334,O
in,3334,O
vitro,3334,O
.,3334,O
These,3335,O
observations,3335,O
led,3335,O
us,3335,O
to,3335,O
hypothesize,3335,O
that,3335,O
a,3335,O
high,3335,O
intake,3335,O
of,3335,O
vitamin,3335,B-Chemical
C,3335,I-Chemical
in,3335,O
diabetic,3335,B-Disease
persons,3335,O
might,3335,O
promote,3335,O
atherosclerosis,3335,B-Disease
.,3335,O
OBJECTIVE,3336,O
:,3336,O
The,3336,O
objective,3336,O
was,3336,O
to,3336,O
examine,3336,O
the,3336,O
relation,3336,O
between,3336,O
vitamin,3336,B-Chemical
C,3336,I-Chemical
intake,3336,O
and,3336,O
mortality,3336,O
from,3336,O
cardiovascular,3336,B-Disease
disease,3336,I-Disease
.,3336,O
DESIGN,3337,O
:,3337,O
We,3337,O
studied,3337,O
the,3337,O
relation,3337,O
between,3337,O
vitamin,3337,B-Chemical
C,3337,I-Chemical
intake,3337,O
and,3337,O
mortality,3337,O
from,3337,O
total,3337,O
cardiovascular,3337,B-Disease
disease,3337,I-Disease
(,3337,O
n,3337,O
=,3337,O
281,3337,O
),3337,O
",",3337,O
coronary,3337,B-Disease
artery,3337,I-Disease
disease,3337,I-Disease
(,3337,O
n,3337,O
=,3337,O
175,3337,O
),3337,O
",",3337,O
and,3337,O
stroke,3337,B-Disease
(,3337,O
n,3337,O
=,3337,O
57,3337,O
),3337,O
in,3337,O
1923,3337,O
postmenopausal,3337,O
women,3337,O
who,3337,O
reported,3337,O
being,3337,O
diabetic,3337,B-Disease
at,3337,O
baseline,3337,O
.,3337,O
Diet,3338,O
was,3338,O
assessed,3338,O
with,3338,O
a,3338,O
food-frequency,3338,O
questionnaire,3338,O
at,3338,O
baseline,3338,O
",",3338,O
and,3338,O
subjects,3338,O
initially,3338,O
free,3338,O
of,3338,O
coronary,3338,B-Disease
artery,3338,I-Disease
disease,3338,I-Disease
were,3338,O
prospectively,3338,O
followed,3338,O
for,3338,O
15,3338,O
y,3338,O
.,3338,O
RESULTS,3339,O
:,3339,O
After,3339,O
adjustment,3339,O
for,3339,O
cardiovascular,3339,B-Disease
disease,3339,I-Disease
risk,3339,O
factors,3339,O
",",3339,O
type,3339,O
of,3339,O
diabetes,3339,B-Disease
medication,3339,O
used,3339,O
",",3339,O
duration,3339,O
of,3339,O
diabetes,3339,B-Disease
",",3339,O
and,3339,O
intakes,3339,O
of,3339,O
folate,3339,B-Chemical
",",3339,O
vitamin,3339,B-Chemical
E,3339,I-Chemical
",",3339,O
and,3339,O
beta-carotene,3339,B-Chemical
",",3339,O
the,3339,O
adjusted,3339,O
relative,3339,O
risks,3339,O
of,3339,O
total,3339,O
cardiovascular,3339,B-Disease
disease,3339,I-Disease
mortality,3339,O
were,3339,O
1.0,3339,O
",",3339,O
0.97,3339,O
",",3339,O
1.11,3339,O
",",3339,O
1.47,3339,O
",",3339,O
and,3339,O
1.84,3339,O
(,3339,O
P,3339,O
for,3339,O
trend,3339,O
<,3339,O
0.01,3339,O
),3339,O
across,3339,O
quintiles,3339,O
of,3339,O
total,3339,O
vitamin,3339,B-Chemical
C,3339,I-Chemical
intake,3339,O
from,3339,O
food,3339,O
and,3339,O
supplements,3339,O
.,3339,O
Adjusted,3340,O
relative,3340,O
risks,3340,O
of,3340,O
coronary,3340,B-Disease
artery,3340,I-Disease
disease,3340,I-Disease
were,3340,O
1.0,3340,O
",",3340,O
0.81,3340,O
",",3340,O
0.99,3340,O
",",3340,O
1.26,3340,O
",",3340,O
and,3340,O
1.91,3340,O
(,3340,O
P,3340,O
for,3340,O
trend,3340,O
=,3340,O
0.01,3340,O
),3340,O
and,3340,O
of,3340,O
stroke,3340,B-Disease
were,3340,O
1.0,3340,O
",",3340,O
0.52,3340,O
",",3340,O
1.23,3340,O
",",3340,O
2.22,3340,O
",",3340,O
and,3340,O
2.57,3340,O
(,3340,O
P,3340,O
for,3340,O
trend,3340,O
<,3340,O
0.01,3340,O
),3340,O
.,3340,O
When,3341,O
dietary,3341,O
and,3341,O
supplemental,3341,O
vitamin,3341,B-Chemical
C,3341,I-Chemical
were,3341,O
analyzed,3341,O
separately,3341,O
",",3341,O
only,3341,O
supplemental,3341,O
vitamin,3341,B-Chemical
C,3341,I-Chemical
showed,3341,O
a,3341,O
positive,3341,O
association,3341,O
with,3341,O
mortality,3341,O
endpoints,3341,O
.,3341,O
Vitamin,3342,B-Chemical
C,3342,I-Chemical
intake,3342,O
was,3342,O
unrelated,3342,O
to,3342,O
mortality,3342,O
from,3342,O
cardiovascular,3342,B-Disease
disease,3342,I-Disease
in,3342,O
the,3342,O
nondiabetic,3342,O
subjects,3342,O
at,3342,O
baseline,3342,O
.,3342,O
CONCLUSION,3343,O
:,3343,O
A,3343,O
high,3343,O
vitamin,3343,B-Chemical
C,3343,I-Chemical
intake,3343,O
from,3343,O
supplements,3343,O
is,3343,O
associated,3343,O
with,3343,O
an,3343,O
increased,3343,O
risk,3343,O
of,3343,O
cardiovascular,3343,B-Disease
disease,3343,I-Disease
mortality,3343,O
in,3343,O
postmenopausal,3343,O
women,3343,O
with,3343,O
diabetes,3343,B-Disease
.,3343,O
Optical,3344,O
coherence,3344,O
tomography,3344,O
can,3344,O
measure,3344,O
axonal,3344,O
loss,3344,O
in,3344,O
patients,3344,O
with,3344,O
ethambutol-induced,3344,B-Chemical
optic,3344,B-Disease
neuropathy,3344,I-Disease
.,3344,O
PURPOSE,3345,O
:,3345,O
To,3345,O
map,3345,O
and,3345,O
identify,3345,O
the,3345,O
pattern,3345,O
",",3345,O
in,3345,O
vivo,3345,O
",",3345,O
of,3345,O
axonal,3345,B-Disease
degeneration,3345,I-Disease
in,3345,O
ethambutol-induced,3345,B-Chemical
optic,3345,B-Disease
neuropathy,3345,I-Disease
using,3345,O
optical,3345,O
coherence,3345,O
tomography,3345,O
(,3345,O
OCT,3345,O
),3345,O
.,3345,O
Ethambutol,3346,B-Chemical
is,3346,O
an,3346,O
antimycobacterial,3346,O
agent,3346,O
often,3346,O
used,3346,O
to,3346,O
treat,3346,O
tuberculosis,3346,B-Disease
.,3346,O
A,3347,O
serious,3347,O
complication,3347,O
of,3347,O
ethambutol,3347,B-Chemical
is,3347,O
an,3347,O
optic,3347,B-Disease
neuropathy,3347,I-Disease
that,3347,O
impairs,3347,O
visual,3347,O
acuity,3347,O
",",3347,O
contrast,3347,O
sensitivity,3347,O
",",3347,O
and,3347,O
color,3347,O
vision,3347,O
.,3347,O
However,3348,O
",",3348,O
early,3348,O
on,3348,O
",",3348,O
when,3348,O
the,3348,O
toxic,3348,O
optic,3348,B-Disease
neuropathy,3348,I-Disease
is,3348,O
mild,3348,O
and,3348,O
partly,3348,O
reversible,3348,O
",",3348,O
the,3348,O
funduscopic,3348,O
findings,3348,O
are,3348,O
often,3348,O
subtle,3348,O
and,3348,O
easy,3348,O
to,3348,O
miss,3348,O
.,3348,O
METHODS,3349,O
:,3349,O
Three,3349,O
subjects,3349,O
with,3349,O
a,3349,O
history,3349,O
of,3349,O
ethambutol,3349,B-Chemical
(,3349,O
EMB,3349,B-Chemical
),3349,O
-induced,3349,O
optic,3349,B-Disease
neuropathy,3349,I-Disease
of,3349,O
short-,3349,O
",",3349,O
intermediate-,3349,O
",",3349,O
and,3349,O
long-term,3349,O
visual,3349,B-Disease
deficits,3349,I-Disease
were,3349,O
administered,3349,O
a,3349,O
full,3349,O
neuro-ophthalmologic,3349,O
examination,3349,O
including,3349,O
visual,3349,O
acuity,3349,O
",",3349,O
color,3349,O
vision,3349,O
",",3349,O
contrast,3349,O
sensitivity,3349,O
",",3349,O
and,3349,O
fundus,3349,O
examination,3349,O
.,3349,O
In,3350,O
addition,3350,O
",",3350,O
OCT,3350,O
(,3350,O
OCT,3350,O
3000,3350,O
",",3350,O
Humphrey-Zeiss,3350,O
",",3350,O
Dublin,3350,O
",",3350,O
CA,3350,O
),3350,O
was,3350,O
performed,3350,O
on,3350,O
both,3350,O
eyes,3350,O
of,3350,O
each,3350,O
subject,3350,O
using,3350,O
the,3350,O
retinal,3350,O
nerve,3350,O
fiber,3350,O
layer,3350,O
(,3350,O
RNFL,3350,O
),3350,O
analysis,3350,O
protocol,3350,O
.,3350,O
OCT,3351,O
interpolates,3351,O
data,3351,O
from,3351,O
100,3351,O
points,3351,O
around,3351,O
the,3351,O
optic,3351,O
nerve,3351,O
to,3351,O
effectively,3351,O
map,3351,O
out,3351,O
the,3351,O
RNFL,3351,O
.,3351,O
RESULTS,3352,O
:,3352,O
The,3352,O
results,3352,O
were,3352,O
compared,3352,O
to,3352,O
the,3352,O
calculated,3352,O
average,3352,O
RNFL,3352,O
of,3352,O
normal,3352,O
eyes,3352,O
accumulated,3352,O
from,3352,O
four,3352,O
prior,3352,O
studies,3352,O
using,3352,O
OCT,3352,O
",",3352,O
n=661,3352,O
.,3352,O
In,3353,O
all,3353,O
subjects,3353,O
with,3353,O
history,3353,O
of,3353,O
EMB-induced,3353,B-Chemical
optic,3353,B-Disease
neuropathy,3353,I-Disease
",",3353,O
there,3353,O
was,3353,O
a,3353,O
mean,3353,O
loss,3353,O
of,3353,O
72,3353,O
%,3353,O
nerve,3353,O
fiber,3353,O
layer,3353,O
thickness,3353,O
in,3353,O
the,3353,O
temporal,3353,O
quadrant,3353,O
(,3353,O
patient,3353,O
A,3353,O
",",3353,O
with,3353,O
eventual,3353,O
recovery,3353,O
of,3353,O
visual,3353,O
acuity,3353,O
and,3353,O
fields,3353,O
",",3353,O
58,3353,O
%,3353,O
loss,3353,O
;,3353,O
patient,3353,O
B,3353,O
",",3353,O
with,3353,O
intermediate,3353,O
visual,3353,B-Disease
deficits,3353,I-Disease
",",3353,O
68,3353,O
%,3353,O
loss,3353,O
;,3353,O
patient,3353,O
C,3353,O
",",3353,O
with,3353,O
chronic,3353,O
visual,3353,B-Disease
deficits,3353,I-Disease
",",3353,O
90,3353,O
%,3353,O
loss,3353,O
),3353,O
",",3353,O
with,3353,O
an,3353,O
average,3353,O
mean,3353,O
optic,3353,O
nerve,3353,O
thickness,3353,O
of,3353,O
26+/-16,3353,O
microm,3353,O
.,3353,O
There,3354,O
was,3354,O
a,3354,O
combined,3354,O
mean,3354,O
loss,3354,O
of,3354,O
46,3354,O
%,3354,O
of,3354,O
fibers,3354,O
from,3354,O
the,3354,O
superior,3354,O
",",3354,O
inferior,3354,O
",",3354,O
and,3354,O
nasal,3354,O
quadrants,3354,O
in,3354,O
the,3354,O
(,3354,O
six,3354,O
),3354,O
eyes,3354,O
of,3354,O
all,3354,O
three,3354,O
subjects,3354,O
(,3354,O
mean,3354,O
average,3354,O
thickness,3354,O
of,3354,O
55+/-29,3354,O
microm,3354,O
),3354,O
.,3354,O
In,3355,O
both,3355,O
sets,3355,O
(,3355,O
four,3355,O
),3355,O
of,3355,O
eyes,3355,O
of,3355,O
the,3355,O
subjects,3355,O
with,3355,O
persistent,3355,O
visual,3355,B-Disease
deficits,3355,I-Disease
(,3355,O
patients,3355,O
B,3355,O
and,3355,O
C,3355,O
),3355,O
",",3355,O
there,3355,O
was,3355,O
an,3355,O
average,3355,O
loss,3355,O
of,3355,O
79,3355,O
%,3355,O
of,3355,O
nerve,3355,O
fiber,3355,O
thickness,3355,O
in,3355,O
the,3355,O
temporal,3355,O
quadrant,3355,O
.,3355,O
CONCLUSIONS,3356,O
:,3356,O
The,3356,O
OCT,3356,O
results,3356,O
in,3356,O
these,3356,O
patients,3356,O
with,3356,O
EMB-induced,3356,B-Chemical
optic,3356,B-Disease
neuropathy,3356,I-Disease
show,3356,O
considerable,3356,O
loss,3356,O
especially,3356,O
of,3356,O
the,3356,O
temporal,3356,O
fibers,3356,O
.,3356,O
This,3357,O
is,3357,O
consistent,3357,O
with,3357,O
prior,3357,O
histopathological,3357,O
studies,3357,O
that,3357,O
show,3357,O
predominant,3357,O
loss,3357,O
of,3357,O
parvo-cellular,3357,O
axons,3357,O
(,3357,O
or,3357,O
small-caliber,3357,O
axons,3357,O
),3357,O
within,3357,O
the,3357,O
papillo-macular,3357,O
bundle,3357,O
in,3357,O
toxic,3357,O
or,3357,O
hereditary,3357,O
optic,3357,B-Disease
neuropathies,3357,I-Disease
.,3357,O
OCT,3358,O
can,3358,O
be,3358,O
a,3358,O
valuable,3358,O
tool,3358,O
in,3358,O
the,3358,O
quantitative,3358,O
analysis,3358,O
of,3358,O
optic,3358,B-Disease
neuropathies,3358,I-Disease
.,3358,O
Additionally,3359,O
",",3359,O
in,3359,O
terms,3359,O
of,3359,O
management,3359,O
of,3359,O
EMB-induced,3359,B-Chemical
optic,3359,B-Disease
neuropathy,3359,I-Disease
",",3359,O
it,3359,O
is,3359,O
important,3359,O
to,3359,O
properly,3359,O
manage,3359,O
ethambutol,3359,B-Chemical
dosing,3359,O
in,3359,O
patients,3359,O
with,3359,O
renal,3359,B-Disease
impairment,3359,I-Disease
and,3359,O
to,3359,O
achieve,3359,O
proper,3359,O
transition,3359,O
to,3359,O
a,3359,O
maintenance,3359,O
dose,3359,O
once,3359,O
an,3359,O
appropriate,3359,O
loading,3359,O
dose,3359,O
has,3359,O
been,3359,O
reached,3359,O
.,3359,O
Hypoxia,3360,B-Disease
in,3360,O
renal,3360,B-Disease
disease,3360,I-Disease
with,3360,O
proteinuria,3360,B-Disease
and/or,3360,O
glomerular,3360,O
hypertension,3360,B-Disease
.,3360,O
Despite,3361,O
the,3361,O
increasing,3361,O
need,3361,O
to,3361,O
identify,3361,O
and,3361,O
quantify,3361,O
tissue,3361,O
oxygenation,3361,O
at,3361,O
the,3361,O
cellular,3361,O
level,3361,O
",",3361,O
relatively,3361,O
few,3361,O
methods,3361,O
have,3361,O
been,3361,O
available,3361,O
.,3361,O
In,3362,O
this,3362,O
study,3362,O
",",3362,O
we,3362,O
developed,3362,O
a,3362,O
new,3362,O
hypoxia-responsive,3362,B-Disease
reporter,3362,O
vector,3362,O
using,3362,O
a,3362,O
hypoxia-responsive,3362,B-Disease
element,3362,O
of,3362,O
the,3362,O
5,3362,O
',3362,O
vascular,3362,O
endothelial,3362,O
growth,3362,O
factor,3362,O
untranslated,3362,O
region,3362,O
and,3362,O
generated,3362,O
a,3362,O
novel,3362,O
hypoxia-sensing,3362,B-Disease
transgenic,3362,O
rat,3362,O
.,3362,O
We,3363,O
then,3363,O
applied,3363,O
this,3363,O
animal,3363,O
model,3363,O
to,3363,O
the,3363,O
detection,3363,O
of,3363,O
tubulointerstitial,3363,O
hypoxia,3363,B-Disease
in,3363,O
the,3363,O
diseased,3363,B-Disease
kidney,3363,I-Disease
.,3363,O
With,3364,O
this,3364,O
model,3364,O
",",3364,O
we,3364,O
were,3364,O
able,3364,O
to,3364,O
identify,3364,O
diffuse,3364,O
cortical,3364,O
hypoxia,3364,B-Disease
in,3364,O
the,3364,O
puromycin,3364,B-Chemical
aminonucleoside-induced,3364,O
nephrotic,3364,B-Disease
syndrome,3364,I-Disease
and,3364,O
focal,3364,O
and,3364,O
segmental,3364,O
hypoxia,3364,B-Disease
in,3364,O
the,3364,O
remnant,3364,O
kidney,3364,O
model,3364,O
.,3364,O
Expression,3365,O
of,3365,O
the,3365,O
hypoxia-responsive,3365,B-Disease
transgene,3365,O
increased,3365,O
throughout,3365,O
the,3365,O
observation,3365,O
period,3365,O
",",3365,O
reaching,3365,O
2.2-fold,3365,O
at,3365,O
2,3365,O
weeks,3365,O
in,3365,O
the,3365,O
puromycin,3365,B-Chemical
aminonucleoside,3365,I-Chemical
model,3365,O
and,3365,O
2.6-fold,3365,O
at,3365,O
4,3365,O
weeks,3365,O
in,3365,O
the,3365,O
remnant,3365,O
kidney,3365,O
model,3365,O
",",3365,O
whereas,3365,O
that,3365,O
of,3365,O
vascular,3365,O
endothelial,3365,O
growth,3365,O
factor,3365,O
showed,3365,O
a,3365,O
mild,3365,O
decrease,3365,O
",",3365,O
reflecting,3365,O
distinct,3365,O
behaviors,3365,O
of,3365,O
the,3365,O
two,3365,O
genes,3365,O
.,3365,O
The,3366,O
degree,3366,O
of,3366,O
hypoxia,3366,B-Disease
showed,3366,O
a,3366,O
positive,3366,O
correlation,3366,O
with,3366,O
microscopic,3366,O
tubulointerstitial,3366,B-Disease
injury,3366,I-Disease
in,3366,O
both,3366,O
models,3366,O
.,3366,O
Finally,3367,O
",",3367,O
we,3367,O
identified,3367,O
the,3367,O
localization,3367,O
of,3367,O
proliferating,3367,O
cell,3367,O
nuclear,3367,O
antigen-positive,3367,O
",",3367,O
ED-1-positive,3367,O
",",3367,O
and,3367,O
terminal,3367,O
dUTP,3367,O
nick-end,3367,O
labeled-positive,3367,O
cells,3367,O
in,3367,O
the,3367,O
hypoxic,3367,B-Disease
cortical,3367,O
area,3367,O
in,3367,O
the,3367,O
remnant,3367,O
kidney,3367,O
model,3367,O
.,3367,O
We,3368,O
propose,3368,O
here,3368,O
a,3368,O
possible,3368,O
pathological,3368,O
tie,3368,O
between,3368,O
chronic,3368,O
tubulointerstitial,3368,O
hypoxia,3368,B-Disease
and,3368,O
progressive,3368,O
glomerular,3368,B-Disease
diseases,3368,I-Disease
.,3368,O
Adequate,3369,O
timing,3369,O
of,3369,O
ribavirin,3369,B-Chemical
reduction,3369,O
in,3369,O
patients,3369,O
with,3369,O
hemolysis,3369,B-Disease
during,3369,O
combination,3369,O
therapy,3369,O
of,3369,O
interferon,3369,B-Chemical
and,3369,O
ribavirin,3369,B-Chemical
for,3369,O
chronic,3369,B-Disease
hepatitis,3369,I-Disease
C.,3369,O
BACKGROUND,3369,O
:,3369,O
Hemolytic,3369,B-Disease
anemia,3369,I-Disease
is,3369,O
one,3369,O
of,3369,O
the,3369,O
major,3369,O
adverse,3369,O
events,3369,O
of,3369,O
the,3369,O
combination,3369,O
therapy,3369,O
of,3369,O
interferon,3369,B-Chemical
and,3369,O
ribavirin,3369,B-Chemical
.,3369,O
Because,3370,O
of,3370,O
ribavirin-related,3370,B-Chemical
hemolytic,3370,B-Disease
anemia,3370,I-Disease
",",3370,O
dose,3370,O
reduction,3370,O
is,3370,O
a,3370,O
common,3370,O
event,3370,O
in,3370,O
this,3370,O
therapy,3370,O
.,3370,O
In,3371,O
this,3371,O
clinical,3371,O
retrospective,3371,O
cohort,3371,O
study,3371,O
we,3371,O
have,3371,O
examined,3371,O
the,3371,O
suitable,3371,O
timing,3371,O
of,3371,O
ribavirin,3371,B-Chemical
reduction,3371,O
in,3371,O
patients,3371,O
with,3371,O
hemolysis,3371,B-Disease
during,3371,O
combination,3371,O
therapy,3371,O
.,3371,O
METHODS,3372,O
:,3372,O
Thirty-seven,3372,O
of,3372,O
160,3372,O
patients,3372,O
who,3372,O
had,3372,O
HCV-genotype,3372,O
1b,3372,O
",",3372,O
had,3372,O
high,3372,O
virus,3372,O
load,3372,O
",",3372,O
and,3372,O
received,3372,O
24-week,3372,O
combination,3372,O
therapy,3372,O
developed,3372,O
anemia,3372,B-Disease
with,3372,O
hemoglobin,3372,O
level,3372,O
<,3372,O
10,3372,O
g/dl,3372,O
or,3372,O
anemia-related,3372,B-Disease
signs,3372,O
during,3372,O
therapy,3372,O
.,3372,O
After,3373,O
that,3373,O
",",3373,O
these,3373,O
37,3373,O
patients,3373,O
were,3373,O
reduced,3373,O
one,3373,O
tablet,3373,O
of,3373,O
ribavirin,3373,B-Chemical
(,3373,O
200,3373,O
mg,3373,O
),3373,O
per,3373,O
day,3373,O
.,3373,O
After,3374,O
reduction,3374,O
of,3374,O
ribavirin,3374,B-Chemical
",",3374,O
27,3374,O
of,3374,O
37,3374,O
patients,3374,O
could,3374,O
continue,3374,O
combination,3374,O
therapy,3374,O
for,3374,O
a,3374,O
total,3374,O
of,3374,O
24,3374,O
weeks,3374,O
(,3374,O
group,3374,O
A,3374,O
),3374,O
.,3374,O
However,3375,O
",",3375,O
10,3375,O
of,3375,O
37,3375,O
patients,3375,O
with,3375,O
reduction,3375,O
of,3375,O
ribavirin,3375,B-Chemical
could,3375,O
not,3375,O
continue,3375,O
combination,3375,O
therapy,3375,O
because,3375,O
their,3375,O
<,3375,O
8.5,3375,O
g/dl,3375,O
hemoglobin,3375,O
values,3375,O
decreased,3375,O
to,3375,O
or,3375,O
anemia-related,3375,B-Disease
severe,3375,O
side,3375,O
effects,3375,O
occurred,3375,O
(,3375,O
group,3375,O
B,3375,O
),3375,O
.,3375,O
We,3376,O
assessed,3376,O
the,3376,O
final,3376,O
efficacy,3376,O
and,3376,O
safety,3376,O
after,3376,O
reduction,3376,O
of,3376,O
ribavirin,3376,B-Chemical
in,3376,O
groups,3376,O
A,3376,O
and,3376,O
B,3376,O
.,3376,O
RESULTS,3377,O
:,3377,O
A,3377,O
sustained,3377,O
virological,3377,O
response,3377,O
(,3377,O
SVR,3377,O
),3377,O
was,3377,O
29.6,3377,O
%,3377,O
(,3377,O
8/27,3377,O
),3377,O
in,3377,O
group,3377,O
A,3377,O
and,3377,O
10,3377,O
%,3377,O
(,3377,O
1/10,3377,O
),3377,O
in,3377,O
group,3377,O
B,3377,O
",",3377,O
respectively,3377,O
.,3377,O
A,3378,O
34.4,3378,O
%,3378,O
(,3378,O
12/27,3378,O
),3378,O
of,3378,O
SVR,3378,O
+,3378,O
biological,3378,O
response,3378,O
in,3378,O
group,3378,O
A,3378,O
was,3378,O
higher,3378,O
than,3378,O
10,3378,O
%,3378,O
(,3378,O
1/10,3378,O
),3378,O
in,3378,O
group,3378,O
B,3378,O
(,3378,O
P,3378,O
=,3378,O
0.051,3378,O
),3378,O
",",3378,O
with,3378,O
slight,3378,O
significance,3378,O
.,3378,O
With,3379,O
respect,3379,O
to,3379,O
hemoglobin,3379,O
level,3379,O
at,3379,O
the,3379,O
time,3379,O
of,3379,O
ribavirin,3379,B-Chemical
reduction,3379,O
",",3379,O
a,3379,O
rate,3379,O
of,3379,O
continuation,3379,O
of,3379,O
therapy,3379,O
in,3379,O
patients,3379,O
with,3379,O
>,3379,O
or,3379,O
=10,3379,O
g/dl,3379,O
hemoglobin,3379,O
was,3379,O
higher,3379,O
than,3379,O
that,3379,O
in,3379,O
patients,3379,O
with,3379,O
<,3379,O
10,3379,O
g/dl,3379,O
(,3379,O
P,3379,O
=,3379,O
0.036,3379,O
),3379,O
.,3379,O
CONCLUSIONS,3380,O
:,3380,O
Reduction,3380,O
of,3380,O
ribavirin,3380,B-Chemical
at,3380,O
hemoglobin,3380,O
level,3380,O
>,3380,O
or,3380,O
=10,3380,O
g/dl,3380,O
is,3380,O
suitable,3380,O
in,3380,O
terms,3380,O
of,3380,O
efficacy,3380,O
and,3380,O
side,3380,O
effects,3380,O
.,3380,O
Aging,3381,O
process,3381,O
of,3381,O
epithelial,3381,O
cells,3381,O
of,3381,O
the,3381,O
rat,3381,O
prostate,3381,O
lateral,3381,O
lobe,3381,O
in,3381,O
experimental,3381,O
hyperprolactinemia,3381,B-Disease
induced,3381,O
by,3381,O
haloperidol,3381,B-Chemical
.,3381,O
The,3382,O
aim,3382,O
of,3382,O
the,3382,O
study,3382,O
was,3382,O
to,3382,O
examine,3382,O
the,3382,O
influence,3382,O
of,3382,O
hyperprolactinemia,3382,B-Disease
",",3382,O
induced,3382,O
by,3382,O
haloperidol,3382,B-Chemical
(,3382,O
HAL,3382,B-Chemical
),3382,O
on,3382,O
age,3382,O
related,3382,O
morphology,3382,O
and,3382,O
function,3382,O
changes,3382,O
of,3382,O
epithelial,3382,O
cells,3382,O
in,3382,O
rat,3382,O
prostate,3382,O
lateral,3382,O
lobe,3382,O
.,3382,O
The,3383,O
study,3383,O
was,3383,O
performed,3383,O
on,3383,O
sexually,3383,O
mature,3383,O
male,3383,O
rats,3383,O
.,3383,O
Serum,3384,O
concentrations,3384,O
of,3384,O
prolactin,3384,O
(,3384,O
PRL,3384,B-Chemical
),3384,O
and,3384,O
testosterone,3384,B-Chemical
(,3384,O
T,3384,B-Chemical
),3384,O
were,3384,O
measured,3384,O
.,3384,O
Tissue,3385,O
sections,3385,O
were,3385,O
evaluated,3385,O
with,3385,O
light,3385,O
and,3385,O
electron,3385,O
microscopy,3385,O
.,3385,O
Immunohistochemical,3386,O
reactions,3386,O
for,3386,O
Anti-Proliferating,3386,O
Cell,3386,O
Nuclear,3386,O
Antigen,3386,O
(,3386,O
PCNA,3386,O
),3386,O
were,3386,O
performed,3386,O
.,3386,O
In,3387,O
rats,3387,O
of,3387,O
the,3387,O
experimental,3387,O
group,3387,O
",",3387,O
the,3387,O
mean,3387,O
concentration,3387,O
of,3387,O
:,3387,O
PRL,3387,B-Chemical
was,3387,O
more,3387,O
than,3387,O
twice,3387,O
higher,3387,O
",",3387,O
whereas,3387,O
T,3387,B-Chemical
concentration,3387,O
was,3387,O
almost,3387,O
twice,3387,O
lower,3387,O
than,3387,O
that,3387,O
in,3387,O
the,3387,O
control,3387,O
group,3387,O
.,3387,O
Light,3388,O
microscopy,3388,O
visualized,3388,O
the,3388,O
following,3388,O
:,3388,O
hypertrophy,3388,B-Disease
and,3388,O
epithelium,3388,O
hyperplasia,3388,B-Disease
of,3388,O
the,3388,O
glandular,3388,O
ducts,3388,O
",",3388,O
associated,3388,O
with,3388,O
increased,3388,O
PCNA,3388,O
expression,3388,O
.,3388,O
Electron,3389,O
microscopy,3389,O
revealed,3389,O
changes,3389,O
in,3389,O
columnar,3389,O
epithelial,3389,O
cells,3389,O
",",3389,O
concerning,3389,O
organelles,3389,O
",",3389,O
engaged,3389,O
in,3389,O
protein,3389,O
synthesis,3389,O
and,3389,O
secretion,3389,O
.,3389,O
The,3390,O
activation,3390,O
of,3390,O
spinal,3390,O
N-methyl-D-aspartate,3390,B-Chemical
receptors,3390,O
may,3390,O
contribute,3390,O
to,3390,O
degeneration,3390,O
of,3390,O
spinal,3390,O
motor,3390,O
neurons,3390,O
induced,3390,O
by,3390,O
neuraxial,3390,O
morphine,3390,B-Chemical
after,3390,O
a,3390,O
noninjurious,3390,O
interval,3390,O
of,3390,O
spinal,3390,B-Disease
cord,3390,I-Disease
ischemia,3390,I-Disease
.,3390,O
We,3391,O
investigated,3391,O
the,3391,O
relationship,3391,O
between,3391,O
the,3391,O
degeneration,3391,O
of,3391,O
spinal,3391,O
motor,3391,O
neurons,3391,O
and,3391,O
activation,3391,O
of,3391,O
N-methyl-d-aspartate,3391,B-Chemical
(,3391,O
NMDA,3391,B-Chemical
),3391,O
receptors,3391,O
after,3391,O
neuraxial,3391,O
morphine,3391,B-Chemical
following,3391,O
a,3391,O
noninjurious,3391,O
interval,3391,O
of,3391,O
aortic,3391,B-Disease
occlusion,3391,I-Disease
in,3391,O
rats,3391,O
.,3391,O
Spinal,3392,B-Disease
cord,3392,I-Disease
ischemia,3392,I-Disease
was,3392,O
induced,3392,O
by,3392,O
aortic,3392,B-Disease
occlusion,3392,I-Disease
for,3392,O
6,3392,O
min,3392,O
with,3392,O
a,3392,O
balloon,3392,O
catheter,3392,O
.,3392,O
In,3393,O
a,3393,O
microdialysis,3393,O
study,3393,O
",",3393,O
10,3393,O
muL,3393,O
of,3393,O
saline,3393,O
(,3393,O
group,3393,O
C,3393,O
;,3393,O
n,3393,O
=,3393,O
8,3393,O
),3393,O
or,3393,O
30,3393,O
mug,3393,O
of,3393,O
morphine,3393,B-Chemical
(,3393,O
group,3393,O
M,3393,O
;,3393,O
n,3393,O
=,3393,O
8,3393,O
),3393,O
was,3393,O
injected,3393,O
intrathecally,3393,O
(,3393,O
IT,3393,O
),3393,O
0.5,3393,O
h,3393,O
after,3393,O
reflow,3393,O
",",3393,O
and,3393,O
30,3393,O
mug,3393,O
of,3393,O
morphine,3393,B-Chemical
(,3393,O
group,3393,O
SM,3393,O
;,3393,O
n,3393,O
=,3393,O
8,3393,O
),3393,O
or,3393,O
10,3393,O
muL,3393,O
of,3393,O
saline,3393,O
(,3393,O
group,3393,O
SC,3393,O
;,3393,O
n,3393,O
=,3393,O
8,3393,O
),3393,O
was,3393,O
injected,3393,O
IT,3393,O
0.5,3393,O
h,3393,O
after,3393,O
sham,3393,O
operation,3393,O
.,3393,O
Microdialysis,3394,O
samples,3394,O
were,3394,O
collected,3394,O
preischemia,3394,O
",",3394,O
before,3394,O
IT,3394,O
injection,3394,O
",",3394,O
and,3394,O
at,3394,O
2,3394,O
",",3394,O
4,3394,O
",",3394,O
8,3394,O
",",3394,O
24,3394,O
",",3394,O
and,3394,O
48,3394,O
h,3394,O
of,3394,O
reperfusion,3394,O
(,3394,O
after,3394,O
IT,3394,O
injection,3394,O
),3394,O
.,3394,O
Second,3395,O
",",3395,O
we,3395,O
investigated,3395,O
the,3395,O
effect,3395,O
of,3395,O
IT,3395,O
MK-801,3395,B-Chemical
(,3395,O
30,3395,O
mug,3395,O
),3395,O
on,3395,O
the,3395,O
histopathologic,3395,O
changes,3395,O
in,3395,O
the,3395,O
spinal,3395,O
cord,3395,O
after,3395,O
morphine-induced,3395,B-Chemical
spastic,3395,B-Disease
paraparesis,3395,I-Disease
.,3395,O
After,3396,O
IT,3396,O
morphine,3396,B-Chemical
",",3396,O
the,3396,O
cerebrospinal,3396,O
fluid,3396,O
(,3396,O
CSF,3396,O
),3396,O
glutamate,3396,B-Chemical
concentration,3396,O
was,3396,O
increased,3396,O
in,3396,O
group,3396,O
M,3396,O
relative,3396,O
to,3396,O
both,3396,O
baseline,3396,O
and,3396,O
group,3396,O
C,3396,O
(,3396,O
P,3396,O
<,3396,O
0.05,3396,O
),3396,O
.,3396,O
This,3397,O
increase,3397,O
persisted,3397,O
for,3397,O
8,3397,O
hrs,3397,O
.,3397,O
IT,3398,O
MK-801,3398,B-Chemical
significantly,3398,O
reduced,3398,O
the,3398,O
number,3398,O
of,3398,O
dark-stained,3398,O
alpha-motoneurons,3398,O
after,3398,O
morphine-induced,3398,B-Chemical
spastic,3398,B-Disease
paraparesis,3398,I-Disease
compared,3398,O
with,3398,O
the,3398,O
saline,3398,O
group,3398,O
.,3398,O
These,3399,O
data,3399,O
indicate,3399,O
that,3399,O
IT,3399,O
morphine,3399,B-Chemical
induces,3399,O
spastic,3399,B-Disease
paraparesis,3399,I-Disease
with,3399,O
a,3399,O
concomitant,3399,O
increase,3399,O
in,3399,O
CSF,3399,O
glutamate,3399,B-Chemical
",",3399,O
which,3399,O
is,3399,O
involved,3399,O
in,3399,O
NMDA,3399,B-Chemical
receptor,3399,O
activation,3399,O
.,3399,O
We,3400,O
suggest,3400,O
that,3400,O
opioids,3400,O
may,3400,O
be,3400,O
neurotoxic,3400,B-Disease
in,3400,O
the,3400,O
setting,3400,O
of,3400,O
spinal,3400,B-Disease
cord,3400,I-Disease
ischemia,3400,I-Disease
via,3400,O
NMDA,3400,B-Chemical
receptor,3400,O
activation,3400,O
.,3400,O
Acute,3401,O
low,3401,B-Disease
back,3401,I-Disease
pain,3401,I-Disease
during,3401,O
intravenous,3401,O
administration,3401,O
of,3401,O
amiodarone,3401,B-Chemical
:,3401,O
a,3401,O
report,3401,O
of,3401,O
two,3401,O
cases,3401,O
.,3401,O
Amiodarone,3402,B-Chemical
represents,3402,O
an,3402,O
effective,3402,O
antiarrhythmic,3402,O
drug,3402,O
for,3402,O
cardioversion,3402,O
of,3402,O
recent-onset,3402,O
atrial,3402,B-Disease
fibrillation,3402,I-Disease
(,3402,O
AF,3402,B-Disease
),3402,O
and,3402,O
maintenance,3402,O
of,3402,O
sinus,3402,O
rhythm,3402,O
.,3402,O
We,3403,O
briefly,3403,O
describe,3403,O
two,3403,O
patients,3403,O
suffering,3403,O
from,3403,O
recent-onset,3403,O
atrial,3403,B-Disease
fibrillation,3403,I-Disease
",",3403,O
who,3403,O
experienced,3403,O
an,3403,O
acute,3403,O
devastating,3403,O
low,3403,B-Disease
back,3403,I-Disease
pain,3403,I-Disease
a,3403,O
few,3403,O
minutes,3403,O
after,3403,O
initiation,3403,O
of,3403,O
intravenous,3403,O
amiodarone,3403,B-Chemical
loading,3403,O
.,3403,O
Notably,3404,O
",",3404,O
this,3404,O
side,3404,O
effect,3404,O
has,3404,O
not,3404,O
been,3404,O
ever,3404,O
reported,3404,O
in,3404,O
the,3404,O
medical,3404,O
literature,3404,O
.,3404,O
Clinicians,3405,O
should,3405,O
be,3405,O
aware,3405,O
of,3405,O
this,3405,O
reaction,3405,O
since,3405,O
prompt,3405,O
termination,3405,O
of,3405,O
parenteral,3405,O
administration,3405,O
leads,3405,O
to,3405,O
complete,3405,O
resolution,3405,O
.,3405,O
Quantitative,3406,O
drug,3406,O
levels,3406,O
in,3406,O
stimulant,3406,O
psychosis,3406,B-Disease
:,3406,O
relationship,3406,O
to,3406,O
symptom,3406,O
severity,3406,O
",",3406,O
catecholamines,3406,B-Chemical
and,3406,O
hyperkinesia,3406,B-Disease
.,3406,O
To,3407,O
examine,3407,O
the,3407,O
relationship,3407,O
between,3407,O
quantitative,3407,O
stimulant,3407,O
drug,3407,O
levels,3407,O
",",3407,O
catecholamines,3407,B-Chemical
",",3407,O
and,3407,O
psychotic,3407,B-Disease
symptoms,3407,I-Disease
",",3407,O
nineteen,3407,O
patients,3407,O
in,3407,O
a,3407,O
psychiatric,3407,B-Disease
emergency,3407,O
service,3407,O
with,3407,O
a,3407,O
diagnosis,3407,O
of,3407,O
amphetamine-,3407,B-Chemical
or,3407,O
cocaine-induced,3407,B-Chemical
psychosis,3407,B-Disease
were,3407,O
interviewed,3407,O
",",3407,O
and,3407,O
plasma,3407,O
and,3407,O
urine,3407,O
were,3407,O
collected,3407,O
for,3407,O
quantitative,3407,O
assays,3407,O
of,3407,O
stimulant,3407,O
drug,3407,O
and,3407,O
catecholamine,3407,B-Chemical
metabolite,3407,O
levels,3407,O
.,3407,O
Methamphetamine,3408,B-Chemical
or,3408,O
amphetamine,3408,B-Chemical
levels,3408,O
were,3408,O
related,3408,O
to,3408,O
several,3408,O
psychopathology,3408,O
scores,3408,O
and,3408,O
the,3408,O
global,3408,O
hyperkinesia,3408,B-Disease
rating,3408,O
.,3408,O
HVA,3409,O
levels,3409,O
were,3409,O
related,3409,O
to,3409,O
global,3409,O
hyperkinesia,3409,B-Disease
but,3409,O
not,3409,O
to,3409,O
psychopathology,3409,O
ratings,3409,O
.,3409,O
Although,3410,O
many,3410,O
other,3410,O
factors,3410,O
such,3410,O
as,3410,O
sensitization,3410,O
may,3410,O
play,3410,O
a,3410,O
role,3410,O
",",3410,O
intensity,3410,O
of,3410,O
stimulant-induced,3410,O
psychotic,3410,B-Disease
symptoms,3410,I-Disease
and,3410,O
stereotypies,3410,B-Disease
appears,3410,O
to,3410,O
be,3410,O
at,3410,O
least,3410,O
in,3410,O
part,3410,O
dose-related,3410,O
.,3410,O
Pheochromocytoma,3411,B-Disease
unmasked,3411,O
by,3411,O
amisulpride,3411,B-Chemical
and,3411,O
tiapride,3411,B-Chemical
.,3411,O
OBJECTIVE,3412,O
:,3412,O
To,3412,O
describe,3412,O
the,3412,O
unmasking,3412,O
of,3412,O
pheochromocytoma,3412,B-Disease
in,3412,O
a,3412,O
patient,3412,O
treated,3412,O
with,3412,O
amisulpride,3412,B-Chemical
and,3412,O
tiapride,3412,B-Chemical
.,3412,O
CASE,3413,O
SUMMARY,3413,O
:,3413,O
A,3413,O
42-year-old,3413,O
white,3413,O
man,3413,O
developed,3413,O
acute,3413,O
hypertension,3413,B-Disease
with,3413,O
severe,3413,O
headache,3413,B-Disease
and,3413,O
vomiting,3413,B-Disease
2,3413,O
hours,3413,O
after,3413,O
the,3413,O
first,3413,O
doses,3413,O
of,3413,O
amisulpride,3413,B-Chemical
100,3413,O
mg,3413,O
and,3413,O
tiapride,3413,B-Chemical
100,3413,O
mg,3413,O
.,3413,O
Both,3414,O
drugs,3414,O
were,3414,O
immediately,3414,O
discontinued,3414,O
",",3414,O
and,3414,O
the,3414,O
patient,3414,O
recovered,3414,O
after,3414,O
subsequent,3414,O
nicardipine,3414,B-Chemical
and,3414,O
verapamil,3414,B-Chemical
treatment,3414,O
.,3414,O
Abdominal,3415,O
ultrasound,3415,O
showed,3415,O
an,3415,O
adrenal,3415,O
mass,3415,O
",",3415,O
and,3415,O
postoperative,3415,O
histologic,3415,O
examination,3415,O
confirmed,3415,O
the,3415,O
diagnosis,3415,O
of,3415,O
pheochromocytoma,3415,B-Disease
.,3415,O
DISCUSSION,3416,O
:,3416,O
Drug-induced,3416,O
symptoms,3416,O
of,3416,O
pheochromocytoma,3416,B-Disease
are,3416,O
often,3416,O
associated,3416,O
with,3416,O
the,3416,O
use,3416,O
of,3416,O
substituted,3416,O
benzamide,3416,B-Chemical
drugs,3416,O
",",3416,O
but,3416,O
the,3416,O
underlying,3416,O
mechanism,3416,O
is,3416,O
unknown,3416,O
.,3416,O
In,3417,O
our,3417,O
case,3417,O
",",3417,O
use,3417,O
of,3417,O
the,3417,O
Naranjo,3417,O
probability,3417,O
scale,3417,O
indicated,3417,O
a,3417,O
possible,3417,O
relationship,3417,O
between,3417,O
the,3417,O
hypertensive,3417,B-Disease
crisis,3417,O
and,3417,O
amisulpride,3417,B-Chemical
and,3417,O
tiapride,3417,B-Chemical
therapy,3417,O
.,3417,O
CONCLUSIONS,3418,O
:,3418,O
As,3418,O
of,3418,O
March,3418,O
24,3418,O
",",3418,O
2005,3418,O
",",3418,O
this,3418,O
is,3418,O
the,3418,O
first,3418,O
reported,3418,O
case,3418,O
of,3418,O
amisulpride-,3418,B-Chemical
and,3418,O
tiapride-induced,3418,B-Chemical
hypertensive,3418,B-Disease
crisis,3418,O
in,3418,O
a,3418,O
patient,3418,O
with,3418,O
pheochromocytoma,3418,B-Disease
.,3418,O
Physicians,3419,O
and,3419,O
other,3419,O
healthcare,3419,O
professionals,3419,O
should,3419,O
be,3419,O
aware,3419,O
of,3419,O
this,3419,O
potential,3419,O
adverse,3419,O
effect,3419,O
of,3419,O
tiapride,3419,B-Chemical
and,3419,O
amisulpride,3419,B-Chemical
.,3419,O
Minor,3420,O
neurological,3420,B-Disease
dysfunction,3420,I-Disease
",",3420,O
cognitive,3420,O
development,3420,O
",",3420,O
and,3420,O
somatic,3420,O
development,3420,O
at,3420,O
the,3420,O
age,3420,O
of,3420,O
3,3420,O
to,3420,O
7,3420,O
years,3420,O
after,3420,O
dexamethasone,3420,B-Chemical
treatment,3420,O
in,3420,O
very-low,3420,O
birth-weight,3420,O
infants,3420,O
.,3420,O
The,3421,O
objective,3421,O
of,3421,O
this,3421,O
study,3421,O
was,3421,O
to,3421,O
assess,3421,O
minor,3421,O
neurological,3421,B-Disease
dysfunction,3421,I-Disease
",",3421,O
cognitive,3421,O
development,3421,O
",",3421,O
and,3421,O
somatic,3421,O
development,3421,O
after,3421,O
dexamethasone,3421,B-Chemical
therapy,3421,O
in,3421,O
very-low-birthweight,3421,O
infants,3421,O
.,3421,O
Thirty-three,3422,O
children,3422,O
after,3422,O
dexamethasone,3422,B-Chemical
treatment,3422,O
were,3422,O
matched,3422,O
to,3422,O
33,3422,O
children,3422,O
without,3422,O
dexamethasone,3422,B-Chemical
treatment,3422,O
.,3422,O
Data,3423,O
were,3423,O
assessed,3423,O
at,3423,O
the,3423,O
age,3423,O
of,3423,O
3-7,3423,O
years,3423,O
.,3423,O
Dexamethasone,3424,B-Chemical
was,3424,O
started,3424,O
between,3424,O
the,3424,O
7th,3424,O
and,3424,O
the,3424,O
28th,3424,O
day,3424,O
of,3424,O
life,3424,O
over,3424,O
7,3424,O
days,3424,O
with,3424,O
a,3424,O
total,3424,O
dose,3424,O
of,3424,O
2.35,3424,O
mg/kg/day,3424,O
.,3424,O
Exclusion,3425,O
criteria,3425,O
were,3425,O
asphyxia,3425,B-Disease
",",3425,O
malformations,3425,B-Disease
",",3425,O
major,3425,O
surgical,3425,O
interventions,3425,O
",",3425,O
small,3425,O
for,3425,O
gestational,3425,O
age,3425,O
",",3425,O
intraventricular,3425,O
haemorrhage,3425,B-Disease
grades,3425,O
III,3425,O
and,3425,O
IV,3425,O
",",3425,O
periventricular,3425,B-Disease
leukomalacia,3425,I-Disease
",",3425,O
and,3425,O
severe,3425,O
psychomotor,3425,B-Disease
retardation,3425,I-Disease
.,3425,O
Each,3426,O
child,3426,O
was,3426,O
examined,3426,O
by,3426,O
a,3426,O
neuropediatrician,3426,O
for,3426,O
minor,3426,O
neurological,3426,B-Disease
dysfunctions,3426,I-Disease
and,3426,O
tested,3426,O
by,3426,O
a,3426,O
psychologist,3426,O
for,3426,O
cognitive,3426,O
development,3426,O
with,3426,O
a,3426,O
Kaufman,3426,O
Assessment,3426,O
Battery,3426,O
for,3426,O
Children,3426,O
and,3426,O
a,3426,O
Draw-a-Man,3426,O
Test,3426,O
.,3426,O
There,3427,O
were,3427,O
no,3427,O
differences,3427,O
in,3427,O
demographic,3427,O
data,3427,O
",",3427,O
growth,3427,O
",",3427,O
and,3427,O
socio-economic,3427,O
status,3427,O
between,3427,O
the,3427,O
two,3427,O
groups,3427,O
.,3427,O
Fine,3428,O
motor,3428,O
skills,3428,O
and,3428,O
gross,3428,O
motor,3428,O
function,3428,O
were,3428,O
significantly,3428,O
better,3428,O
in,3428,O
the,3428,O
control,3428,O
group,3428,O
(,3428,O
p,3428,O
<,3428,O
0.01,3428,O
),3428,O
.,3428,O
In,3429,O
the,3429,O
Draw-a-Man,3429,O
Test,3429,O
",",3429,O
the,3429,O
control,3429,O
group,3429,O
showed,3429,O
better,3429,O
results,3429,O
(,3429,O
p,3429,O
<,3429,O
0.001,3429,O
),3429,O
.,3429,O
There,3430,O
were,3430,O
no,3430,O
differences,3430,O
in,3430,O
development,3430,O
of,3430,O
speech,3430,O
",",3430,O
social,3430,O
development,3430,O
",",3430,O
and,3430,O
the,3430,O
Kaufman,3430,O
Assessment,3430,O
Battery,3430,O
for,3430,O
Children,3430,O
.,3430,O
After,3431,O
dexamethasone,3431,B-Chemical
treatment,3431,O
",",3431,O
children,3431,O
showed,3431,O
a,3431,O
higher,3431,O
rate,3431,O
of,3431,O
minor,3431,O
neurological,3431,B-Disease
dysfunctions,3431,I-Disease
.,3431,O
Neurological,3432,O
development,3432,O
was,3432,O
affected,3432,O
even,3432,O
without,3432,O
neurological,3432,O
diagnosis,3432,O
.,3432,O
Further,3433,O
long-term,3433,O
follow-up,3433,O
studies,3433,O
will,3433,O
be,3433,O
necessary,3433,O
to,3433,O
fully,3433,O
evaluate,3433,O
the,3433,O
impact,3433,O
of,3433,O
dexamethasone,3433,B-Chemical
on,3433,O
neurological,3433,O
and,3433,O
cognitive,3433,O
development,3433,O
.,3433,O
Valproic,3434,B-Chemical
acid,3434,I-Chemical
I,3434,O
:,3434,O
time,3434,O
course,3434,O
of,3434,O
lipid,3434,O
peroxidation,3434,O
biomarkers,3434,O
",",3434,O
liver,3434,B-Disease
toxicity,3434,I-Disease
",",3434,O
and,3434,O
valproic,3434,B-Chemical
acid,3434,I-Chemical
metabolite,3434,O
levels,3434,O
in,3434,O
rats,3434,O
.,3434,O
A,3435,O
single,3435,O
dose,3435,O
of,3435,O
valproic,3435,B-Chemical
acid,3435,I-Chemical
(,3435,O
VPA,3435,B-Chemical
),3435,O
",",3435,O
which,3435,O
is,3435,O
a,3435,O
widely,3435,O
used,3435,O
antiepileptic,3435,O
drug,3435,O
",",3435,O
is,3435,O
associated,3435,O
with,3435,O
oxidative,3435,O
stress,3435,O
in,3435,O
rats,3435,O
",",3435,O
as,3435,O
recently,3435,O
demonstrated,3435,O
by,3435,O
elevated,3435,O
levels,3435,O
of,3435,O
15-F,3435,B-Chemical
(,3435,I-Chemical
2t,3435,I-Chemical
),3435,I-Chemical
-isoprostane,3435,I-Chemical
(,3435,O
15-F,3435,B-Chemical
(,3435,I-Chemical
2t,3435,I-Chemical
),3435,I-Chemical
-IsoP,3435,I-Chemical
),3435,O
.,3435,O
To,3436,O
determine,3436,O
whether,3436,O
there,3436,O
was,3436,O
a,3436,O
temporal,3436,O
relationship,3436,O
between,3436,O
VPA-associated,3436,B-Chemical
oxidative,3436,O
stress,3436,O
and,3436,O
hepatotoxicity,3436,B-Disease
",",3436,O
adult,3436,O
male,3436,O
Sprague-Dawley,3436,O
rats,3436,O
were,3436,O
treated,3436,O
ip,3436,O
with,3436,O
VPA,3436,B-Chemical
(,3436,O
500,3436,O
mg/kg,3436,O
),3436,O
or,3436,O
0.9,3436,O
%,3436,O
saline,3436,O
(,3436,O
vehicle,3436,O
),3436,O
once,3436,O
daily,3436,O
for,3436,O
2,3436,O
",",3436,O
4,3436,O
",",3436,O
7,3436,O
",",3436,O
10,3436,O
",",3436,O
or,3436,O
14,3436,O
days,3436,O
.,3436,O
Oxidative,3437,O
stress,3437,O
was,3437,O
assessed,3437,O
by,3437,O
determining,3437,O
plasma,3437,O
and,3437,O
liver,3437,O
levels,3437,O
of,3437,O
15-F,3437,B-Chemical
(,3437,I-Chemical
2t,3437,I-Chemical
),3437,I-Chemical
-IsoP,3437,I-Chemical
",",3437,O
lipid,3437,B-Chemical
hydroperoxides,3437,I-Chemical
(,3437,O
LPO,3437,B-Chemical
),3437,O
",",3437,O
and,3437,O
thiobarbituric,3437,B-Chemical
acid,3437,I-Chemical
reactive,3437,I-Chemical
substances,3437,I-Chemical
(,3437,O
TBARs,3437,B-Chemical
),3437,O
.,3437,O
Plasma,3438,O
and,3438,O
liver,3438,O
15-F,3438,B-Chemical
(,3438,I-Chemical
2t,3438,I-Chemical
),3438,I-Chemical
-IsoP,3438,I-Chemical
were,3438,O
elevated,3438,O
and,3438,O
reached,3438,O
a,3438,O
plateau,3438,O
after,3438,O
day,3438,O
2,3438,O
of,3438,O
VPA,3438,B-Chemical
treatment,3438,O
compared,3438,O
to,3438,O
control,3438,O
.,3438,O
Liver,3439,O
LPO,3439,B-Chemical
levels,3439,O
were,3439,O
not,3439,O
elevated,3439,O
until,3439,O
day,3439,O
7,3439,O
of,3439,O
treatment,3439,O
(,3439,O
1.8-fold,3439,O
versus,3439,O
control,3439,O
",",3439,O
p,3439,O
<,3439,O
0.05,3439,O
),3439,O
.,3439,O
Liver,3440,O
and,3440,O
plasma,3440,O
TBARs,3440,B-Chemical
were,3440,O
not,3440,O
increased,3440,O
until,3440,O
14,3440,O
days,3440,O
(,3440,O
2-fold,3440,O
vs.,3440,O
control,3440,O
",",3440,O
p,3440,O
<,3440,O
0.05,3440,O
),3440,O
.,3440,O
Liver,3441,B-Disease
toxicity,3441,I-Disease
was,3441,O
evaluated,3441,O
based,3441,O
on,3441,O
serum,3441,O
levels,3441,O
of,3441,O
alpha-glutathione,3441,O
S-transferase,3441,O
(,3441,O
alpha-GST,3441,O
),3441,O
and,3441,O
by,3441,O
histology,3441,O
.,3441,O
Serum,3442,O
alpha-GST,3442,O
levels,3442,O
were,3442,O
significantly,3442,O
elevated,3442,O
by,3442,O
day,3442,O
4,3442,O
",",3442,O
which,3442,O
corresponded,3442,O
to,3442,O
hepatotoxicity,3442,B-Disease
as,3442,O
shown,3442,O
by,3442,O
the,3442,O
increasing,3442,O
incidence,3442,O
of,3442,O
inflammation,3442,B-Disease
of,3442,O
the,3442,O
liver,3442,O
capsule,3442,O
",",3442,O
necrosis,3442,B-Disease
",",3442,O
and,3442,O
steatosis,3442,B-Disease
throughout,3442,O
the,3442,O
study,3442,O
.,3442,O
The,3443,O
liver,3443,O
levels,3443,O
of,3443,O
beta-oxidation,3443,O
metabolites,3443,O
of,3443,O
VPA,3443,B-Chemical
were,3443,O
decreased,3443,O
by,3443,O
day,3443,O
14,3443,O
",",3443,O
while,3443,O
the,3443,O
levels,3443,O
of,3443,O
4-ene-VPA,3443,B-Chemical
and,3443,O
(,3443,O
E,3443,O
),3443,O
"-2,4-diene-VPA",3443,O
were,3443,O
not,3443,O
elevated,3443,O
throughout,3443,O
the,3443,O
study,3443,O
.,3443,O
Overall,3444,O
",",3444,O
these,3444,O
findings,3444,O
indicate,3444,O
that,3444,O
VPA,3444,B-Chemical
treatment,3444,O
results,3444,O
in,3444,O
oxidative,3444,O
stress,3444,O
",",3444,O
as,3444,O
measured,3444,O
by,3444,O
levels,3444,O
of,3444,O
15-F,3444,B-Chemical
(,3444,I-Chemical
2t,3444,I-Chemical
),3444,I-Chemical
-IsoP,3444,I-Chemical
",",3444,O
which,3444,O
precedes,3444,O
the,3444,O
onset,3444,O
of,3444,O
necrosis,3444,B-Disease
",",3444,O
steatosis,3444,B-Disease
",",3444,O
and,3444,O
elevated,3444,O
levels,3444,O
of,3444,O
serum,3444,O
alpha-GST,3444,O
.,3444,O
Assessment,3445,O
of,3445,O
perinatal,3445,O
hepatitis,3445,B-Disease
B,3445,I-Disease
and,3445,O
rubella,3445,B-Disease
prevention,3445,O
in,3445,O
New,3445,O
Hampshire,3445,O
delivery,3445,O
hospitals,3445,O
.,3445,O
OBJECTIVE,3446,O
:,3446,O
To,3446,O
evaluate,3446,O
current,3446,O
performance,3446,O
on,3446,O
recommended,3446,O
perinatal,3446,O
hepatitis,3446,B-Disease
B,3446,I-Disease
and,3446,O
rubella,3446,B-Disease
prevention,3446,O
practices,3446,O
in,3446,O
New,3446,O
Hampshire,3446,O
.,3446,O
METHODS,3447,O
:,3447,O
Data,3447,O
were,3447,O
extracted,3447,O
from,3447,O
2021,3447,O
paired,3447,O
mother-infant,3447,O
records,3447,O
for,3447,O
the,3447,O
year,3447,O
2000,3447,O
birth,3447,O
cohort,3447,O
in,3447,O
New,3447,O
Hampshire,3447,O
's,3447,O
25,3447,O
delivery,3447,O
hospitals,3447,O
.,3447,O
Assessment,3448,O
was,3448,O
done,3448,O
on,3448,O
the,3448,O
following,3448,O
:,3448,O
prenatal,3448,O
screening,3448,O
for,3448,O
hepatitis,3448,B-Disease
B,3448,I-Disease
and,3448,O
rubella,3448,B-Disease
",",3448,O
administration,3448,O
of,3448,O
the,3448,O
hepatitis,3448,B-Disease
B,3448,I-Disease
vaccine,3448,O
birth,3448,O
dose,3448,O
to,3448,O
all,3448,O
infants,3448,O
",",3448,O
administration,3448,O
of,3448,O
hepatitis,3448,B-Disease
B,3448,I-Disease
immune,3448,O
globulin,3448,O
to,3448,O
infants,3448,O
who,3448,O
were,3448,O
born,3448,O
to,3448,O
hepatitis,3448,B-Chemical
B,3448,I-Chemical
surface,3448,I-Chemical
antigen-positive,3448,O
mothers,3448,O
",",3448,O
rubella,3448,B-Disease
immunity,3448,O
",",3448,O
and,3448,O
administration,3448,O
of,3448,O
in-hospital,3448,O
postpartum,3448,O
rubella,3448,B-Disease
vaccine,3448,O
to,3448,O
rubella,3448,B-Disease
nonimmune,3448,O
women,3448,O
.,3448,O
RESULTS,3449,O
:,3449,O
Prenatal,3449,O
screening,3449,O
rates,3449,O
for,3449,O
hepatitis,3449,B-Disease
B,3449,I-Disease
(,3449,O
98.8,3449,O
%,3449,O
),3449,O
and,3449,O
rubella,3449,B-Disease
(,3449,O
99.4,3449,O
%,3449,O
),3449,O
were,3449,O
high,3449,O
.,3449,O
Hepatitis,3450,B-Disease
B,3450,I-Disease
vaccine,3450,O
birth,3450,O
dose,3450,O
was,3450,O
administered,3450,O
to,3450,O
76.2,3450,O
%,3450,O
of,3450,O
all,3450,O
infants,3450,O
.,3450,O
All,3451,O
infants,3451,O
who,3451,O
were,3451,O
born,3451,O
to,3451,O
hepatitis,3451,B-Chemical
B,3451,I-Chemical
surface,3451,I-Chemical
antigen-positive,3451,O
mothers,3451,O
also,3451,O
received,3451,O
hepatitis,3451,B-Disease
B,3451,I-Disease
immune,3451,O
globulin,3451,O
.,3451,O
Multivariate,3452,O
logistic,3452,O
regression,3452,O
showed,3452,O
that,3452,O
the,3452,O
month,3452,O
of,3452,O
delivery,3452,O
and,3452,O
infant,3452,O
birth,3452,O
weight,3452,O
were,3452,O
independent,3452,O
predictors,3452,O
of,3452,O
hepatitis,3452,B-Disease
B,3452,I-Disease
vaccination,3452,O
.,3452,O
The,3453,O
proportion,3453,O
of,3453,O
infants,3453,O
who,3453,O
were,3453,O
vaccinated,3453,O
in,3453,O
January,3453,O
and,3453,O
February,3453,O
2000,3453,O
(,3453,O
48.5,3453,O
%,3453,O
and,3453,O
67.5,3453,O
%,3453,O
",",3453,O
respectively,3453,O
),3453,O
was,3453,O
less,3453,O
than,3453,O
any,3453,O
other,3453,O
months,3453,O
",",3453,O
whereas,3453,O
the,3453,O
proportion,3453,O
who,3453,O
were,3453,O
vaccinated,3453,O
in,3453,O
December,3453,O
2000,3453,O
(,3453,O
88.2,3453,O
%,3453,O
),3453,O
was,3453,O
the,3453,O
highest,3453,O
.,3453,O
Women,3454,O
who,3454,O
were,3454,O
born,3454,O
between,3454,O
1971,3454,O
and,3454,O
1975,3454,O
had,3454,O
the,3454,O
highest,3454,O
rate,3454,O
of,3454,O
rubella,3454,B-Disease
nonimmunity,3454,O
(,3454,O
9.5,3454,O
%,3454,O
),3454,O
.,3454,O
In-hospital,3455,O
postpartum,3455,O
rubella,3455,B-Disease
vaccine,3455,O
administration,3455,O
was,3455,O
documented,3455,O
for,3455,O
75.6,3455,O
%,3455,O
of,3455,O
nonimmune,3455,O
women,3455,O
.,3455,O
CONCLUSION,3456,O
:,3456,O
This,3456,O
study,3456,O
documents,3456,O
good,3456,O
compliance,3456,O
in,3456,O
New,3456,O
Hampshire,3456,O
's,3456,O
birthing,3456,O
hospitals,3456,O
with,3456,O
national,3456,O
guidelines,3456,O
for,3456,O
perinatal,3456,O
hepatitis,3456,B-Disease
B,3456,I-Disease
and,3456,O
rubella,3456,B-Disease
prevention,3456,O
and,3456,O
highlights,3456,O
potential,3456,O
areas,3456,O
for,3456,O
improvement,3456,O
.,3456,O
Succinylcholine-induced,3457,B-Chemical
masseter,3457,B-Disease
muscle,3457,I-Disease
rigidity,3457,I-Disease
during,3457,O
bronchoscopic,3457,O
removal,3457,O
of,3457,O
a,3457,O
tracheal,3457,O
foreign,3457,O
body,3457,O
.,3457,O
Masseter,3458,B-Disease
muscle,3458,I-Disease
rigidity,3458,I-Disease
during,3458,O
general,3458,O
anesthesia,3458,O
is,3458,O
considered,3458,O
an,3458,O
early,3458,O
warning,3458,O
sign,3458,O
of,3458,O
a,3458,O
possible,3458,O
episode,3458,O
of,3458,O
malignant,3458,B-Disease
hyperthermia,3458,I-Disease
.,3458,O
The,3459,O
decision,3459,O
whether,3459,O
to,3459,O
continue,3459,O
or,3459,O
discontinue,3459,O
the,3459,O
procedure,3459,O
depends,3459,O
on,3459,O
the,3459,O
urgency,3459,O
of,3459,O
the,3459,O
surgery,3459,O
and,3459,O
severity,3459,O
of,3459,O
masseter,3459,B-Disease
muscle,3459,I-Disease
rigidity,3459,I-Disease
.,3459,O
Here,3460,O
",",3460,O
we,3460,O
describe,3460,O
a,3460,O
case,3460,O
of,3460,O
severe,3460,O
masseter,3460,B-Disease
muscle,3460,I-Disease
rigidity,3460,I-Disease
(,3460,O
jaw,3460,B-Disease
of,3460,I-Disease
steel,3460,I-Disease
),3460,O
after,3460,O
succinylcholine,3460,B-Chemical
(,3460,O
Sch,3460,B-Chemical
),3460,O
administration,3460,O
during,3460,O
general,3460,O
anesthetic,3460,O
management,3460,O
for,3460,O
rigid,3460,O
bronchoscopic,3460,O
removal,3460,O
of,3460,O
a,3460,O
tracheal,3460,O
foreign,3460,O
body,3460,O
.,3460,O
Anesthesia,3461,O
was,3461,O
continued,3461,O
uneventfully,3461,O
with,3461,O
propofol,3461,B-Chemical
infusion,3461,O
while,3461,O
all,3461,O
facilities,3461,O
were,3461,O
available,3461,O
to,3461,O
detect,3461,O
and,3461,O
treat,3461,O
malignant,3461,B-Disease
hyperthermia,3461,I-Disease
.,3461,O
Dexrazoxane,3462,B-Chemical
protects,3462,O
against,3462,O
myelosuppression,3462,B-Disease
from,3462,O
the,3462,O
DNA,3462,O
cleavage-enhancing,3462,O
drugs,3462,O
etoposide,3462,B-Chemical
and,3462,O
daunorubicin,3462,B-Chemical
but,3462,O
not,3462,O
doxorubicin,3462,B-Chemical
.,3462,O
PURPOSE,3463,O
:,3463,O
The,3463,O
anthracyclines,3463,B-Chemical
daunorubicin,3463,B-Chemical
and,3463,O
doxorubicin,3463,B-Chemical
and,3463,O
the,3463,O
epipodophyllotoxin,3463,B-Chemical
etoposide,3463,B-Chemical
are,3463,O
potent,3463,O
DNA,3463,O
cleavage-enhancing,3463,O
drugs,3463,O
that,3463,O
are,3463,O
widely,3463,O
used,3463,O
in,3463,O
clinical,3463,O
oncology,3463,O
;,3463,O
however,3463,O
",",3463,O
myelosuppression,3463,B-Disease
and,3463,O
cardiac,3463,B-Disease
toxicity,3463,I-Disease
limit,3463,O
their,3463,O
use,3463,O
.,3463,O
Dexrazoxane,3464,B-Chemical
(,3464,O
ICRF-187,3464,B-Chemical
),3464,O
is,3464,O
recommended,3464,O
for,3464,O
protection,3464,O
against,3464,O
anthracycline-induced,3464,B-Chemical
cardiotoxicity,3464,B-Disease
.,3464,O
EXPERIMENTAL,3465,O
DESIGN,3465,O
:,3465,O
Because,3465,O
of,3465,O
their,3465,O
widespread,3465,O
use,3465,O
",",3465,O
the,3465,O
hematologic,3465,B-Disease
toxicity,3465,I-Disease
following,3465,O
coadministration,3465,O
of,3465,O
dexrazoxane,3465,B-Chemical
and,3465,O
these,3465,O
three,3465,O
structurally,3465,O
different,3465,O
DNA,3465,O
cleavage,3465,O
enhancers,3465,O
was,3465,O
investigated,3465,O
:,3465,O
Sensitivity,3465,O
of,3465,O
human,3465,O
and,3465,O
murine,3465,O
blood,3465,O
progenitor,3465,O
cells,3465,O
to,3465,O
etoposide,3465,B-Chemical
",",3465,O
daunorubicin,3465,B-Chemical
",",3465,O
and,3465,O
doxorubicin,3465,B-Chemical
+/-,3465,O
dexrazoxane,3465,B-Chemical
was,3465,O
determined,3465,O
in,3465,O
granulocyte-macrophage,3465,O
colony,3465,O
forming,3465,O
assays,3465,O
.,3465,O
Likewise,3466,O
",",3466,O
in,3466,O
vivo,3466,O
",",3466,O
B6D2F1,3466,O
mice,3466,O
were,3466,O
treated,3466,O
with,3466,O
etoposide,3466,B-Chemical
",",3466,O
daunorubicin,3466,B-Chemical
",",3466,O
and,3466,O
doxorubicin,3466,B-Chemical
",",3466,O
with,3466,O
or,3466,O
without,3466,O
dexrazoxane,3466,B-Chemical
over,3466,O
a,3466,O
wide,3466,O
range,3466,O
of,3466,O
doses,3466,O
:,3466,O
posttreatment,3466,O
",",3466,O
a,3466,O
full,3466,O
hematologic,3466,O
evaluation,3466,O
was,3466,O
done,3466,O
.,3466,O
RESULTS,3467,O
:,3467,O
Nontoxic,3467,O
doses,3467,O
of,3467,O
dexrazoxane,3467,B-Chemical
reduced,3467,O
myelosuppression,3467,B-Disease
and,3467,O
weight,3467,B-Disease
loss,3467,I-Disease
from,3467,O
daunorubicin,3467,B-Chemical
and,3467,O
etoposide,3467,B-Chemical
in,3467,O
mice,3467,O
and,3467,O
antagonized,3467,O
their,3467,O
antiproliferative,3467,O
effects,3467,O
in,3467,O
the,3467,O
colony,3467,O
assay,3467,O
;,3467,O
however,3467,O
",",3467,O
dexrazoxane,3467,B-Chemical
neither,3467,O
reduced,3467,O
myelosuppression,3467,B-Disease
",",3467,O
weight,3467,B-Disease
loss,3467,I-Disease
",",3467,O
nor,3467,O
the,3467,O
in,3467,O
vitro,3467,O
cytotoxicity,3467,B-Disease
from,3467,O
doxorubicin,3467,B-Chemical
.,3467,O
CONCLUSION,3468,O
:,3468,O
Although,3468,O
our,3468,O
findings,3468,O
support,3468,O
the,3468,O
observation,3468,O
that,3468,O
dexrazoxane,3468,B-Chemical
reduces,3468,O
neither,3468,O
hematologic,3468,O
activity,3468,O
nor,3468,O
antitumor,3468,O
activity,3468,O
from,3468,O
doxorubicin,3468,B-Chemical
clinically,3468,O
",",3468,O
the,3468,O
potent,3468,O
antagonism,3468,O
of,3468,O
daunorubicin,3468,B-Chemical
activity,3468,O
raises,3468,O
concern,3468,O
;,3468,O
a,3468,O
possible,3468,O
interference,3468,O
with,3468,O
anticancer,3468,O
efficacy,3468,O
certainly,3468,O
would,3468,O
call,3468,O
for,3468,O
renewed,3468,O
attention,3468,O
.,3468,O
Our,3469,O
data,3469,O
also,3469,O
suggest,3469,O
that,3469,O
significant,3469,O
etoposide,3469,B-Chemical
dose,3469,O
escalation,3469,O
is,3469,O
perhaps,3469,O
possible,3469,O
by,3469,O
the,3469,O
use,3469,O
of,3469,O
dexrazoxane,3469,B-Chemical
.,3469,O
Clinical,3470,O
trials,3470,O
in,3470,O
patients,3470,O
with,3470,O
brain,3470,O
metastases,3470,B-Disease
combining,3470,O
dexrazoxane,3470,B-Chemical
and,3470,O
high,3470,O
doses,3470,O
of,3470,O
etoposide,3470,B-Chemical
is,3470,O
ongoing,3470,O
with,3470,O
the,3470,O
aim,3470,O
of,3470,O
improving,3470,O
efficacy,3470,O
without,3470,O
aggravating,3470,O
hematologic,3470,B-Disease
toxicity,3470,I-Disease
.,3470,O
If,3471,O
successful,3471,O
",",3471,O
this,3471,O
represents,3471,O
an,3471,O
exciting,3471,O
mechanism,3471,O
for,3471,O
pharmacologic,3471,O
regulation,3471,O
of,3471,O
side,3471,O
effects,3471,O
from,3471,O
cytotoxic,3471,O
chemotherapy,3471,O
.,3471,O
Assessment,3472,O
of,3472,O
the,3472,O
onset,3472,O
and,3472,O
persistence,3472,O
of,3472,O
amnesia,3472,B-Disease
during,3472,O
procedural,3472,O
sedation,3472,O
with,3472,O
propofol,3472,B-Chemical
.,3472,O
OBJECTIVES,3473,O
:,3473,O
To,3473,O
assess,3473,O
patients,3473,O
',3473,O
ability,3473,O
to,3473,O
repeat,3473,O
and,3473,O
recall,3473,O
words,3473,O
presented,3473,O
to,3473,O
them,3473,O
while,3473,O
undergoing,3473,O
procedural,3473,O
sedation,3473,O
with,3473,O
propofol,3473,B-Chemical
",",3473,O
and,3473,O
correlate,3473,O
their,3473,O
recall,3473,O
with,3473,O
their,3473,O
level,3473,O
of,3473,O
awareness,3473,O
as,3473,O
measured,3473,O
by,3473,O
bispectral,3473,O
index,3473,O
(,3473,O
BIS,3473,O
),3473,O
monitoring,3473,O
.,3473,O
METHODS,3474,O
:,3474,O
This,3474,O
was,3474,O
a,3474,O
prospective,3474,O
",",3474,O
single-intervention,3474,O
study,3474,O
of,3474,O
consenting,3474,O
adult,3474,O
patients,3474,O
undergoing,3474,O
procedural,3474,O
sedation,3474,O
with,3474,O
propofol,3474,B-Chemical
between,3474,O
December,3474,O
28,3474,O
",",3474,O
2002,3474,O
",",3474,O
and,3474,O
October,3474,O
31,3474,O
",",3474,O
2003,3474,O
.,3474,O
BIS,3475,O
monitoring,3475,O
was,3475,O
initiated,3475,O
starting,3475,O
3,3475,O
minutes,3475,O
before,3475,O
the,3475,O
procedure,3475,O
and,3475,O
continuing,3475,O
until,3475,O
the,3475,O
patient,3475,O
had,3475,O
regained,3475,O
baseline,3475,O
mental,3475,O
status,3475,O
.,3475,O
At,3476,O
1-minute,3476,O
intervals,3476,O
during,3476,O
the,3476,O
procedural,3476,O
sedation,3476,O
",",3476,O
until,3476,O
the,3476,O
patient,3476,O
regained,3476,O
baseline,3476,O
mental,3476,O
status,3476,O
at,3476,O
the,3476,O
end,3476,O
of,3476,O
the,3476,O
procedure,3476,O
",",3476,O
a,3476,O
word,3476,O
from,3476,O
a,3476,O
standardized,3476,O
list,3476,O
was,3476,O
read,3476,O
aloud,3476,O
",",3476,O
and,3476,O
the,3476,O
patient,3476,O
was,3476,O
asked,3476,O
to,3476,O
immediately,3476,O
repeat,3476,O
the,3476,O
word,3476,O
to,3476,O
the,3476,O
investigator,3476,O
.,3476,O
The,3477,O
BIS,3477,O
score,3477,O
at,3477,O
the,3477,O
time,3477,O
the,3477,O
word,3477,O
was,3477,O
read,3477,O
and,3477,O
the,3477,O
patient,3477,O
's,3477,O
ability,3477,O
to,3477,O
repeat,3477,O
the,3477,O
word,3477,O
were,3477,O
recorded,3477,O
.,3477,O
After,3478,O
the,3478,O
procedure,3478,O
",",3478,O
the,3478,O
patient,3478,O
was,3478,O
asked,3478,O
to,3478,O
state,3478,O
all,3478,O
of,3478,O
the,3478,O
words,3478,O
from,3478,O
the,3478,O
list,3478,O
that,3478,O
he,3478,O
or,3478,O
she,3478,O
could,3478,O
recall,3478,O
",",3478,O
and,3478,O
to,3478,O
identify,3478,O
the,3478,O
last,3478,O
word,3478,O
recalled,3478,O
from,3478,O
prior,3478,O
to,3478,O
the,3478,O
start,3478,O
of,3478,O
the,3478,O
procedure,3478,O
and,3478,O
the,3478,O
first,3478,O
word,3478,O
recalled,3478,O
from,3478,O
after,3478,O
the,3478,O
procedure,3478,O
was,3478,O
completed,3478,O
.,3478,O
RESULTS,3479,O
:,3479,O
Seventy-five,3479,O
consenting,3479,O
patients,3479,O
were,3479,O
enrolled,3479,O
;,3479,O
one,3479,O
patient,3479,O
was,3479,O
excluded,3479,O
from,3479,O
data,3479,O
analysis,3479,O
for,3479,O
a,3479,O
protocol,3479,O
violation,3479,O
.,3479,O
No,3480,O
serious,3480,O
adverse,3480,O
events,3480,O
were,3480,O
noted,3480,O
during,3480,O
the,3480,O
procedural,3480,O
sedations,3480,O
.,3480,O
The,3481,O
mean,3481,O
(,3481,O
+/-standard,3481,O
deviation,3481,O
),3481,O
time,3481,O
of,3481,O
data,3481,O
collection,3481,O
was,3481,O
16.4,3481,O
minutes,3481,O
(,3481,O
+/-7.1,3481,O
;,3481,O
range,3481,O
5,3481,O
to,3481,O
34,3481,O
minutes,3481,O
),3481,O
.,3481,O
The,3482,O
mean,3482,O
initial,3482,O
(,3482,O
preprocedure,3482,O
),3482,O
BIS,3482,O
score,3482,O
was,3482,O
97.1,3482,O
(,3482,O
+/-2.3,3482,O
;,3482,O
range,3482,O
92,3482,O
to,3482,O
99,3482,O
),3482,O
.,3482,O
The,3483,O
mean,3483,O
lowest,3483,O
BIS,3483,O
score,3483,O
occurring,3483,O
during,3483,O
these,3483,O
procedural,3483,O
sedations,3483,O
was,3483,O
66.9,3483,O
(,3483,O
+/-14.4,3483,O
;,3483,O
range,3483,O
33,3483,O
to,3483,O
91,3483,O
),3483,O
.,3483,O
The,3484,O
mean,3484,O
lowest,3484,O
BIS,3484,O
score,3484,O
corresponding,3484,O
to,3484,O
the,3484,O
ability,3484,O
of,3484,O
the,3484,O
patient,3484,O
to,3484,O
immediately,3484,O
repeat,3484,O
words,3484,O
read,3484,O
from,3484,O
the,3484,O
list,3484,O
was,3484,O
77.1,3484,O
(,3484,O
95,3484,O
%,3484,O
CI,3484,O
=,3484,O
74.3,3484,O
to,3484,O
80.0,3484,O
),3484,O
.,3484,O
The,3485,O
mean,3485,O
highest,3485,O
BIS,3485,O
score,3485,O
corresponding,3485,O
to,3485,O
the,3485,O
inability,3485,B-Disease
to,3485,I-Disease
repeat,3485,I-Disease
words,3485,I-Disease
was,3485,O
81.5,3485,O
(,3485,O
95,3485,O
%,3485,O
CI,3485,O
=,3485,O
78.1,3485,O
to,3485,O
84.8,3485,O
),3485,O
.,3485,O
The,3486,O
mean,3486,O
BIS,3486,O
score,3486,O
corresponding,3486,O
to,3486,O
the,3486,O
last,3486,O
word,3486,O
recalled,3486,O
from,3486,O
prior,3486,O
to,3486,O
the,3486,O
initiation,3486,O
of,3486,O
the,3486,O
sedation,3486,O
was,3486,O
96.7,3486,O
(,3486,O
+/-2.4,3486,O
;,3486,O
range,3486,O
84,3486,O
to,3486,O
98,3486,O
),3486,O
.,3486,O
The,3487,O
mean,3487,O
BIS,3487,O
score,3487,O
corresponding,3487,O
to,3487,O
the,3487,O
first,3487,O
word,3487,O
recalled,3487,O
after,3487,O
the,3487,O
procedure,3487,O
was,3487,O
completed,3487,O
was,3487,O
91.2,3487,O
(,3487,O
95,3487,O
%,3487,O
CI,3487,O
=,3487,O
88.1,3487,O
to,3487,O
94.3,3487,O
),3487,O
.,3487,O
All,3488,O
patients,3488,O
recalled,3488,O
at,3488,O
least,3488,O
one,3488,O
word,3488,O
that,3488,O
had,3488,O
been,3488,O
read,3488,O
to,3488,O
them,3488,O
during,3488,O
the,3488,O
protocol,3488,O
.,3488,O
The,3489,O
mean,3489,O
lowest,3489,O
BIS,3489,O
score,3489,O
for,3489,O
any,3489,O
recalled,3489,O
word,3489,O
was,3489,O
91.5,3489,O
(,3489,O
+/-11.1,3489,O
;,3489,O
range,3489,O
79,3489,O
to,3489,O
98,3489,O
),3489,O
",",3489,O
and,3489,O
no,3489,O
words,3489,O
were,3489,O
recalled,3489,O
when,3489,O
the,3489,O
corresponding,3489,O
BIS,3489,O
score,3489,O
was,3489,O
less,3489,O
than,3489,O
90,3489,O
.,3489,O
CONCLUSIONS,3490,O
:,3490,O
There,3490,O
is,3490,O
a,3490,O
range,3490,O
of,3490,O
BIS,3490,O
scores,3490,O
during,3490,O
which,3490,O
sedated,3490,O
patients,3490,O
are,3490,O
able,3490,O
to,3490,O
repeat,3490,O
words,3490,O
read,3490,O
to,3490,O
them,3490,O
but,3490,O
are,3490,O
not,3490,O
able,3490,O
to,3490,O
subsequently,3490,O
recall,3490,O
these,3490,O
words,3490,O
.,3490,O
Furthermore,3491,O
",",3491,O
patients,3491,O
had,3491,O
no,3491,O
recall,3491,O
of,3491,O
words,3491,O
repeated,3491,O
prior,3491,O
to,3491,O
procedural,3491,O
sedation,3491,O
in,3491,O
BIS,3491,O
ranges,3491,O
associated,3491,O
with,3491,O
recall,3491,O
after,3491,O
procedural,3491,O
sedation,3491,O
",",3491,O
suggestive,3491,O
of,3491,O
retrograde,3491,B-Disease
amnesia,3491,I-Disease
.,3491,O
Two,3492,O
prodrugs,3492,O
of,3492,O
potent,3492,O
and,3492,O
selective,3492,O
GluR5,3492,O
kainate,3492,B-Chemical
receptor,3492,O
antagonists,3492,O
actives,3492,O
in,3492,O
three,3492,O
animal,3492,O
models,3492,O
of,3492,O
pain,3492,B-Disease
.,3492,O
Amino,3493,O
acids,3493,O
5,3493,O
and,3493,O
7,3493,O
",",3493,O
two,3493,O
potent,3493,O
and,3493,O
selective,3493,O
competitive,3493,O
GluR5,3493,O
KA,3493,B-Chemical
receptor,3493,O
antagonists,3493,O
",",3493,O
exhibited,3493,O
high,3493,O
GluR5,3493,O
receptor,3493,O
affinity,3493,O
over,3493,O
other,3493,O
glutamate,3493,B-Chemical
receptors,3493,O
.,3493,O
Their,3494,O
ester,3494,O
prodrugs,3494,O
6,3494,O
and,3494,O
8,3494,O
were,3494,O
orally,3494,O
active,3494,O
in,3494,O
three,3494,O
models,3494,O
of,3494,O
pain,3494,B-Disease
:,3494,O
reversal,3494,O
of,3494,O
formalin-induced,3494,B-Chemical
paw,3494,O
licking,3494,O
",",3494,O
carrageenan-induced,3494,B-Chemical
thermal,3494,B-Disease
hyperalgesia,3494,I-Disease
",",3494,O
and,3494,O
capsaicin-induced,3494,B-Chemical
mechanical,3494,B-Disease
hyperalgesia,3494,I-Disease
.,3494,O
Possible,3495,O
azithromycin-associated,3495,B-Chemical
hiccups,3495,B-Disease
.,3495,O
OBJECTIVE,3496,O
:,3496,O
To,3496,O
report,3496,O
a,3496,O
case,3496,O
of,3496,O
persistent,3496,O
hiccups,3496,B-Disease
associated,3496,O
by,3496,O
azithromycin,3496,B-Chemical
therapy,3496,O
.,3496,O
CASE,3497,O
SUMMARY,3497,O
:,3497,O
A,3497,O
76-year-old,3497,O
man,3497,O
presented,3497,O
with,3497,O
persistent,3497,O
hiccups,3497,B-Disease
after,3497,O
beginning,3497,O
azithromycin,3497,B-Chemical
for,3497,O
the,3497,O
treatment,3497,O
of,3497,O
pharyngitis,3497,B-Disease
.,3497,O
Hiccups,3498,B-Disease
were,3498,O
persistent,3498,O
and,3498,O
exhausting,3498,O
.,3498,O
Discontinuation,3499,O
of,3499,O
azithromycin,3499,B-Chemical
and,3499,O
therapy,3499,O
with,3499,O
baclofen,3499,B-Chemical
finally,3499,O
resolved,3499,O
hiccups,3499,B-Disease
.,3499,O
No,3500,O
organic,3500,O
cause,3500,O
of,3500,O
hiccups,3500,B-Disease
was,3500,O
identified,3500,O
despite,3500,O
extensive,3500,O
investigation,3500,O
.,3500,O
DISCUSSION,3501,O
:,3501,O
Pharmacotherapeutic,3501,O
agents,3501,O
have,3501,O
been,3501,O
uncommonly,3501,O
associated,3501,O
with,3501,O
hiccups,3501,B-Disease
.,3501,O
Corticosteroids,3502,O
(,3502,O
dexamethasone,3502,B-Chemical
and,3502,O
methylprednisolone,3502,B-Chemical
),3502,O
",",3502,O
benzodiazepines,3502,B-Chemical
(,3502,O
midazolam,3502,B-Chemical
),3502,O
and,3502,O
general,3502,O
anaesthesia,3502,O
have,3502,O
been,3502,O
the,3502,O
specific,3502,O
agents,3502,O
mentioned,3502,O
most,3502,O
frequently,3502,O
in,3502,O
the,3502,O
literature,3502,O
as,3502,O
being,3502,O
associated,3502,O
with,3502,O
the,3502,O
development,3502,O
of,3502,O
hiccups,3502,B-Disease
.,3502,O
Few,3503,O
cases,3503,O
of,3503,O
drug-induced,3503,O
hiccups,3503,B-Disease
have,3503,O
been,3503,O
reported,3503,O
related,3503,O
to,3503,O
macrolide,3503,B-Chemical
antimicrobials,3503,O
.,3503,O
Using,3504,O
the,3504,O
Naranjo,3504,O
adverse,3504,O
effect,3504,O
reaction,3504,O
probability,3504,O
scale,3504,O
this,3504,O
event,3504,O
could,3504,O
be,3504,O
classified,3504,O
as,3504,O
possible,3504,O
(,3504,O
score,3504,O
5,3504,O
points,3504,O
),3504,O
",",3504,O
mostly,3504,O
because,3504,O
of,3504,O
the,3504,O
close,3504,O
temporal,3504,O
sequence,3504,O
",",3504,O
previous,3504,O
reports,3504,O
on,3504,O
this,3504,O
reaction,3504,O
with,3504,O
other,3504,O
macrolides,3504,B-Chemical
and,3504,O
the,3504,O
absence,3504,O
of,3504,O
any,3504,O
alternative,3504,O
explanation,3504,O
for,3504,O
hiccups,3504,B-Disease
.,3504,O
Our,3505,O
hypothesis,3505,O
is,3505,O
that,3505,O
a,3505,O
vagal,3505,O
mechanism,3505,O
mediated,3505,O
by,3505,O
azithromycin,3505,B-Chemical
could,3505,O
be,3505,O
the,3505,O
pathogenesis,3505,O
of,3505,O
hiccups,3505,B-Disease
in,3505,O
our,3505,O
patient,3505,O
.,3505,O
CONCLUSIONS,3506,O
:,3506,O
Diagnosis,3506,O
of,3506,O
drug-induced,3506,O
hiccups,3506,B-Disease
is,3506,O
difficult,3506,O
and,3506,O
often,3506,O
achieved,3506,O
only,3506,O
by,3506,O
a,3506,O
process,3506,O
of,3506,O
elimination,3506,O
.,3506,O
However,3507,O
",",3507,O
macrolide,3507,B-Chemical
antimicrobials,3507,O
have,3507,O
been,3507,O
reported,3507,O
to,3507,O
be,3507,O
associated,3507,O
with,3507,O
hiccups,3507,B-Disease
and,3507,O
vagal,3507,O
mechanism,3507,O
could,3507,O
explain,3507,O
the,3507,O
development,3507,O
of,3507,O
this,3507,O
side-effect,3507,O
.,3507,O
Calcium,3508,B-Chemical
carbonate,3508,I-Chemical
toxicity,3508,B-Disease
:,3508,O
the,3508,O
updated,3508,O
milk-alkali,3508,B-Disease
syndrome,3508,I-Disease
;,3508,O
report,3508,O
of,3508,O
3,3508,O
cases,3508,O
and,3508,O
review,3508,O
of,3508,O
the,3508,O
literature,3508,O
.,3508,O
OBJECTIVE,3509,O
:,3509,O
To,3509,O
describe,3509,O
3,3509,O
patients,3509,O
with,3509,O
calcium,3509,B-Chemical
carbonate-induced,3509,O
hypercalcemia,3509,B-Disease
and,3509,O
gain,3509,O
insights,3509,O
into,3509,O
the,3509,O
cause,3509,O
and,3509,O
management,3509,O
of,3509,O
the,3509,O
milk-alkali,3509,B-Disease
syndrome,3509,I-Disease
.,3509,O
METHODS,3510,O
:,3510,O
We,3510,O
report,3510,O
the,3510,O
clinical,3510,O
and,3510,O
laboratory,3510,O
data,3510,O
in,3510,O
3,3510,O
patients,3510,O
who,3510,O
presented,3510,O
with,3510,O
severe,3510,O
hypercalcemia,3510,B-Disease
(,3510,O
corrected,3510,O
serum,3510,O
calcium,3510,B-Chemical
>,3510,O
or,3510,O
=,3510,O
14,3510,O
mg/dL,3510,O
),3510,O
and,3510,O
review,3510,O
the,3510,O
pertinent,3510,O
literature,3510,O
on,3510,O
milk-alkali,3510,B-Disease
syndrome,3510,I-Disease
.,3510,O
RESULTS,3511,O
:,3511,O
The,3511,O
3,3511,O
patients,3511,O
had,3511,O
acute,3511,B-Disease
renal,3511,I-Disease
insufficiency,3511,I-Disease
",",3511,O
relative,3511,O
metabolic,3511,B-Disease
alkalosis,3511,I-Disease
",",3511,O
and,3511,O
low,3511,O
parathyroid,3511,O
hormone,3511,O
(,3511,O
PTH,3511,O
),3511,O
",",3511,O
PTH-related,3511,O
peptide,3511,O
",",3511,O
and,3511,O
"1,25-dihydroxyvitamin",3511,B-Chemical
D,3511,I-Chemical
concentrations,3511,O
.,3511,O
No,3512,O
malignant,3512,O
lesion,3512,O
was,3512,O
found,3512,O
.,3512,O
Treatment,3513,O
included,3513,O
aggressive,3513,O
hydration,3513,O
and,3513,O
varied,3513,O
amounts,3513,O
of,3513,O
furosemide,3513,B-Chemical
.,3513,O
The,3514,O
2,3514,O
patients,3514,O
with,3514,O
the,3514,O
higher,3514,O
serum,3514,O
calcium,3514,B-Chemical
concentrations,3514,O
received,3514,O
pamidronate,3514,B-Chemical
intravenously,3514,O
(,3514,O
60,3514,O
and,3514,O
30,3514,O
mg,3514,O
",",3514,O
respectively,3514,O
),3514,O
",",3514,O
which,3514,O
caused,3514,O
severe,3514,O
hypocalcemia,3514,B-Disease
.,3514,O
Of,3515,O
the,3515,O
3,3515,O
patients,3515,O
",",3515,O
2,3515,O
were,3515,O
ingesting,3515,O
acceptable,3515,O
doses,3515,O
of,3515,O
elemental,3515,O
calcium,3515,B-Chemical
(,3515,O
1,3515,O
g,3515,O
and,3515,O
2,3515,O
g,3515,O
daily,3515,O
",",3515,O
respectively,3515,O
),3515,O
in,3515,O
the,3515,O
form,3515,O
of,3515,O
calcium,3515,B-Chemical
carbonate,3515,I-Chemical
.,3515,O
In,3516,O
addition,3516,O
to,3516,O
our,3516,O
highlighted,3516,O
cases,3516,O
",",3516,O
we,3516,O
review,3516,O
the,3516,O
history,3516,O
",",3516,O
classification,3516,O
",",3516,O
pathophysiologic,3516,O
features,3516,O
",",3516,O
and,3516,O
treatment,3516,O
of,3516,O
milk-alkali,3516,B-Disease
syndrome,3516,I-Disease
and,3516,O
summarize,3516,O
the,3516,O
cases,3516,O
reported,3516,O
from,3516,O
early,3516,O
1995,3516,O
to,3516,O
November,3516,O
2003,3516,O
.,3516,O
CONCLUSION,3517,O
:,3517,O
Milk-alkali,3517,B-Disease
syndrome,3517,I-Disease
may,3517,O
be,3517,O
a,3517,O
common,3517,O
cause,3517,O
of,3517,O
unexplained,3517,O
hypercalcemia,3517,B-Disease
and,3517,O
can,3517,O
be,3517,O
precipitated,3517,O
by,3517,O
small,3517,O
amounts,3517,O
of,3517,O
orally,3517,O
ingested,3517,O
calcium,3517,B-Chemical
carbonate,3517,I-Chemical
in,3517,O
susceptible,3517,O
persons,3517,O
.,3517,O
Treatment,3518,O
with,3518,O
hydration,3518,O
",",3518,O
furosemide,3518,B-Chemical
",",3518,O
and,3518,O
discontinuation,3518,O
of,3518,O
the,3518,O
calcium,3518,B-Chemical
and,3518,O
vitamin,3518,B-Chemical
D,3518,I-Chemical
source,3518,O
is,3518,O
adequate,3518,O
.,3518,O
Pamidronate,3519,B-Chemical
treatment,3519,O
is,3519,O
associated,3519,O
with,3519,O
considerable,3519,O
risk,3519,O
for,3519,O
hypocalcemia,3519,B-Disease
",",3519,O
even,3519,O
in,3519,O
cases,3519,O
of,3519,O
initially,3519,O
severe,3519,O
hypercalcemia,3519,B-Disease
.,3519,O
Warfarin-induced,3520,B-Chemical
leukocytoclastic,3520,B-Disease
vasculitis,3520,I-Disease
.,3520,O
Skin,3521,O
reactions,3521,O
associated,3521,O
with,3521,O
oral,3521,O
coumarin-derived,3521,B-Chemical
anticoagulants,3521,O
are,3521,O
an,3521,O
uncommon,3521,O
occurrence,3521,O
.,3521,O
Leukocytoclastic,3522,B-Disease
vasculitis,3522,I-Disease
(,3522,O
LV,3522,B-Disease
),3522,O
is,3522,O
primarily,3522,O
a,3522,O
cutaneous,3522,B-Disease
small,3522,I-Disease
vessel,3522,I-Disease
vasculitis,3522,I-Disease
",",3522,O
though,3522,O
systemic,3522,O
involvement,3522,O
may,3522,O
be,3522,O
encountered,3522,O
.,3522,O
We,3523,O
report,3523,O
4,3523,O
patients,3523,O
with,3523,O
late-onset,3523,O
LV,3523,B-Disease
probably,3523,O
due,3523,O
to,3523,O
warfarin,3523,B-Chemical
.,3523,O
All,3524,O
4,3524,O
patients,3524,O
presented,3524,O
with,3524,O
skin,3524,B-Disease
eruptions,3524,I-Disease
that,3524,O
developed,3524,O
after,3524,O
receiving,3524,O
warfarin,3524,B-Chemical
for,3524,O
several,3524,O
years,3524,O
.,3524,O
The,3525,O
results,3525,O
of,3525,O
skin,3525,B-Disease
lesion,3525,I-Disease
biopsies,3525,O
were,3525,O
available,3525,O
in,3525,O
3,3525,O
patients,3525,O
",",3525,O
confirming,3525,O
LV,3525,B-Disease
Cutaneous,3525,I-Disease
lesions,3525,I-Disease
resolved,3525,O
in,3525,O
all,3525,O
patients,3525,O
after,3525,O
warfarin,3525,B-Chemical
was,3525,O
discontinued,3525,O
.,3525,O
In,3526,O
2,3526,O
of,3526,O
the,3526,O
4,3526,O
patients,3526,O
",",3526,O
rechallenge,3526,O
with,3526,O
warfarin,3526,B-Chemical
led,3526,O
to,3526,O
recurrence,3526,O
of,3526,O
the,3526,O
lesions,3526,O
.,3526,O
LV,3527,B-Disease
may,3527,O
be,3527,O
a,3527,O
late-onset,3527,O
adverse,3527,O
reaction,3527,O
associated,3527,O
with,3527,O
warfarin,3527,B-Chemical
therapy,3527,O
.,3527,O
rTMS,3528,O
of,3528,O
supplementary,3528,O
motor,3528,O
area,3528,O
modulates,3528,O
therapy-induced,3528,O
dyskinesias,3528,B-Disease
in,3528,O
Parkinson,3528,B-Disease
disease,3528,I-Disease
.,3528,O
The,3529,O
neural,3529,O
mechanisms,3529,O
and,3529,O
circuitry,3529,O
involved,3529,O
in,3529,O
levodopa-induced,3529,B-Chemical
dyskinesia,3529,B-Disease
are,3529,O
unclear,3529,O
.,3529,O
Using,3530,O
repetitive,3530,O
transcranial,3530,O
magnetic,3530,O
stimulation,3530,O
(,3530,O
rTMS,3530,O
),3530,O
over,3530,O
the,3530,O
supplementary,3530,O
motor,3530,O
area,3530,O
(,3530,O
SMA,3530,O
),3530,O
in,3530,O
a,3530,O
group,3530,O
of,3530,O
patients,3530,O
with,3530,O
advanced,3530,O
Parkinson,3530,B-Disease
disease,3530,I-Disease
",",3530,O
the,3530,O
authors,3530,O
investigated,3530,O
whether,3530,O
modulation,3530,O
of,3530,O
SMA,3530,O
excitability,3530,O
may,3530,O
result,3530,O
in,3530,O
a,3530,O
modification,3530,O
of,3530,O
a,3530,O
dyskinetic,3530,B-Disease
state,3530,O
induced,3530,O
by,3530,O
continuous,3530,O
apomorphine,3530,B-Chemical
infusion,3530,O
.,3530,O
rTMS,3531,O
at,3531,O
1,3531,O
Hz,3531,O
was,3531,O
observed,3531,O
to,3531,O
markedly,3531,O
reduce,3531,O
drug-induced,3531,B-Disease
dyskinesias,3531,I-Disease
",",3531,O
whereas,3531,O
5-Hz,3531,O
rTMS,3531,O
induced,3531,O
a,3531,O
slight,3531,O
but,3531,O
not,3531,O
significant,3531,O
increase,3531,O
.,3531,O
Intracavitary,3532,O
chemotherapy,3532,O
(,3532,O
paclitaxel/carboplatin,3532,B-Chemical
liquid,3532,O
crystalline,3532,O
cubic,3532,O
phases,3532,O
),3532,O
for,3532,O
recurrent,3532,O
glioblastoma,3532,B-Disease
--,3532,O
clinical,3532,O
observations,3532,O
.,3532,O
Human,3533,O
malignant,3533,O
brain,3533,B-Disease
tumors,3533,I-Disease
have,3533,O
a,3533,O
poor,3533,O
prognosis,3533,O
in,3533,O
spite,3533,O
of,3533,O
surgery,3533,O
and,3533,O
radiation,3533,O
therapy,3533,O
.,3533,O
Cubic,3534,O
phases,3534,O
consist,3534,O
of,3534,O
curved,3534,O
biocontinuous,3534,O
lipid,3534,O
bilayers,3534,O
",",3534,O
separating,3534,O
two,3534,O
congruent,3534,O
networks,3534,O
of,3534,O
water,3534,O
channels,3534,O
.,3534,O
Used,3535,O
as,3535,O
a,3535,O
host,3535,O
for,3535,O
cytotoxic,3535,O
drugs,3535,O
",",3535,O
the,3535,O
gel-like,3535,O
matrix,3535,O
can,3535,O
easily,3535,O
be,3535,O
applied,3535,O
to,3535,O
the,3535,O
walls,3535,O
of,3535,O
a,3535,O
surgical,3535,O
resection,3535,O
cavity,3535,O
.,3535,O
For,3536,O
human,3536,O
glioblastoma,3536,B-Disease
recurrences,3536,O
",",3536,O
the,3536,O
feasibility,3536,O
",",3536,O
safety,3536,O
",",3536,O
and,3536,O
short-term,3536,O
effects,3536,O
of,3536,O
a,3536,O
surgical,3536,O
intracavitary,3536,O
application,3536,O
of,3536,O
paclitaxel,3536,B-Chemical
and,3536,O
carboplatin,3536,B-Chemical
encapsulated,3536,O
by,3536,O
liquid,3536,O
crystalline,3536,O
cubic,3536,O
phases,3536,O
are,3536,O
examined,3536,O
in,3536,O
a,3536,O
pilot,3536,O
study,3536,O
.,3536,O
A,3537,O
total,3537,O
of,3537,O
12,3537,O
patients,3537,O
with,3537,O
a,3537,O
recurrence,3537,O
of,3537,O
a,3537,O
glioblastoma,3537,B-Disease
multiforme,3537,O
underwent,3537,O
re-resection,3537,O
and,3537,O
received,3537,O
an,3537,O
intracavitary,3537,O
application,3537,O
of,3537,O
paclitaxel,3537,B-Chemical
and,3537,O
carboplatin,3537,B-Chemical
cubic,3537,O
phases,3537,O
in,3537,O
different,3537,O
dosages,3537,O
.,3537,O
Six,3538,O
of,3538,O
the,3538,O
patients,3538,O
received,3538,O
more,3538,O
than,3538,O
15,3538,O
mg,3538,O
paclitaxel,3538,B-Chemical
and,3538,O
suffered,3538,O
from,3538,O
moderate,3538,O
to,3538,O
severe,3538,O
brain,3538,B-Disease
edema,3538,I-Disease
",",3538,O
while,3538,O
the,3538,O
remaining,3538,O
patients,3538,O
received,3538,O
only,3538,O
a,3538,O
total,3538,O
of,3538,O
15,3538,O
mg,3538,O
paclitaxel,3538,B-Chemical
.,3538,O
In,3539,O
the,3539,O
latter,3539,O
group,3539,O
",",3539,O
brain,3539,B-Disease
edema,3539,I-Disease
was,3539,O
markedly,3539,O
reduced,3539,O
and,3539,O
dealt,3539,O
medically,3539,O
.,3539,O
Intracavitary,3540,O
chemotherapy,3540,O
in,3540,O
recurrent,3540,O
glioblastoma,3540,B-Disease
using,3540,O
cubic,3540,O
phases,3540,O
is,3540,O
feasible,3540,O
and,3540,O
safe,3540,O
",",3540,O
yet,3540,O
the,3540,O
clinical,3540,O
benefit,3540,O
remains,3540,O
to,3540,O
be,3540,O
examined,3540,O
in,3540,O
a,3540,O
clinical,3540,O
phase,3540,O
II,3540,O
study,3540,O
.,3540,O
Lamotrigine,3541,B-Chemical
associated,3541,O
with,3541,O
exacerbation,3541,O
or,3541,O
de,3541,O
novo,3541,O
myoclonus,3541,B-Disease
in,3541,O
idiopathic,3541,B-Disease
generalized,3541,I-Disease
epilepsies,3541,I-Disease
.,3541,O
Five,3542,O
patients,3542,O
with,3542,O
idiopathic,3542,B-Disease
generalized,3542,I-Disease
epilepsies,3542,I-Disease
(,3542,O
IGE,3542,B-Disease
),3542,O
treated,3542,O
with,3542,O
lamotrigine,3542,B-Chemical
(,3542,O
LTG,3542,B-Chemical
),3542,O
experienced,3542,O
exacerbation,3542,O
or,3542,O
de,3542,O
novo,3542,O
appearance,3542,O
of,3542,O
myoclonic,3542,B-Disease
jerks,3542,I-Disease
(,3542,O
MJ,3542,B-Disease
),3542,O
.,3542,O
In,3543,O
three,3543,O
patients,3543,O
",",3543,O
LTG,3543,B-Chemical
exacerbated,3543,O
MJ,3543,B-Disease
in,3543,O
a,3543,O
dose-dependent,3543,O
manner,3543,O
with,3543,O
early,3543,O
aggravation,3543,O
during,3543,O
titration,3543,O
.,3543,O
MJ,3544,B-Disease
disappeared,3544,O
when,3544,O
LTG,3544,B-Chemical
dose,3544,O
was,3544,O
decreased,3544,O
by,3544,O
25,3544,O
to,3544,O
50,3544,O
%,3544,O
.,3544,O
In,3545,O
two,3545,O
patients,3545,O
",",3545,O
LTG,3545,B-Chemical
exacerbated,3545,O
MJ,3545,B-Disease
in,3545,O
a,3545,O
delayed,3545,O
but,3545,O
more,3545,O
severe,3545,O
manner,3545,O
",",3545,O
with,3545,O
myoclonic,3545,B-Disease
status,3545,I-Disease
that,3545,O
only,3545,O
ceased,3545,O
after,3545,O
LTG,3545,B-Chemical
withdrawal,3545,O
.,3545,O
Absence,3546,O
of,3546,O
acute,3546,O
cerebral,3546,O
vasoconstriction,3546,O
after,3546,O
cocaine-associated,3546,B-Chemical
subarachnoid,3546,B-Disease
hemorrhage,3546,I-Disease
.,3546,O
INTRODUCTION,3547,O
:,3547,O
Cocaine,3547,B-Chemical
use,3547,O
has,3547,O
been,3547,O
associated,3547,O
with,3547,O
neurovascular,3547,B-Disease
complications,3547,I-Disease
",",3547,O
including,3547,O
arterial,3547,O
vasoconstriction,3547,O
and,3547,O
vasculitis,3547,B-Disease
.,3547,O
However,3548,O
",",3548,O
there,3548,O
are,3548,O
few,3548,O
studies,3548,O
of,3548,O
angiographic,3548,O
effects,3548,O
of,3548,O
cocaine,3548,B-Chemical
on,3548,O
human,3548,O
cerebral,3548,O
arteries,3548,O
.,3548,O
Information,3549,O
on,3549,O
these,3549,O
effects,3549,O
could,3549,O
be,3549,O
obtained,3549,O
from,3549,O
angiograms,3549,O
of,3549,O
patients,3549,O
with,3549,O
cocaine-associated,3549,B-Chemical
subarachnoid,3549,B-Disease
hemorrhage,3549,I-Disease
(,3549,O
SAH,3549,B-Disease
),3549,O
who,3549,O
underwent,3549,O
angiography,3549,O
shortly,3549,O
after,3549,O
cocaine,3549,B-Chemical
use,3549,O
.,3549,O
METHODS,3550,O
:,3550,O
We,3550,O
screened,3550,O
patients,3550,O
with,3550,O
SAH,3550,B-Disease
retrospectively,3550,O
and,3550,O
identified,3550,O
those,3550,O
with,3550,O
positive,3550,O
urine,3550,O
toxicology,3550,O
for,3550,O
cocaine,3550,B-Chemical
or,3550,O
its,3550,O
metabolites,3550,O
.,3550,O
Quantitative,3551,O
arterial,3551,O
diameter,3551,O
measurements,3551,O
from,3551,O
angiograms,3551,O
of,3551,O
these,3551,O
patients,3551,O
were,3551,O
compared,3551,O
to,3551,O
measurements,3551,O
from,3551,O
control,3551,O
patients,3551,O
with,3551,O
SAH,3551,B-Disease
who,3551,O
were,3551,O
matched,3551,O
for,3551,O
factors,3551,O
known,3551,O
to,3551,O
influence,3551,O
arterial,3551,O
diameter,3551,O
.,3551,O
Qualitative,3552,O
comparisons,3552,O
of,3552,O
small,3552,O
artery,3552,O
changes,3552,O
also,3552,O
were,3552,O
made,3552,O
.,3552,O
RESULTS,3553,O
:,3553,O
Thirteen,3553,O
patients,3553,O
with,3553,O
positive,3553,O
cocaine,3553,B-Chemical
toxicology,3553,O
were,3553,O
compared,3553,O
to,3553,O
26,3553,O
controls,3553,O
.,3553,O
There,3554,O
were,3554,O
no,3554,O
significant,3554,O
differences,3554,O
between,3554,O
groups,3554,O
in,3554,O
the,3554,O
mean,3554,O
diameters,3554,O
of,3554,O
the,3554,O
intradural,3554,O
internal,3554,O
carotid,3554,O
",",3554,O
sphenoidal,3554,O
segment,3554,O
of,3554,O
the,3554,O
middle,3554,O
cerebral,3554,O
",",3554,O
precommunicating,3554,O
segment,3554,O
of,3554,O
the,3554,O
anterior,3554,O
cerebral,3554,O
",",3554,O
or,3554,O
basilar,3554,O
arteries,3554,O
(,3554,O
p,3554,O
greater,3554,O
than,3554,O
0.05,3554,O
for,3554,O
all,3554,O
comparisons,3554,O
",",3554,O
unpaired,3554,O
t-tests,3554,O
),3554,O
.,3554,O
There,3555,O
also,3555,O
were,3555,O
no,3555,O
significant,3555,O
differences,3555,O
between,3555,O
groups,3555,O
when,3555,O
expressing,3555,O
diameters,3555,O
as,3555,O
the,3555,O
sum,3555,O
of,3555,O
the,3555,O
precommunicating,3555,O
segment,3555,O
of,3555,O
the,3555,O
anterior,3555,O
cerebral,3555,O
+,3555,O
sphenoidal,3555,O
segment,3555,O
of,3555,O
the,3555,O
middle,3555,O
cerebral,3555,O
+,3555,O
supraclinoid,3555,O
internal,3555,O
carotid,3555,O
artery,3555,O
+,3555,O
basilar,3555,O
artery,3555,O
divided,3555,O
by,3555,O
the,3555,O
diameter,3555,O
of,3555,O
the,3555,O
petrous,3555,O
internal,3555,O
carotid,3555,O
artery,3555,O
(,3555,O
p,3555,O
greater,3555,O
than,3555,O
0.05,3555,O
",",3555,O
unpaired,3555,O
t-tests,3555,O
),3555,O
.,3555,O
Qualitative,3556,O
assessments,3556,O
showed,3556,O
two,3556,O
arterial,3556,O
irregularities,3556,O
in,3556,O
the,3556,O
distal,3556,O
vasculature,3556,O
in,3556,O
each,3556,O
group,3556,O
.,3556,O
CONCLUSION,3557,O
:,3557,O
No,3557,O
quantitative,3557,O
evidence,3557,O
for,3557,O
narrowing,3557,O
of,3557,O
large,3557,O
cerebral,3557,O
arteries,3557,O
or,3557,O
qualitative,3557,O
angiographic,3557,O
evidence,3557,O
for,3557,O
distal,3557,O
narrowing,3557,O
or,3557,O
vasculitis,3557,B-Disease
could,3557,O
be,3557,O
found,3557,O
in,3557,O
patients,3557,O
who,3557,O
underwent,3557,O
angiography,3557,O
after,3557,O
aneurysmal,3557,B-Disease
SAH,3557,B-Disease
associated,3557,O
with,3557,O
cocaine,3557,B-Chemical
use,3557,O
.,3557,O
Methamphetamine,3558,B-Chemical
causes,3558,O
alterations,3558,O
in,3558,O
the,3558,O
MAP,3558,O
kinase-related,3558,O
pathways,3558,O
in,3558,O
the,3558,O
brains,3558,O
of,3558,O
mice,3558,O
that,3558,O
display,3558,O
increased,3558,O
aggressiveness,3558,B-Disease
.,3558,O
Aggressive,3559,B-Disease
behaviors,3559,I-Disease
have,3559,O
been,3559,O
reported,3559,O
in,3559,O
patients,3559,O
who,3559,O
suffer,3559,O
from,3559,O
some,3559,O
psychiatric,3559,B-Disease
disorders,3559,I-Disease
",",3559,O
and,3559,O
are,3559,O
common,3559,O
in,3559,O
methamphetamine,3559,B-Chemical
(,3559,O
METH,3559,B-Chemical
),3559,O
abusers,3559,O
.,3559,O
Herein,3560,O
",",3560,O
we,3560,O
report,3560,O
that,3560,O
multiple,3560,O
(,3560,O
but,3560,O
not,3560,O
single,3560,O
),3560,O
injections,3560,O
of,3560,O
METH,3560,B-Chemical
significantly,3560,O
increased,3560,O
aggressiveness,3560,B-Disease
in,3560,O
male,3560,O
CD-1,3560,O
mice,3560,O
.,3560,O
This,3561,O
increase,3561,O
in,3561,O
aggressiveness,3561,B-Disease
was,3561,O
not,3561,O
secondary,3561,O
to,3561,O
METH-induced,3561,B-Chemical
hyperactivity,3561,B-Disease
.,3561,O
Analysis,3562,O
of,3562,O
protein,3562,O
expression,3562,O
using,3562,O
antibody,3562,O
microarrays,3562,O
and,3562,O
Western,3562,O
blotting,3562,O
revealed,3562,O
differential,3562,O
changes,3562,O
in,3562,O
MAP,3562,O
kinase-related,3562,O
pathways,3562,O
after,3562,O
multiple,3562,O
and,3562,O
single,3562,O
METH,3562,B-Chemical
injections,3562,O
.,3562,O
There,3563,O
were,3563,O
statistically,3563,O
significant,3563,O
(,3563,O
p,3563,O
<,3563,O
0.05,3563,O
),3563,O
decreases,3563,O
in,3563,O
MEK1,3563,O
",",3563,O
Erk2p,3563,O
",",3563,O
GSK3alpha,3563,O
",",3563,O
14-3-3e,3563,O
",",3563,O
and,3563,O
MEK7,3563,O
in,3563,O
the,3563,O
striata,3563,O
of,3563,O
mice,3563,O
after,3563,O
multiple,3563,O
injections,3563,O
of,3563,O
METH,3563,B-Chemical
.,3563,O
MEK1,3564,O
was,3564,O
significantly,3564,O
decreased,3564,O
also,3564,O
after,3564,O
a,3564,O
single,3564,O
injection,3564,O
of,3564,O
METH,3564,B-Chemical
",",3564,O
but,3564,O
to,3564,O
a,3564,O
much,3564,O
lesser,3564,O
degree,3564,O
than,3564,O
after,3564,O
multiple,3564,O
injections,3564,O
of,3564,O
METH,3564,B-Chemical
.,3564,O
In,3565,O
the,3565,O
frontal,3565,O
cortex,3565,O
",",3565,O
there,3565,O
was,3565,O
a,3565,O
statistically,3565,O
significant,3565,O
decrease,3565,O
in,3565,O
GSK3alpha,3565,O
after,3565,O
multiple,3565,O
(,3565,O
but,3565,O
not,3565,O
single,3565,O
),3565,O
injections,3565,O
of,3565,O
METH,3565,B-Chemical
.,3565,O
These,3566,O
findings,3566,O
suggest,3566,O
that,3566,O
alterations,3566,O
in,3566,O
MAP,3566,O
kinase-related,3566,O
pathways,3566,O
in,3566,O
the,3566,O
prefronto-striatal,3566,O
circuitries,3566,O
might,3566,O
be,3566,O
involved,3566,O
in,3566,O
the,3566,O
manifestation,3566,O
of,3566,O
aggressive,3566,B-Disease
behaviors,3566,I-Disease
in,3566,O
mice,3566,O
.,3566,O
Amisulpride,3567,B-Chemical
related,3567,O
tic-like,3567,B-Disease
symptoms,3567,I-Disease
in,3567,O
an,3567,O
adolescent,3567,O
schizophrenic,3567,B-Disease
.,3567,O
Tic,3568,B-Disease
disorders,3568,I-Disease
can,3568,O
be,3568,O
effectively,3568,O
treated,3568,O
by,3568,O
atypical,3568,O
antipsychotics,3568,O
such,3568,O
as,3568,O
risperidone,3568,B-Chemical
",",3568,O
olanzapine,3568,B-Chemical
and,3568,O
ziprasidone,3568,B-Chemical
.,3568,O
However,3569,O
",",3569,O
there,3569,O
are,3569,O
two,3569,O
case,3569,O
reports,3569,O
that,3569,O
show,3569,O
tic-like,3569,B-Disease
symptoms,3569,I-Disease
",",3569,O
including,3569,O
motor,3569,O
and,3569,O
phonic,3569,O
variants,3569,O
",",3569,O
occurring,3569,O
during,3569,O
treatment,3569,O
with,3569,O
quetiapine,3569,B-Chemical
or,3569,O
clozapine,3569,B-Chemical
.,3569,O
We,3570,O
present,3570,O
a,3570,O
15-year-old,3570,O
girl,3570,O
schizophrenic,3570,B-Disease
who,3570,O
developed,3570,O
frequent,3570,O
involuntary,3570,B-Disease
eye-blinking,3570,I-Disease
movements,3570,I-Disease
after,3570,O
5,3570,O
months,3570,O
of,3570,O
amisulpride,3570,B-Chemical
treatment,3570,O
(,3570,O
1000,3570,O
mg,3570,O
per,3570,O
day,3570,O
),3570,O
.,3570,O
The,3571,O
tic-like,3571,B-Disease
symptoms,3571,I-Disease
resolved,3571,O
completely,3571,O
after,3571,O
we,3571,O
reduced,3571,O
the,3571,O
dose,3571,O
of,3571,O
amisulpride,3571,B-Chemical
down,3571,O
to,3571,O
800,3571,O
mg,3571,O
per,3571,O
day,3571,O
.,3571,O
However,3572,O
",",3572,O
her,3572,O
psychosis,3572,B-Disease
recurred,3572,O
after,3572,O
the,3572,O
dose,3572,O
reduction,3572,O
.,3572,O
We,3573,O
then,3573,O
placed,3573,O
her,3573,O
on,3573,O
an,3573,O
additional,3573,O
100,3573,O
mg,3573,O
per,3573,O
day,3573,O
of,3573,O
quetiapine,3573,B-Chemical
.,3573,O
She,3574,O
has,3574,O
been,3574,O
in,3574,O
complete,3574,O
remission,3574,O
under,3574,O
the,3574,O
combined,3574,O
medications,3574,O
for,3574,O
more,3574,O
than,3574,O
one,3574,O
year,3574,O
and,3574,O
maintains,3574,O
a,3574,O
fair,3574,O
role,3574,O
function,3574,O
.,3574,O
No,3575,O
more,3575,O
tic-like,3575,B-Disease
symptoms,3575,I-Disease
or,3575,O
other,3575,O
side,3575,O
effects,3575,O
have,3575,O
been,3575,O
reported,3575,O
.,3575,O
Together,3576,O
with,3576,O
previously,3576,O
reported,3576,O
cases,3576,O
",",3576,O
our,3576,O
patient,3576,O
suggests,3576,O
that,3576,O
tic-like,3576,B-Disease
symptoms,3576,I-Disease
might,3576,O
occur,3576,O
in,3576,O
certain,3576,O
vulnerable,3576,O
individuals,3576,O
during,3576,O
treatment,3576,O
with,3576,O
atypical,3576,O
antipsychotics,3576,O
such,3576,O
as,3576,O
quetiapine,3576,B-Chemical
",",3576,O
clozapine,3576,B-Chemical
",",3576,O
or,3576,O
amisulpride,3576,B-Chemical
.,3576,O
Microinjection,3577,O
of,3577,O
ritanserin,3577,B-Chemical
into,3577,O
the,3577,O
CA1,3577,O
region,3577,O
of,3577,O
hippocampus,3577,O
improves,3577,O
scopolamine-induced,3577,B-Chemical
amnesia,3577,B-Disease
in,3577,O
adult,3577,O
male,3577,O
rats,3577,O
.,3577,O
The,3578,O
effect,3578,O
of,3578,O
ritanserin,3578,B-Chemical
(,3578,O
5-HT2,3578,O
antagonist,3578,O
),3578,O
on,3578,O
scopolamine,3578,B-Chemical
(,3578,O
muscarinic,3578,O
cholinergic,3578,O
antagonist,3578,O
),3578,O
-induced,3578,O
amnesia,3578,B-Disease
in,3578,O
Morris,3578,O
water,3578,O
maze,3578,O
(,3578,O
MWM,3578,O
),3578,O
was,3578,O
investigated,3578,O
.,3578,O
Rats,3579,O
were,3579,O
divided,3579,O
into,3579,O
eight,3579,O
groups,3579,O
and,3579,O
bilaterally,3579,O
cannulated,3579,O
into,3579,O
CA1,3579,O
region,3579,O
of,3579,O
the,3579,O
hippocampus,3579,O
.,3579,O
One,3580,O
week,3580,O
later,3580,O
",",3580,O
they,3580,O
received,3580,O
repeatedly,3580,O
vehicles,3580,O
(,3580,O
saline,3580,O
",",3580,O
DMSO,3580,B-Chemical
",",3580,O
saline+DMSO,3580,O
),3580,O
",",3580,O
scopolamine,3580,B-Chemical
(,3580,O
2,3580,O
microg/0.5,3580,O
microl,3580,O
saline/side,3580,O
;,3580,O
30,3580,O
min,3580,O
before,3580,O
training,3580,O
),3580,O
",",3580,O
ritanserin,3580,B-Chemical
(,3580,O
2,3580,O
",",3580,O
4,3580,O
and,3580,O
8,3580,O
microg/0.5,3580,O
microl,3580,O
DMSO/side,3580,B-Chemical
;,3580,O
20,3580,O
min,3580,O
before,3580,O
training,3580,O
),3580,O
and,3580,O
scopolamine,3580,B-Chemical
(,3580,O
2,3580,O
microg/0.5,3580,O
microl,3580,O
;,3580,O
30,3580,O
min,3580,O
before,3580,O
ritanserin,3580,B-Chemical
injection,3580,O
),3580,O
+ritanserin,3580,O
(,3580,O
4,3580,O
microg/0.5,3580,O
microl,3580,O
DMSO,3580,B-Chemical
),3580,O
through,3580,O
cannulae,3580,O
each,3580,O
day,3580,O
.,3580,O
Animals,3581,O
were,3581,O
tested,3581,O
for,3581,O
four,3581,O
consecutive,3581,O
days,3581,O
(,3581,O
4,3581,O
trial/day,3581,O
),3581,O
in,3581,O
MWM,3581,O
during,3581,O
which,3581,O
the,3581,O
position,3581,O
of,3581,O
hidden,3581,O
platform,3581,O
was,3581,O
unchanged,3581,O
.,3581,O
In,3582,O
the,3582,O
fifth,3582,O
day,3582,O
",",3582,O
the,3582,O
platform,3582,O
was,3582,O
elevated,3582,O
above,3582,O
the,3582,O
water,3582,O
surface,3582,O
in,3582,O
another,3582,O
position,3582,O
to,3582,O
evaluate,3582,O
the,3582,O
function,3582,O
of,3582,O
motor,3582,O
",",3582,O
motivational,3582,O
and,3582,O
visual,3582,O
systems,3582,O
.,3582,O
The,3583,O
results,3583,O
showed,3583,O
a,3583,O
significant,3583,O
increase,3583,O
in,3583,O
escape,3583,O
latencies,3583,O
and,3583,O
traveled,3583,O
distances,3583,O
to,3583,O
find,3583,O
platform,3583,O
in,3583,O
scopolamine-treated,3583,B-Chemical
group,3583,O
as,3583,O
compared,3583,O
to,3583,O
saline,3583,O
group,3583,O
.,3583,O
Ritanserin-treated,3584,B-Chemical
rats,3584,O
(,3584,O
4,3584,O
microg/0.5,3584,O
microl/side,3584,O
),3584,O
showed,3584,O
a,3584,O
significant,3584,O
decrease,3584,O
in,3584,O
the,3584,O
mentioned,3584,O
parameters,3584,O
as,3584,O
compared,3584,O
to,3584,O
DMSO-treated,3584,B-Chemical
group,3584,O
.,3584,O
However,3585,O
",",3585,O
scopolamine,3585,B-Chemical
and,3585,O
ritanserin,3585,B-Chemical
co-administration,3585,O
resulted,3585,O
in,3585,O
a,3585,O
significant,3585,O
decrease,3585,O
in,3585,O
escape,3585,O
latencies,3585,O
and,3585,O
traveled,3585,O
distances,3585,O
as,3585,O
compared,3585,O
to,3585,O
the,3585,O
scopolamine-treated,3585,B-Chemical
rats,3585,O
.,3585,O
Our,3586,O
findings,3586,O
show,3586,O
that,3586,O
microinjection,3586,O
of,3586,O
ritanserin,3586,B-Chemical
into,3586,O
the,3586,O
CA1,3586,O
region,3586,O
of,3586,O
the,3586,O
hippocampus,3586,O
improves,3586,O
the,3586,O
scopolamine-induced,3586,B-Chemical
amnesia,3586,B-Disease
.,3586,O
PTU-associated,3587,B-Chemical
vasculitis,3587,B-Disease
in,3587,O
a,3587,O
girl,3587,O
with,3587,O
Turner,3587,B-Disease
Syndrome,3587,I-Disease
and,3587,O
Graves,3587,B-Disease
',3587,I-Disease
disease,3587,I-Disease
.,3587,O
Palpable,3588,O
purpura,3588,B-Disease
is,3588,O
a,3588,O
concerning,3588,O
clinical,3588,O
finding,3588,O
in,3588,O
pediatric,3588,O
patients,3588,O
and,3588,O
can,3588,O
have,3588,O
many,3588,O
causes,3588,O
",",3588,O
including,3588,O
infectious,3588,O
and,3588,O
autoimmune,3588,O
processes,3588,O
.,3588,O
A,3589,O
rare,3589,O
cause,3589,O
",",3589,O
drug-induced,3589,O
vasculitis,3589,B-Disease
",",3589,O
may,3589,O
result,3589,O
from,3589,O
the,3589,O
production,3589,O
of,3589,O
antineutrophil,3589,O
cytoplasmic,3589,O
antibodies,3589,O
(,3589,O
ANCAs,3589,O
),3589,O
in,3589,O
response,3589,O
to,3589,O
a,3589,O
medication,3589,O
.,3589,O
We,3590,O
report,3590,O
a,3590,O
girl,3590,O
with,3590,O
Turner,3590,B-Disease
syndrome,3590,I-Disease
and,3590,O
Graves,3590,B-Disease
',3590,I-Disease
disease,3590,I-Disease
who,3590,O
presented,3590,O
with,3590,O
palpable,3590,O
purpuric,3590,B-Disease
lesions,3590,I-Disease
.,3590,O
The,3591,O
diagnosis,3591,O
of,3591,O
propylthiouracil,3591,B-Chemical
(,3591,O
PTU,3591,B-Chemical
),3591,O
-associated,3591,O
vasculitis,3591,B-Disease
was,3591,O
made,3591,O
by,3591,O
observation,3591,O
of,3591,O
consistent,3591,O
clinical,3591,O
features,3591,O
",",3591,O
the,3591,O
detection,3591,O
of,3591,O
elevated,3591,O
ANA,3591,O
and,3591,O
ANCA,3591,O
in,3591,O
the,3591,O
blood,3591,O
",",3591,O
and,3591,O
the,3591,O
observed,3591,O
clinical,3591,O
resolution,3591,O
of,3591,O
symptoms,3591,O
following,3591,O
withdrawal,3591,O
of,3591,O
PTU,3591,B-Chemical
.,3591,O
Subsequent,3592,O
treatment,3592,O
of,3592,O
persistent,3592,O
hyperthyroidism,3592,B-Disease
with,3592,O
radioablation,3592,O
did,3592,O
not,3592,O
result,3592,O
in,3592,O
an,3592,O
exacerbation,3592,O
of,3592,O
the,3592,O
vasculitis,3592,B-Disease
",",3592,O
a,3592,O
complication,3592,O
described,3592,O
in,3592,O
prior,3592,O
case,3592,O
reports,3592,O
.,3592,O
Daidzein,3593,B-Chemical
activates,3593,O
choline,3593,B-Chemical
acetyltransferase,3593,O
from,3593,O
MC-IXC,3593,O
cells,3593,O
and,3593,O
improves,3593,O
drug-induced,3593,O
amnesia,3593,B-Disease
.,3593,O
The,3594,O
choline,3594,B-Chemical
acetyltransferase,3594,O
(,3594,O
ChAT,3594,O
),3594,O
activator,3594,O
",",3594,O
which,3594,O
enhances,3594,O
cholinergic,3594,O
transmission,3594,O
via,3594,O
an,3594,O
augmentation,3594,O
of,3594,O
the,3594,O
enzymatic,3594,O
production,3594,O
of,3594,O
acetylcholine,3594,B-Chemical
(,3594,O
ACh,3594,B-Chemical
),3594,O
",",3594,O
is,3594,O
an,3594,O
important,3594,O
factor,3594,O
in,3594,O
the,3594,O
treatment,3594,O
of,3594,O
Alzheimer,3594,B-Disease
's,3594,I-Disease
disease,3594,I-Disease
(,3594,O
AD,3594,B-Disease
),3594,O
.,3594,O
Methanolic,3595,O
extracts,3595,O
from,3595,O
Pueraria,3595,O
thunbergiana,3595,O
exhibited,3595,O
an,3595,O
activation,3595,O
effect,3595,O
(,3595,O
46,3595,O
%,3595,O
),3595,O
on,3595,O
ChAT,3595,O
in,3595,O
vitro,3595,O
.,3595,O
Via,3596,O
the,3596,O
sequential,3596,O
isolation,3596,O
of,3596,O
Pueraria,3596,O
thunbergiana,3596,O
",",3596,O
the,3596,O
active,3596,O
component,3596,O
was,3596,O
ultimately,3596,O
identified,3596,O
as,3596,O
daidzein,3596,B-Chemical
(,3596,O
"4',7-dihydroxy-isoflavone",3596,B-Chemical
),3596,O
.,3596,O
In,3597,O
order,3597,O
to,3597,O
investigate,3597,O
the,3597,O
effects,3597,O
of,3597,O
daidzein,3597,B-Chemical
from,3597,O
Pueraria,3597,O
thunbergiana,3597,O
on,3597,O
scopolamine-induced,3597,B-Chemical
impairments,3597,O
of,3597,O
learning,3597,O
and,3597,O
memory,3597,O
",",3597,O
we,3597,O
conducted,3597,O
a,3597,O
series,3597,O
of,3597,O
in,3597,O
vivo,3597,O
tests,3597,O
.,3597,O
Administration,3598,O
of,3598,O
daidzein,3598,B-Chemical
(,3598,O
4.5,3598,O
mg/kg,3598,O
body,3598,O
weight,3598,O
),3598,O
to,3598,O
mice,3598,O
was,3598,O
shown,3598,O
significantly,3598,O
to,3598,O
reverse,3598,O
scopolamine-induced,3598,B-Chemical
amnesia,3598,B-Disease
",",3598,O
according,3598,O
to,3598,O
the,3598,O
results,3598,O
of,3598,O
a,3598,O
Y-maze,3598,O
test,3598,O
.,3598,O
Injections,3599,O
of,3599,O
scopolamine,3599,B-Chemical
into,3599,O
mice,3599,O
resulted,3599,O
in,3599,O
impaired,3599,O
performance,3599,O
on,3599,O
Y-maze,3599,O
tests,3599,O
(,3599,O
a,3599,O
37,3599,O
%,3599,O
decreases,3599,O
in,3599,O
alternation,3599,O
behavior,3599,O
),3599,O
.,3599,O
By,3600,O
way,3600,O
of,3600,O
contrast,3600,O
",",3600,O
mice,3600,O
treated,3600,O
with,3600,O
daidzein,3600,B-Chemical
prior,3600,O
to,3600,O
the,3600,O
scopolamine,3600,B-Chemical
injections,3600,O
were,3600,O
noticeably,3600,O
protected,3600,O
from,3600,O
this,3600,O
performance,3600,O
impairment,3600,O
(,3600,O
an,3600,O
approximately,3600,O
12,3600,O
%,3600,O
-21,3600,O
%,3600,O
decrease,3600,O
in,3600,O
alternation,3600,O
behavior,3600,O
),3600,O
.,3600,O
These,3601,O
results,3601,O
indicate,3601,O
that,3601,O
daidzein,3601,B-Chemical
might,3601,O
play,3601,O
a,3601,O
role,3601,O
in,3601,O
acetylcholine,3601,B-Chemical
biosynthesis,3601,O
as,3601,O
a,3601,O
ChAT,3601,O
activator,3601,O
",",3601,O
and,3601,O
that,3601,O
it,3601,O
also,3601,O
ameliorates,3601,O
scopolamine-induced,3601,B-Chemical
amnesia,3601,B-Disease
.,3601,O
Urinary,3602,O
symptoms,3602,O
and,3602,O
quality,3602,O
of,3602,O
life,3602,O
changes,3602,O
in,3602,O
Thai,3602,O
women,3602,O
with,3602,O
overactive,3602,B-Disease
bladder,3602,I-Disease
after,3602,O
tolterodine,3602,B-Chemical
treatment,3602,O
.,3602,O
OBJECTIVES,3603,O
:,3603,O
To,3603,O
study,3603,O
the,3603,O
urinary,3603,O
symptoms,3603,O
and,3603,O
quality,3603,O
of,3603,O
life,3603,O
changes,3603,O
in,3603,O
Thai,3603,O
women,3603,O
with,3603,O
overactive,3603,B-Disease
bladder,3603,I-Disease
(,3603,O
OAB,3603,B-Disease
),3603,O
after,3603,O
tolterodine,3603,B-Chemical
treatment,3603,O
.,3603,O
MATERIAL,3604,O
AND,3604,O
METHOD,3604,O
:,3604,O
Thirty,3604,O
women,3604,O
(,3604,O
aged,3604,O
30-77,3604,O
years,3604,O
),3604,O
diagnosed,3604,O
as,3604,O
having,3604,O
OAB,3604,B-Disease
at,3604,O
the,3604,O
Gynecology,3604,O
Clinic,3604,O
",",3604,O
King,3604,O
Chulalongkorn,3604,O
Memorial,3604,O
Hospital,3604,O
from,3604,O
January,3604,O
to,3604,O
April,3604,O
2004,3604,O
were,3604,O
included,3604,O
in,3604,O
the,3604,O
present,3604,O
study,3604,O
.,3604,O
Tolterodine,3605,B-Chemical
2,3605,O
mg,3605,O
",",3605,O
twice,3605,O
daily,3605,O
was,3605,O
given,3605,O
.,3605,O
After,3606,O
8,3606,O
weeks,3606,O
treatment,3606,O
",",3606,O
changes,3606,O
in,3606,O
micturition,3606,O
diary,3606,O
variables,3606,O
and,3606,O
tolerability,3606,O
were,3606,O
determined,3606,O
.,3606,O
Short,3607,O
form,3607,O
36,3607,O
(,3607,O
SF36,3607,O
),3607,O
questionaires,3607,O
(,3607,O
Thai,3607,O
version,3607,O
),3607,O
were,3607,O
given,3607,O
before,3607,O
and,3607,O
after,3607,O
8,3607,O
weeks,3607,O
of,3607,O
treatment,3607,O
.,3607,O
RESULTS,3608,O
:,3608,O
At,3608,O
8,3608,O
weeks,3608,O
",",3608,O
all,3608,O
micturition,3608,O
per,3608,O
day,3608,O
decreased,3608,O
from,3608,O
16,3608,O
.,3608,O
7,3609,O
+/-,3609,O
5,3609,O
.,3609,O
3,3610,O
to,3610,O
6,3610,O
.,3610,O
7,3611,O
+/-,3611,O
2.4,3611,O
times,3611,O
per,3611,O
day,3611,O
.,3611,O
The,3612,O
number,3612,O
of,3612,O
nocturia,3612,B-Disease
episodes,3612,O
decreased,3612,O
from,3612,O
5.4,3612,O
+/-,3612,O
4.2,3612,O
to,3612,O
1.1,3612,O
+/-,3612,O
1.0,3612,O
times,3612,O
per,3612,O
night,3612,O
.,3612,O
The,3613,O
most,3613,O
common,3613,O
side,3613,O
effect,3613,O
was,3613,O
dry,3613,B-Disease
month,3613,I-Disease
in,3613,O
5,3613,O
cases,3613,O
(,3613,O
16.7,3613,O
%,3613,O
),3613,O
with,3613,O
2,3613,O
cases,3613,O
reporting,3613,O
a,3613,O
moderate,3613,O
degree,3613,O
and,3613,O
1,3613,O
case,3613,O
with,3613,O
severe,3613,O
degree,3613,O
.,3613,O
Only,3614,O
one,3614,O
case,3614,O
(,3614,O
3.3,3614,O
%,3614,O
),3614,O
withdrew,3614,O
from,3614,O
the,3614,O
present,3614,O
study,3614,O
due,3614,O
to,3614,O
a,3614,O
severe,3614,O
dry,3614,B-Disease
mouth,3614,I-Disease
.,3614,O
The,3615,O
SF-36,3615,O
scores,3615,O
changed,3615,O
significantly,3615,O
in,3615,O
the,3615,O
domains,3615,O
of,3615,O
physical,3615,O
functioning,3615,O
",",3615,O
role,3615,O
function,3615,O
emotional,3615,O
",",3615,O
social,3615,O
function,3615,O
and,3615,O
mental,3615,O
heath,3615,O
.,3615,O
CONCLUSION,3616,O
:,3616,O
Tolterodine,3616,B-Chemical
was,3616,O
well,3616,O
tolerated,3616,O
and,3616,O
its,3616,O
effects,3616,O
improved,3616,O
the,3616,O
quality,3616,O
of,3616,O
life,3616,O
in,3616,O
Thai,3616,O
women,3616,O
with,3616,O
OAB,3616,B-Disease
.,3616,O
Remifentanil,3617,B-Chemical
pretreatment,3617,O
reduces,3617,O
myoclonus,3617,B-Disease
after,3617,O
etomidate,3617,B-Chemical
.,3617,O
STUDY,3618,O
OBJECTIVE,3618,O
:,3618,O
The,3618,O
aim,3618,O
of,3618,O
the,3618,O
study,3618,O
was,3618,O
to,3618,O
compare,3618,O
the,3618,O
effect,3618,O
of,3618,O
pretreatment,3618,O
with,3618,O
remifentanil,3618,B-Chemical
1,3618,O
microg/kg,3618,O
and,3618,O
the,3618,O
effect,3618,O
of,3618,O
gender,3618,O
on,3618,O
the,3618,O
incidence,3618,O
of,3618,O
myoclonus,3618,B-Disease
after,3618,O
anesthesia,3618,O
induction,3618,O
with,3618,O
etomidate,3618,B-Chemical
.,3618,O
DESIGN,3619,O
:,3619,O
This,3619,O
was,3619,O
a,3619,O
randomized,3619,O
",",3619,O
double-blind,3619,O
study,3619,O
.,3619,O
SETTING,3620,O
:,3620,O
The,3620,O
study,3620,O
was,3620,O
conducted,3620,O
at,3620,O
a,3620,O
university,3620,O
hospital,3620,O
.,3620,O
PATIENTS,3621,O
:,3621,O
Sixty,3621,O
patients,3621,O
were,3621,O
pretreated,3621,O
in,3621,O
a,3621,O
randomized,3621,O
double-blinded,3621,O
fashion,3621,O
with,3621,O
remifentanil,3621,B-Chemical
1,3621,O
microg/kg,3621,O
or,3621,O
placebo,3621,O
.,3621,O
Two,3622,O
minutes,3622,O
after,3622,O
remifentanil,3622,B-Chemical
or,3622,O
placebo,3622,O
injection,3622,O
",",3622,O
etomidate,3622,B-Chemical
0.3,3622,O
mg/kg,3622,O
was,3622,O
given,3622,O
.,3622,O
MEASUREMENTS,3623,O
:,3623,O
Myoclonus,3623,B-Disease
was,3623,O
recorded,3623,O
with,3623,O
a,3623,O
scale,3623,O
of,3623,O
0,3623,O
to,3623,O
3,3623,O
.,3623,O
The,3624,O
grade,3624,O
of,3624,O
sedation,3624,O
(,3624,O
none,3624,O
",",3624,O
mild,3624,O
",",3624,O
moderate,3624,O
",",3624,O
severe,3624,O
),3624,O
",",3624,O
nausea,3624,B-Disease
",",3624,O
pruritus,3624,B-Disease
",",3624,O
and,3624,O
apnea,3624,B-Disease
were,3624,O
recorded,3624,O
after,3624,O
injection,3624,O
of,3624,O
both,3624,O
drugs,3624,O
.,3624,O
MAIN,3625,O
RESULTS,3625,O
:,3625,O
The,3625,O
incidence,3625,O
of,3625,O
myoclonus,3625,B-Disease
was,3625,O
significantly,3625,O
lower,3625,O
in,3625,O
the,3625,O
remifentanil,3625,B-Chemical
group,3625,O
(,3625,O
6.7,3625,O
%,3625,O
),3625,O
than,3625,O
in,3625,O
the,3625,O
placebo,3625,O
group,3625,O
(,3625,O
70,3625,O
%,3625,O
),3625,O
(,3625,O
P,3625,O
<,3625,O
0.001,3625,O
),3625,O
.,3625,O
None,3626,O
of,3626,O
the,3626,O
patients,3626,O
experienced,3626,O
sedation,3626,O
",",3626,O
apnea,3626,B-Disease
",",3626,O
nausea,3626,B-Disease
",",3626,O
or,3626,O
pruritus,3626,B-Disease
after,3626,O
injection,3626,O
of,3626,O
both,3626,O
drugs,3626,O
.,3626,O
In,3627,O
the,3627,O
placebo,3627,O
group,3627,O
",",3627,O
male,3627,O
patients,3627,O
were,3627,O
associated,3627,O
with,3627,O
significantly,3627,O
increased,3627,O
incidence,3627,O
of,3627,O
myoclonus,3627,B-Disease
after,3627,O
etomidate,3627,B-Chemical
administration,3627,O
.,3627,O
CONCLUSION,3628,O
:,3628,O
Pretreatment,3628,O
with,3628,O
remifentanil,3628,B-Chemical
1,3628,O
microg/kg,3628,O
reduced,3628,O
myoclonus,3628,B-Disease
after,3628,O
etomidate,3628,B-Chemical
induction,3628,O
without,3628,O
side,3628,O
effects,3628,O
such,3628,O
as,3628,O
sedation,3628,O
",",3628,O
apnea,3628,B-Disease
",",3628,O
nausea,3628,B-Disease
",",3628,O
or,3628,O
pruritus,3628,B-Disease
.,3628,O
Men,3629,O
experience,3629,O
increased,3629,O
incidence,3629,O
of,3629,O
myoclonus,3629,B-Disease
than,3629,O
women,3629,O
after,3629,O
etomidate,3629,B-Chemical
administration,3629,O
.,3629,O
Memory,3630,O
function,3630,O
and,3630,O
serotonin,3630,B-Chemical
transporter,3630,O
promoter,3630,O
gene,3630,O
polymorphism,3630,O
in,3630,O
ecstasy,3630,B-Chemical
(,3630,O
MDMA,3630,B-Chemical
),3630,O
users,3630,O
.,3630,O
Although,3631,O
"3,4-methylenedioxymethamphetamine",3631,B-Chemical
(,3631,O
MDMA,3631,B-Chemical
or,3631,O
ecstasy,3631,B-Chemical
),3631,O
has,3631,O
been,3631,O
shown,3631,O
to,3631,O
damage,3631,O
brain,3631,O
serotonin,3631,B-Chemical
(,3631,O
5-HT,3631,B-Chemical
),3631,O
neurons,3631,O
in,3631,O
animals,3631,O
and,3631,O
possibly,3631,O
humans,3631,O
",",3631,O
little,3631,O
is,3631,O
known,3631,O
about,3631,O
the,3631,O
long-term,3631,O
consequences,3631,O
of,3631,O
MDMA-induced,3631,B-Chemical
5-HT,3631,B-Chemical
neurotoxic,3631,B-Disease
lesions,3631,I-Disease
on,3631,O
functions,3631,O
in,3631,O
which,3631,O
5-HT,3631,B-Chemical
is,3631,O
involved,3631,O
",",3631,O
such,3631,O
as,3631,O
cognitive,3631,O
function,3631,O
.,3631,O
Because,3632,O
5-HT,3632,B-Chemical
transporters,3632,O
play,3632,O
a,3632,O
key,3632,O
element,3632,O
in,3632,O
the,3632,O
regulation,3632,O
of,3632,O
synaptic,3632,O
5-HT,3632,B-Chemical
transmission,3632,O
it,3632,O
may,3632,O
be,3632,O
important,3632,O
to,3632,O
control,3632,O
for,3632,O
the,3632,O
potential,3632,O
covariance,3632,O
effect,3632,O
of,3632,O
a,3632,O
polymorphism,3632,O
in,3632,O
the,3632,O
5-HT,3632,B-Chemical
transporter,3632,O
promoter,3632,O
gene,3632,O
region,3632,O
(,3632,O
5-HTTLPR,3632,O
),3632,O
when,3632,O
studying,3632,O
the,3632,O
effects,3632,O
of,3632,O
MDMA,3632,B-Chemical
as,3632,O
well,3632,O
as,3632,O
cognitive,3632,O
functioning,3632,O
.,3632,O
The,3633,O
aim,3633,O
of,3633,O
the,3633,O
study,3633,O
was,3633,O
to,3633,O
investigate,3633,O
the,3633,O
effects,3633,O
of,3633,O
moderate,3633,O
and,3633,O
heavy,3633,O
MDMA,3633,B-Chemical
use,3633,O
on,3633,O
cognitive,3633,O
function,3633,O
",",3633,O
as,3633,O
well,3633,O
as,3633,O
the,3633,O
effects,3633,O
of,3633,O
long-term,3633,O
abstention,3633,O
from,3633,O
MDMA,3633,B-Chemical
",",3633,O
in,3633,O
subjects,3633,O
genotyped,3633,O
for,3633,O
5-HTTLPR,3633,O
.,3633,O
A,3634,O
second,3634,O
aim,3634,O
of,3634,O
the,3634,O
study,3634,O
was,3634,O
to,3634,O
determine,3634,O
whether,3634,O
these,3634,O
effects,3634,O
differ,3634,O
for,3634,O
females,3634,O
and,3634,O
males,3634,O
.,3634,O
Fifteen,3635,O
moderate,3635,O
MDMA,3635,B-Chemical
users,3635,O
(,3635,O
<,3635,O
55,3635,O
lifetime,3635,O
tablets,3635,O
),3635,O
",",3635,O
22,3635,O
heavy,3635,O
MDMA+,3635,B-Chemical
users,3635,O
(,3635,O
>,3635,O
55,3635,O
lifetime,3635,O
tablets,3635,O
),3635,O
",",3635,O
16,3635,O
ex-MDMA+,3635,O
users,3635,O
(,3635,O
last,3635,O
tablet,3635,O
>,3635,O
1,3635,O
year,3635,O
ago,3635,O
),3635,O
and,3635,O
13,3635,O
controls,3635,O
were,3635,O
compared,3635,O
on,3635,O
a,3635,O
battery,3635,O
of,3635,O
neuropsychological,3635,O
tests,3635,O
.,3635,O
DNA,3636,O
from,3636,O
peripheral,3636,O
nuclear,3636,O
blood,3636,O
cells,3636,O
was,3636,O
genotyped,3636,O
for,3636,O
5-HTTLPR,3636,O
using,3636,O
standard,3636,O
polymerase,3636,O
chain,3636,O
reaction,3636,O
methods.A,3636,O
significant,3636,O
group,3636,O
effect,3636,O
was,3636,O
observed,3636,O
only,3636,O
on,3636,O
memory,3636,O
function,3636,O
tasks,3636,O
(,3636,O
p,3636,O
=,3636,O
0.04,3636,O
),3636,O
but,3636,O
not,3636,O
on,3636,O
reaction,3636,O
times,3636,O
(,3636,O
p,3636,O
=,3636,O
0.61,3636,O
),3636,O
or,3636,O
attention/executive,3636,O
functioning,3636,O
(,3636,O
p,3636,O
=,3636,O
0.59,3636,O
),3636,O
.,3636,O
Heavy,3637,O
and,3637,O
ex-MDMA+,3637,O
users,3637,O
performed,3637,O
significantly,3637,O
poorer,3637,O
on,3637,O
memory,3637,O
tasks,3637,O
than,3637,O
controls,3637,O
.,3637,O
In,3638,O
contrast,3638,O
",",3638,O
no,3638,O
evidence,3638,O
of,3638,O
memory,3638,B-Disease
impairment,3638,I-Disease
was,3638,O
observed,3638,O
in,3638,O
moderate,3638,O
MDMA,3638,B-Chemical
users,3638,O
.,3638,O
No,3639,O
significant,3639,O
effect,3639,O
of,3639,O
5-HTTLPR,3639,O
or,3639,O
gender,3639,O
was,3639,O
observed,3639,O
.,3639,O
While,3640,O
the,3640,O
use,3640,O
of,3640,O
MDMA,3640,B-Chemical
in,3640,O
quantities,3640,O
that,3640,O
may,3640,O
be,3640,O
considered,3640,O
``,3640,O
moderate,3640,O
'',3640,O
is,3640,O
not,3640,O
associated,3640,O
with,3640,O
impaired,3640,B-Disease
memory,3640,I-Disease
functioning,3640,I-Disease
",",3640,O
heavy,3640,O
use,3640,O
of,3640,O
MDMA,3640,B-Chemical
use,3640,O
may,3640,O
lead,3640,O
to,3640,O
long,3640,O
lasting,3640,O
memory,3640,B-Disease
impairments,3640,I-Disease
.,3640,O
No,3641,O
effect,3641,O
of,3641,O
5-HTTLPR,3641,O
or,3641,O
gender,3641,O
on,3641,O
memory,3641,O
function,3641,O
or,3641,O
MDMA,3641,B-Chemical
use,3641,O
was,3641,O
observed,3641,O
.,3641,O
Role,3642,O
of,3642,O
mangiferin,3642,B-Chemical
on,3642,O
biochemical,3642,O
alterations,3642,O
and,3642,O
antioxidant,3642,O
status,3642,O
in,3642,O
isoproterenol-induced,3642,B-Chemical
myocardial,3642,B-Disease
infarction,3642,I-Disease
in,3642,O
rats,3642,O
.,3642,O
The,3643,O
current,3643,O
study,3643,O
dealt,3643,O
with,3643,O
the,3643,O
protective,3643,O
role,3643,O
of,3643,O
mangiferin,3643,B-Chemical
",",3643,O
a,3643,O
polyphenol,3643,B-Chemical
from,3643,O
Mangifera,3643,O
indica,3643,O
Linn,3643,O
.,3643,O
(,3644,O
Anacardiaceae,3644,O
),3644,O
",",3644,O
on,3644,O
isoproterenol,3644,B-Chemical
(,3644,O
ISPH,3644,B-Chemical
),3644,O
-induced,3644,O
myocardial,3644,B-Disease
infarction,3644,I-Disease
(,3644,O
MI,3644,B-Disease
),3644,O
in,3644,O
rats,3644,O
through,3644,O
its,3644,O
antioxidative,3644,O
mechanism,3644,O
.,3644,O
Subcutaneous,3645,O
injection,3645,O
of,3645,O
ISPH,3645,B-Chemical
(,3645,O
200,3645,O
mg/kg,3645,O
body,3645,O
weight,3645,O
in,3645,O
1,3645,O
ml,3645,O
saline,3645,O
),3645,O
to,3645,O
rats,3645,O
for,3645,O
2,3645,O
consecutive,3645,O
days,3645,O
caused,3645,O
myocardial,3645,B-Disease
damage,3645,I-Disease
in,3645,O
rat,3645,O
heart,3645,O
",",3645,O
which,3645,O
was,3645,O
determined,3645,O
by,3645,O
the,3645,O
increased,3645,O
activity,3645,O
of,3645,O
serum,3645,O
lactate,3645,B-Chemical
dehydrogenase,3645,O
(,3645,O
LDH,3645,O
),3645,O
and,3645,O
creatine,3645,B-Chemical
phosphokinase,3645,O
isoenzymes,3645,O
(,3645,O
CK-MB,3645,O
),3645,O
",",3645,O
increased,3645,O
uric,3645,B-Chemical
acid,3645,I-Chemical
level,3645,O
and,3645,O
reduced,3645,O
plasma,3645,O
iron,3645,B-Chemical
binding,3645,O
capacity,3645,O
.,3645,O
The,3646,O
protective,3646,O
role,3646,O
of,3646,O
mangiferin,3646,B-Chemical
was,3646,O
analyzed,3646,O
by,3646,O
triphenyl,3646,B-Chemical
tetrazolium,3646,I-Chemical
chloride,3646,I-Chemical
(,3646,O
TTC,3646,B-Chemical
),3646,O
test,3646,O
used,3646,O
for,3646,O
macroscopic,3646,O
enzyme,3646,O
mapping,3646,O
assay,3646,O
of,3646,O
the,3646,O
ischemic,3646,B-Disease
myocardium,3646,I-Disease
.,3646,O
The,3647,O
heart,3647,O
tissue,3647,O
antioxidant,3647,O
enzymes,3647,O
such,3647,O
as,3647,O
superoxide,3647,B-Chemical
dismutase,3647,O
",",3647,O
catalase,3647,O
",",3647,O
glutathione,3647,B-Chemical
peroxidase,3647,O
",",3647,O
glutathione,3647,B-Chemical
transferase,3647,O
and,3647,O
glutathione,3647,B-Chemical
reductase,3647,O
activities,3647,O
",",3647,O
non-enzymic,3647,O
antioxidants,3647,O
such,3647,O
as,3647,O
cerruloplasmin,3647,O
",",3647,O
Vitamin,3647,B-Chemical
C,3647,I-Chemical
",",3647,O
Vitamin,3647,B-Chemical
E,3647,I-Chemical
and,3647,O
glutathione,3647,B-Chemical
levels,3647,O
were,3647,O
altered,3647,O
in,3647,O
MI,3647,B-Disease
rats,3647,O
.,3647,O
Upon,3648,O
pretreatment,3648,O
with,3648,O
mangiferin,3648,B-Chemical
(,3648,O
100,3648,O
mg/kg,3648,O
body,3648,O
weight,3648,O
suspended,3648,O
in,3648,O
2,3648,O
ml,3648,O
of,3648,O
dimethyl,3648,B-Chemical
sulphoxide,3648,I-Chemical
),3648,O
given,3648,O
intraperitoneally,3648,O
for,3648,O
28,3648,O
days,3648,O
to,3648,O
MI,3648,B-Disease
rats,3648,O
protected,3648,O
the,3648,O
above-mentioned,3648,O
parameters,3648,O
to,3648,O
fall,3648,O
from,3648,O
the,3648,O
normal,3648,O
levels,3648,O
.,3648,O
Activities,3649,O
of,3649,O
heart,3649,O
tissue,3649,O
enzymic,3649,O
antioxidants,3649,O
and,3649,O
serum,3649,O
non-enzymic,3649,O
antioxidants,3649,O
levels,3649,O
rose,3649,O
significantly,3649,O
upon,3649,O
mangiferin,3649,B-Chemical
administration,3649,O
as,3649,O
compared,3649,O
to,3649,O
ISPH-induced,3649,B-Chemical
MI,3649,B-Disease
rats,3649,O
.,3649,O
From,3650,O
the,3650,O
present,3650,O
study,3650,O
it,3650,O
is,3650,O
concluded,3650,O
that,3650,O
mangiferin,3650,B-Chemical
exerts,3650,O
a,3650,O
beneficial,3650,O
effect,3650,O
against,3650,O
ISPH-induced,3650,B-Chemical
MI,3650,B-Disease
due,3650,O
to,3650,O
its,3650,O
antioxidant,3650,O
potential,3650,O
",",3650,O
which,3650,O
regulated,3650,O
the,3650,O
tissues,3650,O
defense,3650,O
system,3650,O
against,3650,O
cardiac,3650,B-Disease
damage,3650,I-Disease
.,3650,O
Cardiovascular,3651,O
risk,3651,O
with,3651,O
cyclooxygenase,3651,B-Chemical
inhibitors,3651,I-Chemical
:,3651,O
general,3651,O
problem,3651,O
with,3651,O
substance,3651,O
specific,3651,O
differences,3651,O
?,3651,O
Randomised,3652,O
clinical,3652,O
trials,3652,O
and,3652,O
observational,3652,O
studies,3652,O
have,3652,O
shown,3652,O
an,3652,O
increased,3652,O
risk,3652,O
of,3652,O
myocardial,3652,B-Disease
infarction,3652,I-Disease
",",3652,O
stroke,3652,B-Disease
",",3652,O
hypertension,3652,B-Disease
and,3652,O
heart,3652,B-Disease
failure,3652,I-Disease
during,3652,O
treatment,3652,O
with,3652,O
cyclooxygenase,3652,B-Chemical
inhibitors,3652,I-Chemical
.,3652,O
Adverse,3653,O
cardiovascular,3653,O
effects,3653,O
occurred,3653,O
mainly,3653,O
",",3653,O
but,3653,O
not,3653,O
exclusively,3653,O
",",3653,O
in,3653,O
patients,3653,O
with,3653,O
concomitant,3653,O
risk,3653,O
factors,3653,O
.,3653,O
Cyclooxygenase,3654,B-Chemical
inhibitors,3654,I-Chemical
cause,3654,O
complex,3654,O
changes,3654,O
in,3654,O
renal,3654,O
",",3654,O
vascular,3654,O
and,3654,O
cardiac,3654,O
prostanoid,3654,O
profiles,3654,O
thereby,3654,O
increasing,3654,O
vascular,3654,O
resistance,3654,O
and,3654,O
fluid,3654,O
retention,3654,O
.,3654,O
The,3655,O
incidence,3655,O
of,3655,O
cardiovascular,3655,O
adverse,3655,O
events,3655,O
tends,3655,O
to,3655,O
increase,3655,O
with,3655,O
the,3655,O
daily,3655,O
dose,3655,O
and,3655,O
total,3655,O
exposure,3655,O
time,3655,O
.,3655,O
A,3656,O
comparison,3656,O
of,3656,O
individual,3656,O
selective,3656,O
and,3656,O
unselective,3656,O
cyclooxygenase,3656,B-Chemical
inhibitors,3656,I-Chemical
suggests,3656,O
substance-specific,3656,O
differences,3656,O
",",3656,O
which,3656,O
may,3656,O
depend,3656,O
on,3656,O
differences,3656,O
in,3656,O
pharmacokinetic,3656,O
parameters,3656,O
or,3656,O
inhibitory,3656,O
potency,3656,O
and,3656,O
may,3656,O
be,3656,O
contributed,3656,O
by,3656,O
prostaglandin-independent,3656,B-Chemical
effects,3656,O
.,3656,O
Diagnostic,3657,O
markers,3657,O
such,3657,O
as,3657,O
N-terminal,3657,B-Chemical
pro,3657,I-Chemical
brain,3657,I-Chemical
natriuretic,3657,I-Chemical
peptide,3657,I-Chemical
(,3657,O
NT-proBNP,3657,B-Chemical
),3657,O
or,3657,O
high-sensitive,3657,O
C-reactive,3657,O
protein,3657,O
might,3657,O
help,3657,O
in,3657,O
the,3657,O
early,3657,O
identification,3657,O
of,3657,O
patients,3657,O
at,3657,O
risk,3657,O
",",3657,O
thus,3657,O
avoiding,3657,O
the,3657,O
occurrence,3657,O
of,3657,O
serious,3657,O
cardiovascular,3657,B-Disease
toxicity,3657,I-Disease
.,3657,O
Pilocarpine,3658,B-Chemical
seizures,3658,B-Disease
cause,3658,O
age-dependent,3658,O
impairment,3658,B-Disease
in,3658,I-Disease
auditory,3658,I-Disease
location,3658,I-Disease
discrimination,3658,I-Disease
.,3658,O
Children,3659,O
who,3659,O
have,3659,O
status,3659,B-Disease
epilepticus,3659,I-Disease
have,3659,O
continuous,3659,O
or,3659,O
rapidly,3659,O
repeating,3659,O
seizures,3659,B-Disease
that,3659,O
may,3659,O
be,3659,O
life-threatening,3659,O
and,3659,O
may,3659,O
cause,3659,O
life-long,3659,O
changes,3659,O
in,3659,O
brain,3659,O
and,3659,O
behavior,3659,O
.,3659,O
The,3660,O
extent,3660,O
to,3660,O
which,3660,O
status,3660,B-Disease
epilepticus,3660,I-Disease
causes,3660,O
deficits,3660,B-Disease
in,3660,I-Disease
auditory,3660,I-Disease
discrimination,3660,I-Disease
is,3660,O
unknown,3660,O
.,3660,O
A,3661,O
naturalistic,3661,O
auditory,3661,O
location,3661,O
discrimination,3661,O
method,3661,O
was,3661,O
used,3661,O
to,3661,O
evaluate,3661,O
this,3661,O
question,3661,O
using,3661,O
an,3661,O
animal,3661,O
model,3661,O
of,3661,O
status,3661,B-Disease
epilepticus,3661,I-Disease
.,3661,O
Male,3662,O
Sprague-Dawley,3662,O
rats,3662,O
were,3662,O
injected,3662,O
with,3662,O
saline,3662,O
on,3662,O
postnatal,3662,O
day,3662,O
(,3662,O
P,3662,O
),3662,O
20,3662,O
",",3662,O
or,3662,O
a,3662,O
convulsant,3662,O
dose,3662,O
of,3662,O
pilocarpine,3662,B-Chemical
on,3662,O
P20,3662,O
or,3662,O
P45,3662,O
.,3662,O
Pilocarpine,3663,B-Chemical
on,3663,O
either,3663,O
day,3663,O
induced,3663,O
status,3663,B-Disease
epilepticus,3663,I-Disease
;,3663,O
status,3663,B-Disease
epilepticus,3663,I-Disease
at,3663,O
P45,3663,O
resulted,3663,O
in,3663,O
CA3,3663,O
cell,3663,O
loss,3663,O
and,3663,O
spontaneous,3663,O
seizures,3663,B-Disease
",",3663,O
whereas,3663,O
P20,3663,O
rats,3663,O
had,3663,O
no,3663,O
cell,3663,O
loss,3663,O
or,3663,O
spontaneous,3663,O
seizures,3663,B-Disease
.,3663,O
Mature,3664,O
rats,3664,O
were,3664,O
trained,3664,O
with,3664,O
sound-source,3664,O
location,3664,O
and,3664,O
sound-silence,3664,O
discriminations,3664,O
.,3664,O
Control,3665,O
(,3665,O
saline,3665,O
P20,3665,O
),3665,O
rats,3665,O
acquired,3665,O
both,3665,O
discriminations,3665,O
immediately,3665,O
.,3665,O
In,3666,O
status,3666,B-Disease
epilepticus,3666,I-Disease
(,3666,O
P20,3666,O
),3666,O
rats,3666,O
",",3666,O
acquisition,3666,O
of,3666,O
the,3666,O
sound-source,3666,O
location,3666,O
discrimination,3666,O
was,3666,O
moderately,3666,O
impaired,3666,O
.,3666,O
Status,3667,B-Disease
epilepticus,3667,I-Disease
(,3667,O
P45,3667,O
),3667,O
rats,3667,O
failed,3667,O
to,3667,O
acquire,3667,O
either,3667,O
sound-source,3667,O
location,3667,O
or,3667,O
sound-silence,3667,O
discriminations,3667,O
.,3667,O
Status,3668,B-Disease
epilepticus,3668,I-Disease
in,3668,O
rat,3668,O
causes,3668,O
an,3668,O
age-dependent,3668,O
",",3668,O
long-term,3668,O
impairment,3668,B-Disease
in,3668,I-Disease
auditory,3668,I-Disease
discrimination,3668,I-Disease
.,3668,O
This,3669,O
impairment,3669,O
may,3669,O
explain,3669,O
one,3669,O
cause,3669,O
of,3669,O
impaired,3669,B-Disease
auditory,3669,I-Disease
location,3669,I-Disease
discrimination,3669,I-Disease
in,3669,O
humans,3669,O
.,3669,O
Nerve,3670,O
growth,3670,O
factor,3670,O
and,3670,O
prostaglandins,3670,B-Chemical
in,3670,O
the,3670,O
urine,3670,O
of,3670,O
female,3670,O
patients,3670,O
with,3670,O
overactive,3670,B-Disease
bladder,3670,I-Disease
.,3670,O
PURPOSE,3671,O
:,3671,O
NGF,3671,O
and,3671,O
PGs,3671,B-Chemical
in,3671,O
the,3671,O
bladder,3671,O
can,3671,O
be,3671,O
affected,3671,O
by,3671,O
pathological,3671,O
changes,3671,O
in,3671,O
the,3671,O
bladder,3671,O
and,3671,O
these,3671,O
changes,3671,O
can,3671,O
be,3671,O
detected,3671,O
in,3671,O
urine,3671,O
.,3671,O
We,3672,O
investigated,3672,O
changes,3672,O
in,3672,O
urinary,3672,O
NGF,3672,O
and,3672,O
PGs,3672,B-Chemical
in,3672,O
women,3672,O
with,3672,O
OAB,3672,B-Disease
.,3672,O
MATERIALS,3673,O
AND,3673,O
METHODS,3673,O
:,3673,O
The,3673,O
study,3673,O
groups,3673,O
included,3673,O
65,3673,O
women,3673,O
with,3673,O
OAB,3673,B-Disease
and,3673,O
20,3673,O
without,3673,O
bladder,3673,O
symptoms,3673,O
who,3673,O
served,3673,O
as,3673,O
controls,3673,O
.,3673,O
Evaluation,3674,O
included,3674,O
patient,3674,O
history,3674,O
",",3674,O
urinalysis,3674,O
",",3674,O
a,3674,O
voiding,3674,O
diary,3674,O
and,3674,O
urodynamic,3674,O
studies,3674,O
.,3674,O
Urine,3675,O
samples,3675,O
were,3675,O
collected,3675,O
.,3675,O
NGF,3676,O
",",3676,O
PGE2,3676,B-Chemical
",",3676,O
PGF2alpha,3676,B-Chemical
and,3676,O
PGI2,3676,B-Chemical
were,3676,O
measured,3676,O
using,3676,O
enzyme-linked,3676,O
immunosorbent,3676,O
assay,3676,O
and,3676,O
compared,3676,O
between,3676,O
the,3676,O
groups,3676,O
.,3676,O
In,3677,O
addition,3677,O
",",3677,O
correlations,3677,O
between,3677,O
urinary,3677,O
NGF,3677,O
and,3677,O
PG,3677,B-Chemical
",",3677,O
and,3677,O
urodynamic,3677,O
parameters,3677,O
in,3677,O
patients,3677,O
with,3677,O
OAB,3677,B-Disease
were,3677,O
examined,3677,O
.,3677,O
RESULTS,3678,O
:,3678,O
Urinary,3678,O
NGF,3678,O
",",3678,O
PGE2,3678,B-Chemical
and,3678,O
PGF2alpha,3678,B-Chemical
were,3678,O
significantly,3678,O
increased,3678,O
in,3678,O
patients,3678,O
with,3678,O
OAB,3678,B-Disease
compared,3678,O
with,3678,O
controls,3678,O
(,3678,O
p,3678,O
<,3678,O
0.05,3678,O
),3678,O
.,3678,O
However,3679,O
",",3679,O
urinary,3679,O
PGI2,3679,B-Chemical
was,3679,O
not,3679,O
different,3679,O
between,3679,O
controls,3679,O
and,3679,O
patients,3679,O
with,3679,O
OAB,3679,B-Disease
.,3679,O
In,3680,O
patients,3680,O
with,3680,O
OAB,3680,B-Disease
urinary,3680,O
PGE2,3680,B-Chemical
positively,3680,O
correlated,3680,O
with,3680,O
volume,3680,O
at,3680,O
first,3680,O
desire,3680,O
to,3680,O
void,3680,O
and,3680,O
maximum,3680,O
cystometric,3680,O
capacity,3680,O
(,3680,O
p,3680,O
<,3680,O
0.05,3680,O
),3680,O
.,3680,O
Urinary,3681,O
NGF,3681,O
",",3681,O
PGF2alpha,3681,B-Chemical
and,3681,O
PGI2,3681,B-Chemical
did,3681,O
not,3681,O
correlate,3681,O
with,3681,O
urodynamic,3681,O
parameters,3681,O
in,3681,O
patients,3681,O
with,3681,O
OAB,3681,B-Disease
.,3681,O
CONCLUSIONS,3682,O
:,3682,O
NGF,3682,O
and,3682,O
PGs,3682,B-Chemical
have,3682,O
important,3682,O
roles,3682,O
in,3682,O
the,3682,O
development,3682,O
of,3682,O
OAB,3682,B-Disease
symptoms,3682,O
in,3682,O
female,3682,O
patients,3682,O
.,3682,O
Urinary,3683,O
levels,3683,O
of,3683,O
these,3683,O
factors,3683,O
may,3683,O
be,3683,O
used,3683,O
as,3683,O
markers,3683,O
to,3683,O
evaluate,3683,O
OAB,3683,B-Disease
symptoms,3683,O
.,3683,O
Definition,3684,O
and,3684,O
management,3684,O
of,3684,O
anemia,3684,B-Disease
in,3684,O
patients,3684,O
infected,3684,B-Disease
with,3684,I-Disease
hepatitis,3684,I-Disease
C,3684,I-Disease
virus,3684,I-Disease
.,3684,O
Chronic,3685,B-Disease
infection,3685,I-Disease
with,3685,I-Disease
hepatitis,3685,I-Disease
C,3685,I-Disease
virus,3685,I-Disease
(,3685,O
HCV,3685,O
),3685,O
can,3685,O
progress,3685,O
to,3685,O
cirrhosis,3685,B-Disease
",",3685,O
hepatocellular,3685,B-Disease
carcinoma,3685,I-Disease
",",3685,O
and,3685,O
end-stage,3685,B-Disease
liver,3685,I-Disease
disease,3685,I-Disease
.,3685,O
The,3686,O
current,3686,O
best,3686,O
treatment,3686,O
for,3686,O
HCV,3686,B-Disease
infection,3686,I-Disease
is,3686,O
combination,3686,O
therapy,3686,O
with,3686,O
pegylated,3686,O
interferon,3686,B-Chemical
and,3686,O
ribavirin,3686,B-Chemical
.,3686,O
Although,3687,O
this,3687,O
regimen,3687,O
produces,3687,O
sustained,3687,O
virologic,3687,O
responses,3687,O
(,3687,O
SVRs,3687,O
),3687,O
in,3687,O
approximately,3687,O
50,3687,O
%,3687,O
of,3687,O
patients,3687,O
",",3687,O
it,3687,O
can,3687,O
be,3687,O
associated,3687,O
with,3687,O
a,3687,O
potentially,3687,O
dose-limiting,3687,O
hemolytic,3687,B-Disease
anemia,3687,I-Disease
.,3687,O
Hemoglobin,3688,O
concentrations,3688,O
decrease,3688,O
mainly,3688,O
as,3688,O
a,3688,O
result,3688,O
of,3688,O
ribavirin-induced,3688,B-Chemical
hemolysis,3688,B-Disease
",",3688,O
and,3688,O
this,3688,O
anemia,3688,B-Disease
can,3688,O
be,3688,O
problematic,3688,O
in,3688,O
patients,3688,O
with,3688,O
HCV,3688,B-Disease
infection,3688,I-Disease
",",3688,O
especially,3688,O
those,3688,O
who,3688,O
have,3688,O
comorbid,3688,O
renal,3688,O
or,3688,O
cardiovascular,3688,O
disorders,3688,O
.,3688,O
In,3689,O
general,3689,O
",",3689,O
anemia,3689,B-Disease
can,3689,O
increase,3689,O
the,3689,O
risk,3689,O
of,3689,O
morbidity,3689,O
and,3689,O
mortality,3689,O
",",3689,O
and,3689,O
may,3689,O
have,3689,O
negative,3689,O
effects,3689,O
on,3689,O
cerebral,3689,O
function,3689,O
and,3689,O
quality,3689,O
of,3689,O
life,3689,O
.,3689,O
Although,3690,O
ribavirin-associated,3690,B-Chemical
anemia,3690,B-Disease
can,3690,O
be,3690,O
reversed,3690,O
by,3690,O
dose,3690,O
reduction,3690,O
or,3690,O
discontinuation,3690,O
",",3690,O
this,3690,O
approach,3690,O
compromises,3690,O
outcomes,3690,O
by,3690,O
significantly,3690,O
decreasing,3690,O
SVR,3690,O
rates,3690,O
.,3690,O
Recombinant,3691,O
human,3691,O
erythropoietin,3691,O
has,3691,O
been,3691,O
used,3691,O
to,3691,O
manage,3691,O
ribavirin-associated,3691,B-Chemical
anemia,3691,B-Disease
but,3691,O
has,3691,O
other,3691,O
potential,3691,O
disadvantages,3691,O
.,3691,O
Viramidine,3692,B-Chemical
",",3692,O
a,3692,O
liver-targeting,3692,O
prodrug,3692,O
of,3692,O
ribavirin,3692,B-Chemical
",",3692,O
has,3692,O
the,3692,O
potential,3692,O
to,3692,O
maintain,3692,O
the,3692,O
virologic,3692,O
efficacy,3692,O
of,3692,O
ribavirin,3692,B-Chemical
while,3692,O
decreasing,3692,O
the,3692,O
risk,3692,O
of,3692,O
hemolytic,3692,B-Disease
anemia,3692,I-Disease
in,3692,O
patients,3692,O
with,3692,O
chronic,3692,B-Disease
hepatitis,3692,I-Disease
C,3692,I-Disease
.,3692,O
Impact,3693,O
of,3693,O
alcohol,3693,B-Chemical
exposure,3693,O
after,3693,O
pregnancy,3693,O
recognition,3693,O
on,3693,O
ultrasonographic,3693,O
fetal,3693,O
growth,3693,O
measures,3693,O
.,3693,O
BACKGROUND,3694,O
:,3694,O
More,3694,O
than,3694,O
3,3694,O
decades,3694,O
after,3694,O
Jones,3694,O
and,3694,O
Smith,3694,O
(,3694,O
1973,3694,O
),3694,O
reported,3694,O
on,3694,O
the,3694,O
devastation,3694,O
caused,3694,O
by,3694,O
alcohol,3694,B-Chemical
exposure,3694,O
on,3694,O
fetal,3694,O
development,3694,O
",",3694,O
the,3694,O
rates,3694,O
of,3694,O
heavy,3694,O
drinking,3694,O
during,3694,O
pregnancy,3694,O
remain,3694,O
relatively,3694,O
unchanged,3694,O
.,3694,O
Early,3695,O
identification,3695,O
of,3695,O
fetal,3695,O
alcohol,3695,B-Chemical
exposure,3695,O
and,3695,O
maternal,3695,O
abstinence,3695,O
led,3695,O
to,3695,O
better,3695,O
infant,3695,O
outcomes,3695,O
.,3695,O
This,3696,O
study,3696,O
examined,3696,O
the,3696,O
utility,3696,O
of,3696,O
biometry,3696,O
for,3696,O
detecting,3696,O
alcohol-related,3696,B-Chemical
fetal,3696,O
growth,3696,B-Disease
impairment,3696,I-Disease
.,3696,O
METHODS,3697,O
:,3697,O
We,3697,O
obtained,3697,O
fetal,3697,O
ultrasound,3697,O
measures,3697,O
from,3697,O
routine,3697,O
ultrasound,3697,O
examinations,3697,O
for,3697,O
167,3697,O
pregnant,3697,O
hazardous,3697,O
drinkers,3697,O
who,3697,O
were,3697,O
enrolled,3697,O
in,3697,O
a,3697,O
brief,3697,O
alcohol,3697,B-Chemical
intervention,3697,O
study,3697,O
.,3697,O
The,3698,O
fetal,3698,O
measures,3698,O
for,3698,O
women,3698,O
who,3698,O
quit,3698,O
after,3698,O
learning,3698,O
of,3698,O
their,3698,O
pregnancies,3698,O
were,3698,O
compared,3698,O
with,3698,O
measures,3698,O
for,3698,O
women,3698,O
who,3698,O
continued,3698,O
some,3698,O
drinking,3698,O
throughout,3698,O
the,3698,O
course,3698,O
of,3698,O
their,3698,O
pregnancies,3698,O
.,3698,O
Because,3699,O
intensity,3699,O
of,3699,O
alcohol,3699,B-Chemical
consumption,3699,O
is,3699,O
associated,3699,O
with,3699,O
poorer,3699,O
fetal,3699,O
outcomes,3699,O
",",3699,O
separate,3699,O
analyses,3699,O
were,3699,O
conducted,3699,O
for,3699,O
the,3699,O
heavy,3699,O
(,3699,O
average,3699,O
of,3699,O
>,3699,O
or=5,3699,O
drinks,3699,O
per,3699,O
drinking,3699,O
day,3699,O
),3699,O
alcohol,3699,B-Chemical
consumers,3699,O
.,3699,O
Fetal,3700,O
measures,3700,O
from,3700,O
the,3700,O
heavy-exposed,3700,O
fetuses,3700,O
were,3700,O
also,3700,O
compared,3700,O
with,3700,O
measures,3700,O
from,3700,O
a,3700,O
nondrinking,3700,O
group,3700,O
that,3700,O
was,3700,O
representative,3700,O
of,3700,O
normal,3700,O
",",3700,O
uncomplicated,3700,O
pregnancies,3700,O
from,3700,O
our,3700,O
clinics,3700,O
.,3700,O
Analyses,3701,O
of,3701,O
covariance,3701,O
were,3701,O
used,3701,O
to,3701,O
determine,3701,O
whether,3701,O
there,3701,O
were,3701,O
differences,3701,O
between,3701,O
groups,3701,O
after,3701,O
controlling,3701,O
for,3701,O
influences,3701,O
of,3701,O
gestational,3701,O
age,3701,O
and,3701,O
drug,3701,B-Disease
abuse,3701,I-Disease
.,3701,O
RESULTS,3702,O
:,3702,O
Nearly,3702,O
half,3702,O
of,3702,O
the,3702,O
pregnant,3702,O
drinkers,3702,O
abstained,3702,O
after,3702,O
learning,3702,O
of,3702,O
their,3702,O
pregnancies,3702,O
.,3702,O
When,3703,O
women,3703,O
reportedly,3703,O
quit,3703,O
drinking,3703,O
early,3703,O
in,3703,O
their,3703,O
pregnancies,3703,O
",",3703,O
fetal,3703,O
growth,3703,O
measures,3703,O
were,3703,O
not,3703,O
significantly,3703,O
different,3703,O
from,3703,O
a,3703,O
non-alcohol-exposed,3703,O
group,3703,O
",",3703,O
regardless,3703,O
of,3703,O
prior,3703,O
drinking,3703,O
patterns,3703,O
.,3703,O
Any,3704,O
alcohol,3704,B-Chemical
consumption,3704,O
postpregnancy,3704,O
recognition,3704,O
among,3704,O
the,3704,O
heavy,3704,O
drinkers,3704,O
resulted,3704,O
in,3704,O
reduced,3704,B-Disease
cerebellar,3704,I-Disease
growth,3704,I-Disease
as,3704,O
well,3704,O
as,3704,O
decreased,3704,B-Disease
cranial,3704,I-Disease
to,3704,I-Disease
body,3704,I-Disease
growth,3704,I-Disease
in,3704,O
comparison,3704,O
with,3704,O
women,3704,O
who,3704,O
either,3704,O
quit,3704,O
drinking,3704,O
or,3704,O
who,3704,O
were,3704,O
nondrinkers,3704,O
.,3704,O
Amphetamine,3705,B-Chemical
abuse,3705,O
was,3705,O
predictive,3705,O
of,3705,O
larger,3705,O
cranial,3705,O
to,3705,O
body,3705,O
growth,3705,O
ratios,3705,O
.,3705,O
CONCLUSIONS,3706,O
:,3706,O
Alterations,3706,O
in,3706,O
fetal,3706,O
biometric,3706,O
measurements,3706,O
were,3706,O
observed,3706,O
among,3706,O
the,3706,O
heavy,3706,O
drinkers,3706,O
only,3706,O
when,3706,O
they,3706,O
continued,3706,O
drinking,3706,O
after,3706,O
becoming,3706,O
aware,3706,O
of,3706,O
their,3706,O
pregnancies,3706,O
.,3706,O
Although,3707,O
the,3707,O
reliance,3707,O
on,3707,O
self-reported,3707,O
drinking,3707,O
is,3707,O
a,3707,O
limitation,3707,O
in,3707,O
this,3707,O
study,3707,O
",",3707,O
these,3707,O
findings,3707,O
support,3707,O
the,3707,O
benefits,3707,O
of,3707,O
early,3707,O
abstinence,3707,O
and,3707,O
the,3707,O
potential,3707,O
for,3707,O
ultrasound,3707,O
examinations,3707,O
in,3707,O
the,3707,O
detection,3707,O
of,3707,O
fetal,3707,O
alcohol,3707,B-Chemical
effects,3707,O
.,3707,O
Ethambutol-associated,3708,B-Chemical
optic,3708,B-Disease
neuropathy,3708,I-Disease
.,3708,O
INTRODUCTION,3709,O
:,3709,O
Ethambutol,3709,B-Chemical
is,3709,O
used,3709,O
in,3709,O
the,3709,O
treatment,3709,O
of,3709,O
tuberculosis,3709,B-Disease
",",3709,O
which,3709,O
is,3709,O
still,3709,O
prevalent,3709,O
in,3709,O
Southeast,3709,O
Asia,3709,O
",",3709,O
and,3709,O
can,3709,O
be,3709,O
associated,3709,O
with,3709,O
permanent,3709,O
visual,3709,B-Disease
loss,3709,I-Disease
.,3709,O
We,3710,O
report,3710,O
3,3710,O
cases,3710,O
which,3710,O
presented,3710,O
with,3710,O
bitemporal,3710,B-Disease
hemianopia,3710,I-Disease
.,3710,O
CLINICAL,3711,O
PICTURE,3711,O
:,3711,O
Three,3711,O
patients,3711,O
with,3711,O
ethambutol-associated,3711,B-Chemical
toxic,3711,O
optic,3711,B-Disease
neuropathy,3711,I-Disease
are,3711,O
described,3711,O
.,3711,O
All,3712,O
3,3712,O
patients,3712,O
had,3712,O
loss,3712,B-Disease
of,3712,I-Disease
central,3712,I-Disease
visual,3712,I-Disease
acuity,3712,I-Disease
",",3712,I-Disease
colour,3712,I-Disease
vision,3712,I-Disease
(,3712,I-Disease
Ishihara,3712,I-Disease
),3712,I-Disease
and,3712,I-Disease
visual,3712,I-Disease
field,3712,I-Disease
.,3712,O
The,3713,O
visual,3713,B-Disease
field,3713,I-Disease
loss,3713,I-Disease
had,3713,O
a,3713,O
bitemporal,3713,O
flavour,3713,O
",",3713,O
suggesting,3713,O
involvement,3713,O
of,3713,O
the,3713,O
optic,3713,O
chiasm,3713,O
.,3713,O
TREATMENT,3714,O
:,3714,O
Despite,3714,O
stopping,3714,O
ethambutol,3714,B-Chemical
on,3714,O
diagnosis,3714,O
",",3714,O
visual,3714,O
function,3714,O
continued,3714,O
to,3714,O
deteriorate,3714,O
for,3714,O
a,3714,O
few,3714,O
months,3714,O
.,3714,O
Subsequent,3715,O
improvement,3715,O
was,3715,O
mild,3715,O
in,3715,O
2,3715,O
cases,3715,O
.,3715,O
In,3716,O
the,3716,O
third,3716,O
case,3716,O
",",3716,O
visual,3716,O
acuity,3716,O
and,3716,O
colour,3716,O
vision,3716,O
normalised,3716,O
but,3716,O
the,3716,O
optic,3716,O
discs,3716,O
were,3716,O
pale,3716,O
.,3716,O
OUTCOME,3717,O
:,3717,O
All,3717,O
3,3717,O
patients,3717,O
had,3717,O
some,3717,O
permanent,3717,O
loss,3717,B-Disease
of,3717,I-Disease
visual,3717,I-Disease
function,3717,I-Disease
.,3717,O
CONCLUSIONS,3718,O
:,3718,O
Ethambutol,3718,B-Chemical
usage,3718,O
is,3718,O
associated,3718,O
with,3718,O
permanent,3718,O
visual,3718,B-Disease
loss,3718,I-Disease
and,3718,O
should,3718,O
be,3718,O
avoided,3718,O
if,3718,O
possible,3718,O
or,3718,O
used,3718,O
with,3718,O
caution,3718,O
and,3718,O
proper,3718,O
ophthalmological,3718,O
follow-up,3718,O
.,3718,O
The,3719,O
author,3719,O
postulates,3719,O
that,3719,O
in,3719,O
cases,3719,O
of,3719,O
ethambutol,3719,B-Chemical
associated,3719,O
chiasmopathy,3719,O
",",3719,O
ethambutol,3719,B-Chemical
may,3719,O
initially,3719,O
affect,3719,O
the,3719,O
optic,3719,O
nerves,3719,O
and,3719,O
subsequently,3719,O
progress,3719,O
to,3719,O
involve,3719,O
the,3719,O
optic,3719,O
chiasm,3719,O
.,3719,O
Possible,3720,O
neuroleptic,3720,B-Disease
malignant,3720,I-Disease
syndrome,3720,I-Disease
related,3720,O
to,3720,O
concomitant,3720,O
treatment,3720,O
with,3720,O
paroxetine,3720,B-Chemical
and,3720,O
alprazolam,3720,B-Chemical
.,3720,O
A,3721,O
74-year-old,3721,O
man,3721,O
with,3721,O
depressive,3721,B-Disease
symptoms,3721,I-Disease
was,3721,O
admitted,3721,O
to,3721,O
a,3721,O
psychiatric,3721,B-Disease
hospital,3721,O
due,3721,O
to,3721,O
insomnia,3721,B-Disease
",",3721,O
loss,3721,B-Disease
of,3721,I-Disease
appetite,3721,I-Disease
",",3721,O
exhaustion,3721,O
",",3721,O
and,3721,O
agitation,3721,B-Disease
.,3721,O
Medical,3722,O
treatment,3722,O
was,3722,O
initiated,3722,O
at,3722,O
a,3722,O
daily,3722,O
dose,3722,O
of,3722,O
20,3722,O
mg,3722,O
paroxetine,3722,B-Chemical
and,3722,O
1.2,3722,O
mg,3722,O
alprazolam,3722,B-Chemical
.,3722,O
On,3723,O
the,3723,O
10th,3723,O
day,3723,O
of,3723,O
paroxetine,3723,B-Chemical
and,3723,O
alprazolam,3723,B-Chemical
treatment,3723,O
",",3723,O
the,3723,O
patient,3723,O
exhibited,3723,O
marked,3723,O
psychomotor,3723,B-Disease
retardation,3723,I-Disease
",",3723,O
disorientation,3723,O
",",3723,O
and,3723,O
severe,3723,O
muscle,3723,B-Disease
rigidity,3723,I-Disease
with,3723,O
tremors,3723,B-Disease
.,3723,O
The,3724,O
patient,3724,O
had,3724,O
a,3724,O
fever,3724,B-Disease
(,3724,O
38.2,3724,O
degrees,3724,O
C,3724,O
),3724,O
",",3724,O
fluctuating,3724,O
blood,3724,O
pressure,3724,O
(,3724,O
between,3724,O
165/90,3724,O
and,3724,O
130/70,3724,O
mg,3724,O
mm,3724,O
Hg,3724,O
),3724,O
",",3724,O
and,3724,O
severe,3724,O
extrapyramidal,3724,B-Disease
symptoms,3724,I-Disease
.,3724,O
Laboratory,3725,O
tests,3725,O
showed,3725,O
an,3725,O
elevation,3725,O
of,3725,O
creatine,3725,B-Chemical
phosphokinase,3725,O
(,3725,O
2218,3725,O
IU/L,3725,O
),3725,O
",",3725,O
aspartate,3725,B-Chemical
aminotransferase,3725,O
(,3725,O
134,3725,O
IU/L,3725,O
),3725,O
",",3725,O
alanine,3725,B-Chemical
aminotransferase,3725,O
(,3725,O
78,3725,O
IU/L,3725,O
),3725,O
",",3725,O
and,3725,O
BUN,3725,O
(,3725,O
27.9,3725,O
mg/ml,3725,O
),3725,O
levels,3725,O
.,3725,O
The,3726,O
patient,3726,O
received,3726,O
bromocriptine,3726,B-Chemical
and,3726,O
diazepam,3726,B-Chemical
to,3726,O
treat,3726,O
his,3726,O
symptoms,3726,O
.,3726,O
7,3727,O
days,3727,O
later,3727,O
",",3727,O
the,3727,O
fever,3727,B-Disease
disappeared,3727,O
and,3727,O
the,3727,O
patient,3727,O
's,3727,O
serum,3727,O
CPK,3727,O
levels,3727,O
were,3727,O
normalized,3727,O
(,3727,O
175,3727,O
IU/L,3727,O
),3727,O
.,3727,O
This,3728,O
patient,3728,O
presented,3728,O
with,3728,O
symptoms,3728,O
of,3728,O
neuroleptic,3728,B-Disease
malignant,3728,I-Disease
syndrome,3728,I-Disease
(,3728,O
NMS,3728,B-Disease
),3728,O
",",3728,O
thus,3728,O
demonstrating,3728,O
that,3728,O
NMS-like,3728,B-Disease
symptoms,3728,O
can,3728,O
occur,3728,O
after,3728,O
combined,3728,O
paroxetine,3728,B-Chemical
and,3728,O
alprazolam,3728,B-Chemical
treatment,3728,O
.,3728,O
The,3729,O
adverse,3729,O
drug,3729,O
reaction,3729,O
score,3729,O
obtained,3729,O
by,3729,O
the,3729,O
Naranjo,3729,O
algorithm,3729,O
was,3729,O
6,3729,O
in,3729,O
our,3729,O
case,3729,O
",",3729,O
indicating,3729,O
a,3729,O
probable,3729,O
relationship,3729,O
between,3729,O
the,3729,O
patient,3729,O
's,3729,O
NMS-like,3729,B-Disease
adverse,3729,O
symptoms,3729,O
and,3729,O
the,3729,O
combined,3729,O
treatment,3729,O
used,3729,O
in,3729,O
this,3729,O
case,3729,O
.,3729,O
The,3730,O
involvement,3730,O
of,3730,O
physiologic,3730,O
and,3730,O
environmental,3730,O
aspects,3730,O
specific,3730,O
to,3730,O
this,3730,O
patient,3730,O
was,3730,O
suspected,3730,O
.,3730,O
Several,3731,O
risk,3731,O
factors,3731,O
for,3731,O
NMS,3731,B-Disease
should,3731,O
be,3731,O
noted,3731,O
in,3731,O
elderly,3731,O
depressive,3731,B-Disease
patients,3731,O
whose,3731,O
symptoms,3731,O
often,3731,O
include,3731,O
dehydration,3731,B-Disease
",",3731,O
agitation,3731,B-Disease
",",3731,O
malnutrition,3731,B-Disease
",",3731,O
and,3731,O
exhaustion,3731,O
.,3731,O
Careful,3732,O
therapeutic,3732,O
intervention,3732,O
is,3732,O
necessary,3732,O
in,3732,O
cases,3732,O
involving,3732,O
elderly,3732,O
patients,3732,O
who,3732,O
suffer,3732,O
from,3732,O
depression,3732,B-Disease
.,3732,O
Down-regulation,3733,O
of,3733,O
norepinephrine,3733,B-Chemical
transporter,3733,O
function,3733,O
induced,3733,O
by,3733,O
chronic,3733,O
administration,3733,O
of,3733,O
desipramine,3733,B-Chemical
linking,3733,O
to,3733,O
the,3733,O
alteration,3733,O
of,3733,O
sensitivity,3733,O
of,3733,O
local-anesthetics-induced,3733,O
convulsions,3733,B-Disease
and,3733,O
the,3733,O
counteraction,3733,O
by,3733,O
co-administration,3733,O
with,3733,O
local,3733,O
anesthetics,3733,O
.,3733,O
Alterations,3734,O
of,3734,O
norepinephrine,3734,B-Chemical
transporter,3734,O
(,3734,O
NET,3734,O
),3734,O
function,3734,O
by,3734,O
chronic,3734,O
inhibition,3734,O
of,3734,O
NET,3734,O
in,3734,O
relation,3734,O
to,3734,O
sensitization,3734,O
to,3734,O
seizures,3734,B-Disease
induce,3734,O
by,3734,O
cocaine,3734,B-Chemical
and,3734,O
local,3734,O
anesthetics,3734,O
were,3734,O
studied,3734,O
in,3734,O
mice,3734,O
.,3734,O
Daily,3735,O
administration,3735,O
of,3735,O
desipramine,3735,B-Chemical
",",3735,O
an,3735,O
inhibitor,3735,O
of,3735,O
the,3735,O
NET,3735,O
",",3735,O
for,3735,O
5,3735,O
days,3735,O
decreased,3735,O
[,3735,O
(,3735,O
3,3735,O
),3735,O
H,3735,O
],3735,O
norepinephrine,3735,B-Chemical
uptake,3735,O
in,3735,O
the,3735,O
P2,3735,O
fractions,3735,O
of,3735,O
hippocampus,3735,O
but,3735,O
not,3735,O
cortex,3735,O
",",3735,O
striatum,3735,O
or,3735,O
amygdalae,3735,O
.,3735,O
Co-administration,3736,O
of,3736,O
lidocaine,3736,B-Chemical
",",3736,O
bupivacaine,3736,B-Chemical
or,3736,O
tricaine,3736,B-Chemical
with,3736,O
desipramine,3736,B-Chemical
reversed,3736,O
this,3736,O
effect,3736,O
.,3736,O
Daily,3737,O
treatment,3737,O
of,3737,O
cocaine,3737,B-Chemical
increased,3737,O
[,3737,O
(,3737,O
3,3737,O
),3737,O
H,3737,O
],3737,O
norepinephrine,3737,B-Chemical
uptake,3737,O
into,3737,O
the,3737,O
hippocampus,3737,O
.,3737,O
Daily,3738,O
administration,3738,O
of,3738,O
desipramine,3738,B-Chemical
increased,3738,O
the,3738,O
incidence,3738,O
of,3738,O
appearance,3738,O
of,3738,O
lidocaine-induced,3738,B-Chemical
convulsions,3738,B-Disease
and,3738,O
decreased,3738,O
that,3738,O
of,3738,O
cocaine-induced,3738,B-Chemical
convulsions,3738,B-Disease
.,3738,O
Co-administration,3739,O
of,3739,O
lidocaine,3739,B-Chemical
with,3739,O
desipramine,3739,B-Chemical
reversed,3739,O
the,3739,O
changes,3739,O
of,3739,O
convulsive,3739,B-Disease
activity,3739,O
of,3739,O
lidocaine,3739,B-Chemical
and,3739,O
cocaine,3739,B-Chemical
induced,3739,O
by,3739,O
repeated,3739,O
administration,3739,O
of,3739,O
desipramine,3739,B-Chemical
.,3739,O
These,3740,O
results,3740,O
suggest,3740,O
that,3740,O
down-regulation,3740,O
of,3740,O
hippocampal,3740,O
NET,3740,O
induced,3740,O
by,3740,O
chronic,3740,O
administration,3740,O
of,3740,O
desipramine,3740,B-Chemical
may,3740,O
be,3740,O
relevant,3740,O
to,3740,O
desipramine-induced,3740,B-Chemical
sensitization,3740,O
of,3740,O
lidocaine,3740,B-Chemical
convulsions,3740,B-Disease
.,3740,O
Inhibition,3741,O
of,3741,O
Na,3741,B-Chemical
(,3741,O
+,3741,O
),3741,O
channels,3741,O
by,3741,O
local,3741,O
anesthetics,3741,O
may,3741,O
regulate,3741,O
desipramine-induced,3741,B-Chemical
down-regulation,3741,O
of,3741,O
NET,3741,O
function,3741,O
.,3741,O
Repeated,3742,O
administration,3742,O
of,3742,O
cocaine,3742,B-Chemical
induces,3742,O
up-regulation,3742,O
of,3742,O
hippocampal,3742,O
NET,3742,O
function,3742,O
.,3742,O
Desipramine-induced,3743,B-Chemical
sensitization,3743,O
of,3743,O
lidocaine,3743,B-Chemical
seizures,3743,B-Disease
may,3743,O
have,3743,O
a,3743,O
mechanism,3743,O
distinct,3743,O
from,3743,O
kindling,3743,O
resulting,3743,O
from,3743,O
repeated,3743,O
administration,3743,O
of,3743,O
cocaine,3743,B-Chemical
.,3743,O
Atorvastatin,3744,B-Chemical
prevented,3744,O
and,3744,O
reversed,3744,O
dexamethasone-induced,3744,B-Chemical
hypertension,3744,B-Disease
in,3744,O
the,3744,O
rat,3744,O
.,3744,O
To,3745,O
assess,3745,O
the,3745,O
antioxidant,3745,O
effects,3745,O
of,3745,O
atorvastatin,3745,B-Chemical
(,3745,O
atorva,3745,B-Chemical
),3745,O
on,3745,O
dexamethasone,3745,B-Chemical
(,3745,O
dex,3745,B-Chemical
),3745,O
-induced,3745,O
hypertension,3745,B-Disease
",",3745,O
60,3745,O
male,3745,O
Sprague-Dawley,3745,O
rats,3745,O
were,3745,O
treated,3745,O
with,3745,O
atorva,3745,B-Chemical
30,3745,O
mg/kg/day,3745,O
or,3745,O
tap,3745,O
water,3745,O
for,3745,O
15,3745,O
days,3745,O
.,3745,O
Dex,3746,B-Chemical
increased,3746,O
systolic,3746,O
blood,3746,O
pressure,3746,O
(,3746,O
SBP,3746,O
),3746,O
from,3746,O
109,3746,O
+/-,3746,O
1.8,3746,O
to,3746,O
135,3746,O
+/-,3746,O
0.6,3746,O
mmHg,3746,O
and,3746,O
plasma,3746,O
superoxide,3746,B-Chemical
(,3746,O
5711,3746,O
+/-,3746,O
284.9,3746,O
saline,3746,O
",",3746,O
7931,3746,O
+/-,3746,O
392.8,3746,O
U/ml,3746,O
dex,3746,B-Chemical
",",3746,O
P,3746,O
<,3746,O
0.001,3746,O
),3746,O
.,3746,O
In,3747,O
this,3747,O
prevention,3747,O
study,3747,O
",",3747,O
SBP,3747,O
in,3747,O
the,3747,O
atorva,3747,B-Chemical
+,3747,O
dex,3747,B-Chemical
group,3747,O
was,3747,O
increased,3747,O
from,3747,O
115,3747,O
+/-,3747,O
0.4,3747,O
to,3747,O
124,3747,O
+/-,3747,O
1.5,3747,O
mmHg,3747,O
",",3747,O
but,3747,O
this,3747,O
was,3747,O
significantly,3747,O
lower,3747,O
than,3747,O
in,3747,O
the,3747,O
dex-only,3747,B-Chemical
group,3747,O
(,3747,O
P,3747,O
',3747,O
<,3747,O
0.05,3747,O
),3747,O
.,3747,O
Atorva,3748,B-Chemical
reversed,3748,O
dex-induced,3748,B-Chemical
hypertension,3748,B-Disease
(,3748,O
129,3748,O
+/-,3748,O
0.6,3748,O
mmHg,3748,O
",",3748,O
vs.,3748,O
135,3748,O
+/-,3748,O
0.6,3748,O
mmHg,3748,O
P,3748,O
',3748,O
<,3748,O
0.05,3748,O
),3748,O
and,3748,O
decreased,3748,O
plasma,3748,O
superoxide,3748,B-Chemical
(,3748,O
7931,3748,O
+/-,3748,O
392.8,3748,O
dex,3748,B-Chemical
",",3748,O
1187,3748,O
+/-,3748,O
441.2,3748,O
atorva,3748,B-Chemical
+,3748,O
dex,3748,B-Chemical
",",3748,O
P,3748,O
<,3748,O
0.0001,3748,O
),3748,O
.,3748,O
Plasma,3749,O
nitrate/nitrite,3749,B-Chemical
(,3749,O
NOx,3749,O
),3749,O
was,3749,O
decreased,3749,O
in,3749,O
dex-treated,3749,B-Chemical
rats,3749,O
compared,3749,O
to,3749,O
saline-treated,3749,O
rats,3749,O
(,3749,O
11.2,3749,O
+/-,3749,O
1.08,3749,O
microm,3749,O
",",3749,O
15.3,3749,O
+/-,3749,O
1.17,3749,O
microm,3749,O
",",3749,O
respectively,3749,O
",",3749,O
P,3749,O
<,3749,O
0.05,3749,O
),3749,O
.,3749,O
Atorva,3750,B-Chemical
affected,3750,O
neither,3750,O
plasma,3750,O
NOx,3750,O
nor,3750,O
thymus,3750,O
weight,3750,O
.,3750,O
Thus,3751,O
",",3751,O
atorvastatin,3751,B-Chemical
prevented,3751,O
and,3751,O
reversed,3751,O
dexamethasone-induced,3751,B-Chemical
hypertension,3751,B-Disease
in,3751,O
the,3751,O
rat,3751,O
.,3751,O
Peripheral,3752,B-Disease
neuropathy,3752,I-Disease
caused,3752,O
by,3752,O
high-dose,3752,O
cytosine,3752,B-Chemical
arabinoside,3752,I-Chemical
treatment,3752,O
in,3752,O
a,3752,O
patient,3752,O
with,3752,O
acute,3752,B-Disease
myeloid,3752,I-Disease
leukemia,3752,I-Disease
.,3752,O
The,3753,O
central,3753,O
nervous,3753,O
system,3753,O
toxicity,3753,B-Disease
of,3753,O
high-dose,3753,O
cytosine,3753,B-Chemical
arabinoside,3753,I-Chemical
is,3753,O
well,3753,O
recognized,3753,O
",",3753,O
but,3753,O
the,3753,O
toxicity,3753,B-Disease
of,3753,O
cytosine,3753,B-Chemical
arabinoside,3753,I-Chemical
in,3753,O
the,3753,O
peripheral,3753,O
nervous,3753,O
system,3753,O
has,3753,O
been,3753,O
infrequently,3753,O
reported,3753,O
.,3753,O
A,3754,O
49-year-old,3754,O
Japanese,3754,O
man,3754,O
was,3754,O
diagnosed,3754,O
with,3754,O
acute,3754,B-Disease
myeloid,3754,I-Disease
leukemia,3754,I-Disease
.,3754,O
After,3755,O
he,3755,O
achieved,3755,O
complete,3755,O
remission,3755,O
",",3755,O
he,3755,O
received,3755,O
high-dose,3755,O
cytosine,3755,B-Chemical
arabinoside,3755,I-Chemical
treatment,3755,O
(,3755,O
2,3755,O
g/m2,3755,O
twice,3755,O
a,3755,O
day,3755,O
for,3755,O
5,3755,O
days,3755,O
;,3755,O
total,3755,O
",",3755,O
20,3755,O
g/m2,3755,O
),3755,O
as,3755,O
consolidation,3755,O
therapy,3755,O
.,3755,O
The,3756,O
first,3756,O
course,3756,O
of,3756,O
high-dose,3756,O
cytosine,3756,B-Chemical
arabinoside,3756,I-Chemical
resulted,3756,O
in,3756,O
no,3756,O
unusual,3756,O
symptoms,3756,O
",",3756,O
but,3756,O
on,3756,O
day,3756,O
21,3756,O
of,3756,O
the,3756,O
second,3756,O
course,3756,O
of,3756,O
treatment,3756,O
",",3756,O
the,3756,O
patient,3756,O
complained,3756,O
of,3756,O
numbness,3756,B-Disease
in,3756,O
his,3756,O
right,3756,O
foot,3756,O
.,3756,O
Electromyogram,3757,O
and,3757,O
nerve-conduction,3757,O
studies,3757,O
showed,3757,O
peripheral,3757,B-Disease
neuropathy,3757,I-Disease
in,3757,O
both,3757,O
peroneal,3757,O
nerves,3757,O
.,3757,O
This,3758,O
neuropathy,3758,B-Disease
was,3758,O
gradually,3758,O
resolving,3758,O
;,3758,O
however,3758,O
",",3758,O
after,3758,O
the,3758,O
patient,3758,O
received,3758,O
allogeneic,3758,O
bone,3758,O
marrow,3758,O
transplantation,3758,O
",",3758,O
the,3758,O
symptoms,3758,O
worsened,3758,O
",",3758,O
with,3758,O
the,3758,O
development,3758,O
of,3758,O
graft-versus-host,3758,B-Disease
disease,3758,I-Disease
",",3758,O
and,3758,O
the,3758,O
symptoms,3758,O
subsequently,3758,O
responded,3758,O
to,3758,O
methylprednisolone,3758,B-Chemical
.,3758,O
Although,3759,O
the,3759,O
mechanisms,3759,O
of,3759,O
peripheral,3759,B-Disease
neuropathy,3759,I-Disease
are,3759,O
still,3759,O
unclear,3759,O
",",3759,O
high-dose,3759,O
cytosine,3759,B-Chemical
arabinoside,3759,I-Chemical
is,3759,O
a,3759,O
therapy,3759,O
that,3759,O
is,3759,O
potentially,3759,O
toxic,3759,O
to,3759,O
the,3759,O
peripheral,3759,O
nervous,3759,O
system,3759,O
",",3759,O
and,3759,O
auto/alloimmunity,3759,O
may,3759,O
play,3759,O
an,3759,O
important,3759,O
role,3759,O
in,3759,O
these,3759,O
mechanisms,3759,O
.,3759,O
Effect,3760,O
of,3760,O
alpha-tocopherol,3760,B-Chemical
and,3760,O
deferoxamine,3760,B-Chemical
on,3760,O
methamphetamine-induced,3760,B-Chemical
neurotoxicity,3760,B-Disease
.,3760,O
Methamphetamine,3761,B-Chemical
(,3761,O
MA,3761,B-Chemical
),3761,O
-induced,3761,O
dopaminergic,3761,O
neurotoxicity,3761,B-Disease
is,3761,O
believed,3761,O
to,3761,O
be,3761,O
associated,3761,O
with,3761,O
the,3761,O
increased,3761,O
formation,3761,O
of,3761,O
free,3761,O
radicals,3761,O
.,3761,O
This,3762,O
study,3762,O
examined,3762,O
the,3762,O
effect,3762,O
of,3762,O
alpha-tocopherol,3762,B-Chemical
(,3762,O
alpha-TC,3762,B-Chemical
),3762,O
",",3762,O
a,3762,O
scavenger,3762,O
of,3762,O
reactive,3762,O
oxygen,3762,B-Chemical
species,3762,O
",",3762,O
and,3762,O
deferoxamine,3762,B-Chemical
(,3762,O
DFO,3762,B-Chemical
),3762,O
",",3762,O
an,3762,O
iron,3762,B-Chemical
chelator,3762,O
",",3762,O
on,3762,O
the,3762,O
MA-induced,3762,B-Chemical
neurotoxicity,3762,B-Disease
.,3762,O
Male,3763,O
rats,3763,O
were,3763,O
treated,3763,O
with,3763,O
MA,3763,B-Chemical
(,3763,O
10,3763,O
mg/kg,3763,O
",",3763,O
every,3763,O
2,3763,O
h,3763,O
for,3763,O
four,3763,O
injections,3763,O
),3763,O
.,3763,O
The,3764,O
rat,3764,O
received,3764,O
either,3764,O
alpha-TC,3764,B-Chemical
(,3764,O
20,3764,O
mg/kg,3764,O
),3764,O
intraperitoneally,3764,O
for,3764,O
3,3764,O
days,3764,O
and,3764,O
30,3764,O
min,3764,O
prior,3764,O
to,3764,O
MA,3764,B-Chemical
administration,3764,O
or,3764,O
DFO,3764,B-Chemical
(,3764,O
50,3764,O
mg/kg,3764,O
),3764,O
subcutaneously,3764,O
30,3764,O
min,3764,O
before,3764,O
MA,3764,B-Chemical
administration,3764,O
.,3764,O
The,3765,O
concentrations,3765,O
of,3765,O
dopamine,3765,B-Chemical
(,3765,O
DA,3765,B-Chemical
),3765,O
",",3765,O
serotonin,3765,B-Chemical
and,3765,O
their,3765,O
metabolites,3765,O
decreased,3765,O
significantly,3765,O
after,3765,O
MA,3765,B-Chemical
administration,3765,O
",",3765,O
which,3765,O
was,3765,O
inhibited,3765,O
by,3765,O
the,3765,O
alpha-TC,3765,B-Chemical
and,3765,O
DFO,3765,B-Chemical
pretreatment,3765,O
.,3765,O
alpha-TC,3766,B-Chemical
and,3766,O
DFO,3766,B-Chemical
attenuated,3766,O
the,3766,O
MA-induced,3766,B-Chemical
hyperthermia,3766,B-Disease
as,3766,O
well,3766,O
as,3766,O
the,3766,O
alterations,3766,O
in,3766,O
the,3766,O
locomotor,3766,O
activity,3766,O
.,3766,O
The,3767,O
level,3767,O
of,3767,O
lipid,3767,O
peroxidation,3767,O
was,3767,O
higher,3767,O
and,3767,O
the,3767,O
reduced,3767,O
glutathione,3767,B-Chemical
concentration,3767,O
was,3767,O
lower,3767,O
in,3767,O
the,3767,O
MA-treated,3767,B-Chemical
rats,3767,O
.,3767,O
These,3768,O
changes,3768,O
were,3768,O
significantly,3768,O
attenuated,3768,O
by,3768,O
alpha-TC,3768,B-Chemical
and,3768,O
DFO,3768,B-Chemical
.,3768,O
This,3769,O
suggests,3769,O
that,3769,O
alpha-TC,3769,B-Chemical
and,3769,O
DFO,3769,B-Chemical
ameliorate,3769,O
the,3769,O
MA-induced,3769,B-Chemical
neuronal,3769,B-Disease
damage,3769,I-Disease
by,3769,O
decreasing,3769,O
the,3769,O
level,3769,O
of,3769,O
oxidative,3769,O
stress,3769,O
.,3769,O
Sustained,3770,O
clinical,3770,O
improvement,3770,O
of,3770,O
a,3770,O
patient,3770,O
with,3770,O
decompensated,3770,O
hepatitis,3770,B-Disease
B,3770,I-Disease
virus-related,3770,O
cirrhosis,3770,B-Disease
after,3770,O
treatment,3770,O
with,3770,O
lamivudine,3770,B-Chemical
monotherapy,3770,O
.,3770,O
Hepatitis,3771,B-Disease
B,3771,I-Disease
virus,3771,I-Disease
(,3771,I-Disease
HBV,3771,I-Disease
),3771,I-Disease
infection,3771,I-Disease
",",3771,O
which,3771,O
causes,3771,O
liver,3771,B-Disease
cirrhosis,3771,I-Disease
and,3771,O
hepatocellular,3771,B-Disease
carcinoma,3771,I-Disease
",",3771,O
remains,3771,O
a,3771,O
major,3771,O
health,3771,O
problem,3771,O
in,3771,O
Asian,3771,O
countries,3771,O
.,3771,O
Recent,3772,O
development,3772,O
of,3772,O
vaccine,3772,O
for,3772,O
prevention,3772,O
is,3772,O
reported,3772,O
to,3772,O
be,3772,O
successful,3772,O
in,3772,O
reducing,3772,O
the,3772,O
size,3772,O
of,3772,O
chronically,3772,O
infected,3772,O
carriers,3772,O
",",3772,O
although,3772,O
the,3772,O
standard,3772,O
medical,3772,O
therapies,3772,O
have,3772,O
not,3772,O
been,3772,O
established,3772,O
up,3772,O
to,3772,O
now,3772,O
.,3772,O
In,3773,O
this,3773,O
report,3773,O
",",3773,O
we,3773,O
encountered,3773,O
a,3773,O
patient,3773,O
with,3773,O
decompensated,3773,O
HBV-related,3773,O
cirrhosis,3773,B-Disease
who,3773,O
exhibited,3773,O
the,3773,O
dramatic,3773,O
improvements,3773,O
after,3773,O
antiviral,3773,O
therapy,3773,O
.,3773,O
The,3774,O
patient,3774,O
was,3774,O
a,3774,O
50-year-old,3774,O
woman,3774,O
.,3774,O
Previous,3775,O
conventional,3775,O
medical,3775,O
treatments,3775,O
were,3775,O
not,3775,O
effective,3775,O
for,3775,O
this,3775,O
patient,3775,O
",",3775,O
thus,3775,O
this,3775,O
patient,3775,O
had,3775,O
been,3775,O
referred,3775,O
to,3775,O
our,3775,O
hospital,3775,O
.,3775,O
However,3776,O
",",3776,O
the,3776,O
administration,3776,O
of,3776,O
lamivudine,3776,B-Chemical
",",3776,O
a,3776,O
reverse,3776,O
transcriptase,3776,O
inhibitor,3776,O
",",3776,O
for,3776,O
23,3776,O
months,3776,O
dramatically,3776,O
improved,3776,O
her,3776,O
liver,3776,O
severity,3776,O
.,3776,O
During,3777,O
this,3777,O
period,3777,O
",",3777,O
no,3777,O
drug,3777,O
resistant,3777,O
mutant,3777,O
HBV,3777,O
emerged,3777,O
",",3777,O
and,3777,O
the,3777,O
serum,3777,O
HBV-DNA,3777,O
level,3777,O
was,3777,O
continuously,3777,O
suppressed,3777,O
.,3777,O
These,3778,O
virological,3778,O
responses,3778,O
were,3778,O
also,3778,O
maintained,3778,O
even,3778,O
after,3778,O
the,3778,O
antiviral,3778,O
therapy,3778,O
was,3778,O
discontinued,3778,O
.,3778,O
Moreover,3779,O
",",3779,O
both,3779,O
hepatitis,3779,O
B,3779,O
surface,3779,O
antigen,3779,O
and,3779,O
e,3779,O
antigen,3779,O
were,3779,O
observed,3779,O
to,3779,O
have,3779,O
disappeared,3779,O
in,3779,O
this,3779,O
patient,3779,O
.,3779,O
The,3780,O
administration,3780,O
of,3780,O
lamivudine,3780,B-Chemical
to,3780,O
patients,3780,O
with,3780,O
HBV-related,3780,O
cirrhosis,3780,B-Disease
",",3780,O
like,3780,O
our,3780,O
present,3780,O
case,3780,O
",",3780,O
should,3780,O
be,3780,O
considered,3780,O
as,3780,O
an,3780,O
initial,3780,O
medical,3780,O
therapeutic,3780,O
option,3780,O
",",3780,O
especially,3780,O
in,3780,O
countries,3780,O
where,3780,O
liver,3780,O
transplantation,3780,O
is,3780,O
not,3780,O
reliably,3780,O
available,3780,O
.,3780,O
Passage,3781,O
of,3781,O
mannitol,3781,B-Chemical
into,3781,O
the,3781,O
brain,3781,O
around,3781,O
gliomas,3781,B-Disease
:,3781,O
a,3781,O
potential,3781,O
cause,3781,O
of,3781,O
rebound,3781,O
phenomenon,3781,O
.,3781,O
A,3782,O
study,3782,O
on,3782,O
21,3782,O
patients,3782,O
.,3782,O
AIM,3783,O
:,3783,O
Widespread,3783,O
use,3783,O
of,3783,O
mannitol,3783,B-Chemical
to,3783,O
reduce,3783,O
brain,3783,B-Disease
edema,3783,I-Disease
and,3783,O
lower,3783,O
elevated,3783,B-Disease
ICP,3783,I-Disease
in,3783,O
brain,3783,B-Disease
tumor,3783,I-Disease
patients,3783,O
continues,3783,O
to,3783,O
be,3783,O
afflicted,3783,O
by,3783,O
the,3783,O
so-called,3783,O
rebound,3783,O
phenomenon,3783,O
.,3783,O
Leakage,3784,O
of,3784,O
mannitol,3784,B-Chemical
into,3784,O
the,3784,O
brain,3784,O
parenchyma,3784,O
through,3784,O
an,3784,O
altered,3784,O
BBB,3784,O
and,3784,O
secondary,3784,O
reversal,3784,O
of,3784,O
osmotic,3784,O
gradient,3784,O
is,3784,O
considered,3784,O
the,3784,O
major,3784,O
cause,3784,O
of,3784,O
rebound,3784,O
.,3784,O
This,3785,O
has,3785,O
only,3785,O
been,3785,O
demonstrated,3785,O
experimentally,3785,O
in,3785,O
animals,3785,O
.,3785,O
As,3786,O
a,3786,O
contribution,3786,O
to,3786,O
this,3786,O
issue,3786,O
we,3786,O
decided,3786,O
to,3786,O
research,3786,O
the,3786,O
possible,3786,O
passage,3786,O
of,3786,O
mannitol,3786,B-Chemical
into,3786,O
the,3786,O
brain,3786,O
after,3786,O
administration,3786,O
to,3786,O
21,3786,O
brain,3786,B-Disease
tumor,3786,I-Disease
patients,3786,O
.,3786,O
METHODS,3787,O
:,3787,O
Mannitol,3787,B-Chemical
(,3787,O
18,3787,O
%,3787,O
solution,3787,O
;,3787,O
1,3787,O
g/kg,3787,O
),3787,O
was,3787,O
administered,3787,O
as,3787,O
a,3787,O
bolus,3787,O
to,3787,O
patients,3787,O
(,3787,O
ten,3787,O
had,3787,O
malignant,3787,B-Disease
glioma,3787,I-Disease
",",3787,O
seven,3787,O
brain,3787,O
metastases,3787,B-Disease
and,3787,O
four,3787,O
meningioma,3787,B-Disease
),3787,O
about,3787,O
30,3787,O
minutes,3787,O
before,3787,O
craniotomy,3787,O
.,3787,O
During,3788,O
resection,3788,O
",",3788,O
a,3788,O
sample,3788,O
of,3788,O
the,3788,O
surrounding,3788,O
edematous,3788,B-Disease
white,3788,O
matter,3788,O
was,3788,O
taken,3788,O
at,3788,O
the,3788,O
same,3788,O
time,3788,O
as,3788,O
a,3788,O
10,3788,O
ml,3788,O
venous,3788,O
blood,3788,O
sample,3788,O
.,3788,O
Mannitol,3789,B-Chemical
concentrations,3789,O
were,3789,O
measured,3789,O
in,3789,O
plasma,3789,O
and,3789,O
white,3789,O
matter,3789,O
by,3789,O
a,3789,O
modified,3789,O
version,3789,O
of,3789,O
the,3789,O
enzyme,3789,O
assay,3789,O
of,3789,O
Blonquist,3789,O
et,3789,O
al,3789,O
.,3789,O
RESULTS,3790,O
:,3790,O
In,3790,O
most,3790,O
glioma,3790,B-Disease
patients,3790,O
",",3790,O
mannitol,3790,B-Chemical
concentrations,3790,O
in,3790,O
white,3790,O
matter,3790,O
were,3790,O
2,3790,O
to,3790,O
6,3790,O
times,3790,O
higher,3790,O
than,3790,O
in,3790,O
plasma,3790,O
(,3790,O
mean,3790,O
3.5,3790,O
times,3790,O
),3790,O
.,3790,O
In,3791,O
meningioma,3791,B-Disease
and,3791,O
metastases,3791,B-Disease
patients,3791,O
plasma,3791,O
concentrations,3791,O
of,3791,O
mannitol,3791,B-Chemical
were,3791,O
higher,3791,O
than,3791,O
white,3791,O
matter,3791,O
concentrations,3791,O
except,3791,O
in,3791,O
three,3791,O
cases,3791,O
with,3791,O
infiltration,3791,O
by,3791,O
neoplastic,3791,O
cells,3791,O
.,3791,O
CONCLUSIONS,3792,O
:,3792,O
The,3792,O
results,3792,O
of,3792,O
our,3792,O
study,3792,O
show,3792,O
that,3792,O
even,3792,O
after,3792,O
a,3792,O
single,3792,O
bolus,3792,O
",",3792,O
mannitol,3792,B-Chemical
may,3792,O
leak,3792,O
through,3792,O
the,3792,O
altered,3792,O
BBB,3792,O
near,3792,O
gliomas,3792,B-Disease
",",3792,O
reversing,3792,O
the,3792,O
initial,3792,O
plasma-to-blood,3792,O
osmotic,3792,O
gradient,3792,O
",",3792,O
aggravating,3792,O
peritumoral,3792,O
edema,3792,B-Disease
and,3792,O
promoting,3792,O
rebound,3792,O
of,3792,O
ICP,3792,O
.,3792,O
Placebo-level,3793,O
incidence,3793,O
of,3793,O
extrapyramidal,3793,B-Disease
symptoms,3793,I-Disease
(,3793,O
EPS,3793,B-Disease
),3793,O
with,3793,O
quetiapine,3793,B-Chemical
in,3793,O
controlled,3793,O
studies,3793,O
of,3793,O
patients,3793,O
with,3793,O
bipolar,3793,B-Disease
mania,3793,I-Disease
.,3793,O
OBJECTIVES,3794,O
:,3794,O
To,3794,O
evaluate,3794,O
extrapyramidal,3794,B-Disease
symptoms,3794,I-Disease
(,3794,O
EPS,3794,B-Disease
),3794,O
",",3794,O
including,3794,O
akathisia,3794,B-Disease
",",3794,O
with,3794,O
quetiapine,3794,B-Chemical
in,3794,O
patients,3794,O
with,3794,O
bipolar,3794,B-Disease
mania,3794,I-Disease
.,3794,O
METHODS,3795,O
:,3795,O
Data,3795,O
were,3795,O
analyzed,3795,O
from,3795,O
four,3795,O
similarly,3795,O
designed,3795,O
",",3795,O
randomized,3795,O
",",3795,O
double-blind,3795,O
",",3795,O
3-,3795,O
to,3795,O
12-week,3795,O
studies,3795,O
.,3795,O
Two,3796,O
studies,3796,O
evaluated,3796,O
quetiapine,3796,B-Chemical
monotherapy,3796,O
(,3796,O
up,3796,O
to,3796,O
800,3796,O
mg/day,3796,O
),3796,O
(,3796,O
n,3796,O
=,3796,O
209,3796,O
),3796,O
versus,3796,O
placebo,3796,O
(,3796,O
n,3796,O
=,3796,O
198,3796,O
),3796,O
",",3796,O
with,3796,O
lithium,3796,B-Chemical
or,3796,O
haloperidol,3796,B-Chemical
monotherapy,3796,O
as,3796,O
respective,3796,O
active,3796,O
controls,3796,O
.,3796,O
Two,3797,O
studies,3797,O
evaluated,3797,O
quetiapine,3797,B-Chemical
(,3797,O
up,3797,O
to,3797,O
800,3797,O
mg/day,3797,O
),3797,O
in,3797,O
combination,3797,O
with,3797,O
a,3797,O
mood,3797,O
stabilizer,3797,O
(,3797,O
lithium,3797,B-Chemical
or,3797,O
divalproex,3797,B-Chemical
",",3797,O
QTP,3797,B-Chemical
+,3797,O
Li/DVP,3797,B-Chemical
),3797,O
(,3797,O
n,3797,O
=,3797,O
196,3797,O
),3797,O
compared,3797,O
to,3797,O
placebo,3797,O
and,3797,O
mood,3797,O
stabilizer,3797,O
(,3797,O
PBO,3797,O
+,3797,O
Li/DVP,3797,B-Chemical
),3797,O
(,3797,O
n,3797,O
=,3797,O
203,3797,O
),3797,O
.,3797,O
Extrapyramidal,3798,B-Disease
symptoms,3798,I-Disease
were,3798,O
evaluated,3798,O
using,3798,O
the,3798,O
Simpson-Angus,3798,O
Scale,3798,O
(,3798,O
SAS,3798,O
),3798,O
",",3798,O
the,3798,O
Barnes,3798,O
Akathisia,3798,O
Rating,3798,O
Scale,3798,O
(,3798,O
BARS,3798,O
),3798,O
",",3798,O
adverse,3798,O
event,3798,O
reports,3798,O
and,3798,O
anticholinergic,3798,O
drug,3798,O
usage,3798,O
.,3798,O
RESULTS,3799,O
:,3799,O
The,3799,O
incidence,3799,O
of,3799,O
EPS-related,3799,B-Disease
adverse,3799,O
events,3799,O
",",3799,O
including,3799,O
akathisia,3799,B-Disease
",",3799,O
was,3799,O
no,3799,O
different,3799,O
with,3799,O
quetiapine,3799,B-Chemical
monotherapy,3799,O
(,3799,O
12.9,3799,O
%,3799,O
),3799,O
than,3799,O
with,3799,O
placebo,3799,O
(,3799,O
13.1,3799,O
%,3799,O
),3799,O
.,3799,O
Similarly,3800,O
",",3800,O
EPS-related,3800,B-Disease
adverse,3800,O
events,3800,O
with,3800,O
QTP,3800,B-Chemical
+,3800,O
Li/DVP,3800,B-Chemical
(,3800,O
21.4,3800,O
%,3800,O
),3800,O
were,3800,O
no,3800,O
different,3800,O
than,3800,O
with,3800,O
PBO,3800,O
+,3800,O
Li/DVP,3800,B-Chemical
(,3800,O
19.2,3800,O
%,3800,O
),3800,O
.,3800,O
Adverse,3801,O
events,3801,O
related,3801,O
to,3801,O
EPS,3801,B-Disease
occurred,3801,O
in,3801,O
59.6,3801,O
%,3801,O
of,3801,O
patients,3801,O
treated,3801,O
with,3801,O
haloperidol,3801,B-Chemical
(,3801,O
n,3801,O
=,3801,O
99,3801,O
),3801,O
monotherapy,3801,O
",",3801,O
whereas,3801,O
26.5,3801,O
%,3801,O
of,3801,O
patients,3801,O
treated,3801,O
with,3801,O
lithium,3801,B-Chemical
(,3801,O
n,3801,O
=,3801,O
98,3801,O
),3801,O
monotherapy,3801,O
experienced,3801,O
adverse,3801,O
events,3801,O
related,3801,O
to,3801,O
EPS,3801,B-Disease
.,3801,O
The,3802,O
incidence,3802,O
of,3802,O
akathisia,3802,B-Disease
was,3802,O
low,3802,O
and,3802,O
similar,3802,O
with,3802,O
quetiapine,3802,B-Chemical
monotherapy,3802,O
(,3802,O
3.3,3802,O
%,3802,O
),3802,O
and,3802,O
placebo,3802,O
(,3802,O
6.1,3802,O
%,3802,O
),3802,O
",",3802,O
and,3802,O
with,3802,O
QTP,3802,B-Chemical
+,3802,O
Li/DVP,3802,B-Chemical
(,3802,O
3.6,3802,O
%,3802,O
),3802,O
and,3802,O
PBO,3802,O
+,3802,O
Li/DVP,3802,B-Chemical
(,3802,O
4.9,3802,O
%,3802,O
),3802,O
.,3802,O
Lithium,3803,B-Chemical
was,3803,O
associated,3803,O
with,3803,O
a,3803,O
significantly,3803,O
higher,3803,O
incidence,3803,O
(,3803,O
p,3803,O
<,3803,O
0.05,3803,O
),3803,O
of,3803,O
tremor,3803,B-Disease
(,3803,O
18.4,3803,O
%,3803,O
),3803,O
than,3803,O
quetiapine,3803,B-Chemical
(,3803,O
5.6,3803,O
%,3803,O
),3803,O
;,3803,O
cerebellar,3803,O
tremor,3803,B-Disease
",",3803,O
which,3803,O
is,3803,O
a,3803,O
known,3803,O
adverse,3803,O
effect,3803,O
of,3803,O
lithium,3803,B-Chemical
",",3803,O
may,3803,O
have,3803,O
contributed,3803,O
to,3803,O
the,3803,O
elevated,3803,O
rate,3803,O
of,3803,O
tremor,3803,B-Disease
in,3803,O
patients,3803,O
receiving,3803,O
lithium,3803,B-Chemical
therapy,3803,O
.,3803,O
Haloperidol,3804,B-Chemical
induced,3804,O
a,3804,O
significantly,3804,O
higher,3804,O
incidence,3804,O
(,3804,O
p,3804,O
<,3804,O
0.001,3804,O
),3804,O
of,3804,O
akathisia,3804,B-Disease
(,3804,O
33.3,3804,O
%,3804,O
versus,3804,O
5.9,3804,O
%,3804,O
),3804,O
",",3804,O
tremor,3804,B-Disease
(,3804,O
30.3,3804,O
%,3804,O
versus,3804,O
7.8,3804,O
%,3804,O
),3804,O
",",3804,O
and,3804,O
extrapyramidal,3804,B-Disease
syndrome,3804,I-Disease
(,3804,O
35.4,3804,O
%,3804,O
versus,3804,O
5.9,3804,O
%,3804,O
),3804,O
than,3804,O
quetiapine,3804,B-Chemical
.,3804,O
No,3805,O
significant,3805,O
differences,3805,O
were,3805,O
observed,3805,O
between,3805,O
quetiapine,3805,B-Chemical
and,3805,O
placebo,3805,O
on,3805,O
SAS,3805,O
and,3805,O
BARS,3805,O
scores,3805,O
.,3805,O
Anticholinergic,3806,O
use,3806,O
was,3806,O
low,3806,O
and,3806,O
similar,3806,O
with,3806,O
quetiapine,3806,B-Chemical
or,3806,O
placebo,3806,O
.,3806,O
CONCLUSIONS,3807,O
:,3807,O
In,3807,O
bipolar,3807,B-Disease
mania,3807,I-Disease
",",3807,O
the,3807,O
incidence,3807,O
of,3807,O
EPS,3807,B-Disease
",",3807,O
including,3807,O
akathisia,3807,B-Disease
",",3807,O
with,3807,O
quetiapine,3807,B-Chemical
therapy,3807,O
is,3807,O
similar,3807,O
to,3807,O
that,3807,O
with,3807,O
placebo,3807,O
.,3807,O
Is,3808,O
phenytoin,3808,B-Chemical
administration,3808,O
safe,3808,O
in,3808,O
a,3808,O
hypothermic,3808,B-Disease
child,3808,O
?,3808,O
A,3809,O
male,3809,O
neonate,3809,O
with,3809,O
a,3809,O
Chiari,3809,B-Disease
malformation,3809,I-Disease
and,3809,O
a,3809,O
leaking,3809,O
myelomeningocoele,3809,O
underwent,3809,O
ventriculoperitoneal,3809,O
shunt,3809,O
insertion,3809,O
followed,3809,O
by,3809,O
repair,3809,O
of,3809,O
myelomeningocoele,3809,O
.,3809,O
During,3810,O
anaesthesia,3810,O
and,3810,O
surgery,3810,O
",",3810,O
he,3810,O
inadvertently,3810,O
became,3810,O
moderately,3810,O
hypothermic,3810,B-Disease
.,3810,O
Intravenous,3811,O
phenytoin,3811,B-Chemical
was,3811,O
administered,3811,O
during,3811,O
the,3811,O
later,3811,O
part,3811,O
of,3811,O
the,3811,O
surgery,3811,O
for,3811,O
seizure,3811,B-Disease
prophylaxis,3811,O
.,3811,O
Following,3812,O
phenytoin,3812,B-Chemical
administration,3812,O
",",3812,O
the,3812,O
patient,3812,O
developed,3812,O
acute,3812,O
severe,3812,O
bradycardia,3812,B-Disease
",",3812,O
refractory,3812,O
to,3812,O
atropine,3812,B-Chemical
and,3812,O
adrenaline,3812,B-Chemical
.,3812,O
The,3813,O
cardiac,3813,O
depressant,3813,O
actions,3813,O
of,3813,O
phenytoin,3813,B-Chemical
and,3813,O
hypothermia,3813,B-Disease
can,3813,O
be,3813,O
additive,3813,O
.,3813,O
Administration,3814,O
of,3814,O
phenytoin,3814,B-Chemical
in,3814,O
the,3814,O
presence,3814,O
of,3814,O
hypothermia,3814,B-Disease
may,3814,O
lead,3814,O
to,3814,O
an,3814,O
adverse,3814,O
cardiac,3814,O
event,3814,O
in,3814,O
children,3814,O
.,3814,O
As,3815,O
phenytoin,3815,B-Chemical
is,3815,O
a,3815,O
commonly,3815,O
used,3815,O
drug,3815,O
",",3815,O
clinicians,3815,O
need,3815,O
to,3815,O
be,3815,O
aware,3815,O
of,3815,O
this,3815,O
interaction,3815,O
.,3815,O
Valproate-induced,3816,B-Chemical
chorea,3816,B-Disease
and,3816,O
encephalopathy,3816,B-Disease
in,3816,O
atypical,3816,O
nonketotic,3816,B-Disease
hyperglycinemia,3816,I-Disease
.,3816,O
Nonketotic,3817,B-Disease
hyperglycinemia,3817,I-Disease
is,3817,O
a,3817,O
disorder,3817,B-Disease
of,3817,I-Disease
amino,3817,I-Disease
acid,3817,I-Disease
metabolism,3817,I-Disease
in,3817,O
which,3817,O
a,3817,O
defect,3817,O
in,3817,O
the,3817,O
glycine,3817,B-Chemical
cleavage,3817,O
system,3817,O
leads,3817,O
to,3817,O
an,3817,O
accumulation,3817,O
of,3817,O
glycine,3817,B-Chemical
in,3817,O
the,3817,O
brain,3817,O
and,3817,O
other,3817,O
body,3817,O
compartments,3817,O
.,3817,O
In,3818,O
the,3818,O
classical,3818,O
form,3818,O
it,3818,O
presents,3818,O
as,3818,O
neonatal,3818,O
apnea,3818,B-Disease
",",3818,O
intractable,3818,O
seizures,3818,B-Disease
",",3818,O
and,3818,O
hypotonia,3818,B-Disease
",",3818,O
followed,3818,O
by,3818,O
significant,3818,O
psychomotor,3818,B-Disease
retardation,3818,I-Disease
.,3818,O
An,3819,O
important,3819,O
subset,3819,O
of,3819,O
children,3819,O
with,3819,O
nonketotic,3819,B-Disease
hyperglycinemia,3819,I-Disease
are,3819,O
atypical,3819,O
variants,3819,O
who,3819,O
present,3819,O
in,3819,O
a,3819,O
heterogeneous,3819,O
manner,3819,O
.,3819,O
This,3820,O
report,3820,O
describes,3820,O
a,3820,O
patient,3820,O
with,3820,O
mild,3820,O
language,3820,B-Disease
delay,3820,I-Disease
and,3820,O
mental,3820,B-Disease
retardation,3820,I-Disease
",",3820,O
who,3820,O
was,3820,O
found,3820,O
to,3820,O
have,3820,O
nonketotic,3820,B-Disease
hyperglycinemia,3820,I-Disease
following,3820,O
her,3820,O
presentation,3820,O
with,3820,O
acute,3820,O
encephalopathy,3820,B-Disease
and,3820,O
chorea,3820,B-Disease
shortly,3820,O
after,3820,O
initiation,3820,O
of,3820,O
valproate,3820,B-Chemical
therapy,3820,O
.,3820,O
Behavioral,3821,O
effects,3821,O
of,3821,O
pubertal,3821,O
anabolic,3821,O
androgenic,3821,O
steroid,3821,B-Chemical
exposure,3821,O
in,3821,O
male,3821,O
rats,3821,O
with,3821,O
low,3821,O
serotonin,3821,B-Chemical
.,3821,O
The,3822,O
goal,3822,O
of,3822,O
this,3822,O
study,3822,O
was,3822,O
to,3822,O
assess,3822,O
the,3822,O
interactive,3822,O
effects,3822,O
of,3822,O
chronic,3822,O
anabolic,3822,O
androgenic,3822,O
steroid,3822,B-Chemical
(,3822,O
AAS,3822,O
),3822,O
exposure,3822,O
and,3822,O
brain,3822,O
serotonin,3822,B-Chemical
(,3822,O
5-hydroxytryptamine,3822,B-Chemical
",",3822,O
5-HT,3822,B-Chemical
),3822,O
depletion,3822,O
on,3822,O
behavior,3822,O
of,3822,O
pubertal,3822,O
male,3822,O
rats,3822,O
.,3822,O
Serotonin,3823,B-Chemical
was,3823,O
depleted,3823,O
beginning,3823,O
on,3823,O
postnatal,3823,O
day,3823,O
26,3823,O
with,3823,O
parachlorophenylalanine,3823,B-Chemical
(,3823,O
PCPA,3823,B-Chemical
100,3823,O
mg/kg,3823,O
",",3823,O
every,3823,O
other,3823,O
day,3823,O
),3823,O
;,3823,O
controls,3823,O
received,3823,O
saline,3823,O
.,3823,O
At,3824,O
puberty,3824,O
(,3824,O
P40,3824,O
),3824,O
",",3824,O
half,3824,O
the,3824,O
PCPA-treated,3824,B-Chemical
rats,3824,O
and,3824,O
half,3824,O
the,3824,O
saline-treated,3824,O
rats,3824,O
began,3824,O
treatment,3824,O
with,3824,O
testosterone,3824,B-Chemical
(,3824,O
T,3824,B-Chemical
",",3824,O
5,3824,O
mg/kg,3824,O
",",3824,O
5,3824,O
days/week,3824,O
),3824,O
.,3824,O
Behavioral,3825,O
measures,3825,O
included,3825,O
locomotion,3825,O
",",3825,O
irritability,3825,B-Disease
",",3825,O
copulation,3825,O
",",3825,O
partner,3825,O
preference,3825,O
",",3825,O
and,3825,O
aggression,3825,B-Disease
.,3825,O
Animals,3826,O
were,3826,O
tested,3826,O
for,3826,O
aggression,3826,B-Disease
in,3826,O
their,3826,O
home,3826,O
cage,3826,O
",",3826,O
both,3826,O
with,3826,O
and,3826,O
without,3826,O
physical,3826,O
provocation,3826,O
(,3826,O
mild,3826,O
tail,3826,O
pinch,3826,O
),3826,O
.,3826,O
Brain,3827,O
levels,3827,O
of,3827,O
5-HT,3827,B-Chemical
and,3827,O
its,3827,O
metabolite,3827,O
",",3827,O
5-hydroxyindoleacetic,3827,B-Chemical
acid,3827,I-Chemical
(,3827,O
5-HIAA,3827,B-Chemical
),3827,O
",",3827,O
were,3827,O
determined,3827,O
using,3827,O
HPLC,3827,O
.,3827,O
PCPA,3828,B-Chemical
significantly,3828,O
and,3828,O
substantially,3828,O
depleted,3828,O
5-HT,3828,B-Chemical
and,3828,O
5-HIAA,3828,B-Chemical
in,3828,O
all,3828,O
brain,3828,O
regions,3828,O
examined,3828,O
.,3828,O
Chronic,3829,O
T,3829,B-Chemical
treatment,3829,O
significantly,3829,O
decreased,3829,O
5-HT,3829,B-Chemical
and,3829,O
5-HIAA,3829,B-Chemical
in,3829,O
certain,3829,O
brain,3829,O
areas,3829,O
",",3829,O
but,3829,O
to,3829,O
a,3829,O
much,3829,O
lesser,3829,O
extent,3829,O
than,3829,O
PCPA,3829,B-Chemical
.,3829,O
Chronic,3830,O
exposure,3830,O
to,3830,O
PCPA,3830,B-Chemical
alone,3830,O
significantly,3830,O
decreased,3830,O
locomotor,3830,O
activity,3830,O
and,3830,O
increased,3830,O
irritability,3830,B-Disease
but,3830,O
had,3830,O
no,3830,O
effect,3830,O
on,3830,O
sexual,3830,O
behavior,3830,O
",",3830,O
partner,3830,O
preference,3830,O
",",3830,O
or,3830,O
aggression,3830,B-Disease
.,3830,O
T,3831,B-Chemical
alone,3831,O
had,3831,O
no,3831,O
effect,3831,O
on,3831,O
locomotion,3831,O
",",3831,O
irritability,3831,B-Disease
",",3831,O
or,3831,O
sexual,3831,O
behavior,3831,O
but,3831,O
increased,3831,O
partner,3831,O
preference,3831,O
and,3831,O
aggression,3831,B-Disease
.,3831,O
The,3832,O
most,3832,O
striking,3832,O
effect,3832,O
of,3832,O
combining,3832,O
T+PCPA,3832,B-Chemical
was,3832,O
a,3832,O
significant,3832,O
increase,3832,O
in,3832,O
attack,3832,O
frequency,3832,O
as,3832,O
well,3832,O
as,3832,O
a,3832,O
significant,3832,O
decrease,3832,O
in,3832,O
the,3832,O
latency,3832,O
to,3832,O
attack,3832,O
",",3832,O
particularly,3832,O
following,3832,O
physical,3832,O
provocation,3832,O
.,3832,O
Based,3833,O
on,3833,O
these,3833,O
data,3833,O
",",3833,O
it,3833,O
can,3833,O
be,3833,O
speculated,3833,O
that,3833,O
pubertal,3833,O
AAS,3833,O
users,3833,O
with,3833,O
low,3833,O
central,3833,O
5-HT,3833,B-Chemical
may,3833,O
be,3833,O
especially,3833,O
prone,3833,O
to,3833,O
exhibit,3833,O
aggressive,3833,B-Disease
behavior,3833,I-Disease
.,3833,O
Effects,3834,O
of,3834,O
UMB24,3834,B-Chemical
and,3834,O
(,3834,O
+/-,3834,O
),3834,O
-SM,3834,O
21,3834,I-Chemical
",",3834,O
putative,3834,O
sigma2-preferring,3834,O
antagonists,3834,O
",",3834,O
on,3834,O
behavioral,3834,O
toxic,3834,O
and,3834,O
stimulant,3834,O
effects,3834,O
of,3834,O
cocaine,3834,B-Chemical
in,3834,O
mice,3834,O
.,3834,O
Earlier,3835,O
studies,3835,O
have,3835,O
demonstrated,3835,O
that,3835,O
antagonism,3835,O
of,3835,O
sigma1,3835,O
receptors,3835,O
attenuates,3835,O
the,3835,O
convulsive,3835,B-Disease
",",3835,O
lethal,3835,O
",",3835,O
locomotor,3835,O
stimulatory,3835,O
and,3835,O
rewarding,3835,O
actions,3835,O
of,3835,O
cocaine,3835,B-Chemical
in,3835,O
mice,3835,O
.,3835,O
In,3836,O
contrast,3836,O
",",3836,O
the,3836,O
contribution,3836,O
of,3836,O
sigma2,3836,O
receptors,3836,O
is,3836,O
unclear,3836,O
because,3836,O
experimental,3836,O
tools,3836,O
to,3836,O
selectively,3836,O
target,3836,O
this,3836,O
subtype,3836,O
are,3836,O
unavailable,3836,O
.,3836,O
To,3837,O
begin,3837,O
addressing,3837,O
this,3837,O
need,3837,O
",",3837,O
we,3837,O
characterized,3837,O
UMB24,3837,B-Chemical
(,3837,O
1-,3837,B-Chemical
(,3837,I-Chemical
2-phenethyl,3837,I-Chemical
),3837,I-Chemical
-4-,3837,I-Chemical
(,3837,I-Chemical
2-pyridyl,3837,I-Chemical
),3837,I-Chemical
-piperazine,3837,I-Chemical
),3837,O
and,3837,O
(,3837,O
+/-,3837,O
),3837,O
-SM,3837,O
21,3837,I-Chemical
(,3837,O
3alpha-tropanyl-2-,3837,B-Chemical
(,3837,I-Chemical
4-chorophenoxy,3837,I-Chemical
),3837,I-Chemical
butyrate,3837,I-Chemical
),3837,O
in,3837,O
receptor,3837,O
binding,3837,O
and,3837,O
behavioral,3837,O
studies,3837,O
.,3837,O
Receptor,3838,O
binding,3838,O
studies,3838,O
confirmed,3838,O
that,3838,O
UMB24,3838,B-Chemical
and,3838,O
(,3838,O
+/-,3838,O
),3838,O
-SM,3838,O
21,3838,I-Chemical
display,3838,O
preferential,3838,O
affinity,3838,O
for,3838,O
sigma2,3838,O
over,3838,O
sigma1,3838,O
receptors,3838,O
.,3838,O
In,3839,O
behavioral,3839,O
studies,3839,O
",",3839,O
pretreatment,3839,O
of,3839,O
Swiss,3839,O
Webster,3839,O
mice,3839,O
with,3839,O
UMB24,3839,B-Chemical
or,3839,O
(,3839,O
+/-,3839,O
),3839,O
-SM,3839,O
21,3839,I-Chemical
significantly,3839,O
attenuated,3839,O
cocaine-induced,3839,B-Chemical
convulsions,3839,B-Disease
and,3839,O
locomotor,3839,O
activity,3839,O
",",3839,O
but,3839,O
not,3839,O
lethality,3839,O
.,3839,O
When,3840,O
administered,3840,O
alone,3840,O
",",3840,O
(,3840,O
+/-,3840,O
),3840,O
-SM,3840,O
21,3840,I-Chemical
produced,3840,O
no,3840,O
significant,3840,O
effects,3840,O
compared,3840,O
to,3840,O
control,3840,O
injections,3840,O
of,3840,O
saline,3840,O
",",3840,O
but,3840,O
UMB24,3840,B-Chemical
had,3840,O
locomotor,3840,O
depressant,3840,O
actions,3840,O
.,3840,O
Together,3841,O
",",3841,O
the,3841,O
data,3841,O
suggest,3841,O
that,3841,O
sigma2,3841,O
receptor,3841,O
antagonists,3841,O
have,3841,O
the,3841,O
potential,3841,O
to,3841,O
attenuate,3841,O
some,3841,O
of,3841,O
the,3841,O
behavioral,3841,O
effects,3841,O
of,3841,O
cocaine,3841,B-Chemical
",",3841,O
and,3841,O
further,3841,O
development,3841,O
of,3841,O
more,3841,O
selective,3841,O
",",3841,O
high,3841,O
affinity,3841,O
ligands,3841,O
are,3841,O
warranted,3841,O
.,3841,O
Cardiac,3842,B-Disease
arrest,3842,I-Disease
in,3842,O
a,3842,O
child,3842,O
with,3842,O
cerebral,3842,B-Disease
palsy,3842,I-Disease
undergoing,3842,O
sevoflurane,3842,B-Chemical
induction,3842,O
of,3842,O
anesthesia,3842,O
after,3842,O
preoperative,3842,O
clonidine,3842,B-Chemical
.,3842,O
Clonidine,3843,B-Chemical
is,3843,O
a,3843,O
frequently,3843,O
administered,3843,O
alpha2-adrenergic,3843,O
agonist,3843,O
which,3843,O
can,3843,O
decrease,3843,O
heart,3843,O
rate,3843,O
and,3843,O
blood,3843,O
pressure,3843,O
.,3843,O
We,3844,O
present,3844,O
a,3844,O
case,3844,O
of,3844,O
a,3844,O
5-year-old,3844,O
child,3844,O
with,3844,O
cerebral,3844,B-Disease
palsy,3844,I-Disease
and,3844,O
seizure,3844,B-Disease
disorder,3844,I-Disease
",",3844,O
receiving,3844,O
clonidine,3844,B-Chemical
for,3844,O
restlessness,3844,B-Disease
",",3844,O
who,3844,O
presented,3844,O
for,3844,O
placement,3844,O
of,3844,O
a,3844,O
baclofen,3844,B-Chemical
pump,3844,O
.,3844,O
Without,3845,O
the,3845,O
knowledge,3845,O
of,3845,O
the,3845,O
medical,3845,O
personnel,3845,O
",",3845,O
the,3845,O
patient,3845,O
's,3845,O
mother,3845,O
administered,3845,O
three,3845,O
doses,3845,O
of,3845,O
clonidine,3845,B-Chemical
during,3845,O
the,3845,O
evening,3845,O
before,3845,O
and,3845,O
morning,3845,O
of,3845,O
surgery,3845,O
to,3845,O
reduce,3845,O
anxiety,3845,B-Disease
.,3845,O
During,3846,O
induction,3846,O
of,3846,O
anesthesia,3846,O
",",3846,O
the,3846,O
patient,3846,O
developed,3846,O
bradycardia,3846,B-Disease
and,3846,O
hypotension,3846,B-Disease
requiring,3846,O
cardiac,3846,O
resuscitation,3846,O
.,3846,O
There,3847,O
are,3847,O
no,3847,O
previous,3847,O
reports,3847,O
of,3847,O
clonidine-associated,3847,B-Chemical
cardiac,3847,B-Disease
arrest,3847,I-Disease
in,3847,O
a,3847,O
child,3847,O
undergoing,3847,O
induction,3847,O
of,3847,O
anesthesia,3847,O
.,3847,O
Angiotensin-converting,3848,O
enzyme,3848,O
(,3848,O
ACE,3848,O
),3848,O
inhibitor-associated,3848,O
angioedema,3848,B-Disease
of,3848,O
the,3848,O
stomach,3848,O
and,3848,O
small,3848,O
intestine,3848,O
:,3848,O
a,3848,O
case,3848,O
report,3848,O
.,3848,O
This,3849,O
is,3849,O
a,3849,O
case,3849,O
report,3849,O
on,3849,O
a,3849,O
45-year,3849,O
old,3849,O
African-American,3849,O
female,3849,O
with,3849,O
newly,3849,O
diagnosed,3849,O
hypertension,3849,B-Disease
",",3849,O
who,3849,O
was,3849,O
started,3849,O
on,3849,O
a,3849,O
combination,3849,O
pill,3849,O
of,3849,O
amlodipine/benazapril,3849,B-Chemical
10/5,3849,O
mg,3849,O
.,3849,O
The,3850,O
very,3850,O
next,3850,O
day,3850,O
",",3850,O
she,3850,O
presented,3850,O
at,3850,O
the,3850,O
emergency,3850,O
room,3850,O
(,3850,O
ER,3850,O
),3850,O
with,3850,O
abdominal,3850,B-Disease
pain,3850,I-Disease
",",3850,O
nausea,3850,B-Disease
and,3850,O
vomiting,3850,B-Disease
.,3850,O
Physical,3851,O
exam,3851,O
",",3851,O
complete,3851,O
metabolic,3851,O
panel,3851,O
",",3851,O
and,3851,O
hemogram,3851,O
were,3851,O
in,3851,O
the,3851,O
normal,3851,O
range,3851,O
.,3851,O
She,3852,O
was,3852,O
discharged,3852,O
from,3852,O
the,3852,O
ER,3852,O
after,3852,O
a,3852,O
few,3852,O
hours,3852,O
of,3852,O
treatment,3852,O
with,3852,O
fluid,3852,O
and,3852,O
analgesics,3852,O
.,3852,O
However,3853,O
",",3853,O
she,3853,O
returned,3853,O
to,3853,O
the,3853,O
ER,3853,O
the,3853,O
next,3853,O
day,3853,O
with,3853,O
the,3853,O
same,3853,O
complaints,3853,O
.,3853,O
This,3854,O
time,3854,O
the,3854,O
physical,3854,O
exam,3854,O
was,3854,O
significant,3854,O
for,3854,O
a,3854,O
distended,3854,O
abdomen,3854,O
with,3854,O
dullness,3854,O
to,3854,O
percussion,3854,O
.,3854,O
CT,3855,O
scan,3855,O
of,3855,O
the,3855,O
abdomen,3855,O
revealed,3855,O
markedly,3855,O
thickened,3855,O
antrum,3855,O
of,3855,O
the,3855,O
stomach,3855,O
",",3855,O
duodenum,3855,O
and,3855,O
jejunum,3855,O
",",3855,O
along,3855,O
with,3855,O
fluid,3855,O
in,3855,O
the,3855,O
abdominal,3855,O
and,3855,O
pelvic,3855,O
cavity,3855,O
.,3855,O
Angiotensin-converting,3856,O
enzyme,3856,O
inhibitor,3856,O
(,3856,O
ACEI,3856,O
),3856,O
-induced,3856,O
angioedema,3856,B-Disease
was,3856,O
suspected,3856,O
",",3856,O
and,3856,O
anti-hypertensive,3856,O
medications,3856,O
were,3856,O
discontinued,3856,O
.,3856,O
Her,3857,O
symptoms,3857,O
improved,3857,O
within,3857,O
the,3857,O
next,3857,O
24,3857,O
hours,3857,O
",",3857,O
and,3857,O
repeat,3857,O
CT,3857,O
after,3857,O
72,3857,O
hours,3857,O
revealed,3857,O
marked,3857,O
improvement,3857,O
in,3857,O
stomach,3857,O
and,3857,O
small,3857,O
bowel,3857,O
thickening,3857,O
and,3857,O
resolution,3857,O
of,3857,O
ascites,3857,B-Disease
.,3857,O
The,3858,O
recognition,3858,O
of,3858,O
angiotensin-converting,3858,B-Chemical
enzyme,3858,O
(,3858,O
ACE,3858,O
),3858,O
and,3858,O
angiotensin,3858,B-Chemical
receptor,3858,O
blocker,3858,O
(,3858,O
ARB,3858,O
),3858,O
intestinal,3858,O
angioedema,3858,O
constitutes,3858,O
a,3858,O
challenge,3858,O
to,3858,O
primary,3858,O
care,3858,O
physicians,3858,O
",",3858,O
internists,3858,O
",",3858,O
emergency,3858,O
room,3858,O
personal,3858,O
and,3858,O
surgeons,3858,O
.,3858,O
Syncope,3859,B-Disease
and,3859,O
QT,3859,B-Disease
prolongation,3859,I-Disease
among,3859,O
patients,3859,O
treated,3859,O
with,3859,O
methadone,3859,B-Chemical
for,3859,O
heroin,3859,B-Chemical
dependence,3859,O
in,3859,O
the,3859,O
city,3859,O
of,3859,O
Copenhagen,3859,O
.,3859,O
BACKGROUND,3860,O
:,3860,O
Methadone,3860,B-Chemical
is,3860,O
prescribed,3860,O
to,3860,O
heroin,3860,B-Chemical
addicts,3860,O
to,3860,O
decrease,3860,O
illicit,3860,O
opioid,3860,O
use,3860,O
.,3860,O
Prolongation,3861,O
of,3861,O
the,3861,O
QT,3861,O
interval,3861,O
in,3861,O
the,3861,O
ECG,3861,O
of,3861,O
patients,3861,O
with,3861,O
torsade,3861,B-Disease
de,3861,I-Disease
pointes,3861,I-Disease
(,3861,O
TdP,3861,B-Disease
),3861,O
has,3861,O
been,3861,O
reported,3861,O
in,3861,O
methadone,3861,B-Chemical
users,3861,O
.,3861,O
As,3862,O
heroin,3862,B-Chemical
addicts,3862,O
sometimes,3862,O
faint,3862,O
while,3862,O
using,3862,O
illicit,3862,O
drugs,3862,O
",",3862,O
doctors,3862,O
might,3862,O
attribute,3862,O
too,3862,O
many,3862,O
episodes,3862,O
of,3862,O
syncope,3862,B-Disease
to,3862,O
illicit,3862,O
drug,3862,O
use,3862,O
and,3862,O
thereby,3862,O
underestimate,3862,O
the,3862,O
incidence,3862,O
of,3862,O
TdP,3862,B-Disease
in,3862,O
this,3862,O
special,3862,O
population,3862,O
",",3862,O
and,3862,O
the,3862,O
high,3862,O
mortality,3862,O
in,3862,O
this,3862,O
population,3862,O
may,3862,O
",",3862,O
in,3862,O
part,3862,O
",",3862,O
be,3862,O
caused,3862,O
by,3862,O
the,3862,O
proarrhythmic,3862,O
effect,3862,O
of,3862,O
methadone,3862,B-Chemical
.,3862,O
METHODS,3863,O
:,3863,O
In,3863,O
this,3863,O
cross-sectional,3863,O
study,3863,O
interview,3863,O
",",3863,O
ECGs,3863,O
and,3863,O
blood,3863,O
samples,3863,O
were,3863,O
collected,3863,O
in,3863,O
a,3863,O
population,3863,O
of,3863,O
adult,3863,O
heroin,3863,B-Chemical
addicts,3863,O
treated,3863,O
with,3863,O
methadone,3863,B-Chemical
or,3863,O
buprenorphine,3863,B-Chemical
on,3863,O
a,3863,O
daily,3863,O
basis,3863,O
.,3863,O
Of,3864,O
the,3864,O
patients,3864,O
at,3864,O
the,3864,O
Drug,3864,O
Addiction,3864,O
Service,3864,O
in,3864,O
the,3864,O
municipal,3864,O
of,3864,O
Copenhagen,3864,O
",",3864,O
450,3864,O
(,3864,O
approximately,3864,O
52,3864,O
%,3864,O
),3864,O
were,3864,O
included,3864,O
.,3864,O
The,3865,O
QT,3865,O
interval,3865,O
was,3865,O
estimated,3865,O
from,3865,O
12,3865,O
lead,3865,O
ECGs,3865,O
.,3865,O
All,3866,O
participants,3866,O
were,3866,O
interviewed,3866,O
about,3866,O
any,3866,O
experience,3866,O
of,3866,O
syncope,3866,B-Disease
.,3866,O
The,3867,O
association,3867,O
between,3867,O
opioid,3867,O
dose,3867,O
and,3867,O
QT,3867,O
",",3867,O
and,3867,O
methadone,3867,B-Chemical
dose,3867,O
and,3867,O
reporting,3867,O
of,3867,O
syncope,3867,B-Disease
was,3867,O
assessed,3867,O
using,3867,O
multivariate,3867,O
linear,3867,O
regression,3867,O
and,3867,O
logistic,3867,O
regression,3867,O
",",3867,O
respectively,3867,O
.,3867,O
RESULTS,3868,O
:,3868,O
Methadone,3868,B-Chemical
dose,3868,O
was,3868,O
associated,3868,O
with,3868,O
longer,3868,O
QT,3868,O
interval,3868,O
of,3868,O
0.140,3868,O
ms/mg,3868,O
(,3868,O
p,3868,O
=,3868,O
0.002,3868,O
),3868,O
.,3868,O
No,3869,O
association,3869,O
between,3869,O
buprenorphine,3869,B-Chemical
and,3869,O
QTc,3869,O
was,3869,O
found,3869,O
.,3869,O
Among,3870,O
the,3870,O
subjects,3870,O
treated,3870,O
with,3870,O
methadone,3870,B-Chemical
",",3870,O
28,3870,O
%,3870,O
men,3870,O
and,3870,O
32,3870,O
%,3870,O
women,3870,O
had,3870,O
prolonged,3870,B-Disease
QTc,3870,I-Disease
interval,3870,I-Disease
.,3870,O
None,3871,O
of,3871,O
the,3871,O
subjects,3871,O
treated,3871,O
with,3871,O
buprenorphine,3871,B-Chemical
had,3871,O
QTc,3871,O
interval,3871,O
>,3871,O
0.440,3871,O
s,3871,O
(,3871,O
(,3871,O
1/2,3871,O
),3871,O
),3871,O
.,3871,O
A,3872,O
50,3872,O
mg,3872,O
higher,3872,O
methadone,3872,B-Chemical
dose,3872,O
was,3872,O
associated,3872,O
with,3872,O
a,3872,O
1.2,3872,O
(,3872,O
95,3872,O
%,3872,O
CI,3872,O
1.1,3872,O
to,3872,O
1.4,3872,O
),3872,O
times,3872,O
higher,3872,O
odds,3872,O
for,3872,O
syncope,3872,B-Disease
.,3872,O
CONCLUSIONS,3873,O
:,3873,O
Methadone,3873,B-Chemical
is,3873,O
associated,3873,O
with,3873,O
QT,3873,B-Disease
prolongation,3873,I-Disease
and,3873,O
higher,3873,O
reporting,3873,O
of,3873,O
syncope,3873,B-Disease
in,3873,O
a,3873,O
population,3873,O
of,3873,O
heroin,3873,B-Chemical
addicts,3873,O
.,3873,O
Neuroleptic,3874,B-Disease
malignant,3874,I-Disease
syndrome,3874,I-Disease
induced,3874,O
by,3874,O
ziprasidone,3874,B-Chemical
on,3874,O
the,3874,O
second,3874,O
day,3874,O
of,3874,O
treatment,3874,O
.,3874,O
Neuroleptic,3875,B-Disease
malignant,3875,I-Disease
syndrome,3875,I-Disease
(,3875,O
NMS,3875,B-Disease
),3875,O
is,3875,O
the,3875,O
rarest,3875,O
and,3875,O
most,3875,O
serious,3875,O
of,3875,O
the,3875,O
neuroleptic-induced,3875,O
movement,3875,B-Disease
disorders,3875,I-Disease
.,3875,O
We,3876,O
describe,3876,O
a,3876,O
case,3876,O
of,3876,O
neuroleptic,3876,B-Disease
malignant,3876,I-Disease
syndrome,3876,I-Disease
(,3876,O
NMS,3876,B-Disease
),3876,O
associated,3876,O
with,3876,O
the,3876,O
use,3876,O
of,3876,O
ziprasidone,3876,B-Chemical
.,3876,O
Although,3877,O
conventional,3877,O
neuroleptics,3877,O
are,3877,O
more,3877,O
frequently,3877,O
associated,3877,O
with,3877,O
NMS,3877,B-Disease
",",3877,O
atypical,3877,O
antipsychotic,3877,O
drugs,3877,O
like,3877,O
ziprasidone,3877,B-Chemical
may,3877,O
also,3877,O
be,3877,O
a,3877,O
cause,3877,O
.,3877,O
The,3878,O
patient,3878,O
is,3878,O
a,3878,O
24-year-old,3878,O
male,3878,O
with,3878,O
a,3878,O
history,3878,O
of,3878,O
schizophrenia,3878,B-Disease
who,3878,O
developed,3878,O
signs,3878,O
and,3878,O
symptoms,3878,O
of,3878,O
NMS,3878,B-Disease
after,3878,O
2,3878,O
days,3878,O
of,3878,O
treatment,3878,O
with,3878,O
an,3878,O
80-mg/day,3878,O
dose,3878,O
of,3878,O
orally,3878,O
administrated,3878,O
ziprasidone,3878,B-Chemical
.,3878,O
This,3879,O
case,3879,O
is,3879,O
the,3879,O
earliest,3879,O
(,3879,O
second,3879,O
day,3879,O
of,3879,O
treatment,3879,O
),3879,O
NMS,3879,B-Disease
due,3879,O
to,3879,O
ziprasidone,3879,B-Chemical
reported,3879,O
in,3879,O
the,3879,O
literature,3879,O
.,3879,O
Peripheral,3880,O
iron,3880,B-Chemical
dextran,3880,I-Chemical
induced,3880,O
degeneration,3880,B-Disease
of,3880,I-Disease
dopaminergic,3880,I-Disease
neurons,3880,I-Disease
in,3880,O
rat,3880,O
substantia,3880,O
nigra,3880,O
.,3880,O
Iron,3881,B-Chemical
accumulation,3881,O
is,3881,O
considered,3881,O
to,3881,O
be,3881,O
involved,3881,O
in,3881,O
the,3881,O
pathogenesis,3881,O
of,3881,O
Parkinson,3881,B-Disease
's,3881,I-Disease
disease,3881,I-Disease
.,3881,O
To,3882,O
demonstrate,3882,O
the,3882,O
relationship,3882,O
between,3882,O
peripheral,3882,O
iron,3882,B-Chemical
overload,3882,O
and,3882,O
dopaminergic,3882,O
neuron,3882,O
loss,3882,O
in,3882,O
rat,3882,O
substantia,3882,O
nigra,3882,O
(,3882,O
SN,3882,O
),3882,O
",",3882,O
in,3882,O
the,3882,O
present,3882,O
study,3882,O
we,3882,O
used,3882,O
fast,3882,O
cyclic,3882,O
voltammetry,3882,O
",",3882,O
tyrosine,3882,B-Chemical
hydroxylase,3882,O
(,3882,O
TH,3882,O
),3882,O
immunohistochemistry,3882,O
",",3882,O
Perls,3882,O
',3882,O
iron,3882,B-Chemical
staining,3882,O
",",3882,O
and,3882,O
high,3882,O
performance,3882,O
liquid,3882,O
chromatography-electrochemical,3882,O
detection,3882,O
to,3882,O
study,3882,O
the,3882,O
degeneration,3882,B-Disease
of,3882,I-Disease
dopaminergic,3882,I-Disease
neurons,3882,I-Disease
and,3882,O
increased,3882,O
iron,3882,B-Chemical
content,3882,O
in,3882,O
the,3882,O
SN,3882,O
of,3882,O
iron,3882,B-Chemical
dextran,3882,I-Chemical
overloaded,3882,O
animals,3882,O
.,3882,O
The,3883,O
findings,3883,O
showed,3883,O
that,3883,O
peripheral,3883,O
iron,3883,B-Chemical
dextran,3883,I-Chemical
overload,3883,O
increased,3883,O
the,3883,O
iron,3883,B-Chemical
staining,3883,O
positive,3883,O
cells,3883,O
and,3883,O
reduced,3883,O
the,3883,O
number,3883,O
of,3883,O
TH-immunoreactive,3883,O
neurons,3883,O
in,3883,O
the,3883,O
SN,3883,O
.,3883,O
As,3884,O
a,3884,O
result,3884,O
",",3884,O
dopamine,3884,B-Chemical
release,3884,O
and,3884,O
content,3884,O
",",3884,O
as,3884,O
well,3884,O
as,3884,O
its,3884,O
metabolites,3884,O
contents,3884,O
were,3884,O
decreased,3884,O
in,3884,O
caudate,3884,O
putamen,3884,O
.,3884,O
Even,3885,O
more,3885,O
dramatic,3885,O
changes,3885,O
were,3885,O
found,3885,O
in,3885,O
chronic,3885,O
overload,3885,O
group,3885,O
.,3885,O
These,3886,O
results,3886,O
suggest,3886,O
that,3886,O
peripheral,3886,O
iron,3886,B-Chemical
dextran,3886,I-Chemical
can,3886,O
increase,3886,O
the,3886,O
iron,3886,B-Chemical
level,3886,O
in,3886,O
the,3886,O
SN,3886,O
",",3886,O
where,3886,O
excessive,3886,O
iron,3886,B-Chemical
causes,3886,O
the,3886,O
degeneration,3886,B-Disease
of,3886,I-Disease
dopaminergic,3886,I-Disease
neurons,3886,I-Disease
.,3886,O
The,3887,O
chronic,3887,O
iron,3887,B-Chemical
overload,3887,O
may,3887,O
be,3887,O
more,3887,O
destructive,3887,O
to,3887,O
dopaminergic,3887,O
neurons,3887,O
than,3887,O
the,3887,O
acute,3887,O
iron,3887,B-Chemical
overload,3887,O
.,3887,O
Attenuated,3888,O
disruption,3888,O
of,3888,O
prepulse,3888,O
inhibition,3888,O
by,3888,O
dopaminergic,3888,O
stimulation,3888,O
after,3888,O
maternal,3888,O
deprivation,3888,O
and,3888,O
adolescent,3888,O
corticosterone,3888,B-Chemical
treatment,3888,O
in,3888,O
rats,3888,O
.,3888,O
The,3889,O
development,3889,O
of,3889,O
schizophrenia,3889,B-Disease
may,3889,O
include,3889,O
an,3889,O
early,3889,O
neurodevelopmental,3889,O
stress,3889,O
component,3889,O
which,3889,O
increases,3889,O
vulnerability,3889,O
to,3889,O
later,3889,O
stressful,3889,O
life,3889,O
events,3889,O
",",3889,O
in,3889,O
combination,3889,O
leading,3889,O
to,3889,O
overt,3889,O
disease,3889,O
.,3889,O
We,3890,O
investigated,3890,O
the,3890,O
effect,3890,O
of,3890,O
an,3890,O
early,3890,O
stress,3890,O
",",3890,O
in,3890,O
the,3890,O
form,3890,O
of,3890,O
maternal,3890,O
deprivation,3890,O
",",3890,O
combined,3890,O
with,3890,O
a,3890,O
later,3890,O
stress,3890,O
",",3890,O
simulated,3890,O
by,3890,O
chronic,3890,O
periadolescent,3890,O
corticosterone,3890,B-Chemical
treatment,3890,O
",",3890,O
on,3890,O
behaviour,3890,O
in,3890,O
rats,3890,O
.,3890,O
Acute,3891,O
treatment,3891,O
with,3891,O
apomorphine,3891,B-Chemical
caused,3891,O
disruption,3891,O
of,3891,O
prepulse,3891,O
inhibition,3891,O
(,3891,O
PPI,3891,O
),3891,O
in,3891,O
controls,3891,O
and,3891,O
in,3891,O
rats,3891,O
that,3891,O
had,3891,O
undergone,3891,O
either,3891,O
maternal,3891,O
deprivation,3891,O
or,3891,O
corticosterone,3891,B-Chemical
treatment,3891,O
",",3891,O
but,3891,O
was,3891,O
surprisingly,3891,O
absent,3891,O
in,3891,O
rats,3891,O
that,3891,O
had,3891,O
undergone,3891,O
the,3891,O
combined,3891,O
early,3891,O
and,3891,O
late,3891,O
stress,3891,O
.,3891,O
Amphetamine,3892,B-Chemical
treatment,3892,O
significantly,3892,O
disrupted,3892,O
PPI,3892,O
in,3892,O
both,3892,O
non-deprived,3892,O
groups,3892,O
",",3892,O
but,3892,O
was,3892,O
absent,3892,O
in,3892,O
both,3892,O
maternally,3892,O
deprived,3892,O
groups,3892,O
.,3892,O
The,3893,O
serotonin-1A,3893,B-Chemical
receptor,3893,O
agonist,3893,O
",",3893,O
8-OH-DPAT,3893,B-Chemical
",",3893,O
induced,3893,O
a,3893,O
significant,3893,O
disruption,3893,O
of,3893,O
PPI,3893,O
in,3893,O
all,3893,O
groups,3893,O
.,3893,O
Amphetamine-induced,3894,B-Chemical
locomotor,3894,B-Disease
hyperactivity,3894,I-Disease
was,3894,O
similar,3894,O
in,3894,O
all,3894,O
groups,3894,O
.,3894,O
These,3895,O
results,3895,O
show,3895,O
an,3895,O
inhibitory,3895,O
interaction,3895,O
of,3895,O
early,3895,O
stress,3895,O
",",3895,O
caused,3895,O
by,3895,O
maternal,3895,O
deprivation,3895,O
",",3895,O
combined,3895,O
with,3895,O
'adolescent,3895,O
',3895,O
stress,3895,O
",",3895,O
simulated,3895,O
by,3895,O
corticosterone,3895,B-Chemical
treatment,3895,O
",",3895,O
on,3895,O
dopaminergic,3895,O
regulation,3895,O
of,3895,O
PPI,3895,O
.,3895,O
The,3896,O
altered,3896,O
effects,3896,O
of,3896,O
apomorphine,3896,B-Chemical
and,3896,O
amphetamine,3896,B-Chemical
could,3896,O
indicate,3896,O
differential,3896,O
changes,3896,O
in,3896,O
dopamine,3896,B-Chemical
receptor,3896,O
signalling,3896,O
leading,3896,O
to,3896,O
functional,3896,O
desensitisation,3896,O
",",3896,O
or,3896,O
altered,3896,O
modulation,3896,O
of,3896,O
sensory,3896,O
gating,3896,O
in,3896,O
the,3896,O
nucleus,3896,O
accumbens,3896,O
by,3896,O
limbic,3896,O
structures,3896,O
such,3896,O
as,3896,O
the,3896,O
hippocampus,3896,O
.,3896,O
An,3897,O
extremely,3897,O
rare,3897,O
case,3897,O
of,3897,O
delusional,3897,B-Disease
parasitosis,3897,I-Disease
in,3897,O
a,3897,O
chronic,3897,B-Disease
hepatitis,3897,I-Disease
C,3897,I-Disease
patient,3897,O
during,3897,O
pegylated,3897,B-Chemical
interferon,3897,I-Chemical
alpha-2b,3897,I-Chemical
and,3897,O
ribavirin,3897,B-Chemical
treatment,3897,O
.,3897,O
During,3898,O
treatment,3898,O
of,3898,O
chronic,3898,B-Disease
hepatitis,3898,I-Disease
C,3898,I-Disease
patients,3898,O
with,3898,O
interferon,3898,O
and,3898,O
ribavirin,3898,B-Chemical
",",3898,O
a,3898,O
lot,3898,O
of,3898,O
side,3898,O
effects,3898,O
are,3898,O
described,3898,O
.,3898,O
Twenty-three,3899,O
percent,3899,O
to,3899,O
44,3899,O
%,3899,O
of,3899,O
patients,3899,O
develop,3899,O
depression,3899,B-Disease
.,3899,O
A,3900,O
minority,3900,O
of,3900,O
patients,3900,O
evolve,3900,O
to,3900,O
psychosis,3900,B-Disease
.,3900,O
To,3901,O
the,3901,O
best,3901,O
of,3901,O
our,3901,O
knowledge,3901,O
",",3901,O
no,3901,O
cases,3901,O
of,3901,O
psychogenic,3901,B-Disease
parasitosis,3901,I-Disease
occurring,3901,O
during,3901,O
interferon,3901,O
therapy,3901,O
have,3901,O
been,3901,O
described,3901,O
in,3901,O
the,3901,O
literature,3901,O
.,3901,O
We,3902,O
present,3902,O
a,3902,O
49-year-old,3902,O
woman,3902,O
who,3902,O
developed,3902,O
a,3902,O
delusional,3902,B-Disease
parasitosis,3902,I-Disease
during,3902,O
treatment,3902,O
with,3902,O
pegylated,3902,B-Chemical
interferon,3902,I-Chemical
alpha-2b,3902,I-Chemical
weekly,3902,O
and,3902,O
ribavirin,3902,B-Chemical
.,3902,O
She,3903,O
complained,3903,O
of,3903,O
seeing,3903,O
parasites,3903,O
and,3903,O
the,3903,O
larvae,3903,O
of,3903,O
fleas,3903,O
in,3903,O
her,3903,O
stools,3903,O
.,3903,O
This,3904,O
could,3904,O
not,3904,O
be,3904,O
confirmed,3904,O
by,3904,O
any,3904,O
technical,3904,O
examination,3904,O
.,3904,O
All,3905,O
the,3905,O
complaints,3905,O
disappeared,3905,O
after,3905,O
stopping,3905,O
pegylated,3905,B-Chemical
interferon,3905,I-Chemical
alpha-2b,3905,I-Chemical
and,3905,O
reappeared,3905,O
after,3905,O
restarting,3905,O
it,3905,O
.,3905,O
She,3906,O
had,3906,O
a,3906,O
complete,3906,O
sustained,3906,O
viral,3906,O
response,3906,O
.,3906,O
Hepatonecrosis,3907,B-Disease
and,3907,O
cholangitis,3907,B-Disease
related,3907,O
to,3907,O
long-term,3907,O
phenobarbital,3907,B-Chemical
therapy,3907,O
:,3907,O
an,3907,O
autopsy,3907,O
report,3907,O
of,3907,O
two,3907,O
patients,3907,O
.,3907,O
Phenobarbital,3908,B-Chemical
(,3908,O
PB,3908,B-Chemical
),3908,O
has,3908,O
a,3908,O
reputation,3908,O
for,3908,O
safety,3908,O
",",3908,O
and,3908,O
it,3908,O
is,3908,O
commonly,3908,O
believed,3908,O
that,3908,O
PB-related,3908,B-Chemical
increases,3908,O
in,3908,O
serum,3908,O
aminotransferase,3908,O
levels,3908,O
do,3908,O
not,3908,O
indicate,3908,O
or,3908,O
predict,3908,O
the,3908,O
development,3908,O
of,3908,O
significant,3908,O
chronic,3908,O
liver,3908,B-Disease
disease,3908,I-Disease
.,3908,O
Here,3909,O
we,3909,O
report,3909,O
of,3909,O
two,3909,O
adult,3909,O
patients,3909,O
with,3909,O
a,3909,O
long,3909,O
history,3909,O
of,3909,O
epilepsy,3909,B-Disease
treated,3909,O
with,3909,O
PB,3909,B-Chemical
who,3909,O
died,3909,O
suddenly,3909,O
:,3909,O
one,3909,O
as,3909,O
consequence,3909,O
of,3909,O
cardiac,3909,B-Disease
arrest,3909,I-Disease
",",3909,O
the,3909,O
other,3909,O
of,3909,O
acute,3909,O
bronchopneumonia,3909,B-Disease
.,3909,O
At,3910,O
autopsy,3910,O
",",3910,O
analysis,3910,O
of,3910,O
liver,3910,O
parenchyma,3910,O
revealed,3910,O
rich,3910,O
portal,3910,O
inflammatory,3910,O
infiltrate,3910,O
",",3910,O
which,3910,O
consisted,3910,O
of,3910,O
mixed,3910,O
eosinophil,3910,O
and,3910,O
monocyte,3910,O
cells,3910,O
",",3910,O
associated,3910,O
with,3910,O
several,3910,O
foci,3910,O
of,3910,O
necrosis,3910,B-Disease
surrounded,3910,O
by,3910,O
a,3910,O
hard,3910,O
ring,3910,O
of,3910,O
non-specific,3910,O
granulomatous,3910,O
tissue,3910,O
.,3910,O
Inflammatory,3911,O
reactions,3911,O
of,3911,O
internal,3911,O
and,3911,O
external,3911,O
hepatic,3911,O
biliary,3911,O
ducts,3911,O
were,3911,O
also,3911,O
seen,3911,O
.,3911,O
Our,3912,O
findings,3912,O
illustrate,3912,O
that,3912,O
PB,3912,B-Chemical
may,3912,O
be,3912,O
associated,3912,O
with,3912,O
chronic,3912,O
liver,3912,B-Disease
damage,3912,I-Disease
",",3912,O
which,3912,O
may,3912,O
lead,3912,O
to,3912,O
more,3912,O
serious,3912,O
and,3912,O
deleterious,3912,O
consequences,3912,O
.,3912,O
For,3913,O
this,3913,O
reason,3913,O
",",3913,O
each,3913,O
clinician,3913,O
should,3913,O
recognize,3913,O
this,3913,O
entity,3913,O
in,3913,O
the,3913,O
differential,3913,O
diagnosis,3913,O
of,3913,O
PB-related,3913,B-Chemical
asymptomatic,3913,O
chronic,3913,B-Disease
hepatic,3913,I-Disease
enzyme,3913,I-Disease
dysfunction,3913,I-Disease
.,3913,O
Delayed,3914,O
leukoencephalopathy,3914,B-Disease
with,3914,O
stroke-like,3914,B-Disease
presentation,3914,O
in,3914,O
chemotherapy,3914,O
recipients,3914,O
.,3914,O
BACKGROUND,3915,O
:,3915,O
A,3915,O
transient,3915,O
leukoencephalopathy,3915,B-Disease
mimicking,3915,O
cerebrovascular,3915,B-Disease
accident,3915,I-Disease
has,3915,O
been,3915,O
described,3915,O
as,3915,O
a,3915,O
complication,3915,O
of,3915,O
chemotherapy,3915,O
",",3915,O
most,3915,O
commonly,3915,O
in,3915,O
recipients,3915,O
of,3915,O
intrathecal,3915,O
methotrexate,3915,B-Chemical
for,3915,O
childhood,3915,O
leukaemia,3915,B-Disease
.,3915,O
Recently,3916,O
published,3916,O
neuroimaging,3916,O
data,3916,O
suggest,3916,O
a,3916,O
common,3916,O
pathophysiology,3916,O
associated,3916,O
with,3916,O
a,3916,O
variety,3916,O
of,3916,O
chemotherapy,3916,O
agents,3916,O
and,3916,O
modes,3916,O
of,3916,O
administration,3916,O
.,3916,O
METHODS,3917,O
:,3917,O
We,3917,O
reviewed,3917,O
the,3917,O
medical,3917,O
literature,3917,O
for,3917,O
single,3917,O
reports,3917,O
and,3917,O
case,3917,O
series,3917,O
of,3917,O
patients,3917,O
presenting,3917,O
with,3917,O
stroke-like,3917,B-Disease
episodes,3917,O
while,3917,O
receiving,3917,O
systemic,3917,O
or,3917,O
intrathecal,3917,O
chemotherapy,3917,O
.,3917,O
We,3918,O
only,3918,O
included,3918,O
studies,3918,O
providing,3918,O
detailed,3918,O
neuroimaging,3918,O
data,3918,O
.,3918,O
Patients,3919,O
with,3919,O
cerebrovascular,3919,B-Disease
accidents,3919,I-Disease
were,3919,O
excluded,3919,O
.,3919,O
RESULTS,3920,O
:,3920,O
We,3920,O
identified,3920,O
27,3920,O
reports,3920,O
of,3920,O
toxic,3920,O
leukoencephalopathy,3920,B-Disease
in,3920,O
patients,3920,O
treated,3920,O
with,3920,O
methotrexate,3920,B-Chemical
(,3920,O
intrathecal,3920,O
",",3920,O
systemic,3920,O
),3920,O
",",3920,O
5-fluorouracil,3920,B-Chemical
and,3920,O
its,3920,O
derivative,3920,O
carmofur,3920,B-Chemical
",",3920,O
and,3920,O
capecitabine,3920,B-Chemical
.,3920,O
Diffusion,3921,O
weighted,3921,O
imaging,3921,O
(,3921,O
DWI,3921,O
),3921,O
of,3921,O
all,3921,O
patients,3921,O
revealed,3921,O
well,3921,O
demarcated,3921,O
hyperintense,3921,O
lesions,3921,B-Disease
within,3921,I-Disease
the,3921,I-Disease
subcortical,3921,I-Disease
white,3921,I-Disease
matter,3921,I-Disease
of,3921,O
the,3921,O
cerebral,3921,O
hemispheres,3921,O
and,3921,O
the,3921,O
corpus,3921,O
callosum,3921,O
",",3921,O
corresponding,3921,O
to,3921,O
areas,3921,O
of,3921,O
decreased,3921,O
proton,3921,O
diffusion,3921,O
on,3921,O
apparent,3921,O
diffusion,3921,O
coefficient,3921,O
(,3921,O
ADC,3921,O
),3921,O
maps,3921,O
(,3921,O
available,3921,O
in,3921,O
21/27,3921,O
patients,3921,O
),3921,O
.,3921,O
Lesions,3922,O
exceeded,3922,O
the,3922,O
confines,3922,O
of,3922,O
adjacent,3922,O
vascular,3922,O
territories,3922,O
.,3922,O
Complete,3923,O
resolution,3923,O
of,3923,O
symptoms,3923,O
within,3923,O
1-4,3923,O
days,3923,O
was,3923,O
accompanied,3923,O
by,3923,O
normalisation,3923,O
of,3923,O
ADC,3923,O
abnormalities,3923,O
.,3923,O
However,3924,O
",",3924,O
fluid,3924,O
attenuated,3924,O
inversion,3924,O
recovery,3924,O
(,3924,O
FLAIR,3924,O
),3924,O
sequences,3924,O
frequently,3924,O
revealed,3924,O
persistent,3924,O
white,3924,B-Disease
matter,3924,I-Disease
abnormalities,3924,I-Disease
.,3924,O
CONCLUSIONS,3925,O
:,3925,O
Several,3925,O
pathophysiological,3925,O
models,3925,O
of,3925,O
delayed,3925,O
leukoencephalopathy,3925,B-Disease
after,3925,O
exposure,3925,O
to,3925,O
intrathecal,3925,O
or,3925,O
systemic,3925,O
chemotherapy,3925,O
have,3925,O
been,3925,O
proposed,3925,O
.,3925,O
DWI,3926,O
findings,3926,O
in,3926,O
this,3926,O
cohort,3926,O
are,3926,O
indicative,3926,O
of,3926,O
cytotoxic,3926,B-Disease
oedema,3926,I-Disease
within,3926,I-Disease
cerebral,3926,I-Disease
white,3926,I-Disease
matter,3926,I-Disease
and,3926,O
lend,3926,O
support,3926,O
to,3926,O
an,3926,O
at,3926,O
least,3926,O
partially,3926,O
reversible,3926,O
metabolic,3926,O
derangement,3926,O
as,3926,O
the,3926,O
basis,3926,O
for,3926,O
this,3926,O
syndrome,3926,O
.,3926,O
Prenatal,3927,O
exposure,3927,O
to,3927,O
fluoxetine,3927,B-Chemical
induces,3927,O
fetal,3927,O
pulmonary,3927,O
hypertension,3927,O
in,3927,O
the,3927,O
rat,3927,O
.,3927,O
RATIONALE,3928,O
:,3928,O
Fluoxetine,3928,B-Chemical
is,3928,O
a,3928,O
selective,3928,O
serotonin,3928,B-Chemical
reuptake,3928,O
inhibitor,3928,O
antidepressant,3928,O
widely,3928,O
used,3928,O
by,3928,O
pregnant,3928,O
women,3928,O
.,3928,O
Epidemiological,3929,O
data,3929,O
suggest,3929,O
that,3929,O
fluoxetine,3929,B-Chemical
exposure,3929,O
prenatally,3929,O
increases,3929,O
the,3929,O
prevalence,3929,O
of,3929,O
persistent,3929,O
pulmonary,3929,B-Disease
hypertension,3929,I-Disease
syndrome,3929,I-Disease
of,3929,O
the,3929,O
newborn,3929,O
.,3929,O
The,3930,O
mechanism,3930,O
responsible,3930,O
for,3930,O
this,3930,O
effect,3930,O
is,3930,O
unclear,3930,O
and,3930,O
paradoxical,3930,O
",",3930,O
considering,3930,O
the,3930,O
current,3930,O
evidence,3930,O
of,3930,O
a,3930,O
pulmonary,3930,B-Disease
hypertension,3930,I-Disease
protective,3930,O
fluoxetine,3930,B-Chemical
effect,3930,O
in,3930,O
adult,3930,O
rodents,3930,O
.,3930,O
OBJECTIVES,3931,O
:,3931,O
To,3931,O
evaluate,3931,O
the,3931,O
fluoxetine,3931,B-Chemical
effect,3931,O
on,3931,O
fetal,3931,O
rat,3931,O
pulmonary,3931,O
vascular,3931,O
smooth,3931,O
muscle,3931,O
mechanical,3931,O
properties,3931,O
and,3931,O
cell,3931,O
proliferation,3931,O
rate,3931,O
.,3931,O
METHODS,3932,O
:,3932,O
Pregnant,3932,O
rats,3932,O
were,3932,O
treated,3932,O
with,3932,O
fluoxetine,3932,B-Chemical
(,3932,O
10,3932,O
mg/kg,3932,O
),3932,O
from,3932,O
Day,3932,O
11,3932,O
through,3932,O
Day,3932,O
21,3932,O
of,3932,O
gestation,3932,O
.,3932,O
MEASUREMENTS,3933,O
AND,3933,O
MAIN,3933,O
RESULTS,3933,O
:,3933,O
Fetuses,3933,O
were,3933,O
delivered,3933,O
by,3933,O
cesarean,3933,O
section,3933,O
.,3933,O
As,3934,O
compared,3934,O
with,3934,O
controls,3934,O
",",3934,O
fluoxetine,3934,B-Chemical
exposure,3934,O
resulted,3934,O
in,3934,O
fetal,3934,O
pulmonary,3934,O
hypertension,3934,O
as,3934,O
evidenced,3934,O
by,3934,O
an,3934,O
increase,3934,O
in,3934,O
the,3934,O
weight,3934,O
ratio,3934,O
of,3934,O
the,3934,O
right,3934,O
ventricle,3934,O
to,3934,O
the,3934,O
left,3934,O
ventricle,3934,O
plus,3934,O
septum,3934,O
(,3934,O
P,3934,O
=,3934,O
0.02,3934,O
),3934,O
and,3934,O
by,3934,O
an,3934,O
increase,3934,O
in,3934,O
pulmonary,3934,O
arterial,3934,O
medial,3934,O
thickness,3934,O
(,3934,O
P,3934,O
<,3934,O
0.01,3934,O
),3934,O
.,3934,O
Postnatal,3935,O
mortality,3935,O
was,3935,O
increased,3935,O
among,3935,O
experimental,3935,O
animals,3935,O
",",3935,O
and,3935,O
arterial,3935,O
oxygen,3935,B-Chemical
saturation,3935,O
was,3935,O
96,3935,O
+/-,3935,O
1,3935,O
%,3935,O
in,3935,O
1-day-old,3935,O
control,3935,O
animals,3935,O
and,3935,O
significantly,3935,O
lower,3935,O
(,3935,O
P,3935,O
<,3935,O
0.01,3935,O
),3935,O
in,3935,O
fluoxetine-exposed,3935,B-Chemical
pups,3935,O
(,3935,O
79,3935,O
+/-,3935,O
2,3935,O
%,3935,O
),3935,O
.,3935,O
In,3936,O
vitro,3936,O
",",3936,O
fluoxetine,3936,B-Chemical
induced,3936,O
pulmonary,3936,O
arterial,3936,O
muscle,3936,O
contraction,3936,O
in,3936,O
fetal,3936,O
",",3936,O
but,3936,O
not,3936,O
adult,3936,O
",",3936,O
animals,3936,O
(,3936,O
P,3936,O
<,3936,O
0.01,3936,O
),3936,O
and,3936,O
reduced,3936,O
serotonin-induced,3936,B-Chemical
contraction,3936,O
at,3936,O
both,3936,O
ages,3936,O
(,3936,O
P,3936,O
<,3936,O
0.01,3936,O
),3936,O
.,3936,O
After,3937,O
in,3937,O
utero,3937,O
exposure,3937,O
to,3937,O
a,3937,O
low,3937,O
fluoxetine,3937,B-Chemical
concentration,3937,O
the,3937,O
pulmonary,3937,O
arterial,3937,O
smooth,3937,O
muscle,3937,O
cell,3937,O
proliferation,3937,O
rate,3937,O
was,3937,O
significantly,3937,O
increased,3937,O
in,3937,O
fetal,3937,O
",",3937,O
but,3937,O
not,3937,O
adult,3937,O
",",3937,O
cells,3937,O
(,3937,O
P,3937,O
<,3937,O
0.01,3937,O
),3937,O
.,3937,O
CONCLUSIONS,3938,O
:,3938,O
In,3938,O
contrast,3938,O
to,3938,O
the,3938,O
adult,3938,O
",",3938,O
fluoxetine,3938,B-Chemical
exposure,3938,O
in,3938,O
utero,3938,O
induces,3938,O
pulmonary,3938,B-Disease
hypertension,3938,I-Disease
in,3938,O
the,3938,O
fetal,3938,O
rat,3938,O
as,3938,O
a,3938,O
result,3938,O
of,3938,O
a,3938,O
developmentally,3938,O
regulated,3938,O
increase,3938,O
in,3938,O
pulmonary,3938,O
vascular,3938,O
smooth,3938,O
muscle,3938,O
proliferation,3938,O
.,3938,O
Disulfiram-induced,3939,B-Chemical
transient,3939,O
optic,3939,O
and,3939,O
peripheral,3939,O
neuropathy,3939,O
:,3939,O
a,3939,O
case,3939,O
report,3939,O
.,3939,O
AIM,3940,O
:,3940,O
To,3940,O
report,3940,O
a,3940,O
case,3940,O
of,3940,O
optic,3940,O
and,3940,O
peripheral,3940,O
neuropathy,3940,O
after,3940,O
chronic,3940,O
use,3940,O
of,3940,O
disulfiram,3940,B-Chemical
for,3940,O
alcohol,3940,B-Disease
dependence,3940,I-Disease
management,3940,O
.,3940,O
MATERIALS,3941,O
AND,3941,O
METHODS,3941,O
:,3941,O
A,3941,O
case,3941,O
report,3941,O
.,3941,O
RESULTS,3942,O
:,3942,O
A,3942,O
57-year-old,3942,O
male,3942,O
presented,3942,O
with,3942,O
gradual,3942,O
loss,3942,B-Disease
of,3942,I-Disease
vision,3942,I-Disease
in,3942,O
both,3942,O
eyes,3942,O
with,3942,O
intermittent,3942,O
headaches,3942,B-Disease
for,3942,O
2,3942,O
months,3942,O
.,3942,O
He,3943,O
also,3943,O
complained,3943,O
of,3943,O
paraesthesia,3943,B-Disease
with,3943,O
numbness,3943,B-Disease
in,3943,O
both,3943,O
feet,3943,O
.,3943,O
His,3944,O
vision,3944,O
was,3944,O
6/15,3944,O
and,3944,O
2/60,3944,O
in,3944,O
the,3944,O
right,3944,O
and,3944,O
left,3944,O
eyes,3944,O
",",3944,O
respectively,3944,O
.,3944,O
Fundoscopy,3945,O
revealed,3945,O
bilaterally,3945,O
swollen,3945,O
optic,3945,O
nerve,3945,O
heads,3945,O
.,3945,O
Visual,3946,O
field,3946,O
testing,3946,O
confirmed,3946,O
bilateral,3946,O
central-caecal,3946,O
scotomata,3946,B-Disease
.,3946,O
He,3947,O
had,3947,O
been,3947,O
taking,3947,O
disulfiram,3947,B-Chemical
for,3947,O
alcohol,3947,B-Disease
dependence,3947,I-Disease
for,3947,O
the,3947,O
preceding,3947,O
3,3947,O
years,3947,O
.,3947,O
Disulfiram,3948,B-Chemical
discontinuation,3948,O
lead,3948,O
to,3948,O
an,3948,O
immediate,3948,O
symptomatic,3948,O
improvement,3948,O
.,3948,O
CONCLUSION,3949,O
:,3949,O
Physicians,3949,O
initiating,3949,O
long-term,3949,O
disulfiram,3949,B-Chemical
therapy,3949,O
should,3949,O
be,3949,O
aware,3949,O
of,3949,O
these,3949,O
adverse,3949,O
effects,3949,O
.,3949,O
They,3950,O
should,3950,O
recommend,3950,O
annual,3950,O
ophthalmic,3950,O
reviews,3950,O
with,3950,O
visual,3950,O
field,3950,O
testing,3950,O
.,3950,O
Patients,3951,O
should,3951,O
be,3951,O
reassured,3951,O
with,3951,O
respect,3951,O
to,3951,O
the,3951,O
reversibility,3951,O
of,3951,O
these,3951,O
adverse,3951,O
effects,3951,O
.,3951,O
Intraocular,3952,O
pressure,3952,O
in,3952,O
patients,3952,O
with,3952,O
uveitis,3952,B-Disease
treated,3952,O
with,3952,O
fluocinolone,3952,B-Chemical
acetonide,3952,I-Chemical
implants,3952,O
.,3952,O
OBJECTIVE,3953,O
:,3953,O
To,3953,O
report,3953,O
the,3953,O
incidence,3953,O
and,3953,O
management,3953,O
of,3953,O
elevated,3953,B-Disease
intraocular,3953,I-Disease
pressure,3953,I-Disease
(,3953,O
IOP,3953,O
),3953,O
in,3953,O
patients,3953,O
with,3953,O
uveitis,3953,B-Disease
treated,3953,O
with,3953,O
the,3953,O
fluocinolone,3953,B-Chemical
acetonide,3953,I-Chemical
(,3953,O
FA,3953,B-Chemical
),3953,O
intravitreal,3953,O
implant,3953,O
.,3953,O
DESIGN,3954,O
:,3954,O
Pooled,3954,O
data,3954,O
from,3954,O
3,3954,O
multicenter,3954,O
",",3954,O
double-masked,3954,O
",",3954,O
randomized,3954,O
",",3954,O
controlled,3954,O
",",3954,O
phase,3954,O
2b/3,3954,O
clinical,3954,O
trials,3954,O
evaluating,3954,O
the,3954,O
safety,3954,O
and,3954,O
efficacy,3954,O
of,3954,O
the,3954,O
0.59-mg,3954,O
or,3954,O
2.1-mg,3954,O
FA,3954,B-Chemical
intravitreal,3954,O
implant,3954,O
or,3954,O
standard,3954,O
therapy,3954,O
were,3954,O
analyzed,3954,O
.,3954,O
RESULTS,3955,O
:,3955,O
During,3955,O
the,3955,O
3-year,3955,O
follow-up,3955,O
",",3955,O
71.0,3955,O
%,3955,O
of,3955,O
implanted,3955,O
eyes,3955,O
had,3955,O
an,3955,O
IOP,3955,O
increase,3955,O
of,3955,O
10,3955,O
mm,3955,O
Hg,3955,O
or,3955,O
more,3955,O
than,3955,O
baseline,3955,O
and,3955,O
55.1,3955,O
%,3955,O
",",3955,O
24.7,3955,O
%,3955,O
",",3955,O
and,3955,O
6.2,3955,O
%,3955,O
of,3955,O
eyes,3955,O
reached,3955,O
an,3955,O
IOP,3955,O
of,3955,O
30,3955,O
mm,3955,O
Hg,3955,O
or,3955,O
more,3955,O
",",3955,O
40,3955,O
mm,3955,O
Hg,3955,O
or,3955,O
more,3955,O
",",3955,O
and,3955,O
50,3955,O
mm,3955,O
Hg,3955,O
or,3955,O
more,3955,O
",",3955,O
respectively,3955,O
.,3955,O
Topical,3956,O
IOP-lowering,3956,O
medication,3956,O
was,3956,O
administered,3956,O
in,3956,O
74.8,3956,O
%,3956,O
of,3956,O
implanted,3956,O
eyes,3956,O
",",3956,O
and,3956,O
IOP-lowering,3956,O
surgeries,3956,O
",",3956,O
most,3956,O
of,3956,O
which,3956,O
were,3956,O
trabeculectomies,3956,O
(,3956,O
76.2,3956,O
%,3956,O
),3956,O
",",3956,O
were,3956,O
performed,3956,O
on,3956,O
36.6,3956,O
%,3956,O
of,3956,O
implanted,3956,O
eyes,3956,O
.,3956,O
Intraocular,3957,O
pressure-lowering,3957,O
surgeries,3957,O
were,3957,O
considered,3957,O
a,3957,O
success,3957,O
(,3957,O
postoperative,3957,O
IOP,3957,O
of,3957,O
6-21,3957,O
mm,3957,O
Hg,3957,O
with,3957,O
or,3957,O
without,3957,O
additional,3957,O
IOP-lowering,3957,O
medication,3957,O
),3957,O
in,3957,O
85.1,3957,O
%,3957,O
of,3957,O
eyes,3957,O
at,3957,O
1,3957,O
year,3957,O
.,3957,O
The,3958,O
rate,3958,O
of,3958,O
hypotony,3958,B-Disease
(,3958,O
IOP,3958,O
<,3958,O
/=,3958,O
5,3958,O
mm,3958,O
Hg,3958,O
),3958,O
following,3958,O
IOP-lowering,3958,O
surgery,3958,O
(,3958,O
42.5,3958,O
%,3958,O
),3958,O
was,3958,O
not,3958,O
different,3958,O
from,3958,O
that,3958,O
of,3958,O
implanted,3958,O
eyes,3958,O
not,3958,O
subjected,3958,O
to,3958,O
surgery,3958,O
(,3958,O
35.4,3958,O
%,3958,O
),3958,O
(,3958,O
P,3958,O
=,3958,O
.09,3958,O
),3958,O
.,3958,O
CONCLUSION,3959,O
:,3959,O
Elevated,3959,O
IOP,3959,O
is,3959,O
a,3959,O
significant,3959,O
complication,3959,O
with,3959,O
the,3959,O
FA,3959,O
intravitreal,3959,O
implant,3959,O
but,3959,O
may,3959,O
be,3959,O
controlled,3959,O
with,3959,O
medication,3959,O
and,3959,O
surgery,3959,O
.,3959,O
Myocardial,3960,O
Fas,3960,O
ligand,3960,O
expression,3960,O
increases,3960,O
susceptibility,3960,O
to,3960,O
AZT-induced,3960,B-Chemical
cardiomyopathy,3960,B-Disease
.,3960,O
BACKGROUND,3961,O
:,3961,O
Dilated,3961,B-Disease
cardiomyopathy,3961,I-Disease
(,3961,O
DCM,3961,B-Disease
),3961,O
and,3961,O
myocarditis,3961,B-Disease
occur,3961,O
in,3961,O
many,3961,O
HIV-infected,3961,B-Disease
individuals,3961,O
",",3961,O
resulting,3961,O
in,3961,O
symptomatic,3961,O
heart,3961,B-Disease
failure,3961,I-Disease
in,3961,O
up,3961,O
to,3961,O
5,3961,O
%,3961,O
of,3961,O
patients,3961,O
.,3961,O
Highly,3962,O
active,3962,O
antiretroviral,3962,O
therapy,3962,O
(,3962,O
HAART,3962,O
),3962,O
has,3962,O
significantly,3962,O
reduced,3962,O
morbidity,3962,O
and,3962,O
mortality,3962,O
of,3962,O
acquired,3962,B-Disease
immunodeficiency,3962,I-Disease
syndrome,3962,I-Disease
(,3962,O
AIDS,3962,B-Disease
),3962,O
",",3962,O
but,3962,O
has,3962,O
resulted,3962,O
in,3962,O
an,3962,O
increase,3962,O
in,3962,O
cardiac,3962,B-Disease
and,3962,I-Disease
skeletal,3962,I-Disease
myopathies,3962,I-Disease
.,3962,O
METHODS,3963,O
AND,3963,O
RESULTS,3963,O
:,3963,O
In,3963,O
order,3963,O
to,3963,O
investigate,3963,O
whether,3963,O
the,3963,O
HAART,3963,O
component,3963,O
zidovudine,3963,B-Chemical
(,3963,O
"3'-azido-2',3'-deoxythymidine",3963,B-Chemical
;,3963,O
AZT,3963,B-Chemical
),3963,O
triggers,3963,O
the,3963,O
Fas-dependent,3963,O
cell-death,3963,O
pathway,3963,O
and,3963,O
cause,3963,O
cytoskeletal,3963,O
disruption,3963,O
in,3963,O
a,3963,O
murine,3963,O
model,3963,O
of,3963,O
DCM,3963,B-Disease
",",3963,O
8-week-old,3963,O
transgenic,3963,O
(,3963,O
expressing,3963,O
Fas,3963,O
ligand,3963,O
in,3963,O
the,3963,O
myocardium,3963,O
:,3963,O
FasL,3963,O
Tg,3963,O
),3963,O
and,3963,O
non-transgenic,3963,O
(,3963,O
NTg,3963,O
),3963,O
mice,3963,O
received,3963,O
water,3963,O
ad,3963,O
libitum,3963,O
containing,3963,O
different,3963,O
concentrations,3963,O
of,3963,O
AZT,3963,B-Chemical
(,3963,O
0,3963,O
",",3963,O
0.07,3963,O
",",3963,O
0.2,3963,O
",",3963,O
and,3963,O
0.7,3963,O
mg/ml,3963,O
),3963,O
.,3963,O
After,3964,O
6,3964,O
weeks,3964,O
",",3964,O
cardiac,3964,O
function,3964,O
was,3964,O
assessed,3964,O
by,3964,O
echocardiography,3964,O
and,3964,O
morphology,3964,O
was,3964,O
assessed,3964,O
by,3964,O
histopathologic,3964,O
and,3964,O
immunohistochemical,3964,O
methods,3964,O
.,3964,O
NTg,3965,O
and,3965,O
untreated,3965,O
FasL,3965,O
Tg,3965,O
mice,3965,O
showed,3965,O
little,3965,O
or,3965,O
no,3965,O
change,3965,O
in,3965,O
cardiac,3965,O
structure,3965,O
or,3965,O
function,3965,O
.,3965,O
In,3966,O
contrast,3966,O
",",3966,O
AZT-treated,3966,B-Chemical
FasL,3966,O
Tg,3966,O
mice,3966,O
developed,3966,O
cardiac,3966,B-Disease
dilation,3966,I-Disease
and,3966,O
depressed,3966,O
cardiac,3966,O
function,3966,O
in,3966,O
a,3966,O
dose-dependent,3966,O
manner,3966,O
",",3966,O
with,3966,O
concomitant,3966,O
inflammatory,3966,O
infiltration,3966,O
of,3966,O
both,3966,O
ventricles,3966,O
.,3966,O
These,3967,O
changes,3967,O
were,3967,O
associated,3967,O
with,3967,O
an,3967,O
increased,3967,O
sarcolemmal,3967,O
expression,3967,O
of,3967,O
Fas,3967,O
and,3967,O
FasL,3967,O
",",3967,O
as,3967,O
well,3967,O
as,3967,O
increased,3967,O
activation,3967,O
of,3967,O
caspase,3967,O
3,3967,O
",",3967,O
translocation,3967,O
of,3967,O
calpain,3967,O
1,3967,O
to,3967,O
the,3967,O
sarcolemma,3967,O
and,3967,O
sarcomere,3967,O
",",3967,O
and,3967,O
increased,3967,O
numbers,3967,O
of,3967,O
cells,3967,O
undergoing,3967,O
apoptosis,3967,O
.,3967,O
These,3968,O
were,3968,O
associated,3968,O
with,3968,O
changes,3968,O
in,3968,O
dystrophin,3968,O
and,3968,O
cardiac,3968,O
troponin,3968,O
I,3968,O
localization,3968,O
",",3968,O
as,3968,O
well,3968,O
as,3968,O
loss,3968,O
of,3968,O
sarcolemmal,3968,O
integrity,3968,O
.,3968,O
CONCLUSIONS,3969,O
:,3969,O
The,3969,O
expression,3969,O
of,3969,O
Fas,3969,O
ligand,3969,O
in,3969,O
the,3969,O
myocardium,3969,O
",",3969,O
as,3969,O
identified,3969,O
in,3969,O
HIV-positive,3969,O
patients,3969,O
",",3969,O
might,3969,O
increase,3969,O
the,3969,O
susceptibility,3969,O
to,3969,O
HAART-induced,3969,O
cardiomyopathy,3969,B-Disease
due,3969,O
to,3969,O
activation,3969,O
of,3969,O
apoptotic,3969,O
pathways,3969,O
",",3969,O
resulting,3969,O
in,3969,O
cardiac,3969,O
dilation,3969,O
and,3969,O
dysfunction,3969,O
.,3969,O
Gastrointestinal,3970,O
tolerability,3970,O
of,3970,O
etoricoxib,3970,B-Chemical
in,3970,O
rheumatoid,3970,B-Disease
arthritis,3970,I-Disease
patients,3970,O
:,3970,O
results,3970,O
of,3970,O
the,3970,O
etoricoxib,3970,B-Chemical
vs,3970,O
diclofenac,3970,B-Chemical
sodium,3970,I-Chemical
gastrointestinal,3970,O
tolerability,3970,O
and,3970,O
effectiveness,3970,O
trial,3970,O
(,3970,O
EDGE-II,3970,O
),3970,O
.,3970,O
OBJECTIVE,3971,O
:,3971,O
A,3971,O
randomised,3971,O
",",3971,O
double-blind,3971,O
study,3971,O
to,3971,O
compare,3971,O
the,3971,O
gastrointestinal,3971,O
(,3971,O
GI,3971,O
),3971,O
tolerability,3971,O
",",3971,O
safety,3971,O
and,3971,O
efficacy,3971,O
of,3971,O
etoricoxib,3971,B-Chemical
and,3971,O
diclofenac,3971,B-Chemical
in,3971,O
patients,3971,O
with,3971,O
rheumatoid,3971,B-Disease
arthritis,3971,I-Disease
(,3971,O
RA,3971,B-Disease
),3971,O
.,3971,O
PATIENTS,3972,O
AND,3972,O
METHODS,3972,O
:,3972,O
A,3972,O
total,3972,O
of,3972,O
4086,3972,O
patients,3972,O
(,3972,O
mean,3972,O
age,3972,O
60.8,3972,O
years,3972,O
),3972,O
diagnosed,3972,O
with,3972,O
RA,3972,B-Disease
were,3972,O
enrolled,3972,O
and,3972,O
received,3972,O
etoricoxib,3972,B-Chemical
90,3972,O
mg,3972,O
daily,3972,O
(,3972,O
n,3972,O
=,3972,O
2032,3972,O
),3972,O
or,3972,O
diclofenac,3972,B-Chemical
75,3972,O
mg,3972,O
twice,3972,O
daily,3972,O
(,3972,O
n,3972,O
=,3972,O
2054,3972,O
),3972,O
.,3972,O
Use,3973,O
of,3973,O
gastroprotective,3973,O
agents,3973,O
and,3973,O
low-dose,3973,O
aspirin,3973,B-Chemical
was,3973,O
allowed,3973,O
.,3973,O
The,3974,O
prespecified,3974,O
primary,3974,O
end,3974,O
point,3974,O
consisted,3974,O
of,3974,O
the,3974,O
cumulative,3974,O
rate,3974,O
of,3974,O
patient,3974,O
discontinuations,3974,O
due,3974,O
to,3974,O
clinical,3974,O
and,3974,O
laboratory,3974,O
GI,3974,O
adverse,3974,O
experiences,3974,O
(,3974,O
AEs,3974,O
),3974,O
.,3974,O
General,3975,O
safety,3975,O
was,3975,O
also,3975,O
assessed,3975,O
",",3975,O
including,3975,O
adjudicated,3975,O
thrombotic,3975,B-Disease
cardiovascular,3975,I-Disease
event,3975,O
data,3975,O
.,3975,O
Efficacy,3976,O
was,3976,O
evaluated,3976,O
using,3976,O
the,3976,O
Patient,3976,O
Global,3976,O
Assessment,3976,O
of,3976,O
Disease,3976,O
Status,3976,O
(,3976,O
PGADS,3976,O
;,3976,O
0-4,3976,O
point,3976,O
scale,3976,O
),3976,O
.,3976,O
RESULTS,3977,O
:,3977,O
Mean,3977,O
(,3977,O
SD,3977,O
;,3977,O
maximum,3977,O
),3977,O
duration,3977,O
of,3977,O
treatment,3977,O
was,3977,O
19.3,3977,O
(,3977,O
10.3,3977,O
;,3977,O
32.9,3977,O
),3977,O
and,3977,O
19.1,3977,O
(,3977,O
10.4,3977,O
;,3977,O
33.1,3977,O
),3977,O
months,3977,O
in,3977,O
the,3977,O
etoricoxib,3977,B-Chemical
and,3977,O
diclofenac,3977,B-Chemical
groups,3977,O
",",3977,O
respectively,3977,O
.,3977,O
The,3978,O
cumulative,3978,O
discontinuation,3978,O
rate,3978,O
due,3978,O
to,3978,O
GI,3978,B-Disease
AEs,3978,I-Disease
was,3978,O
significantly,3978,O
lower,3978,O
with,3978,O
etoricoxib,3978,B-Chemical
than,3978,O
diclofenac,3978,B-Chemical
(,3978,O
5.2,3978,O
vs,3978,O
8.5,3978,O
events,3978,O
per,3978,O
100,3978,O
patient-years,3978,O
",",3978,O
respectively,3978,O
;,3978,O
hazard,3978,O
ratio,3978,O
0.62,3978,O
(,3978,O
95,3978,O
%,3978,O
CI,3978,O
:,3978,O
0.47,3978,O
",",3978,O
0.81,3978,O
;,3978,O
p,3978,O
<,3978,O
or=0.001,3978,O
),3978,O
),3978,O
.,3978,O
The,3979,O
incidence,3979,O
of,3979,O
discontinuations,3979,O
for,3979,O
hypertension-related,3979,B-Disease
and,3979,O
oedema-related,3979,B-Disease
AEs,3979,O
were,3979,O
significantly,3979,O
higher,3979,O
with,3979,O
etoricoxib,3979,B-Chemical
(,3979,O
2.5,3979,O
%,3979,O
and,3979,O
1.1,3979,O
%,3979,O
respectively,3979,O
),3979,O
compared,3979,O
with,3979,O
diclofenac,3979,B-Chemical
(,3979,O
1.5,3979,O
%,3979,O
and,3979,O
0.4,3979,O
%,3979,O
respectively,3979,O
;,3979,O
p,3979,O
<,3979,O
0.001,3979,O
for,3979,O
hypertension,3979,B-Disease
and,3979,O
p,3979,O
<,3979,O
0.01,3979,O
for,3979,O
oedema,3979,B-Disease
),3979,O
.,3979,O
Etoricoxib,3980,B-Chemical
and,3980,O
diclofenac,3980,B-Chemical
treatment,3980,O
resulted,3980,O
in,3980,O
similar,3980,O
efficacy,3980,O
(,3980,O
PGADS,3980,O
mean,3980,O
changes,3980,O
from,3980,O
baseline,3980,O
-0.62,3980,O
vs,3980,O
-0.58,3980,O
",",3980,O
respectively,3980,O
),3980,O
.,3980,O
CONCLUSIONS,3981,O
:,3981,O
Etoricoxib,3981,B-Chemical
90,3981,O
mg,3981,O
demonstrated,3981,O
a,3981,O
significantly,3981,O
lower,3981,O
risk,3981,O
for,3981,O
discontinuing,3981,O
treatment,3981,O
due,3981,O
to,3981,O
GI,3981,B-Disease
AEs,3981,I-Disease
compared,3981,O
with,3981,O
diclofenac,3981,B-Chemical
150,3981,O
mg.,3981,O
Discontinuations,3981,O
from,3981,O
renovascular,3981,O
AEs,3981,O
",",3981,O
although,3981,O
less,3981,O
common,3981,O
than,3981,O
discontinuations,3981,O
from,3981,O
GI,3981,B-Disease
AEs,3981,I-Disease
",",3981,O
were,3981,O
significantly,3981,O
higher,3981,O
with,3981,O
etoricoxib,3981,B-Chemical
.,3981,O
Anxiogenic,3982,O
potential,3982,O
of,3982,O
ciprofloxacin,3982,B-Chemical
and,3982,O
norfloxacin,3982,B-Chemical
in,3982,O
rats,3982,O
.,3982,O
INTRODUCTION,3983,O
:,3983,O
The,3983,O
possible,3983,O
anxiogenic,3983,O
effects,3983,O
of,3983,O
fluoroquinolones,3983,B-Chemical
",",3983,O
namely,3983,O
ciprofloxacin,3983,B-Chemical
and,3983,O
norfloxacin,3983,B-Chemical
",",3983,O
were,3983,O
investigated,3983,O
in,3983,O
adult,3983,O
Charles,3983,O
Foster,3983,O
albino,3983,O
rats,3983,O
of,3983,O
either,3983,O
sex,3983,O
",",3983,O
weighing,3983,O
150-200,3983,O
g.,3983,O
METHODS,3983,O
:,3983,O
The,3983,O
drugs,3983,O
were,3983,O
given,3983,O
orally,3983,O
",",3983,O
in,3983,O
doses,3983,O
of,3983,O
50,3983,O
mg/kg,3983,O
for,3983,O
five,3983,O
consecutive,3983,O
days,3983,O
and,3983,O
the,3983,O
experiments,3983,O
were,3983,O
performed,3983,O
on,3983,O
the,3983,O
fifth,3983,O
day,3983,O
.,3983,O
The,3984,O
tests,3984,O
included,3984,O
open-field,3984,O
exploratory,3984,O
behaviour,3984,O
",",3984,O
elevated,3984,O
plus,3984,O
maze,3984,O
and,3984,O
elevated,3984,O
zero,3984,O
maze,3984,O
",",3984,O
social,3984,O
interaction,3984,O
and,3984,O
novelty-suppressed,3984,O
feeding,3984,O
latency,3984,O
behaviour,3984,O
.,3984,O
RESULTS,3985,O
:,3985,O
The,3985,O
results,3985,O
indicate,3985,O
that,3985,O
ciprofloxacin-,3985,B-Chemical
and,3985,O
norfloxacin-treated,3985,B-Chemical
rats,3985,O
showed,3985,O
anxious,3985,B-Disease
behaviour,3985,I-Disease
in,3985,O
comparison,3985,O
to,3985,O
control,3985,O
rats,3985,O
in,3985,O
all,3985,O
the,3985,O
parameters,3985,O
studied,3985,O
.,3985,O
However,3986,O
",",3986,O
ciprofloxacin-,3986,B-Chemical
and,3986,O
norfloxacin-treated,3986,B-Chemical
rats,3986,O
did,3986,O
not,3986,O
differ,3986,O
significantly,3986,O
from,3986,O
each,3986,O
other,3986,O
in,3986,O
various,3986,O
behavioural,3986,O
parameters,3986,O
.,3986,O
CONCLUSION,3987,O
:,3987,O
The,3987,O
present,3987,O
experimental,3987,O
findings,3987,O
substantiate,3987,O
the,3987,O
clinically,3987,O
observed,3987,O
anxiogenic,3987,O
potential,3987,O
of,3987,O
ciprofloxacin,3987,B-Chemical
and,3987,O
norfloxacin,3987,B-Chemical
.,3987,O
Reduction,3988,O
of,3988,O
pain,3988,B-Disease
during,3988,O
induction,3988,O
with,3988,O
target-controlled,3988,O
propofol,3988,B-Chemical
and,3988,O
remifentanil,3988,B-Chemical
.,3988,O
BACKGROUND,3989,O
:,3989,O
Pain,3989,B-Disease
on,3989,O
injection,3989,O
of,3989,O
propofol,3989,B-Chemical
is,3989,O
unpleasant,3989,O
.,3989,O
We,3990,O
hypothesized,3990,O
that,3990,O
propofol,3990,B-Chemical
infusion,3990,O
pain,3990,B-Disease
might,3990,O
be,3990,O
prevented,3990,O
by,3990,O
infusing,3990,O
remifentanil,3990,B-Chemical
before,3990,O
starting,3990,O
the,3990,O
propofol,3990,B-Chemical
infusion,3990,O
in,3990,O
a,3990,O
clinical,3990,O
setting,3990,O
where,3990,O
target-controlled,3990,O
infusions,3990,O
(,3990,O
TCI,3990,O
),3990,O
of,3990,O
both,3990,O
drugs,3990,O
were,3990,O
used,3990,O
.,3990,O
A,3991,O
prospective,3991,O
",",3991,O
randomized,3991,O
",",3991,O
double-blind,3991,O
",",3991,O
placebo-controlled,3991,O
trial,3991,O
was,3991,O
performed,3991,O
to,3991,O
determine,3991,O
the,3991,O
effect-site,3991,O
concentration,3991,O
(,3991,O
Ce,3991,O
),3991,O
of,3991,O
remifentanil,3991,B-Chemical
to,3991,O
prevent,3991,O
the,3991,O
pain,3991,B-Disease
without,3991,O
producing,3991,O
complications,3991,O
.,3991,O
METHODS,3992,O
:,3992,O
A,3992,O
total,3992,O
of,3992,O
128,3992,O
patients,3992,O
undergoing,3992,O
general,3992,O
surgery,3992,O
were,3992,O
randomly,3992,O
allocated,3992,O
to,3992,O
receive,3992,O
normal,3992,O
saline,3992,O
(,3992,O
control,3992,O
),3992,O
or,3992,O
remifentanil,3992,B-Chemical
to,3992,O
a,3992,O
target,3992,O
Ce,3992,O
of,3992,O
2,3992,O
ng,3992,O
ml,3992,O
(,3992,O
-1,3992,O
),3992,O
(,3992,O
R2,3992,O
),3992,O
",",3992,O
4,3992,O
ng,3992,O
ml,3992,O
(,3992,O
-1,3992,O
),3992,O
(,3992,O
R4,3992,O
),3992,O
",",3992,O
or,3992,O
6,3992,O
ng,3992,O
ml,3992,O
(,3992,O
-1,3992,O
),3992,O
(,3992,O
R6,3992,O
),3992,O
administered,3992,O
via,3992,O
TCI,3992,O
.,3992,O
After,3993,O
the,3993,O
target,3993,O
Ce,3993,O
was,3993,O
achieved,3993,O
",",3993,O
the,3993,O
infusion,3993,O
of,3993,O
propofol,3993,B-Chemical
was,3993,O
started,3993,O
.,3993,O
Remifentanil-related,3994,B-Chemical
complications,3994,O
were,3994,O
assessed,3994,O
during,3994,O
the,3994,O
remifentanil,3994,B-Chemical
infusion,3994,O
",",3994,O
and,3994,O
pain,3994,B-Disease
caused,3994,O
by,3994,O
propofol,3994,B-Chemical
was,3994,O
evaluated,3994,O
using,3994,O
a,3994,O
four-point,3994,O
scale,3994,O
during,3994,O
the,3994,O
propofol,3994,B-Chemical
infusion,3994,O
.,3994,O
RESULTS,3995,O
:,3995,O
The,3995,O
incidence,3995,O
of,3995,O
pain,3995,B-Disease
was,3995,O
significantly,3995,O
lower,3995,O
in,3995,O
Groups,3995,O
R4,3995,O
and,3995,O
R6,3995,O
than,3995,O
in,3995,O
the,3995,O
control,3995,O
and,3995,O
R2,3995,O
groups,3995,O
(,3995,O
12/32,3995,O
and,3995,O
6/31,3995,O
vs,3995,O
26/31,3995,O
and,3995,O
25/32,3995,O
",",3995,O
respectively,3995,O
",",3995,O
P,3995,O
<,3995,O
0.001,3995,O
),3995,O
.,3995,O
Pain,3996,B-Disease
was,3996,O
less,3996,O
severe,3996,O
in,3996,O
Groups,3996,O
R4,3996,O
and,3996,O
R6,3996,O
than,3996,O
in,3996,O
the,3996,O
control,3996,O
and,3996,O
R2,3996,O
groups,3996,O
(,3996,O
P,3996,O
<,3996,O
0.001,3996,O
),3996,O
.,3996,O
However,3997,O
",",3997,O
both,3997,O
incidence,3997,O
and,3997,O
severity,3997,O
of,3997,O
pain,3997,B-Disease
were,3997,O
not,3997,O
different,3997,O
between,3997,O
Groups,3997,O
R4,3997,O
and,3997,O
R6,3997,O
.,3997,O
No,3998,O
significant,3998,O
complications,3998,O
were,3998,O
observed,3998,O
during,3998,O
the,3998,O
study,3998,O
.,3998,O
CONCLUSIONS,3999,O
:,3999,O
During,3999,O
induction,3999,O
of,3999,O
anaesthesia,3999,O
with,3999,O
TCI,3999,O
of,3999,O
propofol,3999,B-Chemical
and,3999,O
remifentanil,3999,B-Chemical
",",3999,O
a,3999,O
significant,3999,O
reduction,3999,O
in,3999,O
propofol,3999,B-Chemical
infusion,3999,O
pain,3999,B-Disease
was,3999,O
achieved,3999,O
without,3999,O
significant,3999,O
complications,3999,O
by,3999,O
prior,3999,O
administration,3999,O
of,3999,O
remifentanil,3999,B-Chemical
at,3999,O
a,3999,O
target,3999,O
Ce,3999,O
of,3999,O
4,3999,O
ng,3999,O
ml,3999,O
(,3999,O
-1,3999,O
),3999,O
.,3999,O
Dexmedetomidine,4000,B-Chemical
and,4000,O
cardiac,4000,O
protection,4000,O
for,4000,O
non-cardiac,4000,O
surgery,4000,O
:,4000,O
a,4000,O
meta-analysis,4000,O
of,4000,O
randomised,4000,O
controlled,4000,O
trials,4000,O
.,4000,O
We,4001,O
conducted,4001,O
a,4001,O
systematic,4001,O
review,4001,O
of,4001,O
the,4001,O
effects,4001,O
of,4001,O
dexmedetomidine,4001,B-Chemical
on,4001,O
cardiac,4001,O
outcomes,4001,O
following,4001,O
non-cardiac,4001,O
surgery,4001,O
.,4001,O
We,4002,O
included,4002,O
prospective,4002,O
",",4002,O
randomised,4002,O
peri-operative,4002,O
studies,4002,O
of,4002,O
dexmedetomidine,4002,B-Chemical
that,4002,O
reported,4002,O
mortality,4002,O
",",4002,O
cardiac,4002,O
morbidity,4002,O
or,4002,O
adverse,4002,O
drug,4002,O
events,4002,O
.,4002,O
A,4003,O
PubMed,4003,O
Central,4003,O
and,4003,O
EMBASE,4003,O
search,4003,O
was,4003,O
conducted,4003,O
up,4003,O
to,4003,O
July,4003,O
2007,4003,O
.,4003,O
The,4004,O
reference,4004,O
lists,4004,O
of,4004,O
identified,4004,O
papers,4004,O
were,4004,O
examined,4004,O
for,4004,O
further,4004,O
trials,4004,O
.,4004,O
Of,4005,O
425,4005,O
studies,4005,O
identified,4005,O
",",4005,O
20,4005,O
were,4005,O
included,4005,O
in,4005,O
the,4005,O
meta-analysis,4005,O
(,4005,O
840,4005,O
patients,4005,O
),4005,O
.,4005,O
Dexmedetomidine,4006,B-Chemical
was,4006,O
associated,4006,O
with,4006,O
a,4006,O
trend,4006,O
towards,4006,O
improved,4006,O
cardiac,4006,O
outcomes,4006,O
;,4006,O
all-cause,4006,O
mortality,4006,O
(,4006,O
OR,4006,O
0.27,4006,O
",",4006,O
95,4006,O
%,4006,O
CI,4006,O
0.01-7.13,4006,O
",",4006,O
p,4006,O
=,4006,O
0.44,4006,O
),4006,O
",",4006,O
non-fatal,4006,O
myocardial,4006,B-Disease
infarction,4006,I-Disease
(,4006,O
OR,4006,O
0.26,4006,O
",",4006,O
95,4006,O
%,4006,O
CI,4006,O
0.04-1.60,4006,O
",",4006,O
p,4006,O
=,4006,O
0.14,4006,O
),4006,O
",",4006,O
and,4006,O
myocardial,4006,B-Disease
ischaemia,4006,I-Disease
(,4006,O
OR,4006,O
0.65,4006,O
",",4006,O
95,4006,O
%,4006,O
CI,4006,O
0.26-1.63,4006,O
",",4006,O
p,4006,O
=,4006,O
0.36,4006,O
),4006,O
.,4006,O
Peri-operative,4007,O
hypotension,4007,B-Disease
(,4007,O
26,4007,O
%,4007,O
",",4007,O
OR,4007,O
3.80,4007,O
",",4007,O
95,4007,O
%,4007,O
CI,4007,O
1.91-7.54,4007,O
",",4007,O
p,4007,O
=,4007,O
0.0001,4007,O
),4007,O
and,4007,O
bradycardia,4007,B-Disease
(,4007,O
17,4007,O
%,4007,O
",",4007,O
OR,4007,O
5.45,4007,O
",",4007,O
95,4007,O
%,4007,O
CI,4007,O
2.98-9.95,4007,O
",",4007,O
p,4007,O
<,4007,O
0.00001,4007,O
),4007,O
were,4007,O
significantly,4007,O
increased,4007,O
.,4007,O
An,4008,O
anticholinergic,4008,O
did,4008,O
not,4008,O
reduce,4008,O
the,4008,O
incidence,4008,O
of,4008,O
bradycardia,4008,B-Disease
(,4008,O
p,4008,O
=,4008,O
0.43,4008,O
),4008,O
.,4008,O
A,4009,O
randomised,4009,O
placebo-controlled,4009,O
trial,4009,O
of,4009,O
dexmedetomidine,4009,B-Chemical
is,4009,O
warranted,4009,O
.,4009,O
Myocardial,4010,B-Disease
infarction,4010,I-Disease
in,4010,O
pregnancy,4010,O
associated,4010,O
with,4010,O
clomiphene,4010,B-Chemical
citrate,4010,I-Chemical
for,4010,O
ovulation,4010,O
induction,4010,O
:,4010,O
a,4010,O
case,4010,O
report,4010,O
.,4010,O
BACKGROUND,4011,O
:,4011,O
Clomiphene,4011,B-Chemical
citrate,4011,I-Chemical
(,4011,O
CC,4011,B-Chemical
),4011,O
is,4011,O
commonly,4011,O
prescribed,4011,O
for,4011,O
ovulation,4011,O
induction,4011,O
.,4011,O
It,4012,O
is,4012,O
considered,4012,O
safe,4012,O
",",4012,O
with,4012,O
minimal,4012,O
side,4012,O
effects,4012,O
.,4012,O
Thromboembolism,4013,B-Disease
is,4013,O
a,4013,O
rare,4013,O
but,4013,O
life-threatening,4013,O
complication,4013,O
that,4013,O
has,4013,O
been,4013,O
reported,4013,O
after,4013,O
ovulation,4013,O
induction,4013,O
with,4013,O
CC,4013,B-Chemical
.,4013,O
Spontaneous,4014,O
coronary,4014,B-Disease
thrombosis,4014,I-Disease
or,4014,O
thromboembolism,4014,B-Disease
with,4014,O
subsequent,4014,O
clot,4014,O
lysis,4014,O
has,4014,O
been,4014,O
suggested,4014,O
as,4014,O
one,4014,O
of,4014,O
the,4014,O
most,4014,O
common,4014,O
causes,4014,O
of,4014,O
myocardial,4014,B-Disease
infarction,4014,I-Disease
(,4014,O
MI,4014,B-Disease
),4014,O
during,4014,O
pregnancy,4014,O
",",4014,O
with,4014,O
a,4014,O
subsequently,4014,O
normal,4014,O
coronary,4014,O
angiogram,4014,O
.,4014,O
CASE,4015,O
:,4015,O
A,4015,O
33-year-old,4015,O
woman,4015,O
with,4015,O
a,4015,O
5-week,4015,O
gestation,4015,O
had,4015,O
recently,4015,O
received,4015,O
CC,4015,B-Chemical
for,4015,O
ovulation,4015,O
induction,4015,O
and,4015,O
presented,4015,O
with,4015,O
chest,4015,B-Disease
pain,4015,I-Disease
.,4015,O
An,4016,O
electrocardiogram,4016,O
showed,4016,O
a,4016,O
lateral,4016,O
and,4016,O
anterior,4016,O
wall,4016,O
myocardial,4016,B-Disease
infarction,4016,I-Disease
.,4016,O
Cardiac,4017,O
enzymes,4017,O
showed,4017,O
a,4017,O
peak,4017,O
rise,4017,O
in,4017,O
troponin,4017,O
I,4017,O
to,4017,O
9.10,4017,O
ng/mL,4017,O
.,4017,O
An,4018,O
initial,4018,O
exercise,4018,O
stress,4018,O
test,4018,O
was,4018,O
normal,4018,O
.,4018,O
At,4019,O
the,4019,O
time,4019,O
of,4019,O
admission,4019,O
",",4019,O
the,4019,O
patient,4019,O
was,4019,O
at,4019,O
high,4019,O
risk,4019,O
of,4019,O
radiation,4019,B-Disease
injury,4019,I-Disease
to,4019,O
the,4019,O
fetus,4019,O
",",4019,O
so,4019,O
a,4019,O
coronary,4019,O
angiogram,4019,O
was,4019,O
postponed,4019,O
until,4019,O
the,4019,O
second,4019,O
trimester,4019,O
.,4019,O
It,4020,O
showed,4020,O
normal,4020,O
coronary,4020,O
vessels,4020,O
.,4020,O
CONCLUSION,4021,O
:,4021,O
This,4021,O
appears,4021,O
to,4021,O
be,4021,O
the,4021,O
first,4021,O
reported,4021,O
case,4021,O
documenting,4021,O
a,4021,O
possible,4021,O
association,4021,O
between,4021,O
CC,4021,B-Chemical
and,4021,O
myocardial,4021,B-Disease
infarction,4021,I-Disease
.,4021,O
Thrombosis,4022,B-Disease
might,4022,O
be,4022,O
a,4022,O
rare,4022,O
but,4022,O
hazardous,4022,O
complication,4022,O
of,4022,O
CC,4022,B-Chemical
.,4022,O
Given,4023,O
this,4023,O
life-threatening,4023,O
complication,4023,O
",",4023,O
appropriate,4023,O
prophylactic,4023,O
measures,4023,O
should,4023,O
be,4023,O
used,4023,O
in,4023,O
high-risk,4023,O
woman,4023,O
undergoing,4023,O
ovarian,4023,O
stimulation,4023,O
.,4023,O
Reverse,4024,O
or,4024,O
inverted,4024,O
left,4024,B-Disease
ventricular,4024,I-Disease
apical,4024,I-Disease
ballooning,4024,I-Disease
syndrome,4024,I-Disease
(,4024,O
reverse,4024,O
Takotsubo,4024,B-Disease
cardiomyopathy,4024,I-Disease
),4024,O
in,4024,O
a,4024,O
young,4024,O
woman,4024,O
in,4024,O
the,4024,O
setting,4024,O
of,4024,O
amphetamine,4024,B-Chemical
use,4024,O
.,4024,O
Transient,4025,O
left,4025,B-Disease
ventricular,4025,I-Disease
apical,4025,I-Disease
ballooning,4025,I-Disease
syndrome,4025,I-Disease
was,4025,O
first,4025,O
described,4025,O
in,4025,O
Japan,4025,O
as,4025,O
``,4025,O
Takotsubo,4025,B-Disease
cardiomyopathy,4025,I-Disease
.,4025,O
'',4025,O
This,4026,O
syndrome,4026,O
has,4026,O
been,4026,O
identified,4026,O
in,4026,O
many,4026,O
other,4026,O
countries,4026,O
.,4026,O
Many,4027,O
variations,4027,O
of,4027,O
this,4027,O
syndrome,4027,O
have,4027,O
been,4027,O
recently,4027,O
described,4027,O
in,4027,O
the,4027,O
literature,4027,O
.,4027,O
One,4028,O
of,4028,O
the,4028,O
rarest,4028,O
is,4028,O
the,4028,O
reverse,4028,O
type,4028,O
of,4028,O
this,4028,O
syndrome,4028,O
",",4028,O
with,4028,O
hyperdynamic,4028,O
apex,4028,O
and,4028,O
complete,4028,O
akinesia,4028,B-Disease
of,4028,O
the,4028,O
base,4028,O
(,4028,O
as,4028,O
opposed,4028,O
to,4028,O
the,4028,O
classic,4028,O
apical,4028,B-Disease
ballooning,4028,I-Disease
),4028,O
.,4028,O
In,4029,O
this,4029,O
article,4029,O
",",4029,O
we,4029,O
report,4029,O
an,4029,O
interesting,4029,O
case,4029,O
of,4029,O
a,4029,O
young,4029,O
woman,4029,O
who,4029,O
presented,4029,O
with,4029,O
this,4029,O
rare,4029,O
type,4029,O
of,4029,O
reverse,4029,O
apical,4029,B-Disease
ballooning,4029,I-Disease
syndrome,4029,I-Disease
occurring,4029,O
after,4029,O
amphetamine,4029,B-Chemical
use,4029,O
.,4029,O
This,4030,O
report,4030,O
is,4030,O
followed,4030,O
by,4030,O
review,4030,O
of,4030,O
the,4030,O
literature,4030,O
.,4030,O
Results,4031,O
of,4031,O
a,4031,O
comparative,4031,O
",",4031,O
phase,4031,O
III,4031,O
",",4031,O
12-week,4031,O
",",4031,O
multicenter,4031,O
",",4031,O
prospective,4031,O
",",4031,O
randomized,4031,O
",",4031,O
double-blind,4031,O
assessment,4031,O
of,4031,O
the,4031,O
efficacy,4031,O
and,4031,O
tolerability,4031,O
of,4031,O
a,4031,O
fixed-dose,4031,O
combination,4031,O
of,4031,O
telmisartan,4031,B-Chemical
and,4031,O
amlodipine,4031,B-Chemical
versus,4031,O
amlodipine,4031,B-Chemical
monotherapy,4031,O
in,4031,O
Indian,4031,O
adults,4031,O
with,4031,O
stage,4031,O
II,4031,O
hypertension,4031,B-Disease
.,4031,O
OBJECTIVE,4032,O
:,4032,O
The,4032,O
aim,4032,O
of,4032,O
this,4032,O
study,4032,O
was,4032,O
to,4032,O
evaluate,4032,O
the,4032,O
efficacy,4032,O
and,4032,O
tolerability,4032,O
of,4032,O
a,4032,O
new,4032,O
fixed-dose,4032,O
combination,4032,O
(,4032,O
FDC,4032,O
),4032,O
of,4032,O
telmisartan,4032,B-Chemical
40,4032,O
mg,4032,O
+,4032,O
amlodipine,4032,B-Chemical
5,4032,O
mg,4032,O
(,4032,O
T+A,4032,O
),4032,O
compared,4032,O
with,4032,O
amlodipine,4032,B-Chemical
5-mg,4032,O
monotherapy,4032,O
(,4032,O
A,4032,O
),4032,O
in,4032,O
adult,4032,O
Indian,4032,O
patients,4032,O
with,4032,O
stage,4032,O
II,4032,O
hypertension,4032,B-Disease
.,4032,O
METHODS,4033,O
:,4033,O
This,4033,O
comparative,4033,O
",",4033,O
Phase,4033,O
III,4033,O
",",4033,O
12-week,4033,O
",",4033,O
multicenter,4033,O
",",4033,O
prospective,4033,O
",",4033,O
randomized,4033,O
",",4033,O
double-blind,4033,O
study,4033,O
was,4033,O
conducted,4033,O
in,4033,O
Indian,4033,O
patients,4033,O
aged,4033,O
18,4033,O
to,4033,O
65,4033,O
years,4033,O
with,4033,O
established,4033,O
stage,4033,O
II,4033,O
hypertension,4033,B-Disease
.,4033,O
Patients,4034,O
were,4034,O
treated,4034,O
with,4034,O
oral,4034,O
FDC,4034,O
of,4034,O
T+A,4034,O
or,4034,O
A,4034,O
QD,4034,O
before,4034,O
breakfast,4034,O
for,4034,O
12,4034,O
weeks,4034,O
;,4034,O
blood,4034,O
pressure,4034,O
(,4034,O
BP,4034,O
),4034,O
and,4034,O
heart,4034,O
rate,4034,O
were,4034,O
measured,4034,O
in,4034,O
the,4034,O
sitting,4034,O
position,4034,O
.,4034,O
Primary,4035,O
efficacy,4035,O
end,4035,O
points,4035,O
were,4035,O
reduction,4035,O
in,4035,O
clinical,4035,O
systolic,4035,O
BP,4035,O
(,4035,O
SBP,4035,O
),4035,O
/,4035,O
diastolic,4035,O
BP,4035,O
(,4035,O
DBP,4035,O
),4035,O
from,4035,O
baseline,4035,O
to,4035,O
study,4035,O
end,4035,O
and,4035,O
number,4035,O
of,4035,O
responders,4035,O
(,4035,O
ie,4035,O
",",4035,O
patients,4035,O
who,4035,O
achieved,4035,O
target,4035,O
SBP/,4035,O
DBP,4035,O
<,4035,O
130/,4035,O
<,4035,O
80,4035,O
mm,4035,O
Hg,4035,O
),4035,O
at,4035,O
end,4035,O
of,4035,O
study,4035,O
.,4035,O
Tolerability,4036,O
was,4036,O
assessed,4036,O
by,4036,O
treatment-emergent,4036,O
adverse,4036,O
events,4036,O
",",4036,O
identified,4036,O
using,4036,O
physical,4036,O
examination,4036,O
",",4036,O
laboratory,4036,O
analysis,4036,O
",",4036,O
and,4036,O
electrocardiography,4036,O
.,4036,O
RESULTS,4037,O
:,4037,O
A,4037,O
total,4037,O
of,4037,O
210,4037,O
patients,4037,O
were,4037,O
enrolled,4037,O
in,4037,O
the,4037,O
study,4037,O
;,4037,O
203,4037,O
patients,4037,O
(,4037,O
143,4037,O
men,4037,O
",",4037,O
60,4037,O
women,4037,O
),4037,O
completed,4037,O
the,4037,O
study,4037,O
while,4037,O
7,4037,O
were,4037,O
lost,4037,O
to,4037,O
follow-up,4037,O
(,4037,O
4,4037,O
patients,4037,O
in,4037,O
the,4037,O
T+A,4037,O
group,4037,O
and,4037,O
3,4037,O
in,4037,O
the,4037,O
A,4037,O
group,4037,O
),4037,O
and,4037,O
considered,4037,O
with-drawn,4037,O
.,4037,O
At,4038,O
study,4038,O
end,4038,O
",",4038,O
statistically,4038,O
significant,4038,O
percentage,4038,O
reductions,4038,O
from,4038,O
baseline,4038,O
within,4038,O
groups,4038,O
and,4038,O
between,4038,O
groups,4038,O
were,4038,O
observed,4038,O
in,4038,O
SBP,4038,O
(,4038,O
T+A,4038,O
[,4038,O
-27.4,4038,O
%,4038,O
],4038,O
;,4038,O
A,4038,O
[,4038,O
-16.6,4038,O
%,4038,O
],4038,O
),4038,O
and,4038,O
DBP,4038,O
(,4038,O
T+A,4038,O
[,4038,O
-20.1,4038,O
%,4038,O
],4038,O
;,4038,O
A,4038,O
[,4038,O
-13.3,4038,O
%,4038,O
],4038,O
),4038,O
(,4038,O
all,4038,O
",",4038,O
P,4038,O
<,4038,O
0.05,4038,O
),4038,O
.,4038,O
Response,4039,O
rates,4039,O
were,4039,O
87.3,4039,O
%,4039,O
(,4039,O
89/102,4039,O
),4039,O
in,4039,O
the,4039,O
T+A,4039,O
group,4039,O
and,4039,O
69.3,4039,O
%,4039,O
(,4039,O
70/101,4039,O
),4039,O
in,4039,O
the,4039,O
A,4039,O
group,4039,O
(,4039,O
P,4039,O
<,4039,O
0.05,4039,O
),4039,O
.,4039,O
The,4040,O
prevalences,4040,O
of,4040,O
adverse,4040,O
events,4040,O
were,4040,O
not,4040,O
significantly,4040,O
different,4040,O
between,4040,O
the,4040,O
2,4040,O
treatment,4040,O
groups,4040,O
(,4040,O
T+A,4040,O
",",4040,O
16.0,4040,O
%,4040,O
[,4040,O
17/106,4040,O
],4040,O
;,4040,O
A,4040,O
",",4040,O
15.4,4040,O
%,4040,O
[,4040,O
16/104,4040,O
],4040,O
),4040,O
.,4040,O
Peripheral,4041,O
edema,4041,B-Disease
was,4041,O
reported,4041,O
in,4041,O
8.5,4041,O
%,4041,O
patients,4041,O
(,4041,O
9/106,4041,O
),4041,O
in,4041,O
the,4041,O
T+A,4041,O
group,4041,O
compared,4041,O
with,4041,O
13.5,4041,O
%,4041,O
(,4041,O
14/104,4041,O
),4041,O
in,4041,O
the,4041,O
A,4041,O
group,4041,O
",",4041,O
and,4041,O
cough,4041,B-Disease
was,4041,O
reported,4041,O
in,4041,O
3.8,4041,O
%,4041,O
patients,4041,O
(,4041,O
4/106,4041,O
),4041,O
in,4041,O
the,4041,O
T+A,4041,O
group,4041,O
and,4041,O
1.0,4041,O
%,4041,O
(,4041,O
1/104,4041,O
),4041,O
patients,4041,O
in,4041,O
the,4041,O
A,4041,O
group,4041,O
;,4041,O
these,4041,O
differences,4041,O
did,4041,O
not,4041,O
reach,4041,O
statistical,4041,O
significance,4041,O
.,4041,O
The,4042,O
incidences,4042,O
of,4042,O
headache,4042,B-Disease
",",4042,O
dizziness,4042,B-Disease
",",4042,O
and,4042,O
diarrhea,4042,B-Disease
were,4042,O
similar,4042,O
between,4042,O
the,4042,O
2,4042,O
groups,4042,O
.,4042,O
CONCLUSIONS,4043,O
:,4043,O
Among,4043,O
these,4043,O
Indian,4043,O
patients,4043,O
with,4043,O
stage,4043,O
II,4043,O
hypertension,4043,B-Disease
",",4043,O
the,4043,O
FDC,4043,O
of,4043,O
T+A,4043,O
was,4043,O
found,4043,O
to,4043,O
be,4043,O
significantly,4043,O
more,4043,O
effective,4043,O
",",4043,O
with,4043,O
regard,4043,O
to,4043,O
BP,4043,O
reductions,4043,O
",",4043,O
than,4043,O
A,4043,O
",",4043,O
and,4043,O
both,4043,O
treatments,4043,O
were,4043,O
well,4043,O
tolerated,4043,O
.,4043,O
Increased,4044,O
mental,4044,B-Disease
slowing,4044,I-Disease
associated,4044,O
with,4044,O
the,4044,O
APOE,4044,O
epsilon4,4044,O
allele,4044,O
after,4044,O
trihexyphenidyl,4044,B-Chemical
oral,4044,O
anticholinergic,4044,O
challenge,4044,O
in,4044,O
healthy,4044,O
elderly,4044,O
.,4044,O
OBJECTIVES,4045,O
:,4045,O
The,4045,O
objectives,4045,O
of,4045,O
this,4045,O
study,4045,O
were,4045,O
to,4045,O
examine,4045,O
the,4045,O
relationship,4045,O
between,4045,O
APOE,4045,O
epsilon4,4045,O
and,4045,O
subjective,4045,O
effects,4045,O
of,4045,O
trihexyphenidyl,4045,B-Chemical
on,4045,O
measures,4045,O
reflecting,4045,O
sedation,4045,O
and,4045,O
confusion,4045,B-Disease
and,4045,O
to,4045,O
investigate,4045,O
the,4045,O
relationship,4045,O
between,4045,O
trihexyphenidyl-induced,4045,B-Chemical
subjective,4045,O
effects,4045,O
and,4045,O
objective,4045,O
memory,4045,O
performance,4045,O
.,4045,O
METHODS,4046,O
:,4046,O
This,4046,O
study,4046,O
comprised,4046,O
24,4046,O
cognitively,4046,O
intact,4046,O
",",4046,O
health,4046,O
elderly,4046,O
adults,4046,O
(,4046,O
12,4046,O
APOE,4046,O
epsilon4,4046,O
carriers,4046,O
),4046,O
at,4046,O
an,4046,O
outpatient,4046,O
geriatric,4046,O
psychiatry,4046,O
research,4046,O
clinic,4046,O
.,4046,O
This,4047,O
was,4047,O
a,4047,O
randomized,4047,O
",",4047,O
double,4047,O
blind,4047,O
",",4047,O
placebo-controlled,4047,O
",",4047,O
three-way,4047,O
",",4047,O
crossover,4047,O
experimental,4047,O
design,4047,O
.,4047,O
All,4048,O
participants,4048,O
received,4048,O
1.0,4048,O
mg,4048,O
or,4048,O
2.0,4048,O
mg,4048,O
trihexyphenidyl,4048,B-Chemical
or,4048,O
placebo,4048,O
administered,4048,O
in,4048,O
counterbalanced,4048,O
sequences,4048,O
over,4048,O
a,4048,O
period,4048,O
of,4048,O
three,4048,O
consecutive,4048,O
weeks,4048,O
.,4048,O
Bond,4049,O
and,4049,O
Lader,4049,O
's,4049,O
visual,4049,O
analog,4049,O
scales,4049,O
and,4049,O
alternate,4049,O
versions,4049,O
of,4049,O
the,4049,O
Buschke,4049,O
Selective,4049,O
Reminding,4049,O
Test,4049,O
were,4049,O
administered,4049,O
in,4049,O
a,4049,O
repeated,4049,O
measures,4049,O
design,4049,O
at,4049,O
baseline,4049,O
",",4049,O
1,4049,O
",",4049,O
2.5,4049,O
",",4049,O
and,4049,O
5,4049,O
hours,4049,O
postdrug,4049,O
administration,4049,O
.,4049,O
RESULTS,4050,O
:,4050,O
A,4050,O
2.0-mg,4050,O
oral,4050,O
dose,4050,O
of,4050,O
trihexyphenidyl,4050,B-Chemical
resulted,4050,O
in,4050,O
increased,4050,O
subjective,4050,O
ratings,4050,O
of,4050,O
mental,4050,B-Disease
slowness,4050,I-Disease
in,4050,O
carriers,4050,O
of,4050,O
the,4050,O
APOE,4050,O
epsilon4,4050,O
allele,4050,O
only,4050,O
.,4050,O
Drug,4051,O
effects,4051,O
as,4051,O
determined,4051,O
by,4051,O
difference,4051,O
scores,4051,O
between,4051,O
2.0,4051,O
mg,4051,O
trihexyphenidyl,4051,B-Chemical
and,4051,O
placebo,4051,O
on,4051,O
ratings,4051,O
of,4051,O
mental,4051,B-Disease
slowness,4051,I-Disease
significantly,4051,O
correlated,4051,O
with,4051,O
total,4051,O
and,4051,O
delayed,4051,O
recall,4051,O
on,4051,O
the,4051,O
Buschke,4051,O
Selective,4051,O
Reminding,4051,O
Test,4051,O
in,4051,O
carriers,4051,O
of,4051,O
the,4051,O
APOE,4051,O
epsilon4,4051,O
allele,4051,O
only,4051,O
.,4051,O
However,4052,O
",",4052,O
no,4052,O
significant,4052,O
effects,4052,O
were,4052,O
found,4052,O
with,4052,O
other,4052,O
visual,4052,O
analog,4052,O
scales,4052,O
reflecting,4052,O
subjective,4052,O
sedation,4052,O
and,4052,O
clear-headedness,4052,O
.,4052,O
CONCLUSION,4053,O
:,4053,O
The,4053,O
epsilon4,4053,O
allele,4053,O
in,4053,O
healthy,4053,O
elderly,4053,O
was,4053,O
associated,4053,O
with,4053,O
increased,4053,O
subjective,4053,O
mental,4053,B-Disease
slowing,4053,I-Disease
after,4053,O
trihexyphenidyl,4053,B-Chemical
anticholinergic,4053,O
challenge,4053,O
.,4053,O
An,4054,O
evaluation,4054,O
of,4054,O
amikacin,4054,B-Chemical
nephrotoxicity,4054,B-Disease
in,4054,O
the,4054,O
hematology/oncology,4054,O
population,4054,O
.,4054,O
Amikacin,4055,B-Chemical
is,4055,O
an,4055,O
aminoglycoside,4055,B-Chemical
commonly,4055,O
used,4055,O
to,4055,O
provide,4055,O
empirical,4055,O
double,4055,O
gram-negative,4055,O
treatment,4055,O
for,4055,O
febrile,4055,B-Disease
neutropenia,4055,I-Disease
and,4055,O
other,4055,O
suspected,4055,O
infections,4055,B-Disease
.,4055,O
Strategies,4056,O
of,4056,O
extended-interval,4056,O
and,4056,O
conventional,4056,O
dosing,4056,O
have,4056,O
been,4056,O
utilized,4056,O
extensively,4056,O
in,4056,O
the,4056,O
general,4056,O
medical,4056,O
population,4056,O
;,4056,O
however,4056,O
",",4056,O
data,4056,O
are,4056,O
lacking,4056,O
to,4056,O
support,4056,O
a,4056,O
dosing,4056,O
strategy,4056,O
in,4056,O
the,4056,O
hematology/oncology,4056,O
population,4056,O
.,4056,O
To,4057,O
evaluate,4057,O
amikacin-associated,4057,B-Chemical
nephrotoxicity,4057,B-Disease
in,4057,O
an,4057,O
adult,4057,O
hematology/oncology,4057,O
population,4057,O
",",4057,O
a,4057,O
prospective,4057,O
",",4057,O
randomized,4057,O
",",4057,O
open-label,4057,O
trial,4057,O
was,4057,O
conducted,4057,O
at,4057,O
a,4057,O
university-affiliated,4057,O
medical,4057,O
center,4057,O
.,4057,O
Forty,4058,O
patients,4058,O
with,4058,O
a,4058,O
diagnosis,4058,O
consistent,4058,O
with,4058,O
a,4058,O
hematologic/oncologic,4058,O
disorder,4058,O
that,4058,O
required,4058,O
treatment,4058,O
with,4058,O
an,4058,O
aminoglycoside,4058,B-Chemical
were,4058,O
randomized,4058,O
to,4058,O
either,4058,O
conventional,4058,O
or,4058,O
extended-interval,4058,O
amikacin,4058,B-Chemical
.,4058,O
The,4059,O
occurrence,4059,O
of,4059,O
nephrotoxicity,4059,B-Disease
by,4059,O
means,4059,O
of,4059,O
an,4059,O
increase,4059,O
in,4059,O
serum,4059,O
creatinine,4059,B-Chemical
and,4059,O
evaluation,4059,O
of,4059,O
efficacy,4059,O
via,4059,O
amikacin,4059,B-Chemical
serum,4059,O
concentrations,4059,O
with,4059,O
respective,4059,O
pathogens,4059,O
were,4059,O
assessed,4059,O
.,4059,O
The,4060,O
occurrence,4060,O
of,4060,O
nephrotoxicity,4060,B-Disease
was,4060,O
similar,4060,O
between,4060,O
the,4060,O
conventional,4060,O
and,4060,O
extended-interval,4060,O
groups,4060,O
",",4060,O
at,4060,O
10,4060,O
%,4060,O
and,4060,O
5,4060,O
%,4060,O
",",4060,O
respectively,4060,O
(,4060,O
P,4060,O
=,4060,O
1.00,4060,O
),4060,O
.,4060,O
Six,4061,O
patients,4061,O
in,4061,O
the,4061,O
conventional,4061,O
group,4061,O
had,4061,O
a,4061,O
positive,4061,O
culture,4061,O
",",4061,O
compared,4061,O
with,4061,O
none,4061,O
in,4061,O
the,4061,O
extended-interval,4061,O
group,4061,O
(,4061,O
P,4061,O
=,4061,O
0.002,4061,O
),4061,O
.,4061,O
The,4062,O
occurrence,4062,O
of,4062,O
nephrotoxicity,4062,B-Disease
was,4062,O
similar,4062,O
between,4062,O
the,4062,O
two,4062,O
dosing,4062,O
regimens,4062,O
",",4062,O
but,4062,O
the,4062,O
distribution,4062,O
of,4062,O
risk,4062,O
factors,4062,O
was,4062,O
variable,4062,O
between,4062,O
the,4062,O
two,4062,O
groups,4062,O
.,4062,O
Efficacy,4063,O
could,4063,O
not,4063,O
be,4063,O
assessed,4063,O
.,4063,O
High,4064,O
dose,4064,O
dexmedetomidine,4064,B-Chemical
as,4064,O
the,4064,O
sole,4064,O
sedative,4064,O
for,4064,O
pediatric,4064,O
MRI,4064,O
.,4064,O
OBJECTIVE,4065,O
:,4065,O
This,4065,O
large-scale,4065,O
retrospective,4065,O
review,4065,O
evaluates,4065,O
the,4065,O
sedation,4065,O
profile,4065,O
of,4065,O
dexmedetomidine,4065,B-Chemical
.,4065,O
AIM,4066,O
:,4066,O
To,4066,O
determine,4066,O
the,4066,O
hemodynamic,4066,O
responses,4066,O
",",4066,O
efficacy,4066,O
and,4066,O
adverse,4066,O
events,4066,O
associated,4066,O
with,4066,O
the,4066,O
use,4066,O
of,4066,O
high,4066,O
dose,4066,O
dexmedetomidine,4066,B-Chemical
as,4066,O
the,4066,O
sole,4066,O
sedative,4066,O
for,4066,O
magnetic,4066,O
resonance,4066,O
imaging,4066,O
(,4066,O
MRI,4066,O
),4066,O
studies,4066,O
.,4066,O
BACKGROUND,4067,O
:,4067,O
Dexmedetomidine,4067,B-Chemical
has,4067,O
been,4067,O
used,4067,O
at,4067,O
our,4067,O
institution,4067,O
since,4067,O
2005,4067,O
to,4067,O
provide,4067,O
sedation,4067,O
for,4067,O
pediatric,4067,O
radiological,4067,O
imaging,4067,O
studies,4067,O
.,4067,O
Over,4068,O
time,4068,O
",",4068,O
an,4068,O
effective,4068,O
protocol,4068,O
utilizing,4068,O
high,4068,O
dose,4068,O
dexmedetomidine,4068,B-Chemical
as,4068,O
the,4068,O
sole,4068,O
sedative,4068,O
agent,4068,O
has,4068,O
evolved,4068,O
.,4068,O
METHODS/MATERIALS,4069,O
:,4069,O
As,4069,O
part,4069,O
of,4069,O
the,4069,O
ongoing,4069,O
Quality,4069,O
Assurance,4069,O
process,4069,O
",",4069,O
data,4069,O
on,4069,O
all,4069,O
sedations,4069,O
are,4069,O
reviewed,4069,O
monthly,4069,O
and,4069,O
protocols,4069,O
modified,4069,O
as,4069,O
needed,4069,O
.,4069,O
Data,4070,O
were,4070,O
analyzed,4070,O
from,4070,O
all,4070,O
747,4070,O
consecutive,4070,O
patients,4070,O
who,4070,O
received,4070,O
dexmedetomidine,4070,B-Chemical
for,4070,O
MRI,4070,O
sedation,4070,O
from,4070,O
April,4070,O
2005,4070,O
to,4070,O
April,4070,O
2007,4070,O
.,4070,O
RESULTS,4071,O
:,4071,O
Since,4071,O
2005,4071,O
",",4071,O
the,4071,O
10-min,4071,O
loading,4071,O
dose,4071,O
of,4071,O
our,4071,O
dexmedetomidine,4071,B-Chemical
protocol,4071,O
increased,4071,O
from,4071,O
2,4071,O
to,4071,O
3,4071,O
microg.kg,4071,O
(,4071,O
-1,4071,O
),4071,O
",",4071,O
and,4071,O
the,4071,O
infusion,4071,O
rate,4071,O
increased,4071,O
from,4071,O
1,4071,O
to,4071,O
1.5,4071,O
to,4071,O
2,4071,O
microg.kg,4071,O
(,4071,O
-1,4071,O
),4071,O
.h,4071,O
(,4071,O
-1,4071,O
),4071,O
.,4071,O
The,4072,O
current,4072,O
sedation,4072,O
protocol,4072,O
progressively,4072,O
increased,4072,O
the,4072,O
rate,4072,O
of,4072,O
successful,4072,O
sedation,4072,O
(,4072,O
able,4072,O
to,4072,O
complete,4072,O
the,4072,O
imaging,4072,O
study,4072,O
),4072,O
when,4072,O
using,4072,O
dexmedetomidine,4072,B-Chemical
alone,4072,O
from,4072,O
91.8,4072,O
%,4072,O
to,4072,O
97.6,4072,O
%,4072,O
(,4072,O
P,4072,O
=,4072,O
0.009,4072,O
),4072,O
",",4072,O
reducing,4072,O
the,4072,O
requirement,4072,O
for,4072,O
adjuvant,4072,O
pentobarbital,4072,B-Chemical
in,4072,O
the,4072,O
event,4072,O
of,4072,O
sedation,4072,O
failure,4072,O
with,4072,O
dexmedetomidine,4072,B-Chemical
alone,4072,O
and,4072,O
decreased,4072,O
the,4072,O
mean,4072,O
recovery,4072,O
time,4072,O
by,4072,O
10,4072,O
min,4072,O
(,4072,O
P,4072,O
<,4072,O
0.001,4072,O
),4072,O
.,4072,O
Although,4073,O
dexmedetomidine,4073,B-Chemical
sedation,4073,O
was,4073,O
associated,4073,O
with,4073,O
a,4073,O
16,4073,O
%,4073,O
incidence,4073,O
of,4073,O
bradycardia,4073,B-Disease
",",4073,O
all,4073,O
concomitant,4073,O
mean,4073,O
arterial,4073,O
blood,4073,O
pressures,4073,O
were,4073,O
within,4073,O
20,4073,O
%,4073,O
of,4073,O
age-adjusted,4073,O
normal,4073,O
range,4073,O
and,4073,O
oxygen,4073,B-Chemical
saturations,4073,O
were,4073,O
95,4073,O
%,4073,O
or,4073,O
higher,4073,O
.,4073,O
CONCLUSION,4074,O
:,4074,O
Dexmedetomidine,4074,B-Chemical
in,4074,O
high,4074,O
doses,4074,O
provides,4074,O
adequate,4074,O
sedation,4074,O
for,4074,O
pediatric,4074,O
MRI,4074,O
studies,4074,O
.,4074,O
While,4075,O
use,4075,O
of,4075,O
high,4075,O
dose,4075,O
dexmedetomidine,4075,B-Chemical
is,4075,O
associated,4075,O
with,4075,O
decreases,4075,O
in,4075,O
heart,4075,O
rate,4075,O
and,4075,O
blood,4075,O
pressure,4075,O
outside,4075,O
the,4075,O
established,4075,O
'awake,4075,O
',4075,O
norms,4075,O
",",4075,O
this,4075,O
deviation,4075,O
is,4075,O
generally,4075,O
within,4075,O
20,4075,O
%,4075,O
of,4075,O
norms,4075,O
",",4075,O
and,4075,O
is,4075,O
not,4075,O
associated,4075,O
with,4075,O
adverse,4075,O
sequelae,4075,O
.,4075,O
Dexmedetomidine,4076,B-Chemical
is,4076,O
useful,4076,O
as,4076,O
the,4076,O
sole,4076,O
sedative,4076,O
for,4076,O
pediatric,4076,O
MRI,4076,O
.,4076,O
Hepatotoxicity,4077,B-Disease
associated,4077,O
with,4077,O
sulfasalazine,4077,B-Chemical
in,4077,O
inflammatory,4077,O
arthritis,4077,B-Disease
:,4077,O
A,4077,O
case,4077,O
series,4077,O
from,4077,O
a,4077,O
local,4077,O
surveillance,4077,O
of,4077,O
serious,4077,O
adverse,4077,O
events,4077,O
.,4077,O
BACKGROUND,4078,O
:,4078,O
Spontaneous,4078,O
reporting,4078,O
systems,4078,O
for,4078,O
adverse,4078,O
drug,4078,O
reactions,4078,O
(,4078,O
ADRs,4078,O
),4078,O
are,4078,O
handicapped,4078,O
by,4078,O
under-reporting,4078,O
and,4078,O
limited,4078,O
detail,4078,O
on,4078,O
individual,4078,O
cases,4078,O
.,4078,O
We,4079,O
report,4079,O
an,4079,O
investigation,4079,O
from,4079,O
a,4079,O
local,4079,O
surveillance,4079,O
for,4079,O
serious,4079,O
adverse,4079,O
drug,4079,O
reactions,4079,O
associated,4079,O
with,4079,O
disease,4079,O
modifying,4079,O
anti-rheumatic,4079,O
drugs,4079,O
that,4079,O
was,4079,O
triggered,4079,O
by,4079,O
the,4079,O
occurrence,4079,O
of,4079,O
liver,4079,B-Disease
failure,4079,I-Disease
in,4079,O
two,4079,O
of,4079,O
our,4079,O
patients,4079,O
.,4079,O
METHODS,4080,O
:,4080,O
Serious,4080,O
ADR,4080,O
reports,4080,O
have,4080,O
been,4080,O
solicited,4080,O
from,4080,O
local,4080,O
clinicians,4080,O
by,4080,O
regular,4080,O
postcards,4080,O
over,4080,O
the,4080,O
past,4080,O
seven,4080,O
years,4080,O
.,4080,O
Patients,4081,O
',4081,O
",",4081,O
who,4081,O
had,4081,O
hepatotoxicity,4081,B-Disease
on,4081,O
sulfasalazine,4081,B-Chemical
and,4081,O
met,4081,O
a,4081,O
definition,4081,O
of,4081,O
a,4081,O
serious,4081,O
ADR,4081,O
",",4081,O
were,4081,O
identified,4081,O
.,4081,O
Two,4082,O
clinicians,4082,O
reviewed,4082,O
structured,4082,O
case,4082,O
reports,4082,O
and,4082,O
assessed,4082,O
causality,4082,O
by,4082,O
consensus,4082,O
and,4082,O
by,4082,O
using,4082,O
a,4082,O
causality,4082,O
assessment,4082,O
instrument,4082,O
.,4082,O
The,4083,O
likely,4083,O
frequency,4083,O
of,4083,O
hepatotoxicity,4083,B-Disease
with,4083,O
sulfasalazine,4083,B-Chemical
was,4083,O
estimated,4083,O
by,4083,O
making,4083,O
a,4083,O
series,4083,O
of,4083,O
conservative,4083,O
assumptions,4083,O
.,4083,O
RESULTS,4084,O
:,4084,O
Ten,4084,O
cases,4084,O
were,4084,O
identified,4084,O
:,4084,O
eight,4084,O
occurred,4084,O
during,4084,O
surveillance,4084,O
.,4084,O
Eight,4085,O
patients,4085,O
were,4085,O
hospitalised,4085,O
",",4085,O
two,4085,O
in,4085,O
hepatic,4085,B-Disease
failure,4085,I-Disease
-,4085,O
one,4085,O
died,4085,O
after,4085,O
a,4085,O
liver,4085,O
transplant,4085,O
.,4085,O
All,4086,O
but,4086,O
one,4086,O
event,4086,O
occurred,4086,O
within,4086,O
6,4086,O
weeks,4086,O
of,4086,O
treatment,4086,O
.,4086,O
Seven,4087,O
patients,4087,O
had,4087,O
a,4087,O
skin,4087,B-Disease
rash,4087,I-Disease
",",4087,O
three,4087,O
eosinophilia,4087,B-Disease
and,4087,O
one,4087,O
interstitial,4087,B-Disease
nephritis,4087,I-Disease
.,4087,O
Five,4088,O
patients,4088,O
were,4088,O
of,4088,O
Black,4088,O
British,4088,O
of,4088,O
African,4088,O
or,4088,O
Caribbean,4088,O
descent,4088,O
.,4088,O
Liver,4089,O
enzymes,4089,O
showed,4089,O
a,4089,O
hepatocellular,4089,O
pattern,4089,O
in,4089,O
four,4089,O
cases,4089,O
and,4089,O
a,4089,O
mixed,4089,O
pattern,4089,O
in,4089,O
six,4089,O
.,4089,O
Drug-related,4090,O
hepatotoxicity,4090,B-Disease
was,4090,O
judged,4090,O
probable,4090,O
or,4090,O
highly,4090,O
probable,4090,O
in,4090,O
8,4090,O
patients,4090,O
.,4090,O
The,4091,O
likely,4091,O
frequency,4091,O
of,4091,O
serious,4091,O
hepatotoxicity,4091,B-Disease
with,4091,O
sulfasalazine,4091,B-Chemical
was,4091,O
estimated,4091,O
at,4091,O
0.4,4091,O
%,4091,O
of,4091,O
treated,4091,O
patients,4091,O
.,4091,O
CONCLUSION,4092,O
:,4092,O
Serious,4092,O
hepatotoxicity,4092,B-Disease
associated,4092,O
with,4092,O
sulfasalazine,4092,B-Chemical
appears,4092,O
to,4092,O
be,4092,O
under-appreciated,4092,O
and,4092,O
intensive,4092,O
monitoring,4092,O
and,4092,O
vigilance,4092,O
in,4092,O
the,4092,O
first,4092,O
6,4092,O
weeks,4092,O
of,4092,O
treatment,4092,O
is,4092,O
especially,4092,O
important,4092,O
.,4092,O
Complete,4093,O
atrioventricular,4093,B-Disease
block,4093,I-Disease
secondary,4093,O
to,4093,O
lithium,4093,B-Chemical
therapy,4093,O
.,4093,O
Sinus,4094,B-Disease
node,4094,I-Disease
dysfunction,4094,I-Disease
has,4094,O
been,4094,O
reported,4094,O
most,4094,O
frequently,4094,O
among,4094,O
the,4094,O
adverse,4094,O
cardiovascular,4094,O
effects,4094,O
of,4094,O
lithium,4094,B-Chemical
.,4094,O
In,4095,O
the,4095,O
present,4095,O
case,4095,O
",",4095,O
complete,4095,O
atrioventricular,4095,B-Disease
(,4095,I-Disease
AV,4095,I-Disease
),4095,I-Disease
block,4095,I-Disease
with,4095,O
syncopal,4095,B-Disease
attacks,4095,I-Disease
developed,4095,O
secondary,4095,O
to,4095,O
lithium,4095,B-Chemical
therapy,4095,O
",",4095,O
necessitating,4095,O
permanent,4095,O
pacemaker,4095,O
implantation,4095,O
.,4095,O
Serum,4096,O
lithium,4096,B-Chemical
levels,4096,O
remained,4096,O
under,4096,O
or,4096,O
within,4096,O
the,4096,O
therapeutic,4096,O
range,4096,O
during,4096,O
the,4096,O
syncopal,4096,B-Disease
attacks,4096,I-Disease
.,4096,O
Lithium,4097,B-Chemical
should,4097,O
be,4097,O
used,4097,O
with,4097,O
extreme,4097,O
caution,4097,O
",",4097,O
especially,4097,O
in,4097,O
patients,4097,O
with,4097,O
mild,4097,O
disturbance,4097,O
of,4097,O
AV,4097,O
conduction,4097,O
.,4097,O
Exaggerated,4098,O
expression,4098,O
of,4098,O
inflammatory,4098,O
mediators,4098,O
in,4098,O
vasoactive,4098,O
intestinal,4098,O
polypeptide,4098,O
knockout,4098,O
(,4098,O
VIP-/-,4098,O
),4098,O
mice,4098,O
with,4098,O
cyclophosphamide,4098,B-Chemical
(,4098,O
CYP,4098,B-Chemical
),4098,O
-induced,4098,O
cystitis,4098,B-Disease
.,4098,O
Vasoactive,4099,O
intestinal,4099,O
polypeptide,4099,O
(,4099,O
VIP,4099,O
),4099,O
is,4099,O
an,4099,O
immunomodulatory,4099,O
neuropeptide,4099,O
distributed,4099,O
in,4099,O
micturition,4099,O
pathways,4099,O
.,4099,O
VIP,4100,O
(,4100,O
-/-,4100,O
),4100,O
mice,4100,O
exhibit,4100,O
altered,4100,O
bladder,4100,O
function,4100,O
and,4100,O
neurochemical,4100,O
properties,4100,O
in,4100,O
micturition,4100,O
pathways,4100,O
after,4100,O
cyclophosphamide,4100,B-Chemical
(,4100,O
CYP,4100,B-Chemical
),4100,O
-induced,4100,O
cystitis,4100,B-Disease
.,4100,O
Given,4101,O
VIP,4101,O
's,4101,O
role,4101,O
as,4101,O
an,4101,O
anti-inflammatory,4101,O
mediator,4101,O
",",4101,O
we,4101,O
hypothesized,4101,O
that,4101,O
VIP,4101,O
(,4101,O
-/-,4101,O
),4101,O
mice,4101,O
would,4101,O
exhibit,4101,O
enhanced,4101,O
inflammatory,4101,O
mediator,4101,O
expression,4101,O
after,4101,O
cystitis,4101,B-Disease
.,4101,O
A,4102,O
mouse,4102,O
inflammatory,4102,O
cytokine,4102,O
and,4102,O
receptor,4102,O
RT2,4102,O
profiler,4102,O
array,4102,O
was,4102,O
used,4102,O
to,4102,O
determine,4102,O
regulated,4102,O
transcripts,4102,O
in,4102,O
the,4102,O
urinary,4102,O
bladder,4102,O
of,4102,O
wild,4102,O
type,4102,O
(,4102,O
WT,4102,O
),4102,O
and,4102,O
VIP,4102,O
(,4102,O
-/-,4102,O
),4102,O
mice,4102,O
with,4102,O
or,4102,O
without,4102,O
CYP-induced,4102,B-Chemical
cystitis,4102,B-Disease
(,4102,O
150,4102,O
mg/kg,4102,O
;,4102,O
i.p,4102,O
.,4102,O
;,4103,O
48,4103,O
h,4103,O
),4103,O
.,4103,O
Four,4104,O
binary,4104,O
comparisons,4104,O
were,4104,O
made,4104,O
:,4104,O
WT,4104,O
control,4104,O
versus,4104,O
CYP,4104,O
treatment,4104,O
(,4104,O
48,4104,O
h,4104,O
),4104,O
",",4104,O
VIP,4104,O
(,4104,O
-/-,4104,O
),4104,O
control,4104,O
versus,4104,O
CYP,4104,O
treatment,4104,O
(,4104,O
48,4104,O
h,4104,O
),4104,O
",",4104,O
WT,4104,O
control,4104,O
versus,4104,O
VIP,4104,O
(,4104,O
-/-,4104,O
),4104,O
control,4104,O
",",4104,O
and,4104,O
WT,4104,O
with,4104,O
CYP,4104,O
treatment,4104,O
(,4104,O
48,4104,O
h,4104,O
),4104,O
versus,4104,O
VIP,4104,O
(,4104,O
-/-,4104,O
),4104,O
with,4104,O
CYP,4104,O
treatment,4104,O
(,4104,O
48,4104,O
h,4104,O
),4104,O
.,4104,O
The,4105,O
genes,4105,O
presented,4105,O
represent,4105,O
(,4105,O
1,4105,O
),4105,O
greater,4105,O
than,4105,O
1.5-fold,4105,O
change,4105,O
in,4105,O
either,4105,O
direction,4105,O
and,4105,O
(,4105,O
2,4105,O
),4105,O
the,4105,O
p,4105,O
value,4105,O
is,4105,O
less,4105,O
than,4105,O
0.05,4105,O
for,4105,O
the,4105,O
comparison,4105,O
being,4105,O
made,4105,O
.,4105,O
Several,4106,O
regulated,4106,O
genes,4106,O
were,4106,O
validated,4106,O
using,4106,O
enzyme-linked,4106,O
immunoassays,4106,O
including,4106,O
IL-1beta,4106,O
and,4106,O
CXCL1,4106,O
.,4106,O
CYP,4107,O
treatment,4107,O
significantly,4107,O
(,4107,O
p,4107,O
<,4107,O
or,4107,O
=,4107,O
0.001,4107,O
),4107,O
increased,4107,O
expression,4107,O
of,4107,O
CXCL1,4107,O
and,4107,O
IL-1beta,4107,O
in,4107,O
the,4107,O
urinary,4107,O
bladder,4107,O
of,4107,O
WT,4107,O
and,4107,O
VIP,4107,O
(,4107,O
-/-,4107,O
),4107,O
mice,4107,O
",",4107,O
but,4107,O
expression,4107,O
in,4107,O
VIP,4107,O
(,4107,O
-/-,4107,O
),4107,O
mice,4107,O
with,4107,O
CYP,4107,O
treatment,4107,O
was,4107,O
significantly,4107,O
(,4107,O
p,4107,O
<,4107,O
or,4107,O
=,4107,O
0.001,4107,O
),4107,O
greater,4107,O
(,4107,O
4.2-,4107,O
to,4107,O
13-fold,4107,O
increase,4107,O
),4107,O
than,4107,O
that,4107,O
observed,4107,O
in,4107,O
WT,4107,O
urinary,4107,O
bladder,4107,O
(,4107,O
3.6-,4107,O
to,4107,O
5-fold,4107,O
increase,4107,O
),4107,O
.,4107,O
The,4108,O
data,4108,O
suggest,4108,O
that,4108,O
in,4108,O
VIP,4108,O
(,4108,O
-/-,4108,O
),4108,O
mice,4108,O
with,4108,O
bladder,4108,I-Disease
inflammation,4108,O
",",4108,O
inflammatory,4108,O
mediators,4108,O
are,4108,O
increased,4108,O
above,4108,O
that,4108,O
observed,4108,O
in,4108,O
WT,4108,O
with,4108,O
CYP,4108,O
.,4108,O
This,4109,O
shift,4109,O
in,4109,O
balance,4109,O
may,4109,O
contribute,4109,O
to,4109,O
increased,4109,O
bladder,4109,I-Disease
dysfunction,4109,O
in,4109,O
VIP,4109,O
(,4109,O
-/-,4109,O
),4109,O
mice,4109,O
with,4109,O
bladder,4109,I-Disease
inflammation,4109,O
and,4109,O
altered,4109,O
neurochemical,4109,O
expression,4109,O
in,4109,O
micturition,4109,O
pathways,4109,O
.,4109,O
The,4110,O
hemodynamics,4110,O
of,4110,O
oxytocin,4110,B-Chemical
and,4110,O
other,4110,O
vasoactive,4110,O
agents,4110,O
during,4110,O
neuraxial,4110,O
anesthesia,4110,O
for,4110,O
cesarean,4110,O
delivery,4110,O
:,4110,O
findings,4110,O
in,4110,O
six,4110,O
cases,4110,O
.,4110,O
Oxytocin,4111,B-Chemical
is,4111,O
a,4111,O
commonly,4111,O
used,4111,O
uterotonic,4111,O
that,4111,O
can,4111,O
cause,4111,O
significant,4111,O
and,4111,O
even,4111,O
fatal,4111,O
hypotension,4111,B-Disease
",",4111,O
particularly,4111,O
when,4111,O
given,4111,O
as,4111,O
a,4111,O
bolus,4111,O
.,4111,O
The,4112,O
resulting,4112,O
hypotension,4112,B-Disease
can,4112,O
be,4112,O
produced,4112,O
by,4112,O
a,4112,O
decrease,4112,O
in,4112,O
systemic,4112,O
vascular,4112,O
resistance,4112,O
or,4112,O
cardiac,4112,O
output,4112,O
through,4112,O
a,4112,O
decrease,4112,O
in,4112,O
venous,4112,O
return,4112,O
.,4112,O
Parturients,4113,O
with,4113,O
normal,4113,O
volume,4113,O
status,4113,O
",",4113,O
heart,4113,O
valves,4113,O
and,4113,O
pulmonary,4113,O
vasculature,4113,O
most,4113,O
often,4113,O
respond,4113,O
to,4113,O
this,4113,O
hypotension,4113,B-Disease
with,4113,O
a,4113,O
compensatory,4113,O
increase,4113,O
in,4113,O
heart,4113,O
rate,4113,O
and,4113,O
stroke,4113,B-Disease
volume,4113,O
.,4113,O
Oxytocin-induced,4114,B-Chemical
hypotension,4114,B-Disease
at,4114,O
cesarean,4114,O
delivery,4114,O
may,4114,O
be,4114,O
incorrectly,4114,O
attributed,4114,O
to,4114,O
blood,4114,B-Disease
loss,4114,I-Disease
.,4114,O
Pulse,4115,O
power,4115,O
analysis,4115,O
(,4115,O
also,4115,O
called,4115,O
``,4115,O
pulse,4115,O
contour,4115,O
analysis,4115,O
'',4115,O
),4115,O
of,4115,O
an,4115,O
arterial,4115,O
pressure,4115,O
wave,4115,O
form,4115,O
allows,4115,O
continuous,4115,O
evaluation,4115,O
of,4115,O
systemic,4115,O
vascular,4115,O
resistance,4115,O
and,4115,O
cardiac,4115,O
output,4115,O
in,4115,O
real,4115,O
time,4115,O
",",4115,O
thereby,4115,O
elucidating,4115,O
the,4115,O
causative,4115,O
factors,4115,O
behind,4115,O
changes,4115,O
in,4115,O
blood,4115,O
pressure,4115,O
.,4115,O
Pulse,4116,O
power,4116,O
analysis,4116,O
was,4116,O
conducted,4116,O
in,4116,O
six,4116,O
cases,4116,O
of,4116,O
cesarean,4116,O
delivery,4116,O
performed,4116,O
under,4116,O
neuraxial,4116,O
anesthesia,4116,O
.,4116,O
Hypotension,4117,B-Disease
in,4117,O
response,4117,O
to,4117,O
oxytocin,4117,B-Chemical
was,4117,O
associated,4117,O
with,4117,O
a,4117,O
decrease,4117,O
in,4117,O
systemic,4117,O
vascular,4117,O
resistance,4117,O
and,4117,O
a,4117,O
compensatory,4117,O
increase,4117,O
in,4117,O
stroke,4117,B-Disease
volume,4117,O
",",4117,O
heart,4117,O
rate,4117,O
and,4117,O
cardiac,4117,O
output,4117,O
.,4117,O
Pulse,4118,O
power,4118,O
analysis,4118,O
may,4118,O
be,4118,O
helpful,4118,O
in,4118,O
determining,4118,O
the,4118,O
etiology,4118,O
of,4118,O
and,4118,O
treating,4118,O
hypotension,4118,B-Disease
during,4118,O
cesarean,4118,O
delivery,4118,O
under,4118,O
neuraxial,4118,O
anesthesia,4118,O
.,4118,O
Protective,4119,O
effects,4119,O
of,4119,O
antithrombin,4119,O
on,4119,O
puromycin,4119,B-Chemical
aminonucleoside,4119,I-Chemical
nephrosis,4119,B-Disease
in,4119,O
rats,4119,O
.,4119,O
We,4120,O
investigated,4120,O
the,4120,O
effects,4120,O
of,4120,O
antithrombin,4120,O
",",4120,O
a,4120,O
plasma,4120,O
inhibitor,4120,O
of,4120,O
coagulation,4120,O
factors,4120,O
",",4120,O
in,4120,O
rats,4120,O
with,4120,O
puromycin,4120,B-Chemical
aminonucleoside-induced,4120,O
nephrosis,4120,B-Disease
",",4120,O
which,4120,O
is,4120,O
an,4120,O
experimental,4120,O
model,4120,O
of,4120,O
human,4120,O
nephrotic,4120,B-Disease
syndrome,4120,I-Disease
.,4120,O
Antithrombin,4121,O
(,4121,O
50,4121,O
or,4121,O
500,4121,O
IU/kg/i.v,4121,O
.,4121,O
),4121,O
was,4122,O
administered,4122,O
to,4122,O
rats,4122,O
once,4122,O
a,4122,O
day,4122,O
for,4122,O
10,4122,O
days,4122,O
immediately,4122,O
after,4122,O
the,4122,O
injection,4122,O
of,4122,O
puromycin,4122,B-Chemical
aminonucleoside,4122,I-Chemical
(,4122,O
50,4122,O
mg/kg/i.v,4122,O
.,4122,O
),4122,O
.,4122,O
Treatment,4123,O
with,4123,O
antithrombin,4123,O
attenuated,4123,O
the,4123,O
puromycin,4123,B-Chemical
aminonucleoside-induced,4123,O
hematological,4123,B-Disease
abnormalities,4123,I-Disease
.,4123,O
Puromycin,4124,B-Chemical
aminonucleoside-induced,4124,O
renal,4124,B-Disease
dysfunction,4124,I-Disease
and,4124,O
hyperlipidemia,4124,B-Disease
were,4124,O
also,4124,O
suppressed,4124,O
.,4124,O
Histopathological,4125,O
examination,4125,O
revealed,4125,O
severe,4125,O
renal,4125,B-Disease
damage,4125,I-Disease
such,4125,O
as,4125,O
proteinaceous,4125,O
casts,4125,O
in,4125,O
tubuli,4125,O
and,4125,O
tubular,4125,O
expansion,4125,O
in,4125,O
the,4125,O
kidney,4125,O
of,4125,O
control,4125,O
rats,4125,O
",",4125,O
while,4125,O
an,4125,O
improvement,4125,O
of,4125,O
the,4125,O
damage,4125,O
was,4125,O
seen,4125,O
in,4125,O
antithrombin-treated,4125,O
rats,4125,O
.,4125,O
In,4126,O
addition,4126,O
",",4126,O
antithrombin,4126,O
treatment,4126,O
markedly,4126,O
suppressed,4126,O
puromycin,4126,B-Chemical
aminonucleoside-induced,4126,O
apoptosis,4126,O
of,4126,O
renal,4126,O
tubular,4126,O
epithelial,4126,O
cells,4126,O
.,4126,O
Furthermore,4127,O
",",4127,O
puromycin,4127,B-Chemical
aminonucleoside-induced,4127,O
increases,4127,O
in,4127,O
renal,4127,O
cytokine,4127,O
content,4127,O
were,4127,O
also,4127,O
decreased,4127,O
.,4127,O
These,4128,O
findings,4128,O
suggest,4128,O
that,4128,O
thrombin,4128,O
plays,4128,O
an,4128,O
important,4128,O
role,4128,O
in,4128,O
the,4128,O
pathogenesis,4128,O
of,4128,O
puromycin,4128,B-Chemical
aminonucleoside-induced,4128,O
nephrotic,4128,B-Disease
syndrome,4128,I-Disease
.,4128,O
Treatment,4129,O
with,4129,O
antithrombin,4129,O
may,4129,O
be,4129,O
clinically,4129,O
effective,4129,O
in,4129,O
patients,4129,O
with,4129,O
nephrotic,4129,B-Disease
syndrome,4129,I-Disease
.,4129,O
Heparin-induced,4130,B-Chemical
thrombocytopenia,4130,B-Disease
after,4130,O
liver,4130,O
transplantation,4130,O
.,4130,O
BACKGROUND,4131,O
:,4131,O
Unfractionated,4131,B-Chemical
heparin,4131,I-Chemical
sodium,4131,I-Chemical
(,4131,O
UFH,4131,B-Chemical
),4131,O
or,4131,O
low-molecular,4131,B-Chemical
weight,4131,I-Chemical
heparin,4131,I-Chemical
(,4131,O
LMWH,4131,O
),4131,O
is,4131,O
used,4131,O
in,4131,O
anticoagulant,4131,O
protocols,4131,O
at,4131,O
several,4131,O
institutions,4131,O
to,4131,O
prevent,4131,O
thrombosis,4131,B-Disease
after,4131,O
liver,4131,O
transplantation,4131,O
.,4131,O
Heparin-induced,4132,B-Chemical
thrombocytopenia,4132,B-Disease
(,4132,O
HIT,4132,B-Disease
),4132,O
is,4132,O
an,4132,O
adverse,4132,O
immune-mediated,4132,O
reaction,4132,O
to,4132,O
heparin,4132,B-Chemical
",",4132,O
resulting,4132,O
in,4132,O
platelet,4132,O
count,4132,O
decreases,4132,O
of,4132,O
more,4132,O
than,4132,O
50,4132,O
%,4132,O
.,4132,O
The,4133,O
frequencies,4133,O
of,4133,O
HIT,4133,B-Disease
after,4133,O
liver,4133,O
transplantation,4133,O
and,4133,O
platelet,4133,O
factor,4133,O
4/heparin-reactive,4133,O
antibody,4133,O
(,4133,O
HIT,4133,B-Disease
antibody,4133,O
),4133,O
positivity,4133,O
in,4133,O
liver,4133,O
transplantation,4133,O
patients,4133,O
",",4133,O
however,4133,O
",",4133,O
are,4133,O
unknown,4133,O
.,4133,O
PATIENTS,4134,O
AND,4134,O
METHODS,4134,O
:,4134,O
The,4134,O
32,4134,O
men,4134,O
and,4134,O
20,4134,O
women,4134,O
underwent,4134,O
living,4134,O
donor,4134,O
liver,4134,O
transplantation,4134,O
.,4134,O
We,4135,O
started,4135,O
LMWH,4135,O
(,4135,O
25,4135,O
IU/kg/h,4135,O
),4135,O
on,4135,O
postoperative,4135,O
day,4135,O
(,4135,O
POD,4135,O
),4135,O
1,4135,O
",",4135,O
switching,4135,O
to,4135,O
UFH,4135,B-Chemical
(,4135,O
5000,4135,O
U/d,4135,O
),4135,O
on,4135,O
POD,4135,O
2,4135,O
or,4135,O
3,4135,O
.,4135,O
The,4136,O
dose,4136,O
of,4136,O
UFH,4136,B-Chemical
was,4136,O
changed,4136,O
according,4136,O
to,4136,O
the,4136,O
activated,4136,O
clotting,4136,O
time,4136,O
level,4136,O
.,4136,O
HIT,4137,B-Disease
antibody,4137,O
levels,4137,O
were,4137,O
measured,4137,O
the,4137,O
day,4137,O
before,4137,O
surgery,4137,O
and,4137,O
on,4137,O
POD,4137,O
7,4137,O
and,4137,O
14,4137,O
.,4137,O
Platelet,4138,O
count,4138,O
was,4138,O
measured,4138,O
daily,4138,O
for,4138,O
3,4138,O
weeks,4138,O
.,4138,O
RESULTS,4139,O
:,4139,O
The,4139,O
average,4139,O
platelet,4139,O
counts,4139,O
preoperatively,4139,O
",",4139,O
and,4139,O
on,4139,O
POD,4139,O
7,4139,O
",",4139,O
14,4139,O
",",4139,O
and,4139,O
21,4139,O
were,4139,O
65,4139,O
",",4139,O
88,4139,O
",",4139,O
149,4139,O
",",4139,O
and,4139,O
169,4139,O
x,4139,O
10,4139,O
(,4139,O
9,4139,O
),4139,O
/L,4139,O
",",4139,O
respectively,4139,O
.,4139,O
Two,4140,O
patients,4140,O
developed,4140,O
hepatic,4140,O
artery,4140,O
thrombosis,4140,B-Disease
on,4140,O
POD,4140,O
11,4140,O
and,4140,O
19,4140,O
",",4140,O
respectively,4140,O
",",4140,O
although,4140,O
they,4140,O
were,4140,O
HIT,4140,B-Disease
antibody-negative,4140,O
and,4140,O
their,4140,O
platelet,4140,O
counts,4140,O
were,4140,O
stable,4140,O
.,4140,O
In,4141,O
2,4141,O
other,4141,O
patients,4141,O
",",4141,O
the,4141,O
platelet,4141,O
count,4141,O
decreased,4141,O
suddenly,4141,O
from,4141,O
107,4141,O
x,4141,O
10,4141,O
(,4141,O
9,4141,O
),4141,O
/L,4141,O
on,4141,O
POD,4141,O
4,4141,O
to,4141,O
65,4141,O
x,4141,O
10,4141,O
(,4141,O
9,4141,O
),4141,O
/L,4141,O
on,4141,O
POD,4141,O
6,4141,O
and,4141,O
from,4141,O
76,4141,O
x,4141,O
10,4141,O
(,4141,O
9,4141,O
),4141,O
/L,4141,O
on,4141,O
POD,4141,O
7,4141,O
to,4141,O
33,4141,O
x,4141,O
10,4141,O
(,4141,O
9,4141,O
),4141,O
/L,4141,O
on,4141,O
POD,4141,O
9,4141,O
",",4141,O
respectively,4141,O
.,4141,O
The,4142,O
heparin-induced,4142,B-Chemical
platelet,4142,B-Disease
aggregation,4142,I-Disease
test,4142,O
was,4142,O
negative,4142,O
in,4142,O
these,4142,O
patients,4142,O
.,4142,O
The,4143,O
percentage,4143,O
of,4143,O
HIT,4143,B-Disease
antibody-positive,4143,O
patients,4143,O
was,4143,O
0.5,4143,O
%,4143,O
preoperatively,4143,O
",",4143,O
5.6,4143,O
%,4143,O
on,4143,O
POD,4143,O
7,4143,O
",",4143,O
and,4143,O
5.6,4143,O
%,4143,O
on,4143,O
POD,4143,O
14,4143,O
.,4143,O
None,4144,O
of,4144,O
the,4144,O
subjects/patients,4144,O
developed,4144,O
UFH-related,4144,B-Chemical
HIT,4144,B-Disease
.,4144,O
CONCLUSIONS,4145,O
:,4145,O
In,4145,O
our,4145,O
series,4145,O
",",4145,O
the,4145,O
occurrence,4145,O
of,4145,O
HIT,4145,B-Disease
after,4145,O
liver,4145,O
transplantation,4145,O
was,4145,O
uncommon,4145,O
.,4145,O
Doxorubicin,4146,B-Chemical
cardiomyopathy-induced,4146,B-Disease
inflammation,4146,B-Disease
and,4146,O
apoptosis,4146,O
are,4146,O
attenuated,4146,O
by,4146,O
gene,4146,O
deletion,4146,O
of,4146,O
the,4146,O
kinin,4146,O
B1,4146,O
receptor,4146,O
.,4146,O
Clinical,4147,O
use,4147,O
of,4147,O
the,4147,O
anthracycline,4147,B-Chemical
doxorubicin,4147,B-Chemical
(,4147,O
DOX,4147,B-Chemical
),4147,O
is,4147,O
limited,4147,O
by,4147,O
its,4147,O
cardiotoxic,4147,B-Disease
effects,4147,O
",",4147,O
which,4147,O
are,4147,O
attributed,4147,O
to,4147,O
the,4147,O
induction,4147,O
of,4147,O
apoptosis,4147,O
.,4147,O
To,4148,O
elucidate,4148,O
the,4148,O
possible,4148,O
role,4148,O
of,4148,O
the,4148,O
kinin,4148,O
B1,4148,O
receptor,4148,O
(,4148,O
B1R,4148,O
),4148,O
during,4148,O
the,4148,O
development,4148,O
of,4148,O
DOX,4148,B-Chemical
cardiomyopathy,4148,B-Disease
",",4148,O
we,4148,O
studied,4148,O
B1R,4148,O
knockout,4148,O
mice,4148,O
(,4148,O
B1R,4148,O
(,4148,O
-/-,4148,O
),4148,O
),4148,O
by,4148,O
investigating,4148,O
cardiac,4148,O
inflammation,4148,B-Disease
and,4148,O
apoptosis,4148,O
after,4148,O
induction,4148,O
of,4148,O
DOX-induced,4148,B-Chemical
cardiomyopathy,4148,B-Disease
.,4148,O
DOX,4149,B-Chemical
control,4149,O
mice,4149,O
showed,4149,O
cardiac,4149,B-Disease
dysfunction,4149,I-Disease
measured,4149,O
by,4149,O
pressure-volume,4149,O
loops,4149,O
in,4149,O
vivo,4149,O
.,4149,O
This,4150,O
was,4150,O
associated,4150,O
with,4150,O
a,4150,O
reduced,4150,O
activation,4150,O
state,4150,O
of,4150,O
AKT,4150,O
",",4150,O
as,4150,O
well,4150,O
as,4150,O
an,4150,O
increased,4150,O
bax/bcl2,4150,O
ratio,4150,O
in,4150,O
Western,4150,O
blots,4150,O
",",4150,O
indicating,4150,O
cardiac,4150,B-Disease
apoptosis,4150,I-Disease
.,4150,O
Furthermore,4151,O
",",4151,O
mRNA,4151,O
levels,4151,O
of,4151,O
the,4151,O
proinflammatory,4151,O
cytokine,4151,O
interleukin,4151,O
6,4151,O
were,4151,O
increased,4151,O
in,4151,O
the,4151,O
cardiac,4151,O
tissue,4151,O
.,4151,O
In,4152,O
DOX,4152,B-Chemical
B1R,4152,O
(,4152,O
-/-,4152,O
),4152,O
mice,4152,O
",",4152,O
cardiac,4152,B-Disease
dysfunction,4152,I-Disease
was,4152,O
improved,4152,O
compared,4152,O
to,4152,O
DOX,4152,B-Chemical
control,4152,O
mice,4152,O
",",4152,O
which,4152,O
was,4152,O
associated,4152,O
with,4152,O
normalization,4152,O
of,4152,O
the,4152,O
bax/bcl-2,4152,O
ratio,4152,O
and,4152,O
interleukin,4152,O
6,4152,O
",",4152,O
as,4152,O
well,4152,O
as,4152,O
AKT,4152,O
activation,4152,O
state,4152,O
.,4152,O
These,4153,O
findings,4153,O
suggest,4153,O
that,4153,O
B1R,4153,O
is,4153,O
detrimental,4153,O
in,4153,O
DOX,4153,B-Chemical
cardiomyopathy,4153,B-Disease
in,4153,O
that,4153,O
it,4153,O
mediates,4153,O
the,4153,O
inflammatory,4153,O
response,4153,O
and,4153,O
apoptosis,4153,O
.,4153,O
These,4154,O
insights,4154,O
might,4154,O
have,4154,O
useful,4154,O
implications,4154,O
for,4154,O
future,4154,O
studies,4154,O
utilizing,4154,O
B1R,4154,O
antagonists,4154,O
for,4154,O
treatment,4154,O
of,4154,O
human,4154,O
DOX,4154,B-Chemical
cardiomyopathy,4154,B-Disease
.,4154,O
Detailed,4155,O
spectral,4155,O
profile,4155,O
analysis,4155,O
of,4155,O
penicillin-induced,4155,B-Chemical
epileptiform,4155,B-Disease
activity,4155,I-Disease
in,4155,O
anesthetized,4155,O
rats,4155,O
.,4155,O
Penicillin,4156,B-Chemical
model,4156,O
is,4156,O
a,4156,O
widely,4156,O
used,4156,O
experimental,4156,O
model,4156,O
for,4156,O
epilepsy,4156,B-Disease
research,4156,O
.,4156,O
In,4157,O
the,4157,O
present,4157,O
study,4157,O
we,4157,O
aimed,4157,O
to,4157,O
portray,4157,O
a,4157,O
detailed,4157,O
spectral,4157,O
analysis,4157,O
of,4157,O
penicillin-induced,4157,B-Chemical
epileptiform,4157,B-Disease
activity,4157,I-Disease
in,4157,O
comparison,4157,O
with,4157,O
basal,4157,O
brain,4157,O
activity,4157,O
in,4157,O
anesthetized,4157,O
Wistar,4157,O
rats,4157,O
.,4157,O
Male,4158,O
Wistar,4158,O
rats,4158,O
were,4158,O
anesthetized,4158,O
with,4158,O
i.p,4158,O
.,4158,O
urethane,4159,B-Chemical
and,4159,O
connected,4159,O
to,4159,O
an,4159,O
electrocorticogram,4159,O
setup,4159,O
.,4159,O
After,4160,O
a,4160,O
short,4160,O
period,4160,O
of,4160,O
basal,4160,O
activity,4160,O
recording,4160,O
",",4160,O
epileptic,4160,B-Disease
focus,4160,O
was,4160,O
induced,4160,O
by,4160,O
injecting,4160,O
400IU/2,4160,O
microl,4160,O
penicillin-G,4160,B-Chemical
potassium,4160,I-Chemical
into,4160,O
the,4160,O
left,4160,O
lateral,4160,O
ventricle,4160,O
while,4160,O
the,4160,O
cortical,4160,O
activity,4160,O
was,4160,O
continuously,4160,O
recorded,4160,O
.,4160,O
Basal,4161,O
activity,4161,O
",",4161,O
latent,4161,O
period,4161,O
and,4161,O
the,4161,O
penicillin-induced,4161,B-Chemical
epileptiform,4161,B-Disease
activity,4161,I-Disease
periods,4161,O
were,4161,O
then,4161,O
analyzed,4161,O
using,4161,O
both,4161,O
conventional,4161,O
methods,4161,O
and,4161,O
spectral,4161,O
analysis,4161,O
.,4161,O
Spectral,4162,O
analyses,4162,O
were,4162,O
conducted,4162,O
by,4162,O
dividing,4162,O
the,4162,O
whole,4162,O
spectrum,4162,O
into,4162,O
different,4162,O
frequency,4162,O
bands,4162,O
including,4162,O
delta,4162,O
",",4162,O
theta,4162,O
(,4162,O
slow,4162,O
and,4162,O
fast,4162,O
),4162,O
",",4162,O
alpha-sigma,4162,O
",",4162,O
beta,4162,O
(,4162,O
1,4162,O
and,4162,O
2,4162,O
),4162,O
and,4162,O
gamma,4162,O
(,4162,O
1,4162,O
and,4162,O
2,4162,O
),4162,O
bands,4162,O
.,4162,O
Our,4163,O
results,4163,O
show,4163,O
that,4163,O
the,4163,O
most,4163,O
affected,4163,O
frequency,4163,O
bands,4163,O
were,4163,O
delta,4163,O
",",4163,O
theta,4163,O
",",4163,O
beta-2,4163,O
and,4163,O
gamma-2,4163,O
bands,4163,O
during,4163,O
the,4163,O
epileptiform,4163,B-Disease
activity,4163,I-Disease
and,4163,O
there,4163,O
were,4163,O
marked,4163,O
differences,4163,O
in,4163,O
terms,4163,O
of,4163,O
spectral,4163,O
densities,4163,O
between,4163,O
three,4163,O
investigated,4163,O
episodes,4163,O
(,4163,O
basal,4163,O
activity,4163,O
",",4163,O
latent,4163,O
period,4163,O
and,4163,O
epileptiform,4163,B-Disease
activity,4163,I-Disease
),4163,O
.,4163,O
Our,4164,O
results,4164,O
may,4164,O
help,4164,O
to,4164,O
analyze,4164,O
novel,4164,O
data,4164,O
obtained,4164,O
using,4164,O
similar,4164,O
experimental,4164,O
models,4164,O
and,4164,O
the,4164,O
simple,4164,O
analysis,4164,O
method,4164,O
described,4164,O
here,4164,O
can,4164,O
be,4164,O
used,4164,O
in,4164,O
similar,4164,O
studies,4164,O
to,4164,O
investigate,4164,O
the,4164,O
basic,4164,O
neuronal,4164,O
mechanism,4164,O
of,4164,O
this,4164,O
or,4164,O
other,4164,O
types,4164,O
of,4164,O
experimental,4164,O
epilepsies,4164,B-Disease
.,4164,O
High,4165,O
fat,4165,B-Chemical
diet-fed,4165,O
obese,4165,B-Disease
rats,4165,O
are,4165,O
highly,4165,O
sensitive,4165,O
to,4165,O
doxorubicin-induced,4165,B-Chemical
cardiotoxicity,4165,B-Disease
.,4165,O
Often,4166,O
",",4166,O
chemotherapy,4166,O
by,4166,O
doxorubicin,4166,B-Chemical
(,4166,O
Adriamycin,4166,B-Chemical
),4166,O
is,4166,O
limited,4166,O
due,4166,O
to,4166,O
life,4166,O
threatening,4166,O
cardiotoxicity,4166,B-Disease
in,4166,O
patients,4166,O
during,4166,O
and,4166,O
posttherapy,4166,O
.,4166,O
Recently,4167,O
",",4167,O
we,4167,O
have,4167,O
shown,4167,O
that,4167,O
moderate,4167,O
diet,4167,O
restriction,4167,O
remarkably,4167,O
protects,4167,O
against,4167,O
doxorubicin-induced,4167,B-Chemical
cardiotoxicity,4167,B-Disease
.,4167,O
This,4168,O
cardioprotection,4168,O
is,4168,O
accompanied,4168,O
by,4168,O
decreased,4168,O
cardiac,4168,O
oxidative,4168,O
stress,4168,O
and,4168,O
triglycerides,4168,B-Chemical
and,4168,O
increased,4168,O
cardiac,4168,O
fatty-acid,4168,O
oxidation,4168,O
",",4168,O
ATP,4168,B-Chemical
synthesis,4168,O
",",4168,O
and,4168,O
upregulated,4168,O
JAK/STAT3,4168,O
pathway,4168,O
.,4168,O
In,4169,O
the,4169,O
current,4169,O
study,4169,O
",",4169,O
we,4169,O
investigated,4169,O
whether,4169,O
a,4169,O
physiological,4169,O
intervention,4169,O
by,4169,O
feeding,4169,O
40,4169,O
%,4169,O
high,4169,O
fat,4169,B-Chemical
diet,4169,O
(,4169,O
HFD,4169,O
),4169,O
",",4169,O
which,4169,O
induces,4169,O
obesity,4169,B-Disease
in,4169,O
male,4169,O
Sprague-Dawley,4169,O
rats,4169,O
(,4169,O
250-275,4169,O
g,4169,O
),4169,O
",",4169,O
sensitizes,4169,O
to,4169,O
doxorubicin-induced,4169,B-Chemical
cardiotoxicity,4169,B-Disease
.,4169,O
A,4170,O
LD,4170,O
(,4170,O
10,4170,O
),4170,O
dose,4170,O
(,4170,O
8,4170,O
mg,4170,O
doxorubicin/kg,4170,B-Chemical
",",4170,O
ip,4170,O
),4170,O
administered,4170,O
on,4170,O
day,4170,O
43,4170,O
of,4170,O
the,4170,O
HFD,4170,O
feeding,4170,O
regimen,4170,O
led,4170,O
to,4170,O
higher,4170,O
cardiotoxicity,4170,B-Disease
",",4170,O
cardiac,4170,B-Disease
dysfunction,4170,I-Disease
",",4170,O
lipid,4170,O
peroxidation,4170,O
",",4170,O
and,4170,O
80,4170,O
%,4170,O
mortality,4170,O
in,4170,O
the,4170,O
obese,4170,B-Disease
(,4170,O
OB,4170,B-Disease
),4170,O
rats,4170,O
in,4170,O
the,4170,O
absence,4170,O
of,4170,O
any,4170,O
significant,4170,O
renal,4170,O
or,4170,O
hepatic,4170,O
toxicity,4170,O
.,4170,O
Doxorubicin,4171,B-Chemical
toxicokinetics,4171,O
studies,4171,O
revealed,4171,O
no,4171,O
change,4171,O
in,4171,O
accumulation,4171,O
of,4171,O
doxorubicin,4171,B-Chemical
and,4171,O
doxorubicinol,4171,B-Chemical
(,4171,O
toxic,4171,O
metabolite,4171,O
),4171,O
in,4171,O
the,4171,O
normal,4171,O
diet-fed,4171,O
(,4171,O
ND,4171,O
),4171,O
and,4171,O
OB,4171,B-Disease
hearts,4171,O
.,4171,O
Mechanistic,4172,O
studies,4172,O
revealed,4172,O
that,4172,O
OB,4172,B-Disease
rats,4172,O
are,4172,O
sensitized,4172,O
due,4172,O
to,4172,O
:,4172,O
(,4172,O
1,4172,O
),4172,O
higher,4172,O
oxyradical,4172,O
stress,4172,O
leading,4172,O
to,4172,O
upregulation,4172,O
of,4172,O
uncoupling,4172,O
proteins,4172,O
2,4172,O
and,4172,O
3,4172,O
",",4172,O
(,4172,O
2,4172,O
),4172,O
downregulation,4172,O
of,4172,O
cardiac,4172,O
peroxisome,4172,O
proliferators,4172,O
activated,4172,O
receptor-alpha,4172,O
",",4172,O
(,4172,O
3,4172,O
),4172,O
decreased,4172,O
plasma,4172,O
adiponectin,4172,O
levels,4172,O
",",4172,O
(,4172,O
4,4172,O
),4172,O
decreased,4172,O
cardiac,4172,O
fatty-acid,4172,O
oxidation,4172,O
(,4172,O
666.9+/-14.0,4172,O
nmol/min/g,4172,O
heart,4172,O
in,4172,O
ND,4172,O
versus,4172,O
400.2+/-11.8,4172,O
nmol/min/g,4172,O
heart,4172,O
in,4172,O
OB,4172,B-Disease
),4172,O
",",4172,O
(,4172,O
5,4172,O
),4172,O
decreased,4172,O
mitochondrial,4172,O
AMP-alpha2,4172,B-Chemical
protein,4172,O
kinase,4172,O
",",4172,O
and,4172,O
(,4172,O
6,4172,O
),4172,O
86,4172,O
%,4172,O
drop,4172,O
in,4172,O
cardiac,4172,O
ATP,4172,B-Chemical
levels,4172,O
accompanied,4172,O
by,4172,O
decreased,4172,O
ATP/ADP,4172,B-Chemical
ratio,4172,O
after,4172,O
doxorubicin,4172,B-Chemical
administration,4172,O
.,4172,O
Decreased,4173,O
cardiac,4173,O
erythropoietin,4173,O
and,4173,O
increased,4173,O
SOCS3,4173,O
further,4173,O
downregulated,4173,O
the,4173,O
cardioprotective,4173,O
JAK/STAT3,4173,O
pathway,4173,O
.,4173,O
In,4174,O
conclusion,4174,O
",",4174,O
HFD-induced,4174,O
obese,4174,B-Disease
rats,4174,O
are,4174,O
highly,4174,O
sensitized,4174,O
to,4174,O
doxorubicin-induced,4174,B-Chemical
cardiotoxicity,4174,B-Disease
by,4174,O
substantially,4174,O
downregulating,4174,O
cardiac,4174,O
mitochondrial,4174,O
ATP,4174,B-Chemical
generation,4174,O
",",4174,O
increasing,4174,O
oxidative,4174,O
stress,4174,O
and,4174,O
downregulating,4174,O
the,4174,O
JAK/STAT3,4174,O
pathway,4174,O
.,4174,O
Isoproterenol,4175,B-Chemical
induces,4175,O
primary,4175,O
loss,4175,O
of,4175,O
dystrophin,4175,O
in,4175,O
rat,4175,O
hearts,4175,O
:,4175,O
correlation,4175,O
with,4175,O
myocardial,4175,B-Disease
injury,4175,I-Disease
.,4175,O
The,4176,O
mechanism,4176,O
of,4176,O
isoproterenol-induced,4176,B-Chemical
myocardial,4176,B-Disease
damage,4176,I-Disease
is,4176,O
unknown,4176,O
",",4176,O
but,4176,O
a,4176,O
mismatch,4176,O
of,4176,O
oxygen,4176,B-Chemical
supply,4176,O
vs.,4176,O
demand,4176,O
following,4176,O
coronary,4176,O
hypotension,4176,B-Disease
and,4176,O
myocardial,4176,B-Disease
hyperactivity,4176,I-Disease
is,4176,O
the,4176,O
best,4176,O
explanation,4176,O
for,4176,O
the,4176,O
complex,4176,O
morphological,4176,O
alterations,4176,O
observed,4176,O
.,4176,O
Severe,4177,O
alterations,4177,O
in,4177,O
the,4177,O
structural,4177,O
integrity,4177,O
of,4177,O
the,4177,O
sarcolemma,4177,O
of,4177,O
cardiomyocytes,4177,O
have,4177,O
been,4177,O
demonstrated,4177,O
to,4177,O
be,4177,O
caused,4177,O
by,4177,O
isoproterenol,4177,B-Chemical
.,4177,O
Taking,4178,O
into,4178,O
account,4178,O
that,4178,O
the,4178,O
sarcolemmal,4178,O
integrity,4178,O
is,4178,O
stabilized,4178,O
by,4178,O
the,4178,O
dystrophin-glycoprotein,4178,O
complex,4178,O
(,4178,O
DGC,4178,O
),4178,O
that,4178,O
connects,4178,O
actin,4178,O
and,4178,O
laminin,4178,O
in,4178,O
contractile,4178,O
machinery,4178,O
and,4178,O
extracellular,4178,O
matrix,4178,O
and,4178,O
by,4178,O
integrins,4178,O
",",4178,O
this,4178,O
study,4178,O
tests,4178,O
the,4178,O
hypothesis,4178,O
that,4178,O
isoproterenol,4178,B-Chemical
affects,4178,O
sarcolemmal,4178,O
stability,4178,O
through,4178,O
changes,4178,O
in,4178,O
the,4178,O
DGC,4178,O
and,4178,O
integrins,4178,O
.,4178,O
We,4179,O
found,4179,O
different,4179,O
sensitivity,4179,O
of,4179,O
the,4179,O
DGC,4179,O
and,4179,O
integrin,4179,O
to,4179,O
isoproterenol,4179,B-Chemical
subcutaneous,4179,O
administration,4179,O
.,4179,O
Immunofluorescent,4180,O
staining,4180,O
revealed,4180,O
that,4180,O
dystrophin,4180,O
is,4180,O
the,4180,O
most,4180,O
sensitive,4180,O
among,4180,O
the,4180,O
structures,4180,O
connecting,4180,O
the,4180,O
actin,4180,O
in,4180,O
the,4180,O
cardiomyocyte,4180,O
cytoskeleton,4180,O
and,4180,O
the,4180,O
extracellular,4180,O
matrix,4180,O
.,4180,O
The,4181,O
sarcomeric,4181,O
actin,4181,O
dissolution,4181,O
occurred,4181,O
after,4181,O
the,4181,O
reduction,4181,O
or,4181,O
loss,4181,O
of,4181,O
dystrophin,4181,O
.,4181,O
Subsequently,4182,O
",",4182,O
after,4182,O
lysis,4182,O
of,4182,O
myofilaments,4182,O
",",4182,O
gamma-sarcoglycan,4182,O
",",4182,O
beta-dystroglycan,4182,O
",",4182,O
beta1-integrin,4182,O
",",4182,O
and,4182,O
laminin,4182,O
alpha-2,4182,O
expressions,4182,O
were,4182,O
reduced,4182,O
followed,4182,O
by,4182,O
their,4182,O
breakdown,4182,O
",",4182,O
as,4182,O
epiphenomena,4182,O
of,4182,O
the,4182,O
myocytolytic,4182,O
process,4182,O
.,4182,O
In,4183,O
conclusion,4183,O
",",4183,O
administration,4183,O
of,4183,O
isoproterenol,4183,B-Chemical
to,4183,O
rats,4183,O
results,4183,O
in,4183,O
primary,4183,O
loss,4183,O
of,4183,O
dystrophin,4183,O
",",4183,O
the,4183,O
most,4183,O
sensitive,4183,O
among,4183,O
the,4183,O
structural,4183,O
proteins,4183,O
that,4183,O
form,4183,O
the,4183,O
DGC,4183,O
that,4183,O
connects,4183,O
the,4183,O
extracellular,4183,O
matrix,4183,O
and,4183,O
the,4183,O
cytoskeleton,4183,O
in,4183,O
cardiomyocyte,4183,O
.,4183,O
These,4184,O
changes,4184,O
",",4184,O
related,4184,O
to,4184,O
ischaemic,4184,B-Disease
injury,4184,I-Disease
",",4184,O
explain,4184,O
the,4184,O
severe,4184,O
alterations,4184,O
in,4184,O
the,4184,O
structural,4184,O
integrity,4184,O
of,4184,O
the,4184,O
sarcolemma,4184,O
of,4184,O
cardiomyocytes,4184,O
and,4184,O
hence,4184,O
severe,4184,O
and,4184,O
irreversible,4184,O
injury,4184,O
induced,4184,O
by,4184,O
isoproterenol,4184,B-Chemical
.,4184,O
A,4185,O
case,4185,O
of,4185,O
ventricular,4185,B-Disease
tachycardia,4185,I-Disease
related,4185,O
to,4185,O
caffeine,4185,B-Chemical
pretreatment,4185,O
.,4185,O
Suboptimal,4186,O
seizure,4186,B-Disease
duration,4186,O
is,4186,O
commonly,4186,O
encountered,4186,O
in,4186,O
electroconvulsive,4186,O
therapy,4186,O
practice,4186,O
",",4186,O
especially,4186,O
in,4186,O
older,4186,O
patients,4186,O
with,4186,O
higher,4186,O
seizure,4186,B-Disease
thresholds,4186,O
.,4186,O
Intravenous,4187,O
caffeine,4187,B-Chemical
is,4187,O
commonly,4187,O
used,4187,O
to,4187,O
improve,4187,O
seizure,4187,B-Disease
duration,4187,O
and,4187,O
quality,4187,O
in,4187,O
such,4187,O
patients,4187,O
and,4187,O
is,4187,O
generally,4187,O
well,4187,O
tolerated,4187,O
aside,4187,O
from,4187,O
occasional,4187,O
reports,4187,O
of,4187,O
relatively,4187,O
benign,4187,O
ventricular,4187,B-Disease
ectopy,4187,I-Disease
.,4187,O
We,4188,O
describe,4188,O
a,4188,O
patient,4188,O
with,4188,O
no,4188,O
previous,4188,O
history,4188,O
of,4188,O
cardiac,4188,B-Disease
disease,4188,I-Disease
or,4188,O
arrhythmia,4188,B-Disease
who,4188,O
developed,4188,O
sustained,4188,O
bigeminy,4188,O
and,4188,O
2,4188,O
brief,4188,O
runs,4188,O
of,4188,O
ventricular,4188,B-Disease
tachycardia,4188,I-Disease
after,4188,O
caffeine,4188,B-Chemical
administration,4188,O
.,4188,O
Although,4189,O
intravenous,4189,O
caffeine,4189,B-Chemical
is,4189,O
generally,4189,O
well,4189,O
tolerated,4189,O
",",4189,O
the,4189,O
clinician,4189,O
should,4189,O
be,4189,O
aware,4189,O
of,4189,O
the,4189,O
potential,4189,O
for,4189,O
unpredictable,4189,O
and,4189,O
serious,4189,O
ventricular,4189,B-Disease
arrhythmias,4189,I-Disease
.,4189,O
Fatal,4190,O
haemopericardium,4190,B-Disease
and,4190,O
gastrointestinal,4190,B-Disease
haemorrhage,4190,I-Disease
due,4190,O
to,4190,O
possible,4190,O
interaction,4190,O
of,4190,O
cranberry,4190,O
juice,4190,O
with,4190,O
warfarin,4190,B-Chemical
.,4190,O
We,4191,O
report,4191,O
a,4191,O
case,4191,O
of,4191,O
fatal,4191,O
internal,4191,O
haemorrhage,4191,B-Disease
in,4191,O
an,4191,O
elderly,4191,O
man,4191,O
who,4191,O
consumed,4191,O
only,4191,O
cranberry,4191,O
juice,4191,O
for,4191,O
two,4191,O
weeks,4191,O
while,4191,O
maintaining,4191,O
his,4191,O
usual,4191,O
dosage,4191,O
of,4191,O
warfarin,4191,B-Chemical
.,4191,O
We,4192,O
propose,4192,O
that,4192,O
naturally,4192,O
occurring,4192,O
compounds,4192,O
such,4192,O
as,4192,O
flavonoids,4192,B-Chemical
",",4192,O
which,4192,O
are,4192,O
present,4192,O
in,4192,O
fruit,4192,O
juices,4192,O
",",4192,O
may,4192,O
increase,4192,O
the,4192,O
potency,4192,O
of,4192,O
warfarin,4192,B-Chemical
by,4192,O
competing,4192,O
for,4192,O
the,4192,O
enzymes,4192,O
that,4192,O
normally,4192,O
inactivate,4192,O
warfarin,4192,B-Chemical
.,4192,O
While,4193,O
traditionally,4193,O
regarded,4193,O
as,4193,O
foodstuffs,4193,O
",",4193,O
consumption,4193,O
of,4193,O
fruit,4193,O
juices,4193,O
should,4193,O
be,4193,O
considered,4193,O
when,4193,O
patients,4193,O
develop,4193,O
adverse,4193,O
drug,4193,O
reactions,4193,O
.,4193,O
Effect,4194,O
of,4194,O
increasing,4194,O
intraperitoneal,4194,O
infusion,4194,O
rates,4194,O
on,4194,O
bupropion,4194,B-Chemical
hydrochloride-induced,4194,O
seizures,4194,B-Disease
in,4194,O
mice,4194,O
.,4194,O
BACKGROUND,4195,O
:,4195,O
It,4195,O
is,4195,O
not,4195,O
known,4195,O
if,4195,O
there,4195,O
is,4195,O
a,4195,O
relationship,4195,O
between,4195,O
input,4195,O
rate,4195,O
and,4195,O
incidence,4195,O
of,4195,O
bupropion-induced,4195,B-Chemical
seizures,4195,B-Disease
.,4195,O
This,4196,O
is,4196,O
important,4196,O
",",4196,O
since,4196,O
different,4196,O
controlled,4196,O
release,4196,O
formulations,4196,O
of,4196,O
bupropion,4196,B-Chemical
release,4196,O
the,4196,O
active,4196,O
drug,4196,O
at,4196,O
different,4196,O
rates,4196,O
.,4196,O
METHODS,4197,O
:,4197,O
We,4197,O
investigated,4197,O
the,4197,O
effect,4197,O
of,4197,O
varying,4197,O
the,4197,O
intraperitoneal,4197,O
infusion,4197,O
rates,4197,O
of,4197,O
bupropion,4197,B-Chemical
HCl,4197,I-Chemical
120,4197,O
mg/kg,4197,O
",",4197,O
a,4197,O
known,4197,O
convulsive,4197,B-Disease
dose,4197,O
50,4197,O
(,4197,O
CD50,4197,O
),4197,O
",",4197,O
on,4197,O
the,4197,O
incidence,4197,O
and,4197,O
severity,4197,O
of,4197,O
bupropion-induced,4197,B-Chemical
convulsions,4197,B-Disease
in,4197,O
the,4197,O
Swiss,4197,O
albino,4197,O
mice,4197,O
.,4197,O
A,4198,O
total,4198,O
of,4198,O
69,4198,O
mice,4198,O
",",4198,O
approximately,4198,O
7,4198,O
weeks,4198,O
of,4198,O
age,4198,O
",",4198,O
and,4198,O
weighing,4198,O
21.0,4198,O
to,4198,O
29.1,4198,O
g,4198,O
were,4198,O
randomly,4198,O
assigned,4198,O
to,4198,O
bupropion,4198,B-Chemical
HCl,4198,I-Chemical
120,4198,O
mg/kg,4198,O
treatment,4198,O
by,4198,O
intraperitoneal,4198,O
(,4198,O
IP,4198,O
),4198,O
administration,4198,O
in,4198,O
7,4198,O
groups,4198,O
(,4198,O
9,4198,O
to,4198,O
10,4198,O
animals,4198,O
per,4198,O
group,4198,O
),4198,O
.,4198,O
Bupropion,4199,B-Chemical
HCl,4199,I-Chemical
was,4199,O
infused,4199,O
through,4199,O
a,4199,O
surgically,4199,O
implanted,4199,O
IP,4199,O
dosing,4199,O
catheter,4199,O
with,4199,O
infusions,4199,O
in,4199,O
each,4199,O
group,4199,O
of,4199,O
0,4199,O
min,4199,O
",",4199,O
15,4199,O
min,4199,O
",",4199,O
30,4199,O
min,4199,O
",",4199,O
60,4199,O
min,4199,O
",",4199,O
90,4199,O
min,4199,O
",",4199,O
120,4199,O
min,4199,O
",",4199,O
and,4199,O
240,4199,O
min,4199,O
.,4199,O
The,4200,O
number,4200,O
",",4200,O
time,4200,O
of,4200,O
onset,4200,O
",",4200,O
duration,4200,O
and,4200,O
the,4200,O
intensity,4200,O
of,4200,O
the,4200,O
convulsions,4200,B-Disease
or,4200,O
absence,4200,O
of,4200,O
convulsions,4200,B-Disease
were,4200,O
recorded,4200,O
.,4200,O
RESULTS,4201,O
:,4201,O
The,4201,O
results,4201,O
showed,4201,O
that,4201,O
IP,4201,O
administration,4201,O
of,4201,O
bupropion,4201,B-Chemical
HCl,4201,I-Chemical
120,4201,O
mg/kg,4201,O
by,4201,O
bolus,4201,O
injection,4201,O
induced,4201,O
convulsions,4201,B-Disease
in,4201,O
6,4201,O
out,4201,O
of,4201,O
10,4201,O
mice,4201,O
(,4201,O
60,4201,O
%,4201,O
of,4201,O
convulsing,4201,O
mice,4201,O
),4201,O
in,4201,O
group,4201,O
1,4201,O
.,4201,O
Logistic,4202,O
regression,4202,O
analysis,4202,O
revealed,4202,O
that,4202,O
infusion,4202,O
time,4202,O
was,4202,O
significant,4202,O
(,4202,O
p,4202,O
=,4202,O
0.0004,4202,O
;,4202,O
odds,4202,O
ratio,4202,O
=,4202,O
0.974,4202,O
),4202,O
and,4202,O
increasing,4202,O
the,4202,O
IP,4202,O
infusion,4202,O
time,4202,O
of,4202,O
bupropion,4202,B-Chemical
HCl,4202,I-Chemical
120,4202,O
mg/kg,4202,O
was,4202,O
associated,4202,O
with,4202,O
a,4202,O
91,4202,O
%,4202,O
reduced,4202,O
odds,4202,O
of,4202,O
convulsions,4202,B-Disease
at,4202,O
infusion,4202,O
times,4202,O
of,4202,O
15,4202,O
to,4202,O
90,4202,O
min,4202,O
compared,4202,O
to,4202,O
bolus,4202,O
injection,4202,O
.,4202,O
Further,4203,O
increase,4203,O
in,4203,O
infusion,4203,O
time,4203,O
resulted,4203,O
in,4203,O
further,4203,O
reduction,4203,O
in,4203,O
the,4203,O
odds,4203,O
of,4203,O
convulsions,4203,B-Disease
to,4203,O
99.8,4203,O
%,4203,O
reduction,4203,O
at,4203,O
240,4203,O
min,4203,O
.,4203,O
CONCLUSION,4204,O
:,4204,O
In,4204,O
conclusion,4204,O
",",4204,O
the,4204,O
demonstration,4204,O
of,4204,O
an,4204,O
inverse,4204,O
relationship,4204,O
between,4204,O
infusion,4204,O
time,4204,O
of,4204,O
a,4204,O
fixed,4204,O
and,4204,O
convulsive,4204,B-Disease
dose,4204,O
of,4204,O
bupropion,4204,B-Chemical
and,4204,O
the,4204,O
risk,4204,O
of,4204,O
convulsions,4204,B-Disease
in,4204,O
a,4204,O
prospective,4204,O
study,4204,O
is,4204,O
novel,4204,O
.,4204,O
Graft-versus-host,4205,B-Disease
disease,4205,I-Disease
prophylaxis,4205,O
with,4205,O
everolimus,4205,B-Chemical
and,4205,O
tacrolimus,4205,B-Chemical
is,4205,O
associated,4205,O
with,4205,O
a,4205,O
high,4205,O
incidence,4205,O
of,4205,O
sinusoidal,4205,B-Disease
obstruction,4205,I-Disease
syndrome,4205,I-Disease
and,4205,O
microangiopathy,4205,B-Disease
:,4205,O
results,4205,O
of,4205,O
the,4205,O
EVTAC,4205,O
trial,4205,O
.,4205,O
A,4206,O
calcineurin,4206,O
inhibitor,4206,O
combined,4206,O
with,4206,O
methotrexate,4206,B-Chemical
is,4206,O
the,4206,O
standard,4206,O
prophylaxis,4206,O
for,4206,O
graft-versus-host,4206,B-Disease
disease,4206,I-Disease
(,4206,O
GVHD,4206,B-Disease
),4206,O
after,4206,O
allogeneic,4206,O
hematopoietic,4206,O
stem,4206,O
cell,4206,O
transplantation,4206,O
(,4206,O
HSCT,4206,O
),4206,O
.,4206,O
Everolimus,4207,B-Chemical
",",4207,O
a,4207,O
derivative,4207,O
of,4207,O
sirolimus,4207,B-Chemical
",",4207,O
seems,4207,O
to,4207,O
mediate,4207,O
antileukemia,4207,O
effects,4207,O
.,4207,O
We,4208,O
report,4208,O
on,4208,O
a,4208,O
combination,4208,O
of,4208,O
everolimus,4208,B-Chemical
and,4208,O
tacrolimus,4208,B-Chemical
in,4208,O
24,4208,O
patients,4208,O
(,4208,O
median,4208,O
age,4208,O
",",4208,O
62,4208,O
years,4208,O
),4208,O
with,4208,O
either,4208,O
myelodysplastic,4208,B-Disease
syndrome,4208,I-Disease
(,4208,O
MDS,4208,B-Disease
;,4208,O
n,4208,O
=,4208,O
17,4208,O
),4208,O
or,4208,O
acute,4208,B-Disease
myeloid,4208,I-Disease
leukemia,4208,I-Disease
(,4208,O
AML,4208,B-Disease
;,4208,O
n,4208,O
=,4208,O
7,4208,O
),4208,O
undergoing,4208,O
intensive,4208,O
conditioning,4208,O
followed,4208,O
by,4208,O
HSCT,4208,O
from,4208,O
related,4208,O
(,4208,O
n,4208,O
=,4208,O
4,4208,O
),4208,O
or,4208,O
unrelated,4208,O
(,4208,O
n,4208,O
=,4208,O
20,4208,O
),4208,O
donors,4208,O
.,4208,O
All,4209,O
patients,4209,O
engrafted,4209,O
",",4209,O
and,4209,O
only,4209,O
1,4209,O
patient,4209,O
experienced,4209,O
grade,4209,O
IV,4209,O
mucositis,4209,B-Disease
.,4209,O
Nine,4210,O
patients,4210,O
(,4210,O
37,4210,O
%,4210,O
),4210,O
developed,4210,O
acute,4210,O
grade,4210,O
II-IV,4210,O
GVHD,4210,B-Disease
",",4210,O
and,4210,O
11,4210,O
of,4210,O
17,4210,O
evaluable,4210,O
patients,4210,O
(,4210,O
64,4210,O
%,4210,O
),4210,O
developed,4210,O
chronic,4210,O
extensive,4210,O
GVHD,4210,B-Disease
.,4210,O
Transplantation-associated,4211,B-Disease
microangiopathy,4211,I-Disease
(,4211,O
TMA,4211,B-Disease
),4211,O
occurred,4211,O
in,4211,O
7,4211,O
patients,4211,O
(,4211,O
29,4211,O
%,4211,O
),4211,O
",",4211,O
with,4211,O
2,4211,O
cases,4211,O
of,4211,O
acute,4211,B-Disease
renal,4211,I-Disease
failure,4211,I-Disease
.,4211,O
The,4212,O
study,4212,O
was,4212,O
terminated,4212,O
prematurely,4212,O
because,4212,O
an,4212,O
additional,4212,O
6,4212,O
patients,4212,O
(,4212,O
25,4212,O
%,4212,O
),4212,O
developed,4212,O
sinusoidal,4212,B-Disease
obstruction,4212,I-Disease
syndrome,4212,I-Disease
(,4212,O
SOS,4212,B-Disease
),4212,O
",",4212,O
which,4212,O
was,4212,O
fatal,4212,O
in,4212,O
2,4212,O
cases,4212,O
.,4212,O
With,4213,O
a,4213,O
median,4213,O
follow-up,4213,O
of,4213,O
26,4213,O
months,4213,O
",",4213,O
the,4213,O
2-year,4213,O
overall,4213,O
survival,4213,O
rate,4213,O
was,4213,O
47,4213,O
%,4213,O
.,4213,O
Although,4214,O
this,4214,O
new,4214,O
combination,4214,O
appears,4214,O
to,4214,O
be,4214,O
effective,4214,O
as,4214,O
a,4214,O
prophylactic,4214,O
regimen,4214,O
for,4214,O
acute,4214,O
GVHD,4214,B-Disease
",",4214,O
the,4214,O
incidence,4214,O
of,4214,O
TMA,4214,B-Disease
and,4214,O
SOS,4214,B-Disease
is,4214,O
considerably,4214,O
higher,4214,O
than,4214,O
seen,4214,O
with,4214,O
other,4214,O
regimens,4214,O
.,4214,O
Longitudinal,4215,O
assessment,4215,O
of,4215,O
air,4215,O
conduction,4215,O
audiograms,4215,O
in,4215,O
a,4215,O
phase,4215,O
III,4215,O
clinical,4215,O
trial,4215,O
of,4215,O
difluoromethylornithine,4215,B-Chemical
and,4215,O
sulindac,4215,B-Chemical
for,4215,O
prevention,4215,O
of,4215,O
sporadic,4215,O
colorectal,4215,B-Disease
adenomas,4215,I-Disease
.,4215,O
A,4216,O
phase,4216,O
III,4216,O
clinical,4216,O
trial,4216,O
assessed,4216,O
the,4216,O
recurrence,4216,O
of,4216,O
adenomatous,4216,B-Disease
polyps,4216,I-Disease
after,4216,O
treatment,4216,O
for,4216,O
36,4216,O
months,4216,O
with,4216,O
difluoromethylornithine,4216,B-Chemical
(,4216,O
DFMO,4216,B-Chemical
),4216,O
plus,4216,O
sulindac,4216,B-Chemical
or,4216,O
matched,4216,O
placebos,4216,O
.,4216,O
Temporary,4217,O
hearing,4217,B-Disease
loss,4217,I-Disease
is,4217,O
a,4217,O
known,4217,O
toxicity,4217,B-Disease
of,4217,O
treatment,4217,O
with,4217,O
DFMO,4217,B-Chemical
",",4217,O
thus,4217,O
a,4217,O
comprehensive,4217,O
approach,4217,O
was,4217,O
developed,4217,O
to,4217,O
analyze,4217,O
serial,4217,O
air,4217,O
conduction,4217,O
audiograms,4217,O
.,4217,O
The,4218,O
generalized,4218,O
estimating,4218,O
equation,4218,O
method,4218,O
estimated,4218,O
the,4218,O
mean,4218,O
difference,4218,O
between,4218,O
treatment,4218,O
arms,4218,O
with,4218,O
regard,4218,O
to,4218,O
change,4218,O
in,4218,O
air,4218,O
conduction,4218,O
pure,4218,O
tone,4218,O
thresholds,4218,O
while,4218,O
accounting,4218,O
for,4218,O
within-subject,4218,O
correlation,4218,O
due,4218,O
to,4218,O
repeated,4218,O
measurements,4218,O
at,4218,O
frequencies,4218,O
.,4218,O
Based,4219,O
on,4219,O
290,4219,O
subjects,4219,O
",",4219,O
there,4219,O
was,4219,O
an,4219,O
average,4219,O
difference,4219,O
of,4219,O
0.50,4219,O
dB,4219,O
between,4219,O
subjects,4219,O
treated,4219,O
with,4219,O
DFMO,4219,B-Chemical
plus,4219,O
sulindac,4219,B-Chemical
compared,4219,O
with,4219,O
those,4219,O
treated,4219,O
with,4219,O
placebo,4219,O
(,4219,O
95,4219,O
%,4219,O
confidence,4219,O
interval,4219,O
",",4219,O
-0.64,4219,O
to,4219,O
1.63,4219,O
dB,4219,O
;,4219,O
P,4219,O
=,4219,O
0.39,4219,O
),4219,O
",",4219,O
adjusted,4219,O
for,4219,O
baseline,4219,O
values,4219,O
",",4219,O
age,4219,O
",",4219,O
and,4219,O
frequencies,4219,O
.,4219,O
In,4220,O
the,4220,O
normal,4220,O
speech,4220,O
range,4220,O
of,4220,O
500,4220,O
to,4220,O
"3,000",4220,O
Hz,4220,O
",",4220,O
an,4220,O
estimated,4220,O
difference,4220,O
of,4220,O
0.99,4220,O
dB,4220,O
(,4220,O
-0.17,4220,O
to,4220,O
2.14,4220,O
dB,4220,O
;,4220,O
P,4220,O
=,4220,O
0.09,4220,O
),4220,O
was,4220,O
detected,4220,O
.,4220,O
Dose,4221,O
intensity,4221,O
did,4221,O
not,4221,O
add,4221,O
information,4221,O
to,4221,O
models,4221,O
.,4221,O
There,4222,O
were,4222,O
14,4222,O
of,4222,O
151,4222,O
(,4222,O
9.3,4222,O
%,4222,O
),4222,O
in,4222,O
the,4222,O
DFMO,4222,B-Chemical
plus,4222,O
sulindac,4222,B-Chemical
group,4222,O
and,4222,O
4,4222,O
of,4222,O
139,4222,O
(,4222,O
2.9,4222,O
%,4222,O
),4222,O
in,4222,O
the,4222,O
placebo,4222,O
group,4222,O
who,4222,O
experienced,4222,O
at,4222,O
least,4222,O
15,4222,O
dB,4222,O
hearing,4222,O
reduction,4222,O
from,4222,O
baseline,4222,O
in,4222,O
2,4222,O
or,4222,O
more,4222,O
consecutive,4222,O
frequencies,4222,O
across,4222,O
the,4222,O
entire,4222,O
range,4222,O
tested,4222,O
(,4222,O
P,4222,O
=,4222,O
0.02,4222,O
),4222,O
.,4222,O
Follow-up,4223,O
air,4223,O
conduction,4223,O
done,4223,O
at,4223,O
least,4223,O
6,4223,O
months,4223,O
after,4223,O
end,4223,O
of,4223,O
treatment,4223,O
showed,4223,O
an,4223,O
adjusted,4223,O
mean,4223,O
difference,4223,O
in,4223,O
hearing,4223,O
thresholds,4223,O
of,4223,O
1.08,4223,O
dB,4223,O
(,4223,O
-0.81,4223,O
to,4223,O
2.96,4223,O
dB,4223,O
;,4223,O
P,4223,O
=,4223,O
0.26,4223,O
),4223,O
between,4223,O
treatment,4223,O
arms,4223,O
.,4223,O
There,4224,O
was,4224,O
no,4224,O
significant,4224,O
difference,4224,O
in,4224,O
the,4224,O
proportion,4224,O
of,4224,O
subjects,4224,O
in,4224,O
the,4224,O
DFMO,4224,B-Chemical
plus,4224,O
sulindac,4224,B-Chemical
group,4224,O
who,4224,O
experienced,4224,O
clinically,4224,O
significant,4224,O
hearing,4224,B-Disease
loss,4224,I-Disease
compared,4224,O
with,4224,O
the,4224,O
placebo,4224,O
group,4224,O
.,4224,O
The,4225,O
estimated,4225,O
attributable,4225,O
risk,4225,O
of,4225,O
ototoxicity,4225,B-Disease
from,4225,O
exposure,4225,O
to,4225,O
the,4225,O
drug,4225,O
is,4225,O
8.4,4225,O
%,4225,O
(,4225,O
95,4225,O
%,4225,O
confidence,4225,O
interval,4225,O
",",4225,O
-2.0,4225,O
%,4225,O
to,4225,O
18.8,4225,O
%,4225,O
;,4225,O
P,4225,O
=,4225,O
0.12,4225,O
),4225,O
.,4225,O
There,4226,O
is,4226,O
a,4226,O
<,4226,O
2,4226,O
dB,4226,O
difference,4226,O
in,4226,O
mean,4226,O
threshold,4226,O
for,4226,O
patients,4226,O
treated,4226,O
with,4226,O
DFMO,4226,B-Chemical
plus,4226,O
sulindac,4226,B-Chemical
compared,4226,O
with,4226,O
those,4226,O
treated,4226,O
with,4226,O
placebo,4226,O
.,4226,O
Proteinase,4227,O
3-antineutrophil,4227,O
cytoplasmic,4227,O
antibody-,4227,O
(,4227,O
PR3-ANCA,4227,O
),4227,O
positive,4227,O
necrotizing,4227,O
glomerulonephritis,4227,B-Disease
after,4227,O
restarting,4227,O
sulphasalazine,4227,B-Chemical
treatment,4227,O
.,4227,O
A,4228,O
59-year-old,4228,O
woman,4228,O
with,4228,O
ulcerative,4228,B-Disease
colitis,4228,I-Disease
developed,4228,O
red,4228,B-Disease
eyes,4228,I-Disease
",",4228,O
pleural,4228,B-Disease
effusion,4228,I-Disease
",",4228,O
eosinophilia,4228,B-Disease
and,4228,O
urinary,4228,B-Disease
abnormalities,4228,I-Disease
after,4228,O
restarting,4228,O
of,4228,O
sulphasalazine,4228,B-Chemical
treatment,4228,O
.,4228,O
Light,4229,O
microscopy,4229,O
of,4229,O
a,4229,O
kidney,4229,O
biopsy,4229,O
revealed,4229,O
segmental,4229,B-Disease
necrotizing,4229,I-Disease
glomerulonephritis,4229,I-Disease
without,4229,O
deposition,4229,O
of,4229,O
immunoglobulin,4229,O
or,4229,O
complement,4229,O
.,4229,O
Proteinase,4230,O
3-antineutrophil,4230,O
cytoplasmic,4230,O
antibody,4230,O
(,4230,O
PR3-ANCA,4230,O
),4230,O
titer,4230,O
was,4230,O
elevated,4230,O
at,4230,O
183,4230,O
ELISA,4230,O
units,4230,O
(,4230,O
EU,4230,O
),4230,O
in,4230,O
sera,4230,O
(,4230,O
normal,4230,O
range,4230,O
less,4230,O
than,4230,O
10,4230,O
EU,4230,O
),4230,O
",",4230,O
myeloperoxidase-ANCA,4230,O
was,4230,O
negative,4230,O
.,4230,O
PR3-ANCA,4231,O
titer,4231,O
was,4231,O
250,4231,O
and,4231,O
"1,070",4231,O
EU,4231,O
in,4231,O
pleural,4231,B-Disease
effusions,4231,I-Disease
on,4231,O
right,4231,O
and,4231,O
left,4231,O
side,4231,O
",",4231,O
respectively,4231,O
.,4231,O
Although,4232,O
cessation,4232,O
of,4232,O
sulphasalazine,4232,B-Chemical
treatment,4232,O
resulted,4232,O
in,4232,O
improvements,4232,O
in,4232,O
fever,4232,B-Disease
",",4232,O
red,4232,B-Disease
eyes,4232,I-Disease
",",4232,O
chest,4232,B-Disease
pain,4232,I-Disease
",",4232,O
titer,4232,O
of,4232,O
C-reactive,4232,O
protein,4232,O
and,4232,O
volume,4232,O
of,4232,O
the,4232,O
pleural,4232,B-Disease
effusions,4232,I-Disease
",",4232,O
we,4232,O
initiated,4232,O
steroid,4232,B-Chemical
therapy,4232,O
",",4232,O
because,4232,O
PR3-ANCA,4232,O
titer,4232,O
rose,4232,O
to,4232,O
320,4232,O
EU,4232,O
",",4232,O
eosinophil,4232,O
count,4232,O
increased,4232,O
to,4232,O
"1,100",4232,O
cells/microl,4232,O
",",4232,O
and,4232,O
the,4232,O
pleural,4232,B-Disease
effusion,4232,I-Disease
remained,4232,O
.,4232,O
One,4233,O
month,4233,O
after,4233,O
steroid,4233,B-Chemical
therapy,4233,O
",",4233,O
the,4233,O
pleural,4233,B-Disease
effusion,4233,I-Disease
disappeared,4233,O
",",4233,O
and,4233,O
PR3-ANCA,4233,O
titer,4233,O
normalized,4233,O
3,4233,O
months,4233,O
later,4233,O
.,4233,O
This,4234,O
case,4234,O
suggests,4234,O
that,4234,O
sulphasalazine,4234,B-Chemical
can,4234,O
induce,4234,O
PR3-ANCA-positive,4234,O
necrotizing,4234,O
glomerulonephritis,4234,B-Disease
.,4234,O
Comparison,4235,O
of,4235,O
unilateral,4235,O
pallidotomy,4235,O
and,4235,O
subthalamotomy,4235,O
findings,4235,O
in,4235,O
advanced,4235,O
idiopathic,4235,B-Disease
Parkinson,4235,I-Disease
's,4235,I-Disease
disease,4235,I-Disease
.,4235,O
A,4236,O
prospective,4236,O
",",4236,O
randomized,4236,O
",",4236,O
double-blind,4236,O
pilot,4236,O
study,4236,O
to,4236,O
compare,4236,O
the,4236,O
results,4236,O
of,4236,O
stereotactic,4236,O
unilateral,4236,O
pallidotomy,4236,O
and,4236,O
subthalamotomy,4236,O
in,4236,O
advanced,4236,O
idiopathic,4236,B-Disease
Parkinson,4236,I-Disease
's,4236,I-Disease
disease,4236,I-Disease
(,4236,O
PD,4236,B-Disease
),4236,O
refractory,4236,O
to,4236,O
medical,4236,O
treatment,4236,O
was,4236,O
designed,4236,O
.,4236,O
Ten,4237,O
consecutive,4237,O
patients,4237,O
(,4237,O
mean,4237,O
age,4237,O
",",4237,O
58.4,4237,O
+/-,4237,O
6.8,4237,O
years,4237,O
;,4237,O
7,4237,O
men,4237,O
",",4237,O
3,4237,O
women,4237,O
),4237,O
with,4237,O
similar,4237,O
characteristics,4237,O
at,4237,O
the,4237,O
duration,4237,O
of,4237,O
disease,4237,O
(,4237,O
mean,4237,O
disease,4237,O
time,4237,O
",",4237,O
8.4,4237,O
+/-,4237,O
3.5,4237,O
years,4237,O
),4237,O
",",4237,O
disabling,4237,O
motor,4237,O
fluctuations,4237,O
(,4237,O
Hoehn,4237,O
_,4237,O
Yahr,4237,O
stage,4237,O
3-5,4237,O
in,4237,O
off-drug,4237,O
phases,4237,O
),4237,O
and,4237,O
levodopa-induced,4237,B-Chemical
dyskinesias,4237,B-Disease
were,4237,O
selected,4237,O
.,4237,O
All,4238,O
patients,4238,O
had,4238,O
bilateral,4238,O
symptoms,4238,O
and,4238,O
their,4238,O
levodopa,4238,B-Chemical
equivalent,4238,O
dosing,4238,O
were,4238,O
analysed,4238,O
.,4238,O
Six,4239,O
patients,4239,O
were,4239,O
operated,4239,O
on,4239,O
in,4239,O
the,4239,O
globus,4239,O
pallidus,4239,O
interna,4239,O
(,4239,O
GPi,4239,O
),4239,O
and,4239,O
four,4239,O
in,4239,O
the,4239,O
subthalamic,4239,O
nucleus,4239,O
(,4239,O
STN,4239,O
),4239,O
.,4239,O
Clinical,4240,O
evaluation,4240,O
included,4240,O
the,4240,O
use,4240,O
of,4240,O
the,4240,O
Unified,4240,O
Parkinson,4240,B-Disease
's,4240,I-Disease
Disease,4240,I-Disease
Rating,4240,O
Scale,4240,O
(,4240,O
UPDRS,4240,O
),4240,O
",",4240,O
Hoehn_Yahr,4240,O
score,4240,O
and,4240,O
Schwab,4240,O
England,4240,O
activities,4240,O
of,4240,O
daily,4240,O
living,4240,O
(,4240,O
ADL,4240,O
),4240,O
score,4240,O
in,4240,O
'on'-,4240,O
and,4240,O
'off'-drug,4240,O
conditions,4240,O
before,4240,O
surgery,4240,O
and,4240,O
6,4240,O
months,4240,O
after,4240,O
surgery,4240,O
.,4240,O
There,4241,O
was,4241,O
statistically,4241,O
significant,4241,O
improvement,4241,O
in,4241,O
all,4241,O
contralateral,4241,O
major,4241,O
parkinsonian,4241,B-Disease
motor,4241,O
signs,4241,O
in,4241,O
all,4241,O
patients,4241,O
followed,4241,O
for,4241,O
6,4241,O
months,4241,O
.,4241,O
Levodopa,4242,B-Chemical
equivalent,4242,O
daily,4242,O
intake,4242,O
was,4242,O
significantly,4242,O
reduced,4242,O
in,4242,O
the,4242,O
STN,4242,O
group,4242,O
.,4242,O
Changes,4243,O
in,4243,O
UPDRS,4243,O
",",4243,O
Hoehn,4243,O
_,4243,O
Yahr,4243,O
and,4243,O
Schwab,4243,O
England,4243,O
ADL,4243,O
scores,4243,O
were,4243,O
similar,4243,O
in,4243,O
both,4243,O
groups,4243,O
.,4243,O
Cognitive,4244,O
functions,4244,O
were,4244,O
unchanged,4244,O
in,4244,O
both,4244,O
groups,4244,O
.,4244,O
Complications,4245,O
were,4245,O
observed,4245,O
in,4245,O
two,4245,O
patients,4245,O
:,4245,O
one,4245,O
had,4245,O
a,4245,O
left,4245,O
homonymous,4245,B-Disease
hemianopsia,4245,I-Disease
after,4245,O
pallidotomy,4245,O
and,4245,O
another,4245,O
one,4245,O
developed,4245,O
left,4245,O
hemiballistic,4245,O
movements,4245,O
3,4245,O
days,4245,O
after,4245,O
subthalamotomy,4245,O
which,4245,O
partly,4245,O
improved,4245,O
within,4245,O
1,4245,O
month,4245,O
with,4245,O
Valproate,4245,B-Chemical
1000,4245,O
mg/day,4245,O
.,4245,O
The,4246,O
findings,4246,O
of,4246,O
this,4246,O
study,4246,O
suggest,4246,O
that,4246,O
lesions,4246,O
of,4246,O
the,4246,O
unilateral,4246,O
STN,4246,O
and,4246,O
GPi,4246,O
are,4246,O
equally,4246,O
effective,4246,O
treatment,4246,O
for,4246,O
patients,4246,O
with,4246,O
advanced,4246,O
PD,4246,B-Disease
refractory,4246,O
to,4246,O
medical,4246,O
treatment,4246,O
.,4246,O
DSMM,4247,O
XI,4247,O
study,4247,O
:,4247,O
dose,4247,O
definition,4247,O
for,4247,O
intravenous,4247,O
cyclophosphamide,4247,B-Chemical
in,4247,O
combination,4247,O
with,4247,O
bortezomib/dexamethasone,4247,B-Chemical
for,4247,O
remission,4247,O
induction,4247,O
in,4247,O
patients,4247,O
with,4247,O
newly,4247,O
diagnosed,4247,O
myeloma,4247,B-Disease
.,4247,O
A,4248,O
clinical,4248,O
trial,4248,O
was,4248,O
initiated,4248,O
to,4248,O
evaluate,4248,O
the,4248,O
recommended,4248,O
dose,4248,O
of,4248,O
cyclophosphamide,4248,B-Chemical
in,4248,O
combination,4248,O
with,4248,O
bortezomib,4248,B-Chemical
and,4248,O
dexamethasone,4248,B-Chemical
as,4248,O
induction,4248,O
treatment,4248,O
before,4248,O
stem,4248,O
cell,4248,O
transplantation,4248,O
for,4248,O
younger,4248,O
patients,4248,O
with,4248,O
newly,4248,O
diagnosed,4248,O
multiple,4248,B-Disease
myeloma,4248,I-Disease
(,4248,O
MM,4248,B-Disease
),4248,O
.,4248,O
Thirty,4249,O
patients,4249,O
were,4249,O
treated,4249,O
with,4249,O
three,4249,O
21-day,4249,O
cycles,4249,O
of,4249,O
bortezomib,4249,B-Chemical
1.3,4249,O
mg/m,4249,O
(,4249,O
2,4249,O
),4249,O
on,4249,O
days,4249,O
1,4249,O
",",4249,O
4,4249,O
",",4249,O
8,4249,O
",",4249,O
and,4249,O
11,4249,O
plus,4249,O
dexamethasone,4249,B-Chemical
40,4249,O
mg,4249,O
on,4249,O
the,4249,O
day,4249,O
of,4249,O
bortezomib,4249,B-Chemical
injection,4249,O
and,4249,O
the,4249,O
day,4249,O
after,4249,O
plus,4249,O
cyclophosphamide,4249,B-Chemical
at,4249,O
900,4249,O
",",4249,O
"1,200",4249,O
",",4249,O
or,4249,O
"1,500",4249,O
mg/m,4249,O
(,4249,O
2,4249,O
),4249,O
on,4249,O
day,4249,O
1,4249,O
.,4249,O
The,4250,O
maximum,4250,O
tolerated,4250,O
dose,4250,O
of,4250,O
cyclophosphamide,4250,B-Chemical
was,4250,O
defined,4250,O
as,4250,O
900,4250,O
mg/m,4250,O
(,4250,O
2,4250,O
),4250,O
.,4250,O
At,4251,O
this,4251,O
dose,4251,O
level,4251,O
",",4251,O
92,4251,O
%,4251,O
of,4251,O
patients,4251,O
achieved,4251,O
at,4251,O
least,4251,O
a,4251,O
partial,4251,O
response,4251,O
.,4251,O
The,4252,O
overall,4252,O
response,4252,O
rate,4252,O
[,4252,O
complete,4252,O
response,4252,O
(,4252,O
CR,4252,O
),4252,O
plus,4252,O
partial,4252,O
response,4252,O
(,4252,O
PR,4252,O
),4252,O
],4252,O
across,4252,O
all,4252,O
dose,4252,O
levels,4252,O
was,4252,O
77,4252,O
%,4252,O
",",4252,O
with,4252,O
a,4252,O
10,4252,O
%,4252,O
CR,4252,O
rate,4252,O
.,4252,O
No,4253,O
patient,4253,O
experienced,4253,O
progressive,4253,O
disease,4253,O
.,4253,O
The,4254,O
most,4254,O
frequent,4254,O
adverse,4254,O
events,4254,O
were,4254,O
hematological,4254,O
and,4254,O
gastrointestinal,4254,O
toxicities,4254,O
as,4254,O
well,4254,O
as,4254,O
neuropathy,4254,B-Disease
.,4254,O
The,4255,O
results,4255,O
suggest,4255,O
that,4255,O
bortezomib,4255,B-Chemical
in,4255,O
combination,4255,O
with,4255,O
cyclophosphamide,4255,B-Chemical
at,4255,O
900,4255,O
mg/m,4255,O
(,4255,O
2,4255,O
),4255,O
and,4255,O
dexamethasone,4255,B-Chemical
is,4255,O
an,4255,O
effective,4255,O
induction,4255,O
treatment,4255,O
for,4255,O
patients,4255,O
with,4255,O
newly,4255,O
diagnosed,4255,O
MM,4255,B-Disease
that,4255,O
warrants,4255,O
further,4255,O
investigation,4255,O
.,4255,O
Identification,4256,O
of,4256,O
a,4256,O
simple,4256,O
and,4256,O
sensitive,4256,O
microplate,4256,O
method,4256,O
for,4256,O
the,4256,O
detection,4256,O
of,4256,O
oversulfated,4256,O
chondroitin,4256,B-Chemical
sulfate,4256,I-Chemical
in,4256,O
heparin,4256,B-Chemical
products,4256,O
.,4256,O
Heparin,4257,B-Chemical
is,4257,O
a,4257,O
commonly,4257,O
implemented,4257,O
anticoagulant,4257,O
used,4257,O
to,4257,O
treat,4257,O
critically,4257,O
ill,4257,O
patients,4257,O
.,4257,O
Recently,4258,O
",",4258,O
a,4258,O
number,4258,O
of,4258,O
commercial,4258,O
lots,4258,O
of,4258,O
heparin,4258,B-Chemical
products,4258,O
were,4258,O
found,4258,O
to,4258,O
be,4258,O
contaminated,4258,O
with,4258,O
an,4258,O
oversulfated,4258,O
chondroitin,4258,B-Chemical
sulfate,4258,I-Chemical
(,4258,O
OSCS,4258,O
),4258,O
derivative,4258,O
that,4258,O
could,4258,O
elicit,4258,O
a,4258,O
hypotensive,4258,B-Disease
response,4258,O
in,4258,O
pigs,4258,O
following,4258,O
a,4258,O
single,4258,O
high-dose,4258,O
infusion,4258,O
.,4258,O
Using,4259,O
both,4259,O
contaminated,4259,O
heparin,4259,B-Chemical
products,4259,O
and,4259,O
the,4259,O
synthetically,4259,O
produced,4259,O
derivative,4259,O
",",4259,O
we,4259,O
showed,4259,O
that,4259,O
the,4259,O
OSCS,4259,O
produces,4259,O
dose-dependent,4259,O
hypotension,4259,B-Disease
in,4259,O
pigs,4259,O
.,4259,O
The,4260,O
no,4260,O
observed,4260,O
effect,4260,O
level,4260,O
(,4260,O
NOEL,4260,O
),4260,O
for,4260,O
this,4260,O
contaminant,4260,O
appears,4260,O
to,4260,O
be,4260,O
approximately,4260,O
1mg/kg,4260,O
",",4260,O
corresponding,4260,O
to,4260,O
a,4260,O
contamination,4260,O
level,4260,O
of,4260,O
approximately,4260,O
3,4260,O
%,4260,O
.,4260,O
We,4261,O
also,4261,O
demonstrated,4261,O
that,4261,O
OSCS,4261,O
can,4261,O
be,4261,O
identified,4261,O
in,4261,O
heparin,4261,B-Chemical
products,4261,O
using,4261,O
a,4261,O
simple,4261,O
",",4261,O
inexpensive,4261,O
",",4261,O
commercially,4261,O
available,4261,O
heparin,4261,B-Chemical
enzyme,4261,O
immunoassay,4261,O
(,4261,O
EIA,4261,O
),4261,O
kit,4261,O
that,4261,O
has,4261,O
a,4261,O
limit,4261,O
of,4261,O
detection,4261,O
of,4261,O
approximately,4261,O
0.1,4261,O
%,4261,O
",",4261,O
well,4261,O
below,4261,O
the,4261,O
NOEL,4261,O
.,4261,O
This,4262,O
kit,4262,O
may,4262,O
provide,4262,O
a,4262,O
useful,4262,O
method,4262,O
to,4262,O
test,4262,O
heparin,4262,B-Chemical
products,4262,O
for,4262,O
contamination,4262,O
with,4262,O
oversulfated,4262,O
GAG,4262,O
derivatives,4262,O
.,4262,O
5,4263,B-Chemical
flourouracil-induced,4263,O
apical,4263,B-Disease
ballooning,4263,I-Disease
syndrome,4263,I-Disease
:,4263,O
a,4263,O
case,4263,O
report,4263,O
.,4263,O
The,4264,O
apical,4264,B-Disease
ballooning,4264,I-Disease
syndrome,4264,I-Disease
(,4264,O
ABS,4264,B-Disease
),4264,O
is,4264,O
a,4264,O
recently,4264,O
described,4264,O
stress-mediated,4264,O
acute,4264,B-Disease
cardiac,4264,I-Disease
syndrome,4264,I-Disease
characterized,4264,O
by,4264,O
transient,4264,O
wall-motion,4264,O
abnormalities,4264,O
involving,4264,O
the,4264,O
apex,4264,O
and,4264,O
midventricle,4264,O
with,4264,O
hyperkinesis,4264,B-Disease
of,4264,O
the,4264,O
basal,4264,O
left,4264,O
ventricular,4264,O
(,4264,O
LV,4264,O
),4264,O
segments,4264,O
without,4264,O
obstructive,4264,O
epicardial,4264,B-Disease
coronary,4264,I-Disease
disease,4264,I-Disease
.,4264,O
Cardiotoxicity,4265,B-Disease
is,4265,O
not,4265,O
an,4265,O
uncommon,4265,O
adverse,4265,O
effect,4265,O
of,4265,O
chemotherapeutic,4265,O
agents,4265,O
.,4265,O
However,4266,O
",",4266,O
there,4266,O
are,4266,O
no,4266,O
reports,4266,O
of,4266,O
ABS,4266,B-Disease
secondary,4266,O
to,4266,O
chemotherapeutic,4266,O
agents,4266,O
.,4266,O
We,4267,O
describe,4267,O
the,4267,O
case,4267,O
of,4267,O
a,4267,O
woman,4267,O
who,4267,O
developed,4267,O
the,4267,O
syndrome,4267,O
after,4267,O
chemotherapy,4267,O
for,4267,O
metastatic,4267,O
cancer,4267,B-Disease
.,4267,O
A,4268,O
79-year-old,4268,O
woman,4268,O
presented,4268,O
with,4268,O
typical,4268,O
ischemic,4268,B-Disease
chest,4268,B-Disease
pain,4268,I-Disease
",",4268,O
elevated,4268,O
cardiac,4268,O
enzymes,4268,O
with,4268,O
significant,4268,O
ST-segment,4268,O
abnormalities,4268,O
on,4268,O
her,4268,O
electrocardiogram,4268,O
.,4268,O
She,4269,O
underwent,4269,O
recent,4269,O
chemotherapy,4269,O
with,4269,O
fluorouracil,4269,B-Chemical
for,4269,O
metastatic,4269,O
colorectal,4269,B-Disease
cancer,4269,I-Disease
.,4269,O
Echocardiography,4270,O
revealed,4270,O
a,4270,O
wall-motion,4270,O
abnormality,4270,O
involving,4270,O
the,4270,O
apical,4270,O
and,4270,O
periapical,4270,O
segments,4270,O
which,4270,O
appeared,4270,O
akinetic,4270,B-Disease
.,4270,O
Coronary,4271,O
angiography,4271,O
revealed,4271,O
no,4271,O
obstructive,4271,O
coronary,4271,O
lesions,4271,O
.,4271,O
The,4272,O
patient,4272,O
was,4272,O
stabilized,4272,O
with,4272,O
medical,4272,O
therapy,4272,O
.,4272,O
Four,4273,O
weeks,4273,O
later,4273,O
she,4273,O
remained,4273,O
completely,4273,O
asymptomatic,4273,O
.,4273,O
Echocardiogram,4274,O
revealed,4274,O
a,4274,O
normal,4274,O
ejection,4274,O
fraction,4274,O
and,4274,O
a,4274,O
resolution,4274,O
of,4274,O
the,4274,O
apical,4274,O
akinesis,4274,B-Disease
.,4274,O
Pathogenetic,4275,O
mechanisms,4275,O
of,4275,O
cardiac,4275,B-Disease
complications,4275,I-Disease
in,4275,O
cancer,4275,B-Disease
patients,4275,O
undergoing,4275,O
chemotherapy,4275,O
include,4275,O
coronary,4275,B-Disease
vasospasm,4275,I-Disease
",",4275,O
endothelial,4275,O
damage,4275,O
and,4275,O
consequent,4275,O
thrombus,4275,B-Disease
formation,4275,O
.,4275,O
In,4276,O
our,4276,O
patient,4276,O
",",4276,O
both,4276,O
supraphysiologic,4276,O
levels,4276,O
of,4276,O
plasma,4276,O
catecholamines,4276,B-Chemical
and,4276,O
stress,4276,O
related,4276,O
neuropeptides,4276,O
caused,4276,O
by,4276,O
cancer,4276,B-Disease
diagnosis,4276,O
as,4276,O
well,4276,O
as,4276,O
chemotherapy,4276,O
may,4276,O
have,4276,O
contributed,4276,O
the,4276,O
development,4276,O
of,4276,O
ABS,4276,B-Disease
.,4276,O
Rapid,4277,O
reversal,4277,O
of,4277,O
anticoagulation,4277,O
reduces,4277,O
hemorrhage,4277,B-Disease
volume,4277,O
in,4277,O
a,4277,O
mouse,4277,O
model,4277,O
of,4277,O
warfarin-associated,4277,B-Chemical
intracerebral,4277,B-Disease
hemorrhage,4277,I-Disease
.,4277,O
Warfarin-associated,4278,B-Chemical
intracerebral,4278,B-Disease
hemorrhage,4278,I-Disease
(,4278,O
W-ICH,4278,O
),4278,O
is,4278,O
a,4278,O
severe,4278,O
type,4278,O
of,4278,O
stroke,4278,B-Disease
.,4278,O
There,4279,O
is,4279,O
no,4279,O
consensus,4279,O
on,4279,O
the,4279,O
optimal,4279,O
treatment,4279,O
for,4279,O
W-ICH,4279,O
.,4279,O
Using,4280,O
a,4280,O
mouse,4280,O
model,4280,O
",",4280,O
we,4280,O
tested,4280,O
whether,4280,O
the,4280,O
rapid,4280,O
reversal,4280,O
of,4280,O
anticoagulation,4280,O
using,4280,O
human,4280,O
prothrombin,4280,B-Chemical
complex,4280,I-Chemical
concentrate,4280,I-Chemical
(,4280,O
PCC,4280,B-Chemical
),4280,O
can,4280,O
reduce,4280,O
hemorrhagic,4280,O
blood,4280,O
volume,4280,O
.,4280,O
Male,4281,O
CD-1,4281,O
mice,4281,O
were,4281,O
treated,4281,O
with,4281,O
warfarin,4281,B-Chemical
(,4281,O
2,4281,O
mg/kg,4281,O
over,4281,O
24,4281,O
h,4281,O
),4281,O
",",4281,O
resulting,4281,O
in,4281,O
a,4281,O
mean,4281,O
(,4281,O
+/-s.d,4281,O
.,4281,O
),4281,O
International,4282,O
Normalized,4282,O
Ratio,4282,O
of,4282,O
3.5+/-0.9,4282,O
.,4282,O
First,4283,O
",",4283,O
we,4283,O
showed,4283,O
that,4283,O
an,4283,O
intravenous,4283,O
administration,4283,O
of,4283,O
human,4283,O
PCC,4283,B-Chemical
rapidly,4283,O
reversed,4283,O
anticoagulation,4283,O
in,4283,O
mice,4283,O
.,4283,O
Second,4284,O
",",4284,O
a,4284,O
stereotactic,4284,O
injection,4284,O
of,4284,O
collagenase,4284,O
was,4284,O
administered,4284,O
to,4284,O
induce,4284,O
hemorrhage,4284,B-Disease
in,4284,O
the,4284,O
right,4284,O
striatum,4284,O
.,4284,O
Forty-five,4285,O
minutes,4285,O
later,4285,O
",",4285,O
the,4285,O
animals,4285,O
were,4285,O
randomly,4285,O
treated,4285,O
with,4285,O
PCC,4285,B-Chemical
(,4285,O
100,4285,O
U/kg,4285,O
),4285,O
or,4285,O
saline,4285,O
i.v,4285,O
.,4285,O
(,4286,O
n=12,4286,O
per,4286,O
group,4286,O
),4286,O
.,4286,O
Twenty-four,4287,O
hours,4287,O
after,4287,O
hemorrhage,4287,B-Disease
induction,4287,O
",",4287,O
hemorrhagic,4287,O
blood,4287,O
volume,4287,O
was,4287,O
quantified,4287,O
using,4287,O
a,4287,O
photometric,4287,O
hemoglobin,4287,O
assay,4287,O
.,4287,O
The,4288,O
mean,4288,O
hemorrhagic,4288,O
blood,4288,O
volume,4288,O
was,4288,O
reduced,4288,O
in,4288,O
PCC-treated,4288,B-Chemical
animals,4288,O
(,4288,O
6.5+/-3.1,4288,O
microL,4288,O
),4288,O
compared,4288,O
with,4288,O
saline,4288,O
controls,4288,O
(,4288,O
15.3+/-11.2,4288,O
microL,4288,O
",",4288,O
P=0.015,4288,O
),4288,O
.,4288,O
In,4289,O
the,4289,O
saline,4289,O
group,4289,O
",",4289,O
45,4289,O
%,4289,O
of,4289,O
the,4289,O
mice,4289,O
developed,4289,O
large,4289,O
hematomas,4289,B-Disease
(,4289,O
i.e.,4289,O
",",4289,O
>,4289,O
15,4289,O
microL,4289,O
),4289,O
.,4289,O
In,4290,O
contrast,4290,O
",",4290,O
such,4290,O
extensive,4290,O
lesions,4290,O
were,4290,O
never,4290,O
found,4290,O
in,4290,O
the,4290,O
PCC,4290,B-Chemical
group,4290,O
.,4290,O
We,4291,O
provide,4291,O
experimental,4291,O
data,4291,O
suggesting,4291,O
PCC,4291,B-Chemical
to,4291,O
be,4291,O
an,4291,O
effective,4291,O
acute,4291,O
treatment,4291,O
for,4291,O
W-ICH,4291,O
in,4291,O
terms,4291,O
of,4291,O
reducing,4291,O
hemorrhagic,4291,O
blood,4291,O
volume,4291,O
.,4291,O
Future,4292,O
studies,4292,O
are,4292,O
needed,4292,O
to,4292,O
assess,4292,O
the,4292,O
therapeutic,4292,O
potential,4292,O
emerging,4292,O
from,4292,O
our,4292,O
finding,4292,O
for,4292,O
human,4292,O
W-ICH,4292,O
.,4292,O
Long,4293,O
term,4293,O
hormone,4293,O
therapy,4293,O
for,4293,O
perimenopausal,4293,O
and,4293,O
postmenopausal,4293,O
women,4293,O
.,4293,O
BACKGROUND,4294,O
:,4294,O
Hormone,4294,O
therapy,4294,O
(,4294,O
HT,4294,O
),4294,O
is,4294,O
widely,4294,O
used,4294,O
for,4294,O
controlling,4294,O
menopausal,4294,O
symptoms,4294,O
and,4294,O
has,4294,O
also,4294,O
been,4294,O
used,4294,O
for,4294,O
the,4294,O
management,4294,O
and,4294,O
prevention,4294,O
of,4294,O
cardiovascular,4294,B-Disease
disease,4294,I-Disease
",",4294,O
osteoporosis,4294,B-Disease
and,4294,O
dementia,4294,B-Disease
in,4294,O
older,4294,O
women,4294,O
.,4294,O
This,4295,O
is,4295,O
an,4295,O
updated,4295,O
version,4295,O
of,4295,O
the,4295,O
original,4295,O
Cochrane,4295,O
review,4295,O
first,4295,O
published,4295,O
in,4295,O
2005,4295,O
.,4295,O
OBJECTIVES,4296,O
:,4296,O
To,4296,O
assess,4296,O
the,4296,O
effect,4296,O
of,4296,O
long-term,4296,O
HT,4296,O
on,4296,O
mortality,4296,O
",",4296,O
cardiovascular,4296,O
outcomes,4296,O
",",4296,O
cancer,4296,B-Disease
",",4296,O
gallbladder,4296,B-Disease
disease,4296,I-Disease
",",4296,O
cognition,4296,O
",",4296,O
fractures,4296,B-Disease
and,4296,O
quality,4296,O
of,4296,O
life,4296,O
.,4296,O
SEARCH,4297,O
STRATEGY,4297,O
:,4297,O
We,4297,O
searched,4297,O
the,4297,O
following,4297,O
databases,4297,O
to,4297,O
November,4297,O
2007,4297,O
:,4297,O
Trials,4297,O
Register,4297,O
of,4297,O
the,4297,O
Cochrane,4297,O
Menstrual,4297,B-Disease
Disorders,4297,I-Disease
and,4297,O
Subfertility,4297,O
Group,4297,O
",",4297,O
Cochrane,4297,O
Central,4297,O
Register,4297,O
of,4297,O
Controlled,4297,O
Trials,4297,O
",",4297,O
MEDLINE,4297,O
",",4297,O
EMBASE,4297,O
",",4297,O
Biological,4297,O
Abstracts,4297,O
.,4297,O
Also,4298,O
relevant,4298,O
non-indexed,4298,O
journals,4298,O
and,4298,O
conference,4298,O
abstracts,4298,O
.,4298,O
SELECTION,4299,O
CRITERIA,4299,O
:,4299,O
Randomised,4299,O
double-blind,4299,O
trials,4299,O
of,4299,O
HT,4299,O
versus,4299,O
placebo,4299,O
",",4299,O
taken,4299,O
for,4299,O
at,4299,O
least,4299,O
one,4299,O
year,4299,O
by,4299,O
perimenopausal,4299,O
or,4299,O
postmenopausal,4299,O
women,4299,O
.,4299,O
HT,4300,O
included,4300,O
oestrogens,4300,B-Chemical
",",4300,O
with,4300,O
or,4300,O
without,4300,O
progestogens,4300,B-Chemical
",",4300,O
via,4300,O
oral,4300,O
",",4300,O
transdermal,4300,O
",",4300,O
subcutaneous,4300,O
or,4300,O
transnasal,4300,O
routes,4300,O
.,4300,O
DATA,4301,O
COLLECTION,4301,O
AND,4301,O
ANALYSIS,4301,O
:,4301,O
Two,4301,O
authors,4301,O
independently,4301,O
assessed,4301,O
trial,4301,O
quality,4301,O
and,4301,O
extracted,4301,O
data,4301,O
.,4301,O
MAIN,4302,O
RESULTS,4302,O
:,4302,O
Nineteen,4302,O
trials,4302,O
involving,4302,O
"41,904",4302,O
women,4302,O
were,4302,O
included,4302,O
.,4302,O
In,4303,O
relatively,4303,O
healthy,4303,O
women,4303,O
",",4303,O
combined,4303,O
continuous,4303,O
HT,4303,O
significantly,4303,O
increased,4303,O
the,4303,O
risk,4303,O
of,4303,O
venous,4303,B-Disease
thrombo-embolism,4303,I-Disease
or,4303,O
coronary,4303,O
event,4303,O
(,4303,O
after,4303,O
one,4303,O
year,4303,O
's,4303,O
use,4303,O
),4303,O
",",4303,O
stroke,4303,B-Disease
(,4303,O
after,4303,O
three,4303,O
years,4303,O
),4303,O
",",4303,O
breast,4303,B-Disease
cancer,4303,I-Disease
and,4303,O
gallbladder,4303,B-Disease
disease,4303,I-Disease
.,4303,O
Long-term,4304,O
oestrogen-only,4304,B-Chemical
HT,4304,O
significantly,4304,O
increased,4304,O
the,4304,O
risk,4304,O
of,4304,O
venous,4304,B-Disease
thrombo-embolism,4304,I-Disease
",",4304,O
stroke,4304,B-Disease
and,4304,O
gallbladder,4304,B-Disease
disease,4304,I-Disease
(,4304,O
after,4304,O
one,4304,O
to,4304,O
two,4304,O
years,4304,O
",",4304,O
three,4304,O
years,4304,O
and,4304,O
seven,4304,O
years,4304,O
',4304,O
use,4304,O
respectively,4304,O
),4304,O
",",4304,O
but,4304,O
did,4304,O
not,4304,O
significantly,4304,O
increase,4304,O
the,4304,O
risk,4304,O
of,4304,O
breast,4304,B-Disease
cancer,4304,I-Disease
.,4304,O
The,4305,O
only,4305,O
statistically,4305,O
significant,4305,O
benefits,4305,O
of,4305,O
HT,4305,O
were,4305,O
a,4305,O
decreased,4305,O
incidence,4305,O
of,4305,O
fractures,4305,B-Disease
and,4305,O
(,4305,O
for,4305,O
combined,4305,O
HT,4305,O
),4305,O
colon,4305,B-Disease
cancer,4305,I-Disease
",",4305,O
with,4305,O
long-term,4305,O
use,4305,O
.,4305,O
Among,4306,O
women,4306,O
aged,4306,O
over,4306,O
65,4306,O
who,4306,O
were,4306,O
relatively,4306,O
healthy,4306,O
(,4306,O
i.e,4306,O
.,4306,O
generally,4307,O
fit,4307,O
",",4307,O
without,4307,O
overt,4307,O
disease,4307,O
),4307,O
and,4307,O
taking,4307,O
continuous,4307,O
combined,4307,O
HT,4307,O
",",4307,O
there,4307,O
was,4307,O
a,4307,O
statistically,4307,O
significant,4307,O
increase,4307,O
in,4307,O
the,4307,O
incidence,4307,O
of,4307,O
dementia,4307,B-Disease
.,4307,O
Among,4308,O
women,4308,O
with,4308,O
cardiovascular,4308,B-Disease
disease,4308,I-Disease
",",4308,O
long-term,4308,O
use,4308,O
of,4308,O
combined,4308,O
continuous,4308,O
HT,4308,O
significantly,4308,O
increased,4308,O
the,4308,O
risk,4308,O
of,4308,O
venous,4308,B-Disease
thrombo-embolism.One,4308,O
trial,4308,O
analysed,4308,O
subgroups,4308,O
of,4308,O
2839,4308,O
relatively,4308,O
healthy,4308,O
50,4308,O
to,4308,O
59,4308,O
year,4308,O
old,4308,O
women,4308,O
taking,4308,O
combined,4308,O
continuous,4308,O
HT,4308,O
and,4308,O
1637,4308,O
taking,4308,O
oestrogen-only,4308,B-Chemical
HT,4308,O
",",4308,O
versus,4308,O
similar-sized,4308,O
placebo,4308,O
groups,4308,O
.,4308,O
The,4309,O
only,4309,O
significantly,4309,O
increased,4309,O
risk,4309,O
reported,4309,O
was,4309,O
for,4309,O
venous,4309,B-Disease
thrombo-embolism,4309,I-Disease
in,4309,O
women,4309,O
taking,4309,O
combined,4309,O
continuous,4309,O
HT,4309,O
:,4309,O
their,4309,O
absolute,4309,O
risk,4309,O
remained,4309,O
low,4309,O
",",4309,O
at,4309,O
less,4309,O
than,4309,O
1/500,4309,O
.,4309,O
However,4310,O
",",4310,O
this,4310,O
study,4310,O
was,4310,O
not,4310,O
powered,4310,O
to,4310,O
detect,4310,O
differences,4310,O
between,4310,O
groups,4310,O
of,4310,O
younger,4310,O
women,4310,O
.,4310,O
AUTHORS,4311,O
',4311,O
CONCLUSIONS,4311,O
:,4311,O
HT,4311,O
is,4311,O
not,4311,O
indicated,4311,O
for,4311,O
the,4311,O
routine,4311,O
management,4311,O
of,4311,O
chronic,4311,O
disease,4311,O
.,4311,O
We,4312,O
need,4312,O
more,4312,O
evidence,4312,O
on,4312,O
the,4312,O
safety,4312,O
of,4312,O
HT,4312,O
for,4312,O
menopausal,4312,O
symptom,4312,O
control,4312,O
",",4312,O
though,4312,O
short-term,4312,O
use,4312,O
appears,4312,O
to,4312,O
be,4312,O
relatively,4312,O
safe,4312,O
for,4312,O
healthy,4312,O
younger,4312,O
women,4312,O
.,4312,O
Acute,4313,B-Disease
renal,4313,I-Disease
failure,4313,I-Disease
in,4313,O
patients,4313,O
with,4313,O
AIDS,4313,B-Disease
on,4313,O
tenofovir,4313,B-Chemical
while,4313,O
receiving,4313,O
prolonged,4313,O
vancomycin,4313,B-Chemical
course,4313,O
for,4313,O
osteomyelitis,4313,B-Disease
.,4313,O
Renal,4314,B-Disease
failure,4314,I-Disease
developed,4314,O
after,4314,O
a,4314,O
prolonged,4314,O
course,4314,O
of,4314,O
vancomycin,4314,B-Chemical
therapy,4314,O
in,4314,O
2,4314,O
patients,4314,O
who,4314,O
were,4314,O
receiving,4314,O
tenofovir,4314,B-Chemical
disoproxil,4314,I-Chemical
fumarate,4314,I-Chemical
as,4314,O
part,4314,O
of,4314,O
an,4314,O
antiretroviral,4314,O
regimen,4314,O
.,4314,O
Tenofovir,4315,B-Chemical
has,4315,O
been,4315,O
implicated,4315,O
in,4315,O
the,4315,O
development,4315,O
of,4315,O
Fanconi,4315,B-Disease
syndrome,4315,I-Disease
and,4315,O
renal,4315,B-Disease
insufficiency,4315,I-Disease
because,4315,O
of,4315,O
its,4315,O
effects,4315,O
on,4315,O
the,4315,O
proximal,4315,O
renal,4315,O
tubule,4315,O
.,4315,O
Vancomycin,4316,B-Chemical
nephrotoxicity,4316,B-Disease
is,4316,O
infrequent,4316,O
but,4316,O
may,4316,O
result,4316,O
from,4316,O
coadministration,4316,O
with,4316,O
a,4316,O
nephrotoxic,4316,B-Disease
agent,4316,O
.,4316,O
Clinicians,4317,O
should,4317,O
be,4317,O
aware,4317,O
that,4317,O
tenofovir,4317,B-Chemical
may,4317,O
raise,4317,O
the,4317,O
risk,4317,O
of,4317,O
renal,4317,B-Disease
failure,4317,I-Disease
during,4317,O
prolonged,4317,O
administration,4317,O
of,4317,O
vancomycin,4317,B-Chemical
.,4317,O
Recurrent,4318,O
dysosmia,4318,B-Disease
induced,4318,O
by,4318,O
pyrazinamide,4318,B-Chemical
.,4318,O
Pyrazinamide,4319,B-Chemical
can,4319,O
have,4319,O
adverse,4319,O
effects,4319,O
such,4319,O
as,4319,O
hepatic,4319,B-Disease
toxicity,4319,I-Disease
",",4319,O
hyperuricemia,4319,B-Disease
or,4319,O
digestive,4319,O
disorders,4319,O
.,4319,O
In,4320,O
rare,4320,O
cases,4320,O
",",4320,O
alterations,4320,O
in,4320,O
taste,4320,O
and,4320,O
smell,4320,O
function,4320,O
have,4320,O
been,4320,O
reported,4320,O
for,4320,O
pyrazinamide,4320,B-Chemical
when,4320,O
combined,4320,O
with,4320,O
other,4320,O
drugs,4320,O
.,4320,O
We,4321,O
report,4321,O
a,4321,O
case,4321,O
of,4321,O
reversible,4321,O
olfactory,4321,B-Disease
disorder,4321,I-Disease
related,4321,O
to,4321,O
pyrazinamide,4321,B-Chemical
in,4321,O
a,4321,O
woman,4321,O
",",4321,O
with,4321,O
a,4321,O
positive,4321,O
rechallenge,4321,O
.,4321,O
The,4322,O
patient,4322,O
presented,4322,O
every,4322,O
day,4322,O
a,4322,O
sensation,4322,O
of,4322,O
smelling,4322,O
something,4322,O
burning,4322,O
15,4322,O
min,4322,O
after,4322,O
drug,4322,O
intake,4322,O
.,4322,O
Dysosmia,4323,B-Disease
disappeared,4323,O
completely,4323,O
after,4323,O
pyrazinamide,4323,B-Chemical
withdrawal,4323,O
and,4323,O
recurred,4323,O
after,4323,O
its,4323,O
rechallenge,4323,O
.,4323,O
The,4324,O
case,4324,O
was,4324,O
reported,4324,O
to,4324,O
the,4324,O
Tunisian,4324,O
Centre,4324,O
of,4324,O
Pharmacovigilance,4324,O
.,4324,O
Mice,4325,O
lacking,4325,O
mPGES-1,4325,O
are,4325,O
resistant,4325,O
to,4325,O
lithium-induced,4325,B-Chemical
polyuria,4325,B-Disease
.,4325,O
Cyclooxygenase-2,4326,O
activity,4326,O
is,4326,O
required,4326,O
for,4326,O
the,4326,O
development,4326,O
of,4326,O
lithium-induced,4326,B-Chemical
polyuria,4326,B-Disease
.,4326,O
However,4327,O
",",4327,O
the,4327,O
involvement,4327,O
of,4327,O
a,4327,O
specific,4327,O
",",4327,O
terminal,4327,O
prostaglandin,4327,B-Chemical
(,4327,O
PG,4327,B-Chemical
),4327,O
isomerase,4327,O
has,4327,O
not,4327,O
been,4327,O
evaluated,4327,O
.,4327,O
The,4328,O
present,4328,O
study,4328,O
was,4328,O
undertaken,4328,O
to,4328,O
assess,4328,O
lithium-induced,4328,B-Chemical
polyuria,4328,B-Disease
in,4328,O
mice,4328,O
deficient,4328,O
in,4328,O
microsomal,4328,O
prostaglandin,4328,B-Chemical
E,4328,I-Chemical
synthase-1,4328,O
(,4328,O
mPGES-1,4328,O
),4328,O
.,4328,O
A,4329,O
2-wk,4329,O
administration,4329,O
of,4329,O
LiCl,4329,B-Chemical
(,4329,O
4,4329,O
mmol.kg,4329,O
(,4329,O
-1,4329,O
),4329,O
.day,4329,O
(,4329,O
-1,4329,O
),4329,O
ip,4329,O
),4329,O
in,4329,O
mPGES-1,4329,O
+/+,4329,O
mice,4329,O
led,4329,O
to,4329,O
a,4329,O
marked,4329,O
polyuria,4329,B-Disease
with,4329,O
hyposmotic,4329,O
urine,4329,O
.,4329,O
This,4330,O
was,4330,O
associated,4330,O
with,4330,O
elevated,4330,O
renal,4330,O
mPGES-1,4330,O
protein,4330,O
expression,4330,O
and,4330,O
increased,4330,O
urine,4330,O
PGE,4330,B-Chemical
(,4330,I-Chemical
2,4330,I-Chemical
),4330,I-Chemical
excretion,4330,O
.,4330,O
In,4331,O
contrast,4331,O
",",4331,O
mPGES-1,4331,O
-/-,4331,O
mice,4331,O
were,4331,O
largely,4331,O
resistant,4331,O
to,4331,O
lithium-induced,4331,B-Chemical
polyuria,4331,B-Disease
and,4331,O
a,4331,O
urine,4331,O
concentrating,4331,O
defect,4331,O
",",4331,O
accompanied,4331,O
by,4331,O
nearly,4331,O
complete,4331,O
blockade,4331,O
of,4331,O
high,4331,O
urine,4331,O
PGE,4331,B-Chemical
(,4331,I-Chemical
2,4331,I-Chemical
),4331,I-Chemical
and,4331,O
cAMP,4331,O
output,4331,O
.,4331,O
Immunoblotting,4332,O
",",4332,O
immunohistochemistry,4332,O
",",4332,O
and,4332,O
quantitative,4332,O
(,4332,O
q,4332,O
),4332,O
RT-PCR,4332,O
consistently,4332,O
detected,4332,O
a,4332,O
significant,4332,O
decrease,4332,O
in,4332,O
aquaporin-2,4332,O
(,4332,O
AQP2,4332,O
),4332,O
protein,4332,O
expression,4332,O
in,4332,O
both,4332,O
the,4332,O
renal,4332,O
cortex,4332,O
and,4332,O
medulla,4332,O
of,4332,O
lithium-treated,4332,B-Chemical
+/+,4332,O
mice,4332,O
.,4332,O
This,4333,O
decrease,4333,O
was,4333,O
significantly,4333,O
attenuated,4333,O
in,4333,O
the,4333,O
-/-,4333,O
mice,4333,O
.,4333,O
qRT-PCR,4334,O
detected,4334,O
similar,4334,O
patterns,4334,O
of,4334,O
changes,4334,O
in,4334,O
AQP2,4334,O
mRNA,4334,O
in,4334,O
the,4334,O
medulla,4334,O
but,4334,O
not,4334,O
in,4334,O
the,4334,O
cortex,4334,O
.,4334,O
Similarly,4335,O
",",4335,O
the,4335,O
total,4335,O
protein,4335,O
abundance,4335,O
of,4335,O
the,4335,O
Na-K-2Cl,4335,B-Chemical
cotransporter,4335,O
(,4335,O
NKCC2,4335,O
),4335,O
in,4335,O
the,4335,O
medulla,4335,O
but,4335,O
not,4335,O
in,4335,O
the,4335,O
cortex,4335,O
of,4335,O
the,4335,O
+/+,4335,O
mice,4335,O
was,4335,O
significantly,4335,O
reduced,4335,O
by,4335,O
lithium,4335,B-Chemical
treatment,4335,O
.,4335,O
In,4336,O
contrast,4336,O
",",4336,O
the,4336,O
dowregulation,4336,O
of,4336,O
renal,4336,O
medullary,4336,O
NKCC2,4336,O
expression,4336,O
was,4336,O
significantly,4336,O
attenuated,4336,O
in,4336,O
the,4336,O
-/-,4336,O
mice,4336,O
.,4336,O
We,4337,O
conclude,4337,O
that,4337,O
mPGES-1-derived,4337,O
PGE,4337,B-Chemical
(,4337,I-Chemical
2,4337,I-Chemical
),4337,I-Chemical
mediates,4337,O
lithium-induced,4337,B-Chemical
polyuria,4337,B-Disease
likely,4337,O
via,4337,O
inhibition,4337,O
of,4337,O
AQP2,4337,O
and,4337,O
NKCC2,4337,O
expression,4337,O
.,4337,O
Seizures,4338,B-Disease
associated,4338,O
with,4338,O
levofloxacin,4338,B-Chemical
:,4338,O
case,4338,O
presentation,4338,O
and,4338,O
literature,4338,O
review,4338,O
.,4338,O
PURPOSE,4339,O
:,4339,O
We,4339,O
present,4339,O
a,4339,O
case,4339,O
of,4339,O
a,4339,O
patient,4339,O
who,4339,O
developed,4339,O
seizures,4339,B-Disease
shortly,4339,O
after,4339,O
initiating,4339,O
treatment,4339,O
with,4339,O
levofloxacin,4339,B-Chemical
and,4339,O
to,4339,O
discuss,4339,O
the,4339,O
potential,4339,O
drug-drug,4339,O
interactions,4339,O
related,4339,O
to,4339,O
the,4339,O
inhibition,4339,O
of,4339,O
cytochrome,4339,O
P450,4339,O
(,4339,O
CYP,4339,O
),4339,O
1A2,4339,O
in,4339,O
this,4339,O
case,4339,O
",",4339,O
as,4339,O
well,4339,O
as,4339,O
in,4339,O
other,4339,O
cases,4339,O
",",4339,O
of,4339,O
levofloxacin-induced,4339,B-Chemical
seizures,4339,B-Disease
.,4339,O
METHODS,4340,O
:,4340,O
Several,4340,O
biomedical,4340,O
databases,4340,O
were,4340,O
searched,4340,O
including,4340,O
MEDLINE,4340,O
",",4340,O
Cochrane,4340,O
and,4340,O
Ovid,4340,O
.,4340,O
The,4341,O
main,4341,O
search,4341,O
terms,4341,O
utilized,4341,O
were,4341,O
case,4341,O
report,4341,O
and,4341,O
levofloxacin,4341,B-Chemical
.,4341,O
The,4342,O
search,4342,O
was,4342,O
limited,4342,O
to,4342,O
studies,4342,O
published,4342,O
in,4342,O
English,4342,O
.,4342,O
RESULTS,4343,O
:,4343,O
Six,4343,O
cases,4343,O
of,4343,O
levofloxacin-induced,4343,B-Chemical
seizures,4343,B-Disease
have,4343,O
been,4343,O
reported,4343,O
in,4343,O
the,4343,O
literature,4343,O
.,4343,O
Drug-drug,4344,O
interactions,4344,O
related,4344,O
to,4344,O
the,4344,O
inhibition,4344,O
of,4344,O
CYP1A2,4344,O
by,4344,O
levofloxacin,4344,B-Chemical
are,4344,O
likely,4344,O
involved,4344,O
in,4344,O
the,4344,O
clinical,4344,O
outcome,4344,O
of,4344,O
these,4344,O
cases,4344,O
.,4344,O
CONCLUSIONS,4345,O
:,4345,O
Clinicians,4345,O
are,4345,O
exhorted,4345,O
to,4345,O
pay,4345,O
close,4345,O
attention,4345,O
when,4345,O
initiating,4345,O
levofloxacin,4345,B-Chemical
therapy,4345,O
in,4345,O
patients,4345,O
taking,4345,O
medications,4345,O
with,4345,O
epileptogenic,4345,O
properties,4345,O
that,4345,O
are,4345,O
CYP1A2,4345,O
substrates,4345,O
.,4345,O
Dextran-etodolac,4346,B-Chemical
conjugates,4346,O
:,4346,O
synthesis,4346,O
",",4346,O
in,4346,O
vitro,4346,O
and,4346,O
in,4346,O
vivo,4346,O
evaluation,4346,O
.,4346,O
Etodolac,4347,B-Chemical
(,4347,O
E,4347,B-Chemical
),4347,O
",",4347,O
is,4347,O
a,4347,O
non-narcotic,4347,O
analgesic,4347,O
and,4347,O
antiinflammatory,4347,O
drug,4347,O
.,4347,O
A,4348,O
biodegradable,4348,O
polymer,4348,O
dextran,4348,B-Chemical
has,4348,O
been,4348,O
utilized,4348,O
as,4348,O
a,4348,O
carrier,4348,O
for,4348,O
synthesis,4348,O
of,4348,O
etodolac-dextran,4348,B-Chemical
conjugates,4348,O
(,4348,O
ED,4348,O
),4348,O
to,4348,O
improve,4348,O
its,4348,O
aqueous,4348,O
solubility,4348,O
and,4348,O
reduce,4348,O
gastrointestinal,4348,O
side,4348,O
effects,4348,O
.,4348,O
An,4349,O
activated,4349,O
moiety,4349,O
",",4349,O
i.e,4349,O
.,4349,O
N-acylimidazole,4350,B-Chemical
derivative,4350,O
of,4350,O
etodolac,4350,B-Chemical
(,4350,O
EAI,4350,B-Chemical
),4350,O
",",4350,O
was,4350,O
condensed,4350,O
with,4350,O
the,4350,O
polysaccharide,4350,O
polymer,4350,O
dextran,4350,B-Chemical
of,4350,O
different,4350,O
molecular,4350,O
weights,4350,O
(,4350,O
40000,4350,O
",",4350,O
60000,4350,O
",",4350,O
110000,4350,O
and,4350,O
200000,4350,O
),4350,O
.,4350,O
IR,4351,O
spectral,4351,O
data,4351,O
confirmed,4351,O
formation,4351,O
of,4351,O
ester,4351,O
bonding,4351,O
in,4351,O
the,4351,O
conjugates,4351,O
.,4351,O
Etodolac,4352,B-Chemical
contents,4352,O
were,4352,O
evaluated,4352,O
by,4352,O
UV-spectrophotometric,4352,O
analysis,4352,O
.,4352,O
The,4353,O
molecular,4353,O
weights,4353,O
were,4353,O
determined,4353,O
by,4353,O
measuring,4353,O
viscosity,4353,O
using,4353,O
the,4353,O
Mark-Howink-Sakurada,4353,O
equation,4353,O
.,4353,O
In,4354,O
vitro,4354,O
hydrolysis,4354,O
of,4354,O
ED,4354,O
was,4354,O
done,4354,O
in,4354,O
aqueous,4354,O
buffers,4354,O
(,4354,O
pH,4354,O
1.2,4354,O
",",4354,O
7.4,4354,O
",",4354,O
9,4354,O
),4354,O
and,4354,O
in,4354,O
80,4354,O
%,4354,O
(,4354,O
v/v,4354,O
),4354,O
human,4354,O
plasma,4354,O
(,4354,O
pH,4354,O
7.4,4354,O
),4354,O
.,4354,O
At,4355,O
pH,4355,O
9,4355,O
",",4355,O
a,4355,O
higher,4355,O
rate,4355,O
of,4355,O
etodolac,4355,B-Chemical
release,4355,O
from,4355,O
ED,4355,O
was,4355,O
observed,4355,O
as,4355,O
compared,4355,O
to,4355,O
aqueous,4355,O
buffer,4355,O
of,4355,O
pH,4355,O
7.4,4355,O
and,4355,O
80,4355,O
%,4355,O
human,4355,O
plasma,4355,O
(,4355,O
pH,4355,O
7.4,4355,O
),4355,O
",",4355,O
following,4355,O
first-order,4355,O
kinetics,4355,O
.,4355,O
In,4356,O
vivo,4356,O
investigations,4356,O
were,4356,O
performed,4356,O
in,4356,O
animals,4356,O
.,4356,O
Acute,4357,O
analgesic,4357,O
and,4357,O
antiinflammatory,4357,O
activities,4357,O
were,4357,O
ascertained,4357,O
using,4357,O
acetic,4357,B-Chemical
acid,4357,I-Chemical
induced,4357,O
writhing,4357,B-Disease
model,4357,O
(,4357,O
mice,4357,O
),4357,O
and,4357,O
carrageenan-induced,4357,B-Chemical
rat,4357,O
paw,4357,O
edema,4357,B-Disease
model,4357,O
",",4357,O
respectively,4357,O
.,4357,O
In,4358,O
comparison,4358,O
to,4358,O
control,4358,O
",",4358,O
E,4358,B-Chemical
and,4358,O
ED1-ED4,4358,O
showed,4358,O
highly,4358,O
significant,4358,O
analgesic,4358,O
and,4358,O
antiinflammatory,4358,O
activities,4358,O
(,4358,O
p,4358,O
<,4358,O
0.001,4358,O
),4358,O
.,4358,O
Biological,4359,O
evaluation,4359,O
suggested,4359,O
that,4359,O
conjugates,4359,O
(,4359,O
ED1-ED4,4359,O
),4359,O
retained,4359,O
comparable,4359,O
analgesic,4359,O
and,4359,O
antiinflammatory,4359,O
activities,4359,O
with,4359,O
remarkably,4359,O
reduced,4359,O
ulcerogenicity,4359,O
as,4359,O
compared,4359,O
to,4359,O
their,4359,O
parent,4359,O
drug,4359,O
--,4359,O
etodolac,4359,B-Chemical
.,4359,O
The,4360,O
antiarrhythmic,4360,O
effect,4360,O
and,4360,O
possible,4360,O
ionic,4360,O
mechanisms,4360,O
of,4360,O
pilocarpine,4360,B-Chemical
on,4360,O
animal,4360,O
models,4360,O
.,4360,O
This,4361,O
study,4361,O
was,4361,O
designed,4361,O
to,4361,O
evaluate,4361,O
the,4361,O
effects,4361,O
of,4361,O
pilocarpine,4361,B-Chemical
and,4361,O
explore,4361,O
the,4361,O
underlying,4361,O
ionic,4361,O
mechanism,4361,O
",",4361,O
using,4361,O
both,4361,O
aconitine-induced,4361,B-Chemical
rat,4361,O
and,4361,O
ouabain-induced,4361,B-Chemical
guinea,4361,O
pig,4361,O
arrhythmia,4361,B-Disease
models,4361,O
.,4361,O
Confocal,4362,O
microscopy,4362,O
was,4362,O
used,4362,O
to,4362,O
measure,4362,O
intracellular,4362,O
free-calcium,4362,O
concentrations,4362,O
(,4362,O
[,4362,O
Ca,4362,B-Chemical
(,4362,O
2+,4362,O
),4362,O
],4362,O
(,4362,O
i,4362,O
),4362,O
),4362,O
in,4362,O
isolated,4362,O
myocytes,4362,O
.,4362,O
The,4363,O
current,4363,O
data,4363,O
showed,4363,O
that,4363,O
pilocarpine,4363,B-Chemical
significantly,4363,O
delayed,4363,O
onset,4363,O
of,4363,O
arrhythmias,4363,B-Disease
",",4363,O
decreased,4363,O
the,4363,O
time,4363,O
course,4363,O
of,4363,O
ventricular,4363,O
tachycardia,4363,O
and,4363,O
fibrillation,4363,O
",",4363,O
reduced,4363,O
arrhythmia,4363,B-Disease
score,4363,O
",",4363,O
and,4363,O
increased,4363,O
the,4363,O
survival,4363,O
time,4363,O
of,4363,O
arrhythmic,4363,B-Disease
rats,4363,O
and,4363,O
guinea,4363,O
pigs,4363,O
.,4363,O
[,4364,O
Ca,4364,B-Chemical
(,4364,O
2+,4364,O
),4364,O
],4364,O
(,4364,O
i,4364,O
),4364,O
overload,4364,O
induced,4364,O
by,4364,O
aconitine,4364,B-Chemical
or,4364,O
ouabain,4364,B-Chemical
was,4364,O
reduced,4364,O
in,4364,O
isolated,4364,O
myocytes,4364,O
pretreated,4364,O
with,4364,O
pilocarpine,4364,B-Chemical
.,4364,O
Moreover,4365,O
",",4365,O
M,4365,O
(,4365,O
3,4365,O
),4365,O
-muscarinic,4365,O
acetylcholine,4365,B-Chemical
receptor,4365,O
(,4365,O
mAChR,4365,O
),4365,O
antagonist,4365,O
4-DAMP,4365,B-Chemical
(,4365,O
4-diphenylacetoxy-N-methylpiperidine-methiodide,4365,B-Chemical
),4365,O
partially,4365,O
abolished,4365,O
the,4365,O
beneficial,4365,O
effects,4365,O
of,4365,O
pilocarpine,4365,B-Chemical
.,4365,O
These,4366,O
data,4366,O
suggest,4366,O
that,4366,O
pilocarpine,4366,B-Chemical
produced,4366,O
antiarrhythmic,4366,O
actions,4366,O
on,4366,O
arrhythmic,4366,B-Disease
rat,4366,O
and,4366,O
guinea,4366,O
pig,4366,O
models,4366,O
induced,4366,O
by,4366,O
aconitine,4366,B-Chemical
or,4366,O
ouabain,4366,B-Chemical
via,4366,O
stimulating,4366,O
the,4366,O
cardiac,4366,O
M,4366,O
(,4366,O
3,4366,O
),4366,O
-mAChR,4366,O
.,4366,O
The,4367,O
mechanism,4367,O
may,4367,O
be,4367,O
related,4367,O
to,4367,O
the,4367,O
improvement,4367,O
of,4367,O
Ca,4367,B-Chemical
(,4367,O
2+,4367,O
),4367,O
handling,4367,O
.,4367,O
Effect,4368,O
of,4368,O
Hibiscus,4368,B-Chemical
rosa,4368,I-Chemical
sinensis,4368,I-Chemical
on,4368,O
reserpine-induced,4368,B-Chemical
neurobehavioral,4368,O
and,4368,O
biochemical,4368,O
alterations,4368,O
in,4368,O
rats,4368,O
.,4368,O
Effect,4369,O
of,4369,O
methanolic,4369,O
extract,4369,O
of,4369,O
Hibiscus,4369,B-Chemical
rosa,4369,I-Chemical
sinensis,4369,I-Chemical
(,4369,O
100-300,4369,O
mg/kg,4369,O
),4369,O
was,4369,O
studied,4369,O
on,4369,O
reserpine-induced,4369,B-Chemical
orofacial,4369,O
dyskinesia,4369,B-Disease
and,4369,O
neurochemical,4369,O
alterations,4369,O
.,4369,O
The,4370,O
rats,4370,O
were,4370,O
treated,4370,O
with,4370,O
intraperitoneal,4370,O
reserpine,4370,B-Chemical
(,4370,O
1,4370,O
mg/kg,4370,O
",",4370,O
ip,4370,O
),4370,O
for,4370,O
3,4370,O
days,4370,O
every,4370,O
other,4370,O
day,4370,O
.,4370,O
On,4371,O
day,4371,O
5,4371,O
",",4371,O
vacuous,4371,O
chewing,4371,O
movements,4371,O
and,4371,O
tongue,4371,O
protrusions,4371,O
were,4371,O
counted,4371,O
for,4371,O
5,4371,O
min,4371,O
.,4371,O
Reserpine,4372,B-Chemical
treated,4372,O
rats,4372,O
significantly,4372,O
developed,4372,O
vacuous,4372,O
chewing,4372,O
movements,4372,O
and,4372,O
tongue,4372,O
protrusions,4372,O
however,4372,O
",",4372,O
coadministration,4372,O
of,4372,O
Hibiscus,4372,B-Chemical
rosa,4372,I-Chemical
sinensis,4372,I-Chemical
roots,4372,O
extract,4372,O
(,4372,O
100,4372,O
",",4372,O
200,4372,O
and,4372,O
300,4372,O
mg/kg,4372,O
",",4372,O
per,4372,O
orally,4372,O
),4372,O
attenuated,4372,O
the,4372,O
effects,4372,O
.,4372,O
Biochemical,4373,O
analysis,4373,O
of,4373,O
brain,4373,O
revealed,4373,O
that,4373,O
the,4373,O
reserpine,4373,B-Chemical
treatment,4373,O
significantly,4373,O
increased,4373,O
lipid,4373,O
peroxidation,4373,O
and,4373,O
decreased,4373,O
levels,4373,O
of,4373,O
superoxide,4373,B-Chemical
dismutase,4373,O
(,4373,O
SOD,4373,O
),4373,O
",",4373,O
catalase,4373,O
(,4373,O
CAT,4373,O
),4373,O
and,4373,O
glutathione,4373,B-Chemical
reductase,4373,O
(,4373,O
GSH,4373,O
),4373,O
",",4373,O
an,4373,O
index,4373,O
of,4373,O
oxidative,4373,O
stress,4373,O
process,4373,O
.,4373,O
Coadministration,4374,O
of,4374,O
extract,4374,O
significantly,4374,O
reduced,4374,O
the,4374,O
lipid,4374,O
peroxidation,4374,O
and,4374,O
reversed,4374,O
the,4374,O
decrease,4374,O
in,4374,O
brain,4374,O
SOD,4374,O
",",4374,O
CAT,4374,O
and,4374,O
GSH,4374,O
levels,4374,O
.,4374,O
The,4375,O
results,4375,O
of,4375,O
the,4375,O
present,4375,O
study,4375,O
suggested,4375,O
that,4375,O
Hibiscus,4375,B-Chemical
rosa,4375,I-Chemical
sinensis,4375,I-Chemical
had,4375,O
a,4375,O
protective,4375,O
role,4375,O
against,4375,O
reserpine-induced,4375,B-Chemical
orofacial,4375,O
dyskinesia,4375,B-Disease
and,4375,O
oxidative,4375,O
stress,4375,O
.,4375,O
Dynamic,4376,O
response,4376,O
of,4376,O
blood,4376,O
vessel,4376,O
in,4376,O
acute,4376,B-Disease
renal,4376,I-Disease
failure,4376,I-Disease
.,4376,O
In,4377,O
this,4377,O
study,4377,O
we,4377,O
postulated,4377,O
that,4377,O
during,4377,O
acute,4377,B-Disease
renal,4377,I-Disease
failure,4377,I-Disease
induced,4377,O
by,4377,O
gentamicin,4377,B-Chemical
the,4377,O
transient,4377,O
or,4377,O
dynamic,4377,O
response,4377,O
of,4377,O
blood,4377,O
vessels,4377,O
could,4377,O
be,4377,O
affected,4377,O
",",4377,O
and,4377,O
that,4377,O
antioxidants,4377,O
can,4377,O
prevent,4377,O
the,4377,O
changes,4377,O
in,4377,O
dynamic,4377,O
responses,4377,O
of,4377,O
blood,4377,O
vessels,4377,O
.,4377,O
The,4378,O
new,4378,O
approach,4378,O
to,4378,O
ex,4378,O
vivo,4378,O
blood,4378,O
vessel,4378,O
experiments,4378,O
in,4378,O
which,4378,O
not,4378,O
only,4378,O
the,4378,O
end,4378,O
points,4378,O
of,4378,O
vessels,4378,O
response,4378,O
within,4378,O
the,4378,O
time,4378,O
interval,4378,O
is,4378,O
considered,4378,O
",",4378,O
but,4378,O
also,4378,O
dynamics,4378,O
of,4378,O
this,4378,O
response,4378,O
",",4378,O
was,4378,O
used,4378,O
in,4378,O
this,4378,O
paper,4378,O
.,4378,O
Our,4379,O
results,4379,O
confirm,4379,O
the,4379,O
alteration,4379,O
in,4379,O
dynamic,4379,O
response,4379,O
of,4379,O
blood,4379,O
vessels,4379,O
during,4379,O
the,4379,O
change,4379,O
of,4379,O
pressure,4379,O
in,4379,O
gentamicin-treated,4379,B-Chemical
animals,4379,O
.,4379,O
The,4380,O
beneficial,4380,O
effects,4380,O
of,4380,O
vitamin,4380,B-Chemical
C,4380,I-Chemical
administration,4380,O
to,4380,O
gentamicin-treated,4380,B-Chemical
animals,4380,O
are,4380,O
also,4380,O
confirmed,4380,O
through,4380,O
:,4380,O
lower,4380,O
level,4380,O
of,4380,O
blood,4380,O
urea,4380,B-Chemical
and,4380,O
creatinine,4380,B-Chemical
and,4380,O
higher,4380,O
level,4380,O
of,4380,O
potassium,4380,B-Chemical
.,4380,O
The,4381,O
pressure,4381,O
dynamic,4381,O
responses,4381,O
of,4381,O
isolated,4381,O
blood,4381,O
vessels,4381,O
show,4381,O
a,4381,O
faster,4381,O
pressure,4381,O
change,4381,O
in,4381,O
gentamicin-treated,4381,B-Chemical
animals,4381,O
(,4381,O
8.07,4381,O
+/-,4381,O
1.7,4381,O
s,4381,O
vs.,4381,O
5.64,4381,O
+/-,4381,O
0.18,4381,O
s,4381,O
),4381,O
.,4381,O
Vitamin,4382,B-Chemical
C,4382,I-Chemical
administration,4382,O
induced,4382,O
slowdown,4382,O
of,4382,O
pressure,4382,O
change,4382,O
back,4382,O
to,4382,O
the,4382,O
control,4382,O
values,4382,O
.,4382,O
The,4383,O
pressure,4383,O
dynamic,4383,O
properties,4383,O
",",4383,O
quantitatively,4383,O
defined,4383,O
by,4383,O
comparative,4383,O
pressure,4383,O
dynamic,4383,O
and,4383,O
total,4383,O
pressure,4383,O
dynamic,4383,O
",",4383,O
confirm,4383,O
the,4383,O
alteration,4383,O
in,4383,O
dynamic,4383,O
response,4383,O
of,4383,O
blood,4383,O
vessels,4383,O
during,4383,O
the,4383,O
change,4383,O
of,4383,O
pressure,4383,O
in,4383,O
gentamicin-treated,4383,B-Chemical
animals,4383,O
and,4383,O
beneficial,4383,O
effects,4383,O
of,4383,O
vitamin,4383,B-Chemical
C,4383,I-Chemical
administration,4383,O
.,4383,O
Reversible,4384,O
myocardial,4384,B-Disease
hypertrophy,4384,I-Disease
induced,4384,O
by,4384,O
tacrolimus,4384,B-Chemical
in,4384,O
a,4384,O
pediatric,4384,O
heart,4384,O
transplant,4384,O
recipient,4384,O
:,4384,O
case,4384,O
report,4384,O
.,4384,O
Tacrolimus,4385,B-Chemical
is,4385,O
a,4385,O
potent,4385,O
immunosuppressant,4385,O
that,4385,O
is,4385,O
frequently,4385,O
used,4385,O
in,4385,O
organ,4385,O
transplantation,4385,O
.,4385,O
However,4386,O
",",4386,O
adverse,4386,O
effects,4386,O
include,4386,O
cardiac,4386,B-Disease
toxicity,4386,I-Disease
.,4386,O
Herein,4387,O
we,4387,O
describe,4387,O
transient,4387,O
myocardial,4387,B-Disease
hypertrophy,4387,I-Disease
induced,4387,O
by,4387,O
tacrolimus,4387,B-Chemical
after,4387,O
heart,4387,O
transplantation,4387,O
.,4387,O
The,4388,O
hypertrophy,4388,B-Disease
caused,4388,O
no,4388,O
clinical,4388,O
symptoms,4388,O
but,4388,O
was,4388,O
noted,4388,O
because,4388,O
of,4388,O
elevation,4388,O
of,4388,O
plasma,4388,O
brain,4388,O
natriuretic,4388,O
peptide,4388,O
concentration,4388,O
and,4388,O
confirmed,4388,O
at,4388,O
echocardiography,4388,O
.,4388,O
Initially,4389,O
",",4389,O
allograft,4389,O
rejection,4389,O
was,4389,O
feared,4389,O
;,4389,O
however,4389,O
",",4389,O
myocardial,4389,O
biopsy,4389,O
samples,4389,O
revealed,4389,O
only,4389,O
interstitial,4389,O
edema,4389,B-Disease
and,4389,O
mild,4389,O
myocardial,4389,B-Disease
hypertrophy,4389,I-Disease
;,4389,O
neither,4389,O
cellular,4389,O
nor,4389,O
humoral,4389,O
rejection,4389,O
was,4389,O
detected,4389,O
.,4389,O
The,4390,O
blood,4390,O
tacrolimus,4390,B-Chemical
concentration,4390,O
was,4390,O
higher,4390,O
than,4390,O
usual,4390,O
at,4390,O
that,4390,O
time,4390,O
;,4390,O
thus,4390,O
",",4390,O
tacrolimus,4390,B-Chemical
dosage,4390,O
was,4390,O
reduced,4390,O
.,4390,O
Myocardial,4391,B-Disease
hypertrophy,4391,I-Disease
completely,4391,O
resolved,4391,O
upon,4391,O
reducing,4391,O
the,4391,O
target,4391,O
concentration,4391,O
of,4391,O
tacrolimus,4391,B-Chemical
and,4391,O
did,4391,O
not,4391,O
recur,4391,O
",",4391,O
as,4391,O
confirmed,4391,O
at,4391,O
echocardiography,4391,O
and,4391,O
myocardial,4391,O
biopsy,4391,O
.,4391,O
Thus,4392,O
",",4392,O
we,4392,O
conclude,4392,O
that,4392,O
tacrolimus,4392,B-Chemical
induces,4392,O
reversible,4392,O
myocardial,4392,B-Disease
hypertrophy,4392,I-Disease
.,4392,O
In,4393,O
patients,4393,O
receiving,4393,O
tacrolimus,4393,B-Chemical
therapy,4393,O
",",4393,O
blood,4393,O
concentration,4393,O
should,4393,O
be,4393,O
carefully,4393,O
controlled,4393,O
and,4393,O
extreme,4393,O
attention,4393,O
paid,4393,O
to,4393,O
cardiac,4393,O
involvement,4393,O
.,4393,O
Nimodipine,4394,B-Chemical
prevents,4394,O
memory,4394,B-Disease
impairment,4394,I-Disease
caused,4394,O
by,4394,O
nitroglycerin-induced,4394,B-Chemical
hypotension,4394,B-Disease
in,4394,O
adult,4394,O
mice,4394,O
.,4394,O
BACKGROUND,4395,O
:,4395,O
Hypotension,4395,B-Disease
and,4395,O
a,4395,O
resultant,4395,O
decrease,4395,O
in,4395,O
cerebral,4395,O
blood,4395,O
flow,4395,O
have,4395,O
been,4395,O
implicated,4395,O
in,4395,O
the,4395,O
development,4395,O
of,4395,O
cognitive,4395,B-Disease
dysfunction,4395,I-Disease
.,4395,O
We,4396,O
tested,4396,O
the,4396,O
hypothesis,4396,O
that,4396,O
nimodipine,4396,B-Chemical
(,4396,O
NIMO,4396,B-Chemical
),4396,O
administered,4396,O
at,4396,O
the,4396,O
onset,4396,O
of,4396,O
nitroglycerin,4396,B-Chemical
(,4396,O
NTG,4396,B-Chemical
),4396,O
-induced,4396,O
hypotension,4396,B-Disease
would,4396,O
preserve,4396,O
long-term,4396,O
associative,4396,O
memory,4396,O
.,4396,O
METHODS,4397,O
:,4397,O
The,4397,O
passive,4397,O
avoidance,4397,O
(,4397,O
PA,4397,O
),4397,O
paradigm,4397,O
was,4397,O
used,4397,O
to,4397,O
assess,4397,O
memory,4397,O
retention,4397,O
.,4397,O
For,4398,O
PA,4398,O
training,4398,O
",",4398,O
latencies,4398,O
(,4398,O
seconds,4398,O
),4398,O
were,4398,O
recorded,4398,O
for,4398,O
entry,4398,O
from,4398,O
a,4398,O
suspended,4398,O
platform,4398,O
into,4398,O
a,4398,O
Plexiglas,4398,O
tube,4398,O
where,4398,O
a,4398,O
shock,4398,O
was,4398,O
automatically,4398,O
delivered,4398,O
.,4398,O
Latencies,4399,O
were,4399,O
recorded,4399,O
48,4399,O
h,4399,O
later,4399,O
for,4399,O
a,4399,O
testing,4399,O
trial,4399,O
.,4399,O
Ninety-six,4400,O
Swiss-Webster,4400,O
mice,4400,O
(,4400,O
30-35,4400,O
g,4400,O
",",4400,O
6-8,4400,O
wk,4400,O
),4400,O
",",4400,O
were,4400,O
randomized,4400,O
into,4400,O
6,4400,O
groups,4400,O
1,4400,O
),4400,O
saline,4400,O
(,4400,O
control,4400,O
),4400,O
",",4400,O
2,4400,O
),4400,O
NTG,4400,B-Chemical
immediately,4400,O
after,4400,O
learning,4400,O
",",4400,O
3,4400,O
),4400,O
NTG,4400,B-Chemical
3,4400,O
h,4400,O
after,4400,O
learning,4400,O
",",4400,O
4,4400,O
),4400,O
NTG,4400,B-Chemical
and,4400,O
NIMO,4400,B-Chemical
",",4400,O
5,4400,O
),4400,O
vehicle,4400,O
",",4400,O
and,4400,O
6,4400,O
),4400,O
NIMO,4400,B-Chemical
alone,4400,O
.,4400,O
The,4401,O
extent,4401,O
of,4401,O
hypotension,4401,B-Disease
and,4401,O
changes,4401,O
in,4401,O
brain,4401,O
tissue,4401,O
oxygenation,4401,O
(,4401,O
PbtO,4401,O
(,4401,O
2,4401,O
),4401,O
),4401,O
and,4401,O
in,4401,O
cerebral,4401,O
blood,4401,O
flow,4401,O
were,4401,O
studied,4401,O
in,4401,O
a,4401,O
separate,4401,O
group,4401,O
of,4401,O
animals,4401,O
.,4401,O
RESULTS,4402,O
:,4402,O
All,4402,O
groups,4402,O
exhibited,4402,O
similar,4402,O
training,4402,O
latencies,4402,O
(,4402,O
17.0,4402,O
+/-,4402,O
4.6,4402,O
s,4402,O
),4402,O
.,4402,O
Mice,4403,O
subjected,4403,O
to,4403,O
hypotensive,4403,B-Disease
episodes,4403,O
showed,4403,O
a,4403,O
significant,4403,O
decrease,4403,O
in,4403,O
latency,4403,O
time,4403,O
(,4403,O
178,4403,O
+/-,4403,O
156,4403,O
s,4403,O
),4403,O
compared,4403,O
with,4403,O
those,4403,O
injected,4403,O
with,4403,O
saline,4403,O
",",4403,O
NTG,4403,B-Chemical
+,4403,O
NIMO,4403,B-Chemical
",",4403,O
or,4403,O
delayed,4403,O
NTG,4403,B-Chemical
(,4403,O
580,4403,O
+/-,4403,O
81,4403,O
s,4403,O
",",4403,O
557,4403,O
+/-,4403,O
67,4403,O
s,4403,O
",",4403,O
and,4403,O
493,4403,O
+/-,4403,O
146,4403,O
s,4403,O
",",4403,O
respectively,4403,O
),4403,O
.,4403,O
A,4404,O
Kruskal-Wallis,4404,O
1-way,4404,O
analysis,4404,O
of,4404,O
variance,4404,O
indicated,4404,O
a,4404,O
significant,4404,O
difference,4404,O
among,4404,O
the,4404,O
4,4404,O
treatment,4404,O
groups,4404,O
(,4404,O
H,4404,O
=,4404,O
15.34,4404,O
;,4404,O
P,4404,O
<,4404,O
0.001,4404,O
),4404,O
.,4404,O
In,4405,O
a,4405,O
separate,4405,O
group,4405,O
of,4405,O
mice,4405,O
not,4405,O
subjected,4405,O
to,4405,O
behavioral,4405,O
studies,4405,O
",",4405,O
the,4405,O
same,4405,O
dose,4405,O
of,4405,O
NTG,4405,B-Chemical
(,4405,O
n,4405,O
=,4405,O
3,4405,O
),4405,O
and,4405,O
NTG,4405,B-Chemical
+,4405,O
NIMO,4405,B-Chemical
(,4405,O
n,4405,O
=,4405,O
3,4405,O
),4405,O
caused,4405,O
mean,4405,O
arterial,4405,O
blood,4405,O
pressure,4405,O
to,4405,O
decrease,4405,O
from,4405,O
85.9,4405,O
+/-,4405,O
3.8,4405,O
mm,4405,O
Hg,4405,O
sem,4405,O
to,4405,O
31.6,4405,O
+/-,4405,O
0.8,4405,O
mm,4405,O
Hg,4405,O
sem,4405,O
and,4405,O
from,4405,O
86.2,4405,O
+/-,4405,O
3.7,4405,O
mm,4405,O
Hg,4405,O
sem,4405,O
to,4405,O
32.6,4405,O
+/-,4405,O
0.2,4405,O
mm,4405,O
Hg,4405,O
sem,4405,O
",",4405,O
respectively,4405,O
.,4405,O
Mean,4406,O
arterial,4406,O
blood,4406,O
pressure,4406,O
in,4406,O
mice,4406,O
treated,4406,O
with,4406,O
NIMO,4406,B-Chemical
alone,4406,O
decreased,4406,O
from,4406,O
88.1,4406,O
+/-,4406,O
3.8,4406,O
mm,4406,O
Hg,4406,O
to,4406,O
80.0,4406,O
+/-,4406,O
2.9,4406,O
mm,4406,O
Hg,4406,O
.,4406,O
The,4407,O
intergroup,4407,O
difference,4407,O
was,4407,O
statistically,4407,O
significant,4407,O
(,4407,O
P,4407,O
<,4407,O
0.05,4407,O
),4407,O
.,4407,O
PbtO,4408,O
(,4408,O
2,4408,O
),4408,O
decreased,4408,O
from,4408,O
51.7,4408,O
+/-,4408,O
4.5,4408,O
mm,4408,O
Hg,4408,O
sem,4408,O
to,4408,O
33.8,4408,O
+/-,4408,O
5.2,4408,O
mm,4408,O
Hg,4408,O
sem,4408,O
in,4408,O
the,4408,O
NTG,4408,B-Chemical
group,4408,O
and,4408,O
from,4408,O
38.6,4408,O
+/-,4408,O
6.1,4408,O
mm,4408,O
Hg,4408,O
sem,4408,O
to,4408,O
25.4,4408,O
+/-,4408,O
2.0,4408,O
mm,4408,O
Hg,4408,O
sem,4408,O
in,4408,O
the,4408,O
NTG,4408,B-Chemical
+,4408,O
NIMO,4408,B-Chemical
groups,4408,O
",",4408,O
respectively,4408,O
.,4408,O
There,4409,O
were,4409,O
no,4409,O
significant,4409,O
differences,4409,O
among,4409,O
groups,4409,O
.,4409,O
CONCLUSION,4410,O
:,4410,O
In,4410,O
a,4410,O
PA,4410,O
retention,4410,O
paradigm,4410,O
",",4410,O
the,4410,O
injection,4410,O
of,4410,O
NTG,4410,B-Chemical
immediately,4410,O
after,4410,O
learning,4410,O
produced,4410,O
a,4410,O
significant,4410,O
impairment,4410,O
of,4410,O
long-term,4410,O
associative,4410,O
memory,4410,O
in,4410,O
mice,4410,O
",",4410,O
whereas,4410,O
delayed,4410,O
induced,4410,O
hypotension,4410,B-Disease
had,4410,O
no,4410,O
effect,4410,O
.,4410,O
NIMO,4411,B-Chemical
attenuated,4411,O
the,4411,O
disruption,4411,O
in,4411,O
consolidation,4411,O
of,4411,O
long-term,4411,O
memory,4411,O
caused,4411,O
by,4411,O
NTG,4411,B-Chemical
but,4411,O
did,4411,O
not,4411,O
improve,4411,O
latency,4411,O
in,4411,O
the,4411,O
absence,4411,O
of,4411,O
hypotension,4411,B-Disease
.,4411,O
The,4412,O
observed,4412,O
effect,4412,O
of,4412,O
NIMO,4412,B-Chemical
may,4412,O
have,4412,O
been,4412,O
attributable,4412,O
to,4412,O
the,4412,O
preservation,4412,O
of,4412,O
calcium,4412,B-Chemical
homeostasis,4412,O
during,4412,O
hypotension,4412,B-Disease
",",4412,O
because,4412,O
there,4412,O
were,4412,O
no,4412,O
differences,4412,O
in,4412,O
the,4412,O
PbtO,4412,O
(,4412,O
2,4412,O
),4412,O
indices,4412,O
among,4412,O
groups,4412,O
.,4412,O
Metabotropic,4413,O
glutamate,4413,B-Chemical
7,4413,O
receptor,4413,O
subtype,4413,O
modulates,4413,O
motor,4413,O
symptoms,4413,O
in,4413,O
rodent,4413,O
models,4413,O
of,4413,O
Parkinson,4413,B-Disease
's,4413,I-Disease
disease,4413,I-Disease
.,4413,O
Metabotropic,4414,O
glutamate,4414,B-Chemical
(,4414,O
mGlu,4414,O
),4414,O
receptors,4414,O
modulate,4414,O
synaptic,4414,O
transmission,4414,O
in,4414,O
the,4414,O
central,4414,O
nervous,4414,O
system,4414,O
and,4414,O
represent,4414,O
promising,4414,O
therapeutic,4414,O
targets,4414,O
for,4414,O
symptomatic,4414,O
treatment,4414,O
of,4414,O
Parkinson,4414,B-Disease
's,4414,I-Disease
disease,4414,I-Disease
(,4414,O
PD,4414,B-Disease
),4414,O
.,4414,O
Among,4415,O
the,4415,O
eight,4415,O
mGlu,4415,O
receptor,4415,O
subtypes,4415,O
",",4415,O
mGlu7,4415,O
receptor,4415,O
is,4415,O
prominently,4415,O
expressed,4415,O
in,4415,O
the,4415,O
basal,4415,O
ganglia,4415,O
",",4415,O
but,4415,O
its,4415,O
role,4415,O
in,4415,O
restoring,4415,O
motor,4415,O
function,4415,O
in,4415,O
animal,4415,O
models,4415,O
of,4415,O
PD,4415,B-Disease
is,4415,O
not,4415,O
known,4415,O
.,4415,O
The,4416,O
effects,4416,O
of,4416,O
N,4416,B-Chemical
",",4416,I-Chemical
"N'-dibenzhydrylethane-1,2-diamine",4416,I-Chemical
dihydrochloride,4416,I-Chemical
(,4416,O
AMN082,4416,B-Chemical
),4416,O
",",4416,O
the,4416,O
first,4416,O
selective,4416,O
allosteric,4416,O
activator,4416,O
of,4416,O
mGlu7,4416,O
receptors,4416,O
",",4416,O
were,4416,O
thus,4416,O
tested,4416,O
in,4416,O
different,4416,O
rodent,4416,O
models,4416,O
of,4416,O
PD,4416,B-Disease
.,4416,O
Here,4417,O
",",4417,O
we,4417,O
show,4417,O
that,4417,O
oral,4417,O
(,4417,O
5,4417,O
mg/kg,4417,O
),4417,O
or,4417,O
intrastriatal,4417,O
administration,4417,O
(,4417,O
0.1,4417,O
and,4417,O
0.5,4417,O
nmol,4417,O
),4417,O
of,4417,O
AMN082,4417,B-Chemical
reverses,4417,O
haloperidol-induced,4417,B-Chemical
catalepsy,4417,B-Disease
in,4417,O
rats,4417,O
.,4417,O
AMN082,4418,B-Chemical
(,4418,O
2.5,4418,O
and,4418,O
5,4418,O
mg/kg,4418,O
),4418,O
reduces,4418,O
apomorphine-induced,4418,B-Chemical
rotations,4418,O
in,4418,O
unilateral,4418,O
6-hydroxydopamine,4418,B-Chemical
(,4418,O
6-OHDA,4418,B-Chemical
),4418,O
-lesioned,4418,O
rats,4418,O
.,4418,O
In,4419,O
a,4419,O
more,4419,O
complex,4419,O
task,4419,O
commonly,4419,O
used,4419,O
to,4419,O
evaluate,4419,O
major,4419,O
akinetic,4419,B-Disease
symptoms,4419,O
of,4419,O
PD,4419,B-Disease
patients,4419,O
",",4419,O
5,4419,O
mg/kg,4419,O
AMN082,4419,B-Chemical
reverses,4419,O
the,4419,O
increased,4419,O
reaction,4419,O
time,4419,O
to,4419,O
respond,4419,O
to,4419,O
a,4419,O
cue,4419,O
of,4419,O
bilateral,4419,O
6-OHDA-lesioned,4419,B-Chemical
rats,4419,O
.,4419,O
In,4420,O
addition,4420,O
",",4420,O
AMN082,4420,B-Chemical
reduces,4420,O
the,4420,O
duration,4420,O
of,4420,O
haloperidol-induced,4420,B-Chemical
catalepsy,4420,B-Disease
in,4420,O
a,4420,O
mGlu7,4420,O
receptor-dependent,4420,O
manner,4420,O
in,4420,O
wild-type,4420,O
but,4420,O
not,4420,O
mGlu7,4420,O
receptor,4420,O
knockout,4420,O
mice,4420,O
.,4420,O
Higher,4421,O
doses,4421,O
of,4421,O
AMN082,4421,B-Chemical
(,4421,O
10,4421,O
and,4421,O
20,4421,O
mg/kg,4421,O
p.o,4421,O
.,4421,O
),4421,O
have,4422,O
no,4422,O
effect,4422,O
on,4422,O
the,4422,O
same,4422,O
models,4422,O
of,4422,O
PD,4422,B-Disease
.,4422,O
Overall,4423,O
these,4423,O
findings,4423,O
suggest,4423,O
that,4423,O
mGlu7,4423,O
receptor,4423,O
activation,4423,O
can,4423,O
reverse,4423,O
motor,4423,O
dysfunction,4423,O
associated,4423,O
with,4423,O
reduced,4423,O
dopamine,4423,B-Chemical
activity,4423,O
.,4423,O
Selective,4424,O
ligands,4424,O
of,4424,O
mGlu7,4424,O
receptor,4424,O
subtypes,4424,O
may,4424,O
thus,4424,O
be,4424,O
considered,4424,O
as,4424,O
promising,4424,O
compounds,4424,O
for,4424,O
the,4424,O
development,4424,O
of,4424,O
antiparkinsonian,4424,O
therapeutic,4424,O
strategies,4424,O
.,4424,O
Sorafenib-induced,4425,B-Chemical
acute,4425,O
myocardial,4425,B-Disease
infarction,4425,I-Disease
due,4425,O
to,4425,O
coronary,4425,B-Disease
artery,4425,I-Disease
spasm,4425,I-Disease
.,4425,O
A,4426,O
65-year-old,4426,O
man,4426,O
with,4426,O
advanced,4426,O
renal,4426,B-Disease
cell,4426,I-Disease
carcinoma,4426,I-Disease
was,4426,O
admitted,4426,O
due,4426,O
to,4426,O
continuing,4426,O
chest,4426,B-Disease
pain,4426,I-Disease
at,4426,O
rest,4426,O
.,4426,O
Two,4427,O
weeks,4427,O
before,4427,O
his,4427,O
admission,4427,O
",",4427,O
sorafenib,4427,B-Chemical
had,4427,O
been,4427,O
started,4427,O
.,4427,O
He,4428,O
was,4428,O
diagnosed,4428,O
with,4428,O
non-ST-elevation,4428,O
myocardial,4428,B-Disease
infarction,4428,I-Disease
by,4428,O
laboratory,4428,O
data,4428,O
and,4428,O
electrocardiogram,4428,O
.,4428,O
Enhanced,4429,O
heart,4429,O
magnetic,4429,O
resonance,4429,O
imaging,4429,O
also,4429,O
showed,4429,O
subendocardial,4429,B-Disease
infarction,4429,I-Disease
.,4429,O
However,4430,O
",",4430,O
there,4430,O
was,4430,O
no,4430,O
stenosis,4430,O
in,4430,O
coronary,4430,O
arteries,4430,O
on,4430,O
angiography,4430,O
.,4430,O
Coronary,4431,B-Disease
artery,4431,I-Disease
spasm,4431,I-Disease
was,4431,O
induced,4431,O
by,4431,O
a,4431,O
provocative,4431,O
test,4431,O
.,4431,O
Cessation,4432,O
of,4432,O
sorafenib,4432,B-Chemical
and,4432,O
administration,4432,O
of,4432,O
Ca-channel,4432,B-Chemical
blocker,4432,O
and,4432,O
nitrates,4432,B-Chemical
ameliorated,4432,O
his,4432,O
symptoms,4432,O
",",4432,O
but,4432,O
relapse,4432,O
occurred,4432,O
after,4432,O
resumption,4432,O
of,4432,O
sorafenib,4432,B-Chemical
.,4432,O
Addition,4433,O
of,4433,O
oral,4433,O
nicorandil,4433,B-Chemical
reduced,4433,O
his,4433,O
symptoms,4433,O
and,4433,O
maintained,4433,O
stable,4433,B-Disease
angina,4433,I-Disease
status,4433,O
.,4433,O
We,4434,O
report,4434,O
the,4434,O
first,4434,O
case,4434,O
of,4434,O
sorafenib-induced,4434,B-Chemical
coronary,4434,B-Disease
artery,4434,I-Disease
spasm,4434,I-Disease
.,4434,O
Sorafenib,4435,B-Chemical
is,4435,O
a,4435,O
multikinase,4435,O
inhibitor,4435,O
that,4435,O
targets,4435,O
signaling,4435,O
pathways,4435,O
necessary,4435,O
for,4435,O
cellular,4435,O
proliferation,4435,O
and,4435,O
survival,4435,O
.,4435,O
On,4436,O
the,4436,O
other,4436,O
hand,4436,O
",",4436,O
the,4436,O
Rho/ROCK,4436,O
pathway,4436,O
has,4436,O
an,4436,O
important,4436,O
role,4436,O
in,4436,O
the,4436,O
pathogenesis,4436,O
of,4436,O
coronary,4436,B-Disease
artery,4436,I-Disease
spasm,4436,I-Disease
.,4436,O
Our,4437,O
report,4437,O
may,4437,O
show,4437,O
an,4437,O
adverse,4437,O
effect,4437,O
on,4437,O
the,4437,O
Rho/ROCK,4437,O
pathway,4437,O
by,4437,O
sorafenib,4437,B-Chemical
use,4437,O
.,4437,O
A,4438,O
novel,4438,O
animal,4438,O
model,4438,O
to,4438,O
evaluate,4438,O
the,4438,O
ability,4438,O
of,4438,O
a,4438,O
drug,4438,O
delivery,4438,O
system,4438,O
to,4438,O
promote,4438,O
the,4438,O
passage,4438,O
through,4438,O
the,4438,O
BBB,4438,O
.,4438,O
The,4439,O
purpose,4439,O
of,4439,O
this,4439,O
investigation,4439,O
was,4439,O
to,4439,O
explore,4439,O
the,4439,O
potentiality,4439,O
of,4439,O
a,4439,O
novel,4439,O
animal,4439,O
model,4439,O
to,4439,O
be,4439,O
used,4439,O
for,4439,O
the,4439,O
in,4439,O
vivo,4439,O
evaluation,4439,O
of,4439,O
the,4439,O
ability,4439,O
of,4439,O
a,4439,O
drug,4439,O
delivery,4439,O
system,4439,O
to,4439,O
promote,4439,O
the,4439,O
passage,4439,O
through,4439,O
the,4439,O
blood-brain,4439,O
barrier,4439,O
(,4439,O
BBB,4439,O
),4439,O
and/or,4439,O
to,4439,O
improve,4439,O
the,4439,O
brain,4439,O
localization,4439,O
of,4439,O
a,4439,O
bioactive,4439,O
compound,4439,O
.,4439,O
A,4440,O
Tween,4440,O
80-coated,4440,O
poly-L-lactid,4440,B-Chemical
acid,4440,I-Chemical
nanoparticles,4440,O
was,4440,O
used,4440,O
as,4440,O
a,4440,O
model,4440,O
of,4440,O
colloidal,4440,O
drug,4440,O
delivery,4440,O
system,4440,O
",",4440,O
able,4440,O
to,4440,O
trespass,4440,O
the,4440,O
BBB,4440,O
.,4440,O
Tacrine,4441,B-Chemical
",",4441,O
administered,4441,O
in,4441,O
LiCl,4441,B-Chemical
pre-treated,4441,O
rats,4441,O
",",4441,O
induces,4441,O
electrocorticographic,4441,O
seizures,4441,B-Disease
and,4441,O
delayed,4441,O
hippocampal,4441,B-Disease
damage,4441,I-Disease
.,4441,O
The,4442,O
toxic,4442,O
effects,4442,O
of,4442,O
tacrine-loaded,4442,B-Chemical
poly-L-lactid,4442,B-Chemical
acid,4442,I-Chemical
nanoparticles,4442,O
(,4442,O
5mg/kg,4442,O
),4442,O
",",4442,O
a,4442,O
saline,4442,O
solution,4442,O
of,4442,O
tacrine,4442,B-Chemical
(,4442,O
5mg/kg,4442,O
),4442,O
and,4442,O
an,4442,O
empty,4442,O
colloidal,4442,O
nanoparticle,4442,O
suspension,4442,O
were,4442,O
compared,4442,O
following,4442,O
i.p,4442,O
.,4442,O
administration,4443,O
in,4443,O
LiCl-pre-treated,4443,B-Chemical
Wistar,4443,O
rats,4443,O
.,4443,O
All,4444,O
the,4444,O
animals,4444,O
treated,4444,O
with,4444,O
tacrine-loaded,4444,B-Chemical
nanoparticles,4444,O
showed,4444,O
an,4444,O
earlier,4444,O
outcome,4444,O
of,4444,O
CNS,4444,O
adverse,4444,O
symptoms,4444,O
",",4444,O
i.e,4444,O
.,4444,O
epileptic,4445,B-Disease
onset,4445,O
",",4445,O
with,4445,O
respect,4445,O
to,4445,O
those,4445,O
animals,4445,O
treated,4445,O
with,4445,O
the,4445,O
free,4445,O
compound,4445,O
(,4445,O
10,4445,O
min,4445,O
vs.,4445,O
22,4445,O
min,4445,O
respectively,4445,O
),4445,O
.,4445,O
In,4446,O
addition,4446,O
",",4446,O
tacrine-loaded,4446,B-Chemical
nanoparticles,4446,O
administration,4446,O
induced,4446,O
damage,4446,B-Disease
of,4446,I-Disease
neuronal,4446,I-Disease
cells,4446,I-Disease
in,4446,O
CA1,4446,O
field,4446,O
of,4446,O
the,4446,O
hippocampus,4446,O
in,4446,O
all,4446,O
treated,4446,O
animals,4446,O
",",4446,O
while,4446,O
the,4446,O
saline,4446,O
solution,4446,O
of,4446,O
tacrine,4446,B-Chemical
only,4446,O
in,4446,O
60,4446,O
%,4446,O
of,4446,O
animals,4446,O
.,4446,O
Empty,4447,O
nanoparticles,4447,O
provided,4447,O
similar,4447,O
results,4447,O
to,4447,O
control,4447,O
(,4447,O
saline-treated,4447,O
),4447,O
group,4447,O
of,4447,O
animals,4447,O
.,4447,O
In,4448,O
conclusion,4448,O
",",4448,O
the,4448,O
evaluation,4448,O
of,4448,O
time-to-onset,4448,O
of,4448,O
symptoms,4448,O
and,4448,O
the,4448,O
severity,4448,O
of,4448,O
neurodegenerative,4448,O
processes,4448,O
induced,4448,O
by,4448,O
the,4448,O
tacrine-lithium,4448,B-Chemical
model,4448,O
of,4448,O
epilepsy,4448,B-Disease
in,4448,O
the,4448,O
rat,4448,O
",",4448,O
could,4448,O
be,4448,O
used,4448,O
to,4448,O
evaluate,4448,O
preliminarily,4448,O
the,4448,O
capability,4448,O
of,4448,O
a,4448,O
drug,4448,O
delivery,4448,O
system,4448,O
to,4448,O
trespass,4448,O
(,4448,O
or,4448,O
not,4448,O
),4448,O
the,4448,O
BBB,4448,O
in,4448,O
vivo,4448,O
.,4448,O
High-dose,4449,O
tranexamic,4449,B-Chemical
Acid,4449,I-Chemical
is,4449,O
associated,4449,O
with,4449,O
nonischemic,4449,O
clinical,4449,O
seizures,4449,B-Disease
in,4449,O
cardiac,4449,O
surgical,4449,O
patients,4449,O
.,4449,O
BACKGROUND,4450,O
:,4450,O
In,4450,O
2,4450,O
separate,4450,O
centers,4450,O
",",4450,O
we,4450,O
observed,4450,O
a,4450,O
notable,4450,O
increase,4450,O
in,4450,O
the,4450,O
incidence,4450,O
of,4450,O
postoperative,4450,O
convulsive,4450,B-Disease
seizures,4450,B-Disease
from,4450,O
1.3,4450,O
%,4450,O
to,4450,O
3.8,4450,O
%,4450,O
in,4450,O
patients,4450,O
having,4450,O
undergone,4450,O
major,4450,O
cardiac,4450,O
surgical,4450,O
procedures,4450,O
.,4450,O
These,4451,O
events,4451,O
were,4451,O
temporally,4451,O
coincident,4451,O
with,4451,O
the,4451,O
initial,4451,O
use,4451,O
of,4451,O
high-dose,4451,O
tranexamic,4451,B-Chemical
acid,4451,I-Chemical
(,4451,O
TXA,4451,B-Chemical
),4451,O
therapy,4451,O
after,4451,O
withdrawal,4451,O
of,4451,O
aprotinin,4451,O
from,4451,O
general,4451,O
clinical,4451,O
usage,4451,O
.,4451,O
The,4452,O
purpose,4452,O
of,4452,O
this,4452,O
review,4452,O
was,4452,O
to,4452,O
perform,4452,O
a,4452,O
retrospective,4452,O
analysis,4452,O
to,4452,O
examine,4452,O
whether,4452,O
there,4452,O
was,4452,O
a,4452,O
relation,4452,O
between,4452,O
TXA,4452,B-Chemical
usage,4452,O
and,4452,O
seizures,4452,B-Disease
after,4452,O
cardiac,4452,O
surgery,4452,O
.,4452,O
METHODS,4453,O
:,4453,O
An,4453,O
in-depth,4453,O
chart,4453,O
review,4453,O
was,4453,O
undertaken,4453,O
in,4453,O
all,4453,O
24,4453,O
patients,4453,O
who,4453,O
developed,4453,O
perioperative,4453,O
seizures,4453,B-Disease
.,4453,O
Electroencephalographic,4454,O
activity,4454,O
was,4454,O
recorded,4454,O
in,4454,O
11,4454,O
of,4454,O
these,4454,O
patients,4454,O
",",4454,O
and,4454,O
all,4454,O
patients,4454,O
had,4454,O
a,4454,O
formal,4454,O
neurological,4454,O
evaluation,4454,O
and,4454,O
brain,4454,O
imaging,4454,O
studies,4454,O
.,4454,O
RESULTS,4455,O
:,4455,O
Twenty-one,4455,O
of,4455,O
the,4455,O
24,4455,O
patients,4455,O
did,4455,O
not,4455,O
have,4455,O
evidence,4455,O
of,4455,O
new,4455,O
cerebral,4455,B-Disease
ischemic,4455,I-Disease
injury,4455,I-Disease
",",4455,O
but,4455,O
seizures,4455,B-Disease
were,4455,O
likely,4455,O
due,4455,O
to,4455,O
ischemic,4455,B-Disease
brain,4455,I-Disease
injury,4455,I-Disease
in,4455,O
3,4455,O
patients,4455,O
.,4455,O
All,4456,O
patients,4456,O
with,4456,O
seizures,4456,B-Disease
did,4456,O
not,4456,O
have,4456,O
permanent,4456,O
neurological,4456,B-Disease
abnormalities,4456,I-Disease
.,4456,O
All,4457,O
24,4457,O
patients,4457,O
with,4457,O
seizures,4457,B-Disease
received,4457,O
high,4457,O
doses,4457,O
of,4457,O
TXA,4457,B-Chemical
intraoperatively,4457,O
ranging,4457,O
from,4457,O
61,4457,O
to,4457,O
259,4457,O
mg/kg,4457,O
",",4457,O
had,4457,O
a,4457,O
mean,4457,O
age,4457,O
of,4457,O
69.9,4457,O
years,4457,O
",",4457,O
and,4457,O
21,4457,O
of,4457,O
24,4457,O
had,4457,O
undergone,4457,O
open,4457,O
chamber,4457,O
rather,4457,O
than,4457,O
coronary,4457,O
bypass,4457,O
procedures,4457,O
.,4457,O
All,4458,O
but,4458,O
one,4458,O
patient,4458,O
were,4458,O
managed,4458,O
using,4458,O
cardiopulmonary,4458,O
bypass,4458,O
.,4458,O
No,4459,O
evidence,4459,O
of,4459,O
brain,4459,B-Disease
ischemic,4459,I-Disease
",",4459,O
metabolic,4459,O
",",4459,O
or,4459,O
hyperthermia-induced,4459,B-Disease
causes,4459,O
for,4459,O
their,4459,O
seizures,4459,B-Disease
was,4459,O
apparent,4459,O
.,4459,O
CONCLUSION,4460,O
:,4460,O
Our,4460,O
results,4460,O
suggest,4460,O
that,4460,O
use,4460,O
of,4460,O
high-dose,4460,O
TXA,4460,B-Chemical
in,4460,O
older,4460,O
patients,4460,O
in,4460,O
conjunction,4460,O
with,4460,O
cardiopulmonary,4460,O
bypass,4460,O
and,4460,O
open-chamber,4460,O
cardiac,4460,O
surgery,4460,O
is,4460,O
associated,4460,O
with,4460,O
clinical,4460,O
seizures,4460,B-Disease
in,4460,O
susceptible,4460,O
patients,4460,O
.,4460,O
Sedation,4461,O
depth,4461,O
during,4461,O
spinal,4461,O
anesthesia,4461,O
and,4461,O
the,4461,O
development,4461,O
of,4461,O
postoperative,4461,O
delirium,4461,O
in,4461,O
elderly,4461,O
patients,4461,O
undergoing,4461,O
hip,4461,B-Disease
fracture,4461,I-Disease
repair,4461,O
.,4461,O
OBJECTIVE,4462,O
:,4462,O
To,4462,O
determine,4462,O
whether,4462,O
limiting,4462,O
intraoperative,4462,O
sedation,4462,O
depth,4462,O
during,4462,O
spinal,4462,O
anesthesia,4462,O
for,4462,O
hip,4462,B-Disease
fracture,4462,I-Disease
repair,4462,O
in,4462,O
elderly,4462,O
patients,4462,O
can,4462,O
decrease,4462,O
the,4462,O
prevalence,4462,O
of,4462,O
postoperative,4462,O
delirium,4462,O
.,4462,O
PATIENTS,4463,O
AND,4463,O
METHODS,4463,O
:,4463,O
We,4463,O
performed,4463,O
a,4463,O
double-blind,4463,O
",",4463,O
randomized,4463,O
controlled,4463,O
trial,4463,O
at,4463,O
an,4463,O
academic,4463,O
medical,4463,O
center,4463,O
of,4463,O
elderly,4463,O
patients,4463,O
(,4463,O
>,4463,O
or=65,4463,O
years,4463,O
),4463,O
without,4463,O
preoperative,4463,O
delirium,4463,B-Disease
or,4463,O
severe,4463,O
dementia,4463,B-Disease
who,4463,O
underwent,4463,O
hip,4463,B-Disease
fracture,4463,I-Disease
repair,4463,O
under,4463,O
spinal,4463,O
anesthesia,4463,O
with,4463,O
propofol,4463,B-Chemical
sedation,4463,O
.,4463,O
Sedation,4464,O
depth,4464,O
was,4464,O
titrated,4464,O
using,4464,O
processed,4464,O
electroencephalography,4464,O
with,4464,O
the,4464,O
bispectral,4464,O
index,4464,O
(,4464,O
BIS,4464,O
),4464,O
",",4464,O
and,4464,O
patients,4464,O
were,4464,O
randomized,4464,O
to,4464,O
receive,4464,O
either,4464,O
deep,4464,O
(,4464,O
BIS,4464,O
",",4464,O
approximately,4464,O
50,4464,O
),4464,O
or,4464,O
light,4464,O
(,4464,O
BIS,4464,O
",",4464,O
>,4464,O
or=80,4464,O
),4464,O
sedation,4464,O
.,4464,O
Postoperative,4465,O
delirium,4465,O
was,4465,O
assessed,4465,O
as,4465,O
defined,4465,O
by,4465,O
Diagnostic,4465,O
and,4465,O
Statistical,4465,O
Manual,4465,O
of,4465,O
Mental,4465,B-Disease
Disorders,4465,I-Disease
(,4465,O
Third,4465,O
Edition,4465,O
Revised,4465,O
),4465,O
criteria,4465,O
using,4465,O
the,4465,O
Confusion,4465,O
Assessment,4465,O
Method,4465,O
beginning,4465,O
at,4465,O
any,4465,O
time,4465,O
from,4465,O
the,4465,O
second,4465,O
day,4465,O
after,4465,O
surgery,4465,O
.,4465,O
RESULTS,4466,O
:,4466,O
From,4466,O
April,4466,O
2,4466,O
",",4466,O
2005,4466,O
",",4466,O
through,4466,O
October,4466,O
30,4466,O
",",4466,O
2008,4466,O
",",4466,O
a,4466,O
total,4466,O
of,4466,O
114,4466,O
patients,4466,O
were,4466,O
randomized,4466,O
.,4466,O
The,4467,O
prevalence,4467,O
of,4467,O
postoperative,4467,O
delirium,4467,O
was,4467,O
significantly,4467,O
lower,4467,O
in,4467,O
the,4467,O
light,4467,O
sedation,4467,O
group,4467,O
(,4467,O
11/57,4467,O
[,4467,O
19,4467,O
%,4467,O
],4467,O
vs,4467,O
23/57,4467,O
[,4467,O
40,4467,O
%,4467,O
],4467,O
in,4467,O
the,4467,O
deep,4467,O
sedation,4467,O
group,4467,O
;,4467,O
P=.02,4467,O
),4467,O
",",4467,O
indicating,4467,O
that,4467,O
1,4467,O
incident,4467,O
of,4467,O
delirium,4467,B-Disease
will,4467,O
be,4467,O
prevented,4467,O
for,4467,O
every,4467,O
4.7,4467,O
patients,4467,O
treated,4467,O
with,4467,O
light,4467,O
sedation,4467,O
.,4467,O
The,4468,O
mean,4468,O
+/-,4468,O
SD,4468,O
number,4468,O
of,4468,O
days,4468,O
of,4468,O
delirium,4468,B-Disease
during,4468,O
hospitalization,4468,O
was,4468,O
lower,4468,O
in,4468,O
the,4468,O
light,4468,O
sedation,4468,O
group,4468,O
than,4468,O
in,4468,O
the,4468,O
deep,4468,O
sedation,4468,O
group,4468,O
(,4468,O
0.5+/-1.5,4468,O
days,4468,O
vs,4468,O
1.4+/-4.0,4468,O
days,4468,O
;,4468,O
P=.01,4468,O
),4468,O
.,4468,O
CONCLUSION,4469,O
:,4469,O
The,4469,O
use,4469,O
of,4469,O
light,4469,O
propofol,4469,B-Chemical
sedation,4469,O
decreased,4469,O
the,4469,O
prevalence,4469,O
of,4469,O
postoperative,4469,O
delirium,4469,O
by,4469,O
50,4469,O
%,4469,O
compared,4469,O
with,4469,O
deep,4469,O
sedation,4469,O
.,4469,O
Limiting,4470,O
depth,4470,O
of,4470,O
sedation,4470,O
during,4470,O
spinal,4470,O
anesthesia,4470,O
is,4470,O
a,4470,O
simple,4470,O
",",4470,O
safe,4470,O
",",4470,O
and,4470,O
cost-effective,4470,O
intervention,4470,O
for,4470,O
preventing,4470,O
postoperative,4470,O
delirium,4470,O
in,4470,O
elderly,4470,O
patients,4470,O
that,4470,O
could,4470,O
be,4470,O
widely,4470,O
and,4470,O
readily,4470,O
adopted,4470,O
.,4470,O
The,4471,O
protective,4471,O
role,4471,O
of,4471,O
Nrf2,4471,O
in,4471,O
streptozotocin-induced,4471,B-Chemical
diabetic,4471,B-Disease
nephropathy,4471,I-Disease
.,4471,O
OBJECTIVE,4472,O
:,4472,O
Diabetic,4472,B-Disease
nephropathy,4472,I-Disease
is,4472,O
one,4472,O
of,4472,O
the,4472,O
major,4472,O
causes,4472,O
of,4472,O
renal,4472,B-Disease
failure,4472,I-Disease
",",4472,O
which,4472,O
is,4472,O
accompanied,4472,O
by,4472,O
the,4472,O
production,4472,O
of,4472,O
reactive,4472,O
oxygen,4472,B-Chemical
species,4472,O
(,4472,O
ROS,4472,O
),4472,O
.,4472,O
Nrf2,4473,O
is,4473,O
the,4473,O
primary,4473,O
transcription,4473,O
factor,4473,O
that,4473,O
controls,4473,O
the,4473,O
antioxidant,4473,O
response,4473,O
essential,4473,O
for,4473,O
maintaining,4473,O
cellular,4473,O
redox,4473,O
homeostasis,4473,O
.,4473,O
Here,4474,O
",",4474,O
we,4474,O
report,4474,O
our,4474,O
findings,4474,O
demonstrating,4474,O
a,4474,O
protective,4474,O
role,4474,O
of,4474,O
Nrf2,4474,O
against,4474,O
diabetic,4474,B-Disease
nephropathy,4474,I-Disease
.,4474,O
RESEARCH,4475,O
DESIGN,4475,O
AND,4475,O
METHODS,4475,O
:,4475,O
We,4475,O
explore,4475,O
the,4475,O
protective,4475,O
role,4475,O
of,4475,O
Nrf2,4475,O
against,4475,O
diabetic,4475,B-Disease
nephropathy,4475,I-Disease
using,4475,O
human,4475,O
kidney,4475,O
biopsy,4475,O
tissues,4475,O
from,4475,O
diabetic,4475,B-Disease
nephropathy,4475,I-Disease
patients,4475,O
",",4475,O
a,4475,O
streptozotocin-induced,4475,B-Chemical
diabetic,4475,B-Disease
nephropathy,4475,I-Disease
model,4475,O
in,4475,O
Nrf2,4475,O
(,4475,O
-/-,4475,O
),4475,O
mice,4475,O
",",4475,O
and,4475,O
cultured,4475,O
human,4475,O
mesangial,4475,O
cells,4475,O
.,4475,O
RESULTS,4476,O
:,4476,O
The,4476,O
glomeruli,4476,O
of,4476,O
human,4476,O
diabetic,4476,B-Disease
nephropathy,4476,I-Disease
patients,4476,O
were,4476,O
under,4476,O
oxidative,4476,O
stress,4476,O
and,4476,O
had,4476,O
elevated,4476,O
Nrf2,4476,O
levels,4476,O
.,4476,O
In,4477,O
the,4477,O
animal,4477,O
study,4477,O
",",4477,O
Nrf2,4477,O
was,4477,O
demonstrated,4477,O
to,4477,O
be,4477,O
crucial,4477,O
in,4477,O
ameliorating,4477,O
streptozotocin-induced,4477,B-Chemical
renal,4477,B-Disease
damage,4477,I-Disease
.,4477,O
This,4478,O
is,4478,O
evident,4478,O
by,4478,O
Nrf2,4478,O
(,4478,O
-/-,4478,O
),4478,O
mice,4478,O
having,4478,O
higher,4478,O
ROS,4478,O
production,4478,O
and,4478,O
suffering,4478,O
from,4478,O
greater,4478,O
oxidative,4478,O
DNA,4478,O
damage,4478,O
and,4478,O
renal,4478,B-Disease
injury,4478,I-Disease
compared,4478,O
with,4478,O
Nrf2,4478,O
(,4478,O
+/+,4478,O
),4478,O
mice,4478,O
.,4478,O
Mechanistic,4479,O
studies,4479,O
in,4479,O
both,4479,O
in,4479,O
vivo,4479,O
and,4479,O
in,4479,O
vitro,4479,O
systems,4479,O
showed,4479,O
that,4479,O
the,4479,O
Nrf2-mediated,4479,O
protection,4479,O
against,4479,O
diabetic,4479,B-Disease
nephropathy,4479,I-Disease
is,4479,O
",",4479,O
at,4479,O
least,4479,O
",",4479,O
partially,4479,O
through,4479,O
inhibition,4479,O
of,4479,O
transforming,4479,O
growth,4479,O
factor-beta1,4479,O
(,4479,O
TGF-beta1,4479,O
),4479,O
and,4479,O
reduction,4479,O
of,4479,O
extracellular,4479,O
matrix,4479,O
production,4479,O
.,4479,O
In,4480,O
human,4480,O
renal,4480,O
mesangial,4480,O
cells,4480,O
",",4480,O
high,4480,O
glucose,4480,B-Chemical
induced,4480,O
ROS,4480,O
production,4480,O
and,4480,O
activated,4480,O
expression,4480,O
of,4480,O
Nrf2,4480,O
and,4480,O
its,4480,O
downstream,4480,O
genes,4480,O
.,4480,O
Furthermore,4481,O
",",4481,O
activation,4481,O
or,4481,O
overexpression,4481,O
of,4481,O
Nrf2,4481,O
inhibited,4481,O
the,4481,O
promoter,4481,O
activity,4481,O
of,4481,O
TGF-beta1,4481,O
in,4481,O
a,4481,O
dose-dependent,4481,O
manner,4481,O
",",4481,O
whereas,4481,O
knockdown,4481,O
of,4481,O
Nrf2,4481,O
by,4481,O
siRNA,4481,O
enhanced,4481,O
TGF-beta1,4481,O
transcription,4481,O
and,4481,O
fibronectin,4481,O
production,4481,O
.,4481,O
CONCLUSIONS,4482,O
:,4482,O
This,4482,O
work,4482,O
clearly,4482,O
indicates,4482,O
a,4482,O
protective,4482,O
role,4482,O
of,4482,O
Nrf2,4482,O
in,4482,O
diabetic,4482,B-Disease
nephropathy,4482,I-Disease
",",4482,O
suggesting,4482,O
that,4482,O
dietary,4482,O
or,4482,O
therapeutic,4482,O
activation,4482,O
of,4482,O
Nrf2,4482,O
could,4482,O
be,4482,O
used,4482,O
as,4482,O
a,4482,O
strategy,4482,O
to,4482,O
prevent,4482,O
or,4482,O
slow,4482,O
down,4482,O
the,4482,O
progression,4482,O
of,4482,O
diabetic,4482,B-Disease
nephropathy,4482,I-Disease
.,4482,O
Metformin,4483,B-Chemical
prevents,4483,O
experimental,4483,O
gentamicin-induced,4483,B-Chemical
nephropathy,4483,B-Disease
by,4483,O
a,4483,O
mitochondria-dependent,4483,O
pathway,4483,O
.,4483,O
The,4484,O
antidiabetic,4484,O
drug,4484,O
metformin,4484,B-Chemical
can,4484,O
diminish,4484,O
apoptosis,4484,O
induced,4484,O
by,4484,O
oxidative,4484,O
stress,4484,O
in,4484,O
endothelial,4484,O
cells,4484,O
and,4484,O
prevent,4484,O
vascular,4484,B-Disease
dysfunction,4484,I-Disease
even,4484,O
in,4484,O
nondiabetic,4484,O
patients,4484,O
.,4484,O
Here,4485,O
we,4485,O
tested,4485,O
whether,4485,O
it,4485,O
has,4485,O
a,4485,O
beneficial,4485,O
effect,4485,O
in,4485,O
a,4485,O
rat,4485,O
model,4485,O
of,4485,O
gentamicin,4485,B-Chemical
toxicity,4485,B-Disease
.,4485,O
Mitochondrial,4486,O
analysis,4486,O
",",4486,O
respiration,4486,O
intensity,4486,O
",",4486,O
levels,4486,O
of,4486,O
reactive,4486,O
oxygen,4486,B-Chemical
species,4486,O
",",4486,O
permeability,4486,O
transition,4486,O
",",4486,O
and,4486,O
cytochrome,4486,O
c,4486,O
release,4486,O
were,4486,O
assessed,4486,O
3,4486,O
and,4486,O
6,4486,O
days,4486,O
after,4486,O
gentamicin,4486,B-Chemical
administration,4486,O
.,4486,O
Metformin,4487,B-Chemical
treatment,4487,O
fully,4487,O
blocked,4487,O
gentamicin-mediated,4487,B-Chemical
acute,4487,B-Disease
renal,4487,I-Disease
failure,4487,I-Disease
.,4487,O
This,4488,O
was,4488,O
accompanied,4488,O
by,4488,O
a,4488,O
lower,4488,O
activity,4488,O
of,4488,O
N-acetyl-beta-D-glucosaminidase,4488,O
",",4488,O
together,4488,O
with,4488,O
a,4488,O
decrease,4488,O
of,4488,O
lipid,4488,O
peroxidation,4488,O
and,4488,O
increase,4488,O
of,4488,O
antioxidant,4488,O
systems,4488,O
.,4488,O
Metformin,4489,B-Chemical
also,4489,O
protected,4489,O
the,4489,O
kidney,4489,O
from,4489,O
histological,4489,O
damage,4489,O
6,4489,O
days,4489,O
after,4489,O
gentamicin,4489,B-Chemical
administration,4489,O
.,4489,O
These,4490,O
in,4490,O
vivo,4490,O
markers,4490,O
of,4490,O
kidney,4490,B-Disease
dysfunction,4490,I-Disease
and,4490,O
their,4490,O
correction,4490,O
by,4490,O
metformin,4490,B-Chemical
were,4490,O
complemented,4490,O
by,4490,O
in,4490,O
vitro,4490,O
studies,4490,O
of,4490,O
mitochondrial,4490,O
function,4490,O
.,4490,O
We,4491,O
found,4491,O
that,4491,O
gentamicin,4491,B-Chemical
treatment,4491,O
depleted,4491,O
respiratory,4491,O
components,4491,O
(,4491,O
cytochrome,4491,O
c,4491,O
",",4491,O
NADH,4491,O
),4491,O
",",4491,O
probably,4491,O
due,4491,O
to,4491,O
the,4491,O
opening,4491,O
of,4491,O
mitochondrial,4491,O
transition,4491,O
pores,4491,O
.,4491,O
These,4492,O
injuries,4492,O
",",4492,O
partly,4492,O
mediated,4492,O
by,4492,O
a,4492,O
rise,4492,O
in,4492,O
reactive,4492,O
oxygen,4492,B-Chemical
species,4492,O
from,4492,O
the,4492,O
electron,4492,O
transfer,4492,O
chain,4492,O
",",4492,O
were,4492,O
significantly,4492,O
decreased,4492,O
by,4492,O
metformin,4492,B-Chemical
.,4492,O
Thus,4493,O
",",4493,O
our,4493,O
study,4493,O
suggests,4493,O
that,4493,O
pleiotropic,4493,O
effects,4493,O
of,4493,O
metformin,4493,B-Chemical
can,4493,O
lessen,4493,O
gentamicin,4493,B-Chemical
nephrotoxicity,4493,B-Disease
and,4493,O
improve,4493,O
mitochondrial,4493,O
homeostasis,4493,O
.,4493,O
Risk,4494,O
of,4494,O
nephropathy,4494,B-Disease
after,4494,O
consumption,4494,O
of,4494,O
nonionic,4494,O
contrast,4494,B-Chemical
media,4494,I-Chemical
by,4494,O
children,4494,O
undergoing,4494,O
cardiac,4494,O
angiography,4494,O
:,4494,O
a,4494,O
prospective,4494,O
study,4494,O
.,4494,O
Despite,4495,O
increasing,4495,O
reports,4495,O
on,4495,O
nonionic,4495,O
contrast,4495,B-Chemical
media-induced,4495,O
nephropathy,4495,B-Disease
(,4495,O
CIN,4495,B-Disease
),4495,O
in,4495,O
hospitalized,4495,O
adult,4495,O
patients,4495,O
during,4495,O
cardiac,4495,O
procedures,4495,O
",",4495,O
the,4495,O
studies,4495,O
in,4495,O
pediatrics,4495,O
are,4495,O
limited,4495,O
",",4495,O
with,4495,O
even,4495,O
less,4495,O
focus,4495,O
on,4495,O
possible,4495,O
predisposing,4495,O
factors,4495,O
and,4495,O
preventive,4495,O
measures,4495,O
for,4495,O
patients,4495,O
undergoing,4495,O
cardiac,4495,O
angiography,4495,O
.,4495,O
This,4496,O
prospective,4496,O
study,4496,O
determined,4496,O
the,4496,O
incidence,4496,O
of,4496,O
CIN,4496,B-Disease
for,4496,O
two,4496,O
nonionic,4496,O
contrast,4496,B-Chemical
media,4496,I-Chemical
(,4496,O
CM,4496,B-Chemical
),4496,O
",",4496,O
iopromide,4496,B-Chemical
and,4496,O
iohexol,4496,B-Chemical
",",4496,O
among,4496,O
80,4496,O
patients,4496,O
younger,4496,O
than,4496,O
18,4496,O
years,4496,O
and,4496,O
compared,4496,O
the,4496,O
rates,4496,O
for,4496,O
this,4496,O
complication,4496,O
in,4496,O
relation,4496,O
to,4496,O
the,4496,O
type,4496,O
and,4496,O
dosage,4496,O
of,4496,O
CM,4496,B-Chemical
and,4496,O
the,4496,O
presence,4496,O
of,4496,O
cyanosis,4496,B-Disease
.,4496,O
The,4497,O
80,4497,O
patients,4497,O
in,4497,O
the,4497,O
study,4497,O
consecutively,4497,O
received,4497,O
either,4497,O
iopromide,4497,B-Chemical
(,4497,O
group,4497,O
A,4497,O
",",4497,O
n,4497,O
=,4497,O
40,4497,O
),4497,O
or,4497,O
iohexol,4497,B-Chemical
(,4497,O
group,4497,O
B,4497,O
",",4497,O
n,4497,O
=,4497,O
40,4497,O
),4497,O
.,4497,O
Serum,4498,O
sodium,4498,B-Chemical
(,4498,O
Na,4498,B-Chemical
),4498,O
",",4498,O
potassium,4498,B-Chemical
(,4498,O
K,4498,B-Chemical
),4498,O
",",4498,O
and,4498,O
creatinine,4498,B-Chemical
(,4498,O
Cr,4498,B-Chemical
),4498,O
were,4498,O
measured,4498,O
24,4498,O
h,4498,O
before,4498,O
angiography,4498,O
as,4498,O
baseline,4498,O
values,4498,O
",",4498,O
then,4498,O
measured,4498,O
again,4498,O
at,4498,O
12-,4498,O
",",4498,O
24-,4498,O
",",4498,O
and,4498,O
48-h,4498,O
intervals,4498,O
after,4498,O
CM,4498,B-Chemical
use,4498,O
.,4498,O
Urine,4499,O
samples,4499,O
for,4499,O
Na,4499,B-Chemical
and,4499,O
Cr,4499,B-Chemical
also,4499,O
were,4499,O
checked,4499,O
at,4499,O
the,4499,O
same,4499,O
intervals,4499,O
.,4499,O
Risk,4500,O
of,4500,O
renal,4500,B-Disease
failure,4500,I-Disease
",",4500,O
Injury,4500,B-Disease
to,4500,I-Disease
the,4500,I-Disease
kidney,4500,I-Disease
",",4500,O
Failure,4500,B-Disease
of,4500,I-Disease
kidney,4500,I-Disease
function,4500,I-Disease
",",4500,O
Loss,4500,B-Disease
of,4500,I-Disease
kidney,4500,I-Disease
function,4500,I-Disease
",",4500,O
and,4500,O
End-stage,4500,O
renal,4500,B-Disease
damage,4500,I-Disease
(,4500,O
RIFLE,4500,O
criteria,4500,O
),4500,O
were,4500,O
used,4500,O
to,4500,O
define,4500,O
CIN,4500,B-Disease
and,4500,O
its,4500,O
incidence,4500,O
in,4500,O
the,4500,O
study,4500,O
population,4500,O
.,4500,O
Accordingly,4501,O
",",4501,O
among,4501,O
the,4501,O
15,4501,O
CIN,4501,B-Disease
patients,4501,O
(,4501,O
18.75,4501,O
%,4501,O
),4501,O
",",4501,O
7.5,4501,O
%,4501,O
of,4501,O
the,4501,O
patients,4501,O
in,4501,O
group,4501,O
A,4501,O
had,4501,O
increased,4501,O
risk,4501,O
and,4501,O
3.75,4501,O
%,4501,O
had,4501,O
renal,4501,B-Disease
injury,4501,I-Disease
",",4501,O
whereas,4501,O
5,4501,O
%,4501,O
of,4501,O
group,4501,O
B,4501,O
had,4501,O
increased,4501,O
risk,4501,O
and,4501,O
2.5,4501,O
%,4501,O
had,4501,O
renal,4501,B-Disease
injury,4501,I-Disease
.,4501,O
Whereas,4502,O
33.3,4502,O
%,4502,O
of,4502,O
the,4502,O
patients,4502,O
with,4502,O
CIN,4502,B-Disease
were,4502,O
among,4502,O
those,4502,O
who,4502,O
received,4502,O
the,4502,O
proper,4502,O
dosage,4502,O
of,4502,O
CM,4502,B-Chemical
",",4502,O
the,4502,O
percentage,4502,O
increased,4502,O
to,4502,O
66.6,4502,O
%,4502,O
among,4502,O
those,4502,O
who,4502,O
received,4502,O
larger,4502,O
doses,4502,O
",",4502,O
with,4502,O
a,4502,O
significant,4502,O
difference,4502,O
in,4502,O
the,4502,O
incidence,4502,O
of,4502,O
CIN,4502,B-Disease
related,4502,O
to,4502,O
the,4502,O
different,4502,O
dosages,4502,O
of,4502,O
CM,4502,B-Chemical
(,4502,O
p,4502,O
=,4502,O
0.014,4502,O
),4502,O
.,4502,O
Among,4503,O
the,4503,O
15,4503,O
patients,4503,O
with,4503,O
CIN,4503,B-Disease
",",4503,O
6,4503,O
had,4503,O
cyanotic,4503,O
congenital,4503,B-Disease
heart,4503,I-Disease
diseases,4503,I-Disease
",",4503,O
but,4503,O
the,4503,O
incidence,4503,O
did,4503,O
not,4503,O
differ,4503,O
significantly,4503,O
from,4503,O
that,4503,O
for,4503,O
the,4503,O
noncyanotic,4503,O
patients,4503,O
(,4503,O
p,4503,O
=,4503,O
0.243,4503,O
),4503,O
.,4503,O
Although,4504,O
clinically,4504,O
silent,4504,O
",",4504,O
CIN,4504,B-Disease
is,4504,O
not,4504,O
rare,4504,O
in,4504,O
pediatrics,4504,O
.,4504,O
The,4505,O
incidence,4505,O
depends,4505,O
on,4505,O
dosage,4505,O
but,4505,O
not,4505,O
on,4505,O
the,4505,O
type,4505,O
of,4505,O
consumed,4505,O
nonionic,4505,O
CM,4505,B-Chemical
",",4505,O
nor,4505,O
on,4505,O
the,4505,O
presence,4505,O
of,4505,O
cyanosis,4505,B-Disease
",",4505,O
and,4505,O
although,4505,O
CIN,4505,B-Disease
usually,4505,O
is,4505,O
reversible,4505,O
",",4505,O
more,4505,O
concern,4505,O
is,4505,O
needed,4505,O
for,4505,O
the,4505,O
prevention,4505,O
of,4505,O
such,4505,O
a,4505,O
complication,4505,O
in,4505,O
children,4505,O
.,4505,O
Brainstem,4506,B-Disease
dysgenesis,4506,I-Disease
in,4506,O
an,4506,O
infant,4506,O
prenatally,4506,O
exposed,4506,O
to,4506,O
cocaine,4506,B-Chemical
.,4506,O
Many,4507,O
authors,4507,O
described,4507,O
the,4507,O
effects,4507,O
on,4507,O
the,4507,O
fetus,4507,O
of,4507,O
maternal,4507,O
cocaine,4507,B-Disease
abuse,4507,I-Disease
during,4507,O
pregnancy,4507,O
.,4507,O
Vasoconstriction,4508,O
appears,4508,O
to,4508,O
be,4508,O
the,4508,O
common,4508,O
mechanism,4508,O
of,4508,O
action,4508,O
leading,4508,O
to,4508,O
a,4508,O
wide,4508,O
range,4508,O
of,4508,O
fetal,4508,B-Disease
anomalies,4508,I-Disease
.,4508,O
We,4509,O
report,4509,O
on,4509,O
an,4509,O
infant,4509,O
with,4509,O
multiple,4509,B-Disease
cranial-nerve,4509,I-Disease
involvement,4509,I-Disease
attributable,4509,O
to,4509,O
brainstem,4509,B-Disease
dysgenesis,4509,I-Disease
",",4509,O
born,4509,O
to,4509,O
a,4509,O
cocaine-addicted,4509,B-Disease
mother,4509,O
.,4509,O
A,4510,O
cross-sectional,4510,O
evaluation,4510,O
of,4510,O
the,4510,O
effect,4510,O
of,4510,O
risperidone,4510,B-Chemical
and,4510,O
selective,4510,O
serotonin,4510,B-Chemical
reuptake,4510,O
inhibitors,4510,O
on,4510,O
bone,4510,O
mineral,4510,O
density,4510,O
in,4510,O
boys,4510,O
.,4510,O
OBJECTIVE,4511,O
:,4511,O
The,4511,O
aim,4511,O
of,4511,O
the,4511,O
present,4511,O
study,4511,O
was,4511,O
to,4511,O
investigate,4511,O
the,4511,O
effect,4511,O
of,4511,O
risperidone-induced,4511,B-Chemical
hyperprolactinemia,4511,B-Disease
on,4511,O
trabecular,4511,O
bone,4511,O
mineral,4511,O
density,4511,O
(,4511,O
BMD,4511,O
),4511,O
in,4511,O
children,4511,O
and,4511,O
adolescents,4511,O
.,4511,O
METHOD,4512,O
:,4512,O
Medically,4512,O
healthy,4512,O
7-,4512,O
to,4512,O
17-year-old,4512,O
males,4512,O
chronically,4512,O
treated,4512,O
",",4512,O
in,4512,O
a,4512,O
naturalistic,4512,O
setting,4512,O
",",4512,O
with,4512,O
risperidone,4512,B-Chemical
were,4512,O
recruited,4512,O
for,4512,O
this,4512,O
cross-sectional,4512,O
study,4512,O
through,4512,O
child,4512,O
psychiatry,4512,O
outpatient,4512,O
clinics,4512,O
between,4512,O
November,4512,O
2005,4512,O
and,4512,O
June,4512,O
2007,4512,O
.,4512,O
Anthropometric,4513,O
measurements,4513,O
and,4513,O
laboratory,4513,O
testing,4513,O
were,4513,O
conducted,4513,O
.,4513,O
The,4514,O
clinical,4514,O
diagnoses,4514,O
were,4514,O
based,4514,O
on,4514,O
chart,4514,O
review,4514,O
",",4514,O
and,4514,O
developmental,4514,O
and,4514,O
treatment,4514,O
history,4514,O
was,4514,O
obtained,4514,O
from,4514,O
the,4514,O
medical,4514,O
record,4514,O
.,4514,O
Volumetric,4515,O
BMD,4515,O
of,4515,O
the,4515,O
ultradistal,4515,O
radius,4515,O
was,4515,O
measured,4515,O
using,4515,O
peripheral,4515,O
quantitative,4515,O
computed,4515,O
tomography,4515,O
",",4515,O
and,4515,O
areal,4515,O
BMD,4515,O
of,4515,O
the,4515,O
lumbar,4515,O
spine,4515,O
was,4515,O
estimated,4515,O
using,4515,O
dual-energy,4515,O
x-ray,4515,O
absorptiometry,4515,O
.,4515,O
RESULTS,4516,O
:,4516,O
Hyperprolactinemia,4516,B-Disease
was,4516,O
present,4516,O
in,4516,O
49,4516,O
%,4516,O
of,4516,O
83,4516,O
boys,4516,O
(,4516,O
n,4516,O
=,4516,O
41,4516,O
),4516,O
treated,4516,O
with,4516,O
risperidone,4516,B-Chemical
for,4516,O
a,4516,O
mean,4516,O
of,4516,O
2.9,4516,O
years,4516,O
.,4516,O
Serum,4517,O
testosterone,4517,B-Chemical
concentration,4517,O
increased,4517,O
with,4517,O
pubertal,4517,O
status,4517,O
but,4517,O
was,4517,O
not,4517,O
affected,4517,O
by,4517,O
hyperprolactinemia,4517,B-Disease
.,4517,O
As,4518,O
expected,4518,O
",",4518,O
bone,4518,O
mineral,4518,O
content,4518,O
and,4518,O
BMD,4518,O
increased,4518,O
with,4518,O
sexual,4518,O
maturity,4518,O
.,4518,O
After,4519,O
adjusting,4519,O
for,4519,O
the,4519,O
stage,4519,O
of,4519,O
sexual,4519,O
development,4519,O
and,4519,O
height,4519,O
and,4519,O
BMI,4519,O
z,4519,O
scores,4519,O
",",4519,O
serum,4519,O
prolactin,4519,O
was,4519,O
negatively,4519,O
associated,4519,O
with,4519,O
trabecular,4519,O
volumetric,4519,O
BMD,4519,O
at,4519,O
the,4519,O
ultradistal,4519,O
radius,4519,O
(,4519,O
P,4519,O
<,4519,O
.03,4519,O
),4519,O
.,4519,O
Controlling,4520,O
for,4520,O
relevant,4520,O
covariates,4520,O
",",4520,O
we,4520,O
also,4520,O
found,4520,O
treatment,4520,O
with,4520,O
selective,4520,O
serotonin,4520,B-Chemical
reuptake,4520,O
inhibitors,4520,O
(,4520,O
SSRIs,4520,O
),4520,O
to,4520,O
be,4520,O
associated,4520,O
with,4520,O
lower,4520,O
trabecular,4520,O
BMD,4520,O
at,4520,O
the,4520,O
radius,4520,O
(,4520,O
P,4520,O
=,4520,O
.03,4520,O
),4520,O
and,4520,O
BMD,4520,O
z,4520,O
score,4520,O
at,4520,O
the,4520,O
lumbar,4520,O
spine,4520,O
(,4520,O
P,4520,O
<,4520,O
.05,4520,O
),4520,O
.,4520,O
These,4521,O
findings,4521,O
became,4521,O
more,4521,O
marked,4521,O
when,4521,O
the,4521,O
analysis,4521,O
was,4521,O
restricted,4521,O
to,4521,O
non-Hispanic,4521,O
white,4521,O
patients,4521,O
.,4521,O
Of,4522,O
13,4522,O
documented,4522,O
fractures,4522,B-Disease
",",4522,O
3,4522,O
occurred,4522,O
after,4522,O
risperidone,4522,B-Chemical
and,4522,O
SSRIs,4522,O
were,4522,O
started,4522,O
",",4522,O
and,4522,O
none,4522,O
occurred,4522,O
in,4522,O
patients,4522,O
with,4522,O
hyperprolactinemia,4522,B-Disease
.,4522,O
CONCLUSIONS,4523,O
:,4523,O
This,4523,O
is,4523,O
the,4523,O
first,4523,O
study,4523,O
to,4523,O
link,4523,O
risperidone-induced,4523,B-Chemical
hyperprolactinemia,4523,B-Disease
and,4523,O
SSRI,4523,O
treatment,4523,O
to,4523,O
lower,4523,O
BMD,4523,O
in,4523,O
children,4523,O
and,4523,O
adolescents,4523,O
.,4523,O
Future,4524,O
research,4524,O
should,4524,O
evaluate,4524,O
the,4524,O
longitudinal,4524,O
course,4524,O
of,4524,O
this,4524,O
adverse,4524,O
event,4524,O
to,4524,O
determine,4524,O
its,4524,O
temporal,4524,O
stability,4524,O
and,4524,O
whether,4524,O
a,4524,O
higher,4524,O
fracture,4524,O
rate,4524,O
ensues,4524,O
.,4524,O
Fear-potentiated,4525,O
startle,4525,B-Disease
",",4525,O
but,4525,O
not,4525,O
light-enhanced,4525,O
startle,4525,B-Disease
",",4525,O
is,4525,O
enhanced,4525,O
by,4525,O
anxiogenic,4525,O
drugs,4525,O
.,4525,O
RATIONALE,4526,O
AND,4526,O
OBJECTIVES,4526,O
:,4526,O
The,4526,O
light-enhanced,4526,O
startle,4526,B-Disease
paradigm,4526,O
(,4526,O
LES,4526,O
),4526,O
is,4526,O
suggested,4526,O
to,4526,O
model,4526,O
anxiety,4526,B-Disease
",",4526,O
because,4526,O
of,4526,O
the,4526,O
non-specific,4526,O
cue,4526,O
and,4526,O
the,4526,O
long-term,4526,O
effect,4526,O
.,4526,O
In,4527,O
contrast,4527,O
",",4527,O
the,4527,O
fear-potentiated,4527,O
startle,4527,B-Disease
(,4527,O
FPS,4527,O
),4527,O
is,4527,O
suggested,4527,O
to,4527,O
model,4527,O
conditioned,4527,O
fear,4527,O
.,4527,O
However,4528,O
",",4528,O
the,4528,O
pharmacological,4528,O
profiles,4528,O
of,4528,O
these,4528,O
two,4528,O
paradigms,4528,O
are,4528,O
very,4528,O
similar,4528,O
.,4528,O
The,4529,O
present,4529,O
study,4529,O
investigated,4529,O
the,4529,O
effects,4529,O
of,4529,O
putative,4529,O
anxiogenic,4529,O
drugs,4529,O
on,4529,O
LES,4529,O
and,4529,O
FPS,4529,O
and,4529,O
aimed,4529,O
at,4529,O
determining,4529,O
the,4529,O
sensitivity,4529,O
of,4529,O
LES,4529,O
for,4529,O
anxiogenic,4529,O
drugs,4529,O
and,4529,O
to,4529,O
potentially,4529,O
showing,4529,O
a,4529,O
pharmacological,4529,O
differentiation,4529,O
between,4529,O
these,4529,O
two,4529,O
paradigms,4529,O
.,4529,O
METHODS,4530,O
:,4530,O
Male,4530,O
Wistar,4530,O
rats,4530,O
received,4530,O
each,4530,O
dose,4530,O
of,4530,O
the,4530,O
alpha,4530,O
(,4530,O
2,4530,O
),4530,O
-adrenoceptor,4530,O
antagonist,4530,O
yohimbine,4530,B-Chemical
(,4530,O
0.25-1.0mg/kg,4530,O
),4530,O
",",4530,O
the,4530,O
5-HT,4530,B-Chemical
(,4530,O
2C,4530,O
),4530,O
receptor,4530,O
agonist,4530,O
m-chlorophenylpiperazine,4530,B-Chemical
(,4530,O
mCPP,4530,B-Chemical
",",4530,O
0.5-2.0mg/kg,4530,O
),4530,O
or,4530,O
the,4530,O
GABA,4530,B-Chemical
(,4530,O
A,4530,O
),4530,O
inverse,4530,O
receptor,4530,O
agonist,4530,O
pentylenetetrazole,4530,B-Chemical
(,4530,O
PTZ,4530,B-Chemical
",",4530,O
3-30mg/kg,4530,O
),4530,O
and,4530,O
were,4530,O
subsequently,4530,O
tested,4530,O
in,4530,O
either,4530,O
LES,4530,O
or,4530,O
FPS,4530,O
.,4530,O
RESULTS,4531,O
:,4531,O
None,4531,O
of,4531,O
the,4531,O
drugs,4531,O
enhanced,4531,O
LES,4531,O
",",4531,O
whereas,4531,O
mCPP,4531,B-Chemical
increased,4531,O
percentage,4531,O
FPS,4531,O
and,4531,O
yohimbine,4531,B-Chemical
increased,4531,O
absolute,4531,O
FPS,4531,O
values,4531,O
.,4531,O
Furthermore,4532,O
",",4532,O
yohimbine,4532,B-Chemical
increased,4532,O
baseline,4532,O
startle,4532,B-Disease
amplitude,4532,O
in,4532,O
the,4532,O
LES,4532,O
",",4532,O
while,4532,O
mCPP,4532,B-Chemical
suppressed,4532,O
baseline,4532,O
startle,4532,B-Disease
in,4532,O
both,4532,O
the,4532,O
LES,4532,O
and,4532,O
FPS,4532,O
and,4532,O
PTZ,4532,B-Chemical
suppressed,4532,O
baseline,4532,O
startle,4532,B-Disease
in,4532,O
the,4532,O
FPS,4532,O
.,4532,O
CONCLUSIONS,4533,O
:,4533,O
In,4533,O
contrast,4533,O
to,4533,O
findings,4533,O
in,4533,O
the,4533,O
FPS,4533,O
paradigm,4533,O
",",4533,O
none,4533,O
of,4533,O
the,4533,O
drugs,4533,O
were,4533,O
able,4533,O
to,4533,O
exacerbate,4533,O
the,4533,O
LES,4533,O
response,4533,O
.,4533,O
Thus,4534,O
",",4534,O
a,4534,O
clear,4534,O
pharmacological,4534,O
differentiation,4534,O
was,4534,O
found,4534,O
between,4534,O
LES,4534,O
and,4534,O
FPS,4534,O
.,4534,O
Rosaceiform,4535,O
dermatitis,4535,B-Disease
associated,4535,O
with,4535,O
topical,4535,O
tacrolimus,4535,B-Chemical
treatment,4535,O
.,4535,O
We,4536,O
describe,4536,O
herein,4536,O
3,4536,O
patients,4536,O
who,4536,O
developed,4536,O
rosacea-like,4536,B-Disease
dermatitis,4536,B-Disease
eruptions,4536,B-Disease
while,4536,O
using,4536,O
0.03,4536,O
%,4536,O
or,4536,O
0.1,4536,O
%,4536,O
tacrolimus,4536,B-Chemical
ointment,4536,O
for,4536,O
facial,4536,B-Disease
dermatitis,4536,I-Disease
.,4536,O
Skin,4537,O
biopsy,4537,O
specimens,4537,O
showed,4537,O
telangiectasia,4537,B-Disease
and,4537,O
noncaseating,4537,O
epithelioid,4537,O
granulomatous,4537,O
tissue,4537,O
formation,4537,O
in,4537,O
the,4537,O
papillary,4537,O
to,4537,O
mid,4537,O
dermis,4537,O
.,4537,O
Continuous,4538,O
topical,4538,O
use,4538,O
of,4538,O
immunomodulators,4538,O
such,4538,O
as,4538,O
tacrolimus,4538,B-Chemical
or,4538,O
pimecrolimus,4538,B-Chemical
should,4538,O
be,4538,O
regarded,4538,O
as,4538,O
a,4538,O
potential,4538,O
cause,4538,O
of,4538,O
rosaceiform,4538,O
dermatitis,4538,B-Disease
",",4538,O
although,4538,O
many,4538,O
cases,4538,O
have,4538,O
not,4538,O
been,4538,O
reported,4538,O
.,4538,O
Coenzyme,4539,B-Chemical
Q10,4539,I-Chemical
treatment,4539,O
ameliorates,4539,O
acute,4539,O
cisplatin,4539,B-Chemical
nephrotoxicity,4539,B-Disease
in,4539,O
mice,4539,O
.,4539,O
The,4540,O
nephroprotective,4540,O
effect,4540,O
of,4540,O
coenzyme,4540,B-Chemical
Q10,4540,I-Chemical
was,4540,O
investigated,4540,O
in,4540,O
mice,4540,O
with,4540,O
acute,4540,B-Disease
renal,4540,I-Disease
injury,4540,I-Disease
induced,4540,O
by,4540,O
a,4540,O
single,4540,O
i.p,4540,O
.,4540,O
injection,4541,O
of,4541,O
cisplatin,4541,B-Chemical
(,4541,O
5,4541,O
mg/kg,4541,O
),4541,O
.,4541,O
Coenzyme,4542,B-Chemical
Q10,4542,I-Chemical
treatment,4542,O
(,4542,O
10,4542,O
mg/kg/day,4542,O
",",4542,O
i.p,4542,O
.,4542,O
),4542,O
was,4543,O
applied,4543,O
for,4543,O
6,4543,O
consecutive,4543,O
days,4543,O
",",4543,O
starting,4543,O
1,4543,O
day,4543,O
before,4543,O
cisplatin,4543,B-Chemical
administration,4543,O
.,4543,O
Coenzyme,4544,B-Chemical
Q10,4544,I-Chemical
significantly,4544,O
reduced,4544,O
blood,4544,B-Chemical
urea,4544,I-Chemical
nitrogen,4544,I-Chemical
and,4544,O
serum,4544,O
creatinine,4544,B-Chemical
levels,4544,O
which,4544,O
were,4544,O
increased,4544,O
by,4544,O
cisplatin,4544,B-Chemical
.,4544,O
Coenzyme,4545,B-Chemical
Q10,4545,I-Chemical
significantly,4545,O
compensated,4545,O
deficits,4545,O
in,4545,O
the,4545,O
antioxidant,4545,O
defense,4545,O
mechanisms,4545,O
(,4545,O
reduced,4545,B-Chemical
glutathione,4545,I-Chemical
level,4545,O
and,4545,O
superoxide,4545,B-Chemical
dismutase,4545,O
activity,4545,O
),4545,O
",",4545,O
suppressed,4545,O
lipid,4545,O
peroxidation,4545,O
",",4545,O
decreased,4545,O
the,4545,O
elevations,4545,O
of,4545,O
tumor,4545,B-Disease
necrosis,4545,B-Disease
factor-alpha,4545,O
",",4545,O
nitric,4545,B-Chemical
oxide,4545,I-Chemical
and,4545,O
platinum,4545,B-Chemical
ion,4545,O
concentration,4545,O
",",4545,O
and,4545,O
attenuated,4545,O
the,4545,O
reductions,4545,O
of,4545,O
selenium,4545,B-Chemical
and,4545,O
zinc,4545,B-Chemical
ions,4545,O
in,4545,O
renal,4545,O
tissue,4545,O
resulted,4545,O
from,4545,O
cisplatin,4545,B-Chemical
administration,4545,O
.,4545,O
Also,4546,O
",",4546,O
histopathological,4546,O
renal,4546,B-Disease
tissue,4546,I-Disease
damage,4546,I-Disease
mediated,4546,O
by,4546,O
cisplatin,4546,B-Chemical
was,4546,O
ameliorated,4546,O
by,4546,O
coenzyme,4546,B-Chemical
Q10,4546,I-Chemical
treatment,4546,O
.,4546,O
Immunohistochemical,4547,O
analysis,4547,O
revealed,4547,O
that,4547,O
coenzyme,4547,B-Chemical
Q10,4547,I-Chemical
significantly,4547,O
decreased,4547,O
the,4547,O
cisplatin-induced,4547,B-Chemical
overexpression,4547,O
of,4547,O
inducible,4547,O
nitric,4547,B-Chemical
oxide,4547,I-Chemical
synthase,4547,O
",",4547,O
nuclear,4547,O
factor-kappaB,4547,O
",",4547,O
caspase-3,4547,O
and,4547,O
p53,4547,O
in,4547,O
renal,4547,O
tissue,4547,O
.,4547,O
It,4548,O
was,4548,O
concluded,4548,O
that,4548,O
coenzyme,4548,B-Chemical
Q10,4548,I-Chemical
represents,4548,O
a,4548,O
potential,4548,O
therapeutic,4548,O
option,4548,O
to,4548,O
protect,4548,O
against,4548,O
acute,4548,O
cisplatin,4548,B-Chemical
nephrotoxicity,4548,B-Disease
commonly,4548,O
encountered,4548,O
in,4548,O
clinical,4548,O
practice,4548,O
.,4548,O
Dopamine,4549,B-Chemical
is,4549,O
not,4549,O
essential,4549,O
for,4549,O
the,4549,O
development,4549,O
of,4549,O
methamphetamine-induced,4549,B-Chemical
neurotoxicity,4549,B-Disease
.,4549,O
It,4550,O
is,4550,O
widely,4550,O
believed,4550,O
that,4550,O
dopamine,4550,B-Chemical
(,4550,O
DA,4550,B-Chemical
),4550,O
mediates,4550,O
methamphetamine,4550,B-Chemical
(,4550,O
METH,4550,B-Chemical
),4550,O
-induced,4550,O
toxicity,4550,B-Disease
to,4550,O
brain,4550,O
dopaminergic,4550,O
neurons,4550,O
",",4550,O
because,4550,O
drugs,4550,O
that,4550,O
interfere,4550,O
with,4550,O
DA,4550,B-Chemical
neurotransmission,4550,O
decrease,4550,O
toxicity,4550,B-Disease
",",4550,O
whereas,4550,O
drugs,4550,O
that,4550,O
increase,4550,O
DA,4550,B-Chemical
neurotransmission,4550,O
enhance,4550,O
toxicity,4550,B-Disease
.,4550,O
However,4551,O
",",4551,O
temperature,4551,O
effects,4551,O
of,4551,O
drugs,4551,O
that,4551,O
have,4551,O
been,4551,O
used,4551,O
to,4551,O
manipulate,4551,O
brain,4551,O
DA,4551,B-Chemical
neurotransmission,4551,O
confound,4551,O
interpretation,4551,O
of,4551,O
the,4551,O
data,4551,O
.,4551,O
Here,4552,O
we,4552,O
show,4552,O
that,4552,O
the,4552,O
recently,4552,O
reported,4552,O
ability,4552,O
of,4552,O
L-dihydroxyphenylalanine,4552,B-Chemical
to,4552,O
reverse,4552,O
the,4552,O
protective,4552,O
effect,4552,O
of,4552,O
alpha-methyl-para-tyrosine,4552,B-Chemical
on,4552,O
METH-induced,4552,B-Chemical
DA,4552,B-Chemical
neurotoxicity,4552,B-Disease
is,4552,O
also,4552,O
confounded,4552,O
by,4552,O
drug,4552,O
effects,4552,O
on,4552,O
body,4552,O
temperature,4552,O
.,4552,O
Further,4553,O
",",4553,O
we,4553,O
show,4553,O
that,4553,O
mice,4553,O
genetically,4553,O
engineered,4553,O
to,4553,O
be,4553,O
deficient,4553,O
in,4553,O
brain,4553,O
DA,4553,B-Chemical
develop,4553,O
METH,4553,B-Chemical
neurotoxicity,4553,B-Disease
",",4553,O
as,4553,O
long,4553,O
as,4553,O
the,4553,O
thermic,4553,O
effects,4553,O
of,4553,O
METH,4553,B-Chemical
are,4553,O
preserved,4553,O
.,4553,O
In,4554,O
addition,4554,O
",",4554,O
we,4554,O
demonstrate,4554,O
that,4554,O
mice,4554,O
genetically,4554,O
engineered,4554,O
to,4554,O
have,4554,O
unilateral,4554,O
brain,4554,O
DA,4554,B-Chemical
deficits,4554,O
develop,4554,O
METH-induced,4554,B-Chemical
dopaminergic,4554,B-Disease
deficits,4554,I-Disease
that,4554,O
are,4554,O
of,4554,O
comparable,4554,O
magnitude,4554,O
on,4554,O
both,4554,O
sides,4554,O
of,4554,O
the,4554,O
brain,4554,O
.,4554,O
Taken,4555,O
together,4555,O
",",4555,O
these,4555,O
findings,4555,O
demonstrate,4555,O
that,4555,O
DA,4555,B-Chemical
is,4555,O
not,4555,O
essential,4555,O
for,4555,O
the,4555,O
development,4555,O
of,4555,O
METH-induced,4555,B-Chemical
dopaminergic,4555,O
neurotoxicity,4555,B-Disease
and,4555,O
suggest,4555,O
that,4555,O
mechanisms,4555,O
independent,4555,O
of,4555,O
DA,4555,B-Chemical
warrant,4555,O
more,4555,O
intense,4555,O
investigation,4555,O
.,4555,O
Swallowing-induced,4556,O
atrial,4556,B-Disease
tachyarrhythmia,4556,I-Disease
triggered,4556,O
by,4556,O
salbutamol,4556,B-Chemical
:,4556,O
case,4556,O
report,4556,O
and,4556,O
review,4556,O
of,4556,O
the,4556,O
literature,4556,O
.,4556,O
CASE,4557,O
:,4557,O
A,4557,O
49-year-old,4557,O
patient,4557,O
experienced,4557,O
chest,4557,O
discomfort,4557,O
while,4557,O
swallowing,4557,O
.,4557,O
On,4558,O
electrocardiogram,4558,O
",",4558,O
episodes,4558,O
of,4558,O
atrial,4558,B-Disease
tachyarrhythmia,4558,I-Disease
were,4558,O
recorded,4558,O
immediately,4558,O
after,4558,O
swallowing,4558,O
;,4558,O
24-hour,4558,O
Holter,4558,O
monitoring,4558,O
recorded,4558,O
several,4558,O
events,4558,O
.,4558,O
The,4559,O
arrhythmia,4559,B-Disease
resolved,4559,O
after,4559,O
therapy,4559,O
with,4559,O
atenolol,4559,B-Chemical
",",4559,O
but,4559,O
recurred,4559,O
a,4559,O
year,4559,O
later,4559,O
.,4559,O
The,4560,O
patient,4560,O
noticed,4560,O
that,4560,O
before,4560,O
these,4560,O
episodes,4560,O
he,4560,O
had,4560,O
been,4560,O
using,4560,O
an,4560,O
inhalator,4560,O
of,4560,O
salbutamol,4560,B-Chemical
.,4560,O
After,4561,O
stopping,4561,O
the,4561,O
beta-agonist,4561,O
",",4561,O
and,4561,O
after,4561,O
a,4561,O
week,4561,O
with,4561,O
the,4561,O
atenolol,4561,B-Chemical
",",4561,O
the,4561,O
arrhythmia,4561,B-Disease
disappeared,4561,O
.,4561,O
DISCUSSION,4562,O
:,4562,O
Swallowing-induced,4562,O
atrial,4562,B-Disease
tachyarrhythmia,4562,I-Disease
(,4562,O
SIAT,4562,B-Disease
),4562,O
is,4562,O
a,4562,O
rare,4562,O
phenomenon,4562,O
.,4562,O
Fewer,4563,O
than,4563,O
50,4563,O
cases,4563,O
of,4563,O
SIAT,4563,B-Disease
have,4563,O
been,4563,O
described,4563,O
in,4563,O
the,4563,O
literature,4563,O
.,4563,O
This,4564,O
article,4564,O
summarizes,4564,O
all,4564,O
the,4564,O
cases,4564,O
published,4564,O
",",4564,O
creating,4564,O
a,4564,O
comprehensive,4564,O
review,4564,O
of,4564,O
the,4564,O
current,4564,O
knowledge,4564,O
and,4564,O
approach,4564,O
to,4564,O
SIAT,4564,B-Disease
.,4564,O
It,4565,O
discusses,4565,O
demographics,4565,O
",",4565,O
clinical,4565,O
characteristics,4565,O
and,4565,O
types,4565,O
of,4565,O
arrhythmia,4565,B-Disease
",",4565,O
postulated,4565,O
mechanisms,4565,O
of,4565,O
SIAT,4565,B-Disease
",",4565,O
and,4565,O
different,4565,O
treatment,4565,O
possibilities,4565,O
such,4565,O
as,4565,O
medications,4565,O
",",4565,O
surgery,4565,O
",",4565,O
and,4565,O
radiofrequency,4565,O
catheter,4565,O
ablation,4565,O
(,4565,O
RFCA,4565,O
),4565,O
.,4565,O
CONCLUSION,4566,O
:,4566,O
Salbutamol,4566,B-Chemical
is,4566,O
presented,4566,O
here,4566,O
as,4566,O
a,4566,O
possible,4566,O
trigger,4566,O
for,4566,O
SIAT,4566,B-Disease
.,4566,O
Although,4567,O
it,4567,O
is,4567,O
difficult,4567,O
to,4567,O
define,4567,O
causality,4567,O
in,4567,O
a,4567,O
case,4567,O
report,4567,O
",",4567,O
it,4567,O
is,4567,O
logical,4567,O
to,4567,O
think,4567,O
that,4567,O
a,4567,O
beta-agonist,4567,O
like,4567,O
salbutamol,4567,B-Chemical
(,4567,O
known,4567,O
to,4567,O
induce,4567,O
tachycardia,4567,B-Disease
),4567,O
may,4567,O
be,4567,O
the,4567,O
trigger,4567,O
of,4567,O
adrenergic,4567,O
reflexes,4567,O
originating,4567,O
in,4567,O
the,4567,O
esophagus,4567,O
while,4567,O
swallowing,4567,O
and,4567,O
that,4567,O
a,4567,O
beta-blocker,4567,O
such,4567,O
as,4567,O
atenolol,4567,B-Chemical
(,4567,O
that,4567,O
blocks,4567,O
the,4567,O
adrenergic,4567,O
activity,4567,O
),4567,O
may,4567,O
relieve,4567,O
it,4567,O
.,4567,O
Glutamatergic,4568,O
neurotransmission,4568,O
mediated,4568,O
by,4568,O
NMDA,4568,B-Chemical
receptors,4568,O
in,4568,O
the,4568,O
inferior,4568,O
colliculus,4568,O
can,4568,O
modulate,4568,O
haloperidol-induced,4568,B-Chemical
catalepsy,4568,B-Disease
.,4568,O
The,4569,O
inferior,4569,O
colliculus,4569,O
(,4569,O
IC,4569,O
),4569,O
is,4569,O
primarily,4569,O
involved,4569,O
in,4569,O
the,4569,O
processing,4569,O
of,4569,O
auditory,4569,O
information,4569,O
",",4569,O
but,4569,O
it,4569,O
is,4569,O
distinguished,4569,O
from,4569,O
other,4569,O
auditory,4569,O
nuclei,4569,O
in,4569,O
the,4569,O
brainstem,4569,O
by,4569,O
its,4569,O
connections,4569,O
with,4569,O
structures,4569,O
of,4569,O
the,4569,O
motor,4569,O
system,4569,O
.,4569,O
Functional,4570,O
evidence,4570,O
relating,4570,O
the,4570,O
IC,4570,O
to,4570,O
motor,4570,O
behavior,4570,O
derives,4570,O
from,4570,O
experiments,4570,O
showing,4570,O
that,4570,O
activation,4570,O
of,4570,O
the,4570,O
IC,4570,O
by,4570,O
electrical,4570,O
stimulation,4570,O
or,4570,O
excitatory,4570,O
amino,4570,B-Chemical
acid,4570,I-Chemical
microinjection,4570,O
causes,4570,O
freezing,4570,O
",",4570,O
escape-like,4570,O
behavior,4570,O
",",4570,O
and,4570,O
immobility,4570,O
.,4570,O
However,4571,O
",",4571,O
the,4571,O
nature,4571,O
of,4571,O
this,4571,O
immobility,4571,O
is,4571,O
still,4571,O
unclear,4571,O
.,4571,O
The,4572,O
present,4572,O
study,4572,O
examined,4572,O
the,4572,O
influence,4572,O
of,4572,O
excitatory,4572,O
amino,4572,B-Chemical
acid-mediated,4572,O
mechanisms,4572,O
in,4572,O
the,4572,O
IC,4572,O
on,4572,O
the,4572,O
catalepsy,4572,B-Disease
induced,4572,O
by,4572,O
the,4572,O
dopamine,4572,B-Chemical
receptor,4572,O
blocker,4572,O
haloperidol,4572,B-Chemical
administered,4572,O
systemically,4572,O
(,4572,O
1,4572,O
or,4572,O
0.5,4572,O
mg/kg,4572,O
),4572,O
in,4572,O
rats,4572,O
.,4572,O
Haloperidol-induced,4573,B-Chemical
catalepsy,4573,B-Disease
was,4573,O
challenged,4573,O
with,4573,O
prior,4573,O
intracollicular,4573,O
microinjections,4573,O
of,4573,O
glutamate,4573,B-Chemical
NMDA,4573,B-Chemical
receptor,4573,O
antagonists,4573,O
",",4573,O
MK-801,4573,B-Chemical
(,4573,O
15,4573,O
or,4573,O
30,4573,O
mmol/0.5,4573,O
microl,4573,O
),4573,O
and,4573,O
AP7,4573,B-Chemical
(,4573,O
10,4573,O
or,4573,O
20,4573,O
nmol/0.5,4573,O
microl,4573,O
),4573,O
",",4573,O
or,4573,O
of,4573,O
the,4573,O
NMDA,4573,B-Chemical
receptor,4573,O
agonist,4573,O
N-methyl-d-aspartate,4573,B-Chemical
(,4573,O
NMDA,4573,B-Chemical
",",4573,O
20,4573,O
or,4573,O
30,4573,O
nmol/0.5,4573,O
microl,4573,O
),4573,O
.,4573,O
The,4574,O
results,4574,O
showed,4574,O
that,4574,O
intracollicular,4574,O
microinjection,4574,O
of,4574,O
MK-801,4574,B-Chemical
and,4574,O
AP7,4574,B-Chemical
previous,4574,O
to,4574,O
systemic,4574,O
injections,4574,O
of,4574,O
haloperidol,4574,B-Chemical
significantly,4574,O
attenuated,4574,O
the,4574,O
catalepsy,4574,B-Disease
",",4574,O
as,4574,O
indicated,4574,O
by,4574,O
a,4574,O
reduced,4574,O
latency,4574,O
to,4574,O
step,4574,O
down,4574,O
from,4574,O
a,4574,O
horizontal,4574,O
bar,4574,O
.,4574,O
Accordingly,4575,O
",",4575,O
intracollicular,4575,O
microinjection,4575,O
of,4575,O
NMDA,4575,B-Chemical
increased,4575,O
the,4575,O
latency,4575,O
to,4575,O
step,4575,O
down,4575,O
the,4575,O
bar,4575,O
.,4575,O
These,4576,O
findings,4576,O
suggest,4576,O
that,4576,O
glutamate-mediated,4576,B-Chemical
mechanisms,4576,O
in,4576,O
the,4576,O
neural,4576,O
circuits,4576,O
at,4576,O
the,4576,O
IC,4576,O
level,4576,O
influence,4576,O
haloperidol-induced,4576,B-Chemical
catalepsy,4576,B-Disease
and,4576,O
participate,4576,O
in,4576,O
the,4576,O
regulation,4576,O
of,4576,O
motor,4576,O
activity,4576,O
.,4576,O
Severe,4577,O
congestive,4577,B-Disease
heart,4577,I-Disease
failure,4577,I-Disease
patient,4577,O
on,4577,O
amiodarone,4577,B-Chemical
presenting,4577,O
with,4577,O
myxedemic,4577,O
coma,4577,O
:,4577,O
a,4577,O
case,4577,O
report,4577,O
.,4577,O
This,4578,O
is,4578,O
a,4578,O
case,4578,O
report,4578,O
of,4578,O
myxedema,4578,O
coma,4578,O
secondary,4578,O
to,4578,O
amiodarone-induced,4578,B-Chemical
hypothyroidism,4578,B-Disease
in,4578,O
a,4578,O
patient,4578,O
with,4578,O
severe,4578,O
congestive,4578,B-Disease
heart,4578,I-Disease
failure,4578,I-Disease
(,4578,O
CHF,4578,B-Disease
),4578,O
.,4578,O
To,4579,O
our,4579,O
knowledge,4579,O
and,4579,O
after,4579,O
reviewing,4579,O
the,4579,O
literature,4579,O
there,4579,O
is,4579,O
one,4579,O
case,4579,O
report,4579,O
of,4579,O
myxedema,4579,O
coma,4579,O
during,4579,O
long,4579,O
term,4579,O
amiodarone,4579,B-Chemical
therapy,4579,O
.,4579,O
Myxedema,4580,O
coma,4580,O
is,4580,O
a,4580,O
life,4580,O
threatening,4580,O
condition,4580,O
that,4580,O
carries,4580,O
a,4580,O
mortality,4580,O
reaching,4580,O
as,4580,O
high,4580,O
as,4580,O
20,4580,O
%,4580,O
with,4580,O
treatment,4580,O
.,4580,O
The,4581,O
condition,4581,O
is,4581,O
treated,4581,O
with,4581,O
intravenous,4581,O
thyroxine,4581,B-Chemical
(,4581,O
T4,4581,B-Chemical
),4581,O
or,4581,O
intravenous,4581,O
tri-iodo-thyronine,4581,B-Chemical
(,4581,O
T3,4581,B-Chemical
),4581,O
.,4581,O
Patients,4582,O
with,4582,O
CHF,4582,B-Disease
on,4582,O
amiodarone,4582,B-Chemical
may,4582,O
suffer,4582,O
serious,4582,O
morbidity,4582,O
and,4582,O
mortality,4582,O
from,4582,O
hypothyroidism,4582,B-Disease
",",4582,O
and,4582,O
thus,4582,O
may,4582,O
deserve,4582,O
closer,4582,O
follow,4582,O
up,4582,O
for,4582,O
thyroid,4582,O
stimulating,4582,O
hormone,4582,O
(,4582,O
TSH,4582,O
),4582,O
levels,4582,O
.,4582,O
This,4583,O
case,4583,O
report,4583,O
carries,4583,O
an,4583,O
important,4583,O
clinical,4583,O
application,4583,O
given,4583,O
the,4583,O
frequent,4583,O
usage,4583,O
of,4583,O
amiodarone,4583,B-Chemical
among,4583,O
CHF,4583,B-Disease
patients,4583,O
.,4583,O
The,4584,O
myriad,4584,O
clinical,4584,O
presentation,4584,O
of,4584,O
myxedema,4584,O
coma,4584,O
and,4584,O
its,4584,O
serious,4584,O
morbidity,4584,O
and,4584,O
mortality,4584,O
stresses,4584,O
the,4584,O
need,4584,O
to,4584,O
suspect,4584,O
this,4584,O
clinical,4584,O
syndrome,4584,O
among,4584,O
CHF,4584,B-Disease
patients,4584,O
presenting,4584,O
with,4584,O
hypotension,4584,B-Disease
",",4584,O
weakness,4584,B-Disease
or,4584,O
other,4584,O
unexplained,4584,O
symptoms,4584,O
.,4584,O
Effects,4585,O
of,4585,O
active,4585,O
constituents,4585,O
of,4585,O
Crocus,4585,O
sativus,4585,O
L.,4585,O
",",4585,O
crocin,4585,B-Chemical
on,4585,O
streptozocin-induced,4585,B-Chemical
model,4585,O
of,4585,O
sporadic,4585,O
Alzheimer,4585,B-Disease
's,4585,I-Disease
disease,4585,I-Disease
in,4585,O
male,4585,O
rats,4585,O
.,4585,O
BACKGROUND,4586,O
:,4586,O
The,4586,O
involvement,4586,O
of,4586,O
water-soluble,4586,O
carotenoids,4586,B-Chemical
",",4586,O
crocins,4586,B-Chemical
",",4586,O
as,4586,O
the,4586,O
main,4586,O
and,4586,O
active,4586,O
components,4586,O
of,4586,O
Crocus,4586,O
sativus,4586,O
L.,4586,O
extract,4586,O
in,4586,O
learning,4586,O
and,4586,O
memory,4586,O
processes,4586,O
has,4586,O
been,4586,O
proposed,4586,O
.,4586,O
In,4587,O
the,4587,O
present,4587,O
study,4587,O
",",4587,O
the,4587,O
effect,4587,O
of,4587,O
crocins,4587,B-Chemical
on,4587,O
sporadic,4587,O
Alzheimer,4587,B-Disease
's,4587,I-Disease
disease,4587,I-Disease
induced,4587,O
by,4587,O
intracerebroventricular,4587,O
(,4587,O
icv,4587,O
),4587,O
streptozocin,4587,B-Chemical
(,4587,O
STZ,4587,B-Chemical
),4587,O
in,4587,O
male,4587,O
rats,4587,O
was,4587,O
investigated,4587,O
.,4587,O
METHODS,4588,O
:,4588,O
Male,4588,O
adult,4588,O
Wistar,4588,O
rats,4588,O
(,4588,O
n,4588,O
=,4588,O
90,4588,O
and,4588,O
260-290,4588,O
g,4588,O
),4588,O
were,4588,O
divided,4588,O
into,4588,O
1,4588,O
",",4588,O
control,4588,O
;,4588,O
2,4588,O
and,4588,O
3,4588,O
",",4588,O
crocins,4588,B-Chemical
(,4588,O
15,4588,O
and,4588,O
30,4588,O
mg/kg,4588,O
),4588,O
;,4588,O
4,4588,O
",",4588,O
STZ,4588,B-Chemical
;,4588,O
5,4588,O
and,4588,O
6,4588,O
",",4588,O
STZ,4588,B-Chemical
+,4588,O
crocins,4588,B-Chemical
(,4588,O
15,4588,O
and,4588,O
30,4588,O
mg/kg,4588,O
),4588,O
groups,4588,O
.,4588,O
In,4589,O
Alzheimer,4589,B-Disease
's,4589,I-Disease
disease,4589,I-Disease
groups,4589,O
",",4589,O
rats,4589,O
were,4589,O
injected,4589,O
with,4589,O
STZ-icv,4589,B-Chemical
bilaterally,4589,O
(,4589,O
3,4589,O
mg/kg,4589,O
),4589,O
in,4589,O
first,4589,O
day,4589,O
and,4589,O
3,4589,O
days,4589,O
later,4589,O
",",4589,O
a,4589,O
similar,4589,O
STZ-icv,4589,B-Chemical
application,4589,O
was,4589,O
repeated,4589,O
.,4589,O
In,4590,O
STZ,4590,B-Chemical
+,4590,O
crocin,4590,B-Chemical
animal,4590,O
groups,4590,O
",",4590,O
crocin,4590,B-Chemical
was,4590,O
applied,4590,O
in,4590,O
doses,4590,O
of,4590,O
15,4590,O
and,4590,O
30,4590,O
mg/kg,4590,O
",",4590,O
i.p.,4590,O
",",4590,O
one,4590,O
day,4590,O
pre-surgery,4590,O
and,4590,O
continued,4590,O
for,4590,O
three,4590,O
weeks,4590,O
.,4590,O
Prescription,4591,O
of,4591,O
crocin,4591,B-Chemical
in,4591,O
each,4591,O
dose,4591,O
was,4591,O
repeated,4591,O
once,4591,O
for,4591,O
two,4591,O
days,4591,O
.,4591,O
However,4592,O
",",4592,O
the,4592,O
learning,4592,O
and,4592,O
memory,4592,O
performance,4592,O
was,4592,O
assessed,4592,O
using,4592,O
passive,4592,O
avoidance,4592,O
paradigm,4592,O
",",4592,O
and,4592,O
for,4592,O
spatial,4592,O
cognition,4592,O
evaluation,4592,O
",",4592,O
Y-maze,4592,O
task,4592,O
was,4592,O
used,4592,O
.,4592,O
RESULTS,4593,O
:,4593,O
It,4593,O
was,4593,O
found,4593,O
out,4593,O
that,4593,O
crocin,4593,B-Chemical
(,4593,O
30,4593,O
mg/kg,4593,O
),4593,O
-treated,4593,O
STZ-injected,4593,B-Chemical
rats,4593,O
show,4593,O
higher,4593,O
correct,4593,O
choices,4593,O
and,4593,O
lower,4593,O
errors,4593,O
in,4593,O
Y-maze,4593,O
than,4593,O
vehicle-treated,4593,O
STZ-injected,4593,B-Chemical
rats,4593,O
.,4593,O
In,4594,O
addition,4594,O
",",4594,O
crocin,4594,B-Chemical
in,4594,O
the,4594,O
mentioned,4594,O
dose,4594,O
could,4594,O
significantly,4594,O
attenuated,4594,O
learning,4594,O
and,4594,O
memory,4594,O
impairment,4594,O
in,4594,O
treated,4594,O
STZ-injected,4594,B-Chemical
group,4594,O
in,4594,O
passive,4594,O
avoidance,4594,O
test,4594,O
.,4594,O
CONCLUSION,4595,O
:,4595,O
Therefore,4595,O
",",4595,O
these,4595,O
results,4595,O
demonstrate,4595,O
the,4595,O
effectiveness,4595,O
of,4595,O
crocin,4595,B-Chemical
(,4595,O
30,4595,O
mg/kg,4595,O
),4595,O
in,4595,O
antagonizing,4595,O
the,4595,O
cognitive,4595,B-Disease
deficits,4595,I-Disease
caused,4595,O
by,4595,O
STZ-icv,4595,B-Chemical
in,4595,O
rats,4595,O
and,4595,O
its,4595,O
potential,4595,O
in,4595,O
the,4595,O
treatment,4595,O
of,4595,O
neurodegenerative,4595,B-Disease
diseases,4595,I-Disease
such,4595,O
as,4595,O
Alzheimer,4595,B-Disease
's,4595,I-Disease
disease,4595,I-Disease
.,4595,O
Serotonin,4596,B-Chemical
6,4596,O
receptor,4596,O
gene,4596,O
is,4596,O
associated,4596,O
with,4596,O
methamphetamine-induced,4596,B-Chemical
psychosis,4596,B-Disease
in,4596,O
a,4596,O
Japanese,4596,O
population,4596,O
.,4596,O
BACKGROUND,4597,O
:,4597,O
Altered,4597,O
serotonergic,4597,O
neural,4597,O
transmission,4597,O
is,4597,O
hypothesized,4597,O
to,4597,O
be,4597,O
a,4597,O
susceptibility,4597,O
factor,4597,O
for,4597,O
psychotic,4597,B-Disease
disorders,4597,I-Disease
such,4597,O
as,4597,O
schizophrenia,4597,B-Disease
.,4597,O
The,4598,O
serotonin,4598,B-Chemical
6,4598,O
(,4598,O
5-HT6,4598,B-Chemical
),4598,O
receptor,4598,O
is,4598,O
therapeutically,4598,O
targeted,4598,O
by,4598,O
several,4598,O
second,4598,O
generation,4598,O
antipsychotics,4598,O
",",4598,O
such,4598,O
as,4598,O
clozapine,4598,B-Chemical
and,4598,O
olanzapine,4598,B-Chemical
",",4598,O
and,4598,O
d-amphetamine-induced,4598,B-Chemical
hyperactivity,4598,B-Disease
in,4598,O
rats,4598,O
is,4598,O
corrected,4598,O
with,4598,O
the,4598,O
use,4598,O
of,4598,O
a,4598,O
selective,4598,O
5-HT6,4598,B-Chemical
receptor,4598,O
antagonist,4598,O
.,4598,O
In,4599,O
addition,4599,O
",",4599,O
the,4599,O
disrupted,4599,O
prepulse,4599,O
inhibition,4599,O
induced,4599,O
by,4599,O
d-amphetamine,4599,B-Chemical
or,4599,O
phencyclidine,4599,B-Chemical
was,4599,O
restored,4599,O
by,4599,O
5-HT6,4599,B-Chemical
receptor,4599,O
antagonist,4599,O
in,4599,O
an,4599,O
animal,4599,O
study,4599,O
using,4599,O
rats,4599,O
.,4599,O
These,4600,O
animal,4600,O
models,4600,O
were,4600,O
considered,4600,O
to,4600,O
reflect,4600,O
the,4600,O
positive,4600,O
symptoms,4600,O
of,4600,O
schizophrenia,4600,B-Disease
",",4600,O
and,4600,O
the,4600,O
above,4600,O
evidence,4600,O
suggests,4600,O
that,4600,O
altered,4600,O
5-HT6,4600,B-Chemical
receptors,4600,O
are,4600,O
involved,4600,O
in,4600,O
the,4600,O
pathophysiology,4600,O
of,4600,O
psychotic,4600,B-Disease
disorders,4600,I-Disease
.,4600,O
The,4601,O
symptoms,4601,O
of,4601,O
methamphetamine,4601,B-Chemical
(,4601,O
METH,4601,B-Chemical
),4601,O
-induced,4601,O
psychosis,4601,B-Disease
are,4601,O
similar,4601,O
to,4601,O
those,4601,O
of,4601,O
paranoid,4601,B-Disease
type,4601,I-Disease
schizophrenia,4601,I-Disease
.,4601,O
Therefore,4602,O
",",4602,O
we,4602,O
conducted,4602,O
an,4602,O
analysis,4602,O
of,4602,O
the,4602,O
association,4602,O
of,4602,O
the,4602,O
5-HT6,4602,B-Chemical
gene,4602,O
(,4602,O
HTR6,4602,O
),4602,O
with,4602,O
METH-induced,4602,B-Chemical
psychosis,4602,B-Disease
.,4602,O
METHOD,4603,O
:,4603,O
Using,4603,O
five,4603,O
tagging,4603,O
SNPs,4603,O
(,4603,O
rs6693503,4603,O
",",4603,O
rs1805054,4603,O
",",4603,O
rs4912138,4603,O
",",4603,O
rs3790757,4603,O
and,4603,O
rs9659997,4603,O
),4603,O
",",4603,O
we,4603,O
conducted,4603,O
a,4603,O
genetic,4603,O
association,4603,O
analysis,4603,O
of,4603,O
case-control,4603,O
samples,4603,O
(,4603,O
197,4603,O
METH-induced,4603,B-Chemical
psychosis,4603,B-Disease
patients,4603,O
and,4603,O
337,4603,O
controls,4603,O
),4603,O
in,4603,O
the,4603,O
Japanese,4603,O
population,4603,O
.,4603,O
The,4604,O
age,4604,O
and,4604,O
sex,4604,O
of,4604,O
the,4604,O
control,4604,O
subjects,4604,O
did,4604,O
not,4604,O
differ,4604,O
from,4604,O
those,4604,O
of,4604,O
the,4604,O
methamphetamine,4604,B-Chemical
dependence,4604,O
patients,4604,O
.,4604,O
RESULTS,4605,O
:,4605,O
rs6693503,4605,O
was,4605,O
associated,4605,O
with,4605,O
METH-induced,4605,B-Chemical
psychosis,4605,B-Disease
patients,4605,O
in,4605,O
the,4605,O
allele/genotype-wise,4605,O
analysis,4605,O
.,4605,O
Moreover,4606,O
",",4606,O
this,4606,O
association,4606,O
remained,4606,O
significant,4606,O
after,4606,O
Bonferroni,4606,O
correction,4606,O
.,4606,O
In,4607,O
the,4607,O
haplotype-wise,4607,O
analysis,4607,O
",",4607,O
we,4607,O
detected,4607,O
an,4607,O
association,4607,O
between,4607,O
two,4607,O
markers,4607,O
(,4607,O
rs6693503,4607,O
and,4607,O
rs1805054,4607,O
),4607,O
and,4607,O
three,4607,O
markers,4607,O
(,4607,O
rs6693503,4607,O
",",4607,O
rs1805054,4607,O
and,4607,O
rs4912138,4607,O
),4607,O
in,4607,O
HTR6,4607,O
and,4607,O
METH-induced,4607,B-Chemical
psychosis,4607,B-Disease
patients,4607,O
",",4607,O
respectively,4607,O
.,4607,O
CONCLUSION,4608,O
:,4608,O
HTR6,4608,O
may,4608,O
play,4608,O
an,4608,O
important,4608,O
role,4608,O
in,4608,O
the,4608,O
pathophysiology,4608,O
of,4608,O
METH-induced,4608,B-Chemical
psychosis,4608,B-Disease
in,4608,O
the,4608,O
Japanese,4608,O
population,4608,O
.,4608,O
Neural,4609,O
correlates,4609,O
of,4609,O
S-ketamine,4609,B-Chemical
induced,4609,O
psychosis,4609,B-Disease
during,4609,O
overt,4609,O
continuous,4609,O
verbal,4609,O
fluency,4609,O
.,4609,O
The,4610,O
glutamatergic,4610,O
N-methyl-D-aspartate,4610,B-Chemical
(,4610,O
NMDA,4610,B-Chemical
),4610,O
receptor,4610,O
has,4610,O
been,4610,O
implicated,4610,O
in,4610,O
the,4610,O
pathophysiology,4610,O
of,4610,O
schizophrenia,4610,B-Disease
.,4610,O
Administered,4611,O
to,4611,O
healthy,4611,O
volunteers,4611,O
",",4611,O
a,4611,O
subanesthetic,4611,O
dose,4611,O
of,4611,O
the,4611,O
non-competitive,4611,O
NMDA,4611,B-Chemical
receptor,4611,O
antagonist,4611,O
ketamine,4611,B-Chemical
leads,4611,O
to,4611,O
psychopathological,4611,O
symptoms,4611,O
similar,4611,O
to,4611,O
those,4611,O
observed,4611,O
in,4611,O
schizophrenia,4611,B-Disease
.,4611,O
In,4612,O
patients,4612,O
with,4612,O
schizophrenia,4612,B-Disease
",",4612,O
ketamine,4612,B-Chemical
exacerbates,4612,O
the,4612,O
core,4612,O
symptoms,4612,O
of,4612,O
illness,4612,O
",",4612,O
supporting,4612,O
the,4612,O
hypothesis,4612,O
of,4612,O
a,4612,O
glutamatergic,4612,B-Disease
dysfunction,4612,I-Disease
.,4612,O
In,4613,O
a,4613,O
counterbalanced,4613,O
",",4613,O
placebo-controlled,4613,O
",",4613,O
double-blind,4613,O
study,4613,O
design,4613,O
",",4613,O
healthy,4613,O
subjects,4613,O
were,4613,O
administered,4613,O
a,4613,O
continuous,4613,O
subanesthetic,4613,O
S-ketamine,4613,B-Chemical
infusion,4613,O
while,4613,O
differences,4613,O
in,4613,O
BOLD,4613,O
responses,4613,O
measured,4613,O
with,4613,O
fMRI,4613,O
were,4613,O
detected,4613,O
.,4613,O
During,4614,O
the,4614,O
scanning,4614,O
period,4614,O
",",4614,O
subjects,4614,O
performed,4614,O
continuous,4614,O
overt,4614,O
verbal,4614,O
fluency,4614,O
tasks,4614,O
(,4614,O
phonological,4614,O
",",4614,O
lexical,4614,O
and,4614,O
semantic,4614,O
),4614,O
.,4614,O
Ketamine-induced,4615,B-Chemical
psychopathological,4615,O
symptoms,4615,O
were,4615,O
assessed,4615,O
with,4615,O
the,4615,O
Positive,4615,O
and,4615,O
Negative,4615,O
Syndrome,4615,O
Scale,4615,O
(,4615,O
PANSS,4615,O
),4615,O
.,4615,O
Ketamine,4616,B-Chemical
elicited,4616,O
psychosis,4616,B-Disease
like,4616,O
psychopathology,4616,O
.,4616,O
Post-hoc,4617,O
t-tests,4617,O
revealed,4617,O
significant,4617,O
differences,4617,O
between,4617,O
placebo,4617,O
and,4617,O
ketamine,4617,B-Chemical
for,4617,O
the,4617,O
amounts,4617,O
of,4617,O
words,4617,O
generated,4617,O
during,4617,O
lexical,4617,O
and,4617,O
semantic,4617,O
verbal,4617,O
fluency,4617,O
",",4617,O
while,4617,O
the,4617,O
phonological,4617,O
domain,4617,O
remained,4617,O
unaffected,4617,O
.,4617,O
Ketamine,4618,B-Chemical
led,4618,O
to,4618,O
enhanced,4618,O
cortical,4618,O
activations,4618,O
in,4618,O
supramarginal,4618,O
and,4618,O
frontal,4618,O
brain,4618,O
regions,4618,O
for,4618,O
phonological,4618,O
and,4618,O
lexical,4618,O
verbal,4618,O
fluency,4618,O
",",4618,O
but,4618,O
not,4618,O
for,4618,O
semantic,4618,O
verbal,4618,O
fluency,4618,O
.,4618,O
Ketamine,4619,B-Chemical
induces,4619,O
activation,4619,O
changes,4619,O
in,4619,O
healthy,4619,O
subjects,4619,O
similar,4619,O
to,4619,O
those,4619,O
observed,4619,O
in,4619,O
patients,4619,O
with,4619,O
schizophrenia,4619,B-Disease
",",4619,O
particularly,4619,O
in,4619,O
frontal,4619,O
and,4619,O
temporal,4619,O
brain,4619,O
regions,4619,O
.,4619,O
Our,4620,O
results,4620,O
provide,4620,O
further,4620,O
support,4620,O
for,4620,O
the,4620,O
hypothesis,4620,O
of,4620,O
an,4620,O
NMDA,4620,B-Chemical
receptor,4620,O
dysfunction,4620,O
in,4620,O
the,4620,O
pathophysiology,4620,O
of,4620,O
schizophrenia,4620,B-Disease
.,4620,O
Long-term,4621,O
prognosis,4621,O
for,4621,O
transplant-free,4621,O
survivors,4621,O
of,4621,O
paracetamol-induced,4621,B-Chemical
acute,4621,B-Disease
liver,4621,I-Disease
failure,4621,I-Disease
.,4621,O
BACKGROUND,4622,O
:,4622,O
The,4622,O
prognosis,4622,O
for,4622,O
transplant-free,4622,O
survivors,4622,O
of,4622,O
paracetamol-induced,4622,B-Chemical
acute,4622,B-Disease
liver,4622,I-Disease
failure,4622,I-Disease
remains,4622,O
unknown,4622,O
.,4622,O
AIM,4623,O
:,4623,O
To,4623,O
examine,4623,O
whether,4623,O
paracetamol-induced,4623,B-Chemical
acute,4623,B-Disease
liver,4623,I-Disease
failure,4623,I-Disease
increases,4623,O
long-term,4623,O
mortality,4623,O
.,4623,O
METHODS,4624,O
:,4624,O
We,4624,O
followed,4624,O
up,4624,O
all,4624,O
transplant-free,4624,O
survivors,4624,O
of,4624,O
paracetamol-induced,4624,B-Chemical
acute,4624,B-Disease
liver,4624,I-Disease
injury,4624,I-Disease
",",4624,O
hospitalized,4624,O
in,4624,O
a,4624,O
Danish,4624,O
national,4624,O
referral,4624,O
centre,4624,O
during,4624,O
1984-2004,4624,O
.,4624,O
We,4625,O
compared,4625,O
age-specific,4625,O
mortality,4625,O
rates,4625,O
from,4625,O
1,4625,O
year,4625,O
post-discharge,4625,O
through,4625,O
2008,4625,O
between,4625,O
those,4625,O
in,4625,O
whom,4625,O
the,4625,O
liver,4625,B-Disease
injury,4625,I-Disease
led,4625,O
to,4625,O
an,4625,O
acute,4625,B-Disease
liver,4625,I-Disease
failure,4625,I-Disease
and,4625,O
those,4625,O
in,4625,O
whom,4625,O
it,4625,O
did,4625,O
not,4625,O
.,4625,O
RESULTS,4626,O
:,4626,O
We,4626,O
included,4626,O
641,4626,O
patients,4626,O
.,4626,O
On,4627,O
average,4627,O
",",4627,O
age-specific,4627,O
mortality,4627,O
rates,4627,O
were,4627,O
slightly,4627,O
higher,4627,O
for,4627,O
the,4627,O
101,4627,O
patients,4627,O
whose,4627,O
paracetamol-induced,4627,B-Chemical
liver,4627,B-Disease
injury,4627,I-Disease
had,4627,O
caused,4627,O
an,4627,O
acute,4627,B-Disease
liver,4627,I-Disease
failure,4627,I-Disease
(,4627,O
adjusted,4627,O
mortality,4627,O
rate,4627,O
ratio,4627,O
=,4627,O
1.70,4627,O
",",4627,O
95,4627,O
%,4627,O
CI,4627,O
1.02-2.85,4627,O
),4627,O
",",4627,O
but,4627,O
the,4627,O
association,4627,O
was,4627,O
age-dependent,4627,O
",",4627,O
and,4627,O
no,4627,O
survivors,4627,O
of,4627,O
acute,4627,B-Disease
liver,4627,I-Disease
failure,4627,I-Disease
died,4627,O
of,4627,O
liver,4627,B-Disease
disease,4627,I-Disease
",",4627,O
whereas,4627,O
suicides,4627,O
were,4627,O
frequent,4627,O
in,4627,O
both,4627,O
groups,4627,O
.,4627,O
These,4628,O
observations,4628,O
speak,4628,O
against,4628,O
long-term,4628,O
effects,4628,O
of,4628,O
acute,4628,B-Disease
liver,4628,I-Disease
failure,4628,I-Disease
.,4628,O
More,4629,O
likely,4629,O
",",4629,O
the,4629,O
elevated,4629,O
mortality,4629,O
rate,4629,O
ratio,4629,O
resulted,4629,O
from,4629,O
incomplete,4629,O
adjustment,4629,O
for,4629,O
the,4629,O
greater,4629,O
prevalence,4629,O
of,4629,O
substance,4629,B-Disease
abuse,4629,I-Disease
among,4629,O
survivors,4629,O
of,4629,O
acute,4629,B-Disease
liver,4629,I-Disease
failure,4629,I-Disease
.,4629,O
CONCLUSIONS,4630,O
:,4630,O
Paracetamol-induced,4630,B-Chemical
acute,4630,B-Disease
liver,4630,I-Disease
failure,4630,I-Disease
did,4630,O
not,4630,O
affect,4630,O
long-term,4630,O
mortality,4630,O
.,4630,O
Clinical,4631,O
follow-up,4631,O
may,4631,O
be,4631,O
justified,4631,O
by,4631,O
the,4631,O
cause,4631,O
of,4631,O
the,4631,O
liver,4631,B-Disease
failure,4631,I-Disease
",",4631,O
but,4631,O
not,4631,O
by,4631,O
the,4631,O
liver,4631,B-Disease
failure,4631,I-Disease
itself,4631,O
.,4631,O
In,4632,O
vivo,4632,O
characterization,4632,O
of,4632,O
a,4632,O
dual,4632,O
adenosine,4632,B-Chemical
A2A/A1,4632,I-Chemical
receptor,4632,I-Chemical
antagonist,4632,I-Chemical
in,4632,O
animal,4632,O
models,4632,O
of,4632,O
Parkinson,4632,B-Disease
's,4632,I-Disease
disease,4632,I-Disease
.,4632,O
The,4633,O
in,4633,O
vivo,4633,O
characterization,4633,O
of,4633,O
a,4633,O
dual,4633,O
adenosine,4633,B-Chemical
A,4633,I-Chemical
(,4633,I-Chemical
2A,4633,I-Chemical
),4633,I-Chemical
/A,4633,I-Chemical
(,4633,I-Chemical
1,4633,I-Chemical
),4633,I-Chemical
receptor,4633,I-Chemical
antagonist,4633,I-Chemical
in,4633,O
several,4633,O
animal,4633,O
models,4633,O
of,4633,O
Parkinson,4633,B-Disease
's,4633,I-Disease
disease,4633,I-Disease
is,4633,O
described,4633,O
.,4633,O
Discovery,4634,O
and,4634,O
scale-up,4634,O
syntheses,4634,O
of,4634,O
compound,4634,O
1,4634,O
are,4634,O
described,4634,O
in,4634,O
detail,4634,O
",",4634,O
highlighting,4634,O
optimization,4634,O
steps,4634,O
that,4634,O
increased,4634,O
the,4634,O
overall,4634,O
yield,4634,O
of,4634,O
1,4634,O
from,4634,O
10.0,4634,O
%,4634,O
to,4634,O
30.5,4634,O
%,4634,O
.,4634,O
Compound,4635,O
1,4635,O
is,4635,O
a,4635,O
potent,4635,O
A,4635,O
(,4635,O
2A,4635,O
),4635,O
/A,4635,O
(,4635,O
1,4635,O
),4635,O
receptor,4635,O
antagonist,4635,O
in,4635,O
vitro,4635,O
(,4635,O
A,4635,O
(,4635,O
2A,4635,O
),4635,O
K,4635,O
(,4635,O
i,4635,O
),4635,O
=,4635,O
4.1,4635,O
nM,4635,O
;,4635,O
A,4635,O
(,4635,O
1,4635,O
),4635,O
K,4635,O
(,4635,O
i,4635,O
),4635,O
=,4635,O
17.0,4635,O
nM,4635,O
),4635,O
that,4635,O
has,4635,O
excellent,4635,O
activity,4635,O
",",4635,O
after,4635,O
oral,4635,O
administration,4635,O
",",4635,O
across,4635,O
a,4635,O
number,4635,O
of,4635,O
animal,4635,O
models,4635,O
of,4635,O
Parkinson,4635,B-Disease
's,4635,I-Disease
disease,4635,I-Disease
including,4635,O
mouse,4635,O
and,4635,O
rat,4635,O
models,4635,O
of,4635,O
haloperidol-induced,4635,B-Chemical
catalepsy,4635,B-Disease
",",4635,O
mouse,4635,O
model,4635,O
of,4635,O
reserpine-induced,4635,B-Chemical
akinesia,4635,B-Disease
",",4635,O
rat,4635,O
6-hydroxydopamine,4635,B-Chemical
(,4635,O
6-OHDA,4635,B-Chemical
),4635,O
lesion,4635,O
model,4635,O
of,4635,O
drug-induced,4635,O
rotation,4635,O
",",4635,O
and,4635,O
MPTP-treated,4635,B-Chemical
non-human,4635,O
primate,4635,O
model,4635,O
.,4635,O
Effects,4636,O
of,4636,O
the,4636,O
hippocampal,4636,O
deep,4636,O
brain,4636,O
stimulation,4636,O
on,4636,O
cortical,4636,O
epileptic,4636,B-Disease
discharges,4636,O
in,4636,O
penicillin,4636,B-Chemical
-,4636,O
induced,4636,O
epilepsy,4636,B-Disease
model,4636,O
in,4636,O
rats,4636,O
.,4636,O
AIM,4637,O
:,4637,O
Experimental,4637,O
and,4637,O
clinical,4637,O
studies,4637,O
have,4637,O
revealed,4637,O
that,4637,O
hippocampal,4637,O
DBS,4637,O
can,4637,O
control,4637,O
epileptic,4637,B-Disease
activity,4637,O
",",4637,O
but,4637,O
the,4637,O
mechanism,4637,O
of,4637,O
action,4637,O
is,4637,O
obscure,4637,O
and,4637,O
optimal,4637,O
stimulation,4637,O
parameters,4637,O
are,4637,O
not,4637,O
clearly,4637,O
defined,4637,O
.,4637,O
The,4638,O
aim,4638,O
was,4638,O
to,4638,O
evaluate,4638,O
the,4638,O
effects,4638,O
of,4638,O
high,4638,O
frequency,4638,O
hippocampal,4638,O
stimulation,4638,O
on,4638,O
cortical,4638,O
epileptic,4638,B-Disease
activity,4638,O
in,4638,O
penicillin-induced,4638,B-Chemical
epilepsy,4638,B-Disease
model,4638,O
.,4638,O
MATERIAL,4639,O
AND,4639,O
METHODS,4639,O
:,4639,O
Twenty-five,4639,O
Sprague-Dawley,4639,O
rats,4639,O
were,4639,O
implanted,4639,O
DBS,4639,O
electrodes,4639,O
.,4639,O
In,4640,O
group-1,4640,O
(,4640,O
n=10,4640,O
),4640,O
hippocampal,4640,O
DBS,4640,O
was,4640,O
off,4640,O
and,4640,O
in,4640,O
the,4640,O
group-2,4640,O
(,4640,O
n=10,4640,O
),4640,O
hippocampal,4640,O
DBS,4640,O
was,4640,O
on,4640,O
(,4640,O
185,4640,O
Hz,4640,O
",",4640,O
0.5V,4640,O
",",4640,O
1V,4640,O
",",4640,O
2V,4640,O
",",4640,O
and,4640,O
5V,4640,O
for,4640,O
60,4640,O
sec,4640,O
),4640,O
following,4640,O
penicillin,4640,B-Chemical
G,4640,I-Chemical
injection,4640,O
intracortically,4640,O
.,4640,O
In,4641,O
the,4641,O
control,4641,O
group,4641,O
hippocampal,4641,O
DBS,4641,O
was,4641,O
on,4641,O
following,4641,O
8,4641,O
l,4641,O
saline,4641,O
injection,4641,O
intracortically,4641,O
.,4641,O
EEG,4642,O
recordings,4642,O
were,4642,O
obtained,4642,O
before,4642,O
and,4642,O
15,4642,O
minutes,4642,O
following,4642,O
penicillin-G,4642,B-Chemical
injection,4642,O
",",4642,O
and,4642,O
at,4642,O
10th,4642,O
minutes,4642,O
following,4642,O
each,4642,O
stimulus,4642,O
for,4642,O
analysis,4642,O
in,4642,O
terms,4642,O
of,4642,O
frequency,4642,O
",",4642,O
amplitude,4642,O
",",4642,O
and,4642,O
power,4642,O
spectrum,4642,O
.,4642,O
RESULTS,4643,O
:,4643,O
High,4643,O
frequency,4643,O
hippocampal,4643,O
DBS,4643,O
suppressed,4643,O
the,4643,O
acute,4643,O
penicillin-induced,4643,B-Chemical
cortical,4643,O
epileptic,4643,B-Disease
activity,4643,O
independent,4643,O
from,4643,O
stimulus,4643,O
intensity,4643,O
.,4643,O
In,4644,O
the,4644,O
control,4644,O
group,4644,O
",",4644,O
hippocampal,4644,O
stimulation,4644,O
alone,4644,O
lead,4644,O
only,4644,O
to,4644,O
diffuse,4644,O
slowing,4644,O
of,4644,O
cerebral,4644,O
bioelectrical,4644,O
activity,4644,O
at,4644,O
5V,4644,O
stimulation,4644,O
.,4644,O
CONCLUSION,4645,O
:,4645,O
Our,4645,O
results,4645,O
revealed,4645,O
that,4645,O
continuous,4645,O
high,4645,O
frequency,4645,O
stimulation,4645,O
of,4645,O
the,4645,O
hippocampus,4645,O
suppressed,4645,O
acute,4645,O
cortical,4645,O
epileptic,4645,B-Disease
activity,4645,O
effectively,4645,O
without,4645,O
causing,4645,O
secondary,4645,O
epileptic,4645,B-Disease
discharges,4645,O
.,4645,O
These,4646,O
results,4646,O
are,4646,O
important,4646,O
in,4646,O
terms,4646,O
of,4646,O
defining,4646,O
the,4646,O
optimal,4646,O
parameters,4646,O
of,4646,O
hippocampal,4646,O
DBS,4646,O
in,4646,O
patients,4646,O
with,4646,O
epilepsy,4646,B-Disease
.,4646,O
CCNU,4647,B-Chemical
(,4647,O
lomustine,4647,B-Chemical
),4647,O
toxicity,4647,B-Disease
in,4647,O
dogs,4647,O
:,4647,O
a,4647,O
retrospective,4647,O
study,4647,O
(,4647,O
2002-07,4647,O
),4647,O
.,4647,O
OBJECTIVE,4648,O
:,4648,O
To,4648,O
describe,4648,O
the,4648,O
incidence,4648,O
of,4648,O
haematological,4648,O
",",4648,O
renal,4648,O
",",4648,O
hepatic,4648,O
and,4648,O
gastrointestinal,4648,O
toxicities,4648,O
in,4648,O
tumour-bearing,4648,O
dogs,4648,O
receiving,4648,O
1-,4648,B-Chemical
(,4648,I-Chemical
2-chloroethyl,4648,I-Chemical
),4648,I-Chemical
-3-cyclohexyl-1-nitrosourea,4648,I-Chemical
(,4648,O
CCNU,4648,B-Chemical
),4648,O
.,4648,O
DESIGN,4649,O
:,4649,O
The,4649,O
medical,4649,O
records,4649,O
of,4649,O
206,4649,O
dogs,4649,O
that,4649,O
were,4649,O
treated,4649,O
with,4649,O
CCNU,4649,B-Chemical
at,4649,O
the,4649,O
Melbourne,4649,O
Veterinary,4649,O
Specialist,4649,O
Centre,4649,O
between,4649,O
February,4649,O
2002,4649,O
and,4649,O
December,4649,O
2007,4649,O
were,4649,O
retrospectively,4649,O
evaluated,4649,O
.,4649,O
RESULTS,4650,O
:,4650,O
Of,4650,O
the,4650,O
206,4650,O
dogs,4650,O
treated,4650,O
with,4650,O
CCNU,4650,B-Chemical
",",4650,O
185,4650,O
met,4650,O
the,4650,O
inclusion,4650,O
criteria,4650,O
for,4650,O
at,4650,O
least,4650,O
one,4650,O
class,4650,O
of,4650,O
toxicity,4650,B-Disease
.,4650,O
CCNU,4651,B-Chemical
was,4651,O
used,4651,O
most,4651,O
commonly,4651,O
in,4651,O
the,4651,O
treatment,4651,O
of,4651,O
lymphoma,4651,B-Disease
",",4651,O
mast,4651,B-Disease
cell,4651,I-Disease
tumour,4651,I-Disease
",",4651,O
brain,4651,B-Disease
tumour,4651,I-Disease
",",4651,O
histiocytic,4651,B-Disease
tumours,4651,I-Disease
and,4651,O
epitheliotropic,4651,B-Disease
lymphoma,4651,I-Disease
.,4651,O
Throughout,4652,O
treatment,4652,O
",",4652,O
56.9,4652,O
%,4652,O
of,4652,O
dogs,4652,O
experienced,4652,O
neutropenia,4652,B-Disease
",",4652,O
34.2,4652,O
%,4652,O
experienced,4652,O
anaemia,4652,B-Disease
and,4652,O
14.2,4652,O
%,4652,O
experienced,4652,O
thrombocytopenia,4652,B-Disease
.,4652,O
Gastrointestinal,4653,B-Disease
toxicosis,4653,I-Disease
was,4653,O
detected,4653,O
in,4653,O
37.8,4653,O
%,4653,O
of,4653,O
dogs,4653,O
",",4653,O
the,4653,O
most,4653,O
common,4653,O
sign,4653,O
of,4653,O
which,4653,O
was,4653,O
vomiting,4653,B-Disease
(,4653,O
24.3,4653,O
%,4653,O
),4653,O
.,4653,O
Potential,4654,O
renal,4654,O
toxicity,4654,B-Disease
and,4654,O
elevated,4654,O
alanine,4654,B-Chemical
transaminase,4654,O
(,4654,O
ALT,4654,O
),4654,O
concentration,4654,O
were,4654,O
reported,4654,O
in,4654,O
12.2,4654,O
%,4654,O
and,4654,O
48.8,4654,O
%,4654,O
of,4654,O
dogs,4654,O
",",4654,O
respectively,4654,O
.,4654,O
The,4655,O
incidence,4655,O
of,4655,O
hepatic,4655,B-Disease
failure,4655,I-Disease
was,4655,O
1.2,4655,O
%,4655,O
.,4655,O
CONCLUSIONS,4656,O
:,4656,O
CCNU-associated,4656,B-Chemical
toxicity,4656,B-Disease
in,4656,O
dogs,4656,O
is,4656,O
common,4656,O
",",4656,O
but,4656,O
is,4656,O
usually,4656,O
not,4656,O
life,4656,O
threatening,4656,O
.,4656,O
